PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Motohara, T; Masuda, K; Morotti, M; Zheng, YY; El-Sahhar, S; Chong, KY; Wietek, N; Alsaadi, A; Karaminejadranjbar, M; Hu, ZY; Artibani, M; Gonzalez, LS; Katabuchi, H; Saya, H; Ahmed, AA				Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Katabuchi, Hidetaka; Saya, Hideyuki; Ahmed, Ahmed Ashour			An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment	ONCOGENE			English	Review							MESENCHYMAL STEM-CELLS; TUMOR-ASSOCIATED MACROPHAGES; INDUCIBLE KINASE 2; CD44 VARIANT 6; MILKY SPOTS; TRANSCOELOMIC METASTASIS; PROGRESSION; FIBROBLASTS; PATHOGENESIS; CARCINOMA	Metastasis is a complex multistep process that involves critical interactions between cancer cells and a variety of stromal components in the tumor microenvironment, which profoundly influence the different aspects of the metastatic cascade and organ tropism of disseminating cancer cells. Ovarian cancer is the most lethal gynecological malignancy and is characterized by peritoneal disseminated metastasis. Evidence has demonstrated that ovarian cancer possesses specific metastatic tropism for the adipose-rich omentum, which has a pivotal role in the creation of the metastatic tumor microenvironment in the intraperitoneal cavity. Considering the distinct biology of ovarian cancer metastasis, the elucidation of the cellular and molecular mechanisms underlying the reciprocal interplay between ovarian cancer cells and surrounding stromal cell types in the adipose-rich metastatic microenvironment will provide further insights into the development of novel therapeutic approaches for patients with advanced ovarian cancer. Herein, we review the biological mechanisms that regulate the highly orchestrated crosstalk between ovarian cancer cells and various cancer-associated stromal cells in the metastatic tumor microenvironment with regard to the omentum by illustrating how different stromal cells concertedly contribute to the development of ovarian cancer metastasis and metastatic tropism for the omentum.	[Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Ahmed, Ahmed Ashour] Univ Oxford, Ovarian Canc Cell Lab, Weatherall Inst Mol Med, Oxford OX3 9DS, England; [Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Ahmed, Ahmed Ashour] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Womens & Reprod Hlth, Womens Ctr, Oxford OX3 9DU, England; [Katabuchi, Hidetaka] Kumamoto Univ, Fac Life Sci, Dept Obstet & Gynecol, Chuo Ku, 1-1-1 Honjo, Kumamoto, Kumamoto 8608556, Japan; [Saya, Hideyuki] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan	University of Oxford; University of Oxford; Kumamoto University; Keio University	Ahmed, AA (corresponding author), Univ Oxford, Ovarian Canc Cell Lab, Weatherall Inst Mol Med, Oxford OX3 9DS, England.; Ahmed, AA (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Womens & Reprod Hlth, Womens Ctr, Oxford OX3 9DU, England.	ahmed.ahmed@wrh.ox.ac.uk	Morotti, Matteo/AAE-8922-2020; Hu, Zhiyuan/U-1990-2019; Hu, Zhiyuan/GRY-2701-2022	Morotti, Matteo/0000-0002-1790-1185; Hu, Zhiyuan/0000-0002-1688-6032; Hu, Zhiyuan/0000-0002-1688-6032; Saya, Hideyuki/0000-0001-6610-1902; Alsaadi, Abdulkhaliq/0000-0003-1732-0740	Ovarian Cancer Action; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); Helen Clarke Fund; Wellbeing of Women Scholarship; Japan Society for the Promotion of Science; BCSRC studentship; MRC [G0902418] Funding Source: UKRI	Ovarian Cancer Action(Ovarian Cancer Action); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)(National Institute for Health Research (NIHR)); Helen Clarke Fund; Wellbeing of Women Scholarship; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); BCSRC studentship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Ovarian Cancer Action, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the Helen Clarke Fund. NW is supported by a Wellbeing of Women Scholarship. KM is supported by a fellowship from the Japan Society for the Promotion of Science. LG is supported by a BCSRC studentship.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2012, BJOG-INT J OBSTET GY, V119, P134, DOI 10.1111/j.1471-0528.2011.03149.x; Ahmed AA, 2010, CANCER CELL, V18, P109, DOI 10.1016/j.ccr.2010.06.018; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bon H, 2015, MOL CANCER RES, V13, P620, DOI 10.1158/1541-7786.MCR-13-0182-T; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Cai J, 2012, CARCINOGENESIS, V33, P20, DOI 10.1093/carcin/bgr230; Carroll MJ, 2016, ONCOTARGET, V7, P86608, DOI 10.18632/oncotarget.13474; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Castells M, 2012, CANCER LETT, V326, P59, DOI 10.1016/j.canlet.2012.07.020; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chau YY, 2014, NAT CELL BIOL, V16, P367, DOI 10.1038/ncb2922; Chen F, 2017, BJOG-INT J OBSTET GY, V124, P872, DOI 10.1111/1471-0528.14543; Cho JA, 2011, GYNECOL ONCOL, V123, P379, DOI 10.1016/j.ygyno.2011.08.005; Chu YJ, 2015, EXP CELL RES, V337, P16, DOI 10.1016/j.yexcr.2015.07.020; Clark R, 2013, AM J PATHOL, V183, P576, DOI 10.1016/j.ajpath.2013.04.023; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Cuiffo BG, 2012, CELL ADHES MIGR, V6, P220, DOI 10.4161/cam.20875; Curtis M, 2018, CELL METAB, V28, P1; Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896; Duluc D, 2007, BLOOD, V110, P4319, DOI 10.1182/blood-2007-02-072587; Esselen KM, 2016, JAMA ONCOL, V2, P1427, DOI 10.1001/jamaoncol.2016.1842; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Furuya Mitsuko, 2012, Cancers (Basel), V4, P701, DOI 10.3390/cancers4030701; Gusky HC, 2016, OBES REV, V17, P1015, DOI 10.1111/obr.12450; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hansen JM, 2016, EUR J CANCER, V56, P131, DOI 10.1016/j.ejca.2015.12.016; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Hellner K, 2016, EBIOMEDICINE, V10, P137, DOI 10.1016/j.ebiom.2016.06.048; Hill BS, 2017, ONCOTARGET, V8, P73296, DOI 10.18632/oncotarget.20265; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kamdje AHN, 2017, CANCER BIOL MED, V14, P129, DOI 10.20892/j.issn.2095-3941.2016.0033; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Klopp AH, 2012, CLIN CANCER RES, V18, P771, DOI 10.1158/1078-0432.CCR-11-1916; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Krishnan V, 2018, GYNECOL ONCOL, V149, P205, DOI 10.1016/j.ygyno.2018.01.014; Krishnan V, 2015, JOVE-J VIS EXP, DOI 10.3791/52721; KRIST LFG, 1995, ANAT REC, V241, P163, DOI 10.1002/ar.1092410204; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lau TS, 2017, ONCOGENE, V36, P3576, DOI 10.1038/onc.2016.509; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Lim D, 2013, PATHOLOGY, V45, P229, DOI 10.1097/PAT.0b013e32835f2264; Lis R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038340; Liu JY, 2016, TUMOR BIOL, V37, P5715, DOI 10.1007/s13277-016-4887-3; Liu J, 2014, CLIN CANCER RES, V20, P5150, DOI 10.1158/1078-0432.CCR-14-1312; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Mebius RE, 2009, IMMUNITY, V30, P670, DOI 10.1016/j.immuni.2009.04.005; Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0003-7; Meza-Perez S, 2017, TRENDS IMMUNOL, V38, P526, DOI 10.1016/j.it.2017.03.002; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Miranda F, 2017, CELL CYCLE, V16, P15, DOI 10.1080/15384101.2016.1235846; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Motohara T, 2016, OBSTET GYNECOL, V127, P1003, DOI 10.1097/AOG.0000000000001420; Motohara T, 2011, CARCINOGENESIS, V32, P1597, DOI 10.1093/carcin/bgr183; Motohara T, 2010, CANCER SCI, V101, P1550, DOI 10.1111/j.1349-7006.2010.01556.x; Muraoka M, 2009, AM J PHYSIOL-ENDOC M, V296, pE1430, DOI 10.1152/ajpendo.00024.2009; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nowicka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081859; Olson OC, 2013, CELL RES, V23, P179, DOI 10.1038/cr.2012.123; Orbay H, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/461718; PAGET S, 1989, CANCER METAST REV, V8, P98; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Pearce OMT, 2018, CANCER DISCOV, V8, P304, DOI 10.1158/2159-8290.CD-17-0284; Petrillo M, 2016, GYNECOL ONCOL, V142, P176, DOI 10.1016/j.ygyno.2016.03.037; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reagan MR, 2011, STEM CELLS, V29, P920, DOI 10.1002/stem.645; Reinartz S, 2014, INT J CANCER, V134, P32, DOI 10.1002/ijc.28335; Rizi BS, 2015, CANCER RES, V75, P456, DOI 10.1158/0008-5472.CAN-14-1337; Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; SHIMOTSUMA M, 1992, CANCER RES, V52, P5400; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Suh DH, 2014, BIOCHEM PHARMACOL, V92, P43, DOI 10.1016/j.bcp.2014.08.011; Takaishi K, 2010, CANCER SCI, V101, P2128, DOI 10.1111/j.1349-7006.2010.01652.x; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tayama S, 2017, ONCOTARGET, V8, P44312, DOI 10.18632/oncotarget.17871; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Tjhay F, 2015, CANCER SCI, V106, P1421, DOI 10.1111/cas.12765; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Yeung TL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010003; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zhang YL, 2017, ONCOTARGETS THER, V10, P1655, DOI 10.2147/OTT.S129502; Zhang YA, 2011, CANCER LETT, V303, P47, DOI 10.1016/j.canlet.2011.01.011; Zhou JH, 2017, CLIN CANCER RES, V23, P1945, DOI 10.1158/1078-0432.CCR-16-1562	112	93	95	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2885	2898		10.1038/s41388-018-0637-x	http://dx.doi.org/10.1038/s41388-018-0637-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568223	Green Published, hybrid			2022-12-17	WOS:000465167600001
J	Wendler, F; Favicchio, R; Simon, T; Alifrangis, C; Stebbing, J; Giamas, G				Wendler, F.; Favicchio, R.; Simon, T.; Alifrangis, C.; Stebbing, J.; Giamas, G.			Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention	ONCOGENE			English	Review							CELL-DERIVED EXOSOMES; BREAST-CANCER; ENDOTHELIAL-CELLS; LEUKEMIA-CELLS; LUNG-CANCER; PANCREATIC-CANCER; STEM-CELLS; IN-VITRO; MICROVESICLES; ANGIOGENESIS	Intercellular communication sets the pace for transformed cells to survive and to thrive. Extracellular vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are involved in this process shuttling reciprocal signals and other molecules between transformed and stromal cells, including fibroblasts, endothelial and immune cells. As a result, these cells are adapted or recruited to a constantly evolving cancer microenvironment. Moreover, EVs take part in the response to anticancer therapeutics not least by promoting drug resistance throughout the targeted tumor. Finally, circulating EVs can also transport important molecules to remote destinations in order to prime metastatic niches in an otherwise healthy tissue. Although the understanding of EV biology remains a major challenge in the field, their characteristics create new opportunities for advances in cancer diagnostics and therapeutics.	[Wendler, F.; Simon, T.; Giamas, G.] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Favicchio, R.; Stebbing, J.] Imperial Coll London, Dept Surg & Canc, Div Canc, London, England; [Alifrangis, C.] Hammersmith Hosp, NHS Trust, Imperial Coll London, Dept Med Oncol, London, England	University of Sussex; Imperial College London; Imperial College London	Wendler, F; Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	F.Wendler@sussex.ac.uk; G.Giamas@sussex.ac.uk	Giamas, Georgios/AAP-3487-2021	Simon, Thomas/0000-0002-3280-2716; Stebbing, Justin/0000-0002-1117-6947; Giamas, Georgios/0000-0002-4417-2707	Action Against Cancer; NIHR grant [NIHR-RP-011-053]; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Worldwide Cancer Research [10-0510] Funding Source: researchfish	Action Against Cancer; NIHR grant; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Worldwide Cancer Research	This work was supported by Action Against Cancer and NIHR grant #NIHR-RP-011-053.	Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571-016-0366-z; Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66; Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Amorim M, 2014, PROTEOMICS, V14, P1472, DOI 10.1002/pmic.201300485; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Belmont PJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005516; Bovy N, 2015, ONCOTARGET, V6, P10253, DOI 10.18632/oncotarget.3520; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466; Cazzoli R, 2013, J THORAC ONCOL, V8, P1156, DOI 10.1097/JTO.0b013e318299ac32; Chen WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095240; Chen Y, 2015, ONCOL LETT, V10, P3742, DOI 10.3892/ol.2015.3806; Cho JA, 2012, INT J ONCOL, V40, P130, DOI 10.3892/ijo.2011.1193; Chowdhury R, 2015, ONCOTARGET, V6, P715, DOI 10.18632/oncotarget.2711; Clark DJ, 2016, J PROTEOMICS, V133, P161, DOI 10.1016/j.jprot.2015.12.023; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Fan GC, 2014, BLOOD, V124, P3669, DOI 10.1182/blood-2014-10-607846; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Franzen CA, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.21; Frydrychowicz M, 2015, SCAND J IMMUNOL, V81, P2, DOI 10.1111/sji.12247; Gopal SK, 2016, ONCOTARGET, DOI 10.18632/ONCOTARGET.7573; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hood JL, 2009, LAB INVEST, V89, P1317, DOI 10.1038/labinvest.2009.94; Huber V, 2005, GASTROENTEROLOGY, V128, P1796, DOI 10.1053/j.gastro.2005.03.045; Hurley JH, 2015, EMBO J, V34, P2398, DOI 10.15252/embj.201592484; Ji H, 2008, ELECTROPHORESIS, V29, P2660, DOI 10.1002/elps.200800015; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kerr EM, 2016, NATURE, V531, P110, DOI 10.1038/nature16967; Khan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046737; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kosaka N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020022; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588; Ma X, 2014, P NATL ACAD SCI USA, V111, P6389, DOI 10.1073/pnas.1400272111; Mazzeo C, 2016, CELL DEATH DIFFER, V23, P99, DOI 10.1038/cdd.2015.72; Meckes DG, 2013, P NATL ACAD SCI USA, V110, pE2925, DOI 10.1073/pnas.1303906110; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Millimaggi D, 2007, NEOPLASIA, V9, P349, DOI 10.1593/neo.07133; Minciacchi VR, 2015, ONCOTARGET, V6, P11327, DOI 10.18632/oncotarget.3598; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152; Plebanek MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15724; Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Ragusa Marco, 2014, Oncoscience, V1, P132; Raimondo S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/821613; Ronquist KG, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.29877; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Sun L, 2014, ACTA PHARMACOL SIN, V35, P381, DOI 10.1038/aps.2013.166; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Taverna S, 2012, INT J CANCER, V130, P2033, DOI 10.1002/ijc.26217; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhao H., 2016, ELIFE, V5; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	86	93	95	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					877	884		10.1038/onc.2016.253	http://dx.doi.org/10.1038/onc.2016.253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27546617	Green Accepted			2022-12-17	WOS:000394169100001
J	da Motta, LL; Ledaki, I; Purshouse, K; Haider, S; De Bastiani, MA; Baban, D; Morotti, M; Steers, G; Wigfield, S; Bridges, E; Li, JL; Knapp, S; Ebner, D; Klamt, F; Harris, AL; McIntyre, A				da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; De Bastiani, M. A.; Baban, D.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J-L; Knapp, S.; Ebner, D.; Klamt, F.; Harris, A. L.; McIntyre, A.			The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer	ONCOGENE			English	Article							BROMODOMAIN INHIBITION; EPIGENETIC READERS; ENERGY-METABOLISM; CELL METABOLISM; GENE-EXPRESSION; LYSYL OXIDASE; STEM-CELLS; CHIP-SEQ; IN-VIVO; C-MYC	The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.	[da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J-L; Harris, A. L.; McIntyre, A.] Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Labs, Oxford OX1 2JD, England; [da Motta, L. L.; De Bastiani, M. A.; Klamt, F.] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil; [da Motta, L. L.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil; [Baban, D.] Univ Oxford, Wellcome Trust Ctr Human Genet, High Throughput Genom, Oxford OX1 2JD, England; [Li, J-L] Univ Plymouth, Peninsula Schools Med & Dent, Inst Translat & Stratified Med, Plymouth PL4 8AA, Devon, England; [Knapp, S.] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford, England; [Knapp, S.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Campus Riedberg, Frankfurt, Germany; [Knapp, S.] Buchmann Inst Life Sci, Campus Riedberg, Frankfurt, Germany; [Ebner, D.] Univ Oxford, TDI, Nuffield Dept Med, Oxford, England; [McIntyre, A.] Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England	University of Oxford; Universidade Federal do Rio Grande do Sul; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); University of Oxford; Wellcome Centre for Human Genetics; University of Plymouth; University of Oxford; Goethe University Frankfurt; University of Oxford; University of Nottingham	McIntyre, A (corresponding author), Univ Nottingham, Div Canc & Stem Cells, Canc Biol, Nottingham NG7 2UH, England.; Harris, AL (corresponding author), Univ Oxford, Weatherall Inst Mol Med, Dept Oncol, Mol Oncol Labs, Oxford OX3 9DS, England.	aharris.lab@imm.ox.ac.uk; alan.mcintyre@nottingham.ac.uk	De Bastiani, Marco Antônio/AAD-8366-2019; Motta, Leonardo L/C-1551-2015; De Bastiani, Marco Antônio/AAO-3798-2020; Harris, Adrian L/ABA-3343-2020; Knapp, Stefan/AAG-2347-2019; Morotti, Matteo/AAE-8922-2020	Motta, Leonardo L/0000-0001-6364-5007; De Bastiani, Marco Antônio/0000-0003-3924-5278; Harris, Adrian L/0000-0003-1376-8409; Knapp, Stefan/0000-0001-5995-6494; Morotti, Matteo/0000-0002-1790-1185; Ebner, Daniel/0000-0002-6495-7026; McIntyre, Alan/0000-0002-4791-7292; Purshouse, Karin/0000-0003-0942-6342	Cancer Research UK; Breast Cance Research Foundation; Breast Cancer Now; Oxford NIHR Biomedical Research Centre; CRUK Oxford Centre; CAPES Foundation/Brazil; Cancer Research UK [18974, 11359, 16466] Funding Source: researchfish; Medical Research Council [G0300648] Funding Source: researchfish; National Institute for Health Research [ACF-2015-13-008, NF-SI-0611-10163] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cance Research Foundation; Breast Cancer Now; Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); CRUK Oxford Centre; CAPES Foundation/Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by grants from Cancer Research UK (ALH), Breast Cance Research Foundation (ALH), Breast Cancer Now (AM), Oxford NIHR Biomedical Research Centre, and the CRUK Oxford Centre (ALH). Leonardo Lisboa da Motta has been awarded a scholarship from the CAPES Foundation/Brazil to conduct this study.	Alghamdi S, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0278-3; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernardi R, 2014, CELL RES, V24, P904, DOI 10.1038/cr.2014.61; Bid HK, MOL CANC THER; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Castro MAA, 2009, BIOINFORMATICS, V25, P1468, DOI 10.1093/bioinformatics/btp246; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dubois L, 2011, RADIOTHER ONCOL, V99, P424, DOI 10.1016/j.radonc.2011.05.045; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gieling RG, 2013, J ENZYM INHIB MED CH, V28, P360, DOI 10.3109/14756366.2012.736979; Gonzales-Cope M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2414-y; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Halliday GM, 2009, INT J BIOCHEM CELL B, V41, P725, DOI 10.1016/j.biocel.2008.04.026; Horne GA, 2015, STEM CELLS DEV, V24, P879, DOI 10.1089/scd.2014.0302; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kumler I, 2014, CANCER TREAT REV, V40, P960, DOI 10.1016/j.ctrv.2014.05.006; Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126; Rajagopalan V, 2014, CELL MOL NEUROBIOL, V34, P1059, DOI 10.1007/s10571-014-0083-4; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; SEMENZA GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI DOI 10.1016/J.BBAMCR.2015.05.036; Sena JA, 2013, MOL CELL BIOL, V33, P3849, DOI 10.1128/MCB.00731-13; Sengupta S, 2015, BREAST CANCER RES TR, V150, P265, DOI 10.1007/s10549-015-3319-1; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200; Wani NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3665; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; Waschow M., 2012, NAT METHODS, V9; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991; Wu T, 2015, STEM CELL REP, V4, P390, DOI 10.1016/j.stemcr.2015.01.012; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	59	93	93	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					122	132		10.1038/onc.2016.184	http://dx.doi.org/10.1038/onc.2016.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27292261	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000394069100011
J	Liu, Y; Wang, G; Yang, Y; Mei, Z; Liang, Z; Cui, A; Wu, T; Liu, CY; Cui, L				Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.			Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; GASTRIC-CANCER; HIPPO PATHWAY; BETA-CATENIN; E-CADHERIN; ENHANCER; GROWTH; DISRUPTION; COMPLEX; LINEAGE	Dysregulation of the Hippo pathway occurs in a variety of cancers and often correlates with a poor prognosis. To further explore the potential role of Hippo pathway dysregulation in tumor development and progression, we investigated its downstream transcription factor TEAD4 in colorectal cancer (CRC). Increased expression and nuclear localization of TEAD4 were found in a significant portion of CRC tissues, in association with metastasis and a poor prognosis. In CRC cells, TEAD4 knockdown induced the mesenchymal-epithelial transition and decreased cell mobility in vitro and metastasis in vivo. Microarray analysis revealed that TEAD4 promoted cell adhesion and upregulated the epithelial-mesenchymal transition-related transcriptome in CRC cells. Vimentin was identified as a new direct target gene mediating TEAD4 function in CRC cells, whereby forced vimentin expression markedly reversed TEAD4-knockdown-induced cell morphological changes and decreased mobility. Interestingly, rescued expression of both WT TEAD4 and a Y429H mutant can reverse the mesenchymal-epithelial transition and increase vimentin expression, cell mobility and metastatic potential in TEAD4-knockdown CRC cells. The discrepant expression of YAP and TEAD4 in CRC tissues, the rescue ability of TEAD4 mutant defect in YAP binding and no effect on vimentin expression by YAP knockdown in CRC cells, all implicated a YAP-independent manner of TEAD4 function in CRC. Furthermore, vimentin positively correlated and CDH1 reversely correlated with the level of TEAD4 in CRC tissues and xenograft tumors. Our results suggest that TEAD4 nuclear expression can serve as a biomarker for CRC progression and poor prognosis. The transcription factor TEAD4 regulates a pro-metastasis transcription program in a YAP-independent manner in CRC, thus providing a novel mechanism of TEAD4 transcriptional regulation and its oncogenic role in CRC, independently of the Hippo pathway.	[Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Kongjiang Rd 1665, Shanghai 200092, Peoples R China; [Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.] Shanghai Colorectal Canc Res Ctr, Shanghai, Peoples R China; [Yang, Y.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Ctr Med Res, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Liu, CY; Cui, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Kongjiang Rd 1665, Shanghai 200092, Peoples R China.	cyliu_eric@126.com; longcuidr@126.com	Mei, Zubing/H-7879-2019	Liu, Chen-Ying/0000-0002-8930-6182; cui, long/0000-0003-1838-4471	National Natural Science Foundation of China [81372636, 81302089]; National High Technology Research and Development Program of China (863 Program) [SQ2014SFOZD00314]; Shanghai Excellent Young Teachers Program [ZZjdyx13074]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); Shanghai Excellent Young Teachers Program	This work was supported by National Natural Science Foundation of China (grant no. 81372636 and No. 81302089), the National High Technology Research and Development Program of China (863 Program) (grant no. SQ2014SFOZD00314), the Shanghai Excellent Young Teachers Program (grant no. ZZjdyx13074).	Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Gilles C, 2003, CANCER RES, V63, P2658; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hirate Y, 2012, P NATL ACAD SCI USA, V109, pE3389, DOI 10.1073/pnas.1211810109; Home P, 2012, P NATL ACAD SCI USA, V109, P7362, DOI 10.1073/pnas.1201595109; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hucl T, 2007, CANCER RES, V67, P9055, DOI 10.1158/0008-5472.CAN-07-0474; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kaneko KJ, 2007, GENESIS, V45, P577, DOI 10.1002/dvg.20330; Kaneko KJ, 2013, DEVELOPMENT, V140, P3680, DOI 10.1242/dev.093799; Kobayashi H, 2004, CLIN CANCER RES, V10, P572, DOI 10.1158/1078-0432.CCR-1323-03; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Leung WKC, 2011, ONCOGENE, V30, P4464, DOI 10.1038/onc.2011.161; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang W, 2014, BRIT J CANCER, V110, P450, DOI 10.1038/bjc.2013.724; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yagi R, 2007, DEVELOPMENT, V134, P3827, DOI 10.1242/dev.010223; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhong XY, 2008, HISTOPATHOLOGY, V52, P560, DOI 10.1111/j.1365-2559.2008.02971.x	36	93	95	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2789	2800		10.1038/onc.2015.342	http://dx.doi.org/10.1038/onc.2015.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387538				2022-12-17	WOS:000377472700012
J	Merino, D; Lok, SW; Visvader, JE; Lindeman, GJ				Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.			Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC MARKER; MAMMARY-TUMOR DEVELOPMENT; STRUCTURE-GUIDED DESIGN; BH3 MIMETIC ABT-737; RANDOMIZED PHASE-II; CELL LUNG-CANCER; X-L INHIBITOR; PROTEIN EXPRESSION; TRANSGENIC MICE; IN-VIVO	The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival family members including Mcl-1 and BCL-X-L have been shown to have a key role in keeping pro-apoptotic 'effector' proteins BAK and BAX in check. They also neutralize a group of 'sensor' proteins (such as BIM), which are triggered by cytotoxic stimuli such as chemotherapy. BCL-2 proteins therefore have a central role as guardians against apoptosis, helping cancer cells to evade cell death. More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. The utility of targeting BCL-2 in hematological malignancies has become evident in early-phase studies, with remarkable clinical responses seen in heavily pretreated patients. As BCL-2 is overexpressed in similar to 75% of breast cancer, there has been growing interest in determining whether this new class of drug could show similar promise in breast cancer. This review summarizes our current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer.	[Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.] Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia; [Merino, D.; Visvader, J. E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Lindeman, G. J.] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia	Walter & Eliza Hall Institute; University of Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia.	lindeman@wehi.edu.au	Merino, Delphine/L-9159-2017	Merino, Delphine/0000-0002-8075-6275; Lindeman, Geoffrey/0000-0001-9386-2416	NHMRC [1016701, 1040978, 1078730]; National Breast Cancer Foundation [NC-13-21, NT-13-06, ECF-13-06]; Victorian Cancer Agency [TRP13041]; Victorian Government; Australia Fellowship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; Victorian Cancer Agency; Victorian Government; Australia Fellowship	We thank P Maltezos for assistance with the figures, G Lessene for advice and F Vaillant for helpful comments on the manuscript. We apologize to authors whose contributions have not been cited due to space limitations. Our research in this area is supported by grants from the NHMRC (1016701, 1040978), National Breast Cancer Foundation (NC-13-21, NT-13-06), the Victorian Cancer Agency (TRP13041) and the Victorian Government. DM is supported by an Early Career Fellowship from the National Breast Cancer Foundation (ECF-13-06), JEV by an Australia Fellowship and GJL by a Research Fellowship from the NHMRC (1078730).	Abdel-Fatah TMA, 2013, ANN ONCOL, V24, P2801, DOI 10.1093/annonc/mdt277; Abdel-Fatah TMA, 2010, J PATHOL, V222, P388, DOI 10.1002/path.2775; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ali HR, 2012, J PATHOL, V226, P97, DOI 10.1002/path.2976; Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Anderson MA, 2013, BLOOD, V122; Baggstrom MQ, 2011, J THORAC ONCOL, V6, P1757, DOI 10.1097/JTO.0b013e31822e2941; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Binder C, 1995, ANN ONCOL, V6, P1005, DOI 10.1093/oxfordjournals.annonc.a059064; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bozovic-Spasojevic I, 2014, BREAST, V23, P473, DOI 10.1016/j.breast.2014.03.012; Bruncko M, 2015, J MED CHEM, V58, P2180, DOI 10.1021/jm501258m; Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Chen J, 2011, MOL CANCER THER, V10, P2340, DOI 10.1158/1535-7163.MCT-11-0415; Choi JE, 2014, TUMOR BIOL, V35, P12255, DOI 10.1007/s13277-014-2534-4; Cory AH, 2003, ADV ENZYME REGUL, V43, P29, DOI 10.1016/S0065-2571(02)00026-2; Crawford Anatasha, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P184; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Ermiah E, 2013, TUMOR BIOL, V34, P1569, DOI 10.1007/s13277-013-0687-1; Fang C, 2014, ACS MED CHEM LETT, V5, P1308, DOI 10.1021/ml500388q; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Friberg A, 2013, J MED CHEM, V56, P15, DOI 10.1021/jm301448p; Fu NY, 2015, NAT CELL BIOL, V17, P365, DOI 10.1038/ncb3117; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hwang KT, 2012, INT J CANCER, V131, pE1109, DOI 10.1002/ijc.27539; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jamerson MH, 2004, BRIT J CANCER, V91, P1372, DOI 10.1038/sj.bjc.6602137; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Juin P, 2013, NAT REV CANCER, V13, P455, DOI 10.1038/nrc3538; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kerr Daniel Alan II, 2011, Hormones & Cancer, V2, P261, DOI 10.1007/s12672-011-0080-8; Kim HS, 2012, J BREAST CANCER, V15, P401, DOI 10.4048/jbc.2012.15.4.401; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Langer CJ, 2014, LUNG CANCER, V85, P420, DOI 10.1016/j.lungcan.2014.05.003; Larsen MS, 2012, ACTA ONCOL, V51, P781, DOI 10.3109/0284186X.2011.653009; Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/nchembio.1246, 10.1038/NCHEMBIO.1246]; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Li JY, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-102; Lindeman GJ, 2013, BREAST CANCER MANAG, V2, P1; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Madjd Zahra, 2009, Cancer Immun, V9, P4; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Merino D, 2015, ONCOGENE, V34, P3926, DOI 10.1038/onc.2014.313; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Moldoveanu T, 2014, TRENDS BIOCHEM SCI, V39, P101, DOI 10.1016/j.tibs.2013.12.006; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moulder SL, 2008, CLIN CANCER RES, V14, P7909, DOI 10.1158/1078-0432.CCR-08-1104; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nemati F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080836; Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perry AM, 2014, BRIT J HAEMATOL, V165, P382, DOI 10.1111/bjh.12763; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Ready N, 2011, J THORAC ONCOL, V6, P781, DOI 10.1097/JTO.0b013e31820a0ea6; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rolland P, 2007, INT J CANCER, V120, P1311, DOI 10.1002/ijc.22430; Rom J, 2009, ANN ONCOL, V20, P1829, DOI 10.1093/annonc/mdp208; Rooswinkel RW, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.109; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Rucker EB, 2011, GENESIS, V49, P24, DOI 10.1002/dvg.20691; Schorr K, 1999, CANCER RES, V59, P2541; Seveno C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3214; Seymour JF, 2013, BLOOD, V122, p429s; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Sleebs BE, 2013, J MED CHEM, V56, P5514, DOI 10.1021/jm400556w; Smerage JB, 2013, MOL ONCOL, V7, P680, DOI 10.1016/j.molonc.2013.02.013; Sonpavde G, 2012, ANN ONCOL, V23, P1803, DOI 10.1093/annonc/mdr555; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Tanaka Y, 2013, J MED CHEM, V56, P9635, DOI 10.1021/jm401170c; Tao ZF, 2014, ACS MED CHEM LETT, V5, P1088, DOI 10.1021/ml5001867; Tawfik K, 2012, HUM PATHOL, V43, P23, DOI 10.1016/j.humpath.2011.04.011; Trere D, 2007, ANN ONCOL, V18, P1004, DOI 10.1093/annonc/mdm074; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Whittle JR, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0523-1; Williams MM, 2015, ONCOTARGET, V6, P3519, DOI 10.18632/oncotarget.2792; Wong CW, 2001, CANCER RES, V61, P333; Yin ST, 2012, APOPTOSIS, V17, P388, DOI 10.1007/s10495-011-0687-9; Zheng L, 2011, CANCER LETT, V309, P27, DOI 10.1016/j.canlet.2011.05.011	114	93	95	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1877	1887		10.1038/onc.2015.287	http://dx.doi.org/10.1038/onc.2015.287			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26257067				2022-12-17	WOS:000374010300001
J	Hayashi, H; Arao, T; Togashi, Y; Kato, H; Fujita, Y; De Velasco, MA; Kimura, H; Matsumoto, K; Tanaka, K; Okamoto, I; Ito, A; Yamada, Y; Nakagawa, K; Nishio, K				Hayashi, H.; Arao, T.; Togashi, Y.; Kato, H.; Fujita, Y.; De Velasco, M. A.; Kimura, H.; Matsumoto, K.; Tanaka, K.; Okamoto, I.; Ito, A.; Yamada, Y.; Nakagawa, K.; Nishio, K.			The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer	ONCOGENE			English	Article						POU5F1B; OCT4; pseudogene; gastric cancer; gene amplification	GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER; PROSTATE-CANCER; BREAST-CANCER; BLADDER-CANCER; CELLS; RISK; EXPRESSION; 8Q24; LOCUS	POU5F1B (POU domain class 5 transcription factor 1B), a processed pseudogene that is highly homologous to OCT4, was recently shown to be transcribed in cancer cells, but its clinical relevance and biological function have remained unclear. We now show that POU5F1B, which is located adjacent to MYC on human chromosome 8q24, is frequently amplified in gastric cancer (GC) cell lines. POU5F1B, but not OCT4, was also found to be expressed at a high level in GC cell lines and clinical specimens. In addition, the DNA copy number and mRNA abundance for POU5F1B showed a positive correlation in both cancer cell lines and GC specimens. Overexpression of POU5F1B in GC cells promoted colony formation in vitro as well as both tumorigenicity and tumor growth in vivo, and these effects were enhanced in the additional presence of MYC overexpression. Furthermore, knockdown of POU5F1B expression with a short hairpin RNA confirmed a role for the endogenous pseudogene in the promotion of cancer cell growth in vitro and tumor growth in vivo. POU5F1B overexpression induced upregulation of various growth factors in GC cells as well as exhibited mitogenic, angiogenic and antiapoptotic effects in GC xenografts. Finally, amplification of POU5F1B was detected in 17 (12%) of 145 cases of GC and was a significant predictor of poor prognosis in patients with stage IV disease. In conclusion, we found that the POU5F1B pseudogene is amplified and expressed at a high level in, as well as confers an aggressive phenotype on, GC, and that POU5F1B amplification is associated with a poor prognosis in GC patients.	[Hayashi, H.; Arao, T.; Togashi, Y.; Kato, H.; Fujita, Y.; De Velasco, M. A.; Kimura, H.; Matsumoto, K.; Nishio, K.] Kinki Univ, Fac Med, Dept Genome Biol, Sayama, Osaka 5898511, Japan; [Hayashi, H.; Tanaka, K.; Okamoto, I.; Nakagawa, K.] Kinki Univ, Fac Med, Dept Med Oncol, Sayama, Osaka 5898511, Japan; [Ito, A.] Kinki Univ, Fac Med, Dept Pathol, Sayama, Osaka 5898511, Japan; [Yamada, Y.] Natl Canc Ctr, Dept Gastrointestinal Oncol, Tokyo, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Kindai University (Kinki University); National Cancer Center - Japan	Nishio, K (corresponding author), Kinki Univ, Fac Med, Dept Genome Biol, 377-2 Ohno Higashi, Sayama, Osaka 5898511, Japan.	knishio@med.kindai.ac.jp	De Velasco, Marco/R-1022-2019; Yamada, Yasuhide/AAH-9124-2020	De Velasco, Marco/0000-0002-4011-6572; 	Third-Term Comprehensive 10-Year Strategy for Cancer Control; Ministry of Health, Labor and Welfare of Japan	Third-Term Comprehensive 10-Year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported by the Third-Term Comprehensive 10-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan. We thank Shinji Kurashimo, Yoshihiro Mine, Ayaka Kurumatani and Tomoko Kitayama for technical assistance.	Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Atlasi Y, 2007, INT J CANCER, V120, P1598, DOI 10.1002/ijc.22508; Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530; Bier A, 2009, MOL CANCER THER, V8, P786, DOI 10.1158/1535-7163.MCT-08-0930; Calcagno DQ, 2008, WORLD J GASTROENTERO, V14, P5962, DOI 10.3748/wjg.14.5962; Cantz T, 2008, STEM CELLS, V26, P692, DOI 10.1634/stemcells.2007-0657; Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611; Fletcher O, 2008, CANCER EPIDEM BIOMAR, V17, P702, DOI 10.1158/1055-9965.EPI-07-2564; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Furuta K, 2012, CANCER SCI, V103, P221, DOI 10.1111/j.1349-7006.2011.02132.x; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098; Kalyana-Sundaram S, 2012, CELL, V149, P1622, DOI 10.1016/j.cell.2012.04.041; Kaneda H, 2010, CANCER RES, V70, P2053, DOI 10.1158/0008-5472.CAN-09-2161; Kastler S, PROSTATE, V70, P666; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Liedtke S, 2007, CELL STEM CELL, V1, P364, DOI 10.1016/j.stem.2007.09.003; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Pain D, 2005, J BIOL CHEM, V280, P6265, DOI 10.1074/jbc.C400587200; Panagopoulos I, 2008, ONCOL REP, V20, P1029, DOI 10.3892/or_00000105; Pink RC, 2011, RNA, V17, P792, DOI 10.1261/rna.2658311; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Schumacher FR, 2007, CANCER RES, V67, P2951, DOI 10.1158/0008-5472.CAN-06-3591; Suo GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI 10.1016/j.bbrc.2005.09.157; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeda M, 2007, CLIN CANCER RES, V13, P3051, DOI 10.1158/1078-0432.CCR-06-2743; Tanaka K, 2009, INT J CANCER, V124, P1072, DOI 10.1002/ijc.24065; Wang X, 2010, STEM CELLS, V28, P885, DOI 10.1002/stem.419; Wu CL, 2008, CLIN CANCER RES, V14, P1228, DOI 10.1158/1078-0432.CCR-07-1047; Yamada Y, 2008, CANCER SCI, V99, P2193, DOI 10.1111/j.1349-7006.2008.00935.x; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Yu HJ, 2005, HUM MUTAT, V26, P487, DOI 10.1002/humu.20246; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhao SD, 2011, J PATHOL, V223, P672, DOI 10.1002/path.2827	39	93	98	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					199	208		10.1038/onc.2013.547	http://dx.doi.org/10.1038/onc.2013.547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362523				2022-12-17	WOS:000347790500007
J	Fu, X; Meng, Z; Liang, W; Tian, Y; Wang, X; Han, W; Lou, G; Wang, X; Lou, F; Yen, Y; Yu, H; Jove, R; Huang, W				Fu, X.; Meng, Z.; Liang, W.; Tian, Y.; Wang, X.; Han, W.; Lou, G.; Wang, X.; Lou, F.; Yen, Y.; Yu, H.; Jove, R.; Huang, W.			miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis	ONCOGENE			English	Article						miR-26a; Zcchc11; let-7; miRNA biogenesis; tumorigenesis; metastasis	MICRORNA EXPRESSION; LET-7; TRANSFORMATION; PROLIFERATION; TUMORIGENESIS; MATURATION; REGULATOR; BLOCKADE; ABSENCE; HMGA2	Human cancers often exhibit attenuated microRNA (miRNA) biogenesis and global underexpression of miRNAs; thus, targeting the miRNA biogenesis pathway represents a novel strategy for cancer therapy. Here, we report that miR-26a enhances miRNA biogenesis, which acts as a common mechanism partially accounting for miR-26a function in diverse cancers including melanoma, prostate and liver cancer. miR-26a was broadly reduced in multiple cancers, and overexpression of miR-26a significantly suppressed tumor growth and metastasis both in vitro and in vivo, including melanoma, prostate and liver cancers. Notably, miR-26a overexpression was accompanied by global upregulation of miRNAs, especially let-7, and let-7 expression was concordant with miR-26a expression in cancer cell lines, xenograft tumors and normal human tissues, underscoring their biological relevance. We showed that miR-26a directly targeted Lin28B and Zcchc11-two critical repressors of let-7 maturation. Furthermore, we have demonstrated that Zcchc11 promoted tumor growth and metastasis, and it was prominently overexpressed in human cancers. Our findings thus provide a novel mechanism by which a miRNA acts as a modulator of miRNA biogenesis. These results also define a role of the miR-26a and Zcchc11 in tumorigenesis and metastasis and have implications to develop new strategies for cancer therapy.	[Fu, X.; Meng, Z.; Wang, X.; Han, W.; Lou, G.; Wang, X.; Lou, F.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Diabet Res, Dept Diabet & Metab Dis Res, Duarte, CA 91010 USA; [Meng, Z.; Yen, Y.; Yu, H.; Jove, R.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA; [Liang, W.; Tian, Y.; Jove, R.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Yen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA; [Yu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Immunotherapy & Tumor Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Diabet Res, Dept Diabet & Metab Dis Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.	whuang@coh.org	Yen, Yun/H-9591-2016	YU, Hua/0000-0003-0931-1000; Fu, Xianghui/0000-0001-9808-3892	National Cancer Institute [P30 CA033572]; American Cancer Society [RSG-11-132-01-CCE]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA139158] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Arthur Riggs and Rama Natarajan for reviewing the manuscript, Dr Kyle Sousa and other members of the Huang laboratory for their helpful discussions and Dr Keely Walker for editing the manuscript. This work was supported by the National Cancer Institute (P30 CA033572) and the American Cancer Society (RSG-11-132-01-CCE).	Blahna MT, 2011, J BIOL CHEM, V286, P42381, DOI 10.1074/jbc.M111.259689; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Hammond SM, 2008, CELL, V135, P1013, DOI 10.1016/j.cell.2008.11.026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Newman MA, 2010, INT J BIOCHEM CELL B, V42, P1330, DOI 10.1016/j.biocel.2009.02.023; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Ravi A, 2012, CANCER CELL, V21, P848, DOI 10.1016/j.ccr.2012.04.037; Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Talmadge JE, 2010, METHODS MOL BIOL, V602, P215, DOI 10.1007/978-1-60761-058-8_13; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078; Yuan J, 2012, SCIENCE, V335, P1195, DOI 10.1126/science.1216557; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	46	93	97	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4296	4306		10.1038/onc.2013.385	http://dx.doi.org/10.1038/onc.2013.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24056962	Green Accepted			2022-12-17	WOS:000341156900003
J	Serres, E; Debarbieux, F; Stanchi, F; Maggiorella, L; Grall, D; Turchi, L; Burel-Vandenbos, F; Figarella-Branger, D; Virolle, T; Rougon, G; Van Obberghen-Schilling, E				Serres, E.; Debarbieux, F.; Stanchi, F.; Maggiorella, L.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Figarella-Branger, D.; Virolle, T.; Rougon, G.; Van Obberghen-Schilling, E.			Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice	ONCOGENE			English	Article						extracellular matrix; adhesion; glioma; migration; angiogenesis	EXTRACELLULAR-MATRIX COMPONENTS; STEM-LIKE CELLS; VASCULOGENIC MIMICRY; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MALIGNANT GLIOMAS; ASTROCYTOMA; VIVO; ALPHA-5-BETA-1; SPHEROIDS	Glioblastoma multiforme (GBM) are highly invasive and angiogenic malignancies with a median survival time from diagnosis of <15 months. Previous work has revealed robust overexpression of fibronectin (FN) mRNA in GBM, although immunohistochemical staining of FN in these tumors is typically associated with the angiogenic vasculature. Here we sought to examine the expression of tumor cell FN and address its possible involvement in the invasive phenotype of GBM. We found that FN was expressed and assembled into fibrillar arrays in human tumors and in established GBM lines. Cultured cells spontaneously formed dense cellular networks and spheroid-like domes. Depletion of FN by targeted-short hairpin RNA expression disrupted matrix assembly and multicellular network organization by exerting profound effects on cell adhesion and motility. Although FN depletion enhanced persistent directional migration of single cells, it compromised collective invasion of spheroids through a laminin-rich matrix and sensitized cells to ionizing radiation. In orthotopic grafts, FN depletion significantly reduced tumor growth and angiogenesis. Together our results show that FN produced by the tumor cells has a role in GBM pathophysiology and they provide insights into the implications that targeting FN interactions may have for combating this dreaded disease.	[Serres, E.; Maggiorella, L.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Virolle, T.; Van Obberghen-Schilling, E.] Univ Nice Sophia Antipolis, F-06108 Nice 2, France; [Serres, E.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Virolle, T.; Van Obberghen-Schilling, E.] Fac Med Nice, INSERM, Inst Biol Valrose, CNRS,UMR7277,U1091, F-06034 Nice, France; [Debarbieux, F.; Stanchi, F.; Rougon, G.] Aix Marseille Univ, IBDML, CNRS, UMR7288, Marseille, France; [Burel-Vandenbos, F.] CHU Nice, Hop Pasteur, Serv Anatomopathol, F-06202 Nice, France; [Figarella-Branger, D.] Aix Marseille Univ, INSERM, UMR911, Marseille, France	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Van Obberghen-Schilling, E (corresponding author), Univ Nice Sophia Antipolis, CNRS, IBV, UMR7277,INSERM,U1091,UNS, Parc Valrose, F-06108 Nice 2, France.	vanobber@unice.fr	Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016; Virolle, Thierry/E-5838-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Turchi, Laurent/0000-0003-2020-5831; ROUGON, Genevieve/0000-0003-1316-8200; Stanchi, Fabio/0000-0003-3393-2472	French National Institute of Cancer (INCa) [RS018]; French Association of Cancer Research (ARC) [4965, 5095]; National Agency for Research (JCC PathoVisu3dyn); Fondation de Recherche sur le Cerveau; Canceropole PACA; l'Agence Nationale pour la Recherche (ANR, Jeunes Chercheurs, 'GLIOMIRSTEM')	French National Institute of Cancer (INCa)(Institut National du Cancer (INCA) France); French Association of Cancer Research (ARC); National Agency for Research (JCC PathoVisu3dyn)(French National Research Agency (ANR)); Fondation de Recherche sur le Cerveau; Canceropole PACA(Region Grand-Est); l'Agence Nationale pour la Recherche (ANR, Jeunes Chercheurs, 'GLIOMIRSTEM')(French National Research Agency (ANR))	We thank Jean-Francois Michiels and Philippe Paquis (Pathology and Neurosurgery Departments of the Nice CHU) for their collaboration. We also thank Botond Cseh, Nathalie Baeza-Kallee, Clement Ricard, Sandeep Gopal and Juliette Thariat for valuable discussions, cell lines, help with intracranial xenograft experiments and statistical analyses. Patrick Stern and Richard Hynes are kindly acknowledged for providing the lentiviral vector, Aurelie Rossin for assistance with cytometry, Sebastien Schaub (PRISM Platform, CNRS-UMR6543) and the PICSIL Platform (CNRS-6216) for expert help with image analyses. Serge Marcie and Jean-Louis Fischel (Centre A. Lacassagnc) are gratefully acknowledged for helping with irradiation experiments, and Arnaud Borderie, Sandrine Destree, Coralie Hagnere et Berengere Szczepaniak for immunohistochemistry. Financial support for this work was provided by the French National Institute of Cancer (INCa, RS018), the French Association of Cancer Research (ARC 4965 to EVO-S and 5095 to GB), the National Agency for Research (JCC PathoVisu3dyn to FD), la Fondation de Recherche sur le Cerveau to FD, Canceropole PACA and l'Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, 'GLIOMIRSTEM' to TV).	Argyriou AA, 2009, CRIT REV ONCOL HEMAT, V69, P199, DOI 10.1016/j.critrevonc.2008.05.005; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; BERNSTEIN JJ, 1995, NEUROSURGERY, V36, P124, DOI 10.1227/00006123-199501000-00016; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Burden-Gulley SM, CANC RES, V71, P5932; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Claes A, 2007, ACTA NEUROPATHOL, V114, P443, DOI 10.1007/s00401-007-0293-7; Colin C, 2006, ONCOGENE, V25, P2818, DOI 10.1038/sj.onc.1209305; Cseh B, 2010, J CELL SCI, V123, P3989, DOI 10.1242/jcs.073346; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Farber K, 2008, MOL CELL NEUROSCI, V39, P579, DOI 10.1016/j.mcn.2008.08.005; Friedlander DR, 1996, CANCER RES, V56, P1939; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; Lal A, 1999, CANCER RES, V59, P5403; Maglott A, 2006, CANCER RES, V66, P6002, DOI 10.1158/0008-5472.CAN-05-4105; Mahesparan R, 2003, ACTA NEUROPATHOL, V105, P49, DOI 10.1007/s00401-002-0610-0; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinkova E, 2010, INT J CANCER, V127, P1240, DOI 10.1002/ijc.25187; Maubant S, 2006, BLOOD, V108, P3035, DOI 10.1182/blood-2006-05-023580; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Ohnishi T, 1997, CLIN EXP METASTAS, V15, P538, DOI 10.1023/A:1018422926361; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Ricard C, 2013, PLOS ONE IN PRESS; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Salmenpera P, 2008, EXP CELL RES, V314, P3444, DOI 10.1016/j.yexcr.2008.09.004; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Spencer VA, 2010, J MAMMARY GLAND BIOL, V15, P65, DOI 10.1007/s10911-010-9163-3; Stern P, 2008, P NATL ACAD SCI USA, V105, P13895, DOI 10.1073/pnas.0806907105; Tabatabai G, 2010, TARGET ONCOL, V5, P175, DOI 10.1007/s11523-010-0156-3; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zamecnik J, 2005, ACTA NEUROPATHOL, V110, P435, DOI 10.1007/s00401-005-1078-5	44	93	93	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3451	3462		10.1038/onc.2013.305	http://dx.doi.org/10.1038/onc.2013.305			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912459				2022-12-17	WOS:000338779300012
J	Henkels, KM; Boivin, GP; Dudley, ES; Berberich, SJ; Gomez-Cambronero, J				Henkels, K. M.; Boivin, G. P.; Dudley, E. S.; Berberich, S. J.; Gomez-Cambronero, J.			Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model	ONCOGENE			English	Article						cell signaling; human breast cancer; PLD; cell invasion and metastasis; SCID mice; xenotransplant	PHOSPHATIDIC-ACID; OVEREXPRESSION; EXPRESSION; KINASE; TRANSFORMATION; INHIBITORS; MIGRATION; INSIGHTS; SURVIVAL; PROTEIN	Breast cancer is one of the most common malignancies in human females in the world. One protein that has elevated enzymatic lipase activity in breast cancers in vitro is phospholipase D (PLD), which is also involved in cell migration. We demonstrate that the PLD2 isoform, which was analyzed directly in the tumors, is crucial for cell invasion that contributes critically to the growth and development of breast tumors and lung metastases in vivo. We used three complementary strategies in a SCID mouse model and also addressed the underlying molecular mechanism. First, the PLD2 gene was silenced in highly metastatic, aggressive breast cancer cells (MDA-MB-231) with lentivirus-based short hairpin RNA, which were xenotransplanted in SCID mice. The resulting mouse primary mammary tumors were reduced in size (65%, P<0.05) and their onset delayed when compared with control tumors. Second, we stably overexpressed PLD2 in low-invasive breast cancer cells (MCF-7) with a biscistronic MIEG retroviral vector and observed that these cells were converted into a highly aggressive phenotype, as primary tumors that formed following xenotransplantation were larger, grew faster and developed lung metastases more readily. Third, we implanted osmotic pumps into SCID xenotransplanted mice that delivered two different small-molecule inhibitors of PLD activity (5-fluoro-2-indolyl deschlorohalopemide and N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide). These inhibitors led to significant (>70%, P<0.05) inhibition of primary tumor growth, metastatic axillary tumors and lung metastases. In order to define the underlying mechanism, we determined that the machinery of PLD-induced cell invasion is mediated by phosphatidic acid, Wiscott-Aldrich Syndrome protein, growth receptor-bound protein 2 and Rac2 signaling events that ultimately affect actin polymerization and cell invasion. In summary, this study shows for the first time that PLD2 has a central role in the development, metastasis and level of aggressiveness of breast cancer, raising the possibility that PLD2 could be used as a new therapeutic target.	[Henkels, K. M.; Berberich, S. J.; Gomez-Cambronero, J.] Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA; [Boivin, G. P.; Dudley, E. S.] Wright State Univ, Sch Med, Lab Anim Resources, Dayton, OH 45435 USA; [Boivin, G. P.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Gomez-Cambronero, J (corresponding author), Wright State Univ, Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.	julian.cambronero@wright.edu		Gomez-Cambronero, Julian/0000-0002-7581-9227	National Institutes of Health (NIH/NHBLI) [HL056653]; Wright State University Boonshoft School of Medicine [229102]; State of Ohio Research Incentive [668372]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056653, R29HL056653] Funding Source: NIH RePORTER	National Institutes of Health (NIH/NHBLI); Wright State University Boonshoft School of Medicine; State of Ohio Research Incentive; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work has been supported by grant HL056653 from the National Institutes of Health (NIH/NHBLI) to JGC and from grants 229102 from Wright State University Boonshoft School of Medicine, and 668372 from the State of Ohio Research Incentive, also to JGC. We thank Dr Mary C Dinauer and Christophe Marchal for their help generating the pMIEG-PLD vectors and Dr Michael Frohman for providing the PA sensor and to Dr Frohman and to Dr H Alex Brown for guidance in the use of inhibitors. We also thank Dr Cambronero's lab members Qing Ye, Sam Kantonen, Madhu Mahankali, Nate Hatton and Ramya Ganesan, for their excellent help and care with the mice studies.	Benson JR, 2012, FUTURE ONCOL, V8, P697, DOI [10.2217/FON.12.61, 10.2217/fon.12.61]; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cho JH, 2008, BBA-MOL CELL RES, V1783, P912, DOI 10.1016/j.bbamcr.2007.11.019; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Foster DA, 2003, MOL CANCER RES, V1, P789; Frondorf K, 2010, J BIOL CHEM, V285, P15837, DOI 10.1074/jbc.M109.070524; Gomez-Cambronero J, 2004, LEUKEMIA RES, V28, P755, DOI 10.1016/j.leukres.2003.11.012; Gomez-Cambronero J, 2012, J LEUKOCYTE BIOL, V92, P461, DOI 10.1189/jlb.0212073; Gomez-Cambronero J, 2010, THESCIENTIFICWORLDJO, V10, P1356, DOI 10.1100/tsw.2010.116; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henkels KM, 2013, CELL SIGNAL, V25, P198, DOI 10.1016/j.cellsig.2012.08.010; Henkels KM, 2011, J MOL BIOL, V408, P850, DOI 10.1016/j.jmb.2011.03.017; Henkels KM, 2010, MOL CELL BIOL, V30, P2251, DOI 10.1128/MCB.01239-09; Itoh T, 2009, SCI SIGNAL; Jang JH, 2012, PROG LIPID RES, V51, P71, DOI 10.1016/j.plipres.2011.12.003; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kang DW, 2010, CANCER LETT, V294, P125, DOI 10.1016/j.canlet.2010.01.031; Kantonen S, 2011, MOL CELL BIOL, V31, P4524, DOI 10.1128/MCB.05684-11; Knapek K, 2010, MOL CELL BIOL, V30, P4492, DOI 10.1128/MCB.00229-10; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Mahankali M, 2011, CELL SIGNAL, V23, P1291, DOI 10.1016/j.cellsig.2011.03.010; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Monovich L, 2007, BIOORG MED CHEM LETT, V17, P2310, DOI 10.1016/j.bmcl.2007.01.059; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Neiman AM, 2000, GENETICS, V155, P1643; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Nielsen SE, 1999, BRIT J NUTR, V81, P447, DOI 10.1017/S000711459900080X; Nishikimi A, 2009, SCIENCE, V324, P384, DOI 10.1126/science.1170179; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Park MH, 2009, CARCINOGENESIS, V30, P356, DOI 10.1093/carcin/bgn287; Peng HJ, 2011, MOL CELL BIOL, V31, P2227, DOI 10.1128/MCB.01348-10; Peng HJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.206672; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Riebeling C, 2003, MELANOMA RES, V13, P555, DOI 10.1097/00008390-200312000-00003; Sanematsu F, 2013, J BIOL CHEM, V288, P8092, DOI 10.1074/jbc.M112.410423; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311; Shen YJ, 2002, BIOCHEM BIOPH RES CO, V293, P201, DOI 10.1016/S0006-291X(02)00204-8; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Stasinopoulos I, 2007, MOL CANCER RES, V5, P435, DOI 10.1158/1541-7786.MCR-07-0010; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Su WJ, 2009, FUTURE ONCOL, V5, P1477, DOI [10.2217/fon.09.110, 10.2217/FON.09.110]; Su W, 2009, MOL PHARMACOL, V75, P437, DOI 10.1124/mol.108.053298; Taves J, 2008, ARCH BIOCHEM BIOPHYS, V477, P60, DOI 10.1016/j.abb.2008.05.007; Tsukahara T, 2010, MOL CELL, V39, P421, DOI 10.1016/j.molcel.2010.07.022; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Yamada Y, 2003, J MOL MED, V81, P126, DOI 10.1007/s00109-002-0411-x; You JC, 2009, ENDOCRINOLOGY, V150, P1607, DOI 10.1210/en.2008-0616; Zeniou-Meyer M, 2007, J BIOL CHEM, V282, P21746, DOI 10.1074/jbc.M702968200; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zouwail S, 2005, BIOCHEM J, V389, P207, DOI 10.1042/BJ20050085	61	93	97	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5551	5562		10.1038/onc.2013.207	http://dx.doi.org/10.1038/onc.2013.207			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23752189	Green Accepted, hybrid			2022-12-17	WOS:000328276400006
J	Sankar, S; Bell, R; Stephens, B; Zhuo, R; Sharma, S; Bearss, DJ; Lessnick, SL				Sankar, S.; Bell, R.; Stephens, B.; Zhuo, R.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.			Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; EWS/FLI; NuRD; transcription; repression	PEDIATRIC SOLID TUMORS; DNA-BINDING; RESPONSE ELEMENTS; PROTEIN-PROTEIN; FUSION GENE; EXPRESSION; REVEALS; TARGET; CELLS; TRANSFORMATION	Ewing sarcoma provides an important model for transcription-factor-mediated oncogenic transformation because of its reliance on the ETS-type fusion oncoprotein EWS/FLI. EWS/FLI functions as a transcriptional activator and transcriptional activation is required for its oncogenic activity. Here, we demonstrate that a previously less-well characterized transcriptional repressive function of the EWS/FLI fusion is also required for the transformed phenotype of Ewing sarcoma. Through comparison of EWS/FLI transcriptional profiling and genome-wide localization data, we define the complement of EWS/FLI direct downregulated target genes. We demonstrate that LOX is a previously undescribed EWS/FLI-repressed target that inhibits the transformed phenotype of Ewing sarcoma cells. Mechanistic studies demonstrate that the NuRD co-repressor complex interacts with EWS/FLI, and that its associated histone deacetylase and LSD1 activities contribute to the repressive function. Taken together, these data reveal a previously unknown molecular function for EWS/FLI, demonstrate a more highly coordinated oncogenic transcriptional hierarchy mediated by EWS/FLI than previously suspected, and implicate a new paradigm for therapeutic intervention aimed at controlling NuRD activity in Ewing sarcoma tumors.	[Sankar, S.; Stephens, B.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.] Huntsman Canc Inst, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Bell, R.; Zhuo, R.; Lessnick, S. L.] Huntsman Canc Inst, Ctr Childrens Canc Res, Salt Lake City, UT 84112 USA; [Stephens, B.; Bearss, D. J.] Huntsman Canc Inst, Ctr Invest Therapeut, Salt Lake City, UT 84112 USA; [Sharma, S.] Univ Utah, Sch Med, Div Med Oncol, Salt Lake City, UT USA; [Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT USA	Huntsman Cancer Institute; Huntsman Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Huntsman Canc Inst, Ctr Childrens Canc Res, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu	SANKAR, SAVITA/R-6821-2017; Bearss, David/Q-9141-2019	Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	HHMI Med into Grad program at the University of Utah (U2M2G); NIH/NCI [R01 CA140394, P30 CA042014]; Huntsman Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA140394, P30CA042014] Funding Source: NIH RePORTER	HHMI Med into Grad program at the University of Utah (U2M2G); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Huntsman Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Cairns, Engel and Bhaskara for discussions and critical reading of this manuscript and members of the Lessnick laboratory, and Drs Denny and Ayer, for discussions and reagents. SS acknowledges support from the HHMI Med into Grad program at the University of Utah (U2M2G). This work was supported by NIH/NCI Grants R01 CA140394 (to SLL) and P30 CA042014 (to Huntsman Cancer Institute) and funding from Imaging Diagnostics and Therapeutics Program at Huntsman Cancer Institute (to Sunil Sharma).	Arvand A, 2001, CANCER RES, V61, P5311; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Jaboin J, 2002, CANCER RES, V62, P6108; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Keshelava N, 2009, PEDIATR BLOOD CANCER, V53, P505, DOI 10.1002/pbc.21988; Kim J, 2009, NAT PROTOC, V4, P506, DOI 10.1038/nprot.2009.23; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ramakrishnan R, 2004, ONCOGENE, V23, P7087, DOI 10.1038/sj.onc.1207927; Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050	34	93	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5089	5100		10.1038/onc.2012.525	http://dx.doi.org/10.1038/onc.2012.525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178492	Green Accepted			2022-12-17	WOS:000325937900010
J	Su, SF; Chang, YW; Andreu-Vieyra, C; Fang, JY; Yang, Z; Han, B; Lee, AS; Liang, G				Su, S-F; Chang, Y-W; Andreu-Vieyra, C.; Fang, J. Y.; Yang, Z.; Han, B.; Lee, A. S.; Liang, G.			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer	ONCOGENE			English	Article						microRNA; GRP78; apoptosis; drug resistance; anti-cancer therapy	UNFOLDED PROTEIN RESPONSE; NEGATIVE REGULATION; PROSTATE-CANCER; DOWN-REGULATION; TUMOR-GROWTH; MICRORNAS; STRESS; TARGET; GENES; EXPRESSION	GRP78, a major endoplasmic reticulum chaperone and signaling regulator, is commonly overexpressed in cancer. Moreover, induction of GRP78 by a variety of anti-cancer drugs, including histone deacetylase inhibitors, confers chemoresistance to cancer, thereby contributing to tumorigenesis. Thus, therapies aimed at decreasing GRP78 levels, which results in the inhibition of tumor cell proliferation and resensitization of tumor cells to chemotherapeutic drugs may hold promise for cancer treatment. Despite advances in our understanding of GRP78 actions, little is known about endogenous inhibitors controlling its expression. As endogenous regulators, microRNAs (miRNAs) play important roles in modulating gene expression; therefore, we sought to identify miRNA(s) that target GRP78, under the hypothesis that these miRNAs may serve as therapeutic agents. Here, we report that three miRNAs (miR-30d, miR-181a, miR-199a-5p) predicted to target GRP78 are down-regulated in prostate, colon and bladder tumors, and human cancer cell lines. We show that in C42B prostate cancer cells, these miRNAs down-regulate GRP78 and induce apoptosis by directly targeting its 3' untranslated region. Importantly, we demonstrate that the three miRNAs act cooperatively to decrease GRP78 levels, suggesting that multiple miRNAs may be required to efficiently control the expression of some genes. In addition, delivery of multiple miRNAs by either transient transfection or lentivirus transduction increased the sensitivity of cancer cells to the histone deacetylase inhibitor, trichostatin A, in C42B, HCT116 and HL-60 cells. Together, our results indicate that the delivery of co-transcribed miRNAs can efficiently suppress GRP78 levels and GRP78-mediated chemoresistance, and suggest that this strategy holds therapeutic potential.	[Su, S-F; Chang, Y-W; Andreu-Vieyra, C.; Liang, G.] Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; [Su, S-F] Program Genet Mol & Cellular Biol, Los Angeles, CA USA; [Chang, Y-W; Lee, A. S.] Dept Biochem & Mol Biol, Los Angeles, CA USA; [Fang, J. Y.; Yang, Z.; Han, B.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Liang, G (corresponding author), Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Urol, NOR7338,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	gliang@usc.edu	Su, Sheng-Fang/AAT-3642-2021; Fang, Josephine/AAS-5996-2020	Su, Sheng-Fang/0000-0002-1624-5745; Liang, Gangning/0000-0001-8664-922X; Lee, Amy/0000-0002-0378-5443	NCI [RO1 CA138794, RO1 CA027607]; NATIONAL CANCER INSTITUTE [R01CA027607, R01CA138794] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr PA Jones for supporting this work; Dr KT Pfaffenbach for the experimental suggestions; Drs J Zhou and Q Li for data analysis; Drs TK Kelly for careful reading of the manuscript; Ms K Pandiyan and Mr C Duymich for the overview. This work was supported by NCI Grants (RO1 CA138794, GL, RO1 CA027607, ASL).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Backer MV, 2011, METHOD ENZYMOL, V491, P37, DOI 10.1016/B978-0-12-385928-0.00003-1; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baumeister P, 2009, MOL CANCER THER, V8, P1086, DOI 10.1158/1535-7163.MCT-08-1166; Booth L, 2012, CANCER BIOL THER, V13, P224, DOI 10.4161/cbt.13.4.18877; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Duan QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031518; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grkovic S, 2013, ONCOGENE, V32, P2412, DOI 10.1038/onc.2012.264; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Kahali S, 2012, FASEB J, V26, P2437, DOI 10.1096/fj.11-193706; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kumar M, 2011, ONCOGENE, V30, P843, DOI 10.1038/onc.2010.457; Kuwahara K, 2010, TISSUE ENG PART C-ME, V16, P609, DOI 10.1089/ten.TEC.2009.0406; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Marasa BS, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000442; Mavrakis KJ, 2011, CELL CYCLE, V10, P2845, DOI 10.4161/cc.10.17.16959; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Qiu XN, 2011, BIOCHEM BIOPH RES CO, V411, P276, DOI 10.1016/j.bbrc.2011.06.123; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roue G, 2011, BLOOD, V117, P1270, DOI 10.1182/blood-2010-04-278853; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shen QL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-227; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Yeung BHY, 2008, ONCOGENE, V27, P6782, DOI 10.1038/onc.2008.290; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647	53	93	103	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4694	4701		10.1038/onc.2012.483	http://dx.doi.org/10.1038/onc.2012.483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085757	Green Published, hybrid			2022-12-17	WOS:000325072200011
J	Wang, Q; Xia, N; Li, T; Xu, Y; Zou, Y; Zuo, Y; Fan, Q; Bawa-Khalfe, T; Yeh, ETH; Cheng, J				Wang, Q.; Xia, N.; Li, T.; Xu, Y.; Zou, Y.; Zuo, Y.; Fan, Q.; Bawa-Khalfe, T.; Yeh, E. T. H.; Cheng, J.			SUMO-specific protease 1 promotes prostate cancer progression and metastasis	ONCOGENE			English	Article						SENP1; MMP; HIF1 alpha; prostate cancer; metastasis	MATRIX METALLOPROTEINASE-2; ANDROGEN RECEPTOR; EXPRESSION; DESUMOYLATION; TRANSCRIPTION; SUMOYLATION; HYPOXIA; SENP1; CELLS; ANGIOGENESIS	SUMO-specific protease 1 (SENP1) is a member of de-SUMOylation protease family and has an important role in the regulation of androgen receptor-dependent transcription and hypoxia signaling. This activity profile of SENP1 prompted us to investigate whether SENP1 is involved in the pathogenesis of prostate cancer. In previous studies, we have detected the overexpression of SENP1 in both precancerous prostate intraepithelial neoplasia (PIN) lesions and prostate cancer tissue samples from patients. Whereas our whole-animal model has demonstrated that SENP1 induction is critical for prostate cell transformation, the role of SENP1 in prostate cancer progression is still unknown. In this study, we show that SENP1 expression directly correlates with prostate cancer aggressiveness and reccurrence, by analyzing more than 150 prostate cancer specimens. Modulating SENP1 level dictates colony formation of prostate cancer cell lines, tumor growth in nude mice and also prostate cancer cell migration and invasion. Silencing SENP1 level in highly metastatic prostate cancer cells perturbs their ability to metastasize to the bone and initiates secondary tumors. Mechanistically, the expression of two critical bone remodeling proteins, matrix metalloproteinase 2 (MMP2) and MMP9, is regulated by SENP1 through the HIF1 alpha signaling pathway. All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.	[Wang, Q.; Xia, N.; Xu, Y.; Zou, Y.; Zuo, Y.; Fan, Q.; Cheng, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China; [Wang, Q.; Xia, N.; Zou, Y.; Zuo, Y.; Fan, Q.; Cheng, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200025, Peoples R China; [Li, T.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Rui Jin Hosp, Shanghai 200025, Peoples R China; [Bawa-Khalfe, T.; Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; [Yeh, E. T. H.; Cheng, J.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Texas System; UTMD Anderson Cancer Center; Saint Lukes Episcopal Hospital; Texas Heart Institute	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, 280 Chongqing South Rd, Shanghai 200025, Peoples R China.	jkcheng@shsmu.edu.cn	Xia, Nan/ABG-4600-2021		National Natural Science Foundation of China [81071665, 30900740]; National Basic Research Program of China (973 Program) [2010CB912104]; Shanghai Committee of Science and Technology [10140902000, 10410700900, 11XD1403200, 11DZ2260200]; United States Department of Defense [PC060932]; NIH [CA 239520]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); United States Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr E Benveniste (The University of Alabama at Birmingham) for the MMP2-Luc plasmid. This work was supported in part by National Natural Science Foundation of China (81071665 to JC, 30900740 to YZ), National Basic Research Program of China (973 Program) (2010CB912104 to JC), Shanghai Committee of Science and Technology (10140902000, 10410700900, 11XD1403200 to JC, 11DZ2260200), United States Department of Defense Grants (PC060932 to JC) and NIH (CA 239520 to ETHY). ETHY is the McNair Scholar of the Texas Heart Institute/St Luke's Episcopal Hospital.	Bawa-Khalfe T, 2007, J BIOL CHEM, V282, P37341, DOI 10.1074/jbc.M706978200; Bawa-Khalfe T, 2010, J BIOL CHEM, V285, P25859, DOI 10.1074/jbc.M110.134874; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cheng JK, 2006, NEOPLASIA, V8, P667, DOI 10.1593/neo.06445; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Gohji K, 1998, INT J CANCER, V79, P96, DOI 10.1002/(SICI)1097-0215(19980220)79:1<96::AID-IJC18>3.0.CO;2-F; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Kaikkonen S, 2009, MOL ENDOCRINOL, V23, P292, DOI 10.1210/me.2008-0219; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2006, NAT CELL BIOL, V8, P631, DOI 10.1038/ncb1415; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Sehgal G, 1998, AM J PATHOL, V152, P591; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Stearns M, 1996, ONCOL RES, V8, P69; Trudel D, 2003, CANCER RES, V63, P8511; Xu Y, 2010, J BIOL CHEM, V285, P36682, DOI 10.1074/jbc.M110.164236; Yamaguchi T, 2005, MOL CELL BIOL, V25, P5171, DOI 10.1128/MCB.25.12.5171-5182.2005; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yu LY, 2010, J EXP MED, V207, P1183, DOI 10.1084/jem.20092215; Zhou LX, 2010, ASIAN J ANDROL, V12, P171, DOI 10.1038/aja.2009.81	23	93	105	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2493	2498		10.1038/onc.2012.250	http://dx.doi.org/10.1038/onc.2012.250			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733136				2022-12-17	WOS:000318694900013
J	Xie, C; Jiang, XH; Zhang, JT; Sun, TT; Dong, JD; Sanders, AJ; Diao, RY; Wang, Y; Fok, KL; Tsang, LL; Yu, MK; Zhang, XH; Chung, YW; Ye, L; Zhao, MY; Guo, JH; Xiao, ZJ; Lan, HY; Ng, CF; Lau, KM; Cai, ZM; Jiang, WG; Chan, HC				Xie, C.; Jiang, X. H.; Zhang, J. T.; Sun, T. T.; Dong, J. D.; Sanders, A. J.; Diao, R. Y.; Wang, Y.; Fok, K. L.; Tsang, L. L.; Yu, M. K.; Zhang, X. H.; Chung, Y. W.; Ye, L.; Zhao, M. Y.; Guo, J. H.; Xiao, Z. J.; Lan, H. Y.; Ng, C. F.; Lau, K. M.; Cai, Z. M.; Jiang, W. G.; Chan, H. C.			CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer	ONCOGENE			English	Article						CFTR; miR-193b; uPA	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; NF-KAPPA-B; MESENCHYMAL TRANSITION; MUC4 EXPRESSION; CELL MIGRATION; MIR-200 FAMILY; BREAST-CANCER; RISK; METHYLATION	Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in the epithelial cells of a wide range of organs/tissues from which most cancers are derived. Although accumulating reports have indicated the association of cancer incidence with genetic variations in CFTR gene, the exact role of CFTR in cancer development and the possible underlying mechanism have not been elucidated. Here, we report that CFTR expression is significantly decreased in both prostate cancer cell lines and human prostate cancer tissue samples. Overexpression of CFTR in prostate cancer cell lines suppresses tumor progression (cell growth, adhesion and migration), whereas knockdown of CFTR leads to enhanced malignancies both in vitro and in vivo. In addition, we demonstrate that CFTR knockdown-enhanced cell proliferation, cell invasion and migration are significantly reversed by antibodies against either urokinase plasminogen activator (uPA) or uPA receptor (uPAR), which are known to be involved in various malignant traits of cancer development. More interestingly, overexpression of CFTR suppresses uPA by upregulating the recently described tumor suppressor microRNA-193b (miR-193b), and overexpression of pre-miR-193b significantly reverses CFTR knockdown-enhanced malignant phenotype and abrogates elevated uPA activity in prostate cancer cell line. Finally, we show that CFTR gene transfer results in significant tumor repression in prostate cancer xenografts in vivo. Taken together, the present study has demonstrated a previously undefined tumor-suppressing role of CFTR and its involvement in regulation of miR-193b in prostate cancer development.	[Xie, C.; Jiang, X. H.; Zhang, J. T.; Sun, T. T.; Dong, J. D.; Diao, R. Y.; Wang, Y.; Fok, K. L.; Tsang, L. L.; Yu, M. K.; Zhang, X. H.; Chung, Y. W.; Zhao, M. Y.; Guo, J. H.; Xiao, Z. J.; Chan, H. C.] Chinese Univ Hong Kong, Sch Biomed Sci, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; [Jiang, X. H.; Chan, H. C.] Chinese Univ Hong Kong, Minist Educ Peoples Republ China, Key Lab Regenerat Med, Jinan Univ, Guangzhou, Guangdong, Peoples R China; [Sanders, A. J.; Ye, L.; Jiang, W. G.] Cardiff Univ, Sch Med, Metastasis & Angiogenesis Res Grp, Dept Surg, Cardiff CF10 3AX, S Glam, Wales; [Diao, R. Y.; Cai, Z. M.] Peking Univ, Shenzhen Hosp, Shenzhen Key Lab Male Reprod Med & Genet, Shenzhen, Peoples R China; [Lan, H. Y.] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Ng, C. F.] Chinese Univ Hong Kong, Div Urol, Dept Surg, Shatin, Hong Kong, Peoples R China; [Lau, K. M.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Chan, H. C.] Sichuan Univ, Chinese Univ Hong Kong, West China Second Univ Hosp, Joint Lab Reprod Med, Chengdu 610064, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Ministry of Education, China; Cardiff University; Peking University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Sichuan University	Jiang, WG (corresponding author), Cardiff Univ, Sch Med, Metastasis & Angiogenesis Res Grp, Dept Surg, Cardiff CF10 3AX, S Glam, Wales.	jiangw@cf.ac.uk; hsiaocchan@cuhk.edu.hk	jiang, cynthia xiaohua/F-7580-2017; Fok, Kin Lam/G-2757-2017; jiang, wen/GYI-9662-2022; Dong, Jianda/C-3338-2018; Jiang, Wen G/B-1293-2010; Jiang, Wen G./AAF-1876-2020; Fok, Ellis/M-2784-2019; Ng, Chi-Fai/E-5134-2011; Lan, Hui Yao/C-9734-2015; Sun, Tung-Tien/J-4425-2015; Chi-fai, NG/AAV-8270-2021; Chan, Hsiao Chang/E-1507-2016; Ye, Lin/G-9819-2016	jiang, cynthia xiaohua/0000-0002-7372-4961; Fok, Kin Lam/0000-0003-3038-1337; Dong, Jianda/0000-0001-5583-0210; Jiang, Wen G/0000-0002-3283-1111; Jiang, Wen G./0000-0002-3283-1111; Fok, Ellis/0000-0003-3038-1337; Ng, Chi-Fai/0000-0002-1723-9646; Lan, Hui Yao/0000-0003-4283-9755; Sun, Tung-Tien/0000-0002-6841-1063; Ye, Lin/0000-0002-0303-2409; Lau, Kin-Mang/0000-0001-5888-1937; Zhang, Xiaohu/0000-0002-5329-1599; Sanders, Andrew/0000-0002-7997-5286	Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project [2012CB944900]; Fundamental Research Funds for the Central Universities (JiNan University);  [GRF-CUHK466111]	Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project; Fundamental Research Funds for the Central Universities (JiNan University); 	The work was supported by the Focused Investment Scheme of the Chinese University of Hong Kong and National 973 project (2012CB944900), GRF-CUHK466111, and the Fundamental Research Funds for the Central Universities (JiNan University). We are grateful to Professor Tzyh-Chang Hwang at Department of Biological Engineering, University of Missouri-Columbia, USA for providing CFTR-peGFP-C3 and control plasmids. The authors thank Mrs Huang Xiao ru and Mr Qin Wei from Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, for their helpful technical assistance.	Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; Boncoeur E, 2008, AM J PATHOL, V172, P1184, DOI 10.2353/ajpath.2008.070310; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cozzi PJ, 2006, HUM PATHOL, V37, P1442, DOI 10.1016/j.humpath.2006.05.002; Cuthbert AW, 2011, BRIT J PHARMACOL, V163, P173, DOI 10.1111/j.1476-5381.2010.01137.x; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Ding S, 2004, WORLD J GASTROENTERO, V10, P3433; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hou CC, 2005, AM J PATHOL, V166, P761, DOI 10.1016/S0002-9440(10)62297-3; Hsing AW, 2006, FRONT BIOSCI-LANDMRK, V11, P1388, DOI 10.2741/1891; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumano M, 2009, UROL ONCOL-SEMIN ORI, V27, P180, DOI 10.1016/j.urolonc.2008.01.012; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Li Y, 2010, LUNG CANCER, V70, P14, DOI 10.1016/j.lungcan.2010.01.005; Malinowsky K, 2010, CURR MED CHEM, V17, P4370, DOI 10.2174/092986710793361216; McMahon B, 2007, PATHOPHYSIOL HAEMO T, V36, P184, DOI 10.1159/000175156; McWilliams RR, 2010, CANCER, V116, P203, DOI [10.1002/cncr.24697, 10.1002/cncr.25465]; McWilliams RR, 2005, CANCER, V104, P388, DOI 10.1002/cncr.21166; Mishra DK, 2010, MOL CANCER THER, V9, P33, DOI 10.1158/1535-7163.MCT-09-0486; Moribe T, 2009, INT J CANCER, V125, P388, DOI 10.1002/ijc.24394; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Padua RA, 1997, HUM MUTAT, V10, P45, DOI 10.1002/(SICI)1098-1004(1997)10:1<45::AID-HUMU6>3.3.CO;2-O; Qiao D, 2008, J CYST FIBROS, V7, P210, DOI 10.1016/j.jcf.2007.07.011; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sen R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000257; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Southey MC, 1998, INT J CANCER, V79, P487, DOI 10.1002/(SICI)1097-0215(19981023)79:5<487::AID-IJC7>3.3.CO;2-X; Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; Wiehe Melissa, 2010, AANA J, V78, P246; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	41	93	99	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2282	2291		10.1038/onc.2012.251	http://dx.doi.org/10.1038/onc.2012.251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22797075				2022-12-17	WOS:000318683600005
J	Alikhani, N; Ferguson, RD; Novosyadlyy, R; Gallagher, EJ; Scheinman, EJ; Yakar, S; LeRoith, D				Alikhani, N.; Ferguson, R. D.; Novosyadlyy, R.; Gallagher, E. J.; Scheinman, E. J.; Yakar, S.; LeRoith, D.			Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model	ONCOGENE			English	Article						dyslipidemia; mammary tumor; ApoE; metastasis; Akt	PROSTATE-CANCER CELLS; RICH LIPID RAFTS; BREAST-CANCER; CHOLESTEROL; PROGRESSION; INSULIN; RISK; MICE; SENSITIVITY; CARCINOMA	Dyslipidemia has been associated with an increased risk for developing cancer. However, the implicated mechanisms are largely unknown. To explore the role of dyslipidemia in breast cancer growth and metastasis, we used the apolipoprotein E (ApoE) knockout mice (ApoE(-/-)), which exhibit marked dyslipidemia, with elevated circulating cholesterol and triglyceride levels in the setting of normal glucose homeostasis and insulin sensitivity. Non-metastatic Met-1 and metastatic Mvt-1 mammary cancer cells derived from MM1V-PyVmT/FVB-N transgenic mice and c-Myc/vegf tumor explants respectively, were injected into the mammary fat pad of ApoE(-/-) and wild-type (WT) females consuming a high-fat/high-cholesterol diet and tumor growth was evaluated. ApoE(-/-) mice exhibited increased tumor growth and displayed a greater number of spontaneous metastases to the lungs. Furthermore, intravenous injection of Mvt-1 cells resulted in a greater number of pulmonary metastases in the lungs of ApoE(-/-) mice compared with WT controls. To unravel the molecular mechanism involved in enhanced tumor growth in ApoE(-/-) mice, we studied the response of Mvt-1 cells to cholesterol in vitro. We found that cholesterol increased Akt(S473) phosphorylation in Mvt-1 cells as well as cellular proliferation, whereas cholesterol depletion in the cell membrane abrogated Akt(S473) phosphorylation induced by exogenously added cholesterol. Furthermore, in vivo administration of BKM120, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K), alleviated dyslipidemia-induced tumor growth and metastasis in Mvt-1 model with a concomitant decrease in PI3K/Akt signaling. Collectively, we suggest that the hypercholesterolennic milieu in the ApoE(-/-) mice is a favorable setting for mammary tumor growth and metastasis. Oncogene (2013) 32, 961-967; doi:10.1038/onc.2012.113; published online 2 April 2012	[Alikhani, N.; Ferguson, R. D.; Novosyadlyy, R.; Gallagher, E. J.; Yakar, S.; LeRoith, D.] Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA; [Scheinman, E. J.; LeRoith, D.] CRIR, Diabet & Metab Clin Res Ctr Excellence, Haifa, Israel	Icahn School of Medicine at Mount Sinai; Rambam Health Care Campus	LeRoith, D (corresponding author), Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.	derek.leroith@mssm.edu			ADA mentor-based postdoctoral fellowship award [7-08-MN-33]; National Cancer Institute [RO1CA128799]; Israel Cancer Association; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER	ADA mentor-based postdoctoral fellowship award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by ADA mentor-based postdoctoral fellowship award 7-08-MN-33 and National Cancer Institute Grant RO1CA128799, both to DLR. We thank Novartis for providing us with BKM120 compound. In addition, partial support was from the Israel Cancer Association to DLR.	Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; ALEXOPOULOS CG, 1987, CANCER-AM CANCER SOC, V60, P3065, DOI 10.1002/1097-0142(19871215)60:12<3065::AID-CNCR2820601234>3.0.CO;2-Q; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Caldieri G, 2010, TRENDS CELL BIOL, V20, P64, DOI 10.1016/j.tcb.2009.10.006; Cauley JA, 2003, J WOMENS HEALTH, V12, P749, DOI 10.1089/154099903322447710; Chae YK, 2011, CANCER INVEST, V29, P585, DOI 10.3109/07357907.2011.616252; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dansky HM, 1999, ARTERIOSCL THROM VAS, V19, P1960, DOI 10.1161/01.ATV.19.8.1960; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; DeStefani E, 1997, NUTR CANCER, V29, P83, DOI 10.1080/01635589709514606; Edidin M, 2003, NAT REV MOL CELL BIO, V4, P414, DOI 10.1038/nrm1102; FAVROT MC, 1984, BIOMED PHARMACOTHER, V38, P55; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fierz Y, 2010, DIABETES, V59, P686, DOI 10.2337/db09-1291; Freeman MR, 2010, ONCOGENE, V29, P3745, DOI 10.1038/onc.2010.132; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gallagher EJ, 2011, ENDOCRINOLOGY, V152, P2546, DOI 10.1210/en.2011-0231; Gallagher EJ, 2010, CURR DIABETES REP, V10, P93, DOI 10.1007/s11892-010-0101-y; Giovannucci E, 2007, INT J CANCER, V121, P1571, DOI 10.1002/ijc.22788; Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654; Halton JM, 1998, CANCER, V83, P379, DOI 10.1002/(SICI)1097-0142(19980715)83:2<379::AID-CNCR24>3.3.CO;2-K; Hu J, 2012, ANN ONCOL, V23, P491, DOI 10.1093/annonc/mdr155; Kawashima Y, 2009, DIABETOLOGIA, V52, P1434, DOI 10.1007/s00125-009-1378-8; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Mandal CC, 2011, J BIOL CHEM, V286, P11314, DOI 10.1074/jbc.M110.193714; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mondul Alison M, 2011, Cancer Epidemiol, V35, pe6, DOI 10.1016/j.canep.2010.11.005; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Platz EA, 2008, INT J CANCER, V123, P1693, DOI 10.1002/ijc.23715; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Sekine Y, 2009, CANCER EPIDEMIOL, V33, P16, DOI 10.1016/j.canep.2009.04.004; Xue F, 2007, AM J CLIN NUTR, V86, p823S, DOI 10.1093/ajcn/86.3.823S; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhuang LY, 2005, J CLIN INVEST, V115, P959; Zhuang LY, 2002, CANCER RES, V62, P2227; ZIELINSKI CC, 1988, J CANCER RES CLIN, V114, P514, DOI 10.1007/BF00391503	40	93	98	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					961	967		10.1038/onc.2012.113	http://dx.doi.org/10.1038/onc.2012.113			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469977	Green Accepted			2022-12-17	WOS:000316523200003
J	Brimer, N; Lyons, C; Wallberg, AE; Vande Pol, SB				Brimer, N.; Lyons, C.; Wallberg, A. E.; Vande Pol, S. B.			Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling	ONCOGENE			English	Article						CBF1; RBP-J; RBP-Jk; squamous; epithelial; transformation	SQUAMOUS-CELL CARCINOMA; CERVICAL-CANCER CELLS; TUMOR-SUPPRESSOR FUNCTION; TERMINAL DIFFERENTIATION; GROWTH ARREST; TYPE-1 E6; TRANSCRIPTIONAL COACTIVATOR; HUMAN KERATINOCYTES; NEOPLASTIC LESIONS; HUMAN HOMOLOG	Papillomavirus E6 oncoproteins associate with LXXLL motifs on target cellular proteins to alter their function. Using a proteomic approach, we found the E6 oncoproteins of cutaneous papillomaviruses Bovine Papillomavirus Type 1 (BPV-1) E6 and human papillomavirus (HPV) types 1 and 8 (1E6 and 8E6) associated with the MAML1 transcriptional co-activator. All three E6 proteins bind to an acidic LXXLL motif at the carboxy-terminus of MAML1 and repress transactivation by MAML1. MAML1 is best known as the co-activator and effector of NOTCH-induced transcription, and BPV-1 E6 represses synthetic NOTCH-responsive promoters, endogenous NOTCH-responsive promoters, and is found in a complex with MAML1 in stably transformed cells. BPV-1-induced papillomas show characteristics of repressed NOTCH signal transduction, including suprabasal expression of integrins, talin and basal type keratins, and delayed expression of the NOTCH-dependent HES1 transcription factor. These observations give rise to a model whereby papillomavirus oncoproteins, including BPV-1 E6, and the cancer-associated HPV-8 E6 repress NOTCH-induced transcription, thereby delaying keratinocyte differentiation.	[Brimer, N.; Lyons, C.; Vande Pol, S. B.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Wallberg, A. E.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	University of Virginia; Karolinska Institutet	Vande Pol, SB (corresponding author), Univ Virginia, Dept Pathol, POB 800904, Charlottesville, VA 22908 USA.	vandepol@virginia.edu	Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NIH [CA120352, CA08093]; Swedish Research Council; NATIONAL CANCER INSTITUTE [R01CA120352, R01CA134737] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	SVP, NB and CL were supported by NIH grants (CA120352 and CA08093) to SVP, and institutional support from the University of Virginia and the Department of Pathology Mass Spectrometry Facility. AEW is supported by the Swedish Research Council. We would like to thank Janet Cross and Benjamin Purow at UVA for helpful discussions and critical reading of the manuscript.	ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Allen-Hoffmann BL, 2000, J INVEST DERMATOL, V114, P444, DOI 10.1046/j.1523-1747.2000.00869.x; Alves-Guerra MC, 2007, CANCER RES, V67, P8690, DOI 10.1158/0008-5472.CAN-07-1720; Artayanis-Tsakonas S, 2010, CURR TOP DEV BIOL, V92, P1, DOI 10.1016/S0070-2153(10)92001-2; Baldus CD, 2009, HAEMATOL-HEMATOL J, V94, P1383, DOI 10.3324/haematol.2008.005272; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; Cooper B, 2006, VIROLOGY, V355, P102, DOI 10.1016/j.virol.2006.06.032; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; KAISER HW, 1993, J INVEST DERMATOL, V101, P789, DOI 10.1111/1523-1747.ep12371696; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lathion S, 2003, CANCER RES, V63, P8687; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Moriyama M, 2008, DEV CELL, V14, P594, DOI 10.1016/j.devcel.2008.01.017; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohashi S, 2010, GASTROENTEROLOGY, V139, P2113, DOI 10.1053/j.gastro.2010.08.040; Orth G, 2006, SEMIN IMMUNOL, V18, P362, DOI 10.1016/j.smim.2006.07.008; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066; Peng S, 2011, CELL BIOL INT, V35, P587, DOI 10.1042/CBI20100452; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rasul S, 2009, BRIT J CANCER, V100, P1879, DOI 10.1038/sj.bjc.6605034; Ribeiro MSJ, 2009, CURR PROTEIN PEPT SC, V10, P570; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; Sun Xiao-mei, 2009, Zhonghua Fu Chan Ke Za Zhi, V44, P369; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanigaki K, 2010, CURR TOP DEV BIOL, V92, P231, DOI 10.1016/S0070-2153(10)92007-3; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wade R, 2008, J VIROL, V82, P5962, DOI 10.1128/JVI.02747-07; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Watt FM, 2008, CURR OPIN CELL BIOL, V20, P171, DOI 10.1016/j.ceb.2008.01.010; WATT FM, 1993, J CELL SCI, V106, P175; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yao J, 2007, INT J GYNECOL CANCER, V17, P502, DOI 10.1111/j.1525-1438.2007.00872.x; YEDVOBNICK B, 1988, GENETICS, V118, P483; Yu Hai, 2007, Ai Zheng, V26, P148; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhao YT, 2007, J BIOL CHEM, V282, P11969, DOI 10.1074/jbc.M608974200; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	77	93	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4639	4646		10.1038/onc.2011.589	http://dx.doi.org/10.1038/onc.2011.589			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249263	Green Accepted			2022-12-17	WOS:000310528200007
J	Qin, W; Dong, P; Ma, C; Mitchelson, K; Deng, T; Zhang, L; Sun, Y; Feng, X; Ding, Y; Lu, X; He, J; Wen, H; Cheng, J				Qin, W.; Dong, P.; Ma, C.; Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Feng, X.; Ding, Y.; Lu, X.; He, J.; Wen, H.; Cheng, J.			MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways	ONCOGENE			English	Article						miR-133b; tumorigenesis and metastasis; signal pathways; cervical carcinoma	SQUAMOUS-CELL CARCINOMA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; IN-VIVO; CANCER; EXPRESSION; GROWTH; NEOPLASIA; SURVIVAL; TARGETS	We report that elevated microRNA-133b (miR-133b) acts as an oncogene in human cervical carcinoma to promote tumorigenesis and metastasis. In situ hybridization confirmed that miR-133b is localized in proliferating human cervical carcinoma cells with levels progressively elevating throughout advancing stages. Cellular studies showed that miR-133b enhances cell proliferation and colony formation by targeting mammalian sterile 20-like kinase 2 (MST2), cell division control protein 42 homolog (CDC42) and ras homolog gene family member A (RHOA), which subsequently results in activation of the tumorigenic protein kinase B alpha (AKT1) and mitogen-activated protein kinase (ERK1 and ERK2, here abbreviated as ERK) signaling pathways. Mouse experiments revealed that upregulation of miR-133b in cervical carcinoma cells strongly promotes both in vivo tumorigenesis and independent metastasis to the mouse lung. The data indicates that upregulation of miR-133b shortens the latency of cervical carcinoma. Together, these findings suggest that miR-133b could be a potent marker for the early onset of cervical carcinoma. Oncogene (2012) 31, 4067-4075; doi: 10.1038/onc.2011.561; published online 19 December 2011	[Wen, H.] Xinjiang Med Univ, Affiliated Hosp 1, State Key Lab Incubat Base Xinjiang Major Dis Res, Urumqi 830054, Peoples R China; [Qin, W.; Dong, P.; Mitchelson, K.; Deng, T.; Cheng, J.] Tsinghua Univ, Sch Med, Med Syst Biol Res Ctr, Beijing 100084, Peoples R China; [Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Cheng, J.] Natl Engn Res Ctr Beijing Biochip Technol, Beijing, Peoples R China; [Feng, X.] Peking Union Med Coll, Canc Hosp & Inst, Dept Pathol, Beijing 100021, Peoples R China; [He, J.] Peking Union Med Coll, Canc Hosp & Inst, Dept Thorac Surg, Beijing 100021, Peoples R China; [Feng, X.; He, J.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Cheng, J.] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China	Xinjiang Medical University; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Tsinghua University	Wen, H (corresponding author), Xinjiang Med Univ, Affiliated Hosp 1, State Key Lab Incubat Base Xinjiang Major Dis Res, Urumqi 830054, Peoples R China.	dr.wenhao@163.com; jcheng@mail.tsinghua.edu.cn	DONG, PENG/H-8016-2018	DONG, PENG/0000-0003-4946-1409	National High-tech Program of China [2006AA020701, 2009AA022701]	National High-tech Program of China	We thank Drs Youyong Lu and Yun Zhang for discussions and comments on the manuscript; Suqiong Wang, Zhaoli Chen and Dapeng Ding for help with mouse experiments; Jiantao Cui and Dr Bing Dong for help with IHC and ISH experiments. This study was supported by the National High-tech Program of China (grant no. 2006AA020701 and grant no. 2009AA022701).	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bertelsen BI, 2006, INT J CANCER, V118, P1877, DOI 10.1002/ijc.21461; Burk RD, 1999, NEW ENGL J MED, V341, P1687, DOI 10.1056/NEJM199911253412209; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Crawford M, 2009, BIOCHEM BIOPH RES CO, V388, P483, DOI 10.1016/j.bbrc.2009.07.143; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; GOOD M, 1978, CANCER RES, V38, P4671; Guo HY, 2011, HEPATOLOGY, V54, P808, DOI 10.1002/hep.24441; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186; Kahn JA, 2009, NEW ENGL J MED, V361, P271, DOI 10.1056/NEJMct0806938; Kohrenhagen N, 2008, J OBSTET GYNAECOL RE, V34, P293, DOI 10.1111/j.1447-0756.2008.00749.x; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu XQ, 2009, COMP FUNCT GENOM, DOI 10.1155/2009/837514; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Schiffman M, 2005, NEW ENGL J MED, V353, P2101, DOI 10.1056/NEJMp058171; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Watanabe T, 2005, FEBS LETT, V579, P318, DOI 10.1016/j.febslet.2004.11.067; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	40	93	96	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4067	4075		10.1038/onc.2011.561	http://dx.doi.org/10.1038/onc.2011.561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22179829				2022-12-17	WOS:000308688800007
J	Renault, VM; Thekkat, PU; Hoang, KL; White, JL; Brady, CA; Broz, DK; Venturelli, OS; Johnson, TM; Oskoui, PR; Xuan, Z; Santo, EE; Zhang, MQ; Vogel, H; Attardi, LD; Brunet, A				Renault, V. M.; Thekkat, P. U.; Hoang, K. L.; White, J. L.; Brady, C. A.; Broz, D. Kenzelmann; Venturelli, O. S.; Johnson, T. M.; Oskoui, P. R.; Xuan, Z.; Santo, E. E.; Zhang, M. Q.; Vogel, H.; Attardi, L. D.; Brunet, A.			The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor	ONCOGENE			English	Article						FoxO transcription factors; p53; tumor suppression; cancer; aging; longevity	TRANSCRIPTION FACTOR FOXO3A; PROMOTES CELL-SURVIVAL; WILD-TYPE P53; LIFE-SPAN; P53-DEPENDENT APOPTOSIS; CALORIC RESTRICTION; COLORECTAL-CANCER; DIRECT ACTIVATION; DNA-DAMAGE; EXPRESSION	FoxO transcription factors have a conserved role in longevity, and act as tissue-specific tumor suppressors in mammals. Several nodes of interaction have been identified between FoxO transcription factors and p53, a major tumor suppressor in humans and mice. However, the extent and importance of the functional interaction between FoxO and p53 have not been fully explored. Here, we show that p53 regulates the expression of FoxO3, one of the four mammalian FoxO genes, in response to DNA damaging agents in both mouse embryonic fibroblasts and thymocytes. We find that p53 transactivates FoxO3 in cells by binding to a site in the second intron of the FoxO3 gene, a genomic region recently found to be associated with extreme longevity in humans. While FoxO3 is not necessary for p53-dependent cell cycle arrest, FoxO3 appears to modulate p53-dependent apoptosis. We also find that FoxO3 loss does not interact with p53 loss for tumor development in vivo, although the tumor spectrum of p53-deficient mice appears to be affected by FoxO3 loss. Our findings indicate that FoxO3 is a p53 target gene, and suggest that FoxO3 and p53 are part of a regulatory transcriptional network that may have an important role during aging and cancer. Oncogene (2011) 30, 3207-3221; doi:10.1038/onc.2011.35; published online 21 March 2011	[Renault, V. M.; Thekkat, P. U.; Hoang, K. L.; White, J. L.; Venturelli, O. S.; Oskoui, P. R.; Attardi, L. D.; Brunet, A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Brady, C. A.; Broz, D. Kenzelmann; Johnson, T. M.; Attardi, L. D.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; [Brady, C. A.; Johnson, T. M.; Attardi, L. D.; Brunet, A.] Stanford Univ, Canc Biol Grad Program, Stanford, CA 94305 USA; [Xuan, Z.; Zhang, M. Q.] Univ Texas Dallas, Ctr Syst Biol, Dept Mol & Cell Biol, Richardson, TX 75083 USA; [Santo, E. E.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Zhang, M. Q.] Tsinghua Univ, TNLIS, MOE, Key Lab Bioinformat, Beijing 100084, Peoples R China; [Zhang, M. Q.] Tsinghua Univ, TNLIS, Bioinformat Div, Beijing 100084, Peoples R China; [Vogel, H.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; University of Texas System; University of Texas Dallas; University of Amsterdam; Academic Medical Center Amsterdam; Tsinghua University; Tsinghua University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA.	anne.brunet@stanford.edu		Vogel, Otto Hannes/0000-0002-0960-3508; Xuan, Zhenyu/0000-0001-9344-8493	NIH [R01 AG026648, R01 HG001696]; McCormick Award for Women in Science; Stanford University; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026648] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Award for Women in Science; Stanford University(Stanford University); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Ron DePinho for his generous gift of the FoxO3 <SUP>/</SUP> mice. We thank Julien Sage for critical discussion, reading of the manuscript, help with tumor analysis and for taking the pictures for Figure 8d. We thank Jamie Brett for reading the manuscript. We thank Pauline Chu (Comparative Medicine Department, Stanford Medical School) for her help in processing the histopathology samples. We thank Dan Calnan for participating in earlier aspects of this work. This work was supported by NIH R01 AG026648 and a McCormick Award for Women in Science (AB). ZX, EES and MQZ were supported partly by NIH R01 HG001696. VMR received support from the Dean's Fellowship at Stanford University. Author contributions: VMR designed, performed and analyzed the lifespan and tumor spectrum of compound FoxO3/p53 mice (Figure 8). PUT completed Figure 1b, Figure 5b, Figure 6b, Figure 6e, Figure 7a and helped with Figure 2 and Figure 6d. KLH completed Figure 5d, Figure 5e, Figure 6a, Figure 6b and Figure 6c. JLW completed Figure 2, Figure 6d, and helped with Figure 3 and Figure 7b. CAB completed Figure 3 and Figure 7b. DKB completed Figure 5c. OSV initiated this project as her Honors Thesis and completed Figure 1a. TMJ completed Figure 4b. PRO completed Figure 6f. ZX and EES identified p53 binding sites in FoxO3 regulatory regions (Figure 5a) under the supervision of MQZ. HV performed the tumor identification (Figure 8b). LDA supervised CAB, DKB and TMJ, and provided ideas. AB supervised VMR, PUT, KLH, JLW, OSV and PRO. The manuscript was written by AB, VMR and OSV, with input from LDA.	Anselmi CV, 2009, REJUV RES, V12, P95, DOI 10.1089/rej.2008.0827; Arum O, 2007, J GERONTOL A-BIOL, V62, P951, DOI 10.1093/gerona/62.9.951; Attardi LD, 2000, GENE DEV, V14, P704; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; de la Torre-Ubieta L, 2010, GENE DEV, V24, P799, DOI 10.1101/gad.1880510; DENG G, 1994, CANCER RES, V54, P499; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Furuyama T, 2002, MICROSC RES TECHNIQ, V59, P331, DOI 10.1002/jemt.10213; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs SBR, 2007, CELL DEATH DIFFER, V14, P1374, DOI 10.1038/sj.cdd.4402128; Johnson TM, 2008, P NATL ACAD SCI USA, V105, P1215, DOI 10.1073/pnas.0706764105; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kurinna S, 2010, HEPATOLOGY, V52, P1023, DOI 10.1002/hep.23746; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOCOCO F, 1993, BLOOD, V82, P2289; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marusyk A, 2007, MOL CELL BIOL, V27, P5336, DOI 10.1128/MCB.01316-06; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Pawlikowska L, 2009, AGING CELL, V8, P460, DOI 10.1111/j.1474-9726.2009.00493.x; QUINLAN DC, 1992, CANCER RES, V52, P4828; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharpless NE, 2002, CANCER RES, V62, P2761; Shen J, 2010, EXP GERONTOL, V45, P97, DOI 10.1016/j.exger.2009.10.009; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhao RB, 2000, GENE DEV, V14, P981	94	93	94	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	29					3207	3221		10.1038/onc.2011.35	http://dx.doi.org/10.1038/onc.2011.35			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21423206	Green Accepted			2022-12-17	WOS:000293006800001
J	Takenobu, H; Shimozato, O; Nakamura, T; Ochiai, H; Yamaguchi, Y; Ohira, M; Nakagawara, A; Kamijo, T				Takenobu, H.; Shimozato, O.; Nakamura, T.; Ochiai, H.; Yamaguchi, Y.; Ohira, M.; Nakagawara, A.; Kamijo, T.			CD133 suppresses neuroblastoma cell differentiation via signal pathway modification	ONCOGENE			English	Article						CD133; neuroblastoma; differentiation; RET p38MAPK; PI3K/Akt	CANCER STEM-CELLS; HEMATOPOIETIC STEM; IN-VITRO; RET; IDENTIFICATION; LINES; EXPRESSION; AC133; GENE; AMPLIFICATION	CD133 (prominin-1) is a transmembrane glycoprotein expressed on the surface of normal and cancer stem cells (tumor-initiating cells), progenitor cells, rod photoreceptor cells and a variety of epithelial cells. Although CD133 is widely used as a marker of various somatic and putative cancer stem cells, its contribution to the fundamental properties of cancer cells, such as tumorigenesis and differentiation, remains to be elucidated. In the present report, we found that CD133 was expressed in several neuroblastoma (NB) cell lines/tumor samples. Intriguingly, CD133 repressed NB cell differentiation, for example neurite extension and the expression of differentiation marker proteins, and was decreased by several differentiation stimuli, but accelerated cell proliferation, anchorage-independent colony formation and in vivo tumor formation of NB cells. NB cell line and primary tumor-sphere experiments indicated that the molecular mechanism of CD133-related differentiation suppression in NB was in part dependent on neurotrophic receptor RET tyrosine kinase regulation. RET transcription was suppressed by CD133 in NB cells and glial cell line-derived neurotrophic factor treatment failed to induce RET in CD133-expressing cells; RET overexpression rescued CD133-related inhibition of neurite elongation. Of note, CD133-related NB cell differentiation and RET repression were mainly dependent on p38MAPK and PI3K/Akt pathways. Furthermore, CD133 has a function in growth and RET expression in NB cell line- and primary tumor cell-derived tumor spheres. To the best of our knowledge, this is the first report of the function of CD133 in cancer cells and our findings may be applied to improve differentiation induction therapy for NB patients. Oncogene (2011) 30, 97-105; doi: 10.1038/onc.2010.383; published online 6 September 2010	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, Chiba 2608717, Japan; [Shimozato, O.] Chiba Canc Ctr, Res Inst, Lab Antitumor Res, Chiba 2608717, Japan; [Nakamura, T.] Univ Tokyo, Inst Med Sci, Core Facil Therapeut Vectors, Tokyo, Japan; [Ochiai, H.] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Ohira, M.] Chiba Canc Ctr, Res Inst, Lab Canc Genom, Chiba 2608717, Japan; [Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba 2608717, Japan	Chiba Cancer Center; Chiba Cancer Center; University of Tokyo; Chiba University; Chiba Cancer Center; Chiba Cancer Center	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp	Nakamura, Takafumi/AAO-8199-2020	Nakamura, Takafumi/0000-0002-0196-0754; Takenobu, Hisanori/0000-0001-7355-1565	JSPS [19790274]; Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan [21591377]; Grants-in-Aid for Scientific Research [21790397, 21390317, 21591376] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai and S Matsushita for technical assistance, Dr Hiroyuki Miyoshi (BioResource Center, RIKEN) for the gift of CSII-CMV-MCS-IRES2-Bsd plasmid and Daniel Mrozek, Medical English Service, for editorial assistance. This work was supported in part by a grant-in-aid from JSPS for Young Scientists (B) (number: 19790274), a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer, a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (number: 21591377).	Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Boivin D, 2009, BIOCHEMISTRY-US, V48, P3998, DOI 10.1021/bi900159d; BRODEUR GM, 2000, NEUROBLASTOMA; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Corbeil D, 2001, BIOCHEM BIOPH RES CO, V285, P939, DOI 10.1006/bbrc.2001.5271; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; Crowder RJ, 2004, J BIOL CHEM, V279, P42072, DOI 10.1074/jbc.M403726200; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; Enomoto H, 2000, DEVELOPMENT, V127, P4877; Enomoto H, 2001, DEVELOPMENT, V128, P3963; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hasegawa K, 2006, CLIN CANCER RES, V12, P6170, DOI 10.1158/1078-0432.CCR-06-0992; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; ITOH F, 1992, ONCOGENE, V7, P1201; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KLEIN RM, 1994, FASEB J, V8, pA126; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; MYERS SM, 1995, ONCOGENE, V11, P2039; Nakanishi H, 2007, ONCOL REP, V17, P1315; Nikolova T, 2007, DIFFERENTIATION, V75, P100, DOI 10.1111/j.1432-0436.2006.00119.x; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Olempska M, 2007, HEPATOB PANCREAT DIS, V6, P92; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Weinberg R. A., 2006, BIOL CANC; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zacchigna S, 2009, J NEUROSCI, V29, P2297, DOI 10.1523/JNEUROSCI.2034-08.2009	42	93	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					97	105		10.1038/onc.2010.383	http://dx.doi.org/10.1038/onc.2010.383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818439				2022-12-17	WOS:000285959300009
J	Akita, H; Zheng, Z; Takeda, Y; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Takemasa, I; Nagano, H; Dono, K; Nakamori, S; Monden, M; Mori, M; Doki, Y; Bepler, G				Akita, H.; Zheng, Z.; Takeda, Y.; Kim, C.; Kittaka, N.; Kobayashi, S.; Marubashi, S.; Takemasa, I.; Nagano, H.; Dono, K.; Nakamori, S.; Monden, M.; Mori, M.; Doki, Y.; Bepler, G.			Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; RRM1; ERCC1; AQUA; prognosis; gemcitabine	CELL LUNG-CANCER; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; PHASE-III TRIAL; MESSENGER-RNA LEVELS; FLUOROURACIL CHEMOTHERAPY; GEMCITABINE RESISTANCE; ADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; DNA-SYNTHESIS; SURVIVAL	The identification of molecular markers, useful for therapeutic decisions in pancreatic cancer patients, is crucial for advances in disease management. Gemcitabine, although a cornerstone of current therapy, has limited efficacy. RRM1 is a key molecule for gemcitabine efficacy and is also involved in tumor progression. We determined in situ RRM1 and excision repair cross complementation group 1 (ERCC1) protein levels in 68 pancreatic cancer patients. All had R0 resections without preoperative therapy. Protein levels were determined by automated quantitative analysis (AQUA), a fluorescence-based immunohistochemical method. The relationship between protein expressions and clinical outcomes, including response to gemcitabine at the time of disease recurrence, was determined. Patients with high RRM1 showed significantly better overall survival than patients with low expression (P = 0.0196). There was a trend toward better overall survival for patient with high ERCC1 (P = 0.0552). When both markers were considered together, patients with both high RRM1 and ERCC1 faired the best in terms of overall and disease-free survival (P = 0.0066, P = 0.0127). In addition, treatment benefit from gemcitabine in patients with disease recurrence was observed only in patients with low RRM1. The combination of RRM1 and ERCC1 expression is prognostic in pancreatic cancer patients after a complete resection. On disease recurrence, only patients with low RRM1 derive benefit from gemcitabine. Oncogene (2009) 28, 2903-2909; doi:10.1038/onc.2009.158; published online 22 June 2009	[Akita, H.; Takeda, Y.; Kim, C.; Kittaka, N.; Kobayashi, S.; Marubashi, S.; Takemasa, I.; Nagano, H.; Dono, K.; Monden, M.; Mori, M.; Doki, Y.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; [Zheng, Z.; Bepler, G.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA; [Nakamori, S.] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan	Osaka University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Osaka National Hospital	Takeda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakeda@gesurg.med.osaka-u.ac.jp			National Institutes of Health (NIH) [R01-CA129343]; Ministry of Culture and Science of Japan; NATIONAL CANCER INSTITUTE [R01CA129343, R01CA140314] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Culture and Science of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by National Institutes of Health (NIH) grant R01-CA129343 to GB and by a grant-in-aid for cancer research from the Ministry of Culture and Science of Japan.	Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bepler G, 2004, J CLIN ONCOL, V22, P1878, DOI 10.1200/JCO.2004.12.002; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Boeck S, 2008, J CLIN ONCOL, V26, P1178, DOI 10.1200/JCO.2007.15.3304; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Cao MY, 2003, CLIN CANCER RES, V9, P4553; Cascinu S, 2008, LANCET ONCOL, V9, P188, DOI 10.1016/S1470-2045(08)70042-1; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dumontet C, 1999, BRIT J HAEMATOL, V106, P78, DOI 10.1046/j.1365-2141.1999.01509.x; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203; Goan YG, 1999, CANCER RES, V59, P4204; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Jung CP, 2001, CLIN CANCER RES, V7, P2527; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Kim MK, 2008, CLIN CANCER RES, V14, P4225, DOI 10.1158/1078-0432.CCR-07-4848; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li QD, 2000, ANTICANCER RES, V20, P645; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Okusaka T, 2008, CANCER CHEMOTH PHARM, V61, P615, DOI 10.1007/s00280-007-0514-8; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Reardon JT, 1999, CANCER RES, V59, P3968; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Saif MW, 2008, J PANCREAS, V9, P391; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Staley CA, 1996, AM J SURG, V171, P118, DOI 10.1016/S0002-9610(99)80085-3; Ueno H, 2005, ONCOLOGY-BASEL, V68, P171, DOI 10.1159/000086771; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411	48	93	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2903	2909		10.1038/onc.2009.158	http://dx.doi.org/10.1038/onc.2009.158			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19543324	Green Accepted			2022-12-17	WOS:000268917100006
J	Pinon, JD; Labi, V; Egle, A; Villunger, A				Pinon, J. D.; Labi, V.; Egle, A.; Villunger, A.			Bmf and Bmf in tissue homeostasis and malignant disease	ONCOGENE			English	Review						apoptosis; Bcl2 family; BH3-only proteins; tumorigenesis; drug-response	FAMILY-MEMBER BIM; BH3-ONLY PROTEIN BIM; HISTONE DEACETYLASE INHIBITORS; BCL-X-L; CELL-DEATH; PROAPOPTOTIC PROTEIN; TRANSCRIPTIONAL REGULATION; HOMOZYGOUS DELETIONS; INDUCED APOPTOSIS; LEUKEMIC-CELLS	Among all BH3-only proteins known to date, most information is available on the biological role and function of Bim (Bcl-2 interacting mediator of cell death)/BOD (Bcl-2 related ovarian death agonist), whereas little is still known about its closest relative, Bcl-2 modifying factor (Bmf). Although Bim has been implicated in the regulation of cell death induction in multiple cell types and tissues in response to a large number of stimuli, including growth factor or cytokine deprivation, calcium flux, ligation of antigen receptors on T and B cells, glucocorticoid or loss of adhesion, Bmf seems to play a more restricted role by supporting Bim in some of these cell death processes. This review aims to highlight similarities between Bim and Bmf function in apoptosis signaling and their role in normal development and disease. Oncogene (2009) 27, S41-S52; doi: 10.1038/onc.2009.42	[Labi, V.; Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria; [Pinon, J. D.; Egle, A.] Univ Hosp Salzburg, Lab Immunol & Mol Canc Res, Salzburg, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Hofbauer, Josefina Pinon/S-6826-2019; Labi, Verena/V-2766-2019; Egle, Alexander/AAC-3787-2020	Labi, Verena/0000-0001-7538-1520; Egle, Alexander/0000-0003-0648-4416; Pinon Hofbauer, Josefina/0000-0002-8558-9031	Austrian Science Fund (FWF) [Y212-B13 START, P19481-B12, L488-B13]; Doctoral College MCBO [SFB021]; Association for International Cancer Research (AICR) [EU-FP7]; Austrian National Bank (OeNB) [109900]; Tyrolean Science Fund	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Doctoral College MCBO(Austrian Science Fund (FWF)); Association for International Cancer Research (AICR); Austrian National Bank (OeNB); Tyrolean Science Fund	The work in our laboratories is supported by fellowships and grants from the Austrian Science Fund (FWF): Y212-B13 START, P19481-B12, L488-B13, the Doctoral College MCBO, the SFB021, the Association for International Cancer Research (AICR), EU-FP7 (ApopTrain), the Austrian National Bank (OeNB) # 109900 and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited, but was only referred to indirectly through reviews.	Adachi M, 2005, CELL DEATH DIFFER, V12, P192, DOI 10.1038/sj.cdd.4401529; Barron L, 2008, J IMMUNOL, V180, P2762, DOI 10.4049/jimmunol.180.5.2762; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Fischer SF, 2007, BLOOD, V110, P3978, DOI 10.1182/blood-2007-05-091306; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hughes PD, 2008, IMMUNITY, V28, P197, DOI 10.1016/j.immuni.2007.12.017; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Inta I, 2006, J NEUROSCI, V26, P12896, DOI 10.1523/JNEUROSCI.3670-06.2006; Jette CA, 2008, CELL DEATH DIFFER, V15, P1063, DOI 10.1038/cdd.2008.42; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Morales AA, 2004, LEUKEMIA, V18, P41, DOI 10.1038/sj.leu.2403183; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oliveira JB, 2007, P NATL ACAD SCI USA, V104, P8953, DOI 10.1073/pnas.0702975104; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Pellegrini M, 2004, J EXP MED, V200, P1189, DOI 10.1084/jem.20041328; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Ponassi R, 2008, CELL CYCLE, V7, P3211, DOI 10.4161/cc.7.20.6830; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ralston A, 2006, DEV CELL, V10, P275, DOI 10.1016/j.devcel.2006.02.007; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Rodin SN, 2005, DNA CELL BIOL, V24, P529, DOI 10.1089/dna.2005.24.529; Romano S, 2008, HAEMATOL-HEMATOL J, V93, P1039, DOI 10.3324/haematol.12402; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Schmutte C, 1999, CANCER RES, V59, P4564; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weant AE, 2008, IMMUNITY, V28, P218, DOI 10.1016/j.immuni.2007.12.014; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wick W, 1996, ONCOGENE, V12, P973; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wojciechowski S, 2007, J EXP MED, V204, P1665, DOI 10.1084/jem.20070618; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686; Zhang YB, 2006, APOPTOSIS, V11, P1349, DOI 10.1007/s10495-006-8266-1; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	96	93	95	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S41	S52		10.1038/onc.2009.42	http://dx.doi.org/10.1038/onc.2009.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641506	Green Accepted			2022-12-17	WOS:000268566800004
J	Soulas-Sprauel, P; Rivera-Munoz, P; Malivert, L; Le Guyader, G; Abramowski, V; Revy, P; de Villartay, JP				Soulas-Sprauel, P.; Rivera-Munoz, P.; Malivert, L.; Le Guyader, G.; Abramowski, V.; Revy, P.; de Villartay, J-P			V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining	ONCOGENE			English	Review						V(D)J recombination; class switch recombination; SCID; Artemis; Cernunnos; NHEJ	STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; DEPENDENT PROTEIN-KINASE; COMBINED IMMUNE-DEFICIENCY; CYTIDINE DEAMINASE AID; LIGASE-IV COMPLEX; SACCHAROMYCES-CEREVISIAE; B-CELLS; HOMOLOGOUS RECOMBINATION; SOMATIC HYPERMUTATION	The immune system is the site of intense DNA damage/modification, which occur during the development and maturation of B and T lymphocytes. V(D)J recombination is initiated by the Rag1 and Rag2 proteins and the formation of a DNA double-strand break (DNA dsb). This DNA lesion is repaired through the use of the nonhomologous end-joining (NHEJ) pathway, several factors of which have been identified through the survey of immunodeficient conditions in humans and mice. Upon antigenic recognition in secondary lymphoid organs, mature B cells further diversify their repertoire through class switch recombination (CSR). CSR is a region-specific rearrangement process triggered by the activation-induced cytidine deaminase factor and also proceeds through the introduction of DNA dsb. However, unlike V(D)J recombination, CSR does not rely strictly on NHEJ for the repair of the DNA lesion. Instead, CSR, but not V(D)J recombination, requires the major factors of the DNA damage response. V(D)J recombination and CSR thus represent an interesting paradigm to study the regulation among the various DNA repair pathways.	Hop Necker Enfants Malad, INSERM, U768, F-75015 Paris, France; Univ Paris 05, Fac Med Rene Descartes, IFR94, Paris, France; Hop Necker Enfants Malad, AP HP, Serv Immunol & Hematol Pediat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	de Villartay, JP (corresponding author), Hop Necker Enfants Malad, INSERM, U768, 149 Rue Sevres, F-75015 Paris, France.	devillar@necker.fr	Revy, Patrick/H-8137-2017; de Villartay, jean pierre/H-9353-2017	de Villartay, jean pierre/0000-0001-5987-0463; Revy, Patrick/0000-0003-0758-8022; Malivert, Laurent/0000-0002-0944-6573; Soulas-Sprauel, Pauline/0000-0002-2058-4811				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Ahnesorg P, 2007, DNA REPAIR, V6, P190, DOI 10.1016/j.dnarep.2006.09.010; Aravind L, 1999, In Silico Biol, V1, P69; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bassing CH, 2004, CELL CYCLE, V3, P149; Ben-Omran TI, 2005, AM J MED GENET A, V137A, P283, DOI 10.1002/ajmg.a.30869; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bosma GC, 2002, J EXP MED, V196, P1483, DOI 10.1084/jem.20001871; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Callebaut I, 2006, J BIOL CHEM, V281, P13857, DOI 10.1074/jbc.C500473200; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Catalan N, 2003, J IMMUNOL, V171, P2504, DOI 10.4049/jimmunol.171.5.2504; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Cavero S, 2007, GENETICS, V175, P963, DOI 10.1534/genetics.106.067850; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; Cook AJL, 2003, J IMMUNOL, V171, P6556, DOI 10.4049/jimmunol.171.12.6556; Corneo B, 2007, NATURE, V449, P483, DOI 10.1038/nature06168; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Darroudi F, 2007, MUTAT RES-FUND MOL M, V615, P111, DOI 10.1016/j.mrfmmm.2006.11.029; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Decottignies A, 2007, GENETICS, V176, P1403, DOI 10.1534/genetics.107.071621; Deshpande RA, 2007, DNA REPAIR, V6, P1507, DOI 10.1016/j.dnarep.2007.04.014; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Evans PM, 2006, HUM MOL GENET, V15, P1303, DOI 10.1093/hmg/ddl050; Fischer A, 2004, NAT IMMUNOL, V5, P23, DOI 10.1038/ni1023; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Gennery AR, 2005, CLIN IMMUNOL, V116, P246, DOI 10.1016/j.clim.2005.04.014; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu JF, 2007, NUCLEIC ACIDS RES, V35, P5755, DOI 10.1093/nar/gkm579; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Hentges P, 2006, J BIOL CHEM, V281, P37517, DOI 10.1074/jbc.M608727200; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Inagaki K, 2007, J VIROL, V81, P11304, DOI 10.1128/JVI.01225-07; Ishikawa H, 2006, J BIOCHEM, V140, P535, DOI 10.1093/jb/mvj183; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Kiefer K, 2007, P NATL ACAD SCI USA, V104, P2843, DOI 10.1073/pnas.0611359104; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Krempler A, 2007, CELL CYCLE, V6, P1682, DOI 10.4161/cc.6.14.4480; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Li LY, 2005, J IMMUNOL, V174, P2420, DOI 10.4049/jimmunol.174.4.2420; Li LY, 1998, AM J HUM GENET, V62, P136, DOI 10.1086/301688; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lu HH, 2007, J BIOL CHEM, V282, P11155, DOI 10.1074/jbc.M609904200; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Mandel CR, 2006, NATURE, V444, P953, DOI 10.1038/nature05363; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Niewolik D, 2006, J BIOL CHEM, V281, P33900, DOI 10.1074/jbc.M606023200; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Peron S, 2007, J EXP MED, V204, P1207, DOI 10.1084/jem.20070087; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Povirk LF, 2007, J BIOL CHEM, V282, P3547, DOI 10.1074/jbc.M607745200; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2005, P NATL ACAD SCI USA, V102, P2471, DOI 10.1073/pnas.0409857102; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Roth DB, 2003, NAT REV IMMUNOL, V3, P656, DOI 10.1038/nri1152; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Rush JS, 2004, INT IMMUNOL, V16, P549, DOI 10.1093/intimm/dxh057; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Soubeyrand S, 2006, J MOL BIOL, V358, P1200, DOI 10.1016/j.jmb.2006.02.061; Soulas-Sprauel P, 2007, J EXP MED, V204, P1717, DOI 10.1084/jem.20070255; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; WU PY, 2007, J BIOL CHEM; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Zha S, 2007, P NATL ACAD SCI USA, V104, P4518, DOI 10.1073/pnas.0611734104; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	130	93	95	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7780	7791		10.1038/sj.onc.1210875	http://dx.doi.org/10.1038/sj.onc.1210875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066091				2022-12-17	WOS:000251537900009
J	Olsson, AY; Feber, A; Edwards, S; Poele, RT; Giddings, I; Merson, S; Cooper, CS				Olsson, A. Y.; Feber, A.; Edwards, S.; Poele, R. te; Giddings, I.; Merson, S.; Cooper, C. S.			Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells	ONCOGENE			English	Article						cDNA microarray; cellular proliferation; bladder; prostate; cancer; siRNA	COMPARATIVE GENOMIC HYBRIDIZATION; URINARY-BLADDER; CHROMOSOMAL IMBALANCES; GENETIC ALTERATIONS; COPY NUMBER; AMPLIFICATION; CARCINOMA; TUMORS; RB; SPECIFICITY	cation and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine ( BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.	MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; CRUK Ctr Canc Therapeut, Inst Canc Res, Male Urol Canc Res Ctr, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Olsson, AY (corresponding author), MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	yvonne.olsson@icr.ac.uk		Giddings, Ian/0000-0003-1078-5780; Feber, Andrew/0000-0001-5282-0498	Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bidus MA, 2006, CLIN CANCER RES, V12, P83, DOI 10.1158/1078-0432.CCR-05-0835; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Black EP, 2005, P NATL ACAD SCI USA, V102, P15948, DOI 10.1073/pnas.0504300102; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bruch J, 2000, CANCER RES, V60, P4526; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dolbeare F, 1996, HISTOCHEM J, V28, P531, DOI 10.1007/BF02331377; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Hovey RM, 1998, CANCER RES, V58, P3555; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter J, 1999, CANCER RES, V59, P5687; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sambrook J, 2001, MOL CLONING LAB MANU; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Simon R, 2000, INT J ONCOL, V17, P1025; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Tomovska S, 2001, INT J ONCOL, V18, P1239; Veltman JA, 2003, CANCER RES, V63, P2872; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	43	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1028	1037		10.1038/sj.onc.1209854	http://dx.doi.org/10.1038/sj.onc.1209854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909110	Bronze			2022-12-17	WOS:000244245400009
J	Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A				Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A			Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling	ONCOGENE			English	Article						lung cancer; statins; ras; protein kinase B; receptor tyrosine kinase	PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; PATHWAY; STATINS; PROLIFERATION; SUPPRESSION; PROGRESSION; LINES; MEK	The impact of the 3-hydroxy-3methylglutaryl CoA reductase inhibitor simvastatin on human small-cell lung cancer (SCLC) cell growth and survival was investigated. Simvastatin profoundly impaired basal and growth factor-stimulated SCLC cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin were sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC tumour growth in vivo was inhibited by simvastatin. These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Constitutive activation of the Erk pathway was sufficient to rescue SCLC cell from the effects of simvastatin. The drug did not directly affect activation of c-Kit or its localization to lipid rafts, but in addition to its ability to block Ras membrane localization, it selectively downregulated H-Ras protein levels at the post-translational level. Downregulation of either H- or K-Ras by RNA interference (RNAi) did not impair Erk activation by growth factors, whereas an RNAi specific for N-Ras inhibited activation of Erk, PKB and SCLC cell growth. Together our data demonstrate that inhibiting Ras signalling with simvastatin potently disrupts growth and survival in human SCLC cells.	Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Div Med,Lung Canc Biol Grp, London, England; CRUK London Res Inst, London, England	University Children's Hospital Zurich; Imperial College London; Cancer Research UK	Arcaro, A (corresponding author), Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Alexandre.Arcaro@kispi.unizh.ch	Arcaro, Alexandre/G-1711-2010; Pardo, Oliver/AEM-2071-2022; Downward, Julian/A-3251-2012	Arcaro, Alexandre/0000-0001-9107-2947; Pardo, Oliver/0000-0003-2223-1435; Downward, Julian/0000-0002-2331-4729				Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Chun KH, 2003, CANCER RES, V63, P4796; Furst J, 2002, CELL PHYSIOL BIOCHEM, V12, P19, DOI 10.1159/000047823; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hirai A, 1997, J BIOL CHEM, V272, P13; Hiwasa T, 1998, BIOCHEM BIOPH RES CO, V250, P741, DOI 10.1006/bbrc.1998.9386; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kusama T, 2001, CANCER RES, V61, P4885; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Moore SM, 1998, CANCER RES, V58, P5239; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Tsao H, 2000, CANCER RES, V60, P1800; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200	24	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					877	887		10.1038/sj.onc.1209117	http://dx.doi.org/10.1038/sj.onc.1209117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170339				2022-12-17	WOS:000235212700007
J	Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ				Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ			Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b	ONCOGENE			English	Article						VEGF; TIS11b; mRNA stability; AU-rich element	IN-VIVO; TRISTETRAPROLIN; STABILITY; CELLS; DEADENYLATION; STABILIZATION; DEGRADATION; HYPOXIA; PATHWAY; ELEMENT	Vascular endothelial growth factor (VEGF) is an angiogenic cytokine, which plays a major role in tumor angiogenesis. VEGF mRNA expression is controlled by hypoxia, growth factors and hormones through both transcriptional and post-transcriptional mechanisms. VEGF mRNA has a short half-life and its abundance is regulated by the binding of stabilizing (HuR, hRNP-L) and still uncharacterised destabilizing proteins to its 3'-untranslated region. Here, we report that the ACTH-regulated zinc-finger protein TIS11b and its homologs TIS11 and TIS11d interact with the 3'-untranslated region of VEGF mRNA and decrease its stability (half-life reduced from 130 to 60 min). Within the 2201 by 3'-untranslated region of VEGF mRNA, we identified a 75 by domain, containing two consensus AU-rich motifs, which binds TIS11b and mediates its destabilizing activity. Ribonucleoprotein (RNP) complex immunoprecipitation experiments allowed us to demonstrate that the interaction between TIS11b and VEGF 3'-untranslated region occurs in live cells. Knocking down TIS11b expression in primary adrenocortical cells with small interfering (si)RNAs clearly indicated that TIS11b participates in the control of both basal and, to a larger extent, ACTH-induced VEGF mRNA expression levels. TIS11b is the first VEGF mRNA-destabilizing protein identified so far and therefore appears as a new potential target in antiangiogenic therapies.	CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, F-38054 Grenoble 9, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signalling Dev Biol & Canc Res, F-06189 Nice, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Feige, JJ (corresponding author), CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jjfeige@cea.fr	bailly, sabine/G-3540-2013; Feige, Jean-Jacques/M-8905-2017; Ciais, Delphine/O-9435-2016; Berra, Edurne/F-9692-2011; Cherradi, Nadia/K-9695-2016	bailly, sabine/0000-0003-1043-7030; Feige, Jean-Jacques/0000-0002-1354-7692; Berra, Edurne/0000-0002-3820-5744; Cherradi, Nadia/0000-0002-4292-774X; Ciais, Delphine/0000-0002-1649-897X				Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Brand C, 1998, J BIOL CHEM, V273, P6410, DOI 10.1074/jbc.273.11.6410; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chinn AM, 2002, MOL ENDOCRINOL, V16, P1417, DOI 10.1210/me.16.6.1417; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; NEGOESCU A, 1994, MOL CELL ENDOCRINOL, V105, P155, DOI 10.1016/0303-7207(94)90165-1; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS HJ, 1991, BLOOD, V77, P1787; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000	22	93	96	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8673	8680		10.1038/sj.onc.1207939	http://dx.doi.org/10.1038/sj.onc.1207939			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467755				2022-12-17	WOS:000224988800013
J	Henry, MD; Triplett, AA; Oh, KB; Smith, GH; Wagner, KU				Henry, MD; Triplett, AA; Oh, KB; Smith, GH; Wagner, KU			Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice	ONCOGENE			English	Article						mammary gland; differentiation; Cre recombinase; tumorigenesis; mouse mammary tumor virus; transgenics	PROGENITOR CELLS; EXPRESSION; GLAND; POPULATION; PREGNANCY; PATHOLOGY; DELETION; TSG101; BREAST	Using a Cre-lox-based genetic labeling technique, we have recently discovered a parity-induced mammary epithelial subtype that is abundant in nonlactating and nonpregnant, parous females. These mammary epithelial cells serve as alveolar progenitors in subsequent pregnancies, and transplantation studies revealed that they possess features of multipotent progenitors such as self-renewal and the capability to contribute to ductal and alveolar morphogenesis. Here, we report that these cells are the cellular targets for transformation in MMTV-neu transgenic mice that exhibit accelerated mammary tumorigenesis in multiparous animals. The selective ablation of this epithelial subtype reduces the onset of tumorigenesis in multiparous MMTV-neu transgenics. There is, however, experimental evidence to suggest that parity-induced mammary epithelial cells may not be the only cellular targets in other MMTV-promoter-based transgenic strains. In particular, the heterogeneous MMTV-wnt1 lesions predominantly express the ductal differentiation marker Nkcc1 that is absent in MMTV-neu-derived tumors. Our observations support the idea that tumors originate from distinctly different epithelial subtypes in selected MMTV-promoter-driven cancer models and that diverse oncogenes might exert discrete effects on particular mammary epithelial subtypes.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,Room 8009, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NCI NIH HHS [CA036727, CA93797] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010021, P30CA036727, R01CA093797, Z01BC010021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brisken C, 2000, GENE DEV, V14, P650; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARSTENS MJ, 2004, UNPUB; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Kisseberth WC, 2004, CANCER RES, V64, P857, DOI 10.1158/0008-5472.CAN-03-2701; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; Reed W, 2003, INT J SURG PATHOL, V11, P65, DOI 10.1177/106689690301100201; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rowse GJ, 1998, CANCER RES, V58, P2675; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WELLINGS SR, 1975, J NATL CANCER I, V55, P231	20	93	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6980	6985		10.1038/sj.onc.1207827	http://dx.doi.org/10.1038/sj.onc.1207827			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286714				2022-12-17	WOS:000223750700014
J	Jinawath, N; Furukawa, Y; Hasegawa, S; Li, MH; Tsunoda, T; Satoh, S; Yamaguchi, T; Imamura, H; Inoue, M; Shiozaki, H; Nakamura, Y				Jinawath, N; Furukawa, Y; Hasegawa, S; Li, MH; Tsunoda, T; Satoh, S; Yamaguchi, T; Imamura, H; Inoue, M; Shiozaki, H; Nakamura, Y			Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray	ONCOGENE			English	Article						diffuse-type gastric cancer; cDNA microarray; laser-microbeam microdissection; expression profile	E-CADHERIN; SOMATIC MUTATIONS; LIVER METASTASES; BREAST-CANCER; PATTERNS; CELLS; BETA; ADENOCARCINOMA; CARCINOMA; METALLOPROTEINASES	Gastric cancer is the fourth leading cause of cancer-related death in the world. Two histologically distinct types of gastric carcinoma, 'intestinal' and 'diffuse', have different epidemiological and pathophysiological features that suggest different mechanisms of carcinogenesis. A number of studies have investigated intestinal-type gastric cancers at the molecular level, but little is known about mechanisms involved in the diffuse type, which has a more invasive phenotype and poorer prognosis. To clarify the mechanisms that underlie its development and/or progression, we compared the expression profiles of 20 laser-microbeam-microdissected diffuse-type gastric-cancer tissues with corresponding noncancerous mucosae by means of a cDNA microarray containing 23 040 genes. We identified 153 genes that were commonly upregulated and more than 1500 that were commonly downregulated in the tumors. We also identified a number of genes related to tumor progression. Furthermore, comparison of the expression profiles of diffuse-type with those of intestinal-type gastric cancers identified 46 genes that may represent distinct molecular signatures of each histological type. The putative signature of diffuse-type cancer exhibited altered expression of genes related to cell matrix interaction and extracellular-matrix (ECM) components, whereas that of intestinal-type cancer represented enhancement of cell growth. These data provide insight into different mechanisms underlying gastric carcinogenesis and may also serve as a starting point for identifying novel diagnostic markers and/or therapeutic targets for diffuse-type gastric cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; RIKEN, SNP Res Ctr, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto, Japan; Canc Inst Hosp, Dept Surg, Tokyo, Japan; Sakai City Hosp, Dept Surg, Osaka, Japan; Kinki Univ, Sch Med, Nara Hosp, Dept Surg, Nara, Japan; Kinki Univ, Sch Med, Sayama Hosp, Dept Surg, Osaka 589, Japan	University of Tokyo; RIKEN; Kyoto University; Japanese Foundation for Cancer Research; Kindai University (Kinki University); Kindai University (Kinki University)	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6; BECKER KF, 1994, CANCER RES, V54, P3845; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boussioutas A, 2003, CANCER RES, V63, P2569; Campbell DJ, 2002, J CLIN INVEST, V110, P1079, DOI 10.1172/JCI200216946; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75; CRAANEN ME, 1995, GUT, V36, P848, DOI 10.1136/gut.36.6.848; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Dan S, 2002, CANCER RES, V62, P1139; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hasegawa S, 2002, CANCER RES, V62, P7012; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kim B, 2003, CANCER RES, V63, P8248; Kitahara O, 2001, CANCER RES, V61, P3544; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Ming Si-Chun, 1998, Gastric Cancer, V1, P31, DOI 10.1007/s101200050053; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Padovan E, 2002, CANCER RES, V62, P3453; Park WS, 1999, CANCER RES, V59, P4257; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Peddanna N, 1995, ANTICANCER RES, V15, P2055; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schwartz DR, 2003, CANCER RES, V63, P2913; SIPPONEN P, 1995, AM J SURG PATHOL, V19, pS30; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; St Croix B, 2000, SCIENCE, V289, P1197; Sumi T, 2003, ONCOL REP, V10, P345; Takemoto H, 2001, INT J CANCER, V91, P783, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1121>3.0.CO;2-Z; Tay ST, 2003, CANCER RES, V63, P3309; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; Yanagawa R, 2001, NEOPLASIA, V3, P395, DOI 10.1038/sj.neo.7900185; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	43	93	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6830	6844		10.1038/sj.onc.1207886	http://dx.doi.org/10.1038/sj.onc.1207886			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273739				2022-12-17	WOS:000223653600016
J	Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A				Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A			Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability	ONCOGENE			English	Article						MRE11; MMR defect; colorectal cancer; NBS1; DNA double strand breaks repair	STRAND BREAK REPAIR; DEFICIENT COLORECTAL CANCERS; MISMATCH REPAIR; TARGET GENES; DNA-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; COLON-CANCER; PROTEIN; INACTIVATION	Frequent mutations of coding nucleotide repeats are thought to contribute significantly to carcinogenesis associated with microsatellite instability (MSI). We have shown that shortening of the poly(T) 11 within the polypyrimidine stretch/accessory splicing signal of human MRE11 leads to the reduced expression and functional impairment of the MRE11/NBS1/RAD50 complex. This mutation was selectively found in mismatch repair (MMR) defective cell lines and potentially identifies MRE11 as a novel target for MSI. Here, we examined 70 microsatellite unstable primary human cancers and we report that MRE11 mutations occur in 83.7 and 50% of the colorectal and endometrial cancers, respectively. In the colorectal cancer series, mutated MRE11 is more frequently associated with advanced age at diagnosis and A/B stages. Biallelic mutations were present in 38.8% of the cases and more frequently associated with lower (G1/G2) grade tumors. Impaired MRE11 expression was prevalent in primary colorectal tumors with larger and biallelic shortening of the poly(T)11. Immunohistochemistry confirmed the impaired MRE11 expression and revealed NBS1-defective expression in MRE11 mutated cancers. Together with the observation that perturbation of the MRE11/NBS1/RAD50 complex predisposes to cancer, our work highlights MRE11 as a new common target in the MMR deficient tumorigenesis and suggests its role in colorectal carcinogenesis.	Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, Pozzilli, Italy; Univ Aquila, Dept Expt Med, Laquila L7100, Italy; Ctr Riferimento Oncol, IRCCS, Div Expt Oncol 1, I-33081 Aviano, Italy; Ctr Riferimento Oncol, IRCCS, Dept Preclin & Epidemiol Res, I-33081 Aviano, Italy; Univ Sacred Heart, Dept Gynecol, I-00168 Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, I-00161 Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; IRCCS Neuromed; University of L'Aquila; IRCCS Aviano (CRO); IRCCS Aviano (CRO); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione Cenci Bolognetti	Giannini, G (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Bidoli, Ettore/AAC-1762-2020; Viel, Alessandra/J-7116-2018; Frati, Luigi/ABI-7437-2020; Giannini, Giuseppe/B-5672-2013; d'Amati, Giulia/F-1251-2011	Bidoli, Ettore/0000-0001-8273-9084; Viel, Alessandra/0000-0003-2804-0840; Giannini, Giuseppe/0000-0003-0299-4056; d'Amati, Giulia/0000-0002-6959-691X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Boland CR, 1998, CANCER RES, V58, P5248; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2002, CANCER RES, V62, P2447; Fleiss JL, 1981, STAT METHODS RATES P, V2, P212; Fukuda T, 2001, CANCER RES, V61, P23; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matsuoka S, 2001, CANCER RES, V61, P5362; Mori Y, 2002, CANCER RES, V62, P3641; Park J, 2002, CANCER RES, V62, P1284; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Perucho M, 2003, ONCOGENE, V22, P2223, DOI 10.1038/sj.onc.1206580; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tessitore A, 2003, GENE CHROMOSOME CANC, V36, P198, DOI 10.1002/gcc.10145; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Varon R, 2001, CANCER RES, V61, P3570; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Zhang L, 2001, CANCER RES, V61, P3801	36	93	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2004	23	15					2640	2647		10.1038/sj.onc.1207409	http://dx.doi.org/10.1038/sj.onc.1207409			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048091	Green Published			2022-12-17	WOS:000220714900005
J	Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR				Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR			Role of Bim in the survival pathway induced by Raf in epithelial cells	ONCOGENE			English	Article						Bim; anoikis; phosphorylation; EGF receptor	GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY; PROTEIN BIM; PROAPOPTOTIC ACTIVITY; DEPENDENT PATHWAY; SIGNALING PATHWAY; BH3-ONLY PROTEIN; KINASE PATHWAY; MOTOR COMPLEX; ACTIVATION	Selective and sustained activation of the Raf/MAP kinase pathway in MCF-10A DeltaRaf-ER cells, a spontaneously immortalized human mammary epithelial cell line, was previously shown to protect these cells from suspension-induced cell death, a critical feature of the Ras-transformed phenotype. Although autocrine signalling through the EGF receptor is crucial for the protection induced by Raf in these cells, we report here the existence of an additional, more direct survival mechanism, linking Raf activation to the inhibition of a proapoptotic member of the Bcl-2 family, Bim. While detachment from the matrix results in transcriptional induction of two variants of this BH3-only protein, BimEL and BimL, activation of the Raf/ERK signalling both prevents Bim upregulation specifically and leads to phosphorylation and degradation of the BimEL isoform. This represents an important route to protect epithelial cells from the proapoptotic effect of Bim.	Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Cancer Research UK; Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lemoine, NR (corresponding author), Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, DuCane Rd, London W12 0NN, England.	nick.lemoine@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Tenev, Tencho/0000-0001-8762-1069				Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BOS JL, 1989, CANCER RES, V49, P4682; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEI K, 2003, P NATL ACAD SCI USA, V18, P18; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261	36	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2431	2441		10.1038/sj.onc.1207364	http://dx.doi.org/10.1038/sj.onc.1207364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676826				2022-12-17	WOS:000220558000001
J	Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO				Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO			hScrib is a functional homologue of the Drosophila tumour suppressor Scribble	ONCOGENE			English	Article						hScrib; Scribble; polarity; cell cycle; tumour suppressor; Drosophila; discs large	CELL POLARITY; GENE-EXPRESSION; PROTEIN; DLG; IDENTIFICATION; PROLIFERATION; PROGRESSION; EPITHELIA; GROWTH; CANCER	Scribble (scrib), discs large (dlg) and lethal giant larvae (lgl) encode proteins that regulate cell polarity and have been identified as neoplastic tumour suppressor genes in Drosophila melanogaster. Here, we have used the Drosophila model system to provide the first functional evidence that human Scribble (hScrib) can act as a tumour suppressor. We show that hScrib protein displays highly polarized localization in mammalian epithelial cells and colocalizes with mammalian Dlg, similar to D. melanogaster Scribble (DmScrib) distribution in Drosophila epithelium. Furthermore, hScrib can rescue the polarity and tumorous overgrowth defects of scrib mutant Drosophila. hScrib therefore can act as an effective tumour suppressor in vivo, regulating both apical-basal polarity and cellular proliferation in a manner similar to that of DmScrib in Drosophila. These data demonstrate that hScrib is a functional homologue of DmScrib and therefore predict an important role for hScrib in the suppression of mammalian tumorigenesis.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Cell Cycle & Dev Lab, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Ctr, Canc Cell Death Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Immune Signaling Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3005, Australia	Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.		Richardson, Helena E/A-8080-2013; Russell, Sarah M/B-9341-2009; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Russell, Sarah M/0000-0001-5826-9641; Humbert, Patrick O/0000-0002-1366-6691; Trapani, Joseph/0000-0003-0983-1532; Dow, Lukas/0000-0001-7048-1418				BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; GATEFF E, 1994, INT J DEV BIOL, V38, P565; Huang JHY, 2003, GENE EXPR PATTERNS, V3, P3, DOI 10.1016/s1567-133X(02)00096-0; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	93	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9225	9230		10.1038/sj.onc.1207154	http://dx.doi.org/10.1038/sj.onc.1207154			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681682				2022-12-17	WOS:000187400400004
J	Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T				Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T			Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts	ONCOGENE			English	Article						rheumatoid arthritis; transformation; notch; Jagged; gene expression; TNF	NF-KAPPA-B; INTRACELLULAR DOMAIN; GENE-EXPRESSION; ARTHRITIS; ALPHA; ACTIVATION; KINASE; MICE; IL-6; SYNOVIOCYTES	Rheumatoid arthritis ( RA) is characterized by progressive inflammation associated with abberrant proliferation of synoviocytes. In order to explore the characteristics of rheumatoid synovial fibroblasts (RSF), we performed the comparative gene expression profile analysis between RSF and normal synovial. broblasts (NSF) upon tumor necrosis factor (TNF) stimulation. As an initial screening for the genes preferentially induced by TNF in RSF compared with NSF, we have adopted a cDNA array containing well-defined sets of genes responsible for cell growth, cell fate determination, and cellular invasiveness. Differentially expressed genes of interest were confirmed using real-time RT-PCR. We found that TNF induced the expression of Notch-1, Notch-4, and Jagged-2 in RSF. The expression of these proteins was detected in the RA synovial tissues. The nucleus of RA synoviocytes showed strong staining with anti-Notch-1 and Notch-4 antibody. TNF induced the nuclear translocation of Notch intracellular domain in RSF, indicating the elicitation of the Notch signaling. Notch-1, Notch-4, and Jagged-2 proteins were also detected in the developing synovium of mouse embryo. Thus, RSF may have re-acquired the primordial phenotype, accounting for the hyperproliferation and aggressive invasiveness, exhibiting tumor-like phenotype.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Orthoped, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fassbender H G, 1980, Verh Dtsch Ges Pathol, V64, P193; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 2001, J CLIN INVEST, V107, P1353, DOI 10.1172/JCI13209; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MullerLadner U, 1996, AM J PATHOL, V149, P1607; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; Nakazawa M, 2001, ARTHRITIS RHEUM-US, V44, P1545, DOI 10.1002/1529-0131(200107)44:7<1545::AID-ART278>3.0.CO;2-Q; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sen M, 2002, ARTHRITIS RHEUM, V46, P2867, DOI 10.1002/art.10593; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Watanabe N, 2002, BIOCHEM BIOPH RES CO, V294, P1121, DOI 10.1016/S0006-291X(02)00608-3; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151; Yoshida S, 1999, J IMMUNOL, V163, P351	31	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7796	7803		10.1038/sj.onc.1206965	http://dx.doi.org/10.1038/sj.onc.1206965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586405				2022-12-17	WOS:000186240200009
J	Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K				Chamulitrat, W; Schmidt, R; Tomakidi, P; Stremmel, W; Chunglok, W; Kawahara, T; Rokutan, K			Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes	ONCOGENE			English	Article						redox-signaling; human gingival keratinocytes; anchorage-independent growth; gp91phox homologs; Nox1	SMOOTH-MUSCLE CELLS; NADPH OXIDASE; IN-VITRO; MALIGNANT TRANSFORMATION; SUPEROXIDE GENERATION; RAS TRANSFORMATION; EPITHELIAL-CELLS; FIBROBLASTS; EXPRESSION; LOCALIZATION	Among five members of the NADPH oxidase (Nox) family, Nox1 confers mitogenic properties and is implicated to participate in the process of cell transformation. We have established two phenotypes of carcinogenesis model by ethanol treatment of human gingival keratinocytes immortalized with E6/E7 oncogenes of human papillomavirus type16: immortalized (EPI) nontransformed cells with epithelium-like morphology and more advanced transformed (FIB) cells with spindle fibroblastic-shape morphology. FIB membranes possessed a 63-kDa Nox1 protein at higher levels and exhibited 2.8-fold higher capability for superoxide and hydroxyl radical generation, compared with EPI membranes. Both EPI and FIB cells expressed more abundant Nox1 protein at a proliferating stage than that at a quiescent confluent phase. Immunofluorescence staining with an anti-Nox1 antibody showed that immunoreactive materials were distributed in the whole interior of both types of cells, while they were preferentially localized in the nuclei of FIB cells. Nuclei isolated from EPI and FIB cells contained a 63 kDa-Nox1 protein. Compared with EPI cells, FIB cells expressed elevated levels of Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase proteins. Furthermore, JNK2 was constitutively phosphorylated in FIB cells. Together, our data strongly implicate Nox1 in redox-mediated signaling related to cellular activation of human keratinocytes at a more advanced stage of transformation.	Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, D-69115 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Dept Appl Tumorvirol, D-69120 Heidelberg, Germany; Univ Heidelberg, Sch Dent, Dept Orthodont, D-69120 Heidelberg, Germany; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 770, Japan	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Mahidol University; Tokushima University	Chamulitrat, W (corresponding author), Univ Heidelberg, Univ Clin Hosp, Dept Gastroenterol & Infect Dis, Bergheimer Str 58, D-69115 Heidelberg, Germany.	Walee_Chamulitrat@med.uni-heidelberg.de		Stremmel, Wolfgang/0000-0002-8545-1753				Aplin AE, 2002, J CELL SCI, V115, P2781; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; Chamulitrat W, 2003, EUR J CELL BIOL, V82, P313, DOI 10.1078/0171-9335-00317; Chamulitrat W, 1999, FREE RADICAL BIO MED, V27, P411, DOI 10.1016/S0891-5849(99)00088-X; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chiu C, 2001, INT J MOL MED, V8, P251; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Goldman R, 1999, BBA-MOL CELL BIOL L, V1438, P349, DOI 10.1016/S1388-1981(99)00066-9; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones RD, 2000, FREE RADICAL BIO MED, V29, P416, DOI 10.1016/S0891-5849(00)00320-8; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; PARK NH, 1995, ONCOGENE, V10, P2145; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sashiyama H, 2002, CANCER LETT, V177, P21, DOI 10.1016/S0304-3835(01)00771-6; Schimmel M, 2002, ONCOGENE, V21, P5886, DOI 10.1038/sj.onc.1205740; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yoshida LS, 2002, BIOCHEM BIOPH RES CO, V296, P1322, DOI 10.1016/S0006-291X(02)02059-4	40	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6045	6053		10.1038/sj.onc.1206654	http://dx.doi.org/10.1038/sj.onc.1206654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955083				2022-12-17	WOS:000185137800013
J	Stoecklin, G; Gross, B; Ming, XF; Moroni, C				Stoecklin, G; Gross, B; Ming, XF; Moroni, C			A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA	ONCOGENE			English	Article						ARE; interleukin-3; MRNA decay; tristetraprolin; zinc-finger protein	INTERLEUKIN-3 MESSENGER-RNA; ACTIVATED PROTEIN-KINASE; MAST-CELLS; DEGRADATION PATHWAY; STABILITY FACTOR; CANCER CELLS; GM-CSF; ELEMENTS; TRISTETRAPROLIN; STABILIZATION	The occurrence of pathologically stable mRNAs of protooncogenes, growth factors and cyclins has been proposed to contribute to experimental and human oncogenesis. In normal resting cells, mRNAs containing an AU-rich element (ARE) in their 3' untranslated region are subjected to rapid degradation. Tristetraprolin (TTP) is an RNA-binding zinc-finger protein that promotes decay of ARE-containing mRNAs. Here we report that TTP acts as a potent tumor suppressor in a v-H-ras-dependent mast cell tumor model, where tumors express abnormally stable interleukin-3 (IL-3) mRNA as part of an oncogenic autocrine loop. Premalignant v-H-ras cells were transfected with TTP and injected into syngeneic mice. TTP expression delayed tumor progression by 4 weeks, and late appearing tumors escaped suppression by loss of TTP. When transfected into a fully established tumor line, TTP reduced cloning efficiency in vitro and growth of the inoculated cells in vivo. Transgenic TTP interfered with the autocrine loop by enhancing the degradation of IL-3 mRNA with concomitant reduction of IL-3 secretion. Our data establish the ARE as an antioncogenic target in a model situation, underline the importance of mRNA stabilization in oncogenesis and show for the first time that tumor suppression can be achieved by interfering with mRNA turnover.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Stoecklin, Georg/0000-0001-9284-9834				AGHIB DF, 1990, ONCOGENE, V5, P707; ALGATE PA, 1993, ONCOGENE, V8, P1221; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gouble A, 2002, CANCER RES, V62, P1489; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirsch HH, 1996, GROWTH FACTORS, V13, P99, DOI 10.3109/08977199609034570; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nabors LB, 2001, CANCER RES, V61, P2154; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS HJ, 1991, BLOOD, V77, P1787; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stoecklin G, 2001, RNA, V7, P1578; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200	44	93	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3554	3561		10.1038/sj.onc.1206418	http://dx.doi.org/10.1038/sj.onc.1206418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789264				2022-12-17	WOS:000183399200006
J	Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C				Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C			Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation	ONCOGENE			English	Article						reverse transcriptase inhibitor; endogenous reverse transcriptase; proliferation; differentiation; transformation	EMBRYONAL CARCINOMA-CELLS; ENDOGENOUS RETROVIRAL SEQUENCES; TOXIC EPIDERMAL NECROLYSIS; DEPENDENT DNA POLYMERASE; F9 TERATOCARCINOMA CELLS; ACUTE MYELOID-LEUKEMIA; RETINOIC-ACID; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LINE-1 RNA	Endogenous, nontelomeric reverse transcriptase (RT) is encoded by two classes of repeated elements: retrotransposons and endogenous retroviruses. Expression of RT-coding genes is generally repressed in differentiated nonpathological tissues, yet is active in the mammalian germ line, embryonic tissues and tumor cells. Nevirapine is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin. Here, we show that nevirapine is also an effective inhibitor of the endogenous RT in murine and human cell lines. In addition, progenitor and transformed cells undergo a significant reduction in the rate of cell growth upon exposure to nevirapine. This is accompanied by the onset of differentiation, as depicted in F9 and C2C7 progenitor cells cultures in which nevirapine triggers the expression of differentiation-specific markers. Consistent with this, an extensive reprogramming of cell cycle gene expression was depicted in nevirapine-treated F9 cultures. Furthermore, nevirapine exposure rescued the differentiation block present in acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients, as indicated by morphological, functional and immunophenotypic assays. The finding that an RT inhibitor can modulate cell proliferation and differentiation suggests that RT may represent a novel target in the development of therapeutical approaches to neoplasia.	Ist Super Sanita, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Siena, Dept Paediat Obstet & Reprod Med, I-53100 Siena, Italy; Univ Roma La Sapienza, Dept Med Histol & Embryol, Rome, Italy; Univ Cattolica Sacro Cuore, Med Oncol Unit, Rome, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Siena; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.		Lavia, Patrizia/J-5793-2019; Landriscina, Matteo/K-1092-2016; Lavia, Patrizia/AAL-3982-2021; Travaglini, Lorena/AAA-6245-2020	Lavia, Patrizia/0000-0003-3310-6701; Spadafora, Corrado/0000-0002-5743-3224; Landriscina, Matteo/0000-0003-0591-9799; Spadafora, Corrado/0000-0001-9647-1410; NERVI, Clara/0000-0001-9341-0188; Travaglini, Lorena/0000-0003-0142-6516; Sciamanna, Ilaria/0000-0002-5629-6184				ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; Babich V, 1999, GENE, V239, P341, DOI 10.1016/S0378-1119(99)00391-1; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Banerjee S, 2000, BBA-PROTEIN STRUCT M, V1480, P1, DOI 10.1016/S0167-4838(00)00080-7; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROSIUS J, 1996, VIRUS GENES, V11, P163; Cattelan AM, 2001, J INFECTION, V43, P246, DOI 10.1053/jinf.2001.0902; Chou HK, 2000, BIOCHEM J, V348, P473, DOI 10.1042/0264-6021:3480473; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fagot JP, 2001, AIDS, V15, P1843, DOI 10.1097/00002030-200109280-00014; Ferrara FF, 2001, CANCER RES, V61, P2; Ferrigno O, 2001, NAT GENET, V28, P77, DOI 10.1038/88306; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; KIESSLING AA, 1979, CANCER RES, V39, P2062; LANOTTE M, 1991, BLOOD, V77, P1080; Li Y, 1999, EXP CELL RES, V253, P372, DOI 10.1006/excr.1999.4664; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Nekrutenko A, 2001, TRENDS GENET, V17, P619, DOI 10.1016/S0168-9525(01)02445-3; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; ROGERS MB, 1990, J CELL BIOL, V110, P1767, DOI 10.1083/jcb.110.5.1767; ROSS SA, 1994, J CELL PHYSIOL, V159, P263, DOI 10.1002/jcp.1041590210; SALGANIK RI, 1985, BIOCHEM BIOPH RES CO, V131, P492, DOI 10.1016/0006-291X(85)91829-7; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1971, J NATL CANCER I, V46, P56; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Tomilin NV, 1999, INT REV CYTOL, V186, P1; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	57	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2750	2761		10.1038/sj.onc.1206354	http://dx.doi.org/10.1038/sj.onc.1206354			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12747369				2022-12-17	WOS:000182569300006
J	Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM				Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM			Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells	ONCOGENE			English	Article						Bax; chronic lymphocytic leukemia; proteasome inhibitors	CYTOCHROME-C RELEASE; TRAIL-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; CASPASE ACTIVATION; HUMAN TISSUES; SURVIVAL; KINASE; RESISTANCE; EXPRESSION; PROTEIN	Chemotherapy resistance remains a major clinical problem in patients with B-cell chronic lymphocytic leukemia (B-CLL). Proteasome inhibitors are able to induce apoptosis in chemotherapy-resistant B-CLL cells in vitro. Exposure of B-CLL cells to the proteasome inhibitors, MG132 and lactacystin, resulted in inhibition of proteasomal activity within 30 min of treatment and was accompanied by an increase in the level of ubiquitinated proteins. Proteasome inhibitors did not alter the levels of expression of the proapoptotic Bcl-2 family proteins, Bax and Bid, prior to the onset of apoptosis. Instead, proteasome inhibitors induced a caspase-independent conformational change in Bax (as shown by a conformation-specific Bax antibody) and its translocation to mitochondria, resulting in mitochondrial perturbation, as evidenced by loss of the mitochondrial membrane potential and cytochrome c release. Similar conformational change and subcellular localization of Bax were observed during apoptosis induced with fludarabine, chlorambucil and prednisolone. These data suggest that alteration of Bax conformation and its redistribution to mitochondria are common and early features of B-CLL apoptosis in response to proteasome inhibitors and other chemotherapeutic agents.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Leicester Royal Infirm, Dept Hematol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	dewson, grant/C-7646-2013; Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	dewson, grant/0000-0003-4251-8898; Dyer, Martin/0000-0002-5033-2236				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bannerji R, 2000, CURR OPIN ONCOL, V12, P22, DOI 10.1097/00001622-200001000-00004; Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hideshima T, 2001, CANCER RES, V61, P3071; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kalil N, 1999, Oncologist, V4, P352; Kitada S, 1998, AM J PATHOL, V152, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Murray RZ, 2000, ANTI-CANCER DRUG, V11, P407, DOI 10.1097/00001813-200007000-00001; Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600-0609.2000.065004221.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1998, LEUKEMIA LYMPHOMA, V28, P355, DOI 10.3109/10428199809092690; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Reed JC, 1998, SEMIN HEMATOL, V35, P3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984	71	93	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2643	2654		10.1038/sj.onc.1206326	http://dx.doi.org/10.1038/sj.onc.1206326			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730678				2022-12-17	WOS:000182569000012
J	Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F			Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours	ONCOGENE			English	Article						methylation; 3p21.3 tumour suppressor gene; testicular tumours	HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; PROMOTER HYPERMETHYLATION; LUNG CARCINOMAS; ABERRANT METHYLATION; HUMAN NEOPLASIA; CANCER; HETEROZYGOSITY; REGION; BREAST	Testicular germ cell tumours (TGCTs) are histologically heterogeneous neoplasms with variable malignant potential. Previously, we demonstrated frequent 3p allele loss in TGCTs, and recently we and others have shown that the 3p21.3 RASSF1A tumour suppressor gene (TSG) is frequently inactivated by promoter hypermethylation in a wide range of cancers including lung, breast, kidney and neuroblastoma. In order to investigate the role of epigenctic events in the pathogenesis of TGCTs, we analysed the promoter methylation status of RASSF1A and nine other genes that may be epigenetically inactivated in cancer (p16(INK4A), APC, MGMT, GSTP1, DAPK, CDH1, CDH13, RARbeta and FHIT) in 24 primary TGCTs (28 histologically distinct components). RASSF1A methylation was detected in four of 10 (40%) seminomas and 15 of 18 (83%) nonseminoma TGCT (NSTGCT) components (P = 0.0346). None of the other nine candidate genes were methylated in seminomas, but MGMT (44%), APC (29%) and FHIT (29%) were frequently methylated in NSTGCTs. Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstrated RASSF1A, APC and CDH13 promoter methylation, but the seminoma component was unmethylated for all genes analysed. In the second mixed germ cell tumour, the NSTGCT component was methylated for RASSF1A and MGMT, while the seminoma component was methylated only for RASSF1A. In all, 61% NSTGCT components but no seminoma samples demonstrated promoter methylation at two or more genes (P = 0.0016). These findings are consistent with a multistep model for TGCT pathogenesis in which RASSF1A methylation occurs early in tumorigenesis and additional epigenetic events characterize progression from seminoma to NSTGCTs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Univ Birmingham, Sch Med, Canc Res UK Renal Mol Oncol Res Grp, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Bonn; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chaubert P, 1997, AM J PATHOL, V151, P859; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kraggerud SM, 2002, CANCER RES, V62, P512; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lind Guro Elisabeth, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1120; Lo KW, 2001, CANCER RES, V61, P3877; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; LOOIJENGA LHJ, 1994, GENE CHROMOSOME CANC, V9, P153, DOI 10.1002/gcc.2870090302; LOTHE RA, 1995, LAB INVEST, V73, P606; Maruyama R, 2002, CLIN CANCER RES, V8, P514; MATHEW S, 1994, CANCER RES, V54, P6265; Morrissey C, 2001, CANCER RES, V61, P7277; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Murty VVVS, 1996, ONCOGENE, V12, P2719; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; Rothe M, 1999, J PATHOL, V188, P389, DOI 10.1002/(SICI)1096-9896(199908)188:4<389::AID-PATH364>3.0.CO;2-K; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	43	93	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					461	466		10.1038/sj.onc.1206119	http://dx.doi.org/10.1038/sj.onc.1206119			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545168				2022-12-17	WOS:000180379100016
J	Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F			Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients	ONCOGENE			English	Article						methylation; RASSF1A; sputum; ductal carcinoma in situ	FREQUENT EPIGENETIC INACTIVATION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; CPG ISLAND; 3P21.3; REGION; METHYLATION; LOCUS	The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours. To determine the extent of RASSF1A promoter hypermethylation in early lung tumorigenesis, we analysed sputum samples from lung cancer patients and from current and former smokers using a sensitive methylation-specific PCR (MSP) technique. We also analysed RASSF1A promoter region hypermethylation in trios of normal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patients and DCIS without invasive cancer. We found that 50% of small cell lung cancer (SCLC) and 21% of non-small cell lung cancer (NSCLC) patients had RASSF1A methylation, while one of two former smokers and four of 13 current smokers demonstrated RASSF1A methylation in sputum. Furthermore, two of the four current smokers and one former smoker showing RASSF1A methylation in their sputum developed cancer within 12-14 months of bronchoscopy. In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. In addition, we found that three out of 10 DCIS without invasive breast cancer also underwent RASSF1A promoter hypermethylation. Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer. Furthermore, since RASSF1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be an early event in breast tumorigenesis.	Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Marburg, D-35033 Marburg, Germany; Krankenhaus Neukolln, Abt Innere Med 3, Schwerpunkt Pneumonol Infektiol, Berlin, Germany; Univ Pisa, Dept Oncol, Div Pathol, Pisa, Italy	University of Birmingham; Philipps University Marburg; University of Pisa	Latif, F (corresponding author), Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	MAHER, EAMONN R/A-9507-2008; Caligo, Adelaide Maria/K-4289-2018	MAHER, EAMONN R/0000-0002-6226-6918; Caligo, Adelaide Maria/0000-0003-0589-1829				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Morrissey C, 2001, CANCER RES, V61, P7277; Palmisano WA, 2000, CANCER RES, V60, P5954; Vlacava P, 1999, J PATHOL, V188, P245	17	93	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					147	150		10.1038/sj.onc.1206057	http://dx.doi.org/10.1038/sj.onc.1206057			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527916				2022-12-17	WOS:000180166900015
J	Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L				Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L			Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors	ONCOGENE			English	Article						Wnt signaling; beta-catenin activation; Int2/Fgf3; cytokeratin expression; pilar tumor; transdifferentiation	PROTEIN-KINASE CK2; BETA-CATENIN; TRANSGENIC MICE; CYCLIN D1; FUNCTIONAL INTERACTION; HAIR FOLLICLE; FEMALE MICE; GENE; GLAND; EXPRESSION	The Wnt/beta-catenin signaling pathway controls cell fate and neoplastic transformation. Expression of an endogenous stabilized beta-catenin (DeltaE3 beta-catenin) in mammary epithelium leads to the transdifferentiation into epidermis- and pilar-like structures. Signaling molecules in the canonical Wnt pathway upstream from P-catenin induce glandular tumors but it is not clear whether they also cause squamous transdifferentiation. To address this question we have now investigated mammary epithelium from transgenic mice that express activating molecules of the Wnt pathway: Wnt10b, Int2/Fgf3, CK2alpha, DeltaE3 beta-catenin, Cyclin D1, and dominant negative (dn) GSK3beta. Cytokeratin 5 (CK5), which is expressed in both mammary myoepithelium and epidermis, and the epidermis-specific CK1 and CK6 were used as differentiation markers. Extensive squamous metaplasias and widespread expression of CK1 and CK6 were observed in DeltaE3 beta-catenin transgenic mammary tissue. Wnt10b and Int2 transgenes also induced squamous metaplasias, but expression of CK1 and CK6 was sporadic. While CK5 expression in Wnt I Ob transgenic tissue was still confined to the lining cell layer, its expression in Int2 transgenic tissue was completely disorganized. In contrast, cytokeratin expression in CK2alpha dnGSK3beta and Cyclin D1 transgenic mammary tissues was similar to that in DeltaE3 beta-catenin tissue. In support of transdifferentiation, expression of hard keratins specific for hair and nails was observed in pilar tumors. These results demonstrate that the activation of Wnt signaling components in mammary epithelium induces not only glandular tumors but also squamous differentiation, possibly by activating LEF-1, which is expressed in normal mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Univ Tokushima, Sch Dent, Dept Biochem, Tokushima 7708504, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; McLaughlin Res Inst, Great Falls, MT USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Kyoto Univ, Grad Sch Med, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tokushima University; University of California System; University of California Davis; Boston University; McLaughlin Research Institute for Biomedical Sciences, Inc.; Harvard University; Massachusetts General Hospital; Kyoto University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101,8 Ctr Dr, Bethesda, MD 20892 USA.		Robinson, Gertraud/I-2136-2012	Seldin, David C/0000-0003-0168-2333; Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841	NCRR NIH HHS [U42 RR14905] Funding Source: Medline; NIEHS NIH HHS [P01 ES11624] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR014905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; KLINT P, 1999, FRONT BIOSCI, V4, P165; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Niemann C, 2002, DEVELOPMENT, V129, P95; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; ROSNER A, 2002, IN PRESS AM J PATHOL; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tekmal Rajeshwar Rao, 1997, Frontiers in Bioscience, V2, pD519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	46	93	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5548	5556		10.1038/sj.onc.1205686	http://dx.doi.org/10.1038/sj.onc.1205686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165853				2022-12-17	WOS:000177442000004
J	Oehler, MK; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis	ONCOGENE			English	Article						adrenomedullin; angiogenesis; tumorigenesis; tamoxifen; endometrial cancer	INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; CELL LINES; HYPOXIA; CANCER; TAMOXIFEN; ESTROGEN; MECHANISM; RECEPTOR; PEPTIDE	The angiogenic peptide adrenomedullin (ADM) has been implicated as a mediator of the increased risk of endometrial hyperplasia and cancer resulting from the use of tamoxifen for the treatment and prevention of breast cancer. ADM has been shown to be induced by tamoxifen in the endometrium and to be a growth factor for endometrial endothelial cells in vitro. We have now shown ADM to be strongly angiogenic in the mouse subcutaneous sponge angiogenesis assay. To examine the role of ADM in tumor growth, the ADM cDNA was transfected into endometrial carcinoma cells followed by xenografting into athymic mice. Two endometrial cancer cell lines were employed, those in which transfection and expression of ADM resulted in no effect on growth in vitro (Ishikawa cells) and those in which expression of exogenous ADM stimulated in virtro growth (RL95.2 cells). A clear enhancement of tumor growth was seen with both cell lines but the effect was far greater with the RL95.2 cells. We conclude that ADM is pro-tumorigenic by stimulating either angiogenesis alone or by stimulating angiogenesis and carcinoma cell growth directly. The combined activities lead to a striking increase in tumor growth. These results provide the first direct evidence of tumorigenic activity of ADM and provide further support for ADMs involvement in tamoxifen induced endometrial neoplasia.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK,Mol Angiogenesis Lab, Oxford OX3 9DS, England.	r.bicknell@cancer.org.uk		Bicknell, Roy/0000-0002-0941-8919				Ali SH, 2000, CANCER RES, V60, P7094; ATTIA MAM, 1966, CANCER RES, V26, P1787; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bilimoria MM, 1996, J STEROID BIOCHEM, V58, P479, DOI 10.1016/0960-0760(96)00078-7; Birner P, 2000, CANCER RES, V60, P4693; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Dalton RR, 2001, SOUTH MED J, V94, P7; FOX SB, 1995, J PATHOL, V177, P275, DOI 10.1002/path.1711770310; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hata K, 2000, MOL HUM REPROD, V6, P867, DOI 10.1093/molehr/6.10.867; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lal A, 1999, CANCER RES, V59, P5403; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; NIKITENKO LL, 2002, IN PRESS TRENDS PHAR; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; PIO R, 2000, BIOL CHEM, V486, P3; Rocchi P, 2001, CANCER RES, V61, P1196; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SUNDARESHAN P, 1992, IN VITRO CELL DEV-AN, V28A, P544; Walsh DA, 1996, HISTOCHEM J, V28, P759, DOI 10.1007/BF02272149; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; White INH, 1999, CARCINOGENESIS, V20, P1153, DOI 10.1093/carcin/20.7.1153; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213; ZHANG L, 1995, J CELL SCI, V108, P323; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zhong H, 1999, CANCER RES, V59, P5830	36	93	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2815	2821		10.1038/sj.onc.1205374	http://dx.doi.org/10.1038/sj.onc.1205374			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973640				2022-12-17	WOS:000175063700005
J	Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS				Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS			Regulation of p73 by c-Abl through the p38 MAP kinase pathway	ONCOGENE			English	Article						p73; c-Abl; p38; p53; DNA damage	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; DNA-DAMAGE; CELL-DEATH; APOPTOTIC RESPONSE; P53 GENE; STRESS; FAMILY; AGENTS	p73 is a novel member of the p53 family of tumor suppressor proteins which is involved in cellular differentiation, tumor suppression, and the response to genotoxic stress. The molecular mechanisms regulating p73 activity are still poorly understood. Recently, p73 was found to be a target of the enzymatic activity of c-Abl, a non-receptor tyrosine kinase that potently activated in response to DNA damage. Here, we present evidence that c-Abl induces the phosphorylation of p73 in threonine residues adjacent to prolines, and that the p38 MAP kinase pathway mediates this response. Furthermore, we found that activation of p38 is sufficient to enhance the stability of p73, and that the transcriptional activation of p73 by c-Abl requires the activity of p38. These findings indicate that members of the MAP kinases superfamily of signaling molecules can regulate p73, and support a role for the p38 MAP kinase in a novel biochemical pathway by which c-Abl regulates this p53-related molecule.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Clin Puerta Hierro, Dept Anat Patol, Unidad Patol Mol, Madrid 28035, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019; Sanchez-Prieto, Ricardo/B-6877-2008; Sanchez-Prieto, Ricardo/AAY-4271-2021; Prieto, Ricardo/AAZ-7221-2021; Gutkind, J. Silvio/A-1053-2009; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011	Gutkind, J. Silvio/0000-0002-5150-4482; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; SERVITJA, JOAN-MARC/0000-0002-1241-8004	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agami R, 1999, NATURE, V399, P809; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gong JG, 1999, NATURE, V399, P806; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	32	93	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					974	979		10.1038/sj.onc.1205134	http://dx.doi.org/10.1038/sj.onc.1205134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840343				2022-12-17	WOS:000173427100013
J	Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L				Thomas, M; Glaunsinger, B; Pim, D; Javier, R; Banks, L			HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation	ONCOGENE			English	Article						HPV; E6; DIg; MAGI-1; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE TUMOR-SUPPRESSOR; CARCINOMA CELL-LINES; GUANYLATE-KINASE; PDZ DOMAINS; PHOSPHOINOSITIDE 3-KINASE; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	It has recently been shown that the high-risk human papillomavirus (HPV) E6 proteins can target the PDZ-domain containing proteins, Dlg, MUPP-1, MAGI-1 and hScrib for proteasome-mediated degradation. However, the E6 proteins from HPV-16 and HPV-18 (the two most common high-risk virus types) differ in their ability to target these proteins in a manner that correlates with their malignant potential. To investigate the underlying mechanisms for this, we have mutated HPV-16 and HPV-18 E6s to give each protein the other's PDZ-binding motif. Analysis of these mutants shows that the greater ability of HPV-18 E6 to bind to these proteins and to target them for degradation is indeed due to a single amino acid difference. Using a number of assays, we show that the E6 proteins interact specifically with only one of the five PDZ domains of MAGI-1, and this is the first interaction described for this particular PDZ domain. We also show that the guanylate kinase homology domain and the regions of MAGI-1 down stream of amino acid 733 are pot required for the degradation of MAGI-I. Finally, in a series of comparative analyses, we show that the degradation of MAGI-1 occurs through a different mechanism from that used by the E6 protein to induce the degradation of DIg and p53.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Thomas, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NCI NIH HHS [R01 CA058541-06, R01 CA058541, R01 CA58541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li J, 1998, CANCER RES, V58, P5667; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tashiro H, 1997, CANCER RES, V57, P3935; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	48	93	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5431	5439		10.1038/sj.onc.1204719	http://dx.doi.org/10.1038/sj.onc.1204719			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571640	Green Accepted			2022-12-17	WOS:000170781100003
J	Adams, JW; Brown, JH				Adams, JW; Brown, JH			G-proteins in growth and apoptosis: lessons from the heart	ONCOGENE			English	Review						cardiac; Gq; heart failure; hypertrophy; cardiomyocyte	RAT VENTRICULAR MYOCYTES; MYOCARDIAL-CELL HYPERTROPHY; CARDIAC GENE-EXPRESSION; BETA-ADRENERGIC PATHWAY; II-INDUCED HYPERTROPHY; KINASE-C-EPSILON; TRANSGENIC MICE; IN-VIVO; PRESSURE-OVERLOAD; PERTUSSIS-TOXIN	The acute contractile function of the heart is controlled by the effects of released nonepinephrine (NE) on cardiac adrenergic receptors, NE can also act in a more chronic fashion to induce cardiomyocyte growth, characterized by cell enlargement (hypertrophy), increased protein synthesis, alterations in gene expression and addition of sarcomeres. These responses enhance cardiomyocyte contractile function and thus allow the heart to compensate for increased stress. The hypertrophic effects of NE are mediated through Gq-coupled alpha (1)-adrenergic receptors and are mimicked by the actions of other neurohormones (endothelin, prostaglandin F-2 alpha angiotensin II) that also act on Gq-coupled receptors, Activation of phospholipase C by Gq is necessary for these responses, and protein kinase C and MAP kinases have also been implicated. Gq stimulated cardiac hypertrophy is also evident in transgenic mouse models. In contrast, stimulation of G(s)-coupled beta -adrenergic receptors or G(i)-coupled receptors do not directly effect cardiomyocyte hypertrophy, Apoptosis is also induced by G-protein-coupled receptor stimulation in cardiomyocytes, Sustained or excessive activation of either Gq- or Gs-signaling pathways results in apoptotic loss of cardiomyocytes both in vitro and in vivo, Apoptosis is associated with decreased ventricular function in the failing heart, Cardiomyocytes provide an ideal model system for understanding the basis for G-protein mediated hypertrophy and apoptosis, and the mechanisms responsible for the transition from compensatory to deleterious levels of signaling. This information may prove critical for designing interventions that prevent the pathophysiological consequences of heart failure.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,0636, La Jolla, CA 92093 USA.							Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1994, J MOL CELL CARDIOL, V26, P133, DOI 10.1006/jmcc.1994.1017; BROWN LA, 1992, BRIT J PHARMACOL, V106, P115, DOI 10.1111/j.1476-5381.1992.tb14302.x; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Cigola E, 1997, EXP CELL RES, V231, P363, DOI 10.1006/excr.1997.3477; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Ehmke H, 1999, HYPERTENSION, V33, P954, DOI 10.1161/01.HYP.33.4.954; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Fortuno MA, 1998, HYPERTENSION, V32, P280, DOI 10.1161/01.HYP.32.2.280; Geng YJ, 1999, CIRC RES, V84, P34; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goussev A, 1998, AM J PHYSIOL-HEART C, V275, pH626, DOI 10.1152/ajpheart.1998.275.2.H626; Grupp IL, 1998, AM J PHYSIOL-HEART C, V275, pH1338, DOI 10.1152/ajpheart.1998.275.4.H1338; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; HILALDANDAN R, 1997, J BIOL CHEM, V272, pH130; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Iwase M, 1997, AM J PHYSIOL-HEART C, V272, pH585, DOI 10.1152/ajpheart.1997.272.1.H585; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; Jalili T, 1999, CARDIOVASC RES, V44, P5, DOI 10.1016/S0008-6363(99)00211-4; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Katz AM, 1995, EUR HEART J, V16, P110, DOI 10.1093/eurheartj/16.suppl_O.110; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li ZH, 1997, AM J PHYSIOL-HEART C, V272, pH2313, DOI 10.1152/ajpheart.1997.272.5.H2313; Liggett SB, 2000, CIRCULATION, V101, P1707; LINZ W, 1992, J CARDIOVASC PHARM, V20, pS83, DOI 10.1097/00005344-199200209-00015; LONG CS, 1992, BASIC RES CARDIOL, V87, P19; Matkovich SJ, 2000, J BIOL CHEM, V275, P10845, DOI 10.1074/jbc.275.15.10845; McWhinney C, 2000, J BIOL CHEM, V275, P2087, DOI 10.1074/jbc.275.3.2087; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Miyauchi T, 1999, TRENDS PHARMACOL SCI, V20, P210, DOI 10.1016/S0165-6147(99)01297-3; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; REDMAN CM, 2000, P NATL ACAD SCI USA, V97, P4826; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Sabbah HN, 1999, CLIN CARDIOL, V22, pV16; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Sakata Y, 1998, CIRCULATION, V97, P1488; Sekiguchi K, 1999, CIRC RES, V85, P1000; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; STEINBERG SF, 1995, J MOL CELL CARDIOL, V27, P141, DOI 10.1016/S0022-2828(08)80014-4; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; Tamamori M, 1996, J CLIN INVEST, V97, P366, DOI 10.1172/JCI118424; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Thurmann PA, 1998, CIRCULATION, V98, P2037, DOI 10.1161/01.CIR.98.19.2037; Varma DR, 2000, CAN J PHYSIOL PHARM, V78, P267, DOI 10.1139/cjpp-78-4-267; Vatner DE, 2000, CIRC RES, V86, P802, DOI 10.1161/01.RES.86.7.802; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamazaki T, 1999, HYPERTENS RES-CLIN E, V22, P113, DOI 10.1291/hypres.22.113; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zaugg M, 2000, CIRCULATION, V102, P344; Zhu YC, 1997, AM J CARDIOL, V80, pA110, DOI 10.1016/S0002-9149(97)00465-7; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	103	93	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1626	1634		10.1038/sj.onc.1204275	http://dx.doi.org/10.1038/sj.onc.1204275			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313910				2022-12-17	WOS:000168089800013
J	Tremain, R; Marko, M; Kinnimulki, V; Ueno, H; Bottinger, E; Glick, A				Tremain, R; Marko, M; Kinnimulki, V; Ueno, H; Bottinger, E; Glick, A			Defects in TGF beta signaling overcome senescence of mouse keratinocytes expressing v-ras(Ha)	ONCOGENE			English	Article						TGF beta 1; keratinocytes; replicative senescence; ras oncogene	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR GENE; SQUAMOUS CARCINOMA-CELLS; HARVEY-RAS ONCOGENE; HUMAN BREAST-CANCER; BENIGN SKIN TUMORS; II RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSGENIC MICE	Previous studies have shown that TGF beta 1 expression is upregulated in mouse keratinocytes infected with a v-ras(Ha) retrovirus, although the functional significance of this has not been clear. Here we show that v-ras(Ha) retrovirus transduced primary mouse keratinocytes undergo hyperproliferation followed by a TGF beta 1 dependent G1 growth arrest and senescence. The growth arrest is accompanied by a 15-fold increase in total TGF beta 1 secreted and a fourfold increase in secreted active TGF beta 1. When cultured in the presence of a neutralizing antibody to TGF beta 1, the senescence response is suppressed. Levels of the TGF beta 1 target p15(ink4b) increase during senescence as does association of this kinase inhibitor with cyclinD/cdk4 complexes. However, p16(ink4a), p53 and p19(ARF) expression also increase during senescence. Genetic analysis shows that TGF beta 1 null and dominant negative T beta RII expressing v-ras(Ha) keratinocytes resist the G1 growth arrest and do not senescence. This resistance is associated with low expression of p15(ink4b) and p16(ink4a), constitutive Rb phosphorylation and high levels of cdk4 and cdk2 kinase activity. In contrast, inactivation of TGF beta 1 secretion or response does not block the induction of p53 and p19(ARF), but the level of p21(waf1), a p53 target gene, is reduced in cyclin D/cdk4 and cyclin E/cdk2 complexes. Thus, although multiple senescence pathways are activated in response to a ras oncogene, inactivation of TGF beta 1 secretion or response is sufficient to block the senescence program. Since v-ras(Ha) transduced TGF beta 1-/- keratinocytes form squamous cell carcinomas following skin grafting, these results suggest that in mouse keratinocytes, defects in TGF beta 1 signaling accelerate malignant progression by overcoming oncogene induced replicative senescence.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA; Kyushu Univ, Sch Med, Dept Cardiol, Fukuoka 812, Japan; Albert Einstein Coll Med, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu University; Yeshiva University; Albert Einstein College of Medicine	Glick, A (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bld 37 3B-19, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010284] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALEXANDROW MG, 1995, PERSPECT CANC RES, V30, P1; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bond J, 1996, ONCOGENE, V13, P2097; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Bottinger EP, 1997, CANCER RES, V57, P5564; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CAMPISI J, 1993, ANN NY ACAD SCI, P195; CHANG HL, 1993, CANCER RES, V53, P4391; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DLUGOSZ AA, 1995, METHOD ENZYMOL, P3; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glick AB, 1996, CANCER RES, V56, P3645; Go C, 1999, CANCER RES, V59, P2861; GORSCH SM, 1992, CANCER RES, V52, P6949; Grady WM, 1998, CANCER RES, V58, P3101; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herman JG, 1996, CANCER RES, V56, P722; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; Iavarone A, 1997, NATURE, V387, P417; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.0.CO;2-8; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loughran O, 1996, ONCOGENE, V13, P561; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARSONS R, 1995, CANCER RES, V55, P5548; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUELLE DE, 1995, CELL, V83, P993; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reznikoff CA, 1996, CANCER RES, V56, P2886; Riggins GJ, 1997, CANCER RES, V57, P2578; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUDDLE FH, 1975, ANNU REV GENET, V9, P407, DOI 10.1146/annurev.ge.09.120175.002203; Sambrook J, 1989, MOL CLONING LAB MANU; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETH P, 1994, J VIROL, V68, P933, DOI 10.1128/JVI.68.2.933-940.1994; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1994, CANCER RES, V54, P1178; Zariwala M, 1996, ONCOGENE, V12, P451; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	82	93	95	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1698	1709		10.1038/sj.onc.1203471	http://dx.doi.org/10.1038/sj.onc.1203471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763827				2022-12-17	WOS:000086083800010
J	Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S				Kiley, SC; Clark, KJ; Duddy, SK; Welch, DR; Jaken, S			Increased protein kinase C delta in mammary tumor cells: relationship to transformation and metastatic progression	ONCOGENE			English	Article						protein kinase C; metastasis; adducin; mammary; breast cancer	TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CHO CELLS; ACTIVATION; EXPRESSION; EPSILON; DOMAINS; GROWTH; ALPHA; BINDING	Relatively little is known about the molecular mechanisms of tumor promotion/progression in mammary carcinogenesis. Increased protein kinase C (PKC) activity is known to promote tumor formation in several tissues; however, its role in mammary carcinogenesis is not yet known. To determine if individual PKCs may selectively regulate properties of mammary tumor cells, we compared PKC isozyme levels in mammary tumor cell lines,vith low, moderate and high metastatic potential. All three cell lines expressed alpha, delta, epsilon and zeta PKCs; however, PKC delta levels were relatively increased in the highly metastatic cells. To determine if increased PKC delta could contribute to promotion/progression, we overexpressed PKC delta in the low and moderately metastatic cell lines, PKC delta overexpression had no significant effect on growth of adherent cells, but significantly increased anchorage-independent growth. Conversely, expressing the regulatory domain of PKC delta (RD delta), a putative PKC delta inhibitory fragment, inhibited anchorage-independent growth. The efficacy of RD delta as a PKC delta inhibitor was demonstrated by showing that RD delta selectively interfered with PKC delta subcellular location and significantly interfered with phosphorylation of the PKC cytoskeletal substrate, adducin, PKC-dependent phosphorylation of cytoskeletal substrate proteins, such as adducin, provides a mechanistic link between increased PKC delta activity and phenotypic changes in cytoskeletal-dependent processes such as migration and attachment, two processes that are relevant to metastatic potential. The reciprocal growth effects of expressing PKC delta and RD delta as gain and loss of function constructs, respectively, provide strong evidence that PKC delta regulates processes important for anchorage-independent growth in these mammary tumor cells.	Adirondack Biomed Res Inst Inc, Lake Placid, NY 12946 USA; Penn State Univ, Coll Med, Jake Gittlen Canc Res Inst C7810, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Jaken, S (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg,A249, Burlington, VT 05405 USA.		Welch, Danny R/B-7310-2009	Welch, Danny R/0000-0002-1951-4947	NCI NIH HHS [CA 071604] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; CACACE AM, 1993, ONCOGENE, V8, P2095; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JAKEN S, 1997, PROTEIN KINASE C, P179; KAHN SM, 1994, CARCINOGENESIS, V15, P2915; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Kiley SC, 1999, CANCER RES, V59, P3230; LEACH KL, 1988, J BIOL CHEM, V263, P13223; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, FASEB J, V12, P35; NERI A, 1982, J NATL CANCER I, V68, P507; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; WEINSTEIN IB, 1979, J SUPRAMOLECULAR STR, V12, P527; WELCH DR, 1983, INVAS METAST, V3, P65; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	93	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6748	6757		10.1038/sj.onc.1203101	http://dx.doi.org/10.1038/sj.onc.1203101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597283				2022-12-17	WOS:000083792000017
J	Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH				Li, WQ; Zhang, JC; Flechner, L; Hyun, T; Yam, A; Franke, TF; Pierce, JH			Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal	ONCOGENE			English	Article						apoptosis; Akt/protein kinase B; protein; kinase C-alpha	MYC-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEOLYTIC ACTIVATION; MOLECULAR-CLONING; LEUKEMIA-CELLS; BETA-II; DELTA; FAMILY; TARGET	To investigate the role of protein kinase C (PKC) in apoptotic signaling induced by cytokine withdrawal, we expressed PKC-alpha, -delta and -epsilon individually in the 32D myeloid progenitor cells. The parental and PKC-delta- and PKC-epsilon- transfected 32D cells underwent apoptosis within 24 h in the absence of interleukin 3. In contrast, expression of PKC-alpha inhibited the onset of apoptosis as determined by genomic DNA fragmentation and flow cytometric analysis. Correlating with the inhibition of apoptosis, PKC-alpha transfectants exhibited increased activity of the endogenous Akt serine/threonine kinase. Furthermore, PKC-alpha, but not PKC-delta or -epsilon, specifically activated overexpressed Akt. PKC-alpha-induced Akt activity was partially dependent on phosphoinositol 3' kinase (PI 3'K) since a PI 3'K inhibitor was able to suppress PKC-alpha-induced Akt activation. Both basal and interleukin 3-stimulated phosphorylation of Akt on serine 473 was enhanced in the PKC-alpha and Akt contransfectants. Coexpression of wild type Akt and PKC-alpha resulted in greater suppression of apoptosis than PKC-alpha expression alone. Together, our results demonstrate that suppression of apoptosis by PKC-alpha correlates with its ability of activating endogenous Akt. Furthermore, activation of overexpressed Akt by PKC-alpha is consistent with their synergistic effect on suppressing apoptosis, providing the strong evidence of cross talk between Akt and PKC-alpha.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Stem Cell Res Lab, 3970 Reservoir Rd NW,NRB W309, Washington, DC 20007 USA.		Roszak, Joanna/F-4003-2010	Hyun, Teresa/0000-0002-9350-2733				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; delPeso L, 1997, SCIENCE, V278, P687; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Brian CA, 1998, ONCOL REP, V5, P305; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	45	93	94	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6564	6572		10.1038/sj.onc.1203065	http://dx.doi.org/10.1038/sj.onc.1203065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597260				2022-12-17	WOS:000083709200020
J	Goruppi, S; Ruaro, E; Varnum, B; Schneider, C				Goruppi, S; Ruaro, E; Varnum, B; Schneider, C			Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras	ONCOGENE			English	Article						Axl; signal transduction; apoptosis	RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; PROTEIN-KINASE; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTORS; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY; MAP KINASES	Gas6 isa growth factor membrane of the vitamin K-dependent family of proteins which is preferentially expressed in quiescent cells. Gas6 was identified as the ligand for Axl tyrosine kinase receptor family. Consistent with this, Gas6 was previously reported to induce cell cycle re-entry of serum-starved NIH3T3 cells and to prevent cell death after complete growth factor withdrawal, the survival effect being uncoupled from Gas6-induced mitogenesis. We have previously demonstrated that both Gas6 mitogenic and survival effects are mediated by Src and the phosphatidylinositol3-OH kinase (PI3K). Here we report that Ras is required for Gas6 mitogenesis but is dispensable for its survival effect. Gas6-induced survival requires the activity of the small GTPases of the Rho family, Rac and Rho, together with the downstream kinase Pak. Overexpression of the respective dominant negative constructs abrogates Gas6-mediated survival functions. Addition of Gas6 to serum starved cells results in the activation of AKT/PKB and in the phosphorylation of the Bcl-2 family member, Bad. By ectopic expression of a catalytically inactive form of AKT/PKB, we demonstrate that AKT/PKB is necessary for Gas6-mediated survival functions. We further show evidence that Gas6 stimulation of serum starved NIH3T3 cells results in a transient ERK, JNK/SAPK: and p38 MAPK. activation. Blocking ERK activation did not influence Gas6-induced survival, suggesting that such pathway is not involved in Gas6 protection from cell death. On the contrary we found that the late constitutive increase of p38 MAPK activity associated with cell death was downregulated in Gas6-treated NIH3T3 cells thus suggesting that Gas6 might promote survival by interfering with this pathway. Taken together the evidence here provided identity elements involved in Gas6 signalling more specifically elucidating the pathway responsible for Gas6-induced cell survival under conditions that do not allow cell proliferation.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci Tecnol Biomed, I-33100 Udine, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Amgen	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.				Telethon [770] Funding Source: Medline	Telethon(Fondazione Telethon)		ALESSI DR, 1995, J BIOL CHEM, V254, P1146; Avanzi GC, 1997, EXP HEMATOL, V25, P1219; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Li RH, 1996, J NEUROSCI, V16, P2012; LING L, 1995, MOL CELL BIOL, V15, P6582; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P1455, DOI 10.1002/art.1780400814; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; SYMONS M, 1996, TIBS, V22, P178; Tanaka K, 1998, ENDOCRINOLOGY, V139, P852, DOI 10.1210/en.139.3.852; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO R, 1995, SCIENCE, V2675, P2003; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	79	93	98	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4224	4236		10.1038/sj.onc.1202788	http://dx.doi.org/10.1038/sj.onc.1202788			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435635				2022-12-17	WOS:000081542400006
J	Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC				Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC			Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms	ONCOGENE			English	Article						c-Myc; transformation; tumor supressor; transcription	TUMOR-SUPPRESSOR BIN1; C-MYC; ORNITHINE DECARBOXYLASE; ACTIVATES TRANSCRIPTION; REPRESSOR SIN3; ADENOVIRUS E1A; GROWTH ARREST; PROTEIN; GENE; P53	The tumor suppressor Bin1 nas identified through its interaction with the N-terminal region of Myc which harbors its transcriptional activation domain. Here we show that Bin1 and Myc physically and functionally associate in cells and that Bin1 inhibits cell proliferation through both Myc-dependent and Myc-independent mechanisms. Bin1 specifically inhibited transactivation by Myc as assayed from artificial promoters or from the Myc target genes ornithine decarboxylase (ODC) and alpha prothymosin (pT). Inhibition of ODC but not pT required the presence of the Myc binding domain (MBD) of Bin1 suggesting two mechanisms of action. Consistent with this possibility, a non-MBD region of Bin1 was sufficient to recruit a repression function to DNA that was unrelated to histone deacetylase. Regions outside the MBD required for growth inhibition were mapped in Ras cotransformation or HepG2 hepatoma cell growth assays. Bin1 required the N-terminal BAR domain to suppress focus formation by Myc whereas the C-terminal U1 and SH3 domains were required to inhibit adenovirus E1A or mutant p53, respectively. All three domains contributed to Bin1 suppression or tumor cell growth but BAR-C was most crucial. These findings supported functional interaction between Myc and Bin1 in cells and indicated that Bin1 could inhibit malignant cell growth through multiple mechanisms.	Wistar Inst, Philadelphia, PA 19104 USA; Univ Marburg, Inst Mol Biol & Tumour Res IMT, D-35033 Marburg, Germany; Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA	The Wistar Institute; Philipps University Marburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.			Gaubatz, Stefan/0000-0001-8751-4191; Eilers, Martin/0000-0002-0376-6533				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DYSON N, 1992, CANCER SURV, V12, P161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E., ANTIBODIES LAB MANUA; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARUYAMA K, 1987, ONCOGENE, V1, P361; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YUAN ZM, 1996, J BIOL CHEM, V271, P26257; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	93	101	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3564	3573		10.1038/sj.onc.1202670	http://dx.doi.org/10.1038/sj.onc.1202670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380878				2022-12-17	WOS:000080891700002
J	Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC				Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC			Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway	ONCOGENE			English	Article						apoptosis; Rho proteins; p53; Bcl2; ceramides; TNF alpha	GTP-BINDING PROTEIN; NF-KAPPA-B; FAS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; ACTIN STRESS FIBERS; CELL-DEATH; C-MYC; RAS TRANSFORMATION; GROWTH-FACTOR; ADP-RIBOSYLTRANSFERASE	Rho proteins are a branch of GTPases that belongs to the Ras superfamily which are critical elements of signal transduction pathways leading to a variety of cellular responses. This family of small GTPases has been involved in diverse biological functions such as cytoskeleton organization, cell growth and transformation, cell motility, migration, metastasis, and responses to stress. We report that several human Rho proteins including Rho A, Rho C and Rac I, are capable of inducing apoptosis in different cell systems like murine NIH3T3 fibroblasts and the human erythroleukemia K562 cell line, Since K562 cells are devoid of p53, apoptosis induced by Rho in this system is independent of p53, Rho-dependent apoptosis is mediated by the generation of ceramides, and it is drastically inhibited by ectopic expression of Bcl2, both under in vitro and in vivo conditions. Furthermore, the human oncogenes vav and ost that have been shown to function as guanine exchange factors for Rho proteins, were also able to induce apoptosis under similar conditions. Finally, we also report that the levels of endogenous Rho proteins are increased when U937 myeloid leukemia cells are exposed to apoptosis-inducing conditions such as TNF alpha treatment. Furthermore, TNF alpha-induced apoptosis in these cells is inhibited by expression of a dominant negative mutant of Rac 1 but it is not affected by a similar mutant of Rho A. These results suggest that Rho proteins play an important role in the physiological regulation of the apoptotic response to stress-inducing agents.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; NCI, LCMB, Bethesda, MD 20892 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Universidad de Cantabria; University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lacal, JC (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain.		Cuenca, Benilde Jimenez/K-9959-2014; Lacal, Juan Carlos/AAL-2235-2020; embade, Nieves/K-5190-2014; Leon, Javier/K-4615-2014; del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/N-9064-2015	embade, Nieves/0000-0001-9878-3290; del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Leon, Javier/0000-0001-5803-0112; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; del Peso L, 1997, ONCOGENE, V15, P3047; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Esteve P, 1995, ONCOGENE, V11, P2657; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; MORII N, 1992, J BIOL CHEM, V267, P20921; MOSCOW JA, 1994, GENE, V144, P229, DOI 10.1016/0378-1119(94)90382-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Preston GA, 1996, MOL CELL BIOL, V16, P211; PROKOCIMER M, 1986, BLOOD, V68, P113; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	78	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1855	1869		10.1038/sj.onc.1202082	http://dx.doi.org/10.1038/sj.onc.1202082			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778052				2022-12-17	WOS:000076303300012
J	Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM				Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM			BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins	ONCOGENE			English	Article						prostate cancer; DU-145; BRCA1; DNA damage; apoptosis; p300	OVARIAN-CANCER; GENE BRCA1; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; MUTATIONS; REGION; P53; FRAGMENTS; CARRIERS; FAMILIES	In addition to breast and ovarian cancer in women, recent evidence suggests that germ-line mutations of the breast cancer susceptibility gene-1 (BRCA1) also confer an increased life-time risk for prostate cancer in male probands, However, it is not known if and how BRCA1 functions in prostate cancer, We stably expressed wildtype (wt) and tumor-associated mutant BRCA1 transgenes in DU-145, a human prostate cancer cell line with low endogenous expression of BRCA1, As compared with parental cells and vector transfected clones, wtBRCA1 clones exhibited: (1) a slightly decreased proliferation rate (doubling time = 25 h as compared with 22 h for control cells); (2) a (3-6)-fold increase in sensitivity to chemotherapy drugs (adriamycin, camptothecin, and taxol); (3) increased susceptibility to drug-induced apoptosis; (4) reduced repair of single-strand DNA strand breaks; and (5) alterations in expression of key cellular regulatory proteins (including BRCA2, p300, Mdm-2, p21(WAF1/CIP1), Bcl-2 and Bar). Clones transfected with the 5677insA breast cancer-associated mutant BRCA1 (insBRCA1) displayed a similar phenotype to wtBRCA1 clones, except that insBRCA1 clones had a significantly decreased proliferation rate (doubling time=42 h), On the other hand, cells transfected with with 185delAG mutant BRCA1 showed no obvious phenotype as compared with parental or vector transfected cells, These findings suggest that BRCA1 may function as a human prostate tumor suppressor by virtue of its ability to modulate proliferation and various components of the cellular damage response. They also suggest several potential target gene products for a BRCA1 prostate tumor suppressor function.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Fan, SJ (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.		Meng, Q./GSI-6185-2022					ALLEY MC, 1988, CANCER RES, V48, P589; ANDRES JL, IN PRESS ONCOGENE; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAO X, 1995, ONCOGENE, V11, P1241; Garnick MB, 1996, ANN INTERN MED, V125, P205, DOI 10.7326/0003-4819-125-3-199608010-00009; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JISHI MF, 1995, CANCER, V76, P1416, DOI 10.1002/1097-0142(19951015)76:8<1416::AID-CNCR2820760818>3.0.CO;2-D; Karp JE, 1996, CANCER RES, V56, P5547; Langston AA, 1996, AM J HUM GENET, V58, P881; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Webber MM, 1997, PROSTATE, V30, P58; Williams BJ, 1996, J UROLOGY, V155, P720, DOI 10.1016/S0022-5347(01)66509-1; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	47	93	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3069	3082		10.1038/sj.onc.1202116	http://dx.doi.org/10.1038/sj.onc.1202116			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662340				2022-12-17	WOS:000074125300014
J	Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T				Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T			ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system	ONCOGENE			English	Article						Tob/BTG1 family; antiproliferative activity; ventricular zone; cartilage	SONIC HEDGEHOG; MESSENGER-RNA; GENE; CELL; PROTEIN; ALLELOTYPE; CARCINOMA; INDUCTION; PRODUCT; PC3	Using a polymerase chain reaction-mediated cloning procedure, we have identified a novel member, termed ANA (from Abundant in Nueroepithelium Area), of Tob/BTG1 family of antiproliferative genes, Molecular cloning and analysis of cDNAs revealed that the human and mouse ANA encoded a protein of 252 amino acids, The amino-terminal half of ANA was homologous to the previously characterized antiproliferative gene products, BTG1, PC3/TIS21/BTG2, and Tob, The human, ANA gene was localized at chromosome 21q11.2-q21.1, ANA ,vas expressed in a variety of tissues and cell lines, its expression being high in the ovary, testis, prostate, thymus, and lung. Further analysis revealed that ANA expression was high in the ventricular zone of the developing central nervous system, Finally, overexpression of ANA impaired serum-induced cell cycle progression from the G(0)/G(1) to S phase. In conclusion, ANA is a fourth member of the Tob/BTG1 family that might play roles in neurogenesis in the central nervous system.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.			Umemori, Hisashi/0000-0001-7198-2062				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GILBERT SF, 1994, DEV BIOL, P244; GRAHAM A, 1991, DEVELOPMENT, V112, P255; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JOHNSTON MC, 1985, TERATOLOGY, V31, pA26; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MANTAGNOLI A, 1996, CELL GROWTH DIFFER, V7, P1327; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matsuda S, 1996, ONCOGENE, V12, P705; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sambrook J, 1989, MOL CLONING LAB MANU; SATO S, 1994, CANCER RES, V54, P5652; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TAN SS, 1985, CELL TISSUE RES, V240, P403; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8	27	93	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2687	2693		10.1038/sj.onc.1201805	http://dx.doi.org/10.1038/sj.onc.1201805			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632145				2022-12-17	WOS:000073698200013
J	Leeds, P; Kren, BT; Boylan, JM; Betz, NA; Steer, CJ; Gruppuso, PA; Ross, J				Leeds, P; Kren, BT; Boylan, JM; Betz, NA; Steer, CJ; Gruppuso, PA; Ross, J			Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro	ONCOGENE			English	Article						mRNA stability; coding region determinant; fetal development	MOUSE-LIVER REGENERATION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; CODING REGION; CELL-DIFFERENTIATION; BOUND POLYSOMES; UNDEGRADED FREE; XENOPUS LIVER; HALF-LIFE; RAT-LIVER	We previously isolated and characterized a coding region determinant-binding protein (CRD-BP) that might regulate c-myc mRNA post-transcriptionally. CRD-BP binds specifically to the coding region of c-myc mRNA and might stabilize c-myc mRNA in vitro by protecting it from endonucleolytic cleavage, Since c-myc abundance is regulated during embryonic development and cell replication, we investigated whether CRD-BP is also regulated in animal tissues. We focused on CRD-BP expression during rat liver development and liver regeneration, because c-myc mRNA is regulated post-transcriptionally in both cases, CRD-BP expression parallels c-myc expression during liver development; the protein is present in fetal and neonatal liver but is absent or in low abundance in adult liver, In contrast, the up-regulation of c-myc mRNA following partial hepatectomy is not accompanied by upregulation of CRD-BP, To our knowledge, CRD-BP is the first example of a putative mammalian mRNA-binding protein that is abundant in a fetal tissue but either absent from or scarce in adult tissues, Its expression in fetal liver and in transformed cell lines suggests CRD-BP is an oncofetal protein.	UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PATHOL, MADISON, WI 53706 USA; RHODE ISL HOSP, DEPT PEDIAT, PROVIDENCE, RI 02903 USA; BROWN UNIV, SCH MED, PROVIDENCE, RI 02903 USA; UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT CELL BIOL, MINNEAPOLIS, MN 55455 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA007175, R01CA063676] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA63676] Funding Source: Medline; NICHD NIH HHS [HD24455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fausto Nelson, 1994, P1059; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GRUPPUSO PA, 1996, IN PRESS IN VITRO CE; Gruppuso Philip A., 1993, Pediatric Research, V33, p49A; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Higgins GM, 1931, ARCH PATHOL, V12, P186; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAMSEY JC, 1976, BIOCHEMISTRY-US, V15, P1704, DOI 10.1021/bi00653a018; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKIGUCHI M, 1985, J BIOCHEM, V97, P1447, DOI 10.1093/oxfordjournals.jbchem.a135199; Tiffany HL, 1996, J BIOL CHEM, V271, P12387, DOI 10.1074/jbc.271.21.12387; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zelus BD, 1996, J VIROL, V70, P2411, DOI 10.1128/JVI.70.4.2411-2419.1996	43	93	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1279	1286		10.1038/sj.onc.1201093	http://dx.doi.org/10.1038/sj.onc.1201093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178888				2022-12-17	WOS:A1997WP10900003
J	Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B				Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B			Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2	ONCOGENE			English	Article						MAP kinase; auto-inhibition; DNA-binding; Drosophila; vertebrates	PROTEIN SECONDARY STRUCTURE; TERNARY COMPLEX FACTORS; DNA-BINDING ACTIVITY; GENE FAMILY; V-ETS; DOMAIN PROTEIN; C-FOS; ONCOGENIC CONVERSION; NEURAL NETWORKS; DROSOPHILA EYE	Cell transformation by the Pas oncogene is mediated by members of the ets gene family, To analyse the mechanisms of regulation, we have studied activation of several ets factors by Pas expression, We show that expression of Ha-Pas strongly activates the Ets1 p68 and p54 isoforms and Ets2 in F9 EC cells. We have mapped the Pas responsive elements of Ets1 p68 to two domains, RI+II and RIII. Mutation of threonine 82 to alanine in RI+II abolishes both Pas activation and phosphorylation by MAP kinase. Threonine 82 is part of a sequence that is conserved in Drosophila Pointed P2, an ets protein that has been shown both genetically and biochemically to mediate Pas signalling in Drosophila cells. We extend the comparison of these evolutionary related proteins by showing that Pointed P2 is activated by Pas in mammalian cells and mutation of the homologous threonine abolishes activation. Furthermore, we show that Pointed P2 resembles Ets1, in that it has conserved sequences in a similar position adjacent to the ets DNA binding domain that negatively auto-regulates DNA binding. These results go towards showing that the Drosophila Pointed and vertebrate Ets1 are evolutionary related proteins that have remarkably conserved Pas regulatory mechanisms downstream from MAP kinase.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wasylyk, C (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, CNRS, INSERM, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.		Wasylyk, Bohdan/ABG-6778-2020; Gutierrez-Hartmann, Arthur/F-1295-2011	Wasylyk, Bohdan/0000-0002-1718-1237; 				ALBAGLI O, 1994, ONCOGENE, V9, P3259; ALBAGLI O, 1992, ONCOGENE, V7, P1435; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER P, 1994, ONCOGENE, V9, P911; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GEGONNE A, 1992, NEW BIOL, V4, P512; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIARIS H, 1995, INT J ONCOL, V7, P413; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROSS IL, 1994, ONCOGENE, V9, P121; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VALENTINE MA, 1995, J EXP MED, V182, P1943, DOI 10.1084/jem.182.6.1943; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2	78	93	96	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					899	913		10.1038/sj.onc.1200914	http://dx.doi.org/10.1038/sj.onc.1200914			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050989				2022-12-17	WOS:A1997WK34400003
J	Mymryk, JS				Mymryk, JS			Tumour suppressive properties of the adenovirus 5 E1A oncogene	ONCOGENE			English	Review						E1A; cancer; adenovirus; tumour-suppressor	NECROSIS-FACTOR-ALPHA; NATURAL-KILLER-CELLS; TOXIC LYMPHOCYTES-T; RAT EMBRYO CELLS; RETINOBLASTOMA GENE-PRODUCT; PROTEINS INDUCE APOPTOSIS; F9 TERATOCARCINOMA CELLS; OVARIAN-CANCER CELLS; NERVE GROWTH-FACTOR; C-TERMINAL DOMAIN	The transforming oncogenes of DNA tumour viruses have proven useful as tools to dissect the mechanisms of complex cellular processes. In particular, studies of the multifunctional proteins encoded by the early region 1A (EIA) of human adenovirus types 2 and 5 have provided insight into the regulation of cellular gene expression, growth and differentiation. Despite their well known ability to immortalize primary rodent cells and transform them in cooperation with a second oncogene, the EIA proteins also exhibit significant anti-tumour/tumour suppressive activity. This review focuses on the surprising ability of EIA to function as a tumour suppressor gene.	UNIV WESTERN ONTARIO, LONDON REG CANC CTR, DEPT OBSTET & GYNAECOL, LONDON, ON N6A 4L6, CANADA	Western University (University of Western Ontario)	Mymryk, JS (corresponding author), UNIV WESTERN ONTARIO, LONDON REG CANC CTR, DEPT PHARMACOL & TOXICOL, 790 COMMISSIONERS RD E, LONDON, ON N6A 4L6, CANADA.							ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BERK AJ, 1986, CANCER SURV, V5, P367; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERNHARD EJ, 1995, INT J CANCER, V60, P718, DOI 10.1002/ijc.2910600525; Boulakia CA, 1996, ONCOGENE, V12, P529; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Coffman FD, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000259; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1993, ONCOGENE, V8, P625; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; GRAHAM FL, 1984, ADENOVIRUSES, P339; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HENNIG G, 1995, ONCOGENE, V11, P475; HOFMANN M, 1993, CANCER RES, V53, P1516; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUGHES PD, 1989, J IMMUNOL, V143, P4193; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES NC, 1992, MALIGNANT TRANSFORMA, P87; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; KUPPUSWAMY M, 1988, ONCOGENE, V2, P567; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LASTER SM, 1988, J IMMUNOL, V141, P2629; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER S, 1992, ONCOGENE, V7, P439; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYOL X, 1993, ONCOGENE, V8, P2561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1994, ONCOGENE, V9, P1187; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; NERLOV C, 1991, ONCOGENE, V6, P1583; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PRIETO RS, 1995, ONCOGENE, V11, P675; PRIETO RS, 1995, INT J CANCER, V60, P235; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROUTES JM, 1991, J VIROL, V65, P1450, DOI 10.1128/JVI.65.3.1450-1457.1991; Routes JM, 1996, J IMMUNOL, V156, P1055; ROUTES JM, 1993, J IMMUNOL, V150, P4315; SANTORO M, 1994, EXP CELL RES, V213, P398, DOI 10.1006/excr.1994.1215; SAWADA Y, 1994, INT J CANCER, V57, P598, DOI 10.1002/ijc.2910570426; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHEIDER JF, 1987, EMBO J, V6, P2053; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHEIL JM, 1984, J IMMUNOL, V132, P1578; SHENK T, 1991, ADV CANCER RES, V57, P47; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SLACK RS, 1995, ONCOGENE, V10, P19; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TEODORO JG, 1995, ONCOGENE, V11, P467; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJI Y, 1993, J IMMUNOL, V150, P1897; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDAM H, 1989, ONCOGENE, V4, P1207; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; VELCICH A, 1989, ONCOGENE, V4, P707; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIGEL RJ, 1990, NUCLEIC ACIDS RES, V18, P6107, DOI 10.1093/nar/18.20.6107; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	153	93	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1581	1589						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895502				2022-12-17	WOS:A1996VM88700001
J	Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A				Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A			p21 contains independent binding sites for cyclin and cdk2: Both sites are required to inhibit cdk2 kinase activity	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitor; domains of p21	DEPENDENT KINASES; PHOSPHORYLATION; PROTEIN; ACTIVATION; P34CDC2; SUBUNIT; CDC2; GENE; DNA	Cyclin dependent kinases regulate the progression of eukaryotic cells through the cell cycle, p21(Cip1/Waf1/Sdi1) is an inhibitor of cdk-cyclin kinase activity, and has been shown to form complexes with cdk-cyclins and with PCNA, an accessory protein of DNA polymerase delta, The kinase inhibitory domain maps to the N-terminus (1-82) and contains the cdk2 binding site (28-82), We have generated a panel of deletion mutants of p21, A functional characterization of p21 mutants in the N-terminal domain reveals that cyclins bind to this domain independently of cdk2, Correlating with these results we find that p21 can associate with cyclin-cdk kinases in two functionally distinct forms, one in which the kinase activity is inhibited and the other in which the kinase is still active, The cdk2 and cyclin binding sites on p21 are both required to inhibit kinase activity, The second type of interaction, in which an active cyclin-cdk complex only interacts with p21 either via the cyclin or the cdk2 binding site but not through both, does not lead to inhibition of cyclin kinase activity, These results thus provide a basis for understanding the mechanism by which p21, and perhaps other cdk-cyclin kinase inhibitory proteins, suppress kinase activity.	LA JOLLA INST ALLERGY & IMMUNOL,DIV MOLEC BIOL,LA JOLLA,CA 92037; CTR RECH BIOCHIM MACROMOL,CNRS UPR 9008,F-34033 MONTPELLIER,FRANCE	La Jolla Institute for Immunology; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Fotedar, R (corresponding author), INST BIOL STRUCT JP EBEL,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NIAID NIH HHS [R01AI31453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HU L, 1995, GENE DEV, V9, P1740; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, ONCOGENE, V9, P2261; LORCA T, 1992, J CELL SCI, V102, P55; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	93	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2155	2164						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668341				2022-12-17	WOS:A1996UP28300014
J	Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ				Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ			B-ATF: A novel human bZIP protein that associates with members of the AP-1 transcription factor family	ONCOGENE			English	Article						leucine zipper; transcription factor; AP-1; two hybrid assays	GLUTATHIONE-S-TRANSFERASE; AMP RESPONSE ELEMENT; CYCLIC-AMP; DNA-BINDING; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; SOMATOSTATIN GENE; NUCLEAR-PROTEIN; TAX PROTEIN; FOS PROTEIN	A new member of the ATF/CREB family of transcription factors, called B-ATF, has been isolated from a cDNA library prepared from Epstein-Barr virus stimulated human B cells, B-ATF is a 125 amino acid nuclear protein possessing a basic leucine zipper domain that is most similar to the basic leucine zipper of ATF3. Northern blot analysis of polyadenylated mRNA isolated from a variety of human tissues and established cell lines indicates that the 1.0 kilobase B-ATF mRNA is expressed differentially, with the strongest hybridization detected in lung and in Raji Burkitt's lymphoma, Efficient homodimerization of the B-ATF protein cannot be detected using the yeast two hybrid system or using in vitro binding assays with glutathione-s-transferase-B-ATF and maltose binding protein-B-ATF fusion proteins produced in E. coli. However, a yeast two hybrid library screen has identified the human oncoprotein JunB as a specific binding partner for B-ATF, Glutathione-s-transferase-B-ATF heterodimerizes efficiently with in vitro translated JunB, c-Jun, and JunD, but only weakly associates with c-Fos, In addition, electrophoretic mobility shift assays demonstrate that a B-ATF/c-Jun protein complex can interact with DNA containing a consensus binding site for AP-1, suggesting that B-ATF functions as a tissue-specific modulator of the AP-1 transcription complex in human cells.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [R01-CA42835, F32-CA61635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042835, F32CA061635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Miller JH, 1972, EXPT MOL GENETICS; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; VAIDYA TB, 1992, GENE, V119, P223; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	93	96	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2255	2265						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570175				2022-12-17	WOS:A1995TK70200008
J	TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R				TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R			INDUCTION OF FAS-MEDIATED APOPTOSIS IN P53-TRANSFECTED HUMAN COLON-CARCINOMA CELLS	ONCOGENE			English	Article						P53; FAS; APOPTOSIS; COLON CANCER	WILD-TYPE P53; TUMOR-NECROSIS-FACTOR; HUMAN GASTRIC-CANCER; SUPPRESSOR GENE; GROWTH; MUTATIONS; RECEPTOR; PROTEIN; LINE; DNA	To investigate the biological function of p53 in colon carcinoma cells, a wild-type p53 expression plasmid under the control of the human cytomegalovirus promoter was stably transfected into the human colon adenocarcinoma cell line WiDr, which carries a mutation of the p53 gene at codon 273. Exogenous wild-type p53 transcripts were detected at various expression levels in 8 of 117 G418-resistant clones. The growth rates of the wild-type p53+ clones in culture did not change significantly. The efficiency of colony formation in soft agar, however, was completely suppressed in two wild-type p53+ clones. This is the first to demonstrate the feasibility of stable transfection of the wild-type p53 gene under the control of non-inducible promoter in human colon cancer cells. The major alteration found was that wild-type p53+ cells which were incubated with anti-Fas IgM showed marked cytolysis,vith preferential overexpression of wild-type p53 accompanied by overexpression of a cyclin-dependent kinase inhibitor, WAF1, whereas the endogenous mutant p53 retained its expression level. The findings suggest that a Fas-initiated pathway is incidentally linked to a p53-dependent apoptotic pathway through the reconstituted wild-type p53 gene in WiDr cells. This model should help elucidating the additional role of the p53 tumor suppressor gene and the mechanism of apoptosis in colon carcinoma cells.	KYOTO UNIV,GRAD SCH MED,DEPT PATHOL & TUMOR BIOL,SAKYO KU,KYOTO 606,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT ONCOL,KUMAMOTO 860,JAPAN	Kyoto University; Kobe University; Kumamoto University			Saya, Hideyuki/J-4325-2013					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CAJOT JF, 1992, CANCER RES, V52, P6956; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG JH, 1995, J IMMUNOL, V154, P1239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FRITSCHE M, 1993, ONCOGENE, V8, P307; HABUCHI T, 1993, CANCER RES, V53, P3795; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARPER JW, 1993, CELL, V75, P805; HOLSTEIN M, 1991, SCIENCE, V253, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KYO E, 1993, INT J ONCOL, V3, P265; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATOZAKI T, 1992, CANCER RES, V52, P4335; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MERRITT AJ, 1994, CANCER RES, V54, P614; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1992, CANCER RES, V52, P2340; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WONG GHW, 1994, J IMMUNOL, V152, P1951; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	93	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1939	1946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478511				2022-12-17	WOS:A1995TF29700002
J	ZENKLUSEN, JC; WEITZEL, JN; BALL, HG; CONTI, CJ				ZENKLUSEN, JC; WEITZEL, JN; BALL, HG; CONTI, CJ			ALLELIC LOSS AT 7Q31.1 IN HUMAN PRIMARY OVARIAN CARCINOMAS SUGGESTS THE EXISTENCE OF A TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; OVARY; CHROMOSOME 7	MALIGNANT-TUMORS; FREQUENT LOSS; CANCER; CHROMOSOME-17; HETEROZYGOSITY; ALLELOTYPE; DELETION; MUTATION; P53	We studied loss of heterozygosity (LOH) in chromosome 7q in order to determine the location of a putative tumor suppressor gene (TSG) in human epithelial ovarian carcinomas. Samples were obtained from 26 primary ovarian carcinomas at the time of staging laparotomy. Paired normal and tumoral DNAs were used as templates for polymerase chain reaction amplification of a set of 14 (C-A)(n) microsatellite repeats on 7q21-qter. All the cases studied presented LOH at one or more loci on 7q. Seventy-three percent LON (in 14 of 19 informative cases) were detected in D7S522 at 7q31.1. The percentages of LOH were normally distributed around microsatellite D7S522 determining a smallest common deleted region of 1 cM. The high incidence of LOH in primary ovarian carcinomas suggests that a TSG relevant to the development of ovarian cancers is present at 7q31.1, confirming our previous functional evidence for a TSG in this region.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT OBSTET GYNECOL, DIV GYNECOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA	University of Texas System; UTMD Anderson Cancer Center; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University					NCI NIH HHS [K08 CA01574, CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001574, R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; ATKIN NB, 1991, CANCER GENET CYTOGEN, V52, P113, DOI 10.1016/0165-4608(91)90061-X; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V1, pCH2; CLIBY W, 1993, CANCER RES, V53, P2393; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; EHLEN T, 1990, ONCOGENE, V5, P219; FIGO cancer committee, 1986, GYNECOL ONCOL, V25, P383; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; GALLION HH, 1990, GYNECOL ONCOL, V38, P473, DOI 10.1016/0090-8258(90)90094-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KERE J, 1989, BLOOD, V73, P230; KIBBELAAR RE, 1993, BLOOD, V82, P904; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; LEE JH, 1990, CANCER RES, V50, P2724; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; MILNER BJ, 1993, CANCER RES, V53, P2128; MORI N, 1989, CANCER RES, V49, P5130; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5118; TENERIELLO MG, 1993, CANCER RES, V53, P3103; VACHERLAVENU MC, 1993, B CANCER, V80, P135; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; ZAR JH, 1991, BIOSTAT ANAL, pCH6; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	42	93	95	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					359	363						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624150				2022-12-17	WOS:A1995RK95700016
J	ZHANG, YH; CHELLAPPAN, SP				ZHANG, YH; CHELLAPPAN, SP			CLONING AND CHARACTERIZATION OF HUMAN DP2, A NOVEL DIMERIZATION PARTNER OF E2F	ONCOGENE			English	Article						E2F; RB; DP1; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; DNA-BINDING; GROWTH SUPPRESSION; COMPLEX-FORMATION; S-PHASE; RB; TRANSACTIVATION	The transcription factor E2F consists of a family of proteins that bind to the sequence TTTCGCGC and regulate the expression of various cellular and viral promoters. E2F binds to DNA as homodimers or as heterodimers in association with a protein, DP1 (for dimerization partner 1). E2F-DP1 heterodimers bind more efficiently than homodimers to DNA, retinoblastoma gene product as well as the adenovirus E4 protein and DP1 can stimulate transcription from E2F sites in a synergistic fashion. Here we describe the cloning and characterization of a novel human DP gene, DP2, whose product dimerizes efficiently with E2F. Unlike DP1, there appear to be multiple transcripts for DP2 and their distribution appears to vary in different tissues and cell lines. DP2 binds to E2F as detected by in vitro reconstitution assays and an E2F-DP2 heterodimer can bind to DNA in gel-retardation assays. We believe that DP2 also plays a major role in modulating the function of E2F in cell cycle regulation and oncogenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University					NCI NIH HHS [CA 63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1994, EMBO J, V12, P4317; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JORDAN KL, 1994, ONCOGENE, V9, P1177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SAMBROOK J, 1989, LABORATORY MANUAL; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	62	93	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2085	2093						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784053				2022-12-17	WOS:A1995RB70300003
J	KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK				KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK			THE DCC GENE SUPPRESSES THE MALIGNANT PHENOTYPE OF TRANSFORMED HUMAN EPITHELIAL-CELLS	ONCOGENE			English	Article						DCC; TUMOR SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS; CELL TRANSFORMATION	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; ADHESION MOLECULES; FREQUENT LOSS; EXPRESSION; PROGRESSION; CARCINOMA; CANCER; HPV-18; P53	Loss of heterozygosity and loss of expression of the deleted in colon cancer (DCC) gene is frequently observed in a number of different cancer types. To determine if the DCC gene plays a direct role in tumor suppression, wild-type full-length or truncated DCC cDNA constructs were transfected into nitrosomethylurea (NMU) transformed tumorigenic HPV-immortalized human epithelial cells that had allelic loss and reduced expression of DCC. Full-length DCC suppressed tumorigenicity whereas truncated DCC did not. Tumorigenic reversion of initially suppressed transfectants was associated,vith loss of DCC expression and loss or rearrangement of transfected DCC sequences. These results provide the first direct evidence that DCC is a tumor suppressor gene.	JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [T32CA009657, P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42792, CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLANTON RA, 1991, AM J PATHOL, V138, P673; BROOKS JD, 1993, J UROLOGY, V150, P1278, DOI 10.1016/S0022-5347(17)35760-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1992, J CELL BIOCHEM, P137; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG Y, 1992, CANCER RES, V52, P6525; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KIM MS, 1993, ANTICANCER RES, V13, P1405; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIYAKE K, 1993, BLOOD, V82, P927; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NARAYANAN R, 1992, ONCOGENE, V7, P553; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sambrook J., 1989, MOL CLONING LAB MANU; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUCK PH, 1989, GEO IMMIGR LJ, V3, P1; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	44	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1581	1586						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731713				2022-12-17	WOS:A1995QU68100014
J	HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF				HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF			MOLECULAR-CLONING, SEQUENCING, CHROMOSOMAL LOCALIZATION AND EXPRESSION OF MOUSE P21 (WAF1)	ONCOGENE			English	Note							GENE; INHIBITOR; PROTEIN; KINASES	The recent discovery that expression of Waf1 (p21), an inhibitor of cyclin-dependent kinases, is induced by the tumor suppressor p53 provides an important linkage between growth suppression and the cell cycle. We report here the cloning and sequencing of a mouse p21 cDNA that contains the entire coding region. Hybridization of the mouse p21 probe in Southern blot analyses confirms that p21 is a single-copy gene and that the corresponding locus, Waf1, lies proximal to H-2 on mouse chromosome 17. In northern analyses, the expression of p21 is found in most normal mouse tissues, but a surprising lack of correlation is found. between mRNA levels of p21 and p53. In order to determine which regions of p21 are most evolutionarily conserved, we have compared the cDNA sequences for the entire p21 coding region in 13 different mouse strains or species and the human p21 sequence. We conclude that two regions (corresponding to human codons 21-60 and 130-164) are strongly conserved in p21 and that these regions may represent domains that are especially critical to a functional p21 protein.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUPPI, K (corresponding author), NCI, GENET LAB, BLDG 37, BETHESDA, MD 20892 USA.		Mock, Beverly A/B-3110-2015; Michieli, Paolo/A-2588-2011	Mock, Beverly A/0000-0003-2479-4549; Michieli, Paolo/0000-0002-3093-8871				CHEDID M, 1994, ONCOGENE, V9, P3021; DIETRICH W, 1992, GENETICS, V131, P423; DOSIK JK, IN PRESS MAMMALIAN G; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HIMMELBAUER H, 1993, MAMM GENOME, V4, pS230, DOI 10.1007/BF00360843; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; MOCK BA, 1993, MAMM GENOME, V4, P461, DOI 10.1007/BF00296823; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUSSI T, 1990, ONCOGENE, V5, P945; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	18	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3017	3020						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084607				2022-12-17	WOS:A1994PG82200030
J	YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M				YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M			CLUSTERED MUTATIONS IN THE 2ND EXON OF THE MYC GENE IN SPORADIC BURKITT-LYMPHOMA	ONCOGENE			English	Article							HUMAN C-MYC; CASEIN KINASE-II; PHOSPHORYLATION SITE; NUCLEOTIDE-SEQUENCE; SOMATIC MUTATION; PROTEIN-KINASE; 1ST EXON; ONCOGENE; TRANSCRIPTION; REGION	The primary tumors from 15 untreated patients with Burkitt's lymphoma were analysed for abnormalities in the coding region of the MYC gene by single stranded conformational polymorphism (SSCP) analysis followed by DNA sequencing. Fourteen of the 15 tumors had one or more clonal mutations. Forty one mutations were found in the second exon; only one occurred in the third exon. Seven tumors had mutations that clustered in a region spanning amino acids 38-63. Four of these possessed mutations that altered prolines at positions 57 (3), 60 (1), and 63 (1). Seven tumors were mutated in the central portions of the second exon. These occurred at position 95 (2), position 115 (2), position 137 (1), and position 138 (3). Analysis of the published sequences from five lymphoma cell lines and one primary tumor showed a similar clustering of mutations, with all six having mutations in codons between positions 38-63. The regions where mutations occurred have been associated with a variety of properties, including transcriptional activation and cellular transformation. The number and location of mutations showed no correlation with either chromosome 8 or chromosome 14 breakpoints or with the Epstein-Bar virus positivity of the tumors. This unexpected, frequent occurrence of clustered mutations in the second exon of the MYC gene suggests a rote for the mutated MYC proteins in the pathogenesis of Burkitt's lymphoma, possibly through altered interactions of this domain with other cellular factors.	NCI,PATHOL LAB,HEMATOPATHOL SECT,BLDG 10,ROOM 2N110,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GILLESPIE DAF, 1989, MOL CELL BIOL, V9, P865, DOI 10.1128/MCB.9.2.865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON JM, 1991, BLOOD, V78, P2419; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; Nisson P E, 1991, PCR Methods Appl, V1, P120; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, COLD SH Q B, V56, P163; SAKSELA K, 1992, ONCOGENE, V7, P347; SETH A, 1991, J BIOL CHEM, V266, P23521; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANO T, 1992, BLOOD, V79, P1282, DOI 10.1182/blood.V79.5.1282.bloodjournal7951282; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	41	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2741	2748						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397370				2022-12-17	WOS:A1993LX34300015
J	WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC				WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC			VITAMIN-K3-INDUCED CELL-CYCLE ARREST AND APOPTOTIC CELL-DEATH ARE ACCOMPANIED BY ALTERED EXPRESSION OF C-FOS AND C-MYC IN NASOPHARYNGEAL CARCINOMA-CELLS	ONCOGENE			English	Article							OXIDATIVE STRESS; GROWTH-FACTOR; DNA DAMAGE; ACTIVATION; LINE; INDUCTION; MENADIONE; ONCOGENE; PROTEIN; INVITRO	Vitamin K3 is known to inhibit the growth of various rodent and human tumor cells. However, the molecular mechanism of its action is still elusive. We have found that vitamin K3 induces cell cycle arrest and apoptotic cell death in nasopharyngeal carcinoma (NPC) cells, as evaluated by flow cytometry and DNA gel electrophoresis. Involvement of c-fos and c-myc proto-oncogenes and expression of their proto-oncoproteins in VK3-induced cell cycle arrest and apoptosis were also investigated. Northern blot analysis of NPC cells treated with 50 mum VK3 showed that c-fos was transiently induced for 60 min after treatment, while c-myc was persistently induced for 1-9 h after drug treatment. Western blot analysis also showed that c-Fos was induced at 4-6 h and at 1-4 h after treatment with 50 mum and 200 mum VK3 respectively, while c-Myc was induced at 1-6 h and at 4-6 h, respectively, after such treatments. These results suggest that the expression of c-fos and c-myc may play an important role in the signaling mechanism of VK3-induced growth arrest and apoptotic cell death.			WU, FYH (corresponding author), ACAD SINICA, INST BIOMED SCI, CANC RES GRP, TAIPEI 11529, TAIWAN.							AGARWAL ML, 1991, CANCER RES, V51, P5993; AKMAN SA, 1988, P AN M AM SOC CLIN, V7, P76; AKMAN SA, 1984, P ASCO, V3, P37; ASKEW DS, 1991, ONCOGENE, V6, P1915; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHANG YS, 1989, CANCER RES, V49, P6752; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLOTTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013, DOI 10.1016/0006-291X(90)91130-K; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; GOLD J, 1986, CANCER TREAT REP, V70, P1433; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JUAN CC, 1993, BIOCHEM BIOPH RES CO, V190, P907, DOI 10.1006/bbrc.1993.1135; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4; MARKS DI, 1991, BIOCHEM PHARMACOL, V42, P1859, DOI 10.1016/0006-2952(91)90582-P; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MITCHELL JS, 1965, ACTA RADIOL THER PHY, V3, P329, DOI 10.3109/02841866509133108; MITCHELL JS, 1974, BRIT J CANCER, V29, P373, DOI 10.1038/bjc.1974.85; MITCHELL JS, 1983, INT J RADIAT ONCOL, V9, P57, DOI 10.1016/0360-3016(83)90209-2; NAGOURNEY R, 1987, P AN M AM SOC CLIN, V6, P359; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NOTO V, 1989, CANCER, V63, P901, DOI 10.1002/1097-0142(19890301)63:5<901::AID-CNCR2820630518>3.0.CO;2-G; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SU W-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P454; WICKSTROM EL, 1989, IN VITRO CELL DEV B, V25, P297; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU FYH, 1991, P AM ASSOC CANC RES, V32, P396; WU FYH, 1993, IN PRESS LIFE SCI; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	45	93	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2237	2244						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336946				2022-12-17	WOS:A1993LP17100025
J	SELF, AJ; PATERSON, HF; HALL, A				SELF, AJ; PATERSON, HF; HALL, A			DIFFERENT STRUCTURAL ORGANIZATION OF RAS-EFFECTOR AND RHO-EFFECTOR DOMAINS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; TRIPHOSPHATE CONFORMATION; BINDING DOMAIN; RAS-P21 GTPASE; GAP; P21; IDENTIFICATION; TRANSFORMATION; RESIDUES	Ras regulates proliferation and differentiation signals in cells, and activation of the protein can tead to malignant transformation. Activation of the related protein, Rho, affects cell morphology, and it has been suggested that it may also have some oncogenic potential. We show here that Rho does not induce a malignant phenotype in NIH3T3 cells but instead is a potent activator of actin stress fibre formation. The limited homology between Ras and Rho has enabled us to determine the amino acids specifying their different biological activities and GTPase-activating protein (GAP) protein sensitivities using chimeras. Rho substituted with amino acids 23-46 of Ras induces transformed foci in NIH3T3 monolayers, and we conclude that Ras has a single effector domain required for downstream signalling. Although mutational analysis of Rho has revealed that residues 32-42 are also essential for its biological activity, Ras substituted with amino acids 25-48 of Rho does not induce actin stress fibre formation. On the basis of these experiments, we propose that Rho may have two effector domains: one at amino acids 32-42 and corresponding to the effector region of Ras and the second located elsewhere in the carboxy-terminal two-thirds of the molecule.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	34	93	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					655	661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437849				2022-12-17	WOS:A1993KN00800016
J	ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A				ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A			ALTERED CONFORMATION OF THE P53 PROTEIN IN MYELOID-LEUKEMIA CELLS AND MITOGEN-STIMULATED NORMAL BLOOD-CELLS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; GENE-MUTATIONS; BREAST-CANCER; PHOSPHORYLATION; RETINOBLASTOMA; EXPRESSION; ONCOGENE; OCCUR	Expression of the normal p53 gene promotes cell differentiation, maturation and apoptosis. The mutant p53 gene, which does not function normally, is frequently expressed at elevated levels in tumor cells [for review see Lane, D.P. & Benchimol, S. (1990). Genes Dev., 4, 1-81. We have analysed the expression of and mutational change in the p53 gene in the peripheral blood cells of 49 primary acute myeloid leukemia (AML) patients. The p53 protein levels were elevated in 37 patients (75%) when measured by immunoprecipitation with antibodies PAb1801 and PAb421, which recognize both normal and mutant forms of the protein. The p53 protein from 32 of these 37 patients was immunoprecipitated by PAb240, which recognizes a conformation of p53 protein associated with point mutations. However, point mutations were detected by single-stranded conformation polymorphism (SSCP) assay and direct sequencing in only three patients at codons 178, 245, 273 and 290. Growth stimulation of normal lymphocytes also generated p53 which was immunoprecipitable by PAb240. Thus, alteration of p53 conformation, rather than acquisition of point mutations, could be the mechanism underlying the increased proliferation of myeloid cells in most AML patients.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; FENAUX P, 1991, BLOOD, V78, P1652; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HU G, 1992, IN PRESS BR J HAEMAT; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGIMOTO K, 1991, BLOOD, V77, P1153; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	93	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1645	1647						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630824				2022-12-17	WOS:A1992JE81300022
J	CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A				CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A			OCCURRENCE OF DISTINCT PML RAR-ALPHA FUSION GENE ISOFORMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA DETECTED BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; CELL-LINE; DIFFERENTIATION; TRANSLOCATION; EXPRESSION; BREAKPOINT	A specific 'nested' reverse transcriptase/polymerase chain reaction (RT/PCR) procedure was used to characterize the expression patterns of PML-RAR-alpha chimeric mRNAs in 32 patients with acute promyelocytic leukemia (APL). The sensitivity of the technique was such that the fusion gene transcript could be detected from as little as 2.5 pg of total leukemic cell RNA against a background of 1-mu-g of cellular RNA lacking the PML-RAR-alpha fusion gene transcript(s). In 19 cases the PML-RAR-alpha isoform referred to here as long was identified. A short isoform, which in comparison with the long form lacks three PML exons, was detected in 11 other cases. A third PML-RAR-alpha mRNA isoform, in which the most 3' PML exon present in the long-type isoform was truncated in its sequences lying immediately upstream of RAR-alpha B region, was found and characterized in a single patient. In one APL patient with a variant translocation t(11;17), the PCR product corresponding to PML-RAR-alpha chimeric mRNAs could not be amplified despite the presence of RAR-alpha gene rearrangement. Genomic and PCR analysis showed that the different PML-RAR-alpha isoforms found in APL patients arise as a result of distinct translocation breakpoints. In each case the exons encoding the B-F regions of RAR-alpha are expressed and are spliced downstream from variable PML gene exons. The 'nested' RT/PCR analysis of the PML-RAR-alpha fusion gene proved to be a rapid and sensitive tool for the diagnosis of the APL and for monitoring the residual APL chimeric mRNA expression during complete remission.	SHANGHAI MED UNIV 2, RUI JIN HOSP, SHANGHAI INST HEMATOL, 197 RUI-JIN RD II, SHANGHAI 200025, PEOPLES R CHINA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, ROCHELLE BELFER CHEMOTHERAPY FDN LAB, NEW YORK, NY 10029 USA	Shanghai Jiao Tong University; Icahn School of Medicine at Mount Sinai			Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHANG KS, 1991, LEUKEMIA, V5, P200; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN Z, 1991, LEUKEMIA, V5, P288; CHEN ZX, 1991, BLOOD, V78, P1413; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIDSON JN, 1951, J PATHOL BACTERIOL, V63, P471, DOI 10.1002/path.1700630314; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLYNN PJ, 1983, BLOOD, V62, P1211; GLASS CK, 1991, HORMONAL CONTROL GEN, P129; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUDAS LJ, 1991, PERSPECTIVES CELLULA, P121; HAUNG ME, 1988, BLOOD, V7251, P5673; HEIM S, 1987, CANCER CYTOGENETICS; HUGHES TP, 1991, BLOOD, V77, P874; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACCUMBER M, 1984, SCIENCE, V224, P402, DOI 10.1126/science.6200933; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MENTEN ML, 1953, CANCER RES, V13, P733; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLS KI, 1991, BLOOD, V78, P1155; MORGAN GJ, 1990, BRIT J HAEMATOL, V76, P33, DOI 10.1111/j.1365-2141.1990.tb07833.x; NEGRIN RS, 1991, BLOOD, V78, P255; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; RIBEIRO RC, 1987, BLOOD, V70, P948; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTH MS, 1992, BLOOD, V79, P276; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHAPIRO SS, 1985, RETINOIDS CELL DIFFE, P30; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN GL, 1992, IN PRESS BR J HAEMAT; TONG JH, 1992, ONCOGENE, V7, P311; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WAXMAN S, 1983, BLOOD S, V62, pA154; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; 1985, CYTOGENET CELL GENET, V21, P309	72	93	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1223	1232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375719				2022-12-17	WOS:A1992HU64200021
J	FILMUS, J; ZHAO, J; BUICK, RN				FILMUS, J; ZHAO, J; BUICK, RN			OVEREXPRESSION OF H-RAS ONCOGENE INDUCES RESISTANCE TO THE GROWTH-INHIBITORY ACTION OF TRANSFORMING GROWTH-FACTOR BETA-1 (TGF-BETA-1) AND ALTERS THE NUMBER AND TYPE OF TGF-BETA-1 RECEPTORS IN RAT INTESTINAL EPITHELIAL-CELL CLONES	ONCOGENE			English	Article							TGF-BETA; EXPRESSION; LINES; FACTOR-BETA-1; BINDING; CANCER	In this report, we utilize rat intestinal cell (IEC-18) clones expressing an activated human H-ras gene to investigate the relationship between malignant transformation and growth control by transforming growth factor beta (TGF-beta). We demonstrate that clones expressing high levels of H-ras oncogene lose sensitivity to the growth inhibitory action of TGF-beta. The loss of sensitivity is related to the degree of H-ras expression and is shown to be a direct consequence of H-ras expression through the use of a clonal cell line with inducible expression of activated H-ras. Co-incident with the loss of growth inhibition, ras-expressing clones display an altered expression of TGF-beta-binding proteins as detectable by [I-125]TGF-beta cross-linking. While IEC-18 cells express type II (92 kDa) binding protein predominantly, H-ras expression induces a shift to predominantly type I (69 kDa) binding protein expression.	ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BALIGA BS, 1985, BIOCHEM BIOPH RES CO, V154, P278; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUGGETT AC, 1990, CANCER RES, V50, P7468; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; LAIHO M, 1990, J BIOL CHEM, V265, P18518; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SILBERSTEIN GB, 1987, SCIENCE, V237, P284; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	21	93	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					521	526						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312703				2022-12-17	WOS:A1992HK00500018
J	FLINT, KJ; JONES, NC				FLINT, KJ; JONES, NC			DIFFERENTIAL REGULATION OF 3 MEMBERS OF THE ATF CREB FAMILY OF DNA-BINDING PROTEINS	ONCOGENE			English	Article							CELLULAR TRANSCRIPTION FACTOR; VIRUS TYPE-I; LEUCINE ZIPPER PROTEINS; CAMP-RESPONSIVE ELEMENT; ADENOVIRUS E1A PROTEIN; LONG TERMINAL REPEAT; CYCLIC-AMP; CDNA CLONES; ACTIVATION; PROMOTERS	The ATF/CRE binding site can mediate transcriptional activation by cAMP, the adenovirus EIA protein and the human T-cell leukaemia virus 1 (HTLV1) tax protein. A large number of different proteins bind specifically to this element either as homodimers or as heterodimers. Using GAL4-ATF/CREB fusions, we have investigated the regulatory functions of three members of this family. CREB1 (CREB) is strongly activated by cAMP and weakly activated by the E1A protein. In contrast, CREB2 (CRE-BP1, ATF2) is strongly activated by E1A but is insensitive to cAMP stimulation. ATF1 is weakly activated by cAMP but is not activated by E1A. All three proteins are insensitive to activation by the HTLV1 tax protein. The N-terminal region of CREB2, from amino acid residues 19 to 112, is both necessary and sufficient for E1A activation. This region contains a putative C2H2 metal-binding finger, and single amino acid substitutions of the cysteine residues severely decreased CREB2 activity. In contrast, mutations affecting a potential protein kinase A and casein kinase II phosphorylation site within this region had little effect.	IMPERIAL CANC RES FUND,GENE REGULAT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HURST HC, 1991, IN PRESS NUCLEIC ACI; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAMESON JL, 1990, MOL ENDOCRINOL, V4, P1087; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P6063; SADROWSKI J, 1989, NUCLEIC ACIDS RES, V17, P7539; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	53	93	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2019	2026						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658708				2022-12-17	WOS:A1991GX11900012
J	LANEUVILLE, P; HEISTERKAMP, N; GROFFEN, J				LANEUVILLE, P; HEISTERKAMP, N; GROFFEN, J			EXPRESSION OF THE CHRONIC MYELOGENOUS LEUKEMIA-ASSOCIATED P210BCR/ABL ONCOPROTEIN IN A MURINE IL-3 DEPENDENT MYELOID CELL-LINE	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SENSITIVE V-ABL; INTERLEUKIN-3 DEPENDENCE; TYROSINE PHOSPHORYLATION; GM-CSF; GRANULOCYTIC DIFFERENTIATION; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; AUTOCRINE GROWTH; ABELSON VIRUS	We have studied the effect of a replication-defective murine retroviral vector expressing the chronic myelogenous leukemia associated oncoprotein p210bcr/abl in murine IL-3 dependent myeloid 32D C13(G) cells. This cell line can be induced to differentiate along either the granulocytic or monocytic lineages thus permitting an independent assessment of the effect of p210bcr/abl on growth and differentiation. Cells expressing p210bcr/abl displayed a complete non-autocrine abrogation of IL-3 dependence and an enhanced response to an activity in FBS which is not IGF-I or IGF-II. During the first few generations following infection with the bcr/abl vector, cells became larger with an increased fraction of cells in G2/M and monocyte/macrophage markers were expressed. Four cytoplasmic proteins phosphorylated in response to IL-3 in the parental cell line with apparent molecular weights of 98, 70, 62, and 52 Kd were amongst those constitutively phosphorylated in p210bcr/abl expressing cells. These results suggest that the functional substitution of IL-3 by p210bcr/abl is due to constitutive activation of proteins involved in IL-3 signal transduction. Alterations of cell differentiation, cell cycle and growth which cannot be attributed to IL-3 like effects indicate that p210bcr/abl has pleiotropic effects involving several other pathways of cellular regulation.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, MOLEC DIAG SECT, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles	LANEUVILLE, P (corresponding author), ROYAL VICTORIA HOSP, DIV HEMATOL & ONCOL, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA.		Heisterkamp, Nora/C-1698-2012; Laneuville, Pierre/AAH-2293-2021	Heisterkamp, Nora/0000-0003-2769-2273; 	NCI NIH HHS [CA 47073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BABIOR BM, 1981, METHODS HEMATOLOGY, V3, P1; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BRADY G, 1988, ONCOGENE, V3, P687; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS JPM, 1987, LEUKEMIA, V1, P524; EVANS JPM, 1990, BLOOD, V75, P88; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; IHLE JN, 1986, ADV IMMUNOL, V39, P1; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KATZAV S, 1989, ONCOGENE, V4, P1129; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAVILIO F, 1989, ONCOGENE, V4, P301; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; MURPHY WM, 1986, J UROLOGY, V136, P815, DOI 10.1016/S0022-5347(17)45088-9; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROVERA G, 1987, ONCOGENE, V1, P29; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SORENSEN PHB, 1989, BLOOD, V73, P406; SPIVAK JL, 1985, J CLIN INVEST, V76, P1613, DOI 10.1172/JCI112145; STRIFE A, 1988, CANCER RES, V48, P1035; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VONMELCHNER H, 1988, ONCOGENE, V2, P137; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	59	93	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					275	282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705688				2022-12-17	WOS:A1991FZ13400013
J	YOKOTA, J; WADA, M; YOSHIDA, T; NOGUCHI, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M				YOKOTA, J; WADA, M; YOSHIDA, T; NOGUCHI, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M			HETEROGENEITY OF LUNG-CANCER CELLS WITH RESPECT TO THE AMPLIFICATION AND REARRANGEMENT OF MYC FAMILY ONCOGENES	ONCOGENE			English	Article											YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BLICK MB, 1986, LEUKEMIA RES, V10, P1401, DOI 10.1016/0145-2126(86)90006-8; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1987, CANCER RES, V47, P4248; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GARSON JA, 1986, LANCET, V1, P1496; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MCCARTHY DM, 1984, LANCET, V2, P1362; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; OCADIZ R, 1987, CANCER RES, V47, P4173; RIOU G, 1987, LANCET, V1, P761; ROSEN N, 1986, CANCER RES, V46, P4139; SAGLIO G, 1986, CANCER RES, V46, P1413; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAYA Y, 1987, ADV VIRAL ONCOL, V7, P141; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P293; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WATSON R, 1982, P NATL ACAD SCI US, V79, P4978; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1986, LANCET, V1, P765; YOSHIMOTO K, 1986, JPN J CANCER RES, V77, P731; 1987, TNM CLASSIFICATION M; 1981, INT HISTOLOGICAL TYP, V1	38	93	93	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					607	611						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838790				2022-12-17	WOS:A1988N841500012
J	Yousefi, H; Maheronnaghsh, M; Molaei, F; Mashouri, L; Aref, AR; Momeny, M; Alahari, SK				Yousefi, Hassan; Maheronnaghsh, Maryam; Molaei, Fatemeh; Mashouri, Ladan; Aref, Amir Reza; Momeny, Majid; Alahari, Suresh K.			Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance	ONCOGENE			English	Review							ENHANCES TAMOXIFEN RESISTANCE; CELL-PROLIFERATION; STEM-CELLS; DOWN-REGULATION; POOR-PROGNOSIS; MESENCHYMAL TRANSITION; MEDIATED TRANSFER; EMERGING ROLES; UP-REGULATION; INACTIVE-X	Breast cancer is the most common cancer, and the second cause of cancer-related deaths (after lung cancer) among women. Developing tumor metastasis and invasion is the most important cause of death in breast cancer patients. Several key factors participate in breast cancer metastasis including long noncoding RNAs (lncRNAs). lncRNAs are a category of cellular RNAs that are longer than 200 nucleotides in length. Accumulating evidence suggests that lncRNAs have the potential to be promising diagnostic, prognostic biomarkers and therapeutic targets in breast cancer. Understanding the role of lncRNAs and their mechanisms of functions might help to further discovery of breast cancer biological characteristics. In this review, we discuss physiological functions, epigenetic regulation, transcriptional regulation of lncRNAs, and their important role in tumor progression and metastasis. Some lncRNAs function as oncogenes and some function as tumor suppressors. Interestingly, recent reports depict that hypomethylation of promoters of lncRNAs play a pivotal role in cancer progression, suggesting the importance of epigenetic regulation. Furthermore, we discuss the role of lncRNAs in exosomes and their function in drug resistance, and therapeutic importance of exosomal lncRNAs in cancer biology. In summary, lncRNAs have a great potential to consider them as novel prognostic biomarkers as well as new therapeutic targets in breast cancer	[Yousefi, Hassan; Alahari, Suresh K.] LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Maheronnaghsh, Maryam] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran; [Molaei, Fatemeh] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Razavi Khorasan, Iran; [Mashouri, Ladan] Shahrekord Univ, Fac Sci, Dept Genet, Shahrekord, Iran; [Aref, Amir Reza] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Momeny, Majid] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Momeny, Majid] Abo Akad Univ, Turku, Finland	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tehran University of Medical Sciences; Mashhad University Medical Science; Shahrekord University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Turku; Abo Akademi University	Alahari, SK (corresponding author), LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu	Momeny, Majid/AAR-3398-2020					Alipoor FJ, 2018, J CELL BIOCHEM, V119, P6470, DOI 10.1002/jcb.26678; Amodio N, 2018, LEUKEMIA, V32, P1948, DOI 10.1038/s41375-018-0067-3; Angrand PO, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00165; Aram R, 2017, ONCOTARGET, V8, P67538, DOI 10.18632/oncotarget.18733; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5; Ayers D, 2013, J CANC RES TREATMENT, V1, P31; Bai Y, 2018, EXP THER MED, V16, P2235, DOI 10.3892/etm.2018.6461; Berrondo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147236; Bester AC, 2018, CELL, V173, P649, DOI 10.1016/j.cell.2018.03.052; Bian EB, 2019, INT J ONCOL, V54, P713, DOI 10.3892/ijo.2018.4644; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chang L, 2018, CELL PHYSIOL BIOCHEM, V48, P16, DOI 10.1159/000491659; Chen DQ, 2017, EUR REV MED PHARMACO, V21, P275; Chen S, 2017, CELL DEATH DIS, V8, pe2710; Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004; Cooper C, 2009, NUCLEIC ACIDS RES, V37, P4518, DOI 10.1093/nar/gkp441; Dong HY, 2018, INT J ONCOL, V53, P1013, DOI 10.3892/ijo.2018.4467; Dykes IM, 2017, GENOM PROTEOM BIOINF, V15, P177, DOI 10.1016/j.gpb.2016.12.005; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Fan SL, 2017, BIOMED PHARMACOTHER, V95, P1636, DOI 10.1016/j.biopha.2017.09.076; Fazil MHUT, 2016, SCI REP-UK, V6, DOI 10.1038/srep37721; Ferreira HJ, 2018, CANCER METAST REV, V37, P55, DOI 10.1007/s10555-017-9715-8; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Godinho MFE, 2010, BRIT J CANCER, V103, P1284, DOI 10.1038/sj.bjc.6605884; Godinho M, 2011, J CELL PHYSIOL, V226, P1741, DOI 10.1002/jcp.22503; Gradia Daniela F., 2017, Non-Coding RNA, V3, P26, DOI 10.3390/ncrna3040026; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109-013-1028-y; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hanly DJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0074; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Hood JL, 2016, NANOMEDICINE-UK, V11, P1745, DOI 10.2217/nnm-2016-0102; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Hu HB, 2018, EUR REV MED PHARMACO, V22, P1987, DOI 10.26355/eurrev_201804_14726; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Janakiraman H, 2018, MOL CANCER RES, V16, P567, DOI 10.1158/1541-7786.MCR-17-0547; Jiang J, 2018, ONCOL LETT, V15, P9543, DOI 10.3892/ol.2018.8513; Jiang ZY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0853-2; Kaikkonen MU, 2018, TRENDS BIOCHEM SCI, V43, P654, DOI 10.1016/j.tibs.2018.06.002; Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808; Keshavarz M, 2019, J CELL BIOCHEM, V120, P18398, DOI 10.1002/jcb.29152; Keshavarz M, 2019, FEBS J, V286, P2611, DOI 10.1111/febs.14825; Kojima R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03733-8; Koldemir O, 2017, BIOMED REP, V6, P358, DOI 10.3892/br.2017.848; Kong QL, 2018, BIOCHEM BIOPH RES CO, V495, P1594, DOI 10.1016/j.bbrc.2017.12.013; Kooijmans SAA, 2013, J CONTROL RELEASE, V172, P229, DOI 10.1016/j.jconrel.2013.08.014; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Krichevsky AM, 2019, NEUROTHERAPEUTICS, V16, P319, DOI 10.1007/s13311-018-00702-3; Lang HL, 2017, EUR REV MED PHARMACO, V21, P959; Li BZ, 2018, ONCOGENE, V37, P5508, DOI 10.1038/s41388-018-0359-0; Li CL, 2019, J CELL PHYSIOL, V234, P20721, DOI 10.1002/jcp.28678; Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464; Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0707-8; Li JT, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0454-2; Li PC, 2018, INT J MED SCI, V15, P1227, DOI 10.7150/ijms.25662; Li SQ, 2018, BIOMED PHARMACOTHER, V104, P451, DOI 10.1016/j.biopha.2018.05.056; Li SP, 2018, ACTA PHARMACOL SIN, V39, P542, DOI 10.1038/aps.2017.178; Li WX, 2017, EUR REV MED PHARMACO, V21, P3397; Li WT, 2016, ONCOTARGET, V7, P27778, DOI 10.18632/oncotarget.8413; Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9; Li Y, 2018, BIOMED PHARMACOTHER, V103, P939, DOI 10.1016/j.biopha.2018.04.087; Li ZH, 2018, ONCOGENE, V37, P3822, DOI 10.1038/s41388-018-0237-9; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Liang  Y., 2018, ADV MATER INTERFACES, V5, P1, DOI DOI 10.1017/S0266466617000317; Liang YR, 2018, CANCER BIOL THER, V19, P120, DOI 10.1080/15384047.2017.1394543; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123742; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu CY, 2019, THERANOSTICS, V9, P1015, DOI 10.7150/thno.30853; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Liu Q, 2013, NUCLEIC ACIDS RES, V41, P4976, DOI 10.1093/nar/gkt182; Liu T, 2016, ONCOTARGET, V7, P85551, DOI 10.18632/oncotarget.13465; Liu Yin, 2015, Front Biosci (Schol Ed), V7, P94; Lo PK, 2016, ONCOTARGET, V7, P65067, DOI 10.18632/oncotarget.11364; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Lu GM, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0945-6; Luan T, 2017, ONCOTARGET, V8, P76153, DOI 10.18632/oncotarget.19190; Luo LY, 2018, ONCOGENE, V37, P6166, DOI 10.1038/s41388-018-0396-8; Ma F, 2019, CANCER LETT, V450, P63, DOI 10.1016/j.canlet.2019.02.008; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Marin-Bejar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1331-y; Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5; Mathias C, 2019, CLIN GENET, V95, P558, DOI 10.1111/cge.13502; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Morlando M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020570; Naderi-Meshkin H, 2018, J BIOINFORM, V35, P352; Niknafs YS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12791; Niu YY, 2014, INT J CLIN EXP PATHO, V7, P5144; Ozes AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00966-3; Pan L, 2017, J CANCER RES CLIN, V143, P991, DOI 10.1007/s00432-017-2361-2; Peng F, 2018, ONCOGENE, V37, P1062, DOI 10.1038/onc.2017.368; Peng F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.438; Pickard MR, 2015, GENES-BASEL, V6, P484, DOI 10.3390/genes6030484; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Qiu JJ, 2018, INT J BIOL SCI, V14, P1960, DOI 10.7150/ijbs.28048; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Richard John Lalith Charles, 2018, Oncotarget, V9, P20179, DOI 10.18632/oncotarget.24591; Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi F, 2016, ARCH MED RES, V47, P446, DOI 10.1016/j.arcmed.2016.11.001; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Shin VY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1513-5; Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263; Skalska L, 2017, NAT REV MOL CELL BIO, V18, P1, DOI 10.1038/nrm.2017.12; Soifer Harris S., 2011, METHOD MOL BIOL, P333; Su JC, 2017, MOL MED REP, V16, P4887, DOI 10.3892/mmr.2017.7163; Sun H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0648-7; Sun SJ, 2017, EUR REV MED PHARMACO, V21, P504; Sun W, 2019, INT J CANCER, V145, P842, DOI 10.1002/ijc.32185; Taherian-Esfahani Z, 2019, J CELL PHYSIOL, V234, P22044, DOI 10.1002/jcp.28767; Teng Y, 2019, GENET TEST MOL BIOMA, V23, P235, DOI 10.1089/gtmb.2018.0103; Tu ZB, 2019, STEM CELLS, V37, P1281, DOI 10.1002/stem.3055; Usman WM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04791-8; Vidovic D, 2020, CELL DEATH DIFFER, V27, P363, DOI 10.1038/s41418-019-0362-1; Wang DN, 2016, CELL PHYSIOL BIOCHEM, V40, P644, DOI 10.1159/000452577; Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478; Wang HH, 2017, ONCOTARGET, V8, P64638, DOI 10.18632/oncotarget.18344; Wang J, 2017, ARCH GYNECOL OBSTET, V295, P1469, DOI 10.1007/s00404-017-4365-1; Wang JS, 2018, MED SCI MONITOR, V24, P9307, DOI 10.12659/MSM.912018; Wang Jin-Peng, 2018, Oncotarget, V9, P12487, DOI 10.18632/oncotarget.23552; Wang M, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12534; Wang MZ, 2018, CANCER SCI, V109, P1764, DOI 10.1111/cas.13592; Wang OC, 2017, AM J TRANSL RES, V9, P533; Wang RM, 2018, J CELL MOL MED, V22, P4068, DOI 10.1111/jcmm.13679; Wang Y, 2017, BIOCHEM BIOPH RES CO, V493, P429, DOI 10.1016/j.bbrc.2017.09.005; Wang YH, 2018, CELL PHYSIOL BIOCHEM, V46, P532, DOI 10.1159/000488620; Wang YL, 2019, BREAST, V46, P64, DOI 10.1016/j.breast.2019.05.003; Wu CH, 2016, MED SCI MONITOR, V22, P3860, DOI 10.12659/MSM.900689; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Wu ZJ, 2017, EUR REV MED PHARMACO, V21, P706; Xia EJ, 2018, AM J CANCER RES, V8, P1273; Xing Z, 2018, CANCER RES, V78, P4524, DOI 10.1158/0008-5472.CAN-17-0385; Xu CG, 2016, EUR REV MED PHARMACO, V20, P4362; Xu J, 2017, CELL PHYSIOL BIOCHEM, V41, P635, DOI 10.1159/000457938; Xu SP, 2015, TUMOR BIOL, V36, P9807, DOI 10.1007/s13277-015-3746-y; Xu SP, 2015, INT J CLIN EXP PATHO, V8, P4881; Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8; Xue X, 2016, ONCOGENE, V35, P2746, DOI 10.1038/onc.2015.340; Yan MD, 2017, BIOTECHNOL APPL BIOC, V64, P5, DOI 10.1002/bab.1461; Yang F, 2016, BIOCHEM BIOPH RES CO, V470, P479, DOI 10.1016/j.bbrc.2016.01.147; Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6; Yang QL, 2015, ONCOTARGET, V6, P3268, DOI 10.18632/oncotarget.3065; Yuan ZX, 2016, INT J ONCOL, V48, P2675, DOI 10.3892/ijo.2016.3447; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311; Zhang HY, 2014, STEM CELLS, V32, P2858, DOI 10.1002/stem.1795; Zhang H, 2017, CANCER CHEMOTH PHARM, V79, P49, DOI 10.1007/s00280-016-3194-4; Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385; Zhang M, 2017, EUR REV MED PHARMACO, V21, P1020; Zhang P, 2018, ONCOTARGETS THER, V11, P291, DOI 10.2147/OTT.S155134; Zhang R, 2017, BIOCHEM BIOPH RES CO, V490, P406, DOI 10.1016/j.bbrc.2017.06.055; Zhang XF, 2015, INT J CLIN EXP PATHO, V8, P9440; Zhang ZX, 2015, BIOCHEM BIOPH RES CO, V465, P225, DOI 10.1016/j.bbrc.2015.07.158; Zhang ZR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1139-6; Zhao Dan, 2018, Non-Coding RNA, V4, P39, DOI 10.3390/ncrna4040039; Zheng A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1315-8; Zheng R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0880-3; Zheng RN, 2018, BIOCHEM BIOPH RES CO, V498, P1002, DOI 10.1016/j.bbrc.2018.03.104; Zheng ZQ, 2019, MED SCI MONITOR, V25, P2211, DOI 10.12659/MSM.915419; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou SY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180772; Zou QY, 2018, J CELL BIOCHEM, V119, P2189, DOI 10.1002/jcb.26380	170	92	93	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					953	974		10.1038/s41388-019-1040-y	http://dx.doi.org/10.1038/s41388-019-1040-y			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31601996				2022-12-17	WOS:000511209700001
J	Xu, TP; Wang, WY; Ma, P; Shuai, Y; Zhao, K; Wang, YF; Li, W; Xia, R; Chen, WM; Zhang, EB; Shu, YQ				Xu, Tong-peng; Wang, Wen-yu; Ma, Pei; Shuai, You; Zhao, Kun; Wang, Yan-fen; Li, Wei; Xia, Rui; Chen, Wen-ming; Zhang, Er-bao; Shu, Yong-qian			Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; EXPRESSION; PROGRESSION; ENHANCER; GENE; INVASIVENESS	Accumulating data indicate that long noncoding RNAs (lncRNAs) serve as important modulators in biological processes and are dysregulated in diverse tumors. The function of FOXD2-AS1 in gastric cancer (GC) progression and related biological mechanisms remain undefined. A comprehensive analysis identified that FOXD2-AS1 enrichment was upregulated markedly in GC and positively correlated with a large tumor size, a later pathologic stage, and a poor prognosis. Gene-set enrichment analysis (GSEA) in GEO datasets uncovered that cell cycle and DNA replication associated genes were enriched in patients with high FOXD2-AS1 expression. Loss of FOXD2-AS1 function inhibited cell growth via inhibiting the cell cycle in GC, whereas upregulation of FOXD2-AS1 expression promoted cancer progression. The enhancer of zeste homolog 2 (EZH2) and lysine (K)-specific demethylase 1A (LSD1) proteins were found to serve as binding partners of FOXD2-AS1 and mediators of FOXD2-AS1 function. Mechanically, FOXD2-AS1 promoted GC tumorigenesis partly through EZH2 and LSD1 mediated EphB3 downregulation. The present results revealed that FOXD2-AS1 acted as a tumor inducer in GC partly through EphB3 inhibition by direct interaction with EZH2 and LSD1, and may prove to be a potential biomarker of carcinogenesis.	[Xu, Tong-peng; Wang, Wen-yu; Ma, Pei; Shuai, You; Zhao, Kun; Shu, Yong-qian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Wang, Yan-fen] Yangzhou Univ, Affiliated Hosp, Dept Pathol, Yangzhou, Jiangsu, Peoples R China; [Li, Wei] CloudSeq Biotech Inc, Shanghai, Peoples R China; [Xia, Rui] Nanjing Chest Hosp, Dept Med Lab, 215 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Wen-ming] Jining 1 Peoples Hosp, Dept Oncol, Jining City 272011, Shandong, Peoples R China; [Zhang, Er-bao] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Yangzhou University; Nanjing Medical University	Xu, TP; Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	tongpeng_xu_njmu@163.com; yongqian_shu@163.com	Ma, Pei/ABD-6343-2021; Shu, Yongqian/ABD-5698-2021	zhang, erbao/0000-0002-5752-7976; Wang, Wenyu/0000-0002-7374-4567; Shu, Yongqian/0000-0002-3034-685X	National Natural Science Foundation of China [81602071, 81672896]; Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center) [BL2012008]; Natural Science Foundation of Jiangsu Province for Youth [BK20161066]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine) [JX10231801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center); Natural Science Foundation of Jiangsu Province for Youth(Natural Science Foundation of Jiangsu Province); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine)	This study was supported by the National Natural Science Foundation of China (81602071 and 81672896); Jiangsu Provincial Clinical Science and Technology Projects (Clinical Research Center, BL2012008); the Natural Science Foundation of Jiangsu Province for Youth (BK20161066); and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine, JX10231801). We thank CloudSeq Biotech, Inc. (Shanghai, China) for help with bioinformatics analyses.	Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen JS, 2016, NEOPLASMA, V63, P223, DOI 10.4149/207_150821N454; Cheng ASL, 2013, GASTROENTEROLOGY, V144, P122, DOI 10.1053/j.gastro.2012.10.002; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Sarma Kavitha, 2010, Proc Natl Acad Sci U S A, V107, P22196, DOI 10.1073/pnas.1009785107; Shang C, 2016, CANCER CHEMOTH PHARM, V77, P1061, DOI 10.1007/s00280-016-3029-3; Shen L, 2013, LANCET ONCOL, V14, pE535, DOI 10.1016/S1470-2045(13)70436-4; Shin J, 2015, MOL CELL, V57, P949, DOI 10.1016/j.molcel.2015.03.007; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18; Xu TP, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.205; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	41	92	96	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					5020	5036		10.1038/s41388-018-0308-y	http://dx.doi.org/10.1038/s41388-018-0308-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789713				2022-12-17	WOS:000443823600009
J	Konno, H; Yamauchi, S; Berglund, A; Putney, RM; Mule, JJ; Barber, GN				Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders; Putney, Ryan M.; Mule, James J.; Barber, Glen N.			Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production	ONCOGENE			English	Article							CYCLIC GMP-AMP; INNATE IMMUNE RECOGNITION; INFECTION; SYNTHASE; CGAS	The production of cytokines in response to DNA-damage events may be an important host defense response to help prevent the escape of pre-cancerous cells. The innate immune pathways involved in these events are known to be regulated by cellular molecules such as stimulator of interferon genes (STING), which controls type I interferon and pro-inflammatory cytokine production in response to the presence of microbial DNA or cytosolic DNA that has escaped from the nucleus. STING signaling has been shown to be defective in a variety of cancers, such as colon cancer and melanoma, actions that may enable damaged cells to escape the immunosurveillance system. Here, we report through examination of databases that STING signaling may be commonly suppressed in a greater variety of tumors due to loss-of-function mutation or epigenetic silencing of the STING/cGAS promoter regions. In comparison, RNA activated innate immune pathways controlled by RIGI/ MDA5 were significantly less affected. Examination of reported missense STING variants confirmed that many exhibited a loss-of-function phenotype and could not activate cytokine production following exposure to cytosolic DNA or DNAdamage events. Our data imply that the STING signaling pathway may be recurrently suppressed by a number of mechanisms in a considerable variety of malignant disease and be a requirement for cellular transformation.	[Konno, Hiroyasu; Yamauchi, Shota; Barber, Glen N.] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Berglund, Anders; Putney, Ryan M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA; [Mule, James J.] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol, Tampa, FL USA; [Mule, James J.] H Lee Moffitt Canc Ctr & Res Inst, Immunol Programs, Tampa, FL USA	University of Miami; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Barber, GN (corresponding author), Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA.	gbarber@med.miami.edu		Berglund, Anders/0000-0002-0393-3530	NCI [R01CA194404]; NCI-NIH [1R01 CA148995, 1R01 CA184845, P30 CA076292, P50 CA168536]; Cindy and Jon Gruden Fund; Chris Sullivan Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [R01CA148995, P30CA076292, R01CA184845, P50CA168536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079336] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cindy and Jon Gruden Fund; Chris Sullivan Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from NCI (R01CA194404) (G.N. Barber) and NCI-NIH (1R01 CA148995, 1R01 CA184845, P30 CA076292, P50 CA168536), Cindy and Jon Gruden Fund, Chris Sullivan Fund, and Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (J. J. Mule). We thank the staff of the Moffitt Cancer Center Cancer Informatics and Collaborative Data Services.	Ahn J, 2015, ONCOGENE, V34, P5302, DOI 10.1038/onc.2014.457; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kolodkin-Gal D, 2009, GENE THER, V16, P905, DOI 10.1038/gt.2009.44; Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049; Kranzusch PJ, 2014, CELL, V158, P1011, DOI 10.1016/j.cell.2014.07.028; Li X, 2013, IMMUNITY, V39, P1019, DOI 10.1016/j.immuni.2013.10.019; Ma YJ, 2012, J VIROL, V86, P2188, DOI 10.1128/JVI.05376-11; Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003; Song SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep39858; Spitzer M, 2014, NAT METHODS, V11, P121, DOI 10.1038/nmeth.2811; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114; Zhang X, 2014, CELL REP, V6, P421, DOI 10.1016/j.celrep.2014.01.003	31	92	94	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2037	2051		10.1038/s41388-017-0120-0	http://dx.doi.org/10.1038/s41388-017-0120-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367762	Green Accepted			2022-12-17	WOS:000429899400007
J	Liang, WC; Ren, JL; Wong, CW; Chan, SO; Waye, MMY; Fu, WM; Zhang, JF				Liang, Wei-Cheng; Ren, Jia-Lin; Wong, Cheuk-Wa; Chan, Sun-On; Waye, Mary Miu-Yee; Fu, Wei-Ming; Zhang, Jin-Fang			LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/beta-catenin signaling	ONCOGENE			English	Article							LONG NONCODING RNAS; BETA-CATENIN; DIFFERENTIATION; EXPRESSION; PROMOTES; GENE; SUPPRESSES; CARCINOMA; ASSOCIATE	Emerging evidence indicates that the long noncoding RNAs extensively participate in cancer progression. Nevertheless, the molecular pathogenesis of how these lncRNAs regulate tumorigenesis has not been fully elucidated especially in hepatocellular carcinoma (HCC). Here, we sought to define the role of a novel lncRNA named lncRNA-NEF in modulating epithelial to mesenchymal transition (EMT) in HCC. It was found that the lncRNA-NEF was transcriptionally activated by EMT suppressor FOXA2 and frequently downregulated in HCC cell lines as well as clinical specimens. Although enhanced expression of lncRNA-NEF did not affect tumor cell growth, ectopic expression of lncRNA-NEF significantly suppressed EMT program and cell migration. Animal studies validated that lncRNA-NEF alleviated in vivo tumor metastasis and protected mice from tumor-induced mortality. Interestingly, we verified that lncRNA-NEF acted as a novel activator of its neighbor gene FOXA2, which formed a positive feedback loop. Subsequent studies revealed that lncRNA-NEF physically interacted with beta-catenin to increase the binding of GSK3 beta with beta-catenin and therefore promoted the inhibitory phosphorylation of beta-catenin, leading to the suppression on Wnt/beta-catenin signaling and activation of FOXA2 expression. Hence, our findings illustrated a novel feedback loop including FOXA2 and its neighboring gene lncRNA-NEF, which might provide mechanistic insights into the metastatic progress of HCC.	[Liang, Wei-Cheng; Ren, Jia-Lin; Wong, Cheuk-Wa; Chan, Sun-On; Waye, Mary Miu-Yee] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Waye, Mary Miu-Yee] Chinese Univ Hong Kong, Nethersole Sch Nursing, Shatin, Hong Kong, Peoples R China; [Fu, Wei-Ming] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Fu, Wei-Ming] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China; [Zhang, Jin-Fang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Clin Med Coll 1, Key Lab Orthopaed & Traumatol, Guangzhou, Guangdong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Southern Medical University - China; Southern Medical University - China; Guangzhou University of Chinese Medicine	Fu, WM (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.; Fu, WM (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China.; Zhang, JF (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Clin Med Coll 1, Key Lab Orthopaed & Traumatol, Guangzhou, Guangdong, Peoples R China.	fuweiming76@smu.edu.cn; zhangjf06@cuhk.edu.hk	韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Chan, Sun-On/R-6547-2018	韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; Chan, Sun-On/0000-0002-3221-3786	National Natural Science Foundation of China [81773066, 81772404]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81773066 to W.F. and 81772404 to J.Z.).	Akagi T, 2008, BRIT J CANCER, V99, P781, DOI 10.1038/sj.bjc.6604544; Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Fu WM, 2016, ONCOTARGET, V7, P4712, DOI 10.18632/oncotarget.6731; Fu WM, 2015, J HEPATOL, V63, P886, DOI 10.1016/j.jhep.2015.05.016; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang W, 2015, CELL REP, V11, P137, DOI 10.1016/j.celrep.2015.03.008; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HK, 2006, NUCLEIC ACIDS RES, V34, P5705, DOI 10.1093/nar/gkl698; Liang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20121; Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154; Liang WC, 2015, J CELL BIOCHEM, V116, P2658, DOI 10.1002/jcb.25214; Liang WC, 2014, RNA BIOL, V11, P845, DOI 10.4161/rna.29356; Liang WC, 2013, J CELL BIOCHEM, V114, P2699, DOI 10.1002/jcb.24617; Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi W, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/358902; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Rossi L, 2010, WORLD J GASTRO ONCOL, V2, P348, DOI 10.4251/wjgo.v2.i9.348; Simons BW, 2012, DEV BIOL, V371, P246, DOI 10.1016/j.ydbio.2012.08.016; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang D, 2015, HEPATOL INT, V9, P438, DOI 10.1007/s12072-015-9642-0; Wang J, 2014, CARCINOGENESIS, V35, P2576, DOI 10.1093/carcin/bgu180; Xiang C, 2015, FASEB J, V29, P1986, DOI 10.1096/fj.14-264580; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	38	92	98	3	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1445	1456		10.1038/s41388-017-0041-y	http://dx.doi.org/10.1038/s41388-017-0041-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29311643				2022-12-17	WOS:000427459500004
J	Collins, CT; Hess, JL				Collins, C. T.; Hess, J. L.			Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNA; HEMATOPOIETIC STEM-CELLS; BONE-MARROW-CELLS; ACUTE MYELOGENOUS LEUKEMIA; GENE-EXPRESSION PATTERN; MIXED-LINEAGE LEUKEMIA; HOMEOBOX-GENE; TRANSCRIPTION FACTORS; POOR-PROGNOSIS	HOXA9 is a homeodomain-containing transcription factor that has an important role in hematopoietic stem cell expansion and is commonly deregulated in acute leukemias. A variety of upstream genetic alterations in acute myeloid leukemia lead to overexpression of HOXA9, which is a strong predictor of poor prognosis. In many cases, HOXA9 has been shown to be necessary for maintaining leukemic transformation; however, the molecular mechanisms through which it promotes leukemogenesis remain elusive. Recent work has established that HOXA9 regulates downstream gene expression through binding at promoter distal enhancers along with a subset of cell-specific cofactor and collaborator proteins. Increasing efforts are being made to identify both the critical cofactors and target genes required for maintaining transformation in HOXA9-overexpressing leukemias. With continued advances in understanding HOXA9-mediated transformation, there is a wealth of opportunity for developing novel therapeutics that would be applicable for greater than 50% of AML with overexpression of HOXA9.	[Collins, C. T.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Hess, J. L.] Indiana Univ, Sch Med, Dept Pathol & Lab Med, 340 West 10th St, Indianapolis, IN 46202 USA; [Hess, J. L.] Indiana Univ, Sch Med, Dept Med, 340 West 10th St, Indianapolis, IN 46202 USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Hess, JL (corresponding author), Indiana Univ, Sch Med, Univ Clin Affairs, 340 West 10th St, Indianapolis, IN 46202 USA.	jayhess@iu.edu			NATIONAL CANCER INSTITUTE [R01CA151425] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA151425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Andreeff M, 2008, LEUKEMIA, V22, P2041, DOI 10.1038/leu.2008.198; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bandyopadhyay S, 2012, MOL CELL BIOL, V32, P1202, DOI 10.1128/MCB.05977-11; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Bantignies F, 2011, CELL, V144, P214, DOI 10.1016/j.cell.2010.12.026; Bei L, 2007, J BIOL CHEM, V282, P16846, DOI 10.1074/jbc.M609744200; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; Bergiers I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080387; Bijl J, 2006, BLOOD, V108, P116, DOI 10.1182/blood-2005-06-2245; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Brayer KJ, 2011, P NATL ACAD SCI USA, V108, pE414, DOI 10.1073/pnas.1100990108; Breitinger C, 2013, LEUKEMIA, V27, P236, DOI 10.1038/leu.2012.166; Breitinger C, 2012, BLOOD, V120, P4018, DOI 10.1182/blood-2011-10-384685; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Brumatti G, 2013, ONCOTARGET, V4, P1933, DOI 10.18632/oncotarget.1306; Brun ACM, 2004, BLOOD, V103, P4126, DOI 10.1182/blood-2003-10-3557; Busser BW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069385; Calero-Nieto FJ, 2013, ONCOGENE, V32, P5471, DOI 10.1038/onc.2013.175; Chen FJ, 2013, MOL CARCINOGEN, V52, P908, DOI 10.1002/mc.21944; Choe SK, 2014, DEV CELL, V28, P203, DOI 10.1016/j.devcel.2013.12.011; Choo SW, 2011, ADV GENET, V76, P55, DOI 10.1016/B978-0-12-386481-9.00003-1; Choo SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014778; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Cui Ling, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P57; Dasse E, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.20; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Davidson AJ, 2006, DEV BIOL, V292, P506, DOI 10.1016/j.ydbio.2006.01.003; de Rooij JDE, 2013, LEUKEMIA, V27, P2280, DOI 10.1038/leu.2013.87; Dieppois G, 2010, J CELL SCI, V123, P1989, DOI 10.1242/jcs.053694; Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108; Dintilhac A, 2004, GENE EXPR PATTERNS, V4, P215, DOI 10.1016/j.modgep.2003.08.006; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eklund E. A., 2011, Critical Reviews in Oncogenesis, V16, P65; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; Falini B, 2009, CURR OPIN ONCOL, V21, P573, DOI 10.1097/CCO.0b013e3283313dfa; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Fung TK, 2012, CURR OPIN HEMATOL, V19, P280, DOI 10.1097/MOH.0b013e3283545615; Ge XS, 2013, CANCER SCI, V104, P1675, DOI 10.1111/cas.12296; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goodman FR, 2002, AM J MED GENET, V112, P256, DOI 10.1002/ajmg.10776; Gough SM, 2011, BLOOD, V118, P6247, DOI 10.1182/blood-2011-07-328880; Guerreiro I, 2012, DEVELOPMENT, V139, P2703, DOI 10.1242/dev.081448; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; Gwin K, 2010, J IMMUNOL, V185, P6572, DOI 10.4049/jimmunol.0904203; Hassawi M, 2014, DEV DYNAM, V243, P145, DOI 10.1002/dvdy.24056; He XY, 2014, INT J MOL MED, V33, P325, DOI 10.3892/ijmm.2013.1570; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hoelz A, 2011, ANNU REV BIOCHEM, V80, P613, DOI 10.1146/annurev-biochem-060109-151030; Hollink IHIM, 2011, BLOOD, V118, P3645, DOI 10.1182/blood-2011-04-346643; Hu YL, 2007, BLOOD, V109, P4732, DOI 10.1182/blood-2006-08-043356; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Inoue D, 2013, J CLIN INVEST, V123, P4627, DOI 10.1172/JCI70739; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Karakas T, 1998, ANN ONCOL, V9, P159, DOI 10.1023/A:1008255511404; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Ko KH, 2007, EXP HEMATOL, V35, P465, DOI 10.1016/j.exphem.2006.10.014; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Ladam F, 2014, DEV DYNAM, V243, P4, DOI 10.1002/dvdy.23997; Lambert B, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-29; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Lelli KM, 2011, P NATL ACAD SCI USA, V108, P21122, DOI 10.1073/pnas.1114118109; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Liu XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-464; Longobardi E, 2014, DEV DYNAM, V243, P59, DOI 10.1002/dvdy.24016; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Rivas ML, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003252; Mann RS, 2009, CURR TOP DEV BIOL, V88, P63, DOI 10.1016/S0070-2153(09)88003-4; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; McKinney-Freeman SL, 2008, BLOOD, V111, P4944, DOI 10.1182/blood-2007-11-124644; Merabet S, 2014, DEV DYNAM, V243, P16, DOI 10.1002/dvdy.24002; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Min H, 2013, INT J BIOL SCI, V9, P960, DOI 10.7150/ijbs.6739; Misra M, 2012, DEV DYNAM, V241, P718, DOI 10.1002/dvdy.23763; Monroe SC, 2011, EXP HEMATOL, V39, P77, DOI 10.1016/j.exphem.2010.09.003; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mullighan CG, 2007, LEUKEMIA, V21, P2000, DOI 10.1038/sj.leu.2404808; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakayama I, 2013, INT J ONCOL, V43, P63, DOI 10.3892/ijo.2013.1935; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Ng RK, 2014, J PATHOL, V232, P65, DOI 10.1002/path.4279; Novak RL, 2012, EXP HEMATOL, V40, P1016, DOI 10.1016/j.exphem.2012.08.001; Noyes MB, 2008, CELL, V133, P1277, DOI 10.1016/j.cell.2008.05.023; Ohno Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053161; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Papadopoulos DK, 2012, DEV BIOL, V367, P78, DOI 10.1016/j.ydbio.2012.04.021; Penkov D, 2013, CELL REP, V3, P1321, DOI 10.1016/j.celrep.2013.03.029; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Polychronidou M, 2013, FLY, V7, DOI 10.4161/fly.22939; Pombo A, 2015, NAT REV MOL CELL BIO, V16, P245, DOI 10.1038/nrm3965; Radulovic V, 2013, LEUKEMIA, V27, P523, DOI 10.1038/leu.2012.368; Rawat VPS, 2012, BLOOD, V120, P519, DOI 10.1182/blood-2012-02-385898; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Rezsohazy R, 2014, DEV DYNAM, V243, P117, DOI 10.1002/dvdy.24060; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sambrani N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003307; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Saw J, 2013, LEUKEMIA RES, V37, P1668, DOI 10.1016/j.leukres.2013.09.013; Schaefer LK, 2001, J BIOL CHEM, V276, P43074, DOI 10.1074/jbc.M102552200; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Serrano E, 2006, ACTA HAEMATOL-BASEL, V116, P77, DOI 10.1159/000093636; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sheth R, 2014, DEV DYNAM, V243, P182, DOI 10.1002/dvdy.24019; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Shima H, 2014, INT J HEMATOL, V99, P21, DOI 10.1007/s12185-013-1466-x; Shimamoto T, 1999, J EXP ZOOL, V283, P186; Sitwala KV, 2008, INT J CLIN EXP PATHO, V1, P461; Slattery M, 2011, CELL, V147, P1270, DOI 10.1016/j.cell.2011.10.053; Slattery M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014686; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Sorge S, 2012, EMBO J, V31, P3323, DOI 10.1038/emboj.2012.179; Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657; Steger J, 2015, LEUKEMIA, V29, P901, DOI 10.1038/leu.2014.287; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; Tholouli E, 2012, BIOCHEM BIOPH RES CO, V425, P333, DOI 10.1016/j.bbrc.2012.07.092; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Tolhuis B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001343; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Vijapurkar U, 2004, MOL CELL BIOL, V24, P3827, DOI 10.1128/MCB.24.9.3827-3837.2004; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang Y, 2008, P NATL ACAD SCI USA, V105, P7756, DOI 10.1073/pnas.0708951105; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Whelan JT, 2008, LEUKEMIA, V22, P1161, DOI 10.1038/leu.2008.57; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Wolff L, 2013, BLOOD CELL MOL DIS, V50, P227, DOI 10.1016/j.bcmd.2013.01.006; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622; Yasunaga S, 2013, MOL CELL BIOL, V33, P644, DOI 10.1128/MCB.00974-12; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang JX, 2013, NEURO-ONCOLOGY, V15, P1595, DOI 10.1093/neuonc/not131; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577; Zhou B, 2012, P NATL ACAD SCI USA, V109, P8931, DOI 10.1073/pnas.1200874109; Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35	166	92	94	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1090	1098		10.1038/onc.2015.174	http://dx.doi.org/10.1038/onc.2015.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028034	Green Accepted			2022-12-17	WOS:000371351700003
J	Kundu, ST; Byers, LA; Peng, DH; Roybal, JD; Diao, L; Wang, J; Tong, P; Creighton, CJ; Gibbons, DL				Kundu, S. T.; Byers, L. A.; Peng, D. H.; Roybal, J. D.; Diao, L.; Wang, J.; Tong, P.; Creighton, C. J.; Gibbons, D. L.			The miR-200 family and the miR-183 similar to 96 similar to 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; TRANSCRIPTIONAL REPRESSOR; DOWN-REGULATION; CELL-SURVIVAL; FEEDBACK LOOP; BOX PROTEINS; MICRORNAS; ZEB1; EMT	Metastatic lung cancer is one of the most lethal forms of cancer and molecular pathways driving metastasis are still not clearly elucidated. Metastatic cancer cells undergo an epithelial-mesenchymal transition (EMT) where they lose their epithelial properties and acquire a migratory and invasive phenotype. Here we identify that the expression of microRNAs from the miR-200 family and the miR-183 similar to 96 similar to 182 cluster are significantly co-repressed in non-small cell lung cancer cell lines and primary tumors from multiple TCGA dataset with high EMT scores. Ectopic expression of the miR-183 similar to 96 similar to 182 cluster inhibited cancer cell migration and invasion, whereas its expression was tightly modulated by miR-200. We identified Foxf2 as a common, novel and direct target of both these microRNA families. Foxf2 expression tightly correlates with the transcription factor Zeb1 and is elevated in mesenchymal-like metastatic lung cancer cells. Foxf2 expression induced robust EMT, migration, invasion and metastasis in lung cancer cells, whereas Foxf2 inhibition significantly repressed these phenotypes. We also demonstrated that Foxf2 transcriptionally represses E-cadherin and miR-200, independent of Zeb1, to form a double-negative feedback loop. We, therefore, identified a novel mechanism whereby the miR-200 family and the miR-183 similar to 96 similar to 182 cluster inhibit lung cancer invasion and metastasis by targeting Foxf2.	[Kundu, S. T.; Byers, L. A.; Peng, D. H.; Roybal, J. D.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Diao, L.; Wang, J.; Tong, P.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432,Room FC9-2038, Houston, TX 77030 USA.	dlgibbon@mdanderson.org		Kundu, Samrat/0000-0002-0117-6986; Peng, David/0000-0003-0511-1888	NCI [K08 CA151661, CA125123]; MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CDMRP Lung Cancer Research Program [W81XWH-12-10294]; CPRIT Graduate Scholar Training Grant [RP140106]; Lung SPORE [P50 CA070907]; Cancer Center Support Grant [CCSG CA016672]; Mary K. Chapman Foundation; CPRIT [RP120713]; Jeane F. Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA070907, K08CA151651, P30CA125123] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CDMRP Lung Cancer Research Program; CPRIT Graduate Scholar Training Grant; Lung SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Mary K. Chapman Foundation; CPRIT; Jeane F. Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J. Larner (University of Virginia Health System, VA) for the kind gift of the pTRIPZ-GFP vector. We thank Dr G. Goodall (University of Adelaide, Australia) for the kind gift of the miR-200 promoter reporter construct. 16 This work was supported by NCI K08 CA151661 (DLG), an MD Anderson Cancer Center Physician Scientist Award (DLG), Rexanna's Foundation for Fighting Lung Cancer (DLG), a CDMRP Lung Cancer Research Program award W81XWH-12-10294 (DLG and STK). DP was supported by a CPRIT Graduate Scholar Training Grant (RP140106). LD, JW, PT are supported by Lung SPORE (P50 CA070907), Cancer Center Support Grant (CCSG CA016672) and Mary K. Chapman Foundation. CJC was supported by CPRIT grant RP120713 and NCI grant CA125123. DLG and LAB are R. Lee Clark Fellows of the University of Texas MD Anderson Cancer Center, supported by the Jeane F. Shelby Scholarship Fund. We would like to thank members of the Gibbons lab for the assistance and critical reading of the manuscript.	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Feng Xiangling, 2014, Cancer Lett, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hirata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055502; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Huynh C, 2011, ONCOGENE, V30, P1481, DOI 10.1038/onc.2010.523; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Knouf EC, 2012, NUCLEIC ACIDS RES, V40, P499, DOI 10.1093/nar/gkr731; Kong PZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061591; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65; Li GR, 2010, J BIOL CHEM, V285, P5461, DOI 10.1074/jbc.M109.037127; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Liu XG, 2012, MED ONCOL, V29, P618, DOI 10.1007/s12032-011-9923-y; Lo PK, 2013, EXP MOL PATHOL, V94, P262, DOI 10.1016/j.yexmp.2012.10.014; Lowery AJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-502; Mizuguchi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032449; Nik AM, 2013, GASTROENTEROLOGY, V144, P1001, DOI 10.1053/j.gastro.2013.01.045; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; Pacurari M, 2013, INT J ONCOL, V43, P548, DOI 10.3892/ijo.2013.1963; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pieraccioli M, 2013, CELL CYCLE, V12, P2309, DOI 10.4161/cc.25405; Roy SS, 2014, ONCOGENE, V33, P3707, DOI 10.1038/onc.2013.332; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wang T, 2003, DEV BIOL, V259, P83, DOI 10.1016/S0012-1606(03)00176-3; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Weeraratne SD, 2012, ACTA NEUROPATHOL, V123, P539, DOI 10.1007/s00401-012-0969-5; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Zhao HE, 2012, INT J MOL MED, V30, P1013, DOI 10.3892/ijmm.2012.1111; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zhu JF, 2012, AM J PATHOL, V180, P2440, DOI 10.1016/j.ajpath.2012.02.023	76	92	97	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					173	186		10.1038/onc.2015.71	http://dx.doi.org/10.1038/onc.2015.71			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25798833	Green Accepted			2022-12-17	WOS:000368193900004
J	Daniel, AR; Gaviglio, AL; Knutson, TP; Ostrander, JH; D'Assoro, AB; Ravindranathan, P; Peng, Y; Raj, GV; Yee, D; Lange, CA				Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Ostrander, J. H.; D'Assoro, A. B.; Ravindranathan, P.; Peng, Y.; Raj, G. V.; Yee, D.; Lange, C. A.			Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1-and estrogen receptor-containing transcription complexes	ONCOGENE			English	Article						estrogen receptor; progesterone receptor; PELP1; IGF1R; cathepsin-D; breast cancer	C-SRC; ENDOCRINE RESISTANCE; TAMOXIFEN RESISTANCE; HORMONE-RECEPTORS; GROWTH; ACTIVATION; PATHWAY; EXPRESSION; KINASE; PHOSPHORYLATION	Progesterone and estrogen are important drivers of breast cancer proliferation. Herein, we probed estrogen receptor-a (ER) and progesterone receptor (PR) cross-talk in breast cancer models. Stable expression of PR-B in PR-low/ER+ MCF7 cells increased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in growth assays performed in the absence of exogenous progestin; similar results were obtained in PR-null/ER+ T47D cells stably expressing PR-B. Genome-wide microarray analyses revealed that unliganded PR-B induced robust expression of a subset of estradiol-responsive ER target genes, including cathepsin-D (CTSD). Estradiol-treated MCF7 cells stably expressing PR-B exhibited enhanced ER Ser167 phosphorylation and recruitment of ER, PR and the proline-, glutamate-and leucine-rich protein 1 (PELP1) to an estrogen response element in the CTSD distal promoter; this complex co-immunoprecipitated with IGF1 receptor (IGFR1) in whole-cell lysates. Importantly, ER/PR/PELP1 complexes were also detected in human breast cancer samples. Inhibition of IGF1R or phosphoinositide 3-kinase blocked PR-B-dependent CTSD mRNA upregulation in response to estradiol. Similarly, inhibition of IGF1R or PR significantly reduced ER recruitment to the CTSD promoter. Stable knockdown of endogenous PR or onapristone treatment of multiple unmodified breast cancer cell lines blocked estradiol-mediated CTSD induction, inhibited growth in soft agar and partially restored tamoxifen sensitivity of resistant cells. Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone. In summary, unliganded PR-B enhanced proliferative responses to estradiol and IGF1 via scaffolding of ER-alpha/PELP1/IGF1R-containing complexes. Our data provide a strong rationale for targeting PR in combination with ER and IGF1R in patients with luminal breast cancer.	[Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Ostrander, J. H.; Yee, D.; Lange, C. A.] Univ Minnesota, Mason Canc Ctr, Dept Med, Minneapolis, MN 55455 USA; [Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Yee, D.; Lange, C. A.] Univ Minnesota, Mason Canc Ctr, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA; [D'Assoro, A. B.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA; [Ravindranathan, P.; Raj, G. V.] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Peng, Y.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Lange, CA (corresponding author), Univ Minnesota, Mason Canc Ctr, Dept Med, Canc Cardiology Res Bldg,2231 6th St SE, Minneapolis, MN 55455 USA.	Lange047@umn.edu	Knutson, Todd P/H-8304-2012	Yee, Douglas/0000-0002-3387-4009; Lange, Carol/0000-0003-2751-3976	NIH [R01 CA159712, P30 CA077598, K07 CA131501]; NATIONAL CANCER INSTITUTE [R01CA074285, P30CA077598, R01CA159712, K07CA131501] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Deepali Sachdev (University of Minnesota) for the kind gift of the MCF7L cells. Onapristone was kindly provided by Arno Therapeutics Inc. (Flemington, NJ, USA). The Masonic Cancer Center Biostatistics and Bioinformatics core performed the normalization of the raw microarray data. AEW541 was a gift from Novartis Pharmaceuticals (Basel, Switzerland). This work was supported by NIH R01 CA159712 (CAL), P30 CA077598 (DY) and K07 CA131501 (JHO).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aupperlee MD, 2007, ENDOCRINOLOGY, V148, P2290, DOI 10.1210/en.2006-1721; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287; Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028; Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286; Daniel AR, 2011, EXPERT REV ENDOCRINO, V6, P359, DOI 10.1586/EEM.11.25; Daniel AR, 2009, P NATL ACAD SCI USA, V106, P14287, DOI 10.1073/pnas.0905118106; Daniel AR, 2009, MOL CELL ENDOCRINOL, V308, P47, DOI 10.1016/j.mce.2009.01.004; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fox EM, 2008, MOL ENDOCRINOL, V22, P1781, DOI 10.1210/me.2007-0419; Fox EM, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00145; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giulianelli S, 2012, CANCER RES, V72, P2416, DOI 10.1158/0008-5472.CAN-11-3290; Gupta A, 2013, J STEROID BIOCHEM, V133, P30, DOI 10.1016/j.jsbmb.2012.08.004; Hagan CR, 2011, MOL CELL BIOL, V31, P2439, DOI 10.1128/MCB.01246-10; Hilton HN, 2012, MOL CELL ENDOCRINOL, V361, P191, DOI 10.1016/j.mce.2012.04.010; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Lanari C, 2012, ENDOCR-RELAT CANCER, V19, pR35, DOI 10.1530/ERC-11-0378; Leontovich AA, 2012, INT J ONCOL, V40, P1858, DOI 10.3892/ijo.2012.1407; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Riggins RB, 2008, CANCER RES, V68, P8908, DOI 10.1158/0008-5472.CAN-08-2669; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Sachdev D, 2003, CANCER RES, V63, P627; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shimizu T, 2010, PHYSIOL GENOMICS, V42A, P290, DOI 10.1152/physiolgenomics.00107.2010; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Tang QZ, 2011, CANCER RES, V71, P6940, DOI 10.1158/0008-5472.CAN-11-2091; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Zhang Y, 2008, MOL CELLULAR BIOL; Zukiwski AA, 2013, ASCO AM SOC CLIN ONC	50	92	98	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					506	515		10.1038/onc.2013.579	http://dx.doi.org/10.1038/onc.2013.579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469035	Green Accepted			2022-12-17	WOS:000348451300011
J	Pugh, TJ; Yu, W; Yang, J; Field, AL; Ambrogio, L; Carter, SL; Cibulskis, K; Giannikopoulos, P; Kiezun, A; Kim, J; McKenna, A; Nickerson, E; Getz, G; Hoffher, S; Messinger, YH; Dehner, LP; Roberts, CWM; Rodriguez-Galindo, C; Williams, GM; Rossi, CT; Meyerson, M; Hill, DA				Pugh, T. J.; Yu, W.; Yang, J.; Field, A. L.; Ambrogio, L.; Carter, S. L.; Cibulskis, K.; Giannikopoulos, P.; Kiezun, A.; Kim, J.; McKenna, A.; Nickerson, E.; Getz, G.; Hoffher, S.; Messinger, Y. H.; Dehner, L. P.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Williams, G. M.; Rossi, C. T.; Meyerson, M.; Hill, D. A.			Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences	ONCOGENE			English	Article							COPY-NUMBER ALTERATION; EMBRYONAL RHABDOMYOSARCOMA; MUTATIONS; CANCER; TUMORS	Pleuropulmonary blastoma is a rare childhood malignancy of lung mesenchymal cells that can remain dormant as epithelial cysts or progress to high-grade sarcoma. Predisposing germline loss-of-function DICER1 variants have been described. We sought to uncover additional contributors through whole exome sequencing of 15 tumor/normal pairs, followed by targeted resequencing, miRNA analysis and immunohistochemical analysis of additional tumors. In addition to frequent biallelic loss of TP53 and mutations of NRAS or BRAF in some cases, each case had compound disruption of DICER1: a germline (12 cases) or somatic (3 cases) loss-of-function variant plus a somatic missense mutation in the RNase IIIb domain. 5p-Derived microRNA (miRNA) transcripts retained abnormal precursor miRNA loop sequences normally removed by DICER1. This work both defines a genetic interaction landscape with DICER1 mutation and provides evidence for alteration in miRNA transcripts as a consequence of DICER1 disruption in cancer.	[Pugh, T. J.; Ambrogio, L.; Carter, S. L.; Cibulskis, K.; Giannikopoulos, P.; Kiezun, A.; Kim, J.; McKenna, A.; Nickerson, E.; Getz, G.; Meyerson, M.] Broad Inst MIT & Harvard, Cambridge, MA USA; [Pugh, T. J.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Meyerson, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Pugh, T. J.; Roberts, C. W. M.; Rodriguez-Galindo, C.; Meyerson, M.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Rossi, C. T.; Hill, D. A.] George Washington Univ, Dept Integrat Syst Biol, Washington, DC USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Hill, D. A.] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; [Yu, W.; Yang, J.; Field, A. L.; Hoffher, S.; Hill, D. A.] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA; [Messinger, Y. H.; Williams, G. M.] Childrens Hosp, Minneapolis, MN USA; [Messinger, Y. H.; Williams, G. M.] Clin Minnesota, Minneapolis, MN USA; [Dehner, L. P.] Washington Univ, Med Ctr, Dept Pathol & Immunol, St Louis, MO USA; [Roberts, C. W. M.; Rodriguez-Galindo, C.] Boston Childrens Hosp, Boston, MA USA; [Roberts, C. W. M.; Rodriguez-Galindo, C.] Dana Farber Childrens Canc Ctr, Boston, MA USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; George Washington University; Children's National Health System; Children's National Health System; Children's Hospitals & Clinics of Minnesota; Washington University (WUSTL); Harvard University; Boston Children's Hospital	Meyerson, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Mailstop Dana 1540, Boston, MA 02215 USA.	matthew_meyerson@dfci.harvard.edu; dashill@childrensnational.org	Cibulskis, Kristian/AAC-7380-2019; Pugh, Trevor/Y-2535-2019; Roberts, Charles/N-2541-2018; Rodriguez-Galindo, Carlos/N-8071-2018	Pugh, Trevor/0000-0002-8073-5888; Roberts, Charles/0000-0003-1135-1896; Meyerson, Matthew/0000-0002-9133-8108; Cibulskis, Kristian/0000-0003-1343-1582; Kiezun, Adam/0000-0002-6634-1073	Carlos Slim Health Institute in Mexico; Canadian Institutes of Health Research Fellowship; National Cancer Institute [R01CA143167]; National Heart, Lung and Blood Institute [R01HL109265, R01HL111190]; NATIONAL CANCER INSTITUTE [R01CA143167] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109265, R01HL111190] Funding Source: NIH RePORTER	Carlos Slim Health Institute in Mexico; Canadian Institutes of Health Research Fellowship(Canadian Institutes of Health Research (CIHR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Sequence data used for this analysis are available from dbGaP under accession phs000543. The work was conducted as part of the Slim Initiative for Genomic Medicine, a project funded by the Carlos Slim Health Institute in Mexico. We would like to acknowledge the technical expertise and data generation efforts of The Broad Institute Genomics Platform and Cancer Genome Analysis group. TJP was supported by a Canadian Institutes of Health Research Fellowship. DAH is supported by National Cancer Institute (R01CA143167), and National Heart, Lung and Blood Institute (R01HL109265 and R01HL111190). We thank the members of the Ogawa Laboratory for shared insights during reporting of genomic findings of PPB.<SUP>34</SUP>	Anglesio MS, 2013, J PATHOL, V229, P400, DOI 10.1002/path.4135; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809; Dehner LP, 2012, MODERN PATHOL, V25, P602, DOI 10.1038/modpathol.2011.185; Doros L, 2012, PEDIATR BLOOD CANCER, V59, P558, DOI 10.1002/pbc.24020; Doros LA, 2014, MODERN PATHOL, V27, P1267, DOI 10.1038/modpathol.2013.242; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Foulkes WD, 2011, HUM MUTAT, V32, P1381, DOI 10.1002/humu.21600; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Getz G, 2007, SCIENCE, V317, DOI 10.1126/science.1138764; Gurtan AM, 2012, RNA, V18, P1116, DOI 10.1261/rna.032680.112; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hill DA, 2008, AM J SURG PATHOL, V32, P282, DOI 10.1097/PAS.0b013e3181484165; Hou P, 2007, CELL CYCLE, V6, P377, DOI 10.4161/cc.6.3.3818; Lawrence MS, 2013, NATURE; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; Seki M, 2014, CANCER RES, V74, P2742, DOI 10.1158/0008-5472.CAN-13-2470; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002	34	92	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5295	5302		10.1038/onc.2014.150	http://dx.doi.org/10.1038/onc.2014.150			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24909177	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000345120400007
J	Kao, SH; Wang, WL; Chen, CY; Chang, YL; Wu, YY; Wang, YT; Wang, SP; Nesvizhskii, AI; Chen, YJ; Hong, TM; Yang, PC				Kao, S-H; Wang, W-L; Chen, C-Y; Chang, Y-L; Wu, Y-Y; Wang, Y-T; Wang, S-P; Nesvizhskii, A. I.; Chen, Y-J; Hong, T-M; Yang, P-C			GSK3 beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug	ONCOGENE			English	Article						GSK3 beta; Slug; CHIP; post-translational modification	UBIQUITIN LIGASE CHIP; GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN; TRANSCRIPTION FACTORS; CANCER; PROTEIN; PHOSPHORYLATION; CHAPERONE; INHIBITION; EXPRESSION	Glycogen synthase kinase 3 beta (GSK3 beta) is highly inactivated in epithelial cancers and is known to inhibit tumor migration and invasion. The zinc-finger-containing transcriptional repressor, Slug, represses E-cadherin transcription and enhances epithelial mesenchymal transition (EMT). In this study, we find that the GSK3 beta-pSer9 level is associated with the expression of Slug in non-small cell lung cancer. GSK3 beta-mediated phosphorylation of Slug facilitates Slug protein turnover. Proteomic analysis reveals that the carboxyl terminus of Hsc70-interacting protein (CHIP) interacts with wild-type Slug (wtSlug). Knockdown of CHIP stabilizes the wtSlug protein and reduces Slug ubiquitylation and degradation. In contrast, nonphosphorylatable Slug-4SA is not degraded by CHIP. The accumulation of nondegradable Slug may further lead to the repression of E-cadherin expression and promote cancer cell migration, invasion and metastasis. Our findings provide evidence of a de novo GSK3 beta-CHIP-Slug pathway that may be involved in the progression of metastasis in lung cancer.	[Kao, S-H; Yang, P-C] Natl Taiwan Univ, Inst Mol Med, Taipei 100, Taiwan; [Wang, W-L; Chen, C-Y; Wu, Y-Y; Wang, S-P; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Chen, C-Y] Chang Gung Univ Sci & Technol, Dept Nutr & Hlth Sci, Taoyuan, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Dept Pathol, Taipei 100, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Grad Inst Pathol, Taipei 100, Taiwan; [Wu, Y-Y; Hong, T-M] Natl Cheng Kung Univ, Grad Inst Clin Med, Taipei, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Inst Chem, Taipei, Taiwan; [Wang, Y-T] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei 100, Taiwan; [Wang, S-P] Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA; [Nesvizhskii, A. I.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Nesvizhskii, A. I.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei 100, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Chang Gung University of Science & Technology; National Taiwan University; National Taiwan University; National Cheng Kung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; Rockefeller University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, 138 Sheng Li Rd, Tainan 704, Taiwan.	tmhong@mail.ncku.edu.tw; pcyang@ntu.edu.tw	Chen, Yu-Ju/E-9481-2015; Nesvizhskii, Alexey/A-5410-2012; Wang, Shu-Ping/S-4379-2018	Chen, Yu-Ju/0000-0002-3178-6697; Nesvizhskii, Alexey/0000-0002-2806-7819; Wang, Shu-Ping/0000-0002-5895-1269; CHANG, YIH-LEONG/0000-0001-5309-0554; YANG, PAN-CHYR/0000-0001-6330-6048	National Science Council, Taiwan [NSC99-2628-B-006-031-MY3 NSC101-2325-B-006-018, NSC100-2321-8-002-071, NSC101-2321-B002-068]; National Taiwan University, Taiwan [10R71601-2]; National Institute of Health, USA [R01-GM-094231]; Human Frontier Science Program long-term fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094231] Funding Source: NIH RePORTER	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Taiwan University, Taiwan(National Taiwan University); National Institute of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program long-term fellowship(Human Frontier Science Program); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank MC Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, USA) for providing the plasmids for GSK3 beta, and Wen-Lung Wang, Yi-Ying Wu, Chi-Yuan Chen for technical assistance. This work was supported by grants from the National Science Council, Taiwan (NSC99-2628-B-006-031-MY3 NSC101-2325-B-006-018, NSC100-2321-8-002-071 and NSC101-2321-B002-068), National Taiwan University, Taiwan (10R71601-2), and National Institute of Health, USA (R01-GM-094231, to AIN). SP Wang is supported by a Human Frontier Science Program long-term fellowship. shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan.	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Al-Mulla F, 2011, CANCER RES, V71, P1334, DOI 10.1158/0008-5472.CAN-10-3102; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cheng JC, PLOS ONE, V7; Choi H, 2011, NAT METHODS, V8, P70, DOI [10.1038/nmeth.1541, 10.1038/NMETH.1541]; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEGROOT RP, 1993, ONCOGENE, V8, P841; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; G-Amlak M, 2002, BIOCHEM BIOPH RES CO, V297, P760, DOI 10.1016/S0006-291X(02)02278-7; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hajra KM, 2002, CANCER RES, V62, P1613; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; John JK, 2012, J INVEST DERMATOL, V132, P2818, DOI 10.1038/jid.2012.237; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karrasch T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026340; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Lee HY, 2005, CLIN CANCER RES, V11, P6065, DOI 10.1158/1078-0432.CCR-05-0009; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rees I, 2006, BBA-PROTEINS PROTEOM, V1764, P1073, DOI 10.1016/j.bbapap.2006.03.013; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zheng HC, 2007, ANTICANCER RES, V27, P3561; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	68	92	94	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3172	3182		10.1038/onc.2013.279	http://dx.doi.org/10.1038/onc.2013.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851495	Green Accepted			2022-12-17	WOS:000338410000010
J	Lee, JY; Park, MK; Park, JH; Lee, HJ; Shin, DH; Kang, Y; Lee, CH; Kong, G				Lee, J-Y; Park, M. K.; Park, J-H; Lee, H. J.; Shin, D. H.; Kang, Y.; Lee, C. H.; Kong, G.			Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer	ONCOGENE			English	Article						Mel-18; miR-205; ZEB1; ZEB2; epithelial-mesenchymal transition; polycomb	GROWTH-FACTOR-BETA; TUMOR INVASION; MICRORNAS; BMI-1; CELLS; OVEREXPRESSION; REPRESSION; FAMILY	The epithelial-mesenchymal transition (EMT) is the pivotal mechanism underlying the initiation of cancer invasion and metastasis. Although Mel-18 has been implicated in several biological processes in cancer, its function in the EMT of human cancers has not yet been studied. Here, we demonstrate that Mel-18 negatively regulates the EMT by epigenetically modulating miR-205. We identified miR-205 as a novel target of Mel-18 using a microRNA microarray analysis and found that Mel-18 increased miR-205 transcription by the inhibition of DNA methyltransferase-mediated DNA methylation of the miR-205 promoter, thereby downregulating its target genes, ZEB1 and ZEB2. Furthermore, the loss of Mel-18 promoted ZEB1- and ZEB2-mediated downregulation of E-cadherin transcription and also enhanced the expression of mesenchymal markers, leading to increased migration and invasion in MCF-7 cells. In MDA-MB-231 cells, Mel-18 overexpression restored E-cadherin expression, resulting in reduced migration and invasion. These effects were reversed by miR-205 overexpression or inhibition. A tumor xenograft with Mel-18 knockdown MCF-7 cells consistently showed increased ZEB1 and ZEB2 expression and decreased E-cadherin expression. Taken together, these results suggest that Mel-18 functions as a tumor suppressor by its novel negative control of the EMT, achieved through regulating the expression of miR-205 and its target genes, ZEB1 and ZEB2.	[Lee, J-Y; Kong, G.] Hanyang Univ, IBBR, Seoul 133791, South Korea; [Park, M. K.; Lee, H. J.; Lee, C. H.] Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea; [Park, J-H; Shin, D. H.; Kong, G.] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Hanyang University; Dongguk University; Hanyang University; Princeton University	Lee, CH (corresponding author), Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea.	uatheone@gmail.com; gkong@hanyang.ac.kr		Kang, Yibin/0000-0002-1626-6730	Korea Healthcare Technology RD Project [A101836]; Ministry of Health Welfare and Family Affairs; Research Program for New Drug Target Discovery [2011-0030173]	Korea Healthcare Technology RD Project; Ministry of Health Welfare and Family Affairs(Ministry of Health & Welfare (MOHW), Republic of Korea); Research Program for New Drug Target Discovery(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This study was supported by grants from the Korea Healthcare Technology R&D Project (A101836), the Ministry of Health Welfare and Family Affairs and the Research Program for New Drug Target Discovery (2011-0030173).	Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; AuS Leung-Kuen, 2012, HEPATOLOGY, V56, P622; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blumenberg M, 2007, CELLS TISSUES ORGANS, V185, P162, DOI 10.1159/000101317; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Negishi M, 2007, BIOCHEM BIOPH RES CO, V353, P992, DOI 10.1016/j.bbrc.2006.12.166; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rush Margaret, 2009, Epigenetics, V4, P404; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Shin DH, 2011, J CELL PHYSIOL, V226, P1340, DOI 10.1002/jcp.22462; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wanami LS, 2008, EXP CELL RES, V314, P2448, DOI 10.1016/j.yexcr.2008.05.004; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	44	92	94	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1325	1335		10.1038/onc.2013.53	http://dx.doi.org/10.1038/onc.2013.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474752				2022-12-17	WOS:000332631100013
J	Krajewska, M; Heijink, AM; Bisselink, YJWM; Seinstra, RI; Sillje, HHW; de Vries, EGE; van Vugt, MATM				Krajewska, M.; Heijink, A. M.; Bisselink, Y. J. W. M.; Seinstra, R. I.; Sillje, H. H. W.; de Vries, E. G. E.; van Vugt, M. A. T. M.			Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination	ONCOGENE			English	Article						Wee1; homologous recombination; DNA repair; cell cycle checkpoint; MK-1775	CYCLIN-DEPENDENT KINASES; DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND-BREAK; CELL-CYCLE; END RESECTION; REGULATORY MECHANISM; MAMMALIAN-CELLS; REPAIR; PHOSPHORYLATION; RECOVERY	In response to DNA breaks, the 'DNA damage response' provokes a cell cycle arrest to facilitate DNA repair. Recent findings have indicated that cells can respond to DNA damage throughout the cell cycle, except during mitosis. Specifically, various mitotic kinases, including Cdk1, Aurora A and Plk1, were shown to inactivate key DNA damage checkpoint proteins when cells enter mitosis. Aberrant activation of mitotic kinases during interphase could therefore modulate cellular responses to DNA damage. In this study, our aim was to determine how aberrant activation of Cdk1 affects the cellular responses to DNA damage. We used Wee1 inhibition, using MK-1775, to force Cdk1 activation, which did not cause cytotoxicity in non-transformed cells. Instead, it accelerated mitotic entry and caused radio sensitization in p53-defective cancer cells, but not in p53-proficient cancer cells. Interestingly, we showed that Wee1 inhibition leads to elevation of Cdk1 activity in interphase cells. When we subsequently analyzed DNA damage responses in cells with forced Cdk1 activation, we observed a marked reduction of 53BP1 at sites of DNA damage along with an increase in g-H2AX staining after irradiation, indicative of defective DNA repair. Indeed, when DNA repair was analyzed using in vivo endonuclease-induced homologous recombination (HR) assays, compromised DNA repair after Wee1 inhibition was confirmed. This defect in HR was accompanied by increased phosphorylation of BRCA2 at the Cdk1 phosphorylation site S3291. Taken together, our results indicate that Wee1 inhibition leads to forced Cdk1 activation in interphase cells, which interferes with normal DNA damage responses.	[Krajewska, M.; Heijink, A. M.; Bisselink, Y. J. W. M.; Seinstra, R. I.; de Vries, E. G. E.; van Vugt, M. A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; [Sillje, H. H. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.vugt@umcg.nl	Krajewska, Malgorzata/AAH-1158-2021	de Vries, Elisabeth/0000-0002-8949-7425; Heijink, Anne Margriet/0000-0001-9229-0575; Krajewska, Malgorzata/0000-0002-2243-5924	NWO-VENI grant [916.76.062]	NWO-VENI grant	This work was supported by a NWO-VENI grant (916.76.062) to MATMVV. We thank Drs Maria Jasin, Jeff Parvin, Reuven Agami, James Ferrell Jr and Vera Gorbunova for generously supplying materials, Dr Gerben Vader for critically reading the manuscript and members of the Medical Oncology laboratory for helpful discussions.	Adams Bret R, 2010, Aging (Albany NY), V2, P582; Cerqueira A, 2009, J CELL BIOL, V187, P773, DOI 10.1083/jcb.200903033; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Crescenzi E, 2005, CLIN CANCER RES, V11, P8158, DOI 10.1158/1078-0432.CCR-05-1042; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enserink JM, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-11; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; HARPER JW, 1993, CELL, V75, P805; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee SE, 2000, COLD SPRING HARB SYM, V65, P303, DOI 10.1101/sqb.2000.65.303; Leijen S, 2010, CURR CLIN PHARMACOL, V5, P186, DOI 10.2174/157488410791498824; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARVIN J, 2011, J VIS EXP, V48, pE2468; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Scully R, 2005, ONCOGENE, V24, P2871, DOI 10.1038/sj.onc.1208609; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Vugt MATM, 2010, CELL CYCLE, V9, P2097, DOI 10.4161/cc.9.11.11840; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	41	92	93	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2013	32	24					3001	3008		10.1038/onc.2012.296	http://dx.doi.org/10.1038/onc.2012.296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797065				2022-12-17	WOS:000320369700010
J	Moleirinho, S; Chang, N; Sims, AH; Tilston-Lunel, AM; Angus, L; Steele, A; Boswell, V; Barnett, SC; Ormandy, C; Faratian, D; Gunn-Moore, FJ; Reynolds, PA				Moleirinho, S.; Chang, N.; Sims, A. H.; Tilston-Luenel, A. M.; Angus, L.; Steele, A.; Boswell, V.; Barnett, S. C.; Ormandy, C.; Faratian, D.; Gunn-Moore, F. J.; Reynolds, P. A.			KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals	ONCOGENE			English	Article						KIBRA; Hippo pathway; Merlin; Willin; breast cancer; claudin-low	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; ORGAN SIZE CONTROL; CYCLE EXIT; DROSOPHILA; YAP; APOPTOSIS; PROLIFERATION; ONCOGENE; PROTEIN	The Salvador/Warts/Hippo (Hippo) signaling pathway defines a novel signaling cascade regulating cell contact inhibition, organ size control, cell growth, proliferation, apoptosis and cancer development in mammals. The upstream regulation of this pathway has been less well defined than the core kinase cassette. KIBRA has been shown to function as an upstream member of the Hippo pathway by influencing the phosphorylation of LATS and YAP, but functional consequences of these biochemical changes have not been previously addressed. We show that in MCF10A cells, loss of KIBRA expression displays epithelial-to-mesenchymal transition (EMT) features, which are concomitant with decreased LATS and YAP phosphorylation, but not MST1/2. In addition, ectopic KIBRA expression antagonizes YAP via the serine 127 phosphorylation site and we show that KIBRA, Willin and Merlin differentially regulate genes controlled by YAP. Finally, reduced KIBRA expression in primary breast cancer specimens correlates with the recently described claudin-low subtype, an aggressive sub-group with EMT features and a poor prognosis. Oncogene (2013) 32, 1821-1830; doi: 10.1038/onc.2012.196; published online 21 May 2012	[Moleirinho, S.; Chang, N.; Steele, A.; Boswell, V.; Reynolds, P. A.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland; [Moleirinho, S.; Tilston-Luenel, A. M.; Angus, L.; Gunn-Moore, F. J.] Univ St Andrews, Sch Biol, St Andrews KY16 9TF, Fife, Scotland; [Sims, A. H.; Faratian, D.] Univ Edinburgh, Western Gen Hosp, Breakthrough Res Unit, Edinburgh, Midlothian, Scotland; [Sims, A. H.; Faratian, D.] Univ Edinburgh, Western Gen Hosp, Div Pathol, Edinburgh, Midlothian, Scotland; [Barnett, S. C.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Ormandy, C.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of St Andrews; University of St Andrews; University of Edinburgh; University of Edinburgh; University of Glasgow; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Gunn-Moore, FJ (corresponding author), Univ St Andrews, Sch Biol, Med & Biol Sci Bldg, St Andrews KY16 9TF, Fife, Scotland.	fjg1@st-andrews.ac.uk; par10@st-andrews.ac.uk	Ormandy, Chris/G-4165-2014; Sims, Andrew/E-4819-2012	Tilston-Lunel, Andrew/0000-0002-5582-6884; Gunn-Moore, Francis James/0000-0003-3422-3387; Sims, Andrew/0000-0001-9082-3665; Ormandy, Christopher/0000-0002-2504-7919; Reynolds, Paul/0000-0001-8738-1245	Scottish University Life Science Alliance; Breakthrough Breast Cancer; National Health and Medical Research Council of Australia; New South Wales Cancer Council; Cancer Institute New South Wales; Banque Nationale de Paris-Paribas Australia; Banque Nationale de Paris-Paribas New Zealand; RT Hall Trust; Australian Cancer Research Foundation; National Breast Cancer Foundation	Scottish University Life Science Alliance; Breakthrough Breast Cancer; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Cancer Council(Cancer Council New South Wales); Cancer Institute New South Wales; Banque Nationale de Paris-Paribas Australia; Banque Nationale de Paris-Paribas New Zealand; RT Hall Trust; Australian Cancer Research Foundation; National Breast Cancer Foundation	We are very grateful to Dr Avruch for providing the MOBKL1A/B antibody and to Dr Takeichi for providing the Willin antibody. We thank V Fedele and E Campbell for technical assistance. We also thank the Scottish University Life Science Alliance for funding for SM and Breakthrough Breast Cancer for funding for AHS and DF. CJO was funded by The National Health and Medical Research Council of Australia, New South Wales Cancer Council, Cancer Institute New South Wales, Banque Nationale de Paris-Paribas Australia and New Zealand, RT Hall Trust, Australian Cancer Research Foundation and the National Breast Cancer Foundation.	Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; Bates TC, 2009, NEUROSCI LETT, V458, P140, DOI 10.1016/j.neulet.2009.04.050; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Corneveaux JJ, 2010, NEUROBIOL AGING, V31, P901, DOI 10.1016/j.neurobiolaging.2008.07.014; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hilton HN, 2008, BBA-MOL CELL RES, V1783, P383, DOI 10.1016/j.bbamcr.2007.12.007; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kremerskothen J, 2003, BIOCHEM BIOPH RES CO, V300, P862, DOI 10.1016/S0006-291X(02)02945-5; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Papassotiropoulos A, 2006, SCIENCE, V314, P475, DOI 10.1126/science.1129837; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Praskova M, 2008, CURR BIOL, V18, P311, DOI 10.1016/j.cub.2008.02.006; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schaper K, 2008, NEUROBIOL AGING, V29, P1123, DOI 10.1016/j.neurobiolaging.2007.02.001; Sims AH, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-42; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	50	92	94	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1821	1830		10.1038/onc.2012.196	http://dx.doi.org/10.1038/onc.2012.196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614006				2022-12-17	WOS:000317043900008
J	Veldhoen, RA; Banman, SL; Hemmerling, DR; Odsen, R; Simmen, T; Simmonds, AJ; Underhill, DA; Goping, IS				Veldhoen, R. A.; Banman, S. L.; Hemmerling, D. R.; Odsen, R.; Simmen, T.; Simmonds, A. J.; Underhill, D. A.; Goping, I. S.			The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis	ONCOGENE			English	Article						autophagy; paclitaxel; apoptosis	PROGRAMMED CELL-DEATH; BREAST-CANCER; RAT-LIVER; ANTIMITOTIC DRUGS; GENE-EXPRESSION; CARCINOMA-CELLS; MITOTIC BLOCK; MICROTUBULES; LYSOSOMES; FUSION	Anti-mitotic agents such as paclitaxel and docetaxel are widely used for the treatment of breast, ovarian and lung cancers. Although paclitaxel induces apoptosis, this drug also modulates autophagy. How autophagy affects paclitaxel activity, is unclear. We discovered that paclitaxel inhibited autophagy through two distinct mechanisms dependent on cell cycle stage. In mitotic cells, paclitaxel blocked activation of the class III phosphatidyl inositol 3 kinase, Vps34, a critical initiator of autophagosome formation. In non-mitotic paclitaxel-treated cells, autophagosomes were generated but their movement and maturation was inhibited. Chemically or genetically blocking autophagosome formation diminished paclitaxel-induced cell death suggesting that autophagosome accumulation sensitized cells to paclitaxel toxicity. In line with these observations, we identified that primary breast tumors that expressed diminished levels of autophagy-initiating genes were resistant to taxane therapy, identifying possible mechanisms and prognostic markers of clinical chemotherapeutic resistance. Oncogene (2013) 32, 736-746; doi:10.1038/onc.2012.92; published online 19 March 2012	[Veldhoen, R. A.; Banman, S. L.; Odsen, R.; Goping, I. S.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; [Hemmerling, D. R.] Concordia Univ Coll, Dept Biol & Environm Sci, Edmonton, AB, Canada; [Simmen, T.; Simmonds, A. J.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Underhill, D. A.; Goping, I. S.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Alberta; Concordia University - Canada; University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Veldhoen, Richard/M-8168-2019	Veldhoen, Richard/0000-0003-4643-2960; Simmonds, Andrew/0000-0001-7165-9302; Underhill, Darrell/0000-0003-0957-7407	Canadian Breast Cancer Foundation; Alberta Cancer Foundation/Alberta Innovates-Health Solutions [25011]	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Alberta Cancer Foundation/Alberta Innovates-Health Solutions	This work was supported by operating grants from the Canadian Breast Cancer Foundation and Alberta Cancer Foundation/Alberta Innovates-Health Solutions (project #25011) awarded to ISG. We thank Dr Junying Yuan for the kind gift of the anti-phospho T159 Vps34 antibody. We thank the Gaping lab, Simmen lab and Signal Transduction Research Group for valuable discussions. Owing to journal reference restraints, we apologize to those investigators whose work was not cited.	Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; APLIN A, 1992, J CELL PHYSIOL, V152, P458, DOI 10.1002/jcp.1041520304; ARSTILA AU, 1974, EXP CELL RES, V87, P249, DOI 10.1016/0014-4827(74)90477-7; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Craik AC, 2010, ONCOGENE, V29, P5381, DOI 10.1038/onc.2010.272; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Derry WB, 1998, CANCER RES, V58, P1177; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gorka M, 2005, ANTI-CANCER DRUG, V16, P777; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kimura S, 2008, CELL STRUCT FUNCT, V33, P109, DOI 10.1247/csf.08005; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liu LY, 2009, CELL CYCLE, V8, P1616, DOI 10.4161/cc.8.10.8577; MARZELLA L, 1980, EXP CELL RES, V128, P291, DOI 10.1016/0014-4827(80)90065-8; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Paglin S, 2001, CANCER RES, V61, P439; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026; Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	40	92	95	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					736	746		10.1038/onc.2012.92	http://dx.doi.org/10.1038/onc.2012.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430212				2022-12-17	WOS:000315746700007
J	Wang, X; Venugopal, C; Manoranjan, B; McFarlane, N; O'Farrell, E; Nolte, S; Gunnarsson, T; Hollenberg, R; Kwiecien, J; Northcott, P; Taylor, MD; Hawkins, C; Singh, SK				Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O'Farrell, E.; Nolte, S.; Gunnarsson, T.; Hollenberg, R.; Kwiecien, J.; Northcott, P.; Taylor, M. D.; Hawkins, C.; Singh, S. K.			Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells	ONCOGENE			English	Article						Bmi1; sonic hedgehog; medulloblastoma; brain tumor-initiating cells; CD133; chromatin immunoprecipitation	STEM-LIKE CELLS; BETA-CATENIN STATUS; MOUSE MODEL; SELF-RENEWAL; CHILDHOOD MEDULLOBLASTOMA; GENETIC PROFILES; N-MYC; PATHWAY; CANCER; GROWTH	Bmi1 is a key stem cell regulatory gene implicated in the pathogenesis of many aggressive cancers, including medulloblastoma. Overexpression of Bmi1 promotes cell proliferation and is required for hedgehog (Hh) pathway-driven tumorigenesis. This study aimed to determine if Sonic hedgehog (Shh) modulates the key stem cell regulatory gene Bmi1 in childhood medulloblastoma brain tumor-initiating cells (BTICs). Although current literature suggests that there is a correlation between Shh pathway genes and Bmi1 expression, it is unclear whether there is indeed a direct regulatory mechanism. To address whether Shh induces expression of Bmi1, stem cell-enriched populations from medulloblastoma cell lines and primary samples were treated with Shh ligand and KAAD-cyclopamine (Shh antagonist). Our data indicate that Bmi1 expression positively correlates with increasing Shh ligand concentrations. Chromatin immunoprecipitation reveals that Gli1 preferentially binds to the Bmi1 promoter, and Bmi1 transcript levels are increased and decreased by Gli1 overexpression and down-regulation, respectively. Knockdown experiments of Bmi1 in vitro and in vivo demonstrate that Hh signaling not only drives Bmi1 expression, but a feedback mechanism exists wherein downstream effectors of Bmi1 may, in turn, activate Hh pathway genes. These findings implicate Bmi1 and Hh as mutually indispensable pathways in medulloblastoma BTIC maintenance. Recent molecular characterization of medulloblastoma also reveals that Bmi1 is overexpressed across all subgroups of medulloblastoma, particularly in the most aggressive subtypes. Lastly, despite recent identification of BTIC markers, the molecular characterization of these cell populations remains unclear. In this work, we propose that the BTIC marker CD133 may segregate a cell population with a Hh-receptor phenotype, thus demonstrating a cell-cell interaction between the CD133+ Hh receptor cells and the CD133- Hh-secreting cells. Oncogene (2012) 31, 187-199; doi:10.1038/onc.2011.232; published online 20 June 2011	[Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O'Farrell, E.; Nolte, S.; Singh, S. K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Singh, S. K.] McMaster Univ, Dept Surg, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Kwiecien, J.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Northcott, P.; Taylor, M. D.] Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; [Northcott, P.; Taylor, M. D.; Hawkins, C.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Northcott, P.; Taylor, M. D.; Hawkins, C.] Univ Toronto, Toronto, ON, Canada; [Hawkins, C.] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Singh, S. K.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Singh, S. K.] McMaster Univ, Fac Hlth Sci, Dept Neurosci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; McMaster University	Singh, SK (corresponding author), McMaster Univ, Dept Surg, Stem Cell & Canc Res Inst, MDCL 5027,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ssingh@mcmaster.ca	Wang, Xin/U-7221-2017; Northcott, Paul A/N-4022-2018; Hawkins, Cynthia/M-2571-2019; Singh, Sheila K/W-2799-2018; Wang, Xin/O-8779-2019; Gunnarsson, Thorsteinn/AAA-1238-2019	Wang, Xin/0000-0001-6292-3087; Northcott, Paul A/0000-0002-1220-5252; Singh, Sheila K/0000-0003-1272-5300; Wang, Xin/0000-0001-6292-3087; Wang, Xin/0000-0001-8783-4080; Taylor, Michael/0000-0001-7009-3466; Gunnarsson, Thorsteinn/0000-0001-6657-4187	Department of Surgery at McMaster University; Ontario Institute for Cancer Research (OICR); JP Bickell Foundation; Stem Cell Network	Department of Surgery at McMaster University; Ontario Institute for Cancer Research (OICR); JP Bickell Foundation; Stem Cell Network	We are very grateful to Atsushi Iwama for kind provision of Bmi1 shRNA lentiviral construct. We thank Merry Wang for artistic illustrations. This work was supported by funds from the Department of Surgery at McMaster University, the Ontario Institute for Cancer Research (OICR) and the JP Bickell Foundation. XW held a training award from the Stem Cell Network.	Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Annabi B, 2008, MOL CANCER RES, V6, P907, DOI 10.1158/1541-7786.MCR-07-2184; Annabi B, 2010, MOL CARCINOGEN, V49, P710, DOI 10.1002/mc.20645; Ayrault O, 2010, CANCER RES, V70, P5618, DOI 10.1158/0008-5472.CAN-09-3740; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Ellison DW, 2010, ACTA NEUROPATHOL, V120, P305, DOI 10.1007/s00401-010-0726-6; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Johnson R, 2009, CURR ONCOL REP, V11, P68, DOI 10.1007/s11912-009-0011-9; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; McCord AM, 2009, CLIN CANCER RES, V15, P5145, DOI 10.1158/1078-0432.CCR-09-0263; Michael LE, 2008, NEOPLASIA, V10, P1343, DOI 10.1593/neo.81078; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pallini R, 2010, CANCER, V117, P162; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pistollato F, 2010, STEM CELLS, V28, P1918, DOI 10.1002/stem.518; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Thon N, 2010, MOL CELL NEUROSCI, V43, P51, DOI 10.1016/j.mcn.2008.07.022; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wiederschain D, 2007, MOL CELL BIOL, V27, P4968, DOI 10.1128/MCB.02244-06; Yan XW, 2011, P NATL ACAD SCI USA, V108, P1591, DOI 10.1073/pnas.1018696108; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yu CC, 2010, CHILD NERV SYST, V26, P897, DOI 10.1007/s00381-010-1087-0; Zakrzewska M, 2011, CHILD NERV SYST, V27, P79, DOI 10.1007/s00381-010-1260-5	69	92	96	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					187	199		10.1038/onc.2011.232	http://dx.doi.org/10.1038/onc.2011.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685941				2022-12-17	WOS:000299307400005
J	Booy, EP; Henson, ES; Gibson, SB				Booy, E. P.; Henson, E. S.; Gibson, S. B.			Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer	ONCOGENE			English	Article						Mcl-1; Elk-1; breast cancer; regulation; drug resistance	ACTIVATED PROTEIN-KINASE; BCL-2 FAMILY PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL-CANCER; MULTIPLE-MYELOMA; MEK INHIBITION; FACTOR COMPLEX; APOPTOSIS; RESISTANCE; GENE	Myeloid cell leukaemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family that is elevated in a variety of tumour types including breast cancer. In breast tumours, increased Mcl-1 expression correlates with high tumour grade and poor patient survival. We have previously demonstrated that Her-2 levels correspond to increased Mcl-1 expression in breast tumours. Epidermal growth factor (EGF) receptor signalling is frequently deregulated in breast cancer and leads to increased proliferation and survival. Herein, we determined the critical downstream signals responsible for the EGF mediated increase of Mcl-1 and their role in cell survival. We found that both Mcl-1 mRNA and protein levels are rapidly induced upon stimulation with EGF. Promoter analysis revealed that an Elk-1 transcription factor-binding site is critical for EGF activation of the Mcl-1 promoter. Furthermore, we found that knockdown of Elk-1 or inhibition of the Erk signalling pathway was sufficient to block EGF upregulation of Mcl-1 and EGF mediated cell survival. Using chromatin immunoprecipitation and biotin labelled probes of the Mcl-1 promoter, we found that Elk-1 and serum response factor are bound to the promoter after EGF stimulation. To determine whether Mcl-1 confers a survival advantage, we found that knockdown of Mcl-1 expression increased apoptosis whereas overexpression of Mcl-1 inhibited drug induced cell death. In human breast tumours, we found a correlation between phosphorylated Elk-1 and Mcl-1 protein levels. These results indicate that the EGF induced activation of Elk-1 is an important mediator of Mcl-1 expression and cell survival and therefore a potential therapeutic target in breast cancer. Oncogene (2011) 30, 2367-2378; doi: 10.1038/onc.2010.616; published online 24 January 2011	[Booy, E. P.; Henson, E. S.; Gibson, S. B.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; [Booy, E. P.; Henson, E. S.; Gibson, S. B.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	gibsonsb@cc.umanitoba.ca		Gibson, Spencer/0000-0003-0119-732X	Canadian Breast Cancer Foundation; Prairie chapter; Canadian Institutes for Health Research (CIHR)	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Prairie chapter; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The work is supported by a grant from the Canadian Breast Cancer Foundation, Prairie chapter. Evan Booy is supported by the Canadian Institutes for Health Research (CIHR) CGS Doctoral award. Dr Gibson is a Manitoba Research Chair. The Manitoba Tumour Bank is a member of the Canadian Tumour Repository Network (CTRNet) and is supported by a grant from the CIHR	Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Backus HHJ, 2001, ANN ONCOL, V12, P779, DOI 10.1023/A:1011112227044; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Boros J, 2009, NUCLEIC ACIDS RES, V37, P7368, DOI 10.1093/nar/gkp804; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Cetin Z, 2010, MED ONCOL, V27, P853, DOI 10.1007/s12032-009-9296-7; Chen FM, 2006, BIOORG MED CHEM LETT, V16, P6281, DOI 10.1016/j.bmcl.2006.09.038; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Johnston JB, 2006, CURR MED CHEM, V13, P3483, DOI 10.2174/092986706779026174; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Martin AP, 2009, CANCER BIOL THER, V8, P2084; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nanda R, 2007, REV RECENT CLIN TRIA, V2, P111, DOI 10.2174/157488707780599375; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Sambade MJ, 2009, RADIOTHER ONCOL, V93, P639, DOI 10.1016/j.radonc.2009.09.006; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Schulze-Bergkamen H, 2008, WORLD J GASTROENTERO, V14, P3829, DOI 10.3748/wjg.14.3829; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Skliris GP, 2008, HISTOPATHOLOGY, V52, P355, DOI 10.1111/j.1365-2559.2007.02955.x; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Tsutsui M, 2010, INT J LAB HEMATOL, V32, P419, DOI 10.1111/j.1751-553X.2009.01204.x; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vickers ER, 2004, MOL CELL BIOL, V24, P10340, DOI 10.1128/MCB.24.23.10340-10351.2004; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watson PH, 1996, CAN MED ASSOC J, V155, P281; Witters LM, 2007, ONCOL REP, V17, P465; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zoppoli G, 2010, CURR CANCER DRUG TAR, V10, P168, DOI 10.2174/156800910791054211	57	92	95	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2367	2378		10.1038/onc.2010.616	http://dx.doi.org/10.1038/onc.2010.616			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258408	Green Published, hybrid			2022-12-17	WOS:000290789200008
J	Rai, P; Young, JJ; Burton, DGA; Giribaldi, MG; Onder, TT; Weinberg, RA				Rai, P.; Young, J. J.; Burton, D. G. A.; Giribaldi, M. G.; Onder, T. T.; Weinberg, R. A.			Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence	ONCOGENE			English	Article						cellular senescence; DNA damage; oxidative stress; 8-oxoguanine; MTH1; RAS oncogene	LABILE IRON POOL; CANCER-CELLS; HUMAN FIBROBLASTS; MECHANISM	Approximately 20% of tumors contain activating mutations in the RAS family of oncogenes. As tumors progress to higher grades of malignancy, the expression of oncogenic RAS has been reported to increase, leading to an oncogene-induced senescence (OIS) response. Evasion of this senescence barrier is a hallmark of advanced tumors indicating that OIS serves a critical tumor-suppressive function. Induction of OIS has been attributed to either RAS-mediated production of reactive oxygen species (ROS) or to induction of a DNA damage response (DDR). However, functional links between these two processes in triggering the senescent phenotype have not been explicitly described. Our previous work has shown that, in cultured untransformed cells, preventing elimination of oxidized guanine deoxyribonucleotides, which was achieved by suppressing expression of the cellular 8-oxo-dGTPase, human MutT homolog 1 (MTH1), sufficed to induce a DDR as well as premature senescence. Here, we demonstrate that overexpression of MTH1 can prevent the oncogenic H-RAS-induced DDR and attendant premature senescence, although it does not affect the observed elevation in ROS levels produced by RAS oncoprotein expression. Conversely, we find that loss of MTH1 preferentially induces an in vitro proliferation defect in tumorigenic cells overexpressing oncogenic RAS. These results indicate that the guanine nucleotide pool is a critical target for intracellular ROS produced by oncogenic RAS and that RAS-transformed cells require robust MTH1 expression to proliferate. Oncogene (2011) 30, 1489-1496; doi:10.1038/onc.2010.520; published online 15 November 2010	[Rai, P.; Burton, D. G. A.; Giribaldi, M. G.] Univ Miami, Miller Sch Med, Div Gerontol & Geriatr Med, Dept Med, Miami, FL 33136 USA; [Young, J. J.; Onder, T. T.; Weinberg, R. A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Young, J. J.; Onder, T. T.; Weinberg, R. A.] MIT, Dept Biol, Cambridge, MA USA; [Weinberg, R. A.] Ludwig Ctr Mol Oncol, Cambridge, MA USA	University of Miami; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Rai, P (corresponding author), Univ Miami, Miller Sch Med, Div Gerontol & Geriatr Med, Dept Med, 1600 NW 10th Ave,RMSB 7094,Locator Code D-503, Miami, FL 33136 USA.	prai@med.miami.edu	Burton, Dominick/C-5282-2013; Onder, Tamer T/H-3330-2013; Onder, Tamer/O-3669-2019	Burton, Dominick/0000-0003-3631-6448; Onder, Tamer T/0000-0002-2372-9158; Onder, Tamer/0000-0002-2372-9158; Young-Glazer, Jennifer/0000-0002-3265-9112; Rai, Priyamvada/0000-0001-7822-7553	Leukemia and Lymphoma Society; James and Esther King Florida Biomedical Research Program; Howard Hughes Medical Institute; Ellison Medical Foundation for Aging Research; Ludwig Center for Molecular Oncology; Breast Cancer Research Fund	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); James and Esther King Florida Biomedical Research Program; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Ellison Medical Foundation for Aging Research; Ludwig Center for Molecular Oncology; Breast Cancer Research Fund	We are grateful to Anisleidys Munoz for experimental assistance. We thank Dr Carlos Perez-Stable and Dr Ramiro Verdun for helpful comments on this manuscript. RAW is a Professor at American Cancer Society Research and at Daniel K Ludwig Cancer Research. This work was supported by a Leukemia and Lymphoma Society Postdoctoral fellowship and a James and Esther King Florida Biomedical Research Program New Investigator grant (to PR), a Howard Hughes Medical Institute summer undergraduate fellowship (to JJY) and grants from the Ellison Medical Foundation for Aging Research, The Ludwig Center for Molecular Oncology and the Breast Cancer Research Fund (to RAW).	Algarra Ignacio, 1998, Invasion and Metastasis, V18, P261, DOI 10.1159/000024519; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gackowski D, 2002, J BIOL INORG CHEM, V7, P548, DOI 10.1007/s00775-001-0335-x; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Haghdoost S, 2006, FREE RADICAL BIO MED, V41, P620, DOI 10.1016/j.freeradbiomed.2006.05.003; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Nakabeppu Y, 2001, MUTAT RES-FUND MOL M, V477, P59, DOI 10.1016/S0027-5107(01)00096-3; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rai P, 2009, P NATL ACAD SCI USA, V106, P169, DOI 10.1073/pnas.0809834106; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serra V, 2003, J BIOL CHEM, V278, P6824, DOI 10.1074/jbc.M207939200; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yoon SH, 2005, BIOCHEM BIOPH RES CO, V327, P342, DOI 10.1016/j.bbrc.2004.12.013	32	92	94	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1489	1496		10.1038/onc.2010.520	http://dx.doi.org/10.1038/onc.2010.520			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076467				2022-12-17	WOS:000288743800011
J	Kaplan, FM; Shao, Y; Mayberry, MM; Aplin, AE				Kaplan, F. M.; Shao, Y.; Mayberry, M. M.; Aplin, A. E.			Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells	ONCOGENE			English	Article						apoptosis; B-RAF; N-RAS; PLX4720	KINASE INHIBITOR; BRAF; MUTATIONS; ACTIVATION; PATHWAY; PHOSPHORYLATION; PROGRESSION	Activating mutations in B-RAF and N-RAS occur in similar to 60 and similar to 15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK-ERK1/2 pathway. Thus, B-RAF(V600E) is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720 treatment rapidly induces hyperactivation of the MEK-ERK1/2 pathway in mutant N-RAS melanoma cells. Furthermore, we demonstrate that C-RAF is the major RAF isoform involved in this process. Importantly, PLX4720-induced hyperactivation of the MEK-ERK1/2 pathway promotes resistance to apoptosis in both non-invasive and invasive mutant N-RAS melanoma cells but does not enhance cell cycle properties. These findings underscore the need to genotypically stratify melanoma patients before enrollment on a mutant B-RAF inhibitor trial. Oncogene (2011) 30, 366-371; doi:10.1038/onc.2010.408; published online 6 September 2010	[Aplin, A. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	Andrew.Aplin@KimmelCancerCenter.Org	Shao, Yongping/D-9966-2011		National Institutes of Health [R01-GM067893, R01-CA125103]; Pennsylvania Department of Health [AF0301]; NATIONAL CANCER INSTITUTE [R01CA125103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Gideon Bollag (Plexxikon) for providing PLX4720, Dr Meenhard Herlyn (Wistar Institute) for cell lines and Dr Michele Weiss for comments on the manuscript. This work was supported by National Institutes of Health Grants (R01-GM067893 and R01-CA125103), and Pennsylvania Department of Health (AF0301) to AE Aplin.	ALBINO AP, 1989, ONCOGENE, V4, P1363; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; FLAHERTY K, 2009, J CLIN ONCOL S, V27, pNIL18; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hunger-Glaser I, 2004, J CELL PHYSIOL, V200, P213, DOI 10.1002/jcp.20018; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Salerno P, 2010, J CLIN ENDOCR METAB, V95, P450, DOI 10.1210/jc.2009-0373; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sondak Vernon K, 2009, Pigment Cell Melanoma Res, V22, P386, DOI 10.1111/j.1755-148X.2009.00593.x; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6	26	92	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					366	371		10.1038/onc.2010.408	http://dx.doi.org/10.1038/onc.2010.408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20818433	Green Accepted			2022-12-17	WOS:000286418800011
J	Giannoni, E; Fiaschi, T; Ramponi, G; Chiarugi, P				Giannoni, E.; Fiaschi, T.; Ramponi, G.; Chiarugi, P.			Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals	ONCOGENE			English	Article						anoikis; prostate cancer cell; EGFR; reactive oxygen species; Src	REACTIVE-OXYGEN; TUMOR PROGRESSION; OXIDATIVE STRESS; GROWTH; ACTIVATION; ADHESION; MECHANISMS; KINASE; CARCINOGENESIS; ANCHORAGE	Resistance to detachment-induced apoptosis, a process commonly referred as anoikis, is emerging as a hallmark of metastatic malignancies, mainly because it can ensure anchorage-independent growth and survival during organ colonization. Besides, a sustained oxidative stress has been associated with several steps of carcinogenesis, including transformation and achievement of a motile mesenchymal phenotype. Here, we demonstrate that metastatic prostate carcinoma cells, undergoing a constitutive deregulated production of reactive oxygen species due to sustained activation of 5-lipoxygenase, lack suicidal pathways in response to lack of matrix contact. These amplified and persistent redox signals in PC3 cells leads to maintenance of Src oxidation and activation in the absence of adhesion, thereby sustaining a ligand-independent phosphorylation of epidermal growth factor receptor. This leads to chronic activation of pro-survival signals, culminating in degradation of the pro-apoptotic protein Bim, thereby promoting cell survival even in the absence of proper adhesion. Anoikis sensitivity of metastatic cells is restored with antioxidant intervention or genetic manipulation of the redox-mediated pro-survival pathway, as well as exposure to a pro-oxidant environment strongly increases anoikis resistance in nontransformed prostate epithelial cells. Hence, our results allow new insight into the aetiology of the molecular mechanisms granting anoikis resistance of metastatic cancers, opening new avenues to pharmacological intervention for antioxidant-sensitive invasive tumours. Oncogene (2009) 28, 2074-2086; doi:10.1038/onc.2009.77; published online 20 April 2009	[Giannoni, E.; Fiaschi, T.] Univ Florence, Dept Biochem Sci, Florence, Italy; [Ramponi, G.; Chiarugi, P.] Univ Florence, Ctr Res Transfer & High Educ, Florence, Italy	University of Florence; University of Florence	Chiarugi, P (corresponding author), Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098	Italian Association for Cancer Research (AIRC); Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004); Progetto TRESOR (Regione Toscana); Cassa di Risparmio di Firenze; Consorzio Interuniversitario Biotecnologie (CIB)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Progetto TRESOR (Regione Toscana)(Regione Toscana); Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Consorzio Interuniversitario Biotecnologie (CIB)	This work was supported by the Italian Association for Cancer Research (AIRC), by the Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004), by the Progetto TRESOR (Regione Toscana), by the Cassa di Risparmio di Firenze and by the Consorzio Interuniversitario Biotecnologie (CIB).	Bouillet P, 2002, J CELL SCI, V115, P1567; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2007, CELL SIGNAL, V19, P672, DOI 10.1016/j.cellsig.2006.11.009; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Diaz-Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giannoni E, 2008, CELL DEATH DIFFER, V15, P867, DOI 10.1038/cdd.2008.3; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420; Haklar G, 2001, CANCER LETT, V165, P219, DOI 10.1016/S0304-3835(01)00421-9; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Kairouz-Wahbe R, 2008, P NATL ACAD SCI USA, V105, P1528, DOI 10.1073/pnas.0711357105; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Mallozzi C, 2001, FREE RADICAL BIO MED, V30, P1108, DOI 10.1016/S0891-5849(01)00509-3; Martinez-Sanchez G, 2007, J EXP CLIN CANC RES, V26, P39; Moldovan L, 2006, CARDIOVASC RES, V71, P236, DOI 10.1016/j.cardiores.2006.05.003; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Quadros MRD, 2004, CANCER RES, V64, P3934, DOI 10.1158/0008-5472.CAN-04-0214; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taddei ML, 2007, ANTIOXID REDOX SIGN, V9, P469, DOI 10.1089/ars.2006.1392; Toyokuni S, 2006, ANTIOXID REDOX SIGN, V8, P1373, DOI 10.1089/ars.2006.8.1373; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Wu WS, 2008, CANCER METAST REV, V27, P303, DOI 10.1007/s10555-008-9112-4; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhu ZY, 2001, CANCER RES, V61, P1707	46	92	95	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2074	2086		10.1038/onc.2009.77	http://dx.doi.org/10.1038/onc.2009.77			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377510				2022-12-17	WOS:000266235800002
J	Shiota, M; Izumi, H; Onitsuka, T; Miyamoto, N; Kashiwagi, E; Kidani, A; Hirano, G; Takahashi, M; Naito, S; Kohno, K				Shiota, M.; Izumi, H.; Onitsuka, T.; Miyamoto, N.; Kashiwagi, E.; Kidani, A.; Hirano, G.; Takahashi, M.; Naito, S.; Kohno, K.			Twist and p53 reciprocally regulate target genes via direct interaction	ONCOGENE			English	Article						YB-1; Twist; p53; GST-fusion protein array; membrane pull-down assay	SAETHRE-CHOTZEN SYNDROME; BOX-BINDING-PROTEIN; BHLH PROTEIN; CANCER-CELLS; DRUG-RESISTANCE; NEURAL-TUBE; EXPRESSION; DNA; MORPHOGENESIS; CISPLATIN	Twist is basic helix-loop-helix transcription factor that binds to E-boxes in gene promoters. Twist possesses an oncogenic function by interfering with the tumor suppressor function of p53. Using a membrane pull-down assay, we found that Twist directly interacts with p53 and that this interaction underlies the inhibitory effects on p53 target gene expression. Twist interacted with the DNA-binding domain of p53 and suppressed the DNA-binding activity of p53. Transcriptional activation of the p21 promoter by p53 was significantly repressed by the expression of Twist. On the other hand, p53 interacted with the N-terminal domain of Twist and repressed Twist-dependent YB-1 promoter activity. Importantly, we found that p53-dependent growth suppression was canceled by the expression of either Twist or YB-1. Thus, our data suggest that Twist inhibits p53 function via a direct interaction with p53.	[Shiota, M.; Izumi, H.; Onitsuka, T.; Miyamoto, N.; Kashiwagi, E.; Kidani, A.; Hirano, G.; Takahashi, M.; Kohno, K.] Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Shiota, M.; Kashiwagi, E.; Naito, S.] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp	Shiota, Masaki/Q-9387-2019	Shiota, Masaki/0000-0002-3306-4858	Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext) [13218132, 17590257]; Kobayashi Institute for Innovative Cancer Chemotherapy; grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kobayashi Institute for Innovative Cancer Chemotherapy; grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan	This work was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext), Kakenhi (13218132 and 17590257), the Kobayashi Institute for Innovative Cancer Chemotherapy and a grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan. We thank Satoko Takazaki and Yukiko Yoshiura for their technical assistance.	Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401; Castanon I, 2001, DEVELOPMENT, V128, P3145; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Liu L, 1999, MOL CELL BIOL, V19, P1202; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Wakasugi T, 2007, ONCOGENE, V26, P5194, DOI 10.1038/sj.onc.1210326; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	33	92	95	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5543	5553		10.1038/onc.2008.176	http://dx.doi.org/10.1038/onc.2008.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504427				2022-12-17	WOS:000259280800001
J	Adachi, Y; Shibai, Y; Mitsushita, J; Shang, WH; Hirose, K; Kamata, T				Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Hirose, K.; Kamata, T.			Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6	ONCOGENE			English	Article						Ras; Nox1; ROS; GATA-6; gene expression	COLON EPITHELIAL-CELLS; NADPH OXIDASE; TRANSCRIPTION FACTORS; NAD(P)H OXIDASE; REACTIVE OXYGEN; MUSCLE-CELLS; BINDING; SUPEROXIDE; PROTEIN; NOX1	Ras oncogene upregulates the expression of nicotinamide adenine dinucleotide phosphate oxidase (Nox) 1 via the Raf/MEK/ERK pathway, leading to the elevated production of reactive oxygen species that is essential for maintenance of Ras-transformation phenotypes. However, the precise transcriptional control mechanism underlying Ras-induced Nox1 expression remains to be elucidated. Here we demonstrated that via the MEK/ERK pathway, Ras signaling enhances the activity of the functional Nox1 promoter (nt -321 to -1) in colon cancer CaCo-2 cells and thereby induces the formation of the specific protein DNA complexes in the two GATA-binding site-containing regions (nt -161 to -136 and -125 to -100). Supershift assays with GATA antibodies, protein analyses and chromatin immunoprecipitation revealed that GATA-6 is a component of the specific protein - DNA complexes at the Nox1 promoter. GATA-6 was able to trans-activate the Nox1 promoter but not a promoter in which the GATA-binding sites are mutated. Moreover, GATA-6 was phosphorylated at serine residues by MEK-activated ERK, which increased GATA-6 DNA binding, correlating with suppression of the Nox1 promoter activity by an MEK inhibitor PD98059. Finally, the site-directed mutation of the consensus ERK phosphorylation site (PYS(120)P to PYA(120)P) of GATA-6 abolished its trans-activation activity, suppressing of the growth of CaCo-2 cells. On the basis of these results, we propose that oncogenic Ras signaling upregulates the transcription of Nox1 through MEK-ERK-dependent phosphorylation of GATA-6.	[Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Kamata, T.] Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Hirose, K.] Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr J Downward, Dr E Nishida and Dr M Maeda for plasmid DNAs. This study was supported by Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (TK).	ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brewer AC, 2006, FREE RADICAL BIO MED, V40, P260, DOI 10.1016/j.freeradbiomed.2005.08.022; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Debruyne PR, 2003, ONCOGENE, V22, P7199, DOI 10.1038/sj.onc.1206628; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Yu YL, 2005, J BIOL CHEM, V280, P29533, DOI 10.1074/jbc.M506514200	35	92	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4921	4932		10.1038/onc.2008.133	http://dx.doi.org/10.1038/onc.2008.133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454176				2022-12-17	WOS:000258596900006
J	Vasiljeva, O; Korovin, M; Gajda, M; Brodoefel, H; Bojic, L; Kruger, A; Schurigt, U; Sevenich, L; Turk, B; Peters, C; Reinheckel, T				Vasiljeva, O.; Korovin, M.; Gajda, M.; Brodoefel, H.; Bojic, L.; Kruger, A.; Schurigt, U.; Sevenich, L.; Turk, B.; Peters, C.; Reinheckel, T.			Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice	ONCOGENE			English	Article						apoptosis; cathepsin; differentiation; mammary cancer; mouse model; proliferation	LYSOSOMAL CYSTEINE PROTEASES; BREAST-CANCER; APOPTOSIS; PROGRESSION; METASTASIS; EXPRESSION; MEMBRANE; DEATH; ASSOCIATION; SECRETION	Expression levels of the papain-like cysteine protease cathepsin B (Ctsb) have been positively correlated with mammary tumour progression and metastasis; however, its roles in the hallmark processes of malignant growth remain poorly defined. Using Ctsb-deficient mice we investigated tumour cell differentiation, proliferation and apoptosis in the Tg(MMTV-PyMT) mouse mammary cancer model. Absence of Ctsb significantly impaired development of high-grade invasive ductal carcinomas and reduced the metastatic burden in the lungs. Mice lacking Ctsb exhibited reduced cell proliferation in mammary carcinomas and their lung metastases. Notably, intravenous injection of primarily isolated, Ctsb-expressing tumour cells into congenic Ctsb-deficient mice revealed impaired cell proliferation in the resulting experimental lung metastases, providing evidence for the involvement of Ctsb in paracrine regulation of cancer cell proliferation. No Ctsb genotype-dependent difference in tumour cell death was observed in vivo or by treatment of isolated PyMT cancer cells with tumour necrosis factor-alpha. However, cancer cells lacking Ctsb exhibited significantly higher resistance to apoptosis induction by the lysosomotropic agent Leu-Leu-OMe. Thus, our results indicate an in vivo role for Ctsb in promoting cellular anaplasia in mammary cancers and proliferation in lung metastases.	[Vasiljeva, O.; Korovin, M.; Brodoefel, H.; Schurigt, U.; Sevenich, L.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; [Vasiljeva, O.; Bojic, L.; Turk, B.] Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Ljubljana, Slovenia; [Gajda, M.] Univ Jena, Inst Pathol, Jena, Germany; [Kruger, A.] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Munich, Germany	University of Freiburg; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Friedrich Schiller University of Jena; Technical University of Munich	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Stefan Meier Str 17, D-79104 Freiburg, Germany.	Thomas.Reinheckel@uniklinik-freiburg.de	Korovin, Matvei/S-3137-2016; Reinheckel, Thomas/AAL-9761-2021	Korovin, Matvei/0000-0002-1278-1401; Reinheckel, Thomas/0000-0001-9866-9105; Schurigt, Uta/0000-0003-4423-5955; Turk, Boris/0000-0002-9007-5764				Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427; Fernandez PL, 2001, INT J CANCER, V95, P51, DOI 10.1002/1097-0215(20010120)95:1<51::AID-IJC1009>3.0.CO;2-J; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Huveneers S, 2007, CANCER RES, V67, P2693, DOI 10.1158/0008-5472.CAN-06-3654; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Lechner AM, 2006, J BIOL CHEM, V281, P39588, DOI 10.1074/jbc.M513439200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Loffek Stefanie, 2006, J Dtsch Dermatol Ges, V4, P496, DOI 10.1111/j.1610-0387.2006.05991.x; McKerrow JH, 2000, MOL MED, V6, P450, DOI 10.1007/BF03401787; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nagaraj NS, 2007, APOPTOSIS, V12, P125, DOI 10.1007/s10495-006-0490-1; Podgorski I, 2003, BIOCHEM SOC SYMP, V70, P263, DOI 10.1042/bss0700263; Rossi A, 2004, BIOL CHEM, V385, P363, DOI 10.1515/BC.2004.040; ROZHIN J, 1994, CANCER RES, V54, P6517; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Stoka V, 2005, IUBMB LIFE, V57, P347, DOI 10.1080/15216540500154920; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038; vanRoozendaal KEP, 1996, INT J CANCER, V65, P120, DOI 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Zajc I, 2006, ANTICANCER RES, V26, P3357; Zheng X, 2004, CANCER RES, V64, P1773, DOI 10.1158/0008-5472.CAN-03-0820	36	92	93	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4191	4199		10.1038/onc.2008.59	http://dx.doi.org/10.1038/onc.2008.59			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345026				2022-12-17	WOS:000257496800006
J	Zwerner, JP; Joo, J; Warner, KL; Christensen, L; Hu-Lieskovan, S; Triche, TJ; May, WA				Zwerner, J. P.; Joo, J.; Warner, K. L.; Christensen, L.; Hu-Lieskovan, S.; Triche, T. J.; May, W. A.			The EWS/FLI1 oncogenic transcription factor deregulates GLI1	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI1; GLI1; Hedgehog; Ewing family tumors	HEDGEHOG SIGNALING PATHWAY; DNA-BINDING; SONIC HEDGEHOG; EWINGS-SARCOMA; FUSION PROTEIN; TARGET GENES; GROWTH-FACTOR; SELF-RENEWAL; STEM-CELLS; PDGF-C	Ewing family tumors ( EFT), classically Ewing's sarcoma and peripheral primitive neuroectodermal tumor, share a common class of tumor-specific fusion genes thought to be key mediators of tumor biology. Here we demonstrate that the most common Ewing's fusion, EWS/FLI1, produces transcriptional upregulation of GLI1 and its direct transcriptional target PATCHED1 in a model transformation system. This deregulation of GLI1 is common to other EWS/ets chimera and depends on the functional transcriptional regulatory domains. Inhibition of GLI1 via RNAi or via overexpression of endogenous inhibitors results in a reduction of EWS/FLI1 transformation activity. Activation of GLI1 appears to occur in a Hedgehog- independent fashion as blockade of Hedgehog signaling has only a modest effect on EFT cells. We present evidence that EWS/FLI1 upregulation of cMYC may play a role in the upregulation of GLI1 in EWS/ FLI1-transformed NIH3T3 cells. Finally, we demonstrate that observations made in a model transformation system translate to an Ewing cellular background. EFT cell lines express GLI1 and PATCHED and this expression is EWS/ FLI1 dependent. Inhibition of GLI1 expression via RNAi results in reduced anchorage-independent growth in an EFT cell line. GLI1 appears to be a transcriptionally deregulated target of EWS/FLI1 that mediates a portion of its tumorigenic phenotype.	[Joo, J.; Warner, K. L.; Christensen, L.; May, W. A.] Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pediat,Div Hematol Oncol, Los Angeles, CA 90027 USA; [Zwerner, J. P.] Stanford Univ, Sch Med, Dept Dermatol, Palo Alto, CA 94304 USA; [Hu-Lieskovan, S.; Triche, T. J.] Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pathol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Stanford University; Children's Hospital Los Angeles; University of Southern California	May, WA (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pediat,Div Hematol Oncol, 4650 Sunset Blvd Mail Stop 54, Los Angeles, CA 90027 USA.	wmay@chla.usc.edu			NCI NIH HHS [CA90666, R01 CA090666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Aparicio LMA, 2007, CLIN TRANSL ONCOL, V9, P66, DOI 10.1007/s12094-007-0015-6; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BACCI G, 1982, CANCER-AM CANCER SOC, V48, P1561, DOI 10.1002/1097-0142(19820415)49:8<1561::AID-CNCR2820490808>3.0.CO;2-K; Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOYER CW, 1967, CANCER, V20, P1602, DOI 10.1002/1097-0142(196710)20:10<1602::AID-CNCR2820201006>3.0.CO;2-H; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hepker J, 1997, DEVELOPMENT, V124, P549; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Koch A, 2004, NEUROPATH APPL NEURO, V30, P532, DOI 10.1111/j.1365-2990.2004.00560.x; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lazar A, 2006, ARCH PATHOL LAB MED, V130, P1199; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lokker NA, 2002, CANCER RES, V62, P3729; Marigo V, 1996, DEVELOPMENT, V122, P1225; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Pizzo PA, 2005, PRINCIPLES PRACTICE; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Stein U, 1999, CANCER RES, V59, P1890; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Teitell MA, 1999, LAB INVEST, V79, P1535; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Zhou JX, 2006, HUM REPROD, V21, P1698, DOI 10.1093/humrep/del086; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	47	92	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3282	3291		10.1038/sj.onc.1210991	http://dx.doi.org/10.1038/sj.onc.1210991			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084326				2022-12-17	WOS:000256111400007
J	Shen, Q; Uray, IP; Li, Y; Krisko, TI; Strecker, TE; Kim, HT; Brown, PH				Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.			The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors	ONCOGENE			English	Article						AP-1 factor; proliferation arrest; cyclin D1; E2F factors; gene expression regulation; breast cancer cells	C-JUN; KINASE-ACTIVITY; BINDING-SITE; ACTIVATION; EXPRESSION; GENE; FOS; DIFFERENTIATION; OVEREXPRESSION; TRANSFORMATION	The activating protein-1 (AP-1) transcription factor transduces growth signals through signal transduction pathways to the nucleus, leading to the expression of genes involved in growth and malignant transformation in many cell types. We have previously shown that overexpression of a dominant negative form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcriptional activity, induces a G(1) cell cycle block and inhibits breast cancer cell growth in vitro and in vivo. We found that AP-1 blockade by Tam67 in MCF-7 breast cancer cells downregulates cyclin D1 transcriptional activity by at least two mechanisms: by suppressing transcription at the known AP-1 binding site (-934/-928) and by suppressing growth factor-induced expression through suppressing E2F activation at the E2F-responsive site (-726/-719). AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels. Chromatin immunoprecipitation and supershift assays demonstrated that AP-1 blockade caused decreased binding of E2F1 protein to the E2F site in the cyclin D1 promoter. We also found that Tam67 suppressed the expression of the E2F1 dimerizing partner, DP1 and E2F-upregulated cell cycle genes (cyclins E, A, B and D3) and enhanced the expression of E2F-downregulated cell cycle genes (cyclins G2 and I). Reduced expression of other E2F-regulated genes was also seen with AP-1 blockade and E2F suppression. Thus, the AP-1 factor regulates the expression of cyclin D and E2F (the latter in turn regulates E2F-downstream genes), leading to cell cycle progression and breast cancer cell proliferation.	[Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; [Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu	Krisko, Tibor/AAG-7595-2020	Krisko, Tibor/0000-0002-9414-5846; Brown, Powel/0000-0002-3398-163X; Shen, Qiang/0000-0002-1491-5434				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BROWN PH, 1993, ONCOGENE, V8, P877; Bu X, 2005, ONCOGENE, V24, P2398, DOI 10.1038/sj.onc.1208466; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Han S, 2003, BREAST CANCER RES TR, V82, P11, DOI 10.1023/B:BREA.0000003843.53726.63; HERBER, 1994, ONCOGENE, V9, P2105; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lavia P, 1999, BIOESSAYS, V21, P221; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen FH, 2006, TOXICOL LETT, V160, P185, DOI 10.1016/j.toxlet.2005.07.009; Shen Q, 2004, ONCOGENE, V23, P2454, DOI 10.1038/sj.onc.1207354; Shen Q, 2006, DEV BIOL, V295, P589, DOI 10.1016/j.ydbio.2006.03.042; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	26	92	94	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					366	377		10.1038/sj.onc.1210643	http://dx.doi.org/10.1038/sj.onc.1210643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637753				2022-12-17	WOS:000252256000013
J	Cavarretta, IT; Neuwirt, H; Untergasser, G; Moser, PL; Zaki, MH; Steiner, H; Rumpold, H; Fuchs, D; Hobisch, A; Nemeth, JA; Culig, Z				Cavarretta, I. T.; Neuwirt, H.; Untergasser, G.; Moser, P. L.; Zaki, M. H.; Steiner, H.; Rumpold, H.; Fuchs, D.; Hobisch, A.; Nemeth, J. A.; Culig, Z.			The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1	ONCOGENE			English	Article						interleukin-6; anti-interleukin-6 antibody; Mc1-1; ERK1/2 mitogen-activated protein kinase; apoptosis; prostate cancer	ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; ACTIVATED PROTEIN-KINASE; HUMAN MYELOMA CELLS; ANDROGEN RECEPTOR EXPRESSION; SIGNAL-REGULATED KINASE; MULTIPLE-MYELOMA; GROWTH-FACTOR; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; INTERLEUKIN-6 RECEPTOR	Levels of the proinflammatory cytokine interleukin-6 (IL-6) are increased in therapy-resistant prostate cancer. IL-6 has been considered a positive growth factor in late-stage prostate cancer cells and a potential target for therapeutic interference. Effects of inhibition of IL-6 on cell survival were studied in LNCaP-IL6+ cells, a model system for advanced prostate cancer, which produce IL-6. We show that the autocrine IL-6 loop is responsible for resistance to apoptosis and increased cellular levels of myeloid cell leukemia-1 (Mcl-1) protein, an antiapoptotic member of the Bcl-2 family. Treatment of cells with a chimeric anti-IL-6 antibody (CNTO 328) led to the induction of apoptosis and downregulation of Mcl-1 protein levels. Specific knockdown of Mcl-1 gene expression by small interfering RNA also yielded an increase in apoptosis of LNCaP-IL-6+ cells. Vice versa, inactivation of IL-6 autocrine loop had no influence on apoptosis levels in the absence of Mcl-1, thus suggesting this molecule as a mediator of the survival action of IL-6. Mcl-1 protein regulation by the endogenous cytokine directly involved the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway. Our data support the concept of anti-IL-6 targeted therapy in therapy-resistant prostate cancer.	Innsbruck Med Univ, Dept Urol, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Med, Div Hematol & Oncol, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Pathol, A-6020 Innsbruck, Austria; Centocor Inc, R&D, Malvern, PA 19355 USA; Innsbruck Med Univ, Bioctr, Dept Biol Chem, A-6020 Innsbruck, Austria; Gen Hosp Feldkirch, Dept Urol, Feldkirch, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Medical University of Innsbruck	Culig, Z (corresponding author), Innsbruck Med Univ, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	zoran.culig@uibk.ac.at	Cavarretta, Ilaria/AAN-4111-2020; Fuchs, Dietmar/AAL-8011-2021; Neuwirt, Hannes/AAF-1090-2019	Fuchs, Dietmar/0000-0003-1627-9563; Neuwirt, Hannes/0000-0003-1064-0098; Cavarretta, Ilaria/0000-0002-3531-2931				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BORSELLINO N, 1995, CANCER RES, V55, P4633; Borsellino N, 1999, CANCER, V85, P134, DOI 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chung DDL, 2003, MAT SCI ENG R, V42, P1, DOI 10.1016/S0927-796X(03)00037-8; Chung TDK, 1999, PROSTATE, V38, P199; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Gioeli D, 1999, CANCER RES, V59, P279; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; GONG YW, 1995, ENDOCRINOLOGY, V136, P2172, DOI 10.1210/en.136.5.2172; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hideshima T, 2005, BEST PRACT RES CL HA, V18, P509, DOI 10.1016/j.beha.2005.01.003; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kawada M, 2006, CANCER LETT, V242, P46, DOI 10.1016/j.canlet.2005.10.040; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Li Jie, 2005, Curr Opin Investig Drugs, V6, P639; Lin DL, 2001, CLIN CANCER RES, V7, P1773; LOTEM J, 1992, BLOOD, V80, P1750; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Okamoto M, 1997, CANCER RES, V57, P141; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pu YS, 2004, PROSTATE, V60, P120, DOI 10.1002/pros.20057; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Royuela M, 2001, EUR CYTOKINE NETW, V12, P654; Royuela M, 2002, HUM PATHOL, V33, P299, DOI 10.1053/hupa.2002.32227; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Selzer E, 2002, MOL MED, V8, P877, DOI 10.1007/BF03402094; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Smith PC, 2001, PROSTATE, V48, P47; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297; Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; STEINER H, 2006, IN PRESS CNTO, V328; Trikha M, 2003, CLIN CANCER RES, V9, P4653; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	68	92	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2822	2832		10.1038/sj.onc.1210097	http://dx.doi.org/10.1038/sj.onc.1210097			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072336				2022-12-17	WOS:000246210800002
J	Oliva-Trastoy, M; Berthonaud, V; Chevalier, A; Ducrot, C; Marsolier-Kergoat, MC; Mann, C; Leteurtre, F				Oliva-Trastoy, M.; Berthonaud, V.; Chevalier, A.; Ducrot, C.; Marsolier-Kergoat, M-C; Mann, C.; Leteurtre, F.			The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase	ONCOGENE			English	Article						Wip1 oncogene; PPM1D; PPZC phosphatase; Chk2 tumour suppressor; DNA damage checkpoints	DNA-DAMAGE RESPONSE; PROTEIN PHOSPHATASE; IONIZING-RADIATION; PP2C PHOSPHATASES; CHECKPOINT; PHOSPHORYLATION; AUTOPHOSPHORYLATION; OLIGOMERIZATION; INACTIVATION; INTERACTS	We previously demonstrated that type 2C protein phosphatases (PP2C) Ptc2 and Ptc3 are required for DNA checkpoint inactivation after DNA double-strand break repair or adaptation in Saccharomyces cerevisiae. Here, we show the conservation of this pathway in mammalian cells. In response to DNA damage, ataxia telangiectasia mutated (ATM) phosphorylates the Chk2 tumour suppressor kinase at threonine 68 (Thr68), allowing Chk2 kinase dimerization and activation by autophosphorylations in the T-loop. The oncogenic protein Wip1, a PP2C phosphatase, binds Chk2 and dephosphorylates phospho-Thr68. Consequently, Wip1 opposes Chk2 activation by ATM after ionizing irradiation of cells. In HCT15 colorectal cancer cells corrected for functional Chk2 activity, Wip1 overexpression suppressed the contribution of Chk2 to the G2/M DNA damage checkpoint. These results indicate that Wip1 is one of the phosphatases regulating the activity of Chk2 in response to DNA damage.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, F-91191 Gif Sur Yvette, France; Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Uniformed Services University of the Health Sciences - USA	Mann, C (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 144, F-91191 Gif Sur Yvette, France.	carl.mann@cea.fr; francois.leteurtre@cea.fr		Mann, Carl/0000-0001-7212-1512; Francois, Leteurtre/0000-0001-7373-6180				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lee SB, 2001, CANCER RES, V61, P8062; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Liang XB, 2006, INT J MOL MED, V17, P703; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; NANNENGA B, 2006, IN PRESS MOL CARCINO; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Schweighofer A, 2004, TRENDS PLANT SCI, V9, P236, DOI 10.1016/j.tplants.2004.03.007; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	92	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1449	1458		10.1038/sj.onc.1209927	http://dx.doi.org/10.1038/sj.onc.1209927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936775				2022-12-17	WOS:000244558800009
J	Colin, C; Baeza, N; Bartoli, C; Fina, F; Eudes, N; Nanni, I; Martin, PM; Ouafik, L; Figarella-Branger, D				Colin, C; Baeza, N; Bartoli, C; Fina, F; Eudes, N; Nanni, I; Martin, PM; Ouafik, L; Figarella-Branger, D			Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization	ONCOGENE			English	Article						human gliomas; SSH (suppression subtractive hybridization); real-time quantitative RT-PCR; SPOCK1; fibronectin	MAMMARY EPITHELIAL-CELLS; MICROARRAY ANALYSIS; LOW-GRADE; MOLECULAR CLASSIFICATION; DNA-MICROARRAY; MESSENGER-RNA; HUMAN GLIOMA; OSTEOPONTIN; PROGRESSION; PROFILES	Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery. We have used Suppression Subtractive Hybridization to de. ne markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups. We have identified 106 genes expressed in PA versus GBM and 80 genes expressed in GBM versus PA. Subsequent analysis identified a subset of 20 transcripts showing a common differential expression pattern for the two groups. GBM differs from PA by the expression of five genes involved in invasion and angiogenesis: fibronectin, osteopontin, chitinase-3-like-1 (YKL-40), keratoepithelin and fibromodulin. PA differs from GBM by the expression of genes related to metabolism ( apolipoprotein D), proteolysis (protease-serine-11), receptor and signal transduction (PLEKHB1 for Pleckstrin-Homology-domain-containing-protein-family-B-member-1), transcription/translation (eukaryotic-translation-elongation-factor-1-alpha 1) processes and cell adhesion ( SPOCK1 for SPARC/Osteonectin-CWCV-kazal-like-domains-proteoglycan). The expression of these genes was confirmed by real-time quantitative RT-PCR and immunohistochemistry. This study highlights the crucial role of brain invasion in GBM and identifies specific molecules involved in this process. In addition, it offers a restricted list of markers that accurately distinguish PA from GBM.	Fac Med Timone, Lab Biopathol Adhes & Signalisat, EA3281, IPHM, F-13005 Marseille, France; Fac Med Nord, APHM, Lab Transfert Oncol Biol, F-13015 Marseille, France; Fac Med Nord, Inst Fed Jean Roche, Lab Cancerol Expt, INSERM,EMI 0359, F-13015 Marseille, France; Hop La Timone, Serv Anat Pathol & Neuropathol, APHM, F-13005 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Figarella-Branger, D (corresponding author), Fac Med Timone, Lab Biopathol Adhes & Signalisat, EA3281, IPHM, 27 Bd Jean Moulin, F-13005 Marseille, France.	dominique.figarella-branger@medecine.univ-mrs.fr		Ouafik, L'Houcine/0000-0002-4848-1232				Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; Caskey LS, 2000, HISTOL HISTOPATHOL, V15, P971, DOI 10.14670/HH-15.971; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Charbonnier F, 1998, GENOMICS, V48, P377, DOI 10.1006/geno.1997.5199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Edgell CJS, 2004, INT REV CYTOL, V236, P101, DOI 10.1016/S0074-7696(04)36003-1; Eikmans M, 2003, J AM SOC NEPHROL, V14, P899, DOI 10.1097/01.ASN.0000056611.92730.7B; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Gutmann DH, 2002, CANCER RES, V62, P2085; Hunter S, 2002, J NEUROPATH EXP NEUR, V61, P275, DOI 10.1093/jnen/61.3.275; Khatua S, 2003, CANCER RES, V63, P1865; Kleihues, 2000, WHO CLASSIFICATION T; Kumazaki T, 1999, J CELL SCI, V112, P1449; Lal A, 1999, CANCER RES, V59, P5403; Lam P, 2005, MOL THER, V12, P144, DOI 10.1016/j.ymthe.2005.02.028; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mittler MA, 1996, J NEUROSURG, V85, P1091, DOI 10.3171/jns.1996.85.6.1091; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rickman DS, 2001, CANCER RES, V61, P6885; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rocchi P, 2004, ONCOGENE, V23, P9111, DOI 10.1038/sj.onc.1208154; SAITOH Y, 1995, LAB INVEST, V72, P55; Sallinen SL, 2000, CANCER RES, V60, P6617; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Tanwar MK, 2002, CANCER RES, V62, P4364; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wong KK, 2005, CANCER RES, V65, P76	35	92	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2818	2826		10.1038/sj.onc.1209305	http://dx.doi.org/10.1038/sj.onc.1209305			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314830				2022-12-17	WOS:000237272900014
J	Somasundaram, K; Reddy, SP; Vinnakota, K; Britto, R; Subbarayan, M; Nambiar, S; Hebbar, A; Samuel, C; Shetty, M; Sreepathi, HK; Santosh, V; Hegde, AS; Hegde, S; Kondaiah, P; Rao, MRS				Somasundaram, K; Reddy, SP; Vinnakota, K; Britto, R; Subbarayan, M; Nambiar, S; Hebbar, A; Samuel, C; Shetty, M; Sreepathi, HK; Santosh, V; Hegde, AS; Hegde, S; Kondaiah, P; Rao, MRS			Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma	ONCOGENE			English	Article						glioma; astrocytoma; ASCL1; Notch signaling; glioblastoma multiforme; microarray	GROWTH-FACTOR; ACHAETE-SCUTE; GENE-EXPRESSION; NEUROENDOCRINE DIFFERENTIATION; TUMOR-SUPPRESSOR; HUMAN GLIOMAS; MICROARRAY; PROTEIN; CANCER; BRAIN	Astrocytoma is the most common type of brain cancer constituting more than half of all brain tumors. With an aim to identify markers describing astrocytoma progression, we have carried out microarray analysis of astrocytoma samples of different grades using cDNA microarray containing 1152 cancer-specific genes. Data analysis identified several differentially regulated genes between normal brain tissue and astrocytoma as well as between grades II/III astrocytoma and glioblastoma multiforme (GBM; grade IV). We found several genes known to be involved in malignancy including Achaetescute complex-like 1(Drosophila) (ASCL1; Hash 1). As ASCL has been implicated in neuroendocrine, medullary thyroid and small-cell lung cancers, we chose to examine the role of ASCL1 in the astrocytoma development. Our data revealed that ASCL1 is overexpressed in progressive astrocytoma as evidenced by increased levels of ASCL1 transcripts in 85.71% (6/7) of grade II diffuse astrocytoma (DA), 90% (9/10) of grade III anaplastic astrocytoma (AA) and 87.5% (7/8) of secondary GBMs, while the majority of primary de novo GBMs expressed similar to or less than normal brain levels (66.67%; 8/12). ASCL1 upregulation in progressive astrocytoma is accompanied by inhibition of Notch signaling as seen by uninduced levels of HES1, a transcriptional target of Notch1, increased levels of HES6, a dominant-negative inhibitor of HES1-mediated repression of ASCL1, and increased levels of Notch ligand Delta1, which is capable of inhibiting Notch signaling by forming intracellular Notch ligand autonomous complexes. Our results imply that inhibition of Notch signaling may be an important early event in the development of grade II DA and subsequent progression to grade III AA and secondary GBM. Furthermore, ASCL1 appears to be a putative marker to distinguish primary GBM from secondary GBM.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Mol Reproduct Dev & Genet, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India; Sri Satya Sai Inst Higher Med Sci, Bangalore 560066, Karnataka, India; Manipal Hosp, Bangalore 560017, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); National Institute of Mental Health & Neurosciences - India	Rao, MRS (corresponding author), Indian Inst Sci, Dept Biochem, CV Raman Ave, Bangalore 560012, Karnataka, India.	mrsrao@biochem.iisc.ernet.in	Reddy, Sreekanth/B-3395-2008	Britto, Ramona/0000-0003-1011-5410				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bae SK, 2000, DEVELOPMENT, V127, P2933; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Brock CS, 1997, MED ONCOL, V14, P103, DOI 10.1007/BF02990955; Campomenosi P, 1996, CANCER GENET CYTOGEN, V88, P95, DOI 10.1016/0165-4608(95)00359-2; Casarosa S, 1999, DEVELOPMENT, V126, P525; Cavenee WK, 2000, GLIOBLASTOMA, P29; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fathallah-Shaykh HM, 2002, ONCOGENE, V21, P7164, DOI 10.1038/sj.onc.1205654; FLEMING TP, 1992, CANCER RES, V52, P4550; FREDERICK L, 2000, ANN INTERN MED, V138, P658; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; Gibert JM, 2003, INT J DEV BIOL, V47, P643; Godard S, 2003, CANCER RES, V63, P6613; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Heitzler P, 1996, DEVELOPMENT, V122, P161; HERMANSON M, 1992, CANCER RES, V52, P3213; Hermanson M, 1996, CANCER RES, V56, P164; Hill JR, 1999, ARCH NEUROL-CHICAGO, V56, P439, DOI 10.1001/archneur.56.4.439; Ito T, 2000, DEVELOPMENT, V127, P3913; JAMES CD, 1991, CANCER RES, V51, P1684; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Jordanova ES, 2003, INT J CANCER, V103, P393, DOI 10.1002/ijc.10824; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kumanogoh A, 2002, NATURE, V419, P629, DOI 10.1038/nature01037; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liau LM, 2000, CANCER RES, V60, P1353; Ljubimova JY, 2001, CANCER RES, V61, P5601; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; Mischel PS, 2001, BRAIN TUMOR IMMUNOTHERAPY, P3; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Nutt CL, 2003, CANCER RES, V63, P1602; OLOPADE OI, 1992, CANCER RES, V52, P2523; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phatak P, 2002, J BIOSCIENCES, V27, P673, DOI 10.1007/BF02708375; Post LC, 2000, MECH DEVELOP, V98, P95, DOI 10.1016/S0925-4773(00)00432-9; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rickman DS, 2001, CANCER RES, V61, P6885; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sallinen SL, 2000, CANCER RES, V60, P6617; Satow T, 2001, J NEUROSCI, V21, P1265; Scheffer GL, 2002, BRIT J CANCER, V86, P1943, DOI 10.1038/sj.bjc.6600354; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tanwar MK, 2002, CANCER RES, V62, P4364; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Wang H, 2003, CANCER RES, V63, P4315; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watson MA, 2001, CANCER RES, V61, P1825; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	78	92	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7073	7083		10.1038/sj.onc.1208865	http://dx.doi.org/10.1038/sj.onc.1208865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16103883				2022-12-17	WOS:000232833200009
J	Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G				Svensson, S; Jirstrom, K; Ryden, L; Roos, G; Emdin, S; Ostrowski, MC; Landberg, G			ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis	ONCOGENE			English	Article						breast cancer; ERK; MAPK; Ets-2; VEGF; VEGFR2; proliferation; prognosis; tamoxifen	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; RETINOBLASTOMA PROTEIN; ESTROGEN-RECEPTOR; DNA-SYNTHESIS; PLC-GAMMA; G1 PHASE; CYCLIN-E; PATHWAY	Extracellular signal-regulated kinase (ERK) 1/2 signalling mediates communication between growth factor receptors and the cell nucleus and has been linked to several key events in the transformation process such as proliferation and invasion. We therefore sought to delineate the degree of phosphorylated ERK1/2 in breast cancer and potential links to upstream receptors such as VEGFR2, ErbB2, downstream targets, such as Ets-2, as well as clinicopathological parameters, clinical outcome and response to tamoxifen. ERK1/2 phosphorylation was assessed by immunohistochemistry using a phospho-specific ERK1/2 antibody in three breast cancer cohorts including a total of 886 tumours arranged in tissue arrays. Cohort I consisted of 114 patients, cohort II of 248 postmenopausal patients randomized to either 2 years of tamoxifen or no adjuvant treatment and cohort III of 524 patients. Surprisingly, ERK1/2 phosphorylation correlated inversely with tumour size. Phosphorylated ERK1/2 was further associated with the presence of VEGFR2 (cohorts II and III) and the degree of phosphorylated Ets-2, indicating in vivo, a signalling cascade from VEGFR2 via ERK1/2 to Ets-2 phosphorylation. Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph- node status and tumour size indicating that ERK1/2 signalling might be associated with a less aggressive phenotype. Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden; Helsingborg Hosp, Dept Surg, SE-25187 Helsingborg, Sweden; Umea Univ, Dept Pathol, SE-90187 Umea, Sweden; Umea Univ, Dept Surg, SE-90187 Umea, Sweden; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Lund University; Skane University Hospital; Helsingborgs Hospital; Umea University; Umea University; University System of Ohio; Ohio State University	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, SE-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se	Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297				Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Catalano A, 2003, FASEB J, V17, P358, DOI 10.1096/fj.03-0513fje; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clarke M, 1998, LANCET, V351, P1451; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kollermann J, 2001, AM J CLIN PATHOL, V116, P115; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Loden M, 2003, ANTICANCER RES, V23, P2053; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; SAHL B, 1999, ANTICANCER RES, V19, P731; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; Stendahl M, 2004, BRIT J CANCER, V90, P1942, DOI 10.1038/sj.bjc.6601831; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yang BS, 1996, MOL CELL BIOL, V16, P538	38	92	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4370	4379		10.1038/sj.onc.1208626	http://dx.doi.org/10.1038/sj.onc.1208626			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806151	Green Submitted			2022-12-17	WOS:000229976900006
J	Gao, N; Rahmani, M; Dent, P; Grant, S				Gao, N; Rahmani, M; Dent, P; Grant, S			2-methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process	ONCOGENE			English	Article						2ME; apoptosis; leukemia; Akt; ROS	PROSTATE-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; HISTONE DEACETYLASE INHIBITORS; FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; IN-VITRO	The effects of 2-Methoxyestradiol (2ME)-induced apoptosis was examined in human leukemia cells (U937 and Jurkat) in relation to mitochondrial injury, oxidative damage, and perturbations in signaling pathways. 2ME induced apoptosis in these cells in a dose-dependent manner associated with release of mitochondrial proteins ( cytochrome c, AIF), generation of reactive oxygen species (ROS), downregulation of Mcl-1 and XIAP, and inactivation ( dephosphorylation) of Akt accompanied by activation of JNK. In these cells, enforced activation of Akt by a constitutively active myristolated Akt construct prevented 2ME-mediated mitochondrial injury, XIAP and Mcl-1 downregulation, JNK activation, and apoptosis, but not ROS generation. Conversely, 2ME lethality was potentiated by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Furthermore, in U937 cells, the hydrogen peroxide scavenger catalase and a superoxide dismutase ( SOD) mimetic, TBAP, blocked these events, as well as Akt inactivation. Interruption of the JNK pathway by pharmacologic or genetic ( e. g. siRNA) means attenuated 2ME-induced mitochondrial injury, XIAP and Mcl-1 downregulation, and apoptosis. Collectively, these findings suggest a hierarchical model of 2ME-related apoptosis induction in human leukemia cells in which 2ME-induced oxidative injury represents a primary event resulting in Akt inactivation, leading, in turn, to JNK activation, and culminating in XIAP and Mcl-1 downregulation, mitochondrial injury, and apoptosis. They also suggest that in human leukemia cells, the Akt pathway plays a critical role in mediating the response to oxidative stress induced by 2ME.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753, R01CA100866] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63753, R01 CA093738, R01 CA063753, CA 93738, CA 100866, R01 CA100866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Fuino L, 2003, MOL CANCER THER, V2, P971; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Harris TK, 2003, IUBMB LIFE, V55, P117, DOI 10.1080/1521654031000115951; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hughes RA, 2002, MOL PHARMACOL, V61, P1053, DOI 10.1124/mol.61.5.1053; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kausalya S, 2001, J IMMUNOL, V166, P4721, DOI 10.4049/jimmunol.166.7.4721; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim YS, 2004, EXP MOL MED, V36, P157, DOI 10.1038/emm.2004.22; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LaVallee TM, 2002, CANCER RES, V62, P3691; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li SY, 2004, J BIOL CHEM, V279, P11244, DOI 10.1074/jbc.M308011200; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; MANNING BD, 2003, BIOCHEM SOC T, V31, P3; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; Minutoli L, 2004, LIFE SCI, V75, P2853, DOI 10.1016/j.lfs.2004.03.040; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Ozaki M, 2003, CELL DEATH DIFFER, V10, P508, DOI 10.1038/sj.cdd.4401172; Paez Juan, 2003, Cancer Treat Res, V115, P145; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosato RR, 2003, CANCER RES, V63, P3637; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Tinley TL, 2003, CANCER RES, V63, P1538; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zoubine MN, 1999, INT J ONCOL, V15, P639	67	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3797	3809		10.1038/sj.onc.1208530	http://dx.doi.org/10.1038/sj.onc.1208530			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782127	Green Accepted			2022-12-17	WOS:000229346300010
J	Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S				Edwards, LA; Thiessen, B; Dragowska, WH; Daynard, T; Bally, MB; Dedhar, S			Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth	ONCOGENE			English	Article						glioblastomas; integrin-linked kinase; brain cancer	INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; GERMLINE MUTATIONS; SIGNALING PATHWAYS; COWDEN-DISEASE; CELL-ADHESION; BREAST-CANCER; IN-VITRO; EXPRESSION	The tumor suppressor gene phosphatase and tensin homologue ( PTEN) regulates the phosphatidylinositol-3'- kinase ( PI3K) signaling pathway and has been shown to correlate with poor prognosis in high- grade astrocytomas when mutational inactivation or loss of the PTEN gene occurs. PTEN mutation leads to constitutive activation of protein kinase B ( PKB)/ Akt with phosphorylation at the PKB/ Akt sites Thr- 308 and Ser- 473. Integrin- linked kinase ( ILK) has been shown to regulate PKB/ Akt activity with the loss of PTEN in prostate cancer. We now demonstrate that ILK activity regulates PKB/ Akt activity in glioblastoma cells. The activity of ILK is constitutively elevated in a serum- independent manner in PTEN mutant cells, and transfection of wild- type PTEN under the control of an inducible promoter into mutant PTEN cells inhibits ILK activity. Transfection of ILK antisense ( ILKAS) or exposure to a small- molecule ILK inhibitor suppresses the constitutive phosphorylation of PKB/ Akt on Ser- 473 in PTEN- mutant glioblastoma cell lines. In addition, the delivery of ILKAS to PTEN-negative glioblastoma cells resulted in apoptosis. Rag- 2M mice bearing established ( similar to 100 mg) human U87MG glioblastoma tumors, treated QD x 5 for 3 consecutive weeks with ILKAS ( i. p. 5 mg/ kg), exhibited stable disease with <= 7% increase in tumor volume over the 3- week course of treatment. In contrast, animals treated with an oligonucleotide control or saline exhibited a > 100% increase in tumor volume over the same time period. Our initial results indicate that therapeutic strategies targeting ILK maybe beneficial in the treatment of glioblastomas.	British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada; QLT Inc, Dept Med Chem, Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; British Columbia Canc Agcy, Dept Canc Genet, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; British Columbia Cancer Agency	Edwards, LA (corresponding author), British Columbia Canc Agcy, British Columbia Canc Res Ctr, Dept Adv Therapeut, 601 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	ledwards@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Cheyney IW, 1999, CANCER RES, V59, P2318; Choe G, 2003, CANCER RES, V63, P2742; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EDWARDS L, 2003, NEURO-ONCOLOGY, V5, P300; EDWARDS LA, 2004, INTEGRIN LINKED KINA; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, CANCER RES, V57, P5017; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Park MJ, 2002, CANCER RES, V62, P6318; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pore N, 2003, CANCER RES, V63, P236; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Wang SI, 1997, CANCER RES, V57, P4183; Waterhouse DN, 2004, CANCER BIOL THER, V3, P197, DOI 10.4161/cbt.3.2.622; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	39	92	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3596	3605		10.1038/sj.onc.1208427	http://dx.doi.org/10.1038/sj.onc.1208427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782140				2022-12-17	WOS:000229221800007
J	Martoriati, A; Doumont, G; Alcalay, M; Bellefroid, E; Pelicci, PG; Marine, JC				Martoriati, A; Doumont, G; Alcalay, M; Bellefroid, E; Pelicci, PG; Marine, JC			dapk1, encoding an activator of a p19(ARF)-p53-mediated apoptotic checkpoint, is a transcription target of p53	ONCOGENE			English	Article						apoptosis; dapk1; p53; Mdm4	REGULATES P53-DEPENDENT APOPTOSIS; PROMOTER HYPERMETHYLATION; CANCER PATIENTS; GENES; GROWTH; MDM2; DEGRADATION; PHOSPHATASE; EXPRESSION; RADIATION	The p53 tumour suppressor functions as a transcriptional activator, and several p53-inducible genes that play a critical proapoptotic role have been described. Moreover, p53 regulates the expression of various proteins participating in autoregulatory feedback loops, including proteins that negatively control p53 stability (Mdm2 and Pirh2) or modulate stress-induced phosphorylation of p53 on Ser-46 (p53DINP1 or Wip1), a key event for p53-induced apoptosis. Here, we describe a new systematic analysis of p53 targets using oligonucleotide chips, and report the identification of dapk1 as a novel p53 target. We demonstrate that dapk1 mRNA levels increase in a p53-dependent manner in various cellular settings. Both human and mouse dapk1 genomic loci contain DNA sequences that bind p53 in vitro and in vivo. Since dapk1 encodes a serine/threonine kinase previously shown to suppress oncogene-induced transformation by activating a p19(ARF)/p53-dependent apoptotic checkpoint, our results suggest that Dapk1 participates in a new positive feedback loop controlling p53 activation and apoptosis.	Flanders Interuniv Inst Biotechnol VIB, Lab Mol Canc Biol, B-9052 Ghent, Belgium; Free Univ Brussels, ULB, IBMM, Unit Mol Embryol, Gosselies, Belgium; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC, Inst Mol Oncol, I-20139 Milan, Italy	Flanders Institute for Biotechnology (VIB); Universite Libre de Bruxelles; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Marine, JC (corresponding author), Flanders Interuniv Inst Biotechnol VIB, Lab Mol Canc Biol, Technol Pk,927, B-9052 Ghent, Belgium.	chris.marine@dmbr.ugent.be	Marine, Jean Christophe/J-2237-2015; Pelicci, Pier Giuseppe/AAL-6572-2020; Marine, Jean-Christophe/K-3292-2016; Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019	Marine, Jean-Christophe/0000-0003-2433-9837; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Martoriati, Alain/0000-0002-5684-1728				Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Esteller M, 1999, CANCER RES, V59, P67; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kuo ML, 2003, CANCER RES, V63, P1046; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marine JC, 2004, CELL CYCLE, V3, P900; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	25	92	96	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1461	1466		10.1038/sj.onc.1208256	http://dx.doi.org/10.1038/sj.onc.1208256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608685				2022-12-17	WOS:000227092600016
J	Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T				Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T			Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis	ONCOGENE			English	Article						oral cancer; susceptibility; polymorphism; Ras; Aurora-A	CENTROSOME AMPLIFICATION; LIM PROTEIN; KINASE; GENE; RAS; CANCER; CELLS; PHOSPHORYLATION; SUSCEPTIBILITY; IDENTIFICATION	Aurora kinases are known to play a key role in maintaining mitotic fidelity, and overexpression of aurora kinases has been noted in various tumors. Overexpression of aurora kinase activity is thought to promote cancer development through a loss of centrosome or chromosome number integrity. Here we observed augmentation of G12V-mutated HRAS-induced neoplastic transformation in BALB/c 3T3 A31-1-1 cells transfected with Aurora-A. Aurora-A-short hairpin RNA (shRNA) experiments showed that the expression level of Aurora-A determines susceptibility to transformation. Aurora-A gene amplification was noted in human patients with tongue or gingival squamous carcinoma (4/11). Amplification was observed even in pathologically normal epithelial tissue taken at sites distant from the tumors in two patients with tongue cancer. However, overexpression of Aurora-A mRNA was observed only within the tumors of all patients examined (11/11). Our data indicate that Aurora-A gene amplification and overexpression play a role in human carcinogenesis, largely due to the effect of Aurora-A on oncogenic cell growth, rather than a loss of maintenance of centrosomal or chromosomal integrity.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Sch Dent, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dent Hosp, Minami Ku, Hiroshima 7348553, Japan; Kanazawa Med Univ, Med Res Inst, Div Mol Oncol & Virol, Kanazawa, Ishikawa 9200293, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Kanazawa Medical University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kitajima, Shojiro/0000-0002-4000-0473; Kawai, Hidehiko/0000-0003-2213-7166				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; KAKUNAGA T, 1985, TRANSF ASS EST CELL; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tatsuka M, 1997, INT J CANCER, V71, P88, DOI 10.1002/(SICI)1097-0215(19970328)71:1<88::AID-IJC15>3.3.CO;2-8; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	22	92	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1122	1127		10.1038/sj.onc.1208293	http://dx.doi.org/10.1038/sj.onc.1208293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592510				2022-12-17	WOS:000226749200020
J	Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ				Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ			Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers	ONCOGENE			English	Article						breast cancer; comparative genomic hybridization; expression microarrays; tumor-suppressor genes; chromosome 8	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED PROTEIN-KINASE; YOUNG-WOMEN; CARCINOMA; REGION; PCM-1; RISK; POLYMORPHISMS; ABERRATIONS; APOPTOSIS	Loss of genetic material from chromosome arm 8p occurs commonly in breast carcinomas, suggesting that this region is the site of one or more tumor-suppressor genes (TSGs). Comparative genomic hybridization analysis showed that 8p loss is more common in breast cancers from pre-menopausal compared with post-menopausal patients, as well as in high-grade breast cancers, regardless of the menopausal status. Subsequent high-resolution gene expression profiling of genes mapped to chromosome arm 8p, on an extended cohort of clinical tumor samples, indicated a similar dichotomy of breast cancer clinicopathologic types. Some of these genes showed differential downregulation in early-onset and later-onset, high-grade cancers compared with lower-grade, later-onset cancers. Three such genes were analysed further by in situ technologies, performed on tissue microarrays representing breast tumor and normal tissue samples. PCM1, which encodes a centrosomal protein, and DUSP4/MKP-2, which encodes a MAP kinase phosphatase, both showed frequent gene and protein loss in carcinomas. In contrast, there was an excess of cases showing loss of expression in the absence of reduced gene copy number of SFRP1, which encodes a dominant-negative receptor for Wnt-family ligands. These candidate TSGs may constitute some of the molecular drivers of chromosome arm 8p loss in breast carcinogenesis.	St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia; Victorian Breast Canc Res Consortium, Mol Pathol Lab, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Canc Genom Lab, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Peter MacCallum Canc Inst, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia; Prot Design Labs, Fremont, CA 94555 USA; Womens & Childrens Hlth, Melbourne, Vic 3053, Australia	St Vincent's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Armes, JE (corresponding author), St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia.	jane.armes@svhm.org.au	Susan, Ramus/C-1607-2008; Armes, Jane/D-6396-2012; Ramus, Susan/AAG-8352-2019; Price, Gareth/A-4832-2017	Armes, Jane/0000-0002-2215-0347; Ramus, Susan/0000-0003-0005-7798; Soo, Wee Kheng/0000-0002-5774-9800; Price, Gareth/0000-0003-2439-8650				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Bouras T, 2002, CANCER RES, V62, P1289; Charafe-Jauffret E, 2002, INT J ONCOL, V21, P989; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Ishibe N, 1998, CANCER RES, V58, P667; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Konig JJ, 1999, UROL RES, V27, P3, DOI 10.1007/s002400050082; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lai H, 2002, CANCER BIOL THER, V1, P31, DOI 10.4161/cbt.1.1.37; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Liu QQ, 2001, J CELL SCI, V114, P797; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; RADFORD DM, 1995, CANCER RES, V55, P3399; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sigbjornsdottir BI, 2000, J MED GENET, V37, P342, DOI 10.1136/jmg.37.5.342; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Venables W., 2002, MODERN APPL STAT S, VFourth; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Willis S, 2003, GENE CHROMOSOME CANC, V36, P382, DOI 10.1002/gcc.10138; Xiong P, 2001, CANCER RES, V61, P8465; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	35	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5697	5702		10.1038/sj.onc.1207740	http://dx.doi.org/10.1038/sj.onc.1207740			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184884				2022-12-17	WOS:000222629500016
J	Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E				Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E			PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma	ONCOGENE			English	Article						PIN1; peptidyl-prolyl-isomerase; beta-catenin; hepatocellular carcinoma	CYCLIN D1 OVEREXPRESSION; TARGET; AMPLIFICATION; ACTIVATION; EXPRESSION; FREQUENT; PATHWAY; CANCER; MOUSE	The peptidyl-proplyl-isomerase, PIN1, upregulates beta-catenin by inhibiting its interaction with APC. beta-catenin accumulation occurs in about 70% of hepatocellular carcinoma (HCC), of which only 20% are due to beta-catenin mutations. The role of PIN1 in beta-catenin upregulation in HCC was investigated. PIN1 was shown to be overexpressed in more than 50% of HCC. All cases with PIN1 overexpression also showed beta-catenin accumulation, with 68% of cases showing concomitant beta-catenin and cyclin D1 accumulation. PIN1 was shown to contribute to beta-catenin and cyclin D1 overexpression directly by in vitro cell-line transfection experiments. Finally, we showed that PIN1 overexpression and beta-catenin gene mutations appeared to be mutually exclusive events, leading to beta-catenin accumulation in HCC. These results showed that PIN1 overexpression leading to beta-catenin accumulation might be a critical event in hepatocarcinogenesis, and that PIN1 is a potential target for therapeutic intervention in HCC.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Gastroenterol & Hepatol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Kwong, YL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China.	ylkwong@hku.hk; ewctse@hku.hk.or	Tse, Eric/ABB-4021-2020; Fan, Sheung Tat/C-4138-2009; WONG, Chun-Ming/A-6739-2009	Tse, Eric/0000-0002-8351-4722; WONG, Chun-Ming/0000-0002-2497-7858; Ng, Irene Oi-lin/0000-0001-7532-2029; Lai, Ching-Lung/0000-0002-5927-2436; Lee, Kin Wah/0000-0003-0682-322X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; Chen TC, 1998, CANCER LETT, V134, P23, DOI 10.1016/S0304-3835(98)00238-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deane NG, 2001, CANCER RES, V61, P5389; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIDA N, 1994, CANCER RES, V54, P3107; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	25	92	102	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4182	4186		10.1038/sj.onc.1207493	http://dx.doi.org/10.1038/sj.onc.1207493			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064734				2022-12-17	WOS:000221520200018
J	Scheijen, B; Ngo, HT; Kang, H; Griffin, JD				Scheijen, B; Ngo, HT; Kang, H; Griffin, JD			FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins	ONCOGENE			English	Article						Akt; Bim; FLT3; forkhead transcription factors; p27(Kip1)	FORKHEAD TRANSCRIPTION FACTOR; ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; BCL-2 FAMILY; FACTOR FKHR; GENE-EXPRESSION; FACTOR AFX; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; CAENORHABDITIS-ELEGANS	In about 30% of the patients with acute myeloid leukemia, activating FLT3 receptor mutations have been identified, often as in-frame internal tandem duplications (ITD) at the juxtamembrane domain of the receptor. FLT3-ITD receptors exhibit constitutive tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine-dependent cell lines and primary hematopoietic cells suppress programmed cell death and increase cell division. However, the signaling pathways important for transformation, in particular the nuclear targets, are unknown. Here we demonstrate that FLT3-ITD expression in Ba/F3 cells results in activation of Akt and concomitant phosphorylation of the Forkhead family member Foxo3a. Phosphorylation of Foxo proteins through FLT3-ITD signaling promotes their translocation from the nucleus into the cytoplasm, which requires the presence of conserved Akt phosphorylation sites in Forkhead transcription factors and PI3K activity. Induction of Foxo3a phosphorylation by FLT3-ITD receptors in Ba/F3 cells correlates with the suppression of Foxo-target genes p27(Kip1) and the proapoptotic Bcl-2 family member Bim. Specifically, FLT3-ITD expression prevents Foxo3a-mediated apoptosis and upregulation of p27(Kip1) and Bim gene expression. These data indicate that the oncogenic tyrosine kinase FLT3 can negatively regulate Foxo transcription factors, thereby promoting cell survival and proliferation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 540,44 Binney St, Boston, MA 02115 USA.	James_Griffin@dfci.harvard.edu	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230	NCI NIH HHS [R01 CA66996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; DASILVA N, 1994, LEUKEMIA, V8, P885; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; DEL PL, 1997, SCIENCE, V278, P687; Dierov J, 2002, BLOOD, V99, P1758, DOI 10.1182/blood.V99.5.1758; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engstrom M, 2003, EXP HEMATOL, V31, P316, DOI 10.1016/S0301-472X(03)00002-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nakao M, 1996, LEUKEMIA, V10, P1911; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Spiekermann K, 2003, CLIN CANCER RES, V9, P2140; Spiekermann K, 2002, BLOOD, V100, P3423, DOI 10.1182/blood-2002-03-0953; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680; Zheng R, 2002, BLOOD, V100, P4154, DOI 10.1182/blood-2002-03-0936	81	92	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3338	3349		10.1038/sj.onc.1207456	http://dx.doi.org/10.1038/sj.onc.1207456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14981546				2022-12-17	WOS:000220975000008
J	Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D				Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D			Role of promoter methylation in regulation of the mammalian heparanase gene	ONCOGENE			English	Article						promoter methylation; epigenetic regulation; 5-azacytidine; 5-aza-2 ' deoxycytidine; mammalian heparanase; tumour metastasis	DNA METHYLATION; TUMOR-METASTASIS; EXTRACELLULAR-MATRIX; ABL1 METHYLATION; CPG METHYLATION; EXPRESSION; CANCER; CLONING; HYPERMETHYLATION; INHIBITION	Mammalian heparanase (endo-beta-glucuronidase) degrades heparan sulfate proteoglycans and is an important modulator of the extracellular matrix and associated factors. The enzyme is preferentially expressed in neoplastic tissues and contributes to tumour metastasis and angiogenesis. To investigate the epigenetic regulation of the heparanase locus, methylation-specific and bisulfite PCR were performed on a panel of 22 human cancer cell lines. Cytosine methylation of the heparanase promoter was associated with inactivation of the affected allele. Despite lack of sequence homology, extensively methylated CpG islands were found both in human choriocarcinoma (JAR) and rat glioma (C-6) cells which lack heparanase activity. Treatment of these cells with demethylating agents (5-azacytidine, 5-aza-2'-deoxycytidine) resulted in stable dose- and time-dependant promoter hypomethylation accompanied by reappearance of heparanase mRNA, protein and enzymatic activity. An inhibitor of histone deacetylase, Trichostatin A, failed to induce either of these effects. Upregulation of heparanase expression and activity by demethylating drugs was associated with a marked increase in lung colonization by pretreated C-6 rat glioma cells. The increased metastatic potential in vivo was inhibited in mice treated with laminaran sulfate, a potent inhibitor of heparanase activity. We propose a model wherein expression of mammalian heparanase gene is modulated by the interplay between trans-activating genetic and cis-inhibitory epigenetic elements in its promoter.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Med Ctr, Dept Hematol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il	Ashhab, Yaqoub/AAC-8789-2019		NATIONAL CANCER INSTITUTE [R21CA087085] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andela VB, 2000, CANCER RES, V60, P6557; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bitan M, 2002, EXP HEMATOL, V30, P34, DOI 10.1016/S0301-472X(01)00766-4; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 2001, CANCER RES, V61, P3225; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Koliopanos A, 2001, CANCER RES, V61, P4655; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Lynch Catherine A, 2002, Mol Cancer, V1, P2, DOI 10.1186/1476-4598-1-2; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Melki JR, 1999, CANCER RES, V59, P3730; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Miyakura Y, 2003, GENE CHROMOSOME CANC, V36, P17, DOI 10.1002/gcc.10134; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2001, LEUKEMIA, V15, P575, DOI 10.1038/sj.leu.2402026; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; VanLint C, 1996, GENE EXPRESSION, V5, P245; Velinov M, 2000, MOL GENET METAB, V69, P81, DOI 10.1006/mgme.1999.2941; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	72	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7737	7749		10.1038/sj.onc.1207056	http://dx.doi.org/10.1038/sj.onc.1207056			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586400				2022-12-17	WOS:000186240200004
J	Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O				Anastasi, S; Fiorentino, L; Fiorini, M; Fraioli, R; Sala, G; Castellani, L; Alema, S; Alimandi, M; Segatto, O			Feedback inhibition by RALT controls signal output by the ErbB network	ONCOGENE			English	Article						ErbB; feedback inhibition; Mig-6; negative signaling; RALT	EPIDERMAL-GROWTH-FACTOR; CELL-CYCLE PROGRESSION; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; TYROSINE KINASES; BREAST-CANCER; TRANSCRIPTION FACTORS; RECEPTOR FAMILY; HETERODIMERIZATION; PHOSPHORYLATION	The ErbB-2 interacting protein receptor-associated late transducer (RALT) was previously identified as a feedback inhibitor of ErbB-2 mitogenic signals. We now report that RALT binds to ligand-activated epidermal growth factor receptor (EGFR), ErbB-4 and ErbB-2.ErbB-3 dimers. When ectopically expressed in 32D cells reconstituted with the above ErbB receptor tyrosine kinases (RTKs) RALT behaved as a pan-ErbB inhibitor. Importantly, when tested in either cell proliferation assays or biochemical experiments measuring activation of ERK and AKT, RALT affected the signalling activity of distinct ErbB dimers with different relative potencies. RALT DeltaEBR, a mutant unable to bind to ErbB RTKs, did not inhibit ErbB-dependent activation of ERK and AKT, consistent with RALT exerting its suppressive activity towards these pathways at a receptor-proximal level. Remarkably, RALT DeltaEBR retained the ability to suppress largely the proliferative activity of ErbB-2.ErbB-3 dimers over a wide range of ligand concentrations, indicating that RALT can intercept ErbB-2.ErbB-3 mitogenic signals also at a receptor-distal level. A suppressive function of RALT DeltaEBR towards the mitogenic activity of EGFR and ErbB-4 was detected at low levels of receptor occupancy, but was completely overcome by saturating concentrations of ligand. We propose that quantitative and qualitative aspects of RALT signalling concur in defining identity, strength and duration of signals generated by the ErbB network.	Regina Elena Inst Canc Res, I-00158 Rome, Italy; Univ Cassino, Cassino, Italy; Univ Roma Tor Vergata, INFM, Sez B, Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Via Delle Messi Oro 156, I-00158 Rome, Italy.		Rocco, Fraioli/J-2638-2017; Sala, Gianluca/C-2056-2017; anastasi, sergio/AAB-9585-2020; Alimandi, Maurizio/AAG-9246-2019	Rocco, Fraioli/0000-0001-7906-6077; Sala, Gianluca/0000-0002-4494-915X; anastasi, sergio/0000-0003-1009-6117; Alimandi, Maurizio/0000-0002-1409-6803; Castellani, Loriana/0000-0002-8519-3504; Segatto, Oreste/0000-0003-2561-1142; Alema, Stefano/0000-0002-9869-6354				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Cook SJ, 1999, MOL CELL BIOL, V19, P330; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LONARDO F, 1990, New Biologist, V2, P992; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Tang CK, 1998, CANCER RES, V58, P3415; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	92	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4221	4234		10.1038/sj.onc.1206516	http://dx.doi.org/10.1038/sj.onc.1206516			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833145				2022-12-17	WOS:000183979800009
J	Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro	ONCOGENE			English	Article						extracellular signal regulated kinase; invasion; gliomas; stable transfectants; MMP-9	ACTIVATED PROTEIN-KINASE; HUMAN GLIOBLASTOMA CELLS; IV COLLAGENASE GENE; TRANSCRIPTION FACTOR; GELATINASE-B; C-JUN; HA-RAS; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INVASIVENESS	We previously showed that enhanced expression of MMP-9, an endopeptidase that digests basement-membrane type IV collagen, is related to tumor progression in vitro and in vivo; antisense-MMP-9 stably transfected clones were less invasive than untransfected parental cells and did not form tumors in nude mice. In this study, we examined the role of ERK-1 in the regulation of MMP-9 production and the invasive behavior of the human glioblastoma cell line SNB19, in which ERK1 is constitutively activated. SNB19 cells were stably transfected with mt-ERK, a vector encoding ERK-1 cDNA in which the conserved lysine at codon 71 was changed to arginine, thus impairing the catalytic efficiency of this enzyme. Gelatin zymography showed reduced levels of MMP-9 in the mt-ERK-transfected cell lines relative to those in vector-transfected and parental control cells. Reductions in MMP-9 protein mRNA levels were also detected in the mt-ERK-transfected cells by Western and Northern blotting. The mt-ERK-transfected cells were much less invasive than parental or vector control cells in a Matrigel invasion assay and in a spheroid coculture assay. Thus an ERK-dependent signaling pathway seems to regulate MMP-9 mediated glioma invasion in SNB19 cells; interfering with this pathway could be developed into a therapeutic approach, which aims at a reduction of cancer cell invasion.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76350, CA75557, CA-85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL S, 1995, ONCOGENE, V11, P427; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Forsyth PA, 1998, J NEURO-ONCOL, V36, P21, DOI 10.1023/A:1005879027267; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Genersch E, 2000, J CELL SCI, V113, P4319; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Simon C, 1998, CANCER RES, V58, P1135; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOZERI O, 1992, ONCOGENE, V7, P2259; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	38	92	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5601	5608		10.1038/sj.onc.1205646	http://dx.doi.org/10.1038/sj.onc.1205646			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165859				2022-12-17	WOS:000177442000010
J	Neve, RM; Holbro, T; Hynes, NE				Neve, RM; Holbro, T; Hynes, NE			Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells	ONCOGENE			English	Article						ErbB2; p27(kip1); p38MAPK; PI3K; MAPK; heregulin	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; DOWN-REGULATION; CDK INHIBITORS; ERBB RECEPTORS; MYC; PROLIFERATION; NEUREGULIN	Addition of the ErbB-ligand, Heregulinbeta1 (HRG), to breast tumour-derived T47D cells promotes D-cyclin expression, p21(cip1) synthesis, cyclin-dependent kinase (CDK) activation through re-disiribution of p27(kip1) and DNA synthesis. In contrast EGF has no effect on T47D cell cycle progression. By comparing these two ligands and the use of specific inhibitors for phosphatidylinositol-3 kinase (PI3K), mitogen-activated protein kinase (MAPK) and p38MAPK, we have identified several molecular mechanisms required for ErbB receptor-mediated proliferation. The PI3K, MAPK and p38MAPK pathways each displayed distinct activation profiles in response to either HRG or EGF, with obvious differences in both the intensity and duration of signal output. Through inhibition of each of these pathways it is apparent that each pathway is necessary, yet insufficient alone, to stimulate proliferation. Each pathway regulates distinct subsets of essential cell cycle regulators and integration of these signal networks is required for the timely expression of these components, which culminates in cell cycle progression. Significantly, the mechanisms controlling ligand-stimulated proliferation through ErbB2 are strikingly similar to the mechanisms through which overexpressed, constitutively activated, ErbB2 orchestrates uncontrolled proliferation in cancer cells. This suggests that downstream effectors of ErbB receptors represent good therapeutic targets for breast cancer.	Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Buck Inst, Novato, CA 94945 USA; UCSF, Dept Hematol Oncol, San Francisco, CA USA	Friedrich Miescher Institute for Biomedical Research; Novartis; Buck Institute for Research on Aging; University of California System; University of California San Francisco	Neve, RM (corresponding author), Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	rneve@buckinstitute.org						Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; JONGEWARD GD, 1995, GENETICS, V139, P1553; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORKIN A, 1993, ONCOGENE, V8, P3021; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woldeyesus MT, 1999, GENE DEV, V13, P2538, DOI 10.1101/gad.13.19.2538; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3	62	92	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4567	4576		10.1038/sj.onc.1205555	http://dx.doi.org/10.1038/sj.onc.1205555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085235				2022-12-17	WOS:000176476700011
J	Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K				Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K			Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells	ONCOGENE			English	Article						A3 adenosine receptor; IB-MECA; cAMP; Wnt pathway; GSK-3 beta	A3 ADENOSINE RECEPTOR; GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; BETA-CATENIN; PHOSPHORYLATION; TELOMERASE; ACTIVATION; INSULIN; MUSCLE; CAMP	The A3 adenosine receptor, A3AR, belongs to the family of Gi proteins, which upon induction, suppresses the formation of cAMP and its downstream effectors. Recent studies have indicated that activation of A3AR by its agonist, IB-MECA, results in growth inhibition of malignant cells. Here we demonstrate the ability of IB-MECA to decrease the levels of protein kinase A, a downstream effector of cAMP, and protein kinase B/Akt in melanoma cells. Examination of glycogen synthase kinase 3beta, GSK-3beta, whose phosphorylation is controlled by protein kinase A and B, showed a substantial decrease in the levels of its phosphorylated form and an increase in total GSK-3beta levels in IB-MECA treated melanoma cells. This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3beta in the cells. Evaluation of beta-catenin, a key component of Wnt signaling pathway which, upon phosphorylation by GSK-3beta rapidly ubiquitinates, showed a substantial decrease in its level after IB-MECA treatment. Accordingly, the level of beta-catenin responsive cell growth regulatory genes including c-myc and cyclin D1 was severely declined upon treatment of the cells with IB-MECA. These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists.	Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel; Can Fite Biopharma Ltd, Kiryat Matalon, Petach Tikva, Israel; Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishman, P (corresponding author), Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel.	pfishman@post.tau.ac.il	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				AUSUBEL F, 1989, CURRENT PROTOCOLS MO, P342; Bar-Yehuda S, 2001, NEOPLASIA, V3, P125, DOI 10.1038/sj.neo.7900138; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fishman P, 1998, CANCER RES, V58, P3181; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fishman P, 2000, EUR J CANCER, V36, P1452, DOI 10.1016/S0959-8049(00)00130-1; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; McEwen DG, 2000, CURR BIOL, V10, pR562, DOI 10.1016/S0960-9822(00)00611-4; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; OHANA G, 2000, J CELLULAR PHYSL, V186, P19; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; STILES GL, 1990, CLIN RES, V38, P10; Zhao ZH, 2000, BBA-MOL BASIS DIS, V1500, P280, DOI 10.1016/S0925-4439(99)00111-8	27	92	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4060	4064		10.1038/sj.onc.1205531	http://dx.doi.org/10.1038/sj.onc.1205531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037688				2022-12-17	WOS:000175869900012
J	Lotem, J; Sachs, L				Lotem, J; Sachs, L			Cytokine control of developmental programs in normal hematopoiesis and leukemia	ONCOGENE			English	Review						hematopoiesis; in vitro colony forming cells; cytokine network; stem cells; reprograming leukemic cells; apoptosis	COLONY-STIMULATING FACTOR; WILD-TYPE P53; BONE-MARROW-CELLS; CANCER-CHEMOTHERAPY COMPOUNDS; GROWTH-FACTOR WITHDRAWAL; NORMAL MAST-CELLS; MYELOID-LEUKEMIA; NORMAL DIFFERENTIATION; INHIBITORY FACTOR; GENE-EXPRESSION	The establishment of a system for in vitro clonal development of hematopoietic cells made it possible to discover the cytokines that regulate hematopoiesis. These cytokines include colony stimulating factors and others, which interact in a network, and there is a cytokine cascade which couples growth and differentiation. A network allows considerable flexibility and a ready amplification of response to a particular stimulus. A network may also be necessary to stabilize the whole system. Cells called hematopoietic stem cells (HSC) can repopulate all hematopoietic lineages in lethally irradiated hosts, and under appropriate conditions give rise to neuronal, muscle, and epithelial cells. Granulocyte colony stimulating factor induces migration of both HSC and in vitro colony forming cells from the bone marrow to peripheral blood. Granulocyte colony stimulating factor is also used clinically to repair irradiation and chemotherapy associated suppression of normal hematopoiesis in cancer patients, and to stimulate normal granulocyte develpment in patients with infantile congenital agranulocytosis. It is suggested that there may also be appropriate conditions under which in vitro colony forming cells have a wider differentiation potential similar to that shown by HSC. An essential part of the developmental program is cytokine suppression of apoptosis by changing the balance in expression of apoptosis inducing and suppressing genes. Decreasing the level of cytokines that suppress therapeutic induction of apoptosis in malignant cells can improve cancer therapy. Cytokines and some other compounds can reprogram abnormal developmental programs in leukemia, so that the leukemic cells differentiate to mature non dividing cells, and this can also be used for therapy. There is considerable plasticity in the developmental programs of normal and malignant cells.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sachs, L (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	leo.sachs@weizmann.ac.il						ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Amanullah A, 2000, BLOOD, V96, P475; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Attardi LD, 2000, GENE DEV, V14, P704; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN L, 1981, P NATL ACAD SCI-BIOL, V78, P353, DOI 10.1073/pnas.78.1.353; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEGOS L, 1992, INT J CELL CLONING, V10, P63, DOI 10.1002/stem.5530100202; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FIBACH E, 1972, NATURE-NEW BIOL, V237, P276, DOI 10.1038/newbio237276a0; FIBACH E, 1976, J CELL PHYSIOL, V89, P259, DOI 10.1002/jcp.1040890209; FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gazitt Y, 2001, J HEMATOTH STEM CELL, V10, P229, DOI 10.1089/15258160151134908; GERASSI E, 1976, P NATL ACAD SCI USA, V73, P4546, DOI 10.1073/pnas.73.12.4546; GINSBURG H, 1963, J NATL CANCER I, V31, P1; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0; GRIFFIN JD, 1986, BLOOD, V68, P1185; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gurdon JB, 1999, NATURE, V402, P743, DOI 10.1038/45429; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; Horsfall MJ, 2000, BRIT J HAEMATOL, V109, P751, DOI 10.1046/j.1365-2141.2000.02108.x; Hultner L, 1989, GROWTH FACTORS, V2, P43, DOI 10.3109/08977198909069080; ICHIKAWA Y, 1967, P NATL ACAD SCI USA, V58, P1480, DOI 10.1073/pnas.58.4.1480; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1982, J IMMUNOL, V129, P2431; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; JACOBSEN SEW, 1991, BLOOD, V77, P1706; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kaplinsky C, 1996, LEUKEMIA, V10, P460; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LANDAU T, 1971, P NATL ACAD SCI USA, V68, P2540, DOI 10.1073/pnas.68.10.2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIN EY, 1993, J IMMUNOL, V151, P1979; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lotem J, 1997, P NATL ACAD SCI USA, V94, P9349, DOI 10.1073/pnas.94.17.9349; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1991, BLOOD, V78, P953; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1983, INT J CANCER, V32, P127, DOI 10.1002/ijc.2910320120; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; LOTEM J, 1992, BLOOD, V80, P1750; Lotem J, 1996, LEUKEMIA, V10, P925; LOTEM J, 1991, CELL GROWTH DIFFER, V2, P421; LOTEM J, 1986, EMBO J, V5, P2163, DOI 10.1002/j.1460-2075.1986.tb04480.x; LOTEM J, 1989, BLOOD, V74, P579; LOTEM J, 1987, INT J CANCER, V40, P532, DOI 10.1002/ijc.2910400417; LOTEM J, 1992, LEUKEMIA, V6, P426; LOTEM J, 1981, INT J CANCER, V28, P375, DOI 10.1002/ijc.2910280318; LOTEM J, 1988, BLOOD, V71, P375; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; LOTEM J, 1984, INT J CANCER, V33, P147, DOI 10.1002/ijc.2910330122; LOTEM J, 1990, BLOOD, V76, P1315; LOTEM J, 1977, P NATL ACAD SCI USA, V74, P5554, DOI 10.1073/pnas.74.12.5554; LOTEM J, 1974, P NATL ACAD SCI USA, V71, P3507, DOI 10.1073/pnas.71.9.3507; LOTEM J, 1982, P NATL ACAD SCI-BIOL, V79, P4347, DOI 10.1073/pnas.79.14.4347; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Lotem J, 1999, APOPTOSIS, V4, P187, DOI 10.1023/A:1009614723237; LOTEM J, 1995, LEUKEMIA, V9, P685; LOTEM J, 1978, P NATL ACAD SCI USA, V75, P3781, DOI 10.1073/pnas.75.8.3781; LOTEM J, 2002, IN PRESS SEM CANC BI; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; METCALF D, 1975, J EXP MED, V142, P1534, DOI 10.1084/jem.142.6.1534; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PARAN M, 1969, J CELL PHYSIOL, V73, P91, DOI 10.1002/jcp.1040730113; PARAN M, 1970, P NATL ACAD SCI USA, V67, P1542, DOI 10.1073/pnas.67.3.1542; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; PLUZNIK DH, 1966, EXP CELL RES, V43, P553, DOI 10.1016/0014-4827(66)90026-7; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Renne C, 1998, J BIOL CHEM, V273, P27213, DOI 10.1074/jbc.273.42.27213; SACHS L, 1980, P NATL ACAD SCI-BIOL, V77, P6152, DOI 10.1073/pnas.77.10.6152; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SACHS L, 1986, SCI AM, V254, P40, DOI 10.1038/scientificamerican0186-40; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SACHS L, 1987, PROC R SOC SER B-BIO, V231, P289, DOI 10.1098/rspb.1987.0045; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SACHS L, 1995, ADV CANCER RES, V66, P1, DOI 10.1016/S0065-230X(08)60250-X; Sachs L, 1982, CANCER SURV, V1, P321; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; SCHNEIDER E, 1991, BLOOD, V78, P329; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHABO Y, 1989, LEUKEMIA, V3, P859; SHABO Y, 1988, BLOOD, V72, P2070; SHABO Y, 1989, MOL CELL BIOL, V9, P4109, DOI 10.1128/MCB.9.9.4109; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STEPHENSON JR, 1971, P NATL ACAD SCI USA, V68, P1542, DOI 10.1073/pnas.68.7.1542; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS G, 1983, EMBO J, V2, P663, DOI 10.1002/j.1460-2075.1983.tb01481.x; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEBB CG, 1984, DEV BIOL, V101, P221, DOI 10.1016/0012-1606(84)90132-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Welniak LA, 2001, J IMMUNOL, V166, P2923, DOI 10.4049/jimmunol.166.5.2923; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	166	92	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3284	3294		10.1038/sj.onc.1205319	http://dx.doi.org/10.1038/sj.onc.1205319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032770				2022-12-17	WOS:000175633300005
J	Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D				Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D			A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining	ONCOGENE			English	Article						BRCA1; DNA repair; double strand break; end-joining fidelity; heterozygous state	HISTONE H2AX; DNA; REPAIR; CANCER; CELLS; COMPLEX; IDENTIFICATION; REARRANGEMENTS; RECOMBINATION; ASSOCIATION	Heterozygosity for mutations in the BRCA1 gene in humans confers high risk for developing breast cancer, but a biochemical basis for this phenotype has not yet been determined. Evidence has accumulated implicating BRCA1, in the maintenance of genomic integrity and the protection of cells against DNA double strand breaks (DSB). Here we present evidence that human cells heterozygous for BRCA1 mutations exhibit impaired DNA end-joining, which is the major DSB repair pathway in mammalian somatic cells. Using an in vivo host cell end-joining assay, we observed that the fidelity of DNA end-joining is strongly reduced in three BRCA1(+/-) cell lines in comparison to two control cell lines. Moreover, cell-free BRCA1(+/-) extracts are unable to promote accurate DNA end-joining in an in vitro reaction. The steady-state level of the wild type BRCA1 protein was significantly lower than the 50% expected in BRCA1(+/-) cells and thus may underlie the observed end-joining defect. Together, these data strongly suggest that BRCA1 is necessary for faithful rejoining of broken DNA ends and that a single mutated BRCA1 allele is sufficient to impair this process. This defect will compromise genomic stability in BRCA1 germ-line mutation carriers, triggering the genetic changes necessary for the initiation of neoplastic transformation.	CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France; Sect Med, Inst Curie, Serv Genet Oncol, F-75248 Paris 05, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Papadopoulo, D (corresponding author), CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France.	papadopoulo@curie.fr	Feunteun, Jean/AAZ-1267-2020; Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523; GAD (LAPITEAU), Sophie/0000-0002-3158-6791; Feunteun, Jean/0000-0003-1212-9189				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; GOVEN LC, 1998, SCIENCE, V281, P1009; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Le Page F, 2000, CANCER RES, V60, P5548; Lee MS, 2000, ENDOCRINOLOGY, V141, P883, DOI 10.1210/en.141.3.883; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Pluth JM, 2001, CANCER RES, V61, P2649; Puget N, 1999, CANCER RES, V59, P455; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	37	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1401	1410		10.1038/sj.onc.1205200	http://dx.doi.org/10.1038/sj.onc.1205200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857083				2022-12-17	WOS:000173861000010
J	Dinda, S; Sanchez, A; Moudgil, V				Dinda, S; Sanchez, A; Moudgil, V			Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells	ONCOGENE			English	Article						estrogen; thyroid hormone; p53; retinoblastoma protein; tumor suppressor proteins; breast cancer	RECEPTOR; PROLIFERATION; ACTIVATION; GENE; KINASE; PHOSPHORYLATION; ANTIPROGESTINS; PROGESTIN; PROMOTER; BIOLOGY	T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E-2) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the effects of E-2 and triiodothyronine (T-3) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon confluency, the cells were treated with T-3 (10 (12) to 10(-7) M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E-2 treatment of cells caused a 2-3-fold increase in the level of p53. Presence of T-3 in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS-PAGE) in the presence of E-2 and T-3. Supplementation of growth medium with T-3 (1 muM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this effect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 muM), an ER antagonist, was combined with E-2 (1 muM) or T-3 (1 muM), effects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal fluorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T-3 for the [H-3]E-2 binding. These results indicate that T-3 regulates T47D cell cycle progression and proliferation raising the p53 level and causing hyperphosphorylation of pRb by a common mechanism involving ER and T-3 receptor (T3R)-mediated pathways.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA; Oakland Univ, Ctr Biomed Res, Rochester, MI 48309 USA	Oakland University; Oakland University	Moudgil, V (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.							ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Blohmer J U, 1999, Zentralbl Gynakol, V121, P522; BURKE RE, 1978, CANCER RES, V38, P3769; CERBON MA, 1981, CANCER RES, V41, P4167; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Dellovade TL, 1999, NEUROENDOCRINOLOGY, V70, P168, DOI 10.1159/000054473; Dellovade TL, 2000, NAT NEUROSCI, V3, P472, DOI 10.1038/74846; DELLOVADE TL, 1995, J STEROID BIOCHEM, V53, P27, DOI 10.1016/0960-0760(95)00037-Z; DINDA S, 1998, P 80 ANN M END SOC N; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKLYN JA, 1988, CLIN ENDOCRINOL, V29, P337, DOI 10.1111/j.1365-2265.1988.tb01232.x; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hurd C, 1999, ONCOGENE, V18, P1067, DOI 10.1038/sj.onc.1202398; Iwasaki K, 1999, MOL CELL BIOCHEM, V198, P141, DOI 10.1023/A:1006945813508; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; Lin HY, 1999, BIOCHEM J, V338, P427, DOI 10.1042/0264-6021:3380427; Morgan MA, 2000, HORM BEHAV, V37, P15, DOI 10.1006/hbeh.1999.1553; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nogueira CR, 1996, J STEROID BIOCHEM, V59, P271, DOI 10.1016/S0960-0760(96)00117-3; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; Parhar IS, 2000, ENDOCRINOLOGY, V141, P1618, DOI 10.1210/en.141.5.1618; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; SHAO ZM, 1995, EXP CELL RES, V218, P1, DOI 10.1006/excr.1995.1124; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; WAFIK S, 1994, CANCER RES, V54, P1169; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273	38	92	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					761	768		10.1038/sj.onc.1205136	http://dx.doi.org/10.1038/sj.onc.1205136			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850804				2022-12-17	WOS:000173427000007
J	Seth, P; Krop, I; Porter, D; Polyak, K				Seth, P; Krop, I; Porter, D; Polyak, K			Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)	ONCOGENE			English	Article						estrogen; tamoxifen; SAGE (Serial Analysis of Gene Expression); breast cancer	SURGICAL ADJUVANT BREAST; FACTOR-RESPONSIVE GENE; MESSENGER-RNAS; CANCER; GROWTH; SM-20; POLYMORPHISM; DISPLAY	The breast cancer promoting effects of estrogen and the chemopreventive effects of tamoxifen are thought to be mediated by the estrogen receptor, a ligand-dependent transcription factor. Therefore, comprehensive analysis of gene expression profiles following estrogen or tamoxifen treatment may help us better understand the role estrogen plays in tumorigenesis. We utilized SAGE (Serial Analysis of Gene Expression) technology to identify genes regulated by estrogen and tamoxifen in the ZR75-1 estrogen dependent breast cancer cell line. In this manner we have identified several genes that were regulated by estrogen or tamoxifen. Here we report the identification and initial characterization of EIT-6 (Estrogen Induced Tag-6), a novel nuclear protein and a new member of the evolutionarily conserved SM-20 family of growth regulatory immediate-early genes. EIT-6 appears to be a direct transcriptional target of the estrogen receptor and constitutive expression of EIT-6 promotes colony growth in human breast cancer cells. These data indicate that EIT-6 may play a role in estrogen induced cell growth.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Polyak, K (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St D740C, Boston, MA 02115 USA.	Kornelia_Polyak@dfci.harvard.edu						Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Charpentier AH, 2000, CANCER RES, V60, P5977; deCupis A, 1997, TRENDS PHARMACOL SCI, V18, P245, DOI 10.1016/S0165-6147(97)90632-5; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Lal A, 1999, CANCER RES, V59, P5403; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANNING DL, 1990, CANCER RES, V50, P4098; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Nakashiro K, 1998, CANCER RES, V58, P549; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter DA, 2001, CANCER RES, V61, P5697; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Seth P, 2000, CANCER RES, V60, P6859; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; TRENT C, 1983, GENETICS, V104, P619; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAX SD, 1994, J BIOL CHEM, V269, P13041; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89	41	92	97	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					836	843		10.1038/sj.onc.1205113	http://dx.doi.org/10.1038/sj.onc.1205113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850811				2022-12-17	WOS:000173427000014
J	Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL				Ng, PWP; Iha, H; Iwanaga, Y; Bittner, M; Chen, YD; Jiang, Y; Gooden, G; Trent, JM; Meltzer, P; Jeang, KT; Zeichner, SL			Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappa B activation	ONCOGENE			English	Article						HTLV-1; Tax; microarray; gene expression; MLK-3; JPX-9	T-CELL LEUKEMIA; VIRUS TYPE-I; VIRAL TRANSACTIVATOR TAX; HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN-KINASE; TYPE-1 TAX; MOLECULAR-MECHANISMS; CYCLE PROGRESSION; 1-INFECTED CELLS	The Tax protein of human T-lymphotropic virus type 1 (HTLV-1), an oncoprotein that transactivates viral and cellular genes, plays a key role in HTLV-1 replication and pathogenesis. We used cDNA microarrays to examine Tax-mediated transcriptional changes in the human Jurkat T-cell lines JPX-9 and JPX-M which express Tax and Tax-mutant protein, respectively, under the control of an inducible promoter. Approximately 300 of the over 2000 genes examined were differentially expressed in the presence of Tax. These genes were grouped according to their function and are discussed in the context of existing findings in the literature. There was strong agreement between our results and genes previously reported as being Tax-responsive. Genes that were differentially expressed in the presence of Tax included those related to apoptosis, the cell cycle and DNA repair, signaling factors, immune modulators, cytokines and growth factors, and adhesion molecules. Functionally, we provide evidence that one of these genes, the mixed-lineage kinase MLK-3, is involved in Tax-mediated NF-kappaB signaling. Our current results provide additional insights into Tax-mediated signaling.	NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Zeichner, SL (corresponding author), NCI, HIV & AIDS Malignancy Branch, NIH, Bldg 10,Room 10S255, Bethesda, MD 20892 USA.	kj7e@nih.gov; zeichner@nih.gov	Jeang, Kuan-Teh/A-2424-2008	Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.3.CO;2-L; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FLORENES VA, 1992, CANCER RES, V52, P6088; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; Mori N, 2000, BLOOD, V95, P3915; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; Ratajczak MZ, 1997, BRIT J HAEMATOL, V99, P228, DOI 10.1046/j.1365-2141.1997.3563170.x; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; To CTT, 1998, ONCOL REP, V5, P1013; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe T, 1997, INT J HEMATOL, V66, P257; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	75	92	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4484	4496		10.1038/sj.onc.1204513	http://dx.doi.org/10.1038/sj.onc.1204513			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494144				2022-12-17	WOS:000170074900006
J	Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A				Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A			Smad7 inhibits the survival nuclear factor kappa B and potentiates apoptosis in epithelial cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; Smad7	PROTEIN-KINASE B/AKT; ACTIVATION; RAS; INSULIN; PATHWAY; GENES; DEATH	In this study, we examined the effect of the stable expression of Smad7 in two different cell lines on apoptosis induced by various stimuli including TGF-beta, serum withdrawal, loss of cell adhesion (anoikis) and TNF-alpha. Smad7 increased TGF-beta -mediated apoptosis in Mv1Lu cells as well as anoikis and/or serum withdrawal-induced apoptosis in Mv1Lu and MDCK cells. Smad7 markedly decreased the activity of the survival NF-kappaB transcription factor in MDCK cells, Interestingly, the stable expression of oncogenic Ras in MDCK cells which suppressed Smad7 inhibition of NF-kappaB also suppressed Smad7 potentiation of serum withdrawal-induced apoptosis and anoikis, In addition, Smad7 inhibited TNF-alpha stimulation of NF-kappaB and increased TNF-alpha -mediated apoptosis in MDCK cells. Our results provide the first evidence that Smad7 induces sensitization of cells to different forms of cell death. They moreover demonstrate that Smad7 inhibits the survival NF-kappaB factor, providing a potential mechanism whereby Smad7 potentiates cell death.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U402, F-75571 Paris, France; Hoechst Marion Roussel, Romainville, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Roman-Roman, Sergio/K-9993-2014; Frottier, Celine Prunier/G-8259-2017	Roman-Roman, Sergio/0000-0001-6459-2613; Frottier, Celine Prunier/0000-0002-7784-0273				Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bitzer M, 2000, GENE DEV, V14, P187; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	25	92	99	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					879	884		10.1038/sj.onc.1204167	http://dx.doi.org/10.1038/sj.onc.1204167			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314022				2022-12-17	WOS:000166924400012
J	Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A				Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A			Regulation of Pax3 transcriptional activity by SUMO-1-modified PML	ONCOGENE			English	Article						PML; SUMO; Pax3; Daxx; nuclear bodies	TUMOR ALVEOLAR RHABDOMYOSARCOMA; PROMYELOCYTIC LEUKEMIA FUSES; NUCLEAR-PORE COMPLEX; PAIRED BOX GENE; COVALENT MODIFICATION; WAARDENBURG SYNDROME; INTERACTING PROTEIN; BINDING PROTEIN; DOMAIN GENE; RAR-ALPHA	Pax3 is an evolutionarily conserved transcription factor that plays a major role in a variety of developmental processes, Mutations in Pax3 lead to severe malformations as seen in human Waardenburg syndrome and in the Splotch mutant mice. The transcriptional activity of Pax3 was recently shown to be repressed by Daxx whereas the oncogenic fusion protein Pax3-FKHR is unresponsive to this repressive action. Here we demonstrate that Daxx-mediated repression of Pax3 can be inhibited by the nuclear body (NB)-associated protein PML, Interestingly, this suppression of Daxx properties correlates with its recruitment to the NBs, Factors such as arsenicals and interferons that enhance NE formation, trigger both the targeting of Daxx to these nuclear structures and the relief of the repressive activity of Daxx, Conversely, lack of structurally intact NBs profoundly impairs Pax3 transcriptional activity, likely by increasing the pool of available nucleoplasmic Daxx, Moreover, a PML mutant that can not be modified by the ubiquitin-related SUMO-1 modifier is no more able to interact with Daxx, Consistently, such a mutant fails both to inhibit the Daxx repressing effect on Pax3 and to induce its accumulation into the NBs, Taken together, these results argue that SUMO-I modified PML can derepress Pax3 transcriptional activity through sequestration of the Daxx repressor into the NBs and suggest a role for these nuclear structures in the transcriptional control by Pax proteins.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	Muller, Stefan/0000-0002-8792-7700				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pluta AF, 1998, J CELL SCI, V111, P2029; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	50	92	95	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					1	9		10.1038/sj.onc.1204063	http://dx.doi.org/10.1038/sj.onc.1204063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244500				2022-12-17	WOS:000166361400001
J	Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G				Asaad, NA; Zeng, ZC; Guan, J; Thacker, J; Iliakis, G			Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants	ONCOGENE			English	Article						caffeine; DNA; Double Strand Breaks (DSB); repair; homologous recombination; non-homologous end joining	IRRADIATED HELA-CELLS; DOUBLE-STRAND BREAKS; RADIATION-SENSITIVE MUTANT; INDUCED CHROMOSOMAL-ABERRATIONS; INDUCED G2 DELAY; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; CHO-CELLS; PROTEIN-KINASE	The radiosensitizing effect of caffeine has been associated with the disruption of multiple DNA damage-responsive cell cycle checkpoints, but several lines of evidence also implicate inhibition of DNA repair. The role of DNA repair inhibition in caffeine radiosensitization remains uncharacterized, and it is unknown which repair process, or lesion, is affected. We show that a radiosensitive cell line, mutant for the RAD51 homolog XRCC2 and defective in homologous recombination repair (HRR), displays significantly diminished caffeine radiosensitization that can be restored by expression of XRCC2, Despite the reduced radiosensitization, caffeine effectively abrogates checkpoints in S and G2 phases in XRCC2 mutant cells indicating that checkpoint abrogation is not sufficient for radiosensitization, Another radiosensitive line, mutant for XRCC3 and defective in HRR, similarly shows reduced caffeine radiosensitization, On the other hand, a radiosensitive mutant (irs-20) of DNA-PKcs with a defect in non-homologous end-joining (NHEJ) is radiosensitized by caffeine to an extent comparable to wild-type cells. In addition, rejoining of radiation-induced DNA DSBs, that mainly reflects NHEJ, remains unaffected by caffeine in XRCC2 and XRCC3 mutants, or their wild-type counterparts. These observations suggest that caffeine targets steps in HRR but not in NHEJ and that abrogation of checkpoint response is not sufficient to explain radiosensitization, Indeed, immortalized fibroblasts from AT patients show caffeine radiosensitization despite the checkpoint defects associated with ATM mutation. We propose that caffeine radiosensitization is mediated by inhibition of stages in DNA DSB repair requiring HRR and that checkpoint disruption contributes by allowing these DSBs to transit into irreparable states. Thus, checkpoints may contribute to genomic stability by promoting error-free HRR.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England	Jefferson University	Iliakis, G (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,Rm B-1, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P30CA056036, R01CA042026] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA42026, P30-CA56036] Funding Source: Medline; PHS HHS [56706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Bebb DG, 1998, MUTAT RES-FUND MOL M, V401, P27, DOI 10.1016/S0027-5107(97)00214-5; BEETHAM KL, 1982, RADIAT RES, V91, P199, DOI 10.2307/3575827; BEETHAM KL, 1984, RADIAT RES, V100, P104, DOI 10.2307/3576526; BEETHAM KL, 1986, RADIAT RES, V107, P272, DOI 10.2307/3576814; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; Dibiase SJ, 2000, CANCER RES, V60, P1245; DOMON M, 1969, RADIAT RES, V39, P207, DOI 10.2307/3572642; FABRE F, 1972, MOL GEN GENET, V117, P153, DOI 10.1007/BF00267612; FAN SJ, 1995, CANCER RES, V55, P1649; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; FURCINITTI PS, 1993, RADIAT RES, V95, P197; GARATTINI S, 1993, CAFFEINE COFFEE HLTH, P1; GENTNER NE, 1981, MOL GEN GENET, V181, P283, DOI 10.1007/BF00425598; GENTNER NE, 1978, MOL GEN GENET, V167, P43, DOI 10.1007/BF00270320; GRIFFITHS TD, 1978, INT J RADIAT BIOL, V33, P493, DOI 10.1080/09553007814550401; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HANSSON K, 1984, HUM GENET, V67, P329, DOI 10.1007/BF00291363; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY AN, 1994, MUTAT RES, V304, P203, DOI 10.1016/0027-5107(94)90212-7; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; ILIAKIS G, 1983, RADIAT RES, V95, P87, DOI 10.2307/3576074; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEHMANN AR, 1972, BIOPHYS J, V12, P1316, DOI 10.1016/S0006-3495(72)86165-4; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOPRIENO N, 1973, MUTAT RES, V21, P275; LOPRIENO N, 1974, MUTAT RES, V26, P83, DOI 10.1016/S0027-5107(74)80038-2; LOPRIENO N, 1971, MOL GEN GENET, V110, P348, DOI 10.1007/BF00438276; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; MURNANE JP, 1980, NATURE, V285, P326, DOI 10.1038/285326a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; MUSK SRR, 1991, RADIAT RES, V125, P262, DOI 10.2307/3578108; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NASIM A, 1974, MOL GEN GENET, V132, P13, DOI 10.1007/BF00268226; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; PAINTER RB, 1980, J MOL BIOL, V143, P289, DOI 10.1016/0022-2836(80)90191-6; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PAWLAK AL, 1990, MUTAT RES, V230, P197, DOI 10.1016/0027-5107(90)90057-B; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; POWELL SN, 1995, CANCER RES, V55, P1643; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rowley R, 1999, GENETICS, V152, P61; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shinomiya N, 1997, CYTOMETRY, V27, P365, DOI 10.1002/(SICI)1097-0320(19970401)27:4<365::AID-CYTO8>3.3.CO;2-F; SIEDE W, 1985, RADIAT ENVIRON BIOPH, V24, P1, DOI 10.1007/BF01212648; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; STACKHOUSE MA, 1994, INT J RADIAT BIOL, V65, P571, DOI 10.1080/09553009414550661; STACKHOUSE MA, 1993, RADIAT RES, V136, P250, DOI 10.2307/3578618; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TATSUMI K, 1979, J MOL BIOL, V135, P435, DOI 10.1016/0022-2836(79)90445-5; TAYLOR YC, 1993, INT J RADIAT BIOL, V64, P57, DOI 10.1080/09553009314551111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; TIMSON J, 1977, MUTAT RES, V47, P1, DOI 10.1016/0165-1110(77)90016-1; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WANG H, 2000, UNPUB; Wang SW, 1999, J CELL SCI, V112, P927; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZAMPETTIBOSSELER F, 1985, MUTAT RES, V143, P251, DOI 10.1016/0165-7992(85)90089-2; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	100	92	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5788	5800		10.1038/sj.onc.1203953	http://dx.doi.org/10.1038/sj.onc.1203953			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126366				2022-12-17	WOS:000165477700011
J	Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R				Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R			IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE(2) synthesis in Caco-2 human colon carcinoma cells	ONCOGENE			English	Article						IGF-II; IGF-Ir; COX-2; PGE(2); colon cancer	GROWTH-FACTOR-I; ENTEROCYTE-LIKE DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; MESSENGER-RNA EXPRESSION; NF-KAPPA-B; CANCER-CELLS; CYCLOOXYGENASE-2 EXPRESSION; COLORECTAL-CANCER; PROSTAGLANDIN E-2; EPITHELIAL-CELLS	Nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer and this effect is mediated in part through inhibition of type 2 prostaglandin endoperoxide synthase/cyclo-oxygenase (COX-2). In the present study, me demonstrate that COX-2 expression and PGE(2) synthesis are up-regulated by an IGF-II/IGF-I receptor autocrine pathway in Caco-2 colon carcinoma cells. COX-2 mRNA and PGE(2) levels are higher in proliferating cells compared with post-confluent differentiated cells and in cells that constitutively overexpress IGF-II, Up-regulation of COX-2 expression by IGF-II is mediated through activation of IGF-I receptor because: (i) treatment of Caco-2 cells with a blocking antibody to the IGF-I receptor inhibits COX-2 mRNA expression; (ii) transfection of Caco-2 cells with a dominant negative IGF-I receptor reduces COX-2 expression and activity, Also, the blockade of the PI3-kinase, that mediates the proliferative effect of IGF-I receptor in Caco-2 cells, inhibits IGF-II-dependent COX-2 up-regulation and PGE(2) synthesis. Moreover, COX-2 expression and activity inversely correlate with the increase of apoptosis in parental, IGF-II and dominant-negative IGF-I receptor transfected cells. This study suggests that induction of proliferation and tumor progression of colon cancer cells by the IGF-II/IGF-I receptor pathway may depend on the activation of COX-2-related events.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, I-80131 Naples, Italy; II Ateneo Napoli, Dipartimento Internist Clin & Sperimentale, Div Gastroenterol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Acquaviva, AM (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Ricchi, Paolo/J-5140-2019; Zarrilli, Raffaele/F-5067-2012	Ricchi, Paolo/0000-0001-7361-3308; Zarrilli, Raffaele/0000-0003-4191-9032; ACQUAVIVA, Angela Maria/0000-0001-9538-2766				Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; Garrouste FL, 1997, ENDOCRINOLOGY, V138, P2021, DOI 10.1210/en.138.5.2021; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KATO H, 1993, J BIOL CHEM, V268, P2655; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; PINTO M, 1983, BIOL CELL, V47, P323; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; PODOLSKY DK, 1993, AM J PHYSIOL, V264, P179; POMMIER GJ, 1992, CANCER RES, V52, P3182; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ricchi P, 1997, INT J CANCER, V73, P880; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUBIN R, 1995, LAB INVEST, V73, P311; Sheng HM, 1998, CANCER RES, V58, P362; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Zarrilli R, 1999, AM J GASTROENTEROL, V94, P3376, DOI 10.1111/j.1572-0241.1999.03376.x; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zarrilli R, 1999, GASTROENTEROLOGY, V116, P1358, DOI 10.1016/S0016-5085(99)70500-7; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	40	92	96	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5517	5524		10.1038/sj.onc.1203952	http://dx.doi.org/10.1038/sj.onc.1203952			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114729				2022-12-17	WOS:000165396100012
J	Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z				Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z			Mutations in the beta-propeller domain of the Drosophila brain tumor (brat) protein induce neoplasm in the larval brain	ONCOGENE			English	Article						invertebrate; tumorigenesis; tumor suppressor; neuroblastoma; plasmid rescue; NHL repeats	RNA-POLYMERASE-III; DECARBOXYLASE GENE-CLUSTER; RETINOBLASTOMA PROTEIN; SUPPRESSOR GENE; DOPA-DECARBOXYLASE; HUMAN HOMOLOG; RING FINGER; ZINC-FINGER; CAENORHABDITIS-ELEGANS; MALIGNANT NEOPLASMS	Inactivation of both alleles of the fruit fly D. melanogaster brain tumor (brat) gene results in the production of a tumor-like neoplasm in the larval brain, and lethality in the Larval third instar and pupal stages. We cloned the brat gene from a transposon-tagged allele and identified its gene product. hr nt encodes for an 1037 amino acid protein with an N-terminal B-box1 zinc finger followed ba a B-box2 zinc finger, a coiled-coil domain, and a C-terminal beta-propeller domain with six blades. All these motifs are known to mediate protein-protein interactions. Sequence analysis of four br at alleles revealed that all of them are mutated at the beta-propeller domain. The clustering of mutations in this domain strongly suggests that it has a crucial role in the normal function of Brat, and defines a novel protein motif involved in tumor suppression activity. The brat gene is expressed in the embryonic central and peripheral nervous systems including the embryonic brain. In third instar larva br nt expression was detected in the Larval central nervous sa stem including the brain and the ventral ganglion, in two glands - the ring gland and the salivary gland, and in parts of the foregut - the gastric caecae and the proventriculus. A second brat-like gene was found in D, melanogaster, and homologs were identified in the nematode, mouse, rat, and human. Accumulated data suggests that Brat may regulate proliferation and differentiation by secretion/transport mediated processes.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Technion Israel Institute of Technology; Johns Hopkins University	Lev, Z (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Arama, Eli/GYJ-0491-2022					Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CLINE TW, 1976, GENETICS, V83, pS16; DERENZINI M, 1991, VIRCHOWS ARCH B, V61, P1; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Frank DJ, 1998, J CELL BIOL, V140, P1321, DOI 10.1083/jcb.140.6.1321; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Gateff E, 1996, IN VIVO, V10, P211; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gateff E., 1978, GENETICS BIOL DROS B, V2b, P181; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; Hartenstein V., 1993, ATLAS DROSOPHILA DEV; HEDGECOCK EM, 1995, GENETICS, V141, P989; INOUYE S, 1986, EUR J BIOCHEM, V154, P417, DOI 10.1111/j.1432-1033.1986.tb09414.x; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McNellis TW, 1996, PLANT CELL, V8, P1491, DOI 10.1105/tpc.8.9.1491; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBERTSON HM, 1988, GENETICS, V118, P461; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; SMETANA K, 1970, CANCER RES, V30, P1149; Spradling AC, 1999, GENETICS, V153, P135; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; STATHAKIS DG, 1995, GENETICS, V141, P629; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK T, 1993, GENETICS, V135, P71; WATSON KL, 1994, J CELL SCI, P19; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015; WRIGHT TRF, 1976, GENETICS, V84, P287; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983	62	92	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3706	3716		10.1038/sj.onc.1203706	http://dx.doi.org/10.1038/sj.onc.1203706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949924				2022-12-17	WOS:000088568400002
J	Mils, V; Baldin, V; Goubin, F; Pinta, I; Papin, C; Waye, M; Eychene, A; Ducommun, B				Mils, V; Baldin, V; Goubin, F; Pinta, I; Papin, C; Waye, M; Eychene, A; Ducommun, B			Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase	ONCOGENE			English	Article						cell cycle; CDC25B phosphatase; 14-3-3 proteins; checkpoint	XENOPUS EGG EXTRACTS; DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; TYROSINE PHOSPHATASE; MITOTIC INDUCER; ACTIVATION; PHOSPHORYLATION; REGULATORS	CDC25 dual-specificity phosphatases are essential regulators that activate cyclin-dependent kinases (CDKs) at critical stages of the cell cycle. In human cells, CDC25A and C are involved in the control of G1/S and G2/M respectively, whereas CDC25B is proposed to act both in S phase and G2/M. Evidence for an interaction between CDC25 phosphatases and members of the 14-3-3 protein family has been obtained in vitro and in vivo in several organisms. On the basis of the work performed with CDC25C, it has been proposed that phosphorylation is required to mediate the interaction with 14-3-3. Here we have examined the molecular basis of the interaction between CDC25B phosphatases and 14-3-3 proteins. We show that in the two-hybrid assay all three splice variants of CDC25B interact similarly and strongly with 14-3-3 eta, beta and zeta proteins, but poorly with epsilon and theta. In vitro, CDC25B interacts at a low level with 14-3-3 beta, epsilon, zeta, eta, and theta isoforms. This interaction is not increased upon phosphorylation of CDC25B by CHK1 and is not abolished by dephosphorylation. In contrast, a specific, strong interaction between CDC25B and 14-3-3 zeta and eta isoforms is revealed by a deletion of 288 residues in the amino-terminal region of CDC25B. This interaction requires the integrity of Ser 323, although it is independent of phosphorylation. Thus, interaction between 14-3-3 proteins and CDC25B is regulated in a manner that is different from that with CDC25C. We propose that, in addition to a low affinity binding site that is available for all 14-3-3 isoforms, post-translational modification of CDC25B in vivo exposes a high-affinity binding site that is specific for the zeta and eta 14-3-3 isoforms.	Univ Toulouse 3, CNRS, LBCMCP, F-31062 Toulouse, France; Ctr Univ Orsay, Inst Curie Rech, Lab Oncogenese REtrovirale & Mol, CNRS,UMR 146, F-91405 Orsay, France; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Chinese University of Hong Kong	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP, 118 Route Narbonne, F-31062 Toulouse, France.		Eychene, Alain/M-8838-2017; BALDIN, Véronique/Y-8397-2019; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; DUCOMMUN, Bernard/0000-0002-7126-8368; EYCHENE, Alain/0000-0002-6818-7225				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; BALDIN V, 1999, PROGR CYCLE RES, V4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGATA A, 1991, NEW BIOL, V3, P959; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5144; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Xu X, 1996, J BIOL CHEM, V271, P5118; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	43	92	93	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1257	1265		10.1038/sj.onc.1203419	http://dx.doi.org/10.1038/sj.onc.1203419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713667				2022-12-17	WOS:000085743800002
J	Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M				Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M			Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product	ONCOGENE			English	Article						PTTG; cell cycle; proliferation; phosphorylation; Cdc2	MITOSIS-SPECIFIC PHOSPHORYLATION; TUMOR-TRANSFORMING GENE; DEPENDENT KINASES; MICROTUBULE DYNAMICS; HUMAN HOMOLOG; CDC2 KINASE; M-PHASE; PROTEINS; P34CDC2; IDENTIFICATION	We recently isolated a cDNA for hpttg, the human homolog of rat pituitary tumor transforming gene, Now we have analysed the expression of hpttg as a function of cell proliferation. hPTTG protein level is up-regulated in rapidly proliferating cells, is down-regulated in response to serum starvation or cell confluence, and is regulated in a cell cycle-dependent manner, peaking in mitosis, In addition, we show that hPTTG is phosphorylated during mitosis. Immunodepletion and in vitro phosphorylation experiments, together with the use of a specific inhibitor, indicate that Cdc2 is the kinase that phosphorylates hPTTG. These results suggest that hpttg is induced by, and may have a role in, regulatory pathways involved in the control of cell proliferation.	Univ Seville, Dept Microbiol, Fac Biol, E-41080 Seville, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Rhone Poulenc Rorer, CRVA, F-94403 Vitry Sur Seine, France	University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Sanofi-Aventis; Sanofi France	Ramos-Morales, F (corresponding author), Univ Seville, Dept Microbiol, Fac Biol, Apdo 1095, E-41080 Seville, Spain.		Romero, Francisco/K-2101-2014; Ramos-Morales, Francisco/C-5734-2008; Tortolero, Maria/K-5744-2014; LUNA, ROSA/F-3974-2016; Pintor-Toro, Jose/L-4737-2014	Romero, Francisco/0000-0002-9588-6881; Ramos-Morales, Francisco/0000-0002-1151-4547; Tortolero, Maria/0000-0003-1797-9940; LUNA, ROSA/0000-0002-6131-6610; Pintor-Toro, Jose/0000-0002-9060-5243				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; BUDAY L, 1995, ONCOGENE, V11, P1327; BUENDIA B, 1991, COLD SPRING HARB SYM, V56, P523; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HERSHKOVITZ M, 1995, P NATL ACAD SCI USA, V92, P2379, DOI 10.1073/pnas.92.6.2379; HIRAMA T, 1995, BLOOD, V86, P841; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Reed SI, 1997, CANCER SURV, V29, P7; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					403	409		10.1038/sj.onc.1203320	http://dx.doi.org/10.1038/sj.onc.1203320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656688				2022-12-17	WOS:000084873700011
J	Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH				Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH			Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis	ONCOGENE			English	Article						Dlk/ZIP kinase; two hybrid interaction screen; leucine zipper; Par-4; actin filaments; apoptosis	ATAXIA-TELANGIECTASIA GENE; SERINE THREONINE KINASE; ZIPPER PROTEIN PAR-4; LEUCINE-ZIPPER; SERINE/THREONINE KINASE; MOLECULAR-CLONING; CATALYTIC DOMAIN; DNA-BINDING; HUMAN BRAIN; CELL-DEATH	Dlk/ZIP kinase is a newly discovered serine/threonine kinase which, due to its homology to DAP kinase, was named DAP like kinase, Dlk. This kinase is tightly associated with nuclear structures, it undergoes extensive autophosphorylation and phosphorylates myosin light chain and core histones H3, H2A and H4 in vitro. Moreover, it possesses a leucine zipper which mediates interaction with transcription factor ATF-4, therefore it was called ZIP kinase. We employed the yeast two-hybrid system to identify interaction partners of Dlk that might serve as regulators or targets. Besides ATF-4 and others we found Par-4, a modulator of transcription factor WT1 and mediator of apoptosis. Complex formation between Dlk and Par-4 was confirmed by GST pull-down experiments and kinase reactions in vitro and coexpression experiments in vivo. The interaction domain within Dlk was mapped to an arginine-rich region between residues 338-417, rather than to the leucine zipper. Strikingly, coexpression of Dlk and Par-4 lead to relocation of Dlk from the nucleus to the cytoplasm, particularly to actin filaments. These interactions provoked a dramatic reorganization of the cytoskeleton and morphological symptoms of apoptosis, thus suggesting a functional relationship between Dlk and Par-4 in the control of apoptosis.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Kentucky, Lexington, KY 40536 USA	University of Bonn; University of Kentucky	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MULLER E, 1995, ONCOGENE, V10, P1175; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sambrook J, 1989, MOL CLONING LAB MANU; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854	48	92	99	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7265	7273		10.1038/sj.onc.1203170	http://dx.doi.org/10.1038/sj.onc.1203170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602480				2022-12-17	WOS:000084119400010
J	Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K				Takao, N; Kato, H; Mori, R; Morrison, C; Sonada, E; Sun, XG; Shimizu, H; Yoshioka, K; Takeda, S; Yamamoto, K			Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation	ONCOGENE			English	Article						ATM disruption; p53; cell cycle checkpoint; DNA repair	ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK REPAIR; CYCLE CHECKPOINTS; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; DNA-DAMAGE; NUCLEOTIDE-SEQUENCE; DEFICIENT MICE; P53; DEFECTS	ATM is a member of the large phosphatidylinositol-3 kinase family and plays an important role in cellular response to DNA damage. To further define the physiological roles of ATM at the cellular level, me created an isogenic set of stable cell lines differing only in their ATM status from the chicken B cell line DT40 by targeted integration. These stable DT40 cell lines, as most of transformed chicken cell lines, do not express p53. However, ATM(-/-) DT40 cells displayed retarded cellular proliferation, defective G(2)/M checkpoint control and radio-resistant DNA synthesis. Furthermore, ATM(-/-) DT40 cells were sensitive to ionizing radiation and showed highly elevated frequencies of both spontaneous and radiation-induced chromosomal aberrations. In addition, a slight but significant reduction in targeted integration frequency was observed in,ATM(-/-) DT40 cells. These results suggest that ATM has multiple p53-independent functions in cell cycle checkpoint control and in maintenance of chromosomal DNA. These ATM deficient DT40 clones therefore provide a useful model system for analysing p53-independent ATM functions.	Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Fac Med, Kanazawa, Ishikawa 9200934, Japan; Kyoto Univ, Fac Med, Dept Radiat Genet, Kyoto 6068501, Japan	Kanazawa University; Kanazawa University; Kyoto University	Yamamoto, K (corresponding author), Kanazawa Univ, Fac Med, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan.		Morrison, Ciaran/AAH-2034-2019; Morrison, Ciaran/B-6568-2008	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Mori, Ryoichi/0000-0002-7596-9620; Takeda, Shunichi/0000-0002-7924-7991				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BUERSTEDDE JM, 1991, CELL, V82, P685; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; *ISCN1985, 1985, REP STAND COMM HUM C; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WESTPHAL CH, 1997, CANCER RES, V57, P164; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	92	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7002	7009		10.1038/sj.onc.1203172	http://dx.doi.org/10.1038/sj.onc.1203172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597300				2022-12-17	WOS:000083901900006
J	Heusch, M; Lin, L; Geleziunas, R; Greene, WC				Heusch, M; Lin, L; Geleziunas, R; Greene, WC			The generation of nfkb2 p52: mechanism and efficiency	ONCOGENE			English	Article						nfkb2; cotranslational processing; p52; p100; proteasome	NF-KAPPA-B; DNA-BINDING SUBUNIT; SPLENIC MICROARCHITECTURE; GENE-PRODUCT; PROTEINS; SIGNAL; TRANSCRIPTION; TRANSLOCATION; ACTIVATION; PROTEASOME	nfkb2 encodes two members of the NF-kappa B/Rel family of proteins: p52 and p100. The p100 polypeptide has been proposed to serve as a precursor of p52, which corresponds to the N-terminal half of p100. While p52 functions as a Rel transcription factor,the larger p100 protein acts as a cytoplasmic inhibitor of select NF-kappa B/Rel transcription factor complexes. Because of their distinct functions, we have studied the biochemical basis for the production of these two nfkb2-derived gene products. Like the p50 product of the nfkb1 gene, p52 is principally generated in a cotranslational manner involving proteolytic processing by the proteasome. The generation of p52 is dependent on a glycine-rich region (GRR) located upstream of the p52 C-terminus, and repositioning of this GRR alters the location of proteasome processing. In most cells, small amounts of p52 are produced relative to the levels of p100, unlike the usually balanced production of nfkb1-derived p50 and p105. Using p100/p105 chimeras containing different segments of the nfkb1 and nfkb2 genes, we have found that diminished p52 processing is a property conferred by peptide sequences located downstream of the GRR, flanking the site of p52 processing.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Feuillard J, 1996, EUR J IMMUNOL, V26, P2547, DOI 10.1002/eji.1830261102; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	31	92	97	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6201	6208		10.1038/sj.onc.1203022	http://dx.doi.org/10.1038/sj.onc.1203022			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597218				2022-12-17	WOS:000083934100003
J	Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ				Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ			Stable overexpression of MEN1 suppresses tumorigenicity of RAS	ONCOGENE			English	Article						menin; MEN1; RAS; neoplasia; NIH3T3; oncogene; tumor suppressor	ENDOCRINE NEOPLASIA TYPE-1; HUMAN CANCER-CELLS; MUTATION ANALYSIS; GENE; PROTEIN; GROWTH; TRANSFORMATION; ACTIVATION; ONCOGENE; PATHWAY	Although there is indirect genetic evidence that MEN1, the gene for multiple endocrine neoplasia type 1, is a tumor suppressor gene, little is known about the MEN1-encoded protein, menin. Menin was stably overexpressed in a well-characterized murine tumor cell line, (valine-12)-RAS-transformed NTH3T3 cells. Menin overexpression reverted the morphology of the RAS-transformed NIH3T3 cells towards the more flattened and more spread, fibroblastic shape of wild type NIH3T3 cells. The proliferation rate of the RAS-transformed cells in 0.5% calf serum was also slower with menin overexpression. Menin overexpression reduced the RAS-induced clonogenicity in soft agar. Menin also reduced tumor growth after injection of cells in nude mice. In conclusion, stable overexpression of MEN1 suppressed partially the RAS-mediated tumor phenotype in vitro and in vivo. Overexpressed menin protein had biological effects, directly supporting MEN1 gene function as a tumor suppressor.	NIDDK, Metab Dis Branch, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Marx, SJ (corresponding author), Bldg 10,Room 9C-101,10 Ctr Dr,MSC 1802, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043310] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; Boni R, 1998, J INVEST DERMATOL, V111, P539; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COX DR, 1970, ANAL BINARY DATA, P14; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; HOLLANDER M, 1997, NONPARAMETRIC STAT M, P67; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LUO XN, 1995, ONCOGENE, V11, P743; Marx S, 1998, GENETIC BASIS HUMAN, P489; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; Mutch MG, 1999, HUM MUTAT, V13, P175, DOI 10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Poncin J, 1999, HUM MUTAT, V13, P54, DOI 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K; SATOH T, 1992, J BIOL CHEM, V267, P24149; Solanas M, 1996, J PHYSIOL BIOCHEM, V52, P173; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; Zhuang ZP, 1997, CANCER RES, V57, P4682	34	92	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5936	5942		10.1038/sj.onc.1203005	http://dx.doi.org/10.1038/sj.onc.1203005			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557080				2022-12-17	WOS:000083270700010
J	Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR				Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR			Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)	ONCOGENE			English	Article						SAPK/JNK; protein kinase; protein phosphorylation; dominant negative; signal transduction; apoptosis; tumor necrosis factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GERMINAL CENTER KINASE; C-JUN; CELL-DEATH; NH2-TERMINAL KINASE; TERMINAL KINASE; MEK KINASE-1; FAMILY; PHOSPHORYLATION	Tumor necrosis factor-alpha (TNF), a major inflammatory cytokine, generates a wide variety of cellular responses via key cytoplasmic adaptor molecules named TNF receptor-associated factors (TRAFs). We report that TRAF2, TRAF5 and TRAF6 associate with apoptosis signal-regulating kinase 1 (ASK1), and a catalytically-inactive ASK1 mutant blocks stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) activation by these TRAFs, A truncated derivative of TRAF2, which inhibits SAPK activation by TNF, blocks TNF-induced ASK1 activation. Furthermore, protection from TNF-induced cell death conferred by an ASK1 mutant is dependent upon TRAF2. Hence, ASK1 is a common mediator of TRAF-regulated SAPK and apoptosis signaling, and the TRAF2-ASK1 connection completes the signaling cascade from TNF to SAPK/JNK activation.	Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Boulder, CO 80301 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Woodgett, JR (corresponding author), Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ADLER V, 1992, J BIOL CHEM, V267, P17001; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kiefer F, 1997, BIOCHEM SOC T, V25, P491, DOI 10.1042/bst0250491; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	92	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5814	5820		10.1038/sj.onc.1202975	http://dx.doi.org/10.1038/sj.onc.1202975			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523862				2022-12-17	WOS:000083095100010
J	Okamoto, K; Prives, C				Okamoto, K; Prives, C			A role of cyclin G in the process of apoptosis	ONCOGENE			English	Article						cyclin G; apoptosis; p53; TNF-alpha; retinoic acid; Bone Morphogenic Protein-4	EMBRYONAL CARCINOMA-CELLS; P53 TUMOR-SUPPRESSOR; CELLULAR-SUSCEPTIBILITY; DNA-DAMAGE; EXPRESSION; PROTEIN; DEATH; INDUCTION; GENE; FAMILY	Cyclin G was previously identified as a target gene of the p53 tumor suppresser protein, and levels of cyclin G are increased after induction of p53 by DNA damage. However, the function of cyclin G has not been established. To determine the effect of increased expression of cyclin G, retroviruses encoding cyclin G mere constructed and used to infect three different murine tell Lines. Cyclin G protein levels induced by the retroviruses were within the range seen after DNA damage induction of p53. In each case we observed that such over-expression of cyclin G augments the apoptotic process. TNF-alpha induction of apoptosis is increased by expression of cyclin G in NIH3T3 fibroblasts which express p53, as well as in 10.1 fibroblasts which contain no p53 allele. Additionally, we observed that while cyclin G expression is markedly reduced upon aggregate formation in embryonic carcinoma P19 cells, retrovirus-mediated over-expression of cyclin G enhances apoptotic cell death in aggregated P19 cells, and increases the extent of apoptosis caused by retinoic acid or serum starvation of these cells. These data demonstrate that cyclin G plays a facilitating role in modulating apoptosis induced by different stimuli. Moreover, we have discovered that cyclin G expression is rapidly induced in P19 cells after exposure to Bone Morphogenic Protein-4 (BMP-4), suggesting that cyclin G may mediate apoptotic signals generated by BMP-4.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NCI NIH HHS [CA 58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bates S, 1996, ONCOGENE, V13, P1103; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jensen MR, 1998, HEPATOLOGY, V28, P537, DOI 10.1002/hep.510280235; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; Ninomiya Y, 1997, J CELL PHYSIOL, V172, P25, DOI 10.1002/(SICI)1097-4652(199707)172:1<25::AID-JCP3>3.3.CO;2-P; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robbins PB, 1997, J VIROL, V71, P9466, DOI 10.1128/JVI.71.12.9466-9474.1997; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; SoferLevi Y, 1996, ONCOGENE, V13, P2431; SORENSON B, 1994, NUCLEIC ACIDS RES, V22, P3551; TAMURA K, 1993, ONCOGENE, V8, P2113; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITE DW, 1995, ONCOGENE, V10, P857; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	47	92	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4606	4615		10.1038/sj.onc.1202821	http://dx.doi.org/10.1038/sj.onc.1202821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467405				2022-12-17	WOS:000082018600010
J	Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG				Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG			Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma	ONCOGENE			English	Article						interleukin-8; brain tumors; cytokines; hypoxia; anoxia; AP-1	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; IL-8 GENE; HYPOXIA; ANGIOGENESIS	Oxygen deprivation is an important biological feature of tumor growth. We previously showed that in glioma, anoxia increases expression of IL-8, a chemokine and angiogenic factor. Here, we analysed for the first time the biochemical mechanisms inducing the IL-8 gene upon anoxia in glioma cells, and showed that they differ from those inducing the VEGF gene. Both genes are induced in biologically and genetically heterogenous glioblastoma cell lines (LN-229, LN-Z308, U87MG, T98G), whereas, in gliosarcoma cells (D247MG), only the VEGF gene is induced. The kinetics of IL-8 and VEGF mRNA inductions differ in these cells and reoxygenation experiments showed that the induction is due to the anoxic stress per se. Furthermore, in LN-229 and Z308 cell lines actinomycin D, DRB and nuclear run-on experiments showed that anoxia stimulates increased transcription of both genes. Electromobility shift assays show increased protein binding to the AP-I site on the IL-8 promoter following anoxia treatment. Finally, in situ hybridization on glioblastoma sections shows that the in vivo expression patterns of IL-8 and VEGF genes overlap, but are not identical. Since intratumoral augmentation of IL-8 and VEGF secretion, following microenvironmental decreases in oxygen pressure, may promote angiogenesis, further definition of these pathways is essential to appropriately target them for antitumoral therapy.	CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland; Emory Univ, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University	Van Meir, EG (corresponding author), CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Damert A, 1997, CANCER RES, V57, P3860; DESBAILLETS I, 1994, INT J CANCER, V58, P240, DOI 10.1002/ijc.2910580216; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DESBAILLETS I, 1997, THESIS U LAUSANNE SW, P189; FOLKMAN J, 1993, CANCER MED, V1, P153; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1957, SCIENCE, V125, P1085, DOI 10.1126/science.125.3257.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KLEIHUES P, 1997, PATHOLOGY GENETICS T, P255; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUNSCH C, 1994, J IMMUNOL, V153, P153; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; MARIE S, 1993, J BIOL CHEM, V268, P23881; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Russell DSRLJBDDMREBJM., 1998, RUSSELL RUBINSTEINS; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sambrook J, 1989, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Stevens T, 1995, ENDOTHELIUM-J ENDOTH, V3, P1, DOI [10.3109/10623329509024653, DOI 10.3109/10623329509024653]; STRIETER RM, 1992, IMMUNOL INVEST, V21, P589, DOI 10.3109/08820139209069393; SZEKANECZ Z, 1994, PATHOBIOLOGY, V62, P134, DOI 10.1159/000163891; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; VAN MEIR E, 1992, CANCER RES, V52, P4297; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; YAMANAKA R, 1995, J NEURO-ONCOL, V25, P59, DOI 10.1007/BF01054723; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	46	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1447	1456		10.1038/sj.onc.1202424	http://dx.doi.org/10.1038/sj.onc.1202424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050881				2022-12-17	WOS:000078651600006
J	Wang, YC; Blandino, G; Oren, M; Givol, D				Wang, YC; Blandino, G; Oren, M; Givol, D			Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs	ONCOGENE			English	Article						inducible p53; senescence; anti-cancer drugs; p21(waf1)	WILD-TYPE P53; HUMAN-DIPLOID FIBROBLASTS; P53-DEFICIENT MICE; MUTANT P53; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; TUMOR SUPPRESSION; IN-VIVO; GROWTH; GENE	The p53-null human lung cancer cell line H1299 was used in order to generate clones with ecdysone-inducible p53 as well as ecdysone-inducible p21(waf1). Induced expression of p53 resulted in irreversible cell growth arrest with characteristics of replicative senescence, suggesting that p53 can prevent immortalization by activating a senescence program. The effect of induced p53 and p21(waf1) expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed. Whereas p21(waf1) overexpression conferred increased resistance to killing by either drug, p53 overexpression enhanced the cytotoxic effect of cisplatin but protected against etoposide cytotoxicity. These results imply that the impact of p53 on susceptibility to chemotherapy may depend greatly on the particular drug and type of DNA damage. Moreover, these data demonstrate the importance of using isogenic cell lines to address this issue.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BODNER SM, 1992, ONCOGENE, V7, P743; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; CHEDID M, 1994, ONCOGENE, V9, P3021; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OConnor PM, 1997, CANCER RES, V57, P4285; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Sambrook J, 1989, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TSUKADA T, 1993, ONCOGENE, V8, P3313; VIKHANSKAYA F, 1995, INT J CANCER, V61, P397, DOI 10.1002/ijc.2910610320; Vikhanskaya F, 1996, EXP CELL RES, V227, P380, DOI 10.1006/excr.1996.0288; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; ZAKUT R, 1995, ONCOGENE, V11, P393	43	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1923	1930		10.1038/sj.onc.1202113	http://dx.doi.org/10.1038/sj.onc.1202113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788435	Bronze			2022-12-17	WOS:000076423500005
J	Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R				Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R			Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas	ONCOGENE			English	Article						breast carcinoma; carcinoma in situ; PTEN; chromosome 10; loss of heterozygosity	IN-SITU; CANCER; HETEROZYGOSITY; ALLELOTYPE; DELETION; REGION; FREQUENCY; 11Q13; P53	To determine the status of chromosome 10q23 in primary breast carcinomas, ill situ and invasive carcinomas were analysed for allelic loss using microsatellite markers spanning the 10q23 region. No LOH was seen in pure intraductal carcinomas (0/20 cases). On the other hand, LOH was observed in 40% (17/42) of invasive carcinomas (P=0.0005). Interestingly, in situ lesions found in invasive tumors displayed LOH. Allelic loss was also significantly associated with loss of the estrogen receptor (P=0.011). Thus, loss of the 10q23 is strongly associated with tumor progression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Epidemiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.			Terry, Mary Beth/0000-0002-4106-5033; Parsons, Ramon/0000-0002-6656-3514				*ACS, 1994, CANC FACTS FIG 1994; ALDAZ CM, 1995, CANCER RES, V55, P3976; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii H, 1996, CANCER RES, V56, P5260; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Ittmann M, 1996, CANCER RES, V56, P2143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RADFORD DM, 1995, CANCER RES, V55, P3399; RADFORD DM, 1995, CANCER RES, V55, P5180; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SATO T, 1990, CANCER RES, V50, P7184; SCHUURING E, 1992, ONCOGENE, V7, P355; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; VARLEY JM, 1991, ONCOGENE, V6, P413; Wang SI, 1997, CANCER RES, V57, P4183; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHUANG ZP, 1995, CANCER RES, V55, P467	32	92	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					123	127		10.1038/sj.onc.1201940	http://dx.doi.org/10.1038/sj.onc.1201940			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671321				2022-12-17	WOS:000074677800014
J	Sirma, H; Weil, R; Rosmorduc, O; Urban, S; Israel, A; Kremsdorf, D; Brechot, C				Sirma, H; Weil, R; Rosmorduc, O; Urban, S; Israel, A; Kremsdorf, D; Brechot, C			Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome	ONCOGENE			English	Article						hepatitis B virus; X protein; proteasomes; NF-kappa B	NF-KAPPA-B; PROGRAMMED CELL-DEATH; HBX PROTEIN; IN-VIVO; VIRAL REPLICATION; DNA-BINDING; GENE; EXPRESSION; TRANSACTIVATOR; TRANSCRIPTION	The hepatitis B virus X protein plays an important role in the regulation of viral genome expression and has also been implicated in the development of liver cancer associated with chronic viral infection. Several effects have been attributed to X but their biological relevance remains elusive. One of the confusing issues has been so far the uncertainty concerning its cellular location. To gain insight into the mechanism(s) how X exerts its effects, me have analysed its subcellular distribution and its dependency on the cell cycle. We used two complementary approaches namely, immunolocalization using a cell line stably expressing X, and characterization of the dynamics of X location in living cells by means of the reporter gene GFP. Our data clearly define the cytosol as the prime location of X, irrespectively of the cell cycle and show in addition the close attachment of a fraction of X to the nuclear membrane. However, X does not associate with any cytoplasmic vesicles and organelles so far tested. In contrast, our study provides strong evidence for the codistribution of X with the cytosolic fraction of proteasomes. In pulse-chase experiments, X decayed with a half-life of less than 30 min and proteasome-inhibitors did not modify its turnover, suggesting that X colocalization with the proteasome does not simply point to its degradation pathway. The proteolytic processing of the p105 precursor of the p50 subunit of the NF-kappa B transcription factor, which has been shown to be proteasome-dependent, is markedly slow down in the presence of X. These findings suggest that X modulates the processing rate of p105 by acting presumably at the level of the proteasome. Thus, targeting of proteasomes by X might be one of the pathways employed by this viral protein to subvert pathways employed by cellular functions.	Necker Inst, INSERM U370, F-75015 Paris, France; Inst Pasteur, Unite Biol Mol Express Gen, URA 1149, F-75724 Paris 15, France; Max Planck Inst Biochem, Dept Virus Res, D-82152 Martinsried, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society	Brechot, C (corresponding author), Necker Inst, INSERM U370, 156 Rue de Vaugirard, F-75015 Paris, France.		Kremsdorf, Dina/O-9797-2017	Weil, Robert/0000-0001-5235-0932				AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUPREZ V, 1994, J CELL SCI, V107, P1289; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldberg AL, 1997, MOL BIOL REP, V24, P69, DOI 10.1023/A:1006860828265; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KLEIN R, 1991, VIRUS GENES, V5, P157, DOI 10.1007/BF00571930; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; LEVRERO M, 1991, HEPATOLOGY, V13, P143, DOI 10.1002/hep.1840130121; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Maki CG, 1996, CANCER RES, V56, P2649; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERSING DH, 1986, J VIROL, V60, P177, DOI 10.1128/JVI.60.1.177-184.1986; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Pitzer F, 1996, FEBS LETT, V394, P47, DOI 10.1016/0014-5793(96)00920-9; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSMORDUC O, 1995, HEPATOLOGY, V22, P10, DOI 10.1016/0270-9139(95)90346-1; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHEK N, 1991, ONCOGENE, V6, P1735; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRIER M, 1994, CELL, V78, P787; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	58	92	102	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2051	2063		10.1038/sj.onc.1201737	http://dx.doi.org/10.1038/sj.onc.1201737			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572486				2022-12-17	WOS:000073177200003
J	Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M				Shaulian, E; Resnitzky, D; Shifman, O; Blandino, G; Amsterdam, A; Yayon, A; Oren, M			Induction of Mdm2 and enhancement of cell survival by bFGF	ONCOGENE			English	Article						Mdm2; bFGF; p53; apoptosis; cisplatin	WILD-TYPE P53; FIBROBLAST GROWTH-FACTOR; AUTOREGULATORY FEEDBACK LOOP; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR PROTEIN; TYROSINE KINASE-ACTIVITY; MYC-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; HEMATOPOIETIC-CELLS; FACTORS STIMULATE	Basic fibroblast growth factor (bFGF) can exert mitogenic and viability-promoting effects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of fibroblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inefficient transcriptional activation of the bar gene promoter. Importantly, unlike Mdm2 accumulation in fibroblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damage-induced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These findings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic effects of bFGF and possibly some other survival factors.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOTTNER D, 1992, EXP NEUROL, V118, P35, DOI 10.1016/0014-4886(92)90020-Q; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1995, ONCOGENE, V10, P1081; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKS Z, 1994, CANCER RES, V54, P2582; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LADANYI M, 1993, CANCER RES, V53, P16; LANDGREN E, 1995, ONCOGENE, V10, P2027; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11653; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SoferLevi Y, 1996, ONCOGENE, V13, P2431; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiang H, 1996, J NEUROSCI, V16, P6753; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	96	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2717	2725		10.1038/sj.onc.1201453	http://dx.doi.org/10.1038/sj.onc.1201453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400998				2022-12-17	WOS:A1997YH46800009
J	Ueno, NT; Yu, DH; Hung, MC				Ueno, NT; Yu, DH; Hung, MC			Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A	ONCOGENE			English	Article						HER-2/neu; E1A; paclitaxel; breast neoplasms; gene therapy	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; EGF RECEPTOR; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; METASTASIS; P53; TRANSFORMATION; C-ERBB-2	Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. In previous work, we showed that the adenovirus type 5 E1A can repress HER-2/neu expression at the transcriptional level, Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. To further test whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel through E1A-mediated HER-2/neu repression, an adenoviral vector was used to transfer the E1A gene into two human breast cancer cell lines, MDA-MB-453 and MDA-MB-361, that overexpress HER-2/neu. After E1A delivery, we observed that HER-2/neu expression level was reduced, and cells mere treated with paclitaxel. Cell proliferation assays showed a synergistic growth inhibition effect of E1A and paclitaxel, The synergistic effect was also confirmed by soft agar colony-formation assay, Breast cancer cell lines that express low levels of HER-2/neu, MDA-MB-435 and MDA-MB-231 cells showed no synergistic growth inhibition effect when treated on the same protocols, Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression. This in turn may have important implications for the development of a novel therapy that combines chemotherapy and gene therapy.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,SECT BLOOD & MARROW TRANSPLANTAT,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA58880, CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Chang JY, 1996, ONCOGENE, V13, P1405; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; FRISCH SM, 1995, CANCER RES, V55, P5551; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATA Y, 1994, ONCOL RES, V6, P19; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MATIN A, 1990, ONCOGENE, V5, P111; MCCANN AH, 1991, CANCER RES, V51, P3296; MILLER SJ, 1995, ONCOL REP, V2, P497; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1994, J NATL CANCER I, V86, P1018, DOI 10.1093/jnci/86.13.1018; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Ullrich Axel, 1989, SCIENCE, V244, P707, DOI DOI 10.1126/SCIENCE.2470152; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG YJ, 1995, ONCOGENE, V10, P1947	52	92	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					953	960		10.1038/sj.onc.1201250	http://dx.doi.org/10.1038/sj.onc.1201250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285690				2022-12-17	WOS:A1997XR76700008
J	Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B				Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B			Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?	ONCOGENE			English	Article						cdc25B; cell cycle; protein phosphatase; splicing	FISSION YEAST CDC25; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; MITOTIC INDUCER; M-PHASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; HOMOLOG	CDC25B2, a protein tyrosine phosphatase closely related to the putative CDC25B oncogene, was identified in a Burkitt lymphoma cDNA library, CDC25B2 differs from CDC25B by a 14 residue insertion and a 41 residue deletion, which are both located in the amino-terminal region of the protein, upstream of the catalytic domain. Examination of the genomic sequence revealed that CDC25B1 (formerly B) and CDC25B2 are splice variants of the same gene, A third variant, CDC25B3, that carries both the 14 and the 41 residue sequences was also identified in the same cDNA library. All three variants were detected in a panel of human primary culture and cell lines, although at different levels. In primary fibroblasts and in HeLa cells the CDC25B expression is cell cycle regulated, reaching a maximum in G(2)-phase. In vitro, CDC25B1 phosphatase is slightly more active than CDC25B2 and B3. However, episomal overexpression of the three CDC25B variants in fission yeast reveals that in vivo, CDC25B2 is largely more active than either B1 or B3 (B2>B3>B1) both to complement a thermosensitive S pombe CDC25 activity and to act as a mitotic inducer, Alternative splicing of CDC25B may therefore contribute to the control of cell proliferation.	UNIV TOULOUSE 2, INST PHARMACOL & BIOL STRUCT, CNRS, F-31077 TOULOUSE, FRANCE; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	Universite de Toulouse; Universite de Toulouse - Jean Jaures; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)			BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	BALDIN, Véronique/0000-0001-8523-0494; Superti-Furga, Giulio/0000-0002-0570-1768; DUCOMMUN, Bernard/0000-0002-7126-8368				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEMETRICK DJ, 1993, GENOMICS, V18, P144, DOI 10.1006/geno.1993.1440; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRANA X, 1994, ONCOGENE, V9, P2097; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LANE SA, 1993, GENOMICS, V15, P693, DOI 10.1006/geno.1993.1129; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATA A, 1991, NEW BIOL, V3, P959; NARGI JL, 1994, IMMUNOGENETICS, V39, P99, DOI 10.1007/BF00188612; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEWING A, 1994, J CELL SCI, V107, P581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1996, IN PRESS NATURE BIOT; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Xu X, 1996, J BIOL CHEM, V271, P5118; YUSHERMAN M, 1992, EMBO J, V11, P71	48	92	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2485	2495		10.1038/sj.onc.1201063	http://dx.doi.org/10.1038/sj.onc.1201063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188863				2022-12-17	WOS:A1997WZ68000012
J	Abdollahi, A; Roberts, D; Godwin, AK; Schultz, DC; Sonoda, G; Testa, JR; Hamilton, TC				Abdollahi, A; Roberts, D; Godwin, AK; Schultz, DC; Sonoda, G; Testa, JR; Hamilton, TC			Identification of a zinc-finger gene at 6q25: A chromosomal region implicated in development of many solid tumors	ONCOGENE			English	Article						cancer; ovary; transcription factor; zinc-finger	EPITHELIAL OVARIAN-CANCER; POLYMERASE CHAIN-REACTION; EUROPEAN CASE-CONTROL; SINGLE-STEP METHOD; SPONTANEOUS TRANSFORMATION; DIFFERENTIAL DISPLAY; POOLED ANALYSIS; MESSENGER-RNAS; CELLS; CARCINOMAS	We have used a rat model of epithelial ovarian cancer to identify a gene that shows decreased or lost expression in independently transformed rat ovarian surface epithelial cell lines compared to the normal progenitor cells, Hence, we refer to this gene as Lot-1 (Lost on transformation 1, GenBank accession no, U72620). Here, we report the cloning of the likely human homologue and its initial characterization. The deduced amino acid sequences of the cDNAs for rat and human LOT-1 (GenBank accession no. U72621) contain seven zinc finger motifs of the C2H2 type as well as proline and glutamine rich areas. The genes share 76.4% identity at the nucleotide level, 67.7% at the amino acid level and 85.5% within the seven zinc finger motifs. LOT-1 is ubiquitously expressed in normal human tissues but was not expressed in four of 11 (36%) human ovarian cancer cell lines or spontaneously transformed human ovarian surface epithelial cells, The human gene maps to chromosome 6 at band q25. We show that there is a 38% incidence of allelic loss at this chromosomal location in human ovarian cancers, This chromosomal region has also been implicated in the genesis of breast, kidney, and pleural mesothelial cancers, We suggest that this newly identified gene is not only of intrinsic interest as a ubiquitously expressed probable transcription factor but is a plausible candidate for the tumor suppressor gene which likely resides in the region of chromosome 6 defined by band q25.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; LEHIGH UNIV, DEPT CHEM, BETHLEHEM, PA 18015 USA	Fox Chase Cancer Center; Lehigh University					NATIONAL CANCER INSTITUTE [R01CA056916] Funding Source: NIH RePORTER; NCI NIH HHS [CA56916] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1997, UNPUB CANC RES; Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; AUERSPERG N, 1995, AM J OBSTET GYNECOL, V173, P558, DOI 10.1016/0002-9378(95)90282-1; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BELLACOSA A, 1993, ONCOGENE, V8, P745; CAPUT D, 1986, P NATL ACAD SCI USA, V77, P4170; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLIBY W, 1993, CANCER RES, V53, P2393; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; FATHALLA MF, 1971, LANCET, V2, P163; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GODWIN A, 1996, ENDOCRINOLOGY, P107; GODWIN A, 1996, GYNEDOLOGICAL ONCOLO, P107; GODWIN AK, 1995, ENDOCRINOLOGY, V136, P4640, DOI 10.1210/en.136.10.4640; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hamilton T. C., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P623; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; JOHNSON SW, 1994, CANCER RES, V54, P5911; Johnson SW, 1996, ANAL BIOCHEM, V236, P348, DOI 10.1006/abio.1996.0178; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LICHTER P, 1992, GENOMICS, V13, P999, DOI 10.1016/0888-7543(92)90013-I; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOK S, 1996, J SOC GYNECOL INVEST, V3, pA375; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; Ozols R. F., 1992, GYNECOL ONCOL, P731; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Saito S, 1996, CANCER RES, V56, P5586; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SATO T, 1991, CANCER RES, V51, P5118; Schultz DC, 1996, CANCER RES, V56, P1997; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TAGUCHI T, 1993, CANCER RES, V53, P4349; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; TESTA JR, 1994, CANCER RES, V54, P2778; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; Theile M, 1996, ONCOGENE, V13, P677; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Tibiletti MG, 1996, CANCER RES, V56, P4493; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WAN MH, 1994, INT J ONCOL, V5, P1043; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; ZHENG JP, 1991, CANCER RES, V51, P4045	58	92	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1973	1979		10.1038/sj.onc.1201034	http://dx.doi.org/10.1038/sj.onc.1201034			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150364				2022-12-17	WOS:A1997WV80400010
J	BeerRomero, P; Glass, S; Rolfe, M				BeerRomero, P; Glass, S; Rolfe, M			Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells	ONCOGENE			English	Article						E6; p53; E6AP; papillomavirus; antisense	HUMAN PAPILLOMAVIRUS TYPE-16; UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS; IN-VIVO; PROTEIN; ASSOCIATION; ONCOPROTEIN; E6-AP; DEFICIENCY	Invasive cervical cancer is very highly correlated with the presence of high-risk human papillomavirus (HPV) types 16 and 18, Two viral proteins, E6 and E7, act in concert to subvert growth control of infected cells by inactivating the tumor suppressor proteins, p53 and Rb, respectively. E6 is thought to abrogate p53 function by stimulating its degradation via ubiquitin-mediated proteolysis in reaction requiring E6AP (EB-Associated Protein), Here we evaluate the in vivo role of E6AP in p53 degradation in normal and HPV-infected cell types using antisense phosphorothioate oligodeoxynucleotides (S-ODNs). This study shows that reduction of E6AP in viva in high-risk HPV-infected cells leads to an elevation of p53, confirming the function of E6AP predicted by in vitro experiments. Further, we demonstrate that reduction of E6AP in normal cells has no effect on p53 levels, indicative of an E6AP-indpendent mechanism for p53 degradation. These experiments show that inhibition of intermediate proteins in the ubiquitin-mediated proteolysis pathway (ubiquitin-conjugating enzymes or associated recognition proteins) can result in specific inhibition of substrate degradation. We propose that modulation of p53 levels by elimination of E6AP function may have therapeutic potential for cervical cancer.			BeerRomero, P (corresponding author), MITOTIX INC,1 KENDALL SQ,BLDG 600,CAMBRIDGE,MA 02139, USA.							Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LANDANYI M, 1993, CANCER RES, V53, P16; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maki CG, 1996, CANCER RES, V56, P2649; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENES DEV, V9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1993, ONCOGENE, V8, P1407; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STREMLAU A, 1985, NATURE, V314, P111; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE C, 1985, AM J PATHOL, V119, P361; zur Hausen H, 1987, Appl Pathol, V5, P19	40	92	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					595	602		10.1038/sj.onc.1200872	http://dx.doi.org/10.1038/sj.onc.1200872			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053858				2022-12-17	WOS:A1997WF52400011
J	Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A				Watson, DK; Robinson, L; Hodge, DR; Kola, I; Papas, TS; Seth, A			FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements	ONCOGENE			English	Article						ETS; FLI1; EWS-FLI1; Egr1; ternary complex factor (TCF); quaternary complex factor (QCF); CArG box; SRE	EWS/FLI-1 FUSION GENE; DNA-BINDING MOTIF; ETS DOMAIN; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; SECONDARY STRUCTURE; ONCOGENIC ACTIVITY; REGULATORY FACTOR; MURINE ETS-1	The ETS gene products are a family of transcriptional regulatory proteins that contain a highly conserved and structurally unique DNA binding domain, termed the ETS domain. Several ETS proteins bind to DNA as monomers, however it has been shown that the DNA binding activity is enhanced or modulated in the presence of other factors. By differential display and whole genome PCR techniques, we have recently shown that the Erg1 gene is a target for ETS proteins. The Egr1 promoter contains multiple ETS binding sites, three of which exist as parts of two serum response elements (SREI and SREII). The SRE is a cis-element that regulates the expression of many growth factor responsive genes. ELK1 and SAP1a have been shown to form ternary complexes with SRF on the SRE located in the c-fos promoter. Similarly, we examined whether the ELK1, SAP1a, FLI1, EWS-FLI1, ETS1, ETS2, PEA3 and PU.1 proteins can form ternary complexes with SRF on the Egr1 SREI and II. Our results demonstrate that indeed ELK1, SAP1a, FLI1 and EWS-FLI1 are able to form ternary complexes with SRF on Egr1 SREs. In addition, ELK1 and SAP1a can also form quarternary complexes on the Egr1 SRE1. However, the proteins ETS1, ETS2, PEA3 and PU.1 were unable to form ternary complexes with SRF on either the Egr1 or c-fos SREs. Our data demonstrate that FLI1 and EWS-FLI1 constitute new members of a subgroup of ETS proteins that can function as ternary complex factors and further implicate a novel function for these ETS transcription factors in the regulation of the Egr1 gene. By amino acid sequence comparison we found that, in fact, 50% of the amino acids present in the B-box of SAP1a and ELK1, which are required for interaction with SRF, are identical to those present in both FLI1 (amino acids 231-248) and EWS-FLI1 proteins. This B-box is not present in ETS1, ETS2, PEA3 or PU.1 and these proteins were unable to form ternary complexes with SRF and Egr1-SREs or c-fos SRE. Furthermore, deletion of 194 amino terminal amino acids of FLI1 did not interfere with its ability to interact with SRF, in fact, this truncation increased the stability of the ternary complex. The FLI1 protein has a unique R-domain located next to the DNA binding region. This R-domain may modulate the interaction with SRF, providing a mechanism that would be unique to FLI1 and EWS-FLI1, thus implicating a novel function for these ETS transcription factors in the regulation of the Egr1 gene.	UNIV TORONTO, MRC, GRP PERIODONTAL PHYSIOL, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, LAB MOL PATHOL, TORONTO, ON M5S 1B2, CANADA; MED UNIV S CAROLINA, CTR MOL & STRUCT BIOL, CHARLESTON, SC 29425 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ONCOL MOL LAB, FREDERICK, MD 21702 USA; MONASH UNIV, MOL GENET & DEV GRP, MELBOURNE, VIC 3168, AUSTRALIA	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Monash University			Kola, Ismail/C-5254-2013					ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bhat NK, 1996, INT J ONCOL, V8, P841; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qi S., 1992, DNA Sequence, V3, P127, DOI 10.3109/10425179209034008; ROBINSON L, 1995, MIAMI SHORT REPORTS, V6, P76; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	49	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					213	221		10.1038/sj.onc.1200839	http://dx.doi.org/10.1038/sj.onc.1200839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010223				2022-12-17	WOS:A1997WC81800009
J	Kitsberg, DI; Leder, P				Kitsberg, DI; Leder, P			Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice	ONCOGENE			English	Article						keratinocyte growth factor; int-2; transformation; MMTV; transgenic mice; fgf	PROTO-ONCOGENE INT-2; HUMAN-BREAST CANCER; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; FACTOR RECEPTORS; NEU ONCOGENE; TUMOR VIRUS; INNER-EAR; IN-VIVO; C-MYC	The kinetics of solitary mammary tumor formation in transgenic mice bearing the MMTV-int-2 (fgf3) fusion gene suggest that several genetic events are required for tumorigenesis, In an effort to identify elements that could contribute to this oncogenic process, we used differential display PCR to identify gene products that are strongly and specifically induced in int-2 mammary tumors, Using this approach we identified a member of the FGF family, kgf (fgf7), as a gene that is strongly upregulated in an int-2-containing mammary tumor, Since int-2 and kgf strongly bind the same receptor, the IIIb isoform of FGFR2, it is possible that their joint expression, one as a transgene, the other as an activated gene, might reinforce the same mitogenic pathway, To test this possibility, we created transgenic mice that carry kgf as a transgene gene under the control of the MMTV promoter/enhancer, Female mice carrying this transgene develop a very dramatic mammary epithelial hyperplasia and go on to develop solitary, metastatic adenocarcinomas of the mammary gland, Consistent with a common signalling pathway, the MMTV-kgf-induced hyperplasia has the morphologic characteristics of that seen in the MMTV-int-2 mice, Male mice also develop hyperplasia of the male genital tract, including the seminal vesicle, the vas deferens and the prostate, Thus KGF can act as a potent proliferative inducer in mammary and specific urogenital tissue and can contribute to the development of adenocarcinoma of the mammary gland in a manner strongly reminiscent of receptor-related ligand, int-2.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; CARDIFF RD, 1993, CANCER SURV, V16, P97; CUNHA GR, 1994, BIOMED PHARMACOTHER, V48, pS9, DOI 10.1016/S0753-3322(09)80003-6; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Krane IM, 1996, ONCOGENE, V12, P1781; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J, 1989, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILSON SE, 1994, CELL MOL BIOL RES, V40, P337; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YI ES, 1994, AM J PATHOL, V145, P1015	43	92	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2507	2515						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000125				2022-12-17	WOS:A1996VZ65400001
J	Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ				Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ			Expression of human immunodeficiency virus type 1 tat results in downregulation of bcl-2 and induction of apoptosis in hematopoietic cells	ONCOGENE			English	Article						HIV-1 tat; apoptosis; bcl-2; bax; Fas	PROTEIN INDUCES APOPTOSIS; HIV-1 TAT; T-CELLS; KAPOSIS-SARCOMA; GENE-EXPRESSION; DEATH; INFECTION; AIDS; LYMPHOCYTES; ACTIVATION	Infection by human immunodeficiency virus type 1 (HIV-1) is characterized by progressive loss of various cell types, mainly CD4(+) T lymphocytes. While a passive role for the virus in cell destruction is recognized, it does not account for the vast amount of cell death including those of uninfected 'bystander' cells. Since in the past we and others have demonstrated the capacity of the Tat protein of HIV-1 to modulate the expression of various cellular genes and that Tat secreted by HIV-infected cells can be readily taken up by various cell types, we have investigated the role of Tat on inducing apoptosis. Our results indicate that T lymphocytes transfected to constitutively express HIV-1 tat, when grown under serum-free conditions results in rapid apoptosis characterized by typical ultrastructural features and DNA fragmentation. Additionally, we observed that in several hematopoietic cell types, including T and B lymphoid cells and monocytoid cells, the expression of HIV-1 tat results in down-regulation of bcl-2, an oncogene with known potential for inhibition of apoptosis. The tat-mediated down-regulation of bcl-2 was observed at both the transcriptional and translational levels. Also, tat-transfected cells expressed increased amounts of bax, a bcl-2 family protein known to induce apoptosis. While these results support reports in the literature of an active role for tnt in inducing cell death in HIV-infected individuals, they point to a new mechanism involving Tat-mediated modulation of bcl-2 and bax.	BAYLOR COLL MED,DEPT MOL PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL ANAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Sastry, KJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET SCI,SCI PK,ROUTE 2,BOX 151-B1,BASTROP,TX 78602, USA.		Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X; Sastry, Jagannadha/0000-0002-6987-4422	NCI NIH HHS [CA 09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; EMBERTSON J, 1993, NATURE, V362, P359; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GORZYCA W, 1992, INT J ONCOL, V1, P639; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1994, HIV PATHOGENESIS AID, P77; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NATURE MED, V2, P118; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORNESELLO ML, 1993, INTERVIROLOGY, V36, P57, DOI 10.1159/000150322; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAULI G, 1993, CANCER RES, V53, P4481	37	92	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					487	493						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760290				2022-12-17	WOS:A1996VB32800006
J	Skilling, JS; Sood, A; Niemann, T; Lager, DJ; Buller, RE				Skilling, JS; Sood, A; Niemann, T; Lager, DJ; Buller, RE			An abundance of p53 null mutations in ovarian carcinoma	ONCOGENE			English	Article						p53 gene; ovarian cancer; deletions; insertions	GENE-MUTATIONS; NUCLEAR ACCUMULATION; CANCER; DNA; PROTEIN; OVEREXPRESSION; DELETIONS; SEQUENCE; EVENT	Ovarian cancers from 64 midwestern US women were screened for p53 dysfunction both by immunohistochemical staining (IHCS) and single strand conformation polymorphism (SSCP) analysis of the entire open reading frame (ORF), Forty SSCP abnormalities in 39 tumors included nine deletion, one insertion, two splice junction, two nonsense, one silent and 25 missense mutations were confirmed by direct genomic sequencing, Eight of the insertion/deletion defects may have occurred due to slippage during the course of DNA replication, This observation suggests that genomic instability may play an important role in ovarian carcinogenesis, Fifteen percent of the mutations encountered were located outside exons 5-9 and four of these were null, The sensitivity of IHCS was 96% for missense mutations but only 14% for null mutations, This contrasted with 100% sensitivity of the SSCP screening methodology, The 21% overall incidence of null mutations in the present study far exceeds the reported 6.8% incidence in the world literature (P=0.0003). Explanations for this difference include: (1) our complete analysis of the entire ORF of the p53 gene; (2) the tendency of others to rely upon IHCS to screen tumors prior to mutation analysis; and (3) environmental or endogenous genetic influences.	UNIV IOWA HOSP & CLIN,DEPT OBSTET & GYNECOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa								BULLER RE, 1993, GYNECOL ONCOL, V51, P160, DOI 10.1006/gyno.1993.1265; BULLER RE, 1995, GYNECOL ONCOL, V58, P368, DOI 10.1006/gyno.1995.1244; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA M, 1994, JPN J CANCER RES, V85, P1247, DOI 10.1111/j.1349-7006.1994.tb02937.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARTMANN A, 1995, ONCOGENE, V10, P681; HELLER MJ, 1991, BIOTECHNIQUES, V11, P372; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; INOUE M, 1994, AM J CLIN PATHOL, V102, P665, DOI 10.1093/ajcp/102.5.665; JEGO N, 1993, ONCOGENE, V8, P209; KAPPES S, 1995, INT J CANCER, V64, P52, DOI 10.1002/ijc.2910640111; KASTAN MB, 1991, CANCER RES, V51, P6304; KIHANA T, 1992, JPN J CANCER RES, V83, P978, DOI 10.1111/j.1349-7006.1992.tb02010.x; KIM JW, 1995, GYNECOL ONCOL, V57, P199, DOI 10.1006/gyno.1995.1125; KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO;2-L; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; KRAWCZAK M, 1991, HUM GENET, V86, P425; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; KUPRYJANCZYK J, 1995, HUM PATHOL, V26, P387, DOI 10.1016/0046-8177(95)90138-8; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOEB LA, 1994, CANCER RES, V54, P5059; MARKS JR, 1991, CANCER RES, V51, P2979; MAZARS R, 1991, ONCOGENE, V6, P1685; MCMANUS DT, 1994, J PATHOL, V174, P159, DOI 10.1002/path.1711740304; MILNER BJ, 1993, CANCER RES, V53, P2128; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOK CH, 1992, CANCER RES, V52, P5119; NAITO M, 1992, JPN J CANCER RES, V83, P1030, DOI 10.1111/j.1349-7006.1992.tb02717.x; NIWA K, 1994, BRIT J CANCER, V70, P1191, DOI 10.1038/bjc.1994.472; OKAMOTO A, 1991, CANCER RES, V51, P5171; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RUNNEBAUM IB, 1994, HUM GENET, V93, P620; SAITOH S, 1994, ONCOGENE, V9, P2869; Sambrook J., 1989, MOL CLONING LAB MANU; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHERIDAN E, 1994, EUR J CANCER, V30A, P1701, DOI 10.1016/0959-8049(94)00325-Y; SHERIDAN E, 1993, CANCER LETT, V68, P83, DOI 10.1016/0304-3835(93)90223-V; SHIAO YH, 1995, CANCER RES, V55, P1485; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Skilling JS, 1996, GYNECOL ONCOL, V61, P180, DOI 10.1006/gyno.1996.0122; Skilling JS, 1996, GYNECOL ONCOL, V60, P72, DOI 10.1006/gyno.1996.0014; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TENERIELLO MG, 1993, CANCER RES, V53, P3103; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146	52	92	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					117	123						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700537				2022-12-17	WOS:A1996UX31900013
J	Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH				Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH			The identification of p130(cas)-binding proteins and their role in cellular transformation	ONCOGENE			English	Article						p130(cas); SRC; CRK; SH2 domain; SH3 domain	PHOSPHOTYROSINE-CONTAINING PROTEINS; CRK ONCOGENE PRODUCT; SRC SH2 DOMAIN; STABLE ASSOCIATION; V-CRK; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; BINDING; PP60SRC; CELLS	Adaptor proteins play an important role in signal transduction by regulating the establishment and maintenance of functionally important protein complexes, A recently described member of this group of proteins is p130(cas) (CAS), which contains numerous sequence motifs predicted to be involved in mediating protein-protein interactions, We propose that adaptor molecules like GAS may help determine the response of a cell to a particular signal by interacting with specific subsets of cellular proteins. To test this hypothesis, we have identified potential binding partners of CAS that may play a role in cellular transformation by the oncoproteins v-SRC and/or v-CRK. We show that individual domains of CAS associate with specific subsets of proteins in vitro, and that many of these interactions are dependent on the state of tyrosine-phosphorylation of GAS. Sequences necessary for interacting with the focal adhesion kinase pp125(FAK) (FAK), v-SRC and v-CRK have been mapped to distinct regions of CAS. In addition, the identification of a number of putative GAS-binding partners that are present in crk-transformed cell extracts but undetectable in normal and src-transformed cell extracts supports a model in which unique protein complexes are formed in response to different signals.	UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Richardson, Alan/I-4631-2015; Richardson, Alan/E-7615-2010	Richardson, Alan/0000-0003-1825-3375; 	NATIONAL CANCER INSTITUTE [R37CA029243, P01CA040042, R01CA029243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOUTON AH, 1991, MOL CARCINOGEN, V4, P145, DOI 10.1002/mc.2940040210; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HARTE MT, 1996, IN PRESS J BIOL CHEM; HILDEBRAND JD, 1995, IN PRESS MOL BIOL CE; HILDEBRAND JD, 1996, IN PRESS MOL CELL BI, V16; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, ONCOGENE, V4, P295; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2467	2472						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649789				2022-12-17	WOS:A1996UQ22000026
J	Arrowsmith, CH; Morin, P				Arrowsmith, CH; Morin, P			New insights into p53 function from structural studies	ONCOGENE			English	Review						tumor suppressor; protein-DNA interaction, oligomerization	TUMOR SUPPRESSOR GENE; WILD-TYPE; DNA-BINDING; MUTANT P53; MONOCLONAL-ANTIBODY; PROTEIN; MUTATIONS; ANTIGEN; CELLS; OLIGOMERIZATION		UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto	Arrowsmith, CH (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.			Arrowsmith, Cheryl/0000-0002-4971-3250				BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CARIELLO NF, 1994, CANCER RES, V54, P4454; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CREIGHTON TE, 1984, PROTEINS STRUCTURES, pCH7; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MILNER J, 1993, ONCOGENE, V8, P2001; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SINGERLAND JM, 1993, EMBO J, V12, P1029; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1987, ONCOGENE, V1, P210; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1995, ONCOGENE, V10, P389; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	92	93	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622853				2022-12-17	WOS:A1996UF07600001
J	Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP			Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells	ONCOGENE			English	Article						brain tumors; tumor suppressor genes; p16/CDKN2; adenovirus		The p16 (MTS1/CDKN2) gene localized at the 9p21 chromosomal region encodes for a cell cycle inhibitor protein and is altered in many human cancers. The frequency of p16 alterations in gliomas exceeds 50%. To restore the missing wild-type p16 gene efficiently in glioma cells an adenovirus vector carrying the full length coding sequence of the wild-type p16 cDNA, Ad5RSV-p16, was constructed. Three human glioma cell lines, U-251 MG, U-87 MG and D54 MG, that did not express endogenous p16/CDKN2 gene and were easily infected with adenovirus vectors were selected for these experiments. Introduction of the Ad5RSV-p16 in these malignant glioma cell lines directed the biosynthesis of functional p16 protein in the majority of the exposed cells, significantly inhibited cell growth, influenced cell morphology and modified the transformed phenotype of cells including the ability to form colonies in soft agar. Flow cytometric studies revealed that the majority of the Ad5RSV-p16 infected glioma cells were arrested in the G0-G1 phases of the cell cycle. These results suggest that p16/CDKN2 inactivation is a significant factor in the genesis and progression of gliomas and that the restoration of the wild-type p16 protein could have clinical and therapeutic utility.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ARAP W, 1995, CANCER RES, V55, P1351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLAYMAN GL, 1995, CANCER RES, V55, P1; GIANI C, 1994, CANCER RES, V54, P6338; Graham FL, 1991, METHOD MOL BIOL, P109; GRUNHAUS A, 1992, SEMIN VIROL, V3, P237; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JEN J, 1994, CANCER RES, V54, P6353; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI Y, 1994, CANCER RES, V54, P6078; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090; WANG JX, 1995, CANCER GENE THER, V2, P9; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; ZHANG WW, 1994, CANCER GENE THER, V1, P5	27	92	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					103	110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552379				2022-12-17	WOS:A1996TQ01400013
J	HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y				HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y			DETECTION OF K-RAS MUTATIONS IN DNAS ISOLATED FROM FECES OF PATIENTS WITH COLORECTAL TUMORS BY MUTANT-ALLELE-SPECIFIC AMPLIFICATION (MASA)	ONCOGENE			English	Article						FECES; COLORECTAL CANCER; GENETIC DIAGNOSIS; K-RAS; MASA (MUTATED ALLELE SPECIFIC AMPLIFICATION	POLYMERASE CHAIN-REACTION; CANCER	K-ras mutations are found in approximately half of all colorectal tumors examined, To explore the possibility of detecting mutated K-ras rapidly and efficiently in DNAs isolated from fecal material, we applied the mutant allele specific amplification (MASA)-PCR method to DNA from feces of patients with colorectal tumors, Among 55 colorectal adenocarcinomas or adenomas examined, 19 were found to carry K-ras mutations in codons 12 or 13, We were able to PCR-amplify DNAs isolated from feces of 15 of these 19 patients, but in only three of the fecal samples, we were able to detect the K-ras mutations corresponding to tumor DNA by MASA and ethidium-bromide staining of the gel, The carcinomas in these three cases were more than 40 mm x 40 mm in size and located in the sigmoid colon or rectum, However, we identified the K-ras mutations in fecal DNAs of additional seven patients by MASA when the gels were blotted and probed with a radio-labeled oligonncleotide; the tumors in those patients had arisen in the distal half of the colon and the smallest of these tumors was only 7 mm x 5 mm, No K-ras mutations were detectable in feces of the remaining five cases, whose tumors were relatively small and/or located in the proximal region, The results suggested that the MASA-PCR system has potential for development as a simple, rapid and noninvasive method for diagnosing the presence of colorectal tumors that carry mutant K-ras alleles, particularly tumors located in the distal colon.	JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT INTERNAL MED, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT SURG, TOSHIMA KU, TOKYO 170, JAPAN; EISAI & CO LTD, TSUKUBA RES LABS, IBARAKI, OSAKA, JAPAN; HAMAMATSU MED UNIV, DEPT SURG 2, SHIZUOKA, JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Eisai Co Ltd; Hamamatsu University School of Medicine								AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BOS JL, 1989, CANCER RES, V49, P4682; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; SATO T, 1990, CANCER RES, V50, P7184; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STORK P, 1991, ONCOGENE, V6, P857; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOBI M, 1994, J NATL CANCER I, V86, P1007; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	12	92	114	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1441	1445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731696				2022-12-17	WOS:A1995QR65100023
J	LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R				LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R			POLYMORPHISMS AND PROBABLE LACK OF MUTATION IN THE WAF1-CIP1 GENE IN COLORECTAL-CANCER	ONCOGENE			English	Note						WAF1-CTP1 GENE; POLYMORPHISM; COLORECTAL	GRADIENT GEL-ELECTROPHORESIS; WILD-TYPE P53; ALLELOTYPE; PROTEIN; APOPTOSIS; INHIBITOR; KINASES; P21	WAF1/CIP1, a gene up-regulated by p53 encodes an inhibitor of cyclin-dependent kinases. Induction of WAF1/CIP1 in cells,vith intact p53 is believed to be instrumental in cell cycle arrest and apoptosis caused by DNA damage. In a model system, WAF1/CIP1 has been shown to have tumor suppressive activity. It is not known however whether WAF1/CIP1 is mutated in human primary tumors. Cells from colorectal cancer have been shown to acquire a series of genetic alterations, including frequent p53 mutations. Thus colorectal tumors, particularly those without identified p53 mutations, are good candidate to search for putative WAF1/CIP1 mutations. DNA extracted from 45 tumors, (including 28 tumors for which p53 mutations had previously been searched for and not found) were PCR amplified for exon 2 of WAF1/CIP1. A search for point mutations was performed in each amplified product using a denaturing gradient gel electrophoresis (DGGE) technique which enables the efficient screening of codons 9 to 139 (i.e. 80% of the WAF1/CIP1 coding sequence). TWO different DNA variants were identified and shown to be present in constitutional DNAs of the corresponding patients. The first variant, a C to A transversion at codon 31, changes a serine for an arginine and was detected in eight tumors (18% of the cases). The second variant, detected in a single case (2%) is a silent A to T transversion at the third base of codon 91. DNA extracted from 70 unrelated members from the Centre d'Etude du Polymorphisme Humain (CEPH) was screened for these polymorphisms. The ser/arg polymorphism of codon 31 was detected in seven cases (10%) thus suggesting that it is not associated with a marked colorectal cancer predisposition. The polymorphism on codon 91 was not detected. Two additional variants (arginine to histidine at position 67 and threonine to methionine at position 80) were observed once each in the CEPH family members. Somatic mutation of the WAF1/CIP1 gene was not observed, indicating that, unless there are hot spots for mutations outside the screened region, this gene is not a frequent site of point mutation in colorectal cancer.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			laurent-puig, pierre/B-2226-2013; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORITA R, 1991, CANCER RES, V51, P820; MOYRET C, 1994, ONCOGENE, V9, P1739; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SATO T, 1991, CANCER RES, V51, P5118; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	26	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					599	601						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845685				2022-12-17	WOS:A1995QF64800021
J	SUZUKI, T; HIRAI, H; YOSHIDA, M				SUZUKI, T; HIRAI, H; YOSHIDA, M			TAX PROTEIN OF HTLV-1 INTERACTS WITH THE REL HOMOLOGY DOMAIN OF NF-KAPPA-B P65 AND C-REL PROTEINS BOUND TO THE NF-KAPPA-B BINDING-SITE AND ACTIVATES TRANSCRIPTION	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; TRANSACTIVATOR; ENHANCER; PROMOTER; P40X	Tax protein of human T cell leukemia virus type 1 (HTLV-1) enhances transcription of several cellular genes through activation of a specific enhancer, the NF-kappa B binding site. We found previously that Tax binds to NF-kappa B p50, which is a member of the Rel/NF-kappa B family proteins, and associates with the DNA sequence of the NF-kappa B binding site. In the present study, we tested other NF-kappa B family proteins and found that NF-kappa B p65 and c-Rel proteins also bind to Tax and that their complexes with Tax bind to the DNA sequence of the NF-kappa B binding site. The Tax binding site on NF-kappa B p50 is the Rel homology domain, which is conserved in the Rel/NF-kappa B family proteins. The formations of these complexes by Tax mutants were well correlated with their transactivating capacities. In F9 embryonic carcinoma cells, Tax enhanced transcription synergistically with NF-kappa B p65 or c-Rel. Thus Tax interacts with the Rel homology domain of Rel/NF-kappa B family proteins which bind to the NF-kappa B binding site and activates transcription.	UNIV TOKYO,INST MED SCI,DEPT CELL & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BAUERLE PA, 1988, CELL, V53, P211; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GESSAIN A, 1985, LANCET, V2, P407; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KIYOKAWA T, 1984, JPN J CANCER RES, V75, P747; LANOIX J, 1994, ONCOGENE, V9, P841; Leonardo MJ, 1998, CELL, V58, P227; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	36	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3099	3105						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936632				2022-12-17	WOS:A1994PM65800001
J	DALY, RJ; BINDER, MD; SUTHERLAND, RL				DALY, RJ; BINDER, MD; SUTHERLAND, RL			OVEREXPRESSION OF THE GRB2 GENE IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; MITOGENIC SIGNAL TRANSDUCTION; RETINOIC ACID RECEPTOR; PHOSPHOLIPASE-C; ADAPTER PROTEIN; TRANSGENIC MICE; EGF RECEPTOR; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING	A receptor blotting technique was used to detect SH2 domain containing epidermal growth factor receptor (EGFR) substrates that exhibited differential expression either between normal breast epithelial cells and breast cancer cells or between different human breast cancer cell lines. This identified a 25 kD protein, subsequently identified as Grb2, which was markedly overexpressed in three breast cancer cell lines (MCF-7, MDA-MB-361 and -453) relative to both normal breast epithelial cells and the majority of breast cancer cell lines. Northern blot analysis revealed that 7/19 breast cancer cell lines exhibited more than twofold overexpression of Grb2 mRNA, with overexpression correlating with high expression of erbB receptors. In MCF-7, MDA-MB-361 and -453 cells the overexpression of Grb2 mRNA and protein was accompanied by a small amplification of the Grb2 gene locus. Overexpression of Grb2 correlated with increased complex formation between Grb2 and the hSos-1 Ras GDP-GTP exchange protein. This upregulation of the Ras signalling pathway might modulate the growth factor sensitivity of human breast cancer cells and therefore play a role in tumour progression.			DALY, RJ (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Binder, Michele/0000-0002-4494-6717; Daly, Roger/0000-0002-5739-8027				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BOS JL, 1989, CANCER RES, V49, P4682; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUCKLEY MF, 1993, ONCOGENE, V8, P5127; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1988, GROWTH FACTORS ONCOG, P119; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN E, 1993, NAT GENET, V5, P242, DOI 10.1038/ng1193-242; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HARLOW E, 1988, ANTIBODIES LABORATOR; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KOGA M, 1990, CANCER RES, V50, P4849; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500	47	92	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2723	2727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058337				2022-12-17	WOS:A1994PC05400034
J	RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M				RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M			TERMINAL DIFFERENTIATION AND APOPTOSIS IN EXPERIMENTAL LUNG METASTASES OF HUMAN OSTEOGENIC-SARCOMA CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TUMOR PROGRESSION; MUTANT; MUTATIONS; PROTEIN; GROWTH; GENE; INDUCTION	Human SAOS-2 osteogenic sarcoma cells are not metastatic in nude mice and do not express p53. We have selected a variant line (SAOS-LM2) that is tumorigenic and metastatic in nude mice. These cells were transfected with the p53 wild-type (p53(wt)) or mutated (p53(mut) 143A) gene, whose expression was verified by reverse transcriptase PCR, cDNA sequencing, and protein immunoprecipitation. Cells were injected i.v. into nude mice, and 4 months later, the mice were necropsied. All cell lines produced a similar number of visible lung metastases, albeit of different sizes, Microscopic examination revealed that most lung metastases in mice injected with p53(wt) cells (but not p53(mut) 143A or control cells) consisted of osteoid matrix and apoptotic;cells. Expression of either p53(wt) or p53(mut) 143A verified the origin of the metastases. These data suggest that transfection of SAOS-LM2 cells with p53(wt) is associated with in vivo induction of terminal differentiation and apoptosis that inhibit progressive growth of metastases.			RADINSKY, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HMB 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NCI NIH HHS [R35-CA 42107, CA 41525, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672, R01CA041525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARELI M, 1993, ANTICANCER RES, V13, P1619; BARELI M, 1989, BLOOD, V73, P281; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coolidge BJ, 1979, ANIMAL HISTOLOGY PRO; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIAS L, 1991, LEUKEMIA, V5, P879; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIDLER IJ, 1990, CANCER RES, V50, P6130; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FOTI A, 1991, BLOOD, V77, P2441; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KEY L, 1984, NEW ENGL J MED, V310, P409, DOI 10.1056/NEJM198402163100701; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUCA M, 1993, INT J ONCOL, V3, P19; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RADINSKY R, 1991, INT J CANCER, V48, P148; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rodan GA, 1983, BONE MINERAL RES ANN, V2, P244; RODAN SB, 1987, CANCER RES, V47, P4961; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIESS YH, 1986, ENDOCRINOLOGY, V118, P1340, DOI 10.1210/endo-118-4-1340; Thompson SW, 1966, SELECTED HISTOCHEMIC; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, ONCOGENE, V8, P2555	48	92	93	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1877	1883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208533				2022-12-17	WOS:A1994NR68500010
J	VEILLETTE, A; CARON, L; FOURNEL, M; PAWSON, T				VEILLETTE, A; CARON, L; FOURNEL, M; PAWSON, T			REGULATION OF THE ENZYMATIC FUNCTION OF THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK BY THE NONCATALYTIC SH2 AND SH3 DOMAINS	ONCOGENE			English	Article							AMINO-TERMINAL DOMAIN; SIGNAL TRANSDUCTION; CD4 RECEPTOR; CYTOPLASMIC DOMAINS; CROSS-LINKING; C-ABL; V-FPS; PHOSPHORYLATION; ACTIVATION; GENE	The enzymatic activity of the lymphocyte-specific tyrosine protein kinase p56lck appears to be tightly regulated by phosphorylation of the conserved carboxy-terminal tyrosine residue 505. Indeed, substitution of this tyrosine residue by a non-phosphorylatable phenylalanine results in a constitutively activated version of p56lck that can transform rodent fibroblasts. In this report, we evaluate the functions of the conserved non-catalytic Src homology (SH) domains 2 and 3 of p56lck in the regulation of its enzymatic activity in NIH3T3 fibroblasts. We found that deletion of the SH2 or, to a lesser extent, the SH3 domain of p56lck resulted in an increase in the tyrosine protein kinase activity of wild-type Lck polypeptides. The SH2 domain (but not the SH3 domain) was also required for full oncogenic transformation by Lck molecules activated through removal of tyrosine 505. This effect did not appear to be the result of a diminution of the enhanced catalytic activity of F505 Lck polypeptides. However, it may relate to the findings that the SH2 domain can bind and possibly enhance phosphorylation of specific phosphotyrosine-containing proteins. Taken together, these observations imply roles for the non-catalytic SH2 and SH3 domains in the regulation of the catalytic activity of p56lck. They suggest that the enzymatic function of this Src-related polypeptide is physiologically repressed by processes dependent on the presence of the SH2 and SH3 sequences. Moreover, they indicate that the SH2 domain also plays a positive role in the function of activated p56lck molecules in NIH3T3 cells.	MCGILL UNIV, MCGILL CANC CTR, DEPT BIOCHEM & ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	VEILLETTE, A (corresponding author), MCGILL UNIV, MCGILL CANC CTR, DEPT MED, ROOM 701, MCINTYRE MED SCI BLDG, MONTREAL H3G 1Y6, QUEBEC, CANADA.		Pawson, Tony J/E-4578-2013					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, 1989, ONCOGENES, P121; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	48	92	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					971	980						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570157				2022-12-17	WOS:A1992HP64200017
J	BOEHM, T; FORONI, L; KENNEDY, M; RABBITTS, TH				BOEHM, T; FORONI, L; KENNEDY, M; RABBITTS, TH			THE RHOMBOTIN GENE BELONGS TO A CLASS OF TRANSCRIPTIONAL REGULATORS WITH A POTENTIAL NOVEL PROTEIN DIMERIZATION MOTIF	ONCOGENE			English	Note											BOEHM, T (corresponding author), LAB MOLEC BIOL,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Kennedy, Martin A/A-4942-2008; Rabbitts, Terence/D-6262-2016	Kennedy, Martin A/0000-0002-6445-8526; Rabbitts, Terence/0000-0002-4982-2609				BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2	19	92	92	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1103	1105						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115645				2022-12-17	WOS:A1990DP41500026
J	LIEBERMANN, DA; HOFFMANLIEBERMANN, B				LIEBERMANN, DA; HOFFMANLIEBERMANN, B			PROTO-ONCOGENE EXPRESSION AND DISSECTION OF THE MYELOID GROWTH TO DIFFERENTIATION DEVELOPMENTAL CASCADE	ONCOGENE			English	Article											LIEBERMANN, DA (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.							BARTOCCI A, 1987, P NATL ACAD SCI USA, V84, P6179, DOI 10.1073/pnas.84.17.6179; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS SJ, 1987, BLOOD, V70, P1233; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONDA TJ, 1985, EMBO J, V6, P3995; GOWDA SD, 1986, J CLIN INVEST, V77, P271, DOI 10.1172/JCI112287; GROSSO LE, 1985, CANCER RES, V45, P847; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEIDORN K, 1987, BLOOD, V70, P456; HOFFMANLIEBERMANN B, 1981, INT J CANCER, V28, P615, DOI 10.1002/ijc.2910280514; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1985, MOL CELL BIOL, V5, P991, DOI 10.1128/MCB.5.5.991; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HORAK H, 1982, EXP HEMATOL, V10, P123; IHLE JN, 1982, J IMMUNOL, V129, P2431; JAFFE BD, 1988, ONCOGENE, V2, P167; LEE J, 1987, BLOOD, V69, P1542; LIEBERMANN D, 1978, CELL, V15, P823, DOI 10.1016/0092-8674(78)90267-2; LIEBERMANN D, 1982, INT J CANCER, V29, P159, DOI 10.1002/ijc.2910290208; LIEBERMANN D, 1986, MOL CELL BIOL, V6, P218, DOI 10.1128/MCB.6.1.218; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN D, 1983, NATURE, V306, P342, DOI 10.1038/306342a0; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN D, 1977, NATURE, V269, P173, DOI 10.1038/269173a0; LIEBERMANN D, 1979, P NATL ACAD SCI USA, V76, P3353, DOI 10.1073/pnas.76.7.3353; LIEBERMANN D, 1980, VIROLOGY, V107, P121, DOI 10.1016/0042-6822(80)90278-0; LOTEM J, 1988, INT J CANCER, V41, P101, DOI 10.1002/ijc.2910410119; LOTEM J, 1986, EMBO J, V5, P2163, DOI 10.1002/j.1460-2075.1986.tb04480.x; LOTEM J, 1981, INT J CANCER, V28, P375, DOI 10.1002/ijc.2910280318; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; ONOZAKI K, 1988, J IMMUNOL, V140, P112; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PRYSTOWSKY MB, 1983, EXP HEMATOL, V11, P931; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SARBAN E, 1985, NATURE, V316, P64; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SHABO Y, 1988, INT J CANCER, V41, P622, DOI 10.1002/ijc.2910410424; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TRINCHIERI G, 1986, J EXP MED, V164, P1209; WIENSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35	66	92	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					583	592						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2471131				2022-12-17	WOS:A1989U768800008
J	Franzetti, GA; Laud-Duval, K; van der Ent, W; Brisac, A; Irondelle, M; Aubert, S; Dirksen, U; Bouvier, C; de Pinieux, G; Snaar-Jagalska, E; Chavrier, P; Delattre, O				Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Irondelle, M.; Aubert, S.; Dirksen, U.; Bouvier, C.; de Pinieux, G.; Snaar-Jagalska, E.; Chavrier, P.; Delattre, O.			Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells	ONCOGENE			English	Article							CHROMOSOME-TRANSLOCATION; MOLECULAR PATHOGENESIS; TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; GENOMIC LANDSCAPE; MELANOMA-CELLS; HUMAN TUMORS; IN-VITRO; GROWTH; EXPRESSION	Ewing sarcoma is characterized by the expression of the chimeric EWSR1-FLI1 transcription factor. Proteomic analyses indicate that the decrease of EWSR1-FLI1 expression leads to major changes in effectors of the dynamics of the actin cytoskeleton and the adhesion processes with a shift from cell-to-cell to cell-matrix adhesion. These changes are associated with a dramatic increase of in vivo cell migration and invasion potential. Importantly, EWSR1-FLI1 expression, evaluated by single-cell RT-ddPCR/immunofluorescence analyses, and activity, assessed by expression of EWSR1-FLI1 downstream targets, are heterogeneous in cell lines and in tumours and can fluctuate along time in a fully reversible process between EWSR1-FLI1(high) states, characterized by highly active cell proliferation, and EWSR1-FLI1(low) states where cells have a strong propensity to migrate, invade and metastasize. This new model of phenotypic plasticity proposes that the dynamic fluctuation of the expression level of a dominant oncogene is an intrinsic characteristic of its oncogenic potential.	[Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Irondelle, M.; Chavrier, P.; Delattre, O.] PSL Res Univ, Inst Curie, Paris 05, France; [Franzetti, G-A; Laud-Duval, K.; van der Ent, W.; Brisac, A.; Delattre, O.] Inst Curie, Res Ctr, INSERM U830, Genet & Biol Pediat Tumors Grp, 26 Rue Ulm, F-75005 Paris, Ile De France, France; [van der Ent, W.; Snaar-Jagalska, E.] Leiden Univ, Inst Biol, Leiden, Netherlands; [Irondelle, M.; Chavrier, P.] Inst Curie, Res Ctr, UMR144, Membrane & Cytoskeleton Dynam Grp, Paris, France; [Irondelle, M.] Inst Curie, Res Ctr, UMR144, Cell & Tissue Imaging Facil PICT IBiSA, Paris, France; [Aubert, S.] Univ Hosp, Dept Pathol, Lille, France; [Dirksen, U.] Univ Hosp Muenster, Dept Pediat Hematol & Oncol, Albert Schweitzer Campus 1,A1, Munster, Germany; [Dirksen, U.] Westfalian Wilhelms Univ, Munster, Germany; [Bouvier, C.] La Timone Univ Hosp, Dept Pathol, Marseille, France; [de Pinieux, G.] Univ Hosp Tours, Dept Pathol, Chambray Les Tours, France; [de Pinieux, G.] Univ Tours, Chambray Les Tours, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Leiden University; Leiden University - Excl LUMC; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; University of Munster; University of Munster; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Tours; Universite de Tours	Delattre, O (corresponding author), Inst Curie, Res Ctr, INSERM U830, Genet & Biol Pediat Tumors Grp, 26 Rue Ulm, F-75005 Paris, Ile De France, France.	Olivier.delattre@curie.fr	Dirksen, Uta/AGX-8472-2022; CHAVRIER, Philippe/B-4707-2010; CHAVRIER, Philippe/AAG-2645-2020	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; van der Ent, Wietske/0000-0003-2165-9624; delattre, olivier/0000-0002-8730-2276	INSERM; Ligue Nationale Contre le Cancer (Equipe labellisse); Institut National du Cancer [PLBIO14-237]; European PROVABES [ERA-649, 01KT1310]; ASSET [FP7- HEALTH- 2010-259348]; EEC [HEALTH-F2-2013-602856]; German Cancer Aid [DKH 108128]; Ministere de l'Enseignement Superieur et de la Recherche (France); FRM [FDT20130928190]; Stichting Kinderen Kankervrij [30677]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale Contre le Cancer (Equipe labellisse); Institut National du Cancer(Institut National du Cancer (INCA) France); European PROVABES; ASSET; EEC; German Cancer Aid(Deutsche Krebshilfe); Ministere de l'Enseignement Superieur et de la Recherche (France); FRM(Fondation pour la Recherche Medicale); Stichting Kinderen Kankervrij	This work was supported by grants from the Institut Curie, the INSERM, the Ligue Nationale Contre le Cancer (Equipe labellisse), the Institut National du Cancer (PLBIO14-237), the European PROVABES (ERA-649 NET TRANSCAN JTC- 2011; 01KT1310), ASSET (FP7- HEALTH- 2010-259348), and EEC (HEALTH-F2-2013-602856) projects, the German Cancer Aid (DKH 108128) and the following associations: the Societe Francaise de lutte contre les Cancers et des leucemies de l'enfant et de l'adolescent, the Etoile de Martin, Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon, Enfants et Sante, les Amis de Claire and M la vieavec Lisa. Georges-Alain Franzetti was supported by a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche (France) and from the FRM (FDT20130928190). Wietske van der Ent was supported by Stichting Kinderen Kankervrij (Grant No. 30677). The authors are grateful to Laura Brulle-Soumare (INSERM U1143, CNRS UMR3666, Institut Curie, Paris, France) for her help with mice experiments. The authors would like to acknowledge the Nikon Imaging Center @ Institut Curie-CNRS and the Cell and Tissue Imaging Platform (member of FranceBioimaging) of the Genetics and Developmental Biology Department (UMR3215/U934) of Institut Curie, and also the Cytometry Plateform of Tumor Biology Department of Institut Curie.	Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; Amsellem V, 2005, EXP CELL RES, V304, P443, DOI 10.1016/j.yexcr.2004.10.035; Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Ban J, 2014, CANCER RES, V74, P6578, DOI 10.1158/0008-5472.CAN-14-1736; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; BIEDLER JL, 1973, CANCER RES, V33, P2643; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Chakrabarti Lina, 2012, Front Oncol, V2, P82, DOI 10.3389/fonc.2012.00082; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; DAHLIN DC, 1961, J BONE JOINT SURG AM, V43, P185, DOI 10.2106/00004623-196143020-00004; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deley M-CL, 2014, J CLIN ONCOL, V32, P2440; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Ghotra VPS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031281; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; HaDuong JH, 2015, PEDIATR CLIN N AM, V62, P179, DOI 10.1016/j.pcl.2014.09.012; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; Kovar H, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00054; Krook MA, 2014, MOL CANCER RES, V12, P953, DOI 10.1158/1541-7786.MCR-13-0668; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Montagnac G, 2013, NATURE, V502, P567, DOI 10.1038/nature12571; Noursadeghi M, 2008, J IMMUNOL METHODS, V329, P194, DOI 10.1016/j.jim.2007.10.015; Poomthavorn P, 2009, ENDOCR-RELAT CANCER, V16, P991, DOI 10.1677/ERC-08-0340; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sengupta A, 2013, INT J ONCOL, V43, P803, DOI 10.3892/ijo.2013.2016; Sibarita JB, 2005, ADV BIOCHEM ENG BIOT, V95, P201, DOI 10.1007/b102215; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Stoll G, 2013, NUCLEIC ACIDS RES, V41, P8853, DOI 10.1093/nar/gkt678; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; van der Ent W, 2014, J PATHOL, V233, P415, DOI 10.1002/path.4378; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; Wiles Elizabeth T, 2013, Genes Cancer, V4, P486, DOI 10.1177/1947601913506115	49	91	94	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3505	3514		10.1038/onc.2016.498	http://dx.doi.org/10.1038/onc.2016.498			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28135250	hybrid, Green Published			2022-12-17	WOS:000403878600001
J	Karunarathna, U; Kongsema, M; Zona, S; Gong, C; Cabrera, E; Gomes, AR; Man, EPS; Khongkow, P; Tsang, JWH; Khoo, US; Medema, RH; Freire, R; Lam, EWF				Karunarathna, U.; Kongsema, M.; Zona, S.; Gong, C.; Cabrera, E.; Gomes, A. R.; Man, E. P. S.; Khongkow, P.; Tsang, J. W-H; Khoo, U-S; Medema, R. H.; Freire, R.; Lam, E. W-F			OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance	ONCOGENE			English	Article							EXPRESSION; PROTEIN; DOMAIN; BINDING; ENZYME; CELLS; OVEREXPRESSION; SPECIFICITY; DOXORUBICIN; MUTATIONS	The forkhead transcription factor FOXM1 has a key role in DNA damage response, and its deregulated overexpression is associated with genotoxic drug resistance in breast cancer. However, little is known about the posttranslational mechanisms by which FOXM1 expression is regulated by genotoxic agents and how they are deregulated in resistant cells. Initial co-immunoprecipitation studies verified previous proteomic analysis finding that the OTUB1 is a novel FOXM1-interacting protein. Western blot analysis showed that both OTUB1 and FOXM1 expression reduced upon genotoxic agent treatment in MCF-7 cells, but remained relatively constant in resistant cells. FOXM1 expression reduced upon OTUB1 depletion by siRNA and increased with OTUB1 overexpression in MCF-7 cells, arguing that OTUB1 positively regulates FOXM1 expression. In agreement, co-immunoprecipitation experiments demonstrated that FOXM1 expression is associated with OTUB1 binding but inversely correlates with conjugation to the protein degradation-associated Lys-48-linked ubiquitin-chains. Overexpression of wild-type (WT) OTUB1, but not the OTUB1( C91S) mutant, disrupted the formation of Lys48-linked ubiquitin-conjugates on FOXM1. Importantly, knockdown of OTUB1 by siRNA resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overexpression of WT OTUB1, but not the OTUB1( C91S) mutant, significantly enhances the half-life of FOXM1. In addition, proliferative and clonogenic assays also show that OTUB1 can enhance the proliferative rate and epirubicin resistance through targeting FOXM1, as OTUB1 has little effect on FOXM1-deficient cells. The physiological relevance of the regulation of FOXM1 by OTUB1 is further underscored by the significant correlations between FOXM1 and OTUB1 expression in breast cancer patient samples. Cox-regression survival analysis indicates that OTUB1 overexpression is linked to poorer outcome in particular in patients treated with chemotherapy. Collectively, these data suggest that OTUB1 limits the ubiquitination and degradation of FOXM1 in breast cancer and has a key role in genotoxic agent resistance.	[Karunarathna, U.; Kongsema, M.; Zona, S.; Gong, C.; Gomes, A. R.; Khongkow, P.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London, England; [Gong, C.; Man, E. P. S.; Khoo, U-S] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Cabrera, E.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, Tenerife, Spain; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Imperial College London; University of Hong Kong; Universidad de la Laguna; University of Hong Kong; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, ICTEM, Hammersmith Hosp Campus,Room 134,1st Floor, London W12 0NN, England.	eric.lam@imperial.ac.uk	Kongsema, Mesayamas/H-3063-2017; Cabrera, Elisa/GPX-3455-2022; Khoo, Ui Soon/C-4293-2009; Freire, Raimundo/Q-7660-2019; Khoo, Ui Soon/C-1345-2014; Lam, Eric W-F/AAW-8566-2020; Khoo, Ui Soon/K-2041-2019	Khoo, Ui Soon/0000-0003-2200-7505; Freire, Raimundo/0000-0003-4473-8894; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381; Khongkow, Pasarat/0000-0003-3068-2412	Cancer Research UK; Breast Cancer Campaign; BBSRC studentship; Royal Thai Government Scholarship; Committee on Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; Biotechnology and Biological Sciences Research Council [1243234, BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; BBSRC studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Royal Thai Government Scholarship; Committee on Research and Conference Grants from the University of Hong Kong (CRCG); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Breast Cancer Campaign	EW-F Lam and AR Gomes were supported by grants from Cancer Research UK, EW-F Lam and S Zona by grants from Breast Cancer Campaign. U Karunarathna is the recipient of a BBSRC studentship. P Khongkow and M Kongsema were supported by grants from the Royal Thai Government Scholarship. US Khoo received funding from Committee on Research and Conference Grants from the University of Hong Kong (CRCG) (201007176118). We also thank for help with this work.	CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cohen MM, 2011, J CELL SCI, V124, P1403, DOI 10.1242/jcs.079293; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fox EM, 2008, STEROIDS, V73, P1039, DOI 10.1016/j.steroids.2008.04.006; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Iglesias-Gato D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0280-2; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Li YH, 2014, J BIOL CHEM, V289, P5097, DOI 10.1074/jbc.M113.533109; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu X, 2014, PATHOL RES PRACT, V210, P770, DOI 10.1016/j.prp.2014.05.008; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mevissen TET, 2013, CELL, V154, P169, DOI 10.1016/j.cell.2013.05.046; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Savarese DMF, 1997, J CLIN ONCOL, V15, P2981, DOI 10.1200/JCO.1997.15.8.2981; SINGH S, 1993, HUM GENET, V90, P635; Stanisic V, 2009, J BIOL CHEM, V284, P16135, DOI 10.1074/jbc.M109.007484; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Wang T, 2009, J MOL BIOL, V386, P1011, DOI 10.1016/j.jmb.2008.12.085; Weissman AM, 2011, NAT REV MOL CELL BIO, V12, P605, DOI 10.1038/nrm3173; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258	37	91	94	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1433	1444		10.1038/onc.2015.208	http://dx.doi.org/10.1038/onc.2015.208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26148240	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000372196400009
J	Skibinski, A; Kuperwasser, C				Skibinski, A.; Kuperwasser, C.			The origin of breast tumor heterogeneity	ONCOGENE			English	Review							MAMMARY EPITHELIAL-CELLS; BASAL-LIKE SUBTYPE; STEM-CELLS; MOLECULAR PORTRAITS; MESENCHYMAL TRANSITION; STATE TRANSITIONS; GLAND DEVELOPMENT; PROGENITOR CELLS; MOUSE MODELS; LIFE-SPAN	How breast diversity is generated is a fascinating and fundamental question with important clinical implications. It is clear that the diversity of phenotypes displayed by breast cancer cells reflects the array of cell types present in the disease-free breast epithelium, including luminal, basal and stem cells. Therefore, it is hypothesized that the molecular regulators governing normal development of the breast epithelium may double as engines of breast tumor diversity. In the past few years, a deepened understanding of the mammary epithelial hierarchy has prompted the search for the cellular precursors of breast tumors. At the same time, the use of novel experimental strategies including the new technology of massively parallel sequencing has provided insight into the origin and evolution of breast tumors. Here, we review the current understanding of the basis of the intrinsic subtypes and the sources of inter-tumor heterogeneity.	[Skibinski, A.; Kuperwasser, C.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA; [Skibinski, A.; Kuperwasser, C.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Kuperwasser, C (corresponding author), Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, 800 Washington St,Box 5609, Boston, MA 02111 USA.	Charlotte.Kuperwasser@tufts.edu			NCI NIH HHS [R01 CA170851] Funding Source: Medline; NICHD NIH HHS [R01 HD073035] Funding Source: Medline; NIGMS NIH HHS [T32 GM008448] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD073035] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA170851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asselin-Labat ML, 2008, COLD SH Q B, V73, P469, DOI 10.1101/sqb.2008.73.020; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Booth BW, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1538; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chang TH, 2014, BREAST CANCER RES, V16, P1; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; de Ruijter TC, 2011, J CANCER RES CLIN, V137, P183, DOI 10.1007/s00432-010-0957-x; DEOME KB, 1959, CANCER RES, V19, P515; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hollern DP, 2014, BREAST CANCER RES, V16, P3; HOSHINO K, 1967, NATURE, V213, P193, DOI 10.1038/213193a0; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Liu JC, 2014, EMBO MOL MED, V6, P1542, DOI 10.15252/emmm.201404402; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Melchor L, 2014, J PATHOL, V233, P124, DOI 10.1002/path.4345; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morel E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003000; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Tsai YC, 1996, CANCER RES, V56, P402; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553	86	91	92	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5309	5316		10.1038/onc.2014.475	http://dx.doi.org/10.1038/onc.2014.475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25703331	Green Accepted			2022-12-17	WOS:000363479200001
J	Huang, H; Daniluk, J; Liu, Y; Chu, J; Li, Z; Ji, B; Logsdon, CD				Huang, H.; Daniluk, J.; Liu, Y.; Chu, J.; Li, Z.; Ji, B.; Logsdon, C. D.			Oncogenic K-Ras requires activation for enhanced activity	ONCOGENE			English	Article						cancer; Ras-GTP	PANCREATIC-CANCER; GENE MUTATION; MICE; PROGRESSION; EXPRESSION; INDUCTION; KRAS	Oncogenic Ras mutations are widely considered to be locked in a permanent 'On' state and 'constitutively active'. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.	[Huang, H.; Daniluk, J.; Liu, Y.; Chu, J.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Huang, H.; Li, Z.] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Daniluk, J.] Med Univ Bialystok, Dept Gastroenterol & Internal Med, Bialystok, Poland; [Ji, B.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Naval Medical University; Medical University of Bialystok; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center	Ji, B (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.	ji.baoan@mayo.edu; clogsdon@mdanderson.org	Daniluk, Jaroslaw/T-3437-2018	Daniluk, Jaroslaw/0000-0002-0787-1461	NIH [DK052067, CA016672, P20 CA101936, CA155165, P50 CA102701]; Lockton Endowment; National Natural Science Foundation of China [30910103911]; NATIONAL CANCER INSTITUTE [P20CA101936, R21CA155165, K12CA090628, P50CA102701, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052067] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lockton Endowment; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr David Tuveson (UK Cambridge Research Institute) for providing the mouse pancreatic cancer cell line K8484. This work was supported by NIH DK052067, CA016672, P20 CA101936, CA155165, P50 CA102701 and the Lockton Endowment. The work was supported in part by grant 30910103911 (to Z Li) from the National Natural Science Foundation of China.	Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji BA, 2008, GENESIS, V46, P390, DOI 10.1002/dvg.20411; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KOEFFLER HP, 1991, WESTERN J MED, V155, P505; Lu XH, 2002, CHINESE MED J-PEKING, V115, P1632; Parsons BL, 2009, BIOMARK MED, V3, P757, DOI 10.2217/BMM.09.95; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; SPAARGAREN M, 1995, GENE EXPRESSION, V4, P345; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Yan L, 2005, GASTROENTEROLOGY, V128, P2124, DOI 10.1053/j.gastro.2005.03.006	21	91	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					532	535		10.1038/onc.2012.619	http://dx.doi.org/10.1038/onc.2012.619			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334325	Green Accepted			2022-12-17	WOS:000330214600014
J	Ceppi, P; Peter, ME				Ceppi, P.; Peter, M. E.			MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells	ONCOGENE			English	Review						miRNAs; epithelial-to-mesenchymal transition; cancer stem cells	E-CADHERIN EXPRESSION; HUMAN OVARIAN-CANCER; DRUG-RESISTANCE; MIR-200 FAMILY; ALDEHYDE DEHYDROGENASE; PROSTATE-CANCER; DOWN-REGULATION; STEM/PROGENITOR CELLS; UNFAVORABLE PROGNOSIS; DYNAMIC EQUILIBRIUM	Concepts and experimental models derived from basic research have been successfully applied to the field of molecular oncology, tremendously increasing our knowledge of the nature and the progression of tumors. The process of epithelial-to-mesenchymal transition, the cancer stem cell hypothesis, and their functional association and interdependence represent some of the most significant examples. The molecular determinants underlying the plasticity of cancers are currently the object of extensive research efforts, and a substantial body of evidence suggests that these models can be connected by the regulatory role of microRNAs, small noncoding RNA molecules with a fundamental role in many cellular functions. This review will highlight and discuss this link and its possible implications for the fight against cancer.	[Ceppi, P.; Peter, M. E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Peter, ME (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 6-123, Chicago, IL 60611 USA.	m-peter@northwestern.edu	Ceppi, Paolo/GPS-8668-2022	Peter, Marcus Ernst/0000-0003-3216-036X; Ceppi, Paolo/0000-0002-3632-8476				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Achuthan S, 2011, J BIOL CHEM, V286, P37813, DOI 10.1074/jbc.M110.200675; Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Akunuru S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.93; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043726; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Barroso-delJesus A, 2008, MOL CELL BIOL, V28, P6609, DOI 10.1128/MCB.00398-08; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beillard E, 2012, RNA, V18, P1091, DOI 10.1261/rna.031831.111; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Burgos-Ojeda D, 2012, CANCER LETT, V322, P1, DOI 10.1016/j.canlet.2012.02.002; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chang CJ, 2011, ONCOL REP, V26, P1003, DOI 10.3892/or.2011.1360; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021428, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144]; Chiou GY, 2012, J CONTROL RELEASE, V159, P240, DOI 10.1016/j.jconrel.2012.01.014; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Connelly CM, 2012, J BIOMOL SCREEN, V17, P822, DOI 10.1177/1087057112439606; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Dahiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002436; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Davies JA, 1996, ACTA ANAT, V156, P187; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Di Stefano B, 2011, STEM CELLS, V29, P1684, DOI 10.1002/stem.726; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Du ZY, 2011, DIGEST DIS SCI, V56, P741, DOI 10.1007/s10620-010-1340-0; Duong HQ, 2012, INT J ONCOL, V41, P855, DOI 10.3892/ijo.2012.1516; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Falso MJS, 2012, ANTICANCER RES, V32, P733; Fan XL, 2011, INT J COLORECTAL DIS, V26, P1279, DOI 10.1007/s00384-011-1248-y; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Gentner B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001522; Ghosh G, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-95; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y; Han M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032383; Han ML, 2012, CANCER SCI, V103, P1058, DOI 10.1111/j.1349-7006.2012.02281.x; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Inada S, 1999, SURG TODAY, V29, P493, DOI 10.1007/BF02482343; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jesus ABD, 2009, CELL CYCLE, V8, P394; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jung DE, 2011, PANCREAS, V40, P1180, DOI 10.1097/MPA.0b013e318221b33e; Kamata M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011834; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kobayashi Y, 2011, GYNECOL ONCOL, V121, P390, DOI 10.1016/j.ygyno.2010.12.366; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Kwon O, 2010, CARCINOGENESIS, V31, P1194, DOI 10.1093/carcin/bgq071; Lang MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036248; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Leskela S, 2011, ENDOCR-RELAT CANCER, V18, P85, DOI 10.1677/ERC-10-0148; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Ling ZQ, 2011, INT J MOL MED, V27, P625, DOI 10.3892/ijmm.2011.640; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Ma L, 2010, ACTA BIOCH BIOPH SIN, V42, P593, DOI 10.1093/abbs/gmq067; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mikhail S, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/486954; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Nam EJ, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-18; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pestereva E, 2012, BRIT J CANCER, V106, P1702, DOI 10.1038/bjc.2012.161; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Phuc PV, 2011, ONCOTARGETS THER, V4, P71, DOI 10.2147/OTT.S21431; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Qian PX, 2012, CANCER RES, V72, P6036, DOI 10.1158/0008-5472.CAN-12-1507; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sabisz M, 2009, CELL CYCLE, V8, P3208, DOI 10.4161/cc.8.19.9758; Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z; Salahshor S, 2001, BREAST CANCER RES, V3, P199, DOI 10.1186/bcr295; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862; Sugimura K, 2012, CLIN CANCER RES, V18, P5144, DOI 10.1158/1078-0432.CCR-12-0701; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tang Qing-Lian, 2011, Chin J Cancer, V30, P426; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Tonelli DDP, 2006, BIOTECHNIQUES, V41, P727, DOI 10.2144/000112296; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Uchida Y, 2010, ONCOL REP, V24, P1147, DOI 10.3892/or_00000966; UMBAS R, 1994, CANCER RES, V54, P3929; Vira D, 2012, CANCER METAST REV, V31, P733, DOI 10.1007/s10555-012-9382-8; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vlashi E, 2009, JNCI-J NATL CANCER I, V101, P350, DOI 10.1093/jnci/djn509; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang CX, 2012, ONCOL REP, V28, P1301, DOI 10.3892/or.2012.1951; Wang LJ, 2012, MOL CELL BIOCHEM, V363, P257, DOI 10.1007/s11010-011-1178-6; Wang LX, 2012, ONCOL LETT, V3, P119, DOI 10.3892/ol.2011.431; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Xia HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044206; Xia HP, 2010, J BIOL CHEM, V285, P36995, DOI 10.1074/jbc.M110.133744; Xu CX, 2012, J BIOL CHEM, V287, P34970, DOI 10.1074/jbc.M112.374611; Xu XT, 2012, BRIT J CANCER, V106, P1320, DOI 10.1038/bjc.2012.88; Xue ZF, 2012, J CELL BIOCHEM, V113, P302, DOI 10.1002/jcb.23356; Yang G, 2012, BRIT J CANCER, V106, P1512, DOI 10.1038/bjc.2012.126; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Yang YP, 2012, BIOMATERIALS, V33, P1462, DOI 10.1016/j.biomaterials.2011.10.071; Yi H, 2012, KOREAN J PHYSIOL PHA, V16, P11, DOI 10.4196/kjpp.2012.16.1.11; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhang LL, 2012, J CANCER RES CLIN, V138, P675, DOI 10.1007/s00432-011-1146-2	193	91	97	2	36	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					269	278		10.1038/onc.2013.55	http://dx.doi.org/10.1038/onc.2013.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23455327				2022-12-17	WOS:000330214000001
J	Fang, YX; Gao, WQ				Fang, Y-X; Gao, W-Q			Roles of microRNAs during prostatic tumorigenesis and tumor progression	ONCOGENE			English	Review						microRNA; prostate cancer; tumorigenesis; progression; cancer stem cells; castration resistance	EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TRANSCRIPTIONAL ACTIVITY; ATTENUATES PACLITAXEL-RESISTANCE; CANCER STEM-CELLS; ANDROGEN RECEPTOR; CIRCULATING MICRORNAS; GENE-EXPRESSION; CLINICAL-SIGNIFICANCE; NEGATIVE FEEDBACK; SIGNAL TRANSDUCER	Prostate cancer (PCa) is considered to be a frequently diagnosed cancer in males with high mortality worldwide, but the molecular mechanism responsible for prostate tumorigenesis and progression remains unclear. Increasing evidence has shown that microRNAs (miRNAs) play an important role in PCa. In this review, we focus on the current advances about the role of miRNAs in regulating tumorigenesis and progression of PCa, mainly in suppressing or promoting PCa growth and metastasis, and maintaining the pluripotency of PCa stem cells (PCSC). More studies on miRNAs will provide a better understanding of their regulatory mechanisms in PCa.	[Fang, Y-X; Gao, W-Q] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr,Renji Hosp, Shanghai 200127, Peoples R China; [Gao, W-Q] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Stem Cell Res Ctr, Sch Med, Renji Hosp, 1630 Dong Fang Rd, Shanghai 200127, Peoples R China.	gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022		Chinese Ministry of Science and Technology [2012CB966800, 2013CB945600]; National Natural Science Foundation of China [81130038]; Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee Key Disciplines and Specialties Foundation [J50208]; Shanghai Health Bureau Key Disciplines and Specialties Foundation; KC Wong foundation	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee Key Disciplines and Specialties Foundation; Shanghai Health Bureau Key Disciplines and Specialties Foundation; KC Wong foundation	This study was supported by funds to W-Q Gao from the Chinese Ministry of Science and Technology (2012CB966800 and 2013CB945600), the National Natural Science Foundation of China (81130038), Science and Technology Commission of Shanghai Municipality (Pujiang program), Shanghai Education Committee Key Disciplines and Specialties Foundation (J50208), Shanghai Health Bureau Key Disciplines and Specialties Foundation and KC Wong foundation.	Acunzo M, 2012, ONCOGENE, V31, P634, DOI 10.1038/onc.2011.260; Agaoglu FY, 2011, TUMOR BIOL, V32, P583, DOI 10.1007/s13277-011-0154-9; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Al-Alwan M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027339; Alshalalfa M, 2012, ADV BIOINFORMATICS, V2012, DOI DOI 10.1155/2012/839837; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Bao JJ, 2002, CANCER RES, V62, P7264; Barron N, 2012, PROSTATE, V72, P1193, DOI 10.1002/pros.22469; Barton BE, 2004, MOL CANCER THER, V3, P11; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Budd WT, 2012, CHEM BIODIVERS, V9, P857, DOI 10.1002/cbdv.201100386; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen Y, 2011, CANCER PREV RES, V4, P76, DOI 10.1158/1940-6207.CAPR-10-0167; Chiang YP, 2011, J GASTROINTEST SURG, V15, P63, DOI 10.1007/s11605-010-1367-8; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Chiyomaru T, 2011, PROSTATE, DOI [10.1002/pros.21372, DOI 10.1002/PR0S.21372)]; Chuang AY, 2007, AM J SURG PATHOL, V31, P1246, DOI 10.1097/PAS.0b013e31802f5d33; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Dong QC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010147; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Folini M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-12; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Fuse M, 2012, J HUM GENET, V57, P691, DOI 10.1038/jhg.2012.95; Fuse M, 2011, INT J ONCOL, V38, P1093, DOI 10.3892/ijo.2011.919; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Galardi S, 2011, NUCLEIC ACIDS RES, V39, P3892, DOI 10.1093/nar/gkr006; Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gong AY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-492; Gonzales JC, 2011, CLIN GENITOURIN CANC, V9, P39, DOI 10.1016/j.clgc.2011.05.008; Green D, 2010, CELL CYCLE, V9, P656, DOI 10.4161/cc.9.4.10729; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; Hao YB, 2011, CANCER INVEST, V29, P318, DOI 10.3109/07357907.2011.554477; He X, 2008, CANCER RES, V68, P5591, DOI 10.1158/0008-5472.CAN-08-0025; Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651; Hsieh IS, CARCINOGENESIS; Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186; Hu L, 2009, CANCER RES, V69, P3374, DOI 10.1158/0008-5472.CAN-08-4290; Huang S, 2012, ONCOL REP, V28, P1831, DOI 10.3892/or.2012.2015; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia YS, 2012, ONCOL REP, V27, P1865, DOI 10.3892/or.2012.1701; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Kasahara K, 2002, CANCER GENET CYTOGEN, V137, P59, DOI 10.1016/S0165-4608(02)00552-6; Kashat M, 2012, AM J TRANSL RES, V4, P432; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kim K, 2012, MOL CANCER THER, V11, P1852, DOI 10.1158/1535-7163.MCT-12-0181; Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866; Kojima K, 2010, PROSTATE, V70, P1501, DOI 10.1002/pros.21185; Kojima S, 2012, BRIT J CANCER, V106, P405, DOI 10.1038/bjc.2011.462; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Kong DJ, 2012, AM J TRANSL RES, V4, P14; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082; Lin D, 2011, J INT MED RES, V39, P1870, DOI 10.1177/147323001103900530; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139; Liu T, 2012, EXP CELL RES, V318, P424, DOI 10.1016/j.yexcr.2011.12.004; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Millikan RE, 2008, J CLIN ONCOL, V26, P5936, DOI 10.1200/JCO.2007.15.9830; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mora LB, 2002, CANCER RES, V62, P6659; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Patron JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035345; Peng XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020341; Pili R, 2011, J CLIN ONCOL, V29, P4022, DOI 10.1200/JCO.2011.35.6295; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Porkka KP, 2011, GENE CHROMOSOME CANC, V50, P499, DOI 10.1002/gcc.20873; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Reis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-14; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rokhlin OW, 2008, CANCER BIOL THER, V7, P1288, DOI 10.4161/cbt.7.8.6284; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Sanders I, 2012, INT J UROL, V19, P1017, DOI 10.1111/j.1442-2042.2012.03082.x; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; Selth LA, 2012, INT J CANCER, V131, P652, DOI 10.1002/ijc.26405; Shen J, 2012, PROSTATE, V72, P1469, DOI 10.1002/pros.22499; Shi GH, 2010, ACTA PHARMACOL SIN, V31, P867, DOI 10.1038/aps.2010.48; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Slabakova E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Stewart CJR, 2012, J CLIN PATHOL, V65, P213, DOI 10.1136/jclinpath-2011-200425; Stinson S, 2011, SCI SIGNAL, V4, ppt5; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Tao J, 2012, ONCOL REP, V27, P1967, DOI 10.3892/or.2012.1711; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Vandewalle C, 2007, NUCLEIC ACIDS RES, V33, P6566; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; White NMA, 2012, BIOL CHEM, V393, P379, DOI 10.1515/hsz-2011-0246; White RWD, 2009, UROL ONCOL-SEMIN ORI, V27, P307, DOI 10.1016/j.urolonc.2009.01.004; Wu YJ, 2011, CANCER-AM CANCER SOC, V117, P3989, DOI 10.1002/cncr.25944; Wu Z, 2012, PROSTATE, DOI [10.1002/pros.22600, DOI 10.1002/PR0S.22600)]; Xiao J, 2012, PROSTATE, V72, P1514, DOI 10.1002/pros.22501; Xu B, 2011, MOL CELL BIOCHEM, V350, P207, DOI 10.1007/s11010-010-0700-6; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yamaguchi S, 2011, ATHEROSCLEROSIS, V219, P468, DOI 10.1016/j.atherosclerosis.2011.09.004; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yamasaki T, 2012, INT J ONCOL, V40, P1821, DOI 10.3892/ijo.2012.1391; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Yu DC, 2011, INT J MOL SCI, V12, P2055, DOI 10.3390/ijms12032055; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zaman MS, 2010, BRIT J CANCER, V103, P256, DOI 10.1038/sj.bjc.6605742; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008	179	91	95	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					135	147		10.1038/onc.2013.54	http://dx.doi.org/10.1038/onc.2013.54			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23455326				2022-12-17	WOS:000329440700001
J	Hayashi, MT; Karlseder, J				Hayashi, M. T.; Karlseder, J.			DNA damage associated with mitosis and cytokinesis failure	ONCOGENE			English	Review						mitosis; DNA damage; telomeres; checkpoints; cytokinesis	KINETOCHORE-MICROTUBULE ATTACHMENT; ANAPHASE-PROMOTING COMPLEX; DOUBLE-STRAND BREAKS; POLO-LIKE KINASE-1; HUMAN-CELLS; AURORA-B; MITOTIC CHECKPOINT; CHROMOSOME MISSEGREGATION; EXTRA CENTROSOMES; MAMMALIAN-CELLS	Mitosis is a highly dynamic process, aimed at separating identical copies of genomic material into two daughter cells. A failure of the mitotic process generates cells that carry abnormal chromosome numbers. Such cells are predisposed to become tumorigenic upon continuous cell division and thus need to be removed from the population to avoid cancer formation. Cells that fail in mitotic progression indeed activate cell death or cell cycle arrest pathways; however, these mechanisms are not well understood. Growing evidence suggests that the formation of de novo DNA damage during and after mitotic failure is one of the causal factors that initiate those pathways. Here, we analyze several distinct malfunctions during mitosis and cytokinesis that lead to de novo DNA damage generation.	[Hayashi, M. T.; Karlseder, J.] Salk Inst Biol Studies, Dept Mol & Cellular Biol, La Jolla, CA 92037 USA	Salk Institute	Karlseder, J (corresponding author), Salk Inst Biol Studies, Dept Mol & Cellular Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Karlseder@salk.edu	Hayashi, Makoto/K-7155-2019	Hayashi, Makoto/0000-0001-6360-7131	Human Frontier Science Program Long Term Fellowship; Japan Society for the Promotion of Science; NIH [P30 CA014195-38, GM087476]; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087476] Funding Source: NIH RePORTER	Human Frontier Science Program Long Term Fellowship(Human Frontier Science Program); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	MTH is supported by a Human Frontier Science Program Long Term Fellowship and a Japan Society for the Promotion of Science Postdoctoral Fellowships for Research Abroad. This work was supported by the Cancer Center Core Grant P30 CA014195-38 and a grant from the NIH to JK (GM087476).	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baker DJ, 2005, CURR OPIN CELL BIOL, V17, P583, DOI 10.1016/j.ceb.2005.09.011; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cesare AJ, 2009, NAT STRUCT MOL BIOL, V16, P1244, DOI 10.1038/nsmb.1725; Chan KL, 2011, SEMIN CELL DEV BIOL, V22, P906, DOI 10.1016/j.semcdb.2011.07.001; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Compton DA, 2011, CURR OPIN CELL BIOL, V23, P109, DOI 10.1016/j.ceb.2010.08.007; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Dalton WB, 2010, ONCOGENE, V29, P1929, DOI 10.1038/onc.2009.477; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dalton WB, 2009, FUTURE ONCOL, V5, P1363, DOI 10.2217/FON.09.118; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fuller BG, 2008, NATURE, V453, P1132, DOI 10.1038/nature06923; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giunta S, 2011, CELL CYCLE, V10, P1215, DOI 10.4161/cc.10.8.15334; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Huang YF, 2009, MOL CELL BIOL, V29, P2935, DOI 10.1128/MCB.01837-08; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Liu D, 2009, SCIENCE, V323, P1350, DOI 10.1126/science.1167000; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nezi LG, 2009, CURR OPIN CELL BIOL, V21, P785, DOI 10.1016/j.ceb.2009.09.007; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pampalona J, 2012, PLOS GENET, V8, P601, DOI 10.1371/journal.pgen.1002679; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; Rankin S, 2005, MOL CELL, V18, P185, DOI 10.1016/j.molcel.2005.03.017; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Rieder CL, 2011, CHROMOSOME RES, V19, P291, DOI 10.1007/s10577-010-9178-z; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Shen K, 2006, J CELL BIOCHEM, V99, P1267, DOI 10.1002/jcb.20848; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Slonim DK, 2009, P NATL ACAD SCI USA, V106, P9425, DOI 10.1073/pnas.0903909106; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Thompson SL, 2011, P NATL ACAD SCI USA, V108, P17974, DOI 10.1073/pnas.1109720108; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wang EX, 2011, J CELL BIOL, V194, P538, DOI 10.1083/jcb.201103044; Westhorpe FG, 2011, J CELL SCI, V124, P3905, DOI 10.1242/jcs.093286; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yanagida M, 2009, NAT REV MOL CELL BIO, V10, P489, DOI 10.1038/nrm2712; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang T, 2009, DEV CELL, V17, P541, DOI 10.1016/j.devcel.2009.09.006; Zhang W, 2011, J BIOL CHEM, V286, P35899, DOI 10.1074/jbc.M111.267690	96	91	94	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4593	4601		10.1038/onc.2012.615	http://dx.doi.org/10.1038/onc.2012.615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23318447	Green Accepted			2022-12-17	WOS:000325072200001
J	Momi, N; Ponnusamy, MP; Kaur, S; Rachagani, S; Kunigal, SS; Chellappan, S; Ouellette, MM; Batra, SK				Momi, N.; Ponnusamy, M. P.; Kaur, S.; Rachagani, S.; Kunigal, S. S.; Chellappan, S.; Ouellette, M. M.; Batra, S. K.			Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha 7nAChR-mediated MUC4 upregulation	ONCOGENE			English	Article						MUC4; mucin; cigarette smoke; nicotine; metastasis and pancreatic cancer	NICOTINIC ACETYLCHOLINE-RECEPTOR; MEDIATED TOBACCO TOXICITY; ORAL EPITHELIAL-CELLS; CIGARETTE-SMOKING; GENE-EXPRESSION; RETINOIC ACID; TUMOR-GROWTH; ACTIVATION; STAT3; PROLIFERATION	Despite evidence that long-term smoking is the leading risk factor for pancreatic malignancies, the underlying mechanism(s) for cigarette-smoke (CS)-induced pancreatic cancer (PC) pathogenesis has not been well established. Our previous studies revealed an aberrant expression of the MUC4 mucin in PC as compared with the normal pancreas, and its association with cancer progression and metastasis. Interestingly, here we explore a potential link between MUC4 expression and smoking-mediated PC pathogenesis and report that both cigarette smoke extract and nicotine, which is the major component of CS, significantly upregulates MUC4 in PC cells. This nicotine-mediated MUC4 overexpression was via the alpha 7 subunit of nicotinic acetylcholine receptor (nAChR) stimulation and subsequent activation of the JAK2/STAT3 downstream signaling cascade in cooperation with the MEK/ERK1/2 pathway; this effect was blocked by the alpha 7nAChR antagonists, alpha-bungarotoxin and mecamylamine, and by specific siRNA-mediated STAT3 inhibition. In addition, we demonstrated that nicotine-mediated MUC4 upregulation promotes the PC cell migration through the activation of the downstream effectors, such as HER2, c-Src and FAK; this effect was attenuated by shRNA-mediated MUC4 abrogation, further implying that these nicotine-mediated pathological effects on PC cells are MUC4 dependent. Furthermore, the in vivo studies showed a marked increase in the mean pancreatic tumor weight (low dose (100 mg/m(3) total suspended particulate (TSP)), P = 0.014; high dose (247 mg/m(3) TSP), P = 0.02) and significant tumor metastasis to various distant organs in the CS-exposed mice, orthotopically implanted with luciferase-transfected PC cells, as compared with the sham controls. Moreover, the CS-exposed mice had elevated levels of serum cotinine (low dose, 155.88 +/- 35.96 ng/ml; high dose, 216.25 +/- 29.95 ng/ml) and increased MUC4, alpha 7nAChR and pSTAT3 expression in the pancreatic tumor tissues. Altogether, our findings revealed for the first time that CS upregulates the MUC4 mucin in PC via the alpha 7nAChR/JAK2/STAT3 downstream signaling cascade, thereby promoting metastasis of PC. Oncogene (2013) 32, 1384-1395; doi:10.1038/onc.2012.163; published online 21 May 2012	[Momi, N.; Ponnusamy, M. P.; Kaur, S.; Rachagani, S.; Ouellette, M. M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Kunigal, S. S.; Chellappan, S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Ouellette, M. M.; Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu		Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	National Institutes of Health [RO1 CA133774, RO1 CA131944, RO1 CA78590, UO1 CA111294, P50 CA127297, U54 CA163120]; NATIONAL CANCER INSTITUTE [R01CA133774, U54CA163120, U01CA111294, R01CA131944, R01CA078590, P50CA127297] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Kristi L Berger for editing the manuscript. We acknowledge the invaluable technical support from Mr Erik Moore and Mrs Kavita Mallya. We also thank Janice A Tayor and James R Talaska, the members of the confocal laser scanning microscope core facility at UNMC, for their support. This work was, in part, supported by grants from the National Institutes of Health (RO1 CA133774,RO1 CA131944, RO1 CA78590, UO1 CA111294, P50 CA127297 and U54 CA163120).	Andoh A, 2009, J IMMUNOL, V183, P687, DOI 10.4049/jimmunol.0804169; Andrianifahanana M, 2007, ONCOGENE, V26, P7251, DOI 10.1038/sj.onc.1210532; Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, CANCER BIOL THER, V5, P511, DOI 10.4161/cbt.5.5.2601; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Boyle P, 1996, INT J CANCER, V67, P63, DOI 10.1002/(SICI)1097-0215(19960703)67:1<63::AID-IJC12>3.0.CO;2-D; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RJ, 2010, TOXICOL SCI, V115, P118, DOI 10.1093/toxsci/kfq028; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Dasgupta P, 2006, J CLIN INVEST, V116, P2208, DOI 10.1172/JCI28164; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Finnie IA, 1996, CLIN SCI, V91, P359, DOI 10.1042/cs0910359; Fuchs CS, 1996, ARCH INTERN MED, V156, P2255, DOI 10.1001/archinte.156.19.2255; Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740; Lowenfels AB, 2005, J CELL BIOCHEM, V95, P649, DOI 10.1002/jcb.20461; LUK ISC, 1994, DIGESTION, V55, P399, DOI 10.1159/000201172; Macha MA, 2011, CARCINOGENESIS, V32, P368, DOI 10.1093/carcin/bgq278; MAJUMDAR APN, 1985, AM J PHYSIOL, V248, pG158, DOI 10.1152/ajpgi.1985.248.2.G158; Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x; Marrero MB, 2009, BRAIN RES, V1256, P1, DOI 10.1016/j.brainres.2008.11.053; Mejias-Luque R, 2010, ONCOGENE, V29, P1753, DOI 10.1038/onc.2009.467; Mejias-Luque R, 2008, BBA-MOL CELL RES, V1783, P1728, DOI 10.1016/j.bbamcr.2008.05.020; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Muscat JE, 1997, CANCER EPIDEM BIOMAR, V6, P15; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Rachagani S, 2009, BIOFACTORS, V35, P509, DOI 10.1002/biof.64; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Shen JX, 2009, ACTA PHARMACOL SIN, V30, P673, DOI 10.1038/aps.2009.64; Sheppard BJ, 2000, INT J ONCOL, V16, P513; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wittel UA, 2006, AM J GASTROENTEROL, V101, P148, DOI 10.1111/j.1572-0241.2006.00405.x; Wittel UA, 2006, PANCREAS, V33, P364, DOI 10.1097/01.mpa.0000240601.80570.31; Wong HPS, 2009, DIGESTION, V80, P209, DOI 10.1159/000231898	51	91	94	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1384	1395		10.1038/onc.2012.163	http://dx.doi.org/10.1038/onc.2012.163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22614008	Green Accepted			2022-12-17	WOS:000316455600005
J	Babbio, F; Pistore, C; Curti, L; Castiglioni, I; Kunderfranco, P; Brino, L; Oudet, P; Seiler, R; Thalman, GN; Roggero, E; Sarti, M; Pinton, S; Mello-Grand, M; Chiorino, G; Catapano, CV; Carbone, GM; Bonapace, IM				Babbio, F.; Pistore, C.; Curti, L.; Castiglioni, I.; Kunderfranco, P.; Brino, L.; Oudet, P.; Seiler, R.; Thalman, G. N.; Roggero, E.; Sarti, M.; Pinton, S.; Mello-Grand, M.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.; Bonapace, I. M.			The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression	ONCOGENE			English	Article						prostate cancer; epigenetics; UHRF1; EZH2; Suv39H1	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PERICENTROMERIC HETEROCHROMATIN; TRANSCRIPTION FACTOR; CPG ISLAND; E-CADHERIN; CELLS; REPRESSION; EXPRESSION; EZH2	Epigenetic silencing of tumour suppressor genes is an important mechanism involved in cell transformation and tumour progression. The Set and RING-finger-associated domain-containing protein UHRF1 might be an important link between different epigenetic pathways. Here, we report that UHRF1 is frequently overexpressed in human prostate tumours and has an important role in prostate cancer pathogenesis and progression. Analysis of human prostate cancer samples by microarrays and immunohistochemistry showed increased expression of UHRF1 in about half of the cases. Moreover, UHRF1 expression was associated with reduced overall survival after prostatectomy in patients with organ-confined prostate tumours (P<0.0001). UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. UHRF1 knockdown reduced proliferation, clonogenic capability and anchorage-independent growth of prostate cancer cells. Depletion of UHRF1 resulted in reactivation of several tumour suppressor genes. Gene reactivation upon UHRF1 depletion was associated with changes in histone H3K9 methylation, acetylation and DNA methylation, and impaired binding of the H3K9 HMT Suv39H1 to the promoter of silenced genes. Co-immunoprecipitation experiments showed direct interaction between UHRF1 and Suv39H1. Our data support the notion that UHRF1, along with Suv39H1 and DNA methyltransferases, contributes to epigenetic gene silencing in prostate tumours. This could represent a parallel and convergent pathway to the H3K27 methylation catalyzed by EZH2 to synergistically promote inactivation of tumour suppressor genes. Deregulated expression of UHRF1 is involved in the prostate cancer pathogenesis and might represent a useful marker to distinguish indolent cancer from those at high risk of lethal progression.	[Babbio, F.; Pistore, C.; Castiglioni, I.; Bonapace, I. M.] Univ Insubria, Dept Struct & Funct Biol, I-21052 Busto Arsizio, Varese, Italy; [Curti, L.; Kunderfranco, P.; Sarti, M.; Pinton, S.; Catapano, C. V.; Carbone, G. M.] IOR, Bellinzona, Switzerland; [Curti, L.; Kunderfranco, P.; Roggero, E.; Sarti, M.; Pinton, S.; Catapano, C. V.; Carbone, G. M.] Oncol Inst So Switzerland IOSI, Bellinzona, Switzerland; [Brino, L.; Oudet, P.; Bonapace, I. M.] ULP, INSERM U596, UMR CNRS 7104, IGBMC,Dept Biol Canc, Strasbourg, France; [Brino, L.; Oudet, P.] Canc Pole Grand Est, Tranfected Cell Array Platform, Strasbourg, France; [Seiler, R.; Thalman, G. N.] Univ Bern, Inselspital, Dept Urol, Urol Res Lab, CH-3010 Bern, Switzerland; [Mello-Grand, M.; Chiorino, G.] Fondo Edo Tempia, Lab Canc Genom, Biella, Italy	University of Insubria; Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Institute of Oncology Research (IOR); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bern; University Hospital of Bern	Bonapace, IM (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via A da Giussano 12, I-21052 Busto Arsizio, Varese, Italy.	pina.carbone@irb.unisi.ch; ian.bonapace@uninsubria.it	Kunderfranco, Paolo/J-7636-2016; Kunderfranco, Paolo/GUQ-8968-2022; Kunderfranco, Paolo/ABH-9294-2020; Chiorino, Giovanna/K-5037-2016	Kunderfranco, Paolo/0000-0003-3636-3391; Kunderfranco, Paolo/0000-0001-7477-8710; Kunderfranco, Paolo/0000-0001-7477-8710; Chiorino, Giovanna/0000-0002-9502-6400; Catapano, Carlo V./0000-0002-7079-557X; Brino, laurent/0000-0002-9036-1461; Castiglioni, Ilaria/0000-0003-1165-7844; Seiler, Roland/0000-0002-3529-2088; BONAPACE, IAN MARC/0000-0001-6580-8893	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-10742]; Fondazione Cariplo 'Progetto Nobel'; Oncosuisse [OCS-01913-08]; Swiss National Science Foundation [FNS-31003A-118113]; Ticino Foundation for Cancer Research; Fondazione Compagnia di San Paolo; Universite de Strasbourg; Region Alsace; Conseil General du Bas Rhin; Communaute Urbaine de Strasbourg; Canceropole du Grand Est, France; Institut National du Cancer (INCa); Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo 'Progetto Nobel'(Fondazione Cariplo); Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ticino Foundation for Cancer Research; Fondazione Compagnia di San Paolo(Compagnia di San Paolo); Universite de Strasbourg; Region Alsace(Region Grand-Est); Conseil General du Bas Rhin; Communaute Urbaine de Strasbourg; Canceropole du Grand Est, France(Region Grand-Est); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC)	We acknowledge Benoit Fischer, Laure Froidevaux and Amelie Weiss from the High-Throughput Screening facility (IGBMC) for their contribution to the project; Martina Mandruzzato and Giada Tamolli for their collaboration as undergraduate students; Dr Giampaolo Perletti for reviewing the manuscript and Professor Gianfranco Badaracco for constant support. Grant support: This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) project No IG-10742 and Fondazione Cariplo 'Progetto Nobel' to IMB and by Oncosuisse (OCS-01913-08), the Swiss National Science Foundation (FNS-31003A-118113) and Ticino Foundation for Cancer Research to GMC, and the Fondazione Compagnia di San Paolo to GC. Further support is acknowledged from the Universite de Strasbourg, Region Alsace, Conseil General du Bas Rhin, Communaute Urbaine de Strasbourg, Canceropole du Grand Est, France, Institut National du Cancer (INCa) and Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC).	Abdulkadir SA, 2005, ANN NY ACAD SCI, V1059, P33, DOI 10.1196/annals.1339.018; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bastian PJ, 2007, EUR UROL, V51, P665, DOI 10.1016/j.eururo.2006.08.008; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Chuang TD, 2010, J BIOL CHEM, V285, P23598, DOI 10.1074/jbc.M109.098301; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Jeronimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Li QA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013732; Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Napoli S, 2009, EMBO J, V28, P1708, DOI 10.1038/emboj.2009.139; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Papait R, 2008, MOL BIOL CELL, V19, P3554, DOI 10.1091/mbc.E07-10-1059; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Park JY, 2007, CANCER DETECT PREV, V31, P359, DOI 10.1016/j.cdp.2007.09.002; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Prtilo A, 2005, J UROLOGY, V174, P1814, DOI 10.1097/01.ju.0000176796.47988.64; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yang YJ, 2010, NUCLEIC ACIDS RES, V38, P382, DOI 10.1093/nar/gkp991; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498	50	91	100	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4878	4887		10.1038/onc.2011.641	http://dx.doi.org/10.1038/onc.2011.641			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22330138				2022-12-17	WOS:000311210700008
J	Harris, LG; Pannell, LK; Singh, S; Samant, RS; Shevde, LA				Harris, L. G.; Pannell, L. K.; Singh, S.; Samant, R. S.; Shevde, L. A.			Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61	ONCOGENE			English	Article						SHH; CYR61; GLI; hedgehog; angiogenesis; metastasis	SONIC HEDGEHOG; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; TUBE FORMATION; GROWTH-FACTOR; CARCINOMA; PATHWAY; PROGRESSION; EXPRESSION; PROTEINS	The Hedgehog (Hh) pathway is well known for its involvement in angiogenesis and vasculogenesis during ontogeny. The ligand, Sonic Hh (SHH), has an important role in vascular formation during development. However, SHH expression is upregulated on tumor cells and can impact the tumor microenvironment. We have investigated the effects of autocrine as well as paracrine Hh signaling on tumor cells as well as on endothelial cells, respectively. Upon constitutive expression of SHH, breast cancer cells showed aggressive behavior and rapid xenograft growth characterized by highly angiogenic tumors that were spontaneously metastatic. In these cells, SHH caused activation of the Hh transcription factor, GLI1, leading to upregulated expression of the potent pro-angiogenic secreted molecule, CYR61 (cysteine-rich angiogenic inducer 61). Silencing of CYR61 from these SHH-expressing Hh activated cells blunted the malignant behavior of the tumor cells and resulted in reduced tumor vasculature and limited hematogenous metastases. Thus, CYR61 is a critical downstream contributor to the Hh influenced pro-angiogenic tumor microenvironment. We also observed concomitant upregulation of SHH and CYR61 transcripts in tumors from patients with advanced breast cancer, further ratifying the clinical relevance of our findings. In summary, we have defined a novel, VEGF-independent, clinically relevant, pro-angiogenic factor, CYR61, that is a transcriptional target of Hh-GLI signaling. Oncogene (2012) 31, 3370-3380; doi: 10.1038/onc.2011.496; published online 7 November 2011	[Harris, L. G.; Pannell, L. K.; Singh, S.; Samant, R. S.; Shevde, L. A.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA	University of South Alabama	Shevde, LA (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, MCI 3018,1660 Springhill Ave, Mobile, AL 36604 USA.	lsamant@usouthal.edu		Samant, Rajeev/0000-0001-5681-4976	NIH [CA138850, CA140472]; Department of Defense (IDEA) [BC061257]; Mayer Mitchell Award; USA-Mitchell Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA138850, R01CA140472] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (IDEA)(United States Department of Defense); Mayer Mitchell Award; USA-Mitchell Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the NIH (CA138850 to L. A. S. and CA140472 to R. S. S.), Department of Defense (IDEA Award BC061257 to L. A. S.), Mayer Mitchell Award (to L. A. S.) and the USA-Mitchell Cancer Institute. We also would like to thank Dr Laurie Owen, Scientific Director, USAMitchell Cancer Institute for her support of this work and the Department of Pathology and Prof Troy Stevens, Anna Buford and Linn Ayers, Center for Lung Biology, University of South Alabama for generously providing us with endothelial cells.	Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Beachy PA, 2010, GENE DEV, V24, P2001, DOI 10.1101/gad.1951710; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535-6108(03)00336-2; Byrd N, 2004, TRENDS CARDIOVAS MED, V14, P308, DOI 10.1016/j.tcm.2004.09.003; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Cohen MM, 2010, AM J MED GENET A, V152A, P1875, DOI 10.1002/ajmg.a.32909; Das S, 2011, J BIOL CHEM, V286, P9612, DOI 10.1074/jbc.M110.174920; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Dobroff AS, 2009, J BIOL CHEM, V284, P26194, DOI 10.1074/jbc.M109.019836; Feng P, 2008, INT J BIOCHEM CELL B, V40, P98, DOI 10.1016/j.biocel.2007.06.020; Fox SB, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1796; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hochman E, 2006, J BIOL CHEM, V281, P33860, DOI 10.1074/jbc.M605905200; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Kleer CG, 2007, CELLS TISSUES ORGANS, V185, P95, DOI 10.1159/000101308; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Lu Zhi-hao, 2008, Beijing Da Xue Xue Bao Yi Xue Ban, V40, P480; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mazumdar T, 2011, ONCOTARGET, V2, P638; Mbeunkui F, 2007, J PROTEOME RES, V6, P2993, DOI 10.1021/pr060629m; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003; Samant RS, 2011, ONCOTARGET, V2, P122; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Trimmer C, 2010, CANCER RES, V70, P7489, DOI 10.1158/0008-5472.CAN-10-0900; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Vokes SA, 2004, DEVELOPMENT, V131, P4371, DOI 10.1242/dev.01304; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHANG RD, 1991, INVAS METAST, V11, P204; Zhou ZQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-291; Zunich SM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-12	52	91	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3370	3380		10.1038/onc.2011.496	http://dx.doi.org/10.1038/onc.2011.496			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056874	Green Accepted			2022-12-17	WOS:000306367600006
J	Farabaugh, SM; Micalizzi, DS; Jedlicka, P; Zhao, R; Ford, HL				Farabaugh, S. M.; Micalizzi, D. S.; Jedlicka, P.; Zhao, R.; Ford, H. L.			Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties	ONCOGENE			English	Article						Six1; Eya; TGF-beta; epithelial-mesenchymal transition; cancer stem cells	BRANCHIOOTORENAL BOR SYNDROME; HOMEOBOX GENE-EXPRESSION; EYES-ABSENT; BREAST-CANCER; HOMEOPROTEIN SIX1; CARCINOMA CELLS; COFACTOR EYA2; TUMOR-GROWTH; MUTATIONS; PROTEIN	Six1 is a critical regulator of embryonic development that requires interaction with the Eya family of proteins (Eya1-4) to activate the transcription of genes involved in neurogenesis, myogenesis and nephrogenesis. Although expression of Six1 and Eya family members is predominantly observed in development, their overexpression is observed in numerous cancers. Importantly, both Six1 and Eya have independently been shown to mediate breast cancer metastasis, but whether they functionally interact during tumor progression has not been explored. Herein, we demonstrate that knockdown of Eya2 in MCF7 mammary carcinoma cells reverses the ability of Six1 to induce transforming growth factor-beta signaling, as well as to induce characteristics associated with epithelial-mesenchymal transition and cancer stem cells, suggesting that Six1 is dependent on Eya2 to mediate numerous pro-metastatic characteristics. The importance of the Six1-Eya interaction in human breast cancer is underscored by the finding that high levels of Six1 correlate with shortened time to relapse and metastasis as well as decreased survival only when co-expressed with high levels of Eya2. Overall, these data implicate Eya2 as a necessary co-factor for many of the metastasis promoting functions of Six1, suggesting that targeting the Six1-Eya interaction may inhibit breast cancer progression. As Six1 and Eya2 are not highly expressed in most adult tissues, the Six1-Eya interaction may be a valuable future therapeutic target whose inhibition would be expected to impair breast cancer progression while conferring limited side effects. Oncogene (2012) 31, 552-562; doi:10.1038/onc.2011.259; published online 27 June 2011	[Ford, H. L.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Farabaugh, S. M.; Zhao, R.; Ford, H. L.] Univ Colorado, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; [Micalizzi, D. S.; Ford, H. L.] Univ Colorado, Program Mol Biol, Aurora, CO 80045 USA; [Micalizzi, D. S.; Ford, H. L.] Univ Colorado, Med Scientist Training Program, Aurora, CO 80045 USA; [Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, Anschutz Med Campus,RC1 N,Room 5102, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu		Micalizzi, Douglas/0000-0002-0306-9914	National Cancer Institute [2RO1-CA095277]; American Cancer Society [RSG-07-183-01-DDC]; Department of Defense [BC084105, W81XWH-08-1-0332, W81XWH-06-1-0757]; NATIONAL CANCER INSTITUTE [R01CA157790, R01CA095277] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grants from the National Cancer Institute (2RO1-CA095277) and the American Cancer Society (#RSG-07-183-01-DDC) to HLF, and the Department of Defense Breast Cancer Synergistic Idea Award (BC084105) to HLF and RZ. SMF and DSM were funded by predoctoral fellowships from the Department of Defense Breast Cancer Research Program (W81XWH-08-1-0332 and W81XWH-06-1-0757, respectively). We would like to thank Alana Welm for training in microarray datamining techniques, database sharing and helpful datamining discussions, and Katherine Martin, of Bioarray Therapeutics, for data analysis of the Wang data set.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247; Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ando Z, 2005, FEBS J, V272, P3026, DOI 10.1111/j.1742-4658.2005.04716.x; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Embry AC, 2004, MOL PHARMACOL, V66, P1325, DOI 10.1124/mol.104.004093; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Jemc J, 2007, DEV BIOL, V310, P416, DOI 10.1016/j.ydbio.2007.07.024; Kochhar A, 2008, HUM MUTAT, V29, P565, DOI 10.1002/humu.20714; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krishnan N, 2009, J BIOL CHEM, V284, P16066, DOI 10.1074/jbc.C900032200; Laclef C, 2003, MECH DEVELOP, V120, P669, DOI 10.1016/S0925-4773(03)00065-0; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Orten DJ, 2008, HUM MUTAT, V29, P537, DOI 10.1002/humu.20691; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Patrick AN, 2009, J BIOL CHEM, V284, P20781, DOI 10.1074/jbc.M109.016832; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Ruf RG, 2004, P NATL ACAD SCI USA, V101, P8090, DOI 10.1073/pnas.0308475101; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schonberger J, 2005, NAT GENET, V37, P418, DOI 10.1038/ng1527; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincent C, 1997, EUR J HUM GENET, V5, P242, DOI 10.1159/000484770; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xiong WJ, 2009, DEV CELL, V16, P271, DOI 10.1016/j.devcel.2008.12.005; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Xu PX, 2002, DEVELOPMENT, V129, P3033; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang L, 2005, CANCER RES, V65, P925; Zhang YZ, 2004, JARO-J ASSOC RES OTO, V5, P295, DOI 10.1007/s10162-004-4044-3; Zheng XH, 2010, INT J GYNECOL CANCER, V20, P1587, DOI 10.1111/IGC.0b013e3181f9defb; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	57	91	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					552	562		10.1038/onc.2011.259	http://dx.doi.org/10.1038/onc.2011.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706047	Green Accepted			2022-12-17	WOS:000300221800002
J	Cao, X; Geradts, J; Dewhirst, MW; Lo, HW				Cao, X.; Geradts, J.; Dewhirst, M. W.; Lo, H-W			Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells	ONCOGENE			English	Article						GLI1; tGLI1; breast cancer; angiogenesis; migration and invasion; VEGF	GROWTH-FACTOR RECEPTOR; SONIC-HEDGEHOG; STEM-CELLS; HUMAN GLIOMA; MAMMALIAN HEPARANASE; DOWN-REGULATION; SELF-RENEWAL; TUMOR-GROWTH; FLOOR PLATE; PATHWAY	The Hedgehog signaling pathway is one of the most dysregulated pathways in human cancers. The glioma-associated oncogene homolog 1 (GLI1) transcription factor is the terminal effector of the Hedgehog pathway, frequently activated in human breast cancer and an emerging target of breast cancer therapy. While somatic mutations in the human GLI1 gene have never been reported in any cell or tumor type, we recently uncovered the existence of a novel alternatively spliced, truncated GLI1 (tGLI1) that has an in-frame deletion of 41 codons spanning the entire exon 3 and part of exon 4 of the GLI1 gene. Using glioblastoma models, we showed that tGLI1 has gained the ability to promote glioblastoma migration and invasion via its gain-of-function transcriptional activity. However, the pathological impact of tGLI1 on breast cancer remains undefined. Here, we report that tGLI1 is frequently expressed in human breast cancer cell lines and primary specimens we have examined to date, but is undetectable in normal breast tissues. We found for the first time that tGLI1, but not GLI1, binds to and enhances the human vascular endothelial growth factor-A (VEGF-A) gene promoter, leading to its upregulation. Consequently, tGLI1-expressing MDA-MB-231 breast cancer cells secret higher levels of VEGF-A and contain a higher propensity, than the isogenic cells with control vector and GLI1, to stimulate in vitro angiogenesis of human vascular endothelial cells. We further showed that tGLI1 has gained the ability to enhance the motility and invasiveness of breast cancer cells in a proliferation-independent manner and that this functional gain is associated with increased expression of migration/invasion-associated genes, CD24, MMP-2 and MMP-9. tGLI1 has also acquired the property to facilitate anchorage-independent growth of breast cancer cells. Collectively, our results define tGLI1 as a gain-of-function GLI1 transcription factor and a novel mediator of the behavior of clinically more aggressive breast cancer. Oncogene (2012) 31, 104-115; doi: 10.1038/onc.2011.219; published online 13 June 2011	[Cao, X.; Lo, H-W] Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Durham, NC 27710 USA; [Geradts, J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; [Dewhirst, M. W.] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27710 USA; [Geradts, J.; Dewhirst, M. W.; Lo, H-W] Duke Canc Inst, Durham, NC USA; [Lo, H-W] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Lo, HW (corresponding author), Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Box 3156,433A MSRB I,103 Res Dr, Durham, NC 27710 USA.	huiwen.lo@duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; Lo, Hui-Wen/0000-0002-0681-7914	NIH [K01-CA118423]; DOD [W81XWH-07-1-0390]; Pediatric Brain Tumor Foundation; Beez Foundation; Intramural Division of Surgical Sciences Dani P. Bolognesi; NATIONAL CANCER INSTITUTE [K01CA118423] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Pediatric Brain Tumor Foundation; Beez Foundation; Intramural Division of Surgical Sciences Dani P. Bolognesi; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH grant K01-CA118423, DOD grant W81XWH-07-1-0390, the Pediatric Brain Tumor Foundation and the Beez Foundation and the Intramural Division of Surgical Sciences Dani P. Bolognesi, PhD Award (to H-WL).	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Cao XY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-26; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dasari VR, 2010, AGING-US, V2, P791, DOI 10.18632/aging.100217; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Kameda C, 2009, ANTICANCER RES, V29, P871; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145; Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530; Kim HJ, 2007, CANCER LETT, V258, P98, DOI 10.1016/j.canlet.2007.08.025; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lee JH, 2009, ONCOL REP, V22, P1149, DOI 10.3892/or_00000548; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; Nagase T, 2008, ANGIOGENESIS, V11, P71, DOI 10.1007/s10456-008-9105-5; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Runz S, 2008, BIOCHEM BIOPH RES CO, V365, P35, DOI 10.1016/j.bbrc.2007.10.139; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schmidt M, 2008, ANTICANCER RES, V28, P1719; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298; Timoshenko AV, 2006, BRIT J CANCER, V94, P1154, DOI 10.1038/sj.bjc.6603067; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028; Zhu H, 2010, CURR GENOMICS, V11, P238, DOI 10.2174/138920210791233108	52	91	96	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					104	115		10.1038/onc.2011.219	http://dx.doi.org/10.1038/onc.2011.219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666711	Green Accepted			2022-12-17	WOS:000299176200010
J	Malik, SA; Orhon, I; Morselli, E; Criollo, A; Shen, S; Marino, G; BenYounes, A; Benit, P; Rustin, P; Maiuri, MC; Kroemer, G				Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Benit, P.; Rustin, P.; Maiuri, M. C.; Kroemer, G.			BH3 mimetics activate multiple pro-autophagic pathways	ONCOGENE			English	Article						autophagy; Beclin 1; Bcl-2 family protein; ABT737	BH3-ONLY PROTEINS; BCL-2 FAMILY; BECLIN 1; INDUCTION; COMPLEX; CELLS; IKK	The BH3 mimetic ABT737 induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-XL, thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34. Here, we examined whether ABT737 stimulates other pro-autophagic signal-transduction pathways. ABT737 caused the activating phosphorylation of AMP-dependent kinase (AMPK) and of the AMPK substrate acetyl CoA carboxylase, the activating phosphorylation of several subunits of the inhibitor of NF-kappa B (I kappa B) kinase (IKK) and the hyperphosphorylation of the IKK substrate I kappa B, inhibition of the activity of mammalian target of rapamycin (mTOR) and consequent dephosphorylation of the mTOR substrate S6 kinase. In addition, ABT737 treatment dephosphorylates (and hence likewise inhibits) p53, glycogen synthase kinase-3 and Akt. All these effects were shared by ABT737 and another structurally unrelated BH3 mimetic, HA14-1. Functional experiments revealed that pharmacological or genetic inhibition of IKK, Sirtuin and the p53-depleting ubiquitin ligase MDM2 prevented ABT737-induced autophagy. These results point to unexpected and pleiotropic proautophagic effects of BH3 mimetics involving the modulation of multiple signalling pathways. Oncogene (2011) 30, 3918-3929; doi:10.1038/onc.2011.104; published online 4 April 2011	[Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, Val De Marne, France; [Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Maiuri, M. C.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Benit, P.; Rustin, P.] INSERM, U676, Paris, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr	GARCÍA, GUILLERMO MARIÑO/AAI-8015-2020; Kroemer, Guido/AAY-9859-2020; orhon, idil/AAB-1940-2020; Malik, Shoaib Ahmad/O-7022-2017; GARCÍA, GUILLERMO MARIÑO/J-1726-2012; marino, guillermo/HGB-8664-2022; KROEMER, Guido/B-4263-2013; SHEN, Shensi/AAW-2735-2020	orhon, idil/0000-0002-0779-8719; Malik, Shoaib Ahmad/0000-0002-0843-8512; GARCÍA, GUILLERMO MARIÑO/0000-0003-1960-1677; KROEMER, Guido/0000-0002-9334-4405; SHEN, Shensi/0000-0002-5087-8220; Criollo, Alfredo/0000-0002-2737-7751	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); AXA Foundation; European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; Higher Education Commission (HEC) of Pakistan	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); AXA Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Higher Education Commission (HEC) of Pakistan(Higher Education Commission of Pakistan)	We thank Drs B Vogelstein (John Hopkins University, Bethesda, MD, USA) and S Korsmeyer (Harvard University) for HCT116 cells and double-knockout MEF, respectively. We thank Dr K-L Guan for Rheb constructs. GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), AXA Foundation (Chair for Longevity Research), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain, ArtForce), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. SA Malik is the recipient of a grant from the Higher Education Commission (HEC) of Pakistan.	Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Benit P, 2006, CLIN CHIM ACTA, V374, P81, DOI 10.1016/j.cca.2006.05.034; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2009, ONCOGENE, V28, P2125, DOI 10.1038/onc.2009.83; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2008, CURR MOL MED, V8, P78; Harborth J, 2001, J CELL SCI, V114, P4557; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kessel D, 2007, CANCER LETT, V249, P294, DOI 10.1016/j.canlet.2006.09.009; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zhang XD, 2009, J NEUROSCI RES, V87, P3600, DOI 10.1002/jnr.22152; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	38	91	95	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3918	3929		10.1038/onc.2011.104	http://dx.doi.org/10.1038/onc.2011.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460857				2022-12-17	WOS:000294890400002
J	Bist, P; Leow, SC; Phua, QH; Shu, S; Zhuang, Q; Loh, WT; Nguyen, TH; Zhou, JB; Hooi, SC; Lim, LHK				Bist, P.; Leow, S. C.; Phua, Q. H.; Shu, S.; Zhuang, Q.; Loh, W. T.; Nguyen, T. H.; Zhou, J. B.; Hooi, S. C.; Lim, L. H. K.			Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-kappa B: implication in breast cancer metastasis	ONCOGENE			English	Article						metastasis; transcription factor; NF-kappa B; CXCR4	CHEMOKINE RECEPTOR CXCR4; A1 EXPRESSION; TUMOR-CELLS; BONE-MARROW; IN-VITRO; PROTEIN; PROGRESSION; PATHWAY; DOMAIN; MIGRATION	The molecular mechanisms underlying constitutive nuclear factor-kappa B (NF-kappa B) activation in solid tumors has not been elucidated. We show that Annexin-1 (ANXA1) is involved in this process, and suppression of ANXA1 in highly metastatic breast cancer cells impedes migration and metastasis capabilities in vitro and in vivo. ANXA1 expression correlates with NF-kappa B activity, suggesting that ANXA1 may be required for the constitutive activity of I kappa B kinase (IKK) and NF-kappa B in highly metatstatic breast cancer. Gel-filtration analysis demonstrated that ANXA1 co-elutes with the members of the IKK complex and NF-kappa B signaling pathway, and immunoprecipitation confirmed that ANXA1 can bind to and interact with IKK gamma or NEMO, but not IKK alpha or IKK beta. Importantly, silencing of ANXA1 prevents the interaction of NEMO and RIP1, which indicates that ANXA1 is required for the recruitment of RIP1 to the IKK complex, which may be important for the activation of NF-kappa B. Downstream targets of NF-kappa B include uPA and CXCR4, which can be modulated by ANXA1 silencing. CXCR4-mediated migration of breast cancer cell lines in response to CXCL12 was significantly modulated by ANXA1, indicating its importance in the tissue-specific migration of breast cancer cells. Chromatin immunoprecipitation experiments confirmed that in ANXA1 overexpressed cells, NF-kappa B was recruited to CXCR4 promoter without external stimulation, indicating that ANXA1 is critical for the constitutive activation of NF-kappa B in breast cancer to promote metastasis. Finally, we show that ANXA1 overexpression enhances metastasis and reduces survival in an intracardiac metastasis model, while ANXA1-deficient mice crossed with MMTV-PyMT mice display significantly less metastasis than their heterozygous littermates, indicating that ANXA1 is an important gene in breast cancer metastasis. Our data reveal that ANXA1 can constitutively activate NF-kappa B in breast cancer cells through the interaction with the IKK complex, and suggests that modulating ANXA1 levels has therapeutic potential to suppress breast cancer metastasis. Oncogene (2011) 30, 3174-3185; doi:10.1038/onc.2011.28; published online 7 March 2011	[Lim, L. H. K.] Natl Univ Singapore, Dept Physiol, Inflammat & Canc Lab, Yong Loo Lin Sch Med,Ctr Life Sci, Singapore 117456, Singapore; [Bist, P.; Leow, S. C.; Phua, Q. H.; Shu, S.; Zhuang, Q.; Loh, W. T.; Nguyen, T. H.; Lim, L. H. K.] Natl Univ Singapore, NUS Immunol Program, Inflammat & Canc Lab, Singapore 117456, Singapore; [Zhou, J. B.] Natl Univ Singapore, Oncol Res Inst, Singapore 117456, Singapore; [Lim, L. H. K.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Lim, LHK (corresponding author), Natl Univ Singapore, Dept Physiol, Inflammat & Canc Lab, Yong Loo Lin Sch Med,Ctr Life Sci, Level 3,28 Med Dr, Singapore 117456, Singapore.	linalim@nus.edu.sg	Nguyen, Hung/M-8118-2014; Hooi, Shing/C-8588-2012; BIST, PRADEEP/AAG-7986-2019	Nguyen, Hung/0000-0001-8378-555X; Lim, Lina/0000-0002-2935-2275; Hooi, Shing Chuan/0000-0003-3249-903X	Biomedical Research Council of Singapore [07/1/21/19/507, 04/1/21/19/319]; A*Star [SIgN 07-011]	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); A*Star(Agency for Science Technology & Research (A*STAR))	This work was supported by grants from the Biomedical Research Council of Singapore (07/1/21/19/507) and A*Star (SIgN 07-011) to LL and Biomedical Research Council of Singapore (04/1/21/19/319) to SCH. We thank Professor Rod Flower (William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, London) for generously providing us with the pCDNA3.1-V5 ANXA1 construct and Professor Michael Karin (University of California San Diego, CA, USA) for the HA-IKK alpha, HA-IKK beta and HA-IKK gamma plasmid constructs.	Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Ang EZF, 2009, MOL CANCER RES, V7, P266, DOI 10.1158/1541-7786.MCR-08-0147; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Cao Y, 2008, APPL IMMUNOHISTO M M, V16, P530, DOI 10.1097/PAI.0b013e31817432c3; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Cicek M, 2004, CLIN EXP METASTAS, V21, P149, DOI 10.1023/B:CLIN.0000024729.19084.f0; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kreunin P, 2007, PROTEOMICS, V7, P299, DOI 10.1002/pmic.200600272; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Monks NR, 2006, J CELL BIOCHEM, V98, P221, DOI 10.1002/jcb.20789; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Palkowitsch L, 2008, J BIOL CHEM, V283, P76, DOI 10.1074/jbc.M708856200; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Perretti M, 2003, NEWS PHYSIOL SCI, V18, P60, DOI 10.1152/nips.01424.2002; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; Zhang ZQ, 2010, CANCER RES, V70, P2379, DOI 10.1158/0008-5472.CAN-09-4204	37	91	93	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3174	3185		10.1038/onc.2011.28	http://dx.doi.org/10.1038/onc.2011.28			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383699				2022-12-17	WOS:000292726300006
J	Kalamarides, M; Stemmer-Rachamimov, AO; Niwa-Kawakita, M; Chareyre, F; Taranchon, E; Han, ZY; Martinelli, C; Lusis, EA; Hegedus, B; Gutmann, DH; Giovannini, M				Kalamarides, M.; Stemmer-Rachamimov, A. O.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Lusis, E. A.; Hegedus, B.; Gutmann, D. H.; Giovannini, M.			Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes	ONCOGENE			English	Article						neurofibromatosis type 2; arachnoid; brain tumours	PROSTAGLANDIN-D SYNTHASE; BETA-TRACE; NATURAL-HISTORY; CHOROID-PLEXUS; SKULL BASE; NF2; EXPRESSION; MICE; LOCALIZATION; MUTATION	Meningiomas are among the most common primary central nervous system tumours in adults. Studies focused on the molecular basis for meningioma development are hampered by a lack of information with regard to the cell of origin for these brain tumours. Herein, we identify a prostaglandin D synthase-positive meningeal precursor as the cell of origin for murine meningioma, and show that neurofibromatosis type 2 (Nf2) inactivation in prostaglandin D2 synthase (PGDS) (+) primordial meningeal cells, before the formation of the three meningeal layers, accounts for the heterogeneity of meningioma histological subtypes. Using a unique PGDSCre strain, we define a critical embryonic and early postnatal developmental window in which biallelic Nf2 inactivation in PGDS (+) progenitor cells results in meningioma formation. Moreover, we identify differentially expressed markers that characterize the two major histological meningioma subtypes both in human and mouse tumours. Collectively, these findings establish the cell of origin for these common brain tumours as well as a susceptible developmental period in which signature genetic mutations culminate in meningioma formation. Oncogene (2011) 30, 2333-2344; doi: 10.1038/onc.2010.609; published online 17 January 2011	[Giovannini, M.] House Ear Res Inst, Ctr Neural Tumor Res, Los Angeles, CA 90057 USA; [Kalamarides, M.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Giovannini, M.] INSERM, U674, Paris, France; [Kalamarides, M.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Giovannini, M.] Univ Paris 07, Inst Univ Hematol, Paris, France; [Kalamarides, M.] Hop Beaujon, AP HP, Serv Neurochirurg, Clichy, France; [Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Mol Neurooncol & Pathol Dept, Boston, MA 02114 USA; [Stemmer-Rachamimov, A. O.] Harvard Univ, Sch Med, Boston, MA USA; [Lusis, E. A.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA; [Hegedus, B.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	House Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL)	Giovannini, M (corresponding author), House Ear Res Inst, Ctr Neural Tumor Res, 2100W 3rd St, Los Angeles, CA 90057 USA.	mgiovannini@hei.org	Hegedus, Balazs/B-6076-2008	Hegedus, Balazs/0000-0002-4341-4153; Gutmann, David/0000-0002-3127-5045; Kawakita, Michiko/0000-0002-9450-583X	US Army Medical Research and Materiel Command [DAMD17-02-1-0645]; James S McDonnell Foundation; Association Neurofibromatoses et Recklinghausen; Vincent Buono Research Fund; Inserm	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); James S McDonnell Foundation; Association Neurofibromatoses et Recklinghausen; Vincent Buono Research Fund; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank A Berns for p16<SUP>Ink4a</SUP> and p53<SUP>flox</SUP> mutant mice; S Dufour and JP Thiery for HtPACre mice; Y Urade for the PGDS genomic fragment; M Pla and staff of the Institut Universitaire d'Hematologie (IUH), Universite Paris 7, for mouse housing; N Karboul for technical assistance; and M Catala and W Van Furth for helpful discussions. This work was supported by Grants from the US Army Medical Research and Materiel Command (DAMD17-02-1-0645 to MG), James S McDonnell Foundation (to DHG and MG), Association Neurofibromatoses et Recklinghausen, the Vincent Buono Research Fund (to DHG and MG) and Inserm.	Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ANGELOV DN, 1989, CELL TISSUE RES, V257, P207; Beuckmann CT, 2000, J COMP NEUROL, V428, P62, DOI 10.1002/1096-9861(20001204)428:1<62::AID-CNE6>3.0.CO;2-E; Catala M., 1998, Archives d'Anatomie et de Cytologie Pathologiques, V46, P153; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; da Cruz MJ, 2000, BRIT J NEUROSURG, V14, P101; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Fevre-Montange M, 2009, INT J ONCOL, V35, P1395, DOI 10.3892/ijo_00000457; Giovannini M, 2000, GENE DEV, V14, P1617; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hartmann C, 2006, BRAIN PATHOL, V16, P15, DOI 10.1111/j.1750-3639.2006.tb00557.x; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2008, BRAIN PATHOL, V18, P62, DOI 10.1111/j.1750-3639.2007.00105.x; KAMIRYO T, 1990, ANAT RECORD, V227, P207, DOI 10.1002/ar.1092270209; Kawashima M, 2001, MODERN PATHOL, V14, P197, DOI 10.1038/modpathol.3880285; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Krutilkova V, 2005, EUR J CANCER, V41, P1597, DOI 10.1016/j.ejca.2005.01.026; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; Lee JH, 2006, J NEUROSURG, V105, P60, DOI 10.3171/jns.2006.105.1.60; Louis D. N., 2000, PATHOLOGY GENETICS T, P176; Marino S, 2000, GENE DEV, V14, P994; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58; NAKASU S, 1987, SURG NEUROL, V27, P319, DOI 10.1016/0090-3019(87)90005-X; OLIVERO WC, 1995, J NEUROSURG, V83, P222, DOI 10.3171/jns.1995.83.2.0222; Pietri T, 2003, DEV BIOL, V259, P176, DOI 10.1016/S0012-1606(03)00175-1; Robanus-Maandag E, 2004, ONCOGENE, V23, P6541, DOI 10.1038/sj.onc.1207858; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; SCHWECHHEIMER K, 1984, LAB INVEST, V51, P584; Stuart JE, 2010, J NEUROPATHOL EXP NE; TOHMA Y, 1992, CANCER RES, V52, P1981; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; Vandenabeele F, 1996, J ANAT, V189, P417; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Yamashima T, 1997, J NEUROSCI, V17, P2376; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007	44	91	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2333	2344		10.1038/onc.2010.609	http://dx.doi.org/10.1038/onc.2010.609			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242963	Bronze			2022-12-17	WOS:000290789200005
J	Lewis, DA; Travers, JB; Somani, AK; Spandau, DF				Lewis, D. A.; Travers, J. B.; Somani, A-K; Spandau, D. F.			The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer	ONCOGENE			English	Article						aging; IGF-1R; skin cancer; keratinocytes; fibroblasts; UVB	GROWTH-FACTOR-I; HUMAN KERATINOCYTES; INSULIN; RECEPTOR; FIBROBLASTS; APOPTOSIS; LINK	The appropriate response of human keratinocytes to ultraviolet-B (UVB) is dependent on the activation status of the insulin-like growth factor 1 (IGF-1) receptor. Keratinocytes grown in conditions in which the IGF-1 receptor is inactive inappropriately replicate in the presence of UVB-induced DNA damage. In human skin, epidermal keratinocytes do not express IGF-1, and hence the IGF-1 receptor on keratinocytes is activated by IGF-1 secreted from dermal fibroblasts. We now show that the IGF-1 produced by human fibroblasts is essential for the appropriate UVB response of keratinocytes. Furthermore, the expression of IGF-1 is silenced in senescent fibroblasts in vitro. Using quantitative reverse transcriptase-PCR and immunohistochemisty, we can show that IGF-1 expression is also silenced in geriatric dermis in vivo. The diminished IGF-1 expression in geriatric skin correlates with an inappropriate UVB response in geriatric volunteers. Finally, the appropriate UVB response is restored in geriatric skin in vivo through pretreatment with exogenous IGF-1. These studies provide further evidence for a role of the IGF-1 receptor (IGF-1R) in suppressing UVB-induced carcinogenesis, suggest that fibroblasts have a critical role in maintaining appropriate activation of the keratinocyte IGF-1R, and imply that reduced expression of IGF-1 in geriatric skin could be an important component in the development of aging-related non-melanoma skin cancer. Oncogene (2010) 29, 1475-1485; doi:10.1038/onc.2009.440; published online 7 December 2009	[Lewis, D. A.; Travers, J. B.; Somani, A-K; Spandau, D. F.] Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; [Travers, J. B.] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Travers, J. B.] Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Travers, J. B.] Univ Sch Med, Richard L Roudebush VA Med Ctr, Indianapolis, IN USA; [Spandau, D. F.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis	Spandau, DF (corresponding author), Indiana Univ, Sch Med, Dept Dermatol, 975 W Walnut St,Room 349, Indianapolis, IN 46202 USA.	dspanda@iupui.edu	Somani, ally-khan/AAA-9656-2020	Travers, Jeffrey/0000-0001-7232-1039; Somani, Ally-Khan/0000-0003-2166-4896	National Institutes of Health [R01ES11155, R21CA131901, R01HL062996, U19A1070448]; VA Merit Award; NATIONAL CANCER INSTITUTE [R21CA131901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011155] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are grateful to Dr Raymond Konger for his valuable suggestions. The recombinant human IGF-1 was generously provided by Tercica, Inc. This work was supported by grants from the National Institutes of Health (R01ES11155 and R21CA131901 to DFS; R01HL062996 and U19A1070448 to JBT) and VA Merit Award (JBT).	Chuang TY, 2005, BRIT J DERMATOL, V153, P552, DOI 10.1111/j.1365-2133.2005.06738.x; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Donovan EA, 2008, CRIT REV ONCOL HEMAT, V66, P91, DOI 10.1016/j.critrevonc.2007.09.003; Dziadziuszko R, 2008, J THORAC ONCOL, V3, P815, DOI 10.1097/JTO.0b013e31818180f5; FERBER A, 1993, J BIOL CHEM, V268, P17883; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x; Lewis DA, 2003, EXP CELL RES, V284, P316, DOI 10.1016/S0014-4827(02)00043-5; Lewis DA, 2003, J INVEST DERMATOL, V120, P483, DOI 10.1046/j.1523-1747.2003.12060.x; LEWIS DA, 2007, J INVEST DERMATOL, V128, P1022; Lewis DA, 2008, MOL BIOL CELL, V19, P1346, DOI 10.1091/mbc.E07-10-1041; Lewis DA, 2009, J INVEST DERMATOL, V129, P787, DOI 10.1038/jid.2008.293; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928	20	91	94	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1475	1485		10.1038/onc.2009.440	http://dx.doi.org/10.1038/onc.2009.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966862	Green Accepted			2022-12-17	WOS:000275392400006
J	Beck, AH; Lee, CH; Witten, DM; Gleason, BC; Edris, B; Espinosa, I; Zhu, S; Li, R; Montgomery, KD; Marinelli, RJ; Tibshirani, R; Hastie, T; Jablons, DM; Rubin, BP; Fletcher, CD; West, RB; van de Rijn, M				Beck, A. H.; Lee, C-H; Witten, D. M.; Gleason, B. C.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; Marinelli, R. J.; Tibshirani, R.; Hastie, T.; Jablons, D. M.; Rubin, B. P.; Fletcher, C. D.; West, R. B.; van de Rijn, M.			Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling	ONCOGENE			English	Article						sarcoma; leiomyosarcoma; integrative genomics; gene expression profiling; array comparative genomic hybridization; tissue microarrays	SOFT-TISSUE SARCOMAS; GENE-EXPRESSION ANALYSIS; TUMORS; SIGNATURE; PATTERNS; METASTASIS; SUBCLASSES; PROGNOSIS; RELEVANT; REGION	Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and molecular heterogeneity. We used integrative molecular pro. ling to discover and characterize molecular subtypes of LMS. Gene expression pro. ling was performed on 51 LMS samples. Unsupervised clustering showed three reproducible LMS clusters. Array comparative genomic hybridization (aCGH) was performed on 20 LMS samples and showed that the molecular subtypes defined by gene expression showed distinct genomic changes. Tumors from the 'muscle-enriched' cluster showed significantly increased copy number changes (P = 0.04). A majority of the muscle-enriched cases showed loss at 16q24, which contains Fanconi anemia, complementation group A, known to have an important role in DNA repair, and loss at 1p36, which contains PRDM16, of which loss promotes muscle differentiation. Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n = 377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). Expression of the five markers was associated with improved disease-specific survival in a multivariate Cox regression analysis (P<0.04). In this analysis that combined gene expression pro. ling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers. Oncogene (2010) 29, 845-854; doi:10.1038/onc.2009.381; published online 9 November 2009	[Beck, A. H.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; West, R. B.; van de Rijn, M.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lee, C-H] Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; [Lee, C-H] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Witten, D. M.; Tibshirani, R.; Hastie, T.] Stanford Univ, Med Ctr, Dept Stat, Stanford, CA 94305 USA; [Gleason, B. C.; Fletcher, C. D.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Marinelli, R. J.] Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; [Jablons, D. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Rubin, B. P.] Cleveland Clin, Dept Anat Pathol, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Rubin, B. P.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [West, R. B.] Palo Alto Vet Affairs Hlth Care Syst, Dept Pathol & Lab Serv, Palo Alto, CA USA	Stanford University; University of British Columbia; British Columbia Cancer Agency; Stanford University; Harvard University; Brigham & Women's Hospital; Stanford University; University of California System; University of California San Francisco; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,L235, Stanford, CA 94305 USA.	mrijn@stanford.edu		West, Robert/0000-0002-8330-8283; van de Rijn, Matt/0000-0002-1909-9739; Hastie, Trevor/0000-0002-0164-3142	NIH [CA112270]; National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE [R01CA112270] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support came from NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation. The authors dedicate this paper to the memory of Suzanne Kurtz, LMS patient and founder of LMSdr. This work was supported by NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation.	ABBAS AK, 2005, ROBBINS COTRAN PATHO, V15; ACKERMAN L.V, 2004, ROSAI ACKERMANS SURG, V9th; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; BECK AH, 2009, VIRCHOWS ARCH; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Borden EC, 2003, CLIN CANCER RES, V9, P1941; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Espinosa I, 2009, AM J PATHOL, V174, P2347, DOI 10.2353/ajpath.2009.081037; FLETCHER CDM, PATHOLOGY GENETICS T; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Henderson SR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r76; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; JUN HJ, 2009, MED ONCOL; Kapp AV, 2007, BIOSTATISTICS, V8, P9, DOI 10.1093/biostatistics/kxj029; Kattan MW, 2002, J CLIN ONCOL, V20, P791, DOI 10.1200/JCO.20.3.791; Kochetkova M, 2002, CANCER RES, V62, P4599; Lakhani SR, 2001, NAT REV CANCER, V1, P151, DOI 10.1038/35101087; Landis-Piwowar KR, 2008, J CELL BIOCHEM, V105, P514, DOI 10.1002/jcb.21853; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Larramendy ML, 2008, CANCER GENET CYTOGEN, V187, P1, DOI 10.1016/j.cancergencyto.2008.06.005; Lee CH, 2008, CLIN CANCER RES, V14, P1423, DOI 10.1158/1078-0432.CCR-07-1712; Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Meza-Zepeda LA, 2006, CANCER RES, V66, P8984, DOI 10.1158/0008-5472.CAN-06-1972; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Ottone T, 2009, GENE CHROMOSOME CANC, V48, P213, DOI 10.1002/gcc.20633; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Pervaiz N, 2008, CANCER-AM CANCER SOC, V113, P573, DOI 10.1002/cncr.23592; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Quade BJ, 2004, GENE CHROMOSOME CANC, V40, P97, DOI 10.1002/gcc.20018; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ren BG, 2003, HUM PATHOL, V34, P549, DOI 10.1016/S0046-8177(03)00014-5; RONG S, 1993, CANCER RES, V53, P5355; Sarcoma Meta-analysis Collaboration, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001419, DOI 10.1002/14651858.CD001419]; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shmulevich I, 2002, CANCER-AM CANCER SOC, V94, P2069, DOI 10.1002/cncr.10425; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Skubitz KM, 2003, CANCER, V98, P1029, DOI 10.1002/cncr.11586; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Weigelt B, 2004, CELL CYCLE, V3, P756; Weiss SW, 2008, ENZINGER WEISSS SOFT, P303; Zou H, 2006, J COMPUT GRAPH STAT, V15, P265, DOI 10.1198/106186006X113430	56	91	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					845	854		10.1038/onc.2009.381	http://dx.doi.org/10.1038/onc.2009.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901961	Green Submitted, Green Accepted			2022-12-17	WOS:000274397800007
J	Cherrier, T; Suzanne, S; Redel, L; Calao, M; Marban, C; Samah, B; Mukerjee, R; Schwartz, C; Gras, G; Sawaya, BE; Zeichner, SL; Aunis, D; Van Lint, C; Rohr, O				Cherrier, T.; Suzanne, S.; Redel, L.; Calao, M.; Marban, C.; Samah, B.; Mukerjee, R.; Schwartz, C.; Gras, G.; Sawaya, B. E.; Zeichner, S. L.; Aunis, D.; Van Lint, C.; Rohr, O.			p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1	ONCOGENE			English	Article						CTIP2; p21(WAF1); SUV39H1; HIV-1	CELL-CYCLE ARREST; HISTONE DEACETYLASE INHIBITORS; MICROGLIAL CELLS; T-LYMPHOCYTES; HIV-1 VPR; TRANSCRIPTIONAL ACTIVATION; P21/WAF1/CIP1 GENE; DNA-REPLICATION; NURD COMPLEX; IN-VIVO	Mainly regulated at the transcriptional level, the cellular cyclin-dependent kinase inhibitor, CDKN1A/p21(WAF1) (p21), is a major cell cycle regulator of the response to DNA damage, senescence and tumor suppression. Here, we report that COUP-TF-interacting protein 2 (CTIP2), recruited to the p21 gene promoter, silenced p21 gene transcription through interactions with histone deacetylases and methyltransferases. Importantly, treatment with the specific SUV39H1 inhibitor, chaetocin, repressed histone H3 lysine 9 trimethylation at the p21 gene promoter, stimulated p21 gene expression and induced cell cycle arrest. In addition, CTIP2 and SUV39H1 were recruited to the silenced p21 gene promoter to cooperatively inhibit p21 gene transcription. Induction of p21(WAF1) gene upon human immunodeficiency virus 1 (HIV-1) infection benefits viral expression in macrophages. Here, we report that CTIP2 further abolishes Vpr-mediated stimulation of p21, thereby indirectly contributing to HIV-1 latency. Altogether, our results suggest that CTIP2 is a constitutive p21 gene suppressor that cooperates with SUV39H1 and histone methylation to silence the p21 gene transcription. Oncogene (2009) 28, 3380-3389; doi: 10.1038/onc.2009.193; published online 6 July 2009	[Cherrier, T.; Suzanne, S.; Redel, L.; Marban, C.; Schwartz, C.; Aunis, D.; Rohr, O.] Univ Strasbourg, INSERM, Inst Virol, U575, F-67000 Strasbourg, France; [Samah, B.; Gras, G.] Serv Neurovirol, CEA, UMRE 01, Fontenay Aux Roses, France; [Mukerjee, R.; Sawaya, B. E.] Temple Univ, Dept Neurol, Sch Med, Mol Virol Lab, Philadelphia, PA 19122 USA; [Zeichner, S. L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Pediat & Microbiol, Washington, DC USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Immunol, Washington, DC USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Trop Med, Washington, DC USA; [Calao, M.; Van Lint, C.] Univ Libre Bruxelles, Inst Biol & Med Mol, Mol Virol Lab, Gosselies, Belgium; [Rohr, O.] IUT Louis Pasteur Schiltigheim, Schiltigheim, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CEA; UDICE-French Research Universities; Universite Paris Saclay; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Children's National Health System; George Washington University; George Washington University; George Washington University; Universite Libre de Bruxelles	Rohr, O (corresponding author), Univ Strasbourg, INSERM, Inst Virol, U575, 3 Rue Koeberle, F-67000 Strasbourg, France.	cvlint@ulb.ac.be; olivier.rohr@iutlpa.u-strasbg.fr	Dominique, Aunis/W-1419-2019; CHERRIER, Thomas/F-8727-2018	ROHR, Olivier/0000-0001-8992-2025; CHERRIER, Thomas/0000-0002-0707-9204	Institut National de la Sante et de la Recherche Medicale (INSERM); Agence Nationale de Recherches sur le SIDA (ANRS); Sidaction; French Ministry of Research [ACI JC 5364]; Fonds National de la Recherche Scientifique (FNRS, Belgium); Action de Recherche concertee du Ministere de la Communaute Francaise [04/09-309]; Internationale Brachet Stiftung (IBS); Region Wallonne-Commission Europeenne FEDER; Theyskens-Mineur Foundation; NIH; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059327] Funding Source: NIH RePORTER	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de Recherches sur le SIDA (ANRS)(ANRSFrench National Research Agency (ANR)); Sidaction; French Ministry of Research(Ministry of Research, FranceEuropean Commission); Fonds National de la Recherche Scientifique (FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Action de Recherche concertee du Ministere de la Communaute Francaise; Internationale Brachet Stiftung (IBS); Region Wallonne-Commission Europeenne FEDER; Theyskens-Mineur Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr D Kardassis for providing us with p21-LUC plasmids and Dr Yannick Goumon for his technical support. This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), by grants from the Agence Nationale de Recherches sur le SIDA (ANRS) to OR and CVL, from Sidaction to OR and TC and from the French Ministry of Research ('ACI JC 5364' to OR and doctoral grant to TC and SS) The work in CVL's laboratory was supported by grants from the 'Fonds National de la Recherche Scientifique' (FNRS, Belgium), the Televie-Program of the FNRS, from the 'Action de Recherche concertee du Ministere de la Communaute Francaise (ULB, ARC program no. 04/09-309), from the Internationale Brachet Stiftung (IBS), from the Region Wallonne-Commission Europeenne FEDER (Intergenes Project, Interreg III program) and from the Theyskens-Mineur Foundation. CVL is 'Directeur de Recherches' of the FNRS. This work was supported by NIH to BES.	Amini S, 2004, J BIOL CHEM, V279, P46046, DOI 10.1074/jbc.M403792200; Anderson MR, 2008, CULT HEALTH SEX, V10, P1, DOI 10.1080/13691050701516363; Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cismasiu VB, 2006, BLOOD, V108, P2695, DOI 10.1182/blood-2006-05-021790; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grabarczyk P, 2007, ONCOGENE, V26, P3797, DOI 10.1038/sj.onc.1210152; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; Kamimura K, 2007, ONCOGENE, V26, P5840, DOI 10.1038/sj.onc.1210388; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; Leone C, 2006, GLIA, V54, P183, DOI 10.1002/glia.20372; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; Marban C, 2007, EMBO J, V26, P412, DOI 10.1038/sj.emboj.7601516; Moon HS, 2006, MOL CELLS, V21, P7; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Rohr O, 2003, J VIROL, V77, P5415, DOI 10.1128/JVI.77.9.5415-5427.2003; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schrofelbauer B, 2007, P NATL ACAD SCI USA, V104, P4130, DOI 10.1073/pnas.0610167104; Sowa Y, 1999, CANCER RES, V59, P4266; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Thierry S, 2004, J VIROL, V78, P12198, DOI 10.1128/JVI.78.22.12198-12206.2004; Topark-Ngarm A, 2006, J BIOL CHEM, V281, P32272, DOI 10.1074/jbc.M602776200; Vazquez N, 2005, J VIROL, V79, P4479, DOI 10.1128/JVI.79.7.4479-4491.2005; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Yoshizuka N, 2005, J VIROL, V79, P11366, DOI 10.1128/JVI.79.17.11366-11381.2005; Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971	44	91	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3380	3389		10.1038/onc.2009.193	http://dx.doi.org/10.1038/onc.2009.193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19581932	Green Published, Green Accepted			2022-12-17	WOS:000270103300005
J	Mitani, Y; Oue, N; Matsumura, S; Yoshida, K; Noguchi, T; Ito, M; Tanaka, S; Kuniyasu, H; Kamata, N; Yasui, W				Mitani, Y.; Oue, N.; Matsumura, S.; Yoshida, K.; Noguchi, T.; Ito, M.; Tanaka, S.; Kuniyasu, H.; Kamata, N.; Yasui, W.			Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy	ONCOGENE			English	Article						reg IV; apoptosis; 5-fluorouracil; serum tumor marker; SAGE; gastric cancer	DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; CELL-LINE TMK-1; GENE-EXPRESSION; COLONIC CARCINOMAS; SERIAL ANALYSIS; APOPTOSIS; SENSITIVITY; METASTASIS; SEARCH	Regenerating gene family, member 4 (Reg IV), a secreted protein, is overexpressed in several cancers, including gastric cancer (GC). In the present study, we measured Reg IV levels in sera from patients with GC by enzyme-linked immunosorbent assay. We also examined the effect of forced Reg IV expression on the apoptotic susceptibility to 5-fluorouracil(5-FU). Forced expression of Reg IV inhibited 5-FU-induced apoptosis. Induction of Bcl-2 and dihydropyrimidine dehydrogenase was involved in inhibition of apoptosis. Among 36 GC patients treated with a combination chemotherapy of low-dose 5-FU and cisplatin, all 14 Reg IV-positive patients showed no change or disease progression. The serum Reg IV concentration was similar between healthy individuals mean +/- s.e., (0.52 +/- 0.05 ng/ml) and patients with chronic-active gastritis (0.36 +/- 0.09 ng/ml). However, the serum Reg IV concentration in presurgical GC patients was signifi. cantly elevated (1.96 +/- 0.17 ng/ml), even at stage I. The diagnostic sensitivity of serum Reg IV (36.1%) was superior to that of serum carcinoembryonic antigen (11.5%) or carbohydrate antigen 19-9 (13.1%). These results indicate that expression of Reg IV is a marker for prediction of resistance to 5-FU-based chemotherapy in patients with GC. Serum Reg IV represents a novel biomarker for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Surg, Div Cervico Gnathostomatol, Hiroshima, Japan; Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Oita University; Hiroshima University; Nara Medical University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				ALLEY MC, 1988, CANCER RES, V48, P589; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bishnupuri KS, 2006, GASTROENTEROLOGY, V130, P137, DOI 10.1053/j.gastro.2005.10.001; Buckhaults P, 2001, CANCER RES, V61, P6996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS BE, 1990, CANCER RES, V50, P197; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Inada T, 2000, ANTICANCER RES, V20, P2457; Ishikawa Y, 2000, JPN J CANCER RES, V91, P105, DOI 10.1111/j.1349-7006.2000.tb00866.x; Kari C, 2003, CANCER RES, V63, P1; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim R, 1999, INT J ONCOL, V15, P921; Kochi Mitsugu, 2000, Gastric Cancer, V3, P177, DOI 10.1007/PL00011715; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393; Ukon K, 2005, CANCER RES, V65, P1055; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; YASUI W, 1988, CANCER RES, V48, P137	33	91	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4383	4393		10.1038/sj.onc.1210215	http://dx.doi.org/10.1038/sj.onc.1210215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237819	Green Submitted			2022-12-17	WOS:000247620000006
J	Alli, E; Yang, JM; Hait, WN				Alli, E.; Yang, J-M; Hait, W. N.			Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53	ONCOGENE			English	Article						stathmin; cell-cycle arrest; mitosis; apoptosis; breast cancer	DOWN-REGULATION; CYCLE ARREST; EXPRESSION; OVEREXPRESSION; CHECKPOINT; MUTATIONS; GENES; ONCOPROTEIN-18; APOPTOSIS; NETWORK	Cancers harboring dominant-negative p53 mutations are often aggressive and difficult to treat. Direct attempts to restore wild-type p53 function have produced little clinical benefit. We investigated whether targeting a p53-target gene could induce certain tumor-suppressor characteristics. We found that inhibition of stathmin, a microtubule regulator that can be transcriptionally repressed by wildtype p53, restored certain wild-type functions to cancer cells with mutant p53. Silencing of stathmin by small interfering RNA ( siRNA) in mutant p53 cell lines lowered expression to that observed following activation of wildtype p53 by DNA damage in wild-type p53 cell lines. siRNA-induced repression of stathmin decreased cell proliferation, viability and clonogenicity in mutant p53 cell lines. Furthermore, knockdown of stathmin partially restored cell-cycle regulation and activation of apoptosis. Therefore, targeting stathmin, a gene product that is overexpressed in the presence of mutant p53, may represent a novel approach to treating cancers with aberrant p53 function.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Hait, WN (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08901 USA.	jyang@umdnj.edu; haitwn@umdnj.edu			NCI NIH HHS [CA 78695, CA 72720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078695, P30CA072720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alli E, 2002, CANCER RES, V62, P6864; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Bieche I, 2003, MOL BRAIN RES, V114, P55, DOI 10.1016/S0169-328X(03)00132-3; Bossi G, 2004, ONCOGENE, V23, P418, DOI 10.1038/sj.onc.1207042; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang CL, 2001, PROTEOMICS, V1, P1415, DOI 10.1002/1615-9861(200111)1:11<1415::AID-PROT1415>3.3.CO;2-6; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meek DW, 2000, PATHOL BIOL, V48, P246; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oesterreich S, 1999, ENDOCR-RELAT CANCER, V6, P405, DOI 10.1677/erc.0.0060405; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOBEL A, 1983, J BIOL CHEM, V258, P312; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vecil GG, 2003, J NEURO-ONCOL, V65, P237, DOI 10.1023/B:NEON.0000003653.45635.32; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569	43	91	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1003	1012		10.1038/sj.onc.1209864	http://dx.doi.org/10.1038/sj.onc.1209864			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909102				2022-12-17	WOS:000244245400006
J	Yamanaka, R; Arao, T; Yajima, N; Tsuchiya, N; Homma, J; Tanaka, R; Sano, M; Oide, A; Sekijima, M; Nishio, K				Yamanaka, R.; Arao, T.; Yajima, N.; Tsuchiya, N.; Homma, J.; Tanaka, R.; Sano, M.; Oide, A.; Sekijima, M.; Nishio, K.			Identification of expressed genes characterizing long-term survival in malignant glioma patients	ONCOGENE			English	Article						cDNA array; gene expression profiles; glioma; survival predictor; siRNA	MOLECULAR SUBTYPES; MICROARRAY ANALYSIS; DNA-MICROARRAY; CLASSIFICATION; GLIOBLASTOMA; PROFILES; CANCER; PROGRESSION; PREDICTOR; ADHESION	Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to de. ne subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.	Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata 9518585, Japan; Natl Canc Ctr, Res Inst, Div Pharmacol, Chuo Ku, Tokyo 104, Japan; Mitsubishi Chem Safety Inst, Ibaraki, Japan	Niigata University; National Cancer Center - Japan; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical Safety Institute	Yamanaka, R (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurosurg, Asahimachi Dori 1-757, Niigata 9518585, Japan.	ryaman@bri.niigata-u.ac.jp		Yamanaka, Ryuya/0000-0003-2941-7996				Afra D, 2002, LANCET, V359, P1011; Agrawal D, 2002, J NATL CANCER I, V94, P513; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Godard S, 2003, CANCER RES, V63, P6613; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Hunter SB, 2003, INT J ONCOL, V23, P857; Karpeh M. S., 2001, CANC PRINCIPLES PRAC, P1092; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kim S, 2002, MOL CANCER THER, V1, P1229; Kleihues, 2000, WHO CLASSIFICATION T; Li K, 2002, J BIOL CHEM, V277, P47052, DOI 10.1074/jbc.M205374200; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Nutt CL, 2003, CANCER RES, V63, P1602; Ogawa K, 2001, J IMMUNOL, V166, P6404, DOI 10.4049/jimmunol.166.10.6404; Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Weiner HL, 2000, CANCER INVEST, V18, P544, DOI 10.3109/07357900009012194; Wong KK, 2005, CANCER RES, V65, P76; Yoshimura T, 2005, IMMUNOL RES, V31, P219, DOI 10.1385/IR:31:3:219	34	91	100	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5994	6002		10.1038/sj.onc.1209585	http://dx.doi.org/10.1038/sj.onc.1209585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652150				2022-12-17	WOS:000240826300008
J	Marini, P; Denzinger, S; Schiller, D; Kauder, S; Welz, S; Humphreys, R; Daniel, PT; Jendrossek, V; Budach, W; Belka, C				Marini, P.; Denzinger, S.; Schiller, D.; Kauder, S.; Welz, S.; Humphreys, R.; Daniel, P. T.; Jendrossek, V.; Budach, W.; Belka, C.			Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo	ONCOGENE			English	Article						TRAIL receptor antibodies; HGS-ETR1; HGS-ETR2; radiotherapy; apoptosis; molecular targeted therapy	APOPTOSIS-INDUCING LIGAND; IRRADIATION-INDUCED APOPTOSIS; CELL-DEATH PATHWAY; NF-KAPPA-B; IONIZING-RADIATION; MONOCLONAL-ANTIBODIES; CANCER-THERAPY; CYTOCHROME-C; DNA-DAMAGE; BAX	We and others have demonstrated already that TRAIL (TNF-related apoptosis-inducing ligand) is a very promising candidate for molecular targeted anticancer therapy, especially when combined with ionizing radiation or other DNA-damaging agents. Agonist monoclonal antibodies that activate and are specific for the death signaling TRAIL receptors are an alternative method to stimulate the programmed cell death pathway. Phase 1 clinical trials have subsequently been conducted and shown a very good tolerability of these antibodies. In order to assess the efficacy of TRAIL receptor stimulation to induce cell death by this alternate method, we studied the combination of the agonistic-TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 with radiation in vitro and in vivo. Induction of apoptosis after combined treatment with TRAIL receptor antibodies HGS-ETR1 and/or HGS-ETR2 (0.01, 0.1, 1.0 mg/ml) and irradiation with 2, 5 or 10 Gy was determined by fluorescence microscopy and Western blot analysis of caspase-8 and PARP. The colorectal tumour cell lines Colo 205, HCT 116 and HCT-15 were used for in vitro experiments. Growth delay experiments were performed with combined treatment with fractionated irradiation (days 1-5 and 3Gy single dose/day) and the receptor antibodies (intraperitonially, three different concentrations, application on days 1, 4 and 8) on Colo 205 xenograft-bearing NMRI (nu/nu) nude mice. HGS-ETR1 and HGS-ETR2 induced apoptotic cell death in a dose-dependent fashion and significantly increased cell death in combination with irradiation in vitro when compared to either irradiation or antibody treatment alone. The efficacy of the combined treatment seems to be at least partially Bax-dependent. Similar to the results from cell culture experiments, in vivo experiments demonstrated a dose-dependent delay in tumour growth after combined treatment. In vivo, in the Colo205 xenograft model, HGS-ETR2 revealed a higher activity than HGS-ETR1. This is the first study to demonstrate significant efficacy of combined treatment with the monoclonal agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and ionising radiation in in vitro and in vivo models. We postulate that HGS-ETR1 and HGS-ETR2 will be very promising new agents in the field of molecular targeted multi-modality anticancer therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Dusseldorf, Dept Radiat Oncol & Radiotherapy, D-4000 Dusseldorf, Germany; Human Genome Sci Inc, Dev Sci & Res, Rockville, MD USA; Humboldt Univ, Berlin, Germany	Eberhard Karls University of Tubingen; Heinrich Heine University Dusseldorf; GlaxoSmithKline; Human Genome Sciences Inc; Humboldt University of Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				ALDERSON RF, 2003, 94 AACR ANN M; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; ATTARD G, 2005, AACRNCIEORTC INT C M; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEBONO JS, 2004, 16 EORTCNCIAACR S MO; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUDLA S, 2002, NAT MED, V8, P808; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hamasu T, 2005, J RADIAT RES, V46, P103, DOI 10.1269/jrr.46.103; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOTTE SJ, 2004, 94 AACR ANN M GEN SW; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Marini P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Marini Patrizia, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P334, DOI 10.2174/1568011033482297; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Rubel A, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-6; SALCEDO TW, 2002, AM ASS CANC RES 93 A; SARANTOPOULOS J, 2005, AACRNCIEORTC INT C M; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Stuben G, 1994, Strahlenther Onkol, V170, P36; STUSCHKE M, 1990, RADIAT RES, V122, P172, DOI 10.2307/3577603; TOLCHER AW, 2004, AM SOC CLIN ONC ANN; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	58	91	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5145	5154		10.1038/sj.onc.1209516	http://dx.doi.org/10.1038/sj.onc.1209516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636678				2022-12-17	WOS:000240063700007
J	Li, Y; Xie, M; Yang, J; Yang, D; Deng, R; Wan, Y; Yan, B				Li, Y.; Xie, M.; Yang, J.; Yang, D.; Deng, R.; Wan, Y.; Yan, B.			The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter	ONCOGENE			English	Article						DEC1; survivin; Sp1 element; transcription activation	WILD-TYPE P53; GENE-EXPRESSION; RESPONSE ELEMENTS; CANCER CELLS; E-BOX; HYPOXIA; STRA13; ACTIVATION; APOPTOSIS; PATHWAY	Human differentially expressed in chondrocytes (DEC), mouse stimulated with retinoic acid and rat split and hairy related proteins constitute a structurally distinct class of the basic helix-loop-helix proteins. DEC1 is abundantly expressed in tumors and protects against apoptosis induced by serum starvation. In this study, we report that DEC1 antiapoptosis is achieved by inducing survivin, an antiapoptotic protein. In paired tumor-normal tissues, survivin and DEC1 exhibited a paralleled expression pattern. Tetracycline-induced expression of DEC1 in stable lines proportionally increased the expression of survivin. In reporter assays, DEC1 trans activated the survivin promoter but repressed the DEC2 promoter. In contrast to the repression, the activation was delayed and varied depending on serum concentrations and cycle blockers. Studies with reporter mutants located, in the survivin promoter, two Sp1 sites that supported DEC1 transactivation. Electrophoretic mobility shift assay and chromatin immunoprecipitation detected the presence of DEC1 in the survivin promoter. These findings establish that the survivin gene is a transcription target of DEC1, and induction of survivin is at least in part responsible for DEC1 antiapoptosis.	Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; Providence Coll, Dept Biol, Providence, RI 02908 USA	University of Rhode Island; Providence College	Yan, B (corresponding author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	byan@uri.edu	Yan, Bingfang/C-7706-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT003019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061988] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05AT003019, F05 AT003019] Funding Source: Medline; NIEHS NIH HHS [R01 ES007965, R01ES07965] Funding Source: Medline; NIGMS NIH HHS [R01 GM061988, R01GM61988] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chakrabarti J, 2004, BRIT J CANCER, V91, P954, DOI 10.1038/sj.bjc.6602059; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Currie MJ, 2004, J CLIN PATHOL, V57, P829, DOI 10.1136/jcp.2003.015644; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halaban R, 2005, CANCER METAST REV, V24, P339, DOI 10.1007/s10555-005-1582-z; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li YX, 2004, BIOCHEM J, V382, P895, DOI 10.1042/BJ20040592; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Song XL, 2004, DRUG METAB DISPOS, V32, P35, DOI 10.1124/dmd.32.1.35; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Turley H, 2004, J PATHOL, V203, P808, DOI 10.1002/path.1585; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Xie MX, 2003, DRUG METAB DISPOS, V31, P21, DOI 10.1124/dmd.31.1.21; Xie MX, 2002, DRUG METAB DISPOS, V30, P541, DOI 10.1124/dmd.30.5.541; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	43	91	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3296	3306		10.1038/sj.onc.1209363	http://dx.doi.org/10.1038/sj.onc.1209363			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462771	Green Accepted			2022-12-17	WOS:000237951200008
J	Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S				Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S			The G(12/13)-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration	ONCOGENE			English	Article						LPA; FAK; cell migration	OVARIAN-CANCER CELLS; FOCAL ADHESION KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-D; RAC ACTIVATION; RHO-GTPASES; EXPRESSION; LPA; RECEPTORS	The membrane redistribution and phosphorylation of focal adhesion kinase (FAK) have been reported to be important for cell migration. We previously showed that Lysophosphatidic acid (LPA) induced FAK membrane redistribution and autophosphorylation in ovarian cancer SK-OV3 cells and the signaling pathway consisting of G(i)-Ras-MEKK1 mediated LPA-induced FAK membrane redistribution but not FAK autophosphorylation. We also showed that the disruption of the Gi-Ras-MEKK1 pathway led to a significant reduction in LPA-stimulated cell migration. These findings raised the question of whether LPA-induced FAK autophosphorylation was required for LPA-stimulated cell migration and what signaling mechanism was involved in LPA-induced FAK autophosphorylation. In this study, we expressed the membrane anchored wild-type FAK (CD2-FAK) in SK-OV3 cells and found that the expression of CD2-FAK greatly rescued LPA-stimulated cell migration in G(i) or Ras-inhibited cells. However, Gi inhibitor pertussis toxin or dominant-negative H-Ras still significantly inhibited LPA-stimulated cell migration in cells expressing the membrane anchored FAK containing a mutation in the autophosphorylation site [CD2-FAK(Y397A)]. These results suggest that FAK autophosphorylation plays a role in LPA-stimulated cell migration. With the aid of p115Rho-GEF-RGS, G(12) and G(13) minigenes to inhibit G12/13, we found that the G12/13 pathway was required for LPA-induced FAK autophosphorylation and efficient cell migration. Moreover, LPA activated RhoA and Rho kinase (ROCK) in a G(12/13)-dependent manner and their activities were required for LPA-induced FAK autophosphorylation. However, Rho or ROCK inhibitors displayed no effect on LPA-induced FAK membrane redistribution although they abolished LPA-induced cytoskeleton reorganization. Our studies show that the G(12/13)-RhoA-ROCK signaling pathway mediates LPA-induced FAK autophosphorylation and contributes to LPA-stimulated cell migration.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; W Virginia Univ, Sch Med, Morgantown, WV USA; Med Coll Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA	Scripps Research Institute; West Virginia University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NCI NIH HHS [R01 CA93926] Funding Source: Medline; NIAID NIH HHS [R01 AI043524, R01 AI043524-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fishman DA, 2001, CANCER RES, V61, P3194; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gschwind A, 2002, CANCER RES, V62, P6329; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; KOZASA T, 2004, G PROTEIN SIGNALING, P153; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; Luquain C, 2003, J LIPID RES, V44, P1963, DOI 10.1194/jlr.M300188-JLR200; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sawada K, 2002, CANCER RES, V62, P6015; SCHALLER MD, 2003, BIOCHIM BIOPHYS ACTA, V1540, P1; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Tanyi JL, 2003, CANCER RES, V63, P1073; van Leeuwen FN, 2003, BIOCHEM SOC T, V31, P1209; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	61	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2234	2244		10.1038/sj.onc.1209261	http://dx.doi.org/10.1038/sj.onc.1209261			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301993				2022-12-17	WOS:000236581200010
J	Carles, A; Millon, R; Cromer, A; Ganguli, G; Lemaire, F; Young, J; Wasylyk, C; Muller, D; Schultz, I; Rabouel, Y; Dembele, D; Zhao, C; Marchal, P; Ducray, C; Bracco, L; Abecassis, J; Poch, O; Wasylyk, B				Carles, A; Millon, R; Cromer, A; Ganguli, G; Lemaire, F; Young, J; Wasylyk, C; Muller, D; Schultz, I; Rabouel, Y; Dembele, D; Zhao, C; Marchal, P; Ducray, C; Bracco, L; Abecassis, J; Poch, O; Wasylyk, B			Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display	ONCOGENE			English	Article						macroarray; microarray; integrative genomics; bioinformatics	GENE-EXPRESSION; IDENTIFICATION; CANCER; 11Q13; GENERATION; ARHGAP10; ADAPTER	Head and neck squamous cell carcinoma (HNSCC) is common worldwide and is associated with a poor rate of survival. Identification of new markers and therapeutic targets, and understanding the complex transformation process, will require a comprehensive description of genome expression, that can only be achieved by combining different methodologies. We report here the HNSCC transcriptome that was determined by exhaustive differential display (DD) analysis coupled with validation by different methods on the same patient samples. The resulting 820 nonredundant sequences were analysed by high throughput bioinformatics analysis. Human proteins were identified for 73% (596) of the DD sequences. A large proportion (> 50%) of the remaining unassigned sequences match ESTs (expressed sequence tags) from human tumours. For the functionally annotated proteins, there is significant enrichment for relevant biological processes, including cell motility, protein biosynthesis, stress and immune responses, cell death, cell cycle, cell proliferation and/or maintenance and transport. Three of the novel proteins (TMEM16A, PHLDB2 and ARH-GAP21) were analysed further to show that they have the potential to be developed as therapeutic targets.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Lab Biol Tumorale, UPRES EA 34 30, Strasbourg, France; Exonhit Therapeut, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Dembélé, Doulaye/O-6513-2017; Wasylyk, Bohdan/ABG-6778-2020; Young, Julia/A-7219-2013; Indra, Gitali/G-2963-2016	Dembélé, Doulaye/0000-0003-3879-6940; Wasylyk, Bohdan/0000-0002-1718-1237; RABOUEL, Yannick/0000-0001-8201-7209; Young, Julia/0000-0001-7219-7824				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Basseres DS, 2002, BIOCHEM BIOPH RES CO, V294, P579; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Broude Natalia E, 2002, Expert Rev Mol Diagn, V2, P209, DOI 10.1586/14737159.2.3.209; Chalmel F, 2005, BIOINFORMATICS, V21, P2095, DOI 10.1093/bioinformatics/bti252; Cirelli C, 2000, BRAIN RES, V885, P303, DOI 10.1016/S0006-8993(00)03008-0; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dancey JE, 2004, ANN ONCOL, V15, P233, DOI 10.1093/annonc/mdh932; Ding CM, 2004, J BIOCHEM MOL BIOL, V37, P1; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Draghici S, 2003, BIOINFORMATICS, V19, P1348, DOI 10.1093/bioinformatics/btg165; Hasina R, 2004, SEMIN ONCOL, V31, P718, DOI 10.1053/j.seminoncol.2004.09.012; Heilig M, 2004, NEUROTOX RES, V6, P363, DOI 10.1007/BF03033310; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Huang Zhong-xi, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P798; Katoh M, 2003, INT J ONCOL, V22, P1375; Katoh M, 2004, INT J ONCOL, V25, P1201; Katsanis N, 2002, P NATL ACAD SCI USA, V99, P14326, DOI 10.1073/pnas.222409099; Lemaire F, 2003, BRIT J CANCER, V89, P1940, DOI 10.1038/sj.bjc.6601373; Liang P, 2003, NAT REV CANCER, V3, P869, DOI 10.1038/nrc1214; Liang P, 1998, METHODS, V16, P361, DOI 10.1006/meth.1998.0690; Liang P, 2002, BIOTECHNIQUES, V33, P338, DOI 10.2144/02332rv01; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Oetting WS, 2000, PIGM CELL RES, V13, P21, DOI 10.1034/j.1600-0749.2000.130105.x; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Paranavitane V, 2003, J BIOL CHEM, V278, P1328, DOI 10.1074/jbc.M208352200; Pascal T, 2005, FEBS LETT, V579, P3651, DOI 10.1016/j.febslet.2005.05.056; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Stein J, 2002, CELL MOL LIFE SCI, V59, P1235, DOI 10.1007/s00018-002-8501-z; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Trenkle T, 1999, BIOTECHNIQUES, V27, P554, DOI 10.2144/99273rr03; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wells JM, 1999, ALZ DIS ASSOC DIS, V13, pS78; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787	40	91	100	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1821	1831		10.1038/sj.onc.1209203	http://dx.doi.org/10.1038/sj.onc.1209203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261155				2022-12-17	WOS:000236013700015
J	Engle, LJ; Simpson, CL; Landers, JE				Engle, LJ; Simpson, CL; Landers, JE			Using high-throughput SNP technologies to study cancer	ONCOGENE			English	Review						SNP; polymorphisms; cancer; genotyping	SINGLE-NUCLEOTIDE POLYMORPHISMS; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; METHYLENETETRAHYDROFOLATE REDUCTASE; BREAST-CANCER; COLORECTAL-CANCER; COMPLEX DISEASE; GASTRIC-CANCER; 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	Identifying genes involved in the development of cancer is crucial to fully understanding cancer biology, for developing novel therapeutics for cancer treatment and for providing methods for cancer prevention and early diagnosis. The use of polymorphic markers, in particular single nucleotide polymorphisms ( SNPs), promises to provide a comprehensive tool for analysing the human genome and identifying those genes and genomic regions contributing to the cancer phenotype. This review summarizes the various analytical methodologies in which SNPs are used and presents examples of how each of these methodologies have been used to locate genes and genomic regions of interest for various cancer types. Additionally many of the current SNP-analysing technologies will be reviewed with particular attention paid to the advantages and disadvantages of each and how each technology can be applied to the analysis of the genome for identifying cancer-related genes.	Cetek Corp, Marlborough, MA USA; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; Massachusetts Gen Hosp, Day Lab Neuromuscular Res, Charlestown, MA USA	University of London; King's College London; Harvard University; Massachusetts General Hospital	Landers, JE (corresponding author), 13th St,CNY149-3-3310, Charlestown, MA 02129 USA.	jelanders@partners.org		Landers, John/0000-0001-8084-5043; Simpson, Claire/0000-0003-2244-7690				Avi-Itzhak Hadar I, 2003, Pac Symp Biocomput, P466; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Bell PA, 2002, BIOTECHNIQUES, P70; BELL PA, 2002, BIOTECHNIQUES S, V32, P76; BELL PA, 2002, BIOTECHNIQUES S, V32, P74; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlini LE, 2005, CLIN CANCER RES, V11, P1226; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630; Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Emahazion T, 2001, TRENDS GENET, V17, P407, DOI 10.1016/S0168-9525(01)02342-3; Freedman ML, 2005, CANCER RES, V65, P7516, DOI 10.1158/0008-5472.CAN-05-0132; Freedman ML, 2004, HUM MOL GENET, V13, P2431, DOI 10.1093/hmg/ddh270; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Geesaman BJ, 2003, P NATL ACAD SCI USA, V100, P14115, DOI 10.1073/pnas.1936249100; Gershoni-Baruch R, 2000, EUR J CANCER, V36, P2313, DOI 10.1016/S0959-8049(00)00306-3; Gissen P, 2004, NAT GENET, V36, P400, DOI 10.1038/ng1325; Graziano F, 2006, INT J CANCER, V118, P628, DOI 10.1002/ijc.21397; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Haiman CA, 2003, HUM MOL GENET, V12, P2679, DOI 10.1093/hmg/ddg294; Halldorsson BV, 2004, GENOME RES, V14, P1633, DOI 10.1101/gr.2570004; Han J, 2004, BRIT J CANCER, V91, P1604, DOI 10.1038/sj.bjc.6602174; Han JL, 2004, CANCER RES, V64, P3009, DOI 10.1158/0008-5472.CAN-04-0246; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Herr A, 2005, GENOMICS, V85, P392, DOI 10.1016/j.ygeno.2004.07.015; Hinds DA, 2004, AM J HUM GENET, V74, P317, DOI 10.1086/381716; Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247; Hu ZB, 2005, CLIN CANCER RES, V11, P5433, DOI 10.1158/1078-0432.CCR-05-0311; Huang Jing, 2004, Human Genomics, V1, P287; Irving JAE, 2005, CANCER RES, V65, P3053, DOI 10.1158/0008-5472.CAN-04-2604; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jiang QT, 2005, CANCER DETECT PREV, V29, P146, DOI 10.1016/j.cdp.2004.11.004; John S, 2004, AM J HUM GENET, V75, P54, DOI 10.1086/422195; Jordan B, 2002, P NATL ACAD SCI USA, V99, P2942, DOI 10.1073/pnas.261710699; Ju H, 2005, INT J CANCER, V117, P957, DOI 10.1002/ijc.21281; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Koed K, 2005, CANCER RES, V65, P34; Kono S, 2005, CANCER SCI, V96, P535, DOI 10.1111/j.1349-7006.2005.00090.x; Koppert LB, 2004, BRIT J CANCER, V90, P892, DOI 10.1038/sj.bjc.6601589; Krajinovic M, 2004, BLOOD, V103, P252, DOI 10.1182/blood-2003-06-1794; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Larson GP, 2005, CANCER RES, V65, P805; Li DH, 2005, CANCER EPIDEM BIOMAR, V14, P1470, DOI 10.1158/1055-9965.EPI-04-0894; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lindmark F, 2005, BRIT J CANCER, V93, P493, DOI 10.1038/sj.bjc.6602729; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Loukola A, 2004, EUR J HUM GENET, V12, P321, DOI 10.1038/sj.ejhg.5201101; Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631; Maris JM, 2005, GENOME RES, V15, P1168, DOI 10.1101/gr.3865305; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; Metherell LA, 2005, NAT GENET, V37, P166, DOI 10.1038/ng1501; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Middleton FA, 2004, AM J HUM GENET, V74, P886, DOI 10.1086/420775; Murray SS, 2004, NAT METHODS, V1, P113, DOI 10.1038/NMETH712; NIKIFOROV TT, 1994, NUCLEIC ACIDS RES, V22, P4167, DOI 10.1093/nar/22.20.4167; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101; Raghavan M, 2005, CANCER RES, V65, P375; Reumers J, 2005, NUCLEIC ACIDS RES, V33, pD527; Roshani L, 2005, CANCER GENET CYTOGEN, V158, P137, DOI 10.1016/j.cancergencyto.2004.08.034; Saba TG, 2005, HUM GENET, V116, P167, DOI 10.1007/s00439-004-1193-8; Sawcer S, 2005, AM J HUM GENET, V77, P454; Sawcer SJ, 2004, HUM MOL GENET, V13, P1943, DOI 10.1093/hmg/ddh202; Schaid DJ, 2004, AM J HUM GENET, V75, P948, DOI 10.1086/425870; Sellick GS, 2003, DIABETES, V52, P2636, DOI 10.2337/diabetes.52.10.2636; Shen HB, 2001, INT J CANCER, V95, P332, DOI 10.1002/1097-0215(20010920)95:5&lt;332::AID-IJC1058&gt;3.0.CO;2-9; Shrimpton AE, 2004, AM J HUM GENET, V75, P92, DOI 10.1086/422015; SPIELMAN RS, 1994, AM J HUM GENET, V54, P559; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Stephens LA, 2005, THYROID, V15, P100, DOI 10.1089/thy.2005.15.100; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Thompson ER, 2005, HUM MUTAT, V26, P384, DOI 10.1002/humu.20220; Uhlenberg B, 2004, AM J HUM GENET, V75, P251, DOI 10.1086/422763; Ulvik A, 2004, CANCER EPIDEM BIOMAR, V13, P2175; Wong KK, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh072; Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhou XF, 2004, HUM GENET, V115, P327, DOI 10.1007/s00439-004-1163-1	91	91	97	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1594	1601		10.1038/sj.onc.1209368	http://dx.doi.org/10.1038/sj.onc.1209368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550159				2022-12-17	WOS:000235904700001
J	Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB				Li, H; Zhang, Y; Su, T; Santella, RM; Weinstein, IB			Hint1 is a haplo-insufficient tumor suppressor in mice	ONCOGENE			English	Article						Hint1; PKCI-1; Fhit; tumorigenesis; tumor-suppressor gene	NUCLEOTIDE-BINDING PROTEIN; HISTIDINE TRIAD PROTEINS; C-INTERACTING PROTEIN-1; FHIT-DEFICIENT MICE; TRANSGENIC MICE; MAMMARY-TUMORS; MAST-CELLS; CANCER; FAMILY; GENE	The HINT1 protein, a member of the histidine triad ( HIT) family, is highly conserved in diverse species and ubiquitously expressed in mammalian tissues. However, its precise function in mammalian cells is not known. As a result of its structural similarity to the tumor-suppressor protein FHIT, we used homozygous-deleted Hint1 mice to study its role in tumorigenesis. We discovered that after 2 to 3 years of age the spontaneous tumor incidence in Hint1 -/- mice was significantly greater than that in wildtype Hint1 +/+ mice (P < 0.05). Using a well-established mouse model of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis we found a marked and significant (P < 0.05) increase in the incidence of mammary and ovarian tumors in both, Hint1 -/- and +/- mice versus +/+ mice. The Hint1 -/- and +/- mice had similar tumor incidence and similar tumor histologies. Therefore, deletion of Hint1 in mice enhances both spontaneous tumor development and susceptibility to tumor induction by DMBA. In addition, since the Hint1 +/- tumors retained expression of the unmutated wild type allele, Hint1 is haplo-insufficient with respect to tumor suppression in this model system.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, 701 W 168th St,HHSC 1509, New York, NY 10032 USA.	ibw1@columbia.edu			NATIONAL CANCER INSTITUTE [R37CA026056, R01CA026056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005116, P30ES009089] Funding Source: NIH RePORTER; NCI NIH HHS [CA26056-24] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089, P30ES09089, ES05116, R01 ES005116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Buters J, 2003, CARCINOGENESIS, V24, P327, DOI 10.1093/carcin/24.2.327; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Guranowski A, 2004, FRONT BIOSCI-LANDMRK, V9, P1398, DOI 10.2741/1338; GURANOWSKI A, 1989, BIOCHEM J, V262, P241, DOI 10.1042/bj2620241; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 2001, SEMIN CANCER BIOL, V11, P361, DOI 10.1006/scbi.2001.0391; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Jackson RJ, 2003, CANCER RES, V63, P3021; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; MALKINSON AM, 1986, CANCER RES, V46, P1694; MEDINA D, 1980, CANCER RES, V40, P368; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Qing WG, 1997, CARCINOGENESIS, V18, P553, DOI 10.1093/carcin/18.3.553; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Vartanian A, 1999, FEBS LETT, V456, P175, DOI 10.1016/S0014-5793(99)00956-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WITTY JP, 1995, CANCER RES, V55, P1401; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	91	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					713	721		10.1038/sj.onc.1209111	http://dx.doi.org/10.1038/sj.onc.1209111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186798				2022-12-17	WOS:000235068800007
J	Niiya, F; Tatsumoto, T; Lee, KS; Miki, T				Niiya, F; Tatsumoto, T; Lee, KS; Miki, T			Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA	ONCOGENE			English	Article						protooncogene; Rho GTPase; exchange factor; polo-box domain; interacting protein	POLO-BOX DOMAIN; CELL-DIVISION; EXCHANGE FACTOR; FAMILY GTPASES; SPINDLE; EXPRESSION; PROTEINS; SRF	The epithelial cell transforming gene 2 (ECT2) proto-oncogene encodes a Rho exchange factor, and regulates cytokinesis. ECT2 is phosphorylated in G2/M phases, but its role in the biological function is not known. Here we show that two mitotic kinases, Cdk1 and polo-like kinase 1 (Plk1), phosphorylate ECT2 in vitro. We identified an in vitro Cdk1 phosphorylation site (T412) in ECT2, which comprises a consensus phosphospecific-binding module for the Plk1 polo-box domain (PBD). Endogenous ECT2 in mitotic cells strongly associated with Plk1 PBD, and this binding was inhibited by phosphatase treatment. A phosphorylation-deficient mutant form of ECT2, T412A, did not exhibit strong association with Plk1 PBD compared with wild-type (WT) ECT2. Moreover, ECT2 T412A, but not phosphomimic T412D, displayed a diminished accumulation of GTP-bound RhoA compared with WT ECT2, suggesting that phosphorylation of Thr-412 is critical for the catalytic activity of ECT2. Moreover, while overexpression of WT ECT2 or the T412D mutant caused cortical hyperactivity in U2OS cells during cell division, this activity was not observed in cells expressing ECT2 T412A. These results suggest that ECT2 is regulated by Cdk1 and Plk1 in concert.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bldg 37 Rm 2144,37 Convent Dr, Bethesda, MD 20892 USA.	toru@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Reiter NJ, 2002, BIOCHEMISTRY-US, V41, P1051, DOI 10.1021/bi011577b; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Seong YS, 2003, CANCER RES, V63, P7384; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	29	91	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					827	837		10.1038/sj.onc.1209124	http://dx.doi.org/10.1038/sj.onc.1209124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247472				2022-12-17	WOS:000235212700002
J	Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A				Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A			Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling	ONCOGENE			English	Article						neuroblastoma; expression profiling; outcome prediction; microarray	N-MYC; GENES; AMPLIFICATION; CANCER; CLASSIFICATION; IDENTIFICATION; MICROARRAYS; DIAGNOSIS; SURVIVAL; 17Q	Neuroblastoma is a common childhood tumor comprising cases with rapid disease progression as well as spontaneous regression. Although numerous prognostic factors have been identified, risk evaluation in individual patients remains difficult. To de. ne a reliable prognostic predictor and gene signatures characteristic of biological subgroups, we performed mRNA expression profiling of 68 neuroblastomas of all stages. Expression data were analysed using support vector machines (SVM-rbf), prediction analysis of microarrays (PAM), k-nearest neighbors (k-NN) algorithms and multiple decision trees. SVM-rbf performed best of all methods, and predicted recurrence of neuroblastoma with an accuracy of 85% (sensitivity 77%, specificity 94%). PAM identified a classifer of 39 genes reliably predicting outcome with an accuracy of 80%. In comparison, conventional risk strati. cation based on stage, age and MYCN-status only reached a predictive accuracy of 64%. Kaplan-Meier analysis using the PAM classifer indicated a 5-year survival of 20 versus 78% for patients with unfavorably versus favorably predicted neuroblastomas, respectively (P=0.0001). Significance analysis of microarrays (SAM) identified additional genes differentially expressed among subgroups. MYCN-amplification and high expression of NTRK1/TrkA demonstrated a strong association with specific gene expression patterns. Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and de. ning biological properties of neuroblastoma.	Univ Hosp Essen, Dept Pediat Oncol & Hematol, D-45122 Essen, Germany; Univ Hosp Essen, Inst Cell Biol, Essen, Germany; Univ Childrens Hosp, Dept Pediat Oncol, Heidelberg, Germany; Univ Childrens Hosp, Dept Hematol, Heidelberg, Germany; Univ Childrens Hosp, Marburg, Germany; German Canc Res Ctr, DKFZ, Div Intelligent Bioinformat Syst, Heidelberg, Germany	University of Duisburg Essen; University of Duisburg Essen; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Eggert, A (corresponding author), Univ Hosp Essen, Dept Pediat Oncol & Hematol, Hufelandstr 55, D-45122 Essen, Germany.	angelika.eggert@uni-essen.de	Eggert, Angelika/AAE-6907-2022; Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013; Schramm, Alexander/G-5688-2010; Schulte, Johannes H./V-2474-2018; Schulte, Johannes H/G-3981-2010	Eggert, Angelika/0000-0003-3476-8184; Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101; Schramm, Alexander/0000-0001-7670-7529; Schulte, Johannes Hubertus/0000-0003-0671-1201				Alaminos M, 2003, CANCER RES, V63, P4538; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chang CC, 2001, NEURAL COMPUT, V13, P2119, DOI 10.1162/089976601750399335; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hiyama E, 2004, PEDIATR SURG INT, V20, P33, DOI 10.1007/s00383-003-1077-3; Hiyama E, 2003, J PEDIATR SURG, V38, P1730, DOI 10.1016/j.jpedsurg.2003.08.042; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Nutt CL, 2003, CANCER RES, V63, P1602; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Quinlan J.R., 1993, C4 5 PROGRAMS MACHIN; Rosenwald A, 2002, SEMIN ONCOL, V29, P258, DOI 10.1053/sonc.2002.32901; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schulte JH, 2003, KLIN PADIATR, V215, P298; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Scott D, 2003, CANCER LETT, V197, P81, DOI 10.1016/S0304-3835(03)00086-7; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Su WT, 2004, CANCER GENET CYTOGEN, V154, P131, DOI 10.1016/j.cancergencyto.2004.02.009; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; WITTEN A, 2002, DATA MINING PRACTICA; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265	40	91	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7902	7912		10.1038/sj.onc.1208936	http://dx.doi.org/10.1038/sj.onc.1208936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103881				2022-12-17	WOS:000233463000009
J	Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N				Galli, UM; Sauter, M; Lecher, B; Maurer, S; Herbst, H; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors	ONCOGENE			English	Article						endogenous retrovirus; Rec; Rev; Rex; germ cell tumor; PLZF	HTDV/HERV-K; PROTEIN; PLZF; EXPRESSION; TESTIS; IDENTIFICATION; FAMILY; CORF	Germ cell tumors (GCTs) are among the most common malignancies in young men. We have previously documented that patients with GCT frequently produce serum antibodies directed against proteins encoded by human endogenous retrovirus ( HERV) type K sequences. Transcripts originating from the env gene of HERV-K, including the rec-relative of human immunodeficiency virus rev, are highly expressed in GCTs. We report here that mice that inducibly express HERV-K rec show a disturbed germ cell development and may exhibit, by 19 months of age, changes reminiscent of carcinoma in situ, the predecessor lesion of classic seminoma in humans. This provides the first direct evidence that the expression of a human endogenous retroviral gene previously established as a marker in human germ cell tumors may contribute to organ-specific tumorigenesis in a transgenic mouse model.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Mainz, MFD Diagnost Lab GdbR, D-55131 Mainz, Germany; Univ Hosp, Inst Pathol, D-48149 Munster, Germany	Saarland University; Johannes Gutenberg University of Mainz; University of Munster	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@uniklinik-saarland.de						Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Herbst H, 1996, AM J PATHOL, V149, P1727; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; LEIBMOSCH C, 1996, VIRUS GENES, V11, P133; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Meng XJ, 2001, CANCER RES, V61, P3267; MOLLER H, 1993, EUR UROL, V23, P8; MOSTOFI FK, 1980, CANCER, V45, P1735, DOI 10.1002/cncr.1980.45.s7.1735; Patience C, 1997, TRENDS GENET, V13, P116, DOI 10.1016/S0168-9525(97)01057-3; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Veeramachaneni DNR, 1999, INT J ANDROL, V22, P97; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404	25	91	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3223	3228		10.1038/sj.onc.1208543	http://dx.doi.org/10.1038/sj.onc.1208543			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735668	Bronze			2022-12-17	WOS:000228728100016
J	Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM				Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM			Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; ovarian surface epithelial cells; apoptosis; cancer cell invasion; metastasis	SURFACE EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; ORAL-CONTRACEPTIVES; INDUCED APOPTOSIS; B ISOFORMS; LONG ARM; PR-A; EXPRESSION; RECEPTOR	Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial ( HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional pro. ling with a cDNA microarray containing approximate to2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and ( 2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 ( NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes forOCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Pittsburgh, Inst Canc, Benedum Ctr Oncol Informat, Ctr Pathol Informat,Dept Pathol, Pittsburgh, PA 15232 USA; Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Japanese Fdn Canc Res, Tokyo 170, Japan; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese University of Hong Kong; Prince of Wales Hospital; Japanese Foundation for Cancer Research; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu	Lyons-Weiler, James/Q-4948-2019	Lyons-Weiler, James/0000-0001-9343-7508; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; Athanassiadou P, 1998, EUR J CANCER PREV, V7, P225, DOI 10.1097/00008469-199806000-00007; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bender FC, 2000, CANCER RES, V60, P5870; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; CRAMER DW, 1982, NEW ENGL J MED, V307, P1047, DOI 10.1056/NEJM198210213071703; Das H, 2000, BRIT J CANCER, V82, P1682; Davis M, 1996, CANCER RES, V56, P741; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Freshney RI, 1994, MANUAL BASIC TECHNIQ; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; KEITH BM, 2001, GYNECOL ONCOL, V82, P127, DOI DOI 10.1006/GYN0.2001.6221); Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Koike M, 1999, ONCOLOGY-BASEL, V56, P160, DOI 10.1159/000011958; La Vecchia C, 2001, EUR J CANCER PREV, V10, P125, DOI 10.1097/00008469-200104000-00002; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lyons-Weiler J, 2003, GENOME RES, V13, P503, DOI 10.1101/gr.104003; Makrigiannakis A, 2000, ANN NY ACAD SCI, V900, P16; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Murdoch WJ, 2002, REPRODUCTION, V123, P743, DOI 10.1530/rep.0.1230743; Ng IOL, 2000, CANCER RES, V60, P6581; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; RAJA RLT, 1981, PROGR CLIN BIOL RES, P149; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Salazar-Martinez E, 1999, CANCER RES, V59, P3658; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32; SCHNEIDER HP, 1995, INT J FERTIL MENOP S, V1, P40; Shao R, 2003, BIOL REPROD, V68, P914, DOI 10.1095/biolreprod.102.009035; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Tas F, 2002, AM J CLIN ONCOL-CANC, V25, P164, DOI 10.1097/00000421-200204000-00012; Thomas HV, 1998, ANN HUM BIOL, V25, P69, DOI 10.1080/03014469800005432; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yen SS, 1994, MATERNAL FETAL MED P, P382; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	67	91	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1774	1787		10.1038/sj.onc.1207991	http://dx.doi.org/10.1038/sj.onc.1207991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674352				2022-12-17	WOS:000227345100013
J	van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N				van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N			Nomenclature for Runt-related (RUNX) proteins	ONCOGENE			English	Article									Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ito, Y (corresponding author), Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, 30 Med Dr, Singapore 117609, Singapore.	itoy@imcb.nus.edu.sg	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))			0	91	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4209	4210		10.1038/sj.onc.1207758	http://dx.doi.org/10.1038/sj.onc.1207758			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156174				2022-12-17	WOS:000221586000003
J	Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L				Vultur, A; Cao, J; Arulanandam, R; Turkson, J; Jove, R; Greer, P; Craig, A; Elliott, B; Raptis, L			Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells	ONCOGENE			English	Article						Stat3; cell confluence; cell-to-cell adhesion; breast cancer; breast carcinoma lines; rodent fibroblasts	GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; NEOPLASTIC TRANSFORMATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SRC ONCOPROTEIN; KINASE-ACTIVITY	Stat3 (signal transducer and activator of transcription-3) activity is required for transformation by a number of oncogenes, while a constitutively active form of Stat3 alone is sufficient to induce neoplastic transformation. Although in most instances Stat3 is growth-promoting, the impact of cell density on Stat3 activation status and the biological importance of Stat3 during growth arrest have not been characterized. Previous results indicated that cell density alters tyrosine phosphorylation levels of cultured cells. Since signalling through Stat3 is determined by a key phosphorylation at tyr705, we examined the effects of cell density upon Stat3 activity in normal breast epithelial cells, breast carcinoma lines and normal mouse fibroblasts. Intriguingly, the results revealed a dramatic increase in Stat3, tyr705 phosphorylation and activity with cell density, which gradually declined at later stages. This activation was dependent upon cell-cell contact, since it was eliminated if cell adhesion was disrupted through calcium chelation, while it was reinstated through cell aggregation. Furthermore, this activation was suppressed following inhibition of JAKs (Janus kinases) but not inhibition of Fer, IGF1-R, or kinases of the c-Src family. On the other hand, constitutively active Stat3 in carcinoma lines, known to harbor activated Src, was blocked by pharmacological inhibitors of Src as well as JAKs. These results point to the existence of two distinct pathways of Stat3 activation in breast carcinomas, based on Src dependence. More importantly, our results suggest that Stat3 activity is upregulated during the confluence-mediated growth arrest by a signalling mechanism that requires JAKs.	Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA	Queens University - Canada; Queens University - Canada; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Raptis, L (corresponding author), Queens Univ, Dept Microbiol & Immunol, Botterell Hall,Rm 715, Kingston, ON K7L 3N6, Canada.	raptisl@post.queensu.ca	Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; Vultur, Adina/0000-0003-0068-9496				Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Deng JB, 2000, ENDOCRINOLOGY, V141, P2370, DOI 10.1210/en.141.7.2370; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin JY, 2002, CANCER RES, V62, P376; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mora LB, 2002, CANCER RES, V62, P6659; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Raptis L, 1997, EXP CELL RES, V235, P188, DOI 10.1006/excr.1997.3646; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; Raptis L, 2000, CELL GROWTH DIFFER, V11, P293; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Whittard JD, 2002, MATRIX BIOL, V21, P525, DOI 10.1016/S0945-053X(02)00037-9; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	58	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2600	2616		10.1038/sj.onc.1207378	http://dx.doi.org/10.1038/sj.onc.1207378			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007380	Green Published			2022-12-17	WOS:000220714900002
J	Krynetski, E; Evans, WE				Krynetski, E; Evans, WE			Drug methylation in cancer therapy: lessons from the TPMT polymorphism	ONCOGENE			English	Review						thiopurine S-methyltransferase; pharmacogenetics	THIOPURINE S-METHYLTRANSFERASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; AZATHIOPRINE-INDUCED MYELOSUPPRESSION; GENOTYPE-PHENOTYPE CORRELATION; HEART-TRANSPLANT RECIPIENT; BIOCHEMICAL-PROPERTIES; GENETIC-POLYMORPHISM; CATALYTIC-ACTIVITY; MUTANT ALLELES; FUNCTIONAL-CHARACTERIZATION	The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine). Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency demonstrates how pharmacogenetic traits can be identified, characterized, and translated to the bedside. Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322	NCI NIH HHS [R37 CA 36401, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R37CA036401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN PW, 1971, BIOCHEM PHARMACOL, V20, P847, DOI 10.1016/0006-2952(71)90046-3; Alves S, 1999, PHARMACOGENETICS, V9, P257; Alves S, 2001, CLIN PHARMACOL THER, V70, P165, DOI 10.1067/mcp.2001.117284; Ando M, 2001, PHARMACOGENETICS, V11, P269, DOI 10.1097/00008571-200104000-00011; Bemi V, 1999, INT J CANCER, V82, P556, DOI 10.1002/(SICI)1097-0215(19990812)82:4<556::AID-IJC14>3.0.CO;2-Y; Black AJ, 1998, ANN INTERN MED, V129, P716, DOI 10.7326/0003-4819-129-9-199811010-00007; Brouwer C, 2001, LEUKEMIA, V15, P1792, DOI 10.1038/sj.leu.2402285; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Colombel JF, 2000, GASTROENTEROLOGY, V118, P1025, DOI 10.1016/S0016-5085(00)70354-4; Coulthard SA, 2000, BRIT J HAEMATOL, V110, P599, DOI 10.1046/j.1365-2141.2000.02218.x; Coulthard SA, 1998, BLOOD, V92, P2856, DOI 10.1182/blood.V92.8.2856.420k05_2856_2862; Cournoyer B, 1998, BBA-GENE STRUCT EXPR, V1397, P161, DOI 10.1016/S0167-4781(98)00020-7; de la Moureyre CSV, 1999, PHARMACOGENETICS, V9, P189; de la Moureyre CSV, 1998, HUM MUTAT, V12, P177, DOI 10.1002/(SICI)1098-1004(1998)12:3<177::AID-HUMU5>3.0.CO;2-E; de la Moureyre CSV, 1998, BRIT J PHARMACOL, V125, P879, DOI 10.1038/sj.bjp.0702152; DEININGER M, 1994, BIOCHEM PHARMACOL, V48, P2135, DOI 10.1016/0006-2952(94)90515-0; Dervieux T, 2001, CANCER RES, V61, P5810; ELION GB, 1989, IN VITRO CELL DEV B, V25, P321; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; Fessing MY, 1998, EUR J BIOCHEM, V256, P510, DOI 10.1046/j.1432-1327.1998.2560510.x; Fessing MY, 1998, FEBS LETT, V424, P143, DOI 10.1016/S0014-5793(98)00159-8; Foster AP, 2000, J VET INTERN MED, V14, P552, DOI 10.1892/0891-6640(2000)014&lt;0552:DOTMAI&gt;2.3.CO;2; HASSOUN BS, 1995, RES COMMUN MOL PATH, V90, P133; HILL DL, 1969, BIOCHEMISTRY-US, V8, P122, DOI 10.1021/bi00829a017; Hon YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/hmg/8.2.371; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Ishioka S, 1999, INTERNAL MED, V38, P944, DOI 10.2169/internalmedicine.38.944; Jang IJ, 1996, BRIT J CLIN PHARMACO, V42, P638, DOI 10.1111/j.1365-2125.1996.tb00061.x; JINNAH HA, 2000, METABOLIC MOL BASES; Krynetski EY, 1997, PHARM RES-DORDR, V14, P1672, DOI 10.1023/A:1012111325397; Krynetski EY, 2000, PHARMACOLOGY, V61, P136, DOI 10.1159/000028394; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; KRYNETSKI EY, 1995, MOL PHARMACOL, V47, P1141; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; KRYNETSKI EY, 1999, ANTICANCER DRUG TOXI, P392; Kubota T, 2001, BRIT J CLIN PHARMACO, V51, P475, DOI 10.1046/j.1365-2125.2001.01371.x; Kumagai K, 2001, PHARMACOGENETICS, V11, P275, DOI 10.1097/00008571-200104000-00012; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; Liu MF, 2000, J BACTERIOL, V182, P6509, DOI 10.1128/JB.182.22.6509-6513.2000; Loennechen T, 1998, CLIN PHARMACOL THER, V64, P46, DOI 10.1016/S0009-9236(98)90021-2; Loennechen T, 2001, CLIN PHARMACOL THER, V70, P183, DOI 10.1067/mcp.2001.117445; Lowenthal A, 2001, EUR J CLIN PHARMACOL, V57, P43, DOI 10.1007/s002280100267; McDonald OG, 2002, PHARMACOGENETICS, V12, P93, DOI 10.1097/00008571-200203000-00003; MCLEOD HL, 1995, BLOOD, V85, P1897, DOI 10.1182/blood.V85.7.1897.bloodjournal8571897; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Otterness DM, 1998, J CLIN INVEST, V101, P1036, DOI 10.1172/JCI1004; ParkHah JO, 1996, CLIN PHARMACOL THER, V60, P68, DOI 10.1016/S0009-9236(96)90169-1; PIETERS R, 1992, INT J CANCER, V51, P213, DOI 10.1002/ijc.2910510208; Ranjard L, 2002, J BACTERIOL, V184, P3146, DOI 10.1128/JB.184.11.3146-3149.2002; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; REMY CN, 1967, BIOCHIM BIOPHYS ACTA, V138, P258, DOI 10.1016/0005-2787(67)90487-X; REMY CN, 1963, J BIOL CHEM, V238, P1078; Rossi AM, 2001, EUR J CLIN PHARMACOL, V57, P51, DOI 10.1007/s002280000246; Scerri L, 1999, ADV EXP MED BIOL, V455, P343; Schaeffeler E, 2001, CLIN CHEM, V47, P548; Schutz E, 2000, CLIN CHEM, V46, P1728; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; Seki T, 2000, J HUM GENET, V45, P299, DOI 10.1007/s100380070020; Srivastava T, 2002, AM J MED GENET, V108, P219, DOI 10.1002/ajmg.10217; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; SZUMLANSKI CL, 1992, PHARMACOGENETICS, V2, P148, DOI 10.1097/00008571-199208000-00002; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; Tai HL, 1996, AM J HUM GENET, V58, P694; Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; VANLOON JA, 1982, BIOCHEM GENET, V20, P637, DOI 10.1007/BF00483962; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; WEINSHILBOUM RM, 1996, 2 THIOP S HAMB; White SD, 2000, J VET INTERN MED, V14, P499, DOI 10.1892/0891-6640(2000)014&lt;0499:TMIRBC&gt;2.3.CO;2; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WOODSON LC, 1982, J PHARMACOL EXP THER, V222, P174; WOODSON LC, 1983, BIOCHEM PHARMACOL, V32, P819, DOI 10.1016/0006-2952(83)90582-8; Yan L, 2000, CLIN PHARMACOL THER, V68, P210, DOI 10.1067/mcp.2000.108674; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003	84	91	98	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7403	7413		10.1038/sj.onc.1206944	http://dx.doi.org/10.1038/sj.onc.1206944			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576848				2022-12-17	WOS:000186112500013
J	Druker, BJ				Druker, BJ			Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML	ONCOGENE			English	Article						Bcr-Abl; tyrosine kinase; inhibitor; CML; STI571	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMATINIB MESYLATE; CYTOGENETIC RESPONSES; BLAST CRISIS; ERYTHROID-DIFFERENTIATION; CLINICAL RESISTANCE; CELL-PROLIFERATION; POSITIVE LEUKEMIA		Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA	Oregon Health & Science University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, L592,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.			Druker, Brian/0000-0001-8331-8206				ANAFI M, 1993, BLOOD, V82, P3524; Beran M, 1998, CLIN CANCER RES, V4, P1661; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Buchdunger E, 2001, BBA-REV CANCER, V1551, pM11, DOI 10.1016/S0304-419X(01)00022-1; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHANG CJ, 1992, J NAT PROD, V55, P1529, DOI 10.1021/np50089a001; Corbin AS, 2002, J BIOL CHEM, V277, P32214, DOI 10.1074/jbc.M111525200; Corbin AS, 2000, BLOOD, V96, p470A; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Dorsey JF, 2000, CANCER RES, V60, P3127; Druker B.J, 2002, P AN M AM SOC CLIN, V21, P1; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; HOCHHAUS A, 2002, IN PRESS LEUKEMIA; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; HONMA Y, 1990, JPN J CANCER RES, V81, P1132, DOI 10.1111/j.1349-7006.1990.tb02524.x; HONMA Y, 1989, CANCER RES, V49, P331; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kasper B, 1999, CANCER CHEMOTH PHARM, V44, P433, DOI 10.1007/s002800051001; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; KAWADA M, 1993, DRUG EXP CLIN RES, V19, P235; La Rosee P, 2002, EXP HEMATOL, V30, P729, DOI 10.1016/S0301-472X(02)00836-6; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; PENG B, 2001, P AN M AM SOC CLIN, V20, pA280; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TENHOEVE J, 1994, BLOOD, V84, P1731; Topaly J, 2001, BLOOD, V98, p617A; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	59	91	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8541	8546		10.1038/sj.onc.1206081	http://dx.doi.org/10.1038/sj.onc.1206081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476300				2022-12-17	WOS:000179734300003
J	Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB				Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB			MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance	ONCOGENE			English	Article						breast cancer; estrogen receptor; MAPK; cross-talk; anti-estrogens	ACTIVATED PROTEIN-KINASE; DEPENDENT TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; ER-ALPHA; PHOSPHORYLATION; ESTRADIOL; IDENTIFICATION; DOMAINS; CELLS; COACTIVATOR	The estrogen receptor alpha (ERalpha) signaling plays an essential role in breast cancer progression and endocrine therapy. Mitogen-activated protein kinase (MAPK/Erk1/2) has been implicated in ligand-independent activation of ER, resulting in the cross-talk between growth factor and ER mediated signaling. In this study, we examined the effect of the cross-talk on estradiol (E-2)-mediated signaling, tumor growth and its effect on anti-estrogen therapy. Our findings demonstrate that expression of constitutively activated mitogen activated kinase kinase (MEK1), an immediate upstream activator of MAPK in estrogen receptor positive MCF-7 breast cancer cells (MEK/MCF-7), showed an increase in ERalpha-driven transcriptional activation. In MEK/MCF-7 cells maximal transactivation levels were achieved in response to treatment with much lower E-2 concentrations (10(10) M E-2) when compared to MCF-7 control cells (10(8) M E-2) Furthermore, we have seen an increased association between ERalpha and its nuclear coactivators AIB1 or TIF2, in MEK/MCF-7 cells relative to those seen in MCF-7 control cells. In addition, in vivo studies show that mEK/MCF-7 cell tumors are similar tothreefold larger than those of MCF-7 cell, in the presence of E-2. Immunohistochemical staining demonstrates that progesterone receptor (PR) and pS2, two E-2-regulated gene products, are significantly increased in MEK/MCF-7 cell tumors compared to those of MCF-7 control tumors, suggesting that activation of ERalpha by MAPK enhances the expression of E-2-regulated genes and accelerates tumor growth. Remarkably, the antiestrogens tamoxifen and ICI 182,780, were shown both in vitro and in giro studies to efficiently antagonize the stimulatory effects of E-2 on ER regulated transactivation and tumor growth in MEK/MCF-7 as well as MCF-7 cell lines. Taken together, these data suggest that MAPK/ER cross-talk enhances ERalpha-mediated signaling and accelerates E-2-dependent tumor growth without diminishing sensitivity to the inhibitory effects of anti-estrogens.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83964, CA 64248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Kurokawa H, 2000, CANCER RES, V60, P5887; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun M, 2001, CANCER RES, V61, P5985; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Welch DR, 2000, CANCER RES, V60, P1552; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	42	91	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4000	4008		10.1038/sj.onc.1205506	http://dx.doi.org/10.1038/sj.onc.1205506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037682				2022-12-17	WOS:000175869900006
J	Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD				Grinstein, E; Jundt, F; Weinert, I; Wernet, P; Royer, HD			Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells	ONCOGENE			English	Article						cell cycle; transcription factor Sp1; G1 phase	PROTEASOME-DEPENDENT DEGRADATION; DNA-BINDING ACTIVITY; GROWTH-FACTOR; GENE-EXPRESSION; RECEPTOR; ACTIVATION; TRANSACTIVATION; D1; PHOSPHORYLATION; INHIBITION	Sp1 binding sites have been identified in enhancer/promoter regions of several growth and cell cycle regulated genes, and it has been shown that Sp1 is increasingly phosphorylated in G1 phase of the cell cycle. Interactions of Sp1 with proteins involved in control of cell cycle and tumor formation have been reported. Here we show that expression of Sp1 protein predominates in the G1 phase of the cell cycle in epithelial cells. This is achieved by proteasome-dependent degradation. Inhibition of endogeneous Sp1 activity by a dominant-negative Sp1 mutant was associated with a cell cycle arrest in G1 phase, a strongly reduced expression of cyclin D1, the EGF-receptor and increased levels of p27Kip1. We have thus identified Sp1 as an important regulator of the cell cycle in G1 phase.	Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, D-40225 Dusseldorf, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Fak Med, Robert Rossle Klin, D-13122 Berlin, Germany	Heinrich Heine University Dusseldorf; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Grinstein, E (corresponding author), Univ Dusseldorf, Inst Transplantat Diagnost & Zelltherapeut, Moorenstr 5, D-40225 Dusseldorf, Germany.	Edgar.Grinstein@itz.uni-duesseldorf.de	Jundt, Franziska/E-9748-2014; Royer, Hans-dieter/AAH-6293-2019	Jundt, Franziska/0000-0002-8661-7110; 				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; LABELLA F, 1991, MOL CELL BIOL, V11, P5825, DOI 10.1128/MCB.11.12.5825; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Opitz OG, 2000, CANCER RES, V60, P2825; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wu XP, 1996, ONCOGENE, V12, P1397; XU J, 1993, J BIOL CHEM, V268, P16065; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O	49	91	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1485	1492		10.1038/sj.onc.1205211	http://dx.doi.org/10.1038/sj.onc.1205211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896576				2022-12-17	WOS:000173956800003
J	Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E				Mazurek, S; Zwerschke, W; Jansen-Durr, P; Eigenbrodt, E			Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7	ONCOGENE			English	Article						metabolome; glycolysis; glutaminolysis; M2-PK; adenylate kinase; nucleotides	HUMAN-PAPILLOMAVIRUS TYPE-16; ROUS-SARCOMA VIRUS; PYRUVATE-KINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; MALIGNANT TRANSFORMATION; MELANOMA-CELLS; C-MYC; PROLIFERATION; CYCLE	The metabolism of tumor cells (tumor metabolome) is characterized by a high concentration of glycolytic enzymes including pyruvate kinase isoenzyme type M2 (M2-PK), a high glutaminolytic capacity, high fructose 1,6-bisphosphate (FBP) levels and a low (ATP + GTP):(CTP+UTP) ratio. The sequence of events required for the establishment of the tumor metabolome is presently unknown. In non-transformed rat kidney (NRK) cells we observed a high glutaminolytic flux rate and a low (ATP + GTP):(CTP + UTP) ratio, whereas FBP levels and M2-PK activity are still extremely low. After stable expression of oncogenic ras in NRK cells a strong upregulation of FBP levels and of M2-PK activity was observed. Elevated FBP levels induce a tetramerization of M2-PK and its migration into the glycolytic enzyme complex. AMP levels increase whereas UTP and CTP levels strongly decrease. Thus, ras expression completes the glycolytic part of tumor metabolism leading to the inhibition of nucleic acid synthesis and cell proliferation. The HPV-16 E7 oncoprotein, which cooperates with ras in cell transformation, directly binds to M2-PK, induces its dimerization and restores nucleic acid synthesis as well as cell proliferation. Apparently, the combination of the different metabolic effects of ras and E7 constructs the perfect tumor metabolome as generally found in tumor cells.	Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, D-35392 Giessen, Germany; Austrian Acad Sci, Inst Biomed Ageing Res, A-6020 Innsbruck, Austria; Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria	Justus Liebig University Giessen; Austrian Academy of Sciences; University of Innsbruck	Mazurek, S (corresponding author), Univ Giessen, Fac Vet, Inst Biochem & Endocrinol, Frankfurter Str 100, D-35392 Giessen, Germany.		Mazurek, Sybille/ABH-2089-2020; Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				AON MA, 1995, EXP CELL RES, V217, P42, DOI 10.1006/excr.1995.1061; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boros LG, 1997, CANCER RES, V57, P4242; Boros LG, 2000, CANCER RES, V60, P1183; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cascante M, 2000, NUTR CANCER, V36, P150, DOI 10.1207/S15327914NC3602_2; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Downes CS, 2000, J CELL SCI, V113, P1089; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; EIGENBRODT E, 1998, CELL GROWTH ONCOGENE, P15; EIGENBRODT E, 1985, REGULATION CARBOHYDR, P141; Glass-Marmor L, 1999, EUR J PHARMACOL, V370, P195, DOI 10.1016/S0014-2999(99)00155-7; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; GREGORY SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P644, DOI 10.1016/0003-9861(76)90555-5; HENDERSON JF, 1981, PHARMACOL THERAPEUT, V8, P539; HUNTING D, 1981, CAN J BIOCHEM CELL B, V59, P821, DOI 10.1139/o81-114; Inouye S, 1999, BIOCHEM BIOPH RES CO, V254, P618, DOI 10.1006/bbrc.1998.0116; JACKSON RC, 1980, CANCER RES, V40, P1286; Kim CY, 1997, CANCER RES, V57, P4200; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; MAZUREK S, 2001, IN PRESS BR J NUTR; MOYER JD, 1982, CANCER RES, V42, P4525; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Noma T, 1999, BIOCHEM BIOPH RES CO, V264, P990, DOI 10.1006/bbrc.1999.1616; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; WEBER G, 1971, CANCER RES, V31, P2177; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	51	91	99	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6891	6898		10.1038/sj.onc.1204792	http://dx.doi.org/10.1038/sj.onc.1204792			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687968				2022-12-17	WOS:000171641000010
J	Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM				Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM			Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage	ONCOGENE			English	Article						GADD45; p53; DNA damage; transcription; factor Oct-1; NF-YA	TUMOR-SUPPRESSOR P53; HISTONE H2B GENE; HUMAN-CELLS; EXPRESSION; ACTIVATION; PROTEINS; GROWTH; INHIBITION; PROMOTER; ELEMENTS	The p53-regulated GADD45 gene is one of the important players in cellular response to DNA damage, and probably involved in the control of cell cycle checkpoint, apoptosis and DNA repair, There are both the p53-dependent and -independent pathways that regulate GADD45 induction. Following ionizing radiation, induction of the GADD45 gene is regulated by p53 through the p53-binding motif located in the third intron of the GADD45 gene. In contrast, GADD45 induction by methyl methanesulfonate (MMS), UV radiation (UV), and medium starvation is independent of p53 status although p53 may contribute to these responses. However, the regulatory elements that control the p53-independent induction of GADD45 remain uncertain. In this report, we have performed detailed analyses to characterize the responsive components that are required for the induction of the GADD45 promoter. We have found that the region between -107 and -62 of the GADD45 promoter is crucial for the induction. Sequence analysis indicates that there are two OCT-1 sites and one CAAT box located in this region. Site-directed mutations of both OCT-1 and CAAT motifs substantially abrogate the induction of the GADD45 promoter by DNA damage. In addition, both Oct-1 protein (binding to OCT-1 site) and NP-YA protein (binding to CAAT hox) are induced after cell exposure to DNA damaging agents. Moreover, the Electrophoretic Mobility Shift Assay (EMSA) has demonstrated the direct bindings of Oct-1 and NF-YA proteins to their consensus sequences in the GADD45 promoter. Therefore, these results have presented the novel observation that transcription factors Oct-1 and NF-YA participate in the cellular response to DNA damage and are involved in the regulation of stress-inducible genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.							BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MIYASHITA T, 1995, CELL, V80, P293; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Prives C, 1999, J PATHOL, V187, P112; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; STURM RA, 1988, NUCLEIC ACIDS RES, V16, P8571, DOI 10.1093/nar/16.17.8571; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	35	91	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2683	2690		10.1038/sj.onc.1204390	http://dx.doi.org/10.1038/sj.onc.1204390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420680				2022-12-17	WOS:000168652600009
J	Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F				Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F			Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways	ONCOGENE			English	Article						urokinase; integrins; chemotaxis; cytoskeleton	SMOOTH-MUSCLE CELLS; UROKINASE RECEPTOR; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; KINASE FUNCTIONS; GROWTH-FACTORS; MIGRATION; VITRONECTIN; ADHESION	Vitronectin (VN) and pro-urokinase (pro-uPA) stimulated migration of rat smooth muscle cells in a dose-dependent and additive way, and induced motile-type changes in cell morphology together with a complete reorganization of the actin filaments and of the microtubules, All these effects were inhibited by pertussis toxin, or by antibodies directed against the urokinase receptor (uPAR) or against the VN receptor alpha (v)beta (3) suggesting that an association between the two receptors is required to mediate both signals. Investigation of the signaling pathways showed that increasing the intracellular cAMP resulted in a selective inhibition of VN-induced cell migration. On the other hand, PD 98059, an inhibitor of MEK, differentially inhibited the pro-uPA but not the VN-induced cell migration. Phosphorylation and nuclear translocation of Erk by pro-uPA was directly observed. We conclude that the signaling pathways of pro-uPA and VN must be at least in part different.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, I-20132 Milan, Italy; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal, PQ H3A 1A1, Canada	Vita-Salute San Raffaele University; McGill University; Royal Victoria Hospital; McGill University	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Via Olgettina 58, I-20132 Milan, Italy.		Massimo, Resnati/AAN-5854-2020	Massimo, Resnati/0000-0002-4804-4569; rabbani, shafaat/0000-0001-5594-3899; Blasi, Francesco/0000-0001-9406-1784				BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOYLE MDP, 1987, J IMMUNOL, V139, P169; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Carriero MV, 1999, CANCER RES, V59, P5307; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DELROSSO M, 1992, EXP CELL RES, V203, P427; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KJOELLER L, 1997, EXP CELL RES, V232, P420; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lin TH, 1997, J BIOL CHEM, V272, P8849; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Slepian MJ, 1998, CIRCULATION, V97, P1818, DOI 10.1161/01.CIR.97.18.1818; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TARUI T, 2000, J BIOL CHEM, V276, P3938; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Webb DJ, 2000, J CELL SCI, V113, P123; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	58	91	97	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2032	2043		10.1038/sj.onc.1204261	http://dx.doi.org/10.1038/sj.onc.1204261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360187	Bronze			2022-12-17	WOS:000168043800011
J	Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H				Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H			p53 upregulates cFLIP, inhibits transcription of NF-kappa B-regulated genes and induces caspase-8-independent cell death in DLD-1 cells	ONCOGENE			English	Article						apoptosis; FLIP; NF-kappa B; p53; caspase; death receptors	DOMAIN-CONTAINING PROTEIN; P53-DEPENDENT APOPTOSIS; CASPASE HOMOLOG; IN-VIVO; ACTIVATION; FLICE; FAS; EXPRESSION; INTERACTS; INDUCTION	One of the main functions of the tumor suppressor p53 is the induction of programmed cell death, Here we investigated in detail the molecular mechanisms that underlay p53 transactivation-dependent apoptosis in the human colon cancer cell line DLD-1, Although p53 upregulated the death receptors Fas, TRAIL-R1 and TRAIL-R2 in this cell line, p53-induced cell death occurred without detectable caspase-8 activation whereas, activation of caspase-9 and caspase-3 was readily observed. In addition to the upregulation of death receptors, p53 induced the pro-apoptotic Bcl-2 family members Bik and Bak and downregulated the anti-apoptotic Bcl-xL protein. Moreover, in RNase protection assay analyses as well as in reporter gene analyses we found a p53-dependent upregulation of the death receptor-inhibitory protein cFLIP. Together, these data argue for a p53-mediated activation of the mitochondrial pathway of apoptosis, In contrast to recently published data obtained in different cellular systems, there was no evidence for an essential role of NF-kappaB in p53-induced cell death. Moreover, induction of p53 interfered,with TNF-induced NF-kappaB activation independently from apoptosis-induction.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; EL DW, 1993, CELL, V75, P817; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Uberti D, 2000, AMINO ACIDS, V19, P253, DOI 10.1007/s007260070056; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	41	91	94	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					571	580		10.1038/sj.onc.1204124	http://dx.doi.org/10.1038/sj.onc.1204124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313989				2022-12-17	WOS:000166755000004
J	Thomas, A; Giesler, T; White, E				Thomas, A; Giesler, T; White, E			p53 mediates Bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway	ONCOGENE			English	Article						Cdc42; p53; Bcl-2; JNK1; PAK1; apoptosis	SIGNAL-TRANSDUCTION PATHWAY; WISKOTT-ALDRICH SYNDROME; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; E1B 19K PROTEIN; P53-DEPENDENT APOPTOSIS; ACTIN CYTOSKELETON; RHO-GTPASES; ION-CHANNEL; BAX GENE	A member of the small G protein family, cdc42, was isolated from a screen undertaken to identify p53-inducible genes during apoptosis in primary baby rat kidney (BRK) cells transformed with E1A and a temperature-sensitive mutant p53 using a PCR-based subtractive hybridization method. Cdc42 is a GTPase that belongs to the Rho/Rac subfamily of Ras-like GTPases, In response to external stimuli, Cdc42 is known to transduce signals to regulate the organization of the actin cytoskeleton, induce DNA synthesis in quiescent fibroblasts, and promote apoptosis in neuronal and immune cells. In this study, we have demonstrated that cdc42 mRNA and protein were up-regulated in the presence of wild-type p53 in BRK cells, followed by cytoplasmic to plasma membrane translocation of Cdc42, Overexpression of Cdc42 in the presence of a dominant-negative mutant p53 induced apoptosis rapidly, indicating that Cdc42 functions downstream of p53, Furthermore, stable expression of a dominant-negative mutant of Cdc42 partially inhibited p53-mediated apoptosis, The Bcl-2 family members Bcl-x(L), and the adenovirus protein E1B 19K, inhibited Cdc42-mediated apoptosis, whereas Bcl-2 did not. We provide evidence that PAK1 and JNK1 may play a role downstream of Cdc42 to transduce its apoptotic signal. Cdc42/PAK1 activates JNK1-induced phosphorylation of Bcl-2, thereby inactivating its function, and that a phosphorylation resistant mutant (Bcl-2S70,87A,T56,74A) gains the ability to inhibit Cdc42- and p53-mediated apoptosis, Thus, one mechanism by which p53 promotes apoptosis is through activation of Cdc42 and inactivation of Bcl-2.	Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	White, E (corresponding author), HHMI, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MCGLADE CJ, 1989, VIROLOGY, V168, P119, DOI 10.1016/0042-6822(89)90410-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muraoka M, 1996, ONCOGENE, V12, P1565; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG W, 1997, J BIOL CHEM, V222, P24819; Zhao RB, 2000, GENE DEV, V14, P981; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	67	91	94	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5259	5269		10.1038/sj.onc.1203895	http://dx.doi.org/10.1038/sj.onc.1203895			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077443				2022-12-17	WOS:000165059700007
J	Cheng, QW; Lee, HH; Li, Y; Parks, TP; Cheng, GH				Cheng, QW; Lee, HH; Li, Y; Parks, TP; Cheng, GH			Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappa B inhibition	ONCOGENE			English	Article						NF-kappa B; Bcl-x; Bfl-1; chemoresistance; chemosensitization	ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; UP-REGULATION; ACTIVATION; EXPRESSION; RECEPTORS; INDUCTION; SURVIVAL; PROTEIN; C-IAP2	In A549 human lung adenocarcinoma cells, we found that TNF-alpha and several commonly used chemotherapeutic agents upregulated the expression of Bcl-x and/or Bfl-1/A1 through an NF-kappa B-dependent pathway. While parental A549 cells were resistant to the cytotoxic effects of both TNF-alpha and chemotherapy agents, NF-kappa B-blocked A549 cells were sensitized to both. Expression of either Bcl-x or Bfl-1/A1 in the NF-kappa B-deficient cells at physiological levels provided differential protection against TNF-alpha and chemotherapeutic treatment. These studies provide a potential mechanism for the phenomenon of chemotherapy-induced chemoresistance, and also reveal a potential strategy by which chemoresistance can be overcome.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; CuraGen Corp, New Haven, CT 06511 USA; Cellegy Pharmaceut Inc, S San Francisco, CA 94080 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU Z, 1997, CELL, V87, P565; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	21	91	98	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4936	4940		10.1038/sj.onc.1203861	http://dx.doi.org/10.1038/sj.onc.1203861			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039911				2022-12-17	WOS:000089757800016
J	Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B				Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B			Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation	ONCOGENE			English	Article						HFH-11; HPV; trident; WIN; winged helix	KINASE-II PHOSPHORYLATION; M-PHASE PHOSPHOPROTEINS; TYPE-16 E7; DNA-BINDING; HUMAN KERATINOCYTES; TRANSGENIC MICE; FACTOR TRIDENT; CELL-CYCLE; HPV-16 E7; HPV16 E7	The high risk human papillomavirus (HPV) type 16 E7 protein affects cell growth control and promotes transformation by interfering with functions of cellular proteins. A keg target of E7 is the tumor suppressor protein p105RB. Although this interaction is required for E7-dependent transformation, other cellular molecules must also be involved, because some E7 mutants that have reduced transforming abilities still bind to p10RB. In order to identify additional proteins that interact with E7 and that may be responsible to mediate its transforming function, we have used the C-terminal half of E7 in a yeast two-hybrid screen. We identified the fork head domain transcription factor hi phase phosphoprotein 2 (MPP2) as an interaction partner of E7, Specific interaction of the tno proteins both in ratio and in vivo in mammalian cells was detected. The interaction of MPP2 with E7 is functionally relevant since MPP2 enhances the E7/Ha-Ras co-transformation of rat embryo fibroblasts. In addition HPV16 E7, but neither non-transforming mutants of HPV16 E7 nor low risk HPV6 E7, was able to stimulate MPP2-specific transcriptional activity. Thus, MPP2 is a potentially important target for E7-mediated transformation.	Med Hsch Hannover, Inst Molekularbiol, D-30625 Hannover, Germany; CEA Grenoble, Lab Cytosquelette, DBMS, INSERM,U366, F-38054 Grenoble 9, France; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Hannover Medical School; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Philipps University Marburg	Luscher-Firzlaff, JM (corresponding author), Med Hsch Hannover, Inst Molekularbiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Müller, Rolf/L-4997-2016; Pirollet, Fabienne/L-3088-2013; Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Müller, Rolf/0000-0003-3339-4248; Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKS L, 1990, ONCOGENE, V5, P1383; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DEVILLIERS EM, 1981, J VIROL, V40, P932, DOI 10.1128/JVI.40.3.932-935.1981; DIPAOLO JA, 1989, ONCOGENE, V4, P395; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FIRZLAFF JM, 1987, CANCER CELL, V5, P105; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1995, ONCOGENE, V10, P1789; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Massimi P, 1996, ONCOGENE, V12, P2325; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MAZZARELLI JM, 1995, ONCOGENE, V11, P1859; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MITELMAN F, 1994, CATALOG CHROMOSOME A; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, J VIROL, V63, P4417; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 1996, ONCOGENE, V12, P213; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	78	91	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5620	5630		10.1038/sj.onc.1202967	http://dx.doi.org/10.1038/sj.onc.1202967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523841				2022-12-17	WOS:000083016500002
J	Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI				Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI			Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line	ONCOGENE			English	Article						RhoA; actin stress fibers; H-Ras; lovastatin; geranylgeraniol; farnesol	ACTIN STRESS FIBERS; CULTURED MESANGIAL CELLS; RAS TRANSFORMATION; FOCAL ADHESIONS; SIGNALING PATHWAY; PROTEIN-KINASES; TRAMP MODEL; GTPASES; PROGRESSION; RAC1	Prostate cancer cells derived from transgenic mice with adenocarcinoma of the prostate (TRAMP cells) were treated with the HMG-CoA reductase inhibitor, lovastatin, This caused inactivation of the small GTPase RhoA, actin stress fiber disassembly, cell rounding, growth arrest in the GZ phase of the cell cycle, cell detachment and apoptosis, Addition of geranylgeraniol (GGOL) in the presence of lovastatin, to stimulate protein geranylgeranylation, prevented lovastatin's effects. That is, RhoA was activated, actin stress fibers were assembled, the cells assumed a flat morphology and cell growth resumed. The following observations support an essential role for RhoA in TRAMP cell growth: (1) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein displayed few actin stress fibers and grew at a slower rate than controls (35 h doubling time for cells expressing RhoA (T19N) vs 20 h for untransfected cells); (2) TRAMP cells expressing constitutively active RhoA. (Q63L) mutant protein displayed a contractile phenotype and grew faster than controls (13 h doubling time), Interestingly, addition of farnesol (FOL) with lovastatin, to stimulate protein farnesylation, prevented lovastatin-induced cell rounding, cell detachment and apoptosis, and stimulated cell spreading to a spindle shaped morphology. However, RhoA remained inactive and growth arrest persisted. The morphological effects of FOL addition were prevented in TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein. Thus, it appears that H-Ras is capable of inducing cell spreading, but incapable of supporting cell proliferation, in the absence of geranylgeranylated proteins like RhoA.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Audie L Murphy Mem Vet Hosp, Res & Dev Serv, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Kreisberg, JI (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAGINA EE, 1976, EXP CELL RES, V97, P241, DOI 10.1016/0014-4827(76)90613-3; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Foster BA, 1997, CANCER RES, V57, P3325; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Ghosh PM, 1997, BBA-MOL CELL RES, V1359, P13, DOI 10.1016/S0167-4889(97)00091-8; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; NEWMAN A, 1994, LEUKEMIA, V8, P274; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SPOONER BS, 1982, J CELL BIOL, V49, P595; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	91	93	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4120	4130		10.1038/sj.onc.1202792	http://dx.doi.org/10.1038/sj.onc.1202792			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435593				2022-12-17	WOS:000081431000009
J	Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ				Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ			The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53	ONCOGENE			English	Article						H19; p53; tumor suppressor; gene regulation; TATA-less promoter	SMOOTH-MUSCLE CELLS; BINDING PROTEIN; FUNCTIONAL INTERACTION; MOUSE EMBRYOGENESIS; IMPRINTED GENES; IGF2 EXPRESSION; BREAST-CANCER; DNA-BINDING; MUTANT P53; IN-VIVO	The developmentally regulated H19 gene displays several remarkable properties: expression of an apparently non-translated mRNA, genomic imprinting (maternal allele only expressed), relaxation of the imprinting and/or epigenetic lesions demonstrated in some tumors. Despite several observations after relaxation of imprinting status of the gene, data on tr ans and cis-acting factors required for the human H19 gene expression are still missing. As a first approach to address identification of factors involved in the regulation of the gene, we found that cells from a p53 antisense-transfected HeLa clone displayed increased amounts of H19 transcripts when compared to the non-transfected cells. Moreover, a HeLa clone stably transfected with a temperature sensitive (ts) 143 Ala p53 mutant exhibited temperature-dependent regulation of H19 expression. This preliminary indication of the repressing effect of the p53 protein on H19 expression has been confirmed by transient cotransfection experiments in HeLa cells, using luciferase surrogate constructs under the control of the 823 bp sequence immediately upstream of the transcription start point of the H19 gene, and different constructs containing sense, antisense or a ts 143 Ala mutant p53 cDNA. We observed an increase of H19 promoter-driven activity in transient cotransfections with the antisense p53 cDNA and the temperature sensitive mutant p53 at the non-permissive temperature, but a decrease with sense wild-type p53 cDNA. Furthermore, the cotransfection experiments were repeated in a cell line lacking endogenous p53, (Calu 6 cells) and the results provided additional evidence for a down regulation of the expression of the H19 gene by the p53 protein.	Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; Inst Pasteur, Unite Oncol Mol, CNRS, URA 1160, F-59019 Lille, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Curgy, JJ (corresponding author), Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, SN3, F-59655 Villeneuve Dascq, France.			MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB SP, 1994, ONCOGENE, V9, P1341; DOUCRASY S, 1993, INT J ONCOL, V2, P753; DoucRasy S, 1996, ONCOGENE, V12, P423; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; EDEN S, 1995, NATURE, V375, P16, DOI 10.1038/375016a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Iotsova V, 1996, ONCOGENE, V13, P2331; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; JOOSS K, 1995, ONCOGENE, V10, P1529; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; KONDO M, 1995, ONCOGENE, V10, P1193; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Pellegata NS, 1996, EUR J HISTOCHEM, V40, P273; PERREM K, 1995, ONCOGENE, V11, P1299; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; vanderKooy K, 1996, AM J EPIDEMIOL, V144, P924, DOI 10.1093/oxfordjournals.aje.a008862; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; WALSH C, 1995, CANCER RES, V55, P1111; WILES MV, 1988, DEVELOPMENT, V104, P403; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	90	91	96	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2395	2401		10.1038/sj.onc.1201742	http://dx.doi.org/10.1038/sj.onc.1201742			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620557				2022-12-17	WOS:000073428000012
J	Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB				Dahia, PLM; Aguiar, RCT; Honegger, J; Fahlbush, R; Jordan, S; Lowe, DG; Lu, X; Clayton, R; Besser, GM; Grossman, AB			Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours	ONCOGENE			English	Article						Cushing's disease; ACTH-tumour; p27-kip1; mutation; carcinoid; cell cycle inhibitor; pituitary tumour	DEPENDENT KINASE INHIBITOR; HUMAN PITUITARY-TUMORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA GENE; P27(KIP1) GENE; CDK INHIBITOR; MICE LACKING; CELL-CYCLE; P27; G1	The molecular mechanisms leading to Cushing's disease are unclear, Inhibitors of cyclin-cyclin dependent kinase (CDK) complexes are regulators of the cell cycle and may function as tumour suppressor genes, many of which have been involved in the pathogenesis of several human malignancies, A member of this family, the p27/kip1 gene, maps to chromosome 12p13 and encodes an inhibitor of several cyclin-CDK complexes; these control the progression of the cell cycle from G1 to S-phase, Complete lack of p27/kip1 function, as occurs in the p27/kip1 'knockout' mouse, produces a complex phenotype associated with the development of pituitary tumours, specifically those of the intermediate lobe corticotrophs, We therefore investigated whether structural and functional abnormalities of the p27/kip1 gene and loss at the chromosome 12p13 region were present in human corticotrophin (ACTH)-secreting pituitary tumours, We studied 21 pituitary tumours, of which 20 were ACTH-secreting (two of these had biochemical and histological features of 'intermediate-lobe' tumours and one was malignant) while the remaining tumour was a prolactinoma; three ectopic secretors of ACTH (two bronchial and one thymic carcinoid); and a non-secretory thymic carcinoid, The whole coding region of the p27/kip1 gene was screened for mutations by PGR-SSCP analysis and/or direct sequencing, while tumour mRNA expression was analysed by means of a semi-quantitative duplex PGR, Three polymorphic microsatellite markers of the 12p13 region were used to assess loss of heterozygosity (LOH) in 12 samples, Finally, tumour p27/kip1 protein expression was assessed by immunohistochemistry using a monoclonal antibody in 12 samples suitable for analysis, No sequence abnormalities were found in any of the samples other than a previously-described polymorphism, No LOH was observed in the tumours analysed, p27/kip1 mRNA expression was similar in tumour samples in comparison with normal pituitaries, Seven of the eight corticotroph tumours analysed by immunohistochemistry stained positive for p27/kip1, including the intermediate lobe, The only malignant pituitary tumour in the original series showed an absence of staining for p27/kip1, In addition, the three carcinoid tumours studied were negative on immunohistochemistry. Of a further three malignant pituitary tumours assessed, two (including a prolactinoma) were essentially negative, while the third was moderately positive, We conclude that mutations of the p27/kip1 gene, deletions of the 12p13 area or changes in expression, are not a general feature of corticotroph tumours, even those with intermediate lobe characteristics, However, other mechanisms of p27/kip1 inactivation, such as an abnormality at the post-translational level, may be related to more aggressive histological subtypes of ACTH-secreting and possibly other pituitary tumours.	St Bartholomews Hosp, Dept Endocrinol, London, England; St Bartholomews Hosp, Dept Pathol, London, England; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Neurochirurg Klin, D-8520 Erlangen, Germany; St Marys Hosp, Ludwig Inst Canc Res, London, England; Univ Keele, Postgrad Med Sch, Dept Med, Stoke On Trent, Staffs, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Harvard University; Dana-Farber Cancer Institute; University of Erlangen Nuremberg; Imperial College London; Ludwig Institute for Cancer Research; Keele University	Grossman, AB (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London, England.			Lu, Xin/0000-0002-6587-1152				BATES AS, 1995, CLIN ENDOCRINOL, V42, P663, DOI 10.1111/j.1365-2265.1995.tb02697.x; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dahia PLM, 1996, J CLIN ENDOCR METAB, V81, P1768, DOI 10.1210/jc.81.5.1768; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HALE AC, 1988, CLIN ENDOCRINOL, V28, P215, DOI 10.1111/j.1365-2265.1988.tb03658.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Spirin KS, 1996, CANCER RES, V56, P2400; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Woloschak M, 1996, INT J CANCER, V67, P16, DOI 10.1002/(SICI)1097-0215(19960703)67:1<16::AID-IJC4>3.0.CO;2-2	34	91	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					69	76		10.1038/sj.onc.1201516	http://dx.doi.org/10.1038/sj.onc.1201516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467944				2022-12-17	WOS:000071236800008
J	Kornmann, M; Ishiwata, T; Beger, HG; Korc, M				Kornmann, M; Ishiwata, T; Beger, HG; Korc, M			Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions	ONCOGENE			English	Article						fibroblast growth factor-5; fibroblast growth factor receptor splice variant; in situ hybridization; mitogenic signaling; pancreatic cancer; protein kinases	FGF RECEPTORS; CELL-LINES; EXPRESSION; TRANSDUCTION; FAMILY; SPECIFICITY; ACTIVATION; MECHANISMS; INDUCTION; ONCOGENES	Fibroblast growth factor (FGF)-1 and -2 are overexpressed in human pancreatic cancer. In this study the role of FGF-5 in human pancreatic cancer was investigated, as FGF-5 has a classical signal sequence for secretion not found in FGF-1 or -2. Northern blot analysis with a 306 bp FGF-5 cDNA revealed the presence of 4.0 kb and 1.6 kb FGF-5 mRNA transcripts in both normal and cancerous pancreatic tissues. Densitometric analysis indicated that 4.0 kb and 1.6 kb FGF-5 mRNA transcripts levels were increased 2.4- and 2.7-fold in the cancers by comparison with normal tissues, respectively (P<0.002, P<0.0001). Immunohistochemistry and in situ hybridization demonstrated that FGF-5 localized in the cancer cells, stromal fibroblast and inflitrating macrophages. FGF-5 mRNA was also detected in COLO-357 human pancreatic cancer cells. Furthermore, secreted FGF-5 protein was present in conditioned medium of COLO-357 cells. Exogeneous FGF-5 (0.37 nM) increased the growth of COLO-357 cells by 48% (P<0.0001) and increased mitogen-activated protein kinase activity. COLO-357 cells expressed the IIIc isoform of the type I FGF receptor, the preferred FGF receptor for FGF-5. These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo.	UNIV CALIF IRVINE,MED SCI INST C240,DEPT MED BIOL CHEM & PHARMACOL,IRVINE,CA 92697; UNIV ULM,DEPT GEN SURG,D-89075 ULM,GERMANY	University of California System; University of California Irvine; Ulm University			Ishiwata, Toshiyuki/H-1151-2014	Ishiwata, Toshiyuki/0000-0002-4180-0069	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; Burgess W. H., 1996, P154; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EBERT M, 1995, INT J CANCER, V62, P529, DOI 10.1002/ijc.2910620507; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5441; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HERBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KITAOKA T, 1994, INVEST OPHTH VIS SCI, V35, P3189; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NGUYEN C, 1988, ONCOGENE, V3, P703; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1991, ONCOGENE, V6, P2137; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAMASAKI M, 1996, J BIOL CHEM, V271, P15919; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yoshimura K, 1996, CANCER LETT, V103, P91, DOI 10.1016/0304-3835(96)04198-5; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	91	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1417	1424		10.1038/sj.onc.1201307	http://dx.doi.org/10.1038/sj.onc.1201307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333017				2022-12-17	WOS:A1997XW41100005
J	Palmero, I; McConnell, B; Parry, D; Brookes, S; Hara, E; Bates, S; Jat, P; Peters, G				Palmero, I; McConnell, B; Parry, D; Brookes, S; Hara, E; Bates, S; Jat, P; Peters, G			Accumulation of p(16INK4a) in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status	ONCOGENE			English	Article						CDKN2a; tumor suppressor; retinoblastoma protein; SV40 T-antigen; replicative lifespan; Cdk inhibitor	TUMOR-SUPPRESSOR GENE; CYCLIN-DEPENDENT KINASES; D-CDK COMPLEXES; CELL-LINES; P16(INK4) EXPRESSION; GROWTH SUPPRESSION; LUNG CANCERS; PROTEIN; INHIBITION; P16	Viral transformation of mouse and human fibroblasts has very different effects on the composition of cyclin-dependent kinase (Cdk) complexes. In human cells transformed by the large T-antigen of simian virus 40 (SV40 T-Ag) and human tumour cell lines that lack a functional retinoblastoma gene product (pRb) no cyclin D1-Cdk4 complexes can be detected because all the available Cdk4 is associated with the Cdk-inhibitor p16(INK4a). In contrast, SV40-transformed mouse cells and fibroblasts from Rb1-nullizygous mouse embryos contain normal levels of cyclin D1-Cdk4 complexes. To investigate this species difference, we have compared the biochemical properties and expression of mouse p16(INK4a) with that of its human counterpart. There is a marked increase in p16 RNA and protein levels as primary embryo fibroblasts approach their finite lifespan in culture, but mouse p16 expression does not appear to be influenced by the status of pRb. Transformed or spontaneously immortalized mouse cells therefore do not achieve the very high levels of p16 characteristic of pRb-negative human cell lines. We suggest that these differences may be related to the different frequencies with which mouse and human cells can be immortalized in culture.	IMPERIAL CANC RES FUND,MOL ONCOL LAB,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research			Palmero, Ignacio/B-4346-2013					AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNAPEK DF, 1995, CANCER RES, V55, P1607; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TAM SW, 1994, ONCOGENE, V9, P2663; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996	52	91	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					495	503		10.1038/sj.onc.1201212	http://dx.doi.org/10.1038/sj.onc.1201212			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247303				2022-12-17	WOS:A1997XN25500001
J	Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y				Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y			Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway	ONCOGENE			English	Article						apoptosis; cysteine protease; Fas(APO-1/CD95); caspase-4(TX/ICH-2/ICErelII)	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYSTEINE PROTEASES; CELL-DEATH; FAMILY; CED-3	Proteases of the caspase family, especially caspase-1 (ICE)(-like), caspase-3 (CPP32/Yama/apopain)(-like) and caspase-8 (MACH/FLICE/Mch5) proteases, are implicated in Pas (APO-1/CD95)-mediated apoptosis. Here, we show that the caspase-4 (TX/ICH-2/ICErelII)(-like) protease, another member of the caspase family, is also involved in Pas-mediated apoptosis, based upon the observations: (i) caspase-4 is processed in response to an agonistic anti-Pas antibody treatment, (ii) overexpression of a mutant caspase-4 with active site mutations in both p20 and p10 subunits delays Pas-mediated apoptosis, (iii) microinjected anti-caspase-4 antibodies inhibit Fas-mediated apoptosis. Together with our observations that the mutant caspase-4 inhibits the Pas-mediated activation of caspase-3(-like) proteases and purified caspase-4 cleaves pro-caspase-3 to generate a subunit of active form, these results suggest that Pas-mediated apoptosis is driven by a caspase cascade in which the caspase-4(like) protease transmits a death signal from caspase-8 to caspase-3(-like) proteases probably through directly cleaving pro-caspase-3(-like) proteases.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BEIDLER DR, 1995, J BIOL CHEM, V270, P16527; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hasegawa J, 1996, CANCER RES, V56, P1713; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMADA S, 1995, CANCER RES, V55, P354; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	91	94	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					285	290		10.1038/sj.onc.1201192	http://dx.doi.org/10.1038/sj.onc.1201192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233763				2022-12-17	WOS:A1997XK99900005
J	Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH				Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH			WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						apoptosis; cisplatin; glioma; p53/WAF1/CIP1	HUMAN GLIOBLASTOMA CELLS; WILD-TYPE P53; LEUKEMIA-CELLS; COMBINATION THERAPY; ANTICANCER AGENTS; BRAIN-TUMORS; PHASE-II; INDUCTION; GENE; EXPRESSION	Induction of apoptosis in tumor cells is an important determinant in the outcome of therapy. Molecular details of the apoptosis pathway, however, are still poorly defined. The recently discovered WAF1/CIP1 gene is a potent inhibitor of cyclin-dependent kinases and a mediator of tumor-suppressor p53-dependent apoptosis by DNA damage. In addition, WAF1/CIP1 expression is shown to be triggered through the p53-independent pathway. The relationship between WAF1/CIP1 and p53-independent apoptosis by DNA damage, however, remains unclear. In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. In contrast, the p53-independent apoptosis of GB-1 glioma cells by cisplatin did not express WAF1/CIP1. Overexpression of WAF1/CIP1 inhibited DNA synthesis in GB-1 cells, but did not induce apoptosis. Interestingly, WAF1/CIP1 increased the susceptibility of GB-1 cells to cisplatin-induced apoptosis. These results suggest that overexpression of WAF1/CIP1 may have potential for the treatment of tumors with non-functional p53.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO 616,JAPAN	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR CANC CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERTOLONE SJ, 1989, J NEURO-ONCOL, V7, P5, DOI 10.1007/BF00149372; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CHEDID M, 1994, ONCOGENE, V9, P3021; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEAN FD, 1993, J NEUROONCOL, V16, P243; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JIANG HP, 1994, ONCOGENE, V9, P3397; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MICHIELI P, 1994, CANCER RES, V54, P3391; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEXAUER CL, 1985, CANCER, V56, P1497, DOI 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SOMERS KD, 1992, CANCER RES, V52, P5997; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANAKA Y, 1995, VIRUS RES, V36, P131, DOI 10.1016/0168-1702(94)00111-O; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	49	91	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1279	1285						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808702				2022-12-17	WOS:A1996VJ20200019
J	Meazza, R; Verdiani, S; Biassoni, R; Coppolecchia, M; Gaggero, A; Orengo, AM; Colombo, MP; Azzarone, B; Ferrini, S				Meazza, R; Verdiani, S; Biassoni, R; Coppolecchia, M; Gaggero, A; Orengo, AM; Colombo, MP; Azzarone, B; Ferrini, S			Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines	ONCOGENE			English	Article						human IL-15; small cell lung cancer; RT-PCR; alternative splicing	MESSENGER-RNA PRECURSORS; HUMAN-MELANOMA CELLS; FIBRONECTIN ISOFORM; BETA-CHAIN; RECEPTOR; EXPRESSION	IL-15 is a cytokine promoting growth and differentiation of T, B add NK lymphocytes. By RT-PCR analysis, using primers allowing amplification of the entire IL-15 mRNA coding region, 9/11 small cell lung cancer (SCLC) cell lines displayed detectable IL-15 gene expression, In addition to the expected band sizing 524 bp, a larger band was also observed, Cloning and sequence analysis of the larger cDNA from two SCLC cell lines revealed a size of 643 bp due to the presence of additional 119 bp within the previously reported IL-15 cDNA sequence, The 119 bp sequence matched with an IL-15 genomic sequence downstream the IL-15 second coding exon and may represent a previously unreported alternative exon (exon A), The SCLC-associated IL-15 mRNA isoform has a shorter open reading frame (ORF) due to stop codons in exon A, followed by a new AUG codon, The predicted IL-15 precursor protein displays a shorter signal peptide but shares the same aminoacidic composition of mature IL-15 protein, A possible functional role of IL-15, different from 'IL-2-like' activity, in human tumours, is suggested.	IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ONCOL CLIN & SPERIMENTALE,I-16132 GENOA,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY; HOP PAUL BROUSSE,INSERM U268,F-94800 VILLEJUIF,FRANCE	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Fondazione IRCCS Istituto Nazionale Tumori Milan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Orengo, Anna Maria/AAC-2108-2020; BIASSONI, ROBERTO/J-4677-2018; Meazza, Raffaella/AAC-2425-2019; Azzarone, Bruno/AAH-9251-2019; Colombo, Mario P./V-7166-2017	Orengo, Anna Maria/0000-0003-2959-6859; BIASSONI, ROBERTO/0000-0002-4365-8166; Meazza, Raffaella/0000-0003-0242-3157; Azzarone, Bruno/0000-0002-5962-3849; Colombo, Mario P./0000-0003-0042-7955; Ferrini, Silvano/0000-0001-7254-2616				ANDERSON DM, 1995, GENOMICS, V25, P701, DOI 10.1016/0888-7543(95)80013-C; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BORSI L, 1995, J BIOL CHEM, V270, P6243, DOI 10.1074/jbc.270.11.6243; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; MCMILLAN DN, 1995, INT J CANCER, V60, P766, DOI 10.1002/ijc.2910600606; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WALDMAN TA, 1995, P AACR SPEC C CYT CY; WEIDMANN E, 1992, CANCER RES, V52, P5963; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	30	91	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2187	2192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668345				2022-12-17	WOS:A1996UP28300018
J	CORBEIL, HB; WHYTE, P; BRANTON, PE				CORBEIL, HB; WHYTE, P; BRANTON, PE			CHARACTERIZATION OF TRANSCRIPTION FACTOR E2F COMPLEXES DURING MUSCLE AND NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						CELL CYCLE; DIFFERENTIATION E2F; TRANSCRIPTION FACTOR RETINOBLASTOMA	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; NERVE GROWTH-FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; VIRAL ONCOPROTEINS; PC12 CELLS; P107; FAMILY	The activities of E2F transcription factors are inhibited by interactions with members of the retinoblastoma (RE) tumor suppressor family, p105(RB), p107 and p130, In cycling cells p107 and p130 also interact with heterodimers comprised of Cdk2 and either A or E cyclins. We characterized E2F complexes present in C2C12 and P19 mouse cells induced to differentiate into muscle and neuronal cells, respectively. In both undifferentiated C2C12 and P19 cells, in addition to free species, E2F was found in complexes containing p107 or p130 and Cdk2. No E2F-pRB complexes were detected by electrophoretic mobility shift assays even though such cells were shown to contain pRB and E2F species capable of interacting in vitro. These results suggested that although present, pRB was unable to interact with E2F. Following differentiation of C2C12 cells into myotubes, E2F was present in at least two complexes which contained p130, but not in those containing p107 or Cdk2. Low levels of E2F-pRB complexes were also detected in fully differentiated C2C12 myotubes and in freshly isolated skeletal muscle. In the case of differentiated P19 neuronal cells, E2F was found in complexes containing pRB, p107 and p130. However, such cells may not be representative of fully differentiated neurons, as studies with rodent brain extracts indicated that only pRB-E2F complexes and those recognized by a p130-specific serum were present. These results suggested that in both muscle and neurons, pRB and p130 may play specific roles in the development or maintenance of terminal differentiation.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8S 4K1,CANADA	McGill University; McGill University; McMaster University								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V353, P249; BARBEAU D, 1994, ONCOGENE, V9, P359; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P128; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1994, FASEB J, V7, P846; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V55, P1144; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; SMITH DB, 1988, GENE, V657, P31; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIMAN KG, 1994, FASEB J, V7, P841; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	71	91	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					909	920						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675450				2022-12-17	WOS:A1995RU79800012
J	ROLLEY, N; BUTCHER, S; MILNER, J				ROLLEY, N; BUTCHER, S; MILNER, J			SPECIFIC DNA-BINDING BY DIFFERENT CLASSES OF HUMAN P53 MUTANTS	ONCOGENE			English	Article						P53; DNA BINDING; STRUCTURAL MUTANTS; DNA CONTACT MUTANTS	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; PROTEIN; CONFORMATION; APOPTOSIS; GENE; TRANSCRIPTION; P53-PROTEIN; COMPLEXES; INHIBITOR	The p53 protein is a multifunctional transcription factor which orchestrates cellular responses to DNA damage, so helping to conserve genomic stability. It may also regulate genes involved in intercellular signalling, such as thrombospondin, a negative regulator of angiogenesis and metastatic spread. Activation of p53 target genes requires sequence-specific DNA binding, a function which maps to the central core of the protein. Missense point mutations within this domain inactivate p53 tumour suppressor function and involve either (i) DNA contact residues, or (ii) residues important for conformational structure. Using in vitro techniques we have analysed seven DNA contact mutants and 17 structural mutants known to occur in cancer. We show that DNA contact mutants can be carried into specific DNA interaction when co-expressed with wild type protein. For structural mutants, 9/17 retained DNA binding capacity and, with one exception, DNA binding correlated with conformational flexibility of the mutant protein. The exception was Asp(281), which appeared essential for DNA interaction, probably due to its ability to form salt bridges with DNA contact residues Arg(273) and Arg(280). We suggest that different classes of p53 mutant may prove amenable to different strategies for restoration of wild type tumour suppressor function as means of anti-cancer therapy.	UNIV YORK,DEPT BIOL,YORKSHIRE CANC RES CAMPAIGN P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHIBA I, 1990, ONCOGENE, V5, P1603; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1992, CELL, V75, P817; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HAINAUT P, 1993, CANCER RES, V53, P4463; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARPER JW, 1993, CELL, V75, P805; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEDCALF EA, 1991, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOMAND J, 1992, CELL, V69, P1273; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; ROLLEY N, 1994, ONCOGENE, V9, P3067; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V6, P1143; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	59	91	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					763	770						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651740				2022-12-17	WOS:A1995RQ46900019
J	LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ				LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ			EXPRESSION, PROMOTER USAGE AND PARENTAL IMPRINTING STATUS OF INSULIN-LIKE GROWTH-FACTOR-II (IGF2) IN HUMAN HEPATOBLASTOMA - UNCOUPLING OF IGF2 AND H19 IMPRINTING	ONCOGENE			English	Article						IGF2; H19; HEPATOBLASTOMA; PARENTAL IMPRINTING; PROMOTER; METHYLATION	BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; GENE; RELAXATION; ALLELE; RNA	We have studied the promoter utilization and parental imprinting status of human IGF2 in three genetically informative hepatoblastomas from patients ranging in age from 9 months to 3 years, In all three cases, there is a downregulation of promoter P1 in the tumor tissues while the P2 and P3 promoters are upregulated compared to the normal liver, One of the three patients displayed loss of imprinting (LOI) of IGF2 in the tumor tissue, We also investigated the expression of the H19 gene in all three cases and the methylation pattern in H19 from the patient with LOI of IGF2. The expression of H19 was greatly reduced in all tumors. Monoallelic H19 expression however, was retained even in the case which showed LOI of IGF2. Unlike the situation in Wilms' tumor, no differences in the methylation pattern between the normal liver and tumor tissues were observed in the H19 promoter or 3' region, using HpaII analysis. We show here, that in contrast to the situation in Wilms' tumor, H19 expression is not a prerequisite for maintaining a monoallelic IGF2 expression.	KAROLINSKA HOSP,DEPT CLIN NEUROSCI,EXPTL ALCOHOL & DRUG ADDICT RES SECT,S-17176 STOCKHOLM,SWEDEN; UNIV UPPSALA,DEPT ANIM DEV & GENET,S-75236 UPPSALA,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,DIV PEDIAT,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Uppsala University; Karolinska Institutet; Karolinska University Hospital			Cui, Hengmi/A-2598-2008; Ekström, Tomas/B-7764-2013					BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRICE AL, 1989, DEVELOPMENT, V106, P543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RECHLER MM, 1990, INSULIN LIKE GROWTH, P263; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCHNEID H, 1993, ENDOCRINOLOGY, V132, P1145, DOI 10.1210/en.132.3.1145; SHAFFORD EA, 1994, EUR J CANCER, V30A, P1050, DOI 10.1016/0959-8049(94)90453-7; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1993, ADV EXP MED BIOL, V343, P63; SUSSENBACH JS, 1991, ADV EXP MED BIOL, V293, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WALSH C, 1995, CANCER RES, V55, P1111; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	37	91	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					221	229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624139				2022-12-17	WOS:A1995RK95700002
J	BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP				BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP			MUTANT P53 INCREASES RADIORESISTANCE IN RAT EMBRYO FIBROBLASTS SIMULTANEOUSLY TRANSFECTED WITH HPV16-E7 AND/OR ACTIVATED H-RAS	ONCOGENE			English	Article							WILD-TYPE P53; SQUAMOUS-CELL CARCINOMAS; IONIZING-RADIATION; INVITRO RADIOSENSITIVITY; SKIN FIBROBLASTS; CYCLE CHECKPOINT; NIH-3T3 CELLS; EXPRESSION; ONCOGENE; CANCER	Recently, it has been suggested that abrogation of the wild type p53 protein function may alter the cellular response to DNA damaging agents, including ionizing radiation. This study was designed to compare the relative radiosensitivity and tumorigenicity of rat embryo fibroblast (REF) cell lines transfected with a mutant form of the p53 gene (plasmid MTp53pro193), alone, or in combination, with the H-ras (plasmid pEJ6.6) and HPV16-E7 (plasmid pJ4 Omega 16.E7) oncogenes. Transfection of the mutant p53pro193 gene alone resulted in selected clones having increased radioresistance in culture which correlated with increased mutant p53 expression in these clones. However, the co-transfection of mutant p53 and H-vas genes or triple transfection of mutant p53, H-uas and E7 genes resulted in clones with high mutant p53 expression, significantly increased radioresistance and uniform tumorigenicity. There was no correlation between intrinsic radioresistance and spontaneous metastasis in the tumorigenic REF transfectant clones. Stepwise acquisition of radioresistance and an aggressive tumor cell phenotype is observed when the mutant p53 gene and HPV E7 co-operate with the ras oncogene in transfection assays, and can be correlated to increases in mutant p53 expression.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RES, DIV CELL & MOLEC BIOL, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	BRISTOW, RG (corresponding author), PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RADIAT ONCOL, DIV EXPTL THERAPEUT, 500 SHERBOURNE ST, TORONTO M4X 1K9, ON, CANADA.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				ALAPETITE C, 1991, INT J RADIAT BIOL, V59, P385, DOI 10.1080/09553009114550351; ALLAM A, 1993, J NATL CANCER I, V85, P1954, DOI 10.1093/jnci/85.23.1954; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360-3016(90)90098-5; BROCK WA, 1989, INT J RADIAT BIOL, V56, P751, DOI 10.1080/09553008914552001; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DAVIDOFF AM, 1991, SURGERY, V110, P259; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FUJIWARA T, 1993, CANCER RES, V53, P4129; GIRINSKY T, 1992, INT J RADIAT ONCOL, V25, P3; GRANT ML, 1990, ONCOGENE, V5, P1159; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASID U, 1993, CANCER RES, V61, P195; KASID UN, 1989, CANCER RES, V49, P3396; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKENNA WG, 1990, CANCER RES, V50, P97; MENDONCA MS, 1991, INT J RADIAT BIOL, V59, P1195, DOI 10.1080/09553009114551071; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; ONG A, 1993, RADIAT RES, V134, P251, DOI 10.2307/3578467; PARDO FS, 1991, P NATL ACAD SCI USA, V88, P10652, DOI 10.1073/pnas.88.23.10652; PEACOCK J, 1990, ONCOGENE, V2, P1769; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SASAKI K, 1986, CYTOMETRY, V7, P391, DOI 10.1002/cyto.990070415; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SIDERANSKY D, 1992, NATURE, V355, P846; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEEG PS, 1988, CANCER RES, V48, P6550; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; SUIT HD, 1992, INT J RADIAT ONCOL, V23, P653, DOI 10.1016/0360-3016(92)90025-D; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAYLOR WR, 1992, ONCOGENE, V7, P1383; TISHLER RB, 1993, CANCER RES, V53, P2212; TOMMASINO M, 1993, ONCOGENE, V8, P195; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WEISCHELBAUM RR, 1991, JNCI-J NATL CANCER I, V83, P480; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	91	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1527	1536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183546				2022-12-17	WOS:A1994NL81500002
J	GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD				GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD			THE ECK RECEPTOR TYROSINE KINASE IS IMPLICATED IN PATTERN-FORMATION DURING GASTRULATION, HINDBRAIN SEGMENTATION AND LIMB DEVELOPMENT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; MOUSE MUTANT EMBRYOS; GERM-CELL SURVIVAL; NEURAL CREST; REPEATED EPILATION; PROTEIN-KINASE; CHICK-EMBRYO; SCATTER FACTOR; MET RECEPTOR; KIT RECEPTOR	Members of the protein superfamily of transmembrane receptor tyrosine kinases are key components of intercellular signal transduction pathways that elicit appropriate cellular responses to environmental cues during development of multicellular organisms. In a search for additional receptor tyrosine kinases expressed during mouse embryogenesis we cloned the murine homolog of Eck, a member of the Eph subfamily, that maps to the distal region of mouse chromosome 4. Specific antisera defined Eck in murine embryonic cells as a glycoprotein of 130 kDa with an intrinsic autophosphorylation activity. Immunohistochemical staining and laser scanning microscopy revealed a dynamic and tightly regulated distribution of Eck receptor protein in the developing mouse embryo. During gastrulation, a high transient distribution of Eck was seen in mesodermal cells aggregating in the midline as notochordal plate. A similar restriction of Eck receptor protein was apparent along the rostrocaudal axis of the developing neural tube. In hindbrain neuroepithelia, Eck protein localised specifically to cells of rhombomere 4 and was also seen transiently in cells populating second and third branchial arches and neurogenic facial crest VII-VIII and IX-X. Receptor distribution also implicated Eck in development of the proximodistal axis of the limb, expression being restricted to distal regions of limb bud mesenchyme. At later stages, additional sites of Eck protein expression were seen in the cartilaginous model of the skeleton, tooth primordia, infundibular component of the pituitary and various fetal tissue epithelia. Taken together, our data suggest pleiotropic functions for the Eck receptor, initially in distinctive aspects of pattern formation and subsequently in development of several fetal tissues, and reveal possible allelism with known mouse developmental mutant loci.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				BEDDINGTON RSP, 1992, DEVELOPMENT, P157; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAKRAVARTI S, 1991, MAMM GENOME, V1, P270, DOI 10.1007/BF00352338; CHAN J, 1991, ONCOGENE, V6, P1057; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; END P, 1992, EUR J BIOCHEM, V209, P1041, DOI 10.1111/j.1432-1033.1992.tb17380.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V168, P219, DOI 10.1111/j.1365-2818.1992.tb03265.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V165, P347, DOI 10.1111/j.1365-2818.1992.tb01492.x; ENTWISTLE A, 1990, T ROY MICR, V1, P405; ENTWISTLE A, 1990, T ROY MICR, V1, P361; FAUST C, 1993, CURR OPIN GENET DEV, V3, P491, DOI 10.1016/0959-437X(93)90125-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUENET JL, 1979, J HERED, V70, P90, DOI 10.1093/oxfordjournals.jhered.a109223; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASIMOTO K, 1987, DEVELOPMENT, V100, P587; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERRMANN BG, 1992, CIBA F SYMP, V165, P78; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KOMADA M, 1993, ONCOGENE, V8, P2381; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; MEREDITH R, 1964, MOUSE NEWS LETT, V31, P25; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN BA, 1993, CURR OPIN GENET DEV, V3, P668, DOI 10.1016/0959-437X(93)90105-X; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PESCE M, 1993, DEVELOPMENT, V118, P1089; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; REITH AD, 1991, GENOME ANAL, V3, P105; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SALZGEBER B, 1984, J CRAN GENET DEV BIO, V4, P95; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSIN MT, 1983, J CRAN GENET DEV BIO, V3, P289; TAYLOR BA, 1977, J VIROL, V23, P106, DOI 10.1128/JVI.23.1.106-109.1977; VERWOERD CDA, 1979, ADV ANATOMY EMBRYOLO, V58; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILCOX FH, 1981, J HERED, V72, P387, DOI 10.1093/oxfordjournals.jhered.a109537; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZAKUT R, 1993, ONCOGENE, V8, P2221	80	91	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1613	1624						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183555				2022-12-17	WOS:A1994NL81500012
J	KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM				KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM			STRUCTURAL-ANALYSIS OF THE HUMAN RET PROTOONCOGENE USING EXON TRAPPING	ONCOGENE			English	Article							THYROID PAPILLARY CARCINOMAS; MULTIPLE ENDOCRINE NEOPLASIA; RECEPTOR TYROSINE KINASE; NEUROBLASTOMA CELL-LINES; C-KIT; PROTOONCOGENE; CLONING; PTC; EXPRESSION; FRAGMENTS	A genomic contig of the human ret proto-oncogene was created with four overlapping cosmid clones isolated from two libraries. After southern analysis with portions of the ret cDNA, eight cosmid fragments were analysed in detail for the presence of ret exons using exon trapping. PCR products corresponding to spliced exons were isolated and subcloned. Exon boundaries were delineated by comparison of the PCR product sequence and the published ret cDNA sequence. The exons were initially positioned on a genomic map defined by BamHI, EcoRI and HindIII restriction sites. The positions of the exons were then refined by amplifying genomic DNA using primer pairs derived from one or more exons along the ret gene, the length of the PCR product indicating the approximate genomic distance between the exon sequences. The ret proto-oncogene is composed of at least 20 exons, ranging in size from 60 bp to 287 bp, distributed along 30 kb of genomic DNA. The extracellular domain is encoded by 10 exons and the cytoplasmic domain by 9 exons. The transmembrane domain is encoded by a single exon.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,SCOTLAND	University of Cambridge; University of Edinburgh				Kwok, John/0000-0001-9574-6195; warner, jonathan peter/0000-0001-5301-675X				ANDRE C, 1992, ONCOGENE, V7, P685; AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V34, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOMEN RH, 1993, HUM MOL GENET, V2, P5, DOI 10.1093/hmg/2.1.5; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HAMAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P9779, DOI 10.1073/pnas.89.20.9779; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1201; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JHIANG SM, 1992, ONCOGENE, V7, P1331; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; Lorens J B, 1991, PCR Methods Appl, V1, P140; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Miya A, 1992, Henry Ford Hosp Med J, V40, P215; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SOZZI G, 1991, ONCOGENE, V6, P339; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKINO T, 1991, GENOMICS, V12, P401; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	91	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361767				2022-12-17	WOS:A1993LT36800031
J	TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M				TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME 1P36 REGION	ONCOGENE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; ENDOCRINE NEOPLASIA; COLORECTAL TUMORS; HIGH-FREQUENCY; WILMS-TUMOR; SHORT ARM; TUMORIGENICITY; DNA; SEQUENCE; GENE	Development of colon carcinomas appears to be associated with inactivation of multiple tumour suppressor genes. Cytogenetic and DNA analyses of colon carcinomas have detected a high frequency of chromosome 1p deletion, which suggests the presence of a tumour suppressor gene. We therefore introduced normal human chromosome 1 into colon carcinoma COKFu cells, through microcell hybridization. Six clones of hybrid cells containing normal chromosome 1 were obtained, four of which had a small fragment of the introduced chromosome 1, including 1p36-34. The morphology of hybrid cells with chromosome 1 markedly altered to a flat shape. The cloning efficiency of all six hybrid cells in soft agar was significantly reduced, and the tumourigenicity in athymic nude mice was completely suppressed. Hybrid cells containing only the region of 1p36-34, as well as those containing intact chromosome 1, showed suppressed transformed phenotype. Furthermore, several tumourigenic revertant cells were obtained from the hybrid cells. These revertant cells had a morphology similar to that of COKFu cells, and were found to have lost the 1p36 region from the introduced chromosome 1. These results indicate that a normal chromosome 1p36 carries a tumour suppressor gene for colon carcinogenesis.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT CHEMOTHERAPY & SURG,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BENEDICT WF, 1984, CANCER RES, V44, P3471; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN G, 1971, J CELL SCI, V8, P659; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MOLEY JF, 1992, CANCER RES, V52, P770; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9367, DOI 10.1093/nar/16.19.9367; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9368, DOI 10.1093/nar/16.19.9368; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P9622, DOI 10.1093/nar/15.22.9622; NEGRINI M, 1992, CANCER RES, V52, P1297; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1989, CANCER RES, V49, P1282; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANNI R, 1990, GENE CHROMOSOME CANC, V2, P255, DOI 10.1002/gcc.2870020316; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISS MJ, 1987, NUCLEIC ACIDS RES, V15, P860, DOI 10.1093/nar/15.2.860; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLIAMS AC, 1990, CANCER RES, V50, P4724; YANOSHITA R, 1992, CANCER RES, V52, P3965	45	91	101	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101648				2022-12-17	WOS:A1993LP17100027
J	SLEEMAN, JP				SLEEMAN, JP			XENOPUS A-MYB IS EXPRESSED DURING EARLY SPERMATOGENESIS	ONCOGENE			English	Article							HUMAN LYMPHOCYTES-T; C-MYB; V-MYB; ERYTHROID-DIFFERENTIATION; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; CDNA CLONES; CELL-LINES; GENE; ONCOGENE	c-myb has been studied intensely, but other members of the myb gene family have been largely overlooked. This paper describes the isolation and characterization of a Xenopus cDNA sequence, XAMyb, closely related to human A-myb. Xenopus provides a valuable experimental model for investigating the involvement of genes in cell proliferation, differentiation and development. Although no expression of XAMyb was detected in oocytes or eggs or during early embryogenesis, there is a low level of expression within ovarian tissue, which is down-regulated in response to hormones that stimulate oocyte maturation. However, in adult male Xenopus, virtually all A-myb expression is in the testis, particularly within the nuclei of spermatogonial cells, the mitotically proliferating early progenitors of spermatozoa. Expression falls dramatically during meiosis and is virtually undetectable during subsequent spermiogenesis. This pattern of expression of Xenopus A-myb during the preterminal differentiation/ proliferation phase of germ cell development resembles the expression of c-myb in similar phases during haematopoiesis. These results suggest related roles for myb variants during the development of different stem cell-derived populations.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOL, V152; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLURMAN B, 1988, IMMUNOL SER, V41, P55; CRAIG RW, 1984, CANCER RES, V44, P442; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JACKSON R, 1987, METHOD ENZYMOL, V96, P50; KALT MR, 1976, J EXP ZOOL, V195, P393, DOI 10.1002/jez.1401950306; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KREIG PA, 1989, DEV BIOL, V133, P93; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFTS B, 1974, PHYSL AMPHIBIA; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEINESS D, 1984, MOL CELL BIOL, V9, P5456; SHENONG G, 1991, BIOCHIM BIOPHYS ACTA, V1032, P39; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTON K, 1989, CELL, V58, P83	53	91	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1931	1941						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510936				2022-12-17	WOS:A1993LG68200026
J	MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P				MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P			BIOCHEMICAL-CHARACTERIZATION AND ANALYSIS OF THE TRANSFORMING POTENTIAL OF THE FLT3/FLK2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; C-KIT RECEPTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; FMS PROTO-ONCOGENE; W-MUTANT MICE; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PROGENITOR CELLS; BONE-MARROW	We recently cloned an additional member of the receptor type tyrosine kinase class III. This new gene, called Flt3 by our group [Rosnet, O., Mattei, M.G., Marchetto, S. & Birnbaum, D. (1991). Genomics, 9, 380-385; Rosnet, O., Marchetto, S., deLapeyriere, 0. & Birnbaum, D. (1991). Oncogene, 6, 1641-16501 and Flk2 by others [Matthews, W., Jordan, C.T., Wieg, G.W., Pardoll, D. & Lemischka, I.R. (1991). Cell, 65, 1143-11521 is strongly related to the important developmental genes Kit, Fms and Pdgfr. The murine 3.2-kb full-length cDNA, when introduced into COS-1 cells, shows the expression of two polypeptides with apparent molecular weights of 155 kDa and 132 kDa. Treatment of cells with N-linked glycosylation inhibitors results in the expression of a 110-kDa protein. We have shown that FLT3 contains an intrinsic tyrosine kinase activity. A point mutation in a highly conserved residue within the phosphoryltransferase domain inactivates the catalytic function of this receptor, whereas activation by way of a chimeric molecule between the ligand-binding domain of colony-stimulating factor type 1 (CSF-1) receptor (CSF-1R) and the kinase domain of FLT3 results, in the presence of CSF-1, in the development of the transforming activity of this receptor as shown by anchorage-independent cell growth. Finally, expression analysis of the FLT3 protein shows that, in addition to the hematopoietic system, FLT3 is strongly expressed in neural, gonadal, hepatic and placental tissues in the mouse.	INSERM, UNITE 119, MOLEC ONCOL LAB, 27 BD ROURE, F-13009 MARSEILLE, FRANCE; INSERM, UNITE 119, MOLEC HEMATOL LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; Rosnet, Olivier/G-3536-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X; Rottapel, Robert/0000-0002-6024-5558; Rosnet, Olivier/0000-0002-3020-910X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BIRG F, 1903, IN PRESS BLOOD; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CAO Y, 1990, Technique (Philadelphia), V2, P109; CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; QUELLE FW, 1991, J BIOL CHEM, V266, P609; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1993, IN PRESS ONCOGENE; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORRENTINO V, 1991, ONCOGENE, V6, P149; STANLEY ER, 1980, MONONUCLEAR PHAGOC 1, P415; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TSUJI K, 1991, BLOOD, V78, P1223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	91	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					909	918						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384358				2022-12-17	WOS:A1993KT22000012
J	CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A				CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A			REGULATION OF MYOD GENE-TRANSCRIPTION AND PROTEIN FUNCTION BY THE TRANSFORMING DOMAINS OF THE ADENOVIRUS E1A ONCOPROTEIN	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DNA-BINDING PROTEIN; LARGE T-ANTIGENS; HUMAN CYCLIN-A; CELL-CYCLE; MYOGENIC DIFFERENTIATION; RETINOBLASTOMA PROTEIN; REPRESS TRANSCRIPTION; G1 PHASE; PRODUCT	It has been demonstrated that the adenovirus E1A gene products inhibit myogenic differentiation in the mouse C2 muscle cell line. During myogenic differentiation, cell growth and tissue-specific gene expression are mutually exclusive. Since E1A exerts multiple effects on different cellular pathways through alteration of cell growth control and transcriptional regulation, we investigated in more detail the molecular mechanisms underlying the inhibitory effect of E1A on myogenic differentiation. To this end, we used mutant derivatives of E1A that lack the 'conserved domain' sequences to which the functional domains of E1A have been mapped, and we observed the effect of constitutive expression of these E1A mutants on myogenesis in the murine C2 muscle cell line. Our results demonstrate that E1A interferes with myogenesis through at least two mechanisms: (i) the inhibition of MyoD expression; (ii) the repression of MyoD-dependent transcriptional activation. In addition, we demonstrate also that the repression of MyoD transcription depends upon sequences located in the N-terminus of E1A and correlates well with the site of E1A/p300 association. Further, the inhibition of transcriptional activation by MyoD depends both on conserved region 1 and on conserved region 2, the two transforming domains of E1A. We demonstrate also that a similar inhibitory effect on the MyoD transactivating function is provided by the polyomavirus and SV40 large T oncoproteins.	CRS,IST REGINA ELENA STUDIO & CURA TUMORI,VIA DELLE MESSI DORO 156,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL & BIOCHEM,PHILADELPHIA,PA 19140; CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Giordano, Antonio/F-1927-2010; Felsani, Armando/D-1784-2010; Caruso, Maurizia/G-8895-2013; Martelli, Fabio/AAL-3788-2020	Giordano, Antonio/0000-0002-5959-016X; Felsani, Armando/0000-0001-8851-6295; Caruso, Maurizia/0000-0001-5445-6343; Martelli, Fabio/0000-0002-8624-7738				BADER D, 1992, J CELL BIOL, V5, P763; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MAIONE R, 1992, ONCOGENE, V7, P85; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANORMONDT H, 1978, GENE, V4, P309, DOI 10.1016/0378-1119(78)90048-3; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984; ZINGG JM, 1991, NUCLEIC ACIDS RES, V19, P6433, DOI 10.1093/nar/19.23.6433	91	91	93	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					267	278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381218				2022-12-17	WOS:A1993KN00600005
J	PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P				PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P			BINDING OF THE HUMAN E2F TRANSCRIPTION FACTOR TO THE RETINOBLASTOMA PROTEIN BUT NOT TO CYCLIN-A IS ABOLISHED IN HPV-16-IMMORTALIZED CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; E1A PROTEINS; DNA-BINDING; ADENOVIRUS-E1A; KERATINOCYTES; EXPRESSION; INTERACT	The adenovirus E1A, SV40 large T and papillomavirus E7 proteins immortalize primary cells by virtue of their ability to bind the retinobtastoma gene product (pRB) and other cellular proteins, including cyclin A and the prRB-related protein, p107. It has been demonstrated that these viral oncogene products will prevent the inhibition of positive growth regulators by pRB, one of them being the E2F transcription factor. Here we show that the interactions of pRB and cyclin A with E2F are present also in normal keratinocytes and in primary human fibroblasts. In human keratinocytes immortalized by human papillomavirus 16 (HPV-16), expressing high levels of HPV-16 E7 protein, complexes between E2F and pRB are disrupted. In this cell line, as well as in HeLa cells which express HPV-18 E7, complexes containing E2F and cyclin A are maintained, indicating that this interaction is not sensitive to the viral oncoprotein and that cyclin A can associate with E2F independently of pRB. In vitro binding experiments suggest that the E7 gene product is able to preferentially abolish the interaction of pRB with E2F, leaving the cyclin A complexes intact. Our findings suggest that E7-dependent immortalization of human cells is associated with modifications of E2F multiprotein complexes.	DEUTSCH KREBSFORSCHUNGSZENTRUM,PROJEKTGRP ANGEW TUMORVIROL,NEUENHEIMER FELD 506,W-6900 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIARD F, 1991, CELL, V67, P1169; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANSENDURR P, 1990, J VIROL, V64, P2384, DOI 10.1128/JVI.64.5.2384-2387.1990; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KUMAR V, 1988, CELL, V55, P507; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL	42	91	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1681	1686						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323816				2022-12-17	WOS:A1992JJ37600002
J	LIN, YZJ; CLINTON, GM				LIN, YZJ; CLINTON, GM			A SOLUBLE-PROTEIN RELATED TO THE HER-2 PROTOONCOGENE PRODUCT IS RELEASED FROM HUMAN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; FACTOR STIMULATE PHOSPHORYLATION; NEU ONCOGENE; EGF RECEPTOR; AMPLIFICATION; EXPRESSION; ADENOCARCINOMA; OVEREXPRESSION; MECHANISMS	Amplified expression of p185HER-2, the protein product of the HER-2/neu proto-oncogene, appears to be involved in carcinogenesis of human mammary epithelial cells. Our data suggest that an extracellular 130 Kda glycoprotein released from breast carcinoma cells may be related to the ectodomain of p185HER-2: (1) Both cellular p185HER-2 and extracellular p130, when reduced and alkylated, reacted with antipeptide antibody against the N-terminus of the HER-2 protein [alpha-N(HER-21)] and reactivity was blocked by cognate peptide; (2) Neither p130 nor other extracellular proteins reacted with antiserum against the C-terminus of p185HER-2 [alpha-C(HER-2)]; (3) Partial proteolysis of p185HER-2 generated an immunoreactive fragment of 130 kDa that was similar to extracellular p130; (4) Both p130 and p185HER-2 contained carbohydrate that bound to Con-A Sepharose; (50 The amount of p130 released from breast cells corresponded to the levels of expression of cellular p185HER-2. Release of the ectodomain of p185HER-2 from breast carcinoma cells may be involved in their malignant growth and may be a useful marker for assessing the expression of p185HER-2 in human tumors.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL CANCER INSTITUTE [R01CA039641] Funding Source: NIH RePORTER; NCI NIH HHS [CA39641] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YHJ, 1990, MOL CELL ENDOCRINOL, V69, P111, DOI 10.1016/0303-7207(90)90004-R; LOUGHNAN MS, 1988, P NATL ACAD SCI USA, V85, P3115, DOI 10.1073/pnas.85.9.3115; MCDONALD RG, 1989, J BIOL CHEM, V264, P3256; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; ZHOU DJ, 1987, CANCER RES, V47, P6123	25	91	97	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					639	643						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1674366				2022-12-17	WOS:A1991FR93900020
J	ZHAO, YH; KRUEGER, JG; SUDOL, M				ZHAO, YH; KRUEGER, JG; SUDOL, M			EXPRESSION OF CELLULAR-YES PROTEIN IN MAMMALIAN-TISSUES	ONCOGENE			English	Article									ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,INVEST DERMATOL LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University					NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NCI NIH HHS [CA45757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GHYSDAEL J, 1981, VIROLOGY, V111, P386, DOI 10.1016/0042-6822(81)90342-1; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PAWSON T, 1988, ONCOGENE, V3, P491; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZHENG XF, 1989, ONCOGENE, V4, P99	24	91	92	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1629	1635						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267131				2022-12-17	WOS:A1990EL40100003
J	FINLEY, GG; SCHULZ, NT; HILL, SA; GEISER, JR; PIPAS, JM; MEISLER, AI				FINLEY, GG; SCHULZ, NT; HILL, SA; GEISER, JR; PIPAS, JM; MEISLER, AI			EXPRESSION OF THE MYC GENE FAMILY IN DIFFERENT STAGES OF HUMAN COLORECTAL-CANCER	ONCOGENE			English	Article									UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15240; UNIV PITTSBURGH,VET ADM MED CTR,SCH MED,PITTSBURGH,PA 15240; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA046547] Funding Source: NIH RePORTER; NCI NIH HHS [CA46547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER RJ, 1986, GASTROENTEROLOGY, V91, P1503, DOI 10.1016/0016-5085(86)90208-8; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bussey H, 1975, FAMILIAL POLYPOSIS C; CALABRETTA B, 1985, CANCER RES, V45, P6000; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Farber E, 1980, Adv Cancer Res, V31, P125, DOI 10.1016/S0065-230X(08)60658-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOULDS L, 1975, NEOPLASTIC DEV, V2; GARDNER EJ, 1962, AM J HUM GENET, V14, P376; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; Maniatis T., 1982, MOL CLONING; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RULEY HE, 1984, CANCER CELL, V2, P481; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TORELLI G, 1987, CANCER RES, V47, P5266; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	59	91	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668847				2022-12-17	WOS:A1989AJ29700003
J	Yang, Z; Qu, CB; Zhang, Y; Zhang, WF; Wang, DD; Gao, CC; Ma, L; Chen, JS; Liu, KL; Zheng, B; Zhang, XH; Zhang, ML; Wang, XL; Wen, JK; Li, W				Yang, Zhan; Qu, Chang-Bao; Zhang, Yong; Zhang, Wen-Feng; Wang, Dan-Dan; Gao, Chun-Cheng; Ma, Long; Chen, Jin-Suo; Liu, Kai-Long; Zheng, Bin; Zhang, Xin-Hua; Zhang, Man-Li; Wang, Xiao-Lu; Wen, Jin-Kun; Li, Wei			Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULAR RNA; REVEALS; THERAPY; P53; PROTOCADHERINS; METHYLATION; EXPRESSION; ANGIOMOTIN; MIGRATION	p53, circRNAs and miRNAs are important components of the regulatory network that activates the EMT program in cancer metastasis. In prostate cancer (PCa), however, it has not been investigated whether and how p53 regulates EMT by circRNAs and miRNAs. Here we show that a Amotll-derived circRNA, termed circAMOTL1L, is downregulated in human PCa, and that decreased circAMOTL1L facilitates PCa cell migration and invasion through downregulating E-cadherin and upregulating vimentin, thus leading to EMT and PCa progression. Mechanistically, we demonstrate that circAMOTL1L serves as a sponge for binding miR-193a-5p in PCa cells, relieving miR-193a-5p repression of Pcdha gene cluster (a subset of the cadherin superfamily members). Accordingly, dysregulation of the circAMOTL1L-miR-193a-5p-Pcdha8 regulatory pathway mediated by circAMOTL1L downregulation contributes to PCa growth in vivo. Further, we show that RBM25 binds directly to circAMOTL1L and induces its biogenesis, whereas p53 regulates EMT via direct activation of RBM25 gene. These findings have linked p53/RBM25-mediated circAMOTL1L-miR-193a-5p-Pcdha regulatory axis to EMT in metastatic progression of PCa. Targeting this newly identified regulatory axis provides a potential therapeutic strategy for aggressive PCa.	[Yang, Zhan; Qu, Chang-Bao; Zhang, Yong; Zhang, Wen-Feng; Wang, Dan-Dan; Gao, Chun-Cheng; Ma, Long; Chen, Jin-Suo; Liu, Kai-Long; Wang, Xiao-Lu; Li, Wei] Hebei Med Univ, Dept Urol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Yang, Zhan; Zheng, Bin; Zhang, Xin-Hua; Zhang, Man-Li; Wen, Jin-Kun] Hebei Med Univ, Dept Biochem & Mol Biol, Minist Educ China, 361 Zhongshan E Rd, Shijiazhuang 050017, Hebei, Peoples R China; [Yang, Zhan] Hebei Med Univ, Dept Sci & Technol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, Man-Li] Hebei Med Univ, Dept Emergency Med, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China	Hebei Medical University; Hebei Medical University; Ministry of Education, China; Hebei Medical University; Hebei Medical University	Wang, XL; Li, W (corresponding author), Hebei Med Univ, Dept Urol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China.; Wen, JK (corresponding author), Hebei Med Univ, Dept Biochem & Mol Biol, Minist Educ China, 361 Zhongshan E Rd, Shijiazhuang 050017, Hebei, Peoples R China.	wx12106@126.com; wjk@hebmu.edu.cn; Weill_hb2h@163.com	Yang, Zhan/GQG-9995-2022	Yang, Zhan/0000-0001-7191-2910; Wen, Jinkun/0000-0002-8453-4549	National Natural Science Foundation of China [81672555, 81600237]; Hebei Province Natural Science Foundation [H2017206032]; Higher Education Science and Technology Research Project of Hebei Province [BJ2018001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hebei Province Natural Science Foundation(Natural Science Foundation of Hebei Province); Higher Education Science and Technology Research Project of Hebei Province	We thank Dr. Yu-mei Ma (Department of Pathology, The Second Hospital of Hebei Medical University) for scoring PCa histology and pathological analysis. We are grateful to Hao Huang (Leica, China) and Qian Du (Biocaring Biotechnology Co., Ltd, Shijiazhuang) for technical support. This study was partially supported by The National Natural Science Foundation of China (No. 81672555 and 81600237), Hebei Province Natural Science Foundation (H2017206032), and Higher Education Science and Technology Research Project of Hebei Province (No. BJ2018001).	Amini-Nik S, 2014, J CLIN INVEST, V124, P2599, DOI 10.1172/JCI62059; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Banelli B, 2012, LAB INVEST, V92, P458, DOI 10.1038/labinvest.2011.169; Biferi MG, 2017, MOL THER, V25, P2038, DOI 10.1016/j.ymthe.2017.05.017; Carlson SM, 2017, J BIOL CHEM, V292, P13381, DOI 10.1074/jbc.M117.784371; Castellanos JA, 2013, ONCOTARGETS THER, V6, P1261, DOI 10.2147/OTT.S34670; Chen YH, 2016, J MED GENET, V53, P359, DOI 10.1136/jmedgenet-2016-103758; Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159-8290.CD-13-0346; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Dallosso AR, 2012, ONCOGENE, V31, P4409, DOI 10.1038/onc.2011.609; Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Guo F, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-19; Hall MP, 2013, RNA, V19, P627, DOI 10.1261/rna.038422.113; Han MH, 2010, MOL CELL PROTEOMICS, V9, P71, DOI 10.1074/mcp.M900343-MCP200; Han ZW, 2018, CANCER RES, V78, P2550, DOI 10.1158/0008-5472.CAN-17-1575; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katori S, 2009, J NEUROSCI, V29, P9137, DOI 10.1523/JNEUROSCI.5478-08.2009; Keeler AB, 2015, CELL ADHES MIGR, V9, P214, DOI 10.1080/19336918.2014.1000069; Khan MAF, 2016, CIRC RES, V119, P996, DOI 10.1161/CIRCRESAHA.116.309568; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Lee HM, 2017, MOL CELL ENDOCRINOL, V457, P103, DOI 10.1016/j.mce.2016.12.026; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Matsumoto A, 2009, INT J UROL, V16, P687, DOI 10.1111/j.1442-2042.2009.02341.x; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Ortiz A, 2015, FASEB J, V29, P1080, DOI 10.1096/fj.14-261594; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ren D, 2013, INT J ONCOL, V42, P1473, DOI 10.3892/ijo.2013.1825; Sun Y, 2017, CIRC RES, V121, P628, DOI 10.1161/CIRCRESAHA.117.311441; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yang Z, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0649-3; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang GW, 2018, BIOMED PHARMACOTHER, V97, P736, DOI 10.1016/j.biopha.2017.10.163; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zheng YJ, 2009, CIRC RES, V105, P260, DOI 10.1161/CIRCRESAHA.109.195156; Zhou A, 2008, MOL CELL BIOL, V28, P5924, DOI 10.1128/MCB.00560-08; Zou C, 2007, NEUROSCIENCE, V144, P579, DOI 10.1016/j.neuroscience.2006.10.011	54	90	94	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2516	2532		10.1038/s41388-018-0602-8	http://dx.doi.org/10.1038/s41388-018-0602-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531834	Green Published, hybrid			2022-12-17	WOS:000463335200006
J	Qin, Y; Vasilatos, SN; Chen, L; Wu, H; Cao, ZS; Fu, YM; Huang, M; Vlad, AM; Lu, BF; Oesterreich, S; Davidson, NE; Huang, Y				Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Cao, Zhishen; Fu, Yumei; Huang, Min; Vlad, Anda M.; Lu, Binfeng; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi			Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade	ONCOGENE			English	Article							INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; CANCER; LSD1; EXPRESSION; CHEMOKINES; MICROENVIRONMENT; PEMBROLIZUMAB; REEXPRESSION; MPDL3280A	Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.	[Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA; [Qin, Ye; Huang, Min; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Cao, Zhishen; Vlad, Anda M.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Fu, Yumei] Allegheny Gen Hosp Pathol, Pittsburgh, PA USA; [Vlad, Anda M.; Lu, Binfeng] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Davidson, Nancy E.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA; [Davidson, Nancy E.] Univ Washington, Seattle, WA 98195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle	Huang, Y (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA.; Huang, Y (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	yih26@pitt.edu	Huang, Yi/AAW-7892-2021	Huang, Yi/0000-0002-9982-117X; Chen, Lin/0000-0002-8126-3333	US Army Breast Cancer Research Program [W81XWH-14-1-0237, W81XWH-14-1-0238]; Breast Cancer Research Foundation; NIH/NCI [P30CA047904]; Natural Science Foundation of China [81502366]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER	US Army Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by US Army Breast Cancer Research Program (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED/SO), Breast Cancer Research Foundation (to NED and SO), NIH/NCI P30CA047904 and Natural Science Foundation of China (81502366 to YQ).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Akahori T, 2006, TRANSPLANT P, V38, P3366, DOI 10.1016/j.transproceed.2006.10.115; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bhatti S, 2017, JCO PRECIS ONCOL, V1, P1; Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186; Cao CY, 2018, INT J CANCER, V143, P1388, DOI 10.1002/ijc.31419; Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014; Cunnick GH, 2002, HISTOL HISTOPATHOL, V17, P863, DOI 10.14670/HH-17.863; Deken MA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238557; Dirix L, 2016, CANC RES S, V76, pS1; Dong HD, 1999, NAT MED, V5, P1365; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Huang Y, 2012, ROYAL SOC CHEM DRUG, V17, P238; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Janzer A, 2012, J BIOL CHEM, V287, P30984, DOI 10.1074/jbc.M112.341040; Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Muthuswamy R, 2012, CANCER RES, V72, P3735, DOI 10.1158/0008-5472.CAN-11-4136; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Pasculli B, 2018, SEMIN CANCER BIOL, V51, P22, DOI 10.1016/j.semcancer.2018.01.007; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rugo HS, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-S5-07; Sandhu R, 2015, AM J PATHOL, V185, P282, DOI 10.1016/j.ajpath.2014.12.003; Shayan G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1261779; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Solinas C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000255; Terranova-Barberio M, 2017, ONCOTARGET, V8; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033; Wang K, 2017, HUM PATHOL, V69, P110, DOI 10.1016/j.humpath.2017.09.012; Wimberly H, 2015, CANCER IMMUNOL RES, V3, P326, DOI 10.1158/2326-6066.CIR-14-0133; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584	55	90	93	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					390	405		10.1038/s41388-018-0451-5	http://dx.doi.org/10.1038/s41388-018-0451-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30111819	Green Accepted			2022-12-17	WOS:000455851200007
J	Lu, L; Dong, JL; Wang, LL; Xia, Q; Zhang, D; Kim, HJ; Yin, T; Fan, SJ; Shen, Q				Lu, Lu; Dong, Jiali; Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Fan, Saijun; Shen, Qiang			Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide	ONCOGENE			English	Article							HUMAN TUMOR-CELLS; ACQUIRED RADIORESISTANCE; LUNG-CANCER; STEM-CELLS; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; CARCINOMA-CELLS; PATHWAY; GENERATION; MICE	Radiotherapy significantly improves the therapeutic outcomes and survival of breast cancer patients. However, the acquired resistance to this therapeutic modality is a major clinical challenge. Here we show that ionizing irradiation (IR)-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at the Tyr705 residue and the induction of reactive oxygen species (ROS) in wild-type and radioresistant MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) cell lines. Comparing with radiosensitive parental TNBC cells, significantly low levels of ROS and higher protein levels of phospho-STAT3 and Bcl-2 were observed in TNBC cells with acquired radioresistance. Moreover, knockdown of STAT3 by shRNA sensitized the TNBC cells to IR. Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS. In combination with radiation, niclosamide treatment resulted in significant increase of ROS generation and induction of apoptosis in parental and radioresistant TNBC cells in vitro and TNBC xenograft tumors in vivo. These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors. Our findings suggest that niclosamide in combination with irradiation may offer an effective alternative approach for restoring the sensitivity of radioresistant TNBC cells to IR for improved therapeutic efficacy and outcomes.	[Lu, Lu; Dong, Jiali; Fan, Saijun] Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China; [Lu, Lu; Dong, Jiali; Fan, Saijun] Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China; [Wang, Lili] Soochow Univ, Dept Radiat Oncol, Affiliated Hosp 1, Suzhou 215006, Jiangshu, Peoples R China; [Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Shen, Qiang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA; [Xia, Qing] Shanghai Jiao Tong Univ, Dept Oncol, Affiliated Renji Hosp, Sch Med,Pancreat Canc Ctr, Shanghai 200127, Peoples R China; [Zhang, Dan] Shandong Univ Tradit Chinese Med, Coll Basic Med Sci, Jinan 250355, Shandong, Peoples R China; [Yin, Tao] Huazhong Univ Sci & Technol, Pancreat Dis Inst, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Soochow University - China; University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Shandong University of Traditional Chinese Medicine; Huazhong University of Science & Technology	Fan, SJ (corresponding author), Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China.; Fan, SJ (corresponding author), Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China.; Shen, Q (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA.	fansaijun@irm-cams.ac.cn; qshen@mdanderson.org	wang, lili/HDL-7210-2022	Shen, Qiang/0000-0002-1491-5434	National Natural Science Foundation of China [81472495, 81572969, 81172127, 81703169, 81730086]; Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology [2014EG150134]; Tianjin Science and Technology Support Plan Project [14ZCZDSY00001]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-017]; University of Texas M. D. Anderson Cancer Center; Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention; Duncan Family Institute	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology; Tianjin Science and Technology Support Plan Project; CAMS Innovation Fund for Medical Sciences (CIFMS); University of Texas M. D. Anderson Cancer Center; Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention; Duncan Family Institute	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81472495, 81572969, 81172127, 81703169, and 81730086); the Technology and Development and Research Projects for Research Institutes, Chinese Ministry of Science and Technology (2014EG150134); the Tianjin Science and Technology Support Plan Project (14ZCZDSY00001); the CAMS Innovation Fund for Medical Sciences (CIFMS, No. 2016-I2M-1-017); in part by startup funds from The University of Texas M. D. Anderson Cancer Center (to QS); Prevent Cancer Foundation Holden Family Research Grant in Breast Cancer Prevention (to QS); and Seed Funding Research Program of Duncan Family Institute (to QS). We also thank Amy Ninetto, PhD, ELS, Department of Scientific Publications, The University of Texas MD Anderson Cancer Center, for her editing of the manuscript.	Al-Hadiya Badraddin M H, 2005, Profiles Drug Subst Excip Relat Methodol, V32, P67, DOI 10.1016/S0099-5428(05)32002-8; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Arend RC, 2016, ONCOTARGET, V7, P86803, DOI 10.18632/oncotarget.13466; Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Desai S, 2018, BBA-MOL CELL RES, V1865, P196, DOI 10.1016/j.bbamcr.2017.10.006; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dumont FJ, 2012, CURR CANCER DRUG TAR, V12, P899; Fan SJ, 2013, P NATL ACAD SCI USA, V110, P18650, DOI 10.1073/pnas.1308206110; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Han TJ, 2016, J NEURO-ONCOL, V130, P89, DOI 10.1007/s11060-016-2231-9; Hernandez-Aya LF, 2011, J CLIN ONCOL, V29, P2628, DOI 10.1200/JCO.2010.32.1877; Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950; Jin YY, 2018, EXP CELL RES, V362, P362, DOI 10.1016/j.yexcr.2017.11.037; Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465; Kim JS, 2016, ONCOTARGET, V7, P7055, DOI 10.18632/oncotarget.6855; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Li HZ, 2005, CLIN CANCER RES, V11, P5863, DOI 10.1158/1078-0432.CCR-05-0562; Li XX, 2017, BIOMED PHARMACOTHER, V96, P434, DOI 10.1016/j.biopha.2017.09.149; Liu H, 2015, ONCOTARGETS THER, V8, P509, DOI 10.2147/OTT.S76958; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Liu XY, 2012, BIOCHEM PHARMACOL, V83, P1456, DOI 10.1016/j.bcp.2012.02.010; Londono-Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535-7163.MCT-13-0555; Lu L, 2016, FREE RADICAL BIO MED, V99, P463, DOI 10.1016/j.freeradbiomed.2016.09.007; Marmol I, 2017, J INORG BIOCHEM, V176, P123, DOI 10.1016/j.jinorgbio.2017.08.020; Pan JX, 2012, CHIN J CANCER, V31, P178, DOI 10.5732/cjc.011.10290; Peter B, 2018, LEUKEMIA, V32, P1016, DOI 10.1038/leu.2017.338; Ren XM, 2010, ACS MED CHEM LETT, V1, P454, DOI 10.1021/ml100146z; Sato K, 2017, CANCER SCI, V108, P2004, DOI 10.1111/cas.13323; Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238; Shimura T, 2014, RADIOTHER ONCOL, V112, P302, DOI 10.1016/j.radonc.2014.07.015; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tinoco G, 2013, J CANCER, V4, P117, DOI 10.7150/jca.4925; Turaga K, 2010, CANCER CONTROL, V17, P177, DOI 10.1177/107327481001700306; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang LL, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.SABCS14-P6-12-04; Wang TL, 2005, CANCER RES, V65, P10338, DOI 10.1158/0008-5472.CAN-04-4614; Wang X, 2018, CLIN CANCER RES, V24, P858, DOI 10.1158/1078-0432.CCR-17-0345; Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003; Wang Y, 2017, MOL CANCER THER, V16, P578, DOI 10.1158/1535-7163.MCT-16-0606; Wang YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074538; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Ye TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085887; Yeh Jennifer E, 2013, JAKSTAT, V2, pe24635, DOI 10.4161/jkst.24635; You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535-7163.MCT-13-0608; Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329	55	90	91	5	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5292	5304		10.1038/s41388-018-0340-y	http://dx.doi.org/10.1038/s41388-018-0340-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855616				2022-12-17	WOS:000445759700004
J	Noto, A; De Vitis, C; Pisanu, ME; Roscilli, G; Ricci, G; Catizone, A; Sorrentino, G; Chianese, G; Taglialatela-Scafati, O; Trisciuoglio, D; Del Bufalo, D; Di Martile, M; Di Napoli, A; Ruco, L; Costantini, S; Jakopin, Z; Budillon, A; Melino, G; Del Sal, G; Ciliberto, G; Mancini, R				Noto, A.; De Vitis, C.; Pisanu, M. E.; Roscilli, G.; Ricci, G.; Catizone, A.; Sorrentino, G.; Chianese, G.; Taglialatela-Scafati, O.; Trisciuoglio, D.; Del Bufalo, D.; Di Martile, M.; Di Napoli, A.; Ruco, L.; Costantini, S.; Jakopin, Z.; Budillon, A.; Melino, G.; Del Sal, G.; Ciliberto, G.; Mancini, R.			Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ	ONCOGENE			English	Article							CELL-DEATH; HEPATOCELLULAR-CARCINOMA; CENTER STAGE; FATTY-ACIDS; TAZ; EXPRESSION; YAP; PROGRESSION; METABOLISM; EXTRACTION	Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/ TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.	[Noto, A.; De Vitis, C.; Roscilli, G.; Di Napoli, A.; Ruco, L.; Mancini, R.] Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy; [Pisanu, M. E.; Costantini, S.; Budillon, A.; Ciliberto, G.] Fdn G Pascale, Natl Canc Inst, IRCCS, Naples, Italy; [Ricci, G.] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy; [Catizone, A.] Sapienza Univ Rome, Fac Pharm & Med, Dept Anat Histol Forens Med & Orthoped, Sect Histol & Embryol, Rome, Italy; [Sorrentino, G.] Lab Nazl CIB LNCIB, Area Sci Pk, Trieste, Italy; [Chianese, G.; Taglialatela-Scafati, O.] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Trisciuoglio, D.; Del Bufalo, D.; Di Martile, M.] IRCSS Natl Canc Inst Regina Elena, Res Adv Diagnost & Technol Innovat Dept, Preclin Models & New Therapeut Agents Units, Rome, Italy; [Jakopin, Z.] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia; [Melino, G.] Univ Leicester, Toxicol Unit, Med Res Council, Leicester, Leics, England; [Del Sal, G.] Univ Trieste, Dept Sci Vita, Trieste, Italy; [Ciliberto, G.] IRCSS Natl Canc Inst Regina Elena, Via Elio Chianesi 53, I-00144 Rome, Italy	Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Fondazione Pascale; Universita della Campania Vanvitelli; Sapienza University Rome; University of Naples Federico II; University of Ljubljana; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; University of Trieste	Ciliberto, G (corresponding author), IRCSS Natl Canc Inst Regina Elena, Via Elio Chianesi 53, I-00144 Rome, Italy.	gennaro.ciliberto@ifo.gov.it	trisciuoglio, daniela/AAL-4002-2021; Del Bufalo, Donatella/AAC-1594-2021; Di Martile, Marta/K-3348-2018; De Vitis, Claudia/K-4726-2016; Di Napoli, Arianna/AAB-3210-2022; Ciliberto, Gennaro/J-4131-2017; Budillon, Alfredo/K-4763-2016; Pisanu, Maria Elena/AAC-9143-2019; Del Bufalo, Donatella/K-8673-2016; Jakopin, Žiga/B-7089-2019; Trisciuoglio, Daniela/H-2131-2016	Del Bufalo, Donatella/0000-0002-3148-6096; Di Martile, Marta/0000-0001-9924-9022; De Vitis, Claudia/0000-0001-8899-2347; Di Napoli, Arianna/0000-0002-3159-5380; Ciliberto, Gennaro/0000-0003-2851-8605; Budillon, Alfredo/0000-0002-6330-6053; Del Bufalo, Donatella/0000-0002-3148-6096; Jakopin, Žiga/0000-0001-9384-0858; Costantini, Susan/0000-0002-7538-4657; Sorrentino, Giovanni/0000-0001-8628-8778; pisanu, maria elena/0000-0002-0029-3523; Trisciuoglio, Daniela/0000-0002-7007-7914	Italian Association for Cancer Research (AIRC) grant [IG17009, IG15216]; Fondo di Ricerca di Ateneo [C26A142LZ8]; POR FESR Lazio; Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille' [10016]; AIRC IG [17659]; Italian Ministry of Health [RF-2011-02346976]	Italian Association for Cancer Research (AIRC) grant(Fondazione AIRC per la ricerca sul cancro); Fondo di Ricerca di Ateneo; POR FESR Lazio; Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille'(Fondazione AIRC per la ricerca sul cancro); AIRC IG(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	The work was supported by Italian Association for Cancer Research (AIRC) grant IG17009 to RM, and grant IG15216 to GC. Fondo di Ricerca di Ateneo 2014 (C26A142LZ8) and by POR FESR Lazio 2007/2013 to RM. We are grateful to Stefano Piccolo for kindly providing TOP-FLASH reporter plasmid. We acknowledge Claudia Cippittelli for technical support on immunohistochemistry. We acknowledge Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille' (grant no. 10016), AIRC IG (grant no. 17659) and the Italian Ministry of Health (RF-2011-02346976), to GDS.	Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Belkaid A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1452-1; Byagowi S, 2015, CAN J DIABETES, V39, P123, DOI 10.1016/j.jcjd.2014.09.006; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castro LFC, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-132; Chen LiPing, 2016, Journal of Zhejiang A&F University, V33, P1; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Leger S, 2010, BIOORG MED CHEM LETT, V20, P499, DOI 10.1016/j.bmcl.2009.11.111; LEPAGE G, 1984, J LIPID RES, V25, P1391; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Mancini R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021320; Mason P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033823; Mauvoisin D, 2013, CANCER SCI, V104, P36, DOI 10.1111/cas.12032; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Noguchi S, 2014, CLIN CANCER RES, V20, P4660, DOI 10.1158/1078-0432.CCR-13-3328; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Ntambi JM, 1999, J LIPID RES, V40, P1549; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Piccolo S, 2013, CLIN CANCER RES, V19, P4925, DOI 10.1158/1078-0432.CCR-12-3172; Potze L, 2016, ONCOGENE, V35, P427, DOI 10.1038/onc.2015.102; Rappa G, 2013, EXP CELL RES, V319, P810, DOI 10.1016/j.yexcr.2013.01.003; Rios-Esteves J, 2014, J BIOL CHEM, V289, P17009, DOI 10.1074/jbc.M114.561209; Rios-Esteves J, 2013, CELL REP, V4, P1072, DOI 10.1016/j.celrep.2013.08.027; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Roscilli G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0816-x; Santinon G, 2016, TRENDS CELL BIOL, V26, P289, DOI 10.1016/j.tcb.2015.11.004; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Southam AD, 2015, CANCER RES, V75, P2530, DOI 10.1158/0008-5472.CAN-15-0202; Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837; von Roemeling CA, 2015, J CLIN ENDOCR METAB, V100, pE697, DOI 10.1210/jc.2014-2764; von Roemeling CA, 2013, CLIN CANCER RES, V19, P2368, DOI 10.1158/1078-0432.CCR-12-3249; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Yeung B, 2016, INT J CANCER, V138, P533, DOI 10.1002/ijc.29457; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	48	90	94	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4573	4584		10.1038/onc.2017.75	http://dx.doi.org/10.1038/onc.2017.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368399				2022-12-17	WOS:000407246200005
J	Ogino, S; Lochhead, P; Giovannucci, E; Meyerhardt, JA; Fuchs, CS; Chan, AT				Ogino, S.; Lochhead, P.; Giovannucci, E.; Meyerhardt, J. A.; Fuchs, C. S.; Chan, A. T.			Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology	ONCOGENE			English	Review						molecular pathologic epidemiology; systems biology; systems pathology; network medicine; unique tumor principle; translational epidemiology	ISLAND METHYLATOR PHENOTYPE; III COLON-CANCER; BODY-MASS INDEX; KRAS-MUTATION; PHYSICAL-ACTIVITY; MICROSATELLITE INSTABILITY; POOR SURVIVAL; LIFE-STYLE; PROVOCATIVE QUESTIONS; ADJUVANT THERAPY	Regular use of aspirin reduces incidence and mortality of various cancers, including colorectal cancer. Anticancer effect of aspirin represents one of the 'Provocative Questions' in cancer research. Experimental and clinical studies support a carcinogenic role for PTGS2 (cyclooxygenase-2), which is an important enzymatic mediator of inflammation, and a target of aspirin. Recent 'molecular pathological epidemiology' (MPE) research has shown that aspirin use is associated with better prognosis and clinical outcome in PIK3CA-mutated colorectal carcinoma, suggesting somatic PIK3CA mutation as a molecular biomarker that predicts response to aspirin therapy. The PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase) enzyme has a pivotal role in the PI3K-AKT signaling pathway. Activating PIK3CA oncogene mutations are observed in various malignancies including breast cancer, ovarian cancer, brain tumor, hepatocellular carcinoma, lung cancer and colon cancer. The prevalence of PIK3CA mutations increases continuously from rectal to cecal cancers, supporting the 'colorectal continuum' paradigm, and an important interplay of gut microbiota and host immune/inflammatory reaction. MPE represents an interdisciplinary integrative science, conceptually defined as 'epidemiology of molecular heterogeneity of disease'. As exposome and interactome vary from person to person and influence disease process, each disease process is unique (the unique disease principle). Therefore, MPE concept and paradigm can extend to non-neoplastic diseases including diabetes mellitus, cardiovascular diseases, metabolic diseases, and so on. MPE research opportunities are currently limited by paucity of tumor molecular data in the existing large-scale population-based studies. However, genomic, epigenomic and molecular pathology testings (for example, analyses for microsatellite instability, MLH1 promoter CpG island methylation, and KRAS and BRAF mutations in colorectal tumors) are becoming routine clinical practices. In order for integrative molecular and population science to be routine practice, we must first reform education curricula by integrating both population and molecular biological sciences. As consequences, next-generation hybrid molecular biological and population scientists can advance science, moving closer to personalized precision medicine and health care.	[Ogino, S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ogino, S.; Meyerhardt, J. A.; Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Ogino, S.; Giovannucci, E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Lochhead, P.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland; [Giovannucci, E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Giovannucci, E.; Fuchs, C. S.; Chan, A. T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA; [Chan, A. T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Aberdeen; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Ogino, S (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room M422, Boston, MA 02215 USA.	shuji_ogino@dfci.harvard.edu			USA National Institute of Health (NIH) [R01 CA151993, R01 CA137178, P50 CA127003, R01 CA124908, P01 CA87969, UM1 CA167552]; NATIONAL CANCER INSTITUTE [R01CA169141, R01CA151993, R01CA137178, P01CA087969, R01CA124908, P50CA127003, UM1CA167552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK098311] Funding Source: NIH RePORTER; Chief Scientist Office [CAF/10/15] Funding Source: researchfish	USA National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Chief Scientist Office	This work was supported by grants from the USA National Institute of Health (NIH) (R01 CA151993 (to SO), R01 CA137178 (to ATC), P50 CA127003 (to CSF), R01 CA124908 (to CSF), P01 CA87969 (to SEH) and UM1 CA167552 to WCW). ATC is a Damon Runyon Clinical Investigator.	Abubaker J, 2008, ONCOGENE, V27, P3539, DOI 10.1038/sj.onc.1211013; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Baba Y, 2011, CANCER-AM CANCER SOC, V117, P1399, DOI 10.1002/cncr.25630; Baba Y, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-125; Bae JM, 2013, HISTOL HISTOPATHOL, V28, P585, DOI 10.14670/HH-28.585; Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936; Bastiaannet E, 2012, BRIT J CANCER, V106, P1564, DOI 10.1038/bjc.2012.101; Begg CB, 2012, AM J EPIDEMIOL, V176, P512, DOI 10.1093/aje/kws128; Begg CB, 2011, INT J CANCER, V129, P931, DOI 10.1002/ijc.25714; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Benamouzig R, 2012, GUT, V61, P255, DOI 10.1136/gutjnl-2011-300113; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Boyle T, 2011, AM J EPIDEMIOL, V173, P1183, DOI 10.1093/aje/kwq513; Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316; Buchanan DD, 2013, CANCER EPIDEM BIOMAR, V22, P917, DOI 10.1158/1055-9965.EPI-12-1211; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Burnett-Hartman AN, 2013, CANCER RES, V73, P2863, DOI 10.1158/0008-5472.CAN-12-3462; Burnett-Hartman AN, 2013, AM J EPIDEMIOL, V177, P625, DOI 10.1093/aje/kws282; Campbell PT, 2013, J CLIN ONCOL, V31, P876, DOI 10.1200/JCO.2012.45.9735; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Chen CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055793; Chia WK, 2012, NAT REV CLIN ONCOL, V9, P561, DOI 10.1038/nrclinonc.2012.137; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Coghill AE, 2011, GUT, V60, P491, DOI 10.1136/gut.2010.221143; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; Colditz GA, 2010, CANCER CAUSE CONTROL, V21, P649, DOI 10.1007/s10552-009-9498-5; Curtin Karen, 2011, Patholog Res Int, V2011, P902674, DOI 10.4061/2011/902674; Dahlin AM, 2011, MODERN PATHOL, V24, P671, DOI 10.1038/modpathol.2010.234; Dahlin AM, 2010, CLIN CANCER RES, V16, P1845, DOI 10.1158/1078-0432.CCR-09-2594; Damania D, 2012, CANCER RES, V72, P2720, DOI 10.1158/0008-5472.CAN-11-3807; Day FL, CLIN CANCER RES, DOI [10.1158/1078-0432.CCR-1112-3614, DOI 10.1158/1078-0432.CCR-1112-3614]; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Deming DA, 2014, ONCOGENE, V33, P2245, DOI 10.1038/onc.2013.167; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Dube C, 2007, ANN INTERN MED, V146, P365, DOI 10.7326/0003-4819-146-5-200703060-00009; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; Eklof V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212; Estecio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399; Farina-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258; Febbo PG, 2011, J NATL COMPR CANC NE, V9, pS1, DOI 10.6004/jnccn.2011.0137; Fernandez AF, 2010, ONCOGENE, V29, P1405, DOI 10.1038/onc.2009.517; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Funkhouser WK, 2012, J MOL DIAGN, V14, P91, DOI 10.1016/j.jmoldx.2011.11.001; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Garcia-Solano J, 2012, INT J CANCER, V131, P1790, DOI 10.1002/ijc.27454; Garrido-Laguna I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038033; Gavin PG, 2012, CLIN CANCER RES, V18, P6531, DOI 10.1158/1078-0432.CCR-12-0605; Gay LJ, 2012, J PATHOL, V228, P405, DOI 10.1002/path.4085; Ghosh S, 2011, NAT REV GENET, V12, P821, DOI 10.1038/nrg3096; Goel A, 2012, GASTROENTEROLOGY, V143, P1442, DOI 10.1053/j.gastro.2012.09.032; Greystoke A, 2012, GASTROENT RES PRACT, V2012; He YJ, 2009, CLIN CANCER RES, V15, P6956, DOI 10.1158/1078-0432.CCR-09-1165; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Hsieh LL, 2012, CLIN CHIM ACTA, V413, P1605, DOI 10.1016/j.cca.2012.04.029; Hughes LAE, 2012, INT J EPIDEMIOL, V41, P1060, DOI 10.1093/ije/dys055; Hughes LAE, 2012, BBA-REV CANCER, V1825, P77, DOI 10.1016/j.bbcan.2011.10.005; Hughes LAE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018571; Iida S, 2012, ONCOL LETT, V3, P565, DOI 10.3892/ol.2011.544; Imamura Y, 2012, CLIN CANCER RES, V18, P4753, DOI 10.1158/1078-0432.CCR-11-3210; Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769; Jehan Z, 2009, J PATHOL, V219, P337, DOI 10.1002/path.2601; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Kamiyama H, 2012, ONCOGENE, V31, P5029, DOI 10.1038/onc.2011.652; Kato S, 2007, INT J CANCER, V121, P1771, DOI 10.1002/ijc.22890; Kaur J, 2010, TUMOR BIOL, V31, P623, DOI 10.1007/s13277-010-0078-9; Kelley RK, 2011, J NATL COMPR CANC NE, V9, P1293, DOI 10.6004/jnccn.2011.0105; Khoury MJ, 2013, CANCER EPIDEM BIOMAR, V22, P508, DOI 10.1158/1055-9965.EPI-13-0146; Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8; Koshiol J, 2012, ANN EPIDEMIOL, V22, P520, DOI 10.1016/j.annepidem.2012.03.001; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Ku CS, 2012, MODERN PATHOL, V25, P1055, DOI 10.1038/modpathol.2012.62; Kuller LH, 2012, AM J EPIDEMIOL, V176, P668, DOI 10.1093/aje/kws227; Kure S, 2009, CANCER EPIDEM BIOMAR, V18, P2765, DOI 10.1158/1055-9965.EPI-09-0490; Lam TK, 2013, CANCER EPIDEM BIOMAR, V22, P496, DOI 10.1158/1055-9965.EPI-13-0101; Lam TK, 2013, CANCER EPIDEM BIOMAR, V22, P181, DOI 10.1158/1055-9965.EPI-12-1262; Langley RE, 2013, NAT REV CLIN ONCOL, V10, P8, DOI 10.1038/nrclinonc.2012.216; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410; Lievre A, 2010, ONCOGENE, V29, P3033, DOI 10.1038/onc.2010.89; Limburg PJ, 2012, CANCER EPIDEM BIOMAR, V21, P681, DOI 10.1158/1055-9965.EPI-11-1168; Markowitz SD, 2007, NEW ENGL J MED, V356, P2195, DOI 10.1056/NEJMe078044; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McCowan C, 2013, EUR J CANCER, V49, P1049, DOI 10.1016/j.ejca.2012.10.024; McFarland CD, 2013, P NATL ACAD SCI USA, V110, P2910, DOI 10.1073/pnas.1213968110; Miyaki M, 2007, INT J CANCER, V121, P1627, DOI 10.1002/ijc.22829; Monzon FA, 2009, ARCH PATHOL LAB MED, V133, P1600, DOI 10.1043/1543-2165-133.10.1600; Morikawa T, 2011, JAMA-J AM MED ASSOC, V305, P1685, DOI 10.1001/jama.2011.513; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Neugut AI, 2009, JAMA-J AM MED ASSOC, V302, P688, DOI 10.1001/jama.2009.1145; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774; Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082; Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214; Ogino S, 2012, AM J EPIDEMIOL, V176, P659, DOI 10.1093/aje/kws226; Ogino S, 2012, AM J EPIDEMIOL, V176, P672, DOI 10.1093/aje/kws229; Ogino S, 2012, EXPERT REV MOL DIAGN, V12, P621, DOI [10.1586/ERM.12.46, 10.1586/erm.12.46]; Ogino S, 2011, NAT REV CLIN ONCOL, V8, P711, DOI 10.1038/nrclinonc.2011.122; Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182; Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031; Ogino S, 2008, J CLIN ONCOL, V26, P5713, DOI 10.1200/JCO.2009.22.8858; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Pasche B, 2012, NEW ENGL J MED, V367, P1650, DOI 10.1056/NEJMe1210322; Pelucchi C, 2011, ANN ONCOL, V22, P1487, DOI 10.1093/annonc/mdq610; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Phipps AI, 2013, INT J COLORECTAL DIS, DOI [10.1007/s00384-00013-01715-00388, DOI 10.1007/S00384-00013-01715-00388]; Phipps AI, 2013, J CLIN ONCOL, V31, P2016, DOI 10.1200/JCO.2012.46.2457; Phipps AI, 2012, CANCER EPIDEM BIOMAR, V21, P1792, DOI 10.1158/1055-9965.EPI-12-0674; Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Rosty C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065479; Rosty C, 2013, MODERN PATHOL, V26, P825, DOI 10.1038/modpathol.2012.240; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanchez JA, 2009, BRIT J SURG, V96, P1196, DOI 10.1002/bjs.6683; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Sepulveda Antonia R, 2009, J Mol Diagn, V11, P266, DOI 10.2353/jmoldx.2009.080125; Shanmuganathan R, 2013, J MOL DIAGN, V15, P17, DOI 10.1016/j.jmoldx.2012.06.007; Sharp PA, 2011, SCIENCE, V333, P527, DOI 10.1126/science.1205008; Sidler D, 2011, ONCOGENE, V30, P2411, DOI 10.1038/onc.2010.629; Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164; Spitz MR, 2012, CANCER DISCOV, V2, P1087, DOI 10.1158/2159-8290.CD-12-0424; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022; Tian S, 2013, GUT, V62, P540, DOI 10.1136/gutjnl-2012-302423; Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819; Tol J, 2010, EUR J CANCER, V46, P1997, DOI 10.1016/j.ejca.2010.03.036; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uddin S, 2010, INT J CANCER, V126, P382, DOI 10.1002/ijc.24757; Varmus H, 2012, NATURE, V481, P436, DOI 10.1038/481436a; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Voutsina A, 2013, MODERN PATHOL, V26, P302, DOI 10.1038/modpathol.2012.150; Vrieling A, 2010, AM J CLIN NUTR, V92, P471, DOI [10.3945/ajcn.2009.29005, 10.3945/ajcn.2010.29005]; Waldron L, 2012, CLIN CANCER RES, V18, P6136, DOI 10.1158/1078-0432.CCR-12-1915; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang Dingzhi, 2011, Cancers (Basel), V3, P3894, DOI 10.3390/cancers3043894; Weijenberg Matty P, 2013, Curr Nutr Rep, V2, P19; Whitehall VLJ, 2012, INT J CANCER, V131, P813, DOI 10.1002/ijc.26440; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Worthley DL, 2010, ONCOGENE, V29, P1653, DOI 10.1038/onc.2009.449; Wu SJ, 2013, J CANCER RES CLIN, V139, P891, DOI 10.1007/s00432-013-1400-x; Wuchty S, 2007, SCIENCE, V316, P1036, DOI 10.1126/science.1136099; Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608; Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111; Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007; Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yang Q, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2209; Zell JA, 2009, CANCER-AM CANCER SOC, V115, P5662, DOI 10.1002/cncr.24705; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zlobec I, 2011, J PATHOL, V225, P336, DOI 10.1002/path.2879; Zlobec I, 2010, INT J CANCER, V127, P367, DOI 10.1002/ijc.25042	169	90	95	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2949	2955		10.1038/onc.2013.244	http://dx.doi.org/10.1038/onc.2013.244			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23792451	Green Accepted			2022-12-17	WOS:000337232200001
J	Bianchi-Smiraglia, A; Paesante, S; Bakin, AV				Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.			Integrin beta 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways	ONCOGENE			English	Article						integrin; focal adhesion kinase (FAK); extracellular signal-regulated kinase (ERK); anchorage-independent growth; transforming growth factor beta (TGF-beta)	FOCAL-ADHESION KINASE; GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; REGULATED KINASE; PHOSPHORYLATION; ALPHA-V-BETA-5; EXPRESSION; MATRIX-METALLOPROTEINASE-9; TYROSINE-861; MIGRATION	Cancer progression, response to therapy and metastasis depend on tumor microenvironment. Integrins are cell-adhesion receptors that mediate interactions of cells with extracellular matrix. The alpha v-beta-family of integrins contributes to tumorigenesis, response to therapy and cancer stem cell biology. Thus, understanding the function of specific integrins in cancer is critical for the development of therapeutic approaches targeting integrins. The study investigated the role of integrin beta 5 in breast carcinomas by depleting integrin b5 using RNA interference and reexpression of integrin beta 5. Depletion of integrin b5 in triple-negative breast carcinoma cells markedly reduced tumor take, growth and tumor angiogenesis, whereas reexpression of integrin b5 rescued this phenotype. Reduction in tumor angiogenesis is associated with lower expression of vascular endothelial growth factor-A in integrin beta 5-depleted tumors. Tumor cells deficient in integrin beta 5 have lower migration and proliferative capacities. Biochemical assays revealed that integrin beta 5 mediates the Src-focal adhesion kinase and MEK-extracellular signal-regulated kinase signaling events that operate independently, and inhibition of these pathways phenocopies integrin beta 5 deficiency. Breast carcinoma cells express high levels of integrin beta 5, whereas expression of integrin beta 3 is limited to stromal compartments and integrin beta 6 is lost in metastatic cells. Together, these findings show a critical role for integrin beta 5 in the tumorigenic potential of breast carcinoma cells and therapeutic targeting of integrin beta 5 is especially attractive for triple-negative breast carcinomas, which are refractory to most of the current therapies.	[Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm Carlton St, Buffalo, NY 14263 USA.	Andrei.Bakin@RoswellPark.org		Bianchi-Smiraglia, Anna/0000-0002-5963-103X; Bakin, Andrei/0000-0002-7728-1969	NYSDOH-HSRB Peter T Rowley Breast Cancer Project; RPCI Cancer Center Support Grant [CA 16056]; NATIONAL CANCER INSTITUTE [R01CA095263, P30CA016056] Funding Source: NIH RePORTER	NYSDOH-HSRB Peter T Rowley Breast Cancer Project; RPCI Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NYSDOH-HSRB Peter T Rowley Breast Cancer Project and in part by RPCI Cancer Center Support Grant CA 16056. We thank Dr Irwin Gelman for his helpful discussion of the manuscript, Drs Raymond Birge, Jianmin Zhang and Yahao Bu for providing reagents and Drs Kitty De Jong and Janice Hoffmann (RPCI flow cytometry facility) for their technical help.	Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Alvarez RH, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2572; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bianchi A, 2010, CELL CYCLE, V9, P1647, DOI 10.4161/cc.9.8.11517; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Colombo PE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2890; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frey RS, 1997, CANCER RES, V57, P628; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Ishigaki T, 2011, J CELL PHYSIOL, V226, P2617, DOI 10.1002/jcp.22614; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Maubant S, 2002, INT J CANCER, V97, P186, DOI 10.1002/ijc.1600; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Monferran S, 2008, INT J CANCER, V123, P357, DOI 10.1002/ijc.23498; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Ogata H, 2001, CANCER LETT, V172, P159, DOI 10.1016/S0304-3835(01)00648-6; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneider BP, 2007, NAT CLIN PRACT ONCOL, V4, P181, DOI 10.1038/ncponc0740; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yom CK, 2011, BREAST CANCER RES TR, V128, P647, DOI 10.1007/s10549-010-1150-2; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	47	90	96	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3049	3058		10.1038/onc.2012.320	http://dx.doi.org/10.1038/onc.2012.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824793	Green Accepted, Green Submitted			2022-12-17	WOS:000320705700005
J	Pyonteck, SM; Gadea, BB; Wang, HW; Gocheva, V; Hunter, KE; Tang, LH; Joyce, JA				Pyonteck, S. M.; Gadea, B. B.; Wang, H-W; Gocheva, V.; Hunter, K. E.; Tang, L. H.; Joyce, J. A.			Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development	ONCOGENE			English	Article						cancer; tumor-associated macrophage; tumor microenvironment; human PNET; myeloid cell	COLONY-STIMULATING FACTOR-1; MOUSE MODEL; ANGIOGENIC SWITCH; SURVIVAL BENEFIT; RECEPTOR; PROGRESSION; MICE; INFLAMMATION; RESPONSES	Tumor-associated macrophages have recently emerged as a key regulatory cell type during cancer progression, and have been found to promote tumor malignancy in the majority of studies performed to date. We show in this study that CD68(+) macrophages positively correlate with tumor grade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs). To investigate the potential mechanisms whereby macrophages can promote PNET progression, we crossed the RIP1-Tag2 (RT2) mouse model of pancreatic islet cancer to colony-stimulating factor-1 (CSF-1)-deficient Csf1(op/op) mice, which have reduced numbers of tissue macrophages. Csf1(op/op) RT2 mice had a substantial reduction in cumulative tumor burden, which interestingly resulted from a significant decrease in angiogenic switching and tumor number, rather than an evident effect on tumor growth. In the tumors that did develop in CSF-1-deficient animals, however, there were no significant differences in tumor cell proliferation, apoptosis, angiogenesis or invasion. CSF-1 deficiency decreased macrophage infiltration by approximately 50% during all stages of RT2 tumor progression. Interestingly, several cytokines were upregulated in CSF-1-deficient RT2 tumors, and neutrophil infiltration was increased. These results show that macrophages are important for promoting PNET development and suggest that additional factors contribute to the recruitment and survival of myeloid cells in RT2 tumors in the absence of CSF-1. Oncogene (2012) 31, 1459-1467; doi:10.1038/onc.2011.337; published online 8 August 2011	[Pyonteck, S. M.; Gadea, B. B.; Wang, H-W; Gocheva, V.; Hunter, K. E.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Tang, L. H.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Pyonteck, S. M.; Wang, H-W; Gocheva, V.] Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10065 USA.	joycej@mskcc.org		Pyonteck, Stephanie/0000-0002-4143-0969	National Cancer Institute TMEN [NIH U54-CA126518]; NCI [CA125162]; Geoffrey Beene Foundation; NIH; American Cancer Society; Frank L. Horsfall Fellowship; Geoffrey Beene Fellowship; NATIONAL CANCER INSTITUTE [U54CA126518, R01CA125162] Funding Source: NIH RePORTER	National Cancer Institute TMEN; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Geoffrey Beene Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Frank L. Horsfall Fellowship; Geoffrey Beene Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Xiaoping Chen and Kenishana Simpson for excellent technical assistance; Dr Jeffrey Pollard, Albert Einstein College of Medicine for the Csf1<SUP>op</SUP> pyrosequencing protocol; Drs Jan Hendrikx and Jennifer Wilshire, MSKCC Flow Cytometry Core Facility for assistance with flow cytometric sorting; Drs Agnes Viale, Juan Li, Magali Cavatore, Liliana Villafania, MSKCC Genomics Core Facility for assistance with RT-PCR and pyrosequencing; Drs Guangli Li and Ouathek Ouerfelli, MSKCC Organic Synthesis Core Facility for synthesis of the Cy3B-Cathepsin-ABP; and Elyn Reidel, MSKCC Epidemiology and Biostatistics Department, for statistical analysis of tumor size distribution. This research was supported by the following: National Cancer Institute TMEN Grant (NIH U54-CA126518), NCI R01 (CA125162), and the Geoffrey Beene Foundation (JAJ); NIH T32 Training Fellowship (SMP); American Cancer Society Postdoctoral Fellowship (BBG); Frank L. Horsfall Fellowship (HWW, VG); and Geoffrey Beene Fellowship (VG).	Abboud SL, 2002, ENDOCRINOLOGY, V143, P1942, DOI 10.1210/en.143.5.1942; Banaei-Bouchareb L, 2004, J LEUKOCYTE BIOL, V76, P359, DOI 10.1189/jlb.1103591; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006; Chiu CW, 2010, J CLIN ONCOL, V28, P4425, DOI 10.1200/JCO.2010.28.0198; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Gocheva V, 2010, BIOL CHEM, V391, P937, DOI 10.1515/BC.2010.080; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Greenbaum D, 2002, MOL CELL PROTEOMICS, V1, P60, DOI 10.1074/mcp.T100003-MCP200; Halfdanarson TR, 2008, ENDOCR-RELAT CANCER, V15, P409, DOI 10.1677/ERC-07-0221; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hu Wenwei, 2010, Genes Cancer, V1, P360; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kohler C, 2007, CELL TISSUE RES, V330, P291, DOI 10.1007/s00441-007-0474-7; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; MacDonald KPA, 2010, BLOOD, V116, P3955, DOI 10.1182/blood-2010-02-266296; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reidy DL, 2009, NAT CLIN PRACT ONCOL, V6, P143, DOI 10.1038/ncponc1326; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Steiner GE, 2000, J IMMUNOL METHODS, V237, P39, DOI 10.1016/S0022-1759(99)00240-9; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Wei SW, 2010, J LEUKOCYTE BIOL, V88, P495, DOI 10.1189/jlb.1209822; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	41	90	96	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1459	1467		10.1038/onc.2011.337	http://dx.doi.org/10.1038/onc.2011.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822305				2022-12-17	WOS:000301780000012
J	Oka, T; Schmitt, AP; Sudol, M				Oka, T.; Schmitt, A. P.; Sudol, M.			Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP	ONCOGENE			English	Article						angiomotin family; WW domains; PDZ domains; YAP as scaffold; cell detachment; apoptosis	YES-ASSOCIATED PROTEIN; HIPPO SIGNALING PATHWAY; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; JUNCTIONS; COMPONENT; FAMILY; MST2	YAP (Yes-associated protein) oncogene has been found to form a stable complex with members of the Angiomotin (Amot) family of proteins, which bind WW domains of YAP and sequester the protein in the cytoplasm and junctional complexes. The Amot-mediated retention of YAP in the cytoplasm results in the inhibition of its proliferative function. Using apoptotic 'read-out' of YAP in HEK293 cells, we confirmed the molecular mode by which Amot regulates YAP. We showed that a representative member of the Amot family, AmotL1 (Angiomotin-like-1), uses its PPxY motifs to bind WW domains of YAP and inhibit YAP's nuclear translocation and pro-apoptotic function. Recently we also showed that YAP uses its PDZ-binding motif to interact with zona occludens-2 (ZO-2) protein, which promotes YAP's translocation to the nucleus. We also asked if AmotL1, YAP and ZO-2 signal together. We report here that AmotL1 and ZO-2 form a tripartite complex with YAP and regulate its function in HEK293 cells in opposite directions. AmotL1 inhibits proapoptotic function of YAP, whereas ZO-2 enhances it. As YAP is a potent oncogene, the identification and characterization of its regulators is important. AmotL1 and ZO-2 are two candidates that could be harnessed to control the oncogenic function of YAP. Oncogene (2012) 31, 128-134; doi: 10.1038/onc.2011.216; published online 20 June 2011	[Oka, T.; Sudol, M.] Geisinger Med Clin, Weis Ctr Res, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Schmitt, A. P.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	Geisinger Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Geisinger Med Clin, Weis Ctr Res, Lab Signal Transduct & Prote Profiling, 100 N Acad Ave, Danville, PA 17822 USA.	msudol1@geisinger.edu		Schmitt, Anthony/0000-0001-9272-058X	PA Breast Cancer Coalition grants [60707, 9200903]; Geisinger Clinic	PA Breast Cancer Coalition grants; Geisinger Clinic	This research was supported by PA Breast Cancer Coalition grants(#60707 and #9200903) and by Geisinger Clinic.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Nishimura M, 2002, J BIOL CHEM, V277, P5583, DOI 10.1074/jbc.M110154200; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Oka T, 2009, GENES CELLS, V14, P607, DOI 10.1111/j.1365-2443.2009.01292.x; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pei ZF, 2010, VIROLOGY, V397, P155, DOI 10.1016/j.virol.2009.11.002; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sudol Marius, 2010, Genes Cancer, V1, P1115, DOI 10.1177/1947601911401911; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; Sugihara-Mizuno Y, 2007, GENES CELLS, V12, P473, DOI 10.1111/j.1365-2443.2007.01066.x; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	23	90	92	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					128	134		10.1038/onc.2011.216	http://dx.doi.org/10.1038/onc.2011.216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21685940				2022-12-17	WOS:000299176200012
J	Lau, MT; Klausen, C; Leung, PCK				Lau, M-T; Klausen, C.; Leung, P. C. K.			E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression	ONCOGENE			English	Article						E-cadherin; PTEN; PI3K/Akt; beta-catenin; ovarian cancer	GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; OVARIAN-CANCER; PHOSPHATASE-ACTIVITY; CARCINOMA-CELLS; FACTOR RECEPTOR; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; INCREASES SENSITIVITY	E-cadherin is a cell-cell adhesion protein and tumor suppressor that is silenced in many malignancies. E-cadherin is thought to suppress tumor cell growth by antagonizing beta-catenin signaling. However, the role of E-cadherin in ovarian cancer progression is still controversial. In this study, we showed that loss of E-cadherin induced ovarian cancer cell growth and constitutive activation of phosphoinositide 3-kinase (PI3K)/Akt signaling by the inhibition of phosphatase and tensin homolog (PTEN) transcription through the downregulation of early growth response gene 1 (Egr1). In addition, immunofluorescence microscopy and T-cell factor promoter/luciferase reporter assays showed that E-cadherin loss was associated with enhanced nuclear beta-catenin signaling. Constitutive activation of PI3K/Akt signaling reinforced nuclear beta-catenin signaling by inactivating glycogen synthase kinase-3 beta indicating cross-talk between the PI3K/Akt and beta-catenin signaling pathways. Finally, we found that E-cadherin negatively regulates tumor cell growth, in part, by positively regulating PTEN expression via beta-catenin-mediated Egr1 regulation, thus influencing PI3K/Akt signaling. In summary, endogenous E-cadherin inhibits PI3K/Akt signaling by antagonizing beta-catenin-Egr1-mediated repression of PTEN expression. Thus, the loss of E-cadherin itself may contribute to dysregulated PI3K/Akt signaling through its effects on PTEN, or it may exacerbate the frequent activation of PI3K/Akt signaling that occurs as a result of overexpression, mutation and/or amplification. Oncogene (2011) 30, 2753-2766; doi: 10.1038/onc.2011.6; published online 7 February 2011	[Lau, M-T; Klausen, C.; Leung, P. C. K.] Univ British Columbia, Dept Obstet Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3N1, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet Gynecol, Child & Family Res Inst, 2H30,4490 Oak St, Vancouver, BC V6H 3N1, Canada.	peleung@interchange.ubc.ca		Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; Interdisciplinary Women's Reproductive Health Research Training Program	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Interdisciplinary Women's Reproductive Health Research Training Program	We thank Dr H Clevers (University Hospital, the Netherlands), Dr E Fearon (University of Michigan School of Medicine, Detroit, MI, USA), Dr A Passaniti (University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA), Dr AH Ross (University of Massachusetts Medical School, Worcester, MA, USA), Dr V Stambolic (Ontario Cancer Institute, Toronto, Ontario, Canada), Dr RA Weinberg (Massachusetts Institute of Technology, Cambridge, MA, USA) and Dr J Woodgett (Ontario Cancer Institute) for kindly and generously giving us the constructs. This work was supported by the Canadian Institutes of Health Research (PCKL). PCKL is recipient of a Distinguished Scientist Award from the Child and Family Research Institute and MTL is the recipient of a Graduate Studentship Award from the Interdisciplinary Women's Reproductive Health Research Training Program.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Black PC, 2008, CLIN CANCER RES, V14, P1478, DOI 10.1158/1078-0432.CCR-07-1593; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Fournier MV, 2009, CANCER RES, V69, P4545, DOI 10.1158/0008-5472.CAN-08-1694; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Furnari FB, 1998, CANCER RES, V58, P5002; Geiger B, 1995, ACTA ANAT, V154, P46; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hu YL, 2007, ARCH BIOCHEM BIOPHYS, V467, P1, DOI 10.1016/j.abb.2007.07.027; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li ZX, 2007, BIOCHEM BIOPH RES CO, V363, P165, DOI 10.1016/j.bbrc.2007.08.154; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maher MT, 2009, J CELL BIOL, V186, P219, DOI 10.1083/jcb.200811108; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reddy P, 2005, MOL ENDOCRINOL, V19, P2564, DOI 10.1210/me.2004-0342; Sasaki CY, 2000, INT J CANCER, V86, P660, DOI 10.1002/(SICI)1097-0215(20000601)86:5<660::AID-IJC9>3.0.CO;2-X; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Woenckhaus J, 2007, VIRCHOWS ARCH, V450, P387, DOI 10.1007/s00428-006-0358-3; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wu C, 2008, DIFFERENTIATION, V76, P193, DOI 10.1111/j.1432-0436.2007.00193.x; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; Yagi T, 2000, GENE DEV, V14, P1169; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Yu YC, 2006, CLIN EXP METASTAS, V23, P65, DOI 10.1007/s10585-006-9020-3	58	90	100	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2753	2766		10.1038/onc.2011.6	http://dx.doi.org/10.1038/onc.2011.6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21297666				2022-12-17	WOS:000291678500006
J	Li, P; Wang, D; Yao, H; Doret, P; Hao, G; Shen, Q; Qiu, H; Zhang, X; Wang, Y; Chen, G; Wang, Y				Li, P.; Wang, D.; Yao, H.; Doret, P.; Hao, G.; Shen, Q.; Qiu, H.; Zhang, X.; Wang, Y.; Chen, G.; Wang, Y.			Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression	ONCOGENE			English	Article						histone citrullination; histone deacetylation; PAD4; HDAC2; p53	TRANSCRIPTIONAL REGULATION; CHROMATIN MODIFICATIONS; ARGININE METHYLATION; STRUCTURAL BASIS; HISTONE; P53; ACTIVATION; ACETYLATION; NUCLEOSOME; REPRESSION	Histone Arg methylation and Lys acetylation have been found to cooperatively regulate the expression of p53-target genes. Peptidylarginine deiminase 4 (PAD4) is an enzyme that citrullinates histone arginine and monomethyl-arginine residues thereby regulating histone Arg methylation. We have recently found that PAD4 serves as a p53 corepressor to regulate histone Arg methylation at the p53-target gene p21/WAF1/CIP1 promoter. However, it has not been tested whether histone Arg citrullination coordinates with other histone modifications to repress transcription. Here, we show that histone deacetylase (HDAC2) and PAD4 interact with p53 through distinct domains and simultaneously associate with the p21 promoter to regulate gene expression. After DNA damage, PAD4 and HDAC2 dissociate from several p53-target gene promoters (for example, p21, GADD45, and PUMA) with a concomitant increase in histone Lys acetylation and Arg methylation at these promoters. Furthermore, PAD4 promoter association and histone Arg modifications are regulated by p53 and HDAC activity. In contrast, HDAC2 promoter association and histone Lys acetylation are affected by p53 and PAD4 activity at minor degrees. Importantly, PAD4 inhibitor Cl-amidine and HDAC inhibitor suberoylanilide hydroxamic acid show additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner. Our results unveil an important crosstalk between histone deacetylation and citrullination, suggesting that a combination of PAD4 and HDAC2 inhibitors as a potential strategy for cancer treatment. Oncogene (2010) 29, 3153-3162; doi: 10.1038/onc.2010.51; published online 1 March 2010	[Li, P.; Wang, D.; Yao, H.; Doret, P.; Shen, Q.; Wang, Y.] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, 454 N Frear, University Pk, PA 16802 USA; [Hao, G.] Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; [Qiu, H.; Wang, Y.] Univ Calif Riverside, Dept Chem 027, Riverside, CA 92521 USA; [Zhang, X.] Univ S Florida, Coll Med, Dept Pathol & Cell Biol, Tampa, FL USA; [Chen, G.] Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cornell University; University of California System; University of California Riverside; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wang, Y (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, 454 N Frear, University Pk, PA 16802 USA.	yuw12@psu.edu	Chen, Gong/A-8063-2013	Chen, Gong/0000-0002-5067-9889; Wang, Yanming/0000-0002-0710-043X	PSU; NIH [R01 CA136856, R01 CA116522]; NATIONAL CANCER INSTITUTE [R01CA136856, R01CA116522] Funding Source: NIH RePORTER	PSU; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs JC Reese, DS Gilmour, BF Pugh, and S Tan for discussions and helpful comments. Research is supported in part by a PSU start-up fund and NIH Grants R01 CA136856 to YW (PSU) and R01 CA116522 to YW (UC Riverside).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arita K, 2004, NAT STRUCT MOL BIOL, V11, P777, DOI 10.1038/nsmb799; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Causey CP, 2008, TETRAHEDRON LETT, V49, P4383, DOI 10.1016/j.tetlet.2008.05.021; Chang XT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-40; Chang XT, 2006, MOL CARCINOGEN, V45, P183, DOI 10.1002/mc.20169; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Levesque AA, 2007, CARCINOGENESIS, V28, P13, DOI 10.1093/carcin/bgl214; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Yao HJ, 2008, J BIOL CHEM, V283, P20060, DOI 10.1074/jbc.M802940200	38	90	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3153	3162		10.1038/onc.2010.51	http://dx.doi.org/10.1038/onc.2010.51			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20190809	Green Accepted			2022-12-17	WOS:000278133100012
J	Loayza-Puch, F; Yoshida, Y; Matsuzaki, T; Takahashi, C; Kitayama, H; Noda, M				Loayza-Puch, F.; Yoshida, Y.; Matsuzaki, T.; Takahashi, C.; Kitayama, H.; Noda, M.			Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs	ONCOGENE			English	Article						RECK; invasion; metastasis; MMP; hypoxia; RAS	GENE-EXPRESSION; MESENCHYMAL TRANSITION; INVASION; MIR-21; METASTASIS; INVOLVEMENT; GROWTH; INHIBITION; APOPTOSIS; CELLS	Cancer cells show characteristic gene expression profiles. Recent studies support the potential importance of microRNA (miRNA) expression signatures as biomarkers and therapeutic targets. The membrane-anchored protease regulator RECK is downregulated in many cancers, and forced expression of RECK in tumor cells results in decreased malignancy in animal models. RECK is also essential for mammalian development. In this study, we found that RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373); that RECK mutants lacking the target sites for these miRNA show augmented tumor/metastasis-suppressor activities; and that miR-372/373 are upregulated in response to hypoxia through HIF1 alpha and TWIST1, whereas miR-21 is upregulated by RAS/ERK signaling. These data indicate that the hypoxia- and RAS-signaling pathways converge on RECK through miRNAs, cooperatively downregulating this tumor suppressor and thereby promoting malignant cell behavior. Oncogene (2010) 29, 2638-2648; doi:10.1038/onc.2010.23; published online 15 February 2010	[Noda, M.] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Noda, M (corresponding author), Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp		Loayza-Puch, Fabricio/0000-0002-2999-8594	JSPS; MEXT; Grants-in-Aid for Scientific Research [22501010] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Takao Miki, EPS Chandana and Awad Shamma for valuable discussion; Masahiro Sonoshita for advice on animal experiments; Aiko Nishimoto and Hai-Ou Gu for technical support; Aki Miyazaki for secretarial assistance and David B Alexander and Oana Maria Cusen for critical reading of the paper. This work was supported by a Grant-in-Aid for Creative Scientific Research from JSPS. FL has been supported by fellowships from MEXT and the Global COE Program, JSPS.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Hu SJ, 2008, J BIOL CHEM, V283, P23473, DOI 10.1074/jbc.M800406200; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawada K, 2007, ONCOGENE, V26, P4679, DOI 10.1038/sj.onc.1210267; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; WANG GL, 1993, BLOOD, V82, P3610; Yang L, 2008, WD SCI P COMP ENG, V1, P295, DOI 10.1142/9789812799470_0048; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	43	90	93	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2638	2648		10.1038/onc.2010.23	http://dx.doi.org/10.1038/onc.2010.23			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154725	Green Submitted			2022-12-17	WOS:000277354600004
J	Periyasamy, S; Hinds, T; Shemshedini, L; Shou, W; Sanchez, ER				Periyasamy, S.; Hinds, T., Jr.; Shemshedini, L.; Shou, W.; Sanchez, E. R.			FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A	ONCOGENE			English	Article						transcription; prostate cancer; androgen receptor; Cyp40; FKBP51; FKBP52	NF-KAPPA-B; PEPTIDYL-PROLYL ISOMERASE; IMMUNOPHILIN FKBP51; IDIOPATHIC MYELOFIBROSIS; GLUCOCORTICOID-RECEPTOR; INSENSITIVITY SYNDROME; MOLECULAR-MECHANISMS; MEDIATED REGULATION; FACTOR INDEPENDENCE; SQUIRREL-MONKEY	Prostate cancer (PCa) growth is dependent on androgens and on the androgen receptor (AR), which acts by modulating gene transcription. Tetratricopeptide repeat (TPR) proteins (FKBP52, FKBP51 and Cyp40) interact with AR in PCa cells, suggesting roles in AR-mediated gene transcription and cell growth. We report here that FKBP51 and Cyp40, but not FKBP52, are significantly elevated in PCa tissues and in androgen-dependent (AD) and androgen-independent (AI) cell lines. Overexpression of FKBP51 in AD LNCaP cells increased AR transcriptional activity in the presence and absence of androgen, whereas siRNA knockdown of FKBP51 dramatically decreased AD gene transcription and proliferation. Knockdown of Cyp40 also inhibited androgen-mediated transcription and growth in LNCaP cells. However, disruption of FKBP51 and Cyp40 in AI C4-2 cells caused only a small reduction in proliferation, indicating that Cyp40 and FKBP51 predominantly regulate AD cell proliferation. Under knockdown conditions, the inhibitory effects of TPR ligands, cyclosporine A (CsA) and FK506, on AR activity were not observed, indicating that Cyp40 and FKBP51 are the targets of CsA and FK506, respectively. Our findings show that FKBP51 and Cyp40 are positive regulators of AR that can be selectively targeted by CsA and FK506 to achieve inhibition of androgen-induced cell proliferation. These proteins and their cognate ligands thus provide new strategies in the treatment of PCa. Oncogene (2010) 29, 1691-1701; doi:10.1038/onc.2009.458; published online 21 December 2009	[Shemshedini, L.] Univ Toledo Main Campus, Dept Biol Sci, Toledo, OH USA; [Shou, W.] Indiana Univ, Sch Med, Dept Pediat, Pediat Cardiol Sect,Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Periyasamy, S.; Hinds, T., Jr.; Sanchez, E. R.] Univ Toledo, Coll Med, Dept Physiol & Pharmacol, CeDER, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University of Toledo Health Science Campus; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; University of Toledo	Periyasamy, S (corresponding author), Univ Toledo Hlth Sci Campus, Dept Physiol & Pharmacol, 3000 Arlington Ave,Mail Stop 1008, Toledo, OH 43614 USA.	sumudra.periyasamy@utoledo.edu	Hinds, Terry/B-8495-2015	Hinds, Terry/0000-0002-7599-1529	National Institutes of Health [DK73402, DK70127]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070127, R01DK073402, F31DK084958] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Theo Rein (Max Planck Institute of Psychiatry) and Marianne Sadar (British Columbia Cancer Agency) for the generous gift of Flag-tagged FKBP51 and PSA-luciferase reporter plasmid, respectively. This study was supported in part by National Institutes of Health grants DK73402 to WS and DK70127 to ERS.	Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; Amler LC, 2000, CANCER RES, V60, P6134; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Banerjee A, 2008, BIOCHEMISTRY-US, V47, P10471, DOI 10.1021/bi8011862; BATCH JA, 1992, HUM MOL GENET, V1, P497, DOI 10.1093/hmg/1.7.497; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Cinar B, 2004, BIOCHEM J, V379, P421, DOI 10.1042/BJ20031661; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Dehm SM, 2007, CANCER RES, V67, P10067, DOI 10.1158/0008-5472.CAN-07-1267; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Febbo PG, 2005, J UROLOGY, V173, P1772, DOI 10.1097/01.ju.0000155845.44729.ba; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Giraudier S, 2002, BLOOD, V100, P2932, DOI 10.1182/blood-2002-02-0485; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hubler TR, 2003, ENDOCRINOLOGY, V144, P2380, DOI 10.1210/en.2003-0092; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang W, 2008, NEOPLASIA, V10, P235, DOI 10.1593/neo.07929; Komura E, 2003, EXP HEMATOL, V31, P622, DOI 10.1016/S0301-472X(03)00085-7; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872; Lee SO, 2005, PROSTATE, V64, P160, DOI 10.1002/pros.20218; Li TH, 2007, NUCLEIC ACIDS RES, V35, P2767, DOI 10.1093/nar/gkm198; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Makkonen H, 2009, NUCLEIC ACIDS RES, V37, P4135, DOI 10.1093/nar/gkp352; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; Periyasamy S, 2007, ENDOCRINOLOGY, V148, P4716, DOI 10.1210/en.2007-0145; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Riggs DL, 2007, MOL CELL BIOL, V27, P8658, DOI 10.1128/MCB.00985-07; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Romano MF, 2004, EUR J CANCER, V40, P2829, DOI 10.1016/j.ejca.2004.08.017; Scherr D, 2003, UROLOGY, V61, P14, DOI 10.1016/S0090-4295(02)02395-6; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Thalmann GN, 2000, PROSTATE, V44, P91; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Yong WD, 2007, J BIOL CHEM, V282, P5026, DOI 10.1074/jbc.M609360200; Zhu W, 2001, CARCINOGENESIS, V22, P1399, DOI 10.1093/carcin/22.9.1399	64	90	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1691	1701		10.1038/onc.2009.458	http://dx.doi.org/10.1038/onc.2009.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023700	Green Accepted			2022-12-17	WOS:000275694700014
J	Mumm, JB; Oft, M				Mumm, J. B.; Oft, M.			Cytokine-based transformation of immune surveillance into tumor-promoting inflammation	ONCOGENE			English	Review						IL-23; IL-12; Th17; inflammation; tumor immune surveillance	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; COLLAGEN-INDUCED ARTHRITIS; CD8(+) T-CELLS; TGF-BETA; AUTOIMMUNE INFLAMMATION; CANCER PROGRESSION; ANTICANCER THERAPY; COLORECTAL-CANCER; LYMPHOCYTES-T	During the last decade, it has become clear that the mammalian immune system is able to recognize and partially suppress nascent tumors. Human T cells specific to oncogenes and onco-fetal antigens are present in human cancer patients and their tumors. At the same time, molecular links between tumor-associated inflammation and tumor progression have been uncovered, providing an explanation for the long recognized epidemiological link between inflammation and cancer. The synopsis of these findings suggests a new interpretation of tumor immunity. It appears that antigen recognition or antigen-specific T-cell expansion at large is not as profoundly impaired in tumor patients as the correct polarization, the survival and the effector function of tumor-infiltrating T cells. This review will focus on pro-inflammatory cytokines likely to contribute to the deregulation of tumor-specific immunity and its consequences.	[Mumm, J. B.; Oft, M.] Schering Plough Biopharma, Dept Oncol, Palo Alto, CA 94303 USA	Merck & Company	Oft, M (corresponding author), Schering Plough Biopharma, Dept Oncol, 901 Calif Ave, Palo Alto, CA 94303 USA.	martin.oft@spcorp.com						Aggarwal BB, 2006, ANN NY ACAD SCI, V1091, P151, DOI 10.1196/annals.1378.063; Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Atkins MB, 1997, CLIN CANCER RES, V3, P409; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAFFET G, 1991, MOL BIOL MED, V8, P141; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Betti M, 2006, ANN ONCOL, V17, P235; Betz UAK, 1998, INT IMMUNOL, V10, P1175, DOI 10.1093/intimm/10.8.1175; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; Bowman EP, 2006, CURR OPIN INFECT DIS, V19, P245, DOI 10.1097/01.qco.0000224818.42729.67; BRANDES ME, 1991, J IMMUNOL, V147, P1600; Cebon Jonathan, 2003, Cancer Immun, V3, P7; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KNUTH A, 1984, P NATL ACAD SCI-BIOL, V81, P3511, DOI 10.1073/pnas.81.11.3511; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Landi S, 2003, CANCER RES, V63, P3560; Langowski JL, 2007, TRENDS IMMUNOL, V28, P207, DOI 10.1016/j.it.2007.03.006; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Letterio JJ, 2005, ONCOGENE, V24, P5701, DOI 10.1038/sj.onc.1208922; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Lo CH, 2003, J IMMUNOL, V171, P600, DOI 10.4049/jimmunol.171.2.600; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Naito Y, 1998, CANCER RES, V58, P3491; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Novelli F, 2004, CYTOKINE GROWTH F R, V15, P367, DOI 10.1016/j.cytogfr.2004.03.009; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Rao VSR, 2006, ONCOL REP, V15, P179; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rohekar S, 2008, ARTHRITIS RHEUM-US, V58, P82, DOI 10.1002/art.23185; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Scott KA, 2003, MOL CANCER THER, V2, P445; Sepulveda H, 1999, J IMMUNOL, V163, P1133; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Strobl H, 1996, J IMMUNOL, V157, P1499; Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Williams RO, 2000, J IMMUNOL, V165, P7240, DOI 10.4049/jimmunol.165.12.7240; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	78	90	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5913	5919		10.1038/onc.2008.275	http://dx.doi.org/10.1038/onc.2008.275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836472				2022-12-17	WOS:000259722600006
J	Olmeda, D; Montes, A; Moreno-Bueno, G; Flores, JM; Portillo, F; Cano, A				Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Flores, J. M.; Portillo, F.; Cano, A.			Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines	ONCOGENE			English	Article						Snai1; Snai2; E-cadherin; EMT; invasion; metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CADHERIN GENE-EXPRESSION; REPRESSES E-CADHERIN; ADHESION MOLECULE; FACTOR SLUG; PROGRESSION; SUPERFAMILY; PATHWAY; OVARIAN	Snai1 (Snail) and Snai2 (Slug), the two main members of Snail family factors, are important mediators of epithelial-mesenchymal transitions and involved in tumor progression. We recently reported that Snai1 plays a major role in tumor growth, invasion and metastasis, but the contribution of Snai2 to tumorigenesis is not yet well understood. To approach this question we have silenced Snai2 and/or Snai1 by stable RNA interference in two independent mouse skin carcinoma (HaCa4 and CarB) cell lines. We demonstrate that Snai2 knockdown has a milder effect, but collaborates with Snai1 silencing in reduction of tumor growth potential of either carcinoma cell line when injected into nude mice. Importantly, Snai1 or Snai2 silencing dramatically influences the metastatic ability of squamous carcinoma HaCa4 cells, inducing a strong reduction in liver and lung distant metastasis. However, only Snai1 knockdown has an effective action on invasiveness and fully abolishes tumor cell dissemination into the spleen. These results demonstrate that Snai1 and Snai2 collaborate on primary tumor growth and specifically contribute to site-specific metastasis of HaCa4 cells. These data also indicate that Snai1 is the major regulator of local invasion, supporting a hierarchical participation of both factors in the metastatic process.	[Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Portillo, F.; Cano, A.] UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, Madrid 28029, Spain; [Flores, J. M.] Univ Complutense Madrid, Fac Vet, Dept Cirugia & Med Anim, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Cano, A (corresponding author), UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Olmeda, David/L-4270-2017	Moreno-Bueno, Gema/0000-0002-5030-6687; Olmeda, David/0000-0001-5513-5621; Portillo Perez, Francisco/0000-0003-4922-346X				Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Elloul S, 2006, VIRCHOWS ARCH, V449, P520, DOI 10.1007/s00428-006-0274-6; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1006/dbio.1998.8909; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	34	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4690	4701		10.1038/onc.2008.118	http://dx.doi.org/10.1038/onc.2008.118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408755				2022-12-17	WOS:000258236300007
J	Engelbert, D; Schnerch, D; Baumgarten, A; Wasch, R				Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.			The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells	ONCOGENE			English	Article						Cdh1; anaphase-promoting complex; mitotic exit; genomic instability; ubiquitin-dependent proteolysis	ANAPHASE-PROMOTING COMPLEX; DNA-DAMAGE; CENTROSOME AMPLIFICATION; DEPENDENT PROTEOLYSIS; CYCLIN-E; INSTABILITY; OVEREXPRESSION; DEGRADATION; ACTIVATION; CHECKPOINT	Ensuring precise DNA replication and chromosome segregation is essential during cell division in order to provide genomic stability and avoid malignant growth. Proteolytic control of cell cycle regulators by the anaphase-promoting complex, activated by Cdh1 (APC(Cdh1)), is responsible for a stable G(1) phase after mitotic exit allowing accurate preparation for DNA replication in the following S phase. APCCdh1 target proteins are frequently upregulated in tumor cells and the inactivation of human Cdh1 might interfere with genome integrity by target stabilization. Here we show that APCCdh1 is required for maintaining genomic integrity in primary human cells. Lentiviral-delivered strong and stable suppression of Cdh1 by RNA interference (RNAi) causes aberrant accumulation of several APCCdh1 target proteins, such as cyclin A, B, Aurora A or Plk1, which control accurate and equal distribution of the genetic information to daughter cells. This induces a premature and prolonged S phase, mitotic-entry delay and defects in chromosome separation and cytokinesis. Cell cycle deregulation by stable knockdown of Cdh1 leads to activation of p53/p21 and genomic instability, which is further increased by codepletion of p53. Thus, stabilization of APCCdh1 targets may initiate aberrant DNA replication and chromosome separation, and trigger a p53 response by deregulating G(1) in primary human cells.	[Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Wasch, R (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter St 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Holt, Janet E/B-2415-2013; Waesch, Ralph/F-6282-2019					Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Lehman NL, 2006, CELL CYCLE, V5, P1569, DOI 10.4161/cc.5.14.2925; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; Park KH, 2005, BREAST CANCER RES, V7, pR238, DOI 10.1186/bcr978; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; VEELKEN H, 1994, HUM GENE THER, V5, P1203, DOI 10.1089/hum.1994.5.10-1203; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	46	90	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					907	917		10.1038/sj.onc.1210703	http://dx.doi.org/10.1038/sj.onc.1210703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700535	Bronze			2022-12-17	WOS:000252946300003
J	Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q				Jin, H.; Wang, X.; Ying, J.; Wong, A. H. Y.; Li, H.; Lee, K. Y.; Srivastava, G.; Chan, A. T. C.; Yeo, W.; Ma, B. B. Y.; Putti, T. C.; Lung, M. L.; Shen, Z-Y; Xu, L-Y; Langford, C.; Tao, Q.			Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas	ONCOGENE			English	Article						ADAMTS18; methylation; tumor suppressor gene; carcinoma; promoter	STRESS-RESPONSIVE GENE; METHYLATION STATUS; HUMAN BREAST; CANCER; DNA; EXPRESSION; HYPERMETHYLATION; METALLOPROTEINASES; TRANSFORMATION; TUMORIGENESIS	Tumor suppressor genes (TSGs) often locate at chromosomal regions with frequent deletions in tumors. Loss of 16q23 occurs frequently in multiple tumors, indicating the presence of critical TSGs at this locus, such as the well-studied WWOX. Herein, we found that ADAMTS18, located next to WWOX, was significantly downregulated in multiple carcinoma cell lines. No deletion of ADAMTS18 was detected with multiplex differential DNA-PCR or high-resolution 1-Mb array-based comparative genomic hybridization (CGH) analysis. Instead, methylation of the ADAMTS18 promoter CpG Island was frequently detected with methylation-specific PCR and bisulfite genome sequencing in multiple carcinoma cell lines and primary carcinomas, but not in any nontumor cell line and normal epithelial tissue. Both pharmacological and genetic demethylation dramatically induced the ADAMTS18 expression, indicating that CpG methylation directly contributes to the tumor-specific silencing of ADAMTS18. Ectopic ADAMTS18 expression led to significant inhibition of both anchorage-dependent and - independent growth of carcinoma cells lacking the expression. Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Hong Kong Canc Inst & Li Ka Shing Inst Hlth Sci, Dept Clin Oncol, Sir YK Pao Ctr Canc State Key Lab Oncol S China, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore; Hong Kong Univ Sci & Technol, Canc Res Ctr, Dept Biol, Hong Kong, Peoples R China; Shantou Univ, Coll Med, SUMC CUHK Joint Epigenet Grp, Shantou, Peoples R China; Well Trust Sanger Inst, Microarray Facil, Cambridge, England	Chinese University of Hong Kong; University of Hong Kong; National University of Singapore; Hong Kong University of Science & Technology; Shantou University; Wellcome Trust Sanger Institute	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc, PWH, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Jin, Hongchuan/C-3686-2009; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Yeo, Winnie/R-4792-2018; B.Y., Brigette/H-4681-2017; Lung, Maria Li/C-4495-2009	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Yeo, Winnie/0000-0002-0863-8469; B.Y., Brigette/0000-0003-4802-1102; Lung, Maria Li/0000-0003-2559-3626; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bishop JM, 1996, FASEB J, V10, P362, DOI 10.1096/fasebj.10.2.8641572; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x; Cui Y, 2007, LAB INVEST; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Dunn JR, 2004, BRIT J CANCER, V91, P1149, DOI 10.1038/sj.bjc.6602107; Gius D, 2005, CANCER, V104, P1789, DOI 10.1002/cncr.21395; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lind GE, 2006, CELL ONCOL, V28, P259; Lo KW, 2000, CANCER RES, V60, P3348; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Masui T, 2001, CLIN CANCER RES, V7, P3437; Morin D, 1999, PC WEEK, V16, P80; Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Riegman PHJ, 2001, CANCER RES, V61, P3164; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	35	90	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7490	7498		10.1038/sj.onc.1210559	http://dx.doi.org/10.1038/sj.onc.1210559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546048	Green Accepted			2022-12-17	WOS:000251282000010
J	Mehta, SA; Christopherson, KW; Bhat-Nakshatri, P; Goulet, RJ; Broxmeyer, H; Kopelovich, L; Nakshatri, H				Mehta, S. A.; Christopherson, K. W.; Bhat-Nakshatri, P.; Goulet, R. J., Jr.; Broxmeyer, He; Kopelovich, L.; Nakshatri, H.			Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion	ONCOGENE			English	Article						CXCR4; p53; breast cancer; invasion; PRIMA-1	GENE-EXPRESSION; MUTANT P53; GROWTH SUPPRESSION; METASTASIS; TRANSCRIPTION; REPRESSION; MIGRATION; APOPTOSIS; PRIMA-1; AP-1	Chemokine receptor CXCR4 and its ligand CXCL12 are suggested to be involved in migration, invasion and metastasis of breast cancer cells. Mutation of the tumor suppressor gene p53 in breast cancer is associated with metastasis and aggressive clinical phenotype. In this report, we demonstrate that wild type but not the dominant-negative mutant (V143A)or cancer-specific mutants (R175H or R280K) of p53 repress CXCR4 expression. Recently described cancer-specific p53 isoform, Delta 133p53, also failed to repress CXCR4 promoter activity. Short-interfering RNA-mediated depletion of p53 increased endogenous CXCR4 expression in MCF-7 breast cancer cells that contain wild-type p53. Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of p53 [HCT116(p53KO)] was 10-fold higher compared to that in parental HCT116 cells with functional wild-type p53. Deletion analysis of CXCR4 promoter identified a seven-base pair p53-repressor element homologous to cyclic AMP/AP-1 response (CRE/AP-1) element. Electrophoretic mobility shift and chromatin immunoprecipitation assays revealed binding of ATF-1 and cJun to the CRE/AP-1 element. The p53 rescue drug PRIMA-1 reduced CXCR4 mRNA and cell surface expression in MDA-MB-231 cells, which express R280K mutant p53. CP-31398, another p53 rescue drug, similarly reduced cell surface levels of CXCR4. PRIMA-1-mediated decrease in CXCR4 expression correlated with reduced invasion of MDA-MB-231 cells through matrigel. These results suggest a mechanism for elevated CXCR4 expression and metastasis of breast cancers with p53 mutations or isoform expression. We propose that p53 rescue drugs either alone or in combination with chemotherapeutic drugs may be effective in reducing CXCR4-mediated metastasis.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Bloomington, IN 47405 USA; Natl Canc Inst, DCP, CADRG, Bethesda, MD USA; Walther Canc Inst, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, Dept Surg Biochem & Mol Biol, R4-202,1044 W Walnut St,R4-268, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052	NCI NIH HHS [N01-CN-15133, R01 CA89153] Funding Source: Medline; NHLBI NIH HHS [R01 HL67384] Funding Source: Medline; NIDDK NIH HHS [R01 DK53674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 2002, CANCER RES, V62, P1129; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; CASEY G, 1991, ONCOGENE, V6, P1791; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khan MZ, 2005, MOL CELL NEUROSCI, V30, P58, DOI 10.1016/j.mcn.2005.05.007; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Lee BC, 2005, CANCER RES, V65, P2840, DOI 10.1158/0008-5472.CAN-04-3309; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Liang ZX, 2005, CANCER RES, V65, P967; Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sheridan C, 2006, EXP HEMATOL, V34, P1085, DOI 10.1016/j.exphem.2006.03.013; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	38	90	91	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3329	3337		10.1038/sj.onc.1210120	http://dx.doi.org/10.1038/sj.onc.1210120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130833				2022-12-17	WOS:000246579600003
J	Wong, YF; Cheung, TH; Lo, KWK; Yim, SF; Siu, NSS; Chan, SCS; Ho, TWF; Wong, KWY; Yu, MY; Wang, VW; Li, C; Gardner, GJ; Bonome, T; Johnson, WB; Smith, DI; Chung, TKH; Birrer, MJ				Wong, Y. F.; Cheung, T. H.; Lo, K. W. K.; Yim, S. F.; Siu, N. S. S.; Chan, S. C. S.; Ho, T. W. F.; Wong, K. W. Y.; Yu, M. Y.; wang, V. W.; Li, C.; Gardner, G. J.; Bonome, T.; Johnson, W. B.; Smith, D. I.; Chung, T. K. H.; Birrer, M. J.			Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling	ONCOGENE			English	Article						endometrioid endometrial cancer; signaling pathway; gene expression profiling	DIFFERENT HISTOLOGIC TYPES; CLEAR-CELL-CARCINOMA; MATRIX-METALLOPROTEINASE; BREAST-CANCER; SEROUS CARCINOMA; MESSENGER-RNA; CYCLIN-E; NUCLEAR TRANSLOCATION; ENDOGENOUS INHIBITOR; MICROARRAY ANALYSIS	Endometrial cancer is the third most common gynecologic malignancy and the ninth most common malignancy for females overall in Hong Kong. Approximately 80% or more of these cancers are endometrioid endometrial adenocarcinomas. The aim of this study was to reveal genes contributing to the development of endometrioid endometrial cancer, which may impact diagnosis, prognosis and treatment of the disease. Whole-genome gene expression analysis was completed for a set of 55 microdissected sporadic endometrioid endometrial adenocarcinomas and 29 microdissected normal endometrium specimens using the Affymetrix Human U133 Plus 2.0 oligonucleotide microarray. Selected genes of interest were validated by quantitative real-time-polymerase chain reaction (qRT-PCR). Pathway analysis was performed to reveal gene interactions involved in endometrial tumorigenesis. Unsupervised hierarchical clustering displayed a distinct separation between the endometrioid adenocarcinomas and normal endometrium samples. Supervised analysis identified 117 highly differentially regulated genes (>= 4.0-fold change), which distinguished the endometrial cancer specimens from normal endometrium. Twelve novel genes including DKK4, ZIC1, KIF1A, SAA2, LOC16378, ALPP2, CCL20, CXCL5, BST2, OLFM1, KLRC1 and MBC45780 were deregulated in the endometrial cancer, and further validated in an independent set of 56 cancer and 29 normal samples using qRT-PCR. In addition, 10 genes were differentially regulated in late-stage cancer, as compared to early-stage disease, and may be involved in tumor progression. Pathway analysis of the expression data from this tumor revealed an interconnected network consisting of 21 aberrantly regulated genes involved in angiogenesis, cell proliferation and chromosomal instability. The results of this study highlight the molecular features of endometrioid endometrial cancer and provide insight into the events underlying the development and progression of endometrioid endometrial cancer.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat, Boston, MA 02115 USA; NCI, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Mayo Clin, Sch Med, Dept Expt Pathol, Rochester, MN USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Wong, YF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China.	yickfuwong@cuhk.edu.hk		Lo, Kwok Wai/0000-0002-3488-6124; CHUNG, Tony/0000-0002-6362-8546				ABELER VM, 1991, GYNECOL ONCOL, V40, P207; Acs G, 2004, INT J GYNECOL PATHOL, V23, P110, DOI 10.1097/00004347-200404000-00004; Albright CD, 2001, EXP MOL PATHOL, V70, P71, DOI 10.1006/exmp.2000.2354; Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; [Anonymous], 2005, HONG KONG CANC STAT; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bein K, 1998, J BIOL CHEM, V273, P21423, DOI 10.1074/jbc.273.33.21423; BONOME T, 2000, CANCER RES, V65, P10602; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cao QJ, 2004, INT J GYNECOL PATHOL, V23, P321, DOI 10.1097/01.pgp.0000139646.32997.3a; Cha HJ, 1998, ONCOGENE, V16, P771, DOI 10.1038/sj.onc.1201587; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Ferguson SE, 2005, CLIN CANCER RES, V11, P2252, DOI 10.1158/1078-0432.CCR-04-1353; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Hrzenjak A, 2004, J PATHOL, V204, P19, DOI 10.1002/path.1616; Ilvan S, 2004, GYNECOL ONCOL, V94, P232, DOI 10.1016/j.ygyno.2004.04.005; Kalsheker N, 2002, BIOCHEM SOC T, V30, P93, DOI 10.1042/bst0300093; Kamochi J, 2003, ONCOL REP, V10, P881; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; LI C, 2003, DNA CHIP ANAL CHIP A; Liu WM, 1999, CANCER RES, V59, P5695; LIU YH, 1991, J BIOL CHEM, V266, P21880; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Massaad-Massade L, 2004, FEBS LETT, V559, P89, DOI 10.1016/S0014-5793(04)00032-8; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; Milde-Langosch K, 2001, J CANCER RES CLIN, V127, P537, DOI 10.1007/s004320100256; Miyashita R, 2004, INT IMMUNOL, V16, P163, DOI 10.1093/intimm/dxh013; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; MULLER PT, 1903, J CHIM PHYS PCB, V1, P190; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Risinger JI, 2003, CANCER RES, V63, P6; RUTANEN EM, 1994, INT J CANCER, V59, P307, DOI 10.1002/ijc.2910590303; Saidi SA, 2004, ONCOGENE, V23, P6677, DOI 10.1038/sj.onc.1207562; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smid-Koopman E, 2004, GYNECOL ONCOL, V93, P292, DOI 10.1016/j.ygyno.2004.01.022; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Suzumori N, 2004, FERTIL STERIL, V81, P305, DOI 10.1016/j.fertnstert.2003.08.011; Takeba Y, 2001, J RHEUMATOL, V28, P2176; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Tashiro H, 1997, AM J PATHOL, V150, P177; Tong W, 1999, MOL CELL BIOL, V19, P2251; WALMER DK, 1995, CANCER RES, V55, P1168; Warren CD, 2002, MOL BIOL CELL, V13, P3029, DOI 10.1091/mbc.E02-04-0203; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903	67	90	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1971	1982		10.1038/sj.onc.1209986	http://dx.doi.org/10.1038/sj.onc.1209986			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043662				2022-12-17	WOS:000245117700015
J	Walker, SR; Nelson, EA; Frank, DA				Walker, S. R.; Nelson, E. A.; Frank, D. A.			STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas	ONCOGENE			English	Article						STAT5; BCL6; transcription; chromatin	B-CELL LYMPHOMA; AFFECTING BAND 3Q27; CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; GENE-EXPRESSION; SELF-RENEWAL; DIFFERENTIATION; TRANSLOCATIONS; IDENTIFICATION	Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT) 5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high interspecies homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St,M522B, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu						Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; Baron BW, 2004, P NATL ACAD SCI USA, V101, P14198, DOI 10.1073/pnas.0406138101; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Buitenhuis M, 2003, BLOOD, V101, P134, DOI 10.1182/blood-2002-03-0740; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Frank DA, 1999, MOL MED, V5, P432; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; HAPP B, 1993, J STEROID BIOCHEM, V47, P21, DOI 10.1016/0960-0760(93)90053-Y; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V104, P19, DOI 10.1016/S0165-4608(97)00412-3; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Niu HF, 2003, J EXP MED, V198, P211, DOI 10.1084/jem.20021395; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otaki JM, 2005, NEUROSCI RES, V53, P189, DOI 10.1016/j.neures.2005.06.018; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Xi SC, 2003, CANCER RES, V63, P6763; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zhou G, 2005, EXP MOL PATHOL, V78, P25, DOI 10.1016/j.yexmp.2004.08.008	62	90	90	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					224	233		10.1038/sj.onc.1209775	http://dx.doi.org/10.1038/sj.onc.1209775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819511				2022-12-17	WOS:000243398300006
J	Tamborini, E; Pricl, S; Negri, T; Lagonigro, MS; Miselli, F; Greco, A; Gronchi, A; Casali, PG; Ferrone, M; Fermeglia, M; Carbone, A; Pierotti, MA; Pilotti, S				Tamborini, E.; Pricl, S.; Negri, T.; Lagonigro, M. S.; Miselli, F.; Greco, A.; Gronchi, A.; Casali, P. G.; Ferrone, M.; Fermeglia, M.; Carbone, A.; Pierotti, M. A.; Pilotti, S.			Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients	ONCOGENE			English	Article						imatinib secondary resistance; gastrointestinal stromal tumors (GIST); molecular modeling	GASTROINTESTINAL STROMAL TUMORS; CAVITY-CREATING MUTATIONS; ACQUIRED-RESISTANCE; BCR-ABL; PROTEIN; STABILITY; INSIGHTS; DYNAMICS; INTERIOR; POLAR	Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors. Here, transient transfection experiments with plasmids carrying two different KIT-acquired point mutations were performed along with immunoprecipitation of total protein extracts, derived from imatinib-treated and untreated cells. The molecular mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the molecular level. Biochemical analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes. Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concentrations, whereas V654A was inhibited by 6 mu M of imatinib. The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes. We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter. The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance.	Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, I-20133 Milan, Italy; Univ Trieste, DICAMP, Mol Simulat Engn Lab, Trieste, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Surg, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Clin Oncol, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Trieste; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pilotti, S (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, Via Venezian 1, I-20133 Milan, Italy.	silvana.pilotti@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Carbone, Antonino/AAA-2217-2019; casali, Paolo Giovanni/D-1524-2017; Gronchi, Alessandro/O-6589-2016; Pricl, Sabrina/M-7493-2015; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Fermeglia, Maurizio/O-3973-2018	Tamborini, Elena/0000-0002-3819-8687; Carbone, Antonino/0000-0003-2211-639X; casali, Paolo Giovanni/0000-0003-4056-8023; Gronchi, Alessandro/0000-0002-4703-3534; Pricl, Sabrina/0000-0001-8380-4474; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Negri, Tiziana/0000-0002-3528-7115; Fermeglia, Maurizio/0000-0001-8810-5082	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CASE DA, 2000, AMBER 7; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dwyer JJ, 2000, BIOPHYS J, V79, P1610, DOI 10.1016/S0006-3495(00)76411-3; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Lazaridis T, 1995, ADV PROTEIN CHEM, V47, P231, DOI 10.1016/S0065-3233(08)60547-1; LEE B, 1993, PROTEIN SCI, V2, P733, DOI 10.1002/pro.5560020505; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; Pricl S, 2005, MOL CANCER THER, V4, P1167, DOI 10.1158/1535-7163.MCT-05-0101; Reyes CM, 2000, J MOL BIOL, V295, P1, DOI 10.1006/jmbi.1999.3319; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; Takano K, 2001, BIOCHEMISTRY-US, V40, P4853, DOI 10.1021/bi002792f; Tamborini E, 2005, CANCER RES, V65, P1115; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8; Wilson EB., 1995, MOL VIBRATIONS	35	90	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6140	6146		10.1038/sj.onc.1209639	http://dx.doi.org/10.1038/sj.onc.1209639			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16751810				2022-12-17	WOS:000241101200012
J	Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y				Xie, Y; Xu, K; Dai, B; Guo, Z; Jiang, T; Chen, H; Qiu, Y			The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs	ONCOGENE			English	Article						kinase; cancer; phosphorylation; signal transduction; apoptosis	HETEROCHROMATIN PROTEIN-1 HP1; PLECKSTRIN-HOMOLOGY DOMAIN; PIM-1 TRANSGENIC MICE; C-MYC; PHOSPHORYLATION; ACTIVATION; ANDROGEN; LEUKEMIA; LYMPHOMAGENESIS; EXPRESSION	Protein kinase Pim-1 has been implicated in the development of hematopoietic and prostatic malignancies. Here, we present the evidence that two isoforms, the 44 and 33 kDa Pim-1, are expressed in all human prostate cancer cell lines examined. The subcellular localization of human 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus in PCA cells. The 44 kDa Pim-1 contains the proline-rich motif at the N-terminus and directly binds to the SH3 domain of tyrosine kinase Etk. Such interaction leads to the activation of Etk kinase activity possibly by competing with the tumor suppressor p53. This is corroborated by the fact that overexpression of the 44 kDa Pim-1 in prostate cancer cells confers the resistance to chemotherapeutic drugs. Our results suggest that these two isoforms of Pim-1 kinase may regulate distinct substrates and the 44 kDa Pim-1 may play a more prominent role in drug resistance in prostate cancer cells.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gregory CW, 2001, CANCER RES, V61, P2892; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jiang TY, 2004, J BIOL CHEM, V279, P50181, DOI 10.1074/jbc.M409108200; Kim O, 2004, ONCOGENE, V23, P1838, DOI 10.1038/sj.onc.1207304; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VONLINDERN M, 1989, ONCOGENE, V4, P75; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Zhao T, 2001, J BIOL CHEM, V276, P9512, DOI 10.1074/jbc.M010098200	26	90	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					70	78		10.1038/sj.onc.1209058	http://dx.doi.org/10.1038/sj.onc.1209058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16186805				2022-12-17	WOS:000234406400008
J	Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H				Wang, JD; Kataoka, H; Suzuki, M; Sato, N; Nakamura, R; Tao, H; Maruyama, K; Isogaki, J; Kanaoka, S; Ihara, M; Tanaka, M; Kanamori, M; Nakamura, T; Shinmura, K; Sugimura, H			Downregulation of EphA7 by hypermethylation in colorectal cancer	ONCOGENE			English	Article						EphA7; colorectal cancer; DNA methylation	RECEPTOR TYROSINE KINASES; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; BREAST-CARCINOMA; COLON-CANCER; C-ELEGANS; OVEREXPRESSION; METHYLATION; EXPRESSION; LIGANDS	A significant reduction of EphA7 expression in human colorectal cancers was shown using semiquantitative reverse transcription-polymerase chain reaction analysis in 59 colorectal cancer tissues, compared to corresponding normal mucosas (P=0.008), and five colon cancer cell lines. To investigate the mechanism of EphA7 down-regulation in colorectal cancer, we examined the methylation status of the 5'CpG island around the translation start site in five colon cancer cell lines using restriction enzymes, methylation-specific PCR, and bisulfite sequencing and found evidence of aberrant methylation. The expression of EphA7 in colon cancer cell lines was restored after treatment with 5-aza-2'-deoxycytidine. Analysis of methylation status in totally 75 tumors compared to clinicopathological parameters revealed that hypermethylation of colorectal cancers was more frequent in male than in female (P=0.0078), and in moderately differentiated than in well-differentiated adenocarcinomas (P=0.0361). There was a tendency that hypermethylation in rectal cancers was more frequent than in colon cancers (P=0.0816). Hypermethylation was also observed in colorectal adenomas. This is the first report describing the downregulation of an Eph family gene in a solid tumor via aberrant 5'CpG island methylation. It provides the evidence that EphA7 gene is involved in human colorectal carcinogenesis.	Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Clin Nursing, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Surg, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Publ Hlth, Hamamatsu, Shizuoka 4313192, Japan; Biwako Seikei Sport Coll, Dept Lifelong Sport, Shiga 5200503, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Chin-Sang ID, 2002, DEVELOPMENT, V129, P5499, DOI 10.1242/dev.00122; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cunningham JM, 1998, CANCER RES, V58, P3455; Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; ENDO Y, 1995, PATHOL INT, V45, P602, DOI 10.1111/j.1440-1827.1995.tb03509.x; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hsieh CJ, 1998, CANCER RES, V58, P3942; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kataoka H, 2002, J CANCER RES CLIN, V128, P343, DOI 10.1007/s00432-002-0355-0; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sullivan DD, 2003, BRIT J CANCER, V89, P228, DOI 10.1038/sj.bjc.6601107; Tang XX, 1999, CLIN CANCER RES, V5, P455; Tao H, 2004, CARCINOGENESIS, V25, P1859, DOI 10.1093/carcin/bgh206; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405	34	90	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 25	2005	24	36					5637	5647		10.1038/sj.onc.1208720	http://dx.doi.org/10.1038/sj.onc.1208720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007213	Green Submitted			2022-12-17	WOS:000231296100010
J	Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB				Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB			Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3	ONCOGENE			English	Article						acute promyelocytic leukemia; promyelocytic leukemia protein; nuclear body	ACUTE PROMYELOCYTIC LEUKEMIA; COVALENT MODIFICATION; CENP-E; UBIQUITIN; IDENTIFICATION; PATHOGENESIS; INTERACTS; COMPONENT; MODIFIER; RANGAP1	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML localizes to discrete nuclear bodies (NBs) that are disrupted in APL cells, resulting from a reciprocal chromosome translocation t (15;17). Here we show that the nuclear localization of PML is also regulated by SUMO-3, one of the three recently identified SUMO isoforms in human cells. SUMO-3 bears similar subcellular distribution to those of SUMO-1 and -2 in the interphase nuclear body, which is colocalized with PML protein. However, both SUMO-2 and -3 are also localized to nucleoli, a region lacking SUMO-1. Immunoprecipitated PML protein bears SUMO-3 moiety in a covalently modified form, supporting the notion that PML is conjugated by SUMO-3. To determine the functional relevance of SUMO-3 conjugation on PML molecular dynamics, we suppressed SUMO-3 protein expression using a siRNA-mediated approach. Depletion of SUMO-3 markedly reduced the number of PML-containing NBa and their integrity, which is rescued by exogenous expression of SUMO-3 but not SUMO-1 or SUMO-2. The specific requirement of SUMO-3 for PML nuclear localization is validated by expression of SUMO-3 conjugation defective mutant. Moreover, we demonstrate that oligomerization of SUMO-3 is required for PML retention in the nucleus. Taken together, our studies provide first line of evidence showing that SUMO-3 is essential for PML localization and offer novel insight into the pathobiochemistry of APL.	Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Proteom Res Lab, Beijing 100086, Peoples R China	Zhejiang University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine	Huang, H (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China.	hehuang@mail.hz.zj.cn; yaoxb@ustc.edu.cn	Ding, Husheng/K-9688-2013; Yao, Xuebiao/P-5771-2014; MIAO, YONG/D-4244-2015; Fu, Chuanhai/G-8303-2016; Shi, Yunyu/B-3240-2009	Ding, Husheng/0000-0003-1877-7961; Fu, Chuanhai/0000-0003-4354-3796; Shi, Yunyu/0000-0002-1348-4759; huang, he/0000-0002-2723-1621	NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER; NCI NIH HHS [CA89019] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wang ZG, 1998, SCIENCE, V279, P1547; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887	31	90	91	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5401	5413		10.1038/sj.onc.1208714	http://dx.doi.org/10.1038/sj.onc.1208714			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940266				2022-12-17	WOS:000231222300001
J	Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM				Romero-Gallo, J; Sozmen, EG; Chytil, A; Russell, WE; Whitehead, R; Parks, WT; Holdren, MS; Her, MF; Gautam, S; Magnuson, M; Moses, HL; Grady, WM			Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy	ONCOGENE			English	Article						TGF-beta; liver regeneration	TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE ARREST; LIVER EPITHELIAL-CELLS; RAT-LIVER; DNA-SYNTHESIS; II RECEPTOR; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The transforming growth factor beta (TGF-beta) signaling pathway, which is activated by the TGF-beta receptor complex consisting of type I and type II TGF-beta receptors (TGFBR1 and TGFBR2), regulates cell growth and death. TGF-beta and components of its signaling pathway, particularly TGFBR2, have been implicated as tumor suppressor genes and important antimitogenic factors in the gastrointestinal tract and liver. An in vivo approach to study these effects has been hindered by the embryonic lethality of Tgfbr2(-/-) mice and poor viability of the Tgfb1(-/-) mice. Consequently, we have developed a hepatocyte-specific Tgfbr2 knockout mouse, the Alb-cre Tgfbr2(flx/flx) mouse, to study the physiologically relevant effects of TGF-beta signaling on epithelial cell proliferation in vivo. After 70% hepatectomy, we observed increased proliferation and an increased liver mass : body weight ratio in the Alb-cre Tgfbr2(flx/flx) mice compared to Tgfbr2(flx/flx) mice. We also observed decreased expression and increased phosphorylation of p130 in the livers from the Alb-cre Tgfbr2(flx/flx) mice as well as increased expression of cyclin E, which is transcriptionally regulated, in part, by p130:E2F4. Consistent with these results, in a hepatocyte cell line derived from the Tgfbr2(flx/flx) mice, we found that TGF-beta increases the nuclear localization of E2F4, and presumably the transcriptional repression of the p130: E2F4 complex. Thus, we have demonstrated that TGF-beta signaling in vivo regulates the mitogenic response in the regenerating liver, affecting the liver mass : body weight ratio after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated in vivo by TGF-beta during liver regeneration.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Beth Israel Deaconess Med Ctr, Dept Biostat, Boston, MA 02215 USA; Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA	Fred Hutchinson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98104 USA.	wgrady@fhcrc.org	Russell, William/A-7307-2009; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499; Parks, W. Tony/0000-0001-7341-3277	NCI NIH HHS [R01CA85492, R01 CA102162] Funding Source: Medline; NIDDK NIH HHS [R01 DK53804, R01 DK60669-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102162, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060669, R01DK053804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akita K, 2002, GASTROENTEROLOGY, V123, P352, DOI 10.1053/gast.2002.34234; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Allen KJ, 2000, J GASTROEN HEPATOL, V15, P1325, DOI 10.1046/j.1440-1746.2000.02328.x; BARBIROLI B, 1971, SCIENCE, V172, P738, DOI 10.1126/science.172.3984.738; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouzahzah B, 2000, CANCER RES, V60, P4531; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; CARR BI, 1986, CANCER RES, V46, P2330; CHARI RS, 1995, AM J SURG, V169, P126, DOI 10.1016/S0002-9610(99)80120-2; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; COUGHLIN JP, 1987, J PEDIATR SURG, V22, P566, DOI 10.1016/S0022-3468(87)80223-3; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Enami Y, 2001, J Hepatobiliary Pancreat Surg, V8, P250, DOI 10.1007/s005340170025; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iavarone A, 1997, NATURE, V387, P417; Im YH, 2001, CANCER RES, V61, P6665; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; KO TC, 1995, ONCOGENE, V10, P177; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; MACIASSILVA M, 2002, J BIOL CHEM, V21, P21; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagoshi S, 1998, J GASTROEN HEPATOL, V13, P786, DOI 10.1111/j.1440-1746.1998.tb00734.x; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; Oe S, 2004, HEPATOLOGY, V40, P1098, DOI 10.1002/hep.20426; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RICHARDS GM, 1974, ANAL BIOCHEM, V57, P369, DOI 10.1016/0003-2697(74)90091-8; RUSSELL W, 1988, J CELL PHYSL, V35, P253; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; RUSSELL WE, 1983, AM J PHYSIOL, V245, P321; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SchulteHermann R, 1995, MUTAT RES-FUND MOL M, V333, P81, DOI 10.1016/0027-5107(95)00134-4; Scotte M, 1997, CYTOKINE, V9, P859, DOI 10.1006/cyto.1997.0273; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRAIN AJ, 1986, CELL BIOL INT REP, V10, P855, DOI 10.1016/0309-1651(86)90102-5; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200	84	90	99	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3028	3041		10.1038/sj.onc.1208475	http://dx.doi.org/10.1038/sj.onc.1208475			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735717				2022-12-17	WOS:000228649500012
J	Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A				Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A			Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors	ONCOGENE			English	Article						PTEN; germ cell tumors; ITGCN; p27(kip1)	KINASE INHIBITOR P27(KIP1); PRIMARY PROSTATE-CANCER; MOUSE SERTOLI CELLS; GROWTH-FACTOR; NEURONAL DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; COWDEN DISEASE; BREAST-CANCER; EXPRESSION; MUTATIONS	PTEN/MMAC1/TEP1 ( hereafter PTEN) is a tumor suppressor gene (located at 10q23) that is frequently mutated or deleted in sporadic human tumors. PTEN encodes a multifunctional phosphatase, which negatively regulates cell growth, migration and survival via the phosphatidylinositol 3'-kinase/AKT signalling pathway. Accordingly, Pten(+/-) mice develop various types of tumors including teratocarcinomas and teratomas. We have investigated PTEN expression in 60 bioptic specimens of germ cell tumors (32 seminomas, 22 embryonal carcinomas and six teratomas) and 22 intratubular germ cell neoplasias (ITGCN) adjacent to the tumors for PTEN protein and mRNA expression. In total, 10 testicular biopsies were used as controls. In the testis, PTEN was abundantly expressed in germ cells whereas it was virtually absent from 56% of seminomas as well as from 86% of embryonal carcinomas and virtually all teratomas. On the contrary, ITGCN intensely expressed PTEN, indicating that loss of PTEN expression is not an early event in testicular tumor development. The loss of PTEN expression occurs mainly at the RNA level as determined by in situ hybridization of cellular mRNA (17/22) but also it may involve some kind of post-transcriptional mechanisms in the remaining 25% of cases. Analysis of microsatellites D10S551, D10S541 and D10S1765 in GCTs (n = 22) showed LOH at the PTEN locus at 10q23 in at least 36% of GCTs (three embryonal carcinoma, three seminoma, two teratoma); one seminoma and one embryonal (9%) carcinoma presented an inactivating mutation in the PTEN gene (2/22). Finally, we demonstrated that the phosphatidylinositol 3'-kinase/AKT pathway, which is regulated by the PTEN phosphatase, is crucial in regulating the proliferation of the NT2/D1 embryonal carcinoma cells, and that the cyclin-dependent kinase inhibitor p27(kip1) is a key downstream target of this pathway.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, I-88100 Catanzaro, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Sci Biomorol & Funz, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy	Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli	Viglietto, A (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, Campus Univ Germaneto Viale Europa, I-88100 Catanzaro, Italy.	viglietto@sun.ceos.na.cnr.it	Chieffi, Paolo/ABA-7892-2020; Schepis, Filippo/H-9417-2014	Schepis, Filippo/0000-0001-6549-5102; chieffi, paolo/0000-0001-8483-5635; Fusco, Alfredo/0000-0003-3332-5197; PETTINATO, Guido/0000-0003-2599-0357				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cairns P, 1997, CANCER RES, V57, P4997; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; IQBAL UA, 2000, J NATL CANCER I, V92, P861; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsui Y, 1998, APMIS, V106, P142, DOI 10.1111/j.1699-0463.1998.tb01329.x; McMenamin ME, 1999, CANCER RES, V59, P4291; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Mertens F, 1997, CANCER RES, V57, P2765; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Risinger JI, 1997, CANCER RES, V57, P4736; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scala S, 1998, INT J ONCOL, V13, P665; Sette C, 1997, DEVELOPMENT, V124, P2267; Skotheim RI, 2003, APMIS, V111, P136, DOI 10.1034/j.1600-0463.2003.11101181.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Viglietto G, 1996, ONCOGENE, V13, P577; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; Wang SI, 1997, CANCER RES, V57, P4183; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	59	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1882	1894		10.1038/sj.onc.1208368	http://dx.doi.org/10.1038/sj.onc.1208368			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674339				2022-12-17	WOS:000227542000007
J	Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD				Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD			Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase	ONCOGENE			English	Article						palmitoylation; protein; palmitoyl acyltransferase; RAS; intracellular signaling	ACYL TRANSFERASE-ACTIVITY; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; H-RAS; SACCHAROMYCES-CEREVISIAE; N-RAS; LOCALIZATION; PURIFICATION; CANCER; CELLS	Protein palmitoyltransferases (PATs) represent an exciting new target for anticancer drug design due to their pivotal roles in the subcellular localization of a number of oncogenes. We show that the Huntingtin interacting protein 14 (HIP14) is a PAT with a preference for the farnesyl-dependent palmitoylation motif found in H- and N-RAS. Characterization of HIP14 in mouse cells has revealed that it has the ability to induce colony formation in cell culture, anchorage-independent growth, and tumors in mice. Activity of the enzyme and its ability to transform cells is dependent on critical residues in the active site of the enzyme.	Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Smith, CD (corresponding author), Penn State Univ, Dept Pharmacol, Coll Med, H078,500 Univ Dr, Hershey, PA 17033 USA.	cdsmith@psu.edu			NCI NIH HHS [R01 CA75248, R01 CA075248-09, R01 CA075248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Danesi R, 1996, MOL PHARMACOL, V49, P972; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Eummer JT, 1999, BIOORGAN MED CHEM, V7, P241, DOI 10.1016/S0968-0896(98)00202-8; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hiol A, 2003, BBA-MOL CELL BIOL L, V1635, P10, DOI 10.1016/j.bbalip.2003.10.001; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Ueno K, 1997, J BIOL CHEM, V272, P13519, DOI 10.1074/jbc.272.21.13519; Varner AS, 2003, BIOCHEM J, V373, P91, DOI 10.1042/BJ20021598; Varner AS, 2002, ANAL BIOCHEM, V308, P160, DOI 10.1016/S0003-2697(02)00212-9; Waddick KG, 1998, BIOCHEM PHARMACOL, V56, P1411, DOI 10.1016/S0006-2952(98)00211-1	39	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9230	9237		10.1038/sj.onc.1208171	http://dx.doi.org/10.1038/sj.onc.1208171			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489887	Green Accepted			2022-12-17	WOS:000225638000008
J	Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ				Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ			Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression	ONCOGENE			English	Article						neurofibromatosis; NF2; merlin; phosphorylation; PAK2	CELL EXTENSION ACTIVITY; N-TERMINAL DOMAIN; TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; ERM PROTEINS; FERM DOMAIN; EZRIN; MEMBRANE	The neurofibromatosis 2 (NF2) tumor suppressor protein, merlin, functions as a negative growth regulator; however, the molecular mechanisms that underlie merlin regulation remain elusive. Recent studies have implicated merlin phosphorylation in regulating merlin subcellular localization and growth suppression. P21-activated kinase (PAK), a downstream target of Rac1/Cdc42, directly phosphorylates merlin at Serine 518. In this report, we show that PAK2 directly phosphorylates wild-type merlin, whereas merlin truncation mutants with impaired GST-amino-terminal domain ( N-term or NTD)/GST-carboxy-terminal domain ( C-term or CTD) intramolecular association exhibit impaired S518 phosphorylation. We directly demonstrate that PAK2 phosphorylation impairs merlin N-term/C-term binding in vitro and in vivo. Lastly, we show that PAK2 phosphorylation impairs the ability of merlin to bind to two interacting proteins, CD44 and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), both critical for merlin growth suppression. These observations suggest that merlin S518 phosphorylation directly modulates merlin intramolecular and intermolecular associations important for the ability of merlin to function as a tumor suppressor.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Emory University; Washington University (WUSTL)	Ye, KQ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu		Gutmann, David/0000-0002-3127-5045	NINDS NIH HHS [NS35848] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533; Brault E, 2001, J CELL SCI, V114, P1901; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7	36	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8447	8454		10.1038/sj.onc.1207794	http://dx.doi.org/10.1038/sj.onc.1207794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378014				2022-12-17	WOS:000224870700005
J	Bertucci, F; Borie, N; Ginestier, C; Groulet, A; Charafe-Jauffret, E; Adelaide, J; Geneix, J; Bachelart, L; Finetti, P; Koki, A; Hermitte, F; Hassoun, J; Debono, S; Viens, P; Fert, V; Jacquemier, J; Birnbaum, D				Bertucci, F; Borie, N; Ginestier, C; Groulet, A; Charafe-Jauffret, E; Adelaide, J; Geneix, J; Bachelart, L; Finetti, P; Koki, A; Hermitte, F; Hassoun, J; Debono, S; Viens, P; Fert, V; Jacquemier, J; Birnbaum, D			Identification and validation of an ERBB2 gene expression signature in breast cancers	ONCOGENE			English	Article						breast cancer; DNA microarrays; ERBB2/HER2; FISH; gene expression; expression profiles; tissue microarrays	IN-SITU HYBRIDIZATION; MICROARRAY ANALYSIS; COPY NUMBER; MOLECULAR CLASSIFICATION; CLINICAL-SIGNIFICANCE; TISSUE MICROARRAYS; DNA AMPLIFICATION; HORMONE RECEPTORS; OVEREXPRESSION; CELL	ERBB2 is a transmembrane tyrosine kinase receptor encoded by a gene located in chromosome region 17q12. Overexpression of ERBB2, generally by way of gene amplification, plays a role in mammary oncogenesis. This alteration can be overcome by use of the humanized monoclonal antibody trastuzumab (Herceptint(TM)). Accurate determination of ERBB2 status is required for appropriate use of this targeted therapy and is currently analysed by immunohistochemistry (IHC) on tissue sections and/or fluorescence in situ hybridisation (FISH) on interphase chromosomes. W e have studied the gene expression profiles of a series of 213 breast tumours and 16 breast cancer cell lines with known ERBB2 status, using Ipsogen's DiscoveryChip microarrays with similar to9000 cDNAs. W e have identified 36 genes and expressed sequence tags that were differentially expressed in tumours and in cell lines with and without ERBB2 protein overexpression. This ERBB2-specific gene expression signature (GES) contained 29 overexpressed genes including the ERBB2 gene itself, five genes located in its immediate vicinity on 17q12, non-17q genes such as GATA4 and eight downregulated genes including oestrogen receptor alpha ( ER). Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples.	Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; INSERM, UMR117, IFR57, F-13258 Marseille, France; Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; IPSOGEN SA, Marseille, France; Inst J Paoli I Calmettes, Dept Biopathol, F-13009 Marseille, France	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Dept Mol Oncol, 217 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017; ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017; Finetti, Pascal/O-8669-2017	Ginestier, Christophe/0000-0002-7477-3837; ADELAIDE, José JA/0000-0003-4364-9857; Bertucci, Francois/0000-0002-0157-0959; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Birnbaum, Daniel/0000-0001-7920-9883; Finetti, Pascal/0000-0002-2674-3123				Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Bertucci F, 2003, LAB INVEST, V83, P305, DOI 10.1097/01.LAB.0000059936.28369.19; Bertucci F, 2003, INT J CANCER, V103, P565, DOI 10.1002/ijc.10867; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bilous M, 2003, MODERN PATHOL, V16, P173, DOI 10.1097/01.MP.0000052102.90815.82; Callagy G, 2003, DIAGN MOL PATHOL, V12, P27, DOI 10.1097/00019606-200303000-00004; Dressman MA, 2003, CANCER RES, V63, P2194; Frade R, 2002, ONCOGENE, V21, P861, DOI 10.1038/sj.onc.1205177; Garratt AN, 2003, TRENDS CARDIOVAS MED, V13, P80, DOI 10.1016/S1050-1738(02)00231-1; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GINESTIER C, IN PRESS J PATHOL; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; KESHGEGIAN AA, 1995, BREAST CANCER RES TR, V35, P201, DOI 10.1007/BF00668210; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1200/JCO.2002.09.094; Rampaul RS, 2002, CRIT REV ONCOL HEMAT, V43, P231, DOI 10.1016/S1040-8428(01)00207-4; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Sabatti C, 2002, MATH BIOSCI, V176, P17, DOI 10.1016/S0025-5564(01)00102-X; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tan M, 1997, CANCER RES, V57, P1199; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TIWARI RK, 1991, ANTICANCER RES, V11, P1383; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; van de Vijver M, 2002, ONCOLOGY-BASEL, V63, P33, DOI 10.1159/000066199; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Willis S, 2003, GENE CHROMOSOME CANC, V36, P382, DOI 10.1002/gcc.10138; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yang RB, 2002, J BIOL CHEM, V277, P46364, DOI 10.1074/jbc.M207410200	56	90	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2564	2575		10.1038/sj.onc.1207361	http://dx.doi.org/10.1038/sj.onc.1207361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14743203				2022-12-17	WOS:000220558000015
J	Kao, CF; Chen, SY; Chen, JY; Lee, YHW				Kao, CF; Chen, SY; Chen, JY; Lee, YHW			Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein	ONCOGENE			English	Article						HCV; core protein; p53; post-translational modification	PML NUCLEAR-BODIES; TUMOR-SUPPRESSOR; COMPLEX-FORMATION; DNA-BINDING; CELL-PROLIFERATION; GENE-EXPRESSION; IN-VITRO; ACTIVATION; RNA; INHIBITION	Oncogenic virus proteins often target to tumor suppressor p53 during virus life cycle. In the case of hepatitis C virus (HCV) core protein, it has been shown to affect p53-dependent transcription. Here, we further characterized the in vitro and in vivo interactions between HCV core protein and p53 and showed that these two proteins colocalized in subnuclear granular structures and the perinuclear area. By use of a reporter assay, we observed that while low level of HCV core protein enhanced the transactivational activity of p53, high level of HCV core protein inhibited this activity. In both cases, however, HCV core protein increased the p53 DNA-binding affinity in gel retardation analyses, likely due to the hyperacetylation of p53 Lys(373) and Lys(382) residues. Additionally, HCV core protein, depending on its expression level, had differential effects on the Ser(15) phosphorylation of p53. Moreover, HCV core protein could rescue p53-mediated suppressive effects on both RNA polymerase I and III transcriptions. Collectively, our results indicate that HCV core protein targets to p53 pathway via at least three means: physical interaction, modulation of p53 gene regulatory activity and post-translational modification. This feature of HCV core protein, may potentially contribute to the HCV-associated pathogenesis.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018	Lee Wu, Yan-Hwa/0000-0001-7299-7354				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BUKH J, 1993, P NATL ACAD SCI USA, V90, P1848, DOI 10.1073/pnas.90.5.1848; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHEN JY, 1993, ONCOGENE, V8, P2159; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Cho JW, 2001, LIVER, V21, P137, DOI 10.1034/j.1600-0676.2001.021002137.x; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirohashi S, 1991, Princess Takamatsu Symp, V22, P87; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JAMAL S, 1995, ONCOGENE, V10, P2095; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SANG BC, 1994, ONCOGENE, V9, P853; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; TERAMOTO T, 1992, CANER RES, V54, P231; TERRIS B, 1995, CANCER RES, V55, P1590; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	80	90	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2472	2483		10.1038/sj.onc.1207368	http://dx.doi.org/10.1038/sj.onc.1207368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14968111				2022-12-17	WOS:000220558000005
J	Attardi, LD; de Vries, A; Jacks, T				Attardi, LD; de Vries, A; Jacks, T			Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer	ONCOGENE			English	Article						p53; cell cycle arrest; apoptosis; chemotherapeutics; DNA damage	CELL-CYCLE ARREST; P53; APOPTOSIS; P21; PHOSPHORYLATION; RADIATION	The p53 tumor suppressor protein inhibits proliferation by inducing either cell cycle arrest or apoptosis in response to cellular stresses. Mouse embryo fibroblasts (MEFs) provide a primary cell model system in which to examine both functions of p53. MEFs treated with gamma-rays undergo p53-dependent G1 arrest, while oncogene-expressing METs treated with a variety of DNA-damaging agents undergo p53-dependent apoptosis. Although the p53-dependent G1 arrest checkpoint response to gamma-rays in MEFs has been well characterized, the response to other DNA-damaging agents has not. Here, we examine the effects of commonly utilized chemotherapeutics, including doxorubicin, etoposide, and cisplatin, on cell cycle arrest in MEFs, and we define the p53 dependence of these effects. In addition, we examine the response of MEFs to ultraviolet light (UVC), as a representative agent acting by inducing pyrimidine dimers. Although p53 is clearly activated by all the agents examined, as measured by p21 induction, there are surprising differences in the activities of these agents. For example, doxorubicin but not cisplatin can effectively induce a p53-dependent G1 arrest. UVC, in contrast, induces a p53-independent G1 arrest response. Thus, the exact response of cells to DNA damage depends on the specific agent used.	Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Natl Inst Publ Hlth, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.	attardi@stanford.edu						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Attardi LD, 2000, GENE DEV, V14, P704; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; ODWYER PJ, 1997, PRINCIPLES PRACTICE, P419; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STEWART CF, 1997, PRINCIPLES PRACTICE, P452; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	22	90	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					973	980		10.1038/sj.onc.1207026	http://dx.doi.org/10.1038/sj.onc.1207026			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749764				2022-12-17	WOS:000188486600013
J	Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S				Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S			Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels	ONCOGENE			English	Article						Nrf2; oxidative stress; apoptosis; fas; TNF-receptor I	TUMOR-NECROSIS-FACTOR; PLANAR AROMATIC-COMPOUNDS; OXIDATIVE STRESS; INDUCIBLE EXPRESSION; APOPTOSIS; MICE; DEPLETION; IDENTIFICATION; ACETAMINOPHEN; ELEMENTS	Nrf2 is a basic leucine zipper transcriptional activator that is essential for the coordinate transcriptional induction of various antioxidant drug-metabolizing enzymes. Numerous studies have firmly established Nrf2's importance in protection from oxidative stress and certain chemical insults. Given the protective function of Nrf2, surprisingly few studies have focused on the relationship between Nrf2 and apoptosis. Therefore, we analysed how Nrf2 influences Fas signaling using Nrf2-deficient T cells. At a concentration of 1 mug/ml, the anti-Fas antibody induced 60% of cell death in Nrf2-deficient cultured thymocytes while, using the same treatment, only 40% of Nrf2 wildtype thymocytes died (P < 0.05). Nrf2 deficiency enhances the sensitivity of Fas-mediated apoptosis in T cells. Next we examined the effect of Nrf2 deficiency during hepatocellular apoptosis in vivo. In comparison to wildtype mice, Nrf2-deficient mice displayed more severe hepatitis after induction with the anti-Fas antibody or tumor necrosis factor (TNF)-alpha. The enhanced sensitivity to anti-Fas or TNF-alpha stimulation was restored by preadministration of glutathione ethyl monoester, a compound capable of passing the cell membrane and upregulating the intracellular levels of glutathione. The results indicated that Nrf2 activity regulates the sensitivity of death signals by means of intracellular glutathione levels.	Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Takahashi, S (corresponding author), Univ Tsukuba, Inst Basic Med Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	satoruta@md.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010; Hirayama, Aki/G-7842-2017	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; Hirayama, Aki/0000-0001-5777-4208				Anderson M E, 1997, Adv Pharmacol, V38, P65; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen TS, 2000, MECH AGEING DEV, V120, P127, DOI 10.1016/S0047-6374(00)00214-1; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DROGE W, 1994, FASEB J, V8, P1131; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JONES TW, 1986, ARCH TOXICOL, P259; Kotlo KU, 2003, ONCOGENE, V22, P797, DOI 10.1038/sj.onc.1206077; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEISTER A, 1992, BIOCHEM PHARMACOL, V44, P1905, DOI 10.1016/0006-2952(92)90091-V; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Srivastava SK, 2000, CANCER LETT, V153, P35, DOI 10.1016/S0304-3835(00)00333-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	40	90	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9275	9281		10.1038/sj.onc.1207024	http://dx.doi.org/10.1038/sj.onc.1207024			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681686	Bronze, Green Submitted			2022-12-17	WOS:000187400400009
J	Campochiaro, PA; Hackett, SF				Campochiaro, PA; Hackett, SF			Ocular neovascularization: a valuable model system	ONCOGENE			English	Review						VEGF; angiogenesis; angiopoietins; retinopathies; age-related macular degeneration	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; COMBRETASTATIN A-4 PHOSPHATE; RETINAL-PIGMENT EPITHELIUM; RECEPTOR TYROSINE KINASE; VASCULAR-TARGETING AGENT; CHOROIDAL NEOVASCULARIZATION; INTEGRIN ALPHA(V)BETA(3); INCREASED EXPRESSION; FACTOR VEGF	There is no unique formula for angiogenesis. Instead there is a large group of potential participating proteins that interact in complex ways. Depending upon the surrounding cell types and the relative expression levels of angiogenesis-related proteins, the 'angiogenesis cascade' can vary. Therefore, it is valuable to study and compare the role of proteins in several well-characterized vascular beds. The eye provides a useful model system, because it contains several vascular beds sandwiched between avascular tissue. This allows for unequivocal identification and quantitation of new vessels. Retina-specific promoters combined with inducible promoter systems provide a means to regulate the expression of proteins of interest. As a relatively isolated compartment, the eye also provides advantages for gene transfer. By gaining insight regarding the molecular signals involved in various types of ocular angiogenesis, general concepts can emerge that may apply to other settings, including tumor angiogenesis. One concept that has emerged is that despite participation of multiple stimulatory factors for ocular neovascularization, VEGF plays an essential role and interruption of VEGF signaling is an important therapeutic strategy. Another concept is that while most studies have focused on prevention of ocular neovascularization, regression of new vessels is desirable and is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived factor, and angiopoietin-2. Finally, endostatin and angiostatin, which have been sources of controversy because of inconsistent results in tumor models, have been shown to have good efficacy when delivered by gene transfer in models of ocular neovascularization. These results provide leads for new ocular treatments and perspective for evaluation of studies of neovascularization in extraocular tissues.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@inmi.edu			NEI NIH HHS [EY05951, EY12609, P30EY1765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012609, P30EY001765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539; Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083; [Anonymous], 1991, Arch Ophthalmol, V109, P1109; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chaplin DJ, 1999, ANTICANCER RES, V19, P189; Dark GG, 1997, CANCER RES, V57, P1829; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; DAVEL LE, 1985, TRANSPLANTATION, V39, P564, DOI 10.1097/00007890-198505000-00023; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEUTSCH TA, 1979, AM J OPHTHALMOL, V87, P536, DOI 10.1016/0002-9394(79)90245-9; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dowlati A, 2002, CANCER RES, V62, P3408; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Edgren M, 1999, ANTICANCER RES, V19, P869; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931; Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grosios K, 1999, BRIT J CANCER, V81, P1318, DOI 10.1038/sj.bjc.6692174; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; Hazzard TM, 2000, MOL HUM REPROD, V6, P993, DOI 10.1093/molehr/6.11.993; HILL SA, 1993, EUR J CANCER, V29A, P1320, DOI 10.1016/0959-8049(93)90082-Q; Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203; Horsman MR, 1998, INT J RADIAT ONCOL, V42, P895, DOI 10.1016/S0360-3016(98)00299-5; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jones MK, 1999, NAT MED, V5, P1418; Joukov V, 1996, EMBO J, V15, P290; Kawamori T, 1998, CANCER RES, V58, P409; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kukk E, 1996, DEVELOPMENT, V122, P3829; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401; Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959; Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Luna J, 1996, LAB INVEST, V75, P563; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Masferrer JL, 2000, CANCER RES, V60, P1306; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; NAMBU H, 2003, IN PRESS INVEST OPHT; Nicol D, 1997, J UROLOGY, V157, P1482, DOI 10.1016/S0022-5347(01)65028-6; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OSHIMA Y, 2003, UNPUB DIFFERENT EFFE; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299; PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299; Rasmussen H, 2001, Hum Gene Ther, V12, P2029; Reichelt M, 2003, CLIN EXP OPHTHALMOL, V31, P61, DOI 10.1046/j.1442-9071.2003.00602.x; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawaoka H, 1999, LAB INVEST, V79, P1469; Schwartz SD, 2001, INVEST OPHTH VIS SCI, V42, pS522; Seed L, 1940, SURGERY, V7, P696; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8; Takano S, 1996, CANCER RES, V56, P2185; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Tozer GM, 1999, CANCER RES, V59, P1626; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; WOODS JA, 1995, BRIT J CANCER, V71, P705, DOI 10.1038/bjc.1995.138; WRIGHT AD, 1969, BRIT MED J, V2, P346, DOI 10.1136/bmj.2.5653.346; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87; Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y; Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	133	90	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6537	6548		10.1038/sj.onc.1206773	http://dx.doi.org/10.1038/sj.onc.1206773			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528278				2022-12-17	WOS:000185700700010
J	Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D				Baron, V; De Gregorio, G; Krones-Herzig, A; Virolle, T; Calogero, A; Urcis, R; Mercola, D			Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						prostate cancer; Egr-1; antisense oligonucleotide; TRAMP mouse	TRANSCRIPTION FACTOR EGR-1; GROWTH-FACTOR; ANTISENSE OLIGONUCLEOTIDES; GENE-EXPRESSION; UP-REGULATION; INVOLVEMENT; INDUCTION; APOPTOSIS; BINDING; PROTEIN	Transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we developed phosphorothioate antisense oligonucleotides that efficiently inhibit Egr-1 expression without altering the expression of other family members Egr-2, Egr-3 and Egr-4. In TRAMP mouse-derived prostate cancer cell lines, our optimal antisense oligonucleotide decreased the expression of the Egr-1 target gene transforming growth factor-beta1 whereas a control oligonucleotide had no effect, indicating that the antisense blocked Egr-1 function as a transcription factor. The antisense oligonucleotide deregulated cell cycle progression and decreased proliferation of the three TRAMP cell lines by an average of 54+/-3%. Both colony formation and growth in soft agar were inhibited by the antisense oligonucleotide. When TRAMP mice were treated systemically for 10 weeks, the incidence of palpable tumors at 32 weeks of age in untreated mice or mice injected with the control scramble oligonucleotide was 87%, whereas incidence of tumors in antisense-Egr-1-treated mice was significantly reduced to 37% (P=0.026). Thus, Egr-1 plays a functional role in the transformed phenotype and may represent a valid target for prostate cancer therapy.	Sidnet Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Ricovero & Cura Carattere Sci, I-86077 Pozzilli, Italy; Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Baron, V (corresponding author), Sidnet Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	vbaron@skcc.org; danmercola@skcc.org	mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019; Virolle, Thierry/E-5838-2016	mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916	NATIONAL CANCER INSTITUTE [R01CA084107, R01CA076173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84107, CA 76173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; BERUBE NG, 1994, CANCER RES, V54, P3077; Bost F, 2000, METHOD ENZYMOL, V314, P342; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Eid MA, 1998, CANCER RES, V58, P2461; Foster BA, 1997, CANCER RES, V57, P3325; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gousseva N, 2001, J CELL BIOCHEM, V81, P523, DOI 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, CANCER RES, V55, P5054; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; Jackson MW, 2002, CANCER RES, V62, P854; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kroon ME, 2001, J CELL SCI, V114, P825; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; McMenamin ME, 1999, CANCER RES, V59, P4291; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nishi H, 2002, CANCER RES, V62, P827; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; Russell PJ, 1998, CLIN CHEM, V44, P705; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	48	90	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4194	4204		10.1038/sj.onc.1206560	http://dx.doi.org/10.1038/sj.onc.1206560			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833142				2022-12-17	WOS:000183979800006
J	Burgermeister, E; Tencer, L; Liscovitch, M				Burgermeister, E; Tencer, L; Liscovitch, M			Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells	ONCOGENE			English	Article						cancer; caveolin; differentiation; peroxisome proliferator-activated receptor-gamma; transcriptional regulation; multidrug resistance	HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; ANCHORAGE-INDEPENDENT GROWTH; HUMAN PROSTATE-CANCER; D7S522 LOCUS 7Q31.1; MAP KINASE CASCADE; GENE-EXPRESSION; IN-VIVO; PPAR-GAMMA; TERMINAL DIFFERENTIATION	Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear receptor for eicosanoids that promotes differentiation of human epithelial and mesenchymal cells in vitro and in vivo. PPARgamma was proposed as a target for drug-induced differentiation therapy of cancer. Caveolin-1 is a constituent of plasma membrane caveolae in epithelial cells that is often downregulated upon oncogenic transformation. Caveolin-1 has growth-inhibitory activities and its disruption is sufficient to induce transformation in fibroblasts. Herein we have tested the hypothesis that caveolins are transcriptional target genes for PPARgamma. In human HT-29 colon carcinoma cells, thiazolidinedione PPARgamma ligands increased the levels of caveolin-1 and caveolin-2 proteins two to fivefold in a concentration-dependent manner within 24 h. In human MCF-7 breast adenocarcinoma cells, nonthiazolidinedione PPARgamma ligands elevated caveolin-2 protein three to fourfold, while the thiazoli-dinediones were less effective. Caveolin-1 mRNA levels were found to be upregulated by PPARgamma ligands already after 3 h in both the cell lines. Ectopic expression of a dominant-negative PPARgamma construct attenuated ligand-induced upregulation of caveolins in both HT-29 and HEK-293T cells, indicating that ligand action is mediated by PPARgamma. Ligand-treated MCF-7 cells exhibited a differentiated phenotype, as evinced by analysis of cell-specific differentiation markers: protein levels of maspin were elevated and perinuclear lipid droplets accumulated. In contrast, in HT-29 cells, caveolin expression was not correlated with differentiation. Interestingly, PPARgamma partially cofractionated in lipid rafts and could be coimmunoprecipitated from cell lysates with caveolin-1, indicating that PPARgamma and caveolin-1 may coexist in a complex. Our data indicate that PPARgamma participates in the regulation of caveolin gene expression in human carcinoma cells and suggest that caveolin-1 may mediate some of the phenotypic changes induced by this nuclear receptor in cancer cells. These findings may have potentially important functional implications in the context of cancer differentiation therapy and multidrug resistance.	Weizmann Inst Sci, Dept Biochem Regulat, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Biochem Regulat, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Bender FC, 2000, CANCER RES, V60, P5870; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; Fra AM, 2000, GENE, V243, P75, DOI 10.1016/S0378-1119(99)00559-4; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kilgore MW, 1997, MOL CELL ENDOCRINOL, V129, P229, DOI 10.1016/S0303-7207(97)04057-4; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kubota T, 1998, CANCER RES, V58, P3344; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Matveev S, 1999, J LIPID RES, V40, P1647; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Pignatelli M, 2001, J CELL SCI, V114, P4117; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Samid D, 2000, CLIN CANCER RES, V6, P933; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tahir SA, 2001, CANCER RES, V61, P3882; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Wu YF, 2003, J BIOL CHEM, V278, P8637, DOI 10.1074/jbc.M210910200; Yamamoto M, 1999, LIFE SCI, V64, P1349, DOI 10.1016/S0024-3205(99)00070-3; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	66	90	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3888	3900		10.1038/sj.onc.1206625	http://dx.doi.org/10.1038/sj.onc.1206625			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813462				2022-12-17	WOS:000183612000008
J	Kim, JE; Kim, SJ; Jeong, HW; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS				Kim, JE; Kim, SJ; Jeong, HW; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS			RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis	ONCOGENE			English	Article						beta ig-h3; RGD peptide; apoptosis; TGF-beta; cell adhesion; anoikis	GROWTH-FACTOR-BETA; IN-VITRO; PROTEIN; GENE; CHONDROCYTES; INVOLVEMENT; FIBROBLASTS; PROTEASES; CLONING; LINE	betaig-h3 is a transforming growth factor-beta (TGF-beta)-induced cell-adhesive molecule and has an RGD sequence at its C-terminus. A previous report suggested that betaig-h3 normally undergoes carboxy-terminal processing that results in the loss of the RGD sequence. RGD peptides appear to play various roles in cell function. Here we show that the RGD peptides released from betaig-h3 may facilitate TGF-beta-induced apoptosis. We found that carboxy-terminal cleavage of betaig-h3 occurred after its secretion, and that overexpression of the wild-type betaig-h3 induced apoptosis, unlike the C-terminal deleted but RGD-containing mutant betaig-h3, which is resistant to C-terminal processing. The betaig-h3-induced apoptosis was abolished by either deletion of the RGD sequence or mutation of RGD to RAE. Synthetic peptides of ERGDEL and GRGDSP derived from betaig-h3 and fibronectin, respectively, also induced apoptosis, unlike ERGEEL and GRGESP. Culture supernatants of cells overexpressing betaig-h3 filtered to isolate molecules smaller than 3 kDa also induced apoptosis. A fusion protein composed of the N-terminal 100 amino acids of fibronectin and the RGD-containing C-terminal part of betaig-h3 was also subjected to C-terminal cleavage and overexpression resulted in apoptosis. The anti-betaig-h3 antibody blocks TGF-beta-induced apoptosis. Thus, betaig-h3 may be important in regulating cell apoptosis by providing soluble RGD peptides.	Kyungpook Natl Univ, Dept Biochem, Sch Med, Jung Gu, Taegu 700722, South Korea; Kyungpook Natl Univ, Sch Med, Natl Res Lab, Taegu 700722, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu 700722, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Kim, IS (corresponding author), Kyungpook Natl Univ, Dept Biochem, Sch Med, Jung Gu, 101 Dongin Dong, Taegu 700722, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014					Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Genini M, 1996, INT J CANCER, V66, P571; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511	26	90	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					2045	2053		10.1038/sj.onc.1206269	http://dx.doi.org/10.1038/sj.onc.1206269			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673209				2022-12-17	WOS:000181967700014
J	Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA				Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA			Genomic profiling of gastric cancer predicts lymph node status and survival	ONCOGENE			English	Article						gastric cancer; genomic profiling; survival; microarray CGH	DNA COPY NUMBER; HELICOBACTER-PYLORI; GENETIC ALTERATIONS; INTESTINAL-TYPE; CARCINOMA; HYBRIDIZATION; DISSECTION; AMPLICON; SUBTYPES; GAINS	Gastric carcinogenesis is driven by an accumulation of genetic changes that to a large extent occur at the chromosomal level. We analysed the patterns of chromosomal instability in 35 gastric carcinomas and their clinical correlations. With microarray competitive genomic hybridization, genomewide chromosomal copy number changes can be studied with high resolution and sensitivity. A genomewide scanning array with 2275 BAC and PI clones spotted in triplicate was used. This array provided an average resolution of 1.4 Mb across the genome. Patterns of chromosomal aberrations were analysed by hierarchical cluster analysis of the normalized 1092 tumour to normal fluorescence ratios of all clones, and cluster membership was correlated to clinicopathological data including survival. Hierarchical cluster analysis revealed three groups with different genomic profiles that correlated significantly with lymph node status (P = 0.02). Moreover, gastric cancer cases from cluster 3 showed a significantly better prognosis than those from clusters I and 2 (P = 0.02). Genomic profiling of gastric adenocarcinomas based on microarray analysis of chromosomal copy number changes predicted lymph node status and survival. The possibility to discriminate between patients with a high risk of lymph node metastasis could clinically be helpful for selecting patients for extended lymph node resection.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Gastroenterol, NL-1007 MB Amsterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; KiQ Ltd, Amsterdam, Netherlands; Slotervaart Hosp, Dept Pathol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of California System; University of California San Francisco; Slotervaart Hospital	Meijer, GA (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	ga.meijer@vumc.nl	Kuipers, Ernst J/H-3293-2019	Kuipers, Ernst J/0000-0002-0633-3098; Meijer, Gerrit/0000-0003-0330-3130; Weiss, Marjan M./0000-0002-0936-1406				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202; Cuschieri A, 1999, BRIT J CANCER, V79, P1522, DOI 10.1038/sj.bjc.6690243; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Guan XY, 2000, CANCER GENET CYTOGEN, V123, P27, DOI 10.1016/S0165-4608(00)00306-X; HAUSEN AZ, 2001, GASTROENTEROLOGY, V121, P612; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Kokkola A, 1997, GENE CHROMOSOME CANC, V20, P38, DOI 10.1002/(SICI)1098-2264(199709)20:1<38::AID-GCC6>3.0.CO;2-A; Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97, DOI 10.1016/S0165-4608(99)00152-1; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SASAKO M, 1995, BRIT J SURG, V82, P346, DOI 10.1002/bjs.1800820321; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sipponen P, 1998, ALIMENT PHARM THER, V12, P61, DOI 10.1111/j.1365-2036.1998.00005.x; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SUDBERY P, 2002, HUMAN MOL GENETICS; van Dekken H, 2001, AM J PATHOL, V158, P1961, DOI 10.1016/S0002-9440(10)64666-4; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varis A, 2002, CANCER RES, V62, P2625; VISSER O, 2001, INCIDENCE CANC NETHE; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; WEISS MM, 2003, IN PRESS J PATHOL; Wu MS, 2001, GENE CHROMOSOME CANC, V30, P80, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1062>3.0.CO;2-R; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4	34	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1872	1879		10.1038/sj.onc.1206350	http://dx.doi.org/10.1038/sj.onc.1206350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660823				2022-12-17	WOS:000181678200014
J	Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG				Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG			Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas	ONCOGENE			English	Article						phaeochromocytoma; paraganglioma; SDHB; SDHD; leaky splicing	GERM-LINE MUTATIONS; COMPLEX-II GENE; RET; VHL	Phaeochromocytomas arising in adrenal or extra-adrenal sites and paragangliomas of the head and neck, in particular of the carotid bodies, occur sporadically and also in a familial setting. In addition to mutations in RET and VHL in familial disease, germline mutations in SDHD and SDHB genes that encode subunits of mitochondrial complex 11 have also been associated with the development of familial phaeochromocytomas. To further investigate the role of SDHD and SDHB in the development of these tumours we determined the occurrence of germline SDHD and SDHB mutations in four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma, one of whom had early onset disease. Secondly, we investigated whether somatic SDHB mutations correlated with loss of heterozygosity at 1p36 in a subgroup of 11 sporadic and three MEN 2-associated RET-mutation-positive phaeochromocytomas. Novel SDHB mutations were identified in the probands from four families and two apparently sporadic cases (six of seven probands studied), including two missense mutations, a single nonsense and frameshift mutation, as well as two splice site mutations, one of which was shown to have partial penetrance resulting in 'leaky' splicing Further, five intronic polymorphisms in SDHB were found. No SDHD mutations were identified. In addition, no somatic SDHB mutations were found in the remaining allele of the 11 sporadic adrenal phaeochromocytomas with allelic loss at 1p36 or the three MEN 2-associated RET-mutation-positive phaeochromocytomas. Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained.	Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Mol Med, Sydney, NSW 2006, Australia; Auckland Hosp, Dept Endocrinol, Auckland, New Zealand; Prince Wales Hosp, Hereditary Canc Clin, Sydney, NSW 2031, Australia; Univ New S Wales, Sch Med, Sydney, NSW 2031, Australia; Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Surg, Sydney, NSW 2006, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia; Univ WA, Dept Med, Nedlands, WA 6009, Australia; Melbourne Hypertens Clin, Melbourne, Vic 3002, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney; Auckland City Hospital; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney; University of Western Australia; University of Western Australia; University of Sydney	Marsh, DJ (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	Debbie_Marsh@med.usyd.edu.au; bgr@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Delbridge, leigh/0000-0001-8281-8831				Astuti, 2002, AM J HUM GENET, V70, P565; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2001, OTOLARYNG CLIN N AM, V34, P863, DOI 10.1016/S0030-6665(05)70352-2; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Benn DE, 2000, CANCER RES, V60, P7048; BENN DE, 2002, CURR OPIN ENDOCRINOL, V9, P79; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Elder EE, 2002, WORLD J SURG, V26, P965, DOI 10.1007/s00268-002-6626-8; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; Gimm O, 2000, CANCER RES, V60, P6822; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; Koch CA, 2002, ONCOGENE, V21, P479, DOI 10.1038/sj.onc.1205133; Lack EE, 1997, ATLAS TUMOR PATHOL, V3, P223; LECKSCHAT S, 1993, SOMAT CELL MOLEC GEN, V19, P505, DOI 10.1007/BF01233256; LEE SP, 1977, PATHOLOGY, V9, P173, DOI 10.3109/00313027709085255; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; SOLCIA E, 2000, WORLD HLTH ORG INT H; Svenson IK, 2001, AM J HUM GENET, V69, P1407, DOI 10.1086/324593; Taschner PEM, 2001, GENE CHROMOSOME CANC, V31, P274, DOI 10.1002/gcc.1144; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617	27	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1358	1364		10.1038/sj.onc.1206300	http://dx.doi.org/10.1038/sj.onc.1206300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618761				2022-12-17	WOS:000181360900010
J	Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R				Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R			Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines	ONCOGENE			English	Article						She family proteins; anaplastic lymphoma kinase (ALK); constitutive phosphorylation; neuroblastoma; gene amplification	NON-HODGKINS-LYMPHOMA; PHOSPHOTYROSINE BINDING DOMAIN; RECEPTOR TYROSINE KINASE; HUMAN N-MYC; ADAPTER PROTEIN; MAMMARY TUMORIGENESIS; TRANSFORMING ACTIVITY; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION	She family of docking proteins, ShcA, Shell and ShcC, play roles in cellular signal transduction by binding to phosphotyrosine residues of various activated receptor tyrosine kinases. Both Shell and ShcC proteins are selectively expressed in the neural system of adult mouse tissues. In most of neuroblastoma cells, obvious tyrosine phosphorylation of ShcC was observed, whereas expression of ShcB was considerably low. Phosphoproteins associated with hyperphosphorylated ShcC were purified from neuroblastoma cell lines, and identified by mass-spectrometry. Anaplastic lymphoma kinase (ALK), which turned out to be one of these phosphoproteins, was constitutively activated and associated with the PTB domain of ShcC in three neuroblastoma cells. In vitro kinase assay revealed that ShcC is a potent substrate of the activated ALK kinase. The ALK gene locus was significantly amplified in both of these cell lines, suggesting that gene amplification leads to constitutive activation of the ALK kinase, which results in hyperphosphorylation of ShcC. Constitutive activation of ALK appeared to interfere with signals from other receptor tyrosine kinases. ALK-ShcC signal activation, possibly caused. by co-amplification with the N-myc gene, might give additional effects on malignant tumor progression of neuroblastoma.	Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuo Ku, Tokyo 1040045, Japan; Kirin Brewery Co Ltd, Lab Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Meiji Pharm Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Kirin Brewery Company Limited; Meiji Pharmaceutical University; Kitasato University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, 5-1-1 Tsukuji, Tokyo 1040045, Japan.			Sakai, Ryuichi/0000-0001-6833-1103				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; George RE, 1996, ONCOGENE, V12, P1583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; KUGA N, 1975, GANN, V66, P547; Lai KMV, 2000, GENE DEV, V14, P1132; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LAYFIELD LJ, 1995, J SURG ONCOL, V59, P21, DOI 10.1002/jso.2930590107; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nojiri H, 1999, FEBS LETT, V453, P140, DOI 10.1016/S0014-5793(99)00709-7; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; OLE NJ, 1996, RAPID COMMUN MASS SP, V10, P1371; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, J BIOL CHEM, V269, P32740; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SOUTHERN EM, 1975, J MOL BIOL, V94, P51, DOI 10.1016/0022-2836(75)90404-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGIMOTO T, 1984, J NATL CANCER I, V72, P923; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287	54	90	95	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5823	5834		10.1038/sj.onc.1205735	http://dx.doi.org/10.1038/sj.onc.1205735			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185581				2022-12-17	WOS:000177520900001
J	Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F				Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F			Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer	ONCOGENE			English	Article						erbA; thyroid receptor genes; thyroid hormone; breast cancer; mutation	MOUSE MAMMARY-GLANDS; C-ERBA-BETA; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; V-ERBA; ESTROGEN; TUMORS; AMPLIFICATION; MUTATIONS; PROMOTER	The relation between thyroid status and diseases and cancer is unclear. No detailed analysis of thyroid hormone receptor (TR) expression in human breast cancer has been reported. We have analysed the expression and mutational status of the TRalpha1, encoded by the c-erbA proto-oncogene, TRbeta1 and TRbeta2 isoforms in 70 sporadic breast cancers. Alterations in the RNA level of TRbeta1, TRalpha1, or both were found in a number of patients. No expression of TRbeta2 RNA was detected. Western blotting analysis confirmed the differences in expression at the protein level in those cases where sufficient tumor sample was available. Additionally, tumor-specific truncated TRbeta1 RNA was found in six patients. Strikingly, three transcripts shared the same breakpoint. Only one tumor carried the corresponding deletion at the genomic DNA level, suggesting that the remaining abnormal TR[11 transcripts are aberrant splicing products. Though no significant correlation was found between TRbeta1 alteration and any clinical parameter, it showed a tendency to associate with early age of onset (<50 years). Our results reveal specific alterations in the expression of TRbeta and TRalpha genes in a subset of breast cancer patients, suggesting that deregulation of thyroid hormone target genes may be involved in the generation of this neoplasia.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.	felixbv@stnet.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Munoz, Alberto/O-6393-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Munoz, Alberto/0000-0003-3890-4251				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARBUTHNOT P, 1989, ANTICANCER RES, V9, P885; Armitage P., 1987, STAT METHODS MED RES; Ballinger SW, 1996, CANCER RES, V56, P5692; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BURKE RE, 1978, CANCER RES, V38, P3769; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CERBON MA, 1981, CANCER RES, V41, P4167; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CIDLOWSKI JA, 1975, ENDOCRINOLOGY, V97, P59, DOI 10.1210/endo-97-1-59; Collingwood TN, 1998, EMBO J, V17, P4760, DOI 10.1093/emboj/17.16.4760; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DOBROVIC A, 1988, CANCER RES, V48, P682; Dressel U., 2001, NUCL RECEPTORS DIS, P59; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V166, P155, DOI 10.1016/S0303-7207(00)00328-2; FEI ZL, 1992, ENDOCRINOLOGY, V130, P1145; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; FUTREAL PA, 1994, CANCER RES, V54, P1791; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gonzalez-Sancho JM, 1999, MOL CARCINOGEN, V24, P99, DOI 10.1002/(SICI)1098-2744(199902)24:2<99::AID-MC4>3.0.CO;2-#; GUERNSEY DL, 1993, CANCER J - FRANCE, V6, P253; HEDLEY AJ, 1981, LANCET, V1, P131; HOUDEBINE LM, 1978, BIOCHIMIE, V60, P809, DOI 10.1016/S0300-9084(78)80027-3; HuberGieseke T, 1997, ONCOLOGY, V54, P214; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x; Lukas J, 2001, CANCER RES, V61, P3212; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MARTINEZ L, 1995, EUR J ENDOCRINOL, V132, P673, DOI 10.1530/eje.0.1320673; Martinez MB, 2000, CANCER CHEMOTH PHARM, V45, P93, DOI 10.1007/s002800050016; McCabe CJ, 1999, J CLIN ENDOCR METAB, V84, P649, DOI 10.1210/jc.84.2.649; Munoz A, 1997, EUR J ENDOCRINOL, V137, P433, DOI 10.1530/eje.0.1370433; Nogueira CR, 1996, J STEROID BIOCHEM, V59, P271, DOI 10.1016/S0960-0760(96)00117-3; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SELLITTI DF, 1983, CANCER RES, V43, P1030; SINGH DV, 1969, J ENDOCRINOL, V45, P579, DOI 10.1677/joe.0.0450579; SMALLRIDGE RC, 1980, CLIN RES, V28, pA421; Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335; Smyth PPA, 1996, J CLIN ENDOCR METAB, V81, P937, DOI 10.1210/jc.81.3.937; Strain JJ, 1997, NUTR CANCER, V27, P48, DOI 10.1080/01635589709514500; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; Vasudevan N, 2001, MOL BRAIN RES, V95, P9, DOI 10.1016/S0169-328X(01)00165-6; Vasudevan N, 2001, J NEUROENDOCRINOL, V13, P779, DOI 10.1046/j.1365-2826.2001.00693.x; VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409; VONDERHAAR BK, 1986, ENDOCRINOLOGY, V119, P580, DOI 10.1210/endo-119-2-580; VONDERHAAR BK, 1977, ENDOCRINOLOGY, V100, P1423, DOI 10.1210/endo-100-5-1423; WALLIN G, 1992, THYROID, V2, P307, DOI 10.1089/thy.1992.2.307; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Yokoe T, 1997, ANTICANCER RES, V17, P695; Zhu YS, 1996, P NATL ACAD SCI USA, V93, P12587, DOI 10.1073/pnas.93.22.12587	63	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4307	4316		10.1038/sj.onc.1205534	http://dx.doi.org/10.1038/sj.onc.1205534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082618				2022-12-17	WOS:000176174200013
J	Coles, LC; Shaw, PE				Coles, LC; Shaw, PE			PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway	ONCOGENE			English	Article						Rho proteins; PAKs; MEKs; phospho-specific antibodies; regulatory phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; RAS; SERINE; BINDING; IDENTIFICATION; INHIBITION; RESIDUES; COMPLEX; SITES	The serine/threonine kinase Raf-1 acts downstream of Ras in the MAPK pathway leading to ERK activation in response to mitogens. Raf-1 has oncogenic potential, but is normally controlled by a complex interplay of inhibitory and activating mechanisms. Although Raf-1 is phosphorylated in unstimulated cells, mitogens cause its membrane recruitment by Ras and subsequent phosphorylation on additional sites. Some of these events modulate Raf-1 kinase activity while others determine interactions with other proteins. These changes regulate the ability of Raf-I to phosphorylate its downstream targets MEK1 and MEK2. Rho family small G proteins act synergistically with Raf-I to stimulate the ERK pathway by a cross-cascade mechanism that enhances MEK phosphorylation by Raf-1. Here we show that both Raf-1 and MEK1 are phosphorylated by PAK1 and that mutations at PAK1 phosphorylation sites in either protein prevent cross-cascade activation. In contrast, MEK1 activation by constitutively-active Raf-1 is refractory to mutations at PAK1 phosphorylation sites. Phosphorylation of MEK1 on serine 298 does not appear to regulate the interaction between Raf-1 and MEK1, but rather the ability of Raf-I to phosphorylate MEK1 with which it is complexed in vivo. Our findings indicate that PAK1 primes MEK1 for activation by Raf-1 and imply another level of regulation in the ERK cascade.	Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	33	90	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2236	2244		10.1038/sj.onc.1205302	http://dx.doi.org/10.1038/sj.onc.1205302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948406				2022-12-17	WOS:000174555300012
J	Aspland, SE; Bendall, HH; Murre, C				Aspland, SE; Bendall, HH; Murre, C			The role of E2A-PBX1 in leukemogenesis	ONCOGENE			English	Article						E2A-Pbx1; pre-B cell acute lymphoblastic leukemia; Hox cofactor	COOPERATIVE DNA-BINDING; LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; CHIMERIC ONCOPROTEIN E2A-PBX1; ACUTE MYELOID-LEUKEMIA; B-CELL DEVELOPMENT; WNT GENE FAMILY; PRE-B; HOMEODOMAIN PROTEIN		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Aspland, SE (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Aspland SE, 1997, DEVELOPMENT, V124, P741; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; Bayly R, 2000, MOL CELL BIOL, V20, P5789, DOI 10.1128/MCB.20.16.5789-5796.2000; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Buske C, 2000, INT J HEMATOL, V71, P301; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; CARROLL AJ, 1984, BLOOD, V63, P721; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; CHU C, 2000, J BIOL CHEM, V12, P12; CRIST WM, 1990, BLOOD, V76, P117; de Lau WBM, 1998, ONCOGENE, V17, P503, DOI 10.1038/sj.onc.1201967; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Feldman BJ, 2000, BLOOD, V96, P1906, DOI 10.1182/blood.V96.5.1906.h8001906_1906_1913; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; Fu XY, 1999, ONCOGENE, V18, P4920, DOI 10.1038/sj.onc.1202874; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; HUNGER SP, 1991, BLOOD, V77, P687; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kurant E, 1998, DEVELOPMENT, V125, P1037; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LeBrun DP, 1997, ONCOGENE, V15, P2059, DOI 10.1038/sj.onc.1201367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Massari ME, 1996, MOL CELL BIOL, V16, P121; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Polakis P, 2000, GENE DEV, V14, P1837; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Shimamoto T, 1998, INT J HEMATOL, V67, P339; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; THROSTEINSDOTTI. U, 1997, MOL CELL BIOL, V17, P495; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	99	90	93	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5708	5717		10.1038/sj.onc.1204592	http://dx.doi.org/10.1038/sj.onc.1204592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607820				2022-12-17	WOS:000170887500011
J	Wolffe, AP				Wolffe, AP			Chromatin remodeling: why it is important in cancer	ONCOGENE			English	Review						cell cycle; acetyltransferase; reacetylase methyltransferase; ATPase; RNA polymerase	CORE HISTONE ACETYLATION; NUCLEOSOME MOBILITY; POSITIVE ROLE; TRANSCRIPTION; DNA; COMPLEX; GENE	A typical human cell expresses only a few thousand of the more than 30000 genes contained within our chromosomes. The chromosomal infrastructure is essential for gene control, determining both active and repressed states. It is important not only to turn the right genes on but also to turn the right genes off. Histones and chromatin components have key roles in this decision making process. Mistakes ha re severe consequences. If as few as three inappropriate genes are turned off, a normal cell can be converted into a cancer cell. This epigenetic silencing of genes underlies a new approach to cancer therapy. Advances in the biochemistry and genetics of chromatin remodeling reveal that gene inactivation depends on the recruitment of enzymes that control the display of DNA within the chromosome. Mistargeting of these enzymes leads to tumorigenesis, but inhibition of their activity presents a novel approach to therapy.	Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.							GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, V2, P949; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU PQ, 2001, IN PRESS J BIOL CHEM; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; VETESSEDADEY M, 1996, EMBO J, V15, P2508; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; Wolffe AP., 1998, CHROMATIN STRUCTURE; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	20	90	93	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					2988	2990		10.1038/sj.onc.1204322	http://dx.doi.org/10.1038/sj.onc.1204322			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420713				2022-12-17	WOS:000169308500001
J	Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y				Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y			p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues	ONCOGENE			English	Article						PCNA; p21; tumor; PIP box	CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; D-TYPE CYCLINS; DNA-REPLICATION; BINDING; P21; P21(WAF1/CIP1); PROGNOSIS; INHIBITOR; CARCINOMA	Proliferating cell nuclear antigen (PCNA) is an essential protein in both DNA replication and DNA damage repair. A novel 15 kD protein, p15(PAF), was identified as a PCNA-associated factor in a yeast two-hybrid screen using PCNA as the bait, p15(PAF) is localized primarily in the nucleus. p15(PAF) shares the conserved PCNA binding motif with several other PCNA binding proteins including CDK inhibitor p21. Overexpression of p15(PAF) competes with p21-PCNA binding. Mutation of this motif in p15(PAF) abolished its PCNA-binding activity. Notably, p15(PAF) expression in several types of tumor tissues was significantly increased, especially in esophageal tumors. Like PCNA, p15(PAF) may possess prognostic significance in a broad array of human cancers.	Rigel Pharmaceut Inc, S San Francisco, CA 94080 USA; Univ N Carolina, Lineberger Canc Ctr 22012, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Luo, Y (corresponding author), Rigel Pharmaceut Inc, 240 E Grand Ave, S San Francisco, CA 94080 USA.							Baekelandt M, 1999, CLIN CANCER RES, V5, P2848; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kuwahara M, 1999, DIS ESOPHAGUS, V12, P116, DOI 10.1046/j.1442-2050.1999.00034.x; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Natsugoe S, 1999, CLIN CANCER RES, V5, P2445; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	26	90	98	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					484	489		10.1038/sj.onc.1204113	http://dx.doi.org/10.1038/sj.onc.1204113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313979				2022-12-17	WOS:000166562500008
J	Bartel, FO; Higuchi, T; Spyropoulos, DD				Bartel, FO; Higuchi, T; Spyropoulos, DD			Mouse models in the study of the Ets family of transcription factors	ONCOGENE			English	Article						Ets family; knockout; targeted disruption; hematopoiesis; angiogenesis	EMBRYONIC STEM-CELLS; FACTOR PU.1; SPI-B; MICE LACKING; BONE-MARROW; DIFFERENTIATION; HEMATOPOIESIS; GENE; PROTOONCOGENE; PROGENITORS	The Ets family of transcription factors is one of a growing number of master regulators of development. This family was originally defined by the presence of a conserved DNA binding domain, the Ets domain. To date, nearly 30 members of this family have been identified and implicated in a wide range of physiological and pathological processes. Despite the likely importance of Ets-family members, each of their precise roles has not been delineated. Herein, we describe the elucidation of essential functions of a few of these family members in vivo using knockout mouse models, Of the knockouts generated to date, the majority shows important functions in hematopoiesis, ranging from PU.1, a principle regulator of myelo-lymphopoiesis, to Spi-B which regulates the proper function of terminally differentiated cells. Ets1 was shown to be of intermediate importance as a regulator of pan-lymphoid development. Other Ets family members such as Fli1 and TEL1 display distinct and/or overlapping functions in vasculo/angiogenesis, hemostasis and hematopoiesis. The remaining knockouts generated, Ets2 and Er81, show non-hematopoietic defects related to extraembryonic development and neurogenesis, respectively. The pioneering group of knockout models described reveals only the most distinct functions of each of these Ets family members. A better understanding of the roles and hierarchies of Ets family members in cellular differentiation will come with the generation of new null alleles in previously untargeted family members, more mutant alleles in members already disrupted, double knockouts, ES cell differentiation and chimera rescue experiments, and tissue-specific inducible knockouts.	Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Spyropoulos, DD (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA.				NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Garrett-Sinha LA, 1999, IMMUNITY, V10, P399, DOI 10.1016/S1074-7613(00)80040-0; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Henkel GW, 1999, BLOOD, V93, P2849; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Lichanska AM, 1999, BLOOD, V94, P127, DOI 10.1182/blood.V94.1.127.413k07_127_138; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melet F, 1996, MOL CELL BIOL, V16, P2708; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Orkin SH, 1999, CANCER RES, V59, p1784S; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Spain LM, 1999, J IMMUNOL, V163, P2681; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WATSON DK, 2001, ENCY CANC; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	44	90	94	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6443	6454		10.1038/sj.onc.1204038	http://dx.doi.org/10.1038/sj.onc.1204038			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175360				2022-12-17	WOS:000166595000006
J	Wang, T; Hopkins, D; Schmidt, C; Silva, S; Houghton, R; Takita, H; Repasky, E; Reed, SG				Wang, T; Hopkins, D; Schmidt, C; Silva, S; Houghton, R; Takita, H; Repasky, E; Reed, SG			Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis	ONCOGENE			English	Article						lung squamous cell carcinoma (LSCC); microarray; cDNA subtraction; connexin 26; plakophilin 1; keratin	PROLINE-RICH PROTEIN; CANCER; PEPTIDE; TUMORS; P53; BREAST; TISSUE; LINES; ATM	In order to develop effective vaccine products against human cancer, we are interested in identifying genes over-expressed in tumor cells. Through a combination of cDNA library subtraction and microarray technology, we identified seventeen genes preferentially expressed in lung squamous cell carcinoma, including four novel genes. To date, expression profiles of these genes were confirmed by Northern and/or real-time analysis, and several genes were also found to be expressed in head and neck squamous tumors. Thus, these combined methods represent a high throughput approach for identifying tumor specific genes. Furthermore, the report of characterization on these genes will allow them to be exploited for their diagnostic, prognostic, and therapeutic potentials including immunotherapy and antibody based anticancer therapy.	Corixa Corp, Dept Tumor Antigen Discovery, Seattle, WA 98104 USA; Roswell Pk Canc Ctr, Dept Surg, Buffalo, NY 14263 USA; Roswell Pk Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA	Corixa; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Wang, T (corresponding author), Corixa Corp, Dept Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.							AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Brechot JM, 1997, EUR J CANCER, V33, P385, DOI 10.1016/S0959-8049(97)89010-7; Davidson LA, 1996, J PATHOL, V178, P398; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hibi K, 1998, CANCER RES, V58, P5690; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; OCCLESTON NL, 1993, CANCER LETT, V71, P203, DOI 10.1016/0304-3835(93)90117-R; Pastor A, 1997, EUR RESPIR J, V10, P603; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; Robbins PF, 1996, CURR OPIN IMMUNOL, V8, P628, DOI 10.1016/S0952-7915(96)80078-1; ROBINSON PA, 1994, ARCH ORAL BIOL, V39, P251, DOI 10.1016/0003-9969(94)90051-5; SARGENT TD, 1983, SCIENCE, V222, P133; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P4305, DOI 10.1074/jbc.270.9.4305; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101	29	90	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1519	1528		10.1038/sj.onc.1203457	http://dx.doi.org/10.1038/sj.onc.1203457			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734311	hybrid			2022-12-17	WOS:000086108100004
J	Zrihan-Licht, S; Fu, YG; Settleman, H; Schinkmann, K; Shaw, L; Keydar, I; Avraham, S; Avraham, H				Zrihan-Licht, S; Fu, YG; Settleman, H; Schinkmann, K; Shaw, L; Keydar, I; Avraham, S; Avraham, H			RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion	ONCOGENE			English	Article						RAFTK; RhoGAP; RasGAP; ErbB-2; invasion	FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; GROWTH-FACTOR; ACTIN CYTOSKELETON; PHOSPHORYLATION; RECEPTOR; BINDING; MEGAKARYOCYTES; STIMULATION	Focal adhesions and actin cytoskeleton are involved in cell growth, shape and movement and in tumor invasion. Mitogen-induced changes in actin cytoskeleton are accompanied by changes in the tyrosine phosphorylation of several focal adhesion proteins. in this study, we have investigated the role of RAFTK, a cytoplasmic tyrosine kinase related to focal adhesion kinase (FAK), in heregulin-mediated signal transduction in breast cancer cells. Stimulation of T47D cells with heregulin (HRG) induced the tyrosine phosphorylation of RAFTK and the formation of a multiprotein complex;, Analyses of the members of the HRG-stimulated complex revealed that RAFTK is associated with p190 RhoGAP (p190), RasGAP and ErbB-2, and plays an essential role in mediating the tyrosine phosphorylation of plop by Src, Mutation of the Src binding site within RAFTK (402) abolished the phosphorylation of p190. In addition, upon HRG stimulation of T47D cells, association of ErbB-2 with RAFTK was observed and found to be indirect and mediated by Src. Expression of wild-type RAFTK (WT) significantly increased MDA-MB-435 and MCF-7 breast cancer cell invasion, while expression of the kinase-mutated RAFTK-R457 (KM) or the Src binding site mutant RAFTM (402) did not affect this cell invasion. Furthermore, HRG leads to tbe activation of MAP kinase which is mediated by RAFTK. These findings indicate that RAFTK serves as a mediator and an integration paint between the GAP proteins and HRG-mediated signaling in breast cancer cells, and implicate RAFTK involvement in the MAP kinase pathway and in breast cancer cell invasion.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02125 USA; Harvard Univ, Sch Med, Boston, MA 02125 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tel Aviv University	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55455, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen HC, 1996, EUR J BIOCHEM, V235, P495, DOI 10.1111/j.1432-1033.1996.00495.x; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; Cohen BM, 1996, J BIOL CHEM, V271, P4813; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kumar R, 1996, J CELL BIOCHEM, V62, P102; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, J CELL SCI, V108, P225; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AL, 1993, CELL, V70, P389; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063	50	90	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1318	1328		10.1038/sj.onc.1203422	http://dx.doi.org/10.1038/sj.onc.1203422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713673				2022-12-17	WOS:000085743800008
J	Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y				Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y			Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31	ONCOGENE			English	Article						chromosome 9; microsatellites; bladder cancer; tumor suppressor gene	TRANSITIONAL-CELL CARCINOMA; INTERNATIONAL WORKSHOP; HOMOZYGOUS DELETIONS; GENE; YAC; UK; HETEROZYGOSITY; LOCALIZATION; CAMBRIDGE; COLLEGE	The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9, However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been Located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-I, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.	Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada; CHU Quebec, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada.			Fradet, Yves/0000-0002-7581-2500	NCI NIH HHS [CA47526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047526, R01CA047526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1995, CLIN CANCER RES, V1, P1195; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DEVLIN J, 1994, ONCOGENE, V9, P2757; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KAMB A, 1994, SCIENCE, V264, P440; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LARUE H, 1995, CLIN CANCER RES, V1, P435; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MARCHUK DA, 1994, ANN HUM GENET, V58, P224; MCDONALD MT, 1994, NAT GENET, V6, P197, DOI 10.1038/ng0294-197; MELDGAARD P, 1995, INT J CANCER, V63, P341, DOI 10.1002/ijc.2910630306; MERLO A, 1994, CANCER RES, V54, P2322; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORTHRUP H, 1994, ANN HUM GENET, V58, P229; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; Ozelius LJ, 1997, GENOME RES, V7, P483, DOI 10.1101/gr.7.5.483; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; Povey S, 1997, ANN HUM GENET, V61, P183, DOI 10.1017/S0003480097006106; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; POVEY S, 1992, ANN HUM GENET, V56, P167, DOI 10.1111/j.1469-1809.1992.tb01145.x; ROUSSEAU F, 1994, HUM MUTAT, V4, P51, DOI 10.1002/humu.1380040107; RUPPERT JM, 1993, CANCER RES, V53, P5093; Shapiro GI, 1996, BBA-REV CANCER, V1242, P165, DOI 10.1016/0304-419X(95)00011-4; Simoneau AR, 1996, CANCER RES, V56, P5039; STADLER WM, 1994, CANCER RES, V54, P2060; TANAKA M, 1995, CANCER RES, V55, P3228; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	39	90	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					157	163		10.1038/sj.onc.1202277	http://dx.doi.org/10.1038/sj.onc.1202277			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926930	Bronze			2022-12-17	WOS:000078166000017
J	Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M				Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M			Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering	ONCOGENE			English	Article						HGF; cell scattering; MAP kinase signaling pathway; MEK inhibitor	MET PROTOONCOGENE PRODUCT; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; RAS ACTIVATION; FAMILY; CASCADE; INHIBITION	Hepatocyte growth factor (HGF) markedly induced the spreading, dissociation and scattering of Madin-Darby canine kidney epithelial cells (MDCK) and human stomach adenocarcinoma cells (TMK1). Scattering of MDCK and TMK1 cells was induced by 12-O-tetradecanoyl-phorbol-13-acetate (PMA) and epidermal growth factor (EGF), respectively. In all these agent-stimulated cells, rapid activation of Raf-l, MAP kinase/ERK kinase (MEK), 41/43 kDa MAP kinases and p90(rsk) was commonly observed. In contrast, PMA neither induced the scattering nor activation of all these kinases in TMK1 cells. Pretreatment of MDCK and TMK1 cells with 2-(2-amino-3-methoxyphenyl) choromone (AMPC), a specific inhibitor of MEK, selectively inhibited the HGF-, PMA- and EGF-stimulated activities of MEM, 41/43 kDa MAP kinases and p90(rsk) in a dose dependent manner. AMPC-pretreatment, however, did not affect HGF-, PMA- or EGF-induced activation of Raf-l, nor HGF-induced activation of phosphatidylinositol 3-kinase in these cells. Importantly, HGF-, PMA- and EGF-induced scattering of MDCK and TMK1 cells was inhibited at doses of AMPC similar to those that gave comparable levels of inhibition of the activities of MER, 41/43 kDa MAP kinases and p90(rsk), These results suggest that activation of the 41/43 kDa MAP kinase signaling pathway is required for the motility response of MDCK and TMK1 cells induced by agents such as HGF, PMA and EGF.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 502, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan	Nagasaki University; Gifu Pharmaceutical University; Osaka University	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P273; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1995, ONCOGENE, V11, P1327; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Schramek H, 1997, J BIOL CHEM, V272, P11426; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883	44	90	95	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					57	65		10.1038/sj.onc.1201905	http://dx.doi.org/10.1038/sj.onc.1201905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671314				2022-12-17	WOS:000074677800007
J	Le, XF; Vallian, S; Mu, ZM; Hung, MC; Chang, KS				Le, XF; Vallian, S; Mu, ZM; Hung, MC; Chang, KS			Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis	ONCOGENE			English	Article						Ad-PML; breast cancer; tumorgenicity; G1 arrest; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; GENE-THERAPY; RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR MATRIX; NUDE-MICE; PROTEIN; ONCOPROTEIN; EXPRESSION; BODIES	Our previous studies demonstrated that the promyelocytic leukemia gene, PML which involved in the 15;17 translocation in acute promyelocytic leukemia (APL) is a growth and transformation suppressor. In this study, recombinant PML adenovirus, Ad-PML was constructed and used to infect human breast cancer cells in vitro and in vivo, the anti-oncogenic function of PML and its mechanism of growth suppressing effect in breast cancer cells were examined. We showed that Ad-PML effectively infected the MCF-7 and SK-BR-3 cells. A high level of PML protein was expressed within 24 h post-infection and a detectable level remained at day 16. Ad-PML significantly suppressed the growth rate, clonogenicity, and tumorigenicity of breast cancer cells. Intratumoral injections of MCF-7-induced tumors by high titer Ad-PML suppressed tumor growth in nude mice by about 80%. The injection sites expressed high level of PML and associated with a massive apoptotic cell death. To elucidate the molecular mechanism of PML's growth suppressing function, we examined the effect of Ad-PML on cell cycle distribution in MCF-7 and SK-BR-3 cells. We found that Ad-PML infection caused a cell cycle arrest at the G1 phase, We further showed that G1 arrest of MCF-7 cells is associated with a significant decrease in cyclin DI and CDK2. An increased expression of p53, p21 and cyclin E was found. The Rb protein became predominantly hypophosphorylated 48 h post-infection. These findings indicate that PML exerts its growth suppressing effects by modulating several key G1 regulatory proteins. Our study provides important insight into the mechanism of tumor suppressing function of PML and suggests a potential application of Ad-PML in human cancer gene therapy.	Univ Texas, Md Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA.		Vallian, Sadeq/AAA-7085-2020; Hung, Mien-Chie/ABD-5911-2021	Vallian, Sadeq/0000-0002-5151-5923; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA-55577, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA055577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ealovega MW, 1996, CANCER RES, V56, P1965; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FORBES JF, 1997, SEMIN ONCOL S1, V24; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorospe M, 1996, MOL CELL BIOL, V16, P762; He DL, 1997, CANCER RES, V57, P1868; Hortobagyi GN, 1996, SEMIN ONCOL, V23, P1; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Katayose D, 1995, CLIN CANCER RES, V1, P889; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Kwong YL, 1996, CANCER GENE THER, V3, P339; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mu ZM, 1996, LEUKEMIA LYMPHOMA, V23, P277, DOI 10.3109/10428199609054830; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MU ZM, 1997, IN PRESS CARCINOGENE; NASONBURCHENAL K, 1996, BLOOD, V88, P3928; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Piccart M, 1996, ANTI-CANCER DRUG, V7, P5, DOI 10.1097/00001813-199608001-00002; RUNNEBAUM IB, 1995, HYBRIDOMA, V14, P153, DOI 10.1089/hyb.1995.14.153; Seth P, 1996, CANCER RES, V56, P1346; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stadler M, 1995, ONCOGENE, V11, P2565; SU N, 1994, BREAST CANCER RES TR, V31, P349, DOI 10.1007/BF00666167; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yee D, 1996, HUM GENE THER, V7, P1251, DOI 10.1089/hum.1996.7.10-1251; ZHANG JF, 1996, P NATL ACAD SCI USA, V93, P4518	52	90	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1839	1849		10.1038/sj.onc.1201705	http://dx.doi.org/10.1038/sj.onc.1201705			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583681				2022-12-17	WOS:000072994600007
J	Hellin, AC; Calmant, P; Gielen, J; Bours, V; Merville, MP				Hellin, AC; Calmant, P; Gielen, J; Bours, V; Merville, MP			Nuclear factor - kappa B-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug	ONCOGENE			English	Article						daunomycin; p53; transcriptional activation; NF-kappa B	DAUNORUBICIN-INDUCED APOPTOSIS; CELLULAR TUMOR-ANTIGEN; WILD-TYPE P53; TRANSCRIPTION FACTOR; DNA-BINDING; ONCOPROTEIN BCL-3; ALPHA PROTEOLYSIS; NECROSIS-FACTOR; SUPPRESSOR P53; CYCLE ARREST	Anthracycline drugs are widely used for the treatment of solid tumors and leukemia, but the molecular basis of their biological effect is still poorly understood, In the HCT 116 colon carcinoma cell line, which retains a wild-type inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kappa B transcription factors, Nuclear accumulation of p53 protein occurred because of increased protein stability and enhanced gene expression, In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappa B heterodimers to the kappa B site in the p53 promoter, Under our conditions, the free radical scavengers NAC and PDTC were not able to block NF-kappa B activation or p53 induction, indicating that reactive oxygen intermediates were not involved in the cellular response to daunomycin stimulation. Overexpression of a stable unresponsive I kappa B alpha mutant in HCT116 cells resulted in a complete inhibition of the NF-kappa B activation but only a partial impairment of the p53 protein accumulation induced by daunomycin, We conclude that the p53-activating signal generated by daunomycin is partially regulated by NF-kappa B.	Univ Liege, Med Chem Lab, B-4000 Liege, Belgium; Univ Liege, Lab Med Oncol, B-4000 Liege, Belgium	University of Liege; University of Liege	Merville, MP (corresponding author), Univ Liege, Med Chem Lab, B-4000 Liege, Belgium.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BAE L, 1995, CANCER RES, V55, P2387; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GINSBERG D, 1990, ONCOGENE, V5, P1285; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P77; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; PIRET B, 1995, EUR J BIOCHEM, V228, P444; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1989, ONCOGENE, V4, P945; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WU HY, 1994, J BIOL CHEM, V269, P20067; YAMAMOTO K, 1992, PROGR IMMUNOL, V8, P369	76	90	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1187	1195		10.1038/sj.onc.1201638	http://dx.doi.org/10.1038/sj.onc.1201638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528861				2022-12-17	WOS:000072336000010
J	Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG				Viglietto, G; Romano, A; Manzo, G; Chiappetta, G; Paoletti, I; Califano, D; Galati, MG; Mauriello, V; Bruni, P; Lago, CT; Fusco, A; Persico, VG			Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization	ONCOGENE			English	Article						PlGF; VEGF; TSH; thyroid goiter; hypervascularization	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; PLACENTA; CELLS; EXPRESSION; HEPARIN; IDENTIFICATION; THYROTROPIN; STIMULATION	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) represent two closely related angiogenic growth factors active as homodimers or heterodimers. Since goiters of the thyroid gland are extremely hypervascular, we investigated the expression of PlGF, VEGF and their receptors, Flt-1 and Flk-1/KDR, in a small panel of human goiters from patients with Graves's disease, in an animal model of thyroid goitrogenesis and in in vitro cultured thyroid cells. Here we report that the mRNA expression of PlGF, VEGF and their receptors is markedly enhanced in biopsies of goiters resected from Graves's patients. in vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PlGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation. In vitro studies confirmed the existence of such TSH-dependent paracrine communication between thyroid epithelial cells and endothelium since the conditioned medium collected from TSH-stimulated thyrocytes acquired mitogenic activity for human umbilical vein endothelial (HUVE) cells, Altogether, these data suggest that PlGF and VEGF, released by thyrocytes in response to the chronic activation of the TSH receptor pathway, may act through a paracrine mechanism on thyroid endothelium.	CNR, INT INST GENET & BIOPHYS, I-80125 NAPLES, ITALY; IST NAZL TUMORI FONDAZ SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universita Mediterranea di Reggio Calabria			Viglietto, Giuseppe/AAC-2852-2019; Califano, Daniela/Y-6313-2018	Viglietto, Giuseppe/0000-0003-2327-7515; Califano, Daniela/0000-0001-6945-3209; Fusco, Alfredo/0000-0003-3332-5197				BRANDT R, 1994, J BIOL CHEM, V269, P17320; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DiPalma T, 1996, MAMM GENOME, V7, P6, DOI 10.1007/s003359900003; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOODMAN AL, 1987, ENDOCRINOLOGY, V121, P2131, DOI 10.1210/endo-121-6-2131; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; ROGNONI JB, 1984, ACTA ENDOCRINOL-COP, V105, P40, DOI 10.1530/acta.0.1050040; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMEDS S, 1983, LAB INVEST, V48, P285; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; VANSANDE J, 1975, ENDOCRINOLOGY, V96, P781, DOI 10.1210/endo-96-3-781; Viglietto G, 1996, ONCOGENE, V13, P577; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WILSON JD, 1989, THYROID TXB ENDOCRIN; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; WYNFORDTHOMAS D, 1982, J ENDOCRINOL, V94, P131, DOI 10.1677/joe.0.0940131; YUN K, 1986, J ENDOCRINOL, V111, P397, DOI 10.1677/joe.0.1110397; Ziche M, 1997, LAB INVEST, V76, P517	33	90	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2687	2698		10.1038/sj.onc.1201456	http://dx.doi.org/10.1038/sj.onc.1201456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400995				2022-12-17	WOS:A1997YH46800006
J	Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ				Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ			Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1	ONCOGENE			English	Article						Wilms' tumor; DNA-binding protein; zincfinger; WT1; kidney development; syndecan-1	ZINC FINGER PROTEIN; GENE-PRODUCT; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; MAMMALIAN-CELLS; DNA-BINDING; EXPRESSION; REPRESSION; GROWTH; LOCUS	The Wilms' tumor suppressor gene (wt1) encodes a zinc finger DNA binding protein (WT1) which functions as a transcriptional regulator and is essential for normal urogenital development. WT1 has previously been shown to repress the transcription of a variety of target genes whose products stimulate growth, such as growth factors, growth factor receptors and other transcription factors. In this study, we identify syndecan-1 as a target gene for WT1-mediated activation. Syndecan-1 is a cell surface proteoglycan whose induction is coincident with epithelial differentiation during kidney development and whose loss of expression is correlated with the loss of the epithelial phenotype and malignant transformation. The murine syndecan-1 promoter contains several potential binding sites for WT1. We demonstrate that both WT1 (-KTS) and WT1 (+KTS) isoforms bind to multiple sites in this highly G+C-rich region, as detected by gel-shift analyses. These WT1 isoforms function as transcriptional activators of syndecan-1 expression in transient transfection assays. Activation of syndecan-1 by WT1 is dependent on an intact zinc-finger region as well as a 179 amino acid proline-rich region in the amino terminus of the protein. Moreover, the endogenous syndecan-1 gene is activated by WT1 in a novel inducible cell line based upon the sheep metallothionein promoter. These results highlight an emerging role for WT1 as an activator of genes like syndecan-1 which may potentiate epithelial differentiation and maintenance in the developing kidney.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	The Wistar Institute; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006763, R01HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HINKES MT, 1993, J BIOL CHEM, V268, P11440; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INKI P, 1991, AM J PATHOL, V139, P1333; JALKANEN M, 1991, BIOCHEM SOC T, V19, P1069, DOI 10.1042/bst0191069; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KATO M, 1995, MOL CELL BIOL, V6, P554; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LELONGT B, 1988, DEV BIOL, V128, P256, DOI 10.1016/0012-1606(88)90289-8; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MORRIS JF, 1991, ONCOGENE, V6, P2339; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PARK S, 1993, CANCER RES, V53, P457; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J, 1989, MOL CLONING LAB MANU; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Saxen L., 1987, ORGANOGENESIS KIDNEY; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P10984; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU P, 1995, ONCOGENE, V11, P571	57	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1789	1799						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895526				2022-12-17	WOS:A1996VM88700025
J	SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR				SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR			Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene	ONCOGENE			English	Article						carcinoma cell lines; adenovirus E1a; drug resistance; apoptosis; p53	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; P53-INDEPENDENT MECHANISMS; CLINICAL IMPLICATIONS; DIFFERENT ONCOGENES; INDUCE APOPTOSIS; CANCER-THERAPY; PROTEIN	Squamous cell carcinomas can show different oncogenic alterations, histological patterns, and an unpredictable clinical behavior, We previously reported that the adenovirus E1a gene may induce sensitivity to DNA-damaging agents in mouse keratinocytes. In order to study whether E1a expression could be used as a therapeutic agent in different malignant cell lines carrying mutations on the p53 gene and other oncogenic alterations, we transfected and infected several murine and human carcinoma cell lines (HaCa4; MSC11A5; HeLa) with vectors containing the 13S or 12S E1a region, We evaluated the sensitivity to cisplatin (CDDP), doxorubicin (DOX) and gamma irradiation (RX) by the crystal violet method, The induction of apoptosis was assessed by flow cytometry and presence of DNA ladders in agarose gels, The expression of E1a and the tumor suppressor p53 protein was analysed by Western blotting, The carcinoma cell lines expressing E1a were about four- to ten-fold more sensitive to CDDP and RX, respectively, than the control cells, Moreover, the reduction in cell viability and cell growth after exposure to CDDP or RX was very significant in the carcinoma cells expressing E1a, With these results, we conclude that expression of E1a may confer great sensitivity to DNA-damaging agents on squamous cell carcinoma cells independently of the p53 protein status and other oncogenic alterations.	CLIN PUERTA HIERRO,DEPT PATOL,E-28035 MADRID,SPAIN; CSIC,INST INVEST BIOMED,MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Quintanilla, Miguel/K-9293-2017; Sanchez-Prieto, Ricardo/AAY-4271-2021; LLeonart, Matilde E./Q-2662-2019; Ramon y Cajal, Santiago/H-4955-2016	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; LLeonart, Matilde E./0000-0002-6196-7405; Ramon y Cajal, Santiago/0000-0002-3867-1390				AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BURNS PA, 1991, ONCOGENE, V6, P2363; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARUSO M, 1993, ONCOGENE, V8, P267; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURIHATA M, 1995, INT J ONCOL, V6, P1209; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAVRE PA, 1995, CANCER RES, V55, P4420; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HUNTER T, 1994, CELL, V79, P547; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAULES RS, 1995, CANCER RES, V55, P1763; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAMON, 1995, HISTOL HISTOPATHOL, V10, P811; RAMON, 1991, AM J PATHOL, V138, P349; RAMON, 1994, AM J PATHOL, V145, P846; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SANCHEZPRIETO R, 1995, ONCOL REP, V2, P457; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TATSUKA M, 1989, MUTAT RES, V214, P321; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE P, 1989, CELL, V45, P67; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG YJ, 1995, ONCOGENE, V10, P1947	68	90	95	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1083	1092						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806698				2022-12-17	WOS:A1996VG76600022
J	Wang, JK; Xu, H; Li, HC; Goldfarb, M				Wang, JK; Xu, H; Li, HC; Goldfarb, M			Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras	ONCOGENE			English	Article						FGFR; SLP; Sos; p13(suc1)	FIBROBLAST GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; CELL-CYCLE CONTROL; PC12 CELLS; SIGNAL-TRANSDUCTION; POINT MUTATION; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTOR; INSULIN-RECEPTOR	SNT was originally described as a similar to 90 kilodalton protein in neuronal precursor cells which bears affinity for the yeast cell cycle protein p13(sucl) and which undergoes rapid tyrosine phosphorylation following stimulation with growth factors which trigger terminal differentiation, but not by other growth factors which promote proliferation (Rabin et al,, 1993), We show here that similarly sized SNT-like proteins (SLPs) are expressed in fibroblast, myoblast, and lymphoid cell lines, and undergo robust tyrosine phosphorylation in response to several mitogenic ligands, including fibroblast growth factors (FGFs). SLPs are tyrosine phosphorylated within 15 s of FGF stimulation, are predominantly membrane-associated, and are weakly associated with activated FGF receptor-1, suggesting that these proteins may be direct targets of the receptor kinase, Kinetic analysis of SLP phosphorylation and studies with serine/threonine kinase and phosphatase inhibitors suggest that SLPs are no larger than 70 000 kilodaltons, and that serine/threonine phosphorylation follows tyrosine phosphorylation to substantially retard gel electrophoretic mobility, SLPs are associated with the Grb-2 adaptor and are the major tyrosine phosphorylated proteins associated with the Ras guanine nucleotide exchange factor Sos in FGF-stimulated fibroblasts, suggesting that SLP-Grb2-Sos complexes modulate the activity of Ras proteins.	MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RICCI A, 1995, ONCOGENE, V11, P1519; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	58	90	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					721	729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761293				2022-12-17	WOS:A1996VD43300007
J	Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T				Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T			The human tumour suppressor gene p53 is alternatively spliced in normal cells	ONCOGENE			English	Article						p53; alternative splicing; transcription	WILD-TYPE P53; LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION; PROTEIN; MUTATIONS; GROWTH; DNA; APOPTOSIS; ANTIGEN; YEAST	Alternative splicing affecting the p53 carboxy-terminus has previously been described in mouse but not in normal human cells. We report here the detection in normal human lymphocytes of an alternatively spliced form of human p53 mRNA containing an additional 133 bp exon derived from intron 9. This splice variant encodes a truncated protein of 341 amino-acids including 10 new amino-acids derived from the novel exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails to bind DNA in vitro and has transcriptional defect in vivo in both yeast and mammalian cells. Quantitative RT-PCR experiments suggests that the alternatively spliced form is only present in significant amounts in quiescent cells. Considering the numerous functions ascribed to the carboxy-terminus of the p53 protein, this splice variant may have important implications for the biological role of p53 in normal cells.	CHU ROUEN,LAB GENET MOL,F-76031 ROUEN,FRANCE; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,SERV ORL,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,LAB IMMUN PATHOL CLIN & EXPT,F-76031 ROUEN,FRANCE; HOP UNIV,F-67091 STRASBOURG,FRANCE	CHU de Rouen; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen; CHU Strasbourg			Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MIYASHITA T, 1995, CELL, V80, P293; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	90	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					813	818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632903				2022-12-17	WOS:A1996TW68600012
J	TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J				TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J			ALLELOTYPE OF NEUROBLASTOMA	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENE; ALLELOTYPE; CHROMOSOME 9	N-MYC AMPLIFICATION; NEURO-BLASTOMA; GENE-MUTATIONS; HETEROZYGOSITY; RETINOBLASTOMA; CHROMOSOME-1; TUMOR; IDENTIFICATION; CARCINOMA; ONCOGENE	Although relatively high incidence of loss of heterozygosity (LOH) on chromosomes 1p, 11q, and 14q have been reported in neuroblastoma, it is still unclear whether or not LOH occurs specifically on these chromosome arms in neuroblastoma since only a few chromosomal arms have been examined for LOH in previous studies. Therefore, we screened 81 cases of tumors for LOH on all 22 autosomes and chromosome X using 35 restriction fragment length polymorphism markers and eight microsatellite markers. High incidence of LOH (>20%) was observed on six chromosome arms; 1p (26%), 2q (30%), 9p (36%), 11q (24%), 14q (22%), and 18q (31%), Frequencies of LOH on other chromosome arms were less than 13%. Patients with 9p LOH in the tumors showed statistically significant association with advanced stage of the disease and poor prognosis (P=0.037 and P=0.003, respectively) independently from N-myc amplification, while LOH on other chromosomes did not show association with stage, prognosis, and N-myc amplification. Thus, besides LOH on chromosomes 1p, 11q, and 14q, LOH on chromosomes 2q, 9p, and 18q also occurs relatively frequently in neuroblastoma, indicating the involvement of multiple tumor suppressor genes in the development of neuroblastoma. It is possible that there is a novel tumor suppressor gene on chromosome 9p which is involved in the progression of neuroblastoma.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV CANC INFORMAT & EPIDEMIOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA CHILDRENS MED CTR,DIV HEMATOL ONCOL,IWATSUKI,SAITAMA 339,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Saitama Children's Medical Center								BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; IMAMURA J, 1993, CANCER RES, V53, P4053; JEN J, 1995, CANCER RES, V54, P6353; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOHNO T, 1994, ONCOGENE, V9, P103; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Maniatis T., 1982, MOL CLONING; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TONINI GP, 1993, EUR J CANCER, V29A, P802, DOI 10.1016/S0959-8049(05)80412-5; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; VOGAN K, 1993, CANCER RES, V53, P5269; WEINBERG RA, 1991, SCIENCE, V254, P138	35	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1829	1834						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478611				2022-12-17	WOS:A1995TD09400018
J	SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M			TAX PROTEIN OF HTLV-1 DESTABILIZES THE COMPLEXES OF NF-KAPPA-B AND I-KAPPA-B-ALPHA AND INDUCES NUCLEAR TRANSLOCATION OF NF-KAPPA-B FOR TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						HTLV-1; I-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; NF-KAPPA-B	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEATS; TUMOR-NECROSIS-FACTOR; TRANSACTIVATOR TAX; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; DNA-BINDING; ENHANCER	Tax protein of HTLV-1 stimulates transcription of specific cellular genes through the NF-kappa B binding site. We previously showed that Tax binds to the ankyrin motifs of I kappa B-gamma, and dissociates the I kappa B-gamma/NF-kappa B complexes, resulting in nuclear translocation of NF-kappa B proteins. We herein report the effects of Tax on I kappa B-alpha, another member of I kappa B family proteins expressed in human T cells. Tax binds to I kappa B-alpha and partially dissociates the NF-kappa B/I kappa B-alpha complex in vitro. In Tax-expressing cells, Tax/I kappa B-alpha complex was detected only at low level, but NF-kappa B/I kappa B-alpha complex was mostly dissociated and NF-kappa B was translocated into the nucleus. Furthermore, Tax induced reduction of I kappa B-alpha protein. I kappa B-alpha a protein was stabilized by NF-kappa B protein through forming NF-kappa B/I kappa B-alpha complex, but Tax expression cancelled this stabilization effect on I kappa B-alpha. These findings suggest that Tax induces dissociation of and/or inhibits the formation of NF-kappa B/I kappa B-alpha complexes, resulting in release of NF-kappa B and destabilization of I kappa B-alpha. Consistently, transcription of NF-kappa B directed gene was activated. These Tax effects counteract the negative feedback control of NF-kappa B by I kappa B-alpha and contribute to constitutive activation of NF-kappa B in Tax-transfected and HTLV-1-infected cells.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEURLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P68; BAIL OL, 1993, EMBO J, V12, P5043; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	54	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1199	1207						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700645				2022-12-17	WOS:A1995QN35300022
J	SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD				SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD			MOLECULAR ANALYSIS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN HUMAN LUNG-CANCER CELL-LINES	ONCOGENE			English	Article							CLONAL CHROMOSOME-ABNORMALITIES; HUMAN BREAST CARCINOMAS; FREE DEFINED MEDIUM; SHORT ARM; HOMOZYGOUS DELETION; CLINICAL SPECIMENS; SMALL REGION; P53 GENE; HETEROZYGOSITY; 3P	The deletion of the short arm of chromosome 3 is frequently observed in lung cancer. To determine whether the von Hippel-Lindau (VHL) disease tumor suppressor gene located at 3p25 is responsible for oncogenesis in lung cancer, we searched the known open reading frame using the single-strand conformation polymorphism (SSCP) technique for mutations in the VHL gene in 72 cancer cell lines including small cell (SCLC) and nonsmall cell (NSCLC) lung cancers, carcinoids, and mesotheliomas. SSCP analysis showed that four cell lines have altered SSCP patterns within the coding region and one in an intron of the VHL gene. SCLC line NCI-H1672 had a somatic mutation, G to A at nucleotide (nt) 530, leading to amino acid substitution (glycine to aspartic acid) compared to normal DNA from the same patient. Mesothelioma line NCI-H28 had T to A mutation at nt 479 leading to leucine to histidine amino acid change. We found one frequent polymorphism A (0.72) or G (0.28) at nt 19 resulting in either serine or glycine at this position, changes also found in normal peripheral blood cell DNA, often in a heterozygous state. In addition, we found single rare polymorphisms which did not alter the coding region including: C to G at mt 396, G to T at nt 843, and C to T change in an intron. These results suggest that the VHL gene is only rarely mutated in thoracic malignancies.	UNIV TEXAS,SOUTHWESTERN MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; NCI,SURG BRANCH,UROL ONCOL SECT,BETHESDA,MD 20892	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Sekido, Yoshitaka/P-9756-2015	Gnarra, James/0000-0002-6369-3110; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA58220-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BROWER M, 1986, CANCER RES, V46, P798; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GAZDAR AF, 1986, CANCER RES, V46, P6011; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	90	94	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183553				2022-12-17	WOS:A1994NL81500010
J	CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC				CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC			DELETION MAPPING IN COLORECTAL-CANCER OF A PUTATIVE TUMOR SUPPRESSOR GENE IN 8P22-P21.3	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; POLYMORPHISM; CARCINOMAS; CHROMOSOME-17; LOCUS; PCR	Although previous studies of acquired loss of heterozygosity (LOH) in colorectal tumours have suggested that a tumour suppressor gene may lie within the short arm of chromosome 8, its precise localisation remains to be determined. To obtain a more accurate positional map 120 colorectal cancers were examined with eight chromosome 8 polymorphic markers comprising both restriction fragment length polymorphisms and microsatellite polymorphisms based on (CA)n repeats. 91 cases were informative and LOH was detected in 47 (51%). The markers most commonly sited within the lost region mapped to the lipoprotein lipase gene (LPL) at chromosome 8p22. From study of tumours showing break-points within 8p, a common region of deletion was established extending centromerically from LPL to the ankyrin 1 gene (ANK1) which is mapped to 8p21.1-11.2. This overlaps with common deleted regions observed in other studies of colorectal tumours (8p23.1-p21.3) and bladder tumours (8p21-q11.2). Taken together, the results in colorectal cancer delineate a region in 8p22-p21.3 where the putative tumour suppressor gene must lie. The chromosome 8p deletions appear to be independent of those involving 5q and 17p in the same tumours. No relationship was found between the presence of 8p deletion and site or stage of the tumour, or the sex or age of the patient at diagnosis.	MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND	University of Edinburgh	CUNNINGHAM, C (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				ARMOUR JAL, 1991, NUCLEIC ACIDS RES, V19, P6344; ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRUIN T, 1991, NUCLEIC ACIDS RES, V19, P6346, DOI 10.1093/nar/19.22.6346-a; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P437; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; HEIGHWAY J, 1992, NUCLEIC ACIDS RES, V20, P1160, DOI 10.1093/nar/20.5.1160; HEINZMANN C, 1987, NUCLEIC ACIDS RES, V15, P6763, DOI 10.1093/nar/15.16.6763; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KNOWLES MA, 1993, IN PRESS ONCOGENE; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCDANIEL T, 1991, NUCLEIC ACIDS RES, V19, P4796, DOI 10.1093/nar/19.17.4796-a; MIKI Y, 1991, JPN J CANCER RES, V82, P1003, DOI 10.1111/j.1349-7006.1991.tb01935.x; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1991, CYTOGENET CELL GENET, V58, P1	32	90	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479756				2022-12-17	WOS:A1993KY32800034
J	TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA				TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA			ASSOCIATION OF FYN WITH THE ACTIVATED PLATELET-DERIVED GROWTH-FACTOR RECEPTOR - REQUIREMENTS FOR BINDING AND PHOSPHORYLATION	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHOLIPASE-C; SRC FAMILY; DOMAINS; PRODUCT; IDENTIFICATION	Three members of the Src family of tyrosine kinases [pp60c-src (Src), p59fyn (Fyn) and pp62c-yes (Yes)] are ubiquitously expressed, and are thus likely to have general roles in growth control. We have previously shown that, after addition of platelet-derived growth factor (PDGF) to quiescent cells, all three kinases become activated and associated with the PDGF receptor. We have now addressed the requirements for this association. First, we have used a baculovirus expression system to show that Fyn associates with the activated PDGF receptor in vitro in the absence of other proteins, demonstrating that the association between the two molecules is direct. Second, by generating cell lines expressing chimeric molecules consisting of Fyn sequences fused to a portion of beta-galactosidase, we found that the SH2 domain of Fyn is necessary for ligand-stimulated association with the PDGF receptor in vivo. Third, those fusion proteins that associated with the PDGF receptor also became phosphorylated in vivo following PDGF treatment, and in in vitro kinase assays, suggesting that the amino-terminal half of Fyn contains the sites of PDGF-stimulated phosphorylation. Partially purified, kinase-negative Fyn also became phosphorylated in the activated PDGF receptor complex in vitro, demonstrating that the PDGF receptor phosphorylates Fyn, rather than the novel phosphorylations occurring by autophosphorylation.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Hall, Belinda/AGU-6214-2022; Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X; Hall, Belinda/0000-0002-3753-1978				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUO K, 1990, ONCOGENE, V5, P921; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	34	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1893	1901						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408131				2022-12-17	WOS:A1992JP42400001
J	NARAYANAN, R; LAWLOR, KG; SCHAAPVELD, RQJ; CHO, KR; VOGELSTEIN, B; TRAN, PBV; OSBORNE, MP; TELANG, NT				NARAYANAN, R; LAWLOR, KG; SCHAAPVELD, RQJ; CHO, KR; VOGELSTEIN, B; TRAN, PBV; OSBORNE, MP; TELANG, NT			ANTISENSE RNA TO THE PUTATIVE TUMOR-SUPPRESSOR GENE DCC TRANSFORMS RAT-1 FIBROBLASTS	ONCOGENE			English	Article							ANTI-SENSE RNA; HUMAN RETINOBLASTOMA GENE; THYMIDINE KINASE GENE; PROTO-ONCOGENE; MYC EXPRESSION; CELL-ADHESION; OSTEO-SARCOMA; GROWTH-FACTOR; WILMS TUMOR; C-MYC	Allelic deletions involving chromosomes 18q occur in a significant number of colorectal cancers. Recently, a highly conserved gene called 'deleted in colorectal cancer' (DCC) has been identified on chromosome 18q. DCC has been postulated to be a colorectal tumor-suppressor gene. In order to understand the role of DCC in cell transformation, we have established a stable Rat-1 cell line expressing dexamethasone-inducible DCC antisense RNA. High levels of dexamethasone-inducible DCC antisense RNA were detected in the Rat-1 transfectants. The antisense DCC-expressing Rat-1 cells showed a faster growth rate, anchorage independence and tumorigenicity in nude mice. Exposure of the parental Rat-1 cells to antisense oligodeoxyribonucleotides to DCC resulted in inhibition of cell adhesion to the substratum which could be abrogated by various extracellular matrices. On the other hand, a bone marrow-derived stromal cell line which does not express DCC showed no detachment from the substratum when treated with the antisense oligo to DCC. These results suggest that the DCC gene is involved in cell adhesion and provide the first direct biological evidence for the possible role of DCC as a tumor-suppressor gene.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; MEM SLOAN KETTERING CANC CTR,DEPT SURG,BREST CANC RES LAB,NEW YORK,NY 10021	Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center	NARAYANAN, R (corresponding author), HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,340 KINGSLAND ST,NUTLEY,NJ 07110, USA.			Narayanan, Ramaswamy/0000-0001-9346-9083; Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494, R29CA044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, R29 CA 44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CULP LA, 1986, CIBA F SYMP, V124, P158; DEVILEE P, 1991, ONCOGENE, V6, P311; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; ITO E, 1989, ONCOGENE, V4, P1193; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NISHIKURA K, 1990, ONCOGENE, V5, P981; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TELANG NT, 1991, BREAST CANCER RES TR, V18, P155, DOI 10.1007/BF01990031; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; UCKER DS, 1983, MOL CELL BIOL, V3, P551, DOI 10.1128/MCB.3.4.551; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3385; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	54	90	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					553	561						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549369				2022-12-17	WOS:A1992HK00500023
J	SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H				SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H			MODULATION OF NORMAL ERYTHROID-DIFFERENTIATION BY THE ENDOGENOUS THYROID-HORMONE AND RETINOIC ACID RECEPTORS - A POSSIBLE TARGET FOR V-ERBA ONCOGENE ACTION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; CELLS-INVITRO; C-ERBA; GENE-EXPRESSION; GROWTH; TRANSFORMATION; PHENOTYPE; PROTEIN; PROLIFERATION; FIBROBLASTS	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), inhibits erythroid differentiation and constitutively represses transcription of certain erythrocyte genes, suggesting a normal function of the proto-oncogene c-erbA in erythropoiesis. Here we demonstrate that the endogenous thyroid hormone receptor alpha (c-erbA/TR-alpha) and the closely related retinoic acid receptor alpha (RAR-alpha) play a role in the regulation of normal erythroid differentiation. Retinoic acid (RA) distinctly modulated the erythroid differentiation program of normal erythroid progenitors and erythroblasts reversibly transformed by a conditional tyrosine kinase oncogene. When added pulsewise to immature cells, differentiation was accelerated while more mature cells underwent premature cell death. Thyroid hormone (T3) alone caused similar but weaker effects. Interestingly, T3 strongly enhanced the action of RA, suggesting cooperative action of the two receptors in modulating erythroid differentiation. Expression of the human RAR-alpha in receptor-negative erythroblasts conferred RA-induced regulation of differentiation to the otherwise unresponsive cells, thus showing that the RAR-alpha is essential for the RA effect. Likewise, enhanced expression of exogenous c-erbA/TR-alpha in erythroblasts rendered them susceptible to modulation of differentiation by T3, suggesting a similar function of both receptors.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAMPBELL A, 1985, J CLIN INVEST, V75, P2085, DOI 10.1172/JCI111928; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAINIAK N, 1986, BLOOD, V68, P1289; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; FEIN HG, 1975, MED CLIN N AM, V59, P1133, DOI 10.1016/S0025-7125(16)31963-0; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GARG LC, 1983, DIFFERENTIATION, V25, P79; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HORTON L, 1976, Q J MED, V45, P101; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOEFFLER HP, 1985, CIBA F SYMP, V113, P252; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MULDOWNEY FP, 1957, CLIN SCI, V16, P309; NAGLER A, 1986, EXP HEMATOL, V14, P60; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REIMANN J, 1979, EXP HEMATOL, V7, P45; ROBERTS RA, 1987, J CELL PHYSIOL, V132, P203, DOI 10.1002/jcp.1041320204; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	52	90	91	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					217	227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347914				2022-12-17	WOS:A1992HG98200003
J	WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G				WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G			MUTANT P53 DETECTED IN A MAJORITY OF BURKITT-LYMPHOMA CELL-LINES BY MONOCLONAL-ANTIBODY PAB240	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; TRANSFORMED-CELLS; FRIEND-VIRUS; LUNG-CANCER; NUDE-MICE; GENE; ONCOGENE	The status of the p53 gene in lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines (BLs) was investigated. Southern blot analysis demonstrated that no major deletions or rearrangements had occurred in the p53 gene in any of the cell lines. The p53 protein was examined by immunoprecipitation using two monoclonal anti-p53 antibodies. PAb1801 recognizes both wild-type and mutant p53. PAb240 reacts exclusively with mutant p53. Fourteen LCLs reacted with PAb1801, but not with PAb240, suggesting that none of them expressed mutant p53. However, one LCL had mutant p53. This LCL differs from other LCLs in that it grows to higher cell densities and has a higher agarose clonability. All BLs expressed p53. Out of 15 BLs, nine (60%) carried mutant p53, as indicated by their reactivity with PAb240. Among the nine BLs with mutant p53, eight were Epstein-Barr virus (EBV)-positive. Three out of the six BLs with wild-type p53 were EBV-positive. Multiple EBV-converted sublines all exhibited the same p53 status as the parental line. Our results indicate that the p53 gene is mutated in a majority of Burkitt lymphoma cell lines (BLs), and suggest that p53 mutation contributes to the malignant phenotype of these cell lines.			WIMAN, KG (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA 30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1966, J NATL CANCER I, V37, P547; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRESEN KO, 1976, INT J CANCER, V17, P161, DOI 10.1002/ijc.2910170203; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIOVANELLA B, 1979, INT J CANCER, V24, P103, DOI 10.1002/ijc.2910240118; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINUMA Y, 1967, P SOC EXP BIOL MED, V124, P107; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LENOIR GM, 1985, BURKITTS LYMPHOMA HU, P309; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILLER CW, 1990, CANCER RES, V50, P7950; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VENTURELLI D, 1988, HAEMATOLOGICA, V73, P259; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	65	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1633	1639						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923530				2022-12-17	WOS:A1991GX27400019
J	GINSBERG, D; OREN, M; YANIV, M; PIETTE, J				GINSBERG, D; OREN, M; YANIV, M; PIETTE, J			PROTEIN-BINDING ELEMENTS IN THE PROMOTER REGION OF THE MOUSE P53 GENE	ONCOGENE			English	Article									INST PASTEUR, DEPT BIOL MOLEC,UNITE VIRUS ONCOGENES,CNRS,UA 1149, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE NEUROBIOL MOLEC, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	GINSBERG, D (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.			ginsberg, doron/0000-0002-1257-4920				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CALABRETTA B, 1986, CANCER RES, V46, P5783; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GALOS RS, 1979, CELL, V17, P945, DOI 10.1016/0092-8674(79)90334-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAI S, 1989, VECTORS TOOLS STUDY, P355; HIRAI SI, 1990, ONCOGENE, V5, P39; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINE AJ, 1989, ICN UCI C V, P21; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1985, CANCER CELL, V3, P65; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NIGRO MJ, 1989, NATURE, V343, P705; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PIETTE J, 1985, EMBO J, V4, P2675, DOI 10.1002/j.1460-2075.1985.tb03987.x; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1989, ONCOGENE, V4, P945; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254	51	90	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1285	1290						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216454				2022-12-17	WOS:A1990EC24100002
J	Raggi, C; Mousa, HS; Corrent, M; Sica, A; Invernizzi, P				Raggi, C.; Mousa, H. S.; Corrent, M.; Sica, A.; Invernizzi, P.			Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; BONE-MARROW MICROENVIRONMENT; BREAST-CANCER; FACTOR RECEPTOR; SELF-RENEWAL; MYELOGENOUS LEUKEMIA; SIGNALING PATHWAY; CYTOKINE NETWORKS	The idea that tumor initiation and progression are driven by a subset of cells endowed with stem-like properties was first described by Rudolf Virchow in 1855. 'Cancer stem cells', as they were termed more than a century later, represent a subset of tumor cells that are able to generate all tumorigenic and nontumorigenic cell types within the malignancy. Although their existence was hypothesized > 150 years ago, it was only recently that stem-like cells started to be isolated from different neoplastic malignancies. Interestingly, Virchow, in suggesting a correlation between cancer and the inflammatory microenvironment, also paved the way for the 'Seed and Soil' theory proposed by Paget a few years later. Despite the time that has passed since these two important concepts were suggested, the relationships between Virchow's 'stem-like cells' and Paget's 'soil' are far from being fully understood. One emerging topic is the importance of a stem-like niche in modulating the biological properties of stem-like cancer cells and thus in affecting the response of the tumor to drugs. This review aims to summarize the recent molecular data concerning the multilayered relationship between cancer stem cells and tumor-associated macrophages that form a key component of the tumor microenvironment. We also discuss the therapeutic implications of targeting this synergistic interplay.	[Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy; [Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy; [Sica, A.] Humanitas Clin & Res Ctr, Lab Mol Immunol, Milan, Italy; [Sica, A.] Univ Piemonte Orientale Amedeo Avogadro, Dept Pharmaceut Sci, Novara, Italy	University of Eastern Piedmont Amedeo Avogadro	Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy.; Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy.	Chiara.raggi@humanitasresearch.it	RAGGI, Chiara/U-3081-2017; Sica, Antonio/AAB-9546-2020; Invernizzi, Pietro/AAB-8367-2022	RAGGI, Chiara/0000-0003-2473-3535; Invernizzi, Pietro/0000-0003-3262-1998; Mousa, Hani S./0000-0002-8327-7114	Italian Foundation of Cancer Research (AIRC); Fondazione U Veronesi	Italian Foundation of Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione U Veronesi(Fondazione Umberto Veronesi)	CR, HSM, MC, AS and PI were supported by the Italian Foundation of Cancer Research (AIRC) and Fondazione U Veronesi.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Abel EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091983; Ahmed N, 2006, AM J PHYSIOL-CELL PH, V290, pC1532, DOI 10.1152/ajpcell.00478.2005; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asimakopoulos F, 2013, LEUKEMIA LYMPHOMA, V54, P2112, DOI 10.3109/10428194.2013.778409; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BHATIA R, 1995, BLOOD, V85, P3636, DOI 10.1182/blood.V85.12.3636.bloodjournal85123636; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brissette MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036368; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; BUITING AMJ, 1994, J DRUG TARGET, V2, P357, DOI 10.3109/10611869408996810; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chow A, 2013, NAT MED, V19, P429, DOI 10.1038/nm.3057; Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cook AM, 2014, BLOOD, V123, P2826, DOI 10.1182/blood-2013-05-505735; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Eljaszewicz A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/831387; Esch JSA, 2005, STEM CELLS, V23, P463, DOI 10.1634/stemcells.2004-0283; Ezekowitz RA, 2002, NAT IMMUNOL, V3, P510, DOI 10.1038/ni0602-510; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Gao L, 2014, CELL BIOCHEM BIOPHYS, V70, P273, DOI 10.1007/s12013-014-9900-0; Gao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030676; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gyorki DE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2353; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hassan KA, 2013, CLIN CANCER RES, V19, P1972, DOI 10.1158/1078-0432.CCR-12-0370; He KF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/838632; HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kaur S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01673; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korkaya H, 2011, CELL CYCLE, V10, P2623, DOI 10.4161/cc.10.16.16414; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; LaBarge MA, 2010, CLIN CANCER RES, V16, P3121, DOI 10.1158/1078-0432.CCR-09-2933; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li L, 2014, CELL DEATH DIFFER; Li SH, 2013, MOL CELL BIOCHEM, V373, P217, DOI 10.1007/s11010-012-1493-6; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Liu DQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003291; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ludin A, 2012, NAT IMMUNOL, V13, P1072, DOI 10.1038/ni.2408; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mantovani A, 2009, CANCER CELL, V16, P173, DOI 10.1016/j.ccr.2009.08.014; Margol AS, 2015, CLIN CANCER RES, V21, P1457, DOI 10.1158/1078-0432.CCR-14-1144; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marquardt JU, 2011, HEPATOLOGY, V54, P1031, DOI 10.1002/hep.24454; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ngiow SF, 2011, CANCER RES, V71, P3540, DOI 10.1158/0008-5472.CAN-11-0096; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Ninov N, 2012, DEVELOPMENT, V139, P1557, DOI 10.1242/dev.076000; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; OSULLIVAN C, 1993, LANCET, V342, P148, DOI 10.1016/0140-6736(93)91348-P; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Raggi C, 2015, J HEPATOL, V62, P198, DOI 10.1016/j.jhep.2014.09.007; Raggi C, 2014, HEPATOLOGY, V59, P2251, DOI 10.1002/hep.27026; Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587; Richards DM, 2013, CANCER MICROENVIRON, V6, P179, DOI 10.1007/s12307-012-0123-x; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Riether C, 2015, CELL DEATH DIFFER, V22, P187, DOI 10.1038/cdd.2014.89; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; Samanani S, 2013, CNS NEUROL DISORD-DR, V12, P741, DOI 10.2174/18715273113126660177; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; Sarkar S, 2014, NAT NEUROSCI, V17, P46, DOI 10.1038/nn.3597; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Shang YJ, 2013, ONCOL LETT, V6, P490, DOI 10.3892/ol.2013.1410; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shigdar S, 2012, THER DELIV, V3, P227, DOI 10.4155/TDE.11.148; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sikora A, 2007, J PHYSIOL PHARMACOL, V58, P43; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011; Smith RE, 2003, BLOOD, V102, P2532, DOI 10.1182/blood-2002-11-3596; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Theocharides APA, 2012, J EXP MED, V209, P1883, DOI 10.1084/jem.20120502; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; Virchow R, 1881, Br Med J, V2, P198; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu J, 2013, DNA CELL BIOL, V32, P648, DOI 10.1089/dna.2013.2116; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamashina T, 2014, CANCER RES, V74, P2698, DOI 10.1158/0008-5472.CAN-13-2169; Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664; Zhang Y, 2013, EUR J CANCER, V49, P3320, DOI 10.1016/j.ejca.2013.06.005; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao XW, 2011, P NATL ACAD SCI USA, V108, P18342, DOI 10.1073/pnas.1106550108; Zhou B, 2014, J CLIN INVEST, V124, P553, DOI 10.1172/JCI69804; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	181	89	94	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					671	682		10.1038/onc.2015.132	http://dx.doi.org/10.1038/onc.2015.132			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961921				2022-12-17	WOS:000370331300001
J	Li, X; Roslan, S; Johnstone, CN; Wright, JA; Bracken, CP; Anderson, M; Bert, AG; Selth, LA; Anderson, RL; Goodall, GJ; Gregory, PA; Khew-Goodall, Y				Li, X.; Roslan, S.; Johnstone, C. N.; Wright, J. A.; Bracken, C. P.; Anderson, M.; Bert, A. G.; Selth, L. A.; Anderson, R. L.; Goodall, G. J.; Gregory, P. A.; Khew-Goodall, Y.			MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways	ONCOGENE			English	Article						miR-200; epithelial-mesenchymal transition; breast cancer; metastasis; actin cytoskeleton	EPITHELIAL-MESENCHYMAL TRANSITION; DIFFERENTIAL EXPRESSION; MIRNA-200 FAMILY; DOWN-REGULATION; CELL-MIGRATION; ZEB1; EMT; PROTEINS; INVASION; TARGETS	The microRNA-200 (miR-200) family has a critical role in regulating epithelial-mesenchymal transition and cancer cell invasion through inhibition of the E-cadherin transcriptional repressors ZEB1 and ZEB2. Recent studies have indicated that the miR-200 family may exert their effects at distinct stages in the metastatic process, with an overall effect of enhancing metastasis in a syngeneic mouse breast cancer model. We find in a xenograft orthotopic model of breast cancer metastasis that ectopic expression of members of the miR-200b/200c/429, but not the miR-141/200a, functional groups limits tumour cell invasion and metastasis. Despite modulation of the ZEB1-E-cadherin axis, restoration of ZEB1 in miR-200b-expressing cells was not able to alter metastatic potential suggesting that other targets contribute to this process. Instead, we found that miR-200b repressed several actin-associated genes, with the knockdown of the ezrin-radixin-moesin family member moesin alone phenocopying the repression of cell invasion by miR-200b. Moesin was verified to be directly targeted by miR-200b, and restoration of moesin in miR-200b-expressing cells was sufficient to alleviate metastatic repression. In breast cancer cell lines and patient samples, the expression of moesin significantly inversely correlated with miR-200 expression, and high levels of moesin were associated with poor relapse-free survival. These findings highlight the context-dependent effects of miR-200 in breast cancer metastasis and demonstrate the existence of a moesin-dependent pathway, distinct from the ZEB1-E-cadherin axis, through which miR-200 can regulate tumour cell plasticity and metastasis.	[Li, X.; Roslan, S.; Wright, J. A.; Bracken, C. P.; Anderson, M.; Bert, A. G.; Goodall, G. J.; Gregory, P. A.; Khew-Goodall, Y.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA 5000, Australia; [Johnstone, C. N.; Anderson, R. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Johnstone, C. N.; Anderson, R. L.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia; [Johnstone, C. N.; Anderson, R. L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Johnstone, C. N.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia; [Wright, J. A.; Bracken, C. P.; Goodall, G. J.; Gregory, P. A.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Selth, L. A.] Univ Adelaide, Hanson Inst, Discipline Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Goodall, G. J.; Khew-Goodall, Y.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of Melbourne; University of Adelaide; Hanson Institute; University of Adelaide; University of Adelaide	Gregory, PA (corresponding author), SA Pathol, Ctr Canc Biol, Div Human Immunol, Frome Rd, Adelaide, SA 5000, Australia.	philip.gregory@health.sa.gov.au; yeesim.khew-goodall@health.sa.gov.au	Selth, Luke/AAH-4823-2021; Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Gregory, Philip/F-4089-2013; Anderson, Robin/S-1005-2017	Selth, Luke/0000-0002-4686-1418; Gregory, Philip/0000-0002-0999-0632; Anderson, Robin/0000-0002-6841-7422; Goodall, Gregory/0000-0003-1294-0692; Wright, Josephine/0000-0003-4588-8827; Bracken, Cameron/0000-0001-7722-625X; Bert, Andrew/0000-0003-3876-1537	National Breast Cancer Foundation of Australia [ECF-09-08, PF-09-03]; National Health and Medical Research Council of Australia [566871, APP1020280]; Cancer Council South Australia; Prostate Cancer Foundation of Australia [YI 0810]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	National Breast Cancer Foundation of Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council South Australia(Cancer Council South Australia); Prostate Cancer Foundation of Australia; National Breast Cancer Foundation	We thank Professor Joan Massague for providing the MDA-MB-231 LM2 cell line and Dr Ross Dickins for providing the pLMP-puro-GFP construct. We thank Dr Agatha Labrinidis and Ms Yuka Harata-Lee for assistance with bioluminescence imaging and inoculation of tumour cells, respectively, Dr Peter Diamond for help with bone histological analysis and Professors Andreas Evdokiou and Shaun McColl for insightful discussions. This work was supported by fellowships from the National Breast Cancer Foundation of Australia (PAG, CPB and RLA, nos ECF-09-08 and PF-09-03) and grants from the National Health and Medical Research Council of Australia (PAG, YK-G, GJG, RLA and CNJ, nos 566871 and APP1020280), Cancer Council South Australia (GJG, PAG and YK-G) and Prostate Cancer Foundation of Australia (LAS, no. YI 0810).	Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Charafe-Jauffret E, 2007, INT J CANCER, V121, P1779, DOI 10.1002/ijc.22923; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Estecha A, 2009, J CELL SCI, V122, P3492, DOI 10.1242/jcs.053157; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Giusiano S, 2010, INT J ONCOL, V36, P889, DOI 10.3892/ijo_00000567; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Lo WL, 2011, J PATHOL, V223, P482, DOI 10.1002/path.2826; Lussier YA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028650; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Renthal NE, 2010, P NATL ACAD SCI USA, V107, P20828, DOI 10.1073/pnas.1008301107; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin JO, 2012, HISTOCHEM CELL BIOL, V137, P459, DOI 10.1007/s00418-012-0915-6; Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Sun BC, 2008, CLIN CANCER RES, V14, P7050, DOI 10.1158/1078-0432.CCR-08-0520; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang CC, 2012, HISTOPATHOLOGY, V61, P78, DOI 10.1111/j.1365-2559.2012.04204.x; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xue CS, 2003, CANCER RES, V63, P3386	54	89	93	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4077	4088		10.1038/onc.2013.370	http://dx.doi.org/10.1038/onc.2013.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037528				2022-12-17	WOS:000340595300007
J	Christie, M; Jorissen, RN; Mouradov, D; Sakthianandeswaren, A; Li, S; Day, F; Tsui, C; Lipton, L; Desai, J; Jones, IT; McLaughlin, S; Ward, RL; Hawkins, NJ; Ruszkiewicz, AR; Moore, J; Burgess, AW; Busam, D; Zhao, Q; Strausberg, RL; Simpson, AJ; Tomlinson, IPM; Gibbs, P; Sieber, OM				Christie, M.; Jorissen, R. N.; Mouradov, D.; Sakthianandeswaren, A.; Li, S.; Day, F.; Tsui, C.; Lipton, L.; Desai, J.; Jones, I. T.; McLaughlin, S.; Ward, R. L.; Hawkins, N. J.; Ruszkiewicz, A. R.; Moore, J.; Burgess, A. W.; Busam, D.; Zhao, Q.; Strausberg, R. L.; Simpson, A. J.; Tomlinson, I. P. M.; Gibbs, P.; Sieber, O. M.			Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis	ONCOGENE			English	Article						APC; colorectal cancer; mutation; just-right signalling	FAMILIAL ADENOMATOUS POLYPOSIS; SOMATIC MUTATIONS; PROMOTER HYPERMETHYLATION; GERMLINE MUTATION; COLI GENE; TUMORS; PROTEIN; SITE; INSTABILITY; LOCATION	Biallelic protein-truncating mutations in the adenomatous polyposis coli (APC) gene are prevalent in sporadic colorectal cancer (CRC). Mutations may not be fully inactivating, instead producing WNT/beta-catenin signalling levels 'just-right' for tumourigenesis. However, the spectrum of optimal APC genotypes accounting for both hits, and the influence of clinicopathological features on genotype selection remain undefined. We analysed 630 sporadic CRCs for APC mutations and loss of heterozygosity (LOH) using sequencing and single-nucleotide polymorphism microarrays, respectively. Truncating APC mutations and/or LOH were detected in 75% of CRCs. Most truncating mutations occurred within a mutation cluster region (MCR; codons 1282-1581) leaving 1-3 intact 20 amino-acid repeats (20AARs) and abolishing all Ser-Ala-Met-Pro (SAMP) repeats. Cancers commonly had one MCR mutation plus either LOH or another mutation 5' to the MCR. LOH was associated with mutations leaving 1 intact 20AAR. MCR mutations leaving 1 vs 2-3 intact 20AARs were associated with 5' mutations disrupting or leaving intact the armadillo-repeat domain, respectively. Cancers with three hits had an over-representation of mutations upstream of codon 184, in the alternatively spliced region of exon 9, and 3' to the MCR. Microsatellite unstable cancers showed hyper-mutation at MCR mono- and di-nucleotide repeats, leaving 2-3 intact 20AARs. Proximal and distal cancers exhibited different preferred APC genotypes, leaving a total of 2 or 3 and 0 to 2 intact 20AARs, respectively. In conclusion, APC genotypes in sporadic CRCs demonstrate 'fine-tuned' interdependence of hits by type and location, consistent with selection for particular residual levels of WNT/beta-catenin signalling, with different 'optimal' thresholds for proximal and distal cancers.	[Christie, M.; Jorissen, R. N.; Mouradov, D.; Sakthianandeswaren, A.; Li, S.; Day, F.; Tsui, C.; Lipton, L.; Desai, J.; Gibbs, P.; Sieber, O. M.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Ludwig Colon Canc Initiat Lab, Parkville, Vic 3050, Australia; [Christie, M.; Day, F.; Lipton, L.; Gibbs, P.; Sieber, O. M.] Univ Melbourne, Dept Surg, Royal Melbourne Hosp, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia; [Lipton, L.; Desai, J.; Gibbs, P.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Jones, I. T.] Royal Melbourne Hosp, Dept Colorectal Surg, Parkville, Vic 3050, Australia; [McLaughlin, S.] Western Hosp, Dept Colorectal Surg, Footscray, Vic, Australia; [Ward, R. L.] Univ New S Wales, Prince Wales Clin Sch, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Hawkins, N. J.] Univ New S Wales, Sch Med Sci, Dept Pathol, Sydney, NSW, Australia; [Ruszkiewicz, A. R.] Inst Med & Vet Sci, Dept Pathol, Adelaide, SA 5000, Australia; [Moore, J.] Royal Adelaide Hosp, Dept Colorectal Surg, Adelaide, SA 5000, Australia; [Burgess, A. W.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Parkville, Vic 3050, Australia; [Busam, D.; Zhao, Q.] J Craig Venter Inst, Rockville, MD USA; [Strausberg, R. L.; Simpson, A. J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Ludwig Collaborat Lab Canc Biol & Therapy, Baltimore, MD 21205 USA; [Strausberg, R. L.; Simpson, A. J.] Ludwig Inst Canc Res Ltd, New York, NY USA; [Tomlinson, I. P. M.] Wellcome Trust Ctr Human Genet, Mol & Populat Genet Lab, Oxford, England	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital; Western Hospital; University of New South Wales Sydney; University of New South Wales Sydney; Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; J. Craig Venter Institute; Johns Hopkins University; Ludwig Institute for Cancer Research; University of Oxford; Wellcome Centre for Human Genetics	Sieber, OM (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Ludwig Colon Canc Initiat Lab, POB 2008, Parkville, Vic 3050, Australia.	oliver.sieber@ludwig.edu.au	Desai, Jayesh/AAV-1237-2021; Hawkins, Nicholas J/A-8461-2008; Sieber, Oliver/ABA-9211-2021; Sieber, Oliver/M-9473-2015; Ward, Robyn L/I-2313-2013	Hawkins, Nicholas J/0000-0002-2204-3189; Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786; Ward, Robyn L/0000-0002-6877-8906; Gibbs, Peter/0000-0003-1423-4484; Jorissen, Robert/0000-0001-9634-2803; Day, Fiona/0000-0002-5905-9408; Desai, Jayesh/0000-0003-4246-9344; Mouradov, Dmitri/0000-0001-8149-816X	CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant; NHMRC [489418, 487922]; Hilton Ludwig Cancer Metastasis Initiative; Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant; Victorian Government, Australia; Cancer Council Victoria through Postgraduate Cancer Research Scholarships; CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship; Cancer Research UK [16459] Funding Source: researchfish	CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Hilton Ludwig Cancer Metastasis Initiative; Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant; Victorian Government, Australia; Cancer Council Victoria through Postgraduate Cancer Research Scholarships(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship; Cancer Research UK(Cancer Research UK)	This work was supported by the CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant (to LL, PG and OMS), the NHMRC through a Project Grant (Application ID 489418; to LL, OMS, PG and RLW) and a Program Grant (Application ID 487922; to AWB), the Hilton Ludwig Cancer Metastasis Initiative (to LL, PG and OMS) and the Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant (to LL, PG and OMS). This work was supported by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. MC and FD are supported by the Cancer Council Victoria through Postgraduate Cancer Research Scholarships and LL by the CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship. We thank the Victorian Cancer Biobank for the provision of patient specimens, BioGrid Australia for providing de-identified clinical data.	Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Albuquerque C, 2010, BIOCHIM BIOPHYS ACTA, V1816, P219; Albuquerque C, 2010, GENE CHROMOSOME CANC, V49, P746, DOI 10.1002/gcc.20786; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Boland CR, 1998, CANCER RES, V58, P5248; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; Cheadle JP, 2002, CANCER RES, V62, P363; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Esteller M, 2000, CANCER RES, V60, P4366; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Goss KH, 2002, P NATL ACAD SCI USA, V99, P8161, DOI 10.1073/pnas.112072199; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leedham SJ, 2012, GUT, DOI [10.1136/gutjnl-2011-301601, DOI 10.1136/GUTJNL-2011-301601)]; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sack U, 2011, MOL BIOL CELL, V22, P3344, DOI 10.1091/mbc.E10-09-0739; Samowitz WS, 2007, MOL CANCER RES, V5, P165, DOI 10.1158/1541-7786.MCR-06-0398; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sieber OM, 2006, GUT, V55, P1440, DOI 10.1136/gut.2005.087106; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Yau C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r92	33	89	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4675	4682		10.1038/onc.2012.486	http://dx.doi.org/10.1038/onc.2012.486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085758	Green Published			2022-12-17	WOS:000325072200009
J	Gil-Henn, H; Patsialou, A; Wang, Y; Warren, MS; Condeelis, JS; Koleske, AJ				Gil-Henn, H.; Patsialou, A.; Wang, Y.; Warren, M. S.; Condeelis, J. S.; Koleske, A. J.			Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo	ONCOGENE			English	Article						breast cancer; metastasis; invasion; proliferation; Arg kinase	ABL-FAMILY KINASES; TYROSINE-KINASE; C-ABL; TUMOR SIZE; METASTASIS; CELLS; ARG; EXPRESSION; GENE; T(1/12)(Q25,P13)	Tumor progression is a complex, multistep process involving accumulation of genetic aberrations and alterations in gene expression patterns leading to uncontrolled cell division, invasion into surrounding tissue and finally dissemination and metastasis. We have previously shown that the Arg/Abl2 non-receptor tyrosine kinase acts downstream of the EGF receptor and Src tyrosine kinases to promote invadopodium function in breast cancer cells, thereby promoting their invasiveness. However, whether and how Arg contributes to tumor development and dissemination in vivo has never been investigated. Using a mouse xenograft model, we show that knocking down Arg in breast cancer cells leads to increased tumor cell proliferation and significantly enlarged tumor size. Despite having larger tumors, the Arg-knockdown (Arg KD) tumor-bearing mice exhibit significant reductions in tumor cell invasion, intravasation into blood vessels and spontaneous metastasis to lungs. Interestingly, we found that proliferationassociated genes in the Ras-MAPK (mitogen-activated protein kinase) pathway are upregulated in Arg KD breast cancer cells, as is Ras-MAPK signaling, while invasion-associated genes are significantly downregulated. These data suggest that Arg promotes tumor cell invasion and dissemination, while simultaneously inhibiting tumor growth. We propose that Arg acts as a switch in metastatic cancer cells that governs the decision to 'grow or go' (divide or invade).	[Gil-Henn, H.; Warren, M. S.; Koleske, A. J.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Patsialou, A.; Wang, Y.; Condeelis, J. S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Condeelis, J. S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10461 USA	Yale University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Condeelis, JS (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	john.condeelis@einstein.yu.edu; anthony.koleske@yale.edu			Breast Cancer Alliance [CA133346];  [CA100324]; NATIONAL CANCER INSTITUTE [R01CA133346, P01CA100324, R01CA164468] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100411] Funding Source: NIH RePORTER	Breast Cancer Alliance; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the Einstein Histotechnology and Comparative Pathology Facility for their excellent service, and Dr Rani Sellers for helpful advice and suggestions. This work was supported by PHS grant CA133346 and an Exceptional Project Award from the Breast Cancer Alliance (AJK) and CA100324 (JSC).	Advani AS, 2002, LEUKEMIA RES, V26, P713, DOI 10.1016/S0145-2126(01)00197-7; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Backert S, 2008, TRENDS BIOCHEM SCI, V33, P80, DOI 10.1016/j.tibs.2007.10.006; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iijima Y, 2000, BLOOD, V95, P2126; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Newsome TP, 2006, CELL MICROBIOL, V8, P233, DOI 10.1111/j.1462-5822.2005.00613.x; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Wo JY, 2011, J CLIN ONCOL, V29, P2619, DOI 10.1200/JCO.2010.29.5907; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff JB, 2000, CANCER RES, V60, P2504	38	89	92	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2622	2630		10.1038/onc.2012.284	http://dx.doi.org/10.1038/onc.2012.284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777352	Green Accepted			2022-12-17	WOS:000319806700003
J	Jeong, KJ; Park, SY; Cho, KH; Sohn, JS; Lee, J; Kim, YK; Kang, J; Park, CG; Han, JW; Lee, HY				Jeong, K. J.; Park, S. Y.; Cho, K. H.; Sohn, J. S.; Lee, J.; Kim, Y. K.; Kang, J.; Park, C. G.; Han, J. W.; Lee, H. Y.			The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion	ONCOGENE			English	Article						LPA; Rho/ROCK; invasion; uPA; MMP-9; ovarian cancer	NF-KAPPA-B; MATRIX-DEGRADING PROTEINASES; HUMAN UROKINASE GENE; RHO-GTPASES; CARCINOMA CELLS; MATRIX-METALLOPROTEINASE-9 EXPRESSION; PLASMINOGEN-ACTIVATOR; MEMBRANE-VESICLES; FOCAL ADHESION; GROWTH-FACTORS	Lysophosphatidic acid (LPA) is a biolipid that has diverse biological activities implicated in ovarian cancer initiation and progression. Previous studies have shown the critical role of the Rho/Rho-associated kinase (ROCK) pathway in LPA-induced ovarian cancer progression. However, detailed underlying mechanism by which the Rho/ROCK pathway induces ovarian cancer cell invasion is still incompletely understood. In the present study, we observed that the Rho/ROCK pathway is implicated in the production of proteolytic enzymes, leading to LPA-induced ovarian cancer cell invasion. LPA induced matrix metalloproteinase (MMP)-9 expression in CAOV-3 and PA-1 cells and urokinase-type plasminogen activator (uPA) expression in SKOV-3 cells. LPA-induced proteolytic enzyme expression was required for the invasion of ovarian cancer cells expressing corresponding enzymes. Pretreatment of cells with a pharmacological inhibitor of Rho/ROCK (Y-27632) or overexpression of a dominant-negative mutant of Rho (Rho N19) profoundly inhibited LPA-induced proteolytic enzyme expression as well as the invasive potential of ovarian cancer cells. In addition, transfection with dominant-negative Ras (Ras N17) significantly inhibited LPA-induced Rho activation as well as MMP-9 and uPA expression. Consistently, Y-27632 reduced LPA-induced nuclear factor (NF)-kappa B activation that is critical for proteolytic enzyme expression and cellular invasion. Collectively, we demonstrate a mechanism by which LPA promotes ovarian cancer progression through coordinate activation of a Ras/Rho/ROCK/NF-kappa B signaling pathway and the proteolytic enzyme secretion, providing novel biomarkers and promising therapeutic targets for ovarian cancer cell progression. Oncogene (2012) 31, 4279-4289; doi:10.1038/onc.2011.595; published online 16 January 2012	[Jeong, K. J.; Park, S. Y.; Cho, K. H.; Kang, J.; Park, C. G.; Lee, H. Y.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Taejon 302718, South Korea; [Sohn, J. S.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pathol, Taejon 302718, South Korea; [Lee, J.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Microbiol, Taejon 302718, South Korea; [Kim, Y. K.] Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Seoul, South Korea; [Han, J. W.] Sungkyunkwan Univ, Sch Pharm, Dept Biochem & Mol Biol, Suwon, South Korea	Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Sookmyung Women's University; Sungkyunkwan University (SKKU)	Lee, HY (corresponding author), Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022; Kang, Jaeku/D-4933-2011	Kang, Jaeku/0000-0002-8660-7940	Ministry of Education, Science and Technology [2011-0025912, 2011-0015761, 2011-0028284]	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2011-0025912 and 2011-0015761, HYL; 2011-0028284, JWH). We thank Professor Gordon B Mills for a plasmid-containing uPA promoter and invaluable discussion, Professor Aree Moon for Ras V12 and Ras N17 and Professor Taeg Kyu Kwon for MMP-9 promoters.	Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bese T, 2010, J GYNECOL ONCOL, V21, P248, DOI 10.3802/jgo.2010.21.4.248; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Chang HR, 2010, CHEM-BIOL INTERACT, V183, P172, DOI 10.1016/j.cbi.2009.10.018; DOLO V, 1995, CLIN EXP METASTAS, V13, P277, DOI 10.1007/BF00133483; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fishman DA, 1997, CANCER-AM CANCER SOC, V80, P1457, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1457::AID-CNCR13>3.0.CO;2-4; Fishman DA, 2001, CANCER RES, V61, P3194; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hodge JC, 2003, CANCER RES, V63, P1359; Horiuchi A, 2008, CANCER SCI, V99, P2532, DOI 10.1111/j.1349-7006.2008.00977.x; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kohn EC, 2003, INT J GYNECOL OBSTET, V83, P203, DOI 10.1016/S0020-7292(03)90122-6; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Mills GB, 2003, GYNECOL ONCOL, V88, pS88, DOI 10.1006/gyno.2002.6692; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Mukai M, 2003, INT J ONCOL, V22, P1247; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Park SY, 2011, INT J CANCER, V128, P2306, DOI 10.1002/ijc.25589; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sedlakova I, 2011, TUMOR BIOL, V32, P311, DOI 10.1007/s13277-010-0123-8; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Young TN, 1996, GYNECOL ONCOL, V62, P89, DOI 10.1006/gyno.1996.0195	41	89	98	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4279	4289		10.1038/onc.2011.595	http://dx.doi.org/10.1038/onc.2011.595			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249252				2022-12-17	WOS:000309520200003
J	Buijs, JT; van der Horst, G; van den Hoogen, C; Cheung, H; de Rooij, B; Kroon, J; Petersen, M; van Overveld, PGM; Pelger, RCM; van der Pluijm, G				Buijs, J. T.; van der Horst, G.; van den Hoogen, C.; Cheung, H.; de Rooij, B.; Kroon, J.; Petersen, M.; van Overveld, P. G. M.; Pelger, R. C. M.; van der Pluijm, G.			The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation	ONCOGENE			English	Article						cancer stem cell; bone morphogenetic protein; heterodimer; breast cancer; bone metastasis; transforming growth factor-beta	ALDEHYDE DEHYDROGENASE-ACTIVITY; COMBINATORIAL GENE-THERAPY; MESENCHYMAL TRANSITION; PROSPECTIVE IDENTIFICATION; MORPHOGENETIC PROTEIN-7; INITIATING CELLS; HUMAN PROSTATE; TGF-BETA; RESISTANCE; BMP7	Accumulating evidence suggests that a subpopulation of breast cancer cells, referred to as cancer stem cells (CSCs), have the ability to propagate a tumor and potentially seed new metastases. Furthermore, stimulation of an epithelialto-mesenchymal transition by factors like transforming growth factor-beta (GF beta) is accompanied with the generation of breast CSCs. Previous observations indicated that bone morphogenetic protein-7 (BMP7) antagonizes the protumorigenic and prometastatic actions of TGF beta, but whether BMP7 action is mechanistically linked to breast CSCs has remained elusive. Here, we have studied the effects of BMP7, BMP2 and a BMP2/7 heterodimer on the formation of human breast CSCs (ALDH(hi)/CD44(hi)/CD24(-/low)) and bone metastases formation in a preclinical model of intra-cardiac injection of MDA-MB-231 cells in athymic nude (Balb/c nu/nu) mice. The BMP2/7 heterodimer was the most efficient stimulator of BMP signaling and very effectively reduced TGF beta-driven Smad signaling and cancer cell invasiveness. The tested BMPs-particularly the heterodimeric BMP2/7-srongly reduced the size of the ALDH(hi)/CD44(hi)/CD24(-/low) CSC subpopulation. In keeping with these in vitro observations, pretreatment of cancer cells with BMPs for 72 h prior to systemic inoculation of the cancer cells inhibited the formation of bone metastases. Collectively, our data support the notion that breast CSCs are involved in bone metastasis formation and describe heterodimeric BMP2/7 as a powerful TGFb antagonist with anti-metastatic potency. Oncogene (2012) 31, 2164-2174; doi:10.1038/onc.2011.400; published online 26 September 2011	[Buijs, J. T.; van der Horst, G.; van den Hoogen, C.; Cheung, H.; de Rooij, B.; Kroon, J.; Petersen, M.; van Overveld, P. G. M.; Pelger, R. C. M.; van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Urol, NL-2333 ZA Leiden, Zuid Holland, Netherlands; [van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Zuid Holland, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Pluijm, G (corresponding author), Leiden Univ, Med Ctr, Dept Urol, J3-100,Albinusdreef 2, NL-2333 ZA Leiden, Zuid Holland, Netherlands.	G.van_der_Pluijm@lumc.nl	Pelger, Rob/ABF-9029-2021; Buijs, Jeroen/E-6082-2011	Pelger, Rob/0000-0001-6328-6462; Buijs, Jeroen/0000-0001-5816-9739; van der Horst, Geertje/0000-0003-1696-160X; van Overveld, Petra GM/0000-0003-0216-5004; de Rooij, Bob/0000-0002-6424-0025	PRIMA; PROMET; BRECOSM; Dutch Cancer Society (KWF) [UL-2004-3028]	PRIMA; PROMET; BRECOSM; Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We are grateful to Professor Dr P ten Dijke for providing the reporter constructs. JTB and GvdH were sponsored by the European Sixth Framework Programme PRIMA; CvdH and HC were sponsored by the European Sixth Framework Programme PROMET; MP was sponsored by the European Sixth Framework Programme BRECOSM and PGMvO was sponsored by a grant from Dutch Cancer Society (KWF project UL-2004-3028).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Cheung AMS, 2007, LEUKEMIA, V21, P1423, DOI 10.1038/sj.leu.2404721; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cook C, 2007, DEV BIOL, V312, P217, DOI 10.1016/j.ydbio.2007.09.038; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Klose A, 2011, NEOPLASIA, V13, P276, DOI 10.1593/neo.101540; Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Notting IC, 2005, INVEST OPHTH VIS SCI, V46, P1581, DOI 10.1167/iovs.04-0245; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Schwaninger R, 2007, AM J PATHOL, V170, P160, DOI 10.2353/ajpath.2007.051276; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; ten Dijke P, 2006, CURR MED RES OPIN, V22, pS7, DOI 10.1185/030079906X80576; Uchino M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-414; Valera E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011167; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Winquist RJ, 2009, BIOCHEM PHARMACOL, V78, P326, DOI 10.1016/j.bcp.2009.03.020; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411; Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821	49	89	92	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2164	2174		10.1038/onc.2011.400	http://dx.doi.org/10.1038/onc.2011.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996751				2022-12-17	WOS:000303415900005
J	Jiang, J; Zhang, Y; Chuai, S; Wang, Z; Zheng, D; Xu, F; Zhang, Y; Li, C; Liang, Y; Chen, Z				Jiang, J.; Zhang, Y.; Chuai, S.; Wang, Z.; Zheng, D.; Xu, F.; Zhang, Y.; Li, C.; Liang, Y.; Chen, Z.			Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype	ONCOGENE			English	Article						gastric cancer; cancer stem cells; CD90; ERBB2; trastuzumab (herceptin)	MAMMARY STEM/PROGENITOR CELLS; BREAST-CANCER; INITIATING CELLS; PROSPECTIVE IDENTIFICATION; GASTROINTESTINAL-TRACT; EXPRESSION PATTERNS; GENE AMPLIFICATION; PROGENITOR CELLS; LIVER-CANCER; POPULATION	Identification and characterization of cancer stem cells (CSCs) in gastric cancer are difficult owing to the lack of specific markers and consensus methods. In this study, we show that cells with the CD90 surface marker in gastric tumors could be enriched under non-adherent, serum-free and sphere-forming conditions. These CD90(+) cells possess a higher ability to initiate tumor in vivo and could re-establish the cellular hierarchy of tumors from single-cell implantation, demonstrating their self-renewal properties. Interestingly, higher proportion of CD90(+) cells correlates with higher in vivo tumorigenicity of gastric primary tumor models. In addition, it was found that ERBB2 was overexpressed in about 25% of the gastric primary tumor models, which correlates with the higher level of CD90 expression in these tumors. Trastuzumab (humanized anti-ERBB2 antibody) treatment of high-tumorigenic gastric primary tumor models could reduce the CD90(+) population in tumor mass and suppress tumor growth when combined with traditional chemotherapy. Moreover, tumorigenicity of tumor cells could also be suppressed when trastuzumab treatment starts at the same time as cell implantation. Therefore, we have identified a CSC population in gastric primary tumors characterized by their CD90 phenotype. The finding that trastuzumab targets the CSC population in gastric tumors suggests that ERBB2 signaling has a role in maintaining CSC populations, thus contributing to carcinogenesis and tumor invasion. In conclusion, the results from this study provide new insights into the gastric tumorigenic process and offer potential implications for the development of anticancer drugs as well as therapeutic treatment of gastric cancers. Oncogene (2012) 31, 671-682; doi:10.1038/onc.2011.282; published online 11 July 2011	[Jiang, J.; Zhang, Y.; Chuai, S.; Wang, Z.; Zheng, D.; Xu, F.; Zhang, Y.; Li, C.; Liang, Y.; Chen, Z.] China Novartis Inst Biomed Res, Shanghai, Peoples R China	Novartis	Chen, Z (corresponding author), Novartis Inst Biomed Res, Lab Anim Sci, Bldg 8,Lane 898,Halei Rd,Zhangjiang Hitech Pk,Pud, Shanghai 201203, Peoples R China.	zhi-1.chen@novartis.com			Novartis Education Office	Novartis Education Office	Dr Jiang has been funded by a fellowship from the Novartis Education Office. Other authors declare no conflict of interest.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Araki H, 2007, BLOOD, V109, P3570, DOI 10.1182/blood-2006-07-035287; BERNSTEIN ID, 1980, SCIENCE, V207, P68, DOI 10.1126/science.6965328; Beuzeboc P, 1999, B CANCER, V86, P544; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bowles MJ, 2001, BRIT MED J, V323, P1413, DOI 10.1136/bmj.323.7326.1413; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; CHEN W, 2007, CANCER BIOL THER, V6, P763; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dan YY, 2006, P NATL ACAD SCI USA, V103, P9912, DOI 10.1073/pnas.0603824103; Dennis JE, 2007, STEM CELLS, V25, P2575, DOI 10.1634/stemcells.2007-0204; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fukuda K, 2009, INT J ONCOL, V34, P1201, DOI 10.3892/ijo_00000248; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; HAACKSORENSEN M, 2007, SCAND J CLIN LAB INV, V12, P1; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lazaro CA, 2003, HEPATOLOGY, V38, P1095, DOI 10.1053/jhep.2003.50448; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Marx AH, 2009, HUM PATHOL, V40, P769, DOI 10.1016/j.humpath.2008.11.014; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Nakamura Y, 2006, BRIT J DERMATOL, V154, P1062, DOI 10.1111/j.1365-2133.2006.07209.x; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oikonomou D, 2007, J CANCER RES CLIN, V133, P951, DOI 10.1007/s00432-007-0238-5; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qiang L, 2009, CANCER LETT, V279, P13, DOI 10.1016/j.canlet.2009.01.016; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rege TA, 2006, FASEB J, V20, P1045, DOI 10.1096/fj.05-5460rev; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riley L, 2010, AACR 2010 M; Ruangpratheep Chetana, 2005, J Med Assoc Thai, V88 Suppl 3, pS281; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; SEEGER RC, 1982, J IMMUNOL, V128, P983; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Spisek R, 2007, J EXP MED, V204, P831, DOI 10.1084/jem.20062387; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takaishi S, 2008, J CLIN ONCOL, V26, P2876, DOI 10.1200/JCO.2007.15.2603; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Wang KH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-288; Wang Q, 2009, ANTICANCER RES, V29, P1233; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yano T, 2006, ONCOL REP, V15, P65; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zou GM, 2008, J CELL PHYSIOL, V217, P598, DOI 10.1002/jcp.21541	72	89	96	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					671	682		10.1038/onc.2011.282	http://dx.doi.org/10.1038/onc.2011.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21743497				2022-12-17	WOS:000300222100001
J	Cheong, JK; Nguyen, TH; Wang, H; Tan, P; Voorhoeve, PM; Lee, SH; Virshup, DM				Cheong, J. K.; Nguyen, T. H.; Wang, H.; Tan, P.; Voorhoeve, P. M.; Lee, S. H.; Virshup, D. M.			IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1 delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation	ONCOGENE			English	Article						casein kinase 1; Wnt; IC261; mitotic spindle; cancer; synthetic lethal	CASEIN KINASE-I; DROSOPHILA CLOCK GENE; DOUBLE-TIME; EPSILON; PHOSPHORYLATION; WNT; CK1-EPSILON; PATHWAY; FAMILY; GROWTH	Casein kinase 1 delta and epsilon (CK1 delta/epsilon) are key regulators of diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. Recent studies suggest that they have an important role in oncogenesis. RNA interference screens identified CK1 epsilon as a pro-survival factor in cancer cells in vitro and the CK1 delta/epsilon-specific inhibitor IC261 is remarkably effective at selective, synthetic lethal killing of cancer cells. The recent development of the nanomolar CK1 delta/epsilon-selective inhibitor, PF670462 (PF670) and the CK1 epsilon-selective inhibitor PF4800567 (PF480) offers an opportunity to further test the role of CK1 delta/epsilon in cancer. Unexpectedly, and unlike IC261, PF670 and PF480 were unable to induce cancer cell death. PF670 is a potent inhibitor of CK1 delta/epsilon in cells; nanomolar concentrations are sufficient to inhibit CK1 delta/epsilon activity as measured by repression of intramolecular autophosphorylation, phosphorylation of disheveled2 proteins and Wnt/beta-catenin signaling. Likewise, small interfering RNA knockdown of CK1 delta and CK1 epsilon reduced Wnt/beta-catenin signaling without affecting cell viability, further suggesting that CK1 delta/epsilon inhibition may not be relevant to the IC261-induced cell death. Thus, while PF670 is a potent inhibitor of Wnt signaling, it only modestly inhibits cell proliferation. In contrast, while sub-micromolar concentrations of IC261 neither inhibited CK1 delta/epsilon kinase activity nor blocked Wnt/beta-catenin signaling in cancer cells, it caused a rapid induction of prometaphase arrest and subsequent apoptosis in multiple cancer cell lines. In a stepwise transformation model, IC261-induced killing required both overactive Ras and inactive p53. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing. Oncogene (2011) 30, 2558-2569; doi:10.1038/onc.2010.627; published online 24 January 2011	[Cheong, J. K.; Nguyen, T. H.; Wang, H.; Tan, P.; Voorhoeve, P. M.; Lee, S. H.; Virshup, D. M.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Voorhoeve, P. M.; Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National University of Singapore; National University of Singapore	Virshup, DM (corresponding author), Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Nguyen, Hung/M-8118-2014; Virshup, David M/C-1449-2009	Nguyen, Hung/0000-0001-8378-555X; Virshup, David M/0000-0001-6976-850X; Wang, Hannah/0000-0002-0600-2555	Agency for Science, Technology and Research, Singapore; Ministry of Health, Singapore; National Research Foundation; National Medical Research Council; Singapore Millennium Foundation (SMF)	Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Ministry of Health, Singapore(Ministry of Health-Singapore); National Research Foundation; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Singapore Millennium Foundation (SMF)(Singapore Millennium Foundation)	We thank Velani Utomo, Ha Yin Lee, Simran Kaur and Qin Luo (Duke-NUS) for their excellent technical and computational support. We are also grateful to our Duke and Duke-NUS colleagues Tim Haystead, Sin Tiong Ong, Shirish Shenolikar, Patrick Casey and members of the Virshup laboratory for their helpful discussions. This work was supported by the Duke-NUS Signature Research Program funded by the Agency for Science, Technology and Research, Singapore, and the Ministry of Health, Singapore, and a Singapore Translational Research Investigator Award to DMV funded by the National Research Foundation and the National Medical Research Council. JKC was supported by a Singapore Millennium Foundation (SMF) Postdoctoral Fellowship.	Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Arora S, 2009, CANCER RES, V69, P1910, DOI 10.1158/0008-5472.CAN-08-0877; Badura L, 2007, J PHARMACOL EXP THER, V322, P730, DOI 10.1124/jpet.107.122846; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Brockschmidt C, 2008, GUT, V57, P799, DOI 10.1136/gut.2007.123695; Bryant CD, 2009, PSYCHOPHARMACOLOGY, V203, P703, DOI 10.1007/s00213-008-1417-z; Bryja V, 2007, CELL SIGNAL, V19, P610, DOI 10.1016/j.cellsig.2006.08.011; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clokie S, 2009, FEBS J, V276, P6971, DOI 10.1111/j.1742-4658.2009.07405.x; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gigant B, 2009, TOP CURR CHEM, V286, P259, DOI 10.1007/128_2008_11; Grueneberg DA, 2008, P NATL ACAD SCI USA, V105, P16472, DOI 10.1073/pnas.0808019105; Hampton T, 2004, JAMA-J AM MED ASSOC, V292, P419, DOI 10.1001/jama.292.4.419; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 2005, ONKOLOGIE, V28, P508, DOI 10.1159/000087137; Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Meng QJ, 2008, NEURON, V58, P78, DOI 10.1016/j.neuron.2008.01.019; Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022-1759(97)00043-4; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sprouse J, 2009, PSYCHOPHARMACOLOGY, V204, P735, DOI 10.1007/s00213-009-1503-x; Stoter M, 2005, ONCOGENE, V24, P7964, DOI 10.1038/sj.onc.1208941; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Virshup DM, 2007, COLD SPRING HARB SYM, V72, P413, DOI 10.1101/sqb.2007.72.048; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Yang WS, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-r92; Yu WJ, 2009, MOL CELL BIOL, V29, P1452, DOI 10.1128/MCB.01777-08	47	89	95	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2558	2569		10.1038/onc.2010.627	http://dx.doi.org/10.1038/onc.2010.627			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258417	Green Published, hybrid			2022-12-17	WOS:000291198400007
J	Latonen, L; Moore, HM; Bai, B; Jaamaa, S; Laiho, M				Latonen, L.; Moore, H. M.; Bai, B.; Jaamaa, S.; Laiho, M.			Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability	ONCOGENE			English	Article						proteasome inhibitor; proteasome; ubiquitin; polyadenylated RNA; nuclear export; aggresome	NUCLEAR EXPORT; RIBOSOMAL-SUBUNITS; DNA-DAMAGE; P53; CRM1; ATAXIN-1; LOCALIZATION; BIOGENESIS; AGGRESOMES; COMPONENT	The ubiquitin-proteasome pathway is essential for most cellular processes, including protein quality control, cell cycle, transcription, signaling, protein transport, DNA repair and stress responses. Hampered proteasome activity leads to the accumulation of polyubiquitylated proteins, endoplastic reticulum (ER) stress and even cell death. The ability of chemical proteasome inhibitors (PIs) to induce apoptosis is utilized in cancer therapy. During PI treatment, misfolded proteins accrue to cytoplasmic aggresomes. The formation of aggresome-like structures in the nucleus has remained obscure. We identify here a nucleolus-associated RNA-protein aggregate (NoA) formed by the inhibition of proteasome activity in mammalian cells. The aggregate forms within the nucleolus and is dependent on nucleolar integrity, yet is a separate structure, lacking nucleolar marker proteins, ribosomal RNA (rRNA) and rRNA synthesis activity. The NoAs contain polyadenylated RNA, conjugated ubiquitin and numerous nucleoplasmic proteasome target proteins. Several of these are key factors in oncogenesis, including transcription factors p53 and retinoblastoma protein (Rb), several cell cycle-regulating cyclins and cyclin-dependent kinases (CDKs), and stress response kinases ataxia-telangiectasia mutated (ATM) and Chk1. The aggregate formation depends on ubiquitin availability, as shown by modulating the levels of ubiquitin and deubiquitinases. Furthermore, inhibition of chromosome region maintenance 1 protein homolog (CRM1) export pathway aggravates the formation of NoAs. Taken together, we identify here a novel nuclear stress body, which forms upon proteasome inactivity within the nucleolus and is detectable in mammalian cell lines and in human tissue. These findings show that the nucleolus controls protein and RNA surveillance and export by the ubiquitin pathway in a previously unidentified manner, and provide mechanistic insight into the cellular effects of PIs. Oncogene (2011) 30, 790-805; doi:10.1038/onc.2010.469; published online 18 October 2010	[Bai, B.; Laiho, M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; [Latonen, L.; Moore, H. M.; Jaamaa, S.; Laiho, M.] Univ Helsinki, Mol Canc Biol Program, Helsinki, Finland; [Latonen, L.; Moore, H. M.; Jaamaa, S.; Laiho, M.] Univ Helsinki, Haartman Inst, Helsinki, Finland	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Helsinki	Laiho, M (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, 1550 Orleans St,CRB 2,Room 444, Baltimore, MD 21231 USA.	mlaiho1@jhmi.edu	Latonen, Leena/C-8787-2016; Bai, Baoyan/A-8584-2012	Latonen, Leena/0000-0003-4502-2193; 	Academy of Finland [129699, 108828]; Biocentrum Helsinki; Helsinki Biomedical Graduate School	Academy of Finland(Academy of Finland); Biocentrum Helsinki; Helsinki Biomedical Graduate School	We thank Drs M Olson, A Miyawaki, I Dikic, B Vogelstein and A Salminen for providing reagents and cell lines. M Salo and H Liu are thanked for excellent technical assistance. Members of Laiho lab at Helsinki and Hopkins, O Matilainen and C Holmberg are thanked for helpful discussions. University of Helsinki Molecular Imaging Unit is thanked for assistance in image acquisition. University of Helsinki Advanced Imaging Unit is thanked for assistance in TEM imaging and sample preparation. This work was supported by Academy of Finland (ML Grant No. 129699, LL Grant No. 108828), Biocentrum Helsinki and Helsinki Biomedical Graduate School (HMM).	Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boulon S, 2004, MOL CELL, V16, P777, DOI 10.1016/j.molcel.2004.11.013; Carter S, 2008, CELL CYCLE, V7, P2519, DOI 10.4161/cc.7.16.6422; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Ernoult-Lange M, 2009, MOL BIOL CELL, V20, P176, DOI 10.1091/mbc.E08-09-0904; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fujii K, 2009, GENE DEV, V23, P963, DOI 10.1101/gad.1775609; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hallstrom TMKA, 2007, P NATL ACAD SCI USA, V104, P7211, DOI 10.1073/pnas.0609299104; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Hutten S, 2007, TRENDS CELL BIOL, V17, P193, DOI 10.1016/j.tcb.2007.02.003; Ikeda F, 2008, EMBO REP, V9, P536, DOI 10.1038/embor.2008.93; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kurki S, 2004, CELL CYCLE, V3, P976; Lafontaine DLJ, 2001, NAT REV MOL CELL BIO, V2, P514, DOI 10.1038/35080045; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; Li LB, 2008, NATURE, V453, P1107, DOI 10.1038/nature06909; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Matafora V, 2009, MOL CELL PROTEOMICS, V8, P2243, DOI 10.1074/mcp.M900079-MCP200; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saeki Y, 2009, EMBO J, V28, P359, DOI 10.1038/emboj.2008.305; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stavreva DA, 2006, MOL CELL BIOL, V26, P5131, DOI 10.1128/MCB.02227-05; SUDHA T, 1995, CHROMOSOME RES, V3, P115, DOI 10.1007/BF00710672; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Thomsen R, 2008, RNA, V14, P706, DOI 10.1261/rna.718708; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	63	89	92	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					790	805		10.1038/onc.2010.469	http://dx.doi.org/10.1038/onc.2010.469			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956947				2022-12-17	WOS:000287444600004
J	Ibanez de Caceres, I; Cortes-Sempere, M; Moratilla, C; Machado-Pinilla, R; Rodriguez-Fanjul, V; Manguan-Garcia, C; Cejas, P; Lopez-Rios, F; Paz-Ares, L; de CastroCarpeno, J; Nistal, M; Belda-Iniesta, C; Perona, R				Ibanez de Caceres, I.; Cortes-Sempere, M.; Moratilla, C.; Machado-Pinilla, R.; Rodriguez-Fanjul, V.; Manguan-Garcia, C.; Cejas, P.; Lopez-Rios, F.; Paz-Ares, L.; de CastroCarpeno, J.; Nistal, M.; Belda-Iniesta, C.; Perona, R.			IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer	ONCOGENE			English	Article						CDDP-resistance; IGFBP-3; NSCLC; hypermethylation	INDUCED DNA HYPERMETHYLATION; EPITHELIAL OVARIAN-CANCER; DRUG-RESISTANCE; BINDING PROTEIN-3; PROMOTER HYPERMETHYLATION; ACQUIRED-RESISTANCE; CPG ISLAND; METHYLATION; GROWTH; GENE	Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. Oncogene (2010) 29, 1681-1690; doi:10.1038/onc.2009.454; published online 21 December 2009	[Ibanez de Caceres, I.] FIB La Paz Univ Hosp, Oncol Res Lab, Inst Invest Biomed Madrid, Res Unit, Madrid 28029, Spain; [Cortes-Sempere, M.; Moratilla, C.; Machado-Pinilla, R.; Rodriguez-Fanjul, V.; Manguan-Garcia, C.; Perona, R.] UAM, Translat Oncol Unit, CSIC H La Paz, Inst Invest Biomed CSIC, Madrid, Spain; [Cejas, P.; de CastroCarpeno, J.; Belda-Iniesta, C.] La Paz Univ Hosp, Translat Oncol Unit, CSIC H La Paz, Dept Med Oncol, Madrid, Spain; [Lopez-Rios, F.] Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain; [Paz-Ares, L.] Hosp 12 Octubre, Dept Med Oncol, E-28041 Madrid, Spain; [Nistal, M.] La Paz Univ Hosp, Dept Pathol, Madrid, Spain	Autonomous University of Madrid; Hospital Universitario La Paz; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario La Paz	Ibanez de Caceres, I (corresponding author), FIB La Paz Univ Hosp, Oncol Res Lab, Inst Invest Biomed Madrid, Res Unit, C Arturo Duperier 4, Madrid 28029, Spain.	inma.ibanezca@salud.madrid.org	Rodríguez, Ferran A. A/H-4892-2011; Fanjul, Vanessa VRF Rodriguez/K-8417-2017; Paz-Ares, Luis/AAH-2750-2019	Rodríguez, Ferran A. A/0000-0002-2280-8962; Fanjul, Vanessa VRF Rodriguez/0000-0002-3386-5874; Belda Iniesta, Cristobal/0000-0003-3254-7492	Fondo de Investigacion Sanitaria (ISCIII) [CP08/000689; PI-717, PI06-1234, PI08-1485, PS09/00472]; Fundacion Medica Mutua Madrilena	Fondo de Investigacion Sanitaria (ISCIII)(Instituto de Salud Carlos III); Fundacion Medica Mutua Madrilena(Instituto de Salud Carlos III)	We gratefully acknowledge Javier Perez for the artwork and to J Siegfried, for the English correction of the manuscript. Ibanez de Caceres was partially supported by the Fondo de Investigacion Sanitaria (ISCIII) through the 'Miguel Servet' program (CP08/000689; PI-717). Note: Supported by FIS PI06-1234, PI08-1485, PS09/00472 and Fundacion Medica Mutua Madrilena.	Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 2003, CANCER RES, V63, P7089; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Esteller M, 1999, CANCER RES, V59, P793; Gosepath EM, 2008, INT J CANCER, V123, P2013, DOI 10.1002/ijc.23721; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018; Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Leyland-Jones B, 1999, AM J PATHOL, V155, P77, DOI 10.1016/S0002-9440(10)65102-4; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; MCKEAGE MJ, 1995, DRUG SAFETY, V13, P228, DOI 10.2165/00002018-199513040-00003; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; NYCE J, 1989, CANCER RES, V49, P5829; Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8; Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767; Plasencia C, 2006, INT J ONCOL, V29, P225; Plumb JA, 2000, CANCER RES, V60, P6039; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Riedel RF, 2008, MOL CANCER THER, V7, P3141, DOI 10.1158/1535-7163.MCT-08-0642; Roninson IB, 2003, CANCER RES, V63, P2705; Shen DW, 2004, BRIT J CANCER, V91, P270, DOI 10.1038/sj.bjc.6601956; Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; 2003, CENT EUR J PUBLIC HL, V11, P177	43	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1681	1690		10.1038/onc.2009.454	http://dx.doi.org/10.1038/onc.2009.454			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023704				2022-12-17	WOS:000275694700013
J	Denley, A; Kang, S; Karst, U; Vogt, PK				Denley, A.; Kang, S.; Karst, U.; Vogt, P. K.			Oncogenic signaling of class IPI3K isoforms	ONCOGENE			English	Article						PI3K; oncogenic transformation; signaling; Ras; MEK; inhibitor	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE INHIBITORS; CATALYTIC SUBUNIT; CELL-PROLIFERATION; PI 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; MEDIATED PHOSPHORYLATION; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY	The catalytic subunits of class I PI3Ks comprise four isoforms: p110 alpha, p110 beta, p110 delta and p110 gamma. Cancer-specific gain-of-function mutations in p110 alpha delta beta have been identified in various malignancies. Cancer-specific mutations in the non-alpha isoforms of class I PI3K have not yet been identified, however overexpression of either wild-type p110 beta, p110 gamma or p110 delta is sufficient to induce cellular transformation in chicken embryo fibroblasts. The mechanism whereby these non-a isoforms of class I mediate oncogenic signals is unknown. Here we show that potently transforming class I isoforms signal via Akt/mTOR, inhibit GSK3 beta and cause degradation of FoxO1. A functional Erk pathway is required for p110 gamma and p110 beta transformation but not for transformation by p110 delta or the H1047R mutant of p110 alpha. Transformation and signaling by p110 gamma and p110 beta are sensitive to loss of interaction with Ras, which acts as a membrane anchor. Mutations in the C2 domain of p110 delta reduce transformation, most likely by interfering with membrane association. Several small molecule inhibitors potently and specifically inhibit the oncogenic signaling and transformation of each of the class I PI3K, and, when used in combination with MEK inhibitors, can additively reduce the transformation induced by p110 beta and p110 gamma.	[Denley, A.; Kang, S.; Karst, U.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC-239, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Dong JJ, 2005, CANCER RES, V65, P1961, DOI 10.1158/0008-5472.CAN-04-2501; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fan QW, 2006, CELL CYCLE, V5, P2301, DOI 10.4161/cc.5.20.3362; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; HOOSHMANDRAD R, 2000, J CELL SCI, V3, pP110; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kharas MG, 2004, BLOOD, V103, P4268, DOI 10.1182/blood-2003-07-2193; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Leverrier Y, 2003, J BIOL CHEM, V278, P38437, DOI 10.1074/jbc.M306649200; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okkenhaug K, 2002, SCIENCE, V297, P1031; Orme MH, 2006, NAT CELL BIOL, V8, P1298, DOI 10.1038/ncb1493; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SKORSKI T, 1995, CANCER RES, V55, P2275; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vogt PK, 2006, CELL CYCLE, V5, P946, DOI 10.4161/cc.5.9.2725; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Ward SG, 2003, CURR OPIN PHARMACOL, V3, P426, DOI 10.1016/S1471-4892(03)00078-X; Yip SC, 2004, CELL MOTIL CYTOSKEL, V59, P180, DOI 10.1002/cm.20032; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	75	89	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2561	2574		10.1038/sj.onc.1210918	http://dx.doi.org/10.1038/sj.onc.1210918			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998941				2022-12-17	WOS:000255057000006
J	Jonsson, G; Dahl, C; Staaf, J; Sandberg, T; Bendahl, PO; Ringner, M; Guldberg, P; Borg, A				Joensson, G.; Dahl, C.; Staaf, J.; Sandberg, T.; Bendahl, P-O; Ringner, M.; Guldberg, P.; Borg, A.			Genomic profiling of malignant melanoma using tiling-resolution arrayCGH	ONCOGENE			English	Article						melanoma; arrayCGH; mutation	BRAF MUTATIONS; SUSCEPTIBILITY LOCUS; CUTANEOUS MELANOMA; GENE; DELETION; PATHWAY; TBX2; INACTIVATION; DISRUPTION; SENESCENCE	Malignant melanoma is an aggressive, heterogeneous disease where new biomarkers for diagnosis and clinical outcome are needed. We searched for chromosomal aberrations that characterize its pathogenesis using 47 different melanoma cell lines and tiling-resolution bacterial artificial chromosome-arrays for comparative genomic hybridization. Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4 and PTEN, were examined for mutations. Distinct copy number alterations were detected, including loss or gain of whole chromosomes but also minute amplifications and homozygous deletions. Most common overlapping regions with losses were mapped to 9p24.3-q13, 10 and 11q14.1-qter, whereas copy number gains were most frequent on chromosomes 1q, 7, 17q and 20q. Amplifications were delineated to oncogenes such as MITF (3p14), CCND1 (11q13), MDM2 (12q15), CCNE1 (19q12) and NOTCH2 (1p12). Frequent findings of homozygous deletions on 9p21 and 10q23 confirmed the importance of CDKN2A and PTEN. Pair-wise comparisons revealed distinct sets of alterations, for example, mutually exclusive mutations in BRAF and NRAS, mutual mutations in BRAF and PTEN, concomitant chromosome 7 gain and 10 loss and concomitant chromosome 15q22.2-q26.3 gain and 20 gain. Moreover, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.	Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Lund Univ, Dept Theoret Phys, S-22362 Lund, Sweden	Lund University; Skane University Hospital; Danish Cancer Society; Lund University	Borg, A (corresponding author), Lund Univ, Dept Oncol, SE-22185 Lund, Sweden.	ake.borg@med.lu.se	Jönsson, Göran/D-1212-2014; Ringnér, Markus/G-3641-2011	Ringnér, Markus/0000-0001-5469-8940				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cachia AR, 2000, CLIN CANCER RES, V6, P3511; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Guldberg P, 1997, CANCER RES, V57, P3660; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Massi D, 2006, MODERN PATHOL, V19, P616, DOI 10.1038/modpathol.3800585; McLean WHI, 2003, HUM MOL GENET, V12, P2395, DOI 10.1093/hmg/ddg234; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, MELANOMA RES, V12, P565, DOI 10.1097/00008390-200212000-00006; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Saal LH, 2002, GENOME BIOL, V3; Sauter ER, 2002, CANCER RES, V62, P3200; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Walker GJ, 2004, GENE CHROMOSOME CANC, V41, P56, DOI 10.1002/gcc.20056; ZIPPELIUS A, 2006, CANC IMMUNOL IMMUNOT	38	89	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4738	4748		10.1038/sj.onc.1210252	http://dx.doi.org/10.1038/sj.onc.1210252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17260012				2022-12-17	WOS:000248037900015
J	Rasola, A; Fassetta, M; De Bacco, F; D'Alessandro, L; Gramaglia, D; Di Renzo, M; Comoglio, PM				Rasola, A.; Fassetta, M.; De Bacco, F.; D'Alessandro, L.; Gramaglia, D.; Di Renzo, M. F.; Comoglio, P. M.			A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth	ONCOGENE			English	Article						apoptosis; beta-catenin; colorectal carcinoma; hepatocyte growth factor; invasive growth	WNT SIGNALING PATHWAY; NF-KAPPA-B; C-MET; SCATTER-FACTOR; CARCINOMA-CELLS; COLON-CANCER; APOPTOSIS; EXPRESSION; GENE; OVEREXPRESSION	Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of beta-catenin. We here demonstrate that a functional crosstalk between Met and beta-catenin signaling sustains and increases CRC cell invasive properties. Hepatocyte growth factor (HGF) stimulation prompts beta-catenin tyrosine phosphorylation and dissociation from Met, and upregulates beta-catenin expression via the phosphatidylinositol 3- kinase pathway in conditions that mimic those found by the invading and metastasizing cells. Additionally, a transcriptionally active form of beta-catenin, known to be oncogenic, enhances Met expression. Furthermore, HGF treatment increases the activity of the beta-catenin-regulated T-cell factor transcription factor in cells expressing the wild-type or the oncogenic beta-catenin. In the mirror experiments, either Met or beta-catenin knocking down also reduces their protein level. In biological assays, beta-catenin knocking down abrogates the HGF-induced motile phenotype, whereas active beta-catenin fosters ligand-independent cell scattering. Met and beta-catenin also cooperate in promoting entry into the cell cycle and in protecting cells from apoptosis. In conclusion, Met and beta-catenin pathways are mutually activated in CRC cells. This might generate a self-amplifying positive feedback loop resulting in the upregulation of the invasive growth properties of CRC cells.	Univ Padua, Dept Biomed Sci, I-25121 Brescia, Italy; Univ Turin, Sch Med, Div Mol Oncol, I-10124 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Canc Genet, Candiolo, Italy	University of Padua; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Rasola, A (corresponding author), Univ Padua, Dept Biomed Sci, Viale Giuseoppe Colombo 3, I-25121 Brescia, Italy.	rasola@bio.unipd.it	DI RENZO, Maria Flavia/B-6091-2012; GRAMAGLIA, DANIELA/A-6354-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328; Rasola, Andrea/0000-0003-4522-3008; Gramaglia, Daniela/0000-0001-6259-0059				Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2005, BRIT J CANCER, V92, P1078, DOI 10.1038/sj.bjc.6602405; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gramaglia D, 2004, CELL DEATH DIFFER, V11, P342, DOI 10.1038/sj.cdd.4401326; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Monga SPS, 2002, CANCER RES, V62, P2064; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Vigna E, 2000, J GENE MED, V2, P308; Wielenga VJM, 2000, AM J PATHOL, V157, P1563, DOI 10.1016/S0002-9440(10)64793-1; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	49	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1078	1087		10.1038/sj.onc.1209859	http://dx.doi.org/10.1038/sj.onc.1209859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953230				2022-12-17	WOS:000244245400014
J	Chen, YJ; Chang, JT; Lee, L; Wang, HM; Liao, CT; Chiu, CC; Chen, PJ; Cheng, AJ				Chen, Y-J; Chang, J. T.; Lee, L.; Wang, H-M; Liao, C-T; Chiu, C-C; Chen, P-J; Cheng, A-J			DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis	ONCOGENE			English	Article						DSG3; head neck cancer; clinical association; migration and invasion; therapeutic target	SQUAMOUS-CELL CARCINOMA; INTERMEDIATE FILAMENTS; PEMPHIGUS-VULGARIS; EXPRESSION; DESMOGLEIN; ADHESION; TELOMERASE	To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer ( HNC), we employed differential display analysis to compare the gene expression profiles between HNC and histopathologically normal epithelial tissues. Using reverse transcription - polymerase chain reaction and Western blot analysis, desmoglein 3 (DSG3) was identified as being differentially expressed at both the RNA and protein levels. Of 56 patients assayed, 34 (61%) had overexpression of DSG3, which correlated statistically with T stage (P=0.009), N stage (P = 0.047), overall stage (P = 0.011), tumor depth (P = 0.009) and extracapsular spread in lymph nodes (P = 0.044), suggesting that DSG3 participates in carcinogenesis of HNC. Consistent with the clinical findings, inhibition of DSG3 by RNA interference (RNAi) significantly reduced cell growth and colony formation to 57 - 21% in three HNC cell lines. Use of an in vitro wound healing and Matrigel invasion assays, we found that cell migration and invasive ability were also inhibited to 30 - 48% in three cell lines tested. An in vivo xenograft study showed that administration of DSG3-RNAi plasmid significantly inhibited tumor growth for 2 months in BALB/C nude mice. In conclusion, DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.	Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Radiat Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Surg Pathol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tao Yuan, Taiwan; Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan 333, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Cheng, AJ (corresponding author), Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	ajchen@mail.cgu.edu.tw	Cheng, Ann-Joy/AAI-4374-2020; Chiu, Ching-Chi/AAB-3093-2020; Chun-Ta, Liao/B-9589-2011	Chiu, Ching-Chi/0000-0002-1827-8049; Cheng, Ann-Joy/0000-0002-1317-0725				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Chang JT, 2006, BRIT J CANCER, V94, P870, DOI 10.1038/sj.bjc.6603008; Chang JT, 2005, INT J CANCER, V114, P942, DOI 10.1002/ijc.20663; Chang JT, 2002, CLIN BIOCHEM, V35, P591, DOI 10.1016/S0009-9120(02)00403-4; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; CLAYMAN GL, 1996, CANC MED, P1645; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P1231, DOI 10.1046/j.1523-1747.2002.19648.x; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P27, DOI 10.1046/j.1523-1747.2002.01780.x; Harada H, 1996, ACTA DERM-VENEREOL, V76, P417; IMAI K, 1995, HEAD NECK-J SCI SPEC, V17, P204, DOI 10.1002/hed.2880170307; Krunic ALJ, 1996, ACTA DERM-VENEREOL, V76, P394; Liao CT, 2004, HEAD NECK-J SCI SPEC, V26, P504, DOI 10.1002/hed.20007; Liao SK, 1998, CANCER GENET CYTOGEN, V103, P52, DOI 10.1016/S0165-4608(97)00416-0; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Yang C C, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P357; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	21	89	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					467	476		10.1038/sj.onc.1209802	http://dx.doi.org/10.1038/sj.onc.1209802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878157				2022-12-17	WOS:000243544000016
J	Furukawa, T; Kanai, N; Shiwaku, HO; Soga, N; Uehara, A; Horii, A				Furukawa, T.; Kanai, N.; Shiwaku, H. O.; Soga, N.; Uehara, A.; Horii, A.			AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer	ONCOGENE			English	Article						aurora; gene expression; kinase; microarray; phosphatase; signal transduction	COMMON ALLELIC LOSS; CHROMOSOME ARM 12Q; AURORA-A; RNA INTERFERENCE; DNA-POLYMERASE; KINASE; PROTEIN; GENE; OVEREXPRESSION; CELLS	DUSP6/MKP-3, a specific inhibitor of MAPK1/ERK2, frequently loses its expression in primary pancreatic cancer tissues. This evidence suggests that constitutive activation of MAPK1 synergistically induced by frequent mutation of KRAS2 and the loss of function of DUSP6 plays key roles in pancreatic carcinogenesis and progression. By pro. ling of gene expressions associated with downregulation of MAPK1 induced by exogenous overexpression of DUSP6 in pancreatic cancer cells, we found that AURKA/STK15, the gene encoding Aurora-A kinase, which plays key roles in cellular mitosis, was among the downregulated genes along with its related genes, which included AURKB, TPX2 and CENPA. An association of expression and promoter activity of AURKA with MAPK activity was verified. Knockdown of ETS2 resulted in a reduction of AURKA expression. These results indicate that AURKA is a direct target of the MAPK pathway and that its overexpression in pancreatic cancer is induced by hyperactivation of the pathway, at least via ETS2.	Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi 980, Japan	Tokyo Women's Medical University; Tohoku University	Furukawa, T (corresponding author), Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, 8-1 Kawado Cho, Tokyo 1628666, Japan.	furukawa@imcir.twmu.ac.jp	Furukawa, Toru/AAF-5596-2021; Horii, Akira/AAW-2839-2021	Furukawa, Toru/0000-0002-1083-2324; Horii, Akira/0000-0002-3967-3291				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CALDAS C, 1995, INT J PANCREATOL, V18, P1; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO;2-W; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2004, PANCREAS, V28, P253, DOI 10.1097/00006676-200404000-00007; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Hoshi M, 2000, BRIT J CANCER, V82, P1801, DOI 10.1054/bjoc.2000.1108; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Hussein D, 2002, J CELL SCI, V115, P3403; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kimura M, 1996, GENE CHROMOSOME CANC, V17, P88, DOI 10.1002/(SICI)1098-2264(199610)17:2<88::AID-GCC3>3.0.CO;2-X; Kimura M, 1998, CANCER RES, V58, P2456; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Kita K, 2003, RADIAT RES, V160, P302, DOI 10.1667/RR3039; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Li DH, 2003, CLIN CANCER RES, V9, P991; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Matsuno S, 2004, PANCREAS, V28, P219, DOI 10.1097/00006676-200404000-00002; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Mori Y, 1997, HUM GENET, V99, P590, DOI 10.1007/s004390050411; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PARKER NJ, 1995, GENOMICS, V27, P280, DOI 10.1006/geno.1995.1043; Rojanala S, 2004, MOL CANCER THER, V3, P451; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wang Y, 2000, GENE DEV, V14, P927; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Yamanaka S, 2004, LAB INVEST, V84, P1339, DOI 10.1038/labinvest.3700160; Yatsuoka T, 2004, ONCOL REP, V12, P1263; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	54	89	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4831	4839		10.1038/sj.onc.1209494	http://dx.doi.org/10.1038/sj.onc.1209494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532023				2022-12-17	WOS:000239687100001
J	Giles, RH; Lolkema, MP; Snijckers, CM; Belderbos, M; van der Groep, P; Mans, DA; van Beest, M; van Noort, M; Goldschmeding, R; van Diest, PJ; Clevers, H; Voest, EE				Giles, R. H.; Lolkema, M. P.; Snijckers, C. M.; Belderbos, M.; van der Groep, P.; Mans, D. A.; van Beest, M.; van Noort, M.; Goldschmeding, R.; van Diest, P. J.; Clevers, H.; Voest, E. E.			Interplay between VHL/HIF1 alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis	ONCOGENE			English	Article						von Hippel-Lindau; Wnt signaling; hypoxiainducible factor; colorectal cancer	HYPOXIA-INDUCIBLE FACTOR; ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; COLON-CARCINOMA; CANCER CELLS; HIF-ALPHA; FACTOR-I; EXPRESSION	Activation of the Wnt signaling pathway initiates the transformation of colorectal epithelial cells, although the transition to metastatic cancer requires angiogenesis. We have investigated the expression of the von Hippel-Lindau (VHL) tumor suppressor in the intestines from humans and mice. Here, we show that VHL expression is regulated by TCF4 and is restricted to the proliferative compartment at the bottom of intestinal crypts. Accordingly, VHL is completely absent from the proliferative intestinal pockets of Tcf4(-/-) perinatal mice. We observed complementary staining of the hypoxia-inducible factor (HIF) 1 alpha to VHL in normal intestinal epithelium as well as in all stages of colorectal cancer (CRC). To the best of our knowledge, this is the first report demonstrating the presence of nuclear HIF1 alpha in normoxic healthy adult tissue. Although we observed upregulated levels of VHL in very early CRC lesions from sporadic and familial adenomatous polyposis patients-presumably due to activated Wnt signaling - a clear reduction of VHL expression is observed in later stages of CRC progression, coinciding with stabilization of HIF1 alpha. As loss of VHL in later stages of CRC progression results in stabilization of HIF, these data provide evidence that selection for VHL downregulation provides a proangiogenic impulse for CRC progression.	Univ Utrecht, Med Ctr, Dept Med Oncol, Expt Oncol Lab, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Urol, Utrecht, Netherlands; NIOB, Hubrecht Lab, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Voest, EE (corresponding author), Univ Utrecht, Med Ctr, Dept Med Oncol, Expt Oncol Lab, Heidelberglaan 100,Rm F02-126, NL-3584 CX Utrecht, Netherlands.	e.e.voest@umcutrecht.nl	Lolkema, M.P./AAE-2906-2019; Goldschmeding, Roel/I-1723-2014	Lolkema, M.P./0000-0003-0466-2928; Belderbos, Mirjam/0000-0002-6164-2918; Giles, Rachel/0000-0001-9133-2008				Aotake T, 1999, CLIN CANCER RES, V5, P135; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Easwaran V, 2003, CANCER RES, V63, P3145; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Fujii H, 2002, J PATHOL, V197, P298, DOI 10.1002/path.1122; Fukuda R, 2003, CANCER RES, V63, P2330; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goel A, 2003, CANCER RES, V63, P1608; Iniesta P, 2000, CANCER-AM CANCER SOC, V89, P1220, DOI 10.1002/1097-0142(20000915)89:6<1220::AID-CNCR5>3.0.CO;2-Z; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuwai T, 2004, CANCER SCI, V95, P149, DOI 10.1111/j.1349-7006.2004.tb03196.x; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Los M, 1997, ANN ONCOL, V8, P1015, DOI 10.1023/A:1008213320642; Los M, 1996, LAB INVEST, V75, P231; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mayer RJ, 2004, NEW ENGL J MED, V350, P2406, DOI 10.1056/NEJMe048098; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OOSTERWEGEL MA, 1991, INT IMMUNOL, V3, P1189, DOI 10.1093/intimm/3.11.1189; Shibamoto S, 1998, GENES CELLS, V3, P659; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1993, J BIOL CHEM, V268, P21513; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhong H, 1999, CANCER RES, V59, P5830; Zhuang ZP, 1996, HUM PATHOL, V27, P152, DOI 10.1016/S0046-8177(96)90368-8	41	89	94	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3065	3070		10.1038/sj.onc.1209330	http://dx.doi.org/10.1038/sj.onc.1209330			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407833				2022-12-17	WOS:000237950800011
J	Pickering, MT; Kowalik, TF				Pickering, MT; Kowalik, TF			Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation	ONCOGENE			English	Article						Rb inactivation; double-strand breaks; DSBs; E2F1; c-Myc	S-PHASE; C-MYC; DAMAGE CHECKPOINT; HISTONE H2AX; APOPTOSIS; E2F1; PHOSPHORYLATION; INSTABILITY; CELLS; P53	Although it is unclear which cellular factor(s) is responsible for the genetic instability associated with initiating and sustaining cell transformation, it is known that many cancers have mutations that inactivate the Rb-mediated proliferation pathway. We show here that pRb inactivation and the resultant deregulation of one E2F family member, E2F1, leads to DNA double-strand break (DSB) accumulation in normal diploid human cells. These DSBs occur independent of Atm, p53, caspases, reactive oxygen species, and apoptosis. Moreover, E2F1 does not contribute to c-Myc-associated DSBs, indicating that the DSBs associated with these oncoproteins arise through distinct pathways. We also find E2F1-associated DSBs in an Rb mutated cancer cell line in the absence of an exogenous DSB stimulus. These basal, E2F1-associated DSBs are not observed in a p16(ink4a) inactivated cancer cell line that retains functional pRb, unless pRb is depleted. Thus, Rb status is key to regulating both the proliferation promoting functions associated with E2F and for preventing DNA damage accumulation if E2F1 becomes deregulated. Taken together, these data suggest that loss of Rb creates strong selective pressure, via DSB accumulation, for inactivating p53 mutations and that E2F1 contributes to the genetic instability associated with transformation and tumorigenesis.	Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kowalik, TF (corresponding author), Univ Massachusetts, Med Ctr, Sch Med, Program Immunol & Virol,Dept Mol Genet & Microbio, Room S5-216,55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Pickering, Mary/0000-0002-0515-7248	NATIONAL CANCER INSTITUTE [R01CA086038] Funding Source: NIH RePORTER; NCI NIH HHS [CA86038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Duensing S, 2002, CANCER RES, V62, P7075; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OLIVE PL, 1991, CANCER RES, V51, P4671; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	27	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					746	755		10.1038/sj.onc.1209103	http://dx.doi.org/10.1038/sj.onc.1209103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186801				2022-12-17	WOS:000235068800010
J	Gallo, RC				Gallo, RC			History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2	ONCOGENE			English	Article						human retroviruses; discovery; human T-cell lymphotropicvirus 1 and 2; human leukemia viruses	T-CELL LEUKEMIA; DEPENDENT DNA POLYMERASE; NORMAL HUMAN LYMPHOCYTES; REVERSE-TRANSCRIPTASE; DEOXYTHYMIDINE SYNTHESIS; HUMAN LEUKOCYTES; ENZYMATIC MECHANISMS; SEROLOGICAL ANALYSIS; HUMAN LYMPHOBLASTS; SARCOMA-VIRUS	HTLV-1 was discovered in the US in 1979, and published in 1980. This was rapidly followed by four additional reports in early 1981 describing additional isolates, characterization of some of the HTLV-1 proteins, serological assays for specific antibodies indicative of HTLV-1 infection, and evidence for integrated DNA proviruses in infected cells. None of this early work was dependent upon or influenced by the subclassiffication of some T-cell malignancies as ATL (in Japan). Instead, I was stimulated by prior work from many investigators in the US and Europe on retroviruses which caused leukemia in animals and our discoveries were made possible by our technical approaches developed in the 1970s involving especially sensitive assays for RT as a surrogate marker for a retrovirus and our discovery of Il-2 which made it possible to culture human T cells. However, following our reports the same virus was isolated in Japan, and both groups provided evidence that HTLV-1 caused ATL, a subclassification of T-cell malignancies first recognized in Japan.	Inst Human Virol, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore	Gallo, RC (corresponding author), Inst Human Virol, Baltimore, MD USA.	gallo@umbi.umd.edu						BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BOBROW SN, 1972, P NATL ACAD SCI USA, V69, P3228, DOI 10.1073/pnas.69.11.3228; FERRER JF, 1975, BIBL HAEMATOL, V40, P59; GALLO RC, 1967, J BIOL CHEM, V242, P5059; GALLO RC, 1981, CANCER RES, V41, P4738; GALLO RC, 1972, MEDICINE, V51, P159; GALLO RC, 1968, J BIOL CHEM, V243, P4936; GALLO RC, 1978, VIROLOGY, V84, P359, DOI 10.1016/0042-6822(78)90255-6; GALLO RC, 1968, J BIOL CHEM, V243, P4943; GALLO RC, 1970, J MOL BIOL, V52, P195, DOI 10.1016/0022-2836(70)90025-2; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KALYANARAMAN VS, 1981, J VIROL, V38, P906, DOI 10.1128/JVI.38.3.906-915.1981; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KETTMANN R, 1975, ACTA HAEMATOL-BASEL, V54, P201, DOI 10.1159/000208076; LOTEM J, 1986, EMBO J, V5, P2163, DOI 10.1002/j.1460-2075.1986.tb04480.x; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; MIER JW, 1982, J IMMUNOL, V128, P1122; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; PRIVAL JT, 1974, J NATL CANCER I, V53, P1583; REITZ MS, 1974, BIOCHEM BIOPH RES CO, V57, P934, DOI 10.1016/0006-291X(74)90635-4; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; ROBERT MS, 1972, SCIENCE, V176, P798, DOI 10.1126/science.176.4036.798; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROBERTGUROFF M, 1981, J EXP MED, V154, P1957, DOI 10.1084/jem.154.6.1957; ROBERTGUROFF M, 1977, BIOCHEMISTRY-US, V16, P2874, DOI 10.1021/bi00632a011; RUSCETTI FW, 1977, J IMMUNOL, V119, P131; SARNGADHARAN MG, 1972, NATURE-NEW BIOL, V240, P67, DOI 10.1038/newbio240067a0; SCHRECKER AW, 1974, CANCER RES, V34, P286; SCHRECKER AW, 1972, CANCER RES, V32, P1547; SMITH RG, 1975, J BIOL CHEM, V250, P1702; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Ting R C, 1975, Bibl Haematol, P693; TING RC, 1972, NATURE-NEW BIOL, V236, P163, DOI 10.1038/newbio236163a0; TING RC, 1973, COMP LEUKEMIA RES, P693; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1981, NATURE, V294, P273, DOI 10.1038/294273a0; YANG SS, 1972, J NATL CANCER I, V49, P7	43	89	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					5926	5930		10.1038/sj.onc.1208980	http://dx.doi.org/10.1038/sj.onc.1208980			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155599				2022-12-17	WOS:000231623400002
J	Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S				Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S			Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX	ONCOGENE			English	Article						integrin-linked kinase; Rac; Cdc42; cell spreading; beta-parvin; alpha-PIX	CELL-SUBSTRATE INTERACTION; FOCAL ADHESION PROTEIN; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; RHO-GTPASES; SIGNALING PATHWAYS; BINDING PROTEIN; ADAPTER PROTEIN; CH-ILKBP; ACTIVATION	Cell spreading and migration are regulated in a Rho family GTPase-dependent manner by growth factors and integrin-mediated cell-extracellular matrix (ECM) interactions. The molecular mechanisms involved in the ECM- and growth factor-mediated activation of these small GTPases remain unclear. In the present study, we demonstrate that integrin-linked kinase (ILK), which is a focal adhesion protein activated by both ECM and growth factors, is required for the activation of Rac and Cdc42 in epithelial cells. Ectopic expression of active ILK in mammary epithelial cells induces dramatic reorganization of the actin cytoskeleton and promotes rapid cell spreading on fibronectin. These effects are associated with constitutive activation of both Rac and Cdc42, but not Rho. The use of ILK siRNA or small molecule inhibitors to inhibit ILK expression and kinase activity, respectively, results in diminished cell spreading and actin cytoskeleton reorganization, concomitant with a reduction in Rac and Cdc42 activation. Studies into the mechanism of ILK-mediated Rac activation suggest an important role for the ILK-beta-parvin interaction and the activity of the Rac/Cdc42-specific guanine nucleotide exchange factor alpha-PIX downstream of ILK. Taken together, these data demonstrate an essential role of ILK kinase activity in Rac- and Cdc42-mediated actin cytoskeleton reorganization in epithelial cells, further solidifying a role for ILK in the regulation of cancer cell motility and invasiveness.	British Columbia Canc Agcy, Vancouver, BC, Canada; Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca	Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Anton IM, 2003, J CELL SCI, V116, P2443, DOI 10.1242/jcs.00433; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Chun SJ, 2003, J CELL BIOL, V163, P397, DOI 10.1083/jcb.200304154; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Li FG, 1999, J CELL SCI, V112, P4589; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Mills J, 2003, J NEUROSCI, V23, P1638; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; QIAN Y, 2005, ONCOGENE; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenberger G, 2005, J BIOL CHEM, V280, P6879, DOI 10.1074/jbc.M412119200; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	65	89	92	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5837	5849		10.1038/sj.onc.1208737	http://dx.doi.org/10.1038/sj.onc.1208737			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897874				2022-12-17	WOS:000231590400006
J	Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK				Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK			The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin	ONCOGENE			English	Article						ENL; MLL; leukemia; histone; chromatin	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION; HISTONE METHYLTRANSFERASE; SWI/SNF COMPLEX; ONCOGENIC ACTIVATION; PAF1 COMPLEX; SET DOMAIN; FAMILY; DIMERIZATION; METHYLATION	Mixed lineage leukemia (MLL) fusion proteins are derived from translocations at 11q23 that occur in aggressive subtypes of leukemia. As a consequence, MLL is joined to different unrelated proteins to form oncogenic transcription factors. Here we demonstrate a direct interaction between several nuclear MLL fusion partners and present evidence for a role of these proteins in histone binding. In two-hybrid studies, ENL interacted with AF4 and AF5q31 as well as with a fragment of AF10. A structure-function analysis revealed that the AF4/AF5q31/AF10 binding domain in ENL coincided with the C-terminus that is essential for transformation by MLL-ENL. The ENL/AF4 association was corroborated by GST-pulldown experiments and by mutual coprecipitation. Both proteins colocalized in vivo in a nuclear speckled pattern. Moreover, AF4 and ENL coeluted on sizing columns together with the known ENL binding partner Polycomb3, suggesting the presence of a multiprotein complex. The overexpression of ENL alone activated a reporter construct and a mutational screen indicated the conserved YEATS domain as essential for this function. Overlay and pulldown-assays finally showed a specific and YEATS domain-dependent association of ENL with histones H3 and H1. In summary, our studies support a common role for nuclear MLL fusion partners in chromatin biology.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Erlangen Nuremberg; University of Pennsylvania	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.	rslany@biologie.uni-erlangen.de		Bittner, Claudia/0000-0002-7641-0351	NCI NIH HHS [CA92251, CA78815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bittner CB, 2004, EUKARYOT CELL, V3, P976, DOI 10.1128/EC.3.4.976-983.2004; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Estable MC, 2002, J BIOMED SCI, V9, P234, DOI 10.1159/000059424; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MILNE TA, 2005, UNPUB CANC RES; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schreiner S, 2001, CANCER RES, V61, P6480; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Srinivasan RS, 2004, LEUKEMIA, V18, P1364, DOI 10.1038/sj.leu.2403415; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004	40	89	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5525	5532		10.1038/sj.onc.1208699	http://dx.doi.org/10.1038/sj.onc.1208699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856011				2022-12-17	WOS:000231222300013
J	Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				Mazieres, J; You, L; He, B; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis	ONCOGENE			English	Article						Wnt; Wnt16; leukemia; apoptosis; human antibody; RNA interference	PRE-B; SIGNALING PATHWAY; E2A-PBX1; GENE; ACTIVATION; EXPRESSION; CLASSIFICATION; CANCER	The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis. Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia. Less is known concerning acute leukemia. One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis. Wnt16 has been shown to be targeted by E2A-Pbx1. We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation. We found that Wnt16 and many Wnt signaling-related genes were upregulated in the translocation-containing cells. As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines. We then directly addressed the role played by both isoforms in this type of leukemia. Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death. We also demonstrated that Wnt16b mediates its effect through the canonical Wnt pathway involving dishevelled-2, beta-catenin and survivin. We thus propose that Wnt16 plays an important role in leukemogenesis, raising its therapeutic interest.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Inst Claudius Regaud, INSERM, U563, Dept Innovat Therapeut & Oncol Mol, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708, R01 CA093708-01A3] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspland SE, 2001, ONCOGENE, V20, P5708, DOI 10.1038/sj.onc.1204592; Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fear MW, 2000, BIOCHEM BIOPH RES CO, V278, P814, DOI 10.1006/bbrc.2000.3852; Fu XY, 1999, ONCOGENE, V18, P4920, DOI 10.1038/sj.onc.1202874; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	22	89	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5396	5400		10.1038/sj.onc.1208568	http://dx.doi.org/10.1038/sj.onc.1208568			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007226				2022-12-17	WOS:000231158500014
J	Crockett, DK; Lin, ZD; Elenitoba-Johnson, KSJ; Lim, MS				Crockett, DK; Lin, ZD; Elenitoba-Johnson, KSJ; Lim, MS			Identification of NPM-ALK interacting proteins by tandem mass spectrometry	ONCOGENE			English	Article						NPM-ALK; anaplastic lymphoma kinase; functional proteomics; mass spectrometry	ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; KI-1 LYMPHOMA; DOWN-REGULATION; EXPRESSION; ACTIVATION; GENE; TRANSLOCATION	Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal aberration t(2;5)(p23;q35). Proteins that interact with ALK tyrosine kinase play important roles in mediating downstream cellular signals, and are potential targets for novel therapies. Using a functional proteomic approach, we determined the identity of proteins that interact with the ALK tyrosine kinase by co-immunoprecipitation with anti-ALK antibody, followed by electro-spray ionization and tandem mass spectrometry (MS/MS). A total of 46 proteins were identified as unique to the ALK immunocomplex using monoclonal and polyclonal antibodies, while 11 proteins were identified in the NPM immunocomplex. Previously reported proteins in the ALK signal pathway were identified including PI3-K, Jak2, Jak3, Stat3, Grb2, IRS, and PLC1gamma. More importantly, many proteins previously not recognized to be associated with NPM-ALK, but with potential NPM-ALK interacting protein domains, were identified. These include adaptor molecules (SOCS, Rho-GTPase activating protein, RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin G-associated kinase, EphA1, JNK kinase, MAP kinase 1), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). Proteins identified by MS were confirmed by Western blotting and reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by tandem mass spectrometry for the elucidation of ALK-binding proteins, and its potential signal transduction pathways.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories	Elenitoba-Johnson, KSJ (corresponding author), Univ Utah, Sch Med, Dept Pathol, 50 N Med Dr,Room A565, Salt Lake City, UT 84132 USA.	kojo.elenitobaj@path.utah.edu; megan.lim@path.utah.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867				Amin HM, 2003, ONCOGENE, V22, P5399, DOI 10.1038/sj.onc.1206849; Baba T, 2003, BIOCHEM BIOPH RES CO, V304, P67, DOI 10.1016/S0006-291X(03)00542-4; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bernhard OK, 2003, PROTEOMICS, V3, P139, DOI 10.1002/pmic.200390022; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Bonvini P, 2002, CANCER RES, V62, P1559; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; DAVIS TH, 1992, NEW ENGL J MED, V326, P1115, DOI 10.1056/NEJM199204233261704; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4; Figeys D, 2001, METHODS, V24, P230, DOI 10.1006/meth.2001.1184; FISCHER P, 1988, BLOOD, V72, P234; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Hubinger G, 2003, EXP HEMATOL, V31, P226, DOI 10.1016/S0301-472X(02)01084-6; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Kai M, 2001, MOL CELL BIOL, V21, P3289, DOI 10.1128/MCB.21.10.3289-3301.2001; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Khoury JD, 2003, CLIN CANCER RES, V9, P3692; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Raetz EA, 2002, AM J PATHOL, V161, P875, DOI 10.1016/S0002-9440(10)64248-4; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200; Rey M, 2002, J IMMUNOL, V169, P5410, DOI 10.4049/jimmunol.169.10.5410; Rossi L, 2003, INT J DEV BIOL, V47, P293; Ruchatz H, 2003, EXP HEMATOL, V31, P309, DOI 10.1016/S0301-472X(03)00007-9; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota Mami, 1997, Leukemia (Basingstoke), V11, P538; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slupianek A, 2001, CANCER RES, V61, P2194; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; STEIN H, 1985, BLOOD, V66, P848; Taimen P, 2000, EXP CELL RES, V256, P140, DOI 10.1006/excr.2000.4799; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	55	89	93	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2617	2629		10.1038/sj.onc.1207398	http://dx.doi.org/10.1038/sj.onc.1207398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14968112				2022-12-17	WOS:000220714900003
J	Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY				Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY			Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis	ONCOGENE			English	Article						hepatitis B virus; integration; X gene; sequence	HEPATITIS-B-VIRUS; HEPATOMA-CELL LINE; TRANSGENIC MICE; TRANSCRIPTION FACTOR; DNA-REPAIR; IN-VIVO; PROTEIN; HEPATOCARCINOGENESIS; EXPRESSION; APOPTOSIS	Although the integration of hepatitis B virus (HBV) into human DNA has been found to be associated with the development of hepatocellular carcinoma (HCC), the molecular mechanism remains unclear. In order to obtain additional insight into the correlation of HBV integration and HCC development, integrated HBV in 14 primary HCC cases was isolated and characterized by sequencing analysis. Our findings in this study showed that: (1) none of the known cellular oncogene or tumor suppressor gene was affected by the HBV integration; (2) although the integration of HBV is random, the integration site was often within or close to human repetitive sequences; (3) integrated HBV may possess the capacity to transpose to another chromosome region through reintegration; (4) rearrangements of HBV sequence were observed in all the 14 integrants, involving (most frequently) X (12/14 integrants), P (8/14), S (7/14), and C (7/14) genes; and (5) 3'-deleted X gene and consequent C-terminal truncated X protein caused by HBV integration was observed in 10 cases. These deletions cause the losses of p53-dependent transcriptional repression binding site, transcription factor Sp1 binding site, and growth-suppressive effect domain, leading to cell proliferation and transformation. This finding suggests that 3'-deleted X gene caused by the HBV integration may play an important role in the HCC development.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; GROZUACIK D, 2001, ONCOGENE, V20, P6233; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; JASPERS NGJ, 1995, CURR BIOL, V5, P700, DOI 10.1016/S0960-9822(95)00137-0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NATOLI G, 1994, ONCOGENE, V9, P2837; PETERSON MG, 1991, NATURE, V354, P369; Reifenberg K, 1997, J HEPATOL, V26, P119, DOI 10.1016/S0168-8278(97)80018-9; ROBINSON WS, 1994, ANNU REV MED, V45, P297; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Su TS, 1998, DNA CELL BIOL, V17, P415, DOI 10.1089/dna.1998.17.415; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; Tu H, 2001, CANCER RES, V61, P7803; URANO Y, 1991, CANCER RES, V51, P1460; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	32	89	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					142	148		10.1038/sj.onc.1206889	http://dx.doi.org/10.1038/sj.onc.1206889			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712219				2022-12-17	WOS:000187895300015
J	Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S				Rahmani, M; Yu, CR; Reese, E; Ahmed, W; Hirsch, K; Dent, P; Grant, S			Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition	ONCOGENE			English	Article						sodium butyrate; LY294002; apoptosis; AKT; MEK/ERK; p21(CIP1/WAF1)	GLYCOGEN-SYNTHASE KINASE-3; BREAST-CANCER CELLS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; SODIUM-BUTYRATE; SIGNALING PATHWAY; GRANULOCYTIC DIFFERENTIATION; DEPSIPEPTIDE FR901228; RECEPTOR-GAMMA; UP-REGULATION	Effects of the PI-3 kinase inhibitor LY294002 (LY) have been examined in relation to responses of human leukemia cells to histone deacetylase inhibitors (HDIs). Coexposure of U937 cells for 24 h to marginally toxic concentrations of LY294002 (e.g., 30 mum) and sodium butyrate (SB; 1 mM) resulted in a marked increase in mitochondrial damage (e.g., cytochrome c and Smac/DIABLO release, loss of DeltaPsi(m)), caspase activation, and apoptosis. Similar results were observed in Jurkat, HL-60, and K562 leukemic cells and with other HDIs (e.g., SAHA, MS-275). Exposure of cells to SB/LY was associated with Bcl-2 and Bid cleavage, XIAP and Mcl-1 downregulation, and diminished CD11b expression. While LY blocked SB-mediated Akt activation, enforced expression of a constitutively active (myristolated) Akt failed to attenuate SB/LY-mediated lethality. Unexpectedly, treatment of cells with SB+/-LY resulted in a marked reduction in phosphorylation ( activation) of p44/42 mitogen-activated protein ( MAP) kinase. Moreover, enforced expression of a constitutively active MEK1 construct partially but significantly attenuated SB/LY-induced apoptosis. Lastly, cotreatment with LY blocked SB-mediated induction of p21(CIP1/WAF1); moreover, enforced expression of p21(CIP1/WAF1) significantly reduced SB/LY-mediated apoptosis. Together, these findings indicate that LY promotes SB-mediated apoptosis through an AKT-independent process that involves MEK/MAP kinase inactivation and interference with p21(CIP1/WAF1) induction.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, MCV Stn Box 230, Richmond, VA 23298 USA.			Rahmani, Mohamed/0000-0002-3992-8039; Hirsch, Karen/0000-0002-5474-3243	NATIONAL CANCER INSTITUTE [R01CA093798, R01CA063753, R55CA093798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93798, CA 63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; Cartee L, 2001, CANCER RES, V61, P2583; Cataldi A, 2000, CELL SIGNAL, V12, P667, DOI 10.1016/S0898-6568(00)00109-1; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; Lee BI, 2001, CANCER RES, V61, P931; Lewandowski D, 2002, BRIT J HAEMATOL, V118, P535, DOI 10.1046/j.1365-2141.2002.03601.x; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nakashio A, 2000, CANCER RES, V60, P5303; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Page C, 2000, ANTICANCER RES, V20, P407; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Park SJ, 2002, IMMUNOPHARM IMMUNOT, V24, P211, DOI 10.1081/IPH-120003751; Rahmani M, 2002, EXP CELL RES, V277, P31, DOI 10.1006/excr.2002.5548; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosato RR, 2002, MOL CANCER THER, V1, P253; Rosato RR, 2001, INT J ONCOL, V19, P181; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sidhu JS, 2001, MOL PHARMACOL, V59, P1138, DOI 10.1124/mol.59.5.1138; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang QD, 2002, CLIN CANCER RES, V8, P1940; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu CR, 2003, CANCER RES, V63, P1822; Yu XD, 2002, J NATL CANCER I, V94, P504; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200	61	89	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6231	6242		10.1038/sj.onc.1206646	http://dx.doi.org/10.1038/sj.onc.1206646			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679862				2022-12-17	WOS:000185506200013
J	Amundson, SA; Bittner, M; Fornace, AJ				Amundson, SA; Bittner, M; Fornace, AJ			Functional genomics as a window on radiation stress signaling	ONCOGENE			English	Article						gene induction; cDNA microarray; cancer cells	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; IONIZING-RADIATION; TARGET GENES; MALIGNANT-MELANOMA; GENOTOXIC STRESS; DNA-REPAIR; P53; INDUCTION	Exposure to ionizing radiation, as well as other stresses, results in the activation of complex signal transduction pathways, which eventually shape the response of cells and organisms. Some of the important pathways responding to radiation include the ATM/P53 pathway, MAPK cascades and NF-kappaB activation, as well as signaling events initiated at the cell membrane and within the cytoplasm. Alterations in gene expression play roles both as intermediaries in signaling and as downstream effector genes. Differences in cell type, interindividual genetic differences and crosstalk occurring between signaling pathways may help to channel radiation stress signals between cell cycle delay, enhanced DNA repair, and apoptosis. These differences may in turn help determine the likelihood of late effects of radiation exposure, including carcinogenesis and fibrosis. The tools of the postgenomic era enable high-throughput studies of the multiple changes resulting from the interplay of radiation signaling pathways. Gene expression profiling, in particular shows great promise, both in terms of insight into basic molecular mechanisms and for the future hope of biomarker development and individual tailoring of cancer therapy.	NCI, NIH, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Amundson, SA (corresponding author), NCI, NIH, 37 Convent Dr,Bldg 37,Room 6144, Bethesda, MD 20892 USA.	amundson@mail.nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 1999, RADIAT RES, V152, P225, DOI 10.2307/3580321; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Ardekani Ali M, 2002, Expert Rev Mol Diagn, V2, P312, DOI 10.1586/14737159.2.4.312; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chapman K, 2002, BIOCHEM SOC T, V30, P82, DOI 10.1042/BST0300082; Chen XF, 2002, CANCER RES, V62, P1213; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dumic J, 2000, CELL PHYSIOL BIOCHEM, V10, P149, DOI 10.1159/000016345; Eickhoff Holger, 2002, Adv Biochem Eng Biotechnol, V77, P103; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Geffrotin C, 1998, RADIAT RES, V149, P472, DOI 10.2307/3579787; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hallahan DE, 1998, CANCER RES, V58, P5484; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Johnston CJ, 2002, RADIAT RES, V157, P256, DOI 10.1667/0033-7587(2002)157[0256:RIPFEO]2.0.CO;2; Kawai H, 1999, CANCER RES, V59, P6038; Koch-Paiz CA, 2000, BIOTECHNIQUES, V29, P706, DOI 10.2144/00294bm07; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Mori K, 2000, FREE RADICAL RES, V33, P157, DOI 10.1080/10715760000300711; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Raju U, 1999, RADIAT ONCOL INVESTI, V7, P145, DOI 10.1002/(SICI)1520-6823(1999)7:3<145::AID-ROI2>3.0.CO;2-R; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robles AI, 2001, CANCER RES, V61, P6660; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Sreekumar A, 2001, CANCER RES, V61, P7585; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yacoub A, 2001, INT J RADIAT BIOL, V77, P1067, DOI 10.1080/09553000110069317; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao WL, 2001, CANCER RES, V61, P5537	52	89	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5828	5833		10.1038/sj.onc.1206681	http://dx.doi.org/10.1038/sj.onc.1206681			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947389				2022-12-17	WOS:000185086100009
J	Avvakumov, N; Torchia, J; Mymryk, JS				Avvakumov, N; Torchia, J; Mymryk, JS			Interaction of the HPV E7 proteins with the pCAF acetyltransferase	ONCOGENE			English	Article						human papillomavirus; E7; pCAF; acetyltransferase; transcription	HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRAL ONCOPROTEIN E1A; CREB-BINDING PROTEIN/P300; DNA-DAMAGE; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION; P300/CBP-ASSOCIATED FACTOR; SACCHAROMYCES-CEREVISIAE	Most cervical carcinomas express the E6 and E7 proteins of a high-risk human papillomavirus (HPV). These proteins affect growth control by interfering with the functions of cell regulatory proteins, promoting oncogenic transformation. A key target of E7 is the tumor suppressor protein pRb, which directly interacts with E7. However, binding to additional cellular regulatory proteins is clearly required for oncogenesis, as mutants of E7 have been identified that bind to pRb, yet fail to transform efficiently. Here we demonstrate the interaction of the HPV 6, 16 and 18 E7 proteins with the pCAF acetyltransferase, which has been reported to function as a coactivator for a variety of transcription factors including p53. Mutation of a highly conserved leucine residue within the zinc finger region of HPV 16 E7 disrupts binding to pCAF and also impairs transformation and transcriptional activation. HPV 16 E7 interacts with the acetyltransferase domain of pCAF, and reduces its acetyltransferase activity in vitro. Our analysis of the interaction between the pCAF acetyltransferase and E7 provides new insight into the mechanisms by which the E7 oncoproteins can alter cellular gene expression and growth.	Univ Western Ontario, Dept Microbiol & Immunol, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Oncol, London Reg Canc Ctr, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Mymryk, JS (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London Reg Canc Ctr, London, ON N6A 4L6, Canada.	jmymryk@uwo.ca						BANKS L, 1990, ONCOGENE, V5, P1383; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brehm A, 1999, MOL CELL BIOL, V19, P2635; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Bryant LA, 2000, J VIROL, V74, P7230, DOI 10.1128/JVI.74.16.7230-7237.2000; CARTER JJ, 1991, VIROLOGY, V182, P513, DOI 10.1016/0042-6822(91)90592-Y; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KAWABATA H, 2001, J BIOL CHEM; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Massimi P, 1997, VIROLOGY, V227, P255, DOI 10.1006/viro.1996.8315; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Roberts SM, 1997, GENETICS, V147, P451; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 1996, ONCOGENE, V12, P213	57	89	91	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3833	3841		10.1038/sj.onc.1206562	http://dx.doi.org/10.1038/sj.onc.1206562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813456				2022-12-17	WOS:000183612000002
J	Rossow, KL; Janknecht, R				Rossow, KL; Janknecht, R			Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300	ONCOGENE			English	Article						CBP; E1A; p300; p68 RNA helicase; RNA polymerase II; transcription	ESTROGEN-RECEPTOR-ALPHA; DEAD BOX PROTEIN; COLORECTAL TUMORS; POLYMERASE-II; GENE; ACTIVATION; COAMPLIFICATION; OVEREXPRESSION; IDENTIFICATION; NEUROBLASTOMA	p68 RNA helicase has been implicated in a variety of processes, including rearrangement of RNA secondary structures, RNA splicing, gene transcription and tumor development, yet its mechanisms of action are not well understood. In this study, we show that p68 is predominantly localized to the cell nucleus, where it partially colocalizes with the transcriptional coactivator p300. Accordingly, p68 and p300, or the paralogous CREB-binding protein (CBP), coimmunoprecipitate. Similarly, p68 and RNA polymerase II (Pol II) are able to interact in vivo. GST pull-down assays confirmed these interactions in vitro, demonstrating that p68 can interact with several domains of CBP, while CBP/p300 bind to amino acids 176-388 of p68 and RNA Pol II binds to the N-terminal 80 amino acids of p68. Furthermore, p68 stimulates transcription mediated by the C-terminal transactivation domain of CBP. p68 is also able to stimulate TPA oncogene responsive unit (TORU) promoter activity, and p300 acts in synergy with p68. On the other hand, suppression of CBP/p300 function by the adenoviral protein E1A abolishes TORU promoter activation by p68. Altogether, our results suggest the existence of a multiprotein complex in which p68 RNA helicase, CBP/p300 and RNA Pol II jointly promote gene expression.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St,SW,Guggenheim Bldg 1501A, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				AKAO Y, 1995, CANCER RES, V55, P3444; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Goodman RH, 2000, GENE DEV, V14, P1553; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE CG, 1993, J BIOL CHEM, V268, P16822; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MONTE D, 1995, ONCOGENE, V11, P771; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Rossow KL, 2001, CANCER RES, V61, P2690; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341	33	89	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					151	156		10.1038/sj.onc.1206067	http://dx.doi.org/10.1038/sj.onc.1206067			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527917				2022-12-17	WOS:000180166900016
J	Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y				Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y			Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth	ONCOGENE			English	Article						Id-1; prostate cancer; MAPK; cell growth	LOOP-HELIX PROTEINS; HUMAN KERATINOCYTES; PANCREATIC-CANCER; G(1) PROGRESSION; SENESCENCE; EXPRESSION; GENES; ID1; P16/INK4A; CARCINOMA	The helix-loop-helix protein Id-1 has been suggested to play a positive role in cell proliferation and tumorigenesis of many types of human cancers. However, little is known about the molecular mechanism involved in the function of Id-1. In this study, using four stable Id-1 transfectant clones, we investigated the involvement of MAPK signaling pathway in the Id-1 induced serum independent prostate cancer cell growth. Our results demonstrated that both transient and stable ectopic Id-1 expression in prostate cancer LNCaP cells led to activation of the Raf/MEK1/2 signaling pathway. In addition, inhibition of MEK1/2 phosphorylation by one of its inhibitors, PD098059, resulted in the decreased cell cycle S phase fraction and cell growth rate, suggesting that activation of MAPK signaling pathway is essential for Id-1 induced prostate cancer cell proliferation. Furthermore, treatment with antisense oligonucleotide complementary to Id-1 mRNA in PC-3 and DU145 cells resulted in a decreased Id-1 expression which was accompanied by decreased Egr-1 protein. Our results suggest for the first time that the function of Id-1 is associated with MAPK signaling pathway activation and indicate a possible novel mechanism in which Id-1 regulates prostate cancer cell growth and tumorigenesis.	Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Cent Lab, Inst Mol Technol Drug Discovery & Synthesis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, Y (corresponding author), Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009	Lee, Kin Wah/0000-0003-0682-322X				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eid MA, 1998, CANCER RES, V58, P2461; Fan MY, 2000, CANCER RES, V60, P6403; Gioeli D, 1999, CANCER RES, V59, P279; HARA E, 1994, J BIOL CHEM, V269, P2139; Kawashita Y, 1999, HUM GENE THER, V10, P1509, DOI 10.1089/10430349950017842; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Polsky D, 2001, CANCER RES, V61, P6008; Ristow HJ, 1996, GROWTH REGULAT, V6, P96; Sakurai D, 2001, BIOCHEM BIOPH RES CO, V284, P436, DOI 10.1006/bbrc.2001.4974; Schindl M, 2001, CANCER RES, V61, P5703; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	29	89	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8498	8505		10.1038/sj.onc.1206007	http://dx.doi.org/10.1038/sj.onc.1206007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466969				2022-12-17	WOS:000179480100012
J	Loden, M; Stighall, M; Nielsen, HN; Roos, G; Emdin, SO; Ostlund, H; Landberg, G				Loden, M; Stighall, M; Nielsen, HN; Roos, G; Emdin, SO; Ostlund, H; Landberg, G			The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node	ONCOGENE			English	Article						breast cancer; cell cycle; cyclins; cdk-inhibitors; pRb pathway; proliferation	CELL-CYCLE; RETINOBLASTOMA PROTEIN; TUMOR PROLIFERATION; EXPRESSION; P53; DEREGULATION; P27(KIP1); G(1); MARKERS; FAMILY	In an attempt to identify subtypes of breast cancer and pinpoint patterns of cell cycle regulatory defects associated with clinical behaviour, proliferation and other transformation associated events, a multitude of cell cycle regulatory proteins were analysed in a material of 113 primary breast cancers. Increased proliferation was observed in two different scenarios; (1) with high cyclin D1 and elevated retinoblastoma protein (pRb) phosphorylation, (cyclin D1(high) tumours) or (2) with high cyclin E protein but low cyclin D1 and lack of corresponding pRb phosphorylation (cyclin E high tumours) indicative of an interrupted pRb pathway. Characteristic for cyclin E-high tumours were further defects in p53, p27 and bcl-2, while c-erbB2 overexpression and c-myc amplification was found in both cyclin D1(high) and E-high tumours. Using transfected cell lines overexpressing cyclin E, cyclin E-high and D1(high) tumours were mimicked and the cyclin D1(high) cell line normalized the cyclin E kinase activity by an induction and redirection of p21 and p27 to the cyclin E complex whereas cyclin E-high cell lines obtained increased kinase activity with out redirection or inhibitors. Based on differences in genetic aberrations as well as function of the pRb node we therefore propose a model in which cyclin D1(high) and cyclin E-high tumours represent two alternative mechanisms to inactivate the pRb pathway and thereby achieve unrestrained growth in the tumorogenesis of breast cancer.	Lund Univ, Malmo Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden; Umea Univ, Dept Pathol, S-90187 Umea, Sweden; Umea Univ, Dept Oncol, S-90187 Umea, Sweden; Umea Univ, Dept Surg, S-90187 Umea, Sweden	Lund University; Skane University Hospital; Umea University; Umea University; Umea University	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se						Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BOSARI S, 1995, VIRCHOWS ARCH, V427, P229; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jares P, 1997, J PATHOL, V182, P160; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang GJ, 1997, CLIN CANCER RES, V3, P2329; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	48	89	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4680	4690		10.1038/sj.onc.1205578	http://dx.doi.org/10.1038/sj.onc.1205578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096344				2022-12-17	WOS:000176625100009
J	Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D				Delpuech, O; Trabut, JB; Carnot, F; Feuillard, J; Brechot, C; Kremsdorf, D			Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinomas; hepatitis B Virus; Hepatitis C Virus; cDNA macroarray; distinct gene profiles	HEPATITIS-C VIRUS; BETA-CATENIN GENE; MESSENGER-RNA; CYCLIN D1; PROTEIN; GROWTH; OVEREXPRESSION; CANCER; INDUCTION; APOPTOSIS	It is still unclear as to whether the gene expression profile in HCV- or HBV-related HCC exhibits a degree of specificity and whether the development of HCC in a context of cirrhosis influences this gene profile. To address these issues, the expression profiles of 15 cases of HCC were analysed using cDNA macroarray. A global analysis and hierarchical clustering, demonstrated the heterogeneity of HCC patterns, with a majority of down-regulated genes. Statistical analysis clearly showed a distinction between the gene expression profiles of HCV- and HBV-related HCC. HBV-associated HCC exhibited involvement of different cellular pathways, those controlling apoptosis, p53 signalling and G1/S transition. In HCV-related HCC we identified a more heterogenous pattern with an over-expression of the TGF-beta induced gene. In HCC developing on noncirrhotic tissues, beta-catenin encoding gene and genes implicated in the PKC pathway were specifically up-regulated. In addition, our investigation highlighted a distinct profiles of TGF-beta superfamily encoding genes in well, moderately or poorly differentiated HCC. Overall, our study supports the hypothesis that despite the heterogeneity of the HCC pattern, the large-scale screening of gene expression may provide data significant to our understanding of the mechanism of liver carcinogenesis.	CHU Necker, INSERM, Inst Pasteur, U370, F-75015 Paris, France; Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop Avicenne, EA ATHSCO, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Kremsdorf, D (corresponding author), Fac Med Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.	kremsdor@necker.fr	Kremsdorf, Dina/O-9797-2017; Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Benvegnu L, 2001, ANTIVIR RES, V52, P199, DOI 10.1016/S0166-3542(01)00185-1; Benvegnu L, 2001, GUT, V48, P110, DOI 10.1136/gut.48.1.110; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V174, pM43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Garrett SH, 1999, PROSTATE, V41, P196, DOI 10.1002/(SICI)1097-0045(19991101)41:3<196::AID-PROS7>3.0.CO;2-U; Gilles C, 1998, CANCER RES, V58, P5529; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Hidalgo J, 1998, NEUROTOXICOLOGY, V19, P661; Hol FA, 1998, CLIN GENET, V53, P119; Honda M, 2001, GASTROENTEROLOGY, V120, P955, DOI 10.1053/gast.2001.22468; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Juengel JL, 1998, J REPROD FERTIL, V113, P299, DOI 10.1530/jrf.0.1130299; Jungmann RA, 1998, J EXP ZOOL, V282, P188, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<188::AID-JEZ21>3.0.CO;2-P; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kasai Y, 1996, SEMIN SURG ONCOL, V12, P155, DOI 10.1002/(SICI)1098-2388(199605/06)12:3<155::AID-SSU2>3.0.CO;2-6; Kim Hyung Gun, 2000, Korean Journal of Internal Medicine, V15, P165; Knight J, 2001, NATURE, V410, P860, DOI 10.1038/35073680; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lau WY, 2000, ONCOL RES, V12, P59; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; LeBail B, 1997, J PATHOL, V181, P330; Liu CT, 1998, CANCER GENE THER, V5, P3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MIRA L, 1995, ARCH BIOCHEM BIOPHYS, V318, P53, DOI 10.1006/abbi.1995.1203; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Okabe H, 2001, CANCER RES, V61, P2129; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porte H, 1998, CLIN CANCER RES, V4, P1375; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schulze K, 1995, EUR HEART J, V16, P64, DOI 10.1093/eurheartj/16.suppl_O.64; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079; Takano T, 2001, CANCER LETT, V168, P51, DOI 10.1016/S0304-3835(01)00509-2; Takayasu H, 2001, CLIN CANCER RES, V7, P901; TERAMOTO T, 1994, CANCER RES, V54, P231; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; Tornillo L, 2000, J PATHOL, V192, P307, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH706&gt;3.0.CO;2-O; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VENEZIANI BM, 1990, J CELL BIOL, V111, P2703, DOI 10.1083/jcb.111.6.2703; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu L, 2001, CANCER RES, V61, P3176; Yamashita T, 2001, BIOCHEM BIOPH RES CO, V282, P647, DOI 10.1006/bbrc.2001.4610; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; ZHAN QM, 1994, CANCER RES, V54, P2755	80	89	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2926	2937		10.1038/sj.onc.1205392	http://dx.doi.org/10.1038/sj.onc.1205392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973655				2022-12-17	WOS:000175063700020
J	Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP				Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP			RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1	ONCOGENE			English	Article						RASSF1; tumor suppressor gene; Ras association domain; Nore1	COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENETIC INACTIVATION; CPG ISLAND; DNA METHYLATION; FAMILY; BREAST; CANCER; LUNG; HYPERMETHYLATION; 3P21.3	RASSF1A, one of the two major isoforms of the putative tumor suppressor gene RASSF1, located at 3p21.3, is inactivated in a variety of human cancers including lung, breast, bladder and renal cell carcinomas. We have isolated and cloned two human homologues of this gene, RASSF3 and NORE1, located at 12q14.1 and 1q32.1, respectively. Both RASSF3 and NORE1 share almost 60% homology, at the amino acid level, with RASSF1. The RASSF3 gene contains five exons and encodes a 247 amino acid protein (MW of 28.6 kDa) with a highly conserved Ras association (RalGDS/AF-6) (RA) domain at the C-terminus. RASSF3 is ubiquitously expressed in all normal tissues and cancer cell tines analysed. NORE1, which is homologous to the previously described mouse Nore1 gene, exists in at least two spliced isoforms, A and B. Transcript A encodes a protein of 418 amino acids (MW or 47 kDa) while transcript B contains an ORF of 265 aa (MW of 30.5 kDa). Both share a RA domain, encoded by exons 3 through 6. NORE1A and NORE1B are expressed in most of the normal tissues analysed but they appear to be down-regulated in several cancer cell lines. However, contrary to RASSF1A, gene silencing by methylation of the CpG islands at which the two NORE1 transcripts initiate is not a common event in human primary tumors. RASSF3 and NORE1B are very similar, at the N-terminus, to the splice variant C of RASSF1 (RASSF1C), which does not seem to be involved in tumorigenesis. NORE1A is most closely related to RASSF1A, for sequence homology and genomic organization. However, aberrations in tumors have so far not been found. The presence of a Ras association domain common to NORE1, RASSF1, and RASSF3 suggests their possible involvement in Ras-like signaling pathways.	Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Harvard University; Massachusetts General Hospital	Tommasi, S (corresponding author), Beckman Res Inst, Dept Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	stommasi@coh.org		Tommasi, Stella/0000-0001-6897-4985; Jin, Seung-Gi/0000-0001-5041-0559	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Almeida A, 1998, ONCOGENE, V16, P2997, DOI 10.1038/sj.onc.1201828; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOKHLATCHEV A, 2002, IN PRESS CURR BIOL; Kros JM, 1999, J PATHOL, V188, P282; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; ORTIZVEGA S, 2002, IN PRESS ONCOGENE; Petersen C, 2000, J BIOL CHEM, V275, P4081, DOI 10.1074/jbc.275.6.4081; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIED T, 1995, CANCER RES, V55, P5415; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Thompson L, 1994, Work, V4, P22, DOI 10.3233/WOR-1994-4104; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wistuba II, 2000, CANCER RES, V60, P1949; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	41	89	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2713	2720		10.1038/sj.onc.1205365	http://dx.doi.org/10.1038/sj.onc.1205365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965544				2022-12-17	WOS:000174996500011
J	Porter, TR; Richards, FM; Houlston, RS; Evans, DGR; Jankowski, JA; Macdonald, F; Norbury, G; Payne, SJ; Fisher, SA; Tomlinson, I; Maher, ER				Porter, TR; Richards, FM; Houlston, RS; Evans, DGR; Jankowski, JA; Macdonald, F; Norbury, G; Payne, SJ; Fisher, SA; Tomlinson, I; Maher, ER			Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer	ONCOGENE			English	Article						colorectal cancer; E-cadherin; cyclin d1; CCND1; CDH1; genetics	MICROSATELLITE INSTABILITY; GASTRIC-CANCER; EARLY-ONSET; GENE; MUTATIONS; EXPRESSION; BREAST	The molecular basis for most non-HNPCC familial colorectal cancer cases is unknown, but there is increasing evidence that common genetic variants may play a role. We investigated the contribution of polymorphisms in two genes implicated in the pathogenesis of colorectal cancer, cyclin D1 (CCND1) and E-cadherin (CDH1), to familial and sporadic forms of the disease. The CCND1 870A/G polymorphism is thought to affect the expression of CCND1 through mRNA splicing and has been reported to modify the penetrance of HNPCC. Inactivation of E-cadherin is common in colorectal cancer, and truncating germline mutations have been reported to confer susceptibility to colorectal as well as diffuse gastric cancer. The - 160A/C CDH1 polymorphism appears to affect expression of CDH1 and may therefore also confer an increased risk. We found a significantly higher frequency of CCND1 870A allele in 206 familial cases compared to 171 controls (P=0.03). Odds ratios in heterozygotes and homozygotes were 1.7 (95% CI: 1.0-2.66) and 1.8 (95% CI: 1.0-3.3) respectively. The difference was accounted for by an over-representation of A allele in non-HNPCC familial cases (P = 0.007). Over-representation of the CCND1 A allele was also seen in sporadic colorectal cancer cases compared to controls but this did not attain statistical significance (P = 0.08). No significant differences between the frequency of CDH1 - 160A/C genotypes in familial, sporadic colorectal cancer cases and controls were seen, although a possible association between the low expressing A allele and right-sided tumours was detected in familial cases.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Univ Birmingham, Dept Med, Birmingham B15 2TH, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Churchill Hosp, Reg Genet Serv, Oxford OX3 7LJ, England; Northwick Pk Hosp & Clin Res Ctr, Kennedy Galton Ctr, NW Thames Genet Serv, Harrow HA1 3UJ, Middx, England; Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England	University of Birmingham; University of London; Institute of Cancer Research - UK; University of Manchester; University of Birmingham; Birmingham Women's Hospital; University of Oxford; Imperial College London; Cancer Research UK	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	ermaher@hgmp.mrc.ac.uk	MAHER, EAMONN R/A-9507-2008; Jankowski, Janusz/H-2706-2012; Evans, D Gareth/AAB-4308-2022	MAHER, EAMONN R/0000-0002-6226-6918; Jankowski, Janusz/0000-0003-2130-9181; Evans, D Gareth/0000-0002-8482-5784; Houlston, Richard/0000-0002-5268-0242				Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bala S, 2001, CANCER RES, V61, P6042; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Brassett C, 1996, J MED GENET, V33, P981, DOI 10.1136/jmg.33.12.981; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; Gayther SA, 1998, CANCER RES, V58, P4086; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HARDY RG, 2002, IN PRESS GUT; Ilyas M, 1997, GUT, V40, P654, DOI 10.1136/gut.40.5.654; Jankowski JAZ, 1998, LAB INVEST, V78, P1155; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Li LC, 2000, CANCER RES, V60, P873; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lynch HT, 1999, J MED GENET, V36, P801; MacLeod Stewart L., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P149; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; Platz A, 2000, AM J HUM GENET, V67, P86; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; van de Wetering M, 2001, CANCER RES, V61, P278; Verma L, 1999, J MED GENET, V36, P678; Yoon Kyong-Ah, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P343	30	89	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1928	1933		10.1038/sj.onc.1205245	http://dx.doi.org/10.1038/sj.onc.1205245			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896626				2022-12-17	WOS:000174284500016
J	Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A				Mahmud, DL; G-Amlak, M; Deb, DK; Platanias, LC; Uddin, S; Wickrema, A			Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells	ONCOGENE			English	Article						forkhead transcription factors; erythropoietin; stem cell factor; acetylation; p300	CREB-BINDING PROTEIN; FACTOR GATA-1; KINASE; ACTIVATION; AKT; SIGNALS; DEATH; SURVIVAL; PATHWAY; FKHRL1	The mammalian forkhead transcription factors, FOXO3a (FKHRL1), FOXO1a (FKHR) and FOXO4 (AFX) are negatively regulated by PKB/Akt kinase. In the present study we examined the engagement of forkhead family of transcription factors in erythropoietin (Epo)- and stem cell factor (SCF)-mediated signal transduction. Our data show that all three forkhead family members, FOXO3a, FOXO1a and FOXO4 are phosphorylated in human primary erythroid progenitors. Experiments performed to determine various upstream signaling pathways contributing to phosphorylation of forkhead family members show that only PI-3-kinase pathway is required for inactivation of FOXO3a. Our data also demonstrate that during Epo deprivation FOXO3a interacts with the transcriptional coactivator p300 and such interaction is disrupted by stimulation of cells with Epo. To determine the domains in FOXO3a, mediating its interaction with p300, we performed GST pull-down assays and found that the N-terminus region containing the first 52 amino acids was sufficient for binding p300. Finally, our data demonstrate that FOXO3a and FOXO1a are acetylated during growth factor deprivation and such acetylation is reversed by stimulation with Epo. Thus mammalian forkhead transcription factors are involved in Epo and SCF signaling in primary erythroid progenitors and may play a role in the induction of apoptotic and mitogenic signals.	Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Illinois, Med Ctr, Chicago, IL USA	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wickrema, A (corresponding author), Univ Chicago, Hematol Oncol Sect, MC 2115,5841 S Maryland Ave, Chicago, IL 60637 USA.	Awickrem@medicine.bsd.uchicago.edu		Uddin, Shahab/0000-0003-1886-6710				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kaestner KH, 2000, GENE DEV, V14, P142; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; Lee A, 1996, INT J OPER PROD MAN, V16, P12, DOI 10.1108/01443579610119063; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	33	89	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1556	1562		10.1038/sj.onc.1205230	http://dx.doi.org/10.1038/sj.onc.1205230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896584				2022-12-17	WOS:000173956800011
J	Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML				Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML			Implication of p53 in base excision DNA repair: in vivo evidence	ONCOGENE			English	Article						p53; DNA-repair; polymerase-beta	DAMAGE; PROTEIN; CELLS; SENSITIVITY; FIBROBLASTS; EXPRESSION; MUTATIONS; AGENTS; GADD45; REF-1	The tumor suppressor p53 plays an important role in response to DNA damage, including DNA repair. One DNA repair pathway, nucleotide excision repair (NER), has been well-documenteav6d to be regulated by p53. It seemed probable that p53 may affect other DNA repair pathways. We employed matched isogenic pairs of cell lines, wild-type or p53-deficient, to investigate this question using methyl methanesulfonate (MMS), a base-damaging agent. Alkylation damage induced by MMS is repaired exclusively by the base excision repair (BER) pathway. Cells carrying mutant or no p53 genes exhibited slow BER of MMS-induced DNA damage, and exhibited MMS-sensitivity. One contributing factor is the abundance of DNA polymerase beta (beta-pol), an enzyme required for BER, which was almost absent in p53 mutant and p53-null cells. Our findings demonstrate an in vivo requirement for p53 in regulating the base excision repair response, a novel finding of great potential importance in understanding the DNA repair branch of the p53 pathway.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN USA; Indiana Univ, Ctr Canc, Dept Biochem, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Oncol, Indianapolis, IN 46202 USA; NCI, Bethesda, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,R-155, Indianapolis, IN 46202 USA.		Fishel, Melissa L./AAH-6608-2020	Fishel, Melissa L./0000-0002-9436-6382; Kelley, Mark/0000-0002-6120-9532				Brown JM, 1999, CANCER RES, V59, P1391; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; FAN SJ, 1995, CANCER RES, V55, P1649; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Hawkins DS, 1996, CANCER RES, V56, P892; Hollander MC, 2001, CANCER RES, V61, P2487; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Offer H, 2001, CANCER RES, V61, P88; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; SEO YR, 2001, IN PRESS BREAST CANC; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	89	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					731	737		10.1038/sj.onc.1205129	http://dx.doi.org/10.1038/sj.onc.1205129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850801				2022-12-17	WOS:000173427000004
J	Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E				Glondu, M; Coopman, P; Laurent-Matha, V; Garcia, M; Rochefort, H; Liaudet-Coopman, E			A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells	ONCOGENE			English	Article						cathepsin-D; mitogen; mutagenesis; catalytic site	HUMAN IMMUNODEFICIENCY VIRUS; PROCATHEPSIN-D ACTIVATION; BREAST-CANCER; MONOCLONAL-ANTIBODIES; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; MCF7 CELLS; IGF-II; METASTASIS; PROTEASES	Cathepsin-D, a lysosomal aspartyl proteinase, is highly secreted by breast cancer cells and its over-expression by transfection stimulates cancer cell proliferation. The mechanism by which this protease affects proliferation remains, however, unknown. In order to determine whether proteolytic activity is necessary, we abolished its enzymatic activity using site-directed mutagenesis followed by stable transfection in 3Y1-Ad12 cancer cells. Substitution of the aspartic acid residue 231 by an asparagine residue in its catalytic site abrogated the cathepsin-D proteolytic activity but did not affect its expression level, processing or secretion. However, like wild-type cathepsin-D, this mutated catalytically-inactive cathepsin-D retained its capacity to stimulate proliferation of cells embedded in Matrigel or collagen I matrices, colony formation in soft agar and tumor growth in athymic nude mice. Addition on the mock-transfected cells, of either conditioned media containing the wild-ty pe or the mutated pro-cathepsin-D, or of the purified mutated pro-cathepsin-D, partially mimicked the mitogenic activity of the transfected cathepsin-D, indicating a role of the secreted pro-enzyme. Moreover, addition of two anti-cathepsin-D antibodies on the cathepsin-D transfected cells inhibited their proliferation, suggesting an action of the secreted pro-cathepsin-D via an autocrine loop. A synthetic peptide containing the 27-44 residue moiety of the cathepsin-D pro-fragment was, however, not mitogenic suggesting that a receptor for the pro-fragment was not involved. Furthermore, the cathepsin-D mitogenicity was not blocked by inhibiting the interaction of pro-cathepsin-D with the mannose-6-phosphate receptors. Our results altogether demonstrate that a mutated cathepsin-D devoid of catalytic activity is still mitogenic and suggest that it is acting extracellularly by triggering directly or indirectly a yet unidentified cell surface receptor.	Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5539, F-34095 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Rochefort, H (corresponding author), Univ Montpellier 1, INSERM, Endocrinol Mol & Cellulaire Canc U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Liaudet-Coopman, Emmanuelle/N-4744-2017; Coopman, Peter/G-7416-2019	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Coopman, Peter/0000-0003-3720-523X; Valerie, LAURENT-MATHA/0000-0002-3277-7397				BISSELL MJ, 1999, CANCER RES, V59, P1757; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; EMERMAN JT, 1977, P NATL ACAD SCI USA, V74, P4466, DOI 10.1073/pnas.74.10.4466; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FREISS G, 1988, CANCER RES, V48, P3709; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Kane S E, 1990, Semin Cancer Biol, V1, P127; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Rifkin DB, 1997, FIBRINOLYSIS PROTEOL, V11, P3, DOI 10.1016/S0268-9499(97)80003-3; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VEITH FO, 1983, CANCER RES, V43, P1861; Vetvicka V, 1999, BREAST CANCER RES TR, V57, P261, DOI 10.1023/A:1006238003772; VIGNON F, 1992, BREAST CANCER RES TR, V22, P47, DOI 10.1007/BF01833333; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wittlin S, 1999, EUR J BIOCHEM, V265, P384, DOI 10.1046/j.1432-1327.1999.00747.x	40	89	94	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6920	6929		10.1038/sj.onc.1204843	http://dx.doi.org/10.1038/sj.onc.1204843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687971				2022-12-17	WOS:000171641000013
J	Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N				Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N			p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells	ONCOGENE			English	Article						ceramide; glioma; neutral sphingomyelinase; p53; reactive oxygen species	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; P53-INDUCED APOPTOSIS; CASPASE ACTIVATION; GROWTH ARREST; DEATH; INHIBITION	The present study was designed to elucidate the relationship between p53 and ceramide, both of which are involved in apoptotic signaling, Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53. p53 activation was followed by the formation of reactive oxygen species (ROS), superoxide anion (O-2(-.)) measured by hydroethidium oxidation into ethidium and hydrogen peroxide (H2O2) measured by oxidation of 2',7'-dichlorofluorescin (DCFH) into 2',7'-dichlorofluorescein (DCF), which was accompanied with ceramide generation through the activation of neutral, but not acid, sphingomyelinase. Superoxide dismutase (SOD), a selective antioxidant for O-2(-.) had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide, However, catalase, a specific antioxidant for H2O2, only weakly inhibited and sodium formate, a hydroxyl radical ((OH)-O-.) scavenger, unaffected etoposide-induced apoptosis, Like etoposide-induced cell death, treatment of glioma cells with the O-2(-.)-releasing agent, pyrogallol, induced typical apoptosis and ceramide generation even in the presence of catalase, In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level. Moreover, expression of functional p53 protein in glioma cells expressing mutant p53 using a temperature-sensitive human p53(Val138) induced ceramide accumulation by the activation of neutral sphingomyelinase which was dependent on the generation of O-2(-.), Taken together, these results suggest that p53 may modulate ceramide generation by activation of neutral sphingomyelinase through the formation of O-2(-.), but not its downstream compounds H2O2 or (OH)-O-..	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Aichi Canc Ctr, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University; Aichi Cancer Center	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.		Kiyono, Tohru/H-5834-2011					BOREK C, 1987, British Journal of Cancer, V55, P74; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL RH, 1992, CANCER RES, V52, P1427; GomezManzano C, 1996, CANCER RES, V56, P694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Jacobs S, 1996, IN SESSION-PSYCHOTH, V2, P21; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Narayanan PK, 1997, CANCER RES, V57, P3963; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAMAKRISHNAN N, 1992, J IMMUNOL, V148, P1817; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WALKER PR, 1991, CANCER RES, V51, P1078; Xie YW, 1998, CIRC RES, V82, P891; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhang P, 1997, J BIOL CHEM, V272, P9609	53	89	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1368	1378		10.1038/sj.onc.1204207	http://dx.doi.org/10.1038/sj.onc.1204207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313880				2022-12-17	WOS:000167495000010
J	Sibley, K; Cuthbert-Heavens, D; Knowles, MA				Sibley, K; Cuthbert-Heavens, D; Knowles, MA			Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma	ONCOGENE			English	Article						bladder; cancer; FGFR3; mutation	GROWTH-FACTOR RECEPTOR-3; BLADDER-CARCINOMA; URINARY-BLADDER; ACTIVATING MUTATIONS; INCREASED EXPRESSION; CHROMOSOME PATTERN; MULTIPLE-MYELOMA; TISSUE-CULTURE; ALLELIC LOSS; NUDE-MICE	4p16,3 has previously been identified as a region of nonrandom LOH in transitional cell carcinoma, suggesting the presence of a tumour suppressor gene. One candidate within this region is fibroblast growth factor receptor 3 (FGFR3). Germline mutations in FGFR3 are known to cause several autosomal dominant skeletal dysplasias, the severity of which depends on the position and nature of the mutation in the protein. We investigated the frequency and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied the possible link between mutation and loss of heterozygosity (LOH) on 4p16.3. FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and grades, and 18 cell lines,vas analysed by fluorescent SSCP, Samples with abnormal migration patterns were sequenced to identify the mutation or polymorphism. Thirty-one of the 63 tumours had previously been assessed to have LOH at 4p16,3, Twenty -six of the 63 tumours (41%) and 4/18 (22%) of the cell lines had missense mutations in FGFR3. All mutations detected in our panel have been reported in the germline where all apart from one cause lethal conditions. One tumour contained K652Q which has recently been identified in less severe cases of skeletal dysplasia. Tumours with and without LOH at 4p16,3 had mutations in FGFR3 suggesting that these tno events are not causally linked. The frequency of FGFR3 mutation indicates that this protein plays an important role in TCC.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Mutat Detect Family, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868; Knowles, Margaret/0000-0002-9363-8657				Antonarakis SE, 1998, HUM MUTAT, V11, P1; BELLUS GA, 2000, IN PRESS AM J HUM GE; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Caron H, 1996, HUM GENET, V97, P834; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; ELDER PA, 1994, ONCOGENE, V9, P3433; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GEY GO, 1952, CANCER RES, V12, P264; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hadano S, 1998, DNA Res, V5, P177, DOI 10.1093/dnares/5.3.177; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; *HMSO, 1994, CANC REG STAT; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; KNOWLES MA, 1994, CANCER RES, V54, P531; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; Mostofi FK, 1973, HISTOLOGICAL TYPING; NAWROZ H, 1994, CANCER RES, V54, P1152; Onose H, 1999, EUR J ENDOCRINOL, V140, P169, DOI 10.1530/eje.0.1400169; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PAULI BU, 1983, J UROLOGY, V129, P646, DOI 10.1016/S0022-5347(17)52271-5; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Pribill I, 1997, SOMAT CELL MOLEC GEN, V23, P413, DOI 10.1007/BF02673751; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SATO T, 1991, CANCER RES, V51, P5118; Shivapurkar N, 1999, CANCER RES, V59, P3576; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tartaglia M, 1998, MOL CELL PROBE, V12, P335, DOI 10.1006/mcpr.1998.0189; *UICC, 1978, CLASS MAL TUM BLADD; VILIEN M, 1983, EUR J CANCER CLIN ON, V19, P775, DOI 10.1016/0277-5379(83)90010-X; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Yustein AS, 1999, CANCER RES, V59, P1437; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149	51	89	92	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					686	691		10.1038/sj.onc.1204110	http://dx.doi.org/10.1038/sj.onc.1204110			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314002				2022-12-17	WOS:000166806000004
J	Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M				Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M			Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging	ONCOGENE			English	Article						Runx2; Cbfa1; Myc; oncogene collaboration; retroviral tagging; runt domain	MURINE LEUKEMIA-VIRUS; PROVIRAL INSERTION SITE; T-CELL LYMPHOMAGENESIS; PIM-1 TRANSGENIC MICE; ZINC-FINGER PROTEIN; C-MYC; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; P53-DEFICIENT MICE; NERVOUS-SYSTEM	The Runx2 (Cbfa1, Pebp2 alphaA, Aml3) gene was previously identified as a frequent target for transcriptional activation by proviral insertion in T-cell lymphomas of CD2-MYC transgenic mice. We have recently shown that over-expression of the full-length, most highly expressed Runx2 isoform in the thymus perturbs T-cell development, leads to development of spontaneous lymphomas at low frequency and is strongly synergistic with MSc. To gain further insight into the relationship of Runx2 to other lymphomagenic pathways, me tested the effect of combining the CD2-Runx2 transgene either with a Pim1 transgene (E mu -Pim1) or with the p53 null genotype, as each of these displays independent synergy with Myc, In both cases we observed synergistic tumour development. However, Runx2 appeared to have a dominant effect on the tumour phenotype in each case, with most tumours conforming to the CD3(+), CD8(+), CD4(+/-) phenotype seen in CD2-Runx2 mice, Neonatal infection of CD2-Runx2 mice with Moloney murine leukaemia virus (Moloney MLV) also led to a dramatic acceleration of tumour onset. Analysis of known Moloney MLV target genes in these lymphomas showed a high frequency of rearrangement at c-Myc or N-Myc (82%), and a significant number at Pim1 or Pim2 (23%), and at Pal1/Gfi1 (18%), These results indicate that Runx2 makes a distinct contribution to T-cell lymphoma development which does not coincide with any of the oncogene complementation groups previously identified by retroviral tagging.	Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Baxter EW, 1996, J VIROL, V70, P2095, DOI 10.1128/JVI.70.4.2095-2100.1996; Berns A, 1999, CANCER RES, V59, p1773S; BLYTH K, 1995, ONCOGENE, V10, P1717; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; BLYTH K, 1996, THESIS U GLASGOW VET; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; CUYPERS HT, 1984, CELL, V37, P141; DEPINHO R, 1999, ONCOGENE REV MOUSE M, pRG21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAZO PA, 1990, J VIROL, V64, P3948, DOI 10.1128/JVI.64.8.3948-3959.1990; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1997, CANCER RES, V57, P5248; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meyers S, 1996, ONCOGENE, V13, P303; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	50	89	90	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					295	302		10.1038/sj.onc.1204090	http://dx.doi.org/10.1038/sj.onc.1204090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313958				2022-12-17	WOS:000166411000003
J	Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR				Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR			Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation	ONCOGENE			English	Article						BRK; breast cancer; epithelial cells; EGF; erbB3; PI 3-kinase	EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GASTROINTESTINAL-TRACT; RECEPTOR FAMILY; PROTEIN-KINASE; GENE; TUMORS	A high proportion of human breast cancers, in contrast with normal mammary tissue, express the intracellular tyrosine kinase BRK, BRK expression enhances the mitogenic response of mammary epithelial cells to epidermal growth factor, and conferment of a proliferative advantage through this mechanism may account for the frequent elevation of BRK expression in tumours, Here we report that BRK expression in mammary epithelial cells, at pathologically relevant levels, results in an enhanced phosphorylation of the epidermal growth factor receptor-related receptor erbB3 in response to epidermal growth factor. As a consequence, erbB3 recruits increased levels of phosphoinositide 3-kinase, and this is associated with a potentiated activation of Akt, This effect of BRK on the regulation of phosphoinositide 3-kinase and Akt activity may account for BRK's ability to enhance mammary cell mitogenesis, and raises the possibility that breast tumours expressing BRK may acquire a resistance to pro-apoptotic signals.	Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ London Imperial Coll Sci Technol & Med, CRC Labs, Sch Med, London W12 0NN, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of London; Royal Holloway University London; Imperial College London; MRC Laboratory Molecular Biology; University of Reading	Crompton, MR (corresponding author), Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.			Fry, Michael/0000-0001-8518-1370				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	89	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5471	5476		10.1038/sj.onc.1203931	http://dx.doi.org/10.1038/sj.onc.1203931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114724				2022-12-17	WOS:000165396100007
J	Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP				Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP			The anti-proliferative effects of 1 alpha,25(OH)(2)D-3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression	ONCOGENE			English	Article						BRCA1; 1 alpha,25(OH)(2)D-3; vitamin D-3 receptor; antisense; gene expression	VITAMIN-D-RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CLONAL PROLIFERATION; GROWTH-RETARDATION; POTENT INHIBITORS; ANDROGEN RECEPTOR; OVARIAN-CANCER; DIFFERENTIATION; LINES	The anti-proliferative action of the seco-steroid hormone 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3] extends to some, but not all breast and prostate cancer cell lines. By elucidating the molecular mechanisms mediating the sensitivity of these cells, we can identify critical target genes regulated directly or indirectly by 1 alpha,25(OH)(2)D-3 and pathways potentially disrupted during transformation. In this study, we demonstrated the induction of expression of BRCA1 mRNA and protein as well as transcriptional activation from the BRCA1-promoter by 1 alpha,25(OH)(2)D-3 in the sensitive breast cancer cell line MCF-7, This was not observed in the 1 alpha,25(OH)(2)D-3-resistant breast cancer cell Line MDA-MB-436. The induction of BRCA1 mRNA was blocked by cyclohexamide, This indicated that transcriptional activation was mediated indirectly by the vitamin D receptor (VDR). Inhibition of VDR protein levels by stable transformation of the anti-sense VDR in MCF-7 reduced the sensitivity of MCF-7 to 1 alpha,25(OH)(2)D-3 by 50-fold. In addition, the induction of BRCA1 protein and transcriptional activation of a BRCA1 promoter-luciferase reporter construct was abrogated in the stable transformant with the greatest reduction of VDR levels. Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 was strongly associated with an ability to modulate BRCA1 protein. Furthermore, the expression of the estrogen receptor in these cell lines strongly correlated with their sensitivity to 1 alpha,25(OH)(2)D-3 and their ability to modulate BRCA1 expression. Taken together, our data support a model whereby the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 are mediated, in part, by the induction of BRCA1 gene expression via transcriptional activation by factors induced by the VDR and that this pathway is disrupted during the development of prostate and breast cancers.	Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Birmingham; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Campbell, MJ (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England.		Campbell, Moray J/A-1311-2013; Campbell, Moray/ABF-1264-2021	Campbell, Moray/0000-0002-3355-0928				ARASON A, 1993, AM J HUM GENET, V52, P711; Asou H, 1998, BLOOD, V92, P2441, DOI 10.1182/blood.V92.7.2441.2441_2441_2449; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Campbell MJ, 1997, J CELL BIOCHEM, V66, P413, DOI 10.1002/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.3.CO;2-0; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CARRUBA G, 1994, CANCER RES, V54, P1190; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872; ELSTNER E, 1995, CANCER RES, V55, P2822; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fasco MJ, 1998, MOL CELL ENDOCRINOL, V138, P51, DOI 10.1016/S0303-7207(98)00048-3; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GAO X, 1995, CANCER RES, V55, P1002; Gennari L, 1998, J CLIN ENDOCR METAB, V83, P939, DOI 10.1210/jc.83.3.939; Gombart AF, 1997, LEUKEMIA, V11, P1673, DOI 10.1038/sj.leu.2400840; GUDAS JM, 1995, CANCER RES, V55, P4561; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; ISSACS WB, 1994, COLD SPRING HARB SYM, V59, P653; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Langston AA, 1996, AM J HUM GENET, V58, P881; Leygue E, 1999, CANCER RES, V59, P1175; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lundin AC, 1999, CANCER RES, V59, P2332; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Suarez F, 1998, J CLIN ENDOCR METAB, V83, P3563, DOI 10.1210/jcem.83.10.5199; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VILJOEN TC, 1995, PROSTATE, V27, P160, DOI 10.1002/pros.2990270307; Vladusic EA, 1998, CANCER RES, V58, P210; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83	48	89	90	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5091	5097		10.1038/sj.onc.1203888	http://dx.doi.org/10.1038/sj.onc.1203888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042697				2022-12-17	WOS:000089930100006
J	Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A				Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A			Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients	ONCOGENE			English	Article						HCC; HBV; non-B; non-C; losses; amplifications	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN HEPATOCELLULAR CARCINOMAS; SQUAMOUS-CELL CARCINOMA; GENETIC CHANGES; TUMOR-SUPPRESSOR; ALLELIC LOSSES; SOLID TUMORS; SHORT ARM; HETEROZYGOSITY; DELETIONS	To discriminate among the chromosomal abnormalities associated with the etiology of hepatocellular carcinoma (HCC), we performed a comparative genomic hybridization (CGH) analysis on 34 HCCs resected on noncirrhotic livers from patients serologically negative for both hepatitis B (HBV) and C (HCV) viruses. The results mere compared to those of a previous analysis of 50 HCCs selected on the basis of their positivity for HBV infection, The majority of the abnormalities found in the HBV positive cases (losses of chromosome arms 1p, 8p, 6q, 13q and 14q and gains of 1q, 8q, 6p and 17q) were similarly detected in the virus negative specimens. In contrast, a significant decrease (40% on average) was observed for losses at 4q, 16q and 17p in non-viral HCC samples, suggesting that these abnormalities are tightly associated with HBV infection. Thus, in addition to a common pathway towards malignancy, a subset of alterations may preferentially contribute to virus-induced carcinogenesis. In a parallel CGH study of 10 fibrolamellar carcinomas, a rare subtype of HCC, me found in sis out of the seven informative cases, gains of chromosome arm Iq, This region, which is also preferentially amplified in non fibrolamellar tumors (58%), may contain an essential proto-oncogene commonly implicated in liver carcinogenesis.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France; Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, CNRS, URA 1967, Villejuif, France; Hop Beaujon, Anat Pathol Lab, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Dejean, A (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France.		Pineau, Pascal/AAP-5614-2020; Terris, Benoit/P-1497-2017; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				Arribas R, 1999, LAB INVEST, V79, P111; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; Boige V, 1997, CANCER RES, V57, P1986; CRAIG JR, 1980, CANCER, V46, P372, DOI 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; El-Rifai W, 1997, LAB INVEST, V77, P699; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kato A, 1998, DIGEST DIS SCI, V43, P1, DOI 10.1023/A:1018838731634; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lee DJ, 1997, CLIN CANCER RES, V3, P501; LEREBOURS F, 1999, GENE CHROMOSOME CANC, V2, P145; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; Mertens F, 1997, CANCER RES, V57, P2765; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Orsatti G, 1997, LIVER, V17, P152; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Puisieux A, 1997, PATHOL BIOL, V45, P864; RADFORD DM, 1995, CANCER RES, V55, P5180; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; Sambrook J, 1989, MOL CLONING LAB MANU; Schullerus D, 1999, INT J CANCER, V80, P22, DOI 10.1002/(SICI)1097-0215(19990105)80:1<22::AID-IJC5>3.0.CO;2-S; Schwerdtle RF, 1997, CANCER RES, V57, P5009; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; ZHANG X, 1994, CANCER RES, V54, P4177	39	89	94	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3733	3738		10.1038/sj.onc.1203713	http://dx.doi.org/10.1038/sj.onc.1203713			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949927				2022-12-17	WOS:000088568400005
J	Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF				Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF			Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization	ONCOGENE			English	Article						p14ARF; nucleolar localization; hdm2; p53	MELANOMA-PRONE FAMILIES; CELL-CYCLE ARREST; GERMLINE MUTATIONS; NUCLEAR EXPORT; INK4A LOCUS; P53 PROTEIN; MDM2; P19(ARF); GENE; P16(INK4A)	The INK4a/ARF locus encodes two distinct tumour suppressors, p16(INK4a) and p14ARF, that regulate cell cycle progression via the pRB and p53 pathways, respectively, The ARF protein inhibits hdm2 activity, leading to the stabilization of the p53 tumour suppressor and cell cycle inhibition, The amino-terminal domain of human p14ARF and of the mouse homologue, p19ARF, is sufficient for these effects, This domain is also sufficient for the nucleolar localization of the mouse ARF protein. In contrast, we show that the human ARF protein requires two arginine rich domains, one in the amino- and the other in the carboxy-terminus, for nucleolar targeting. The amino-terminal nucleolar-targeting domain of p14ARF is also important for ARF-hdm2 binding and cell cycle inhibition, The carboxy-terminal p14ARF nucleolar localization domain lies within the shared INK4a/ARF exon 2, and is mutated in a small number of melanoma-prone kindreds, The INK4a/ARF exon2-mutations could affect the function of both the p16(INK4a) and p14ARF tumour suppressors.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney	Rizos, H (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lee JY, 1997, BIOCHEM BIOPH RES CO, V237, P667, DOI 10.1006/bbrc.1997.7212; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parry D, 1996, MOL CELL BIOL, V16, P3844; Piccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	89	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2978	2985		10.1038/sj.onc.1203629	http://dx.doi.org/10.1038/sj.onc.1203629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871849				2022-12-17	WOS:000087581400004
J	Levy, DE; Gilliland, DG				Levy, DE; Gilliland, DG			Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice	ONCOGENE			English	Article						growth control; myelodisplasin; tumor immunity; cytokine signaling	HEMATOPOIETIC-CELL LINES; SIGNAL-TRANSDUCTION PATHWAYS; INTERFERON-GAMMA RECEPTOR; DNA-BINDING ACTIVITY; TARGETED DISRUPTION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; LEISHMANIA-MAJOR; FUSION PROTEIN; NULL MUTATION	Stat proteins are latent transcription factors activated by tyrosine phosphorylation downstream of cytokine and growth factor receptors and have been implicated in a variety of cell growth regulatory pathways. Constitutive phosphorylation has also been observed in various transformed cell line and in primary malignant tissue, suggesting that Stat protein activation may contribute to the transformed phenotype. One method to distinguish between a causative role in malignancy as opposed to bystander phosphorylation from the increased tyrosine phosphorylation that accompanies transformation is to investigate cell growth and malignancy in the absence of particular Stat proteins using targeted gene disruptions in transgenic mice, Such studies show that Stat1 primarily mediates growth inhibitory signals and contributes to the host rejection of tumors, and that its activation in transformed cells is not necessary for malignancy. Activation of Stat5 can be both necessary and sufficient for malignant transformation, and single Stat5-target genes have been identified that are critical for heightened proliferation. Nonetheless, some malignancies that are characterized by constitutively phosphorylated Stat5 are not altered by the loss of StatS protein. Its role in these cases may be redundant with other transforming events that are in themselves sufficient to cause disease, rendering tyrosine phosphorylation of Stat5 unnecessary in these transformed cells.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Kaplan Canc Ctr, Sch Med, New York, NY 10016 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Howard Hughes Med Inst,Div Hematol & Oncol, Boston, MA 02115 USA	New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788				Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chai SK, 1997, J IMMUNOL, V159, P4720; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVY D, 1990, New Biologist, V2, P923; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Okuda K, 1996, ONCOGENE, V13, P1147; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shuai K, 1996, ONCOGENE, V13, P247; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sternberg DW, 1999, BLOOD, V94, p389A; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; SWIHART K, 1995, J EXP MED, V181, P961, DOI 10.1084/jem.181.3.961; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WAXMAN DJ, 1995, MOL PHARMACOL, V48, P790	57	89	91	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2505	2510		10.1038/sj.onc.1203480	http://dx.doi.org/10.1038/sj.onc.1203480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851049				2022-12-17	WOS:000087459400006
J	Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H				Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H			alpha PIX nucleotide exchange factor is activated by interaction with phosphatidylinositol 3-kinase	ONCOGENE			English	Article						PAK; PDGF; EphB2; Nck; phosphoinositide	XENOPUS-LAEVIS DEVELOPMENT; FOCAL ADHESION KINASE; ADAPTER PROTEIN NCK; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MEMBRANE LOCALIZATION; CELL MOTILITY; SH3 DOMAIN; RECEPTOR; PHOSPHORYLATION	p21-activated kinase (PAK) is a common effector protein of the small GTPases Cdc42 and Rac, leading to the activation of downstream mitogen activated protein kinases, PAK also mediates polarized cytoskeletal changes induced by these GTPases, The recently identified PAK-interacting exchange factor (PIN) acts as a guanine nucleotide exchange factor on Rac, and colocalizes with PAK in a focal complex, but little is known about the associated signaling cascades, including upstream activators of PIX. In this study, we show that one of the isoforms of PIX, alpha PIX, is activated by signaling cascades from the platelet-derived growth factor (PDGF) receptor and EphB2 receptor, and from integrin-induced signaling through phosphatidylinositol 3-kinase (PW-kinase). alpha PIX is activated ba forming a complex with these receptors either ria association with PAK and Nck, or direct association with the p85 regulatory subunit of PU-kinase. Synthetic phosphoinositide and membrane targeted PW-kinase augmented the alpha PIX activity in vivo. In Xenopus, aggregates of mesodermal cells derived from embryos microinjected with alpha PIX significantly increased the peripheral spreading on fibronectin substrate in response to PDGF through PI3-kinase. These results indicate that alpha PIX is activated by PI3-kinase, and is involved in the receptor mediated signaling leading to the activation of the kinase activity of PAK, and the migration of mesodermal cells on extracellular matrix.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X; Otsuki, Yoshiro/0000-0002-0568-3811				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KELLER R, 1992, DEV DYNAM, V195, P162, DOI 10.1002/aja.1001950303; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Tanaka M, 1998, ONCOGENE, V17, P1509, DOI 10.1038/sj.onc.1202068; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	46	89	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5680	5690		10.1038/sj.onc.1202936	http://dx.doi.org/10.1038/sj.onc.1202936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523848				2022-12-17	WOS:000083016500009
J	Jones, FE; Stern, DF				Jones, FE; Stern, DF			Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation	ONCOGENE			English	Article						ErbB2; dominant negative receptor mutant; transgenic mice; mammary gland development	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; FACTOR RECEPTOR FAMILY; EGF RECEPTOR; DUCTAL MORPHOGENESIS; KINASE-ACTIVITY; NEU ONCOGENE; DIFFERENTIATION; ACTIVATION; PROTEIN	Overexpression of the receptor tyrosine kinase ErbB2/HER2/Neu (ErbB2) occurs in 15-40% of human breast cancers. To determine the function of ErbB2 signaling during normal mouse mammary gland development, me expressed a carboxyl-terminal truncated dominant negative allele of ErbB2 (ErbB2 Delta IC) in the developing mouse mammary gland. Despite ErbB2 Delta IC expression within mammary glands of pubescent virgin and pregnant mice, a phenotype was not observed until late in pregnancy. At 1 day post-partum, lactationally active, distended lobuloalveoli failed to form. This phenotype was exaggerated in multiparous females expressing ErbB2 Delta IC. Immunohistochemical staining for ErbB2 Delta IC revealed a concordance between high levels of ErbB2 Delta IC protein expression and the absence of lactational products within the lumens of ErbB2 Delta IC stained lobuloalveoli. These results demonstrate that ErbB2 signaling is required for proper mammary development and lactation at parturition.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, BML-342,POB 208023, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DiAugustine RP, 1997, J MAMMARY GLAND BIOL, V2, P109, DOI 10.1023/A:1026395513038; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vonderhaar B, 1984, CONTROL CELL GROWTH, P11; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yoo JY, 1998, MOL CELL ENDOCRINOL, V138, P163, DOI 10.1016/S0303-7207(98)00004-5	53	89	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3481	3490		10.1038/sj.onc.1202698	http://dx.doi.org/10.1038/sj.onc.1202698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376526				2022-12-17	WOS:000080850600006
J	Zariwala, M; Liu, JD; Xiong, Y				Zariwala, M; Liu, JD; Xiong, Y			Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins	ONCOGENE			English	Article						cyclin E2; CDK; G1 cell cycle control; cell transformation	CELL-CYCLE; DEPENDENT KINASES; PHASE-TRANSITION; RETINOBLASTOMA-PROTEIN; E GENE; G(1); TRANSFORMATION; TRANSCRIPTION; FIBROBLASTS; INHIBITION	G1 cyclin E controls the initiation of DNA synthesis by activating CDK2, and abnormally high levels of cyclin E expression have frequently been observed in human cancers. We have isolated a novel human cyclin, cyclin E2, that contains significant homology to cyclin E. Cyclin E2 specifically interacts with CDK inhibitors of the CIP/KIP family and activates both CDK2 and CDK3. The expression of cyclin E2 mRNA oscillates periodically throughout the cell cycle, peaking at the G1/S transition, and exhibits a pattern of tissue specificity distinct from that of cyclin El. Cyclin E2 encodes a short lived protein whose turnover is most likely governed by the proteasome pathway and is regulated by phosphorylation on a conserved Thr-392 residue. Expression of the viral E6 oncoprotein in normal human fibroblasts increases the steady state level of cyclin E2, but not cyclin El, while expression of the E7 oncoprotein upregulates both. These data suggest that the expression of these two G1 E-type cyclins may be similarly regulated by the pRb function, but distinctly by the p53 activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	yxiong@unc.edu			NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER; NCI NIH HHS [CA65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Botz J, 1996, MOL CELL BIOL, V16, P3401; Chevalier S, 1996, J CELL SCI, V109, P1173; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL M, 1996, CANCER RES, V68, P1173; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Howe JA, 1996, P NATL ACAD SCI USA, V93, P2060, DOI 10.1073/pnas.93.5.2060; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; KEYOMARSI K, 1994, CANCER RES, V54, P380; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	50	89	96	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2787	2798		10.1038/sj.onc.1202505	http://dx.doi.org/10.1038/sj.onc.1202505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840943				2022-12-17	WOS:000077146700012
J	Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M				Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M			Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F	ONCOGENE			English	Article						mammalian CDC6; E2F; promoter; cell cycle; DNA synthesis	ORIGIN RECOGNITION COMPLEX; S-PHASE ENTRY; DNA-REPLICATION; MCM-PROTEINS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; FISSION YEAST; DISTINCT ROLES; HUMAN HOMOLOG; HUMAN MEMBER	CDC6 of Saccharomyces cerevisiae regulates the DNA replication initiation through the origin recognition complex (ORC), Identification of a human homolog of the CDC6 gene (HsCdc6) suggests a universal role of the gene product in DNA replication. Expression of HsCdc6 is growth-regulated. We investigated the molecular basis of growth-regulated expression of mammalian Cdc6. The promoter activity of isolated HsCdc6 upstream region was activated at late G1 and G1/S boundary in the cell cycle of rat embryonic fibroblast REF52 cells by the addition of serum. The isolated promoter was activated by exogenous expression of E2F without serum stimulation. However a mutant promoter lacking the E2F recognition sites failed to respond to serum stimulation and exogenous expression of E2F, Expression of endogenous Cdc6 was induced by exogenous expression of E2F, Therefore, we concluded that the growth-regulated expression of mammalian Cdc6 was mediated by E2F, Moreover, we demonstrated that exogenous overexpression of either HsCdc6 or HsOrc1 failed to induce DNA synthesis unlike overexpression of E2F1, even though E2F1 induced both Cdc6 and Orc1, suggesting that E2F may regulate the expression of another gene(s), besides Cdc6 and Orc1, required for induction of cellular DNA synthesis in mammalian cells.	Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Geng Y, 1996, ONCOGENE, V12, P1173; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin SY, 1996, MOL CELL BIOL, V16, P1668; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NEVINS JR, 1992, SCIENCE, V258, P424; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	46	89	90	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1777	1785		10.1038/sj.onc.1202105	http://dx.doi.org/10.1038/sj.onc.1202105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778043				2022-12-17	WOS:000076303300003
J	Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P				Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P			Homozygous deletions at 3p12 in breast and lung cancer	ONCOGENE			English	Article						DUTT1/Hrobo-1; lung cancer; U2020 deletion; tumour suppressor gene; familial non-specific dementia	YEAST ARTIFICIAL CHROMOSOMES; MOLECULAR-GENETIC CHANGES; CELL-LINE U2020; SHORT ARM; CLONING; CARCINOMA; SEQUENCES; TUMORS; PCR; DNA	We have constructed a physical map of the region homozygously deleted in the U2020 cell line at 3p12, including the location of putative CpG islands. Adjacent to one of these islands, we have identified and cloned a new gene (DUTT1) and used probes from this gene to detect two other homozygous deletions occurring in lung and breast carcinomas: the smallest deletion is within the gene itself and would result in a truncated protein. The DUTT1 gene is a member of the neural cell adhesion molecule family, although its widespread expression suggests it plays a less specialized role compared to other members of the family.	Med Res Council Ctr, Macclesfield SK10 4TG, Cheshire, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; NCI, Frederick Canc Res Facil, Immunobiol Lab, Frederick, MD 21701 USA; Univ Uppsala, Akad Sjukhuset, Dept Oncol, S-75185 Uppsala, Sweden	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Rabbitts, P (corresponding author), Med Res Council Ctr, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.		Sekido, Yoshitaka/P-9756-2015	Bergh, Jonas/0000-0001-5526-1847; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABURENT H, 1994, AM J HUM GENET S, V55, P269; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BROWN J, 1995, HUM MOL GENET, V4, P1625, DOI 10.1093/hmg/4.9.1625; BUTLER R, 1992, GENOMICS, V12, P42, DOI 10.1016/0888-7543(92)90404-G; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GEMMILL RM, 1995, NATURE, V377, P299; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HEPPELLPARTON AC, 1994, CYTOGENET CELL GENET, V66, P42, DOI 10.1159/000133661; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LERMAN MI, 1991, HUM GENET, V86, P567; OGILVIE D, 1993, METHOD MOL BIOL, V54, P131; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; SUNDARESAN V, 1995, ANN ONCOL, V6, pS27; TASSONE F, 1995, HUM MOL GENET, V4, P1509, DOI 10.1093/hmg/4.9.1509; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODD S, 1995, GENOMICS, V25, P19, DOI 10.1016/0888-7543(95)80105-U; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377	31	89	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1723	1729		10.1038/sj.onc.1202103	http://dx.doi.org/10.1038/sj.onc.1202103			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796701				2022-12-17	WOS:000076200100010
J	Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B				Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B			CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer	ONCOGENE			English	Article						CDX2; caudal; colorectal cancer; microsatellite instability	MICROSATELLITE INSTABILITY; EXPRESSION; CARCINOMA; RECEPTOR; MUCIN; GENE	The Cdx2 gene is one of three murine homologues of the Drosophila homeobox gene caudal, Mice heterozygous for a null mutation in Cdx2 exhibit a variable phenotype including tail abnormalities, stunted growth and a homeotic shift of vertebrae. Most strikingly, however, 90% of heterozygous mice were reported to develop multiple intestinal adenomatous polyps, most notably in the proximal colon (Chawengsaksophak et al., 1997). These observations led us to propose that mutation of CDX2 may be involved in the genesis of some human colorectal tumours, A survey of DNA from 85 colorectal tumours revealed that one with extensive microsatellite instability (RER+ phenotype) has mutations in both alleles of CDX2, Both mutations occur in coding regions which contain repetitive elements and are consistent with those found in RER+ tumours.	Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Bancroft Ctr, Glaxo Gastroenterol Lab, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Brisbane, Qld 4006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia; Queensland Inst Med Res, Herston, Qld 4029, Australia	University of Queensland; University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Melbourne; QIMR Berghofer Medical Research Institute	Wainwright, B (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia.		Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Chawengsaksophak, Kallayanee/G-4427-2014; Leggett, Barbara A/D-3579-2011; Wicking, Carol/J-1814-2014	Chawengsaksophak, Kallayanee/0000-0001-9401-2122; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, Timothy/0000-0001-7962-6863; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092				Ajioka Y, 1996, J CLIN PATHOL, V49, P560, DOI 10.1136/jcp.49.7.560; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; JAMES R, 1994, J BIOL CHEM, V269, P15229; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; WALSH MD, 1993, J CLIN PATHOL, V46, P922, DOI 10.1136/jcp.46.10.922	9	89	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					657	659		10.1038/sj.onc.1201971	http://dx.doi.org/10.1038/sj.onc.1201971			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704932				2022-12-17	WOS:000075195300014
J	Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E				Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E			Persistent oligoclonal expansion of human T-cell leukemia virus type 1 infected circulating cells in patients with Tropical spastic paraparesis HTLV-1 associated myelopathy	ONCOGENE			English	Article						HTLV-1; ATLL; leukemogenesis; TSP/HAM	BLOOD MONONUCLEAR-CELLS; I PROVIRAL DNA; PERIPHERAL-BLOOD; HTLV-1-ASSOCIATED MYELOPATHY; IMMUNOSUPPRESSIVE TREATMENT; ASYMPTOMATIC CARRIERS; NEUROLOGICAL DISEASE; TRANSACTIVATOR TAX; MESSENGER-RNA; KAPPA-B	The pattern of HTLV-1 replication was assessed through PCR amplification of the 3' proviral integration sites in patients with TSP/HAM at different times. Integration sites mere sequenced and oligonucleotides specific for the flanking sequences were synthesized. Together with HTLV-1 LTR specific primers, clonotypic nested PCR was performed on peripheral blood from two patients. The frequencies of five clones studied ranged from 1/300 to 1/1500 PBMCs while four clones persisted for more than 1-5 years. It would seem that Tax driven expansion of T cells may persist for considerable periods of time in TSP/HAM despite strong cellular immunity. This may provide a background for the accumulation of subsequent mutations leading to malignancy.	Inst Rech Canc Lille, INSERM, U124, Paris, France; Hop La Pitie Salpetriere, Federat Neurol, Paris, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Inst Pasteur, Unite Retrovirol Mol, Paris, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Wattel, E (corresponding author), Inst Rech Canc Lille, INSERM, U124, Paris, France.							BEILKE MA, 1991, J MED VIROL, V33, P64, DOI 10.1002/jmv.1890330113; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CHO IM, 1995, AM J TROP MED HYG, V53, P412, DOI 10.4269/ajtmh.1995.53.412; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DUYAO MP, 1992, AIDS RES HUM RETROV, V8, P752; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JENKS PJ, 1995, CLIN INFECT DIS, V21, P992, DOI 10.1093/clinids/21.4.992; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; Newbound GC, 1996, J VIROL, V70, P2101, DOI 10.1128/JVI.70.4.2101-2106.1996; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROBINSON RD, 1990, J TROP MED HYG, V94, P411; SETOYAMA M, 1994, INT J CANCER, V57, P760, DOI 10.1002/ijc.2910570525; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TACHIBANA N, 1988, INT J CANCER, V42, P829, DOI 10.1002/ijc.2910420605; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; TSURUMI H, 1992, AM J HEMATOL, V41, P292, DOI 10.1002/ajh.2830410414; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wattel E, 1996, J ACQUIR IMMUNE D S1, V13, P92; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZANKE BW, 1989, TRANSPLANTATION, V48, P695; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					77	82		10.1038/sj.onc.1201906	http://dx.doi.org/10.1038/sj.onc.1201906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671316				2022-12-17	WOS:000074677800009
J	Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC				Hazzalin, CA; Cuenda, A; Cano, E; Cohen, P; Mahadevan, LC			Effects of the inhibition of p38/RK MAP kinase on induction of five fos and jun genes by diverse stimuli	ONCOGENE			English	Article						MAP kinases; p38/RK; fos, jun; SB 203580	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; C-JUN; TRANSCRIPTIONAL ACTIVATION; OKADAIC ACID; HISTONE H3; PHOSPHORYLATION; STRESS; DOMAIN; IDENTIFICATION	The ERK, JNK/SAPK and p38/RK MAP kinase subtypes are differentially activated by physiological, pharmacological and stress stimuli; all three subtypes are implicated in immediate-early (IF) gene induction by these agents, Here, we have asked whether inhibition of a single MAP kinase subtype under these conditions would generally alter induction of several IF genes in a similar way or whether this would differentially up-and down-regulate particular IF genes, an issue which bears on the question of whether individual MAP kinases ape strictly targeted to specific IE genes, or whether they might catalyse phosphorylation events that affect several IF genes in the same way, SB 203580, an inhibitor of p38/RK, has been used to analyse the role of this kinase in the induction of five IF genes (c-fos, fosB, c-jun, junB and junD) under diverse conditions of stimulation, Bn C3H 10T1/2 cells, p38/RK and its downstream kinase MAPKAP K-2 are activated by all stimuli used with the exception of TPA, The specificity of SB 203580 as a p38/RK inhibitor in these cells is demonstrated; it does not affect ERKs or JNK/SAPKs but does result in a small increase in the activity of the upstream kinase MKK6, the principal p38/RK activator in these cells. We find that inhibition of p38/RK under these conditions produces general effects on all five IE genes as a group in three ways, First, induction of all five genes in response to okadaic acid or tumour necrosis factor-alpha (TNF-alpha) is not significantly altered by SB 203580, Second, in cells stimulated with anisomycin or U.V. radiation, SB 203580 potently inhibits all of the induced IE genes. Finally, SB 203580 enhances induction of all five IE genes in EGF-treated cells; these enhanced mRNA levels are not due to stabilisation of labile mRNA transcripts, The significance of these results to current thinking on the relationship between distinct MAP kinase subtypes and specific IF genes is discussed.	UNIV LONDON KINGS COLL,NUCL SIGNALLING LAB,DEV BIOL RES CTR,RANDALL INST,LONDON WC2B 5RL,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC PROTEIN PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of London; King's College London; University of Dundee			Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135				ALESSI DR, 1995, P NATL ACAD SCI USA, V92, P7686; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BAYAERT R, 1996, EMBO J, V15, P1914; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; Cano E, 1996, ONCOGENE, V12, P805; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUENDA A, 1996, EMBO J, V15, P4293; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P233; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; PRICE MA, 1996, IN PRESS EMBO J; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAN MH, 1994, NATURE, V372, P798; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	60	89	93	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2321	2331		10.1038/sj.onc.1201403	http://dx.doi.org/10.1038/sj.onc.1201403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393876				2022-12-17	WOS:A1997YE15700006
J	Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK				Pelicano, L; Li, FS; Schindler, C; ChelbiAlix, MK			Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action	ONCOGENE			English	Article						interferon; retinoic acid; STAT; IRF-1; signalisation pathways	2'5' OLIGOADENYLATE SYNTHETASE; PML GROWTH-SUPPRESSOR; CONSTITUTIVE EXPRESSION; GENE-EXPRESSION; IFN-ALPHA; TRANSCRIPTIONAL ACTIVATOR; PROMYELOCYTIC LEUKEMIA; VIRUS-INFECTION; CELL-LINES; INDUCTION	Retinoic acid (RA) and interferons (IFNs) are negative regulators of cell proliferation, In vitro and in vivo, their combination leads to a more potent growth inhibition, However, the molecular mechanisms by which RA and IFNs potentiate each other are not fully understood. As some IFN-induced gene products regulate cell growth and/or antiviral activity, we analysed the effects of RA on their expressions. RA increases the level of 2'5'oligoadenylate synthetase, p68 kinase, the promyelocytic leukemia protein (PML) and Sp100 in both HL-60 and WISH cells. Moreover, RA and IFN act cooperatively to increase the expression of these proteins, RA also inhibits vesicular stomatitis virus replication and induces a higher antiviral state and growth inhibition when combined with IFN. RA stimulates the IFN regulatory factor 1 (IRF-1) gene expression directly through the GAS motif and causes the induction and secretion of IFN alpha. Additional mechanisms could he involved as RA increases the level of signal transducing activators of transcription (STAT) proteins, and enhances the IFN-induced STAT activation, suggesting that cooperative effects by RA and IFN are mediated through multiple pathways.	HOP ST LOUIS,CNRS,UPR 9051,F-75010 PARIS,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,DIV MOL MED,NEW YORK,NY 10032	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University								Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOURGEADE MF, 1984, CANCER RES, V44, P5355; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHELBIALIX MK, 1986, BIOCHEM BIOPH RES CO, V141, P1042, DOI 10.1016/S0006-291X(86)80149-8; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHELBIALIX MK, 1994, J CELL PHYSIOL, V158, P47, DOI 10.1002/jcp.1041580107; CHELBIALIX MK, 1996, TUMOR BIOL REGULATIO, P17; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FERBUS D, 1985, MOL CELL BIOCHEM, V67, P125, DOI 10.1007/BF02370171; FREY JR, 1991, CANCER LETT, V57, P223, DOI 10.1016/0304-3835(91)90161-A; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mangelsdorf David J., 1994, P319; Matikainen S, 1996, BLOOD, V88, P114; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1995, RECEPTOR, V5, P81; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	50	89	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2349	2359		10.1038/sj.onc.1201410	http://dx.doi.org/10.1038/sj.onc.1201410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393879				2022-12-17	WOS:A1997YE15700009
J	vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A				vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A			Biochemical characterization of C3G: an exchange factor that discriminates between Rap1 and Rap2 and is not inhibited by Rap1A(S17N)	ONCOGENE			English	Article						Rap; C3G; small G proteins; nucleotide exchange factor; Rap1A(S17N)	GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR ACTIVITY; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; BINDING; MUTANTS; SITE; IDENTIFICATION	A catalytically active fragment of the Rap-specific guanine-nucleotide exchange factor C3G was expressed in E coli. It was purified and its interaction with GTP-binding proteins was investigated using fluorescence spectroscopy, C3G stimulates GDP dissociation from Rap1, but not from Rap2, neither from Bud1, which is believed to be the yeast homologue of Rap1 nor from all other proteins of the human Ras-subfamily, Like the corresponding fragment from CDC25(Mm), the increase in the GDP dissociation rate is linear with increasing concentration of Rap1A.GDP up to 100 mu M, indicating an apparent K-M higher than 100 mu M. Unlike the Ras-CDC25(Mm) system, the Rap1A(S17N) mutant does not inhibit the C3G-activated guanine nucleotide dissociation from wild-type Rap1A in vitro. These data suggest that Rap1A(S17N) is unlikely to titrate away C3G in vivo, the proposed mechanism by which S17N-mutants exert their dominant negative effects.	MAX PLANCK INST MOL PHYSIOL,D-44139 DORTMUND,GERMANY	Max Planck Society				Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNERO A, 1995, BIOCHEM BIOPH RES CO, V216, P748, DOI 10.1006/bbrc.1995.2685; ECCLESTON JF, 1988, NATO ASI A, V165, P87; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOHN J, 1993, J BIOL CHEM, V268, P923; JOHN J, 1988, NATO ASI A, V165, P209; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LEROSEY I, 1991, J BIOL CHEM, V466, P4315; MALY FE, 1994, J BIOL CHEM, V269, P18743; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PIZON V, 1988, ONCOGENE, V3, P210; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATO KY, 1994, CANCER RES, V54, P552; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA X, 1994, P NATL ACAD SCI USA, V91, P3442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	44	89	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					845	850		10.1038/sj.onc.1201407	http://dx.doi.org/10.1038/sj.onc.1201407			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266971				2022-12-17	WOS:A1997XQ11700011
J	Hobeika, AC; Subramaniam, PS; Johnson, HM				Hobeika, AC; Subramaniam, PS; Johnson, HM			IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells	ONCOGENE			English	Article						interferon alpha; prostate cancer; cyclin dependent; kinase 2; cyclin E; p21	RETINOBLASTOMA PROTEIN; INTERFERON-ALPHA; GROWTH; PHOSPHORYLATION; CARCINOMA; GENE; G1; TRANSITION; LINES	Prostate cancer, like other types of cancer, is associated with the loss of cell cycle control, resulting in unregulated growth of cells. We report here on the inhibitory effects of interferon alpha (IFN alpha) on the cell cycle of prostate cancer cells, using the human prostate carcinoma cell line DU145 that has mutations in the tumor suppressor genes pRB, p53 and KAI1. IFN alpha inhibited growth and colony formation of DU145 cells and analysis by flow cytometry suggests that IFN alpha inhibited the progression of these cancer cells from the G(1) through S phase of the cell cycle. IFN alpha treatment of DU145 cells reduced cyclin dependent kinase 2 (cdk2) activity, In particular, cyclin E dependent cdk2 activity was inhibited by IFN alpha treatment. IFN alpha treatment, however, did not affect the amount of cdk2 bound to cyclin E. Consistent with this data, IFN alpha was able to induce expression of the kinase inhibitor p21 in DU145 cells, Furthermore, IFN treatment increased the amounts of p21 complexed with cdk2 in these cells. These data support a role for p21 in mediating the antiproliferative action of IFN alpha. The induction of p21 and its growth inhibitory effects in DU145 cells appears independent of p53, pRB and KAI1 status.			Hobeika, AC (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.				NATIONAL CANCER INSTITUTE [R01CA069959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLALOCK JE, 1980, CELL IMMUNOL, V49, P390, DOI 10.1016/0008-8749(80)90041-6; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; CAVENEE WK, 1995, SCI AM           MAR, P72; CREASEY AA, 1980, P NATL ACAD SCI-BIOL, V77, P1471, DOI 10.1073/pnas.77.3.1471; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Familletti P C, 1981, Methods Enzymol, V78, P387; GARNICK MB, 1994, SCI AM           APR, P72; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; ISAACS WB, 1991, CANCER RES, V51, P4716; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; NAKAJIMA Y, 1994, BIOCHEM BIOPH RES CO, V200, P467, DOI 10.1006/bbrc.1994.1472; NETTO GJ, 1994, AM J CLIN PATHOL, V102, pS57; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PINES J, 1995, CELL CYCLE CONTROL, P144; PONTZER CH, 1991, CANCER RES, V51, P5304; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROOS G, 1984, CANCER RES, V44, P2358; SICA G, 1989, UROL RES, V17, P111; SUBRMANIAM PS, IN PRESS J INTERFERO; TAMM I, 1987, MECHANISMS INTERFERO, V2, P25; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSAI LH, 1993, ONCOGENE, V8, P1593	26	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1165	1170		10.1038/sj.onc.1200939	http://dx.doi.org/10.1038/sj.onc.1200939			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121765				2022-12-17	WOS:A1997WM78200005
J	Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG				Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG			Expression and function of members of the cytokine receptor superfamily on breast cancer cells	ONCOGENE			English	Article						breast cancer; cytokines; receptors; cell growth; growth factors	LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; MAMMARY EPITHELIAL-CELLS; IL-6 SIGNAL TRANSDUCER; CARCINOMA CELLS; PROLACTIN RECEPTORS; MESSENGER-RNAS; EGF RECEPTOR; GM-CSF; INTERLEUKIN-6	Receptors for the cytokines leukemia inhibitory factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and interleukin-11 (IL-11) are members of the structurally conserved hemopoietin receptor superfamily, In addition, they all share the transmembrane signalling protein gp130, In this paper the expression and function of this family of receptors in breast cancer cells was examined, RT-PCR analyses demonstrated that gp130 was expressed in 12/12 breast cell lines and the specific receptor alpha-chains for IL-6, LIF, IL-11 and CNTF were expressed in the majority of these cell lines, This was in contrast to other hemopoitin receptors, Examination of 50 clinical samples of malignant breast tissue by RT-PCR showed a similar pattern of expression of gp130 associated receptors, Treatment of breast cancer cell lines with OSM resulted in changes in cellular morphology. Cellular proliferation was inhibited following exposure to OSM (3/4 cell lines), IL-11 (2/4 cell lines), and by IL-6 and LIF (1/4 cell lines), Cell surface binding of LIF and OSM was also documented, The expression of these receptors in 12/12 cell lines and greater than 95% of clinical samples suggests that these molecules may be important in regulating the growth of breast cells.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA; BAKER MED RES INST, PRAHRAN, VIC 3181, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR GROWTH FACTORS, PARKVILLE, VIC 3050, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Baker Heart and Diabetes Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Douglas, AM (corresponding author), ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LABS, PARKVILLE, VIC 3050, AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013; Berndt, Michael C/D-5580-2012	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; 				ABE O, 1992, LANCET, V339, P71; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BONNETERRE J, 1986, EUR J CANCER CLIN ON, V22, P1331, DOI 10.1016/0277-5379(86)90141-0; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DANFORTH DN, 1993, CANCER RES, V53, P1538; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1992, SEMIN ONCOL, V19, P286; EMERMAN JT, 1994, BONE MARROW TRANSPL, V13, P285; ETHIER SP, 1993, CANCER RES, V53, P627; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KACINSKI BM, 1991, ONCOGENE, V6, P941; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOEHORST SGA, 1993, J STEROID BIOCHEM, V45, P227, DOI 10.1016/0960-0760(93)90336-U; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LASFARGUES EY, 1958, J NATL CANCER I, V21, P1131; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCQUIRE WL, 1986, CANC SURVEYS, V5, P527; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURPHY LJ, 1984, J CLIN ENDOCR METAB, V58, P149, DOI 10.1210/jcem-58-1-149; MURPHY LJ, 1984, CANCER RES, V44, P1963; Nandurkar HH, 1996, ONCOGENE, V12, P585; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STAMPFER MR, 1993, CANCER SURV, V18, P7; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; TAMM I, 1994, P NATL ACAD SCI USA, V91, P4338, DOI 10.1073/pnas.91.10.4338; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	65	89	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					661	669		10.1038/sj.onc.1200882	http://dx.doi.org/10.1038/sj.onc.1200882			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038373				2022-12-17	WOS:A1997WG43000004
J	Biesova, Z; Piccoli, C; Wong, WT				Biesova, Z; Piccoli, C; Wong, WT			Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth	ONCOGENE			English	Article						epidermal growth factor receptor; eps8; SH3 domain; e3B1; signal transduction	TRANSFORMING ACTIVITY; FACTOR RECEPTOR; SUBSTRATE; KINASE; IDENTIFICATION; PROTOONCOGENE; PRODUCT; CLONING; DOMAIN	Eps8, a substrate of receptor tyrosine kinases, is an SH3 domain containing protein that plays an important role in mitogenic signaling. To determine the cellular function of eps8, we used the SH3 domain of eps8 to screen a human fibroblast M426 expression library and identified, a full-length cDNA clone of 3.2 kb. We designated this clone e3B1 for eps8 SH3 domain binding protein 1. Northern analysis revealed that expression of e3B1 mRNA was ubiquitious in human tissues. The e3B1 gene encodes a SH3 domain containing protein. We show that anti-e3B1 antibodies detect three cytosolic protein species of 65, 68 and 72 kDa in cell lysate isolated from asynchronously growing NIH3T3 cells. E3B1 binds to the SH3 domain of eps8 and Abi in vitro. We also demonstrated that e3B1 associates with eps8 in vivo. Phosphatase digestion and phosphoamino acid analysis revealed that p65(e3B1) is a phosphoserine containing protein and p72(e3B1) and p68(e3B1) are hyperserine-phosphorylated form of p65(e3B1). We further determined that the p65(e3B1) was the most abundant in serum-starved NIH/EGFR cells. Time course studies initiated by the addition of epidermal growth factor (EGF) revealed that the p72(e3B1) started to accumulate at 4 h, peaked at 8 h and remained high until 24 h. Finally, we demonstrate that NIH/EGFR fibroblasts overexpressing e3B1 grow more slowly relative to matched controls.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIKI T, 1993, PRACT APPROACH SER, P177; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WONG WT, 1994, ONCOGENE, V9, P3057	23	89	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					233	241		10.1038/sj.onc.1200822	http://dx.doi.org/10.1038/sj.onc.1200822			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010225				2022-12-17	WOS:A1997WC81800011
J	Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI				Rao, G; Rekhtman, N; Cheng, GH; Krasikov, T; Skoultchi, AI			Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation	ONCOGENE			English	Article						PU1; Spi-1; MEL cells; c-myc; c-myb; differentiation	C-MYC ONCOGENE; VIRUS-INDUCED ERYTHROLEUKEMIA; MOUSE ERYTHROLEUKEMIA; FRIEND-ERYTHROLEUKEMIA; ERYTHROID-DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; PUTATIVE ONCOGENE; GENE-EXPRESSION; MESSENGER-RNA; P53 GENE	Murine erythroleukemia (MEL) cells are transformed erythroid precursors that are blocked from completing the late stages of erythroid differentiation. A frequent event in the generation of these malignant cells is deregulation of the hematopoietic-specific transcription factor PU.1 (Spi-1) by retroviral insertion of the spleen-focus-forming virus component of Friend virus. During chemically induced reinitiation of MEL cell terminal differentiation, expression of PU.1 is rapidly downregulated, suggesting that PU.1 might interfere with processes required for terminal differentiation of erythroid precursors. To investigate the role of PU.1 in erythroid differentiation we transfected MEL cells with a PU.1 cDNA controlled by the eucaryotic translation elongation factor EF1 alpha promoter. Deregulated expression of PU.1 blocked chemically induced differentiation and terminal cell division. Deregulated expression of two other protooncogenes, c-myc and c-myb, also has been shown to block MEL differentiation, We present evidence that PU.1 inhibits terminal differentiation at an earlier step than c-Myc and c-Myb. Thus reinitiation of MEL cell terminal differentiation appears to be controlled by an ordered program of turning off several protooncogenes. Down-regulation of PU.1 may be a very early step in this program.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R37CA016368] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330, 5R37CA16368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONG YH, 1995, MOL CELL BIOL, V15, P1889; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRIEDMAN EA, 1978, P NATL ACAD SCI USA, V75, P3813, DOI 10.1073/pnas.75.8.3813; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAMBARI R, 1978, P NATL ACAD SCI USA, V75, P3801, DOI 10.1073/pnas.75.8.3801; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SOEIRO R, 1969, J MOL BIOL, V44, P551, DOI 10.1016/0022-2836(69)90379-9; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	54	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					123	131		10.1038/sj.onc.1200807	http://dx.doi.org/10.1038/sj.onc.1200807			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010239				2022-12-17	WOS:A1997WB76000012
J	Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS				Rader, JS; Kamarasova, T; Huettner, PC; Li, L; Li, Y; Gerhard, DS			Allelotyping of all chromosomal arms in invasive cervical cancer	ONCOGENE			English	Article						cervical cancer; allelotyping; chromosomes; tumor suppressor genes; loss of heterozygosity	COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; CELL-LINE SIHA; MICROSATELLITE POLYMORPHISMS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX; CARCINOMA; HETEROZYGOSITY; DELETION	The best characterized factor in the development of cervical cancer is the integration, of human papillomavirus into cervical cell chromosomes, Tn addition to HPV integration, the neoplastic process probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene function, Loss of heterozygosity analysis in a large sample is used to identify regions which harbor putative tumor suppressor genes (TSG) since the deletion of normal alleles unmask mutated alleles, We evaluated tumor tissue from invasive cervical carcinomas, carefully microdissected to eliminate normal stroma and lymphocytes, for LOH at all 41 chromosomal arms with 50 polymorphic markers, We have evaluated tumor and normal DNA pairs from 48 invasive cervical cancers of which 85% of the tumors are confined to the cervix, The mean loss for all chromosomal arms was 12%. Three regions exhibited LOH two standard deviations above the mean: 3p14.1-12 (40%), 11q23.3 (36%), and 6p22-21.3 (32%), Three regions showed loss one standard deviation above the mean: 19q13.4 (30%), 6q21-23.33 (25%), and 2q33-37 (24%). Our results indicate that a significant number of invasive cervical cancers have lost specific chromsomal regions, thereby suggesting that genes involved in the cell cycle regulation or the suppression of tumor development are located in these regions.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA.							APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BENTZ M, 1995, BLOOD, V85, P3610, DOI 10.1182/blood.V85.12.3610.bloodjournal85123610; CHUNG GTY, 1992, ANTICANCER RES, V12, P1485; *FOG, 1987, INT J GYNECOL OBSTET, V25, P87; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HANADA R, 1995, ONCOGENE, V11, P1829; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JONES MH, 1992, ONCOGENE, V7, P1631; JONES MH, 1994, GENE CHROMOSOME CANC, V9, P119, DOI 10.1002/gcc.2870090207; Kirkwood B., 1988, BR K ESSENTIALS MED; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PETRO R, 1986, VIRAL ETIOLOGY CERVI, P3; RADFORD DM, 1990, CANCER RES, V50, P6529; RUBIO MP, 1994, CANCER RES, V54, P4760; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHENGJING L, 1990, NATURE, V346, P470; SHIBATA D, 1992, AM J PATHOL, V141, P539; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOOK AK, 1991, AM J PREV MED, V7, P208; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; SYRJANEN K, 1990, SCAND J INFECT DIS, P7; TARKKANEN M, 1995, CANCER RES, V55, P1334; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; WALKER GJ, 1994, INT J CANCER, V59, P771, DOI 10.1002/ijc.2910590611; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; YOKOTA J, 1989, CANCER RES, V49, P3598	43	89	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2737	2741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000149				2022-12-17	WOS:A1996VZ65400025
J	Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M				Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M			Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis	ONCOGENE			English	Article						JNK; HTLV-1; tumorigenesis; tax; leukemia	VIRUS TYPE-I; T-CELL LEUKEMIA; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; TAX; PROTEIN; GENE; KINASE; IDENTIFICATION; TRANSFORMATION	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukiemia (ATL) and HTLV-1 associated myelopathy, also called tropical spastic paraparesis (HAM/TSP). Both clinical and in vitro evidence have demonstrated that the virus or its transactivator Tax, are transforming, However, transformation appears to require additional, as yet poorly characterized, genetic changes in infected cells, JNK is a recently characterized member of the MAP kinase family. Its signaling cascade is distinct from other members and has been demonstrated to play an important role in T-cell activation, at least partially through its downstream targets, c-jun and ATF-2. Here we demonstrate constitutive activation of the JNK cascade in human lymphocytes transformed in vitro by HTLV-1 and also in Tax transformed murine fibroblasts. Such activation is not induced by Tax expression alone, and occurs only when infected lymphocytes become IL-2 independent or immortalized. Constitutive JNK activation was also found in leukocytes isolated from ATL patients. The acquisition of constitutive JNK activation may represent an important later event in HTLV-1 tumorigenesis.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; KAGOSHIMA UNIV, DEPT LAB MED, KAGOSHIMA 890, JAPAN; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Scripps Research Institute; Kagoshima University; California State University System; San Diego State University; California State University System; San Diego State University; University of Texas System; UTMD Anderson Cancer Center			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BROWN DA, 1994, TRANSGENICS, V1, P377; BRUNET A, 1994, ONCOGENE, V9, P3379; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; COBB HM, 1995, J BIOL CHEM, V270, P14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1991, ONCOGENE, V6, P1023; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GESSAIN A, 1985, LANCET, V2, P407; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAEDA M, 1987, BLOOD, V70, P1407; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROHWER F, 1994, INT J ONCOL, V5, P1163; SAGGIORO D, 1990, CANCER RES, V50, P4968; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; XU X, 1996, IN PRESS VIROLOGY; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; YAN MH, 1994, NATURE, V372, P798	49	89	90	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700539				2022-12-17	WOS:A1996UX31900015
J	Keegan, K; Cooper, JA				Keegan, K; Cooper, JA			Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7	ONCOGENE			English	Article						SHPT2; Syp; Grb 2; Grb 7; 8H2 domain; two hybrid system	FACTOR RECEPTOR-BETA; PHOSPHOTYROSINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; KINASE; PHOSPHORYLATION; ACTIVATION; CLONING; DOMAINS; SPECIFICITY; CORKSCREW	SHPTP2 is a ubiquitously-expressed SH2-containing tyrosine phosphatase that is tyrosine phosphorylated in response to activation of various receptor and nonreceptor tyrosine kinases. SHPTPZ associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTPZ to this receptor promotes tyrosine phosphorylation of SHPTP2. The yeast two-hybrid system was modified to identify partners of tyrosine-phosphorylated proteins. Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTPZ interacts with another signaling protein, Grb7. We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy-terminus of Grb7. We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine-phosphorylated. These experiments show that this modified two hybrid technique may be useful for the identification of proteins involved in tyrosine kinase signal transduction cascades.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bartel PL, 1993, CELLULAR INTERACTION, P153; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OOI J, 1995, ONCOGENE, V10, P1621; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; Rose M, 1990, LAB COURSE MANUAL ME; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221	47	89	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622870				2022-12-17	WOS:A1996UF07600018
J	LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH				LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH			T-CELL TUMORS OF DISPARATE PHENOTYPE IN MICE TRANSGENIC FOR RBTN-2	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; ANTIGEN RECEPTOR; HOMEOBOX GENE; PROTEIN; LYMPHOMA; FUSION; FAMILY; HOX11; ONCOGENES	RBTN2 is a LIM domain protein which can be activated by the translocation t(11;14)(p13;q11) in childhood T cell acute leukaemia. Transgenic mice were examined in which rbtn2 protein is expressed in the T cell lineage. An average of 72% of these mice developed T cell tumours before 18 months of age, compared with 9% in transgenic mice expressing the related gene Rbtn-1. Rbtn2-induced tumours first appeared at 5 months of age and were clonal. They displayed a range of phenotypes, the most notable being CD3/CD45R double-positive cells. Tumours expressing either T cell receptor alpha/beta or gamma/delta heterodimers were found. Thus rbtn2 can promote tumours within a range of T cell types and maturities. The latency period before tumour development indicates that secondary events must occur before the onset of overt malignancy.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ASENSI V, 1990, CLIN EXP IMMUNOL, V80, P268; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KAPFF CT, 1991, ACUTE LYMPHATIC LEUK; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RIBEIRO RC, 1991, BLOOD, V78, P466; RIBEIRO RC, 1992, LEUKEMIA LYMPHOMA, V7, P351, DOI 10.3109/10428199209049790; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, IN PRESS EMBO J, V13; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	34	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3675	3681						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970726				2022-12-17	WOS:A1994PT39200031
J	JANS, DA; JANS, P				JANS, DA; JANS, P			NEGATIVE CHARGE AT THE CASEIN KINASE-II SITE FLANKING THE NUCLEAR-LOCALIZATION SIGNAL OF THE SV40 LARGE T-ANTIGEN IS MECHANISTICALLY IMPORTANT FOR ENHANCED NUCLEAR IMPORT	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; NF-KAPPA-B; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; GENE-PRODUCT; VASOPRESSIN V2-RECEPTOR; BETA-GALACTOSIDASE	Nuclear import of SV40 large T-antigen (T-ag) is completely dependent on the T-ag nuclear localization sequence (amino acids 126-132), but the rate of nuclear import is greatly increased by the additional presence of the N-terminal flanking sequence (amino acids 111-125), which includes a site for casein kinase II (CKII) (Ser(111/112)). The role of this site was investigated by site-directed mutagenesis and analysis of the effects on phosphorylation and on nuclear import at the single cell level using microinjection and quantitative fluorescent techniques. Removal of the CKII site either by substitution of S-111/112 by nonphosphorylatable amino acid residues, or mutation of the Asp-Asp-Glu(113/115) CKII recognition sequence to Asn-Asn-Gln, resulted in nuclear import rates less than 4% wild type, demonstrating that the CKII site was responsible for the enhancement of nuclear import conferred by T-ag amino acids 111-125. The substitution of Asp for Ser(112), the serine preferentially phosphorylated by purified CKII, enhanced nuclear import to about 45% maximal wild type rates. It is concluded that negative charge at the CKII site, normally provided by phosphorylation, is mechanistically important for nuclear transport enhancement. There was no evidence or a direct role for phosphatases or dephosphorylation in the transport process.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOLEC BIOL, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research	JANS, DA (corresponding author), MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ADAM S, 1989, NATURE, V227, P276; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRZIWA A, 1992, J STRUCT BIOL, V109, P168, DOI 10.1016/1047-8477(92)90048-F; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1991, J CELL BIOL, V114, P53, DOI 10.1083/jcb.114.1.53; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KALDERON D, 1984, NATURE, V311, P499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE H Y, 1991, Korean Journal of Genetics, V13, P1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MOLL T, 1991, CELL, V66, P1; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIHS HP, 1989, THESIS U GIESSEN GIE; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSHLOW CA, 1989, CELL, V59, P1167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; TANAKA K, 1992, NEW BIOL, V4, P173; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382	65	89	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2961	2968						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084599				2022-12-17	WOS:A1994PG82200022
J	MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD				MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD			APOPTOSIS IN BURKITT-LYMPHOMA CELLS IS DRIVEN BY C-MYC	ONCOGENE			English	Article							B-CELLS; GERMINAL-CENTERS; TRANSGENIC MICE; HEMATOPOIETIC-CELLS; PROTEIN EXPRESSION; GENE-EXPRESSION; MESSENGER-RNA; DAUDI CELLS; DEATH; ACTIVATION	Chromosomal translocation and subsequent de-regulation of the c-myc proto-oncogene are considered to be critical events in the multi-stage evolution of Burkitt lymphoma (BL). It is widely accepted that Myc protein functions as a competence factor for proliferation. However, recent studies indicate that it can also act in some cell types as a regulator of apoptosis. BL cell populations display a high frequency of apoptosis in vivo, a property which is also readily demonstrable in vitro in group I BL cell lines. Such lines are known to retain the cell surface marker characteristics of the parental tumour cells and, in the case of Epstein-Barr virus-positive tumours, their restricted viral protein expression. We have shown previously that apoptosis in a group I BL cell line is inhibited by interferon (IFN)-alpha. Here we show that IFN-alpha-mediated suppression of apoptosis in group I BL cells corresponds temporally with inhibition of Myc protein levels. Furthermore, inhibition of Myc expression following treatment with c-myc anti-sense oligonucleotides markedly enhanced survival of group I BL cells. These results indicate that, whilst c-myc may facilitate cycling of tumour cells in which it is de-regulated, it also stimulates their apoptosis.	UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, ENGLAND; UNIV MANCHESTER, MOLEC PHARMACOL GRP, MANCHESTER M13 9PT, ENGLAND	University of Birmingham; University of Birmingham; University of Manchester			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, ONCOGENE, V7, P101; Berard C W, 1985, IARC Sci Publ, P31; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MOGENSEN KE, 1983, EUR J BIOCHEM, V134, P355, DOI 10.1111/j.1432-1033.1983.tb07575.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Penn L J, 1990, Semin Cancer Biol, V1, P69; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STEIN CA, 1988, CANCER RES, V48, P2659; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	47	89	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3385	3391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247541				2022-12-17	WOS:A1993MG78200023
J	TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M				TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M			CHARACTERIZATION OF THE RET PROTOONCOGENE PRODUCTS EXPRESSED IN MOUSE L-CELLS	ONCOGENE			English	Article							PROTOONCOGENE RET; CADHERIN; TYROSINE; NEUROBLASTOMA	The ret proto-oncogene (proto-ret) encodes a receptor type tyrosine kinase with a cadherin-related sequence in the extracellular domain. To investigate whether the proto-Ret protein functions as a cell adhesion molecule like cadherins, we transfected the human proto-ret gene fused to the SV40 promoter or cytomegalovirus (CMV) promoter into mouse L cells in which cadherins are not expressed. Three transfectants with high levels of expression of the proto-Ret proteins were obtained. The proto-Ret proteins were expressed as 150 kDa and 170 kDa glycoproteins in transfectants as observed in human neuroblastoma cells. Cell fractionation experiments revealed that the 170 kDa protein but not the 150 kDa protein was detected predominantly in the plasma membrane fraction, indicating that the 170 kDa protein represents the mature glycosylated form of the proto-Ret protein present on the cell surface. Both 150 kDa and 170 kDa proto-Ret proteins showed tyrosine kinase activity in immunocomplex kinase assay. It is known that cadherins have Ca2+-dependent homophilic binding activity and are resistant to trypsinization in the presence of Ca2+. When L cells expressing the proto-Ret proteins were treated with trypsin in the presence of Ca2+, the 170 kDa protein was resistant to its digestion. On the other hand, it was completely digested in the presence of EGTA, suggesting the possibility that the proto-Ret protein interacts with Ca2+ like cadherins. However, the transfectants did not show clear adhesive properties in cell aggregation assays.	NAGOYA UNIV,SCH MED,DEPT SURG,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT RADIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University	TAKAHASHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1992, P JPN ACAD B-PHYS, V68, P106, DOI 10.2183/pjab.68.106; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187	15	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2925	2929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414495				2022-12-17	WOS:A1993MC09300005
J	LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B				LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B			SIMPLE SEQUENCE REPEAT POLYMORPHISM WITHIN THE P53 GENE	ONCOGENE			English	Note							PROTEIN	This report describes a new polymorphism, in intron 3 of the p53 gene, which consists of a single repeat of 16 nucleotides, absent in the published wild-type p53 gene sequence. In the Caucasian population tested (n = 82), 28% of individuals were heterozygotes for this polymorphism. Using PCR-based analysis, we were able to demonstrate p53 allelic losses in three of six breast tumors from heterozygote patients tested.	INST GUSTAVE ROUSSY,IMMUNOL MOLEC LAB,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ANAT PATHOL LAB C,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94805 VILLEJUIF,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,IMMUNOL LAB,CNRS,URA 1484,F-75006 PARIS,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Lazar, Vladimir/AAQ-2086-2020; Lazar, Vladimir/AAV-2087-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARBONE D, 1991, ONCOGENE, V6, P1691; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; COOPER DN, 1991, HUM GENET, V87, P409; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; SOUSSI T, 1990, ONCOGENE, V5, P945	13	89	92	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1703	1705						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502490				2022-12-17	WOS:A1993LE06400037
J	BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK				BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK			IDENTIFICATION OF MUTATIONS IN THE WT1 GENE IN TUMORS FROM PATIENTS WITH THE WAGR SYNDROME	ONCOGENE			English	Article							ZINC-FINGER GENE; WILMS-TUMOR; BAND 11P13; HUMAN CHROMOSOME-11; ANIRIDIA; DELETION; HETEROZYGOSITY; ASSOCIATION; REGION; LOCUS	Individuals with constitutional, heterozygous deletions of chromosome region 11p13 are predisposed to the development of Wilms' tumour, indicating the site of the tumour predisposition gene. The WT1 gene is a candidate for this cancer predisposition gene. If this gene is truely involved in tumorigenesis it would be expected to be mutant in tumour tissue from patients with 11p13 deletions. We have used single-stranded conformation polymorphism (SSCP) and polymerase chain reaction sequencing to test this hypothesis in an exon-by-exon analysis of the gene. Four tumours were analysed, two of which were from unilaterally affected individuals and two from a bilaterally affected patient. SSCP analysis identified mutations in the two unilateral tumours which, on sequencing, were shown to involve a 10-bp insertion in exon 7 and a single base pair change in exon 8. Both mutations result in the generation of premature stop codons and the predicted proteins would lack part of the zinc finger motif. Despite complete sequencing of the WT] gene in both of the bilateral tumours, no mutations were identified. These results possibly suggest that WT1 may not be involved in tumorigenesis in all tumours. All four tumours retained heterozygosity in the 11p15 region, making it unlikely that a second recessive oncogene in this re ion was involved in tumorigenicity.	ICRF ONCOL GRP,INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	University of London; University College London; Massachusetts Institute of Technology (MIT)				Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BAIRD P, 1991, ONCOGENE, V6, P1147; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1988, ANAL BIOCHEM, V173, P93; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1991, ONCOGENE, V6, P595; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOGG A, 1992, ONCOGENE, V7, P1444; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEMOINE NR, 1992, IN PRESS J PATHOL; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORRIS JF, 1991, ONCOGENE, V6, P2339; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PAL N, 1990, ONCOGENE, V5, P1665; PAL N, 1991, ONCOGENE, V252, P800; PAVLETICH NP, 1991, SCIENCE, V252, P800; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; PRRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WADEY RB, 1990, ONCOGENE, V5, P901	47	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2141	2149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331933				2022-12-17	WOS:A1992JW66500006
J	COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J				COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J			STRUCTURAL REARRANGEMENTS OF THE WT1 GENE IN WILMS-TUMOR CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; PHYSICAL MAP; HUMAN CHROMOSOME-11; WAGR COMPLEX; BAND 11P13; SHORT ARM; ANIRIDIA; HETEROZYGOSITY; DELETIONS; MUTATIONS	We have analysed 55 Wilms' tumour DNAs using the cDNA from the candidate Wilms' predisposition gene, WT1. One tumour, GOS 129, shows a partial homozygous deletion involving only the 3'-most exon of the gene. An adjacent 3' DNA sequence, J7-18, which lies on the same NotI fragment as WT1, is present in GOS 129. Thus, this partial deletion does not extend to the adjacent unmethylated 3' HTF island. These data support the candidature of WT1 as a Wilms' predisposition gene. Tumour GOS 129 has become homozygous as a result of a mitotic recombination event proximal to WT1. Three other tumours showed abnormally sized bands on Southern blot analysis which appear to reflect internal heterozygous rearrangements involving the 5' end of the gene. One of these tumours was from a bilaterally-affected patient and the other 3 were from stage III or IV tumours.	MIT,CTR CANC RES,CAMBRIDGE,MA 02193	Massachusetts Institute of Technology (MIT)	COWELL, JK (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1,ENGLAND.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MITCHELL CD, 1989, ONCOGENE, V4, P253; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WADEY RB, 1990, ONCOGENE, V5, P901; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	35	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					595	599						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851548				2022-12-17	WOS:A1991FR93900014
J	MCGEADY, ML; KERBY, S; SHANKAR, V; CIARDIELLO, F; SALOMON, D; SEIDMAN, M				MCGEADY, ML; KERBY, S; SHANKAR, V; CIARDIELLO, F; SALOMON, D; SEIDMAN, M			INFECTION WITH A TGF-ALPHA RETROVIRAL VECTOR TRANSFORMS NORMAL MOUSE MAMMARY EPITHELIAL-CELLS BUT NOT NORMAL RAT FIBROBLASTS	ONCOGENE			English	Article									OTSUKA PHARMACEUT CO LTD,MARYLAND RES LABS,ROCKVILLE,MD 20851	Otsuka Pharmaceutical	MCGEADY, ML (corresponding author), NCI,TUMOR IMMUNOL & BIOL,BETHESDA,MD 20892, USA.		Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; Ciardiello, Fortunato/0000-0002-3369-4841				ANZANO MA, 1982, CANCER RES, V42, P4776; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; ASSOIAN RK, 1985, J BIOL CHEM, V260, P9613; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEAN M, 1987, ONCOGENE RES, V1, P279; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DELARCO JE, 1985, P NATL ACAD SCI USA, V82, P5015; DELARUE JC, 1988, BREAST CANCER RES TR, V11, P173, DOI 10.1007/BF01805841; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; PIKE LJ, 1982, J BIOL CHEM, V257, P4628; REDMOND SMS, 1988, ONCOGENE, V2, P259; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RIOS MA, 1988, ANTICANCER RES, V8, P173; RIZZINO A, 1984, IN VITRO CELL DEV B, V20, P815, DOI 10.1007/BF02618298; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAINSBURY JRC, 1987, LANCET, V1, P1398; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SHANKAR V, 1989, IN PRESS MOL CARCINO; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TEIXIDO J, 1987, NATURE, V326, P83; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	61	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1375	1382						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2812779				2022-12-17	WOS:A1989AX65900015
J	TSUJIMOTO, Y; LOUIE, E; BASHIR, MM; CROCE, CM				TSUJIMOTO, Y; LOUIE, E; BASHIR, MM; CROCE, CM			THE RECIPROCAL PARTNERS OF BOTH THE T(14-18) AND THE T(11-14) TRANSLOCATIONS INVOLVED IN B-CELL NEOPLASMS ARE REARRANGED BY THE SAME MECHANISM	ONCOGENE			English	Article											TSUJIMOTO, Y (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FUKUHARA S, 1979, CANCER RES, V39, P3119; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1981, NATURE, V294, P631, DOI 10.1038/294631a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	19	89	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					347	351						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3129686				2022-12-17	WOS:A1988M947200006
J	Tabaries, S; Siegel, PM				Tabaries, S.; Siegel, P. M.			The role of claudins in cancer metastasis	ONCOGENE			English	Review							CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; BLOOD-BRAIN-BARRIER; JUNCTION PROTEINS CLAUDIN-3; TIGHT-JUNCTION; BREAST-CANCER; COLORECTAL-CANCER; OVARIAN-CANCER; GENE-EXPRESSION; DECREASED EXPRESSION; REDUCED EXPRESSION	TJs are large intercellular adhesion complexes that maintain cell polarity in normal epithelia and endothelia. During the metastatic process, TJs must be 'loosened' or dismantled in cancer cells to enable migration and dissemination. Diminished TJ integrity must also occur within endothelial cells to allow intravasation and extravasation of cancer cells across endothelial barriers. Claudins are critical components of TJs, forming homo-and heteromeric interactions between the adjacent cells, which have been implicated as key modulators of carcinogenesis and metastasis. Numerous epithelial- derived cancers display altered claudin expression patterns and certain claudins can now be used as biomarkers to predict patient prognosis. Moreover, claudins have been functionally implicated in numerous steps of the metastatic cascade. The distinct roles played by claudins during the cancer progression to metastatic disease are just starting to be elucidated. A more complete understanding of the mechanisms through which claudins augment cancer metastasis is required to develop new therapeutic agents against this family of proteins. In this review, we will summarize the relationship between the claudin expression and clinical outcomes in diverse cancers, discuss tumor intrinisic roles through which claudins regulate metastasis and explore claudin-mediated functions within stromal cells that influence the metastatic process. Finally, we will consider possible strategies for targeting claudins that have the potential to improve the management of metastatic cancer.	[Tabaries, S.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada; [Tabaries, S.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca			CIHR [MOP-136907]	CIHR(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for their thoughtful comments on the manuscript. Research conducted in the author's laboratory was supported by grants from the CIHR (MOP-136907 to PMS). PMS is a William Dawson Scholar of McGill University.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Angelow S, 2008, AM J PHYSIOL-RENAL, V295, pF867, DOI 10.1152/ajprenal.90264.2008; AUGERON C, 1984, CANCER RES, V44, P3961; Avraham HK, 2014, J PATHOL, V232, P369, DOI 10.1002/path.4304; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385; Bhat AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037174; Black JD, 2015, TOXINS, V7, P1116, DOI 10.3390/toxins7041116; Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6; Bornholdt J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-65; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Casagrande F, 2011, CANCER-AM CANCER SOC, V117, P5519, DOI 10.1002/cncr.26215; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Che JJ, 2015, TUMOR BIOL, V36, P6559, DOI 10.1007/s13277-015-3350-1; Choi YL, 2007, HISTOL HISTOPATHOL, V22, P1185, DOI 10.14670/HH-22.1185; Cocco E, 2015, INT J CANCER, V137, P2618, DOI 10.1002/ijc.29632; Cocco E, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-349; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Dahiya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022119; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gao ZJ, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/981626; Gao ZJ, 2011, CLIN CANCER RES, V17, P1065, DOI 10.1158/1078-0432.CCR-10-1644; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gril B, 2010, EUR J CANCER, V46, P1204, DOI 10.1016/j.ejca.2010.02.033; Gunzel D, 2009, J CELL SCI, V122, P1507, DOI 10.1242/jcs.040113; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Hough CD, 2000, CANCER RES, V60, P6281; Huang J, 2015, ONCOTARGET, V6, P1652, DOI 10.18632/oncotarget.2936; Huang J, 2014, INT J ONCOL, V44, P1293, DOI 10.3892/ijo.2014.2298; Huang YH, 2009, P NATL ACAD SCI USA, V106, P3426, DOI 10.1073/pnas.0813348106; Huo Q, 2009, ANTICANCER RES, V29, P851; Hwang TL, 2014, ONCOL LETT, V8, P1367, DOI 10.3892/ol.2014.2295; Hwang TL, 2010, EXP THER MED, V1, P789, DOI 10.3892/etm.2010.116; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Jia W, 2014, MOL MED REP, V9, P779, DOI 10.3892/mmr.2013.1875; Jia W, 2013, ANTICANCER RES, V33, P2353; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Kim CJ, 2011, EUR J CANCER, V47, P918, DOI 10.1016/j.ejca.2010.11.007; Kim TH, 2008, HISTOPATHOLOGY, V53, P48, DOI 10.1111/j.1365-2559.2008.03052.x; Kimbung S, 2014, MOL ONCOL, V8, P119, DOI 10.1016/j.molonc.2013.10.002; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kleinberg L, 2008, HUM PATHOL, V39, P747, DOI 10.1016/j.humpath.2007.10.002; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Kominsky SL, 2007, CANCER RES, V67, P7977, DOI 10.1158/0008-5472.CAN-07-1314; Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Krizbai IA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123845; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Kulka J, 2009, PATHOL ONCOL RES, V15, P59, DOI 10.1007/s12253-008-9089-x; Kuwada M, 2015, CANCER LETT, V369, P212, DOI 10.1016/j.canlet.2015.08.019; Ladwein M, 2005, EXP CELL RES, V309, P345, DOI 10.1016/j.yexcr.2005.06.013; Lal-Nag M, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.32; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Landers KA, 2008, BRIT J CANCER, V99, P491, DOI 10.1038/sj.bjc.6604486; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lazo PA, 2007, CANCER SCI, V98, P1666, DOI 10.1111/j.1349-7006.2007.00584.x; Liu JX, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0626-2; Ma F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112765; Martin TA, 2008, J CELL BIOCHEM, V105, P41, DOI 10.1002/jcb.21797; Martin TA, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.26518; MCCLANE BA, 1988, J BIOL CHEM, V263, P2423; Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124; Micke P, 2014, INT J CANCER, V135, P2206, DOI 10.1002/ijc.28857; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; Mina LA, 2011, NAT REV CLIN ONCOL, V8, P325, DOI 10.1038/nrclinonc.2011.59; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154; Morohashi S, 2007, INT J MOL MED, V20, P139; Nakagawa S, 2011, INT J ONCOL, V39, P791, DOI 10.3892/ijo.2011.1102; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Neesse A, 2012, ARCH BIOCHEM BIOPHYS, V524, P64, DOI 10.1016/j.abb.2012.01.009; Neesse A, 2013, GUT, V62, P1034, DOI 10.1136/gutjnl-2012-302577; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Ohtani S, 2009, GASTRIC CANCER, V12, P43, DOI 10.1007/s10120-008-0497-0; Oshima T, 2008, ONCOL REP, V19, P953; Philip R, 2015, ONCOTARGET, V6, P2046, DOI 10.18632/oncotarget.2858; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; Pitule P, 2013, ANTICANCER RES, V33, P4855; Pope JL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-167; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Protze J, 2015, CELL MOL LIFE SCI, V72, P1417, DOI 10.1007/s00018-014-1761-6; Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Ren Y, 2013, MOL MED REP, V8, P1505, DOI 10.3892/mmr.2013.1675; Rodriguez PL, 2014, INT J CANCER, V134, P1034, DOI 10.1002/ijc.28433; Ruffer C, 2004, EUR J CELL BIOL, V83, P135, DOI 10.1078/0171-9335-00366; Saeki R, 2010, J PHARMACOL EXP THER, V334, P576, DOI 10.1124/jpet.110.168070; Santin AD, 2005, CANCER RES, V65, P4334, DOI 10.1158/0008-5472.CAN-04-3472; Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x; Sharma RK, 2016, CLIN EXP METASTAS, V33, P263, DOI 10.1007/s10585-015-9776-4; Sheehan GM, 2007, HUM PATHOL, V38, P564, DOI 10.1016/j.humpath.2006.11.007; Shibutani M, 2013, ANTICANCER RES, V33, P3301; Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001; Singh AB, 2012, CARCINOGENESIS, V33, P2538, DOI 10.1093/carcin/bgs275; Soini Y, 2004, HUM PATHOL, V35, P1531, DOI 10.1016/j.humpath.2004.09.015; Suzuki H, 2012, ANN NY ACAD SCI, V1258, P65, DOI 10.1111/j.1749-6632.2012.06503.x; Szasz AM, 2011, CLIN EXP METASTAS, V28, P55, DOI 10.1007/s10585-010-9357-5; Szasz AM, 2013, INT UROL NEPHROL, V45, P727, DOI 10.1007/s11255-013-0406-2; Szasz AM, 2010, BJU INT, V105, P716, DOI 10.1111/j.1464-410X.2009.08808.x; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Tabaries S, 2012, MOL CELL BIOL, V32, P2979, DOI 10.1128/MCB.00299-12; Takahashi A, 2011, CURR MED CHEM, V18, P1861, DOI 10.2174/092986711795496809; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; Tamura A, 2011, GASTROENTEROLOGY, V140, P913, DOI 10.1053/j.gastro.2010.08.006; Tanaka H, 2015, GUT, V64, P1529, DOI 10.1136/gutjnl-2014-308419; Tatum R, 2010, AM J PHYSIOL-RENAL, V298, pF24, DOI 10.1152/ajprenal.00450.2009; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Van Itallie CM, 2012, J CELL SCI, V125, P4902, DOI 10.1242/jcs.111237; Van Itallie CM, 2012, ANN NY ACAD SCI, V1258, P60, DOI 10.1111/j.1749-6632.2012.06541.x; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; Wada M, 2013, GASTROENTEROLOGY, V144, P369, DOI 10.1053/j.gastro.2012.10.035; Wang HM, 2015, INT J CLIN EXP PATHO, V8, P881; Wang Q, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S85478; Wilhelm I, 2013, INT J MOL SCI, V14, P1383, DOI 10.3390/ijms14011383; Yamamoto T, 2010, ONCOL LETT, V1, P501, DOI 10.3892/ol_00000088; Yao Q, 2010, BIOCHEM BIOPH RES CO, V398, P413, DOI 10.1016/j.bbrc.2010.06.089; Yoda S, 2014, LUNG CANCER, V85, P366, DOI 10.1016/j.lungcan.2014.06.009; Yoshida T, 2011, ANTICANCER RES, V31, P2517; Yu ASL, 2015, J AM SOC NEPHROL, V26, P11, DOI 10.1681/ASN.2014030284; Yu ASL, 2009, J GEN PHYSIOL, V133, P111, DOI 10.1085/jgp.200810154; Yuan XQ, 2009, MOL CANCER THER, V8, P1906, DOI 10.1158/1535-7163.MCT-09-0106; Zhang GJ, 2013, INT J MOL MED, V31, P1375, DOI 10.3892/ijmm.2013.1348; Zhu JL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-150	146	88	94	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1176	1190		10.1038/onc.2016.289	http://dx.doi.org/10.1038/onc.2016.289			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524421				2022-12-17	WOS:000395861300002
J	Archambault, V; Lepine, G; Kachaner, D				Archambault, V.; Lepine, G.; Kachaner, D.			Understanding the Polo Kinase machine	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; SMALL-MOLECULE INHIBITORS; CELL-CYCLE CONTROL; BOX DOMAIN; AURORA-A; SUBCELLULAR-LOCALIZATION; CENTRIOLE DUPLICATION; PLK1 PHOSPHORYLATION; STRUCTURAL BASIS; MITOTIC ENTRY	The Polo Kinase is a central regulator of cell division required for several events of mitosis and cytokinesis. In addition to a kinase domain (KD), Polo-like kinases (Plks) comprise a Polo-Box domain (PBD), which mediates protein interactions with targets and regulators of Plks. In all organisms that contain Plks, one Plk family member fulfills several essential functions in the regulation of cell division, and here we refer to this conserved protein as Polo Kinase (Plk1 in humans). The PBD and the KD are capable of both cooperation and mutual inhibition in their functions. Crystal structures of the PBD, the KD and, recently, a PBD-KD complex have helped understanding the inner workings of the Polo Kinase. In parallel, an impressive array of molecular mechanisms has been found to mediate the regulation of the protein. Moreover, the targeting of Polo Kinase in the development of anti-cancer drugs has yielded several molecules with which to chemically modulate Polo Kinase to study its biological functions. Here we review our current understanding of the protein function and regulation of Polo Kinase as a fascinating molecular device in control of cell division.	[Archambault, V.; Lepine, G.; Kachaner, D.] Univ Montreal, Inst Res Immunol & Cancerol, Dept Biochim & Med Mol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Archambault, V (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Pavillon Marcelle Coutu,CP 6128, Montreal, PQ H3C 3J7, Canada.	vincent.archambault.1@umontreal.ca			Canadian Institutes of Health Research; Fonds de recherche du Quebec - Sante (FRQS); Cole Foundation; Canada Foundation for Innovation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de recherche du Quebec - Sante (FRQS)(Fonds de la Recherche en Sante du Quebec); Cole Foundation; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR)	Research on Polo Kinase in VA's lab is supported by the Canadian Institutes of Health Research. GL holds a studentship from the Fonds de recherche du Quebec - Sante (FRQS). DK holds a postdoctoral fellowship from the Cole Foundation. IRIC is supported in part by the Canada Foundation for Innovation and the FRQS.	Abe S, 2011, GENE DEV, V25, P863, DOI 10.1101/gad.2016411; Andrysik Z, 2010, NUCLEIC ACIDS RES, V38, P2931, DOI 10.1093/nar/gkq011; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2012, CELL CYCLE, V11, P1490, DOI 10.4161/cc.19724; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Beck J, 2013, NAT CELL BIOL, V15, P430, DOI 10.1038/ncb2695; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bonner AM, 2013, P NATL ACAD SCI USA, V110, pE1222, DOI 10.1073/pnas.1301690110; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carmena M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001250; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; Chen YC, 2010, J BIOL CHEM, V285, P41244, DOI 10.1074/jbc.M110.155242; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Craig SN, 2014, EXPERT OPIN DRUG DIS, V9, P773, DOI 10.1517/17460441.2014.918100; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; de Carcer G, 2011, MOL CELL BIOL, V31, P1225, DOI 10.1128/MCB.00607-10; Eckl JM, 2014, INT J BIOCH MOL BIOL, V4, P157; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Enserink JM, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-11; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Garcia-Alvarez B, 2007, P NATL ACAD SCI USA, V104, P3107, DOI 10.1073/pnas.0609131104; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; GOLDSTEIN LSB, 1986, J CELL BIOL, V102, P2076, DOI 10.1083/jcb.102.6.2076; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; HARTWELL LH, 1973, GENETICS, V74, P267; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kachaner D, 2014, J CELL BIOL, V207, P201, DOI 10.1083/jcb.201408081; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Kang YH, 2006, MOL CELL, V24, P409, DOI 10.1016/j.molcel.2006.10.016; Karpov PA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S1-S14; Kasahara K, 2013, NAT COMMUN, P4; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kong D, 2014, J CELL BIOL, V206, P855, DOI 10.1083/jcb.201407087; Kothe M, 2007, BIOCHEMISTRY-US, V46, P5960, DOI 10.1021/bi602474j; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lera RF, 2012, J BIOL CHEM, V287, P42812, DOI 10.1074/jbc.M112.412544; Liao CZ, 2010, ACS MED CHEM LETT, V1, P110, DOI 10.1021/ml100020e; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liu F, 2011, NAT CHEM BIOL, V7, P595, DOI 10.1038/nchembio.614; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Martins T, 2009, EMBO J, V28, P234, DOI 10.1038/emboj.2008.283; Matsumura F, 2011, J BIOL CHEM, V286, P10825, DOI 10.1074/jbc.M110.169722; Matthew EM, 2007, CELL CYCLE, V6, P2571, DOI 10.4161/cc.6.20.5079; McInnes C, 2006, NAT CHEM BIOL, V2, P608, DOI 10.1038/nchembio825; McInnes C, 2012, MOL CANCER THER, V11, P1683, DOI 10.1158/1535-7163.MCT-12-0006-T; McKinley KL, 2014, CELL, V158, P397, DOI 10.1016/j.cell.2014.06.016; Miller CT, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000498; Mortensen EM, 2005, CURR BIOL, V15, P2033, DOI 10.1016/j.cub.2005.10.046; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Murugan RN, 2011, MOL CELLS, V32, P209, DOI 10.1007/s10059-011-0126-3; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Neef R, 2007, NAT CELL BIOL, V9, P436, DOI 10.1038/ncb1557; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Park JE, 2010, CELL MOL LIFE SCI, V67, P1957, DOI 10.1007/s00018-010-0279-9; Paschal CR, 2012, CHROMOSOMA, V121, P565, DOI 10.1007/s00412-012-0375-8; Petersen J, 2005, NATURE, V435, P507, DOI 10.1038/nature03590; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Qian WJ, 2013, CHEM BIOL, V20, P1255, DOI 10.1016/j.chembiol.2013.09.005; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Ratsima H, 2011, P NATL ACAD SCI USA, V108, pE914, DOI 10.1073/pnas.1106448108; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016/j.chembiol.2008.03.013; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Santamaria A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004457; Sclafani RA, 2000, J CELL SCI, V113, P2111; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sledz P, 2011, ANGEW CHEM INT EDIT, V50, P4003, DOI 10.1002/anie.201008019; Smith SK, 2008, CELL CYCLE, V7, P698, DOI 10.4161/cc.7.6.5568; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; van de Weerdt BCM, 2008, BBA-MOL CELL RES, V1783, P1015, DOI 10.1016/j.bbamcr.2008.02.019; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Watanabe N, 2009, J BIOL CHEM, V284, P2344, DOI 10.1074/jbc.M805308200; Whitfield ZJ, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001648; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Wu ZQ, 2008, P NATL ACAD SCI USA, V105, P1919, DOI 10.1073/pnas.0712063105; Xiang Y, 2007, PLOS BIOL, V5, P2831, DOI 10.1371/journal.pbio.0050323; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yamashiro S, 2008, DEV CELL, V14, P787, DOI 10.1016/j.devcel.2008.02.013; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021/cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zhai B, 2008, J PROTEOME RES, V7, P1675, DOI 10.1021/pr700696a; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zimmerman WC, 2007, P NATL ACAD SCI USA, V104, P1847, DOI 10.1073/pnas.0610856104; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	121	88	94	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4799	4807		10.1038/onc.2014.451	http://dx.doi.org/10.1038/onc.2014.451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25619835				2022-12-17	WOS:000361050000001
J	Guha, M; Srinivasan, S; Ruthel, G; KKashina, A; Carstens, RP; Mendoza, A; Khanna, C; Van Winkle, T; Avadhani, NG				Guha, M.; Srinivasan, S.; Ruthel, G.; Kashina, A. K.; Carstens, R. P.; Mendoza, A.; Khanna, C.; Van Winkle, T.; Avadhani, N. G.			Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells	ONCOGENE			English	Article						mitochondrial DNA; mitochondrial retrograde signaling; epithelial-mesenchymal transition; breast cancer; ESRP1; cancer stem cells	DNA DEPLETION; RESPIRATORY STRESS; GENOME INSTABILITY; MTDNA DEPLETION; COPY NUMBER; IN-VIVO; MUTATIONS; ACTIVATION; RESISTANCE; APOPTOSIS	Metastatic breast tumors undergo epithelial-to-mesenchymal transition (EMT), which renders them resistant to therapies targeted to the primary cancers. The mechanistic link between mtDNA (mitochondrial DNA) reduction, often seen in breast cancer patients, and EMT is unknown. We demonstrate that reducing mtDNA content in human mammary epithelial cells (hMECs) activates Calcineurin (Cn)-dependent mitochondrial retrograde signaling pathway, which induces EMT-like reprogramming to fibroblastic morphology, loss of cell polarity, contact inhibition and acquired migratory and invasive phenotype. Notably, mtDNA reduction generates breast cancer stem cells. In addition to retrograde signaling markers, there is an induction of mesenchymal genes but loss of epithelial markers in these cells. The changes are reversed by either restoring the mtDNA content or knockdown of CnA alpha mRNA, indicating the causal role of retrograde signaling in EMT. Our results point to a new therapeutic strategy for metastatic breast cancers targeted to the mitochondrial retrograde signaling pathway for abrogating EMT and attenuating cancer stem cells, which evade conventional therapies. We report a novel regulatory mechanism by which low mtDNA content generates EMT and cancer stem cells in hMECs.	[Guha, M.; Srinivasan, S.; Kashina, A. K.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Guha, M.; Srinivasan, S.; Kashina, A. K.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Marie Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Ruthel, G.] Univ Penn, Sch Vet Med, Penn Vet Imaging Core, Philadelphia, PA 19104 USA; [Carstens, R. P.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Mendoza, A.; Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Ctr Canc Res, Bethesda, MD 20892 USA; [Van Winkle, T.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Ruthel, Gordon/GYU-9133-2022	Ruthel, Gordon/0000-0001-9193-5589	NIH grant [CA-22762]; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH grant CA-22762 and an Endowment from the Harriet Ellison Woodward Trust to NGA. We thank Benjamin Cieply (Carstens laboratory) for providing reagents for the ESRP1 experiments; Drs Brett Kaufman and Jill Kolesar (Kaufman lab) for providing TFAM shRNA constructs; Dr Joseph Baur for the GFP shRNA plasmid; Dr Mauricio Reginato and members of his laboratory for sharing protocols and reagents for immunostaining of the MCF10A 3D spheres; and Drs Christopher Lengner and Qihong Huang for valuable comments on the manuscript. We thank Dr Leslie King for critical comments and editorial help.	Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Correia RL, 2011, MITOCHONDRION, V11, P48, DOI 10.1016/j.mito.2010.07.001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Fan WW, 2012, GENE DEV, V26, P384, DOI 10.1101/gad.175802.111; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Guha M, 2010, BBA-BIOENERGETICS, V1797, P1055, DOI 10.1016/j.bbabio.2010.02.008; Guha M, 2009, MOL BIOL CELL, V20, P4107, DOI 10.1091/mbc.E09-04-0296; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Guo JH, 2011, CANCER RES, V71, P2978, DOI 10.1158/0008-5472.CAN-10-3482; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; HORWITZ HB, 1971, J CELL BIOL, V49, P546, DOI 10.1083/jcb.49.2.546; Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011; Magda D, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-521; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moro L, 2009, CELL DEATH DIFFER, V16, P571, DOI 10.1038/cdd.2008.178; Naito A, 2008, CANCER SCI, V99, P1584, DOI 10.1111/j.1349-7006.2008.00879.x; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720; Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207; Schonberg MA, 2010, J CLIN ONCOL, V28, P2038, DOI 10.1200/JCO.2009.25.9796; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Tang WG, 2012, CARCINOGENESIS, V33, P1762, DOI 10.1093/carcin/bgs190; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003; Xia P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-454; Yu M, 2007, IUBMB LIFE, V59, P450, DOI 10.1080/15216540701509955; Yu M, 2009, EUR J CANCER PREV, V18, P445, DOI 10.1097/CEJ.0b013e32832f9bd6	54	88	90	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5238	5250		10.1038/onc.2013.467	http://dx.doi.org/10.1038/onc.2013.467			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186204	Green Accepted			2022-12-17	WOS:000345120400002
J	Rao, X; Evans, J; Chae, H; Pilrose, J; Kim, S; Yan, P; Huang, RL; Lai, HC; Lin, H; Liu, Y; Miller, D; Rhee, JK; Huang, YW; Gu, F; Gray, JW; Huang, THM; Nephew, KP				Rao, X.; Evans, J.; Chae, H.; Pilrose, J.; Kim, S.; Yan, P.; Huang, R-L; Lai, H-C; Lin, H.; Liu, Y.; Miller, D.; Rhee, J-K; Huang, Y-W; Gu, F.; Gray, J. W.; Huang, T. H-M; Nephew, K. P.			CpG island shore methylation regulates caveolin-1 expression in breast cancer	ONCOGENE			English	Article						Cav1; CpG island shore; DNA methylation; breast cancer	ANCHORAGE-INDEPENDENT GROWTH; ESTROGEN-RECEPTOR-ALPHA; DNA METHYLATION; CELL-LINES; GENE-EXPRESSION; BASAL-LIKE; UP-REGULATION; EGF-R; PROMOTER; PROTEIN	Caveolin-1 (Cav1) is an integral membrane, scaffolding protein found in plasma membrane invaginations (caveolae). Cav1 regulates multiple cancer-associated processes. In breast cancer, a tumor suppressive role for Cav1 has been suggested; however, Cav1 is frequently overexpressed in aggressive breast cancer subtypes, suggesting an oncogenic function in advanced-stage disease. To further delineate Cav1 function in breast cancer progression, we evaluated its expression levels among a panel of cell lines representing a spectrum of breast cancer phenotypes. In basal-like (the most aggressive BC subtype) breast cancer cells, Cav1 was consistently upregulated, and positively correlated with increased cell proliferation, anchorage-independent growth, and migration and invasion. To identify mechanisms of Cav1 gene regulation, we compared DNA methylation levels within promoter 'CpG islands' (CGIs) with 'CGI shores', recently described regions that flank CGIs with less CG-density. Integration of genome-wide DNA methylation profiles ('methylomes') with Cav1 expression in 30 breast cancer cell lines showed that differential methylation of CGI shores, but not CGIs, significantly regulated Cav1 expression. In breast cancer cell lines having low Cav1 expression (despite promoter CGI hypomethylation), we found that treatment with a DNA methyltransferase inhibitor induced Cav1 expression via CGI shore demethylation. In addition, further methylome assessments revealed that breast cancer aggressiveness associated with Cav1 CGI shore methylation levels, with shore hypermethylation in minimally aggressive, luminal breast cancer cells and shore hypomethylation in highly aggressive, basal-like cells. Cav1 CGI shore methylation was also observed in human breast tumors, and overall survival rates of breast cancer patients lacking estrogen receptor a (ER alpha) negatively correlated with Cav1 expression. Based on this first study of Cav1 (a potential oncogene) CGI shore methylation, we suggest this phenomenon may represent a new prognostic marker for ER alpha-negative, basal-like breast cancer.	[Rao, X.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Interdisciplinary Biochem Grad Program, Bloomington, IN USA; [Rao, X.; Pilrose, J.; Miller, D.; Nephew, K. P.] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA; [Evans, J.; Chae, H.; Kim, S.] Indiana Univ, Sch Informat & Comp, Bioinformat Program, Bloomington, IN USA; [Yan, P.] Ohio State Univ, Ctr Comprehens Canc, NASRIllumina Sequencing Core, Columbus, OH 43210 USA; [Huang, R-L; Lai, H-C] Natl Yang Ming Univ, Inst Biomed Informat, Dept Obstet & Gynecol, Taipei 112, Taiwan; [Lin, H.; Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Rhee, J-K] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Seoul, South Korea; [Huang, Y-W] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Gu, F.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Mol Med, San Antonio, TX 78229 USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Nephew, K. P.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular Physiol, Indianapolis, IN 46202 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Integrat Physiol, Indianapolis, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Yang Ming Chiao Tung University; Indiana University System; Indiana University Bloomington; Seoul National University (SNU); Medical College of Wisconsin; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Oregon Health & Science University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, 302 Jordan Hall,1001 East 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu	Yan, Pearlly S/E-4339-2011; Lin, Hai/N-3860-2016	Yan, Pearlly S/0000-0003-1965-4920; Lin, Hai/0000-0002-2094-758X; Huang, Rui Lan/0000-0001-6458-4672	NIH [CA085289, CA113001]; Integrated Cancer Biology Program; Walther Cancer Foundation (Indianapolis, IN, USA); NATIONAL CANCER INSTITUTE [R01CA085289] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Integrated Cancer Biology Program; Walther Cancer Foundation (Indianapolis, IN, USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Dr F Fang for pyrosequencing analysis, Dr C Balch for manuscript preparation, and the IUB light Microscopy Imaging Center for microscopy resources. This work was supported by NIH grants CA085289 and CA113001, pilot project funding from the Integrated Cancer Biology Program and the Walther Cancer Foundation (Indianapolis, IN, USA). We acknowledge the use of the ICBP45 Kit in this study.	[Anonymous], 2013, ONCOGENE, P4519; Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bachmann N, 2008, CANCER GENET CYTOGEN, V182, P103, DOI 10.1016/j.cancergencyto.2008.01.006; Belanger MM, 2003, ANTI-CANCER DRUG, V14, P281, DOI 10.1097/00001813-200304000-00005; Chan TF, 2003, INT J ONCOL, V23, P599; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Elsheikh SE, 2008, BRIT J CANCER, V99, P327, DOI 10.1038/sj.bjc.6604463; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Glait C, 2006, EXP CELL RES, V312, P3899, DOI 10.1016/j.yexcr.2006.08.016; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022226; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin SY, 2004, ANTICANCER RES, V24, P1645; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Nestl A, 2001, CANCER RES, V61, P1569; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x; Patani N, 2012, BREAST CANCER RES TR, V131, P307, DOI 10.1007/s10549-011-1761-2; Patani N, 2012, BREAST CANCER RES TR, V131, P1, DOI 10.1007/s10549-011-1751-4; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; PINK JJ, 1995, CANCER RES, V55, P2583; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Pinilla SMR, 2006, BREAST CANCER RES TR, V99, P85, DOI 10.1007/s10549-006-9184-1; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Rosman DS, 2008, CANCER RES, V68, P1319, DOI 10.1158/0008-5472.CAN-07-5424; Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029; Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371; Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992; Shatz M, 2008, INT J RADIAT BIOL, V84, P177, DOI 10.1080/09553000701745293; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Thomas NBP, 2010, BREAST CANCER RES TR, V119, P575, DOI 10.1007/s10549-009-0355-8; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tse EYT, 2012, J PATHOL, V226, P645, DOI 10.1002/path.3957; Van den Eynden GG, 2006, BREAST CANCER RES TR, V95, P219, DOI 10.1007/s10549-005-9002-1; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zschocke J, 2002, J BIOL CHEM, V277, P38772, DOI 10.1074/jbc.M205664200; Zuo T, 2011, CANCER RES, V71, P1752, DOI 10.1158/0008-5472.CAN-10-3573	61	88	92	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4519	4528		10.1038/onc.2012.474	http://dx.doi.org/10.1038/onc.2012.474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23128390	Green Published, hybrid			2022-12-17	WOS:000324831300007
J	Paccez, JD; Vasques, GJ; Correa, RG; Vasconcellos, JF; Duncan, K; Gu, X; Bhasin, M; Libermann, TA; Zerbini, LF				Paccez, J. D.; Vasques, G. J.; Correa, R. G.; Vasconcellos, J. F.; Duncan, K.; Gu, X.; Bhasin, M.; Libermann, T. A.; Zerbini, L. F.			The receptor tyrosine kinase Ax1 is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target	ONCOGENE			English	Article						tyrosine kinase receptor; Ax1; prostate cancer; proliferation; NF-kappa B; IL-6	NF-KAPPA-B; ARREST-SPECIFIC GENE-6; BREAST-CANCER; PROLONGS SURVIVAL; ENDOTHELIAL-CELLS; CARCINOMA CELLS; ACTIVATION; PATHWAY; EXPRESSION; GAS6	Deregulation of the receptor tyrosine kinase Ax1 has been implicated in the progression of several human cancers. However, the role of Ax1 in prostate cancer remains poorly understood, and the therapeutic efficacy of Ax1 targeting remains untested. In this report we identified Ax1 as a new therapeutic target for prostate cancer. Ax1 is consistently overexpressed in prostate cancer cell lines and human prostate tumors. Interestingly, the blockage of Ax1 gene expression strongly inhibits proliferation, migration, invasion and tumor growth. Furthermore, inhibition of Ax1 expression by small interfering RNA regulates a transcriptional program of genes involved in cell survival, strikingly all connected to the nuclear factor-kappa B pathway. Additionally, blockage of Ax1 expression leads to inhibition of Akt, IKK alpha and I kappa B alpha phosphorylation, increasing I kappa B alpha expression and stability. Furthermore, induction of Akt phosphorylation by insulin-like growth factor 1 in Ax1 knockdown cells restores Akt activity and proliferation. Taken together, our results establish an unambiguous role for Ax1 in prostate cancer tumorigenesis with implications for prostate cancer treatment. Oncogene (2013) 32, 689-698; doi:10.1038/onc.2012.89; published online 12 March 2012	[Paccez, J. D.; Vasques, G. J.; Duncan, K.; Zerbini, L. F.] Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa; [Paccez, J. D.; Zerbini, L. F.] Univ Cape Town, Div Med Biochem, ZA-7925 Cape Town, South Africa; [Correa, R. G.] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Beth Israel Deaconess Med Ctr, BIDMC Genom & Prote Ctr, Boston, MA 02215 USA; [Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Harvard Univ, Sch Med, Boston, MA USA	International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Zerbini, LF (corresponding author), Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa.	luiz.zerbini@uct.ac.za	Correa, Ricardo G/G-7613-2012; Zerbini, Luiz/B-7720-2015; Paccez, Juliano/K-8560-2012	Correa, Ricardo G/0000-0001-6940-7034; Zerbini, Luiz/0000-0003-0736-9508; Libermann, Towia/0000-0002-4006-8179; Paccez, Juliano/0000-0002-1086-4588; Ferreira de Vasconcellos, Jaira/0000-0001-5011-4493; Bhasin, Manoj/0000-0001-5172-420X	ICGEB post-doctoral fellowship; CAPES international fellowship; Department of Defense [PC051217]; NIH [1RO1 CA85467]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA085467] Funding Source: NIH RePORTER	ICGEB post-doctoral fellowship; CAPES international fellowship; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JDP is recipient of the ICGEB post-doctoral fellowship. JFV is recipient of CAPES international fellowship. This study was supported by the Department of Defense grant PC051217 (LFZ), NIH grants 1RO1 CA85467 (TAL) and the Prostate Cancer Foundation (TAL).	Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Gallicchio M, 2005, BLOOD, V105, P1970, DOI 10.1182/blood-2004-04-1469; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Haas GP, 2008, CAN J UROL, V15, P3866; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Healy AM, 2001, AM J PHYSIOL-LUNG C, V280, pL1273, DOI 10.1152/ajplung.2001.280.6.L1273; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Koch AE, 2005, ARTHRITIS RHEUM, V52, P710, DOI 10.1002/art.20932; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Okamoto M, 1997, CANCER RES, V57, P141; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Seaton A, 2008, CARCINOGENESIS, V29, P1148, DOI 10.1093/carcin/bgn109; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; Tsai KC, 2009, BIOORG MED CHEM LETT, V19, P5665, DOI 10.1016/j.bmcl.2009.08.021; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Walz A, 1997, J LEUKOCYTE BIOL, V62, P604, DOI 10.1002/jlb.62.5.604; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zerbini LF, 2003, CANCER RES, V63, P2206; Zerbini LF, 2006, CANCER RES, V66, P11922, DOI 10.1158/0008-5472.CAN-06-2068; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	50	88	94	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					689	698		10.1038/onc.2012.89	http://dx.doi.org/10.1038/onc.2012.89			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22410775	Green Accepted			2022-12-17	WOS:000315746700003
J	Jan, M; Majeti, R				Jan, M.; Majeti, R.			Clonal evolution of acute leukemia genomes	ONCOGENE			English	Review						acute leukemia; genome; stem cells	ACUTE MYELOID-LEUKEMIA; BCR-ABL1 LYMPHOBLASTIC-LEUKEMIA; COPY NUMBER ALTERATIONS; STEM-CELLS; MUTATIONS; CANCER; TET2; ORIGINS; RELAPSE; ABNORMALITIES	In large part, cancer results from the accumulation of multiple mutations in a single cell lineage that are sequentially acquired and subject to an evolutionary process where selection drives the expansion of more fit subclones. Owing to the technical challenge of distinguishing and isolating distinct cancer subclones, many aspects of this clonal evolution are poorly understood, including the diversity of different subclones in an individual cancer, the nature of the subclones contributing to relapse, and the identity of pre-cancerous mutations. These issues are not just important to our understanding of cancer biology, but are also clinically important given the need to understand the nature of subclones responsible for the refractory and relapsed disease that cause significant morbidity and mortality in patients. Recently, advanced genomic techniques have been used to investigate clonal diversity and evolution in acute leukemia. Studies of pediatric acute lymphoblastic leukemia (ALL) demonstrated that in individual patients there are multiple genetic subclones of leukemia-initiating cells, with a complex clonal architecture. Separate studies also investigating pediatric ALL determined that the clonal basis of relapse was variable and complex, with relapse often evolving from a clone ancestral to the predominant de novo leukemia clone. Additional studies in both ALL and acute myeloid leukemia have identified pre-leukemic mutations in some individual cases. This review will highlight these recent reports investigating the clonal evolution of acute leukemia genomes and discuss the implications for clinical therapy. Oncogene (2013) 32, 135-140; doi:10.1038/onc.2012.48; published online 20 February 2012	[Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Dept Med, Div Hematol,Canc Inst, Palo Alto, CA 94304 USA; [Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Palo Alto, CA 94304 USA; [Jan, M.; Majeti, R.] Stanford Univ, Sch Med, Program Canc Biol, Inst Canc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University	Majeti, R (corresponding author), Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, Lokey Stem Cell Bldg,265 Campus Dr,G3021B, Stanford, CA 94305 USA.	rmajeti@stanford.edu		Majeti, Ravindra/0000-0002-5814-0984	Lucille P Markey Biomedical Research Fellowship; National Science Foundation; Burroughs Wellcome Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL099999] Funding Source: NIH RePORTER	Lucille P Markey Biomedical Research Fellowship; National Science Foundation(National Science Foundation (NSF)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to acknowledge Ryan Corces-Zimmerman for critical review of the manuscript. MJ is supported by the Lucille P Markey Biomedical Research Fellowship and the National Science Foundation Graduate Research Fellowship. RM holds a career award for medical scientists from the Burroughs Wellcome Fund.	Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Bateman CM, 2010, BLOOD, V115, P3553, DOI 10.1182/blood-2009-10-251413; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Cloos J, 2006, LEUKEMIA, V20, P1217, DOI 10.1038/sj.leu.2404246; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Greaves Mel, 2003, Rev Clin Exp Hematol, V7, P233; Greaves Mel, 2009, Hematology Am Soc Hematol Educ Program, P3, DOI 10.1182/asheducation-2009.1.3; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kuster L, 2011, BLOOD, V117, P2658, DOI 10.1182/blood-2010-03-275347; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Link DC, 2011, JAMA-J AM MED ASSOC, V305, P1568, DOI 10.1001/jama.2011.473; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Schaub FX, 2010, BLOOD, V115, P2003, DOI 10.1182/blood-2009-09-245381; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; van Delft FW, 2011, BLOOD, V117, P6247, DOI 10.1182/blood-2010-10-314674; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walter MJ, 2009, P NATL ACAD SCI USA, V106, P12950, DOI 10.1073/pnas.0903091106; Weissman I, 2005, JAMA-J AM MED ASSOC, V294, P1359, DOI 10.1001/jama.294.11.1359; Welch JS, 2011, JAMA-J AM MED ASSOC, V305, P1577, DOI 10.1001/jama.2011.497; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yang JJ, 2008, BLOOD, V112, P4178, DOI 10.1182/blood-2008-06-165027	55	88	90	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					135	140		10.1038/onc.2012.48	http://dx.doi.org/10.1038/onc.2012.48			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349821	Green Accepted			2022-12-17	WOS:000314075500001
J	Yoshikawa, S; Kukimoto-Niino, M; Parker, L; Handa, N; Terada, T; Fujimoto, T; Terazawa, Y; Wakiyama, M; Sato, M; Sano, S; Kobayashi, T; Tanaka, T; Chen, L; Liu, ZJ; Wang, BC; Shirouzu, M; Kawa, S; Semba, K; Yamamoto, T; Yokoyama, S				Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z-J; Wang, B-C; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.			Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor	ONCOGENE			English	Article						EGFR; T790M; gefitinib; tyrosine kinase inhibitor; NSCLC; drug resistance	EGFR KINASE INHIBITORS; DIFFRACTION DATA; MUTATIONS; GEFITINIB; ACTIVATION; RESISTANT; TRANSFORMATION; REFINEMENT; MECHANISM; SOFTWARE	The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain. The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic. They display sensitivity to TK inhibitors, including gefitinib and erlotinib. In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants. In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant. The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity. The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant. Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation. The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands. In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop. Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity. Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-associated EGFR mutations. Oncogene (2013) 32, 27-38; doi:10.1038/onc.2012.21; published online 20 February 2012	[Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Shirouzu, M.; Yokoyama, S.] Yokohama Inst, RIKEN Syst & Struct Biol Ctr, Yokohama, Kanagawa 2300045, Japan; [Yamamoto, T.] Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan; [Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.] Japan Aerosp Explorat Agcy, Ibaraki, Japan; [Chen, L.; Liu, Z-J; Wang, B-C] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Semba, K.] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo, Japan; [Yamamoto, T.] Okinawa Inst Sci & Technol, Cell Signal Unit, Okinawa, Japan; [Yokoyama, S.] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan	RIKEN; University of Tokyo; Japan Aerospace Exploration Agency (JAXA); University System of Georgia; University of Georgia; Waseda University; Okinawa Institute of Science & Technology Graduate University; University of Tokyo	Yokoyama, S (corresponding author), Yokohama Inst, RIKEN Syst & Struct Biol Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	tyamamot@ims.u-tokyo.ac.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Kukimoto-Niino, Mutsuko/C-6704-2017; Liu, Zhi-Jie/A-3946-2012; Yokoyama, Shigeyuki/N-6911-2015; Wakiyama, Motoaki/N-6928-2015; Shirouzu, Mikako/A-6521-2016	Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; Liu, Zhi-Jie/0000-0001-7279-2893; Yokoyama, Shigeyuki/0000-0003-3133-7338; Wakiyama, Motoaki/0000-0002-8029-4795; Sano, Satoshi/0000-0001-5909-7474	US Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]; High-quality Protein Crystal Growth Experiment Project in JEM; RIKEN Structural Genomics/Proteomics Initiative; National Project on Protein Structural and Functional Analyses; Targeted Proteins Research Program (TPRP); Ministry of Education, Culture, Sports, Science and Technology of Japan; Japanese Society for the Promotion of Science Fellowship (LJP)	US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); High-quality Protein Crystal Growth Experiment Project in JEM; RIKEN Structural Genomics/Proteomics Initiative; National Project on Protein Structural and Functional Analyses(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Targeted Proteins Research Program (TPRP)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Society for the Promotion of Science Fellowship (LJP)	We thank C Takemoto, T Kaminishi, M Kawazoe, Y Fujii and S Kishishita for assisting with the data collection; Y Ishizuka-Katsura, R Akasaka, M Yamaguchi-Hirafuji, T Uchikubo-Kamo, A Urushibata and N Maoka for technical assistance; S Kusano for helpful assistance; and K Murayama for helpful advice. We also thank the beamline staffs of the X06SA (SLS), BL-5A (PF), BL41XU (SPring-8) and BL26B2 (SPring-8) beamlines. Portions of the data were collected at the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Supporting institutions may be found at http://www.ser.anl.gov/. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. This study was supported in part by the 'High-quality Protein Crystal Growth Experiment Project in JEM' promoted by the Japan Aerospace Exploration Agency. The Russian Spacecraft 'Progress' and 'Soyuz', provided by the Russian Federal Space Agency, were used for space transportation. A portion of the crystallization technology for the counter-diffusion method was developed by European Space Agency and University of Granada. This work was supported by the RIKEN Structural Genomics/Proteomics Initiative, the National Project on Protein Structural and Functional Analyses, the Targeted Proteins Research Program (TPRP), the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a Japanese Society for the Promotion of Science Fellowship (LJP).	Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254; Carmi C, 2010, J MED CHEM, V53, P2038, DOI 10.1021/jm901558p; Cha MY, 2012, INT J CANCER, V130, P2445, DOI 10.1002/ijc.26276; Cha MY, 2009, J MED CHEM, V52, P6880, DOI 10.1021/jm901146p; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano WL, 2005, PYMOL V 0 98; Dixit A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007485; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; GARCIARUIZ JM, 1994, ACTA CRYSTALLOGR D, V50, P484, DOI 10.1107/S0907444993014350; Gilmer TM, 2008, CANCER RES, V68, P571, DOI 10.1158/0008-5472.CAN-07-2404; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kobayashi N, 2012, LUNG CANCER, V75, P161, DOI 10.1016/j.lungcan.2011.04.022; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kornev AP, 2006, P NATL ACAD SCI USA, V103, P17783, DOI 10.1073/pnas.0607656103; LESLIE AG, 1992, JOINT CCP4 ESF EAMCB, V26; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Taube E, 2012, INT J CANCER, V131, P970, DOI 10.1002/ijc.26461; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wakeling AE, 2002, CANCER RES, V62, P5749; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wu CH, 2010, J MED CHEM, V53, P7316, DOI 10.1021/jm100607r; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhou WJ, 2011, BIOORG MED CHEM LETT, V21, P638, DOI 10.1016/j.bmcl.2010.12.036; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	48	88	91	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					27	38		10.1038/onc.2012.21	http://dx.doi.org/10.1038/onc.2012.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349823				2022-12-17	WOS:000313029500003
J	Ono, H; Imoto, I; Kozaki, K; Tsuda, H; Matsui, T; Kurasawa, Y; Muramatsu, T; Sugihara, K; Inazawa, J				Ono, H.; Imoto, I.; Kozaki, K.; Tsuda, H.; Matsui, T.; Kurasawa, Y.; Muramatsu, T.; Sugihara, K.; Inazawa, J.			SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation	ONCOGENE			English	Article						SIX1; epithelial-mesenchymal transition; colorectal cancer; ZEB1; miR-200 family; CDH1	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; HOMEOPROTEIN SIX1; GENE-EXPRESSION; FEEDBACK LOOP; TUMOR PROGRESSION; METASTASIS; OVEREXPRESSION; REPRESSOR; FAMILY	Epithelial-mesenchymal transition (EMT) has a major role in cancer progression, as well as normal organ development and human pathology such as organ fibrosis and wound healing. Here, we performed a gene expression array specialized in EMT of colorectal cancer (CRC). From a comprehensive gene expression analysis using epithelial- and mesenchymal-like CRC cell lines, and following the ontology (GO) analysis, SIX1 gene was identified to be an EMT-related gene in CRC. Using SW480 cells stably transfected with a SIX1 expression construct and their control counterparts, we demonstrated that SIX1 overexpression represses CDH1 expression and promotes EMT in CRC. SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. In primary tumors of CRC, in accord with the functional findings, aberrant expression of SIX1 in cancer cells was observed at the disruption of the basement membrane and at the tumor invasive front, where tumor cells underwent EMT in vivo. Taken together, SIX1 overexpression is suggested to occur in carcinogenesis, and contribute to repression of CDH1 expression and promotion of EMT partly through repression of miR-200-family expression and activation of ZEB1 in CRC. Oncogene (2012) 31, 4923-4934; doi:10.1038/onc.2011.646; published online 30 January 2012	[Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; [Ono, H.; Sugihara, K.] Tokyo Med & Dent Univ, Grad Sch, Dept Surg, Tokyo 1138510, Japan; [Imoto, I.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Human Genet, Tokushima 770, Japan; [Tsuda, H.] Natl Canc Ctr, Dept Pathol, Tokyo, Japan; [Tsuda, H.] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Matsui, T.] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Tokyo 1138510, Japan; [Matsui, T.] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr Excellence Program Frontier Res Mol De, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokushima University; National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Kozaki, Ken-ichi/M-6281-2014; Imoto, Issei/AAD-5799-2020; Matsui, Takeshi/C-4730-2017	Kozaki, Ken-ichi/0000-0003-3286-819X; 	Ministry of Education, Culture, Sports, Science, and Technology, Japan; Ministry of Health, Labour and Welfare, Japan; New Energy and Industrial Technology Development Organization (NEDO); Grants-in-Aid for Scientific Research [22134002, 23390077, 21790267] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by grants-in-aid for Scientific Research (A), (B) (C) and on Priority Areas, and the Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan; and a grant from the New Energy and Industrial Technology Development Organization (NEDO). We thank Yoko Takagi, Ayako Takahashi, Rumi Mori and Kathy Masker for technical assistance.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Hajra KM, 2002, CANCER RES, V62, P1613; Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053; Hoshino H, 2009, BIOCHEM BIOPH RES CO, V390, P1061, DOI 10.1016/j.bbrc.2009.10.117; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Khanna C, 2001, CANCER RES, V61, P3750; Kumar JP, 2009, CELL MOL LIFE SCI, V66, P565, DOI 10.1007/s00018-008-8335-4; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Rodriguez S, 2008, DEV BIOL, V314, P40, DOI 10.1016/j.ydbio.2007.10.056; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wan F, 2008, INT J CANCER, V123, P32, DOI 10.1002/ijc.23463; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	42	88	92	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4923	4934		10.1038/onc.2011.646	http://dx.doi.org/10.1038/onc.2011.646			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286765				2022-12-17	WOS:000311430200004
J	Kong, D; Piao, YS; Yamashita, S; Oshima, H; Oguma, K; Fushida, S; Fujimura, T; Minamoto, T; Seno, H; Yamada, Y; Satou, K; Ushijima, T; Ishikawa, TO; Oshima, M				Kong, D.; Piao, Y-S; Yamashita, S.; Oshima, H.; Oguma, K.; Fushida, S.; Fujimura, T.; Minamoto, T.; Seno, H.; Yamada, Y.; Satou, K.; Ushijima, T.; Ishikawa, T-O; Oshima, M.			Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells	ONCOGENE			English	Article						miR-7; gastric cancer; inflammation; macrophages	PROSTAGLANDIN E-2 PATHWAY; GROWTH-FACTOR RECEPTOR; ACTIVATED MACROPHAGES; NEURITE OUTGROWTH; DNA METHYLATION; CANCER; MICRORNA-7; TARGETS; INDUCTION; ELEMENT	Inflammation has an important role in cancer development through various mechanisms. It has been shown that dysregulation of microRNAs (miRNAs) that function as oncogenes or tumor suppressors contributes to tumorigenesis. However, the relationship between inflammation and cancer-related miRNA expression in tumorigenesis has not yet been fully understood. Using K19-C2mE and Gan mouse models that develop gastritis and gastritis-associated tumors, respectively, we found that 21 miRNAs were upregulated, and that 29 miRNAs were downregulated in gastric tumors in an inflammation-dependent manner. Among these miRNAs, the expression of miR-7, a possible tumor suppressor, significantly decreased in both gastritis and gastric tumors. Moreover, the expression of miR-7 in human gastric cancer was inversely correlated with the levels of interleukin-1 beta and tumor necrosis factor-alpha, suggesting that miR-7 downregulation is related to the severity of inflammatory responses. In the normal mouse stomach, miR-7 expression was at a basal level in undifferentiated gastric epithelial cells, and was induced during differentiation. Moreover, transfection of a miR-7 precursor into gastric cancer cells suppressed cell proliferation and soft agar colony formation. These results suggest that suppression of miR- 7 expression is important for maintaining the undifferentiated status of gastric epithelial cells, and thus contributes to gastric tumorigenesis. Although epigenetic changes were not found in the CpG islands around miR-7-1 of gastritis and gastric tumor cells, we found that activated macrophage-derived small molecule(s) ( <3kDa) are responsible for miR-7 repression in gastric cancer cells. Furthermore, the miR-7 expression level significantly decreased in the inflamed gastric mucosa of Helicobacter-infected mice, whereas it increased in the stomach of germfree K19-C2mE and Gan mice wherein inflammatory responses were suppressed.	[Kong, D.; Piao, Y-S; Oshima, H.; Oguma, K.; Ishikawa, T-O; Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Yamashita, S.; Ushijima, T.] Natl Canc Ctr, Res Inst, Div Epigen, Tokyo 104, Japan; [Fushida, S.; Fujimura, T.] Kanazawa Univ Hosp, Dept Gastroenterol Surg, Kanazawa, Ishikawa, Japan; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9201192, Japan; [Seno, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Yamada, Y.; Satou, K.] Kanazawa Univ, Inst Sci & Engn, Fac Elect & Comp Engn, Kanazawa, Ishikawa 9201192, Japan; [Piao, Y-S] Yanbian Univ, Med Coll, Dept Pathophysiol, Yanji 133002, Peoples R China	Kanazawa University; National Cancer Center - Japan; Kanazawa University; Kanazawa University; Kyoto University; Kanazawa University; Yanbian University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	oshimam@kenroku.kanazawa-u.ac.jp	Satou, Kenji/C-3316-2015; Ushijima, Toshikazu/AAP-5742-2021; Oshima, Masanobu/F-9958-2014	Satou, Kenji/0000-0001-5474-7087; Ushijima, Toshikazu/0000-0003-3405-7817; Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008; Seno, Hiroshi/0000-0002-8509-8128	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research [22500996, 23659643] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Manami Watanabe for her excellent technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Ministry of Health, Labour and Welfare of Japan.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Korshunova I, 2008, J NEUROSCI RES, V86, P2201, DOI 10.1002/jnr.21678; Nguyen HTT, 2010, J BIOL CHEM, V285, P1479, DOI 10.1074/jbc.M109.057141; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER RES, V69, P2729, DOI 10.1158/0008-5472.CAN-08-4394; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Sonkoly E, 2011, MUTAT RES-FUND MOL M, V717, P46, DOI 10.1016/j.mrfmmm.2011.02.002; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282	39	88	92	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3949	3960		10.1038/onc.2011.558	http://dx.doi.org/10.1038/onc.2011.558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139078	Green Submitted			2022-12-17	WOS:000308342800004
J	Wang, C; Youle, RJ				Wang, C.; Youle, R. J.			Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak	ONCOGENE			English	Article						HCT116; Bax; Bak; DKO; BH3-only; apoptosis	BH3 MIMETIC ABT-737; BCL-2 HOMOLOG BAX; MITOCHONDRIAL PATHWAY; MEDIATED APOPTOSIS; BH3-ONLY PROTEINS; TRAIL; DEATH; RESISTANCE; NBK/BIK; GENE	The intrinsic mitochondrial apoptotic pathway acts through two core pro-apoptotic proteins Bax (Bcl2-associated X protein) and Bak (Bcl2-antagonist/killer 1). Although Bax and Bak seem to have redundant roles in apoptosis, accumulating evidence also suggests that they might not be interchangeable under certain conditions, at least in some human cell lines. Here we report the generation of Bak knockout as well as BaxBak double knockout HCT116 human colon carcinoma cells. We show that Bak is dispensable for apoptosis induced by a variety of stimuli including ABT-737 but not for fluorouracil-induced apoptosis. In addition, Bax deficiency only provides partial protection against camptothecin and cisplatin-induced apoptosis and no protection against killing by Puma or ABT-737 plus Noxa overexpression. Moreover, Bak is activated normally in response to many chemotherapeutic drugs in the presence of Bax, but remains kept in check by Mcl-1 in the absence of Bax. Our data suggest that Bax and Bak are functionally redundant, but they are counteracted by distinct anti-apoptotic Bcl-2 family proteins in different species. Oncogene (2012) 31, 3177-3189; doi:10.1038/onc.2011.497; published online 7 November 2011	[Youle, R. J.] Natl Inst Neurol Disorders & Stroke, Biochem Sect, Surg Neurol Branch, NIH,SNB,NINDS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), Natl Inst Neurol Disorders & Stroke, Biochem Sect, Surg Neurol Branch, NIH,SNB,NINDS, Bldg 35,Room 2C917,35 Lincoln Dr, Bethesda, MD 20892 USA.	youler@ninds.nih.gov	Wang, Chunxin/B-9312-2016	Wang, Chunxin/0000-0001-6015-6806	National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859] Funding Source: NIH RePORTER	National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Bert Vogelstein for Bax KO HCT116 cells, Fred Bunz for pSEPT vector and advice on gene targeting, Jean-Claude Martinou for comments on the manuscript, NINDS DNA sequencing facility, NINDS imaging facility and NINDS FACS facility. This study is supported in part by the Intramural Research Program of the National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH).	Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dunn SR, 2006, J MOL EVOL, V63, P95, DOI 10.1007/s00239-005-0236-7; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; Jiang M, 2009, AM J PHYSIOL-RENAL, V296, pF983, DOI 10.1152/ajprenal.90579.2008; Kagawa S, 2001, CANCER RES, V61, P3330; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee EF, 2008, J CELL BIOL, V180, P341, DOI 10.1083/jcb.200708096; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152; Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007; Theodorakis P, 2002, CANCER RES, V62, P3373; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zmasek CM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r226; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	35	88	89	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3177	3189		10.1038/onc.2011.497	http://dx.doi.org/10.1038/onc.2011.497			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22056880	Green Accepted			2022-12-17	WOS:000305934400006
J	Werner, H				Werner, H.			Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer	ONCOGENE			English	Review						insulin-like growth factors; IGF; IGF-1 receptor; tumor suppressors; p53; BRCA1	FACTOR-I RECEPTOR; ROUND-CELL TUMOR; TRANSCRIPTION FACTOR SP1; VON-HIPPEL-LINDAU; GENE-EXPRESSION; IGF-I; PROSTATE-CANCER; BREAST-CANCER; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; DIFFERENTIAL REGULATION	The insulin-like growth factor (IGF) axis mediates growth, differentiation and developmental processes, and is also involved in control of metabolic activities. Deregulation of IGF axis expression and action is linked to a number of pathologies, ranging from metabolic disorders to growth deficits and cancer development. Activation of the IGF signaling pathway is a crucial prerequisite for malignant transformation. In addition, overexpression of the IGF-1 receptor (IGF-1R) constitutes a typical hallmark of most types of cancer. A series of tumor suppressors have been identified whose mechanisms of action involve transcriptional suppression of the IGF-1R gene. These tumor suppressors include the p53/p63/p73 family, breast cancer gene-1, von-Hippel Lindau protein, Wilms' tumor-1 and others. Comprehensive analyses have identified a complex bidirectional interplay between the IGF and tumor-suppressor signaling pathways. These interactions are of major importance in terms of cancer development and may also predict responsiveness to IGF-1R-targeted therapies. Furthermore, the insulin/IGF system has a pivotal role in the regulation of cancer cell metabolism. Deregulation of IGF axis components by mutated tumor-suppressor proteins may lead to metabolic perturbations, with ensuing pathological consequences. Oncogene (2012) 31, 2703-2714; doi: 10.1038/onc.2011.447; published online 3 October 2011	Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Werner, H (corresponding author), Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel.	hwerner@post.tau.ac.il			Israel Science Foundation; Israel Cancer Association; Insulin-Dependent Diabetes Trust (IDDT, UK); Israel Cancer Research Fund (ICRF, New York and Montreal); US-Israel Binational Science Foundation	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Insulin-Dependent Diabetes Trust (IDDT, UK); Israel Cancer Research Fund (ICRF, New York and Montreal); US-Israel Binational Science Foundation(US-Israel Binational Science Foundation)	Work in the laboratory of HW is supported by grants from the Israel Science Foundation, Israel Cancer Association, Insulin-Dependent Diabetes Trust (IDDT, UK), Israel Cancer Research Fund (ICRF, New York and Montreal) and US-Israel Binational Science Foundation.	Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6; Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Aylon Y, 2011, CURR OPIN GENET DEV, V21, P86, DOI 10.1016/j.gde.2010.10.002; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Bentov Itay, 2004, Pediatr Endocrinol Rev, V1, P352; Bentov I, 2008, ENDOCRINOLOGY, V149, P1890, DOI 10.1210/en.2007-0844; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-306; Bruchim I, 2009, EXPERT OPIN THER TAR, V13, P1179, DOI 10.1517/14728220903201702; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; Dossus L, 2008, BEST PRACT RES CL EN, V22, P551, DOI 10.1016/j.beem.2008.08.003; ESHET R, 1993, J MOL ENDOCRINOL, V10, P115, DOI 10.1677/jme.0.0100115; Finkeltov I, 2002, ONCOGENE, V21, P1890, DOI 10.1038/sj.onc.1205042; Gerald WL, 2005, SEMIN CANCER BIOL, V15, P197, DOI 10.1016/j.semcancer.2005.01.005; Gerald WL, 1998, J CLIN ONCOL, V16, P3028, DOI 10.1200/JCO.1998.16.9.3028; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1989, P NATL ACAD SCI USA, V86, P2868, DOI 10.1073/pnas.86.8.2868; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Happerfield LC, 1997, J PATHOL, V183, P412; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hellawell GO, 2002, CANCER RES, V62, P2942; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Idelman G, 2003, J BIOL CHEM, V278, P3474, DOI 10.1074/jbc.M211606200; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Kim SO, 1996, CANCER RES, V56, P3831; Klammt J, 2011, BEST PRACT RES CL EN, V25, P191, DOI 10.1016/j.beem.2010.09.012; Klammt J, 2008, TRENDS ENDOCRIN MET, V19, P197, DOI 10.1016/j.tem.2008.03.003; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; Kruis T, 2010, J CLIN ENDOCR METAB, V95, P1137, DOI 10.1210/jc.2009-1433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Laron Z, 2004, EUR J ENDOCRINOL, V151, P103, DOI 10.1530/eje.0.1510103; Laron Z, 2004, J CLIN ENDOCR METAB, V89, P1031, DOI 10.1210/jc.2003-031033; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LeRoith D, 2007, NAT CLIN PRACT ENDOC, V3, P302, DOI 10.1038/ncpendmet0427; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040; Maor S, 2007, HORM METAB RES, V39, P179, DOI 10.1055/s-2007-970415; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Maor S, 2007, CANCER LETT, V257, P236, DOI 10.1016/j.canlet.2007.07.019; Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nana-Sinkam SP, 2011, TRANSL RES, V157, P216, DOI 10.1016/j.trsl.2011.01.013; Narod SA, 2010, NAT REV CLIN ONCOL, V7, P702, DOI 10.1038/nrclinonc.2010.166; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; REISS K, 1991, CANCER RES, V51, P5997; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; SALMON WD, 1957, J LAB CLIN MED, V49, P825; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sarfstein Rive, 2010, Cancers (Basel), V2, P233, DOI 10.3390/cancers2020233; Schayek H, 2010, MOL CELL ENDOCRINOL, V323, P239, DOI 10.1016/j.mce.2010.04.017; Schayek H, 2010, GROWTH HORM IGF RES, V20, P68, DOI 10.1016/j.ghir.2009.08.001; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Scotlandi K, 2008, CURR OPIN ONCOL, V20, P419, DOI 10.1097/CCO.0b013e328302edab; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V1, P90; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Steuerman R, 2011, EUR J ENDOCRINOL, V164, P485, DOI 10.1530/EJE-10-0859; Tang D, 2011, ONCOGENE, V30, P1851, DOI 10.1038/onc.2010.573; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; Ungewitter E, 2010, GENE DEV, V24, P2408, DOI 10.1101/gad.1987810; Voskuil DW, 2004, BREAST CANCER RES TR, V84, P225, DOI 10.1023/B:BREA.0000019954.59130.d3; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wallborn T, 2010, J CLIN ENDOCR METAB, V95, P2316, DOI 10.1210/jc.2009-2404; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; WERNER H, 1995, MOL CELL BIOL, V15, P3516; Werner H, 2003, GENE CHROMOSOME CANC, V36, P113, DOI 10.1002/gcc.10157; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2007, CANCER LETT, V247, P84, DOI 10.1016/j.canlet.2006.03.027; Werner Haim, 2009, Pediatr Endocrinol Rev, V7, P2; Werner H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-2; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Wiesener MS, 2009, J MOL MED-JMM, V87, P871, DOI 10.1007/s00109-009-0504-x; Yakar S, 2005, J Endocrinol Invest, V28, P19; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yerushalmi R., 2011, BREAST CANC RES TREA; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zalts Harel, 2011, Pediatr Endocrinol Rev, V8, P354; Zhang LJ, 1996, CANCER RES, V56, P1367; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	114	88	92	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2703	2714		10.1038/onc.2011.447	http://dx.doi.org/10.1038/onc.2011.447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963847				2022-12-17	WOS:000304769000001
J	Zhang, Y; Cheng, Y; Ren, X; Zhang, L; Yap, KL; Wu, H; Patel, R; Liu, D; Qin, ZH; Shih, IM; Yang, JM				Zhang, Y.; Cheng, Y.; Ren, X.; Zhang, L.; Yap, K. L.; Wu, H.; Patel, R.; Liu, D.; Qin, Z-H; Shih, I-M; Yang, J-M			NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response	ONCOGENE			English	Article						NAC1; autophagy; apoptosis; HMGB1; cisplatin; ovarian cancer	EMBRYONIC STEM-CELLS; HMGB1 RELEASE; REGULATES AUTOPHAGY; MEDIATED AUTOPHAGY; PROTEIN NAC-1; TUMOR-CELLS; RESISTANCE; CARCINOMA; APOPTOSIS; PLURIPOTENCY	Nucleus accumbens-1 (NAC1), a nuclear factor belonging to the BTB/POZ gene family, is known to have important roles in proliferation and growth of tumor cells and in chemotherapy resistance. Yet, the mechanisms underlying how NAC1 contributes to drug resistance remain largely unclear. We report here that autophagy was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused an activation of autophagy in ovarian cancer cell lines, A2780, OVCAR3 and SKOV3. We further demonstrated that knockdown of NAC1 by RNA interference or inactivation of NAC1 by inducing the expression of a NAC1 deletion mutant that contains only the BTB/POZ domain significantly inhibited the cisplatin-induced autophagy, resulting in increased cisplatin cytotoxicity. Moreover, inhibition of autophagy and sensitization to cisplatin by NAC1 knockdown or inactivation were accompanied by induction of apoptosis. To confirm that the sensitizing effect of NAC1 inhibition on the cytotoxicity of cisplatin was attributed to suppression of autophagy, we assessed the effects of the autophagy inhibitors 3-methyladenosine and chloroquine, and small interfering RNAs (siRNAs) targeting beclin 1 or Atg5 on the cytotoxicity of cisplatin. Treatment with 3-methyladenosine, chloroquine or beclin 1 and Atg5-targeted siRNA also enhanced the sensitivity of SKOV3, A2780 and OVCAR3 cells to cisplatin, indicating that suppression of autophagy indeed renders tumor cells more sensitive to cisplatin. Regulation of autophagy by NAC1 was mediated by the high-mobility group box 1 (HMGB1), as the functional status of NAC1 was associated with the expression, translocation and release of HMGB1. The results of our study not only revealed a new mechanism determining cisplatin sensitivity but also identified NAC1 as a novel regulator of autophagy. Thus, the NAC1-mediated autophagy may be exploited as a new target for enhancing the efficacy of cisplatin against ovarian cancer and other types of malignancies. Oncogene (2012) 31, 1055-1064; doi:10.1038/onc.2011.290; published online 11 July 2011	[Zhang, Y.; Cheng, Y.; Ren, X.; Liu, D.; Yang, J-M] Penn State Univ, Dept Pharmacol, Penn State Hershey Canc Inst, Coll Med, Hershey, PA 17033 USA; [Zhang, Y.; Cheng, Y.; Ren, X.; Liu, D.; Yang, J-M] Penn State Univ Hosp, Milton S Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Y.; Zhang, L.; Qin, Z-H; Yang, J-M] Soochow Univ, Sch Pharm, Dept Pharmacol, Suzhou, Jiangsu, Peoples R China; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD USA; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Obstet Gynecol, Baltimore, MD USA; [Wu, H.; Patel, R.] Univ Med & Dent New Jersey, Dept Pathol, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Soochow University - China; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Yang, JM (corresponding author), Penn State Univ, Dept Pharmacol, Penn State Hershey Canc Inst, Coll Med, CH74,500 Univ Dr,POB 850, Hershey, PA 17033 USA.	shihie@yahoo.com; juy16@psu.edu	sdsd, shihieih/ABE-6190-2020	Yap, Kai Lee/0000-0003-4496-5464	US Public Health Service [R01CA135038, RO1CA103937]; Penn State College of Medicine; NATIONAL CANCER INSTITUTE [R01CA135038, R01CA103937] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Penn State College of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the US Public Health Service (R01CA135038 and RO1CA103937) and the Penn State College of Medicine	Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930; Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715; Davidson B, 2007, HUM PATHOL, V38, P1030, DOI 10.1016/j.humpath.2006.12.009; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Fanzani A, 2011, TOXICOL APPL PHARM, V250, P312, DOI 10.1016/j.taap.2010.11.003; Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Kaushal GP, 2008, AUTOPHAGY, V4, P710, DOI 10.4161/auto.6309; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Liu D., 2009, MED ONCOL, V28, P105; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Nagatani G, 2001, CANCER RES, V61, P1592; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Sharma A, 2009, DNA CELL BIOL, V28, P311, DOI 10.1089/dna.2009.0851; Sun Y, 2010, CANCER LETT, V294, P204, DOI 10.1016/j.canlet.2010.02.001; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143; Thorburn J, 2009, AUTOPHAGY, V5, P247, DOI 10.4161/auto.5.2.7552; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wei M, 2003, J BIOL CHEM, V278, P1769, DOI 10.1074/jbc.M210562200; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872; Yeasmin S, 2008, CLIN CANCER RES, V14, P1686, DOI 10.1158/1078-0432.CCR-07-4085	32	88	93	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1055	1064		10.1038/onc.2011.290	http://dx.doi.org/10.1038/onc.2011.290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743489	Green Accepted			2022-12-17	WOS:000300709700011
J	Lo, SS; Hung, PS; Chen, JH; Tu, HF; Fang, WL; Chen, CY; Chen, WT; Gong, NR; Wu, CW				Lo, S-S; Hung, P-S; Chen, J-H; Tu, H-F; Fang, W-L; Chen, C-Y; Chen, W-T; Gong, N-R; Wu, C-W			Overexpression of miR-370 and downregulation of its novel target TGF beta-RII contribute to the progression of gastric carcinoma	ONCOGENE			English	Article						carcinoma; microRNA; miR-370; plasma; stomach; TGF beta-RII	MICRORNA EXPRESSION; CANCER; SIGNATURE; GROWTH; RNA; SUPPRESSION; DIAGNOSIS; PATTERNS; PATHWAY; TUMORS	MicroRNAs (miRNAs) are endogenous non-coding RNAs that are known to be involved in the pathogenesis of tumors. Gastric carcinoma (GC) is a common malignancy worldwide. The aim of this study was the identification of the expression signature and functional roles of aberrant miRNAs in GC. Initial screening established a profile of aberrantly expressed miRNAs in tumors. miR-370 was confirmed to be overexpressed in GC tissues. Higher expression of miR-370 in GC tissues was associated with more advanced nodal metastasis and a higher clinical stage compared with controls. In addition, significantly higher level of miR-370 was noted in the plasma of GC patients compared with controls. Patients having more invasive or advanced tumors also exhibited a higher plasma level of miR-370. In vitro assays indicated that exogenous miR-370 expression enhanced the oncogenic potential of GC cells. The AGS-GFPM2 cells with exogenous miR-370 expression also exhibited enhanced abdominal metastatic dissemination in nude mice. Reporter assays confirmed that miR-370 targeted predicted sites in 3'UTR of transforming growth factor-beta receptor II (TGF beta-RII) gene. The exogenous miR-370 expression decreased TGF beta-RII expression and the phosphorylation of Smad3 elicited by TGF beta 1. The TGF beta 1-mediated repression in cell migration was reverted by exogenous miR-370 expression. A reverse correlation between miR-370 and TGF beta-RII expression was noted in GC tissues. This study concludes that miR-370 is a miRNA that is associated with GC progression by downregulating TGF beta-RII. The miRNA expression profile described in this study should contribute to future studies on the role of miRNAs in GC. Oncogene (2012) 31, 226-237; doi:10.1038/onc.2011.226; published online 13 June 2011	[Lo, S-S; Chen, C-Y; Chen, W-T] Natl Yang Ming Univ Hosp, Dept Surg, Yi Lan 26042, Taiwan; [Lo, S-S; Fang, W-L; Chen, C-Y; Chen, W-T; Wu, C-W] Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan; [Hung, P-S; Tu, H-F; Gong, N-R] Natl Yang Ming Univ Hosp, Dept Dent, Yi Lan 26042, Taiwan; [Chen, J-H; Fang, W-L; Wu, C-W] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Lo, SS (corresponding author), Natl Yang Ming Univ Hosp, Dept Surg, 152 Shin Min Rd, Yi Lan 26042, Taiwan.	sslo@ymuh.ym.edu.tw	Xie, Huangming/B-2260-2012		National Science Council [96-2314-B-010-055-MY3]; National Yang-Ming University Hospital [RD 2008-001]	National Science Council(Ministry of Science and Technology, Taiwan); National Yang-Ming University Hospital	We acknowledge helps from Dr Shu-Chun Lin, Dr Kuo-Wei Chang, Ms Yu-Pin Chen, Mr Shi-Wen Chen and Mr Chung-Sheng Chou. This study was supported by grant 96-2314-B-010-055-MY3 from National Science Council, and National Yang-Ming University Hospital Grant RD 2008-001.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Lin HL, 2007, INT J CANCER, V121, P2547, DOI 10.1002/ijc.22963; Hsu KW, 2009, MOL BIOL CELL, V20, P5127, DOI 10.1091/mbc.E09-05-0386; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Liu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000804; Lo SS, 2009, SURGERY, V145, P280, DOI 10.1016/j.surg.2008.11.001; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; van den Brink GR, 2007, CANCER CELL, V11, P109, DOI 10.1016/j.ccr.2007.01.003; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wu CW, 2006, LANCET ONCOL, V7, P309, DOI 10.1016/S1470-2045(06)70623-4; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	43	88	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					226	237		10.1038/onc.2011.226	http://dx.doi.org/10.1038/onc.2011.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666718				2022-12-17	WOS:000299307400008
J	Pavet, V; Portal, MM; Moulin, JC; Herbrecht, R; Gronemeyer, H				Pavet, V.; Portal, M. M.; Moulin, J. C.; Herbrecht, R.; Gronemeyer, H.			Towards novel paradigms for cancer therapy	ONCOGENE			English	Review						apoptosis; TRAIL/Apo2L/TNFSF10; epigenetic drug; tumor-initiating cell; dependence receptor; non-coding RNA	APOPTOSIS-INDUCING LIGAND; ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR-RECEPTOR; METASTATIC COLORECTAL-CANCER; SESQUITERPENE LACTONE PARTHENOLIDE; HISTONE DEACETYLASE INHIBITORS; AGONISTIC MONOCLONAL-ANTIBODY; ACUTE MYELOGENOUS LEUKEMIA; TRAIL-INDUCED APOPTOSIS	Cancer is a complex progressive multistep disorder that results from the accumulation of genetic and epigenetic abnormalities, which lead to the transformation of normal cells into malignant derivatives. Despite enormous progress in the understanding of cancer biology including the decryption of multiple regulatory networks governing cell growth and death, and despite the possibility of analyzing (epi)genetic deregulation at the genome-wide scale, cancer-targeted therapy is still the exception. In fact, to date there are still far too few examples of therapies leading to cure; treatment-derived toxicity is a major issue, and cancer remains to be one of the largest causes of death worldwide. The purpose of this review is to discuss the state of the art of cancer therapy with respect to the key issue of any treatment, namely its target selectivity. Therefore, we recapitulate and discuss current concepts and therapies targeting tumor-specific features, including oncofusion proteins, aberrant kinase activities and epigenetic tumor makeup. We analyze strategies designed to induce tumor-selective death such as the use of oncolytic virus, tumoricidal proteins (NS1, Eorf4, apoptin, HAMLET (human alpha-lactalbumin made lethal to tumor cells)) and activation of signaling pathways involved in tumor surveillance. We emphasize the potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, an essential component of the evolutionary developed defense systems that eradicate malignant cells. Finally, we discuss the necessity of targeting tumor-initiating cells (TICs) to avoid relapse and increase the chances of complete remission, and describe emerging concepts that might provide novel avenues for cancer therapy. Oncogene (2011) 30, 1-20; doi: 10.1038/onc.2010.460; published online 11 October 2010	[Pavet, V.; Portal, M. M.; Moulin, J. C.; Gronemeyer, H.] IGBMC, Dept Canc Biol, F-67404 Illkirch Graffenstaden, Alsace, France; [Moulin, J. C.; Herbrecht, R.] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pavet, V (corresponding author), IGBMC, Dept Canc Biol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, Alsace, France.	vpavet@igbmc.fr; hg@igbmc.fr	Gronemeyer, Hinrich/AAH-5575-2019; Herbrecht, Raoul/D-3471-2013; Gronemeyer, Hinrich/H-7002-2016; Herbrecht, Raoul/AAT-1763-2021; Gronemeyer, Hinrich/G-6240-2011; Herbrecht, Raoul/GVU-1333-2022	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Herbrecht, Raoul/0000-0002-9381-4876; Gronemeyer, Hinrich/0000-0001-9454-2449; PORTAL, Maximiliano/0000-0002-2884-6900	Agence Nationale de la Recherche [ANR-07-PCVI-0031-01]; European Commission [LSHC-CT-2005-518417, HEALTH-F4-2007-200767]; La Ligue Contre le Cancer; Fondation pour la Recherche Medicale	Agence Nationale de la Recherche(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); La Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Work in our laboratory is supported by Agence Nationale de la Recherche (ANR-07-PCVI-0031-01), the European Commission (LSHC-CT-2005-518417 'Epitron,' HEALTH-F4-2007-200767 'Apo-Sys,' H Gronemeyer laboratory), La Ligue Contre le Cancer (H Gronemeyer, laboratoire labellisee; MMP post-doctoral fellow) and Fondation pour la Recherche Medicale (JCM master fellow).	Aits S, 2009, INT J CANCER, V124, P1008, DOI 10.1002/ijc.24076; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Backendorf C, 2008, ANNU REV PHARMACOL, V48, P143, DOI 10.1146/annurev.pharmtox.48.121806.154910; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Belyanskaya LL, 2008, LUNG CANCER, V60, P355, DOI 10.1016/j.lungcan.2007.11.005; Berdis AJ, 2008, BIOCHEMISTRY-US, V47, P8253, DOI 10.1021/bi801179f; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bianco R, 2007, INT J BIOCHEM CELL B, V39, P1416, DOI 10.1016/j.biocel.2007.05.008; Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706; Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707; Castets M, 2009, DEV CELL, V16, P614, DOI 10.1016/j.devcel.2009.02.006; Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cortes J, 2007, CANCER, V110, P1295, DOI 10.1002/cncr.22901; Costa FF, 2008, GENE, V410, P9, DOI 10.1016/j.gene.2007.12.008; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Dorer DE, 2009, ADV DRUG DELIVER REV, V61, P554, DOI 10.1016/j.addr.2009.03.013; Druker B, 2001, SEMIN HEMATOL, V38, P9, DOI 10.1016/S0037-1963(01)90112-X; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Eager R, 2008, EXPERT OPIN BIOL TH, V8, P1633, DOI [10.1517/14712598.8.10.1633, 10.1517/14712598.8.10.1633 ]; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ekmekcioglu S, 2008, CYTOKINE, V43, P34, DOI 10.1016/j.cyto.2008.04.010; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; Emdad L, 2009, CANCER BIOL THER, V8, P402, DOI 10.4161/cbt.8.5.7581; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flygare JA, 2010, EXPERT OPIN THER PAT, V20, P251, DOI 10.1517/13543770903567077; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Fukuhara H, 2005, CLIN CANCER RES, V11, P7886, DOI 10.1158/1078-0432.CCR-05-1090; Fukuhara H, 2010, INT J UROL, V17, P20, DOI 10.1111/j.1442-2042.2009.02383.x; Fulda S, 2009, LEUKEMIA, V23, P467, DOI 10.1038/leu.2008.329; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016/j.chembiol.2007.06.007; Gopalan B, 2005, CANCER RES, V65, P3017, DOI 10.1158/0008-5472.CAN-04-3758; Granchi C, 2010, CURR MED CHEM, V17, P672, DOI 10.2174/092986710790416263; Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; Gustafsson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005229; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hallgren O, 2008, ADV EXP MED BIOL, V606, P217, DOI 10.1007/978-0-387-74087-4_8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hasegawa H, 2005, BRIT J HAEMATOL, V128, P253, DOI 10.1111/j.1365-2141.2004.05289.x; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Idogawa M, 2009, CLIN CANCER RES, V15, P3725, DOI 10.1158/1078-0432.CCR-08-2396; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Jiang HP, 1995, ONCOGENE, V11, P2477; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kantarjian HM, 2006, INT J HEMATOL, V83, P289, DOI 10.1532/IJH97.06024; Kantarjian HM, 2006, ANN INTERN MED, V145, P913, DOI 10.7326/0003-4819-145-12-200612190-00008; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasuya H, 2005, CANCER GENE THER, V12, P725, DOI 10.1038/sj.cgt.7700830; Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002/pros.20931; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kogan SC, 2009, CANCER CELL, V15, P7, DOI 10.1016/j.ccr.2008.12.012; Kohler C, 1999, EXP CELL RES, V249, P260, DOI 10.1006/excr.1999.4472; Landry MC, 2006, B CANCER, V93, P921; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; le Coutre P, 2008, BLOOD, V111, P1834, DOI 10.1182/blood-2007-04-083196; Lebedeva IV, 2007, INT J ONCOL, V31, P985; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Leverkus M, 2000, CANCER RES, V60, P553; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Li SY, 2009, J VIROL, V83, P8340, DOI 10.1128/JVI.00711-09; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TC, 2008, GENE THER, V15, P877, DOI 10.1038/gt.2008.72; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lurje G, 2008, CLIN CANCER RES, V14, P7884, DOI 10.1158/1078-0432.CCR-07-5165; Maddika S, 2006, CANCER BIOL THER, V5, P10, DOI 10.4161/cbt.5.1.2400; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; MASUI H, 1986, CANCER RES, V46, P5592; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mitrus I, 2005, ANTICANCER RES, V25, P1087; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Morel J, 2005, J BIOL CHEM, V280, P15709, DOI 10.1074/jbc.M414469200; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Naka T, 2002, CANCER RES, V62, P5800; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Noteborn MHM, 2009, EUR J PHARMACOL, V625, P165, DOI 10.1016/j.ejphar.2009.06.068; Nuesch JPF, 2008, CANCER BIOL THER, V7, P1376; Nuesch JPF, 2007, P NATL ACAD SCI USA, V104, P12482, DOI 10.1073/pnas.0705533104; Nuesch JPF, 2006, J VIROL, V80, P4729, DOI 10.1128/JVI.80.10.4729-4739.2006; O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Ozoren N, 2000, CANCER RES, V60, P6259; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pavet V, 2010, CANCER RES, V70, P1101, DOI 10.1158/0008-5472.CAN-09-2889; Peng DJ, 2007, CANCER GENE THER, V14, P66, DOI 10.1038/sj.cgt.7700985; Persson H, 2009, NAT CELL BIOL, V11, P1268, DOI 10.1038/ncb1972; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rohn JL, 2004, APOPTOSIS, V9, P315, DOI 10.1023/B:APPT.0000025808.48885.9c; Sarkar D, 2008, CANCER BIOL THER, V7, P109, DOI 10.4161/cbt.7.1.5693; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shankaranarayanan P, 2009, CANCER CELL, V16, P220, DOI 10.1016/j.ccr.2009.07.029; Shanker M, 2007, CANCER LETT, V254, P217, DOI 10.1016/j.canlet.2007.03.004; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shipley JL, 2009, EXP HEMATOL, V37, P649, DOI 10.1016/j.exphem.2009.04.002; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steele AJ, 2006, LEUKEMIA, V20, P1073, DOI 10.1038/sj.leu.2404230; Sun J, 2009, INT J CANCER, V124, P2973, DOI 10.1002/ijc.24279; Sun Y, 2008, CANCER BIOL THER, V7, P1420; Svanborg C, 2003, ADV CANCER RES, V88, P1; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thibert C, 2010, CELL CYCLE, V9, P2085, DOI 10.4161/cc.9.11.11809; Thorburn A, 2008, DRUG RESIST UPDATE, V11, P17, DOI 10.1016/j.drup.2008.02.001; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P1062, DOI 10.1080/10428190500463932; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vilimanovich U, 2008, CELL MOL LIFE SCI, V65, P814, DOI 10.1007/s00018-008-7513-8; Volkmann X, 2007, HEPATOLOGY, V46, P1498, DOI 10.1002/hep.21846; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang M, 2005, IMMUNOLOGY, V114, P166, DOI 10.1111/j.1365-2567.2005.02094.x; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021; Zhenchuk A, 2009, BIOCHEM PHARMACOL, V78, P1351, DOI 10.1016/j.bcp.2009.06.094; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	209	88	93	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					1	20		10.1038/onc.2010.460	http://dx.doi.org/10.1038/onc.2010.460			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20935674				2022-12-17	WOS:000285959300001
J	Aziz, MH; Hafeez, BB; Sand, JM; Pierce, DB; Aziz, SW; Dreckschmidt, NE; Verma, AK				Aziz, M. H.; Hafeez, B. B.; Sand, J. M.; Pierce, D. B.; Aziz, S. W.; Dreckschmidt, N. E.; Verma, A. K.			Protein kinase C epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2)	ONCOGENE			English	Article						PKC epsilon; Stat3; human cancer	INDUCED CUTANEOUS DAMAGE; EPIDERMAL JB6 CELLS; PROSTATE-CANCER; TRANSGENIC MICE; BREAST-CANCER; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; STAT3; CARCINOMA; ACTIVATION	Protein kinase C epsilon (PKC epsilon), a novel calcium-independent PKC isoform, has been shown to be a transforming oncogene. PKC epsilon-mediated oncogenic activity is linked to its ability to promote cell survival. However, the mechanisms by which PKC epsilon signals cell survival remain elusive. We found that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, is a protein partner of PKC epsilon. Stat3 has two conserved amino-acid (Tyr705 and Ser727) residues, which are phosphorylated during Stat3 activation. PKC epsilon interacts with Stat3 alpha isoform, which has Ser727, and not with Stat3 beta isoform, which lacks Ser727. PKC epsilon-Stat3 interaction and Stat3-Ser727 phosphorylation was initially observed during induction of squamous cell carcinomas and in prostate cancer. Now we present that (1) PKC epsilon physically interacts with Stat3 alpha isoform in various human cancer cells: skin melanomas (MeWo and WM266-4), gliomas (T98G and MO59K), bladder (RT-4 and UM-UC-3), colon (Caco-2), lung (H1650), pancreatic (PANC-1), and breast (MCF-7 and MDA: MB-231); (2) inhibition of PKC epsilon expression using specific siRNA inhibits Stat3Ser727 phosphorylation, Stat3-DNA binding, Stat3-regulated gene expression as well as cell invasion; and (3) PKC epsilon mediates Stat3Ser727 phosphorylation through integration with the MAPK cascade (RAF-1, MEK1/2, and ERK1/2). The results indicate that PKC epsilon-mediated Stat3Ser727 phosphorylation is essential for constitutive activation of Stat3 and cell invasion in various human cancers. Oncogene (2010) 29, 3100-3109; doi: 10.1038/onc.2010.63; published online 15 March 2010	[Aziz, M. H.; Hafeez, B. B.; Sand, J. M.; Pierce, D. B.; Aziz, S. W.; Dreckschmidt, N. E.; Verma, A. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Paul P Carbone Comprehens Canc,WIMR, Madison, WI 53792 USA; [Sand, J. M.] Wisconsin Inst Med Res, Mol & Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Verma, AK (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Paul P Carbone Comprehens Canc,WIMR, Room 7103,1111 Highland Ave, Madison, WI 53792 USA.	akverma@facstaff.wisc.edu			DOD [W81XWH]; NIH [CA35368]; NATIONAL CANCER INSTITUTE [R01CA035368] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in parts by DOD Grant W81XWH and NIH Grant CA35368 to AKV.	Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Aziz MH, 2007, MOL CARCINOGEN, V46, P646, DOI 10.1002/mc.20356; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Aziz MH, 2007, CANCER RES, V67, P1385, DOI 10.1158/0008-5472.CAN-06-3350; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Burger AM, 2005, CANCER RES, V65, P10401, DOI 10.1158/0008-5472.CAN-05-2103; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chen D, 2007, J BIOL CHEM, V282, P33776, DOI 10.1074/jbc.M703320200; Christine R, 2005, CANCER RES, V65, P195; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jansen AP, 2001, CANCER RES, V61, P808; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Li L, 2004, BIOCHEM BIOPH RES CO, V322, P1005, DOI 10.1016/j.bbrc.2004.08.014; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nikitakis NG, 2004, CURR CANCER DRUG TAR, V4, P637, DOI 10.2174/1568009043332736; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Reddig PJ, 2000, CANCER RES, V60, P595; Stephanou A, 2005, GROWTH FACTORS, V23, P177, DOI 10.1080/08977190500178745; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Wheeler DL, 2005, PHOTOCHEM PHOTOBIOL, V81, P9, DOI 10.1562/2004-08-12-RA-271.1; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Wheeler DL, 2003, CANCER RES, V63, P6547; Wu DQ, 2004, ONCOGENE, V23, P8659, DOI 10.1038/sj.onc.1207900; Wu DQ, 2002, CANCER RES, V62, P2423; Xuan YT, 2005, CIRCULATION, V112, P1971, DOI 10.1161/CIRCULATIONAHA.105.561522; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zykova TA, 2005, CARCINOGENESIS, V26, P331, DOI 10.1093/carcin/bgh334	43	88	89	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3100	3109		10.1038/onc.2010.63	http://dx.doi.org/10.1038/onc.2010.63			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228845	Green Accepted			2022-12-17	WOS:000278133100007
J	Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Kohle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I				Gramatzki, D.; Pantazis, G.; Schittenhelm, J.; Tabatabai, G.; Koehle, C.; Wick, W.; Schwarz, M.; Weller, M.; Tritschler, I.			Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells	ONCOGENE			English	Article						AhR; TGF-beta; Smad; LTBP-1; gliomas	GROWTH-FACTOR-BETA; MOUSE EMBRYO FIBROBLASTS; DIOXIN RECEPTOR; GLIOMA-CELLS; IN-VIVO; EXPRESSION; GENE; BINDING; MICE; APOPTOSIS	The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and transforming growth factor-beta (TGF-beta) signaling. As TGF-beta is an important mediator of the malignant phenotype of human gliomas, we studied AhR expression and function in glioma cells. AhR was not only expressed in glioma cells in vitro, but was also detected in human gliomas in vivo by immunohistochemistry, with a predominantly nuclear staining in glioblastomas. The AhR agonist, 3-methylcholanthrene, induced AhR nuclear translocation and upregulated mRNA levels of the AhR target gene, cytochrome P450 1A1 (CYP1A1). Conversely, pharmacological inhibition of AhR using the novel AhR antagonist, CH-223191, or AhR gene silencing using small interfering RNA showed that constitutive AhR activity positively controls TGF-beta 1, TGF-beta 2 and latent TGF-beta-binding protein-1 protein levels in malignant glioma cells. Moreover, antagonism of AhR reduced clonogenic survival and invasiveness of glioma cells. In contrast, AhR regulates TGF-beta signaling negatively in non-neoplastic astrocytes. Thus, the pathogenesis of glioma formation may involve altered AhR regulation of the TGF-beta/Smad pathway, and AhR may represent a promising target for the treatment of human malignant gliomas and other diseases associated with pathological TGF-beta activity. Oncogene (2009) 28, 2593-2605; doi: 10.1038/onc.2009.104; published online 25 May 2009	[Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Mol Neurooncol Lab, Dept Gen Neurol, Tubingen, Germany; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Pantazis, G.; Schittenhelm, J.] Univ Tubingen, Inst Brain Res, Dept Neuropathol, D-7400 Tubingen, Germany; [Koehle, C.; Schwarz, M.] Univ Tubingen, Inst Pharmacol & Toxicol, Dept Toxicol, Tubingen, Germany; [Wick, W.] Univ Heidelberg, Dept Neurooncol, Heidelberg, Germany	University of Zurich; University Zurich Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ruprecht Karls University Heidelberg	Weller, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	michael.weller@usz.ch	Tabatabai, Ghazaleh/A-6365-2015; Wick, Wolfgang/AAA-2545-2020	Tabatabai, Ghazaleh/0000-0003-3702-923X; Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Tabatabai, Ghazaleh/0000-0002-3542-8782	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)(Swiss National Science Foundation (SNSF))	We are indebted to Dr Gabrielle Haas for support with confocal microscopy. This study was supported by grants from the Jacqueline Seroussi Memorial Foundation for Cancer Research and the Swiss National Fund (NCCR Neuro) to MW.	Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Carraro G, 2005, MOL CELL PROBE, V19, P181, DOI 10.1016/j.mcp.2004.11.004; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; Gomez-Duran A, 2006, J CELL BIOCHEM, V97, P380, DOI 10.1002/jcb.20637; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAARMANNSTEMMAN T, 2008, BIOCHEM PHARMACOL, V77, P508; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; HUANG SX, 2004, COMPUTER INTEGRATED, V1, P1; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Kim SH, 2006, MOL PHARMACOL, V69, P1871, DOI 10.1124/mol.105.021832; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier MSV, 2007, NEUROTOXICOLOGY, V28, P594, DOI 10.1016/j.neuro.2007.01.002; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; MASON GGF, 1994, J BIOL CHEM, V269, P4438; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2008, BIOCHEM BIOPH RES CO, V370, P541, DOI 10.1016/j.bbrc.2008.03.054; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Schittenhelm J, 2008, BRAIN PATHOL, V18, P344, DOI 10.1111/j.1750-3639.2008.00127.x; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; TRITSCHLER I, 2009, INT J CANC IN PRESS; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024	47	88	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2593	2605		10.1038/onc.2009.104	http://dx.doi.org/10.1038/onc.2009.104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465936				2022-12-17	WOS:000268058900005
J	Naidu, SR; Love, IM; Imbalzano, AN; Grossman, SR; Androphy, EJ				Naidu, S. R.; Love, I. M.; Imbalzano, A. N.; Grossman, S. R.; Androphy, E. J.			The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells	ONCOGENE			English	Article						chromatin remodeling; p53; proteasomal degradation	CREB-BINDING-PROTEIN; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; RETINOBLASTOMA PROTEIN; CYCLE PROGRESSION; GENE ACTIVATION; RNAI SCREEN; STEM-CELLS; IN-VIVO	The tumor suppressor p53 preserves genome integrity by inducing transcription of genes controlling growth arrest or apoptosis. Transcriptional activation involves nucleosomal perturbation by chromatin remodeling enzymes. Mammalian SWI/SNF remodeling complexes incorporate either the Brahma-related gene 1(BRG1) or Brahma (Brm) as the ATPase subunit. The observation that tumor cell lines harboring wild-type p53 specifically maintain expression of BRG1 and that BRG1 complexes with p53 prompted us to examine the role of BRG1 in regulation of p53. Remarkably, RNAi depletion of BRG1, but not Brm, led to the activation of endogenous wild-type p53 and cell senescence. We found a proline-rich region unique to BRG1 was required for binding to the histone acetyl transferase protein, CBP, as well as to p53. Ectopic expression of a proline-rich region deletion mutant BRG1 that is defective for CBP binding inhibited p53 destabilization. Importantly, RNAi knockdown of BRG1 and CBP reduced p53 poly-ubiquitination in vivo. In support of p53 inactivation by the combined activities of BRG1 and CBP, we show that DNA damage signals promoted disassociation of BRG1 from CBP, thereby allowing p53 accumulation. Our data demonstrate a novel function of the evolutionarily conserved chromatin remodeling subunit BRG1, which cooperates with CBP to constrain p53 activity and permit cancer cell proliferation. Oncogene ( 2009) 28, 2492-2501; doi: 10.1038/onc.2009.121; published online 18 May 2009	[Naidu, S. R.; Love, I. M.; Grossman, S. R.; Androphy, E. J.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; [Imbalzano, A. N.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Grossman, S. R.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, 364 Plantation St,LRB 328, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Naidu, Samisubbu/0000-0001-9411-660X; Androphy, Elliot/0000-0002-8104-0703	SRG [R01 CA107532]; ANI [R01 GM56244]; EJA [R01 CA107394]; NATIONAL CANCER INSTITUTE [R01CA107532, R01CA107394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	SRG; ANI; EJA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Marius Pop and Andrew King for CBP and p300 shRNA, Andrew Turnell for GST-CBP fusion constructs, Yuval Bibi Nitzan for comments and assistance with the figures and Neal Silverman for assistance with baculovirus protein production. R01 CA107532 to SRG, R01 GM56244 to ANI and R01 CA107394 to EJA supported this work.	Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hussain MA, 2006, MOL CELL BIOL, V26, P7747, DOI 10.1128/MCB.02353-05; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; LANE DP, 1992, NATURE, V358, P16; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Szutorisz H, 2006, CELL, V127, P1375, DOI 10.1016/j.cell.2006.10.045; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	88	95	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2492	2501		10.1038/onc.2009.121	http://dx.doi.org/10.1038/onc.2009.121			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448667	Green Accepted			2022-12-17	WOS:000267806800002
J	Zhou, J; Huang, W; Tao, R; Ibaragi, S; Lan, F; Ido, Y; Wu, X; Alekseyev, YO; Lenburg, ME; Hu, GF; Luo, Z				Zhou, J.; Huang, W.; Tao, R.; Ibaragi, S.; Lan, F.; Ido, Y.; Wu, X.; Alekseyev, Y. O.; Lenburg, M. E.; Hu, G-F; Luo, Z.			Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells	ONCOGENE			English	Article						AMPK; LKB1; cell proliferation; cell cycle; tumor suppressor	ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHASE; METABOLIC CHECKPOINT; SOMATIC MUTATIONS; DIABETIC-PATIENTS; METFORMIN; LKB1; PHOSPHORYLATION; APOPTOSIS; TUMORIGENESIS	AMP-activated protein kinase (AMPK) serves as a fuel-sensing enzyme that is activated by binding of AMP and subsequent phophorylation by upstream kinases such as the tumor suppressor LKB1, when cells sense an increase in the ratio of AMP to ATP. Acute activation of AMPK stimulates fatty acid oxidation to generate more ATP and simultaneously inhibits ATP-consuming processes including fatty acid and protein syntheses, thereby preserving energy for acute cell-surviving program, whereas chronic activation leads to inhibition of cell growth. The goal of the present study is to explore the mechanisms by which AMPK regulates cell growth. Toward this end, we established stable cell lines by introducing a dominant-negative mutant of AMPK alpha 1 subunit or its shRNA into the prostate cancer C4-2 cells and other cells, or wild type LKB1 into the lung adenocarcinoma A549 and breast MB-MDA-231 cancer cells, both of which lack functional LKB1. Our results showed that the inhibition of AMPK accelerated cell proliferation and promoted malignant behavior such as increased cell migration and anchorage-independent growth. This was associated with decreased G1 population, downregulation of p53 and p21, and upregulation of S6K, IGF-1 and IGF1R. Conversely, treatment of the C4-2 cells with 5-aminoimidazole-4-carboxamide 1-D-ribonucleoside (AICAR), a prototypical AMPK activator, caused opposite changes. In addition, our study using microarray and RT-PCR revealed that AMPK regulated gene expression involved in tumor cell growth and survival. Thus, our study provides novel insights into the mechanisms of AMPK action in cancer cells and presents AMPK as an ideal drug target for cancer therapy. Oncogene (2009) 28, 1993-2002; doi:10.1038/onc.2009.63; published online 6 April 2009	[Zhou, J.; Huang, W.; Luo, Z.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Ibaragi, S.; Alekseyev, Y. O.; Hu, G-F] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Tao, R.; Lan, F.; Ido, Y.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Wu, X.] ADV Biosci LLC, Birmingham, AL USA; [Lenburg, M. E.; Luo, Z.] Boston Univ, Sch Med, Genome Sci Inst, Boston, MA 02118 USA; [Lenburg, M. E.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University; Harvard University; Harvard Medical School; Boston University; Boston University; Boston University	Luo, Z (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,E645, Boston, MA 02118 USA.	zluo@bu.edu	Luo, Zhijun/AAE-9302-2019; Lenburg, Marc/B-8027-2008	Luo, Zhijun/0000-0001-8105-5289; Lenburg, Marc/0000-0002-5760-4708; Ido, Yasuo/0000-0002-3036-9971; Alekseyev, Yuriy/0000-0001-6105-8861	NIH [R01 CA118918, GM 057959]; NATIONAL CANCER INSTITUTE [R01CA118918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project is supported by NIH R01 Grants, CA118918 and GM 057959 (to Z Luo). We thank Dr David Carling for providing us thecDNA construct for the dominant- negative mutant of AMPKa1 subunit.	Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; De Schrijver E, 2003, CANCER RES, V63, P3799; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; GONG YF, 1993, MOL PHARMACOL, V44, P30; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haheim LL, 2006, AM J EPIDEMIOL, V164, P769, DOI 10.1093/aje/kwj284; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; He GB, 2006, CANCER RES, V66, P1873, DOI 10.1158/0008-5472.CAN-05-3111; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; KLIPPERAURBACH Y, 1995, MED HYPOTHESES, V45, P486, DOI 10.1016/0306-9877(95)90228-7; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lee IM, 2003, MED SCI SPORT EXER, V35, P1823, DOI 10.1249/01.MSS.0000093620.27893.23; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Ngo TH, 2003, ENDOCRINOLOGY, V144, P2319, DOI 10.1210/en.2003-221028; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Singh AP, 2008, CANCER LETT, V259, P28, DOI 10.1016/j.canlet.2007.09.018; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133	41	88	93	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1993	2002		10.1038/onc.2009.63	http://dx.doi.org/10.1038/onc.2009.63			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347029	Green Accepted			2022-12-17	WOS:000265820900006
J	Samanta, AK; Chakraborty, SN; Wang, Y; Kantarjian, H; Sun, X; Hood, J; Perrotti, D; Arlinghaus, RB				Samanta, A. K.; Chakraborty, S. N.; Wang, Y.; Kantarjian, H.; Sun, X.; Hood, J.; Perrotti, D.; Arlinghaus, R. B.			Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients	ONCOGENE			English	Article						BCR-ABL; Jak2; Lyn; SET; PP2A; drug-resistance	PROTEIN PHOSPHATASE 2A; BCR-ABL; TYROSINE PHOSPHORYLATION; MYELOID-LEUKEMIA; SODIUM STIBOGLUCONATE; SIGNALING PATHWAY; POTENT INHIBITOR; BLAST CRISIS; BCR/ABL; MESYLATE	Chronic myelogenous leukemia (CML) patients treated with imatinib mesylate (IM) become drug resistant by mutations within the kinase domain of Bcr-Abl, and by other changes that cause progression to advanced stage (blast crisis) and increased expression of the Lyn tyrosine kinase, the regulation of which is not understood yet. In Bcr-Abl + cells inhibition of Jak2, a downstream target of Bcr-Abl, by either Jak2 inhibitors or Jak2-specific short interfering RNA (siRNA) reduced the level of the SET protein, and increased PP2A Ser/Thr phosphatase and Shp1 tyrosine phosphatase activities, which led to decreased levels of activated Lyn. Activation of PP2A combined with Jak2 inhibition enhanced the reduction of activated Lyn kinase compared with Jak2 inhibition alone. In contrast, inhibition of either PP2A or Shp1 combined with Jak2 inhibition interfered with the loss of Lyn kinase activation more so than Jak2 inhibition alone, indicating the involvement of PP2A and Shp1 in the inactivation of the Lyn kinase caused by Jak2 inhibition. Inhibition of Jak2 induced apoptosis and reduced colony formation in IM-sensitive and -resistant Bcr-Abl mutant cell lines. Jak2 inhibition also induced apoptosis in CML cells from blast crisis patients but not in normal hematopoietic cells. These results indicate that Lyn is downstream of Jak2, and Jak2 maintains activated Lyn kinase in CML through the SET-PP2A-Shp1 pathway.	[Arlinghaus, R. B.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, Houston, TX 77054 USA; [Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77054 USA; [Sun, X.] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77054 USA; [Hood, J.] TargeGen Inc, San Diego, CA USA; [Perrotti, D.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University	Arlinghaus, RB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, 7435 Fannin St, Houston, TX 77054 USA.	rarlingh@mdanderson.org	Perrotti, Danilo/E-3852-2011		DOD [WB1XWH-07-1-0270];  [CA49639];  [CA093792];  [CA095512];  [CA100632]; NATIONAL CANCER INSTITUTE [R01CA093792, P01CA049639, R01CA095512, P50CA100632] Funding Source: NIH RePORTER	DOD(United States Department of Defense); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants CA49639 and CA093792 (RBA), CA095512 and DOD WB1XWH-07-1-0270 (DP), Leukemia Spore grant CA100632 (AKS), and Ladies Leukemia League ( AKS). We thank Santhanam Ramasami, PhD in the Perrotti lab for his help in PP2A assay.	Alvarez RH, 2006, CANCER-AM CANCER SOC, V107, P1918, DOI 10.1002/cncr.22215; Bruno O, 2007, MED CHEM, V3, P127, DOI 10.2174/157340607780059549; Chu S, 2004, BLOOD, V103, P3167, DOI 10.1182/blood-2003-04-1271; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; DONATO NJ, 2004, CANCER RES, V22, P5766; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kantarjian HM, 2003, BLOOD, V101, P97, DOI 10.1182/blood-2002-02-0545; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Nawa M, 2008, CELL SIGNAL, V20, P493, DOI 10.1016/j.cellsig.2007.11.004; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Nimmanapalli R, 2002, CANCER RES, V62, P5761; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Pardanani A, 2008, LEUKEMIA, V22, P23, DOI 10.1038/sj.leu.2404948; Pardanani A, 2007, LEUKEMIA, V21, P1658, DOI 10.1038/sj.leu.2404750; Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391; Perrotti D, 2006, BRIT J CANCER, V95, P775, DOI 10.1038/sj.bjc.6603317; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Wu J, 2008, BLOOD, V111, P3821, DOI 10.1182/blood-2007-08-109330; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yi TL, 2002, J IMMUNOL, V169, P5978, DOI 10.4049/jimmunol.169.10.5978; Yokota A, 2007, BLOOD, V109, P306, DOI 10.1182/blood-2006-03-013250; Yokoyama N, 2003, ARCH BIOCHEM BIOPHYS, V417, P87, DOI 10.1016/S0003-9861(03)00333-3; Yokoyama N, 2001, J INTERF CYTOK RES, V21, P369, DOI 10.1089/107999001750277844	35	88	94	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1669	1681		10.1038/onc.2009.7	http://dx.doi.org/10.1038/onc.2009.7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234487	Green Accepted			2022-12-17	WOS:000265022000002
J	Wykosky, J; Palma, E; Gibo, DM; Ringler, S; Turner, CP; Debinski, W				Wykosky, J.; Palma, E.; Gibo, D. M.; Ringler, S.; Turner, C. P.; Debinski, W.			Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor	ONCOGENE			English	Article						ephrinA1; EphA2; glioblastoma; monomer; soluble	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; IN-VITRO; PANCREATIC ADENOCARCINOMA; INDUCED ANGIOGENESIS; CRYSTAL-STRUCTURE; PROSTATE-CANCER; GLIOMA INVASION; ACTIVATION; EXPRESSION	The ephrinA1 ligand exerts antioncogenic effects in tumor cells through activation and downregulation of the EphA2 receptor and has been described as a membrane-anchored protein requiring clustering for function. However, while investigating the ephrinA1/EphA2 system in the pathobiology of glioblastoma multiforme (GBM), we uncovered that ephrinA1 is released from GBM and breast adenocarcinoma cells as a soluble, monomeric protein and is a functional form of the ligand in this state. Conditioned media containing a soluble monomer of ephrinA1 caused EphA2 internalization and downregulation, dramatic alteration of cell morphology and suppression of the Ras-MAPK pathway. Moreover, soluble monomeric ephrinA1 was functional in a physiological context, eliciting collapse of embryonic neuronal growth cones. We also found that ephrinA1 is cleaved from the plasma membrane of GBM cells, an event which involves the action of a metalloprotease. Thus, the ephrinA1 ligand can, indeed, function as a soluble monomer and may act in a paracrine manner on the EphA2 receptor without the need for juxtacrine interactions. These findings have important implications for further deciphering the function of these proteins in pathology and physiology, as well as for the design of ephrinA1-based EphA2-targeted antitumor therapeutics.	[Wykosky, J.; Palma, E.; Gibo, D. M.; Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurosurg,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Palma, E.; Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Radiat Oncol,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Ringler, S.; Turner, C. P.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurobiol & Anat,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Canc Biol,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Debinski, W (corresponding author), Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurosurg,Brain Tumor Ctr Excellence, Med Ctr Blvd, Winston Salem, NC 27157 USA.	debinski@wfubmc.edu			NIH [1 F31 NSO5553301, 5 T32 CA113267-04]; NATIONAL CANCER INSTITUTE [T32CA113267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS055533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by the NIH Grant 1 F31 NSO5553301 to JW, NIH Grant 5 T32 CA113267-04 to Dr Mike Robbins (EP) and Brain Tumor Center of Excellence at Wake Forest University School of Medicine. We thank Dr Hannah Caldas and Ms Amanda Beauchamp for help with real-time PCR and Ms Carla Lema-Tome for preparing cortical neurons.	Aasheim HC, 2000, BLOOD, V95, P221, DOI 10.1182/blood.V95.1.221.001k01_221_230; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cheng N, 2002, MOL CANCER RES, V1, P2; Daniel TO, 1996, KIDNEY INT, V50, pS73; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Knoll B, 2002, TRENDS NEUROSCI, V25, P145, DOI 10.1016/S0166-2236(00)02093-2; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Rashid T, 2005, NEURON, V47, P57, DOI 10.1016/j.neuron.2005.05.030; Sanderson MP, 2006, GROWTH FACTORS, V24, P121, DOI 10.1080/08977190600634373; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Turner CP, 2002, EXP NEUROL, V178, P21, DOI 10.1006/exnr.2002.8027; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Zelinski DP, 2001, CANCER RES, V61, P2301; Zeng GY, 2003, AM J PATHOL, V163, P2271, DOI 10.1016/S0002-9440(10)63584-5; Zhang A, 2006, ONCOL REP, V15, P831; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	57	88	108	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7260	7273		10.1038/onc.2008.328	http://dx.doi.org/10.1038/onc.2008.328			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794797	Green Accepted			2022-12-17	WOS:000261590300004
J	Orloff, MS; Eng, C				Orloff, M. S.; Eng, C.			Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome	ONCOGENE			English	Review						phenomics; personalized; PTEN; -omics; genomics	RILEY-RUVALCABA-SYNDROME; DIMENSIONALITY REDUCTION METHOD; LIPID PHOSPHATASE-ACTIVITY; CELL-CYCLE ARREST; COWDEN-SYNDROME; GERMLINE MUTATIONS; SUPPRESSOR GENE; JUVENILE POLYPOSIS; SPORADIC BREAST; SPLICE VARIANTS	Germline PTEN (Phosphatase and TENsin homologue deleted on chromosome TEN) mutations predispose to phenotypically diverse disorders that share several overlapping clinical features: Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome and Proteus-like syndrome, collectively classified as PTEN hamartoma tumour syndrome (PHTS). The meticulous acquisition and documentation of PHTS phenotypic data at different levels and the pro. ling of the plethora of genetic changes in PTEN and other genes within the same or related pathways are important in resolving the challenge of discriminating heritable cancers from sporadic PHTS-mimicking clinical features. The characterization of PTEN and PTEN-related pathways from a multidisciplinary perspective underscores the importance of incorporating data from different -omics, which is crucial for the advancement of personalized medicine.	[Orloff, M. S.; Eng, C.] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; [Eng, C.] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; [Eng, C.] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA; [Eng, C.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Eng, C (corresponding author), Cleveland Clin, Genom Med Inst, 9500 Euclid Ave,Mailstop NE-50, Cleveland, OH 44195 USA.	engc@ccf.org		Eng, Charis/0000-0002-3693-5145	Doris Duke Distinguished Clinical Scientist Award	Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF))	CE is a recipient of the Doris Duke Distinguished Clinical Scientist Award, holds the Sondra J & Stephen R Hardis Chair in Cancer Genomic Medicine at the Cleveland Clinic and is an Honorary Fellow of the Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, UK.	Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; Bartel F, 2004, MOL CANCER RES, V2, P29; Bracco L, 2003, TRENDS BIOTECHNOL, V21, P346, DOI 10.1016/S0167-7799(03)00146-X; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Chanda P, 2007, AM J HUM GENET, V81, P939, DOI 10.1086/521878; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Chung YJ, 2007, BIOINFORMATICS, V23, P71, DOI 10.1093/bioinformatics/btl557; Dahia PM, 2000, J MED GENET, V37, P715, DOI 10.1136/jmg.37.9.715; Delnatte C, 2006, AM J HUM GENET, V78, P1066, DOI 10.1086/504301; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 2001, NAT GENET, V28, P105, DOI 10.1038/88802; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Haiman CA, 2006, CANCER EPIDEM BIOMAR, V15, P1021, DOI 10.1158/1055-9965.EPI-05-0896; Hamilton JA, 2000, BRIT J CANCER, V82, P1671; Harris TW, 2003, NUCLEIC ACIDS RES, V31, P133, DOI 10.1093/nar/gkg053; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hsieh HF, 1999, J CLIN PATHOL-MOL PA, V52, P25, DOI 10.1136/mp.52.1.25; Kahraman A, 2005, BIOINFORMATICS, V21, P418, DOI 10.1093/bioinformatics/bti010; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SY, 2007, BIOINFORMATICS, V23, P2589, DOI 10.1093/bioinformatics/btm396; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1997, CANCER RES, V57, P5017; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Pezzolesi MG, 2007, HUM MOL GENET, V16, P1058, DOI 10.1093/hmg/ddm053; Pezzolesi MG, 2006, AM J HUM GENET, V79, P923, DOI 10.1086/508943; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Sarquis MS, 2006, AM J HUM GENET, V79, P23, DOI 10.1086/504392; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662; Smith JM, 2002, J MED GENET, V39, P937, DOI 10.1136/jmg.39.12.937; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stambolic V, 2000, CANCER RES, V60, P3605; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Sweet K, 2005, JAMA-J AM MED ASSOC, V294, P2465, DOI 10.1001/jama.294.19.2465; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008-5472.CAN-06-0772; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Tsuchiya KD, 1998, GENE CHROMOSOME CANC, V21, P113, DOI 10.1002/(SICI)1098-2264(199802)21:2<113::AID-GCC6>3.0.CO;2-3; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Wang NM, 1999, INT J MOL MED, V3, P491; Weber F, 2005, J CLIN ENDOCR METAB, V90, P6334, DOI 10.1210/jc.2005-2030; Weber Frank, 2005, Future Oncol, V1, P497; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037; Zhang L, 2006, AM J MED GENET B, V141B, P10, DOI 10.1002/ajmg.b.30240; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	90	88	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5387	5397		10.1038/onc.2008.237	http://dx.doi.org/10.1038/onc.2008.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794875				2022-12-17	WOS:000259280700002
J	Demarest, RM; Ratti, F; Capobianco, AJ				Demarest, R. M.; Ratti, F.; Capobianco, A. J.			It's T-ALL about Notch	ONCOGENE			English	Review						p53; Ikaros; PTEN; Fbw7; C-myc; CSL	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; C-MYC; TRANSCRIPTION FACTOR; IKAROS GENE; TUMOR-SUPPRESSOR; MOLECULAR PATHOGENESIS; PROTEOLYTIC ACTIVATION; LYMPHOCYTE DEVELOPMENT; INTRACELLULAR DOMAIN	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subset of ALL with poor clinical outcome compared to B-ALL. Therefore, to improve treatment, it is imperative to delineate the molecular blueprint of this disease. This review describes the central role that the Notch pathway plays in T-ALL development. We also discuss the interactions between Notch and the tumor suppressors Ikaros and p53. Loss of Ikaros, a direct repressor of Notch target genes, and suppression of p53 mediated apoptosis are essential for development of this neoplasm. In addition to the activating mutations of Notch previously described, this review will outline combinations of mutations in pathways that contribute to Notch signaling and appear to drive T-ALL development by 'mimicking' Notch effects on cell cycle and apoptosis.	[Demarest, R. M.; Ratti, F.; Capobianco, A. J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Capobianco, AJ (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	acapobianco@wistar.org	Ratti, Francesca/AAB-2116-2019	Capobianco, Anthony/0000-0002-3706-6797	NIH [R01]; Wistar Institute [T32 CA09171]; NATIONAL CANCER INSTITUTE [T32CA009171] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wistar Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Capobianco Laboratory for their support and critical reading of the manuscript. This work was funded by NIH Grant R01 (AJ Capobianco). RM Demarest was funded by training program in Basic Cancer Research from Wistar Institute (T32 CA09171).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Bellavia D, 2007, CELL CYCLE, V6, P2730, DOI 10.4161/cc.6.22.4894; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Beverly LJ, 2004, TRENDS MOL MED, V10, P591, DOI 10.1016/j.molmed.2004.10.001; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Goldberg JM, 2003, J CLIN ONCOL, V21, P3616, DOI 10.1200/JCO.2003.10.116; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kathrein KL, 2008, J BIOL CHEM, V283, P10476, DOI 10.1074/jbc.M709643200; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lopez-Nieva P, 2004, CARCINOGENESIS, V25, P1299, DOI 10.1093/carcin/bgh124; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Meek DW, 2003, MOL CANCER RES, V1, P1017; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Qi RZ, 2003, CANCER RES, V63, P8323; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; THIEL E, 1989, BLOOD, V73, P1247; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	85	88	92	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5082	5091		10.1038/onc.2008.222	http://dx.doi.org/10.1038/onc.2008.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758476				2022-12-17	WOS:000258914900001
J	Staub, J; Chien, J; Pan, Y; Qian, X; Narita, K; Aletti, G; Scheerer, M; Roberts, LR; Molina, J; Shridhar, V				Staub, J.; Chien, J.; Pan, Y.; Qian, X.; Narita, K.; Aletti, G.; Scheerer, M.; Roberts, L. R.; Molina, J.; Shridhar, V.			Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance	ONCOGENE			English	Article						methylation; histone modification; tumor suppressor; chemoresponse; apoptosis	HISTONE-DEACETYLASE INHIBITORS; H3 LYSINE-9 METHYLATION; IN-VIVO; CHROMATIN IMMUNOPRECIPITATION; TUMOR-GROWTH; CPG ISLANDS; GENE; HYPERMETHYLATION; CHEMOTHERAPY; CARCINOMA	To investigate the mechanism by which HSulf-1 expression is downregulated in ovarian cancer, DNA methylation and histone acetylation of HSulf-1 was analysed in ovarian cancer cell lines and primary tumors. Treatment of OV207 and SKOV3 by 5-aza-2'-deoxycytidine resulted in increased transcription of HSulf-1. Sequence analysis of bisulfi. te-modi. ed genomic DNA from ovarian cell lines and primary tumors without HSulf-1 expression revealed an increase in the frequency of methylation of 12 CpG sites in exon 1A. Chromatin immunoprecipitation assays showed an increase in histone H3 methylation in cell lines without HSulf-1 expression. To assess the signi. cance of HSulf-1 downregulation in ovarian cancer, OV167 and OV202 cells were transfected with HS ulf-1 siRNA. Downregulation of HSulf-1 expression in OV167 and OV202 cells lead to an attenuation of cisplatin-induced cytotoxicity. Moreover, patients with ovari an tumors expressing higher levels of HSulf-1 showed a 90% response rate (27/30) to chemotherapy compared to a response rate of 63% (19/30) in those with weak or moderate levels (P = 0.0146, chi(2) test). Collectively, these data indicate that HSulf-1 is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting HSulf-1 might sensitize ovarian tumors to conventional. first-line therapies.	Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Med Oncol, Dept Oncol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW,2-46 Stabile, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Narita, Keishi/E-3539-2010; Seal, Sudipta/A-7698-2012; Aletti, Giovanni/AAM-9781-2020; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Chien, Jeremy/0000-0003-4744-8374; Aletti, Giovanni/0000-0003-4602-5601; Roberts, Lewis/0000-0001-7885-8574	NCI NIH HHS [CA106954-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Esteller M, 2002, J NATL CANCER I, V94, P26; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Galm O, 2002, GENOME RES, V12, P153, DOI 10.1101/gr.202501; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Han JW, 2000, CANCER RES, V60, P6068; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109; Lai JP, 2006, GASTROENTEROLOGY, V130, P2130, DOI 10.1053/j.gastro.2006.02.056; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; LaVoie HA, 2005, MOL CELL ENDOCRINOL, V243, P12, DOI 10.1016/j.mce.2005.09.005; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Plumb JA, 2000, CANCER RES, V60, P6039; Qian X, 2004, DIAGN MOL PATHOL, V13, P9, DOI 10.1097/00019606-200403000-00002; Seidl S, 2004, CANCER-AM CANCER SOC, V100, P2598, DOI 10.1002/cncr.20295; Shridhar V, 2001, CANCER RES, V61, P4258; Strathdee G, 2005, GYNECOL ONCOL, V97, P898, DOI 10.1016/j.ygyno.2005.03.023; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yang QW, 2003, CANCER RES, V63, P6299; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	43	88	94	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4969	4978		10.1038/sj.onc.1210300	http://dx.doi.org/10.1038/sj.onc.1210300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310998	Green Published			2022-12-17	WOS:000248322500009
J	Dhanasekaran, DN; Johnson, GL				Dhanasekaran, D. N.; Johnson, G. L.			MAPKs: function, regulation, role in cancer and therapeutic targeting	ONCOGENE			English	Editorial Material									Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.	glj@med.unc.edu							0	88	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3097	3099		10.1038/sj.onc.1210395	http://dx.doi.org/10.1038/sj.onc.1210395			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496908	Bronze			2022-12-17	WOS:000246603600001
J	Huang, HC; Hu, CH; Tang, MC; Wang, WS; Chen, PM; Su, Y				Huang, H.-C.; Hu, C.-H.; Tang, M.-C.; Wang, W.-S.; Chen, P.-M.; Su, Y.			Thymosin beta 4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase	ONCOGENE			English	Article						thymosin beta 4; E-cadherin; beta-catenin; integrin-linked kinase; epithelial-mesenchymal transition	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; REPRESSES E-CADHERIN; CELL-CELL-ADHESION; COLON-CANCER; TUMOR-CELLS; CATENIN; GENE; PHOSPHORYLATION; INVASION	The epithelial-mesenchymal transition (EMT) is crucial for the invasion and metastasis of many epithelial tumors including colorectal carcinoma (CRC). In the present study, a scattering and fibroblastic morphology with reduced intercellular contacts was found in the SW480 colon cancer cells overexpressing the gene encoding thymosin beta 4 (T beta(4)), which was accompanied by a loss of E-cadherin as well as a cytosolic accumulation of beta-catenin, two most prominent markers of EMT. Whereas E-cadherin downregulation was likely to be accounted by a ZEB1-mediated transcriptional repression, the accumulation of beta-catenin was a result of glycogen synthase kinase-3 beta inactivation mediated by integrin-linked kinase (ILK) and/or its downstream effector, Akt. Intriguingly, ILK upregulation in T beta(4)-overexpressing SW480 cells seemed to be attributed mainly to a stabilization of this kinase by complexing with particularly interesting new Cys-His protein (PINCH) more efficiently. In the meantime, a strong correlation between the expression levels of T beta(4), ILK and E-cadherin in CRC patients was also revealed by immunohistochemical analysis. Taken together, these data suggest a novel role of T beta(4) in promoting CRC progression by inducing an EMT in tumor cells via upregulating ILK and consequentially its signal transduction.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Taiwan Ocean Univ, Coll Life Sci, Inst Biosci & Biotechnol, Chilung, Taiwan; Taipei Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Taiwan Ocean University; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hajra KM, 2002, CANCER RES, V62, P1613; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keller SH, 2003, BIOCHEM BIOPH RES CO, V307, P215, DOI 10.1016/S0006-291X(03)01143-4; Kemler R, 1992, Semin Cell Biol, V3, P149; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Noe V, 2001, J CELL SCI, V114, P111; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Pecina-Slaus N, 2005, PATHOL RES PRACT, V201, P557, DOI 10.1016/j.prp.2005.07.001; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang WS, 2004, ONCOGENE, V23, P6666, DOI 10.1038/sj.onc.1207888; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yang SP, 2005, MOL CELL BIOCHEM, V272, P97, DOI 10.1007/s11010-005-7642-4; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	57	88	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2781	2790		10.1038/sj.onc.1210078	http://dx.doi.org/10.1038/sj.onc.1210078			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072345				2022-12-17	WOS:000246210600012
J	Honeycutt, KA; Chen, Z; Koster, MI; Miers, M; Nuchtern, J; Hicks, J; Roop, DR; Shohet, JM				Honeycutt, K. A.; Chen, Z.; Koster, M. I.; Miers, M.; Nuchtern, J.; Hicks, J.; Roop, D. R.; Shohet, J. M.			Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis	ONCOGENE			English	Article						minichromosomal maintenance protein 7; oncogene; Ras; K14 promoter; transgenic mouse; topical carcinogenesis	MOUSE SKIN TUMORS; DNA-REPLICATION; C-MYC; LICENSING FACTOR; GENE-EXPRESSION; STEM-CELLS; CARCINOGENESIS; PROLIFERATION; CANCER; IDENTIFICATION	Minichromosomal maintenance protein 7 (MCM7) is an essential component of the replication helicase complex (MCM2-7) required for DNA replication. Although this function is highly conserved among eukaryotes, additional functions for the MCM molecules continue to be described. Minichromosomal maintenance protein 7 is a marker for proliferation and is upregulated in a variety of tumors including neuroblastoma, prostate, cervical and hypopharyngeal carcinomas. To further investigate the general role of MCM7 in tumorigenesis, we generated a mouse model with deregulated MCM7 expression targeted to the basal layer of the epidermis using the keratin 14 (K14) promoter (K14. MCM7). When subjected to a two-stage chemical carcinogenesis protocol (dimethylbenz[alpha] anthracene (DMBA) initiation with 12-ortho-tetradecanoylphorbol-13-acetate promotion), K14. MCM7 mice showed significantly increased incidence and prevalence of tumor development relative to controls. Furthermore, within 40 weeks of treatment over 45% K14. MCM7 mice exhibited tumors that had converted to squamous cell carcinomas versus none in the control group. As predicted from previous skin carcinogenesis studies using DMBA as the initiating agent, Ras mutations where found in more than 90% of tumors isolated from K14. MCM7 mice. Whereas previous studies have shown that MCM7 is useful as a proliferation marker, our data suggest that deregulated MCM7 expression actively contributes to tumor formation, progression and malignant conversion.	Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Shohet, JM (corresponding author), Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, 1 Baylor Pl, Houston, TX 77030 USA.	jmshohet@texaschildrenshospital.org			NCI NIH HHS [K08 CA90517-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA090517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arin MJ, 2001, J CELL BIOL, V152, P645, DOI 10.1083/jcb.152.3.645; ASHMAN LK, 1982, CARCINOGENESIS, V3, P99, DOI 10.1093/carcin/3.1.99; BARRETT JC, 1993, MOL CARCINOGEN, V7, P1, DOI 10.1002/mc.2940070102; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Brake T, 2003, CANCER RES, V63, P8173; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; Cao TY, 2001, J CELL BIOL, V152, P651, DOI 10.1083/jcb.152.3.651; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DGIOVANNI J, 1987, GENETIC FACTORS CONT; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Going JJ, 2002, GUT, V50, P373, DOI 10.1136/gut.50.3.373; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Homesley L, 2000, GENE DEV, V14, P913; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Nallamshetty S, 2005, FEBS LETT, V579, P6529, DOI 10.1016/j.febslet.2005.10.028; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Pasion SG, 2001, GENET ENG P, V23, P129; REN B, 2005, ONCOGENE; Shohet JM, 2002, CANCER RES, V62, P1123; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tye BK, 2004, FRONT BIOSCI-LANDMRK, V9, P2548, DOI 10.2741/1416; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Wharton SB, 2001, NEUROPATH APPL NEURO, V27, P305, DOI 10.1046/j.0305-1846.2001.00333.x; Woodworth CD, 2004, CARCINOGENESIS, V25, P1771, DOI 10.1093/carcin/bgh170; Yoshida K, 2003, FEBS LETT, V553, P213, DOI 10.1016/S0014-5793(03)01018-4; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	36	88	94	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4027	4032		10.1038/sj.onc.1209435	http://dx.doi.org/10.1038/sj.onc.1209435			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16518415				2022-12-17	WOS:000238802400003
J	Lian, ZL; Di Cristofano, A				Lian, ZL; Di Cristofano, A			Class reunion: PTEN joins the nuclear crew	ONCOGENE			English	Article						PTEN; AKT; nucleus	TUMOR-SUPPRESSOR PTEN; LIPID PHOSPHATASE-ACTIVITY; FOCAL ADHESION KINASE; HUMAN PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; ENDOMETRIAL CARCINOMA; ATYPICAL HYPERPLASIA; MUTATIONAL SPECTRA; ESTROGEN-RECEPTOR	Several recent reports have brought conclusive evidence that the tumor suppressor PTEN, once considered a strictly cytoplasmic protein, shuttles to the nuclear compartment, where it joins a variety of components of the same pathway it regulates in the cytoplasm, among which PI3K, PDK1 and AKT. In this review, we focus on the growing supporting evidence for an important physiological role of this nuclear pathway and on the role that alteration of this novel regulatory circuit may play during cell transformation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Di Cristofano, A (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	antonio.dicristofano@fccc.edu	Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020	di cristofano, antonio/0000-0003-2537-3228	NATIONAL CANCER INSTITUTE [R01CA097097] Funding Source: NIH RePORTER; NCI NIH HHS [CA097097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014-5793(00)01758-0; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Deleris P, 2003, J BIOL CHEM, V278, P38884, DOI 10.1074/jbc.M300816200; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guzeloglu-Kayisli O, 2003, J CLIN ENDOCR METAB, V88, P5017, DOI 10.1210/jc.2003-030414; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; Kokawa K, 1996, J CLIN ENDOCR METAB, V81, P4144, DOI 10.1210/jc.81.11.4144; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SH, 2002, APMIS, V110, P587, DOI 10.1034/j.1600-0463.2002.11007811.x; Levine RL, 1998, CANCER RES, V58, P3254; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martelli AM, 2003, J CELL BIOCHEM, V88, P455, DOI 10.1002/jcb.10379; Martelli AM, 2000, J BONE MINER RES, V15, P1716, DOI 10.1359/jbmr.2000.15.9.1716; Maxwell GL, 1998, CANCER RES, V58, P2500; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Montironi R, 2004, VIRCHOWS ARCH, V444, P503, DOI 10.1007/s00428-004-0996-2; Murphy ME, 2004, CELL CYCLE, V3, P836; Mutter GL, 2000, J CLIN ENDOCR METAB, V85, P2334, DOI 10.1210/jc.85.6.2334; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Neri LM, 1999, BIOCHEM BIOPH RES CO, V259, P314, DOI 10.1006/bbrc.1999.0786; NERI LM, 1994, CELL MOL BIOL, V40, P619; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; PEIFFER SL, 1995, CANCER RES, V55, P1922; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Saji M, 2005, BIOCHEM BIOPH RES CO, V332, P167, DOI 10.1016/j.bbrc.2005.04.109; Sano T, 1999, CANCER RES, V59, P1820; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; Syed NA, 2002, J CELL BIOCHEM, V86, P118, DOI 10.1002/jcb.10189; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tashiro H, 1997, CANCER RES, V57, P3935; Tell G, 2004, ENDOCRINOLOGY, V145, P4660, DOI 10.1210/en.2004-0282; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Yoshinaga K, 1998, JPN J CANCER RES, V89, P985, DOI 10.1111/j.1349-7006.1998.tb00485.x; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	89	88	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7394	7400		10.1038/sj.onc.1209089	http://dx.doi.org/10.1038/sj.onc.1209089			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288286				2022-12-17	WOS:000233201900002
J	Chen, YH; Rodrik, V; Foster, DA				Chen, YH; Rodrik, V; Foster, DA			Alternative phospholipase D/mTOR survival signal in human breast cancer cells	ONCOGENE			English	Article						phospholipase D; survival signals; rapamycin; phosphatidylinositol-3-kinase; Akt; breast cancer	GROWTH-FACTOR RECEPTOR; MAMMALIAN TARGET; V-SRC; DEPENDENT ACTIVATION; TRANSFORMED-CELLS; RAT FIBROBLASTS; RAPAMYCIN; MTOR; PATHWAY; PROTEIN	Cancer cells generate survival signals to suppress default apoptotic programs that protect from cancer. Phosphatidylinositol-3-kinase (PI3K) generates a survival signal that is frequently dysregulated in human cancers. Phospholipase D (PLD) has also been implicated in signals that promote survival. One of the targets of PLD signaling is mTOR ( mammalian target of rapamycin), a critical regulator of cell cycle progression and cell growth. We report here that elevated PLD activity in the MDA-MB-231 human breast cancer cell line generates an mTOR-dependent survival signal that is independent of PI3K. In contrast, MDA-MB-435S breast cancer cells, which have very low levels of PLD activity, are dependent on PI3K for survival signals. The data presented here identify an alternative survival signal that is dependent on PLD and mTOR and is active in a breast cancer cell line where the PI3K survival pathway is not active.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster DA, 2003, MOL CANCER RES, V1, P789; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yamada Y, 2003, J MOL MED, V81, P126, DOI 10.1007/s00109-002-0411-x; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	52	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					672	679		10.1038/sj.onc.1208099	http://dx.doi.org/10.1038/sj.onc.1208099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580312				2022-12-17	WOS:000226420400014
J	Xie, SQ; Xie, B; Lee, MY; Dai, W				Xie, SQ; Xie, B; Lee, MY; Dai, W			Regulation of cell cycle checkpoints by polo-like kinases	ONCOGENE			English	Article						polo; polo-like kinases; cell cycle; checkpoint; cell division	DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE CDC5; ACTIVATED PROTEIN-KINASE; SPINDLE CHECKPOINT; DROSOPHILA POLO; FISSION YEAST; BIPOLAR SPINDLE; BUDDING YEAST; MITOTIC EXIT; PHOSPHORYLATION	Protein kinases play a pivotal role in execution of cell division. Polo and Polo-like kinases have emerged as major regulators for various cell cycle checkpoints. Early genetic studies have demonstrated that CDC5, a budding yeast counterpart of vertebrate Plks, is essential for successful mitotic progression. Mammalian Plks localize primarily to the centrosome during interphase and the mitotic apparatus during mitosis. Many key cell cycle regulators such as p53, Cdc25C, cyclin B, components of the anaphase-promoting complex, and mitotic motor proteins are directly targeted by Plks. Although the exact mechanism of action of these protein kinases in vivo remains to be elucidated, Plks are important mediators for various cell cycle checkpoints that monitor centrosome duplication, DNA replication, formation of bipolar mitotic spindle, segregation of chromosomes, and mitotic exit, thus protecting cells against genetic instability during cell division.	New York Med Coll, Dept Med, Mol Carcinogenesis Div, Valhalla, NY 10595 USA; New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10595 USA; New York Med Coll, Dept Biochem, Mol Carcinogenesis Div, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Mol Carcinogenesis Div, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327	NATIONAL CANCER INSTITUTE [R01CA074229, R01CA090658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NCI NIH HHS [CA90658, CA74229] Funding Source: Medline; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Ahn JY, 2000, CANCER RES, V60, P5934; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; Deming PB, 2002, J BIOL CHEM, V277, P36832, DOI 10.1074/jbc.M206109200; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feng Y, 2001, CELL GROWTH DIFFER, V12, P29; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Haracska L, 2003, MOL CELL BIOL, V23, P1453, DOI 10.1128/MCB.23.4.1453-1459.2003; Heitz MJ, 2001, J CELL SCI, V114, P4521; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Litvak V, 2002, MOL CELL BIOL, V22, P5064, DOI 10.1128/MCB.22.14.5064-5075.2002; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mulvihill DP, 2002, J CELL SCI, V115, P3575, DOI 10.1242/jcs.00031; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Park CJ, 2004, MOL BIOL CELL, V15, P1711, DOI 10.1091/mbc.E03-07-0461; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Shtivelman E, 2003, MOL CANCER RES, V1, P959; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; SUNKEL CE, 1988, J CELL SCI, V89, P25; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Walsh S, 2003, MOL CANCER RES, V1, P280; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	87	88	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					277	286		10.1038/sj.onc.1208218	http://dx.doi.org/10.1038/sj.onc.1208218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640843	Bronze			2022-12-17	WOS:000226183100008
J	Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN				Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN			FAP alpha, a surface peptidase expressed during wound healing, is a tumor suppressor	ONCOGENE			English	Article						peptidase; wound healing; fibroblast activation protein alpha; melanoma; tumor suppressor	FIBROBLAST ACTIVATION PROTEIN; REACTIVE STROMAL FIBROBLASTS; SERINE-PROTEASE; EPITHELIAL CANCERS; MOLECULAR-CLONING; HUMAN MELANOCYTES; MELANOMA; CELLS; DIFFERENTIATION; GROWTH	Fibroblast activation protein-alpha (FAP) is a cell surface serine protease expressed at sites of tissue remodeling in embryonic development. FAP is not expressed by mature somatic tissues except activated melanocytes and fibroblasts in wound healing or tumor stroma. FAP expression is specifically silenced in proliferating melanocytic cells during malignant transformation. To study the role of FAP as a tumor suppressor, the gene for mouse fap was cloned and mutated at the catalytic domain (FAP serine mutant, FSM). We found that expression of FAP or FSM at physiologic levels in mouse melanoma cells abrogated tumorigenicity. Remarkably, the mutant form FSM lacking specific serine protease activity was a more potent tumor suppressor. Tumor rejection was not due to adaptive immune responses because RAG1-/- mice challenged with melanoma cells expressing either FAP or FSM were not tumorigenic. In in vitro assays, FAP or FSM expression restored contact inhibition, led to cell cycle arrest at G0/G1 phase, and increased susceptibility to stress-induced apoptosis. Cell death in FAP + or FSM + melanoma cells was readily triggered by depletion of survival factors from the media, leading to subsequent activation of caspases via the intrinsic pathway. These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival.	Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; St George Hosp, Sch Med, London SW17 0RE, England; Boehringer Ingelheim Austria GmbH, Div Res & Dev, Vienna, Austria; Univ Vienna, Dept Clin Pathol, Gen Hosp, Vienna, Austria	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; Howard Hughes Medical Institute; St Georges University London; Boehringer Ingelheim; University of Vienna	Houghton, AN (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, 1275 York Ave, New York, NY 10021 USA.	a-houghton@ski.mskcc.org	Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009	Bennett, Dorothy C/0000-0002-3639-7527; 				BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERKELHAMMER J, 1982, CANCER RES, V42, P3157; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Cheng JD, 2002, CANCER RES, V62, P4767; DESMOULIERE A, 1995, CELL BIOL INT, V19, P471, DOI 10.1006/cbir.1995.1090; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; HEARING VJ, 1985, INT J CANCER, V35, P403, DOI 10.1002/ijc.2910350317; HEARING VJ, 1988, INT J CANCER, V41, P275, DOI 10.1002/ijc.2910410219; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; RETTIG WJ, 1993, CANCER RES, V53, P3327; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311	23	88	101	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5435	5446		10.1038/sj.onc.1207730	http://dx.doi.org/10.1038/sj.onc.1207730			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133496				2022-12-17	WOS:000222588400003
J	Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S				Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S			Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a)	ONCOGENE			English	Article						ES cells; cyclin D; p16; differentiation	DEPENDENT KINASE CDK6; CYCLIN D1 EXPRESSION; EMBRYONIC STEM-CELLS; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; STRUCTURAL BASIS; INK4 FAMILY; MOUSE; GENE; PROTEIN	Through a screen aimed at identifying genes that are specifically upregulated in embryomic stem (ES) cells but not primitive ectoderm, we identified cyclin D3. This was surprising since cyclin D activity is generally believed to be inactive in ES cells even though retinoblastoma tumor suppressor protein (pRb) accumulates in a predominantly hyperphosphorylated state. Cdk6 is the major catalytic partner for cyclin D3 in ES cells and exhibits robust pRb kinase activity that is downregulated during the early stages of ES embryoid body differentiation. To investigate the basis underlying the insensitivity of ES cells to ectopic p16 expression, we show that Cdk6-cyclin D3 complexes are not subject to inhibition by p16, similar to Cdk-viral cyclin complexes. These observations show that specificity exists between Cdk4/6-cyclin D complexes and their ability to be targeted by p16. Our data suggest that Cdk6-cyclin D3 activity in other cell types, including tumors, may also be refractory to p16-mediated growth inhibition and raises the possibility of additional specificity within the INK4 family.	Univ Georgia, Rhodes Ctr, Athens, GA 30602 USA; Univ Adelaide, Ctr Mol Genet Dev, Bresagen Cell Therapy Program, Dept Mol Biosci, Adelaide, SA, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University System of Georgia; University of Georgia; University of Adelaide; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Dalton, S (corresponding author), Univ Georgia, Rhodes Ctr, 425 River Rd, Athens, GA 30602 USA.	sdalton@uga.edu		Sarcevic, Boris/0000-0002-8063-1050; Wright, Josephine/0000-0003-4588-8827; Dalton, Stephen/0000-0002-3450-1263				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Halaban R, 1999, CANCER METAST REV, V18, P333, DOI 10.1023/A:1006396104073; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HAUB O, 1991, DEVELOPMENT, V112, P397; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; JIANG H, 1998, MOL CELL BIOL, V130, P755; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lake JA, 2000, J CELL SCI, V113, P555; Laman H, 2000, CURR OPIN GENET DEV, V10, P70, DOI 10.1016/S0959-437X(99)00045-3; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; QUELLE DE, 1995, ONCOGENE, V11, P635; Rathjen J, 1999, J CELL SCI, V112, P601; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Swanton C, 1999, TRENDS BIOCHEM SCI, V24, P116, DOI 10.1016/S0968-0004(99)01354-7; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	60	88	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					491	502		10.1038/sj.onc.1207133	http://dx.doi.org/10.1038/sj.onc.1207133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724578				2022-12-17	WOS:000188098300020
J	Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM				Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM			Microarray screening for target genes of the proto-oncogene PLAG1	ONCOGENE			English	Article						PLAG1 gene; oligonucleotide microarray; target genes; pleomorphic adenoma; salivary gland	BINDING PROTEIN-II; PLEOMORPHIC ADENOMAS; SALIVARY-GLANDS; P57/KIP2 PROTEIN; RETINOIC ACID; IGF-II; EXPRESSION; GROWTH; FAMILY; P57(KIP2)	PLAG1 is a proto-oncogene whose ectopic expression can trigger the development of pleomorphic adenomas of the salivary glands and of lipoblastomas. As PLAG1 is a transcription factor, able to activate transcription through the binding to the consensus sequence GRGGC(N)(6-8)GGG, its ectopic expression presumably results in the deregulation of target genes, leading to uncontrolled cell proliferation. The identification of PLAG1 target genes is therefore a crucial step in understanding the molecular mechanisms involved in PLAG1-induced tumorigenesis. To this end, we analysed the changes in gene expression caused by the conditional induction of PLAG1 expression in fetal kidney 293 cell lines. Using oligonucleotide microarray analyses of about 12000 genes, we consistently identified 47 genes induced and 12 genes repressed by PLAG1. One of the largest classes identified as upregulated PLAG1 targets consists of growth factors such as the insulin-like growth factor II and the cytokine-like factor 1. The in silico search for PLAG1 consensus sequences in the promoter of the upregulated genes reveals that a large proportion of them harbor several copies of the PLAG1-binding motif, suggesting that they represent direct PLAG1 targets. Our approach was complemented by the comparison of the expression profiles of pleomorphic adenomas induced by PLAG1 versus normal salivary glands. Concordance between these two sets of experiments pinpointed 12 genes that were significantly and consistently upregulated in pleomorphic adenomas and in PLAG1-expressing cells, identifying them as putative PLAG1 targets in these tumors.	Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B-4000 Sart Tilman Par Liege, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv, Inst Biotechnol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, ESAT SCD, B-3001 Louvain, Belgium; Starlab NV SA, Dept Gen, B-1180 Brussels, Belgium; Katholieke Univ Leuven, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	University of Liege; KU Leuven; KU Leuven; KU Leuven	Voz, ML (corresponding author), Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B6, B-4000 Sart Tilman Par Liege, Belgium.	mvoz@ulg.ac.be		Van Huffel, Christophe/0000-0001-6127-3027; Moreau, Yves/0000-0002-4647-6560				Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; Astrom AK, 1999, CANCER RES, V59, P918; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Burns JL, 2001, DEVELOPMENT, V128, P3819; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coppock D, 2000, BIOCHEM BIOPH RES CO, V269, P604, DOI 10.1006/bbrc.2000.2324; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Frade Gonzalez C., 2001, ACTA OTORRINOLARINGO, V52, P456; Grosso LE, 1996, J ORAL PATHOL MED, V25, P5, DOI 10.1111/j.1600-0714.1996.tb01215.x; Hartmann W, 2000, AM J PATHOL, V157, P1393, DOI 10.1016/S0002-9440(10)64652-4; Hensen K, 2002, CANCER RES, V62, P1510; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito Y, 2002, LIVER, V22, P145, DOI 10.1034/j.1600-0676.2002.01532.x; Ito Y, 2002, INT J MOL MED, V9, P373; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kusafuka K, 1998, VIRCHOWS ARCH, V432, P247, DOI 10.1007/s004280050162; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHRESTHA P, 1994, ORAL ONCOL, V30B, P393; SUNARDHIWIDYAPUTRA S, 1993, PATHOL RES PRACT, V189, P138, DOI 10.1016/S0344-0338(11)80083-X; SunardhiWidyaputra S, 1995, PATHOL RES PRACT, V191, P1186, DOI 10.1016/S0344-0338(11)81124-6; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Vo HP, 1998, ANTICANCER RES, V18, P217; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Zhu Q, 1997, ORAL ONCOL, V33B, P29, DOI 10.1016/S0964-1955(96)00038-3	41	88	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					179	191		10.1038/sj.onc.1207013	http://dx.doi.org/10.1038/sj.onc.1207013			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712223	Green Submitted			2022-12-17	WOS:000187895300019
J	Mothersill, C; Seymour, C				Mothersill, C; Seymour, C			Radiation-induced bystander effects, carcinogenesis and models	ONCOGENE			English	Article						radiation; carcinogenesis; bystander effects; chaos models; social evolution; autopoietic theory	INDUCED GENOMIC INSTABILITY; INFLAMMATORY-TYPE RESPONSES; UNIRRADIATED CELLS; IONIZING-RADIATION; IN-VIVO; CHROMOSOMAL INSTABILITY; IRRADIATED-CELLS; EXPOSURE; INITIATION; MECHANISM	Implications for carcinogenesis of radiation-induced bystander effects are both mechanistic and practical. They include induction of second cancers, perturbations to tissue social control and induction of genomic instability and delayed or immediate mutations in areas not receiving a direct deposition of energy. Bystander effects have consequences for DNA damage-mutation-cancer initiation paradigms of radiation carcinogenesis that provide the mechanistic justification for low-dose risk estimates. If carcinogenesis does not result from directly induced DNA mutations, then the carcinogenic initiation process may not simply relate to radiation dose. Modi. cation of the preclonal state through genetic and epigenetic mechanisms may occur. To deal with the complexity of these interactions, a 'chaotic' or 'bifurcation' model invoking autopoietic theory is proposed that could accommodate both beneficial (hormetic) and harmful effects of radiation at comparable doses. Carcinogenesis may then be thought of as the result of a disturbance of the genetic/epigenetic balance occurring within the organ. Ultimate clonality may reflect domination due to selection processes rather than the initiating damage.	Dublin Inst Technol, Radiat & Environm Sci Ctr, Dublin 8, Ireland; St Lukes Inst Canc Res, Dublin 6, Ireland	Technological University Dublin	Mothersill, C (corresponding author), McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON, Canada.	mothers@mcmaster.ca						Anderson GR, 2001, BIOESSAYS, V23, P1037, DOI 10.1002/bies.1149; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Bedi GC, 1996, CANCER RES, V56, P2484; Goldberg Z, 2002, INT J ONCOL, V21, P337; GRANDJEAN V, UNPUB RAD RES; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; Limoli CL, 1998, CANCER RES, V58, P3712; Loeb LA, 2001, CANCER RES, V61, P3230; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maturana H.R., 1980, AUTOPOIESIS COGNITIO, V42; MATURANA HR, 1975, INT J MAN MACH STUD, V7, P313, DOI 10.1016/S0020-7373(75)80015-0; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mothersill C, 2002, RADIAT RES, V157, P526, DOI 10.1667/0033-7587(2002)157[0526:RBRILD]2.0.CO;2; Mothersill C, 2001, CARCINOGENESIS, V22, P1465, DOI 10.1093/carcin/22.9.1465; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; MOTHERSILL C, 2003, J EXP HAEMATOL; NOGUCHI S, 1995, CANCER LETT, V90, P57, DOI 10.1016/0304-3835(94)03678-C; Osterreicher J, 2003, STRAHLENTHER ONKOL, V179, P69, DOI 10.1007/s00066-003-1000-9; RAMBIHAR VS, 2000, NEW CHAOS BASED MED; Sedivy R, 2000, WIEN KLIN WOCHENSCHR, V112, P177; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Varela F., 1979, PRINCIPLES BIOL AUTO; Watson GE, 2000, CANCER RES, V60, P5608; Werness BA, 1997, HUM PATHOL, V28, P626, DOI 10.1016/S0046-8177(97)90087-3	31	88	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7028	7033		10.1038/sj.onc.1206882	http://dx.doi.org/10.1038/sj.onc.1206882			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557807				2022-12-17	WOS:000185903900007
J	Gridelli, C; Rossi, A; Maione, P				Gridelli, C; Rossi, A; Maione, P			Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents	ONCOGENE			English	Review						NSCLC; chemotherapy; new biologic agents; targeted therapy	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHASE-III; SELECTIVE CYCLOOXYGENASE-2; MOLECULAR HETEROGENEITY; MONOCLONAL-ANTIBODY; INHIBITOR ZD1839; STAGE-II; IN-VITRO; CHEMOTHERAPY	Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant and adjuvant therapies in early stages are under investigation and some progress has been achieved in the management of locally advanced and advanced disease, treatment outcomes for NSCLC are still to be considered dismal. The majority of patients affected from NSCLC experience metastatic disease and optimization of chemotherapy is unlikely to produce further substantial survival improvement, with symptom relief and quality of life still being the primary goal of treatment. Based on this background, clinical investigation of novel treatment strategies is mandatory. As our understanding of tumor cell biology has increased and several molecular targets for NSCLC have been identified, a number of new biologic agents have been developed. Targeted therapy describes treatment strategies that focus on cell signaling and other biologic pathways involved in tumorigenesis. Several targeted agents have been introduced in clinical trials in NSCLC, the majority in advanced disease, and some phase III studies have already produced definitive results. Currently, the minority of these new agents offer promise of improved outcomes and negative results are more common to be reported than positive ones. However, important lessons can be learned from this first generation of clinical trials that should be considered the first step of clinical research in this field.	SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy	San Giuseppe Moscati Hospital	Gridelli, C (corresponding author), SG Moscati Hosp, Div Med Oncol, Via Circumvallaz, I-83100 Avellino, Italy.	cgridelli@libero.it	Gridelli, Cesare/AAA-8621-2019; Gridelli, Cesare/K-7909-2016; Rossi, Antonio/K-7054-2016	Rossi, Antonio/0000-0003-3295-0345				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; ALBERTI W, 1995, BRIT MED J, V311, P899; ALTORKI NK, 2002, P AN M AM SOC CLIN, V21, pA26; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BASSER R, 2001, P AN M AM SOC CLIN, V20, pA100; Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.3.CO;2-I; Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140; Bunn PA, 2001, CLIN CANCER RES, V7, P3239; Burdett S, 1998, LANCET, V352, P257; BURKES RL, 1992, J CLIN ONCOL, V10, P580, DOI 10.1200/JCO.1992.10.4.580; CARBONE D, 2002, P AN M AM SOC CLIN, V21, P1270; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Cox G, 2001, INT J CANCER, V92, P480, DOI 10.1002/ijc.1214; Curran WJ, 2000, P AN M AM SOC CLIN, V19, p484a; DANG T, 2001, P AN M AM SOC CLIN, V20, pA332; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; FALCEY J, 1997, P AN M AM SOC CLIN, V16, pA383; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; FRANQOIS B, 2001, P AN M AM SOC CLIN, V20, pB277; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692; GADGEEL SM, 2003, P AN M AM SOC CLIN, V22, P684; GATZEMEIER U, 2002, P AN M AM SOC CLIN, V21, pA297; Georgoulias V, 2001, LANCET, V357, P1478, DOI 10.1016/S0140-6736(00)04644-4; Giaccone G, 2002, ANN ONCOL, V13, P217, DOI 10.1093/annonc/mdf663; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362; Gridelli C, 2002, CURR MED CHEM, V9, P1487, DOI 10.2174/0929867023369565; GRIDELLI C, 2002, P AN M AM SOC CLIN, V21, P1165; GUPTA E, 2001, P AN M AM SOC CLIN, V20, pA76; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 1998, ANTICANCER RES, V18, P775; Hida T, 2000, CLIN CANCER RES, V6, P2006; JOHNSON DH, 2003, P AN M AM SOC CLIN, V22, P640; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Johnson DH, 2001, P AN M AM SOC CLIN, V20, p315a; KATO H, 2003, P AN M AM SOC CLIN, V22, P621; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; KELLY K, 2003, P AN M AM SOC CLIN, V22, P644; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; KHURI FR, 2000, P AN M AM SOC CLIN, V19, pA205; KIM ES, 2003, P AN M AM SOC CLIN, V22, P642; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Kris MG, 2002, P AN M AM SOC CLIN, V21, p292a; KRUG LM, 2001, P AN M AM SOC CLIN, V20, pA333; Kuenen BC, 2002, J CLIN ONCOL, V20, P1657, DOI 10.1200/JCO.20.6.1657; LANGER CJ, 2001, P AN M AM SOC CLIN, V20, pA315; LECHEVALIER T, 2003, P AN M AM SOC CLIN, V22, P2; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Lynch TJ, 2003, P AM SOC CLIN ONCOL, V22, P623; MININBERG ED, 2003, P AN M AM SOC CLIN, V22, P627; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA310; PICCARTGEBHART MJ, 2001, P AN M AM SOC CLIN, V20, pA80; Pyo H, 2001, CLIN CANCER RES, V7, P2998; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rioux N, 1998, CARCINOGENESIS, V19, P1393, DOI 10.1093/carcin/19.8.1393; ROBERT F, 2003, P AN M AM SOC CLIN, V22, P643; Rosell R, 1999, LUNG CANCER, V26, P7, DOI 10.1016/S0169-5002(99)00045-8; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sanchez-Alcazar JA, 2003, LUNG CANCER-J IASLC, V40, P33, DOI 10.1016/S0169-5002(02)00530-5; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SHIN DM, 2001, P AN M AM SOC CLIN, V20, pA82; SMYLIE M, 2001, P AN M AM SOC CLIN, V20, pA307; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TONATO M, 2002, P AN M AM SOC CLIN, V21, pA290; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Van Meerbeeck JP, 2001, P AN M AM SOC CLIN, V20, p308a; Wakeling AE, 2002, CANCER RES, V62, P5749; Wedge SR, 2002, CANCER RES, V62, P4645; WEDGE SR, 2000, P AM ASSOC CANC RES, V41, P3610; Wolff H, 1998, CANCER RES, V58, P4997; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; YUEN A, 2001, P AN M AM SOC CLIN, V20, pA309; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; ZINNER GR, 2001, P AN M AM SOC CLIN, V20, pA328	89	88	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6629	6638		10.1038/sj.onc.1206957	http://dx.doi.org/10.1038/sj.onc.1206957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528288				2022-12-17	WOS:000185700700020
J	Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ				Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ			High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity	ONCOGENE			English	Article						C-FABP; prostate cancer; antisense transcript; DNA transfection; tumorigenicity	ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMAS; DIFFERENTIAL GENE-EXPRESSION; MESSENGER-RNA; TUMOR-CELLS; RECEPTOR; RAT; METASTASIS; DISPLAY; CANCER	The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues was examined by immunohistochemistry. Among the 76 cases, all seven (100%) normal tissues were unstained. Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens were unstained and 10 (28.6%) were stained positively. For the 34 prostatic carcinomas, the C-FABP expression was remarkably increased: 25 (73.5%) samples stained positively, and only nine (26.5%) were unstained. Transfection of a vector expressing an antisense C-FABP transcript into the PC-3M prostatic cancer cells yielded two transfectant lines: PC-3M-CFABP-1 and PC-3M-CFABP-3, producing, respectively, a 3.8- and a 6.9-fold reduction in C-FABP levels. Comparing with the control transfectants, the in vitro invasiveness of both PC-3M-CFABP-1 and PC-3M-CFABP-3 was significantly reduced. When tested in nude mouse, the average size of tumours produced by PC-3M-CFABP-1 and by PC-3M-CFABP-3 was reduced by 2.9- and 4.2-fold respectively, in comparison with that of tumours produced by the control transfectants. Analysis showed that the decreased vascular endothelial growth factor (VEGF) and microvessel densities in the tumours were associated with the reduced C-FABP. These data show that C-FABP is increased in prostatic carcinoma cells and suppression of its expression can significantly inhibit the tumorigenicity, probably by reducing the expression of VEGF.	Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Niigata University; University of Liverpool	Ke, YQ (corresponding author), Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England.							ALBINI A, 1987, CANCER RES, V47, P3239; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Celis A, 1999, ELECTROPHORESIS, V20, P355, DOI 10.1002/(SICI)1522-2683(19990201)20:2<355::AID-ELPS355>3.0.CO;2-N; Celis JE, 1996, CANCER RES, V56, P4782; Chen HJ, 2000, BRIT J CANCER, V82, P1694; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Deshmukh N, 1997, BRIT J UROL, V80, P869, DOI 10.1046/j.1464-410X.1997.00479.x; Foster CS, 1999, BJU INT, V83, P171; Foster CS, 2002, J PATHOL, V197, P551, DOI 10.1002/path.1194; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P1, DOI 10.1016/S0952-3278(97)90484-1; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Jackson MW, 2002, CANCER RES, V62, P854; JANIK P, 1975, CANCER RES, V35, P3698; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jing C, 2001, CANCER RES, V61, P4357; Jing C, 2000, ANAL BIOCHEM, V287, P334, DOI 10.1006/abio.2000.4864; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; Ke Y, 1998, BRIT J CANCER, V77, P287, DOI 10.1038/bjc.1998.45; KE YQ, 1993, J CELL SCI, V106, P135; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Ke YQ, 1999, ANAL BIOCHEM, V269, P201, DOI 10.1006/abio.1999.4014; Ke YQ, 1999, NUCLEIC ACIDS RES, V27, P912, DOI 10.1093/nar/27.3.912; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Landers J, 1999, COLON LAT AM HIST R, V8, P1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297; Ostergaard M, 1997, CANCER RES, V57, P4111; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H; Smith P, 1998, FEBS LETT, V423, P19, DOI 10.1016/S0014-5793(98)00050-7; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; STORCH J, 1990, J BIOL CHEM, V265, P7827; Veikkola T, 2000, CANCER RES, V60, P203; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Watanabe R, 1997, J DERMATOL SCI, V16, P17, DOI 10.1016/S0923-1811(97)00615-4; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665	42	88	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2739	2749		10.1038/sj.onc.1206341	http://dx.doi.org/10.1038/sj.onc.1206341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743598				2022-12-17	WOS:000182569300005
J	Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K				Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K			Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia	ONCOGENE			English	Article						beta-catenin; prostate; neoplasia; metaplasia	COLORECTAL-CANCER; APC GENE; MAMMARY-GLAND; MICE; CELLS; EXPRESSION; MUTATIONS; POLYPOSIS; ACTIVATION; CARCINOMA	The present study documents that stabilization of beta-catenin is sufficient to induce lesions reminiscent of prostate intraepithelial neoplasia (PIN). Such lesions were present in all compound mutant mice and all prostate acini expressing stabilized beta-catenin. High grade PIN-like lesions resembling early human prostate cancer were detected as early as 10 weeks of age. Surprisingly, stabilization of beta-catenin in other secretory epithelia including salivary, preputial, harderian, and mammary glands induced extensive squamous metaplasia and keratinization associated with terminal differentiation of the target cells, but failed to cause neoplastic transformation. Epidermal hyperplasia, hair follicle cysts, and odontomas were also observed. The prostatic lesions exhibited upregulation of c-myc, increased rate of cellular proliferation, loss of the Na-K-Cl co-transporter NKCC1, and expression of androgen receptor. Basal cell markers such as p63 and keratin 5 were not expressed by the masses of PIN-like lesions, but were present in small foci of proliferating beta-catenin expressing basal cells. Our observations indicate that beta-catenin stabilization is a crucial event for the initiation of PIN-like lesions, but induces squamous metaplasia rather than tumorigenesis in secretory epithelia other than the prostate.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Khazaie, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Klein, Ludger/G-8785-2011	Klein, Ludger/0000-0003-2054-071X				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Davies G, 2000, J UROLOGY, V163, P985, DOI 10.1016/S0022-5347(05)67869-X; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hayward SW, 1996, ACTA ANAT, V155, P81; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; IOZZO RV, 1995, CANCER RES, V55, P3495; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; LAU W, 2001, NAT GENET, V28, P3; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; LUONGO C, 1994, CANCER RES, V54, P5947; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULHOLLAND DJ, 2002, J BIOL CHEM, V20, P20; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Rashid MG, 2001, CANCER RES, V61, P489; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sparks AB, 1998, CANCER RES, V58, P1130; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUNDBERG JP, 2000, COLON CANC STUDY SEC; SUZUKI H, 1994, JPN J CANCER RES, V85, P847, DOI 10.1111/j.1349-7006.1994.tb02957.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; YANG F, 2002, J BIOL CHEM, V15, P15	47	88	92	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4099	4107		10.1038/sj.onc.1205562	http://dx.doi.org/10.1038/sj.onc.1205562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037666				2022-12-17	WOS:000176186000004
J	Hochedlinger, K; Wagner, EF; Sabapathy, K				Hochedlinger, K; Wagner, EF; Sabapathy, K			Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis	ONCOGENE			English	Article						JNK; c-Jun; apoptosis; UV irradiation; TNF-alpha; sorbitol	C-JUN; ACTIVATION; KINASE; ABSENCE	The c-Jun N-terminal kinases (JNKs) are activated by a variety of stress inducing agents and are thought to regulate apoptosis in a cell type and signal-specific manner. We have used fibroblasts lacking JNK1 or JNK2 to define their roles in response to different stress signals. Lack of JNK1 results in reduced c-Jun phosphorylation and resistance to UV-induced cell death. JNK2 deficient cells show increased sensitivity to UV irradiation which correlates with elevated and sustained phosphorylation of JNK1 and c-Jun. On the contrary, both Jnk1(-/-) and Jnk2(-1) cells were more sensitive to tumor necrosis factor - alpha (TNF-alpha) and sorbitol-induced cell death. Treatment of Jnk1(-/-) cells with these reagents resulted in reduced JNK activity and a concomitant reduction of c-Jun phosphorylation, suggesting that phosphorylation of c-Jun does not influence TNF-alpha and sorbitol-induced apoptosis in fibroblasts. Moreover, both JNK1 and JNK2 appear to negatively regulate apoptosis independent of c-Jun phosphorylation. These data provide genetic evidence that although the JNK pathway is activated by a plethora of signals, it is required only for the induction of UV-induced cell death in a c-Jun phosphorylation-dependent manner, but not for TNF-alpha and sorbitol-induced apoptosis.	Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Res Inst Mol Pathol, A-1030 Vienna, Austria	National Cancer Centre Singapore (NCCS); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sabapathy, K (corresponding author), Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	emrksb@nccs.com.sg		Wagner, Erwin F/0000-0001-7872-0196				Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	15	88	90	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2441	2445		10.1038/sj.onc.1205348	http://dx.doi.org/10.1038/sj.onc.1205348			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948429				2022-12-17	WOS:000174635600018
J	Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M				Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M			Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells	ONCOGENE			English	Article						PPAR-gamma; thiazolidinediones; GADD153; apoptosis; lung carcinoma	PREPROTHYROTROPIN-RELEASING HORMONE; HUMAN BREAST-CANCER; PPAR-GAMMA; BINDING PROTEIN; TERMINAL DIFFERENTIATION; INSULIN-RESISTANCE; IN-VITRO; APOPTOSIS; CHOP; EXPRESSION	Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by the thiazolidinedione (TZD) class of antidiabetic drugs elicits growth inhibition in a variety of malignant tumors. We clarified the effects of TZDs on growth of human non-small cell lung carcinoma (NSCLC) cells that express endogenous PPAR-gamma Troglitazone and pioglitazone caused inhibition of cellular growth and induced apoptosis of NSCLC cells, in a time- and dose-dependent manner. Subtraction, cloning analysis identified that troglitazone stimulated, expression of the growth arrest and DNA-damage inducible (GADD) 153 gene, and the increased expression, of GADD153 mRNA was also confirmed by an array analysis of the 160 apoptosis-related genes. Western blot analysis revealed that troglitazone also increased, GADD153 protein levels in a time-dependent manner., Troglitazone did not stimulate GADD153 mRNA levels in undifferentiated 3T3-L1 cells lacking PPAR-gamma expression, whereas its induction was clearly observed in differentiated adipocytes expressing PPAR-gamma. Activity of the GADD153 promoter occurred in a NSCLC cell line in transient transcription assays and was significantly stimulated by troglitazone, although binding of PPAR/retinoid X receptor heterodimer was not detected in the promoter region in gel retardation assays. Inhibition of GADD153 gene expression by an antisense phosphorothionate oligonucleotide attenuated the troglitazone-induced growth inhibition. These findings collectively indicated that activation of PPAR-gamma by TZDs, could cause growth inhibition and apoptosis of NSCLC cells and that GADD153 might be a candidate factor implicated in these processes.	Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan; Gunma Univ, Sch Med, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718511, Japan	Gunma University; Gunma University	Mori, M (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan.	mmori@med.gunma-u.ac.jp						APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang TH, 2000, CANCER RES, V60, P1129; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kameda T, 1999, BBA-GENE STRUCT EXPR, V1445, P31, DOI 10.1016/S0167-4781(99)00018-4; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEUTHY JD, 1990, J BIOL CHEM, V265, P16251; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ohtani K, 1998, ENDOCRINOLOGY, V139, P172, DOI 10.1210/en.139.1.172; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Palakurthi SS, 2001, CANCER RES, V61, P6213; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Ren Y, 1998, ENDOCRINOLOGY, V139, P195, DOI 10.1210/en.139.1.195; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SATOH T, 1993, MOL BRAIN RES, V20, P353, DOI 10.1016/0169-328X(93)90062-T; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	54	88	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2171	2180		10.1038/sj.onc.1205279	http://dx.doi.org/10.1038/sj.onc.1205279			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948400				2022-12-17	WOS:000174555300006
J	Corey, DR				Corey, DR			Telomerase inhibition, oligonucleotides, and clinical trials	ONCOGENE			English	Article						telomerase; oligonucleotides; 2 '-methoxyethyl RNA; telomere	PEPTIDE NUCLEIC-ACIDS; ANTISENSE OLIGONUCLEOTIDES; RNA; CELLS; MECHANISMS; TARGET; GENE	Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2'-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.corey@utsouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907, R01CA085363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060642] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85363, P50CA70907] Funding Source: Medline; NIGMS NIH HHS [GM 60642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; Elayadi AN, 2001, NUCLEIC ACIDS RES, V29, P1683, DOI 10.1093/nar/29.8.1683; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; Geary R S, 2001, Curr Opin Investig Drugs, V2, P562; GEARY RS, 2000, ANTISENSE NUC ACID D, V10, P35; Grillone LR, 2001, DRUG TODAY, V37, P245, DOI 10.1358/dot.2001.37.4.620590; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hamilton SE, 1999, CHEM BIOL, V6, P343, DOI 10.1016/S1074-5521(99)80046-5; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Henry S, 2000, J PHARMACOL EXP THER, V292, P468; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herbert BS, 2001, JNCI-J NATL CANCER I, V93, P39, DOI 10.1093/jnci/93.1.39; Khatsenko O, 2000, ANTISENSE NUCLEIC A, V10, P35, DOI 10.1089/oli.1.2000.10.35; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Ludwig A, 2001, CANCER RES, V61, P3053; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P871, DOI 10.1001/jama.280.10.871; Matthes E, 1999, NUCLEIC ACIDS RES, V27, P1152, DOI 10.1093/nar/27.4.1152; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Rusckowski M, 1997, CANCER, V80, P2699, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2699::AID-CNCR48>3.0.CO;2-4; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; YUEN A, 2001, AM SOC CLIN ONCOLOGY; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	39	88	100	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					631	637		10.1038/sj.onc.1205063	http://dx.doi.org/10.1038/sj.onc.1205063			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850789				2022-12-17	WOS:000173390500016
J	Piazza, F; Gurrieri, C; Pandolfi, PP				Piazza, F; Gurrieri, C; Pandolfi, PP			The theory of APL	ONCOGENE			English	Article						APL; transgenic mice; KO mice; animal models; tumor metamorphosers	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; ZINC FINGER GENE; TRANSGENIC MICE; CELL-DIFFERENTIATION; PREMATURE SENESCENCE; HISTONE DEACETYLASE; FUSION PROTEINS; ONCOGENIC RAS	Acute promyelocytic leukemia (APL) is associated with reciprocal and balanced chromosomal translocations always involving the Retinoic Acid Receptor alpha (RAR alpha) gene on chromosome 17 and variable partner genes (X genes) on distinct chromosomes. RARa fuses to the PML gene in the vast majority of APL cases, and in a few cases to the PLZF, NPM, NuMA and STAT5b genes. As a consequence, X-RAR alpha and RAR alpha -X fusion genes are generated encoding aberrant fusion proteins that can interfere with X and/or RAR alpha function. Here we will review the relevant conclusions and the open questions that stem from a decade of in giro analysis of APL pathogenesis in the mouse in transgenic and knock-out models.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr,Mol Biol Program, Sloan Kettering Div,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr,Mol Biol Program, Sloan Kettering Div,Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Piazza, Francesco/K-6695-2016; Piazza, Francesco/AAD-1600-2019	Piazza, Francesco/0000-0002-2831-623X; Piazza, Francesco/0000-0002-2831-623X; gurrieri, carmela/0000-0001-8233-6007				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	47	88	91	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7216	7222		10.1038/sj.onc.1204855	http://dx.doi.org/10.1038/sj.onc.1204855			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704849				2022-12-17	WOS:000171891900009
J	Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P				Gozuacik, D; Murakami, Y; Saigo, K; Chami, M; Mugnier, C; Lagorce, D; Okanoue, T; Urashima, T; Brechot, C; Paterlini-Brechot, P			Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging	ONCOGENE			English	Article						hepatitis B virus; Alu-PCR; gene trap; cancer; insertional mutagenesis; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; CELLS; INTEGRATION; GENOME; MUTAGENESIS; REPLICATION; IDENTIFY; PROTEINS; LEUKEMIA	Proviral tagging has been used in animals as a powerful tool for cancer genetics. We show that a similar approach is possible in patients with hepatocellular carcinoma (HCC) infected by Hepatitis B Virus (HBV), a human pararetrovirus which may act by insertional mutagenesis. In this work, the HBV genome is used as a probe to identify cancer-related genes. By using HBV-Alu-PCR, we obtained 21 HBV/cellular DNA junctions from 18 different patients. In six of 21, we found the HBV DNA integrated into a cellular gene: (1) Sarco/Endoplasmic Reticulum Calcium ATPase1 Gene; (2) Thyroid Hormone Receptor Associated Protein 150 alpha Gene; (3) Human Telomerase Reverse Transcriptase Gene; (4) Minichromosome Maintenance Protein (MCM)-Related Gene; (5) FR7, a new gene expressed in human liver and cancer tissues; and (6) Nuclear Matrix Protein p84 Gene. Seven junctions contained unique cellular sequences. In the remaining eight, the HBV DNA was next to repetitive sequences, five of them of LINE1 type. The cellular genes targeted by HBV are key regulators of cell proliferation and viability. Our results show that studies on HBV-related HCCs allow to identify cellular genes involved in cancer. We therefore propose this approach as a valuable tool for functional cancer genomic studies in humans.	Necker Inst, INSERM, U370, F-75015 Paris, France; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Necker Enfants Malad Hosp, Dept Biotech & Med Informat, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kyoto Prefectural University of Medicine; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Necker Inst, INSERM, U370, F-75015 Paris, France.		Devrim, Gozuacik/C-3330-2008; Chami, Mounia/S-6471-2019	Devrim, Gozuacik/0000-0001-7739-2346; Chami, Mounia/0000-0003-1498-7187; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Cecconi F, 2000, FEBS LETT, V480, P63, DOI 10.1016/S0014-5793(00)01779-8; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Evans MJ, 1997, TRENDS GENET, V13, P370, DOI 10.1016/S0168-9525(97)01240-7; Fourel G, 1994, PRIMARY LIVER CANC E, P89; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JOHNSON PJ, 1994, PRIMARY LIVER CANC E, P31; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Largaespada DA, 2000, LEUKEMIA, V14, P1174, DOI 10.1038/sj.leu.2401852; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; SCHLUTER V, 1994, ONCOGENE, V9, P1; Todovov IT, 1998, LAB INVEST, V78, P73; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	32	88	95	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6233	6240		10.1038/sj.onc.1204835	http://dx.doi.org/10.1038/sj.onc.1204835			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593432				2022-12-17	WOS:000171206300015
J	Forrest, A; Gabrielli, B				Forrest, A; Gabrielli, B			Cdc25B activity is regulated by 14-3-3	ONCOGENE			English	Article						cdc25; 14-3-3; G2 checkpoint	DNA-DAMAGE CHECKPOINT; MULTIPLE SIGNALING PATHWAYS; HUMAN-CELLS; G2/M PROGRESSION; PHASE-TRANSITION; PROTEIN-KINASE; GROWTH-CONTROL; FISSION YEAST; HELA-CELLS; PHOSPHATASE	In the G2 phase cell cycle checkpoint arrest, the cdc25-dependent activation of cyclin B/cdc2, a critical step in regulating entry into mitosis, is blocked. Studies in yeast have demonstrated that the inhibition of cdc25 function involves 14-3-3 binding to cdc25, In humans, two cdc25 isoforms have roles in G2/M progression, cdc25B and cdc25C, both bind 14-3-3, Abrogating 14-3-3 binding to cdc25C attenuates the G2 checkpoint arrest, but the contribution of 14-3-3 binding to the regulation of cdc25B function is unknown. Here we demonstrate that high level over-expression of cdc25B in G2 checkpoint arrested cells can activate cyclin B/cdc2 and overcome the checkpoint arrest. Mutation of the major 14-3-3 binding site, S323, or removal of the N-terminal regulatory domain are strong activating mutations, increasing the efficiency with which the mutant forms of cdc25B not only overcome the arrest, but also initiate aberrant mitosis, We also demonstrate that 14-3-3 binding to the S323 site on cdc25B blocks access of the substrate cyclin/cdks to the catalytic site of the enzyme, thereby directly inhibiting the activity of cdc25B, This provides direct mechanistic evidence that 14-3-3 binding to cdc25B can regulate its activity, thereby controlling progression into mitosis.	Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Gabrielli, Brian G/B-3655-2011; Forrest, Alistair/A-6597-2008	Gabrielli, Brian G/0000-0003-3933-1651; Forrest, Alistair/0000-0003-4543-1675				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kovelman R, 1996, MOL CELL BIOL, V16, P86; Lammer C, 1998, J CELL SCI, V111, P2445; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	43	88	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4393	4401		10.1038/sj.onc.1204574	http://dx.doi.org/10.1038/sj.onc.1204574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466620				2022-12-17	WOS:000169912600013
J	Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A				Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A			Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations	ONCOGENE			English	Article						FGFR3 mutations; multiple myeloma; t(4;14)	GROWTH-FACTOR RECEPTOR-3; T(4/14)(P16.3,Q32) CHROMOSOMAL TRANSLOCATION; LETHAL SKELETAL DYSPLASIA; CHONDROCYTE PROLIFERATION; ACTIVATING MUTATIONS; GENE; TRANSMEMBRANE; TRANSFORMATION; EXPRESSION; REGION	The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20%, of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the fibroblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/ MMSET, Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial, Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line, All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb, We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation, Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand, In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades, However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition, Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at different levels) but not G384D or the wild-type receptor, can induce transformed foci, Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14).	Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, I-20122 Milan, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; Osped Maggiore, IRCCS, Div Internal Med 3, Milan, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Brescia, Italy; Kawasaki Med Sch, Dept Hyg, Okayama, Japan	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Brescia; Kawasaki Medical School	Neri, A (corresponding author), Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, Via Francesco Sforza 35, I-20122 Milan, Italy.		Neri, Antonino/I-9690-2014; Dell'Era, Patrizia/ABD-5848-2020; Colombo, Gualtiero I./B-4737-2010; Greco, Angela/C-1953-2017; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Neri, Antonino/0000-0001-9047-5912; Colombo, Gualtiero I./0000-0002-7348-1939; Greco, Angela/0000-0003-2994-0349; Dell'Era, Patrizia/0000-0001-6682-6321; RONCHETTI, Domenica/0000-0002-4824-3445				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CATLETTFALCONE R, 1999, IMMUNITY, V16, P2647; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Francomano C. A., 1996, American Journal of Human Genetics, V59, pA25; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kannan K, 2000, IUBMB LIFE, V49, P197; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Li ZH, 1998, BLOOD, V92, p383A; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Malgeri U, 2000, CANCER RES, V60, P4058; MUENKE M, 1997, TIG, V11, P308; MURGUE B, 1994, CANCER RES, V54, P5206; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RONCHETTI D, 2001, IN PRESS LEUKEMIA; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081	45	88	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3553	3562		10.1038/sj.onc.1204465	http://dx.doi.org/10.1038/sj.onc.1204465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429702				2022-12-17	WOS:000169478300011
J	Huang, SM; Schonthal, AH; Stallcup, MR				Huang, SM; Schonthal, AH; Stallcup, MR			Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1	ONCOGENE			English	Article						Zac1; p53; E6 protein; transcriptional coactivator; transcriptional activation	HUMAN-PAPILLOMAVIRUS TYPE-16; ZINC-FINGER PROTEIN; HUMAN BREAST-CANCER; RECEPTOR SIGNALING PATHWAYS; TUMOR-SUPPRESSOR P53; NEGATIVE REGULATOR; E6 ONCOPROTEIN; CELLS; EXPRESSION; GROWTH	A recently discovered potential tumor suppressor protein, Zac1, was previously shown to promote cell cycle arrest and apoptosis, and to act as a positive or negative transcriptional cofactor for nuclear receptors, Since these activities are common to Zac1 and p53, we tested for a functional interaction between these two proteins by investigating possible effects of Zac1 on the transcriptional activator function of p53. Zac1 specifically enhanced the activity of p53-responsive promoters in cells expressing wild type p53, The same promoters were not activated by Zac1 in cells lacking functional p53, but the Zac1 effect was restored by co-expression of p53. Zac1 bound to p53 and enhanced the activity of p53 or its N-terminal transcriptional activation domain fused to the DNA binding domain of Gal4. These results indicate that Zac1 served as a transcriptional coactivator for p53. The enhancement of p53 activity by Zac1 was much more dramatic in HeLa cells than in other cell Lines tested. HeLa cells express human papillomavirus type 18 E6 protein which inactivates and causes the degradation of p53. Physical and functional interactions observed between Zac1 and E6 protein indicated that the dramatic activity of Zac1 in HeLa cells was due not only to Zac1's coactivator effect on p53, but also to the ability of Zac1 to reverse E6 inhibition of p53.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NCI NIH HHS [CA74278] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTEK J, 1990, ONCOGENE, V5, P893; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoffmann A, 1998, ANN NY ACAD SCI, V865, P49, DOI 10.1111/j.1749-6632.1998.tb11162.x; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1987, CANCER RES, V47, P4229; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; TAM SW, 1994, ONCOGENE, V9, P2663; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	31	88	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2134	2143		10.1038/sj.onc.1204298	http://dx.doi.org/10.1038/sj.onc.1204298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360197				2022-12-17	WOS:000168116700008
J	Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B				Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B			Regulation of CDC25B phosphatases subcellular localization	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinases; CDC25B; localization; nuclear export sequence	NUCLEAR EXPORT; FISSION YEAST; TRANSCRIPTION FACTOR; MITOTIC INDUCER; PROTEIN-KINASE; CDK REGULATION; DNA-DAMAGE; MITOSIS; SIGNAL; TRIGGERS	The CDC25B dual specificity phosphatase is involved in the control of the G2/M transition of the cell cycle. Subcellular localization might represent an important aspect of the regulation of its activity, We have examined in transiently transfected asynchronous HeLa cells the localization of HA-tagged CDC25B proteins and found that they are nuclear or cytoplasmic suggesting the existence of an active shuttling. Accordingly, localization analysis of deletion and truncation proteins indicates that CDC25B contains a putative nuclear localization signal located between residues 335 and 353. We also demonstrated that a short 58 residues deletion of the amino-terminus end of CDC25B is sufficient to retain it to the nucleus, Mutational analysis indicates that a nuclear export sequence is located between residues 28 and 40. In addition, treatment of the cells with the exportin inhibitor, Leptomycin B, has the same effect, The mutation of Ser-323, a residue that is essential for the interaction with 14-3-3 proteins, also abolishes cytoplasmic staining. The subcellular localization of CDC25B is therefore dependent on the combined effects of a nuclear localization signal, a nuclear export signal and on the interaction with 14-3-3 proteins.	Univ Toulouse 3, LBCMCP, CNRS UMR5088, F-31062 Toulouse, France; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Tokyo	Ducommun, B (corresponding author), Univ Toulouse 3, LBCMCP, CNRS UMR5088, 118 Route Narbonne, F-31062 Toulouse, France.		BALDIN, Véronique/Y-8397-2019; Forrest, Alistair/A-6597-2008; DUCOMMUN, Bernard/B-3208-2008; Gabrielli, Brian G/B-3655-2011	BALDIN, Véronique/0000-0001-8523-0494; Forrest, Alistair/0000-0003-4543-1675; Gabrielli, Brian G/0000-0003-3933-1651; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	31	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2179	2185		10.1038/sj.onc.1203545	http://dx.doi.org/10.1038/sj.onc.1203545			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822367				2022-12-17	WOS:000086974100002
J	Leu, CM; Chang, CM; Hu, CP				Leu, CM; Chang, CM; Hu, CP			Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway	ONCOGENE			English	Article						EGF; apoptosis; MAP kinase; Mcl-1; human esophageal carcinoma	HUMAN ESOPHAGEAL-CARCINOMA; SQUAMOUS-CELL CARCINOMAS; BREAST-CANCER-CELLS; HAMSTER OVARY CELLS; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; PROGNOSTIC-SIGNIFICANCE; SIGNAL-TRANSDUCTION; SURVIVAL FACTOR; FACTOR-ALPHA	Overexpression of epidermal growth factor receptor (EGFR) and establishment of transforming growth factor alpha (TGF alpha)/EGF autocrine system are frequently detected in tumor cells. In addition to mitogenic ability, we demonstrate in this report that EGF protects a human esophageal carcinoma (CE) cell line, CE81T/VGH, from staurosporine-induced apoptosis, The anti-apoptotic signal of EGF is alleviated by a MEK inhibitor PK98059 or an ERK2 dominant negative mutant but not by a phosphatidylinositol-3'-kinase (PI-3K) inhibitor wortmannin, Furthermore, v-raf blocks apoptosis induced by staurosporine, This evidence implies that the survival signal of EGF is mediated via the Raf-MEK-ERK pathway but not the PI3-K pathway. The survival effect of EGF is coincident with the induction of mcl-1, an anti-apoptotic gene in the bcl-2 family. PD98059 also suppresses the induction of Mcl-1 by EGF, implying that EGF may up-regulate Mcl-1 via the MAP kinase pathway. Overexpression of mcl-1 is sufficient to protect against apoptosis, while transfection of a mcl-1 antisense plasmid causes cell death. The expression of mcl-1 antisense plasmid also suppresses the anti-apoptotic effect of EGF. Taken together, these results indicate that EGF may up-regulate Mcl-1 through the MAP kinase pathway to suppress apoptosis.	Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Hlth Res Inst, Intramural Res Affairs, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Hu, CP (corresponding author), Vet Gen Hosp, Dept Med Res & Educ, 201 Shih Pai Rd,Sec 2, Taipei 11217, Taiwan.		Chang, Chung-Ming/E-3945-2010					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CHEN SC, 1991, CANCER RES, V51, P1898; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dunn SE, 1997, CANCER RES, V57, P2687; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; HU CP, 1984, J NATL CANCER I, V72, P577; IIHARA K, 1993, CANCER, V71, P2902, DOI 10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu YC, 1996, EXP CELL RES, V228, P206, DOI 10.1006/excr.1996.0318; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Minshall C, 1996, J IMMUNOL, V156, P939; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; OZAWA S, 1987, INT J CANCER, V39, P333, DOI 10.1002/ijc.2910390311; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, J BIOL CHEM, V272, P154; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Turner BC, 1997, CANCER RES, V57, P3079; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wong Fen-Hwa, 1992, Chinese Journal of Microbiology and Immunology (Taipei), V25, P59; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	88	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1665	1675		10.1038/sj.onc.1203452	http://dx.doi.org/10.1038/sj.onc.1203452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763823				2022-12-17	WOS:000086083800006
J	Wennbo, H; Tornell, J				Wennbo, H; Tornell, J			The role of prolactin and growth hormone in breast cancer	ONCOGENE			English	Article						prolactin; growth hormone; transgenic mice; mammary cancer; auto/paracrine	MESSENGER-RIBONUCLEIC-ACID; MAMMARY-GLAND DEVELOPMENT; RECEPTOR GENE; TRANSGENIC MICE; PROGESTERONE RECEPTORS; EXPRESSION; RAT; TUMORS; ACTIVATION; PITUITARY	This review will focus on the role for prolactin (PRL) and growth hormone (GH) in mammary tumor formation. Much attention has previously been focused on circulating levels of GH/PRL in relation to mammary tumor formation. We will review data demonstrating that these ligands also could be produced locally in different organs, including the mammary gland and mammary tumors, and suggest that this local production may be of importance for pathological conditions. We will also discuss mechanisms for crosstalk between steroids and GH/PRL. A crosstalk between GH- and PRL response is possible at multiple levels. In the human, GH can activate both the prolactin receptor (PRLR) and the growth hormone receptor (GHR), We have demonstrated that activation of the PRLR, but not the GHR, is inducing mammary tumors in transgenic mice. Furthermore, the elevated levels of insulin-like growth factor 1 (IGF-I) seen in the GHR activating transgenic mice is not sufficient for tumor induction. The induced tumors express functionally active prolactin that could be of importance for the tumor formation. Paracrine/aurocrine stimulation by PRL may be more important than PRL transported via the circulation. In women, the role for stimulation of the PRLR and/or the GHR in mammary tumor formation has not been proven, although experiments from primates suggest that the PRLR could be of importance.	Univ Gothenburg, Dept Physiol, Gothenburg, Sweden; Astra Transgen Ctr, Molndal, Sweden	University of Gothenburg	Tornell, J (corresponding author), Univ Gothenburg, Dept Physiol, Gothenburg, Sweden.							ADLER RA, 1986, ENDOCR REV, V7, P302, DOI 10.1210/edrv-7-3-302; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/edrv-17-6-639; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DECOUVELAERE C, 1995, CELL GROWTH DIFFER, V6, P477; EMERMAN JT, 1985, HORM METAB RES, V17, P421, DOI 10.1055/s-2007-1013563; FELDMAN M, 1993, ENDOCRINOLOGY, V133, P1602, DOI 10.1210/en.133.4.1602; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; GINSBURG E, 1996, BIOL SIGNALING MAMMA; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; Humphreys RC, 1997, MOL ENDOCRINOL, V11, P801, DOI 10.1210/me.11.6.801; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; ITUARTE EA, 1984, ANN INTERN MED, V101, P627, DOI 10.7326/0003-4819-101-5-627; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; KURTZ A, 1993, BIOL REPROD, V48, P1095, DOI 10.1095/biolreprod48.5.1095; KWA HG, 1974, LANCET, V1, P433; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LUENG DD, 1987, NATURE, V330, P1782; MATSUZAWA A, 1986, INT REV CYTOL, V103, P303, DOI 10.1016/S0074-7696(08)60839-6; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Mertani HC, 1998, INT J CANCER, V79, P202; MOL JA, 1995, J CLIN ENDOCR METAB, V80, P3094, DOI 10.1210/jc.80.10.3094; MOL JA, 1995, J CLIN INVEST, V95, P2028, DOI 10.1172/JCI117888; MURPHY LJ, 1984, CANCER RES, V44, P1963; MUSEY VC, 1987, NEW ENGL J MED, V316, P229, DOI 10.1056/NEJM198701293160501; NABARRO JD, 1987, CLIN ENDOCRINOL, V26, P327; NAGASAWA H, 1979, EUR J CANCER, V15, P267, DOI 10.1016/0014-2964(79)90037-9; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SELMAN PJ, 1994, ENDOCRINOLOGY, V134, P287, DOI 10.1210/en.134.1.287; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TORNELL J, 1992, J STEROID BIOCHEM, V43, P237, DOI 10.1016/0960-0760(92)90213-3; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANGILDER JC, 1975, ARCH SURG-CHICAGO, V110, P293; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yang XF, 1996, CANCER RES, V56, P1509; ZUMOFF B, 1988, ANTICANCER RES, V8, P627	56	88	93	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1072	1076		10.1038/sj.onc.1203349	http://dx.doi.org/10.1038/sj.onc.1203349			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713692				2022-12-17	WOS:000085796400014
J	Tallquist, MD; Soriano, P; Klinghoffer, RA				Tallquist, MD; Soriano, P; Klinghoffer, RA			Growth factor signaling pathways in vascular development	ONCOGENE			English	Review						receptor tyrosine kinases; endothelial cells; vascular smooth muscle cells	RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; ENDOTHELIAL-CELL SURVIVAL; NEURAL CREST MIGRATION; MAJOR BINDING-SITE; PDGF-BETA-RECEPTOR; SRC-FAMILY KINASES; LIGAND-BINDING; EPH-FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE	Recent research on the formation and maintenance of the vasculature in the embryo and in the adult has provided a greater understanding of the cellular signals involved in these processes, With this understanding comes the potential means of controlling vascularization in pathological situations such as tumorigenesis and wounding. For the purpose of this review, we will discuss the key receptor tyrosine kinases involved in vascular function and the molecules which relay signals downstream of receptor activation. The receptor tyrosine kinases discussed include the vascular endothelial cell growth factor receptors, Eph receptors, Tie1, and Tie2, all of which: are expressed on vascular endothelial cells. We also discuss the roles of the platelet derived growth factor receptors which are expressed on vascular smooth muscle cells.: While all of these receptor tyrosine kinases activate many similar effector molecules, some of the signals initiated appear to be distinct. This may explain, at least in part, how different receptor tyrosine kinases expressed in overlapping patterns on the developing vasculature, direct unique biological functions.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Tallquist, MD (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA.		Soriano, Philippe M/E-5797-2015; Tallquist, Michelle/AAU-5277-2021	Soriano, Philippe M/0000-0002-0427-926X; Tallquist, Michelle/0000-0002-1383-144X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R01HD025326, R37HD025326] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25326, HD08412, HD24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Barleon B, 1997, J BIOL CHEM, V272, P10382; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BROCK TA, 1991, AM J PATHOL, V138, P213; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen J, 1996, ONCOGENE, V12, P979; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Desai J, 1999, BIOL REPROD, V60, P887, DOI 10.1095/biolreprod60.4.887; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ellis C, 1996, ONCOGENE, V12, P1727; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Esser S, 1998, J CELL SCI, V111, P1853; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HEUCHEL R, 1999, IN PRESS P NATL ACAD; Hidaka M, 1999, P NATL ACAD SCI USA, V96, P7370, DOI 10.1073/pnas.96.13.7370; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; HUANG LW, 1995, ONCOGENE, V11, P2097; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; INUI H, 1994, J BIOL CHEM, V269, P30546; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; KORHONEN J, 1994, ONCOGENE, V9, P395; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Rodewald HR, 1996, ONCOGENE, V12, P397; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; TANAKA S, 1993, MOL CELL BIOL, V14, P5495; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zent R, 1998, EXP CELL RES, V240, P134, DOI 10.1006/excr.1998.4008; ZIEGLER SF, 1993, ONCOGENE, V8, P663; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	193	88	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7917	7932		10.1038/sj.onc.1203216	http://dx.doi.org/10.1038/sj.onc.1203216			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630644				2022-12-17	WOS:000084405900008
J	He, LZ; Merghoub, T; Pandolfi, PP				He, LZ; Merghoub, T; Pandolfi, PP			In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications	ONCOGENE			English	Review						APL; transgenic mice; cell differentiation; retinoic acid; HDACI	PML-RAR-ALPHA; ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; ARSENIC TRIOXIDE AS2O3; CHRONIC MYELOGENOUS LEUKEMIA; NUCLEAR MATRIX PROTEIN; ZINC-FINGER PROTEIN; HISTONE DEACETYLASE; FUSION GENE; DNA-BINDING	Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hemopoietic development, and is associated with reciprocal chromosomal translocations always involving the retinoic acid receptor alpha (RAR alpha) gene on chromosome 17. As a consequence of the translocation RAR alpha variably fuses to the PML, PLZF, NPM and NUMA genes (X genes), leading to the generation of RAR alpha-X and X-RAR alpha fusion genes. The aberrant chimeric proteins encoded by these genes may exert a crucial role in leukemogenesis. Retinoic acid (RA), a metabolite of vitamin A, can overcome the block of maturation at the promyelocytic stage and induce the malignant cells to terminally mature into granulocytes resulting in complete albeit transient disease remission. APL has become, for this reason, the paradigm for 'cancer differentiation therapy'. Furthermore, APL associated with translocation between the RAR alpha and the PLZF genes (PLZF-RAR alpha) shows a distinctly worse prognosis with poor response to chemotherapy and little or no response to treatment with RA, thus defining a new APL syndrome. Here we will focus our attention on the recent progresses made in defining the molecular mechanisms underlying the pathogenesis of this paradigmatic disease in vivo in the mouse. We will review the critical contribution of mouse modeling in unraveling the transcriptional basis for the differential response to RA in APL. We will also discuss how this new understanding has allowed to propose, develop and test in these murine leukemia models as veil as in human APL patients novel therapeutic strategies.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1273 York Ave, New York, NY 10021 USA.							ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Badiani PA, 1996, ONCOGENE, V13, P2205; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 1998, BLOOD, V92, p310A; BOYD AL, 1993, J ANIM SCI, V71, P1; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASSINAT B, 1998, BLOOD S, V92, pSA596; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; DUBOIS C, 1994, BLOOD, V83, P3264; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gudas Lorraine J., 1994, P443; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, BLOOD, V92, p510A; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 1998, BLOOD, V92, p480A; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Ivins S, 1998, BLOOD, V92, p308A; Jansen JH, 1998, BLOOD, V92, p402A; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOLLER E, 1991, LANCET, V338, P1154, DOI 10.1016/0140-6736(91)92021-S; LAFAGEPOCHITALOFF M, 1995, BLOOD, V85, P1169, DOI 10.1182/blood.V85.5.1169.1169; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LAVAU C, 1995, ONCOGENE, V11, P871; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1997, BLOOD, V90, P306; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pandolfi PP, 1998, SEMIN HEMATOL, V35, P136; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PECK R, 1991, EUR J CANCER, V27, P53, DOI 10.1016/0277-5379(91)90061-H; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Pollock Jessica L., 1997, Blood, V90, p320A; PUCCETTI E, 1998, BLOOD S, V92, pSA212; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego E, 1998, BLOOD, V92, p403A; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; TOBAL K, 1995, BRIT J HAEMATOL, V90, P615, DOI 10.1111/j.1365-2141.1995.tb05592.x; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang ZG, 1998, BLOOD, V92, p479A; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, LANCET, V341, P126, DOI 10.1016/0140-6736(93)92611-V; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; WESTERVELT P, 1997, BLOOD S, V92, pA322; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	119	88	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5278	5292		10.1038/sj.onc.1203088	http://dx.doi.org/10.1038/sj.onc.1203088			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498880				2022-12-17	WOS:000082808400006
J	Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A				Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A			Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation	ONCOGENE			English	Article						tumor suppressor gene; glioma; p21-ras; GTPase activating protein; neurofibromin	TYPE-1 GENE-PRODUCT; PROTEIN PRODUCT; RAS PROTEINS; EXPRESSION; CELLS; IDENTIFICATION; BRAIN; TISSUES; NEURONS; GAP	Individuals affected with neurofibromatosis 1 (NF1) harbor increased numbers of GFAP-immunoreactive cerebral astrocytes and develop astrocytomas that can lead to blindness and death. Mice heterozygous for a targeted Nf1 mutation (Nf1+/-) mere employed as a model for the human disease to evaluate the hypothesis that reduced NF1 protein (neurofibromin) expression may confer a growth advantage for astrocytes, such that inactivation of only one NF1 allele is sufficient for abnormal astrocyte proliferation. Here, me report that Nf1+/- mice have increased numbers of cerebral astrocytes and increased astrocyte proliferation compared to wild-type littermates. Intriguingly, primary Nf1+/- astrocyte cultures failed to demonstrate a cell-autonomous growth advantage unless they mere cocultured with C17 neuronal cells. This C17 neuronal cell-induced Nf1+/- increase in proliferation was blocked by MEK inhibition (PD98059), suggesting a p21-ras-dependent effect. Furthermore, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, demonstrated no increases in cerebral astrocyte number. These findings suggest that reduced NF1 expression results in a cell context-dependent increase in astrocyte proliferation that may be sufficient for the development of astrocytic growth abnormalities in patients with NF1.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Texas SW, Dallas, TX 75235 USA	Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.			Gutmann, David/0000-0002-3127-5045; Henkemeyer, Mark/0000-0002-7525-1061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADER JL, 1986, ANN NY ACAD SCI, V486, P57; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; ECCLESTON PA, 1989, DEVELOPMENT, V107, P107; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Giordano MJ, 1996, J NEUROSCI RES, V43, P246; GOLUBIC M, 1992, ONCOGENE, V7, P2151; Greenwood RS, 1997, ANN NEUROL, V42, pP4; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1996, ONCOGENE, V12, P2121; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HABIBY R, 1995, J PEDIATR-US, V126, P364, DOI 10.1016/S0022-3476(95)70449-3; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; HUYNH DP, 1992, NEUROSCI LETT, V143, P233, DOI 10.1016/0304-3940(92)90272-9; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1989, J PEDIATR-US, V114, P778, DOI 10.1016/s0022-3476(89)80137-4; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY PT, 1995, NEUROLOGY, V45, P1897, DOI 10.1212/WNL.45.10.1897; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORDLUND ML, 1995, J NEUROPATH EXP NEUR, V54, P588, DOI 10.1097/00005072-199507000-00013; Norton KK, 1996, NEUROREPORT, V7, P601, DOI 10.1097/00001756-199601310-00054; NORTON KK, 1995, NEUROBIOL DIS, V2, P13, DOI 10.1006/nbdi.1995.0002; PAXINOS G, 1986, MOUSE BRAIN STEREOTA; Pollack IF, 1996, NEUROLOGY, V46, P1652, DOI 10.1212/WNL.46.6.1652; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Rose K, 1993, IN VITRO BIOL METHOD, P46; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Said SMA, 1996, NEUROREPORT, V7, P1941, DOI 10.1097/00001756-199608120-00015; SOBUE G, 1984, BRAIN RES, V324, P175, DOI 10.1016/0006-8993(84)90639-5; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; [No title captured]	52	88	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4450	4459		10.1038/sj.onc.1202829	http://dx.doi.org/10.1038/sj.onc.1202829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442636				2022-12-17	WOS:000081813500007
J	Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE				Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE			NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways	ONCOGENE			English	Article						apoptosis; cell cycle; ErbB receptors; PKB; c-Src kinase	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR-RELATED PEPTIDES; TYROSINE KINASE; CANCER CELLS; EGF-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY	Neu differentiation factor (NDF)/heregulin activates ErbB2 via heterodimerization with the NDF receptors ErbB3 and ErbB4. Cells which express normal levels of these receptors are often growth stimulated by NDF, whereas SKBR3, and other ErbB2-overexpressing breast tumour cells are growth inhibited. We demonstrate here that in SKBR3 cells, NDF induces G1 progression but also causes a G2 delay from day 1 and apoptosis from days 2-3. G1 progression was associated with ErbB2 transactivation of ErbB3 and subsequent stimulation of the phosphatidylinositol 3-kinase (PI3K) whereas apoptosis was dependent on p38 MAPK. Inhibition of ERK1/ERK2 had no effect on cell cycle progression or apoptosis. Activation of ErbB3 and PI3K was also seen with betacellulin (BTC) but not epidermal growth factor (EGF) and. correlated with the growth effects of these ligands. All three ligands induced shortterm activation of p38 MAPK in a c-Src-dependent manner. However, only NDF caused a second, c-Src-independent increase in p38 MAPK activity which was required for apoptosis.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66,R-1066-206, CH-4058 Basel, Switzerland.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BERGER MS, 1988, CANCER RES, V48, P1238; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daly JM, 1997, CANCER RES, V57, P3804; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; Jannot CB, 1996, ONCOGENE, V13, P275; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAX I, 1991, J BIOL CHEM, V266, P13828; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lewis GD, 1996, CANCER RES, V56, P1457; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSBACH M, 1999, IN PRESS BONE; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Traxler PM, 1996, J MED CHEM, V39, P2285, DOI 10.1021/jm960118j; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	64	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3440	3451		10.1038/sj.onc.1202700	http://dx.doi.org/10.1038/sj.onc.1202700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376522				2022-12-17	WOS:000080850600002
J	Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R				Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R			The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis	ONCOGENE			English	Article						HPV E6 and E7 oncogenes; apoptosis; p53; primary keratinocytes; extended life span	MAMMARY EPITHELIAL-CELLS; RAT EMBRYO FIBROBLASTS; S-PHASE ENTRY; E6 ONCOPROTEIN; P53 PROTEIN; MUTATIONAL ANALYSIS; TRANSFORMING GENE; WILD-TYPE; HA-RAS; IMMORTALIZATION	The 'high risk' human papillomaviruses are associated with the development of anogenital carcinomas and their E6 and E7 genes possess immortalizing and transforming functions in several in vitro culture systems, Recently the E6 gene has also been shown to enhance the apoptosis of human mammary epithelial cells, To determine the apoptotic activity of these oncogenes in the natural host cell, we infected genital keratinocytes with retroviruses expressing either HPV-16 E6, E7, or both the E6 and E7 (E6/7) genes. Apoptosis was quantitated under normal growth conditions or when induced by tumor necrosis factor alpha/cycloheximide or sulfur mustard. In contrast to previous findings with mammary epithelial cells, the E6 gene did not significantly augment either spontaneous or induced apoptosis, E6 also did not suppress apoptosis in normal keratinocytes (despite dramatically reducing their p53 levels), suggesting that p53-independent events mediated this effect, In contrast, E7 increased both spontaneous and induced apoptosis as well as the cellular levels of p53 and p21 protein. Interestingly, coexpression of E6 abrogated E7-facilitated apoptosis by tumor necrosis factor alpha nearly completely, but had only a minor protective effect on sulfur mustard induced apoptosis in these cells, demonstrating at least in part the p53-dependence and -independence of these two apoptotic pathways, Finally, our results indicate that the apoptosis of normal and E7-expressing keratinocytes is differentially affected by E6 expression and that E7, when unaccompanied by E6, sensitizes keratinocytes to apoptosis.	Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Marburg, Inst Pharmacol & Toxicol, D-35033 Marburg, Germany; Univ Marburg, Klinikum Lahnberge, Dept Pathol, D-35043 Marburg, Germany; Georgetown Univ, Dept Pathol, Mol Pathol Program, Washington, DC 20007 USA	Georgetown University; Philipps University Marburg; Philipps University Marburg; Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Dept Biochem & Mol Biol, 3900 Reservoir Rd, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dabrowska MI, 1996, TOXICOL APPL PHARM, V141, P568, DOI 10.1006/taap.1996.0324; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, J VIROL, V63, P4417; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; Thomas M, 1996, ONCOGENE, V13, P265; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VILLA LL, 1991, VIROLOGY, V181, P374; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026	68	88	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1207	1214		10.1038/sj.onc.1202053	http://dx.doi.org/10.1038/sj.onc.1202053			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771963				2022-12-17	WOS:000075803300002
J	Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M				Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M			Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains	ONCOGENE			English	Article						Ets family; protein interaction; transcription regulation	DNA-BINDING MOTIF; MURINE ETS-1; SECONDARY STRUCTURE; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE; MEMBER; CELLS; PEA3; PROTOONCOGENES	The ets genes family encodes a group of proteins which function as transcription factors under physiological conditions. We report here that the Erg proteins, members of the Ets family, form homo and heterodimeric complexes in vitro. We demonstrate that the Ergp55 protein isoform forms dimers,vith itself and with the two other isoforms, Ergp49 and Ergp38. Using a set of Erg protein deletion mutants, we define two distinct domains independently involved in dimerization. The first one is located in the amino-terminal part of the protein containing the pointed domain (PNT), conserved in a subset of Ets proteins. The second one resides within the ETS domain, the DNA-binding domain. We also show that the Erg protein central region behaves as an inhibitory domain of dimerization and its removal enhances the Ergp55 transactivation properties. Furthermore, Ergp55 forms heterodimers with some other Ets proteins. Among the latter, we show that Fli-1, Ets-2, Er81 and Pu-1 physically interact with Erg. Finally, rye show that the formation of the previously described ternary complex Ergp55/Fos/jun is mediated by ETS domain and Jun protein, while the ternary complex Ergp49/Fos/Jun is mediated by Fos protein.	Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Duterque-Coquillaud, M (corresponding author), Inst Biol, CNRS, UMR 319, BP447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAVES BJ, 1998, IN PRESS ADV CANC RE, V75; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KHERROUCHE Z, 1998, ONCOGENE; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Melet F, 1996, MOL CELL BIOL, V16, P2708; MONTE D, 1994, ONCOGENE, V9, P1397; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	42	88	91	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3261	3268		10.1038/sj.onc.1201868	http://dx.doi.org/10.1038/sj.onc.1201868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681824				2022-12-17	WOS:000074343600006
J	Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB				Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB			Functional interplay between p53 and E2F through co-activator p300	ONCOGENE			English	Article						p53; E2F; p300; apoptosis; transcription	CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA-PROTEIN; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; DEPENDENT KINASES; GENE-PRODUCT; HELA-CELLS; S-PHASE; EXPRESSION	Both E2F and p53 are sequence specific transcription factors that regulate early cell cycle progression. The pathway of control mediated through E2F governs the transition from G1 into S phase whereas p53 in response to genotoxic stress can facilitate cell cycle arrest or apoptosis, The mechanisms which influence the outcome of p53 induction are not clear, although transcription of the p53 target gene, encoding the cdk-inhibitor p21(Waf1/Cip1), correlates with p53-mediated cell cycle arrest. Here using a combination of biochemical and functional assays we identify p300 as a co-activator required for p53-dependent transcriptional activation of Waf1/Cip1, Furthermore, we show that the cdk-inhibitor p21(Waf1/Cip1) autoregulates in a positive fashion transcription through modulating the activity of the p53/p300 complex, whilst negatively regulating the activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent with a role for p21(Waf1/Cip1) in, the autoregulation of p53-dependent transcription, p300 augments the ability of p53 to cause G1 arrest and, conversely, cells undergoing p53-dependent apoptosis are rescued by p300. Thus, our data suggest that the ability of p300 to interact with p53 influences the physiological consequence of p53 activation. From previous studies it is known that cells expressing aberrant levels of E2F-1 can undergo p53-dependent apoptosis, In addition, we find that E2F-1 can cause apoptosis in p53(-\-) tumour cells and further p300, which also functions as a co-activator for the E2F/DP heterodimer, enhances the apoptotic activity of E2F-1, In conditions where E2F-1 and p53 co-operate in apoptosis E2F-1. can effectively compete for p300, causing a reduction in p53-dependent transcription. Thus, a functional interaction between p300 and either p53 or E2F-1 has a profound impact on early cell cycle progression, specifically in regulating the contrasting outcomes of cell cycle arrest and apoptosis. These results suggest a critical role for p300 in integrating and coordinating the functional interplay between the pathways of growth control mediated by E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P449; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muraoka M, 1996, ONCOGENE, V12, P1565; NEVINS JR, 1992, SCIENCE, V258, P424; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	76	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2695	2710		10.1038/sj.onc.1201818	http://dx.doi.org/10.1038/sj.onc.1201818			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652736				2022-12-17	WOS:000073812200001
J	Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX				Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX			gamma-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175	ONCOGENE			English	Article						neuregulin; receptor tyrosine kinase; autocrine growth stimulation	NEU-DIFFERENTIATION FACTOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CARCINOMA CELLS; GENE-PRODUCT; FACTOR-ALPHA; TUMOR-CELLS; ERBB2; FAMILY; EGF	A novel neuregulin isoform, termed gamma-HRG, was cloned and characterized from the human breast cancer cell line, MDA-MB-175. As observed with other neuregulins, gamma-HRG, is a product of alternative mRNA splicing of the neuregulin gene, gamma-HRG contains the EGF-like and immunoglobulin-like domains that are commonly found in other family members, but lacks a transmembrane and cytoplasmic region. The new isoform possesses a unique N-terminal region that includes a hydrophobic domain that may function as a secretion signal. A purified recombinant version of gamma-HRG competes for binding to soluble ErbB3- and ErbB4-IgG fusion proteins with affinities similar to those observed for rHRG beta 1(177-244). gamma-HRG has a wide distribution in mesenchymal or neuronal tissues but in contrast to other neuregulins, it is not present in breast, lung, liver and small intestine. Expression of gamma-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the stimulation of a growth factor signaling pathway. Treatment of MDA-MB-175 cells with an anti-ErbB2 monoclonal antibody that interferes with the ligand-dependent formation of ErbB2-ErbB3 heterodimer complexes shows a strong growth inhibitory effect on this cell line. Moreover, incubation with a receptor-IgG fusion protein that neutralizes secreted gamma-HRG, also inhibits cell growth. These data suggest that the secretion of gamma-HRG by MDA-MB-175 cells leads to the formation of a constitutively active receptor complex and stimulates the growth of these cells in an autocrine manner.	GENENTECH INC,S SAN FRANCISCO,CA 94080; UNIV FREIBURG,DEPT BIOL,D-7800 FREIBURG,GERMANY	Roche Holding; Genentech; University of Freiburg				Schaefer, Gabriele/0000-0001-9727-3555				ALIMANDI M, 1995, ONCOGENE, V10, P1813; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BURDEN S, 1997, IN PRESS NEURON; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FENDLY BM, 1990, CANCER RES, V50, P1550; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Lewis GD, 1996, CANCER RES, V56, P1457; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; PARK JW, 1993, P AM ASSOC CANC RES, V84, P3107; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Sadick MD, 1996, ANAL BIOCHEM, V235, P207, DOI 10.1006/abio.1996.0114; Sambrook J, 1989, MOL CLONING LAB MANU; Scher HI, 1995, CLIN CANCER RES, V1, P545; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tang CK, 1996, CANCER RES, V56, P3350; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; ZHANG D, 1997, IN PRESS P NATL AC S; Zhang K, 1996, J BIOL CHEM, V271, P3884	50	88	111	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1385	1394		10.1038/sj.onc.1201317	http://dx.doi.org/10.1038/sj.onc.1201317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333014				2022-12-17	WOS:A1997XW41100002
J	Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B				Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B			Bcl-2 and Hsp27 act at different levels to suppress programmed cell death	ONCOGENE			English	Article						apoptosis; p53; simian virus 40; Bcl-2; Hsp27; necrosis	TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; SUBCELLULAR-LOCALIZATION; MITOCHONDRIAL-MEMBRANES; OUTER-MEMBRANE; IN-VIVO; APOPTOSIS; EXPRESSION	Apoptosis and necrosis, two morphologically distinct forms of cell death, can be induced by common stimuli depending on the doses and the cell type, This study compares the protective effect of oncoprotein Bcl-2 and of the small stress protein Hsp27 on these two types of cell death, We use rat embryo fibroblasts conditionally immortalized by the tsA58 mutant of SV40 large T antigen as parental cells to develop cell lines carrying inducible bcl-2 or hsp27 genes. Two apoptotic stimuli were used: shift to the restrictive temperature that induced p53-mediated apoptosis and treatment with low doses of hydrogen peroxide, Necrosis was induced by high doses of hydrogen peroxide. Although Bcl-2 and Hsp27 protect these cells from necrotic death, only Bcl-2 appears capable of preventing apoptotic death, Bcl-2 protection is not mediated by a negative effect on the induction of the p53 responsive genes bax or waf1 but it slows down at least two stages of apoptosis: decrease of mitochondrial membrane potential and subsequent morphological changes, In contrast, although Hsp27 has been recently shown to inhibit apoptosis induced by various stimuli, its overexpression has no effect on apoptosis in this cell system. It should be also noticed that the apoptotic stimuli (temperature shift or hydrogen peroxide treatment) induce Hsp27, but not Bcl-2 accumulation suggesting that, in parental cells, Hsp27 might already provide some protection, However, taken together these results suggest that Hsp27, as well as Bcl-2, acts at several levels to inhibit cell death, but that their protective functions only partially overlap.	CNRS,CTR GENET MOL,UPR 9061,F-91198 GIF SUR YVETTE,FRANCE; UNIV VERSAILLES,F-78035 VERSAILLES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay			Guenal, Isabelle/F-3415-2019; Mignotte, Bernard/A-3499-2009	Guenal, Isabelle/0000-0003-1186-1458; Mignotte, Bernard/0000-0002-8512-8518				AKAO Y, 1994, CANCER RES, V54, P2468; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; DEJONG D, 1994, CANCER RES, V54, P256; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUOT J, 1991, CANCER RES, V51, P5245; ITOH N, 1993, J IMMUNOL, V151, P621; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; KORCHAK HM, 1982, BIOCHEM BIOPH RES CO, V108, P1495, DOI 10.1016/S0006-291X(82)80076-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LU QL, 1994, J CELL SCI, V107, P363; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; NAKAI M, 1993, BIOCHEM BIOPH RES CO, V196, P233, DOI 10.1006/bbrc.1993.2239; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SUSIN SA, 1996, J EXP MED, V184, P1; SUZUKI K, 1994, EUR J CELL BIOL, V63, P280; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPADHYAY S, 1995, CANCER RES, V55, P4520; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZHENG DQ, 1994, ONCOGENE, V9, P3345; ZHENG LT, 1993, P NATL ACAD SCI USA, V90, P4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; [No title captured]	78	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					347	360		10.1038/sj.onc.1201182	http://dx.doi.org/10.1038/sj.onc.1201182			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233769	Bronze			2022-12-17	WOS:A1997XK99900011
J	Zhou, Q; StetlerStevenson, M; Steeg, PS				Zhou, Q; StetlerStevenson, M; Steeg, PS			Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro	ONCOGENE			English	Article						cyclin D; 9-cis retinoic acid; all trans retinoic acid; Cdk2; Cdk4; breast cancer	DEPENDENT KINASE-ACTIVITY; CANCER-CELLS; RETINOBLASTOMA PROTEIN; 9-CIS-RETINOIC ACID; GENE-EXPRESSION; S-PHASE; GROWTH; OVEREXPRESSION; PROGRESSION; AMPLIFICATION	Transfection and transgenic mouse experiments supported an oncogenic role for cyclin D1 in breast cancer, We recently reported that noninvasive carcinoma ill situ lesions of the human breast overexpress cyclin D, suggesting that this molecular event may represent a valuable target for chemoprevention, The purpose of the present series of investigations vr as to identify agents which could reduce the cyclin D expression of breast cells, We report that 9-cis retinoic acid (9-cis RA) and all trans retinoic acid (tRA) inhibited the cyclin D1 and D3 expression levels of human MCF-7, ZR-75 and T-47D breast carcinoma cells in vitro. Where detectable, similar trends were observed in the immortalized, HBL-100 and MCF-10A breast cell lines, Cyclin D2 was undetectable, The effect of retinoids was both dose- and time-dependent, and correlated with altered cell cycle kinetics and proliferative status, Retinoids were also found to inhibit the expression levels of other cell cycle related proteins, including Cdk2 and Cdk4, resulting in lower kinase activities, In contrast to other breast prevention studies? no synergistic effect was observed with retinoids and tamoxifen. The data indicate that retinoids can potently reduce ca clin D expression levels in a variety of breast cell Lines in vitro, and suggest further consideration of this mechanism for the chemoprevention of breast cancer.	NCI,DIV CLIN SCI,PATHOL LAB,FLOW CYTOMETRY UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhou, Q (corresponding author), NCI,WOMENS CANC SECT,BETHESDA,MD 20892, USA.		zhou, qun/AAU-7592-2020	zhou, qun/0000-0001-6271-3143				ANZANO MA, 1994, CANCER RES, V54, P4614; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COSTA A, 1994, CANCER RES, V54, pS2032; Courjal F, 1996, INT J CANCER, V69, P247; DHINGRA K, 1995, J CELL BIOCH S, V23, P19; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GILLETT C, 1994, CANCER RES, V54, P1812; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORSPE M, 1996, MOL CELL BIOL, V14, P762; HAN EKH, 1995, ONCOGENE, V10, P953; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Lama G, 1996, CANCER LETT, V100, P181, DOI 10.1016/0304-3835(95)04099-4; LATAN R, 1996, FASEB J, V10, P1031; LOVE R, 1994, MONOGR NATL CANC I, P61; LOVEC H, 1994, ONCOGENE, V9, P323; MAN T, 1994, LEUKEMIA, V8, P1785; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Noguchi M, 1996, ONCOLOGY-BASEL, V53, P175; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAGE DL, 1993, BREAST CANCER RES TR, V28, P157, DOI 10.1007/BF00666428; RUBIN M, 1994, CANCER RES, V54, P6549; SAVATIER P, 1995, ONCOGENE, V12, P309; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIMPSON JF, IN PRESS AM J PATHOL; SPORN MB, 1983, CANCER RES, V43, P3034; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAM SW, 1994, ONCOGENE, V9, P2663; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264; Zhou P, 1996, CANCER RES, V56, P36; ZUCKERBERG L, 1995, MODERN PATHOL, V8, P560; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	53	88	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					107	115		10.1038/sj.onc.1201142	http://dx.doi.org/10.1038/sj.onc.1201142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233783				2022-12-17	WOS:A1997XH58600012
J	Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA				Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA			Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression	ONCOGENE			English	Article						cyclin D1; p21; E2F; cell cycle; transcription; tetracycline	HUMAN BREAST-CARCINOMA; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DEPENDENT KINASES; MAMMALIAN-CELLS; GROWTH ARREST; IN-VIVO; G(1); E2F	Cyclin D1 plays a key regulatory role during the G(1) phase of the cell cycle and its gene is amplified and overexpressed in many cancers. To address the relationship between cyclin D1 and other cell cycle regulatory proteins, we established human glioma and rodent fibroblast cell lines in which cyclin D1 expression could be regulated ectopically with tetracycline. In both of these cell lines, we found that ectopic expression of cyclin D1 in asynchronously growing cells was accompanied by increased levels of the p53 tumor suppressor protein and the cyclin/cdk inhibitor p21. Despite the induction of these cell cycle inhibitory proteins, cyclin D1-associated cdk kinase remained activated and the cells grew essentially like that of the parent cells. Although growth parameters were unchanged in these cells, morphological changes were clearly identifiable and anchorage independent growth was observed in NIH3T3 cells. In a first step toward elaborating the mechanism for cyclin D1-mediated induction of p21 gene expression we show that co-expression of E2F-1 and DP-1 can specifically transactivate the p21 promoter. In support of these findings and a direct effect of E2F on induction of p21 gene expression a putative E2F binding site was identified within the p21 promoter. In summary, our results demonstrate that ectopic expression of cyclin D1 can induce gene expression of the cdk inhibitor p21 through an E2F mechanism the consequences of which are not to growth arrest tells but possibly to stabilize cyclin D1/cdk function.	MASSACHUSETTS GEN HOSP,CTR NEUROSCI,NEUROSURG SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center								ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bennett JD, 1996, ONCOGENE, V13, P1073; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fueyo J, 1996, ONCOGENE, V12, P103; GomezManzano C, 1996, CANCER RES, V56, P694; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HE J, 1994, CANCER RES, V54, P5804; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JUNG JM, 1995, ONCOGENE, V11, P2021; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAMMIE GA, 1991, ONCOGENE, V6, P439; Liu Y, 1996, CANCER RES, V56, P31; LOVEC H, 1994, ONCOGENE, V9, P323; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marchetti A, 1996, ONCOGENE, V12, P1319; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michieli P, 1996, ONCOGENE, V12, P775; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHUURING E, 1992, ONCOGENE, V7, P355; Sgambato A, 1996, CANCER RES, V56, P1389; SHAO ZH, 1995, ONCOGENE, V10, P221; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	88	89	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2533	2542		10.1038/sj.onc.1201080	http://dx.doi.org/10.1038/sj.onc.1201080			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191053				2022-12-17	WOS:A1997XA94900005
J	LAllemain, G; Lavoie, JN; Rivard, N; Baldin, V; Pouyssegur, J				LAllemain, G; Lavoie, JN; Rivard, N; Baldin, V; Pouyssegur, J			Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts	ONCOGENE			English	Article						cyclin D1; cAMP; cyclin-CDK complexes; p27(KIP1); DNA synthesis	DEPENDENT KINASE; HAMSTER FIBROBLASTS; NUCLEAR-PROTEIN; RETINOBLASTOMA PROTEIN; PHASE-TRANSITION; GENE-EXPRESSION; MAMMALIAN-CELLS; GROWTH-CONTROL; DNA-SYNTHESIS; S-PHASE	We previously described in the CCL39 hamster fibroblast cell line the inhibition of DNA synthesis reinitiation by agents that elevate cyclic AMP. Here, we show that 8Br-cAMP strongly blocks both the growth factor-induced increase in cyclin D1 protein expression and decrease in p27(KIP1) protein levels, leaving untouched the levels of cyclin D3, cdk2 and cdk4. To assess the role of cyclin D1 in the cAMP-mediated inhibition of DNA synthesis, we overexpressed the cyclin D1 gene in CCL39 and analysed the cAMP response in stable transfectants. We showed that the kinase activities associated to G(1) cyclin-cdk complexes are significantly more resistant to cAMP in cyclin D1 transfectants than in their normal counterparts, although the serum-induced p27(KIP1) disparition is still cAMP sensitive in cyclin D1 overexpressors. Interestingly, the mitogen-induced DNA synthesis reinitiation is also much less inhibited by cAMP in cyclin D1 transfectants than in control cells. These data clearly establish that the cAMP-inducible blockade of the G(1) phase of the cell cycle can be partially alleviated by overexpression of cyclin D1 in hamster fibroblasts, thus strongly suggesting that cyclin D1 protein is one of the major targets for cAMP inhibitory action in fibroblasts.			LAllemain, G (corresponding author), FAC SCI, CTR BIOCHIM, CNRS UMR134, PARC VALROSE, F-06108 NICE 02, FRANCE.		BALDIN, Véronique/Y-8397-2019	BALDIN, Véronique/0000-0001-8523-0494; Lavoie, Josee N/0000-0001-6912-1132				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GRANA X, 1995, ONCOGENE, V11, P211; HAN EKH, 1995, ONCOGENE, V10, P953; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; JIANG W, 1993, ONCOGENE, V8, P3447; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, ONCOGENE, V10, P2125; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Noel J, 1996, J CELL SCI, V109, P929; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1994, J CELL SCI, P69; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAM SW, 1994, ONCOGENE, V9, P2663; Vadiveloo PK, 1996, ONCOGENE, V13, P599; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; ZHOU P, 1995, ONCOGENE, V11, P571; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	88	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1981	1990		10.1038/sj.onc.1201038	http://dx.doi.org/10.1038/sj.onc.1201038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150365				2022-12-17	WOS:A1997WV80400011
J	Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL				Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL			Mos proto-oncogene function during oocyte maturation in Xenopus	ONCOGENE			English	Article						Mos; MAP kinase; cell cycle; xenopus oocyte; proto-oncogene	MEIOTIC MATURATION; CYTOSTATIC FACTOR; MAP KINASE; PROTOONCOGENE PRODUCT; PROMOTING FACTOR; CELL-CYCLE; EGGS; REQUIREMENT; METAPHASE; ARREST	The function of the Xenopus c-mos proto-oncogene product (Mos(xe)) has been investigated during oocyte maturation, Experiments with a new antibody able to immunoblot Mos(xe) demonstrated the time course of MAP kinase (MAP K) activation in oocytes paralleled Mos(xe) accumulation, and in activated eggs the deactivation of MAP K paralleled the degradation of Mos(xe), Ablation of Mos synthesis by microinjection of antisense oligodeoxynucleotides abolished activation of MAP K by progesterone, but microinjection of GST-Mos fully restored both MAP K activation and germinal vesicle breakdown (GVBD), The Mos(xe) level at metaphase of Meiosis I(MI) was 2-3-fold less than that at metaphase of Meiosis II (MII), but MAP K activation was maximal at metaphase in both MI and MII, In the transition between MI and MII, both cyclin B and Mos(xe) levels rapidly declined in the presence of cycloheximide and injection of exogenous GST-Mos(xe) did not prevent degradation of either protein, although MAP K was activated, Microinjection of GST-Mos(xe) into oocytes was able to activate MAP K before GVBD and H1 kinase activation, and microinjection of constitutively-activated thiophosphorylated MAP K induced de novo synthesis of Mos(xe) before H1 kinase activation, suggesting the existence of a positive feedback loop between MAP K and Mos(xe) accumulation.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Haccard, Olivier/0000-0002-4305-2746	NCI NIH HHS [F32CA0981] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; VANRENTERGHEM BB, 1993, J BIOL CHEM, V268, P11935; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	43	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2203	2211						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668347				2022-12-17	WOS:A1996UP28300020
J	BOWTELL, DDL; LANGDON, WY				BOWTELL, DDL; LANGDON, WY			THE PROTEIN PRODUCT OF THE C-CBL ONCOGENE RAPIDLY COMPLEXES WITH THE EGF RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING EGF STIMULATION	ONCOGENE			English	Article						TYROSINE KINASE; SRC HOMOLOGY; CBL ONCOGENE; CELL TRANSFORMATION; GROWTH FACTOR SIGNAL TRANSDUCTION	V-CBL; VULVAR INDUCTION; DOMAIN; SH2; IDENTIFICATION; TRUNCATION; RETROVIRUS; PATHWAY; BINDING; KINASES	The cbl oncogene was first identified as part of a transforming retrovirus which arose in a mouse pre-B cell lymphoma. Its protein product, p120(cbl): is cytoplasmic and has several distinctive domains including a highly basic region, a RING finger motif and a large proline-rich domain, A mutation to cbl in the 70Z/3 pre-B cell lymphoma produces an oncogenic protein which exhibits a marked enhancement of tyrosine phosphorylation, Parallel studies have demonstrated that p120(cbl) is a substrate of protein tyrosine kinases activated by engagement of the T cell antigen receptor and that cbl is phosphorylated by oncogenic forms of the Abl tyrosine kinase, A genetic analysis of the Caenorhabditis elegans c61 homologue, sli-1, demonstrates that sli-1 negatively regulates the LET-23 tyrosine kinase receptor, Here we show that p120(cbl) is rapidly phosphorylated on tyrosine residues following EGF stimulation and that it forms an inducible complex with the receptor, Our results also show that the oncogenic 70Z/3 form of cbl has enhanced binding to the EGF receptor and that peptides spanning the proline-rich region bind a range SH3 domains. These findings are consistent with a conserved role for cbl/sli-1 proteins in mammals and nematodes.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	Peter Maccallum Cancer Center; University of Western Australia			Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, IN PRESS J BIOL CHEM; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILA A, 1995, J BIOL CHEM, V5270, P9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, IN PRESS SCIENCE; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	27	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478580				2022-12-17	WOS:A1995TC53500014
J	MACHIDE, M; MANO, H; TODOKORO, K				MACHIDE, M; MANO, H; TODOKORO, K			INTERLEUKIN-3 AND ERYTHROPOIETIN INDUCE ASSOCIATION OF VAV WITH TEC KINASE THROUGH TEC HOMOLOGY DOMAIN	ONCOGENE			English	Article						TEC KINASE; VAV; ERYTHROPOIETIN; IL3; SIGNAL TRANSDUCTION	TYROSINE-PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; SH2 DOMAIN; RECEPTOR; GRB2; ACTIVATION; GENE; RAS	Although hematopoietic cytokine receptors lack tyrosine kinase domains, the binding of their ligands to the receptors induce rapid tyrosine phosphorylation of various cellular target proteins. The specific tyrosine kinases which phosphorylate these substrates, however, have not been identified, other than that JAK kinases which phosphorylate STAT proteins and the receptors. We found that the c-vav proto-oncogene product, Vav, is rapidly and transiently tyrosine-phosphorylated in response to erythropoietin and IL3 stimulations and that Tec kinase is also transiently activated by these cytokines. Immunoprecipitation experiments demonstrated that Tec kinase binds to Vav upon these cytokine stimulations and that Grb2 constitutively associates with Vav. In vitro binding assays showed that erythropoietin and IL3 stimulation induce the specific binding of Vav to Tec kinase through Tec homology domains. We therefore concluded that Tec kinase is one of the key enzymes in Epo and IL3 receptor-mediated signaling pathways and that Vav plays an important role in the cytokine receptor-mediated signal transduction.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,DEPT ZOOL,SAKYO KU,KYOTO,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	RIKEN; Kyoto University; Jichi Medical University								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLDWASSER E, 1990, PEPTIDE GROWTH FACTO, V1, P747; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN HY, 1994, J BIOL CHEM, V269, P19633; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1989, GENE, V67, P31; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V202, P1912; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	57	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					619	625						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651724				2022-12-17	WOS:A1995RQ46900002
J	MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y				MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y			MOLECULAR CHARACTERIZATION OF THE ETS-RELATED HUMAN TRANSCRIPTION FACTOR ER81	ONCOGENE			English	Note						ER81; TRANSCRIPTION FACTOR; ETS GENE; ALTERNATIVE SPLICING	GENE FAMILY; BINDING-PROTEIN; ONCOGENE FAMILY; C-ETS-1 PROTEIN; MESSENGER-RNAS; MEMBER; PEA3; ACTIVATION; EVOLUTION; DOMAIN	The PEA3 group is a homogeneous group of the ets transcription factor family and is composed df three known members, PEA3, ERM and ER81, which, on the amino acid (AA) level, are more than 95% identical within the DNA-binding domain (the Ets domain), more than 85% within a 32 AA domain (the acidic domain) localized in the amino-terminus and almost 50% identical overall. By screening a human kidney cDNA library with a specific probe obtained from mouse ER81 we isolated two clones of 1.6 and 1.5 kb in length encoding a 458 AA open reading frame. When compared to mouse ER81, the present human ER81 lacks the last 13 AA of the acidic domain and the 5 AA contiguous to the carboxy-terminal part of the acidic domain. Of the 458 AA of the human ER81 protein, 97% are identical to mouse ER81. Gel shift analysis indicates that the full-length human ER81 protein is able to bind specifically to an oligonucleotide containing the binding sites recognized by most of the Ets proteins. By transient expression in RK13 mammalian cells, human ER81 protein transactivated a reporter plasmid containing Ets binding sites, indicating that this molecule is a bonafide transcriptional activator, while by expression in Cos-1 transfected cells, we detected the presence of human ER81 protein in the nucleus using immunocytochemistry. In human tissues, ER81 mRNA is very highly expressed in brain, highly expressed in testis, lung and heart, moderately in spleen, small intestine, pancreas and colon, weakly in liver, prostate and thymus, very weakly in skeletal muscle, kidney and ovary and not in placenta and peripheral blood leukocytes. Analysis of human solid or haematopoietic tumour cell lines showed that most of them did not express ER81 detectably. Database searches revealed that ETV1 mRNA is highly similar to human ER81 described here, although it contains the full-length acidic domain present in mouse ER81. By screening a genomic DNA library, we characterized the intron-exon junction within the acidic domain of human ER81 and we showed that this junction corresponds to the site where the remaining AA of the acidic domain of ETV1 or mouse ER81 are inserted.	INST PASTEUR,CNRS,URA 1160,UNITE ONCOL MOLEC,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				coutte, laurent/0000-0002-0031-4742; monte, didier/0000-0002-0613-6203				ALBAGLI O, 1994, ONCOGENE, V9, P3259; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CREPIEUX P, 1995, IN PRESS CRITICAL RE; Crepieux Pascale, 1993, Gene Expression, V3, P215; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LIANG H, 1994, STRUCT BIOL, V1, P871; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MONTE D, 1994, ONCOGENE, V9, P1397; MONTE D, 1995, IN PRESS ANN ENDOCRI; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; POGNONEC P, 1989, ONCOGENE, V4, P691; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOGANATHAN T, 1992, EUR J BIOCHEM, V207, P195, DOI 10.1111/j.1432-1033.1992.tb17037.x; ZHAO HF, 1991, J BIOL CHEM, V266, P583	29	88	89	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					771	779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651741				2022-12-17	WOS:A1995RQ46900020
J	TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K				TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K			CHOLECYSTOKININ-B/GASTRIN RECEPTOR SIGNALING PATHWAY INVOLVES TYROSINE PHOSPHORYLATIONS OF P125(FAK) AND P42(MAP)	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; GASTRIN RECEPTOR; MAP KINASES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PERTUSSIS TOXIN; PDGF RECEPTOR	The neuro-intestinal peptide hormone cholecystokinin (CCK)/gastrin has been suggested to have a trophic effect on gastro-intestinal tract in vivo as well as in vitro. In the present study, the human CCK-B/gastrin receptor was expressed in mouse NIH3T3 fibroblasts to investigate the molecular basis of signal transduction pathway of the guanine nucleotide regulatory protein (G protein)-coupled receptor. Human CCK-B/gastrin receptor expressed in NIH3T3 cells coupled efficiently to phosphoinositide hydrolysis and mobilization of intracellular Ca2+, and transduced mitogenic signals assessed by [H-3]thymidine incorporation in a dose-dependent manner. Moreover, CCK-8 or gastrin I alone promoted the cell growth in serum-free medium. CCK-8 induced tyrosine phosphorylation of several protein species. Among them, mitogen-activated protein (MAP) kinase was tyrosine phosphorylated and activated in response to CCK-8, as was induced by platelet-derived growth factor (PDGF). In contrast, tyrosine phosphorylation of p125(FAK) (focal adhesion kinase) was induced by CCK-8 but not by PDGF. CCK-8 as well as gastrin I induced the expression of early responsive genes such as c-fos and c-myc. These results suggest that CCK-B/gastrin receptors might transmit mitogenic signals by cross-talking with the tyrosine kinase cascades.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT GERONTOL,CHUO KU,KOBE 650,JAPAN	Kobe University; Kobe University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CREAN GP, 1969, GASTROENTEROLOGY, V57, P147; CROSS AJ, 1988, NEUROPEPTIDES, V11, P73, DOI 10.1016/0143-4179(88)90013-3; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAKANSON R, 1986, SCAND J GASTROENTERO, V21, P18, DOI 10.3109/00365528609090883; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOOSEIN NM, 1988, CANCER RES, V48, P7179; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; JOHNSON LR, 1982, SCAND J GASTROENTERO, V17, P89; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; POLACEK MA, 1966, SURGERY, V60, P606; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; RYBERG B, 1990, GASTROENTEROLOGY, V99, P935, DOI 10.1016/0016-5085(90)90610-D; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SETH A, 1991, J BIOL CHEM, V266, P23521; SETHI T, 1991, CANCER RES, V51, P3621; SMITH JP, 1991, REGUL PEPTIDES, V32, P341; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZIMONJIC CB, 1993, IN PRESS CYTOGENET C	56	88	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					861	867						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108129				2022-12-17	WOS:A1994MW55100022
J	BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH				BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH			SEQUENCE AND BIOLOGICAL-ACTIVITY OF CHICKEN SNON CDNA CLONES	ONCOGENE			English	Article							V-SKI ONCOGENE; RETROVIRUS VECTORS; CELLS; GENE; VIRUSES; MUSCLE	cDNA clones of the ski-related gene, sno, were isolated from a chicken cDNA library and sequenced. In contrast to the human system, from which two forms of sno cDNAs have been isolated, we obtained only one type of chicken sno cDNA, that encoding snoN. The coding region for chicken snoN was inserted into the retroviral vectors RCAS(A) and RCASBP(A) and introduced into chicken embryo fibroblasts (CEFs) or quail embryo cells (QECs). Like the various forms of ski, snoN appears to be localized in the nucleus, and high levels of snoN expression cause transformation of CEFs and muscle differentiation of QECs. In contrast to ski however, low-level expression of snoN cannot induce transformation, and is only weakly myogenic.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Maniatis T., 1982, MOL CLONING; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462	13	88	93	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					457	466						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426750				2022-12-17	WOS:A1993KN00600025
J	YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y				YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y			FREQUENT HOMOZYGOUS DELETIONS IN LUNG-CANCER CELL-LINES DETECTED BY A DNA MARKER LOCATED AT 3P21.3-P22	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; K-RAS ONCOGENE; SHORT ARM; HUMAN CHROMOSOME-3; PATIENTS TUMORS; CARCINOMA; HETEROZYGOSITY; ADENOCARCINOMA; GENE; EXPRESSION	Frequent allelic losses of chromosome 3p in lung cancer have been reported in a number of studies, and we previously demonstrated that 3p21.3 is one of the common regions of deletion in lung cancers and renal cell carcinomas. To further define a region containing the putative tumor suppressor gene, we performed Southern-blot analysis of 26 small cell lung cancer (SCLC) cell lines and ten non-small cell lung cancer (NSCLC) cell lines with 40 cosmid markers located at 3p21.3-p22. One marker detected homozygous deletions of four SCLC cell fines and one NSCLC cell line. None of the other markers revealed homozygous deletions or chromosomal rearrangements in these cell lines. The region of homozygous deletion described here is estimated to consist of less than 1 megabase of DNA, and it is very likely to contain at least one of the tumor suppressor genes associated with carcinogenesis of lung cancer and, possibly, renal cell carcinoma.	JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN	Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center; National Institutes for Quantum Science & Technology			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Horio, Yoshitsugu/0000-0003-4661-6399				BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GEMMA A, 1988, CANCER RES, V48, P6025; GERBER MJ, 1986, CYTOGENET CELL GENET, V42, P72, DOI 10.1159/000132254; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; JOHNSON BE, 1988, CANCER RES, V48, P5163; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KURZROCK R, 1986, CANCER RES, V46, P1530; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORI N, 1989, CANCER RES, V49, P5130; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SATO T, 1991, CANCER RES, V51, P5794; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAKASHI E, 1992, IN PRESS GENOMICS, V13; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	41	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					327	330						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381220				2022-12-17	WOS:A1993KN00600011
J	KALKBRENNER, F; GUEHMANN, S; MOELLING, K				KALKBRENNER, F; GUEHMANN, S; MOELLING, K			TRANSCRIPTIONAL ACTIVATION BY HUMAN C-MYB AND V-MYB GENES	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BADING H, 1987, MODERN TRENDS HUMAN, V7, P488; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CAREY M, 1989, IN PRESS J MOL BIOL; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCMAHON J, 1988, ONCOGENE, V3, P717; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SLAMON DJ, 1986, SCIENCE, V233, P247; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	88	89	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					657	661						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189102				2022-12-17	WOS:A1990DG37400004
J	MARU, Y; HIRAI, H; TAKAKU, F				MARU, Y; HIRAI, H; TAKAKU, F			OVEREXPRESSION CONFERS AN ONCOGENIC POTENTIAL UPON THE EPH GENE	ONCOGENE			English	Note									UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8447; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANSER T, 1984, P NATL ACAD SCI-BIOL, V81, P2470, DOI 10.1073/pnas.81.8.2470; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197	27	88	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					445	447						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2314900				2022-12-17	WOS:A1990CW41500027
J	SORVILLO, JM; MCCORMACK, ES; YANEZ, L; VALENZUELA, D; REYNOLDS, FH				SORVILLO, JM; MCCORMACK, ES; YANEZ, L; VALENZUELA, D; REYNOLDS, FH			PREPARATION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR HUMAN TRANSFORMING GROWTH FACTOR-ALPHA	ONCOGENE			English	Article											SORVILLO, JM (corresponding author), ONCOGENE SCI INC,350 COMMUNITY DR,MANHASSET,NY 11030, USA.							ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KIMBALL ES, 1984, CANCER RES, V44, P3616; KOBRIN MS, 1987, ENDOCRINOLOGY, V121, P1412, DOI 10.1210/endo-121-4-1412; KOBRIN MS, 1986, J BIOL CHEM, V261, P4414; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUDLOW JE, 1987, ENDOCRINOLOGY, V121, P1577, DOI 10.1210/endo-121-4-1577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LINSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356, DOI 10.1073/pnas.82.2.356; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; NESTOR JJ, 1985, BIOCHEM BIOPH RES CO, V129, P226, DOI 10.1016/0006-291X(85)91426-3; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; TAM JP, 1986, P NATL ACAD SCI USA, V83, P8082, DOI 10.1073/pnas.83.21.8082; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEYNINGEN V, 1983, J IMMUNOL METHODS, V62, P147, DOI 10.1016/0022-1759(83)90000-5; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WINKLER ME, 1986, J BIOL CHEM, V261, P3838; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	36	88	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					377	386						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690379				2022-12-17	WOS:A1990CW41500016
J	BAICHWAL, VR; SUGDEN, B				BAICHWAL, VR; SUGDEN, B			THE MULTIPLE MEMBRANE-SPANNING SEGMENTS OF THE BNLF-1 ONCOGENE FROM EPSTEIN-BARR VIRUS ARE REQUIRED FOR TRANSFORMATION	ONCOGENE			English	Article											BAICHWAL, VR (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,450 N RANDALL AVE,MADISON,WI 53706, USA.				NCI NIH HHS [CA-07175, CA-22443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANLEY MR, 1987, NATURE, V329, P766, DOI 10.1038/329766a0; HAUSEN HZ, 1981, DNA TUMOR VIRUSES, P747; HERSKOWITZ I, 1987, CELL, V50, P995, DOI 10.1016/0092-8674(87)90162-0; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; KNUTSON JC, 1989, ADV VIROL ONCOLOGY; LEHMANN EL, 1975, NONPARAMETRICS; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1985, VIROLOGY, P563; SALZMAN NP, 1986, PAPOVAVIRIDAE, P27; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	23	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					67	74						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2536919				2022-12-17	WOS:A1989U567400010
J	SUBRAMANIAN, T; KUPPUSWAMY, M; NASR, RJ; CHINNADURAI, G				SUBRAMANIAN, T; KUPPUSWAMY, M; NASR, RJ; CHINNADURAI, G			AN N-TERMINAL REGION OF ADENOVIRUS-E1A ESSENTIAL FOR CELL-TRANSFORMATION AND INDUCTION OF AN EPITHELIAL-CELL GROWTH-FACTOR	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PARK AVE,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORELLI E, 1984, NATURE, V312, P608; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAIMINS LA, 1982, P NATL ACAD SCI US, V76, P3665; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MANIATIS T, 1982, MOL CLONING LABORATO; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUSSENBACH JS, 1984, ADENOVIRUSES, P35; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; TAUB M, 1984, METHODS SERUM FREE C, P3; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; YEE SP, 1985, VIROLOGY, V146, P315, DOI 10.1016/0042-6822(85)90015-7; YOSHIDA K, 1987, GENE DEV, V1, P645, DOI 10.1101/gad.1.7.645; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	42	88	89	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					105	112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2966920				2022-12-17	WOS:A1988M086000002
J	Sun, T; Wu, ZK; Wang, XF; Wang, YL; Hu, XY; Qin, WY; Lu, SX; Xu, DP; Wu, YT; Chen, QC; Ding, XY; Guo, H; Li, YL; Wang, YH; Fu, BS; Yao, WF; Wei, MJ; Wu, HZ				Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Li, Yalun; Wang, Yuanhe; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe			LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression	ONCOGENE			English	Article							RNA METHYLATION; MESSENGER-RNA; NONCODING RNAS; SUPPRESSES	Increasing evidence supports that long noncoding RNAs (lncRNAs) act as master regulators involved in tumorigenesis and development at theN6-methyladenine (m(6)A) epigenetic modification level. However, the underlying regulatory mechanism in breast cancer (BRCA) remains elusive. Here, we unveil that LINC00942 (LNC942) exerts its functions as an oncogene in promoting METTL14-mediated m(6)A methylation and regulating the expression and stability of its target genes CXCR4 and CYP1B1 in BRCA initiation and progression. Specifically, LNC942 and METTL14 were significantly upregulated accompanied with the upregulation of m(6)A levels in BRCA cells and our included BRCA cohorts (n = 150). Functionally, LNC942 elicits potent oncogenic effects on promoting cell proliferation and colony formation and inhibiting cell apoptosis, subsequently elevating METTL14-mediated m(6)A methylation levels and its associated mRNA stability and protein expression of CXCR4 and CYP1B1 in BRCA cells. Mechanistically, LNC942 directly recruits METTL14 protein by harboring the specific recognize sequence (+176-+265), thereby stabilized the expression of downstream targets of LNC942 including CXCR4 and CYP1B1 through posttranscriptional m(6)A methylation modification in vitro and in vivo. Therefore, our results uncover a novel LNC942-METTL14-CXCR4/CYP1B1 signaling axis, which provides new targets and crosstalk m(6)A epigenetic modification mechanism for BRCA prevention and treatment.	[Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China; [Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe] China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal, Minist Educ, Shenyang 110122, Peoples R China; [Li, Yalun] China Med Univ, Dept Anorectal Surg, Hosp 1, Shenyang 110001, Peoples R China; [Wang, Yuanhe] China Med Univ, Liaoning Canc Hosp & Inst, Dept Med Oncol, Canc Hosp, Shenyang 110042, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China.; Wei, MJ; Wu, HZ (corresponding author), China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal, Minist Educ, Shenyang 110122, Peoples R China.	mjwei@cmu.edu.cn; wuhz@cmu.edu.cn		Wu, Huizhe/0000-0001-7964-1342	National Natural Science Foundation of China [31828005, 81872905, 81673475, U1608281]; National Natural Science Foundation of Liaoning [U1608281]; Liaoning Revitalization Talents Program [XLYC1807155]; China Postdoctoral Science Foundation [2019M661180]; Special Foundation of China postdoctoral science foundation [2019T120225]; Shenyang ST Projects [19-109-4-09]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Liaoning; Liaoning Revitalization Talents Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Special Foundation of China postdoctoral science foundation; Shenyang ST Projects	This work was supported by grants from the National Natural Science Foundation of China [No. 31828005, 81872905, and 81673475], National Natural Science Foundation of China and Liaoning joint fund key program [No. U1608281], Liaoning Revitalization Talents Program [XLYC1807155], China Postdoctoral Science Foundation (Grant No. 2019M661180), Special Foundation of China postdoctoral science foundation (Grant No. 2019T120225), and Shenyang S&T Projects (19-109-4-09).	Adhikari S, 2016, RNA BIOL, V13, P756, DOI 10.1080/15476286.2016.1201628; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Ashouri A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13197; Chen S, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1105-6; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Golmohammadzadeh Golpar, 2019, Open Access Maced J Med Sci, V7, P2488, DOI 10.3889/oamjms.2019.667; Gong DK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1223-y; Gu CH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1084-1; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Kashyap D, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117417; Lang FC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007796; Li FX, 2019, CANCER RES, V79, P5785, DOI 10.1158/0008-5472.CAN-18-2868; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Liu N, 2013, RNA, V19, P1848, DOI 10.1261/rna.041178.113; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mathieu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08020-0; Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117; Mego M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2143-2; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Tao Y, 2019, INT J LAB MED, V40, P1541; Wang X, 2019, AM J TRANSL RES, V11, P4909; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Yan JJ, 2020, BIOCHEM BIOPH RES CO, V521, P887, DOI 10.1016/j.bbrc.2019.11.016; Yang DD, 2018, NUCLEIC ACIDS RES, V46, P3906, DOI 10.1093/nar/gky130; Yang F, 2019, CANCER RES, V79, P735, DOI 10.1158/0008-5472.CAN-18-0620; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yao QJ, 2018, CELL RES, V28, P952, DOI 10.1038/s41422-018-0062-2; Yu AM, 2020, APPL MICROBIOL BIOT, V104, P1927, DOI 10.1007/s00253-020-10350-3; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zhang C, 2019, CANCER MED-US, V8, P4766, DOI 10.1002/cam4.2360; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhi H, 2018, ADV EXP MED BIOL, V1094, P49, DOI 10.1007/978-981-13-0719-5_6; Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001	47	87	87	5	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5358	5372		10.1038/s41388-020-1338-9	http://dx.doi.org/10.1038/s41388-020-1338-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32576970				2022-12-17	WOS:000542510500001
J	Aasen, T; Leithe, E; Graham, SV; Kameritsch, P; Mayan, MD; Mesnil, M; Pogoda, K; Tabernero, A				Aasen, Trond; Leithe, Edward; Graham, Sheila V.; Kameritsch, Petra; Mayan, Maria D.; Mesnil, Marc; Pogoda, Kristin; Tabernero, Arantxa			Connexins in cancer: bridging the gap to the clinic	ONCOGENE			English	Review							TRANS-RETINOIC ACID; SUICIDE-GENE-THERAPY; JUNCTIONAL INTERCELLULAR COMMUNICATION; HUMAN PROSTATE-CANCER; TUMOR-CELLS; BREAST-CANCER; UP-REGULATION; IN-VITRO; SPONTANEOUS METASTASIS; MONOCLONAL-ANTIBODIES	Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and -independent functions that are tissue and stage specific. This can elicit both pro- and anti-tumorigenic effects that engender significant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and therapeutic potential.	[Aasen, Trond] Autonomous Univ Barcelona, CIBERONC, Vall dHebron Inst Res VHIR, Translat Mol Pathol, Barcelona, Spain; [Leithe, Edward] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway; [Leithe, Edward] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway; [Graham, Sheila V.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, MRC,Ctr Virus Res, Glasgow, Lanark, Scotland; [Kameritsch, Petra; Pogoda, Kristin] Ludwig Maximilians Univ Munchen, Walter Brendel Ctr Expt Med, Munich, Germany; [Kameritsch, Petra; Pogoda, Kristin] Munich Univ Hosp, Munich, Germany; [Mayan, Maria D.] Univ A Coruna, Serv Galego Saude SERGAS, Inst Invest Biomed A Coruna INIBIC, CellCOM Res Grp, La Coruna, Spain; [Mesnil, Marc] Univ Poitiers, Fac Sci Fondamentales & Appl, STIM Lab, Poitiers, France; [Tabernero, Arantxa] Univ Salamanca, INCYL, Dept Bioquim & Biol Mol, Salamanca, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Oslo; University of Oslo; University of Glasgow; University of Munich; University of Munich; Complejo Hospitalario Universitario A Coruna; Universidade da Coruna; Instituto de Investigacion Biomedica de A Coruna (INIBIC); Universite de Poitiers; University of Salamanca	Aasen, T (corresponding author), Autonomous Univ Barcelona, CIBERONC, Vall dHebron Inst Res VHIR, Translat Mol Pathol, Barcelona, Spain.; Tabernero, A (corresponding author), Univ Salamanca, INCYL, Dept Bioquim & Biol Mol, Salamanca, Spain.	trond.aasen@vhir.org; ataber@usal.es	Aasen, Trond/B-5279-2013; Tabernero, Arantxa/K-5950-2014; Mayan, Maria D./C-8813-2012; Mayán, María D./AAR-9227-2021	Aasen, Trond/0000-0003-0763-2695; Tabernero, Arantxa/0000-0001-6302-6134; Mayan, Maria D./0000-0002-5809-9440; Mayán, María D./0000-0002-5809-9440; Mesnil, Marc/0000-0003-4922-0365	Instituto de Salud Carlos III [PI16/00772, CPII16/00042]; European Regional Development Fund (ERDF); Norwegian Cancer Society [709125]; South-Eastern Norway Regional Health Authority [2016013]; Kristian Gerhard Jebsen Foundation; Ministerio de Economia y Competitividad, Spain; Consejeria de Educacion, Junta de Castilla y Leon, Spain [FEDER BFU2015-70040-R]; FEDER [SA026U16]; Fundacion Ramon Areces; Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM); FECYT-Ministerio de Economia y Competitividad [PRECIPITA-2015-000139]; Xunta de Galicia [IN607B 2017/21]; Instituto de Salud Carlos III (ISCIII, Spain) [PI16/00035]; European Regional Development Fund, 'A way of making Europe' from the European Union; Worldwide Cancer research grant [08-0159]; Medical Research Council; Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne); MRC [MC_UU_12014/3] Funding Source: UKRI	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); Norwegian Cancer Society(Norwegian Cancer Society); South-Eastern Norway Regional Health Authority; Kristian Gerhard Jebsen Foundation; Ministerio de Economia y Competitividad, Spain(Spanish Government); Consejeria de Educacion, Junta de Castilla y Leon, Spain(Junta de Castilla y Leon); FEDER(European Commission); Fundacion Ramon Areces; Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM); FECYT-Ministerio de Economia y Competitividad; Xunta de Galicia(Xunta de GaliciaEuropean Commission); Instituto de Salud Carlos III (ISCIII, Spain)(Instituto de Salud Carlos III); European Regional Development Fund, 'A way of making Europe' from the European Union; Worldwide Cancer research grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors are members of The European Consortium for Research on Connexins and Cancer. We apologise to authors whose work could not be cited due to space limitations. Trond Aasen acknowledges the support from Instituto de Salud Carlos III (grants PI16/00772 and CPII16/00042), co-financed by the European Regional Development Fund (ERDF). Edward Leithe acknowledges the support from the Norwegian Cancer Society (grant number 709125), the South-Eastern Norway Regional Health Authority (grant number 2016013) and the Kristian Gerhard Jebsen Foundation. Arantxa Tabernero acknowledges the support from the Ministerio de Economia y Competitividad, Spain; FEDER BFU2015-70040-R, Consejeria de Educacion, Junta de Castilla y Leon, Spain; FEDER SA026U16 and Fundacion Ramon Areces. Maria D Mayan acknowledges the support from the Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM), grant PRECIPITA-2015-000139 from the FECYT-Ministerio de Economia y Competitividad, grant IN607B 2017/21 from Xunta de Galicia and grant PI16/00035 from the Instituto de Salud Carlos III (ISCIII, Spain), and the European Regional Development Fund, 'A way of making Europe' from the European Union. Sheila Graham acknowledges the support from Worldwide Cancer research grant 08-0159 and from the Medical Research Council as core funding for the MRC University of Glasgow Centre for Virus Research. Marc Mesnil acknowledges the support from Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne).	Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; Aasen T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-31; Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Aasen T, 2015, CELL TISSUE RES, V360, P685, DOI 10.1007/s00441-014-2078-3; Ablasser A, 2013, NATURE, V503, P530, DOI 10.1038/nature12640; Gleisner MA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01067; Alonso F, 2016, ONCOTARGET, V7, P14015, DOI 10.18632/oncotarget.7370; Ariazi J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00333; Artesi M, 2015, NEURO-ONCOLOGY, V17, P392, DOI 10.1093/neuonc/nou215; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Balla P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125316; Benko G, 2011, PROSTATE CANCER P D, V14, P90, DOI 10.1038/pcan.2010.51; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Bijnsdorp IV, 2012, BRIT J CANCER, V107, P1963, DOI 10.1038/bjc.2012.500; Brockmeyer P, 2014, INT J ONCOL, V45, P273, DOI 10.3892/ijo.2014.2394; Buhrmann C, 2015, BIOCHEM PHARMACOL, V98, P51, DOI 10.1016/j.bcp.2015.08.105; Bui Marilyn M., 2011, Sarcoma, V2011, P971050, DOI 10.1155/2011/971050; Busby M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030693; Carystinos GD, 2001, CANCER CHEMOTH PHARM, V47, P126, DOI 10.1007/s002800000231; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chasampalioti M, 2018, BREAST CANC RES TREA; Chekhonin VP, 2012, NANOMED-NANOTECHNOL, V8, P63, DOI 10.1016/j.nano.2011.05.011; Chen JT, 2003, CLIN CANCER RES, V9, P4200; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Chen WL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0487-0; Chen Y, 2005, INT J CANCER, V113, P14, DOI 10.1002/ijc.20498; Chi Y, 2014, J CELL SCI, V127, P1487, DOI 10.1242/jcs.139089; Crespin S, 2016, CANCER MED-US, V5, P1742, DOI 10.1002/cam4.730; Dahle J, 2000, RADIAT RES, V154, P10; Dai P, 2007, MOL BIOL CELL, V18, P2264, DOI 10.1091/mbc.E06-12-1064; Danos K, 2016, APPL IMMUNOHISTO M M, V24, P476, DOI 10.1097/PAI.0000000000000212; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; de Wit C, 2006, ADV CARDIOL, V42, P268, DOI 10.1159/000092575; Defamie N, 2014, FEBS LETT, V588, P1331, DOI 10.1016/j.febslet.2014.01.012; Delvaeye T, 2018, TRENDS MOL MED, V24, P1036, DOI 10.1016/j.molmed.2018.10.005; Dilber MS, 1997, CANCER RES, V57, P1523; Du GJ, 2013, CANCER CHEMOTH PHARM, V71, P893, DOI 10.1007/s00280-013-2080-6; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; Duffy HS, 2007, J BIOL CHEM, V282, P9789, DOI 10.1074/jbc.M605261200; Duflot-Dancer A, 1998, GENE THER, V5, P1372, DOI 10.1038/sj.gt.3300734; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELSABBAN ME, 1991, J CELL BIOL, V115, P1375, DOI 10.1083/jcb.115.5.1375; Elshami AA, 1996, GENE THER, V3, P85; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Ezumi K, 2008, CLIN CANCER RES, V14, P677, DOI 10.1158/1078-0432.CCR-07-1184; Falk S, 2018, PAIN, V159, P1127, DOI 10.1097/j.pain.0000000000001197; FICK J, 1995, P NATL ACAD SCI USA, V92, P11071, DOI 10.1073/pnas.92.24.11071; Fukushima M, 2007, INT J ONCOL, V30, P225; Gartner C, 2012, PHARMACOL RES, V65, P347, DOI 10.1016/j.phrs.2011.11.012; Gangoso E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.560; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Gilleron J, 2018, BBA-BIOMEMBRANES, V1860, P182, DOI 10.1016/j.bbamem.2017.06.004; Glass AM, 2015, CELL MOL LIFE SCI, V72, P2899, DOI 10.1007/s00018-015-1966-3; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Greco R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00095; Grek CL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1229-6; Haass NK, 2010, HISTOCHEM CELL BIOL, V133, P113, DOI 10.1007/s00418-009-0654-5; Haefliger JA, 2017, ARTERIOSCL THROM VAS, V37, P2136, DOI 10.1161/ATVBAHA.117.310072; Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002/ijc.25041; Harris LD, 2008, MOL CARCINOGEN, V47, P678, DOI 10.1002/mc.20420; Hellmann P, 1999, EXP CELL RES, V246, P480, DOI 10.1006/excr.1998.4332; Herrero-Gonzalez S, 2010, ONCOGENE, V29, P5712, DOI 10.1038/onc.2010.299; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Hitomi M, 2015, CELL REP, V11, P1031, DOI 10.1016/j.celrep.2015.04.021; Hong XT, 2015, ONCOTARGET, V6, P15566, DOI 10.18632/oncotarget.3904; Huang RP, 2001, INT J CANCER, V92, P130, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1165>3.3.CO;2-7; Hunter AW, 2005, MOL BIOL CELL, V16, P5686, DOI 10.1091/mbc.E05-08-0737; Inose T, 2009, ANN SURG ONCOL, V16, P1704, DOI 10.1245/s10434-009-0443-3; Ito A, 2006, CANCER LETT, V234, P239, DOI 10.1016/j.canlet.2005.03.049; Ito A, 2004, CARCINOGENESIS, V25, P2015, DOI 10.1093/carcin/bgh208; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; James CC, 2018, MOL BIOL CELL, V29, P797, DOI 10.1091/mbc.E17-06-0406; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jin Z, 2013, CELL MOL NEUROBIOL, V33, P1143, DOI 10.1007/s10571-013-9980-1; Jing YM, 2012, ASIAN PAC J CANCER P, V13, P2363, DOI 10.7314/APJCP.2012.13.5.2363; Kameritsch P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.105; Kameritsch P, 2015, BBA-MOL CELL RES, V1853, P2907, DOI 10.1016/j.bbamcr.2015.08.004; Karpinich NO, 2015, ARTERIOSCL THROM VAS, V35, P1147, DOI 10.1161/ATVBAHA.114.304752; Kawasaki Y, 2011, INT J CANCER, V128, P51, DOI 10.1002/ijc.25308; Khan Z, 2014, CARCINOGENESIS, V35, P145, DOI 10.1093/carcin/bgt292; Khoo NKS, 1998, INT J CANCER, V77, P440; King TJ, 2005, BBA-BIOMEMBRANES, V1719, P146, DOI 10.1016/j.bbamem.2005.08.012; Klymenko T, 2017, J VIROL, V91, DOI 10.1128/JVI.01001-17; Knosel T, 2005, NEOPLASIA, V7, P741, DOI 10.1593/neo.05178; Kong H, 2016, ONCOL REP, V35, P1868, DOI 10.3892/or.2015.4535; Kotini M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06368-x; Kotini M, 2015, DEV BIOL, V401, P143, DOI 10.1016/j.ydbio.2014.12.023; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kyo N, 2008, ONCOL REP, V19, P627; Lai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010127; Laird DW, 2018, NAT REV DRUG DISCOV, V17, P905, DOI 10.1038/nrd.2018.138; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lazar I, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12380; Leithe E, 2018, BBA-BIOMEMBRANES, V1860, P48, DOI 10.1016/j.bbamem.2017.05.008; Leithe E, 2016, BBA-REV CANCER, V1865, P133, DOI 10.1016/j.bbcan.2016.02.001; Li SY, 2011, NEUROSCI LETT, V503, P115, DOI 10.1016/j.neulet.2011.08.019; Li X, 2012, CANCER BIOL THER, V13, P890, DOI 10.4161/cbt.20841; Liang QL, 2010, MED ONCOL, V27, P1164, DOI 10.1007/s12032-009-9354-1; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Lin QT, 2016, MOL MED REP, V13, P1329, DOI 10.3892/mmr.2015.4680; Lin QT, 2010, NEOPLASIA, V12, P748, DOI 10.1593/neo.10602; Lin YP, 2019, ONCOGENE, V38, P822, DOI 10.1038/s41388-018-0471-1; Liu D, 2015, GENE, V574, P217, DOI 10.1016/j.gene.2015.08.052; Liu LX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143438; Liu XL, 2010, INT J MOL MED, V25, P709, DOI 10.3892/ijmm_00000395; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MacDonald AI, 2012, BIOCHEM J, V446, P9, DOI 10.1042/BJ20111144; Martins-Marques T, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32538; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Menachem A, 2016, ONCOTARGET, V7, P12489, DOI 10.18632/oncotarget.7273; Mendoza-Naranjo A, 2007, J IMMUNOL, V178, P6949, DOI 10.4049/jimmunol.178.11.6949; Mesnil M, 2000, CANCER RES, V60, P3989; MESNIL M, 1995, CANCER RES, V55, P629; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Mesnil M, 2018, BBA-BIOMEMBRANES, V1860, P237, DOI 10.1016/j.bbamem.2017.06.015; Miura D, 2007, FEBS LETT, V581, P2541, DOI 10.1016/j.febslet.2007.04.080; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mulkearns-Hubert EE, 2018, DEV CX46 TARGETING S; Munoz JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.111; Murphy SF, 2016, CANCER RES, V76, P139, DOI 10.1158/0008-5472.CAN-15-1286; Naoi Y, 2008, CANCER LETT, V262, P248, DOI 10.1016/j.canlet.2007.12.008; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Naus CC, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1089-0; Nomura S, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-79; Nukolova NV, 2014, B EXP BIOL MED+, V157, P524, DOI 10.1007/s10517-014-2606-x; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Ohba Y, 2007, INT J CANCER, V121, P47, DOI 10.1002/ijc.22608; Olbina G, 2003, MOL CANCER RES, V1, P690; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Osswald M, 2016, NEURO-ONCOLOGY, V18, P479, DOI 10.1093/neuonc/now014; Osswald M, 2015, NATURE, V528, P93, DOI 10.1038/nature16071; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94; PITTS JD, 1994, MOL CARCINOGEN, V11, P127, DOI 10.1002/mc.2940110302; Pogoda K, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0099-3; Polak R, 2015, BLOOD, V126, P2404, DOI 10.1182/blood-2015-03-634238; Pollmann MA, 2005, BREAST CANCER RES, V7, pR522, DOI 10.1186/bcr1042; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Poyet C, 2015, J CLIN PATHOL, V68, P819, DOI 10.1136/jclinpath-2015-202898; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Raza A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08058-y; Rhett JM, 2011, MOL BIOL CELL, V22, P1516, DOI 10.1091/mbc.E10-06-0548; Riquelme MA, 2013, NEUROPHARMACOLOGY, V75, P525, DOI 10.1016/j.neuropharm.2013.02.021; Ryu CH, 2012, BIOCHEM BIOPH RES CO, V421, P585, DOI 10.1016/j.bbrc.2012.04.050; Saccheri F, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000739; Saez CG, 2003, J CELL BIOCHEM, V89, P450, DOI 10.1002/jcb.10519; Saez JC, 2014, FEBS LETT, V588, P1205, DOI 10.1016/j.febslet.2014.03.004; Saito-Katsuragi M, 2007, CANCER, V110, P1162, DOI 10.1002/cncr.22894; Salat-Canela C, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-31; Sato H, 2007, MOL CARCINOGEN, V46, P215, DOI 10.1002/mc.20267; Segal SS, 2015, J VASC RES, V52, P136, DOI 10.1159/000439112; Sentani K, 2010, PATHOBIOLOGY, V77, P241, DOI 10.1159/000314966; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Shen YM, 2018, INT J ONCOL, V52, P872, DOI 10.3892/ijo.2018.4263; Shi Q, 2015, DEV CELL, V35, P483, DOI 10.1016/j.devcel.2015.10.014; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shishido SN, 2014, INT J CANCER, V134, P1474, DOI 10.1002/ijc.28461; Shishido SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044963; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; Sirnes S, 2012, INT J CANCER, V131, P570, DOI 10.1002/ijc.26392; Sirnes S, 2011, EPIGENETICS-US, V6, P602, DOI 10.4161/epi.6.5.15237; Smyth JW, 2013, CELL REP, V5, P611, DOI 10.1016/j.celrep.2013.10.009; Soares AR, 2015, SCI REP-UK, V5, DOI 10.1038/srep13243; Soung YH, 2017, CANCERS, V9, DOI 10.3390/cancers9010008; Stoletov K, 2013, J CELL SCI, V126, P904, DOI 10.1242/jcs.112748; Sun P, 2015, VIRUSES-BASEL, V7, P5243, DOI 10.3390/v7102871; Tabernero A, 2016, NEUROSCIENCE, V323, P183, DOI 10.1016/j.neuroscience.2015.02.029; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Tanaka M, 2004, ONCOL REP, V11, P537; Tanaka M, 2001, HUM GENE THER, V12, P2225, DOI 10.1089/10430340152710568; Tanaka T, 2016, MOL CLIN ONCOL, V4, P989, DOI 10.3892/mco.2016.828; Tang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074527; Teleki I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112541; Teleki I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-50; Thayanithy V, 2014, TRANSL RES, V164, P359, DOI 10.1016/j.trsl.2014.05.011; Thiagarajan PS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02938-1; Thuringer D, 2016, ONCOTARGET, V7, P73925, DOI 10.18632/oncotarget.12136; Thuringer D, 2016, ONCOTARGET, V7, P28160, DOI 10.18632/oncotarget.8583; Thuringer D, 2015, ONCOTARGET, V6, P28800, DOI 10.18632/oncotarget.4894; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Tittarelli A, 2014, J IMMUNOL, V192, P1313, DOI 10.4049/jimmunol.1301297; Touraine RL, 1998, GENE THER, V5, P1705, DOI 10.1038/sj.gt.3300784; Touraine RL, 1998, HUM GENE THER, V9, P2385, DOI 10.1089/hum.1998.9.16-2385; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Ul-Hussain M, 2014, J BIOL CHEM, V289, P20979, DOI 10.1074/jbc.M113.540187; Villares GJ, 2009, CANCER RES, V69, P6730, DOI 10.1158/0008-5472.CAN-09-0300; Vrionis FD, 1997, GENE THER, V4, P577, DOI 10.1038/sj.gt.3300438; Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002; Wang LZ, 2015, ONCOL REP, V34, P2133, DOI 10.3892/or.2015.4192; Wang LZ, 2013, TOXICOLOGY, V312, P149, DOI 10.1016/j.tox.2013.08.013; Wang N, 2013, BBA-BIOMEMBRANES, V1828, P35, DOI 10.1016/j.bbamem.2012.07.002; Wang WK, 2015, INT J MOL SCI, V16, P439, DOI 10.3390/ijms16010439; Wang X, 2010, P NATL ACAD SCI USA, V107, P17194, DOI 10.1073/pnas.1006785107; Wang YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01480-2; Wang ZS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-306; Willebrords J, 2017, PHARMACOL THERAPEUT, V180, P144, DOI 10.1016/j.pharmthera.2017.07.001; Wu JF, 2016, ONCOL REP, V36, P3251, DOI 10.3892/or.2016.5156; Wu L, 2016, MOL MED REP, V13, P3213, DOI 10.3892/mmr.2016.4895; Wygoda MR, 1997, CANCER RES, V57, P1699; Xu N, 2016, ONCOTARGET, V7, P67476, DOI 10.18632/oncotarget.11231; Yang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.197; Yu ML, 2012, BIOL PHARM BULL, V35, P1230, DOI 10.1248/bpb.b110535; Yu SC, 2012, STEM CELLS, V30, P108, DOI 10.1002/stem.1685; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Yusubalieva GM, 2014, B EXP BIOL MED+, V157, P510, DOI 10.1007/s10517-014-2603-0; Yusubalieva GM, 2012, B EXP BIOL MED+, V153, P163, DOI 10.1007/s10517-012-1667-y; Zhang YW, 2003, J BIOL CHEM, V278, P44852, DOI 10.1074/jbc.M305072200; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101; Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218; Zhu T, 2017, ONCOTARGET, V8, P21281, DOI 10.18632/oncotarget.15068; Zibara K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12598; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	222	87	88	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4429	4451		10.1038/s41388-019-0741-6	http://dx.doi.org/10.1038/s41388-019-0741-6			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30814684	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000470240300001
J	Li, L; Cao, BR; Liang, XH; Lu, S; Luo, HC; Wang, ZH; Wang, SX; Jiang, J; Lang, JY; Zhu, GQ				Li, Ling; Cao, Bangrong; Liang, Xinhua; Lu, Shun; Luo, Huaichao; Wang, Zhaohui; Wang, Shaoxin; Jiang, Jian; Lang, Jinyi; Zhu, Guiquan			Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral gamma delta T cell equilibrium via tumor-derived exosomes	ONCOGENE			English	Article							SUPPRESSOR-CELLS; CARCINOMA-CELLS; EXPANSION; HYPOXIA; PROMOTE; ELICIT; REGULATORS; RESPONSES; PROTEINS; GROWTH	gamma delta T cells are a unique lymphocyte population that have been reported to have either anti- or pro-tumoral functions in several cancer types, but the mechanisms are underinvestigated. Exosomes, initially considered to be cellular "garbage dumpsters," are now implicated in mediating interactions with the cellular environment. Hypoxia is a common feature of solid tumors and is believed to alter tumor-derived exosomes (TEXs), which mediate the hypoxic evolution of the tumor microenvironment in return. This study sought to investigate whether TEXs mediate the anti- and pro-tumoral equilibrium of gamma delta T cells under different oxygen pressures in the tumor microenvironment. We show that TEXs can alter the expansion and cytotoxicity of gamma delta T cells in an HSP70-dependent but dendritic cell-independent manner. The stimulating effects of normoxic TEXs on gamma delta T-cell activity were absent from hypoxic TEXs, which enhanced the suppressive effect of myeloid-derived suppressor cells (MDSCs) on gamma delta T cells through a miR-21/PTEN/PD-L1 regulation axis. Finally, the therapeutic outcome benefited from combined miR-21 and PD-Ll targeting in oral squamous cell carcinoma (OSCC)-bearing immunocompetent mice. We conclude that oxygen pressure in the tumor microenvironment orchestrates an anti- and protumoral gamma delta T-cell equilibrium by altering TEX content, which subsequently regulates MDSC function in a miR-21/PTEN/PD-L1 -axis-dependent manner. Our results should prompt further investigation into integrated exosomal miRNA inhibition and immune checkpoint inhibitor therapeutic modalities for patients with OSCC.	[Li, Ling; Wang, Zhaohui; Wang, Shaoxin; Jiang, Jian; Zhu, Guiquan] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Head & Neck Surg, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China; [Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Basic Res, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China; [Liang, Xinhua] Sichuan Univ, State Key Lab Oral Dis, West China Hosp Stomatol, Chengdu, Sichuan, Peoples R China; [Lu, Shun; Lang, Jinyi] Univ Elect Sci & Technol China, Dept Radiat Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China; [Luo, Huaichao] Univ Elect Sci & Technol China, Dept Clin Lab, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; Sichuan University; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Zhu, GQ (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Head & Neck Surg, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China.; Lang, JY (corresponding author), Univ Elect Sci & Technol China, Dept Radiat Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China.	langjy610@163.com; zgq@sichuancancer.org	, 曹邦荣/AAN-3604-2020; Lu, Shun/ABF-8341-2021	lang, jinyi/0000-0002-5406-8671; Zhu, Guiquan/0000-0002-8316-5809; Cao, Bangrong/0000-0002-3865-3563	National Natural Science Foundation of China [81672690, 81772900, 81872196, 81302375]; Department of Science and Technology of Sichuan Province [2015SZ0053, 2017JQ0040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Sichuan Province	This work was supported by the National Natural Science Foundation of China (grant nos. 81672690, 81772900, 81872196, and 81302375) and the Department of Science and Technology of Sichuan Province (grant nos. 2015SZ0053 and 2017JQ0040).	Castella B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1047580; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen TY, 2011, J IMMUNOL, V186, P2219, DOI 10.4049/jimmunol.1002991; Chen WL, 2006, EUR J IMMUNOL, V36, P1598, DOI 10.1002/eji.200535501; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Desiderio V, 2015, ONCOTARGET, V6, P71, DOI 10.18632/oncotarget.2698; Florcken A, 2015, IMMUNOL LETT, V168, P260, DOI 10.1016/j.imlet.2015.10.001; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao L, 2018, NAT IMMUNOL, V19, P233, DOI 10.1038/s41590-017-0043-5; Gu XY, 2015, INT J CANCER, V136, pE74, DOI 10.1002/ijc.29100; Hasan MS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/705831; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328; Kondo M, 2011, JOVE-J VIS EXP, V55, P3182; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Lo Presti E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00607; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Ludwig S, 2017, CLIN CANCER RES, V23, P4843, DOI 10.1158/1078-0432.CCR-16-2819; Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Martins VR, 2013, CURR OPIN ONCOL, V25, P66, DOI 10.1097/CCO.0b013e32835b7c81; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; O'Loughlin AJ, 2012, CURR GENE THER, V12, P262, DOI 10.2174/156652312802083594; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Plebanek MP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01433-3; Rao Q, 2016, HEPATOLOGY, V64, P456, DOI 10.1002/hep.28549; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu D, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.992749; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245; Zhu GQ, 2014, NEOPLASIA, V16, P168, DOI 10.1593/neo.132034	48	87	90	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2830	2843		10.1038/s41388-018-0627-z	http://dx.doi.org/10.1038/s41388-018-0627-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546089				2022-12-17	WOS:000464121600012
J	Sin, WC; Aftab, Q; Bechberger, JF; Leung, JH; Chen, H; Naus, CC				Sin, W. C.; Aftab, Q.; Bechberger, J. F.; Leung, J. H.; Chen, H.; Naus, C. C.			Astrocytes promote glioma invasion via the gap junction protein connexin43	ONCOGENE			English	Article							C-TERMINAL REGION; MALIGNANT GLIOMA; MICROENVIRONMENTAL REGULATION; INTERCELLULAR COMMUNICATION; REACTIVE ASTROCYTES; GENE-EXPRESSION; DIRECTED INACTIVATION; GROWTH-FACTOR; MICE LACKING; TUMOR-CELLS	Reactive astrocytes are integral to the glioma microenvironment. Connexin43 (Cx43) is a major gap junction protein in astrocytes and its expression is enhanced significantly in glioma-associated astrocytes, especially at the peri-tumoral region. Although downregulation of Cx43-mediated intercellular communication is associated with increased malignancy in tumor cells, the role of Cx43 in stromal cells in glioma progression is not defined. Using a mouse model consisting of syngeneic intracranial implantation of GL261 glioma cells into Nestin-Cre: Cx43(fl/fl) mice where Cx43 was eliminated in astrocytes, we demonstrate a role of astrocytic Cx43 in the dissemination of glioma cells from the tumor core. To determine whether heterocellular communication between astrocytes and glioma cells is essential for reduced invasion in the absence of astrocytic Cx43, we abolished channel formation between glioma cells and astrocytes by either knocking down Cx43 in glioma cells with short hairpin RNA (shRNA) or overexpressing a dominant-negative channel-defective Cx43-T154A mutant in these cells. Although Cx43shRNA in glioma cells reduced invasion, expression of Cx43-T154A had no effect on glioma invasion, suggesting tumoral Cx43 may influence motility independently from its channel function. Alteration in astrocytic Cx43 function, such as by replacing the wild-type allele with a C-terminal truncated Cx43 mutant exhibiting reduced intercellular coupling, is sufficient to reduce glioma spreading into the brain parenchyma. Our results reveal a novel role of astrocytic Cx43 in the formation of an invasive niche and raise the possibility to control glioma progression by manipulating the microenvironment.	[Sin, W. C.; Aftab, Q.; Bechberger, J. F.; Leung, J. H.; Chen, H.; Naus, C. C.] Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Sin, WC; Naus, CC (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	wcsin@mail.ubc.ca; cnaus@mail.ubc.ca			Canadian Institutes of Health Research [MOP-102489, MOP-93572]; National Sciences and Engineering Research Council of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	We thank Lina Wang, Elodie Montaudon, Kushal Kolar, Xu Qiu Guo, Aishah Tul-Firdaus Binte Abdul Khalid and Jose Luis Vega for providing technical support for this project. We also wish to thank Maxence Le Vasseur for critical review of the manuscript. This study was supported by two operating grants (MOP-102489 and MOP-93572) to WCS and CCN from the Canadian Institutes of Health Research. CCN holds a Canada Research Chair. QA was supported by a postgraduate scholarship from the National Sciences and Engineering Research Council of Canada.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aronica E, 2001, ACTA NEUROPATHOL, V101, P449; Baklaushev VP, 2011, DRUG DELIV, V18, P331, DOI 10.3109/10717544.2010.549527; Bates DC, 2007, GLIA, V55, P1554, DOI 10.1002/glia.20569; Beahm DL, 2006, J BIOL CHEM, V281, P7994, DOI 10.1074/jbc.M506533200; Behrens J, 2010, EUR J CELL BIOL, V89, P828, DOI 10.1016/j.ejcb.2010.06.003; Berube NG, 2005, J CLIN INVEST, V115, P258, DOI 10.1172/JCI200522329; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Caltabiano R, 2010, ACTA HISTOCHEM, V112, P529, DOI 10.1016/j.acthis.2009.05.008; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Casper KB, 2006, MOL CELL NEUROSCI, V31, P676, DOI 10.1016/j.mcn.2005.12.006; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cina C, 2009, J NEUROSCI, V29, P2009, DOI 10.1523/JNEUROSCI.5025-08.2009; Cotrina ML, 2008, GLIA, V56, P1791, DOI 10.1002/glia.20728; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Crespin S, 2010, J CELL BIOCHEM, V110, P589, DOI 10.1002/jcb.22554; De Bock M, 2014, BBA-MOL CELL RES, V1843, P2211, DOI 10.1016/j.bbamcr.2014.04.016; Dermietzel R, 2000, BRAIN RES REV, V32, P45, DOI 10.1016/S0165-0173(99)00067-3; di Tomaso E, 2011, CANCER RES, V71, P19, DOI 10.1158/0008-5472.CAN-10-2602; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Dubois NC, 2006, GENESIS, V44, P355, DOI 10.1002/dvg.20226; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Edwards LA, 2011, JNCI-J NATL CANCER I, V103, P1162, DOI 10.1093/jnci/djr224; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Fidler IJ, 2010, MOL CELLS, V30, P93, DOI 10.1007/s10059-010-0133-9; Fitzgerald DP, 2008, CLIN EXP METASTAS, V25, P799, DOI 10.1007/s10585-008-9193-z; Fonseca CG, 2002, BRAIN RES, V929, P105, DOI 10.1016/S0006-8993(01)03289-9; Frisch C, 2003, EUR J NEUROSCI, V18, P2313, DOI 10.1046/j.1460-9568.2003.02971.x; Gagliano N, 2009, ONCOL REP, V22, P1349, DOI 10.3892/or_00000574; Giaume C, 2012, METHODS MOL BIOL, V814, P283, DOI 10.1007/978-1-61779-452-0_19; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; HOLNESS CL, 1993, BLOOD, V81, P1607; Homkajorn B, 2010, NEUROSCI LETT, V486, P197, DOI 10.1016/j.neulet.2010.09.051; HOSSAIN MZ, 1994, BRAIN RES, V652, P311, DOI 10.1016/0006-8993(94)90242-9; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Iacobas DA, 2003, PHYSIOL GENOMICS, V15, P177, DOI 10.1152/physiolgenomics.00062.2003; Jacobs VL, 2011, ASN NEURO, V3, DOI 10.1042/AN20110014; Jones TS, 2012, ONCOGENE, V31, P1995, DOI 10.1038/onc.2011.398; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008; Karpuk N, 2011, J NEUROSCI, V31, P414, DOI 10.1523/JNEUROSCI.5247-10.2011; Katz AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032453; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kolar K, 2015, J NEUROPATH EXP NEUR, V74, P64, DOI 10.1097/NEN.0000000000000150; Kozoriz MG, 2010, J NEUROPATH EXP NEUR, V69, P196, DOI 10.1097/NEN.0b013e3181cd44df; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Le DM, 2003, J NEUROSCI, V23, P4034; Le HT, 2014, J BIOL CHEM, V289, P1345, DOI 10.1074/jbc.M113.508390; Lee IH, 2005, J COMP NEUROL, V489, P1, DOI 10.1002/cne.20567; Lee J, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-9; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Maass K, 2004, MOL BIOL CELL, V15, P4597, DOI 10.1091/mbc.E04-04-0324; Maass K, 2007, CIRC RES, V101, P1283, DOI 10.1161/CIRCRESAHA.107.162818; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Matsuuchi L, 2013, BBA-BIOMEMBRANES, V1828, P94, DOI 10.1016/j.bbamem.2012.05.014; Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004; Moreno AP, 2005, BBA-BIOMEMBRANES, V1711, P164, DOI 10.1016/j.bbamem.2005.02.016; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Nagy JI, 1999, NEUROSCIENCE, V88, P447, DOI 10.1016/S0306-4522(98)00191-2; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Naus CCG, 1997, J NEUROSCI RES, V49, P528, DOI 10.1002/(SICI)1097-4547(19970901)49:5<528::AID-JNR3>3.0.CO;2-D; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Newcomb EW, 2009, CNS CANC MODELS MARK, V12, P227, DOI DOI 10.1007/978-1-60327-553-8; O'Carroll SJ, 2013, METHODS MOL BIOL, V1037, P519, DOI 10.1007/978-1-62703-505-7_31; OCHALSKI PAY, 1995, GLIA, V14, P279, DOI 10.1002/glia.440140405; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Olk S, 2010, GLIA, V58, P494, DOI 10.1002/glia.20942; Olk S, 2009, CELL MOTIL CYTOSKEL, V66, P1000, DOI 10.1002/cm.20404; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ponsaerts R, 2010, FASEB J, V24, P4378, DOI 10.1096/fj.09-153007; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rath BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054752; Rhee DY, 2009, DEVELOPMENT, V136, P3185, DOI 10.1242/dev.032334; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivera-Zengotita M, 2012, ADV ANAT PATHOL, V19, P239, DOI 10.1097/PAP.0b013e31825c6a04; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rozental R, 2000, BRAIN RES REV, V32, P11, DOI 10.1016/S0165-0173(99)00095-8; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Scemes E, 1998, GLIA, V24, P65, DOI 10.1002/(SICI)1098-1136(199809)24:1<65::AID-GLIA7>3.0.CO;2-#; Scemes E, 2000, J NEUROSCI, V20, P1435; Schajnovitz A, 2011, NAT IMMUNOL, V12, P391, DOI 10.1038/ni.2017; Schalper KA, 2008, MOL BIOL CELL, V19, P3501, DOI 10.1091/mbc.E07-12-1240; Scheckenbach KEL, 2011, J VASC RES, V48, P91, DOI 10.1159/000316942; Seike T, 2011, CLIN EXP METASTAS, V28, P13, DOI 10.1007/s10585-010-9354-8; Shintani-Ishida K, 2007, AM J PHYSIOL-HEART C, V293, pH1714, DOI 10.1152/ajpheart.00022.2007; Silver DJ, 2013, J NEUROSCI, V33, P15603, DOI 10.1523/JNEUROSCI.3004-12.2013; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Sin WC, 2012, BBA-BIOMEMBRANES, V1818, P2058, DOI 10.1016/j.bbamem.2011.10.022; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Strale PO, 2012, MOL CARCINOGEN, V51, P845, DOI 10.1002/mc.20853; Tafani M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-32; Theis M, 2001, CELL COMMUN ADHES, V8, P383, DOI 10.3109/15419060109080758; Theis M, 2004, GLIA, V46, P130, DOI 10.1002/glia.10350; Theis M, 2003, J NEUROSCI, V23, P766; Theodoric N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047311; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; Williams SP, 2011, CANCER RES, V71, P5374, DOI 10.1158/0008-5472.CAN-10-3026; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zagzag D, 2008, AM J PATHOL, V173, P545, DOI 10.2353/ajpath.2008.071197; Zhang W, 2003, J NEUROSURG, V99, P1039, DOI 10.3171/jns.2003.99.6.1039; Zhang W, 1999, CANCER RES, V59, P1994; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	125	87	96	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1504	1516		10.1038/onc.2015.210	http://dx.doi.org/10.1038/onc.2015.210			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26165844				2022-12-17	WOS:000373063600004
J	Pan, J; Deng, Q; Jiang, C; Wang, X; Niu, T; Li, H; Chen, T; Jin, J; Pan, W; Cai, X; Yang, X; Lu, M; Xiao, J; Wang, P				Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Cai, X.; Yang, X.; Lu, M.; Xiao, J.; Wang, P.			USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; UBIQUITIN LIGASE; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; PROTEIN; PHOSPHORYLATION; METABOLISM; P53; DEGRADATION; GROWTH	The oncoprotein c-Myc is frequently overexpressed in many cancers and is essential for cancer cell proliferation. Ubiquitin-proteasome-dependent degradation is one of the main ways in which cells control c-Myc abundance at a post-translational level. However, the underlying mechanism by which c-Myc is directly deubiquitinated is not fully understood. In this study, by screening ubiquitin-specific proteases (USPs) that may regulate c-Myc stability, we identified USP37 as a novel deubiquitinating enzyme (DUB) that stabilizes c-Myc via direct binding. The overexpression of USP37 markedly increases c-Myc abundance by blocking its degradation, whereas the depletion of USP37 promotes c-Myc degradation and reduces c-Myc levels. Further studies indicate that USP37 directly interacts with c-Myc and deubiquitinates c-Myc in a DUB activity-dependent manner. Functionally, USP37 regulates cell proliferation and the Warburg effect by regulating c-Myc levels. Clinically, USP37 is significantly upregulated in human lung cancer tissues, where its expression is positively correlated with c-Myc protein expression. Thus, our findings uncover a previously unrecognized role for USP37 in the regulation of c-Myc stability in lung cancer and suggest that USP37 might be a potential therapeutic target for the treatment of lung cancer.	[Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Wang, P.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Pan, J.; Deng, Q.; Jiang, C.; Wang, X.; Niu, T.; Li, H.; Chen, T.; Jin, J.; Pan, W.; Wang, P.] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Cai, X.; Yang, X.; Xiao, J.] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China; [Lu, M.; Wang, P.] Tongji Univ, Sch Life Sci & Technol, Shanghai Peoples Hosp 10, Dept Cent Lab, Shanghai 200092, Peoples R China	East China Normal University; East China Normal University; Naval Medical University; Tongji University	Wang, P (corresponding author), E China Normal Univ, Inst Biomed Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.	jianruxiao83@163.com; pwang@bio.ecnu.edu.cn	Xiao, Jian/GYU-4351-2022		National Basic Research Program of China (973 program) [2010CB529704, 2012CB910404]; National Natural Science Foundation of China [30800587, 30971521, 31171338]; Science and Technology Commission of Shanghai Municipality [11DZ2260300, 09QA1401900, 13QH1401]; Doctoral Fund of Ministry of Education of China [20130076110022]; Program for New Century Excellent Talents in University [NCET-10-0387]; Dawn Program of Shanghai Education Commission [11SG27]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Dawn Program of Shanghai Education Commission	We thank other members of the Wang laboratory for their assistance. This work was supported by grants from the National Basic Research Program of China (973 program 2010CB529704 and 2012CB910404), the National Natural Science Foundation of China (30800587, 30971521 and 31171338), the Science and Technology Commission of Shanghai Municipality (11DZ2260300) and the Doctoral Fund of Ministry of Education of China (20130076110022). PW is a scholar of the Shanghai Rising-Star Program from the Science and Technology Commission of Shanghai Municipality (09QA1401900 and 13QH1401), the Program for New Century Excellent Talents in University (NCET-10-0387) and the Dawn Program of Shanghai Education Commission (11SG27).	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Das CM, 2013, ONCOGENE, V32, P1691, DOI 10.1038/onc.2012.182; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Liao P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.536; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Seo HR, 2008, J BIOL CHEM, V283, P15601, DOI 10.1074/jbc.M800987200; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Soga T, 2013, CANCER SCI, V104, P275, DOI 10.1111/cas.12085; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Todi SV, 2011, TRENDS NEUROSCI, V34, P370, DOI 10.1016/j.tins.2011.05.004; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang WC, 2013, ONCOGENE, V32, P5167, DOI 10.1038/onc.2012.537; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874	42	87	93	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3957	3967		10.1038/onc.2014.327	http://dx.doi.org/10.1038/onc.2014.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284584				2022-12-17	WOS:000358544200008
J	Oshima, H; Ishikawa, T; Yoshida, GJ; Naoi, K; Maeda, Y; Naka, K; Ju, X; Yamada, Y; Minamoto, T; Mukaida, N; Saya, H; Oshima, M				Oshima, H.; Ishikawa, T.; Yoshida, G. J.; Naoi, K.; Maeda, Y.; Naka, K.; Ju, X.; Yamada, Y.; Minamoto, T.; Mukaida, N.; Saya, H.; Oshima, M.			TNF-alpha/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells	ONCOGENE			English	Article						gastric cancer; inflammation; TNF-alpha; mouse model	NECROSIS-FACTOR-ALPHA; PROSTAGLANDIN E-2; TNF-ALPHA; PATHWAY ACTIVATION; GENE-EXPRESSION; INCREASED RISK; CANCER; WNT; INFLAMMATION; RECEPTOR	Helicobacter pylori infection induces chronic inflammation that contributes to gastric tumorigenesis. Tumor necrosis factor (TNF-alpha) is a proinflammatory cytokine, and polymorphism in the TNF-alpha gene increases the risk of gastric cancer. We herein investigated the role of TNF-alpha in gastric tumorigenesis using Gan mouse model, which recapitulates human gastric cancer development. We crossed Gan mice with TNF-alpha (Tnf) or TNF-alpha receptor TNFR1 (Tnfrsf1a) knockout mice to generate Tnf -/- Gan and Tnfrsf1a -/- Gan mice, respectively, and examined their tumor phenotypes. Notably, both Tnf -/- Gan mice and Tnfrsf1a -/- Gan mice showed similar, significant suppression of gastric tumor growth compared with control Tnf +/+ or Tnfrsf1a +/+ Gan mice. These results indicate that TNF-alpha signaling through TNFR1 is important for gastric tumor development. Bone marrow (BM) transplantation experiments showed that TNF-alpha expressed by BM-derived cells (BMDCs) stimulates the TNFR1 on BMDCs by an autocrine or paracrine manner, which is important for gastric tumor promotion. Moreover, the microarray analysis and colony formation assay indicated that NADPH oxidase organizer 1 (Noxo1) and Gna14 are induced in tumor epithelial cells in a TNF-alpha-dependent manner, and have an important role in tumorigenicity and tumor-initiating cell property of gastric cancer cells. Accordingly, it is possible that the activation of TNF-alpha/TNFR1 signaling in the tumor microenvironment promotes gastric tumor development through induction of Noxo1 and Gna14, which contribute to maintaining the tumor cells in an undifferentiated state. The present results indicate that targeting the TNF-alpha/TNFR1 pathway may be an effective preventive or therapeutic strategy for gastric cancer.	[Oshima, H.; Ishikawa, T.; Naoi, K.; Maeda, Y.; Ju, X.; Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Yoshida, G. J.; Maeda, Y.; Saya, H.] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan; [Naka, K.] Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Kanazawa, Ishikawa 9201192, Japan; [Yamada, Y.] Kanazawa Univ, Inst Sci & Engn, Fac Elect & Comp Engn, Kanazawa, Ishikawa 9201192, Japan; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9201192, Japan; [Mukaida, N.] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Keio University; Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014; Mukaida, Naofumi/D-7623-2011; Naka, Kazuhito/X-3756-2019; Saya, Hideyuki/J-4325-2013	Oshima, Masanobu/0000-0002-3304-0004; Mukaida, Naofumi/0000-0002-4193-1851; Naka, Kazuhito/0000-0001-6646-6004; Oshima, Hiroko/0000-0001-6855-4008; Yoshida, Go/0000-0002-1472-892X; Saya, Hideyuki/0000-0001-6610-1902	Ministry of Education, Culture, Sports, Science and Technology of Japan [22114005]; CREST; Japan Science and Technology Agency, Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); CREST(Core Research for Evolutional Science and Technology (CREST)); Japan Science and Technology Agency, Japan(Japan Science & Technology Agency (JST))	We thank Manami Watanabe and Ayako Tsuda for their excellent technical assistance. This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (no. 22114005) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and CREST, the Japan Science and Technology Agency, Japan.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Clements WM, 2002, CANCER RES, V62, P3503; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; El-Omar EM, 2006, BEST PRACT RES CL GA, V20, P675, DOI 10.1016/j.bpg.2006.04.006; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Itzkovitz S, 2012, NAT CELL BIOL, V14, P106, DOI 10.1038/ncb2384; Juhasz A, 2009, FREE RADICAL RES, V43, P523, DOI 10.1080/10715760902918683; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; Kostenis E, 2005, TRENDS PHARMACOL SCI, V26, P595, DOI 10.1016/j.tips.2005.09.007; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Lee MMK, 2009, J LEUKOCYTE BIOL, V86, P1319, DOI 10.1189/jlb.0209052; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER SCI, V100, P1779, DOI 10.1111/j.1349-7006.2009.01258.x; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seno H, 2002, CANCER RES, V62, P506; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	44	87	93	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3820	3829		10.1038/onc.2013.356	http://dx.doi.org/10.1038/onc.2013.356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975421	hybrid			2022-12-17	WOS:000339394100008
J	Kim, HP; Han, SW; Song, SH; Jeong, EG; Lee, MY; Hwang, D; Im, SA; Bang, YJ; Kim, TY				Kim, H-P; Han, S-W; Song, S-H; Jeong, E-G; Lee, M-Y; Hwang, D.; Im, S-A; Bang, Y-J; Kim, T-Y			Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer	ONCOGENE			English	Article						Testican-1; epithelial-mesenchymal transition; lapatinib resistance; beta-catenin; XAV939; HER2-positive gastric cancer	TYROSINE KINASE INHIBITOR; CELL-LINES; BREAST-CANCER; LUNG-CANCER; TRASTUZUMAB RESISTANCE; GEFITINIB RESISTANCE; HER2; RECEPTOR; GROWTH; EXPRESSION	Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinib and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited beta-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.	[Kim, H-P; Han, S-W; Song, S-H; Jeong, E-G; Im, S-A; Bang, Y-J; Kim, T-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; [Han, S-W; Im, S-A; Bang, Y-J; Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; [Lee, M-Y; Hwang, D.] Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, WCU Dept Mol Med & Biopharmaceut Sci, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yeongeon Dong, Seoul 110744, South Korea.	kimty@snu.ac.kr	Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597	Korean Healthcare 21 and Technology RD Project; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [20090093820]; Ministry for Health, Welfare and Family Affairs [A091081]	Korean Healthcare 21 and Technology RD Project; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); Ministry for Health, Welfare and Family Affairs	This work was supported by grants from the Korean Healthcare 21 and Technology R&D Project; Ministry for Health, Welfare and Family Affairs (A091081) and in part by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (20090093820).	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; Colleoni M, 2008, ANN ONCOL, V19, P465, DOI 10.1093/annonc/mdm509; Edgell CJS, 2004, INT REV CYTOL, V236, P101, DOI 10.1016/S0074-7696(04)36003-1; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; GlaxoSmithKline, 2011, LAP OPT STUD ERBB2 H; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kim HP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005933; Kim JW, 2008, CANCER LETT, V272, P296, DOI 10.1016/j.canlet.2008.07.018; Kim SY, 2008, INT J ONCOL, V32, P89; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lee MS, 2012, BBA-MOL CELL RES, V1823, P514, DOI 10.1016/j.bbamcr.2011.11.017; Leja J, 2009, MODERN PATHOL, V22, P261, DOI 10.1038/modpathol.2008.174; Li Y, 2013, GASTROENTEROLOGY, V144, P179, DOI 10.1053/j.gastro.2012.09.042; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Nam HJ, 2011, CANCER LETT, V302, P155, DOI 10.1016/j.canlet.2011.01.010; Prenzel KL, 2006, ONCOL REP, V15, P1397; Rusnak DW, 2007, CELL PROLIFERAT, V40, P580, DOI 10.1111/j.1365-2184.2007.00455.x; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667; Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	40	87	89	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3334	3341		10.1038/onc.2013.285	http://dx.doi.org/10.1038/onc.2013.285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873022				2022-12-17	WOS:000338443400013
J	Adesso, L; Calabretta, S; Barbagallo, F; Capurso, G; Pilozzi, E; Geremia, R; Delle Fave, G; Sette, C				Adesso, L.; Calabretta, S.; Barbagallo, F.; Capurso, G.; Pilozzi, E.; Geremia, R.; Delle Fave, G.; Sette, C.			Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway	ONCOGENE			English	Article						eIF4E phosphorylation; MNK2 alternative splicing; drug resistance	INITIATION-FACTOR 4E; MAMMALIAN TARGET; EIF4E; PHOSPHORYLATION; TRANSLATION; MNK2; OVEREXPRESSION; PROLIFERATION; VARIANTS; KINASES	Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic drug for PDAC, elicits only minor benefits, because of the development of escape pathways leading to chemoresistance. Herein, we aimed at investigating the involvement of the mitogen activating protein kinase interacting kinase (MNK)/eIF4E pathway in the acquired drug resistance of PDAC cells. Screening of a cohort of PDAC patients by immunohistochemistry showed that eIF4E phosphorylation correlated with disease grade, early onset of disease and worse prognosis. In PDAC cell lines, chemotherapeutic drugs induced MNK-dependent phosphorylation of eIF4E. Importantly, pharmacological inhibition of MNK activity synergistically enhanced the cytostatic effect of gemcitabine, by promoting apoptosis. RNA interference (RNAi) experiments indicated that MNK2 is mainly responsible for eIF4E phosphorylation and gemcitabine resistance in PDAC cells. Furthermore, we found that gemcitabine induced the expression of the oncogenic splicing factor SRSF1 and splicing of MNK2b, a splice variant that overrides upstream regulatory pathways and confers increased resistance to the drug. Silencing of SRSF1 by RNAi abolished this splicing event and recapitulated the effects of MNK pharmacological or genetic inhibition on eIF4E phosphorylation and apoptosis in gemcitabine-treated cells. Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells to withstand chemotherapeutic treatments.	[Adesso, L.; Calabretta, S.; Barbagallo, F.; Geremia, R.; Delle Fave, G.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy; [Adesso, L.; Calabretta, S.; Capurso, G.; Pilozzi, E.; Delle Fave, G.] Univ Roma La Sapienza, Digest & Liver Dis Unit, Sch Med 2, I-00133 Rome, Italy; [Barbagallo, F.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy	University of Rome Tor Vergata; Sapienza University Rome; IRCCS Santa Lucia	Delle Fave, G (corresponding author), Univ Roma La Sapienza, Digest & Liver Dis Unit, Sch Med 2, I-00133 Rome, Italy.	gianfranco.dellefave@uniroma1.it; claudio.sette@uniroma2.it	PILOZZI, Emanuela/AAC-1854-2022; Sette, Claudio/S-4307-2019; Barbagallo, Federica/K-1185-2018; Capurso, Gabriele/AAB-1389-2019; Adesso, Laura/AAA-7708-2020; Barbagallo, Federica/AAD-4903-2022	PILOZZI, Emanuela/0000-0002-7110-9172; Sette, Claudio/0000-0003-2864-8266; Barbagallo, Federica/0000-0002-2972-370X; Capurso, Gabriele/0000-0002-0019-8753; Adesso, Laura/0000-0003-2121-4924; Barbagallo, Federica/0000-0002-2972-370X; GEREMIA, Raffaele/0000-0001-9056-6603	Associazione Italiana Ricerca sul Cancro [AIRC IG10348]; Association for International Cancer Research (AICR); Worldwide Cancer Research [12-0150] Funding Source: researchfish	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR); Worldwide Cancer Research	We wish to thank Professor CG Proud for the generous gift of MNK2a and MNK2b plasmids, Professor A Scarpa for the gift of HPAF2 cells, Dr Enrica Bianchi for help with FACS analysis, Dr Maria Antonietta Talerico for technical support with immunohistochemistry and Dr Alessia Di Florio for helpful suggestions throughout the study. This work was supported by funds from the Associazione Italiana Ricerca sul Cancro (AIRC IG10348) and Association for International Cancer Research (AICR).	Altman JK, 2010, MOL PHARMACOL, V78, P778, DOI 10.1124/mol.110.064642; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Busa R, 2007, ONCOGENE, V26, P4372, DOI 10.1038/sj.onc.1210224; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Chrestensen CA, 2007, GENES CELLS, V12, P1133, DOI 10.1111/j.1365-2443.2007.01122.x; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Falasca M, 2011, ANTI-CANCER AGENT ME, V11, P455, DOI 10.2174/187152011795677382; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Goncalves V, 2009, MUTAT RES-FUND MOL M, V662, P33, DOI 10.1016/j.mrfmmm.2008.12.001; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Hayes GM, 2006, CANCER RES, V66, P3819, DOI 10.1158/0008-5472.CAN-05-4065; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kern SE, 2011, J PATHOL, V223, P295, DOI 10.1002/path.2813; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Pedrotti S, 2010, EMBO J, V29, P1235, DOI 10.1038/emboj.2010.19; Sanz DJ, 2010, CLIN CANCER RES, V16, P1957, DOI 10.1158/1078-0432.CCR-09-2564; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zhang Y, 2008, BIOCHEM BIOPH RES CO, V367, P54, DOI 10.1016/j.bbrc.2007.12.118; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	32	87	93	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2848	2857		10.1038/onc.2012.306	http://dx.doi.org/10.1038/onc.2012.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797067				2022-12-17	WOS:000320369100005
J	Yin, D; Ogawa, S; Kawamata, N; Leiter, A; Ham, M; Li, D; Doans, NB; Said, JW; Black, KL; Koeffler, HP				Yin, D.; Ogawa, S.; Kawamata, N.; Leiter, A.; Ham, M.; Li, D.; Doans, N. B.; Said, J. W.; Black, K. L.; Koeffler, H. Phillip			miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme; genomic profiling; miR-34a; EGFR; YY-1	GROWTH-FACTOR RECEPTOR; PROSTATE-CANCER; DOWN-REGULATION; EXPRESSION PROFILES; GENE-EXPRESSION; C-MET; APOPTOSIS; IDENTIFICATION; NEUROBLASTOMA; PATHWAY	Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients. Oncogene (2013) 32, 1155-1163; doi:10.1038/onc.2012.132; published online 14 May 2012	[Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Key Lab Malignant Tumor Gene Regulat, Guangzhou 510275, Guangdong, Peoples R China; [Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Target Therapy Guangdong Higher Educ Inst, Guangzhou 510275, Guangdong, Peoples R China; [Yin, D.; Kawamata, N.; Leiter, A.; Ham, M.; Koeffler, H. Phillip] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA; [Ogawa, S.] Univ Tokyo, Sch Med, Tokyo 113, Japan; [Li, D.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Said, J. W.] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; [Black, K. L.] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA USA; [Koeffler, H. Phillip] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore, Singapore; [Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore	Sun Yat Sen University; Sun Yat Sen University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tokyo; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore; National University of Singapore	Yin, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510275, Guangdong, Peoples R China.	Dong.Yin@cshs.org	Ogawa, Seishi/AAE-7088-2019	Black, Keith/0000-0002-0546-4934	National Institutes of Health [1U54CA143930-02, 5R01CA026038-32]; Tom Collier Foundation; A *STAR award of Singapore; Maxine Dunitz Neurosurgical Institute; Cedars-Sinai Medical Center; NSFC [81071788]; '985 project' of Sun Yat-sen University; NATIONAL CANCER INSTITUTE [U54CA143930, P50CA092131, R01CA026038] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tom Collier Foundation; A *STAR award of Singapore; Maxine Dunitz Neurosurgical Institute; Cedars-Sinai Medical Center; NSFC(National Natural Science Foundation of China (NSFC)); '985 project' of Sun Yat-sen University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grant 1U54CA143930-02 and 5R01CA026038-32, Tom Collier Foundation, A *STAR award of Singapore (HPK); a grant from the Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center (KLB); NSFC grant 81071788, '985 project' of Sun Yat-sen University. HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA, and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. This study is in loving memory of matt schreck.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bheda A, 2008, ONCOGENE, V27, P4315, DOI 10.1038/onc.2008.65; Chakravarti A, 2001, CLIN CANCER RES, V7, P2387; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen H, 2009, INT J NEUROPSYCHOPH, V12, P1; Chen QR, 2011, J PROTEOME RES, V10, P479, DOI 10.1021/pr1006697; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Dong Z, 2004, BRIT J CANCER, V91, P1105, DOI 10.1038/sj.bjc.6602093; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Feinberg-Gorenshtein G, 2009, GENE CHROMOSOME CANC, V48, P539, DOI 10.1002/gcc.20662; Ghimenti C, 2003, J NEURO-ONCOL, V61, P95, DOI 10.1023/A:1022127302008; Guessous F, CELL CYCLE, V9, P1031; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Ichimura K, 2008, ONCOGENE, V27, P2097, DOI 10.1038/sj.onc.1210848; Kaller M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010462; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Lee CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007314; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Ljubimova JY, 2001, INT J ONCOL, V18, P287; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rokhlin OW, 2008, CANCER BIOL THER, V7, P1288, DOI 10.4161/cbt.7.8.6284; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Solomon DA, 2008, CANCER RES, V68, P2564, DOI 10.1158/0008-5472.CAN-07-6388; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Ueki K, 1996, CANCER RES, V56, P150; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809; Yan DS, 2009, INVEST OPHTH VIS SCI, V50, P1559, DOI 10.1167/iovs.08-2681; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Yin D, 2009, MOL CANCER RES, V7, P665, DOI 10.1158/1541-7786.MCR-08-0270; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003	45	87	93	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1155	1163		10.1038/onc.2012.132	http://dx.doi.org/10.1038/onc.2012.132			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22580610	Green Accepted			2022-12-17	WOS:000316428800009
J	Shi, J; Wang, E; Zuber, J; Rappaport, A; Taylor, M; Johns, C; Lowe, SW; Vakoc, CR				Shi, J.; Wang, E.; Zuber, J.; Rappaport, A.; Taylor, M.; Johns, C.; Lowe, S. W.; Vakoc, C. R.			The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia	ONCOGENE			English	Article						chromatin; leukemia; epigenetics; MLL; PRC2	HISTONE METHYLTRANSFERASE ACTIVITY; H3 LYSINE 27; GROUP PROTEIN; STEM-CELLS; GENE EZH2; DEVELOPMENTAL REGULATORS; MUTATIONS; METHYLATION; TARGET; DIFFERENTIATION	The Trithorax and Polycomb groups of chromatin regulators are critical for cell-lineage specification during normal development; functions that often become deregulated during tumorigenesis. As an example, oncogenic fusions of the Trithorax-related protein mixed lineage leukemia (MLL) can initiate aggressive leukemias by altering the transcriptional circuitry governing hematopoietic cell differentiation, a process that requires multiple epigenetic pathways to implement. Here we used shRNA screening to identify chromatin regulators uniquely required in a mouse model of MLL-fusion acute myeloid leukemia, which revealed a role for the Polycomb repressive complex 2 (PRC2) in maintenance of this disease. shRNA-mediated suppression of PRC2 subunits Eed, Suz12 or Ezh1/Ezh2 led to proliferation arrest and differentiation of leukemia cells, with a minimal impact on growth of several non-transformed hematopoietic cell lines. The requirement for PRC2 in leukemia is partly because of its role in direct transcriptional repression of genes that limit the self-renewal potential of hennatopoietic cells, including Cdkn2a. In addition to implicating a role for PRC2 in the pathogenesis of MLL-fusion leukemia, our results suggest, more generally, that Trithorax and Polycomb group proteins can cooperate with one another to maintain aberrant lineage programs in cancer. Oncogene (2013) 32, 930-938; doi:10.1038/onc.2012.110; published online 2 April 2012	[Shi, J.; Wang, E.; Zuber, J.; Rappaport, A.; Taylor, M.; Johns, C.; Lowe, S. W.; Vakoc, C. R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Shi, J.] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA; [Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria; [Rappaport, A.] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Lowe, S. W.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cold Spring Harbor Laboratory; Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Vakoc, CR (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowes@mskcc.org; vakoc@cshl.edu	Zuber, Johannes/E-7517-2011; Clovis, Jeff/C-1020-2009	Zuber, Johannes/0000-0001-8810-6835; Wang, Eric/0000-0001-7865-6702; Vakoc, Christopher/0000-0002-1158-7180	Don Monti Memorial Research Foundation; Laurie Strauss Leukemia Foundation; Sass Foundation; Edward P Evans Foundation; FM Kirby Foundation; German Research Foundation (DFG); Andrew Seligson Memorial Clinical Fellowship at CSHL; NIH; Barbara McClintock fellowship; Leukemia and Lymphoma Society of America; National Cancer Institute and by the Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065094] Funding Source: NIH RePORTER	Don Monti Memorial Research Foundation; Laurie Strauss Leukemia Foundation; Sass Foundation; Edward P Evans Foundation; FM Kirby Foundation; German Research Foundation (DFG)(German Research Foundation (DFG)); Andrew Seligson Memorial Clinical Fellowship at CSHL; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barbara McClintock fellowship; Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); National Cancer Institute and by the Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J Simon, E Earl and L Bianco for support with mouse work; S Hearn for microscopy support; G Hannon laboratory for support of shRNA screening methodology; and G Blobel for comments on the manuscript. CRV, JS, EW and MT were supported by the Don Monti Memorial Research Foundation, Laurie Strauss Leukemia Foundation, Sass Foundation, Edward P Evans Foundation and FM Kirby Foundation for research support. JZ was supported by a research fellowship from the German Research Foundation (DFG) and by the Andrew Seligson Memorial Clinical Fellowship at CSHL; ARR was supported by an NIH traineeship and the Barbara McClintock fellowship. SWL is supported by a Specialized Center of Research (SCOR) grant from the Leukemia and Lymphoma Society of America, a Cancer Target Discovery and Development (CTD2) grant from the National Cancer Institute and by the Howard Hughes Medical Institute.	Attardi LD, 2000, GENE DEV, V14, P704; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Dickins RA, 2007, NAT GENET, V39, P914, DOI 10.1038/ng2045; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hellborg F, 2001, ONCOGENE, V20, P5466, DOI 10.1038/sj.onc.1204722; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Maillard I, 2009, BLOOD, V113, P1661, DOI [10.1182/blood-2008-01-135012, 10.1182/blood-2009-01-135012]; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Mochizuki-Kashio M, 2011, BLOOD, V118, P6553, DOI 10.1182/blood-2011-03-340554; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wigle TJ, 2011, FEBS LETT, V585, P3011, DOI 10.1016/j.febslet.2011.08.018; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	49	87	89	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					930	938		10.1038/onc.2012.110	http://dx.doi.org/10.1038/onc.2012.110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469984	Green Accepted			2022-12-17	WOS:000316581100013
J	Mauviel, A; Nallet-Staub, F; Varelas, X				Mauviel, A.; Nallet-Staub, F.; Varelas, X.			Integrating developmental signals: a Hippo in the (path) way	ONCOGENE			English	Review						Hippo signaling; TGF-beta signaling; Wnt signaling; TAZ; YAP; growth control	YES-ASSOCIATED PROTEIN; TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR PATHWAY; STEM-CELL PROLIFERATION; ORGAN SIZE CONTROL; TRANSCRIPTIONAL COACTIVATOR; PROMOTER HYPERMETHYLATION; NUCLEAR-LOCALIZATION; DOWN-REGULATION; WW DOMAINS	The Hippo pathway, a signaling cascade that controls cell cycle progression, apoptosis and cell differentiation, has emerged as a fundamental regulator of many physiological and pathological processes. Recent studies have revealed a complex network of interactions directing Hippo pathway activity, and have connected this pathway with other key signaling pathways. Such crosstalk has uncovered novel roles for Hippo signaling, including regulation of TGF beta/SMAD and WNT/beta-catenin pathways. This review highlights some of the recent findings in the Hippo field with an emphasis on how the Hippo pathway is integrated with other pathways to mediate diverse processes. Oncogene (2012) 31, 1743-1756; doi: 10.1038/onc.2011.363; published online 29 August 2011	[Mauviel, A.] Inst Curie, CNRS, INSERM, U1021,Univ Ctr,UMR3347, F-91400 Orsay, France; [Mauviel, A.; Nallet-Staub, F.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Mauviel, A.; Nallet-Staub, F.] Univ Paris 11, Orsay, France; [Varelas, X.] Boston Univ, Dept Biochem, Sch Med, Boston, MA 02118 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; Boston University	Mauviel, A (corresponding author), Inst Curie, CNRS, INSERM, U1021,Univ Ctr,UMR3347, Bldg 110, F-91400 Orsay, France.	alain.mauviel@curie.fr; xvarelas@bu.edu	MAUVIEL, Alain/F-6251-2013; Varelas, Xaralabos/ABB-9141-2020; han, jing/A-2527-2015	Mauviel, Alain/0000-0002-0438-2793; Varelas, Xaralabos/0000-0002-2882-4541	Karin Grunebaum Cancer Foundation; Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa) [PLBIO-2008]; INSERM; CNRS; Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE); Universite Paris XI; Ligue Nationale Contre le Cancer	Karin Grunebaum Cancer Foundation; Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE); Universite Paris XI; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	Supported by the Karin Grunebaum Cancer Foundation (to X. V.), and Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa, PLBIO-2008), INSERM, CNRS, Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE), Universite Paris XI (to A. M.). F. N-S. the recipient of a Ligue Nationale Contre le Cancer doctoral studentship.	Affolter M, 2007, NAT REV GENET, V8, P663, DOI 10.1038/nrg2166; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Baena-Lopez LA, 2008, P NATL ACAD SCI USA, V105, P9645, DOI 10.1073/pnas.0803747105; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Arnold SJ, 2009, NAT REV MOL CELL BIO, V10, P91, DOI 10.1038/nrm2618; Attisano L, 2004, CANCER METAST REV, V23, P53, DOI 10.1023/A:1025811012690; Aylon Y, 2010, GENE DEV, V24, P2420, DOI 10.1101/gad.1954410; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bulgakova NA, 2009, J CELL SCI, V122, P2587, DOI 10.1242/jcs.023648; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2011, ONCOGENE, V30, P600, DOI 10.1038/onc.2010.438; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Dai FY, 2010, METHODS MOL BIOL, V647, P125, DOI 10.1007/978-1-60761-738-9_7; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Di Palma T, 2009, EXP CELL RES, V315, P162, DOI 10.1016/j.yexcr.2008.10.016; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Duning K, 2010, J BIOL CHEM, V285, P33584, DOI 10.1074/jbc.C110.146381; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Habbig S, 2011, J CELL BIOL, V193, P633, DOI 10.1083/jcb.201009069; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010; Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; Hossain Z, 2007, P NATL ACAD SCI USA, V104, P1631, DOI 10.1073/pnas.0605266104; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Jang SW, 2007, J BIOL CHEM, V282, P30836, DOI 10.1074/jbc.M704542200; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009616; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Liu CY, 2011, J BIOL CHEM, V286, P5558, DOI 10.1074/jbc.M110.194019; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Makita R, 2008, AM J PHYSIOL-RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Meignin C, 2007, CURR BIOL, V17, P1871, DOI 10.1016/j.cub.2007.09.062; Miller BW, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.72; Morin-Kensicki EM, 2006, MOL CELL BIOL, V26, P77, DOI 10.1128/MCB.26.1.77-87.2006; Murakami M, 2006, BIOCHEM BIOPH RES CO, V339, P533, DOI 10.1016/j.bbrc.2005.10.214; Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Nishioka N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Oh H, 2011, DEV CELL, V20, P109, DOI 10.1016/j.devcel.2010.12.002; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Polesello C, 2007, CURR BIOL, V17, P1864, DOI 10.1016/j.cub.2007.09.049; Reddy BVVG, 2010, DEVELOPMENT, V137, P2397, DOI 10.1242/dev.050013; Remue E, 2010, FEBS LETT, V584, P4175, DOI 10.1016/j.febslet.2010.09.020; Ren FF, 2010, P NATL ACAD SCI USA, V107, P21064, DOI 10.1073/pnas.1012759107; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Staley BK, 2010, CURR BIOL, V20, P1580, DOI 10.1016/j.cub.2010.07.041; Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Sudol M, 2011, GENES CANC, V1, P1115; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vigneron AM, 2010, GENE DEV, V24, P2430, DOI 10.1101/gad.1954310; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yim H, 2011, J AM SOC NEPHROL, V22, P832, DOI 10.1681/ASN.2010090992; Yu JZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001761; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Yuan ZQ, 2010, J BIOL CHEM, V285, P3815, DOI 10.1074/jbc.M109.059675; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	146	87	91	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1743	1756		10.1038/onc.2011.363	http://dx.doi.org/10.1038/onc.2011.363			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21874053				2022-12-17	WOS:000302785200001
J	Arozarena, I; Bischof, H; Gilby, D; Belloni, B; Dummer, R; Wellbrock, C				Arozarena, I.; Bischof, H.; Gilby, D.; Belloni, B.; Dummer, R.; Wellbrock, C.			In melanoma, beta-catenin is a suppressor of invasion	ONCOGENE			English	Article						melanoma; invasion; Rho; ROCK; MMP; MITF	TRANSCRIPTION FACTOR; COLORECTAL-CANCER; PROGNOSTIC MARKER; CELL-MIGRATION; EXPRESSION; MITF; PROLIFERATION; PROGRESSION; TARGET; P16(INK4A)	Cell-type-specific signalling determines cell fate under physiological conditions, but it is increasingly apparent that also in cancer development the impact of any given oncogenic pathway on the individual cancer pathology is dependent on cell-lineage-specific molecular traits. For instance in colon and liver cancer canonical Wnt signalling produces increased cytoplasmic and nuclear localised beta-catenin, which correlates with invasion and poor prognosis. In contrast, in melanoma increased cytoplasmic and nuclear beta-catenin is currently emerging as a marker for good prognosis, and thus seems to have a different function compared with other cancer types; however, this function is unknown. We discovered that in contrast to its function in other cancers, in melanoma, beta-catenin blocks invasion. We demonstrate that this opposing role of nuclear beta-catenin in melanoma is mediated through MITF, a melanoma-specific protein that defines the lineage background of this cancer type. Downstream of beta-catenin MITF not only suppresses the Rho-GTPase-regulated cell morphology of invading melanoma cells, but also interferes with beta-catenin-induced expression of the essential collagenase MT1-MMP, thus affecting all aspects of an invasive phenotype. Importantly, overexpression of MITF in invasive colon cancer cells modifies beta-catenin-directed signalling and induces a 'melanoma phenotype'. In summary, the cell-type-specific presence of MITF in melanoma affects beta-catenin's pro-invasive properties otherwise active in colon or liver cancer. Thus our study reveals the general importance of considering cell-type-specific signalling for the accurate interpretation of tumour markers and ultimately for the design of rational therapies. Oncogene (2011) 30, 4531-4543; doi:10.1038/onc.2011.162; published online 16 May 2011	[Arozarena, I.; Bischof, H.; Gilby, D.; Wellbrock, C.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; [Belloni, B.; Dummer, R.] Univ Spital Zurich, Dept Dermatol, Zurich, Switzerland	University of Manchester; University of Zurich; University Zurich Hospital	Wellbrock, C (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	claudia.wellbrock@manchester.ac.uk	Arozarena, Imanol/A-5981-2017	Arozarena, Imanol/0000-0001-6349-2442; Wellbrock, Claudia/0000-0002-3825-6381	BBSRC [BB/G001111/1]; Wellcome Trust; University of Manchester; Cancer Research UK [C11591/A10202]; Biotechnology and Biological Sciences Research Council [BB/G001111/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Manchester; Cancer Research UK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank Steven Rosenberg (NCI) for the 501mel, 888mel and 1290mel cells and Hector Palmer (Vall d'Hebron) for the beta-catenin reporter plasmids. We thank Peter March for his help with microscopy. The Bioimaging Facility microscopes were funded by the BBSRC, the Wellcome Trust and the University of Manchester Strategic Fund. This work was funded by Cancer Research UK (grant C11591/A10202) and the BBSRC (grant BB/G001111/1).	Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Boye K, 2010, EUR J CANCER, V46, P2919, DOI 10.1016/j.ejca.2010.07.013; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demirkan NC, 2007, CLIN EXP DERMATOL, V32, P733, DOI 10.1111/j.1365-2230.2007.02507.x; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Itoh Y, 2006, IUBMB LIFE, V58, P589, DOI 10.1080/15216540600962818; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; O'Connell MP, 2009, PIGM CELL MELANOMA R, V22, P724, DOI 10.1111/j.1755-148X.2009.00627.x; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pecina-Slaus N, 2007, J CUTAN PATHOL, V34, P239, DOI 10.1111/j.1600-0560.2006.00601.x; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; ROBBINS PF, 1995, J IMMUNOL, V154, P5944; Rothberg BEG, 2009, J CLIN ONCOL, V27, P5772, DOI 10.1200/JCO.2009.22.8239; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Salti GI, 2000, CANCER RES, V60, P5012; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	50	87	88	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4531	4543		10.1038/onc.2011.162	http://dx.doi.org/10.1038/onc.2011.162			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21577209	Green Accepted			2022-12-17	WOS:000296890700001
J	Dulak, AM; Gubish, CT; Stabile, LP; Henry, C; Siegfried, JM				Dulak, A. M.; Gubish, C. T.; Stabile, L. P.; Henry, C.; Siegfried, J. M.			HGF-independent potentiation of EGFR action by c-Met	ONCOGENE			English	Article						c-Met; c-Src; EGFR; cross-talk	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; GASTRIN-RELEASING-PEPTIDE; TYROSINE KINASE-ACTIVITY; EPIDERMAL-GROWTH; SCATTER-FACTOR; THERAPEUTIC INHIBITION; GEFITINIB RESISTANCE; CARCINOMA-CELLS; BREAST-CANCER	The c-Met receptor is a potential therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR) have been studied extensively, but signaling intermediates and biological consequences of lateral signaling to c-Met in EGFR wild-type tumors are minimally understood. Our observations indicate that delayed c-Met activation in NSCLC cell lines is initiated by wild-type EGFR, the receptor most often found in NSCLC tumors. EGFR ligands induce accumulation of activated c-Met, which begins at 8 h and continues for 48 h. This effect is accompanied by an increase in c-Met expression and phosphorylation of critical c-Met tyrosine residues without activation of mitogen-activated protein kinase (MAPK) or Akt. Gene transcription is required for delayed c-Met activation; however, phosphorylation of c-Met by EGFR occurs without production of hepatocyte growth factor (HGF) or another secreted factor, supporting a ligand-independent mechanism. Lateral signaling is blocked by two selective c-Met tyrosine kinase inhibitors (TKIs), PF2341066 and SU11274, or with gefitinib, an EGFR TKI, suggesting kinase activity of both receptors is required for this effect. Prolonged c-Src phosphorylation is observed, and c-Src pathway is essential for EGFR to c-Met communication. Pretreatment with pan-Src family kinase inhibitors, PP2 and dasatinib, abolishes delayed c-Met phosphorylation. A c-Src dominant-negative construct reduces EGF-induced c-Met phosphorylation compared with control, further confirming a c-Src requirement. Inhibition of c-Met with PF2341066 and siRNA decreases EGF-induced phenotypes of invasion by similar to 86% and motility by similar to 81%, suggesting that a novel form of c-Met activation is utilized by EGFR to maximize these biological effects. Combined targeting of c-Met and EGFR leads to increased xenograft antitumor activity, demonstrating that inhibition of downstream and lateral signaling from the EGFR-c-Src-c-Met axis might be effective in treatment of NSCLC. Oncogene (2011) 30, 3625-3635; doi:10.1038/onc.2011.84; published online 21 March 2011	[Siegfried, J. M.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Siegfried, J. M.] Univ Pittsburgh, Univ Pittsburgh Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Siegfried, JM (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Suite 2-18,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	siegfriedjm@upmc.edu	Stabile, Laura/AAE-9235-2020		NIH, National Cancer Institute [R01 CA79882]; America Foundation; Predoctoral Fellowship in Pharmacology by Pharmaceutical Research; NATIONAL CANCER INSTITUTE [R01CA079882] Funding Source: NIH RePORTER	NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); America Foundation; Predoctoral Fellowship in Pharmacology by Pharmaceutical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant R01 CA79882 to JMS from the National Cancer Institute and by a Predoctoral Fellowship in Pharmacology by Pharmaceutical Research and Manufacturers of America Foundation awarded to Austin M Dulak. We would like to thank Pfizer for kindly providing PF2341066.	Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Liu XW, 2007, EXP CELL RES, V313, P1361, DOI 10.1016/j.yexcr.2007.01.016; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Molina JR, 2006, CHEST, V130, P1211, DOI 10.1378/chest.130.4.1211; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakajima M, 1999, CANCER, V85, P1894; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Presnell SC, 1997, MOL CARCINOGEN, V18, P244, DOI 10.1002/(SICI)1098-2744(199704)18:4<244::AID-MC8>3.3.CO;2-Y; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Siegfried JM, 2007, MOL PHARMACOL, V72, P769, DOI 10.1124/mol.107.034215; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; Stabile LP, 2008, MOL CANCER THER, V7, P1913, DOI 10.1158/1535-7163.MCT-07-2169; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tang Z, 2008, BRIT J CANCER, V99, P911, DOI 10.1038/sj.bjc.6604559; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wu CC, 2008, CANCER, V113, P3199, DOI 10.1002/cncr.23925; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643	44	87	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3625	3635		10.1038/onc.2011.84	http://dx.doi.org/10.1038/onc.2011.84			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423210	Green Accepted			2022-12-17	WOS:000294005100006
J	Janssen, A; Medema, RH				Janssen, A.; Medema, R. H.			Mitosis as an anti-cancer target	ONCOGENE			English	Review						mitosis; aneuploidy; CIN; therapy; cancer	SMALL-MOLECULE INHIBITOR; SPINDLE ASSEMBLY CHECKPOINT; CHROMOSOME MIS-SEGREGATION; CELL-CYCLE PROGRESSION; POLO-LIKE KINASE-1; AURORA-B KINASE; GROWTH IN-VIVO; CANCER-CELLS; MITOTIC CHECKPOINT; MAMMALIAN-CELLS	Most of the current drugs used to treat cancer can be classified as anti-proliferative drugs. These drugs perturb the proliferative cycle of tumor cells at diverse stages of the cell cycle. Examples of such drugs are DNA-damaging agents and inhibitors of cyclin-dependent kinases that arrest cell cycle progression at different stages of interphase. Another class of anti-proliferative drugs is the so-called anti-mitotic drugs, which selectively perturb progression through mitosis. Mitosis is the shortest and final stage in the cell cycle and has evolved to accurately divide the duplicated genome over the two daughter cells. This review deals with the different strategies that are currently considered to perturb mitotic progression in the treatment of cancer. Oncogene (2011) 30, 2799-2809; doi: 10.1038/onc.2011.30; published online 21 February 2011	[Janssen, A.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, Canc Genom Ctr, Univ Weg 100,Str 2-233, NL-3584 CG Utrecht, Netherlands.	r.h.medema@umcutrecht.nl	Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381; Janssen, Aniek/0000-0001-6731-6657				Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Barr FA, 2007, CELL, V131, P847, DOI 10.1016/j.cell.2007.11.011; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; Brier S, 2006, J MOL BIOL, V360, P360, DOI 10.1016/j.jmb.2006.04.062; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cohen J, 2002, SCIENCE, V296, P2164, DOI 10.1126/science.296.5576.2164; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Cox CD, 2008, J MED CHEM, V51, P4239, DOI 10.1021/jm800386y; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Godinho S, 2009, CANCER METAST REV, V28, P85, DOI 10.1007/s10555-008-9163-6; Goodin S, 2008, AM J HEALTH-SYST PH, V65, pS10, DOI 10.2146/ajhp080089; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Ha GH, 2007, CANCER RES, V67, P7155, DOI 10.1158/0008-5472.CAN-06-3392; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Keen N, 2009, CANCER METAST REV, V28, P185, DOI 10.1007/s10555-009-9184-9; Khodjakov A, 2002, J CELL BIOL, V158, P1171, DOI 10.1083/jcb.200205102; Kitzen JJEM, 2010, CRIT REV ONCOL HEMAT, V73, P99, DOI 10.1016/j.critrevonc.2009.03.009; Kops GJPL, 2008, FRONT BIOSCI-LANDMRK, V13, P3606, DOI 10.2741/2953; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Lok W, 2010, ANTI-CANCER DRUG, V21, P339, DOI 10.1097/CAD.0b013e3283350dd1; Maliga Zoltan, 2006, BMC Chemical Biology, V6, P2, DOI 10.1186/1472-6769-6-2; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mazumdar M, 2006, CURR BIOL, V16, P1559, DOI 10.1016/j.cub.2006.06.029; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Pihan GA, 2001, CANCER RES, V61, P2212; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rieder CL, 2009, CANCER CELL, V16, P274, DOI 10.1016/j.ccr.2009.09.021; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; ROWINSKY EK, 1988, CANCER RES, V48, P4093; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schafer-Hales K, 2007, MOL CANCER THER, V6, P1317, DOI 10.1158/1535-7163.MCT-06-0703; Schmidt M, 2006, CELL CYCLE, V5, P159, DOI 10.4161/cc.5.2.2309; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Stobbe CC, 2002, INT J RADIAT BIOL, V78, P1149, DOI 10.1080/09553000210166570; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tanenbaum ME, 2009, CURR BIOL, V19, P1703, DOI 10.1016/j.cub.2009.08.027; Tcherniuk S, 2010, BIOCHEM PHARMACOL, V79, P864, DOI 10.1016/j.bcp.2009.11.001; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; TUXEN MK, 1994, CANCER TREAT REV, V20, P191, DOI 10.1016/0305-7372(94)90027-2; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Vader G, 2006, J CELL BIOL, V173, P833, DOI 10.1083/jcb.200604032; Vanneste D, 2009, CURR BIOL, V19, P1712, DOI 10.1016/j.cub.2009.09.019; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vitale I, 2008, CELL CYCLE, V7, P1956, DOI 10.4161/cc.7.13.6073; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Wood KW, 2010, P NATL ACAD SCI USA, V107, P5839, DOI 10.1073/pnas.0915068107; Wu LM, 2011, J BIOL CHEM, V286, P2236, DOI 10.1074/jbc.M110.174755; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yue QX, 2010, PLANTA MED, V76, P1037, DOI 10.1055/s-0030-1250073; Yuen KWY, 2005, CURR OPIN CELL BIOL, V17, P576, DOI 10.1016/j.ceb.2005.09.012; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010	131	87	93	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2799	2809		10.1038/onc.2011.30	http://dx.doi.org/10.1038/onc.2011.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339734				2022-12-17	WOS:000291977800001
J	Sachdeva, M; Wu, H; Ru, P; Hwang, L; Trieu, V; Mo, YY				Sachdeva, M.; Wu, H.; Ru, P.; Hwang, L.; Trieu, V.; Mo, Y-Y			MicroRNA-101-mediated Akt activation and estrogen-independent growth	ONCOGENE			English	Article						breast cancer; estrogen receptor; miR-101; tamoxifen resistance	ALPHA MESSENGER-RNA; BREAST-CANCER; TUMOR-SUPPRESSOR; TAMOXIFEN RESISTANCE; RECEPTOR-ALPHA; PROTEIN STABILITY; PTEN; PHOSPHORYLATION; MECHANISMS; EXPRESSION	MicroRNAs are gene regulators that work through a posttranscriptional repression mechanism. Dysregulation of microRNA expression could lead to a variety of disorders, in particular, human cancer, and has also been implicated in antihormone therapy resistance. However, little is known whether microRNAs have a role in estrogen-independent growth, leading to tamoxifen resistance in estrogen receptor (ER)-positive tumors. In this study, we use an in vivo selection system against a microRNA library using the MCF-7 model and demonstrate that miR-101 promotes estrogen-independent growth and causes the upregulation of phosphorylated Akt (pAkt) without impacting the ER level or activity. Importantly, although miR-101 suppresses cell growth in normal estradiol (E2)-containing medium, it promotes cell growth in E2-free medium. Moreover, estrogen deprivation greatly enhances miR-101-mediated Akt activation. Finally, we show that MAGI-2 (membrane-associated guanylate kinase), a scaffold protein required for PTEN (phosphatase and tensin homolog) activity, is a direct target for miR-101; suppression of MAGI-2 by miR-101 reduces PTEN activity, leading to Akt activation. Taken together, these results not only establish a role for miR101 in estrogen-independent signaling but also provide a mechanistic link between miR-101 and Akt activation. Oncogene (2011) 30, 822-831; doi:10.1038/onc.2010.463; published online 18 October 2010	[Sachdeva, M.; Wu, H.; Ru, P.; Mo, Y-Y] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA; [Hwang, L.; Trieu, V.] Abraxis Biosci, Marina Del Rey, CA USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 825 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011		Susan G Komen for the Cure [KG100027]; Department of Defense [BC085629]; Abraxis Bioscience	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Abraxis Bioscience	We are grateful to Andy Wilber for the preparation of the viral stock used in this study and to Dr Yutaka Hata for the MAGI2 construct. This work is supported by KG100027 from Susan G Komen for the Cure, by BC085629 from the Department of Defense and the research fund from Abraxis Bioscience.	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Lykkesfeldt AE, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609083961; Maddika S, 2009, MOL CELL BIOL, V29, P1235, DOI 10.1128/MCB.00668-08; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhang YY, 2009, MOL CANCER RES, V7, P498, DOI 10.1158/1541-7786.MCR-08-0415; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	35	87	93	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					822	831		10.1038/onc.2010.463	http://dx.doi.org/10.1038/onc.2010.463			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956939				2022-12-17	WOS:000287444600006
J	Davies, MA; Samuels, Y				Davies, M. A.; Samuels, Y.			Analysis of the genome to personalize therapy for melanoma	ONCOGENE			English	Review						BRAF; NRAS; C-KIT; ERBB4; GN alpha Q	MULTIKINASE INHIBITOR SORAFENIB; PHASE-II TRIAL; RECOMBINANT INTERLEUKIN-2 THERAPY; COOPERATIVE-ONCOLOGY-GROUP; KIT PROTEIN EXPRESSION; ACUTE MYELOID-LEUKEMIA; PRIMARY UVEAL MELANOMA; METASTATIC MELANOMA; CUTANEOUS MELANOMA; BRAF MUTATIONS	The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease. Oncogene (2010) 29, 5545-5555; doi:10.1038/onc.2010.323; published online 9 August 2010	[Samuels, Y.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Samuels, Y (corresponding author), NHGRI, Canc Genet Branch, NIH, 50 South Dr,MSC 8000,Bldg 50,Room 5140, Bethesda, MD 20892 USA.	samuelsy@mail.nih.gov	Davies, Michael/GWV-2527-2022		ASCO; M D Anderson Cancer Center SPORE in Melanoma [5 P50 CA093459 03 PP-DRP3]; National Human Genome Research Institute, National Institutes of Health, USA; NATIONAL CANCER INSTITUTE [P50CA093459] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200337] Funding Source: NIH RePORTER	ASCO; M D Anderson Cancer Center SPORE in Melanoma; National Human Genome Research Institute, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Darryl Leja for graphical expertize and Nature Genetics for permission to use figures from paper doi:10.1038/ng.438. This work was supported by grants from ASCO (Young Investigator Award) and M D Anderson Cancer Center SPORE in Melanoma (Developmental Research Grant; 5 P50 CA093459 03 PP-DRP3; to MAD) and the Intramural Research Programs of the National Human Genome Research Institute, National Institutes of Health, USA (to YS).	Akslen LA, 2008, MELANOMA RES, V18, P29, DOI 10.1097/CMR.0b013e3282f32517; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Antonescu CR, 2007, INT J CANCER, V121, P257, DOI 10.1002/ijc.22681; Ashida A, 2009, INT J CANCER, V124, P862, DOI 10.1002/ijc.24048; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Baguley BC, 2010, METHODS MOL BIOL, V596, P1, DOI 10.1007/978-1-60761-416-6_1; Baker M, 2008, NATURE, V454, P556, DOI [10.1038/454556a, 10.1038/456553a]; Bastian BC, 1998, CANCER RES, V58, P2170; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brose MS, 2002, CANCER RES, V62, P6997; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Cruz F, 2003, CANCER RES, V63, P5761; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies M, 2006, EXPERT OPIN PHARMACO, V7, P2243, DOI 10.1517/14656566.7.16.2243; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Ernst DS, 2005, INVEST NEW DRUG, V23, P569, DOI 10.1007/s10637-005-1157-4; Fisher D E, 2010, Pigment Cell Melanoma Res, V23, P14, DOI 10.1111/j.1755-148X.2009.00655.x; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guldberg P, 1997, CANCER RES, V57, P3660; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Handolias D, 2010, PIGM CELL MELANOMA R, V23, P210, DOI 10.1111/j.1755-148X.2010.00671.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2008, CANCER-AM CANCER SOC, V112, P982, DOI 10.1002/cncr.23251; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hingorani SR, 2003, CANCER RES, V63, P5198; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang SY, 1996, ONCOGENE, V13, P2339; Inman JL, 2003, J SURG ONCOL, V84, P82, DOI 10.1002/jso.10297; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kim KB, 2008, BRIT J CANCER, V99, P734, DOI 10.1038/sj.bjc.6604482; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; LASSAM N, 1992, ONCOGENE, V7, P51; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maat W, 2008, INVEST OPHTH VIS SCI, V49, P23, DOI 10.1167/iovs.07-0722; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Margolin K, 2005, CANCER-AM CANCER SOC, V104, P1045, DOI 10.1002/cncr.21265; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Omholt K, 2006, MELANOMA RES, V16, P197, DOI 10.1097/01.cmr.0000200488.77970.e3; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Phan GQ, 2001, J CLIN ONCOL, V19, P3477, DOI 10.1200/JCO.2001.19.15.3477; Philp AJ, 2001, CANCER RES, V61, P7426; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintas-Cardama A, 2008, NAT CLIN PRACT ONCOL, V5, P737, DOI 10.1038/ncponc1251; Rimoldi D, 2003, CANCER RES, V63, P5712; Rivera RS, 2008, VIRCHOWS ARCH, V452, P27, DOI 10.1007/s00428-007-0524-2; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwartz RN, 2002, ONCOLOGY-NY, V16, P11; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; SUAREZ HG, 1988, ONCOGENE, V2, P403; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; Torres-Cabala CA, 2009, MODERN PATHOL, V22, P1446, DOI 10.1038/modpathol.2009.116; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Turner EH, 2009, NAT METHODS, V6, P315, DOI 10.1038/nmeth.f.248; Ugurel S, 2005, BRIT J CANCER, V92, P1398, DOI 10.1038/sj.bjc.6602529; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Woodman SE, 2009, MOL CANCER THER, V8, P2079, DOI 10.1158/1535-7163.MCT-09-0459; Wyman K, 2006, CANCER-AM CANCER SOC, V106, P2005, DOI 10.1002/cncr.21834; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	119	87	93	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5545	5555		10.1038/onc.2010.323	http://dx.doi.org/10.1038/onc.2010.323			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20697348	Green Accepted			2022-12-17	WOS:000282946900001
J	Hu, F; Gartenhaus, RB; Eichberg, D; Liu, Z; Fang, HB; Rapoport, AP				Hu, F.; Gartenhaus, R. B.; Eichberg, D.; Liu, Z.; Fang, H-B; Rapoport, A. P.			PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21	ONCOGENE			English	Article						PDZ-binding kinase; tumor suppressor p53; cyclin-dependent kinase inhibitor p21WAF1; PBK/TOPK	ORIGINATED PROTEIN-KINASE; PDZ-BINDING KINASE; DNA-DAMAGE; MITOTIC KINASE; MUTANT P53; HUMAN HOMOLOG; GLIOMA-CELLS; WILD-TYPE; APOPTOSIS; TOPK	PBK/TOPK (PDZ-binding kinase, T-LAK-cell-originated protein kinase) is a serine-threonine kinase that is overexpressed in a variety of tumor cells but its role in oncogenesis remains unclear. Here we show, by co-immunoprecipitation experiments and yeast two-hybrid analysis, that PBK/TOPK physically interacts with the tumor suppressor p53 through its DNA-binding (DBD) domain in HCT116 colorectal carcinoma cells that express wild-type p53. PBK also binds to p53 mutants carrying five common point mutations in the DBD domain. The PBK-p53 interaction appears to down-modulate p53 transactivation function as indicated by PBK/TOPK knockdown experiments, which show upregulated expression of the key p53 target gene and cyclin-dependent kinase inhibitor p21 in HCT116 cells, particularly after genotoxic damage from doxorubicin. Furthermore, stable PBK/TOPK knockdown cell lines (derived from HCT116 and MCF-7 cells) showed increased apoptosis, G(2)/M arrest and slower growth as compared to stable empty vector-transfected control cell lines. Gene microarray studies identified additional p53 target genes involved in apoptosis or cell cycling, which were differentially regulated by PBK knockdown. Together, these data suggest that increased levels of PBK/TOPK may contribute to tumor cell development and progression through suppression of p53 function and consequent reductions in the cell-cycle regulatory proteins such as p21. PBK/TOPK may therefore be a valid target for antineoplastic kinase inhibitors to sensitize tumor cells to chemotherapy-induced apoptosis and growth suppression. Oncogene (2010) 29, 5464-5474; doi:10.1038/onc.2010.275; published online 12 July 2010	[Hu, F.; Gartenhaus, R. B.; Eichberg, D.; Liu, Z.; Fang, H-B; Rapoport, A. P.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rapoport, AP (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	arapoport@umm.edu			Marlene and Stewart Greenebaum Cancer Center	Marlene and Stewart Greenebaum Cancer Center	This work was supported in part by philanthropic gifts from Mr Willard Hackerman, Mr and Mrs Robert Becker, and Mr and Mrs Gaylord Christle. Additional funds were provided by the Marlene and Stewart Greenebaum Cancer Center.	Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Abe Y, 2007, J MOL BIOL, V370, P231, DOI 10.1016/j.jmb.2007.04.067; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; Brooks WS, 2008, J BIOL CHEM, V283, P22304, DOI 10.1074/jbc.M803238200; Brooks WS, 2007, EXP CELL RES, V313, P665, DOI 10.1016/j.yexcr.2006.11.020; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Guo NH, 1997, CANCER RES, V57, P1735; Hagn F, 2010, J BIOL CHEM, V285, P3439, DOI 10.1074/jbc.M109.065391; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Patel S, 2008, NUCLEIC ACIDS RES, V36, P5139, DOI 10.1093/nar/gkn490; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Sot B, 2007, J BIOL CHEM, V282, P29193, DOI 10.1074/jbc.M705544200; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Soussi T, 2006, CLIN CANCER RES, V12, P62, DOI 10.1158/1078-0432.CCR-05-0413; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048; Zykova TA, 2006, CLIN CANCER RES, V12, P6884, DOI 10.1158/1078-0432.CCR-06-0410	42	87	91	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5464	5474		10.1038/onc.2010.275	http://dx.doi.org/10.1038/onc.2010.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20622899				2022-12-17	WOS:000282945800004
J	Lee, CC; Jan, HJ; Lai, JH; Ma, HI; Hueng, DY; Lee, YCG; Cheng, YY; Liu, LW; Wei, HW; Lee, HM				Lee, C-C; Jan, H-J; Lai, J-H; Ma, H-I; Hueng, D-Y; Lee, Y-C Gladys; Cheng, Y-Y; Liu, L-W; Wei, H-W; Lee, H-M			Nodal promotes growth and invasion in human gliomas	ONCOGENE			English	Article						glioma; invasion; MMP-2; Nodal	EMBRYONIC STEM-CELLS; HUMAN GLIOBLASTOMA; GENE-EXPRESSION; FACTOR-BETA; CANCER-CELLS; TUMOR-GROWTH; BRAIN-TUMOR; IN-VITRO; DIFFERENTIATION; PROLIFERATION	Uncontrolled growth and diffused invasion are major causes of mortality in patients with malignant gliomas. Nodal has been shown to have a central role in the tumorigenic signaling pathways of malignant melanoma. In this study, we show that grade IV human glioma cell lines expressed different levels of Nodal, paralleled to the potential for cell invasiveness. Treatment of glioma cell lines with recombinant Nodal (rNodal) increased matrix metalloproteinase 2 (MMP-2) secretion and cell invasiveness. The ectopic expression of Nodal in GBM glioma cells that expressed Nodal at low level resulted in increased MMP-2 secretion, enhanced cell invasiveness, raised cell proliferation rates in vitro, increased tumor growth in vivo, and was associated with poor survival in a mice xenograft model. In contrast, the knockdown of Nodal expression in U87MG glioma cells with high Nodal expression level had reduced MMP-2 secretion, less cell invasiveness, lower tumor growth in vivo and longer lifespan in mice with U87MG/shNodal cell xenografts. In addition, Nodal knockdown promoted the reversion of malignant glioma cells toward a differentiated astrocytic phenotype. Furthermore, our data support the notion that Nodal may regulate glioma progression through the induction of the leukemia inhibitory factor (LIF) and Cripto-1 through activated Smad. Oncogene (2010) 29, 3110-3123; doi: 10.1038/onc.2010.55; published online 12 April 2010	[Jan, H-J; Lai, J-H; Cheng, Y-Y; Liu, L-W; Lee, H-M] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Lee, C-C] Shin Kong Mem Hosp, Dept Pathol, Taipei, Taiwan; [Lee, C-C] Taipei Med Univ, Dept Pathol, Taipei 110, Taiwan; [Lee, C-C] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan; [Ma, H-I; Hueng, D-Y] Triserv Gen Hosp, Natl Def Med Ctr, Dept Neurol Surg, Taipei, Taiwan; [Lee, Y-C Gladys] Taipei Med Univ, Grad Inst Biomed Informat, Taipei 110, Taiwan; [Wei, H-W] Natl Taiwan Univ, Dept Anim Sci & Technol, Taipei 10764, Taiwan; [Lee, H-M] Cent Taiwan Univ Sci & Technol, Inst Pharmaceut Sci & Technol, Taichung, Taiwan; [Lee, H-M] Taipei Med Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Taipei 110, Taiwan	Taipei Medical University; Shin Kong Wu Ho Su Memorial Hospital; Taipei Medical University; Fu Jen Catholic University; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University; National Taiwan University; Central Taiwan University Science & Technology; Taipei Medical University	Lee, HM (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.	leehorng@tmu.edu.tw	Hueng, Dueng-Yuan/AAM-7807-2021	Hueng, Dueng-Yuan/0000-0001-7868-3161; WEI, HEN-WEI/0000-0001-9096-1013				Bennett JT, 2007, NATURE, V450, pE1, DOI 10.1038/nature06314; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Chakravarti Arnab, 2008, P173; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Kargiotis O, 2008, ONCOGENE, V27, P4830, DOI 10.1038/onc.2008.122; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Ma HI, 2002, CANCER RES, V62, P756; Ma HI, 2002, GENE THER, V9, P2, DOI 10.1038/sj.gt.3301616; Mancino M, 2008, J CELL PHYSIOL, V215, P192, DOI 10.1002/jcp.21301; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Postovit LM, 2008, PIGM CELL MELANOMA R, V21, P348, DOI 10.1111/j.1755-148X.2008.00463.x; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Rooprai HK, 2000, BRIT J CANCER, V82, P52, DOI 10.1054/bjoc.1999.0876; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Saha S, 2008, BIOPHYS J, V94, P4123, DOI 10.1529/biophysj.107.119891; Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003; Strizzi Luigi, 2008, Breast Dis, V29, P91; Strizzi L, 2009, CANCER RES, V69, P7131, DOI 10.1158/0008-5472.CAN-09-1199; Strojnik T, 2006, ANTICANCER RES, V26, P2887; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Svechnikova I, 2008, INT J ONCOL, V32, P821; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Wick W, 2006, CURR PHARM DESIGN, V12, P341, DOI 10.2174/138161206775201901; Zhou RX, 2000, EXP CELL RES, V254, P269, DOI 10.1006/excr.1999.4762	35	87	95	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3110	3123		10.1038/onc.2010.55	http://dx.doi.org/10.1038/onc.2010.55			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383200	Green Submitted			2022-12-17	WOS:000278133100008
J	Tennant, DA; Frezza, C; MacKenzie, ED; Nguyen, QD; Zheng, L; Selak, MA; Roberts, DL; Dive, C; Watson, DG; Aboagye, EO; Gottlieb, E				Tennant, D. A.; Frezza, C.; MacKenzie, E. D.; Nguyen, Q. D.; Zheng, L.; Selak, M. A.; Roberts, D. L.; Dive, C.; Watson, D. G.; Aboagye, E. O.; Gottlieb, E.			Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death	ONCOGENE			English	Article						cancer; metabolism; prolyl hydroxylase; hypoxia; alpha-ketoglutarate; HIF	INDUCIBLE FACTORS HIF-1-ALPHA; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; FACTOR-1-ALPHA; INHIBITION; DISEASE; FAMILY; PHD1; OVEREXPRESSION	Cells exposed to low-oxygen conditions (hypoxia) alter their metabolism to survive. This response, although vital during development and high-altitude survival, is now known to be a major factor in the selection of cells with a transformed metabolic phenotype during tumorigenesis. It is thought that hypoxia-selected cells have increased invasive capacity and resistance to both chemo-and radiotherapies, and therefore represent an attractive target for antitumor therapy. Hypoxia inducible factors (HIFs) are responsible for the majority of gene expression changes under hypoxia, and are themselves controlled by the oxygen-sensing HIF prolyl hydroxylases (PHDs). It was previously shown that mutations in succinate dehydrogenase lead to the inactivation PHDs under normoxic conditions, which can be overcome by treatment with alpha-ketoglutarate derivatives. Given that solid tumors contain large regions of hypoxia, the reactivation of PHDs in these conditions could induce metabolic catastrophe and therefore prove an effective antitumor therapy. In this report we demonstrate that derivatized alpha-ketoglutarate can be used as a strategy for maintaining PHD activity under hypoxia. By increasing intracellular alpha-ketoglutarate and activating PHDs we trigger PHD-dependent reversal of HIF1 activation, and PHD-dependent hypoxic cell death. We also show that derivatized alpha-ketoglutarate can permeate multiple layers of cells, reducing HIF1 alpha levels and its target genes in vivo. Oncogene (2009) 28, 4009-4021; doi:10.1038/onc.2009.250; published online 31 August 2009	[Tennant, D. A.; Frezza, C.; MacKenzie, E. D.; Selak, M. A.; Gottlieb, E.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Nguyen, Q. D.; Aboagye, E. O.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Comprehens Canc Imaging Ctr, London, England; [Zheng, L.; Watson, D. G.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Roberts, D. L.; Dive, C.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England	Beatson Institute; Imperial College London; University of Strathclyde; Paterson Institute for Cancer Research; University of Manchester	Gottlieb, E (corresponding author), Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	e.gottlieb@beatson.gla.ac.uk	Gottlieb, Eyal/G-6450-2010; Frezza, Christian/G-2174-2010; Tennant, Daniel/ABE-8145-2021	Gottlieb, Eyal/0000-0002-9770-0956; Frezza, Christian/0000-0002-3293-7397; Tennant, Daniel/0000-0003-0499-2732; Roberts, Darren/0000-0001-7175-7754; Dive, Caroline/0000-0002-1726-8850; Zheng, Liang/0000-0002-5346-4111; ABOAGYE, Eric/0000-0003-2276-6771	Cancer Research UK; Association for International Cancer Research; Cancer Research UK [10337] Funding Source: researchfish; Medical Research Council [MC_U120081322] Funding Source: researchfish; MRC [MC_U120081322] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Cancer Research UK and the Association for International Cancer Research. We thank Tom Hamilton and Derek Miller for their invaluable assistance with the in vivo work, Colin Nixon and Mairi Macdonald for helping with the histology, Margaret O'Prey for help with the microscopy, Celeste Simon for generously providing us with the HIF1 alpha-expressing plasmid and Ayala King for her excellent editorial work.	Aebersold DM, 2001, CANCER RES, V61, P2911; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Birner P, 2001, CLIN CANCER RES, V7, P1661; Bishop T, 2008, MOL CELL BIOL, V28, P3386, DOI 10.1128/MCB.02041-07; Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2008, CELL DEATH DIFFER, V15, P619, DOI 10.1038/cdd.2008.11; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; GOLDBERG MA, 1991, BLOOD, V77, P271; Hewitson KS, 2007, J BIOL CHEM, V282, P3293, DOI 10.1074/jbc.M608337200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ikeda E, 2005, PATHOL INT, V55, P603, DOI 10.1111/j.1440-1827.2005.01877.x; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Khatua S, 2003, CANCER RES, V63, P1865; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Knowles HJ, 2003, CANCER RES, V63, P1764; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; To KKW, 2005, CELL CYCLE, V4, P881, DOI 10.4161/cc.4.7.1839; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williamson J R, 1979, Methods Enzymol, V55, P200; Yoon D, 2006, J BIOL CHEM, V281, P25703, DOI 10.1074/jbc.M602329200	50	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4009	4021		10.1038/onc.2009.250	http://dx.doi.org/10.1038/onc.2009.250			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718054				2022-12-17	WOS:000272560300006
J	Hacker, S; Dittrich, A; Mohr, A; Schweitzer, T; Rutkowski, S; Krauss, J; Debatin, KM; Fulda, S				Haecker, S.; Dittrich, A.; Mohr, A.; Schweitzer, T.; Rutkowski, S.; Krauss, J.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8	ONCOGENE			English	Article						caspase-8; apoptosis; TRAIL; HDACI; medulloblastoma	UP-REGULATING CASPASE-8; DRUG-INDUCED APOPTOSIS; INTERFERON-GAMMA; DEATH RECEPTOR; CELL-DEATH; CHILDHOOD MEDULLOBLASTOMA; PANCREATIC-CARCINOMA; NEUROBLASTOMA-CELLS; EWINGS-SARCOMA; TUMOR CELLS	Evasion of apoptosis can be caused by epigenetic silencing of caspase-8, a key component of the extrinsic apoptosis pathway. Loss of caspase-8 correlates with poor prognosis in medulloblastoma, which highlights the relevance of strategies to upregulate caspase-8 to break apoptosis resistance. Here, we develop a new combinatorial approach, that is treatment using histone deacetylase inhibitors (HDACI) together with interferon (IFN)-gamma, to restore caspase-8 expression and to overcome resistance to the death-receptor ligand TNF-related apoptosis-inducing ligand (TRAIL) in medulloblastoma in vitro and in vivo. HDACI, for example, valproic acid (VA), suberoylanilide hydroxamic acid (SAHA) and MS-275, cooperate with IFN-gamma to upregulate caspase-8 in cancer cells lacking caspase-8, thereby restoring sensitivity to TRAIL-induced apoptosis. Molecular studies show that VA promotes histone acetylation and acts in concert with IFN-gamma to stimulate caspase-8 promoter activity. The resulting increase in caspase-8 mRNA and protein expression leads to enhanced TRAIL-induced activation of caspase-8 at the death-inducing signaling complex, mitochondrial outer-membrane permeabilization and caspase-dependent cell death. Intriguingly, pharmacological or genetic inhibition of caspase-8 also abolishes the VA/IFN-gamma-mediated sensitization for TRAIL-induced apoptosis. It is important to note that VA and IFN-gamma restore caspase-8 expression and sensitivity to TRAIL in primary medulloblastoma samples and significantly potentiate TRAIL-mediated suppression of medulloblastoma growth in vivo. These findings provide the rationale for further (pre)clinical evaluation of VA and IFN-gamma to restore caspase-8 expression and apoptosis sensitivity in cancers with caspase-8 silencing and open new perspectives to overcome TRAIL resistance. Oncogene (2009) 28, 3097-3110; doi: 10.1038/onc.2009.161; published online 13 July 2009	[Haecker, S.; Dittrich, A.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Mohr, A.] Natl Univ Ireland, NCBES, Mol Therapeut Grp, Galway, Ireland; [Schweitzer, T.; Krauss, J.] Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Rutkowski, S.] Univ Wurzburg, Dept Pediat, Wurzburg, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ollscoil na Gaillimhe-University of Galway; University of Wurzburg; University of Wurzburg	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Schweitzer, Tilmann/K-6471-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Mohr, Andrea/0000-0002-4295-0341; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe [IAP6/18]; European Community	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); European Community(European Commission)	We thank R Agami (The Netherlands Cancer Institute, Amsterdam, Netherlands) for providing pRETRO-SUPER vector, CA Schmitt (Berlin, Germany) for mouse Bcl-2 vector, M. Romani (Genova, Italy) for caspase-8 pBL-CAT3 promoter construct, Apoxis (Lausanne, Switzerland) for mega-Fas ligand and F Beguinot (Naples, Italy) for anti-PED antibody. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, IAP6/18 and the European Community (ApopTrain, APOSYS) (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Fulda S, 2006, ONCOGENE, V25, P5125, DOI 10.1038/sj.onc.1209518; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; FULDA S, 2008, ENCY CANC; FULDA S, 2006, APOPTOSIS CANC THERA, P515; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Guerrini Renzo, 2006, Paediatr Drugs, V8, P113, DOI 10.2165/00148581-200608020-00004; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Li XN, 2005, MOL CANCER THER, V4, P1912, DOI 10.1158/1535-7163.MCT-05-0184; Lissat A, 2007, AM J PATHOL, V170, P1917, DOI 10.2353/ajpath.2007.060993; Meistey N, 2007, EUR J CANCER, V43, P1833, DOI 10.1016/j.ejca.2007.05.028; Merchant MS, 2004, CANCER RES, V64, P8349, DOI 10.1158/0008-5472.CAN-04-1705; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Rutkowski S, 2007, CLIN CANCER RES, V13, P2651, DOI 10.1158/1078-0432.CCR-06-1779; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu Q, 2006, CLIN CANCER RES, V12, P4687, DOI 10.1158/1078-0432.CCR-05-2849; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tekautz TM, 2006, BBA-MOL CELL RES, V1763, P1000, DOI 10.1016/j.bbamcr.2006.06.014; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; van Boxel-Dezaire AHH, 2007, CURR TOP MICROBIOL, V316, P119; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; WEXLER L, 1992, P AN M AM SOC CLIN, V11, P368; Yang XZ, 2003, CANCER RES, V63, P1122	52	87	91	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3097	3110		10.1038/onc.2009.161	http://dx.doi.org/10.1038/onc.2009.161			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19597472				2022-12-17	WOS:000269515100002
J	Pen, A; Moreno, MJ; Durocher, Y; Deb-Rinker, P; Stanimirovic, DB				Pen, A.; Moreno, M. J.; Durocher, Y.; Deb-Rinker, P.; Stanimirovic, D. B.			Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling	ONCOGENE			English	Article						glioblastoma; angiogenesis; IGFBP7; TGF-beta; Smad	GROWTH-FACTOR-BETA; BLOOD-BRAIN-BARRIER; PROSTACYCLIN-STIMULATING FACTOR; PROTEIN-RELATED PROTEIN-1; TUMOR-SUPPRESSIVE ACTIVITY; TRANSFORMING GROWTH-FACTOR-BETA-1; ENDOTHELIAL-CELLS; GENE-EXPRESSION; COLON-CANCER; PROSTATE-CANCER	Insulin-like growth factor-binding protein 7 (IGFBP7) is a selective biomarker of glioblastoma (GBM) vessels, stronglyexpressed in tumor endothelial cells and vascular basement membrane. IGFBP7 gene regulation and its potential role in tumor angiogenesis remain unclear. Mechanisms of IGFBP7 induction and its angiogenic capacity were examined in human brain endothelial cells (HBECs) exposed to tumor-like conditions. HBEC treated with GBM cell (U87MG)-conditioned media (-CM) exhibited fourfold upregulation of IGFBP7 mRNA and protein compared to control cells. IGFBP7 gene regulation in HBEC was methylation independent. U87MG-CM analysed by enzyme-linked immunosorbent assay contained similar to 5 pM transforming growth factor (TGF)-beta 1, a concentration sufficient to stimulate IGFBP7 in HBEC to similar levels as U87MG-CM. Both pan-TGF-beta-neutralizing antibody(1D11) and the TGF-beta 1 receptor (activin receptor-like kinase 5, ALK5) antagonist, SB431542, blocked U87MG-CM-induced IGFBP7 expression in HBEC, indicating that TGF-beta 1 is an important tumor-secreted effector capable of IGFBP7 induction in endothelial cells. HBEC exposed to either U87MG-CM or IGFBP7 protein exhibited increased capillary-like tube (CLT) formation in Matrigel. Both TGF-beta 1- and U87MG-CM-induced Smad-2 phosphorylation and U87MG-CM-induced CLT formation in HBEC were inhibited by the ALK5 antagonist, SB431542. These data suggest that proangiogenic IGFBP7 maybe induced in brain endothelial cells by TGF-beta s secreted by GBM, most likely through TGF-beta 1/ALK5/Smad-2 pathway. Oncogene (2008) 27, 6834-6844; doi: 10.1038/onc.2008.287; published online 18 August 2008	[Pen, A.; Moreno, M. J.; Stanimirovic, D. B.] Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Neurobiol Program, Ottawa, ON K1A 0R6, Canada; [Pen, A.; Stanimirovic, D. B.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Durocher, Y.] Natl Res Council Canada, Biotechnol Res Inst, Anim Cell Technol Grp, Montreal, PQ H4P 2R2, Canada; [Deb-Rinker, P.] Natl Res Council Canada, Inst Biol Sci, Neurogenesis & Brain Repair Grp, Montreal, PQ, Canada	National Research Council Canada; University of Ottawa; National Research Council Canada; National Research Council Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Neurobiol Program, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca	Durocher, Yves/K-8709-2019					Ahmed AA, 2006, NAT PROD COMMUN, V1, P273; AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Beaty RM, 2007, J NEURO-ONCOL, V81, P241, DOI 10.1007/s11060-006-9227-9; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DINDA AK, 1993, J NEURO-ONCOL, V16, P149, DOI 10.1007/BF01324702; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Hata Y, 2000, J CLIN INVEST, V106, P541, DOI 10.1172/JCI8338; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kwak HJ, 2006, MOL CANCER RES, V4, P209, DOI 10.1158/1541-7786.MCR-05-0140; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144; LONG DM, 1970, J NEUROSURG, V32, P127, DOI 10.3171/jns.1970.32.2.0127; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moreno MJ, 2006, GLIA, V53, P845, DOI 10.1002/glia.20345; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Mutaguchi K, 2003, CANCER RES, V63, P7717; Nagakubo D, 2003, J IMMUNOL, V171, P553, DOI 10.4049/jimmunol.171.2.553; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; Pen A, 2007, GLIA, V55, P559, DOI 10.1002/glia.20481; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R; Sprenger CC, 1999, CANCER RES, V59, P2370; St Croix B, 2000, SCIENCE, V289, P1197; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; Umeda F, 1998, J GASTROENTEROL, V33, P213, DOI 10.1007/s005350050072; Vajkoczy P, 2000, J NEURO-ONCOL, V50, P99, DOI 10.1023/A:1006474832189; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Watabe T, 2003, J CELL BIOL, V163, P1303, DOI 10.1083/jcb.200305147; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yakmovych I, 2001, FASEB J, V15, P553; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591	67	87	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6834	6844		10.1038/onc.2008.287	http://dx.doi.org/10.1038/onc.2008.287			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18711401				2022-12-17	WOS:000261108000004
J	Lockwood, WW; Chari, R; Coe, BP; Girard, L; MacAulay, C; Lam, S; Gazdar, AF; Minna, JD; Lam, WL				Lockwood, W. W.; Chari, R.; Coe, B. P.; Girard, L.; MacAulay, C.; Lam, S.; Gazdar, A. F.; Minna, J. D.; Lam, W. L.			DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers	ONCOGENE			English	Article						gene amplification; array CGH; gene expression; integrative analysis; lung cancer; EGFR signaling	COPY NUMBER ALTERATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PATH ARRAY CGH; GENE-EXPRESSION; CELL-LINES; MICROARRAY ANALYSIS; CDNA MICROARRAYS; BREAST-CANCER; DEPENDENCY	Chromosomal translocation is the best-characterized genetic mechanism for oncogene activation. However, there are documented examples of activation by alternate mechanisms, for example gene dosage increase, though its prevalence is unclear. Here, we answered the fundamental question of the contribution of DNA amplification as a molecular mechanism driving oncogenesis. Comparing 104 cancer lines representing diverse tissue origins identified genes residing in amplification 'hotspots' and discovered an unexpected frequency of genes activated by this mechanism. The 3431 amplicons identified represent similar to 10 per hematological and similar to 36 per epithelial cancer genome. Many recurrently amplified oncogenes were previously known to be activated only by disease-specific translocations. The 135 hotspots identified contain 538 unique genes and are enriched for proliferation, apoptosis and linage-dependency genes, reflecting functions advantageous to tumor growth. Integrating gene dosage with expression data validated the downstream impact of the novel amplification events in both cell lines and clinical samples. For example, multiple downstream components of the EGFR-family-signaling pathway, including CDK5, AKT1 and SHC1, are overexpressed as a direct result of gene amplification in lung cancer. Our findings suggest that amplification is far more common a mechanism of oncogene activation than previously believed and that specific regions of the genome are hotspots of amplification.	[Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Canc Genet, Vancouver, BC V5Z 1L3, Canada; [Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Dev Biol, Vancouver, BC V5Z 1L3, Canada; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [MacAulay, C.; Lam, S.] British Columbia Canc Res Ctr, Dept Canc Imaging, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; University of Texas System; University of Texas Southwestern Medical Center Dallas; British Columbia Cancer Agency	Lockwood, WW (corresponding author), British Columbia Canc Res Ctr, Dept Canc Genet, 675 W 10th Aveue, Vancouver, BC V5Z 1L3, Canada.	wlockwood@bccrc.ca	MacAulay, Calum/K-1795-2016; Chari, Raj/G-3285-2019; Chari, Rajagopal/B-6980-2008; Lockwood, William W/A-2879-2009; Coe, Bradley/A-2878-2009	Coe, Bradley/0000-0001-8471-4016; MacAulay, Calum/0000-0003-4440-2792	NCI NIH HHS [P50 CA070907, P50 CA070907-03S19001, P50 CA070907-09, P50 CA070907-11, P50 CA070907-110009, P50 CA070907-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Chari R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-324; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fabbro D, 1996, EUR J CANCER, V32A, P512, DOI 10.1016/0959-8049(95)00560-9; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Greshock J, 2007, CANCER RES, V67, P3594, DOI 10.1158/0008-5472.CAN-06-3674; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hemstrom TH, 2006, INT J CANCER, V119, P1028, DOI 10.1002/ijc.21927; Henderson LJ, 2005, BRIT J CANCER, V92, P1553, DOI 10.1038/sj.bjc.6602452; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hyman E, 2002, CANCER RES, V62, P6240; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; Lockwood WW, 2007, INT J CANCER, V120, P436, DOI 10.1002/ijc.22335; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Myllykangas S, 2006, ONCOGENE, V25, P7324, DOI 10.1038/sj.onc.1209717; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; Stenhouse G, 2004, J CLIN PATHOL, V57, P383, DOI 10.1136/jcp.2003.007138; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Watson SK, 2007, HUM GENET, V120, P795, DOI 10.1007/s00439-006-0251-9; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	43	87	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4615	4624		10.1038/onc.2008.98	http://dx.doi.org/10.1038/onc.2008.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391978	Green Accepted			2022-12-17	WOS:000258077300010
J	Pilkinton, M; Sandoval, R; Colamonici, OR				Pilkinton, M.; Sandoval, R.; Colamonici, O. R.			Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex	ONCOGENE			English	Article						cell cycle; LIN-9; pocket proteins; CDK; cyclin; Myb	IN-VIVO; PROTEIN; TRANSCRIPTION; PHOSPHORYLATION; E2F; ACTIVATION; IDENTIFICATION; EXPRESSION; LIN-9; PRB	Mammalian Mip/LIN-9 is a cell cycle regulatory protein that is negatively regulated by CDK4/cyclin D. It has been demonstrated that Mip/LIN-9 collaborates with B-Myb during S and G2/M in the induction of cyclins A and B, and CDK1. The ortholog of Mip/LIN-9 in (D) under bar rosophila, Mip130, is part of a large multisubunit protein complex that includes (R) under bar BF, repressor (E) under bar 2Fs (a) under bar nd (M) under bar yb, in what was termed the dREAM complex. A similar complex, although lacking B-Myb, was also described in Caenorhabditis elegans. Here, we demonstrate that unlike Drosophila, Mip/LIN-9 has mutually exclusive and cell cycle-phasespeci. c interactions with the mammalian orthologs of the dREAM complex. In G(0)/early G(1), Mip/LIN-9 forms a complex with E2F4 and p107 or p130, while in late G(1)/S phase, it associates with B-Myb. The separation of Mip/LIN-9 from p107, p130/E2F4 is likely driven by phosphorylation of the pocket proteins by CDK4 since Mip/LIN-9 fails to interact with phosphorylated forms of p107, p130. Importantly, the repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction since expression of p107 blocks the activation of the cyclin B promoter triggered by B-Myb and Mip/LIN-9.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott,Room E403 M-C 868, Chicago, IL 60612 USA.	ocolamon@uic.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Beitel GJ, 2000, GENE, V254, P253, DOI 10.1016/S0378-1119(00)00296-1; Bhatt AM, 2004, GENE, V336, P219, DOI 10.1016/j.gene.2004.03.033; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Burgess A, 2006, J BIOL CHEM, V281, P9987, DOI 10.1074/jbc.M512714200; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Ciemerych MA, 2005, ONCOGENE, V24, P2877, DOI 10.1038/sj.onc.1208608; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; FERGUSON EL, 1989, GENETICS, V123, P109; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Petrovas C, 2003, ONCOGENE, V22, P2011, DOI 10.1038/sj.onc.1206231; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takahashi Y, 2000, GENE DEV, V14, P804; Vousden K H, 1990, Semin Cancer Biol, V1, P415; White-Cooper H, 1998, DEVELOPMENT, V125, P125; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	51	87	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7535	7543		10.1038/sj.onc.1210562	http://dx.doi.org/10.1038/sj.onc.1210562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563750				2022-12-17	WOS:000251282100005
J	Duensing, A; Liu, Y; Perdreau, SA; Kleylein-Sohn, J; Nigg, EA; Duensing, S				Duensing, A.; Liu, Y.; Perdreau, S. A.; Kleylein-Sohn, J.; Nigg, E. A.; Duensing, S.			Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates	ONCOGENE			English	Article						centrioles; proteasome; CDK2; cyclin e; PLK4; HPV-16E7	CENTROSOME DUPLICATION; CYCLIN-E; CELLS; ASSOCIATION; INSTABILITY; DISRUPTION; DEFECTS	Abnormal centrosome numbers are detected in virtually all cancers. The molecular mechanisms that underlie centrosome amplification, however, are poorly characterized. Based on the model that each maternal centriole serves as a template for the formation of one and only one daughter centriole per cell division cycle, the prevailing view is that centriole overduplication arises from successive rounds of centriole reproduction. Here, we provide evidence that a single maternal centriole can concurrently generate multiple daughter centrioles. This mechanism was initially identified in cells treated with the peptide vinyl sulfone proteasome inhibitor Z- L3VS. We subsequently found that the formation of more than one daughter at maternal centrioles requires cyclin E/cyclin-dependent kinase 2 as well as Polo-like kinase 4 and that overexpression of these proteins mimics this phenotype in the absence of a proteasome inhibitor. Moreover, we show that the human papillomavirus type 16 E7 oncoprotein stimulates aberrant daughter centriole numbers in part through the formation of more than one daughter centriole at single maternal templates. These results help to explain how oncogenic stimuli can rapidly induce abnormal centriole numbers within a single cell-division cycle and provide insights into the regulation of centriole duplication.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Max Planck Society; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, A (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		nigg, erich/0000-0003-4835-5719; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RG, 1971, J CELL BIOL, V50, P10, DOI 10.1083/jcb.50.1.10; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; DIRKSEN ER, 1971, J CELL BIOL, V51, P286, DOI 10.1083/jcb.51.1.286; Duensing A, 2007, ONCOGENE, V26, P215, DOI 10.1038/sj.onc.1209782; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NIGG EA, 2004, CENTROSOMES DEV DIS; Pihan GA, 1998, CANCER RES, V58, P3974; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 2004, CENTROSOMES DEV DIS, P167, DOI DOI 10.1002/3527603808.CH9; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Vidwans SJ, 2003, J CELL SCI, V116, P137, DOI 10.1242/jcs.00204; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X	37	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6280	6288		10.1038/sj.onc.1210456	http://dx.doi.org/10.1038/sj.onc.1210456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438528	Green Accepted			2022-12-17	WOS:000249583300004
J	Huang, P; Senga, T; Hamaguchi, M				Huang, P.; Senga, T.; Hamaguchi, M.			A novel role of phospho-beta-catenin in microtubule regrowth at centrosome	ONCOGENE			English	Article						phospho-beta-catenin; microtubule regrowth; centrosome	WNT-SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; CELL-CYCLE; PROTEIN; KINASE; CANCER; IDENTIFICATION; LOCALIZATION; PROGRESSION	beta-Catenin is a biologically important molecule playing critical roles in both cell adhesion and transcriptional regulation in the Wnt pathway. Here, we show that phospho-beta-atenin (phosphorylated at Ser33/37/Thr41), which is reported to be degraded immediately after its phosphorylation, accumulated in the centrosome. Whereas phospho- mimicking mutant, S33/37/T41E-beta-catenin, could local ize to the centrosome, S33A-beta-catenin that lacks the phosphorylation site lost its localization to the centrosome. Phospho-beta-catenin localized mai nly to mother centrosome during the interphase and was recruited to daughter centrosome in M-phase. Depletion of beta-catenin with small interfering RNA or inhibition of its phosphorylation by LiCl treatment caused disruption of radial microtubule (MT) array and retardation of the MT regrowth during the recovery from nocodazole treatment. In addition, these treatments increased the frequency of mono-astral MT reorganization. Furthermore, overexpression of the nonphosphorylatable beta-catenin, but not the phospho-mimicking beta-catenin, markedly disrupted radial MT array and repressed the MT regrowth. In contrast, phospho-mimicking beta-atenin localized to both of the duplicated centrosomes with aberrant larger and denser radial MTs array formation. In addition, some of the cells overexpressing phospho-mimicking beta-catenin had mul tiple centrosomes. Taken together, this study demonstrates a novel role of phospho-beta-catenin in MT organization at the centrosomes.	Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, 65 Tsurumaicho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						Amin ARMR, 2003, CANCER RES, V63, P6334; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Harwood A, 2003, NAT CELL BIOL, V5, P275, DOI 10.1038/ncb0403-275; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaplan DD, 2004, J BIOL CHEM, V279, P10829, DOI 10.1074/jbc.C400035200; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Liu YZ, 2001, ONCOGENE, V20, P5908, DOI 10.1038/sj.onc.1204738; Lucas FR, 1998, J CELL SCI, V111, P1351; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Ou YY, 2002, J CELL SCI, V115, P1825; Pellman D, 2001, SCIENCE, V291, P2555, DOI 10.1126/science.1057337; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Sadot E, 2002, J CELL SCI, V115, P2771; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	28	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4357	4371		10.1038/sj.onc.1210217	http://dx.doi.org/10.1038/sj.onc.1210217			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260019				2022-12-17	WOS:000247620000004
J	Wang, X; Zhao, J				Wang, X.; Zhao, J.			KLF8 transcription factor participates in oncogenic transformation	ONCOGENE			English	Article						KLF8; transformation; v-Src	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; CELL-CYCLE; COLORECTAL-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; HUMAN BREAST; FAK; PROGRESSION; EXPRESSION	Kruppel-like factor 8 (KLF8) is a member of the family of KLF transcription factors. Several KLF members have been shown to play a role in oncogenesis. We have previously demonstrated that KLF8 mediates cell cycle progression downstream of focal adhesion kinase (FAK) by upregulating cyclin D1. FAK plays a critical role in transformation and tumorigenesis and is aberrantly upregulated in many types of human cancer. Little is known about the function of KLF8 in these regards. Here we provide evidence suggesting a novel role of KLF8 in oncogenic transformation. We show that KLF8 expression is elevated in several types of human cancer cells and primary tumor tissues. Induced expression of ectopic KLF8 causes serum-independent growth and morphological transformation in NIH3T3 cells and enhances anchorage-independent growth of v-Src-transformed cells. In contrast, expression of a dominant-negative mutant of KLF8 dramatically suppresses the transformed phenotypes induced by v-Src. In addition, the KLF8-enhanced transformation in the v-Src cells was prevented by ablating cyclin D1 expression. Overall, these results indicate that KLF8 is required for v-Src-induced transformation and may play a role in tumor progression of human cancer.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Zhao, J (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,Mail Code 165,MS338, Albany, NY 12208 USA.	zhaojh@mail.amc.edu						Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Ellenrieder V, 2004, GASTROENTEROLOGY, V127, P607, DOI 10.1053/j.gastro.2004.05.018; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Grisaru-Granovsky S, 2005, INT J CANCER, V113, P372, DOI 10.1002/ijc.20607; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Lim KH, 2004, MOL CELL, V15, P491, DOI 10.1016/j.molcel.2004.08.014; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	87	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					456	461		10.1038/sj.onc.1209796	http://dx.doi.org/10.1038/sj.onc.1209796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832343				2022-12-17	WOS:000243544000014
J	Ribas, J; Bettayeb, K; Ferandin, Y; Knockaert, M; Garrofe-Ochoa, X; Totzke, F; Schachtele, C; Mester, J; Polychronopoulos, P; Magiatis, P; Skaltsounis, AL; Boix, J; Meijer, L				Ribas, J.; Bettayeb, K.; Ferandin, Y.; Knockaert, M.; Garrofe-Ochoa, X.; Totzke, F.; Schachtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. -L.; Boix, J.; Meijer, L.			7-bromoindirubin-3 '-oxime induces caspase-independent cell death	ONCOGENE			English	Article						indirubin; protein kinase; cell death; autophagy; caspase; cancer	ARYL-HYDROCARBON RECEPTOR; PROTEIN-KINASE INHIBITORS; CYCLIN-DEPENDENT KINASES; INDIRUBIN DERIVATIVES; SELECTIVE INHIBITORS; CRYSTAL-STRUCTURE; TYRIAN PURPLE; AH RECEPTOR; APOPTOSIS; INDUCTION	Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl hydrocarbon receptor (AhR). Indirubin is the active ingredient of a traditional Chinese medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs have been synthesized to optimize this promising kinase inhibitor scaffold. We report here on the cellular effects of 7-bromoindirubin-3'-oxime (7BIO). In contrast to its 5-bromo- and 6-bromo-isomers, and to indirubin-3'-oxime, 7BIO has only a marginal inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell death process distinct from apoptosis. 7-Bromoindirubin-3'-oxime induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7-Bromoindirubin-3'-oxime-induced cell death is not accompanied by cytochrome c release neither by any measurable effector caspase activation. Furthermore, the death process is not altered either by the presence of Q-VD-OPh, a broad-spectrum caspase inhibitor, or the overexpression of Bcl-2 and Bcl-XL proteins. Neither AhR nor p53 is required during 7BIO-induced cell death. Thus, in contrast to previously described indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; CNRS, Biol Stn, F-29682 Roscoff, France; Univ Lleida, Sch Med, DCMB, Mol Pharmacol Lab, Catalunya, Spain; ProQinase GmbH, Freiburg, Germany; INSERM, U482, Paris, France; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universitat de Lleida; ProQinase; Institut National de la Sante et de la Recherche Medicale (Inserm); National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, UPS2682,BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	skaltsounis, alexios leandros/AAE-9617-2019; Ribas, Judit/B-3362-2011; Magiatis, Prokopios/A-2008-2008	Ribas, Judit/0000-0003-0834-2577; Totzke, Frank/0000-0002-7261-8155; Magiatis, Prokopios/0000-0002-0399-5344; , laurent/0000-0003-3511-4916				Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; BACH S, 2006, IN PRESS MONOGRAPHS, V2; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Balfour-Paul Jenny, 1998, INDIGO; Benson C, 2005, BRIT J CANCER, V92, P7, DOI 10.1038/sj.bjc.6602229; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fischer PM, 2004, CURR MED CHEM, V11, P1563, DOI 10.2174/0929867043365062; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Holton S, 2003, STRUCTURE, V11, P1329, DOI 10.1016/j.str.2003.09.020; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee JW, 2005, BIOORG MED CHEM LETT, V15, P3948, DOI 10.1016/j.bmcl.2005.05.105; Lu HS, 2005, J MED CHEM, V48, P737, DOI 10.1021/jm049353p; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Merz K H, 2004, Int J Clin Pharmacol Ther, V42, P656; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ribas J, 2005, EUR J PHARMACOL, V524, P49, DOI 10.1016/j.ejphar.2005.09.021; Ribas J, 2004, EXP CELL RES, V295, P9, DOI 10.1016/j.yexcr.2003.12.019; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Sugihara K, 2004, BIOCHEM BIOPH RES CO, V318, P571, DOI 10.1016/j.bbrc.2004.04.066; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wu ZLL, 2005, CHEM BIODIVERS, V2, P51, DOI 10.1002/cbdv.200490166; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	52	87	97	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6304	6318		10.1038/sj.onc.1209648	http://dx.doi.org/10.1038/sj.onc.1209648			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702956	Green Accepted			2022-12-17	WOS:000241218200007
J	Longworth, MS; Laimins, LA				Longworth, M. S.; Laimins, L. A.			Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src	ONCOGENE			English	Article						HDAC3; c-Src; plasma membrane; tyrosine; phosphorylation	HUMAN-PAPILLOMAVIRUS TYPE-31; PP60C-SRC PROTEIN-KINASE; TYROSINE KINASE; C-SRC; ACTIVATION; EXPRESSION; HDAC3; DIFFERENTIATION; TRANSCRIPTION; PROGRESSION	Histone deacetylases (HDACs) negatively regulate gene expression by removing acetyl groups from lysine residues present in histones and other proteins. Histone deacetylase 3 is unique among the Class I family of HDACs, as it is able to shuttle between the nucleus and the cytoplasm, whereas the other family members remain in the nucleus. Histone deacetylase 3 often forms complexes with corepressor proteins that do not associate with the other Class I HDACs, and its phosphorylation correlates with increased enzymatic activity. Here we show that HDAC3 also localizes to the plasma membrane in multiple cell types. Furthermore, c-Src is shown to form a complex with HDAC3 at the plasma membrane and to use HDAC3 as a substrate for phosphorylation. Our results describe a novel localization and binding partner for the HDAC3 protein, as well as implicate c-Src in HDAC3 regulation.	Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Laimins, LA (corresponding author), Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	l-laimins@northwestern.edu	longworth, michelle/S-8456-2019		NATIONAL CANCER INSTITUTE [T32CA009560, R01CA059655] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09560, R01 CA059655-12, R01 CA059655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; FANNING P, 1992, CANCER RES, V52, P1457; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; FEHRMANN F, 2004, METHOD MOL BIOL, V292, P317; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Guenther MG, 2000, GENE DEV, V14, P1048; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JACOBS C, 1983, CANCER RES, V43, P1696; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longworth MS, 2005, EMBO J, V24, P1821, DOI 10.1038/sj.emboj.7600651; Longworth MS, 2004, J VIROL, V78, P3533, DOI 10.1128/JVI.78.7.3533-3541.2004; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	27	87	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4495	4500		10.1038/sj.onc.1209473	http://dx.doi.org/10.1038/sj.onc.1209473			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532030				2022-12-17	WOS:000239326000013
J	Yang, X; Chen, MW; Terry, S; Vacherot, F; Bemis, DL; Capodice, J; Kitajewski, J; de la Taille, A; Benson, MC; Guo, Y; Buttyan, R				Yang, X.; Chen, M. -W.; Terry, S.; Vacherot, F.; Bemis, D. L.; Capodice, J.; Kitajewski, J.; de la Taille, A.; Benson, M. C.; Guo, Y.; Buttyan, R.			Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Wnt signaling; beta-catenin; PCDH-PC; Akt; MDM2	BETA-CATENIN MUTATIONS; GENE; TRANSCRIPTION; PROGRESSION; ACTIVATION; AKT; PHOSPHORYLATION; PATHWAY; GROWTH; ALPHA	beta-Catenin, a component of the Wnt signaling pathway, is a coactivator of human androgen receptor (hAR) transcriptional activity. Here, we show that Wnt signaling also influences androgen-mediated signaling through its ability to regulate hAR mRNA and protein in prostate cancer (PCa) cells. Three functional LEF-1/TCF binding sites lie within the promoter of the hAR gene as shown by CHIP assays that captured beta-catenin-bound chromatin from Wnt-activated LNCaP cells. Chimeric reporter vectors that use the hAR gene promoter to drive luciferase expression confirmed that these LEF-1/TCF binding elements are able to confer robust upregulation of luciferase expression when stimulated by Wnt-1 or by transfection with beta-catenin and that dominant-negative TCF or mutations within the dominant TCF-binding element abrogated the response. Semi-quantitative and real time RT-PCR assays confirmed that Wnt activation upregulates hAR mRNA in PCa cells. In contrast, hAR protein expression was strongly suppressed by Wnt activation. The reduction of hAR protein is consistent with evidence that Wnt signaling increased phosphorylation of Akt and its downstream target, MDM2 that promotes degradation of hAR protein through a proteasomal pathway. These data indicate that the hAR gene is a direct target of LEF-1/TCF transcriptional regulation in PCa cells but also show that the expression of the hAR protein is suppressed by a degradation pathway regulated by cross-talk of Wnt to Akt that is likely mediated by Wnt-directed degradation of the B regulatory subunit of protein phosphatase, PP2A.	Columbia Univ, Dept Urol, Med Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA; Univ Paris 12, AP HP, CHU Henri Mondor, INSERM,E03 37, Creteil, France; Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China	Columbia University; Columbia University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Peking University	Buttyan, R (corresponding author), Columbia Univ, Dept Urol, Med Ctr, Irving Pavilion-11,161 Ft Washington Ave, New York, NY 10032 USA.	rb46@columbia.edu	Terry, Stephane/K-5351-2013; de la taille, Alex/ABE-8422-2021; Vacherot, Francis/R-6588-2018	Terry, Stephane/0000-0003-3089-7886; Vacherot, Francis/0000-0002-3677-1267	NATIONAL CANCER INSTITUTE [R01CA111618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111618-04, R01 CA111618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Barker N, 2000, BIOESSAYS, V22, P961; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHEN G, 2004, CANCER, V10, P1345; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Craft N, 1999, CANCER RES, V59, P5030; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Latil A, 2001, CANCER RES, V61, P1919; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Ohigashi T, 2005, PROSTATE, V62, P61, DOI 10.1002/pros.20117; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; STACK S, 2004, J BIOL CHEM, V279, P47732; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Voeller HJ, 1998, CANCER RES, V58, P2520; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	37	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3436	3444		10.1038/sj.onc.1209366	http://dx.doi.org/10.1038/sj.onc.1209366			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16474850	Green Accepted			2022-12-17	WOS:000238448100008
J	Soria, G; Podhajcer, O; Prives, C; Gottifredi, V				Soria, G.; Podhajcer, O.; Prives, C.; Gottifredi, V.			P21(Cip1/WAF1) downregulation is required for efficient PCNA ubiquitination after UV irradiation	ONCOGENE			English	Article						p21; PCNA; ubiquitination; proteolysis; DNA repair	CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; KINASE INHIBITOR P21; DOUBLE-STRAND BREAK; DNA-DAMAGE; REPLICATION ARREST; POLYMERASE SWITCH; IN-VITRO; S-PHASE; DEGRADATION	p21(Cip1/WAF1) is a known inhibitor of the short- gap. filling activity of proliferating cell nuclear antigen ( PCNA) during DNA repair. In agreement, p21 degradation after UV irradiation promotes PCNA- dependent repair. Recent reports have identified ubiquitination of PCNA as a relevant feature for PCNA- dependent DNA repair. Here, we show that PCNA ubiquitination in human cells is notably augmented after UV irradiation and other genotoxic treatments such as hydroxyurea, aphidicolin and methylmethane sulfonate. Intriguingly, those DNA damaging agents also promoted downregulation of p21. While ubiquitination of PCNA was not affected by deficient nucleotide excision repair ( NER) and was observed in both proliferating and arrested cells, stable p21 expression caused a significant reduction in UV-induced ubiquitinated PCNA. Surprisingly, the negative regulation of PCNA ubiquitination by p21 does not depend on the direct interaction with PCNA but requires the cyclin dependent kinase binding domain of p21. Taken together, our data suggest that p21 downregulation plays a role in efficient PCNA ubiquitination after UV irradiation.	Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Columbia University	Gottifredi, V (corresponding author), Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina.	vgottifredi@leloir.org.ar	Gottifredi, Vanesa/AAI-1788-2019	Gottifredi, Vanesa/0000-0001-9656-5951; podhajcer, osvaldo/0000-0002-6512-8553	NCI NIH HHS [CA058316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carr AM, 2003, SCIENCE, V300, P1512, DOI 10.1126/science.1085689; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Frouin I, 2005, NUCLEIC ACIDS RES, V33, P5354, DOI 10.1093/nar/gki845; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kuhne C, 2003, NUCLEIC ACIDS RES, V31, P7227, DOI 10.1093/nar/gkg937; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; McDonald E, 1996, CANCER RES, V56, P2250; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nikiforov A, 2004, BIOCHEM BIOPH RES CO, V323, P831, DOI 10.1016/j.bbrc.2004.08.165; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Pickart CM, 2002, NATURE, V419, P120, DOI 10.1038/419120a; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383	51	87	90	12	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2829	2838		10.1038/sj.onc.1209315	http://dx.doi.org/10.1038/sj.onc.1209315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407842				2022-12-17	WOS:000237448200001
J	Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW				Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW			Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; lymphoma; dexamethasone-induced gene; thioredoxin-interacting protein; txnip	LEUKEMIC-CELLS; OXIDATIVE STRESS; T-CELLS; IN-VIVO; RECEPTOR; EXPRESSION; ACTIVATION; DEATH; IDENTIFICATION; DEXAMETHASONE	Glucocorticoid hormones induce apoptosis in lymphoid cells. This process is transcriptionally regulated and requires de novo RNA/protein synthesis. However, the full spectrum of glucocorticoid-regulated genes mediating this cell death process is unknown. Through gene expression pro. ling we discovered that the expression of thioredoxin-intereacting protein (txnip) mRNA is significantly induced by the glucocorticoid hormone dexamethasone not only in the murine T-cell lymphoma line WEHI7.2, but also in normal mouse thymocytes. This result was confirmed by Northern blot analysis in multiple models of dexamethasone-induced apoptosis. The induction of txnip mRNA by dexamethasone appears to be mediated through the glucocorticoid receptor as it is blocked in the presence of RU486, a glucocorticoid receptor antagonist. Deletion and mutation analysis of the txnip promoter identified a functional glucocorticoid response element in the txnip promoter. Reporter assays demonstrated that this glucocorticoid response element was necessary and sufficient for induction of txnip by dexamethasone. Expression of a GFP-TXNIP fusion protein was sufficient to induce apoptosis in WEHI7.2 cells, and repression of endogenous txnip by RNA interference inhibited dexamethasone-induced apoptosis in WEHI7.2 cells. Together, these findings indicate that txnip is a novel glucocorticoid-induced primary target gene involved in mediating glucocorticoid- induced apoptosis.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, WRB 3-133,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu	Davis, Michael C/L-8920-2013	Davis, Michael C/0000-0003-2293-5694	NCI NIH HHS [CP30 CA43703, T32 CA59366, R01 CA42755] Funding Source: Medline; NHLBI NIH HHS [T32 HL07147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA042755] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Baker A, 1997, CANCER RES, V57, P5162; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CAIRNS C, 1991, MOL ENDOCRINOL, V5, P598, DOI 10.1210/mend-5-4-598; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; COHEN JJ, 1984, J IMMUNOL, V132, P38; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kim KY, 2004, BIOCHEM BIOPH RES CO, V315, P369, DOI 10.1016/j.bbrc.2004.01.047; Malone MH, 2004, J BIOL CHEM, V279, P52850, DOI 10.1074/jbc.M408040200; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Oberg HH, 2004, CELL DEATH DIFFER, V11, P674, DOI 10.1038/sj.cdd.4401407; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Planey SL, 2003, CANCER RES, V63, P172; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; Ramdas J, 1998, ENDOCRINOLOGY, V139, P3813, DOI 10.1210/en.139.9.3813; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schoneveld OJLM, 2004, BBA-GENE STRUCT EXPR, V1680, P114, DOI 10.1016/j.bbaexp.2004.09.004; Thompson EB, 1998, STEROIDS, V63, P368, DOI 10.1016/S0039-128X(98)00045-2; Tome ME, 2001, CANCER RES, V61, P2766; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; Wang RX, 1998, J IMMUNOL, V161, P2201; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Webb MS, 2003, J STEROID BIOCHEM, V85, P183, DOI 10.1016/S0960-0760(03)00194-8; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001	46	87	87	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1903	1913		10.1038/sj.onc.1209218	http://dx.doi.org/10.1038/sj.onc.1209218			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301999				2022-12-17	WOS:000236224800007
J	Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA				Liu, J; Lian, Z; Han, S; Waye, MMY; Wang, H; Wu, MC; Wu, K; Ding, J; Arbuthnot, P; Kew, M; Fan, D; Feitelson, MA			Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatitis B X antigen; E-cadherin; migration; hepatocellular carcinoma; beta-catenin	BETA-CATENIN; HBX PROTEIN; CELL-LINES; EXPRESSION; GENE; METHYLATION; ADHESION; LIVER; P53; PROGRESSION	Hepatitis B virus (HBV)-encoded X antigen (HBxAg) contributes to the development of hepatocellular carcinoma (HCC). A frequent characteristic of HCC is reduced or absent expression of the cell adhesion protein, E-cadherin, although it is not known whether HBxAg plays a role. To address this, the levels of E-cadherin were determined in HBxAg-positive and - negative HepG2 cells in culture, and in tumor and surrounding nontumor liver from a panel of HBV carriers. The results showed an inverse relationship between HBxAg and E-cadherin expression both in tissue culture and in vivo. In HBxAg-positive cells, E-cadherin was suppressed at both the mRNA and protein levels. This was associated with hypermethylation of the E-cadherin promoter. Depressed E-cadherin correlated with HBxAg trans-activation function, as did the migration of HepG2 cells in vitro. Decreased expression of E-cadherin was also associated with the accumulation of beta-catenin in the cytoplasm and/or nuclei in tissues and cell lines, which is characteristic of activated beta-catenin. Additional work showed that HBxAg-activated beta-catenin. Together, these results suggest that the HBxAg is associated with decreased expression of E-cadherin, accumulation of beta-catenin in the cytoplasm and nucleus, and increased cell migration, which may contribute importantly to hepatocarcinogenesis.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Dept Digest Dis, Xian 710032, Shaanxi, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; Second Mil Med Univ, Shanghai Eastern Hosp, Shanghai, Peoples R China; Second Mil Med Univ, Inst Hepatobil Surg, Shanghai, Peoples R China; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, ZA-2001 Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Air Force Military Medical University; Chinese University of Hong Kong; Naval Medical University; Naval Medical University; University of Witwatersrand; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Mark.Feitelson@jefferson.edu	韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Arbuthnot, Patrick Brian/B-8163-2009; Han, Shuang/AAE-6982-2020; Lian, Zhaorui/AAW-2379-2020; Wang, Hongyang/B-1340-2010	韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; 	NATIONAL CANCER INSTITUTE [R29CA048656, R01CA066971, R01CA048656] Funding Source: NIH RePORTER; NCI NIH HHS [CA48656, CA66971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SH, 2002, KOREAN J HEPATOL, V8, P297; Calvisi DF, 2004, LAB INVEST, V84, P1137, DOI 10.1038/labinvest.3700147; CASELMANN WH, 1995, J HEPATOL, V22, P34; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feitelson MA, 1999, FALK SYMP, V103C, P156; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inayoshi J, 2003, J GASTROEN HEPATOL, V18, P673, DOI 10.1046/j.1440-1746.2003.03021.x; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Kanai Y, 1997, INT J CANCER, V71, P355; Kondoh N, 2001, INT J ONCOL, V18, P1271; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5; Lian ZR, 2003, NEOPLASIA, V5, P229, DOI 10.1016/S1476-5586(03)80055-6; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liu J, 2004, METH MOLEC MED, V95, P71; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593	43	87	100	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1008	1017		10.1038/sj.onc.1209138	http://dx.doi.org/10.1038/sj.onc.1209138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247464				2022-12-17	WOS:000235361000006
J	Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C				Zu, K; Bihani, T; Lin, A; Park, YM; Mori, K; Ip, C			Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells	ONCOGENE			English	Article						selenium; unfolded protein response; BiP/GRP78 knockdown; ER stress signalings	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; TRANSCRIPTION FACTOR ATF6; ER STRESS; MESSENGER-RNA; DIMERIZATION DOMAIN; INDUCIBLE PROTEIN; MAMMALIAN-CELLS; ACTIVATION; APOPTOSIS	Redox modi. cation of thiol/disulfide interchange in proteins by selenium could lead to protein unfolding. When this occurs in the endoplasmic reticulum ( ER), a process known as unfolded protein response (UPR) is orchestrated for survival through activation of PERK eIF2 alpha (PERK: double-stranded RNA-activated protein kinase-like ER kinase; eIF2 alpha: eucaryotic initiation factor 2 alpha), ATF alpha ( ATF alpha: activating transcription factor 6) and inositol requiring 1 (IRE1)-x-box-binding protein 1 (XBP1) signalings. All three UPR transducer pathways were upregulated very rapidly when PC-3 cells were exposed to selenium. These changes were accompanied by increased expression of UPR target genes, including immunoglobulin heavy chain-binding protein/glucoseregulated protein, 78 kDa and CCAAT/enhancer binding protein-homologous protein/growth arrest- and DNA damage-inducible gene (CHOP/GADD153). Induction of BiP/ GRP78, an ER-resident chaperone, is part of the damage control mechanism, while CHOP/GADD153 is a transcription factor associated with growth arrest and apoptosis in the event of prolonged ER stress. Knocking down BiP/ GRP78 induction by small interference RNA produced a differential response of the three transducers to selenium, suggesting that the signaling intensity of each transducer could be fine-tuned depending on BiP/ GRP78 availability. In the presence of selenium, CHOP/GADD153 expression was raised even higher by BiP/ GRP78 knockdown. Under this condition, the selenium effect on wild-type p53-activated fragment p21 (p21(WAF)), cyclin-dependent kinase (CDK)1 and CDK2 was also magnified in a manner consistent with enhanced cell growth arrest. Additional experiments with CHOP/ GADD153 siRNA knockdown strongly suggested that CHOP/ GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null). Collectively, the above findings support the idea that UPR could be an important mechanism in mediating the anticancer activity of selenium.	Roswell Pk Canc Inst, Dept Canc Chemoprevent, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kyoto University	Ip, C (corresponding author), Roswell Pk Canc Inst, Dept Canc Chemoprevent, Elm & Carlton St, Buffalo, NY 14263 USA.	clement.ip@roswellpark.org	Mori, Kazutoshi/K-6106-2015; Longo, Kenneth A/A-5631-2010		NATIONAL CANCER INSTITUTE [R01CA097963, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 16056, R01 CA097963-03, CA 09796, P30 CA016056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDNARD K, 2004, BASIC CLIN PHARMACOL, V94, P124; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Dong Y, 2003, CANCER RES, V63, P52; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Friedman AD, 1996, CANCER RES, V56, P3250; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; IP C, 1991, CANCER RES, V51, P595; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Kadowaki H, 2004, J CHEM NEUROANAT, V28, P93, DOI 10.1016/j.jchemneu.2004.05.004; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lehotsky J, 2003, PHYSIOL RES, V52, P269; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Park Eun-Mi, 2005, Cancer Genomics & Proteomics, V2, P25; SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zu K, 2003, CANCER RES, V63, P6988	51	87	91	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					546	554		10.1038/sj.onc.1209071	http://dx.doi.org/10.1038/sj.onc.1209071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205645	Green Accepted			2022-12-17	WOS:000234897400006
J	Hall, WW; Fujii, M				Hall, WW; Fujii, M			Deregulation of cell-signaling pathways in HTLV-1 infection	ONCOGENE			English	Review						HTLV-1; tax; cell signaling	LEUKEMIA-VIRUS TYPE-1; LARGE TUMOR-SUPPRESSOR; NF-KAPPA-B; PAPILLOMAVIRUS E6 PROTEINS; TRANSFORMED T-CELLS; I TAX PROTEIN; PROTEASOME-MEDIATED DEGRADATION; TRANSCRIPTION FACTOR AP-1; SERUM RESPONSE FACTOR; IMMEDIATE-EARLY GENES	Human T-lymphotropic virus type 1 (HTLV-1) infection is associated with the clonal expansion and transformation of mature T lymphocytes. While the mechanisms involved are incompletely understood the viral regulatory protein Tax plays a central role in these processes. Recent studies employing genomic and proteomic approaches have demonstrated the marked complexity of gene deregulation associated with Tax expression and confirmed the remarkable pleiotropism of this protein as evidenced by the numerous Tax-cellular protein interactions in infected cells. In this review, we summarize the role of Tax in the deregulation of selected cellular-signaling pathways. Specifically, this has focused on the influence and interaction of Tax with the AP-1 and NF-AT transcription factors, PDZ domain-containing proteins, RhoGTPases, and the Janus kinase/signal transducer and activator of transcription and transforming growth factor-beta-signaling pathways. In addition to identifying the deregulation of events within these pathways, attempts have been made to highlight differences between HTLV-1 and -2, which may relate to differences in their pathogenic properties.	Univ Coll Dublin, Dept Med Microbiol, Ctr Res Infect Dis, Dublin 4, Ireland; Niigata Univ, Grad Sch Med & Dent Sci, Div Virol, Niigata 9518510, Japan	University College Dublin; Niigata University	Hall, WW (corresponding author), Univ Coll Dublin, Dept Med Microbiol, Ctr Res Infect Dis, Dublin 4, Ireland.	William.hall@ucd.ie						Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; Azran Inbal, 2004, Retrovirology, V1, P20; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blot V, 2004, J CELL SCI, V117, P3983, DOI 10.1242/jcs.01266; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De la Fuente C, 2000, AIDS RES HUM RETROV, V16, P1695, DOI 10.1089/08892220050193164; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2003, J VIROL, V77, P11027, DOI 10.1128/JVI.77.20.11027-11039.2003; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fabre S, 2000, MOL BIOL REP, V27, P217, DOI 10.1023/A:1011008313677; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FUJII M, 1995, ONCOGENE, V11, P7; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Fujii M, 1995, INTERVIROLOGY, V38, P221, DOI 10.1159/000150436; FUJII M, 1992, AIDS RES HUM RETROV, V16, P1603; Fujii MI, 2000, AIDS RES HUM RETROV, V16, P1603, DOI 10.1089/08892220050193029; FUNG MM, 2005, ONCOGENE        0228; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Green P. L., 2001, FIELDS VIROLOGY, P1941; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; HUBBARD GB, 1993, LAB ANIM SCI, V43, P301; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; IWAKURA Y, 1995, VIRUS GENES, V9, P161, DOI 10.1007/BF01702659; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Liu XD, 1999, J GEN VIROL, V80, P3073, DOI 10.1099/0022-1317-80-12-3073; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Loh C, 1996, MOL CELL BIOL, V16, P3945; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843; Mariner JM, 2002, J IMMUNOL, V168, P5667, DOI 10.4049/jimmunol.168.11.5667; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Mohapatra S, 2003, CANCER RES, V63, P8523; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Mori N, 2000, BLOOD, V95, P3915; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; NAGAI M, 1995, CLIN IMMUNOL IMMUNOP, V77, P324, DOI 10.1006/clin.1995.1159; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; NIITSU Y, 1988, BLOOD, V71, P263; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pise-Masison CA, 2002, CANCER RES, V62, P3562; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reddy TR, 1998, P NATL ACAD SCI USA, V95, P702, DOI 10.1073/pnas.95.2.702; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; SALVETTI A, 1993, EUR J CELL BIOL, V61, P383; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shuh M, 2000, J VIROL, V74, P11394, DOI 10.1128/JVI.74.23.11394-11397.2000; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sun SC, 1999, ONCOGENE, V18, P1401, DOI 10.1038/sj.onc.1202430; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; TAKATSUKI K, 1985, CANCER RES, V45, P4644; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Trihn D, 1997, J BIOMED SCI, V4, P47, DOI 10.1007/BF02255593; Tsuboi K, 2000, LEUKEMIA, V14, P449, DOI 10.1038/sj.leu.2401696; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Voevodin A, 1996, J VIROL, V70, P1633, DOI 10.1128/JVI.70.3.1633-1639.1996; VOLKMAN DJ, 1985, J IMMUNOL, V134, P4237; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; ZHANG Q, 1999, LEUKEMIA RES, V4, P373	155	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5965	5975		10.1038/sj.onc.1208975	http://dx.doi.org/10.1038/sj.onc.1208975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155603				2022-12-17	WOS:000231623400006
J	Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB				Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB			E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7	ONCOGENE			English	Article						E2F; cancer; cell cycle; transcription factor	ARABIDOPSIS	E2F is a family of transcription factors implicated in cell cycle control. To understand the role of E2F in controlling cell cycle progression, it is necessary to clarify the breadth of the E2F family. To date, seven E2F subunits have been identified. We report here the characterization of a new E2F subunit, E2F-8, which resembles the organization of E2F-7 in the presence of two separate DNA-binding domains, the integrity of which is required for E2F-8 to bind to DNA. Furthermore, like E2F-7, we find that E2F-8 can repress transcription and delay cell cycle progression. The similarities between E2F-7 and E2F-8 define a new subgroup of the E2F family, and further imply that E2F-7 and E2F-8 may act through overlapping mechanisms in mediating cell cycle control.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Glasgow; University System of Ohio; Ohio State University	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk			MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vlieghe K, 2005, CURR BIOL, V15, P59, DOI 10.1016/j.cub.2004.12.038; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	17	87	93	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					5000	5004		10.1038/sj.onc.1208703	http://dx.doi.org/10.1038/sj.onc.1208703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897886				2022-12-17	WOS:000230646500013
J	Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I				Perez-Mancera, PA; Gonzalez-Herrero, I; Perez-Caro, M; Gutierrez-Cianca, N; Flores, T; Gutierrez-Adan, A; Pintado, B; Sanchez-Martin, M; Sanchez-Garcia, I			SLUG in cancer development	ONCOGENE			English	Article						SLUG; development; cancer	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; ABL; REPRESSOR	The SNAIL-related zinc-finger transcription factor, SLUG (SNAI2), is critical for the normal development of neural crest-derived cells and loss-of-function SLUG mutations have been proven to contribute to piebaldism and Waardenburg syndrome type 2 in a dose-dependent fashion. While aberrant induction of SLUG has been documented in cancer cells, relatively little is known about the consequences of SLUG overexpression in malignancy. To investigate the potential role of SLUG overexpression in development and in cancer, we generated mice carrying a tetracycline-repressible Slug transgene. These mice were morphologically normal at birth, and developed mesenchymal tumours ( leukaemia and sarcomas) in almost all cases examined. Suppression of the Slug transgene did not rescue the malignant phenotype. Furthermore, the BCR ABL oncogene, which induces Slug expression in leukaemic cells, did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR - ABL leukaemogenesis in vivo. Overall, the findings indicate that while Slug overexpression is not sufficient to cause overt morphogenetic defects in mice, they demonstrate a specific and critical role for Slug in the pathogenesis of mesenchymal tumours.	Univ Salamanca, CSIC, IBMCC, Lab 13, Salamanca 37007, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Dept Med, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, IBMCC, Lab 13, Campus Unamuno, Salamanca 37007, Spain.	isg@usal.es	Pintado, Belen/N-3233-2014; González-Herrero, Inés/G-8546-2015; Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Gutierrez-Adan, Alfonso/A-1485-2014	Pintado, Belen/0000-0002-8485-2520; González-Herrero, Inés/0000-0003-1142-4362; Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker MW, 2002, CANCER CELL, V2, P249, DOI 10.1016/S1535-6108(02)00156-3; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cohen ME, 1998, GENOMICS, V51, P468, DOI 10.1006/geno.1998.5367; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1006/dbio.1998.8909; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oram KF, 2003, ANAT REC PART A, V271A, P189, DOI 10.1002/ar.a.10027; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANCHEZMARTIN M, 2004, ATLAS GENET CYTOGENE; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; Sefton M, 1998, DEVELOPMENT, V125, P3111; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060	27	87	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3073	3082		10.1038/sj.onc.1208505	http://dx.doi.org/10.1038/sj.onc.1208505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735690				2022-12-17	WOS:000228728100001
J	Mason, DX; Jackson, TJ; Lin, AW				Mason, DX; Jackson, TJ; Lin, AW			Molecular signature of oncogenic ras-induced senescence	ONCOGENE			English	Article						Ras oncogene; G(1) tetraploidy; senescence biomarker; HDAC; topoisomerase; quiescence	DNA TOPOISOMERASE-II; HISTONE DEACETYLASE; HUMAN FIBROBLASTS; GENE-EXPRESSION; GROWTH ARREST; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN-CELLS; CANCER; P53	Senescence irreversibly arrests the proliferation of cells that have sustained significant cellular stress. Replicative senescence, due to the shortening and dysfunction of telomeres, appears to provide a barrier to the immortalization of cells and development of cancer. In normal human fibroblasts, senescence induced by oncogenic H-ras displays a nearly identical cellular phenotype to that of replicative senescence, suggesting the activation of a common senescence mechanism. In this study, we investigated the gene expression profile of oncogenic H-ras-induced senescent human diploid fibroblasts. We found altered gene expression of various cell cycle regulators in both oncogenic H-ras-induced senescent cells and replicative senescent cells. Similar to replicative senescent cells, H-ras-induced senescent cells exhibited specific downregulation of genes involved in G(2)/M checkpoint control and contained tetraploid cells that were arrested in a G(1) state. This observation suggests that the inactivation of G(2)/M checkpoints may be involved in senescence and may play a role in the generation of senescent G(1) tetraploid cells. Lastly, we have identified two genes, topoisomerase IIalpha and HDAC9, whose expression was specifically altered under several conditions associated with senescence, suggesting that these two molecules may be novel biomarkers for senescent human fibroblasts.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Lin, AW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	Athena.lin@roswellpark.org			NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Benanti JA, 2004, CELL CYCLE, V3, P715; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAMPISI J, 1992, ANN NY ACAD SCI, V663, P195, DOI 10.1111/j.1749-6632.1992.tb38663.x; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Castro ME, 2004, J CELL BIOCHEM, V92, P514, DOI 10.1002/jcb.20079; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Greider C W, 2000, Harvey Lect, V96, P33; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kramer DL, 2001, CANCER RES, V61, P7754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen Annette K, 2003, Prog Cell Cycle Res, V5, P295; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEEBADDA WKC, 2004, IN PRESS; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	62	87	91	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9238	9246		10.1038/sj.onc.1208172	http://dx.doi.org/10.1038/sj.onc.1208172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489886				2022-12-17	WOS:000225638000009
J	Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L				Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L			Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins	ONCOGENE			English	Article						aryl hydrocarbon receptor; indirubin; cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; kinase inhibitor; cancer	AH RECEPTOR; CELL-CYCLE; ARYLHYDROCARBON RECEPTOR; CRYSTAL-STRUCTURE; DIOXIN RECEPTOR; MESSENGER-RNAS; TYRIAN PURPLE; MICE LACKING; EXPRESSION; PROTEIN	Indirubin, a bis-indole obtained from various natural sources, is responsible for the reported antileukemia activity of a Chinese Medicinal recipe, Danggui Longhui Wan. However, its molecular mechanism of action is still not well understood. In addition to inhibition of cyclin-dependent kinases and glycogen synthase kinase-3, indirubins have been reported to activate the aryl hydrocarbon receptor (AhR), a cotranscriptional factor. Here, we confirm the interaction of AhR and indirubin using a series of indirubin derivatives and show that their binding modes to AhR and to protein kinases are unrelated. As reported for other AhR ligands, binding of indirubins to AhR leads to its nuclear translocation. Furthermore, the apparent survival of AhR-/- and +/+ cells, as measured by the MTT assay, is equally sensitive to the kinase-inhibiting indirubins. Thus, the cytotoxic effects of indirubins are AhR-independent and more likely to be linked to protein kinase inhibition. In contrast, a dramatic cytostatic effect, as measured by actual cell counts and associated with a sharp G1 phase arrest, is induced by 1-methyl-indirubins, a subfamily of AhR-active but kinase-inactive indirubins. As shown for TCDD (dioxin), this effect appears to be mediated through the AhR-dependent expression of p27(KIP1). Altogether these results suggest that AhR activation, rather than kinase inhibition, is responsible for the cytostatic effects of some indirubins. In contrast, kinase inhibition, rather than AhR activation, represents the main mechanism underlying the cytotoxic properties of this class of promising antitumor molecules.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; Biol Stn, F-29682 Roscoff, France; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Lyon 1, Lab Cytol Analyt & Cytogenet Mol, F-69373 Lyon 08, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Davis; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Rockefeller University; National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Magiatis, Prokopios/A-2008-2008; skaltsounis, alexios leandros/AAE-9617-2019; BACH, Stéphane/ABD-5865-2020; Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Magiatis, Prokopios/0000-0002-0399-5344; , laurent/0000-0003-3511-4916	NATIONAL CANCER INSTITUTE [Z01BC005450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P42ES04699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Balfour-Paul Jenny, 1998, INDIGO; Bergander L, 2003, DRUG METAB DISPOS, V31, P233, DOI 10.1124/dmd.31.2.233; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Bradshaw TD, 2002, CURR PHARM DESIGN, V8, P2475, DOI 10.2174/1381612023392784; Chotani G, 2000, BBA-PROTEIN STRUCT M, V1543, P434, DOI 10.1016/S0167-4838(00)00234-X; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; DEALLER SF, 1988, J CLIN MICROBIOL, V26, P2152, DOI 10.1128/JCM.26.10.2152-2156.1988; Denison MS, 1998, TARG ORG T, P3; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FFRENCH M, 1985, CYTOMETRY, V6, P47, DOI 10.1002/cyto.990060109; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Guthrie C, 1991, GUIDE YEAST GENETICS; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; Kuramoto N, 2003, J NEUROCHEM, V85, P264, DOI 10.1046/j.1471-4159.2003.01679.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MacNeil IA, 2001, J MOL MICROB BIOTECH, V3, P301; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Maugard T, 2001, PHYTOCHEMISTRY, V58, P897, DOI 10.1016/S0031-9422(01)00335-1; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Miller CA, 1997, J BIOL CHEM, V272, P32824, DOI 10.1074/jbc.272.52.32824; Miller CA, 1999, TOXICOL APPL PHARM, V160, P297, DOI 10.1006/taap.1999.8769; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagy SR, 2002, TOXICOL SCI, V65, P200, DOI 10.1093/toxsci/65.2.200; Nagy SR, 2002, BIOCHEMISTRY-US, V41, P861, DOI 10.1021/bi011373v; PETERS JM, 1995, TOXICOL APPL PHARM, V134, P214, DOI 10.1006/taap.1995.1186; Petersen SL, 2000, J COMP NEUROL, V427, P428, DOI 10.1002/1096-9861(20001120)427:3<428::AID-CNE9>3.0.CO;2-P; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; Procopio M, 2002, EUR J BIOCHEM, V269, P13, DOI 10.1046/j.0014-2956.2002.02619.x; RANNUG U, 1992, MUTAT RES, V282, P219, DOI 10.1016/0165-7992(92)90099-4; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Safe S, 2002, INT J ONCOL, V20, P1123; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Santini RP, 2001, J PHARMACOL EXP THER, V299, P718; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yoon BI, 2002, TOXICOL SCI, V70, P150, DOI 10.1093/toxsci/70.1.150	72	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4400	4412		10.1038/sj.onc.1207535	http://dx.doi.org/10.1038/sj.onc.1207535			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077192				2022-12-17	WOS:000221661300006
J	Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G				Chiarugi, P; Taddei, ML; Schiavone, N; Papucci, L; Giannoni, E; Fiaschi, T; Capaccioli, S; Raugei, G; Ramponi, G			LMW-PTP is a positive regulator of tumor onset and growth	ONCOGENE			English	Article						LMW-PTP; tumor onset; tumor progression; ephrin receptors; cell adhesion	PROTEIN-TYROSINE-PHOSPHATASE; HUMAN BREAST-CANCER; FACTOR RECEPTOR; BETA-CATENIN; E-CADHERIN; CELL-PROLIFERATION; EPH RECEPTORS; KINASE; PHOSPHORYLATION; EXPRESSION	Low molecular weight protein tyrosine phosphatases (LMW-PTPs) are an enzyme family that plays a key role in cell proliferation control by dephosphorylating/inactivating both tyrosine kinase receptors ( such as PDGF, insulin, and ephrin receptors) and docking proteins (such, as beta-catenin) endowed with both adhesion and transcriptional activity. Besides being a frequent event in human tumors, overexpression of LMW-PTP has been recently demonstrated to be sufficient to induce neoplastic transformation. We recently demonstrated that overexpression of LMW-PTP strongly potentiates the stability of cell-cell contacts at the adherens junction level, which powerfully suggests that LMW-PTP may also contribute to cancer invasivity. Focusing on mechanisms by which LMW-PTP is involved in cancer onset and progression, the emerging picture is that LMW-PTP strongly increases fibronectin-mediated cell adhesion and mobility but, paradoxically, decreases cell proliferation. Nevertheless, LMW-PTP-transfected NIH3T3 fibroblasts engrafted in nude mice induce the onset of larger fibrosarcomas, which are endowed with higher proliferation activity as compared to mock-transfected controls. Quite opposite effects have been obtained with engrafted fibroblasts transfected with a dominant-negative form of LMW-PTP. Notably, in sarcoma extracts, LMW-PTP overexpression greatly influences the ephrin A2 (EphA2) but not PDGF receptor or beta-catenin tyrosine phosphorylation. The high association of dephosphorylated EphA2 overexpression with most human cancers and our observation that cell growth stimulation by LMW-PTP overexpression is restricted to the in vivo model, strongly suggest that LMW-PTP oncogenic potential is mediated by its EphA2 tyrosine dephosphorylating activity.	Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, I-50134 Florence, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50121 Florence, Italy	University of Florence; University of Florence	Raugei, G (corresponding author), Univ Florence, Dept Biochem Sci, Ctr Res Transfer & High Educ Study Mol & Clin Lev, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Giannoni, Elisa/0000-0001-7136-1098; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244; raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969				Albini A, 2001, CANCER RES, V61, P8171; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bonvini P, 2001, CANCER RES, V61, P1671; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Bruce V, 1999, BRAIN RES, V821, P169, DOI 10.1016/S0006-8993(99)01112-9; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Chiarugi P, 2000, J BIOL CHEM, V275, P37619, DOI 10.1074/jbc.M006375200; COBB BS, 1993, ONCOGENE, V8, P2897; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; EASTY DJ, 1995, CANCER RES, V55, P2528; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kopreski MS, 1996, ANTICANCER RES, V16, P3037; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Orsulic S, 2000, J CELL SCI, V113, P1793; Papucci L, 2002, ANTISENSE NUCLEIC A, V12, P21, DOI 10.1089/108729002753670238; Park EK, 2002, MOL CELL BIOL, V22, P3404, DOI 10.1128/MCB.22.10.3404-3414.2002; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Rigacci S, 1999, FEBS LETT, V459, P191, DOI 10.1016/S0014-5793(99)01234-X; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; SOMMERS CL, 1994, CANCER RES, V54, P3544; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Taddei ML, 2002, CANCER RES, V62, P6489; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; YAGEL S, 1989, CANCER RES, V49, P3553; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	48	87	89	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3905	3914		10.1038/sj.onc.1207508	http://dx.doi.org/10.1038/sj.onc.1207508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021900	Bronze			2022-12-17	WOS:000221382000003
J	Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B				Pradeep, A; Sharma, C; Sathyanarayana, P; Albanese, C; Fleming, JV; Wang, TC; Wolfe, MM; Baker, KM; Pestell, RG; Rana, B			Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells	ONCOGENE			English	Article						cyclin D1; Wnt signaling; transcription; gastrin (G-17); CREB	ELEMENT-BINDING PROTEIN; C-MYC; COLORECTAL-CANCER; ACID-SECRETION; KINASE PATHWAY; MOUSE MODEL; AGS CELLS; EXPRESSION; HYPERGASTRINEMIA; PHOSPHORYLATION	Gastrin and its precursors promote proliferation in different gastrointestinal cells. Since mature, amidated gastrin (G-17) can induce cyclin D1, we determined whether G-17-mediated induction of cyclin D1 transcription involved Wnt signaling and CRE-binding protein (CREB) pathways. Our studies indicate that G-17 induces protein, mRNA expression and transcription of the G(1)-specific marker cyclin D1, in the gastric adenocarcinoma cell line AGSE (expressing the gastrin/cholecystokinin B receptor). This was associated with an increase in steady-state levels of total and nonphospho beta-catenin and its nuclear translocation, indicating the activation of the Wnt-signaling pathway. In addition, G-17-mediated increase in cyclin D1 transcription was significantly attenuated by axin or dominant-negative (dn) T-cell factor 4(TCF4), suggesting crosstalk of G-17 with the Wnt-signaling pathway. Mutational analysis indicated that this effect was mediated through the cyclic AMP response element (CRE) (predominantly) and the TCF sites in the cyclin D1 promoter, which was also inhibited by dnCREB. Furthermore, G-17 stimulation resulted in increased CRE-responsive reporter activity and CREB phosphorylation, indicating an activation of CREB. Chromatin immunoprecipitation studies revealed a G-17-mediated increase in the interaction of beta-catenin with cyclin D1 CRE, which was attenuated by dnTCF4 and dnCREB. These results indicate that G-17 induces cyclin D1 transcription, via the activation of beta-catenin and CREB pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20057 USA; Univ Massachusetts, Sch Med, Gastrointestinal Div, Worcester, MA 01605 USA; Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Georgetown University; University of Massachusetts System; University of Massachusetts Worcester; Boston Medical Center	Rana, B (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Temple, TX 76504 USA.	brana@medicine.tamu.edu		Wang, Timothy/0000-0001-5730-3019	NCI NIH HHS [CA86072, CA70896, CA75503] Funding Source: Medline; NHLBI NIH HHS [HL44883, HL54583] Funding Source: Medline; NIA NIH HHS [AG2033] Funding Source: Medline; NIDDK NIH HHS [DK53158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070896, R29CA070896, R01CA086072, R01CA075503, R55CA075503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hirata Y, 2001, INFECT IMMUN, V69, P3965, DOI 10.1128/IAI.69.6.3965-3971.2001; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Konturek SJ, 2000, REGUL PEPTIDES, V93, P13, DOI 10.1016/S0167-0115(00)00173-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIND T, 1988, SCAND J GASTROENTERO, V23, P1259, DOI 10.3109/00365528809090202; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Miyaji M, 1997, TUMOR BIOL, V18, P311, DOI 10.1159/000218044; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Oda K, 1999, RES COMMUN MOL PATH, V105, P237; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parker D, 1996, MOL CELL BIOL, V16, P694; PENMAN ID, 1993, GUT, V34, P1559, DOI 10.1136/gut.34.11.1559; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Qvigstad G, 2002, APMIS, V110, P132, DOI 10.1034/j.1600-0463.2002.100302.x; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Raychowdhury R, 2002, BIOCHEM BIOPH RES CO, V297, P1089, DOI 10.1016/S0006-291X(02)02345-8; ROSS SE, 2000, SCIENCE, V289, P950, DOI [DOI 10.1126/SCIENCE.289.5481.950, 10.1126/science.289.5481.950]; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; Watson SA, 2001, EXPERT OPIN BIOL TH, V1, P309, DOI 10.1517/14712598.1.2.309; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xu LF, 2000, GENE DEV, V14, P585; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	62	87	91	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3689	3699		10.1038/sj.onc.1207454	http://dx.doi.org/10.1038/sj.onc.1207454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116100				2022-12-17	WOS:000221101700021
J	Wada, M; Yazumi, S; Takaishi, S; Hasegawa, K; Sawada, M; Tanaka, H; Ida, H; Sakakura, C; Ito, K; Ito, Y; Chiba, T				Wada, M; Yazumi, S; Takaishi, S; Hasegawa, K; Sawada, M; Tanaka, H; Ida, H; Sakakura, C; Ito, K; Ito, Y; Chiba, T			Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines	ONCOGENE			English	Article						RUNX3; bile duct cancer; pancreatic cancer; methylation	INTRAHEPATIC CHOLANGIOCARCINOMA; MULTIPLE GENES; ADENOCARCINOMA; GROWTH; HYPERMETHYLATION; HYBRIDIZATION; METHYLATION; MUTATIONS; PEBP2/CBF; DOMAIN	RUNX3, a Runt domain transcription factor involved in TGF-beta signaling, is a candidate tumor-suppressor gene localized in 1p36, a region commonly deleted in a wide variety of human tumors, including those of the stomach, bile duct, and pancreas. Recently, frequent inactivation of RUNX3 has been demonstrated in human gastric carcinomas. In this study, to examine the involvement of RUNX3 abnormalities in tumorigenesis of bile duct as well as pancreatic cancers, we investigated not only the expression but also methylation status of RUNX3 in 10 human bile duct and 12 pancreatic cancer cell lines. Seven (70%) of the bile duct and nine (75%) of the pancreatic cancer cell lines exhibited no expression of RUNX3 by both Northern blot analysis and the reverse transcriptase polymerase chain reaction. All of the 16 cell lines that did not express RUNX3 also showed methylation of the promoter CpG island of the gene, whereas the six cell lines that showed RUNX3 expression were not methylated or only partially methylated in the RUNX3 promoter region. Moreover, treatment with the methylation inhibitor 5'-aza-2'-deoxycitidine activated RUNX3 mRNA expression in all of 16 cancer cell lines that originally lacked RUNX3 expression. Finally, hemizygous deletion of RUNX3, as detected by fluorescence in situ hybridization, was found in 15 of the 16 cancer cell lines that lacked RUNX3 expression. These data suggest that the inactivation of RUNX3 plays an important role in bile duct and pancreatic carcinogenesis, and that methylation is a common mechanism by which the gene is inactivated.	Kyoto Univ, Grad Sch Internal Med, Dept Gastroenterol & Hepatol, Kyoto 6068507, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117609, Singapore; Kyoto Prefectural Univ Med, Dept Digest Surg, Kyoto 6028566, Japan	Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; Kyoto Prefectural University of Medicine	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Internal Med, Dept Gastroenterol & Hepatol, Kyoto 6068507, Japan.	cteya@kuhp.kyoto-u.ac.jp						BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BISGAARD HC, 1991, J CELL PHYSIOL, V147, P333, DOI 10.1002/jcp.1041470220; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HERMAN JG, 2000, MODERN PATHOL, V13, P627; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Kang YK, 2000, MODERN PATHOL, V13, P627, DOI 10.1038/modpathol.3880108; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LOGSDON CD, 1992, AM J PHYSIOL, V262, pG364, DOI 10.1152/ajpgi.1992.262.2.G364; PARSONS R, 1995, CANCER RES, V55, P5548; Schleger C, 2000, J PATHOL, V191, P27, DOI 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J; Schnall SF, 1996, SEMIN ONCOL, V23, P220; Schutte M, 1997, CANCER RES, V57, P3126; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; Ueki T, 2000, CANCER RES, V60, P1835; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Yazumi S, 2000, INT J CANCER, V86, P782; YOSHIDA S, 1995, CANCER RES, V55, P2756	25	87	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2401	2407		10.1038/sj.onc.1207395	http://dx.doi.org/10.1038/sj.onc.1207395			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743205				2022-12-17	WOS:000220427700014
J	Courtois, S; de Fromentel, CC; Hainaut, P				Courtois, S; de Fromentel, CC; Hainaut, P			p53 protein variants: structural and functional similarities with p63 and p73 isoforms	ONCOGENE			English	Review						p53 family; isoform; regulation; alternative splicing; degradation	ALTERNATIVELY SPLICED FORM; TUMOR-SUPPRESSOR GENE; DNA-BINDING ACTIVITY; WILD-TYPE P53; TRANSACTIVATION FUNCTION; PROTEOLYTIC CLEAVAGE; TERMINAL DOMAIN; NORMAL-CELLS; DAMAGED DNA; SAM DOMAIN	Since its discovery in 1979, many studies have reported that the p53 tumour suppressor protein could be expressed in the form of products smaller than those predicted by the full-length amino-acid sequence. These products differ from full-length p53 in their N- or C-terminal regions, but generally conserve the central, DNA-binding domain. They appear to be expressed at rather low levels and to be restricted to particular cell types and/or physiological circumstances, suggesting that they play very narrow and specific roles. Several mechanisms have been proposed to explain their timely occurrence, including alternative splicing, internal initiation of translation or proteolytic cleavage. A precise assessment of the various 'p53 isoforms' reveals striking similarities with several isoforms of the p53 homologous proteins p63 or p73, suggesting that regulated production of specific, N- or C-terminal variants may be a 'trademark' of all family members. In this review, we summarize the published evidence on the structure, mode of production, expression and function of the p53 isoforms, and discuss their properties in the light of recent data on the structure and function of p63/p73 isoforms.	Int Agcy Res Canc, Unit Mol Carcinogenesis, F-69372 Lyon 08, France; Ctr Leon Berard, INSERM, U590, F-69373 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; de Fromentel, Claude Caron/Y-9715-2019	Hainaut, Pierre/0000-0002-1303-1610; de Fromentel, Claude Caron/0000-0001-7566-3958				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Barraille P, 1999, BIOCHEM BIOPH RES CO, V257, P84, DOI 10.1006/bbrc.1999.0334; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; BRAIN R, 1994, ONCOGENE, V9, P1775; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flaman JM, 1996, ONCOGENE, V12, P813; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishimoto O, 2002, CANCER RES, V62, P636; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Laverdiere M, 2000, NUCLEIC ACIDS RES, V28, P1489, DOI 10.1093/nar/28.6.1489; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Molinari M, 1996, ONCOGENE, V13, P2077; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; Sadji-Ouatas Z, 2002, BIOCHEM J, V364, P881, DOI 10.1042/BJ20020349; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Stiewe T, 2002, CANCER RES, V62, P3598; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	59	87	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					631	638		10.1038/sj.onc.1206929	http://dx.doi.org/10.1038/sj.onc.1206929			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737098				2022-12-17	WOS:000188304900001
J	Dan, HC; Jiang, K; Coppola, D; Hamilton, A; Nicosia, SV; Sebti, SM; Cheng, JQ				Dan, HC; Jiang, K; Coppola, D; Hamilton, A; Nicosia, SV; Sebti, SM; Cheng, JQ			Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis	ONCOGENE			English	Article						Akt; PI3K; survivin; GGTI; apoptosis; ovarian cancer	NF-KAPPA-B; HUMAN OVARIAN-CANCER; WILD-TYPE P53; X-LINKED INHIBITOR; V-HA-RAS; FARNESYLTRANSFERASE INHIBITOR; GERANYLGERANYLATED RHOB; GROWTH-FACTORS; UP-REGULATION; CELLS	Geranylgeranyltransferase I inhibitors (GGTIs) represent a new class of anticancer drugs. However, the mechanism by which GGTIs inhibit tumor cell growth is still unclear. Here, we demonstrate that GGTI-298 and GGTI-2166 induce apoptosis in both cisplatin-sensitive and -resistant human ovarian epithelial cancer cells by inhibition of PI3K/AKT and survivin pathways. Following GGTI-298 or GGTI-2166 treatment, kinase levels of PI3K and AKT were decreased and survivin expression was significantly reduced. Ectopic expression of constitutively active AKT2 and/or survivin significantly rescue human cancer cells from GGTI-298-induced apoptosis. Previous studies have shown that Akt mediates growth factor-induced survivin, whereas p53 inhibits survivin expression. However, constitutively active AKT2 failed to rescue the GGTIs downregulation of survivin. Further, GGTIs suppress survivin expression and induce programmed cell death in both wild-type p53 and p53-deficient ovarian cancer cell lines. These data indicate that GGTI-298 and GGTI-2166 induce apoptosis by targeting PI3K/AKT and survivin parallel pathways independent of p53. Owing to the fact that upregulation of Akt and survivin as well as inactivation of p53 are frequently associated with chemoresistance, GGTIs could be valuable agents to overcome antitumor drug resistance.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Drug Discovery Program, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC11, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu; jcheng@hsc.usf.edu			NATIONAL CANCER INSTITUTE [R01CA085709, R01CA089242, U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA89242, CA085709, CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Arboleda MJ, 2003, CANCER RES, V63, P196; Bolick SCE, 2003, LEUKEMIA, V17, P451, DOI 10.1038/sj.leu.2402832; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du W, 1999, MOL CELL BIOL, V19, P1831; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Liu AX, 1998, CANCER RES, V58, P2973; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sasaki H, 2000, CANCER RES, V60, P5659; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Song KM, 1997, ONCOL RES, V9, P603; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun JZ, 1999, CANCER RES, V59, P4919; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	41	87	94	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					706	715		10.1038/sj.onc.1207171	http://dx.doi.org/10.1038/sj.onc.1207171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737105				2022-12-17	WOS:000188304900009
J	Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA				Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA			E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells	ONCOGENE			English	Article						ErbB-2; E6/E7 of HPV; oral epithelial cells; transformation	GROWTH-FACTOR RECEPTOR; ADHESION MOLECULE UVOMORULIN; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; ACTIVATED NEU; E-CADHERIN; CYCLIN D1; CLINICAL-IMPLICATIONS; SIGNALING NETWORK; CANCER	Head and neck squamous cell carcinomas (HNSCC) are characterized by a marked propensity for local invasion and spread to cervical lymph nodes, with distant metastases developing in 30-40% of cases. HPV-16 is an important risk factor for HNSCC. How HPV enhances susceptibility to HNSCC is not fully understood, but seems to involve cofactors. In this study, we examined the effect of the cooperation between HPV-16 and the tyrosine kinase receptor ErbB-2 on E-cadherin/catenin complex patterns and neoplastic transformation of human normal oral epithelial (NOE) cells. We report that overexpression of ErbB-2 or E6/E7 alone does not affect E-cadherin/catenin complex patterns nor does it induce cell transformation of NOE cells. In contrast, coexpression of E6/E7 and ErbB-2 downregulates E-cadherin and catenin expression. This is accompanied by cytoplasmic localization of E-cadherin, as well as nuclear translocation of alpha, beta, and gamma-catenins. Furthermore, we demonstrate that E6/E7 cooperate with overexpressed ErbB-2 to induce tumor formation in nude mice and to upregulate cyclin D1 and c-myc expression. Our data suggest that E6/E7 cooperate with ErbB-2 in head and neck carcinogenesis, at least in part, via the conversion of beta-catenin from a cell adhesion to a nuclear function, that is, to act as a potential transcriptional regulator. This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pharmacol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Therapeut, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Foulkes, WD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room A-803,3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	william.foulkes@mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Al Moustafa AE, 2002, LUNG CANCER, V37, P49, DOI 10.1016/S0169-5002(02)00025-9; Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckert RL, 2000, INT J ONCOL, V16, P853; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Franceschi S, 1996, CANCER EPIDEM BIOMAR, V5, P567; Galipeau J, 1999, CANCER RES, V59, P2384; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; Gillison Maura L., 1999, Current Opinion in Oncology, V11, P191, DOI 10.1097/00001622-199905000-00010; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orr MS, 2000, J NATL CANCER I, V92, P987, DOI 10.1093/jnci/92.12.987; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Wilding J, 1996, CANCER RES, V56, P5285; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Xia WY, 1999, CLIN CANCER RES, V5, P4164; XIE YM, 1995, ONCOGENE, V10, P2409; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972	46	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					350	358		10.1038/sj.onc.1207148	http://dx.doi.org/10.1038/sj.onc.1207148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724563				2022-12-17	WOS:000188098300004
J	Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP				Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP			Coagulation factors VIIa and Xa inhibit apoptosis and anoikis	ONCOGENE			English	Article						apoptosis; anoikis; MAP kinase; PI3 kinase; active-site-blocked FVIIa	FACTOR CYTOPLASMIC DOMAIN; TISSUE FACTOR EXPRESSION; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE PATHWAY; UP-REGULATION; ACTIVATION; METASTASIS; SURVIVAL	The molecular mechanisms enabling cancer cells to survive loss-of-adhesion-induced apoptosis in the early phases of metastasis remain largely obscure. Interestingly, the overexpression of tissue factor (TF) on tumor cells is associated with successful metastasis and it has now become clear that coagulation factor VIIa (FVIIa), the natural binding partner of TF induces signal transduction in TF-expressing cells. Hence, we investigated the effects of FVIIa-TF interaction on cell survival. We observed that FVIIa, at physiologically relevant concentrations, inhibits cell death and caspase-3 activation induced by serum deprivation and loss of adhesion (lack of integrin signaling) in TF-overexpressing cells, but not in non-TF-expressing cells. This FVIIa effect was not dependent on the formation of the downstream coagulation products FXa or thrombin and was inhibited using an active site-blocked form of FVIIa (FVIIai). FVIIa incubation resulted in the prolonged activation of both the phosphatidylinositide-3-(OH) kinase and p42/p44 MAP kinase pathways, and studies employing pharmacological inhibitors revealed that both the pathways are required for FVIIa-induced cell survival and inhibition of caspase-3 activity. Finally, TF:FVIIa-induced FXa generation dramatically increased cell survival. We propose that FVIIa-induced cell survival may explain why overexpression of TF is associated with successful metastasis.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, HH (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, G2-105,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	h.h.versteeg@amc.uva.nl	Spek, Arnold/AAC-5866-2019; Versteeg, Henri/G-1783-2018	Spek, Arnold/0000-0002-2149-4068; Versteeg, Henri/0000-0003-4294-175X; Peppelenbosch, Maikel/0000-0001-9112-6028				Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shigemori C, 1998, THROMB HAEMOSTASIS, V80, P894; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Ueda C, 2001, J GASTROENTEROL, V36, P848, DOI 10.1007/s005350170008; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Versteeg HH, 2003, J THROMB HAEMOST, V1, P1012, DOI 10.1046/j.1538-7836.2003.00205.x; Versteeg HH, 2001, THROMB HAEMOSTASIS, V86, P1353; Versteeg HH, 2002, J BIOL CHEM, V277, P27065, DOI 10.1074/jbc.M110325200; Vrana JA, 1996, CANCER RES, V56, P5063; Wang XL, 2002, J BIOL CHEM, V277, P23620, DOI 10.1074/jbc.M202242200	26	87	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					410	417		10.1038/sj.onc.1207066	http://dx.doi.org/10.1038/sj.onc.1207066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724569				2022-12-17	WOS:000188098300011
J	Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG				Copland, JA; Luxon, BA; Ajani, L; Maity, T; Campagnaro, E; Guo, HP; LeGrand, SN; Tamboli, P; Wood, CG			Genomic profiling identifies alterations in TGF beta signaling through loss of TGF beta receptor expression in human renal cell carcinogenesis and progression	ONCOGENE			English	Article						TGF beta, type III TGF beta receptor, type II TGF beta; receptor, renal cell carcinoma; carcinogenesis; metastasis	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; II RECEPTOR; CARCINOMA; AUTOCRINE; PROLIFERATION; INACTIVATION; BETAGLYCAN; PATTERNS; CULTURE	Renal cell carcinoma (RCC) is a major health issue. Whereas localized disease can be cured surgically, there is no effective therapy for metastatic disease. The development of an effective therapy will require an understanding of the pathways that are important in RCC carcinogenesis and progression. Using genomic profiling of patient-matched tissue, we have identified aberrations in the transforming growth factor beta (TGFbeta) signaling pathway in RCC. We observed loss of type III TGFbeta receptor (TBR3) expression in all RCC samples. This suggests that TBR3 loss is an early event in RCC carcinogenesis and plays a sentinel role in the acquisition of a tumorigenic phenotype. We also observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic RCCs. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and that loss of TBR2 leads to acquisition of a metastatic phenotype. To this end, we have identified a human renal cell carcinoma tine (UMRC6) that is representative of localized, nonmetastatic RCC, reflecting a loss of TBR3, but not TBR2 expression. Another cell line, UMRC3, is highly metastatic, having lost TBR3 and TBR2 expression. We demonstrate functional loss of TGFbeta responsiveness in these cell lines as observed through phenotypic and transcriptional responsiveness to exogenous TGFbeta. Restoring TBR2 and TBR3 expression in UMRC3 cells attenuates cell proliferation, completely restores TGFbeta-mediated transcriptional responses, and completely blocks anchorage independent-growth: while restoration of TBR2 partially restores TGFbeta-mediated signaling. Based on these data, we propose that dysregulation in TGFbeta signaling, through stepwise loss in receptor expression, plays a prominent role in RCC carcinogenesis and progression. In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol & Canc Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Bioinformat Program, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Wood, CG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, Box 446,1515 Holcombe Blvd, Houston, TX 77030 USA.	cgwood@mdanderson.org	Luxon, Bruce A/C-9140-2012	Campagnaro, Erica/0000-0003-3820-3260				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Allander SV, 2001, CANCER RES, V61, P8624; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Boyer AS, 2001, DEV DYNAM, V221, P454, DOI 10.1002/dvdy.1154; Cardillo MR, 2001, ANAL QUANT CYTOL, V23, P109; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Copland JA, 2003, RECENT PROG HORM RES, V58, P25, DOI 10.1210/rp.58.1.25; DEDIR A, 1996, CLIN BIOCHEM, V29, P385; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; DeRisi J, 1996, NAT GENET, V14, P457; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel JD, 1999, UROLOGY, V54, P164, DOI 10.1016/S0090-4295(99)00093-X; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Gilbert RE, 1998, DIABETES, V47, P414, DOI 10.2337/diabetes.47.3.414; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; Hegele A, 2003, UROL RES, V30, P363, DOI 10.1007/s00240-002-0280-3; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kundu SD, 1998, J UROLOGY, V160, P1883, DOI 10.1016/S0022-5347(01)62437-6; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Ramp U, 1997, J UROLOGY, V157, P2345, DOI 10.1016/S0022-5347(01)64778-5; Ramp U, 1997, LAB INVEST, V76, P739; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Sens DA, 1999, EXP NEPHROL, V7, P344; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Trifillis AL, 1999, EXP NEPHROL, V7, P353; Wogensen L, 1999, DIABETES, V48, P182, DOI 10.2337/diabetes.48.1.182; Wunderlich H, 1998, UROL INT, V60, P205, DOI 10.1159/000030255; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	43	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8053	8062		10.1038/sj.onc.1206835	http://dx.doi.org/10.1038/sj.onc.1206835			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970754				2022-12-17	WOS:000185388200021
J	Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J				Moreno-Bueno, G; Rodriguez-Perales, S; Sanchez-Estevez, C; Hardisson, D; Sarrio, D; Prat, J; Cigudosa, JC; Matias-Guiu, X; Palacios, J			Cyclin D1 gene (CCND1) mutations in endometrial cancer	ONCOGENE			English	Article						endometrial carcinoma; cyclin D1 expression; cyclin D1 mutation	BETA-CATENIN; IN-SITU; EXPRESSION; AMPLIFICATION; CARCINOMAS; PHOSPHORYLATION; ABNORMALITIES; PROTEIN; PATHWAY	Cyclin D1 is frequently overexpressed in human neoplasias by gene rearrangement and amplification, but no mutations in the CCND1 gene have so far been reported. However, in vitro mutagenesis of CCND1 has shown that substitutions affecting threonine 286 residue produced cyclin D1 nuclear accumulation, by interfering with protein degradation and induced neoplastic transformation in murine fibroblasts. To test whether similar genetic changes may occur in vivo, we analysed a series of 60 endometrioid endometrial carcinomas (EECs) for cyclin D1 expression and gene amplification by immunohistochemistry and FISH, respectively. Two of 17 carcinomas showing cyclin D1 expression in more than 5% of neoplastic cells, but without gene amplification, were found to harbor single-base substitutions in CCND1 that changed proline 287 into threonine and serine, respectively. Both cases expressed cyclin D1 in more than 50% of neoplastic cells. Additionally, seven tumors with cyclin D1 overexpression of an independent series of 59 EECs were also analysed, and a 12-bp in-frame deletion that eliminated amino acids 289-292 was detected in one case with cylin D1 expression in more than 50% of neoplastic cells. In contrast, no mutations of the CCND1 gene were detected in a set of breast carcinomas with cyclin D1 overexpression without gene amplification. In summary, our data indicate that mutations of CCND1, which probably render the protein insensitive to degradation, represent a previously unreported mechanism of cyclin D1 overexpression in human tumors in vivo.	CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain; CNIO, Biotechnol Programme, Cytogenet Unit, Madrid 28029, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28029, Spain; Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain; Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida 25198, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Hospital of Santa Creu i Sant Pau; Universitat de Lleida; University Hospital Arnau de Vilanova	Palacios, J (corresponding author), CNIO, Mol Pathol Programme, Lab Breast & Gynaecol Canc, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	jpalacios@cnio.es	Corominas, Joan Prat/C-6420-2011; Hardisson, David/AAN-3833-2020; Prat, Jaime/G-4679-2011; SARRIO, DAVID/Y-8903-2019; Hardisson, David/E-2832-2010; Cigudosa, Juan C/E-4105-2016; Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020; Rodriguez-Perales, Sandra/T-7667-2017; matias-guiu, xavier/C-3039-2009; Hardisson, David/A-6259-2011	Hardisson, David/0000-0002-2183-3699; Moreno-Bueno, Gema/0000-0002-5030-6687; Rodriguez-Perales, Sandra/0000-0001-7221-3636; matias-guiu, xavier/0000-0002-7201-6605; Sarrio, David/0000-0003-4886-8290				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Campo E, 1999, SEMIN HEMATOL, V36, P115; Cao QJ, 2002, INT J GYNECOL PATHOL, V21, P147, DOI 10.1097/00004347-200204000-00007; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Kaltz-Wittmer C, 2000, LAB INVEST, V80, P1455, DOI 10.1038/labinvest.3780152; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; Quddus MR, 2002, ARCH PATHOL LAB MED, V126, P459; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schmitz MJ, 2000, GYNECOL ONCOL, V77, P439, DOI 10.1006/gyno.2000.5814; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simpson JF, 1997, AM J PATHOL, V151, P161; Soslow RA, 2000, INT J GYNECOL PATHOL, V19, P329, DOI 10.1097/00004347-200010000-00006; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Tsuda H, 2000, BRIT J CANCER, V82, P675; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257	23	87	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6115	6118		10.1038/sj.onc.1206868	http://dx.doi.org/10.1038/sj.onc.1206868			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955092				2022-12-17	WOS:000185137800022
J	Carr, KM; Bittner, M; Trent, JM				Carr, KM; Bittner, M; Trent, JM			Gene-expression profiling in human cutaneous melanoma	ONCOGENE			English	Article						gene expression profiling; melanoma	B-CELL LYMPHOMA; MALIGNANT-MELANOMA; HUMAN CANCER; MICROARRAY; PATTERNS; CLASSIFICATION; INTERLEUKIN-2; PREDICTION; RESPONSES; SURVIVAL	Genomic technology presents new and exciting opportunities to study complex human diseases. Several types of genomic analysis are helping to elucidate the biology of important human cancers. One of these, gene expression profiling, provides a more comprehensive view of the consequences of the genetic changes in cancer cells than was previously available. In addition to detailing the expression patterns of thousands of genes simultaneously, this exploding field of research has begun to build a new 'molecular taxonomy' of cancer and to identify novel disease genes for many human cancers, including cutaneous melanoma. Whether this new information will lead to improved treatments and prolonged survival for cancer patients remains to be determined. Here, we review the use of complementary DNA microarray technology to study gene expression patterns in cutaneous melanoma and highlight recent advances concerning the identification of novel melanoma disease-related genes. The fundamentals of microarray technology and analysis have been extensively discussed, and readers are referred to several recent reviews in this area.	Translat Genom Res Inst, Phoenix, AZ USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	Translational Genomics Research Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Trent, JM (corresponding author), TGen, 400 N 5th St,Suite 1600, Phoenix, AZ 85004 USA.							Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DeRisi J, 1996, NAT GENET, V14, P457; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; LOTZE MT, 1986, JAMA-J AM MED ASSOC, V256, P3117, DOI 10.1001/jama.256.22.3117; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Palmantier R, 2001, CANCER RES, V61, P2445; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; RISE LAG, 2001, SEER CANC STAT REV 1, V2001; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang E, 2002, CANCER RES, V62, P3581; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157	30	87	97	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3076	3080		10.1038/sj.onc.1206448	http://dx.doi.org/10.1038/sj.onc.1206448			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789283				2022-12-17	WOS:000183096600008
J	Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA				Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA			Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells	ONCOGENE			English	Article						Raf; PI3K; Akt; apoptosis; signal transduction; hematopoietic cells; cytokine dependence; annexin V binding; autocrine transformation	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-RAF; DIFFERENTIAL ABILITIES; NEGATIVE REGULATION; DEREGULATED RAF; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; BAD	The Raf/MEK/ERK kinase cascade is pivotal in transmitting signals from membrane receptors to transcription factors that control gene expression culminating in the regulation of cell cycle progression. This cascade can prevent cell death through ERK2 and p90(Rsk) activation and phosphorylation of apoptotic and cell cycle regulatory proteins. The PI3K/Akt kinase cascade also controls apoptosis and can phosphorylate many apoptotic and cell cycle regulatory proteins. These pathways are interwoven as Akt can phosphorylate Raf and result in its inactivation, and Raf can be required for the antiapoptotic effects of Akt. In this study, the effects of activated Raf (Raf-1, A-Raf and B-Raf) and PI3K/Akt proteins on abrogation of cytokine dependence in FL5.12 hematopoietic cells were examined. Activated Raf, PI3K or Akt expression, by themselves, did not readily relieve cytokine dependence. The presence of activated Raf and PI3K/Akt increased the isolation of factor-independent cells from 400- to 2506-fold depending upon the particular combination examined. The individual effects of activated Raf and Akt on proliferation, apoptosis and autocrine growth factor synthesis were further examined with hormone-inducible constructs (DeltaRaf-1:AR and DeltaAkt:ER*(Myr(+)). Activation of either Raf or Akt hindered cell death; however, both proliferation and maximal synthesis of autocrine cytokines were dependent upon activation of both signaling' pathways. The effects of small molecular weight inhibitors on DNA synthesis and cytokine gene expression were also examined. The PI3K inhibitor, LY294002, inhibited growth and cytokine gene expression. This effect could be synergistically increased by addition of the MEK inhibitor UO126. These cells will be useful in elucidating the interactions between Raf/MEK/ ERK and PI3K/Akt cascades in proliferation, apoptosis, and leukernogenesis, as well as evaluating the efficacy of signal transduction inhibitors that target these cascades.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Biochem, Greenville, NC 27858 USA; Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156				Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Majewski M, 1999, CANCER RES, V59, P2815; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; McCubrey JA, 2001, ADV ENZYME REGUL, V41, P289, DOI 10.1016/S0065-2571(00)00021-2; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; McCubrey JA, 2000, ADV ENZYME REGUL, V40, P305, DOI 10.1016/S0065-2571(99)00033-3; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P17; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Minshall C, 1996, J IMMUNOL, V156, P939; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizutani S, 2001, FEBS LETT, V507, P295, DOI 10.1016/S0014-5793(01)02992-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; RAPP UR, 1988, LUNG CANCER, V4, P162; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Weber CK, 2001, CANCER RES, V61, P3595; Weinstein-Oppenheimer C, 2000, LEUKEMIA, V14, P1921, DOI 10.1038/sj.leu.2401926; WEINSTEINOPPENH.CR, 2000, PHARMACOL THERAPEUT, V88, P230; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	68	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2478	2492		10.1038/sj.onc.1206321	http://dx.doi.org/10.1038/sj.onc.1206321			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717425				2022-12-17	WOS:000182383500011
J	Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP				Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP			Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice	ONCOGENE			English	Article						Notch3; differentiation; pneumocytes; transgenics	RESPIRATORY EPITHELIUM; INTRACELLULAR DOMAIN; KAPPA-B; IN-VIVO; EXPRESSION; GENE; MORPHOGENESIS; CELLS; TRANSLOCATION; NEOPLASMS	Notch3 is a transmembrane receptor and a member of the Notch signaling pathway essential for cellular differentiation in a variety of developing tissues in both invertebrates and vertebrates. Emerging data support the role of the Notch signaling pathway in tumorigenesis. We have previously demonstrated the expression of Notch3 in a subset of lung adenocarcinomas. To further elucidate the role of Notch3 in development of lung cancer, we established a transgenic mouse model in which the intracellular domain of Notch3 is expressed using the surfactant protein C promoter/enhancer. Constitutive expression of Notch3 in the peripheral epithelium in the developing lung resulted in altered lung morphology and delayed development, leading to perinatal lethality in these transgenic mice. Cell-specific markers and electron microscopy examination showed that the majority of the epithelial cells are undifferentiated, with some maturation of type 11 pneumocytes. No type I alveolar cells were evident. Metaplasia of undifferentiated cells in the terminal airways was also observed. Although the mice did not live long enough to assess tumor development, these findings demonstrate that ectopic expression of Notch3 in airway epithelium potentially contributes to the multistep evolution of lung cancer through the inhibition of terminal differentiation.	Vanderbilt Univ, Med Ctr, Div Hematol & Med Oncol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, 642 PRB, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485, P50CA090949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, 1 P50 CA090949] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 1999, DEVELOPMENT, V126, P3925; Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Ito T, 2000, DEVELOPMENT, V127, P3913; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Linnoila RI, 2000, CANCER RES, V60, P4005; Llimargas M, 1999, DEVELOPMENT, V126, P2355; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Post LC, 2000, MECH DEVELOP, V98, P95, DOI 10.1016/S0925-4773(00)00432-9; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Taichman DB, 2002, DEV DYNAM, V225, P166, DOI 10.1002/dvdy.10146; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9	31	87	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1988	1997		10.1038/sj.onc.1206230	http://dx.doi.org/10.1038/sj.onc.1206230			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673204				2022-12-17	WOS:000181967700009
J	Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS				Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS			Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells	ONCOGENE			English	Article						migration; invasion; glioblastoma; antisense uPA	PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; MELANOMA-CELLS; INVASION; SYSTEM; STAUROSPORINE; BIOCHEMISTRY; METASTASIS; EXPRESSION; ADHESION	The ability of glioma cells to migrate great distances from a primary tumor mass is the primary cause of tumor recurrence. The urokinase-type plasminogen activator (uPA) is a serine protease that can initiate proteolytic cascades, which result in remodeling of extracellular matrix and basement membrane, allowing cells to move across and through these barriers. The binding between uPA and its receptor uPAR also mediates several signaling events that seem to contribute to the evolution of a migratory phenotype. In this study, we determined how the downregulation of uPA affects the signaling pathways leading to cell migration. Stably transfecting human glioblastoma cells with antisense uPA decreased the amount of cell-bound uPA and disrupted actin cytoskeleton formation and cell migration. The phosphatidylinositol 3-kinase (PI3k) and Akt signaling pathway has been suggested to mediate migration in various cancer cells. The antisense-uPA clones also had less phosphorylated PI3k and Akt than control cells, a finding associated with decreased cell migration, G2/M-phase arrest, and decreased clonogenic survival. Decreased activation of PI3k and the antiapoptotic factor Akt was not sufficient to induce apoptosis in the antisense-uPA clones, but staurosporine sensitized them to apoptosis to a greater extent than control cells. These results indicate that PI3k/Akt pathway is involved in the signaling cascade required to induce cell migration and that uPA has a direct role in regulating migration.	UIC, Coll Med, Dept Biomed, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Neuropathol, Peoria, IL USA; UIC, Coll Med, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago	Rao, JS (corresponding author), UIC, Coll Med, Dept Biomed, Div Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Berens M E, 1990, Neurosurg Clin N Am, V1, P1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carriero MV, 1999, CANCER RES, V59, P5307; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; HARSH GR, 1990, NEUROLOGICAL SURGERY, P3040; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kim EJ, 2001, INT J ONCOL, V18, P187; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; MacDonald TJ, 1998, J NEURO-ONCOL, V40, P215, DOI 10.1023/A:1006150506789; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Metzner B, 1996, J INVEST DERMATOL, V107, P597, DOI 10.1111/1523-1747.ep12583096; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; PYKE C, 1991, AM J PATHOL, V138, P1059; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; STAHL A, 1994, CANCER RES, V54, P3066; Stepanova V, 1999, MOL CELL BIOCHEM, V195, P199, DOI 10.1023/A:1006936623106; Sturge J, 2002, J CELL SCI, V115, P699; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510	46	87	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					392	400		10.1038/sj.onc.1206164	http://dx.doi.org/10.1038/sj.onc.1206164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545160				2022-12-17	WOS:000180379100008
J	Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA				Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA			Mitochondrial repair of 8-oxoguanine is deficient in Cockayne syndrome group B	ONCOGENE			English	Article						base excision repair; oxidative damage; mitochondria; Cockayne syndrome	RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; OXIDATIVE BASE DAMAGE; HAMSTER OVARY CELLS; INDUCED DNA-DAMAGE; ACTIVE GENES; PREFERENTIAL REPAIR; INDUCED APOPTOSIS; FACTOR CSB/ERCC6; EXCISION-REPAIR	Reactive oxygen species, which are prevalent in mitochondria, cause oxidative DNA damage including the mutagenic DNA lesion 7,8-dihydroxyguanine (8-oxoG). Oxidative damage to mitochondrial DNA has been implicated as a causative factor in a wide variety of degenerative diseases, and in cancer and aging. 8-oxoG is repaired efficiently in mammalian mitochondrial DNA by enzymes in the base excision repair pathway, including the 8-oxoguanine glycosylase (OGG1), which incizes the lesion in the first step of repair. Cockayne syndrome (CS) is a segmental premature aging syndrome in humans that has two complementation groups, CSA and CSB. Previous studies showed that CSB-deficient cells have reduced capacity to repair 8-oxoG. This study examines the role of the CSB gene in regulating repair of 8-oxoG in mitochondrial DNA in human and mouse cells. 8-oxoG repair was measured in liver cells from CSB deficient mice and in human CS-B cells carrying expression vectors for wild type or mutant forms of the human CSB gene. For the first time we report that CSB stimulates repair of 8-oxoG in mammalian mitochondrial DNA. Furthermore, evidence is presented to support the hypothesis that wild type CSB regulates expression of OGG1.	NIA, Lab Mol Gerontol, IRP, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark; Erasmus Univ, Ctr Biomed Genet, Ctr Genet Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Erasmus University Rotterdam	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, IRP, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		van der Horst, Gijsbertus TJ/E-3661-2015; Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Stevnsner, Tinna/0000-0003-1007-0427; Thorslund, Tina/0000-0001-9207-0070	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733, Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aburatani H, 1997, CANCER RES, V57, P2151; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1988, NUCLEIC ACIDS RES, V16, P7397, DOI 10.1093/nar/16.15.7397; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1984, AM J HUM GENET, V36, P311; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SCHNEIDER JE, 1990, NUCLEIC ACIDS RES, V18, P631, DOI 10.1093/nar/18.3.631; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TUO J, 2002, IN PRESS DNA REPAIR; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; Wallace Douglas C., 1998, Biofactors, V7, P187	48	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8675	8682		10.1038/sj.onc.1205994	http://dx.doi.org/10.1038/sj.onc.1205994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483520				2022-12-17	WOS:000179734400001
J	Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC				Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC			Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion	ONCOGENE			English	Article						adhesion; motility; transforming growth factor beta; carcinogenesis	GROWTH-FACTOR-BETA; FOCAL ADHESION KINASE; HEMORRHAGIC TELANGIECTASIA TYPE-1; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; IN-VITRO; INTEGRIN; INHIBITION; TGF-BETA-1	The regulation of cell adhesion and motility in human prostate is not well understood. We have previously shown that the endoglin gene is differently expressed during changes in prostate cell adhesion. Endoglin is a transmembrane transforming growth factor beta binding protein typically expressed by endothelial cells. In this report we demonstrate that endoglin over expression increases prostate cell attachment, while decreasing migration and invasion. Engineered decreases in endoglin expression have opposite effects. While endoglin exerted only relatively small effects upon cell adhesion, large effects upon cell migration and invasion were observed. Endoglin was shown to localize to focal adhesion plaques, consistent with its role in regulating cell adhesion and motility. Loss of endoglin expression in cancer, as compared to normal prostate, was seen in human prostate cell lines. Suppression of endoglin expression in a panel of normal human prostate cell lines led to cell detachment. Endoglin is identified as a regulator of cell adhesion, motility and invasion in human prostate. Loss of endoglin expression appears to be associated with prostate cancer progression, at least in vitro.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Northwestern University	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634	NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER; NCI NIH HHS [CA90386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bright RK, 1997, CANCER RES, V57, P995; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Dakhama A, 1996, J HISTOCHEM CYTOCHEM, V44, P1205, DOI 10.1177/44.10.8813086; Eckstein F, 1996, ANTISENSE NUCLEIC A, V6, P149, DOI 10.1089/oli.1.1996.6.149; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.3.CO;2-M; Fornaro M, 1996, AM J PATHOL, V149, P765; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Games P.A., 1976, J EDUC BEHAV STAT, V1, P113, DOI [10.3102/10769986001002113, DOI 10.2307/1164979]; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldfinger LE, 1999, J CELL SCI, V112, P2615; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; JOVANOVIC BD, 2002, ANAL GENE ARRAY DATA; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; LIU YQ, 2001, PROSTATIC DIS, V4, P1; Loganadane LD, 1999, CELL ADHES COMMUN, V7, P57, DOI 10.3109/15419069909034392; Luo Jan, 1997, Pathol Oncol Res, V3, P264; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; NAGLE RB, 1994, J CELL BIOCHEM, P232; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Teti A, 1997, INT J CANCER, V72, P1013; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9	49	87	94	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8272	8281		10.1038/sj.onc.1206117	http://dx.doi.org/10.1038/sj.onc.1206117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447690				2022-12-17	WOS:000179323900005
J	Steinman, RA				Steinman, RA			Cell cycle regulators and hematopoiesis	ONCOGENE			English	Review						hematopoiesis; quiescence; cyclin-dependent; p21 kinases; differentiation	GROWTH-FACTOR-BETA; TERMINAL ERYTHROID-DIFFERENTIATION; CCAAT/ENHANCER-BINDING PROTEIN; DEPENDENT KINASE INHIBITORS; LINEAGE-SPECIFIC REGULATION; COLONY-STIMULATING FACTOR; MYELOID PROGENITOR CELLS; BLOOD CD34(+) CELLS; GENE-EXPRESSION; STEM-CELLS	The cell cycle behavior of hematopoietic cells varies from extended quiescence to spectacular proliferation. Cell cycle regulators choreograph these transitions through variation in the makeup of cyclin-dependent kinase (cdk)-containing complexes and through alteration in protein expression levels and subcellular localization. The mechanisms through which cell cycle regulators couple proliferation, differentiation and survival is coming into sharper focus. Cdk-inhibitors, once thought of solely in terms of a checkpoint function on cycling, are now known to interact directly with proteins and pathways central to differentiation and apoptosis. By shuttling between binding partners committed to discrete functional pathways, cell cycle regulators may directly coordinate proliferation with differentiation, migration and apoptosis.	Dept Med & Pharmacol, Pittsburgh, PA 15213 USA		Steinman, RA (corresponding author), Dept Med & Pharmacol, E1052 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	Steinman@imap.pitt.edu			NHLBI NIH HHS [HL65172] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065172] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 1997, BLOOD, V90, P126; Amanullah A, 2000, BLOOD, V96, P475; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; Bradford GB, 1997, EXP HEMATOL, V25, P445; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; BURGER C, 1994, J CELL SCI, V107, P2047; CAPEL B, 1990, BLOOD, V75, P2267; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Chen G, 1999, DNA CELL BIOL, V18, P305, DOI 10.1089/104454999315367; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Duarte RF, 2000, BLOOD, V96, P3422; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; EAVES CJ, 1991, BLOOD, V78, P110; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1997, CANCER RES, V57, P1429; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fortunel N, 2000, STEM CELLS, V18, P102, DOI 10.1634/stemcells.18-2-102; Fortunel NO, 2000, BLOOD, V96, P2022; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Glimm H, 2000, BLOOD, V96, P4185, DOI 10.1182/blood.V96.13.4185.h8004185_4185_4193; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Gonze D, 2001, J THEOR BIOL, V210, P167, DOI 10.1006/jtbi.2000.2294; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Gothot A, 1998, EXP HEMATOL, V26, P562; Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; JIANG HP, 1994, ONCOGENE, V9, P3397; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Josefsen D, 2000, STEM CELLS, V18, P261, DOI 10.1634/stemcells.18-4-261; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leemhuis T, 1996, EXP HEMATOL, V24, P1215; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marone M, 2000, BRIT J HAEMATOL, V110, P654, DOI 10.1046/j.1365-2141.2000.02227.x; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; McDonald E, 1996, CANCER RES, V56, P2250; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Okada S, 1999, BLOOD, V93, P816, DOI 10.1182/blood.V93.3.816.403k21_816_825; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PIETRZYK ME, 1985, BLOOD, V66, P1460; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Reid S, 1999, CYTOKINES CELL MOL T, V5, P129; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Romond PC, 1999, ANN NY ACAD SCI, V879, P180, DOI 10.1111/j.1749-6632.1999.tb10419.x; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1994, STEM CELLS, V12, P47; Shimizu T, 2000, ONCOGENE, V19, P4640, DOI 10.1038/sj.onc.1203821; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sriuranpong V, 2001, CANCER RES, V61, P3200; Srour EF, 2000, BLOOD, V96, P1609, DOI 10.1182/blood.V96.4.1609.h8001608b_1609_1612; Steinman R. A., 1997, Blood, V90, p164A; Steinman RA, 2000, MOL MED, V6, P736, DOI 10.1007/BF03402190; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Tian JQ, 1999, AM J PHYSIOL-GASTR L, V276, pG1094, DOI 10.1152/ajpgi.1999.276.5.G1094; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wilpshaar J, 2000, BLOOD, V96, P2100; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yaroslavskiy B, 2001, J CELL BIOCHEM, V83, P380, DOI 10.1002/jcb.1243; YEN A, 1990, CANCER RES, V50, P1411; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhou P, 1999, ANTICANCER RES, V19, P4935	131	87	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3403	3413		10.1038/sj.onc.1205325	http://dx.doi.org/10.1038/sj.onc.1205325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032778				2022-12-17	WOS:000175633300013
J	Gaymes, TJ; North, PS; Brady, N; Hickson, ID; Mufti, GJ; Rassool, FV				Gaymes, TJ; North, PS; Brady, N; Hickson, ID; Mufti, GJ; Rassool, FV			Increased error-prone non homologous DNA end-joining - a proposed mechanism of chromosomal instability in Bloom's syndrome	ONCOGENE			English	Article						Bloom's syndrome; chromosomal abnormalities; double strand break DNA repair; non homologous end-joining	SYNDROME GENE-PRODUCT; DOUBLE-STRAND BREAKS; CELL-FREE-EXTRACTS; NONHOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; HELICASES; REPAIR	BS is an inherited cancer predisposition disorder caused by inactivation of the RecQ family helicase, BLM. One of the defining features of cells from BS individuals is chromosomal instability, characterized by elevated sister chromatid exchanges (SCEs), as well as chromosomal breaks, deletions, and rearrangements. Although the basis for chromosomal instability is poorly understood, there is evidence that chromosomal abnormalities can arise through an alteration in the efficiency or fidelity of DNA double strand break (DSB) repair. Here, we show that BS cells demonstrate aberrant DSB repair mediated by the non-homologous end-joining (NHEJ) pathway for DNA repair, one of the two main pathways for the repair of DSBs in mammalian cells. Through a comparison of BS cell lines, and a derivative in which the BS phenotype has been reverted by expression of the BLM cDNA, we show that BS cells display aberrant end-joining of DSBs. Importantly, DNA end-joining in BS cells is highly error-prone and frequently results in DNA ligation at distant sites of microhomology, creating large DNA deletions. This aberrant repair is dependent upon the presence of the Ku70/86 heterodimer, a key component in the NHEJ pathway. We propose that aberrant NHEJ is a candidate mechanism for the generation of chromosomal instability in BS.	Rayne Inst, GKT Sch Med, Leukaem Sci Labs, Dept Haematol Med, London SE5 9NU, England; Univ Oxford, John Radcliffe Hosp, Imperial Canc Res Fund Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of London; King's College London; Cancer Research UK; University of Oxford	Rassool, FV (corresponding author), Rayne Inst, GKT Sch Med, Leukaem Sci Labs, Dept Haematol Med, London SE5 9NU, England.	feyruz.rassool@kcl.ac.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GERMAN J, 1974, CHROMOSOMA, V48, P361, DOI 10.1007/BF00290993; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	32	87	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2525	2533		10.1038/sj.onc.1205331	http://dx.doi.org/10.1038/sj.onc.1205331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971187				2022-12-17	WOS:000174918400009
J	Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P				Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P			Estrogen induction and overexpression of fibutin-1C mRNA in ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; fibulin-1C; fibulin-1D; estrogen; competitive PCR	EXON-INTRON ORGANIZATION; RECEPTOR-ALPHA; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; HUMAN FIBULIN-1; IN-VITRO; EXPRESSION; GROWTH; PROTEIN; BETA	Fibulin-1 is an extracellular matrix protein induced by estradiol in estrogen receptor (ER) positive ovarian cancer cell lines. Alternative splicing of fibulin-1 mRNA results in four different variants named A, B, C and D that may have distinct biological functions. We studied the relative expression of fibulin-1 mRNA variants and their estrogen regulation in human ovarian cancer cells. In ovarian tissues and cancer cell lines, fibulin-1C and -1D are the predominant forms, whereas fibulin-1A and -1B are weakly expressed. We developed a competitive PCR assay based on coamplification of fibulin-1C and -1D to study the relative expression of these fibulin-1 variants in human ovarian samples. In ovarian cancer cell lines and ovarian cancer samples, there was a marked increase in the fibutin-1C:1D and fibulin-1C:HPRT mRNA ratios as compared to normal ovaries. In the BG1 estrogen receptor positive ovarian cancer cell line, fibulin-1C mRNA was induced by estradiol in a dose- and time-dependent manner. Since others and we have previously shown an increased expression of ERalpha as compared to ERbeta in ovarian cancer cells, we investigated whether ERalpha or ERbeta is involved in this induction. For this aim, MDA-MB-231 breast cancer cell line, which expresses both low basal levels of ERs and fibulin-1, was infected with recombinant ERalpha or ERbeta encoding adenovirus and treated with estradiol. Fibulin-1C was induced by estradiol in ERalpha- but not ERbeta-infected cells, suggesting that fibulin-1C induction is mediated through ERa. In ovarian tumors, a trend towards a correlation between fibulin-1C and ERalpha expression levels was noted. In conclusion, this study showed an increased fibulin-1C: -1D mRNA ratio in ovarian cancer cells as compared to normal ovaries. This finding suggests that the C variant may be involved in ovarian carcinogenesis. Fibulin-1C overexpression may thus be a clue for the understanding of a putative role of estrogens in ERalpha promoted ovarian tumor progression.	Hop Arnaud de Villeneuve, Serv Biol Cellulaire, F-34295 Montpellier, France; Hop Arnaud de Villeneuve, Serv Hormonale, F-34295 Montpellier, France; INSERM, U540, F-34095 Montpellier, France; Dept Obstet & Gynecol, I-10126 Turin, Italy; CHU Montpellier, Hop Arnaud de Villeneuve, F-34295 Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Pujol, P (corresponding author), Hop Arnaud de Villeneuve, Serv Biol Cellulaire, 271 Av G Giraud, F-34295 Montpellier, France.	p-pujol@chu-montpellier.fr		Lazennec, Gwendal/0000-0002-8522-1763; ROGER, Pascal/0000-0002-4040-5892				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; AHLGREN JD, 1993, J CLIN ONCOL, V11, P1957, DOI 10.1200/JCO.1993.11.10.1957; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHIEN CH, 1994, MOL CELL ENDOCRINOL, V99, P11; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; Greenwood M, 2000, HIST TODAY, V50, P3; Hamilton TC, 1999, ANN ONCOL, V10, P69, DOI 10.1023/A:1008367620240; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; Havrilesky LJ, 2001, J SOC GYNECOL INVEST, V8, P104, DOI 10.1016/S1071-5576(01)00093-4; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hillier SG, 1998, MOL HUM REPROD, V4, P811, DOI 10.1093/molehr/4.8.811; JABARA AG, 1962, AUST J EXP BIOL MED, V40, P139, DOI 10.1038/icb.1962.17; KORENBERG JR, 1995, CYTOGENET CELL GENET, V68, P192, DOI 10.1159/000133911; KRYWICKI RF, 1993, EUR J CANCER, V29A, P2015, DOI 10.1016/0959-8049(93)90464-Q; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Makar AP, 2000, ENDOCR-RELAT CANCER, V7, P85, DOI 10.1677/erc.0.0070085; MAZARS R, 1991, ONCOGENE, V6, P1685; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Pan TC, 1999, FEBS LETT, V444, P38, DOI 10.1016/S0014-5793(99)00024-1; PAVLIK EJ, 1991, GYNECOL ONCOL, V42, P245, DOI 10.1016/0090-8258(91)90353-7; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Pujol P, 1998, CANCER RES, V58, P5367; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rey JM, 2000, J MOL ENDOCRINOL, V24, P433, DOI 10.1677/jme.0.0240433; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCHEFORT H, 1984, RECENT RESULTS CANC, V91, P289; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4	47	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1097	1107		10.1038/sj.onc.1205171	http://dx.doi.org/10.1038/sj.onc.1205171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850827				2022-12-17	WOS:000173580100013
J	Nesterov, A; Ivashchenko, Y; Kraft, AS				Nesterov, A; Ivashchenko, Y; Kraft, AS			Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells	ONCOGENE			English	Article						TRAIL; apoptosis; primary; prostate; human	DEATH; INHIBITION; RECEPTORS; INDUCTION; MEMBER; FAMILY	TRAIL is a pro-apoptotic cytokine believed to selectively kill cancer cells without harming normal ones. However, we found that in normal human prostate epithelial cells (PrEC) TRAIL is capable of inducing apoptosis as efficiently as in some tumor cell lines. At the same time, TRAIL did not cause apoptosis in several other human primary cell lines: aorta smooth muscle cells, foreskin fibroblasts, and umbilical vein endothelial cells. Compared to these primary cells, PrEC were found to contain significantly fewer TRAIL receptors DcR1 and DcR2 which are not capable of conducting the apoptotic signal. This result suggests that the unusual sensitivity of PrEC to TRAIL may result from their deficiency in antiapoptotic decoy receptors. The protein synthesis inhibitor cycloheximide significantly enhanced TRAIL toxicity toward PrEC as measured by tetrazolium conversion but had little or no effect on other TRAIL-induced apoptotic responses. Although cycloheximide did not further accelerate the processing of caspases 3 and 8, it significantly enhanced cleavage of the caspase 3 substrate gelsolin, indicating that in PrEC a protein(s) with a short half-life may inhibit the activity of the executioner caspases toward specific substrates. As the majority of prostate cancers are derived from epithelial cells, our data suggest the possibility that TRAIL could be a useful treatment for the early stages of prostate cancer.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Aventis Pharmaceut, D-65926 Frankfurt, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Sanofi-Aventis	Nesterov, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NCI NIH HHS [CA 78631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078631] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leverkus M, 2000, CANCER RES, V60, P553; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; STAMEY TA, 1992, CAMPBELLS UROLOGY, P1159; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Warner HR, 1997, J AM GERIATR SOC, V45, P1140, DOI 10.1111/j.1532-5415.1997.tb05981.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	23	87	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1135	1140		10.1038/sj.onc.1205151	http://dx.doi.org/10.1038/sj.onc.1205151			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850832				2022-12-17	WOS:000173580100018
J	von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H				von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H			Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; signal transduction; cellular transformation	STEM-CELL-FACTOR; GROWTH-FACTOR RECEPTOR; SELF-RENEWAL; IN-VITRO; GLUCOCORTICOID-RECEPTOR; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; KINASE; ROLES	Primary erythroid progenitors can be expanded by the synergistic action of erythropoietin (Epo), stem cell factor (SCF) and glucocorticoids, While Epo is required for erythropoiesis in general, glucocorticoids and SCF mainly contribute to stress erythropoiesis in hypoxic mice, This ability of normal erythroid progenitors to undergo expansion under stress conditions is targeted by the avian erythroblastosis virus (AEV), harboring the oncogenes v-ErbB and v-ErbA, We investigated the signaling pathways required for progenitor expansion under stress conditions and in leukemic transformation. Immortal strains of erythroid progenitors, able to undergo normal, terminal differentiation under appropriate conditions, were established from fetal livers of p53-/- mice. Expression and activation of the EGF-receptor (HER-1/c-ErbB) or its mutated oncogenic version (v-ErbB) in these cells abrogated the requirement for Epo and SCF in expansion of these progenitors and blocked terminal differentiation. Upon inhibition of ErbB function, differentiation into erythrocytes occurred. Signal transducing molecules important for renewal induction, i.e. Stat5- and phosphoinositide 3-kinase (PI3K), are utilized by both EpoR/c-Kit and v/c-ErbB, However, while v-ErbB transformed cells and normal progenitors depended on PI3K signaling for renewal, c-ErbB also induces progenitor expansion by PI3K-independent mechanisms.	Inst Mol Pathol, A-1030 Vienna, Austria; Erasmus MC, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Vienna Bioctr, VBC, Inst Med Biochem, A-1030 Vienna, Austria; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Erasmus University Rotterdam; Erasmus MC; Vienna Biocenter (VBC); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.gt	von Lindern, Marieke/AAH-2350-2020; Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585				Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1996, BLOOD, V88, P75; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOLZNIG H, 2001, IN PRESS FASEB J; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KELLEY MW, 1992, DEV AUDITORY VESTIBU, V2, P139; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Kieslinger M, 2000, GENE DEV, V14, P232; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OZBUN MA, 1993, CELL GROWTH DIFFER, V4, P811; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; van Dijk TB, 2000, BLOOD, V96, P3406; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; VONRUDEN T, 1992, BLOOD, V79, P3145; Wessely O, 1997, CELL GROWTH DIFFER, V8, P481; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	49	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3651	3664		10.1038/sj.onc.1204494	http://dx.doi.org/10.1038/sj.onc.1204494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439328				2022-12-17	WOS:000169400200006
J	Yu, ZK; Geyer, RK; Maki, CG				Yu, ZK; Geyer, RK; Maki, CG			MDM2-dependent ubiquitination of nuclear and cytoplasmic P53	ONCOGENE			English	Article						p53; MDM2; ubiquitination; nuclear export	PROTEIN; DEGRADATION; LOCALIZATION; DOMAIN; COMPLEX; FORMS; HDM2; SITE	Wild-type p53 is stabilized and accumulates in the nucleus of DNA damaged cells. The effect of stabilizing p53 is to inhibit cell growth, either through a G1 cell cycle arrest or apoptotic cell death. MDM2 can inhibit p53 activity, in part, by promoting its rapid degradation through the ubiquitin proteolysis pathway, In the current study, MDM2-mediated degradation of p53 was partially inhibited in cells treated with leptomycin B (LMB), a specific inhibitor of nuclear export. In contrast, levels of ubiquitinated p53 increased in LMB-treated cells, indicating that nuclear export is not required for p53 ubiquitination, To investigate this further, p53 mutants were generated which localize to either the nucleus or cytoplasm, and their susceptibility to MDM2-mediated ubiquitination was assessed. p53 mutants that localized to either the nucleus or the cytoplasm were efficiently ubiquitinated, and their steady-state levels decreased, when coexpressed with MDM2, In addition, an MDM2-mutant that localized to the cytoplasm was able to ubiquitinate and degrade a p53 mutant which was similarly localized in the cytoplasm, Our results indicate that nuclear export is not required for p53 ubiquitination, and that p53 proteins that localize to either the nucleus or cytoplasm can be ubiquitinated and degraded by MDM2.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.							AbouElela S, 1997, CANCER LETT, V117, P23, DOI 10.1016/S0304-3835(97)00196-1; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guerra B, 1998, FEBS LETT, V434, P115, DOI 10.1016/S0014-5793(98)00962-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077	29	87	88	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5892	5897		10.1038/sj.onc.1203980	http://dx.doi.org/10.1038/sj.onc.1203980			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127820				2022-12-17	WOS:000165563100008
J	Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S				Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S			Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma	ONCOGENE			English	Article						non Hodgkin's lymphoma; translocation; RhoH/TTF; small G protein; LAZ3/BCL6	GERMINAL-CENTER FORMATION; CHROMOSOMAL TRANSLOCATIONS; RAS TRANSFORMATION; LAZ3/BCL6 ONCOPROTEIN; B-CELLS; EXPRESSION; BCL-6; RHO; DOMAIN; LAZ3	We recently isolated the RhoH/TTF gene by its fusion to the LAZ3/BCL6 gene, in a non-Hodgkin's lymphoma (NHL) cell line, which bore a t(3;4)(q27;p11-13) translocation, This gene encodes a novel Rho GTP-binding protein and is specifically expressed in hematopoietic tissues. We made its precise mapping at band 4p13, and described its partial genomic structure, Using fluorescence ill situ hybridization and molecular analyses, we report here on the rearrangement of the RhoH/TTF gene, at band 4p13, in four cases of NHL with t(3;4)(q27;p13) translocation and its fusion to the LAZ3/BCL6 gene at band 3q27, in three of these cases. RT-PCR analysis of two cases allowed the detection of variable fusion transcripts emerging from the rearranged alleles, and in one case, a deregulated expression of both RhoH/TTF and LAZ3/BCL6 genes, by promoter substitution, was observed, We also show here another rearrangement of the RhoH/TTF gene in a patient with multiple myeloma slid t(4;14)(p13;q32) translocation, with breakage within the IGH gene. It is the first report which describes the recurrent chromosomal alteration of a GTP-binding protein encoding gene, in patients with hematopoietic malignancies.	Inst Rech Canc, INSERM U524, F-59045 Lille, France; CHU Lille, Lab Hematol A, F-59037 Lille, France; CHU Lille, Lab Cytogenet, F-59037 Lille, France; CHG Valenciennes, Dept Hematol & Cytogenet, Valenciennes, France; Ctr Oscar Lambret, Lab Cytogenet, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; CH de Valenciennes; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Galiegue-Zouitina, S (corresponding author), Inst Rech Canc, INSERM U524, Pl Verdun, F-59045 Lille, France.		Preudhomme, Claude/T-8553-2018	Preudhomme, Claude/0000-0002-1267-9546				Akasaka T, 1997, CANCER RES, V57, P7; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; BASTARD C, 1994, BLOOD, V83, P2423; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; CalletBauchu E, 1996, GENE CHROMOSOME CANC, V17, P185, DOI 10.1002/(SICI)1098-2264(199611)17:3<185::AID-GCC7>3.0.CO;2-0; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLERY E, 1995, ONCOGENE, V10, P2171; DalleryPrudhomme E, 1997, GENOMICS, V43, P89, DOI 10.1006/geno.1997.4788; Daudignon A, 1999, CANCER GENET CYTOGEN, V111, P157, DOI 10.1016/S0165-4608(98)00239-8; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MITELMAN F, 1991, GUIDELINES CANC CY S; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; STORSKI T, 1998, P NATL ACAD SCI USA, V95, P11858; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zandecki M, 1996, BRIT J HAEMATOL, V94, P217	39	87	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2023	2032		10.1038/sj.onc.1203521	http://dx.doi.org/10.1038/sj.onc.1203521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803463				2022-12-17	WOS:000086613200006
J	Tan, A; Bitterman, P; Sonenberg, N; Peterson, M; Polunovsky, V				Tan, A; Bitterman, P; Sonenberg, N; Peterson, M; Polunovsky, V			Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1	ONCOGENE			English	Article						Myc; eIF4E; apoptosis; cyclin D1; translation	NEURONAL CELL-DEATH; MESSENGER-RNA; GENE-EXPRESSION; C-MYC; ORNITHINE DECARBOXYLASE; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; PROTEIN-SYNTHESIS; POOR-PROGNOSIS; BREAST-CANCER	Ectopically expressed eukaryotic translation initiation factor 4E (eIF4E) stimulates cell proliferation, suppresses apoptosis in growth factor restricted cells, and induces malignant transformation in primary rodent fibroblasts when coexpressed with protooncogene myc. We report here that eIF4E rescued rat embryo fibroblasts ectopically expressing c-Myc (REF/Myc) from genotoxic and non-genotoxic cytostatic drugs and identify cyclin D1 as a downstream effector in the antiapoptotic mechanism, In clones of REF/Myc ectopically expressing eIF4E, resistance to apoptosis paralleled steady state levels of cyclin D1. Stable expression of cyclin D1 in REF/Myc inhibited apoptosis in response to a broad range of cell cycle specific cytostatic agents, Partial loss-of-cyclin D1 function in REF/Myc ectopically expressing eIF4E (REF/Myc/4E) significantly increased chemosensitivity; either soluble antisense cyclin D1 oligomers or transfection with a dominant negative cyclin D1 mutant that prevents translocation of cyclin D-dependent kinases to the nucleus, significantly blunted the antiapoptotic effect of eIF4E, These data directly link eIF4E rescue from cytostatic drugs to cyclin D1, Since overexpression of eIF4E and cyclin D1 is observed in many aggressive forms of chemoresistant cancers, these findings provide insight into possible mechanisms responsible for this biological behavior.	Univ Minnesota, Sch Med, Dept Pulm Med, Allergy & Crit Care Div, Minneapolis, MN 55255 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Minnesota System; University of Minnesota Twin Cities; McGill University	Polunovsky, V (corresponding author), Univ Minnesota Hosp & Clin, Div Pulm Allergy & Crit Care Med, Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.			BITTERMAN, PETER/0000-0002-7995-7117	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50-HL50152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Busser J, 1998, J NEUROSCI, V18, P2801; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; de Jong JS, 1998, J CLIN PATHOL-MOL PA, V51, P30, DOI 10.1136/mp.51.1.30; delPeso L, 1997, SCIENCE, V278, P687; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DRISCOLL B, 1999, AM J PHYSIOL-LUNG C, V20, pL679; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EVAN GI, 1992, CELL, V69, P19; Fan G, 1999, APOPTOSIS, V4, P21, DOI 10.1023/A:1009626031179; FRANKE TF, 1997, SCIENCE, V27, P655; Gansauge S, 1997, CANCER RES, V57, P1634; Giardina SF, 1998, J NEUROCHEM, V71, P1325; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Green DR, 1996, J CELL BIOCHEM, V60, P33, DOI 10.1002/(SICI)1097-4644(19960101)60:1<33::AID-JCB6>3.0.CO;2-4; Guegan C, 1997, NEUROREPORT, V8, P1003, DOI 10.1097/00001756-199703030-00037; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hiyama H, 1999, CELL DEATH DIFFER, V6, P565, DOI 10.1038/sj.cdd.4400524; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Katayose Y, 1997, CANCER RES, V57, P5441; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kotelnikov VM, 1997, CLIN CANCER RES, V3, P95; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu W, 1996, NEUROREPORT, V7, P2785, DOI 10.1097/00001756-199611040-00076; LUNGBERG AS, 1999, EUR J CANCER, V25, P531; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mommers ECM, 1998, HUM PATHOL, V29, P1539, DOI 10.1016/S0046-8177(98)90028-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Packham G, 1995, Curr Top Microbiol Immunol, V194, P283; Pardo FS, 1996, SOMAT CELL MOLEC GEN, V22, P135, DOI 10.1007/BF02369903; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; POLUNOVSKY VA, 1993, J CLIN INVEST, V92, P388, DOI 10.1172/JCI116578; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Postigo JA, 1998, NEUROSCI LETT, V241, P107, DOI 10.1016/S0304-3940(97)00981-6; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; RHEE K, 1995, CANCER RES, V55, P4188; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sauter ER, 1999, CANCER RES, V59, P4876; SCHUURING E, 1992, CANCER RES, V52, P5229; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TAM SW, 1994, ONCOGENE, V9, P2663; Tan A, 1999, AM J RESP CRIT CARE, V159, P220, DOI 10.1164/ajrccm.159.1.9802104; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; WANG XT, 1997, ONCOGENE, V9, P2663; Warenius HM, 1996, INT J CANCER, V67, P224, DOI 10.1002/(SICI)1097-0215(19960717)67:2<224::AID-IJC13>3.3.CO;2-5; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	78	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1437	1447		10.1038/sj.onc.1203446	http://dx.doi.org/10.1038/sj.onc.1203446			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723135				2022-12-17	WOS:000085942700009
J	Eichmann, A; Yuan, L; Breant, C; Alitalo, K; Koskinen, PJ				Eichmann, A; Yuan, L; Breant, C; Alitalo, K; Koskinen, PJ			Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system	ONCOGENE			English	Article						pim kinases; quail; expression; embryonic development	E-MU-MYC; TRANSGENIC MICE; INHIBITS APOPTOSIS; ENDOTHELIAL-CELLS; LYMPHOID TUMORS; HIGH-FREQUENCY; MYELOID CELLS; BONE-MARROW; C-MYC; N-MYC	We have cloned a novel quail cDNA with strong homology to the pint family of proto-oncogenes. The deduced amino acid (aa) sequence of the cDNA, named qpim, is more closely related to Xenopus Pim and to the recently identified rat Pim-3 than to human or rodent Pim-1 or Pim-2. The protein encoded by the qpim cDNA can autophosphorylate itself and share substrates with murine Pim-l, suggesting functional redundancy to other Pim family serine/threonine kinases. We have compared the expression of qpim in avian embryos to mouse pim-1, -2 and -3 by in situ hybridization. qpim shows a highly dynamic expression pattern, particularly at early developmental stages. Surprisingly, its expression pattern is not identical to any of the murine pint genes, which show complementary and/or partially overlapping expression sites both in- and outside of the hematopoietic system. Altogether, our results suggest novel functions for Pim family kinases during embryonic development, in particular in epithelia and in the central nervous system.	CNRS, Inst Embryol Cellulaire & Mol, F-94736 Nogent Sur Marne, France; Coll France, F-94736 Nogent Sur Marne, France; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20520 Turku, Finland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; University of Helsinki; Abo Akademi University; University of Turku	Eichmann, A (corresponding author), CNRS, Inst Embryol Cellulaire & Mol, 49Bis,Ave de la Belle Gabrielle, F-94736 Nogent Sur Marne, France.		Koskinen, Päivi J/G-8939-2014; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Koskinen, Paivi/0000-0002-6864-4457				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Feldman JD, 1998, J NEUROSCI RES, V53, P502, DOI 10.1002/(SICI)1097-4547(19980815)53:4<502::AID-JNR13>3.0.CO;2-3; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1991, ONCOGENE, V6, P1941; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wilting J, 1996, DEV BIOL, V176, P76, DOI 10.1006/dbio.1996.9993; Wingett D, 1996, J IMMUNOL, V156, P549; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183	36	87	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1215	1224		10.1038/sj.onc.1203355	http://dx.doi.org/10.1038/sj.onc.1203355			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713710				2022-12-17	WOS:000085567800012
J	Imatani, A; Callahan, R				Imatani, A; Callahan, R			Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines	ONCOGENE			English	Article						NOTCH-4/INT-3; activated gene product; human	MAMMARY EPITHELIAL-CELLS; SPLIT COMPLEX GENES; TRUNCATED INT3 GENE; NOTCH-GENE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; MAMMALIAN NOTCH; HUMAN HOMOLOG; C-MYC; DIFFERENTIATION	Ectopic expression of the intracellular domain of NOTCH-4/INT-3 leads to tumorigenesis in the mouse mammary gland. This results from a gain-of-function mutation. To evaluate gain-of-function NOTCH-4/INT-3 activity in human cancers we have surveyed human breast, lung, and colon carcinoma tissue culture cell lines for evidence of increased NOTCH-4/INT-3 RNA expression. High levels of a 1.8 Kb NOTCH-4/INT-3 RNA species are detected in normal human testis but not in other tissues where a 6.5 Kb species is prevalent. Transformed human cancer cell lines express the 1.8 Kb NOTCH-4/INT-3 RNA species. We show that this RNA species encodes a truncated form of the NOTCH-4/INT3 intracellular domain (ICD), This novel NOTCH-4/ INT-3 protein includes the CDC10 repeats and amino acid residues C-terminal to them, but is missing the CBF-1 binding region of the NOTCH-4/INT-3 ICD, This suggests that it has a different mode of action, Furthermore, we show that a transgene which expresses the 1.8 Kb NOTCH-4/INT-3 RNA species in the 'normal' human mammary epithelial cell line MCF-10A enables these cells to grow in soft agar.	NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Tumor Immunol & Biol Lab, NIH, Bldg 10,Room 5B50, Bethesda, MD 20892 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jolicoeur P, 1998, BIOCHEM SOC SYMP, P159; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Matsuno K, 1997, DEVELOPMENT, V124, P4265; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SARKAR NH, 1994, VIROLOGY, V203, P52, DOI 10.1006/viro.1994.1454; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shawber C, 1996, DEVELOPMENT, V122, P3765; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	38	87	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					223	231		10.1038/sj.onc.1203295	http://dx.doi.org/10.1038/sj.onc.1203295			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645000				2022-12-17	WOS:000084844400007
J	Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA				Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA			Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo	ONCOGENE			English	Article						apoptosis; bcl-2; bax; 5-fluorouracil; gamma-irradiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; HUMAN COLORECTAL ADENOMAS; MURINE SMALL-INTESTINE; CELL-DEATH; GAMMA-IRRADIATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; HIERARCHICAL STATUS; CRYPT CELLS; P53	The influence of bcl-2 and bax expression on apoptotic cell death in mouse intestinal epithelia was assessed using homozygously null mice. Apoptosis was induced in vivo by the enterotoxin 5-fluorouracil (5FU) or by gamma-irradiation and its cell positional incidence was assessed. 5FU and gamma-radiation treated bax-null mice surprisingly showed no reductions in apoptotic yield in the small intestine or midcolon at 4.5 h at cell positions in which both agents had previously been shown to strongly induce p53 protein expression. The colonic epithelia of 5FU treated bcl-2-null mice showed elevated levels of apoptosis at 4.5 h: from 48 apoptotic events in wild-type mice to 273 in the nulls, scoring 200 half crypts. The increase occurred specifically in the cell positions considered to harbour colonic stem cells, at the base of crypts, where there is selective expression of bcl-2. There was a modest but significant increase in apoptosis in the small intestine of the bcl-2-null mice although the epithelia of wild-type mice here are not immunohistochemically positive for bcl-2 protein. These findings show that bcl-2 plays a key role in determining the sensitivity of colonic stem cells to damage-induced death but that bax is not responsible for the p53-dependent induction of apoptosis in this context.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Dept Epithelial Biol, CRC, Manchester M20 9BX, Lancs, England; Dana Farber Canc Inst, Boston, MA 02115 USA; Christie Hosp NHS Trust, Paterson Inst, CRC, Biomath & Comp Unit, Manchester M20 9BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Harvard University; Dana-Farber Cancer Institute; Christie NHS Foundation Trust; Christie Hospital	Hickman, JA (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Stopford Bldg G38, Manchester M13 9PT, Lancs, England.			Pritchard, David Mark/0000-0001-7971-3561				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; HAGUE A, 1994, ONCOGENE, V9, P3367; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; IJIRI K, 1987, BRIT J CANCER, V55, P113, DOI 10.1038/bjc.1987.25; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Lamb JR, 1997, NAT MED, V3, P962, DOI 10.1038/nm0997-962; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MERRITT AJ, 1995, J CELL SCI, V108, P2261; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA H, 1994, DEV HYDROB, V91, P3; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; WILSON JW, 1996, APOPTOSIS, V1, P183; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	38	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7287	7293		10.1038/sj.onc.1203150	http://dx.doi.org/10.1038/sj.onc.1203150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602483				2022-12-17	WOS:000084119400013
J	Govind, S				Govind, S			Control of development and immunity by Rel transcription factors in Drosophila	ONCOGENE			English	Review						dorsal-ventral polarity; immunity; hematopoiesis; muscle; Drosophila; dorsal	DORSAL-VENTRAL POLARITY; NF-KAPPA-B; EMBRYONIC DORSOVENTRAL POLARITY; SIGNAL-TRANSDUCTION PATHWAY; REGULATED NUCLEAR IMPORT; PROTEIN DORSAL; TRANSMEMBRANE PROTEIN; FUNCTIONAL DOMAINS; PATTERN-FORMATION; MORPHOGEN DORSAL	The Drosophila Rel/NF-kappa B transcription factors-Dorsal, Dif, and Relish - control several biological processes, including embryonic pattern formation, muscle development, immunity, and hematopoiesis. Molecular-genetic analysis of 12 mutations that cause embryonic dorsal/ventral patterning defects has defined the steps that control the formation of this axis. Regulated activation of the Toll receptor leads to the establishment of a gradient of nuclear Dorsal protein, which in turn governs the subdivision of the axis and specification of ventral, lateral and dorsal fates. Phenotypic analysis of dorsal-ventral embryonic mutants and the characterization of the two other fly Rel proteins, Dif and Relish, have shown that the intracellular portion of the Toll to Cactus pathway also controls the innate immune response in Drosophila. Innate immunity and hematopoiesis are regulated by analogous Rel/NF-kappa B-family pathways in mammals. The elucidation of the complex regulation and diverse functions of Drosophila Rel proteins underscores the relevance of basic studies in Drosophila.	CUNY City Coll, Dept Biol, New York, NY 10031 USA; CUNY, Grad Ctr, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Govind, S (corresponding author), Novartis Inst Biomed Res, 133-2028A,556 Morris Ave, Summit, NJ USA.			Govind, Shubha/0000-0002-6436-639X				Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Anderson KV, 1998, CELL, V95, P439, DOI 10.1016/S0092-8674(00)81610-4; ANDRESON KV, 1986, GAMETOGENESIS EARLY, P177; BarillasMury C, 1996, EMBO J, V15, P4691, DOI 10.1002/j.1460-2075.1996.tb00846.x; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Cantera R, 1999, J NEUROBIOL, V38, P16, DOI 10.1002/(SICI)1097-4695(199901)38:1<16::AID-NEU2>3.3.CO;2-S; Cantera R, 1999, MOL CELL NEUROSCI, V13, P131, DOI 10.1006/mcne.1999.0739; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; Edwards DN, 1997, DEVELOPMENT, V124, P3855; ENGSTROM T, 1993, PRODUCTIVITY QUALITY, V1, P333; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GOVIND S, 1992, P NATL ACAD SCI USA, V89, P7861, DOI 10.1073/pnas.89.17.7861; Govind S, 1996, BIOCHEM SOC T, V24, P39, DOI 10.1042/bst0240039; Govind S, 1996, MOL CELL BIOL, V16, P1103; GOVIND S, 1993, DEVELOPMENT, V117, P135; Gross I, 1999, GENE, V228, P233, DOI 10.1016/S0378-1119(98)00595-2; GROSS I, 1996, NUCLEIC ACIDS RES, V89, P7861; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HALFON M, 1995, DEV BIOL, V196, P151; Halfon MS, 1998, DEV BIOL, V199, P164, DOI 10.1006/dbio.1998.8915; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; HEDENGREN M, 1999, IN PRESS MOL CELL; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; Huguet C, 1997, ONCOGENE, V15, P2965, DOI 10.1038/sj.onc.1201471; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1992, EMBO J, V11, P3147, DOI 10.1002/j.1460-2075.1992.tb05387.x; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMENS J, 1991, NEW BIOL, V3, P1005; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MEISTER M, 1994, EMBO J, V13, P5958, DOI 10.1002/j.1460-2075.1994.tb06941.x; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Pancer Z, 1999, IMMUNOGENETICS, V49, P773, DOI 10.1007/s002510050551; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Qiu P, 1998, DEVELOPMENT, V125, P1909; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; Rizki T.M., 1984, P579; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Rose D, 1997, DEVELOPMENT, V124, P1561; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; Roth S, 1998, CURR BIOL, V8, pR906, DOI 10.1016/S0960-9822(98)00006-2; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shirokawa JM, 1997, MOL CELL BIOL, V17, P3345, DOI 10.1128/MCB.17.6.3345; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; STEWARD R, 1993, CURR OPIN GENET DEV, V3, P556, DOI 10.1016/0959-437X(93)90090-C; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; TATEI K, 1995, MOL CELL BIOL, V15, P3627; THISSE B, 1987, GENE DEV, V5, P1285; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Towb P, 1998, DEVELOPMENT, V125, P2443; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WILSON I, 1997, CURR BIOL, V7, P175; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Yang J, 1997, P NATL ACAD SCI USA, V94, P14524, DOI 10.1073/pnas.94.26.14524; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	139	87	89	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6875	6887		10.1038/sj.onc.1203223	http://dx.doi.org/10.1038/sj.onc.1203223			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602463				2022-12-17	WOS:000083896500005
J	Heyer, J; Yang, K; Lipkin, M; Edelmann, W; Kucherlapati, R				Heyer, J; Yang, K; Lipkin, M; Edelmann, W; Kucherlapati, R			Mouse models for colorectal cancer	ONCOGENE			English	Article						gastrointestinal cancer; FAP; HNPCC; mouse	DNA MISMATCH REPAIR; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; INTESTINAL NEOPLASIA; APC GENE; MIN MICE; MAJOR MODIFIER; COLI GENE; MUTATION; IDENTIFICATION	Colorectal cancer (CRC) is one of the most common cancers in the Western world. Much has been learned about colorectal cancer from human inherited syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), Mouse models for CRC were generated hg introducing mutations into the mouse genes, whose human counterparts were implicated in the onset and progression of CRC. Central among these are mice carrying mutations in the Adenomatous polyposis coli (Apc) gene. Although most of these Apc mutations share some common phenotypes as homozygous embryonic lethality and tumor predisposition, the severity of the tumor predisposition is variable. Mice with mutations in the mismatch repair genes, Msh2 and Mlh1, exhibit a mismatch repair defect and are predisposed to developing gastrointestinal cancer, lymphomas and tumors of other organ systems. Mice carrying a mutation in the Pms2 gene are predisposed to lymphomas and other tumors, Mice with a mutation in the Msh6 gene have a defect in base mismatch repair and show a tumor predisposition phenotype, Mice with mutations in Mlh1, Pms2 and Msh5 have defects in meiosis suggesting unique roles for these genes in gametogenesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Kucherlapati, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021					Akiyama Y, 1997, CANCER RES, V57, P3920; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BOYER JC, 1995, CANCER RES, V55, P6063; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Burt RW, 1996, GASTROENTEROL CLIN N, V25, P793, DOI 10.1016/S0889-8553(05)70275-2; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CLARKE AR, 1995, ONCOGENE, V11, P1913; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hioki K, 1997, CARCINOGENESIS, V18, P1863, DOI 10.1093/carcin/18.10.1863; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; LUONGO C, 1994, CANCER RES, V54, P5947; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marcus DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P645, DOI 10.1001/archopht.1997.01100150647013; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Reitmair AH, 1996, CANCER RES, V56, P2922; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Ricciardone MD, 1999, CANCER RES, V59, P290; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmutte C, 1998, CANCER RES, V58, P4537; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1997, CANCER RES, V57, P1999; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tishkoff DX, 1998, CANCER RES, V58, P5027; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; Wang Q, 1999, CANCER RES, V59, P294; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068; Yang K, 1998, CANCER RES, V58, P5713; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	76	87	88	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5325	5333		10.1038/sj.onc.1203036	http://dx.doi.org/10.1038/sj.onc.1203036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498885				2022-12-17	WOS:000082808400011
J	Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM				Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM			Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma	ONCOGENE			English	Article						Par-4; renal cell carcinoma; apoptosis	TUMOR-SUPPRESSOR GENE; VONHIPPEL-LINDAU DISEASE; KINASE-C; MUTATIONS; CANCER; IDENTIFICATION; PHENOTYPE; ISOFORMS; TISSUES; PRODUCT	Par-4 is a widely expressed leucine zipper protein that confers sensitization to apoptosis induced by exogenous insults. Because the expression of genes that promote apoptosis may be down-regulated during tumorigenesis, we sought to examine the expression of Par-4 in human tumors, We present here evidence that Par-4 protein levels were severely decreased in human renal cell carcinoma specimens relative to normal tubular cells, Replenishment of Par-4 protein levels in renal cell carcinoma cell lines conferred sensitivity to apoptosis, Because apoptosis may serve as a defense mechanism against malignant transformation or progression, decreased expression of Par-4 may contribute to the pathophysiology of renal cell carcinoma.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; NCI, Urol Oncol Sect, NIH, Bethesda, MD 20892 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.		Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA068258, R01CA060872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044921] Funding Source: NIH RePORTER; NCI NIH HHS [CA68258, CA60872] Funding Source: Medline; NIDDK NIH HHS [DK44921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUO Q, 1998, IN PRESS NAT MED; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Pan HC, 1997, CANCER SURV, V29, P305; QIU G, IN PRESS ONCOGENE; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; WALTHER MM, 1995, J UROLOGY, V154, P278, DOI 10.1016/S0022-5347(01)67294-X; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057	20	87	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1205	1208		10.1038/sj.onc.1202416	http://dx.doi.org/10.1038/sj.onc.1202416			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022126				2022-12-17	WOS:000078510700009
J	Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF				Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF			A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2	ONCOGENE			English	Article						cdc25; cyclin-dependent kinases; colony-stimulating factor-1 receptor; cell cycle; tyrosine phosphatase; p27(Kip1) inhibitor	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; G1 PHASE; PROTEASOME PATHWAY; ACTIVATING KINASE; DNA-REPLICATION; GROWTH-FACTOR; C-MYC; PHOSPHORYLATION	The cdc25A phosphatase removes inhibitory phosphates from threonine-14 and tyrosine-15 of cyclin dependent kinase-2 (cdk2) in vitro, and it is therefore widely assumed that cdc25A positively regulates cyclin E- and A-associated cdk2 activity at the G1 to S phase transition of the mammalian cell division cycle. Human cdc25A was introduced into mouse NIH3T3 fibroblasts co-expressing a form of the colony-stimulating factor-1 (CSF-1) receptor that is partially defective in transducing mitogenic signals. Cdc25A enabled these cells to form colonies in semisolid medium containing serum plus human recombinant CSF-1 in a manner reminiscent of cells rescued by c-myc. However, cdc25A-rescued cells could not proliferate in chemically defined medium containing CSF-1 and continued to require c-myc function for S phase entry. When contact-inhibited cells overexpressing cdc25A were dispersed and stimulated to synchronously enter the cell division cycle, they entered S phase 2-3 h earlier than their parental untransfected counterparts. Shortening of G1 phase temporally correlated with more rapid degradation of the cdk inhibitor p27(Kip1) and with premature activation of cyclin A-dependent cdk2. Paradoxically, tyrosine phosphorylation of cdk2 increased considerably as cells entered S phase, and cdc25A overexpression potentiated rather than diminished this effect. At face value, these results are inconsistent with the hypothesis that cdc25A acts directly on cdk2 to activate its S phase promoting function.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; Inst Child Hlth, London WC1N 1EH, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of London; University College London	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016; Sexl, Veronika/B-8657-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Sexl, Veronika/0000-0001-9363-0412	NCI NIH HHS [CA-21765, CA-56819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA056819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN T, 1993, BONE MARROW TRANSPL, V12, P1; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KARN J, 1989, ONCOGENE, V4, P773; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NAGATA A, 1991, NEW BIOL, V3, P959; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANDHU K, 1990, P NATL ACAD SCI USA, V87, P5139; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu X, 1996, J BIOL CHEM, V271, P5118	68	87	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					573	582		10.1038/sj.onc.1202362	http://dx.doi.org/10.1038/sj.onc.1202362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989807				2022-12-17	WOS:000078394400002
J	Voorhoeve, PM; Hijmans, EM; Bernards, R				Voorhoeve, PM; Hijmans, EM; Bernards, R			Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein	ONCOGENE			English	Article						cell cycle; p107; protein phosphatase 2A; retinoblastoma protein	SERINE THREONINE PHOSPHATASES; CYCLIN-DEPENDENT KINASES; DNA-BINDING ACTIVITY; CELL-PROLIFERATION; CATALYTIC SUBUNIT; GENE FAMILY; IN-VIVO; E2F; COMPLEXES; CDK2	The proteins of the retinoblastoma family are potent inhibitors of cell cycle progression. It is well documented that their growth-inhibitory activity can be abolished by phosphorylation on serine and threonine residues by cyclin dependent kinases, In contrast, very little is known about the dephosphorylation of retinoblastoma-family proteins. We report here the isolation, by virtue of its ability to associate,vith p107, of a novel Protein Phosphatase 2A (PP2A) regulatory subunit, named PR59, PR59 shares sequence homology with a known regulatory subunit of PP2A, PR72, but differs from PR72 in its expression pattern and its functional properties. We show that PR59 co-immunoprecipitates with the PP2A catalytic subunit, indicating that PR59 is a genuine component of PP2A hole-enzymes. In vivo, PR59 associates specifically with p107, but not with pRb, Elevated expression of PR59 results in dephosphorylation of p107, but not of pRb, and inhibits cell proliferation by causing cells to accumulate in G1, These data support a model in which the distinct PP2A regulatory subunits act to target the PP2A catalytic subunit to specific substrates and suggest a role for PP2A in regulation of p107.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAVRE B, 1994, J BIOL CHEM, V269, P16331; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Tung HYL, 1997, FEBS LETT, V401, P197, DOI 10.1016/S0014-5793(96)01470-6; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	57	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					515	524		10.1038/sj.onc.1202316	http://dx.doi.org/10.1038/sj.onc.1202316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927208	Green Published			2022-12-17	WOS:000078166500024
J	Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M				Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M			Pp125(FAK) is required for stretch dependent morphological response of endothelial cells	ONCOGENE			English	Article						uni-axial cyclic stretch; HVJ-liposome; antisense phosphorothioate oligodeoxynucleotides; stretch-activated ion channel	PROTEIN-TYROSINE KINASE; ACTIVATED ION CHANNELS; FOCAL ADHESIONS; HERBIMYCIN-A; PHOSPHORYLATION; ANTIBODIES; INHIBITOR; PAXILLIN; VINCULIN	In this study, critical signaling pathway required for the stretch induced morphological changes of human umbilical endothelial cells (HUVECs) was investigated. Uniaxial cyclic stretch (1 Hz, 20% in length) of the cells cultured on an elastic silicon membrane induced a gradual morphological change in the cells from a polygonal shape to an elongated spindle-like shape whose long axis was aligned perpendicular to the stretch axis, We found that protein tyrosine phosphorylation of cellular proteins increased and peaked at 20 min in response to cyclic stretch. Either treatment of cells with gadolinium (Gd3+), a potent blocker for stretch-activated channels, or removal of extracellular Ca2+ blocked the tyrosine phosphorylation of the proteins, suggesting that stretch-activated (SA) ion channels regulated stretch specific tyrosine phosphorylation, The major phosphorylated proteins had molecular masses of approximately 120-135 kDa, and 70 kDa, Immunoprecipitation experiments revealed that paxillin, focal adhesion kinase (pp125(FAK)) and pp130(CAS) were included in the 70 kDa and 120-135 kDa bands, respectively, The morphological change was inhibited by herbimycin A and genistein, inhibitors of tyrosine kinases, suggesting that tyrosine phosphorylation was required for the morphological change, In addition, the kinase activation of pp125(FAK) was observed in response to cyclic stretch, Moreover, suppression of pp125(FAK) expression by the antisense phosphorothioate oligodeoxynucleotides (S-ODN) in HUVECs resulted in inhibition of tyrosine phosphorylation of paxillin and the stretch-dependent morphological changes. These results suggest that an activation of tyrosine kinase(s) by an increase in intracellular Ca2+ and pp125(FAK) play a critical role in the unique morphological change specifically observed in endothelial cells subjected to uni-axial cyclic stretch.	Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Showa Ku, Nagoya, Aichi 466, Japan	Nagoya University; Nagoya University	Naruse, K (corresponding author), Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, 65 Tsuramai Cho, Nagoya, Aichi 466, Japan.		NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012	naruse, keiji/0000-0003-4100-6444				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BIALECKI RA, 1992, AM J PHYSIOL, V263, pL602, DOI 10.1152/ajplung.1992.263.5.L602; BOWMAN CL, 1992, BRAIN RES, V584, P272, DOI 10.1016/0006-8993(92)90906-P; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CEMERIKIC D, 1993, AM J PHYSIOL, V264, pF697, DOI 10.1152/ajprenal.1993.264.4.F697; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; GRIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA T, 1991, MICROVASC RES, V42, P245, DOI 10.1016/0026-2862(91)90059-K; ILLE D, 1995, NATURE, V377, P539; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MASUDA M, 1990, MORPHOGENESIS FUNCTI, P325; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NARUSE K, 1998, IN PRESS AM J PHYSL; OHMORI H, 1985, J PHYSIOL-LONDON, V359, P189, DOI 10.1113/jphysiol.1985.sp015581; Okada Y, 1990, Neurosci Res Suppl, V12, pS5, DOI 10.1016/0921-8696(90)90004-M; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHIRINSKY VP, 1989, J CELL BIOL, V109, P331, DOI 10.1083/jcb.109.1.331; SOKABE M, 1997, PROGR CELL RES, V6, P139; TURNER CE, 1989, J BIOL CHEM, V264, P11938; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	36	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					455	463		10.1038/sj.onc.1201950	http://dx.doi.org/10.1038/sj.onc.1201950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696039				2022-12-17	WOS:000075043000008
J	James, LA; Mitchell, ELD; Menasce, L; Varley, JM				James, LA; Mitchell, ELD; Menasce, L; Varley, JM			Comparative genomic hybridisation of ductal carcinoma in situ of the breast: Identification of regions of DNA amplification and deletion in common with invasive breast carcinoma	ONCOGENE			English	Article						CGH; DCIS; breast cancer	MOLECULAR CYTOGENETIC ANALYSIS; TERM FOLLOW-UP; IN-SITU; SOLID TUMORS; COPY NUMBER; HYBRIDIZATION; CANCER; HETEROZYGOSITY	Comparative genomic hybridisation has been used to map copy number changes in nine cases of ductal carcinoma in situ of the breast obtained from wax-embedded archive material. A wide variety of abnormalities were detected including gain of regions of 1q, 17q, 19q, 20p and 20q and loss on 13q, 14q, 17p, 16q and 22q. Amplification of areas on 10p, 8q and 20q were also observed, Chromosomal alterations were more frequent in higher grade DCIS and closely resemble those previously detected in invasive breast cancer using the same technique. These data provide strong molecular support for the view that DCIS is a precursor lesion of invasive breast carcinoma.	CHRISTIE HOSP NHS TRUST,DEPT PATHOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital	James, LA (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; COX DW, 1995, CYTOGENET CELL GENET, V69, P160; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frykberg E R, 1993, Adv Surg, V26, P29; ISOLA J, 1994, AM J PATHOL, V145, P1301; James L, 1996, CHROMOSOME RES, V4, P163, DOI 10.1007/BF02259711; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; LUI E, 1992, ONCOGENE, V7, P1027; MITCHELL ELD, 1995, CYTOGENET CELL GENET, V70, P183, DOI 10.1159/000134028; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Munn KE, 1996, BRIT J CANCER, V74, P1578, DOI 10.1038/bjc.1996.592; MUNN KE, 1995, ONCOGENE, V10, P1653; Munn KE, 1996, BRIT J CANCER, V73, P636, DOI 10.1038/bjc.1996.110; *NHS BREAST SCREEN, 1995, NHSBSP PUBL, V3; NIELSEN KV, 1989, ACTA ONCOL, V28, P919, DOI 10.3109/02841868909092332; OMALLEY FP, 1994, LAB INVEST, V71, P67; PAGE DL, 1982, CANCER, V49, P715; RADFORD DM, 1993, CANCER RES, V53, P2947; RIED T, 1995, CANCER RES, V55, P5415; ROSNER D, 1980, ANN SURG, V192, P193; SPEICHER MR, 1995, AM J PATHOL, V146, P1332; SPEICHER MR, 1993, HUM MOL GENET, V2, P1907; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; TANNER MM, 1994, CANCER RES, V54, P4257; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V37, P103, DOI 10.1016/0165-4608(89)90080-0; WILTSHIRE RN, 1995, CANCER RES, V55, P3954	33	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1059	1065		10.1038/sj.onc.1200923	http://dx.doi.org/10.1038/sj.onc.1200923			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070654				2022-12-17	WOS:A1997WM07000007
J	Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF				Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF			ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block	ONCOGENE			English	Article						apoptosis; BCR-ABL; phosphorylation; cdc2; cell cycle; leukaemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; INDUCED APOPTOSIS; DNA-DAMAGE; ANTICANCER AGENTS; P34CDC2 KINASE; G2 ARREST; DEATH; PHOSPHORYLATION	Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide. This effect is achieved in the absence of any detectable changes in the levels of BCL-2, BAX or BCL-x proteins and is independent of proliferative, MAP kinase-dependent effects of BCR-ABL kinase. In contrast to parental cells that transiently arrest in G(2) and then apoptose, p210 BaF3 cells show a pronounced and sustained G(2) arrest following radiation coupled with enhanced phosphorylation of cdc2. A cell cycle block in early M phase induced by the mitotic spindle poison, nocodazole, does not provide protection from apoptosis. Reversal of G(2) arrest by caffeine abolishes the protective effect of BCR-ABL kinase. These data provide further insight into the transforming properties of BCR-ABL and are relevant to the clinical intransigence of Ph-positive leukaemias.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALLEN PB, 1992, MOL GENETICS HAEMATO, P897; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CLARK SS, 1989, MOL DIAGNOSTICS HUMA, P15; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CRIST W, 1990, BLOOD, V76, P489; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HERMANS A, 1989, CANCER CEL, V7, P21; HERZINGER T, 1995, ONCOGENE, V11, P2151; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KHARBANDA S, 1994, CANCER RES, V54, P1412; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1990, CANCER RES, V50, P3767; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McKenna WG, 1996, ONCOGENE, V12, P237; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PALUMBO GJ, 1990, CANCER RES, V50, P1917; PALUMBO GJ, 1991, LEUKEMIA RES, V15, P847, DOI 10.1016/0145-2126(91)90469-A; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; POWELL SN, 1995, CANCER RES, V55, P1643; PROCTOR SJ, 1994, BRIT J HAEMATOL, V88, P229, DOI 10.1111/j.1365-2141.1994.tb05011.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROBERTS WM, 1994, LANCET, V343, P331, DOI 10.1016/S0140-6736(94)91166-5; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; SECKERWALKER LM, 1991, LEUKEMIA, V5, P196; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843	58	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2225	2234						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950990				2022-12-17	WOS:A1996VV14500020
J	Das, R; Vonderhaar, BK				Das, R; Vonderhaar, BK			Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells	ONCOGENE			English	Article						prolactin; breast cancer; JAK2; SHC; STAT5	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-HORMONE RECEPTOR; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LYMPHOMA-CELLS; MAP KINASE; ASSOCIATION; JAK2	The peptide hormone prolactin (Prl) regulates proliferation of normal and malignant mammary cells, In the present study me demonstrate that tate Prl responsive cell Lines, NOG-8 and T47D, activate the JAK2-SHC-MAPK pathway in a rapid and transient manner, Within 1 min of Prl treatment there was an increase in association of JAK2 with SHC, followed by rapid phosphorylation of both the 52 kDa and 46 kDa SHC proteins, Grb2 and Sos associated with the SHC proteins within 1-3 min of Prl treatment in these mammary cells, Within 5 min of hormone treatment we observe an increase in ras-GTP suggesting activation of ras, We also showed a rapid and transient tyrosine phosphorylation of STAT5 in proliferating T47D cells which reached its peak after 30 min of Prl treatment, These results indicate that Prl receptors, after binding the ligand, activate several pathways for signal transduction leading to mitogenesis.	NCI,TUMOR IMMUNOL & BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BISWAS R, 1987, CANCER RES, V47, P3509; BONNETERRE J, 1982, EUR J CANCER CLIN ON, V18, P1157, DOI 10.1016/0277-5379(82)90097-9; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAS R, 1996, IN PRESS BREAST CANC; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; GINSBURG E, 1995, CANCER RES, V55, P2591; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LEPROVOST F, 1994, NEUROENDOCRINOLOGY, V60, P305, DOI 10.1159/000126763; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1994, J BIOL CHEM, V269, P5364; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIUWEN L, 1995, P NATL ACAD SCI USA, V92, P8831; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1139	1145						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808687				2022-12-17	WOS:A1996VJ20200004
J	Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S				Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S			Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia	ONCOGENE			English	Article						retinoid; transcription; leukemia; zinc finger	ZINC-FINGER; RAR-ALPHA; RESPONSE ELEMENT; CELL-LINE; BETA-GENE; PROTEIN; FUSION; PML; IDENTIFICATION; TRANSLOCATION	Acute promyelocytic leukemia (APL) associated with chromosomal rearrangement t(11;17) is a distinct syndrome which, unlike typical t(15;17) APL, fails to respond to all-trans retinoic acid (ATRA) therapy. In t(11;17) the PLZF gene, encoding a Kruppel-like zinc finger protein, is fused to the retinoic acid receptor-alpha (RAR alpha) gene, yielding two classes of chimeric proteins, PLZF protein was found in the nucleus in a punctate speckled pattern that differed from the nuclear body expression pattern of the PML protein affected in t(15;17) APL. The reciprocal PLZF-RAR alpha and RAR alpha-PLZF fusion proteins were localized to the nucleus both in the presence and absence of ATRA, PLZF-RAR alpha, in combination with the retinoid X receptor (RXR) bound to a retinoic acid-responsive element (RARE) less efficiently than RAR alpha and formed multimeric DNA-protein complexes. PLZF-RAR alpha stimulated ATRA-dependent transcription of RARE-containing reporter genes with diminished activity compared to wild-type RAR alpha, In addition, PLZF-RAR alpha antagonized the function of coexpressed wild-type RAR alpha, an effect relieved by over-expression of RXR. Leukemogenesis in t(11;17) APL may be related to interference with ATRA-mediated differentiation due to sequestration of RXR by the PLZF-RAR alpha chimera. However, disruption of the function of the myeloid-specific PLZF protein may also play an important role.	MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; SHANGHAI MED UNIV 2,RUI JIN HOSP,SHANGHAI INST HEMATOL,SHANGHAI,PEOPLES R CHINA; CANC RES INST,LEUKEMIA RES FUND,LONDON SW3 6JB,ENGLAND; MT SINAI SCH MED,DIV NEOPLAST DIS,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Shanghai Jiao Tong University; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,BOX 1126,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Zelent, Arthur/B-3532-2009; Melnick, Ari/AAA-5763-2020; Licht, Jonathan/L-4239-2019	Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [CA 59936] Funding Source: Medline; NIGMS NIH HHS [T32GM07280-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; COREY SJ, 1994, LEUKEMIA, V8, P1350; DANIEL MT, 1993, BLOOD, V82, P1858; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HARLOW E, 1988, ANTIBODIES LABORATOR; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P441; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI JY, 1994, BLOOD, V84, pA41; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVION DF, 1995, EXP CELL RES, V218, P9; REDNER RL, 1994, BLOOD, V84, pA375; REID A, 1995, IN PRESS BLOOD; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TERRIS B, 1995, CANCER RES, V55, P1590; TESTA U, 1994, CANCER RES, V54, P4508; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	57	87	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					323	336						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570209				2022-12-17	WOS:A1996TR53800011
J	DubsPoterszman, MC; Tocque, B; Wasylyk, B				DubsPoterszman, MC; Tocque, B; Wasylyk, B			MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest	ONCOGENE			English	Article						E2F; transcription; Rb; inhibition; anchorage-independent growth	AUTOREGULATORY FEEDBACK LOOP; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MUTATIONS; ONCOGENE	The p53 tumour-suppressor guards the genome in response to genotoxic stress by transcriptional regulation of genes involved in cell-cycle control, DNA replication, repair and apoptosis such as p21, GADD45, bar and mdm2 (Cox and Lane, 1995), Mdm2 is classically considered to be an inhibitor of p53, that forms an auto-regulatory loop (Momand et al., 1992; Oliner et al., 1993; Wu el al., 1993; Chen et al., 1994; Chen and Levine, 1995). It immortalises cells containing wild type p53 and transforms them together with Ras (Finlay, 1993). We show that, in the absence of p53, mdm2 confers a growth advantage to cells (ie ''transforms'' them) and can overcome a G1 cell-cycle arrest induced by p107, a member of the pRb tumour-suppressor family (Adams and Kaelin, 1995), The minimum ''transforming'' and p107 inhibiting region of Mdm2 corresponds to its p53 binding domain, p53 inhibits transformation by Mdm2, apparently without requiring transcription, p53 can be considered to be a suppressor of Mdm2, a positive effector of the cell cycle, Mdm2 over-expression in tumours is reminiscent of p53 mutations with gain of function, in that Mdm2 both transforms cells and inhibits p53 activity.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis				WASYLYK, Bohdan/0000-0002-1718-1237				ADAMS PD, 1995, CANC BIOL, V6, P99; BATES S, 1995, CANCER BIOL, V6, P73; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HAHN BC, 1995, NAT GENET, V9, P221; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEACH FS, 1993, CANCER RES, V53, P2231; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHAULSKY G, 1991, CANCER RES, V51, P5232; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WATANABE T, 1994, BLOOD, V84, P3158; WHARTON W, 1989, CELL GROWTH DIVISION, P139; WHYTE P, 1995, CANCER BIOL, V6, P83; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	37	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2445	2449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570197				2022-12-17	WOS:A1995TK70200030
J	CLARKE, AR; CUMMINGS, MC; HARRISON, DJ				CLARKE, AR; CUMMINGS, MC; HARRISON, DJ			INTERACTION BETWEEN MURINE GERMLINE MUTATIONS IN P53 AND APC PREDISPOSES TO PANCREATIC NEOPLASIA BUT NOT TO INCREASED INTESTINAL MALIGNANCY	ONCOGENE			English	Article						P53; APC; MIN; PANCREATIC CANCER; COLORECTAL CANCER	WILD-TYPE P53; P53-DEFICIENT MICE; CANCER; APOPTOSIS; TUMORS; MOUSE; GENE	Murine strains which bear constitutive inactivating mutations of either the APC or the p53 tumor suppressor genes are characterised by spontaneous tumors. APC mutated (Min) mice develop large and small bowel adenomas, a small proportion of which, in time, become malignant, p53 deficient mice develop predominantly lymphoma and sarcoma. By interbreeding these strains we have shown that there is cooperativity between these mutations, leading to a shift in phenotype. Most notably, this was characterised by a range of abnormalities of the exocrine pancreas in 83% of animals heterozygous for the APC mutation and constitutively null for functional p53, Dysplasia and preneoplastic foci were seen in 61% of these animals and pancreatic acinar cell adenocarcinoma in 22%. Analysis of these tumors showed them to have lost the remaining wild-type copy of APC. Similar loss of APC was not associated with the development of other extraintestinal tumors, Surprisingly, given the proposed role for loss of function mutations of the p53 gene in the development of human colorectal cancer, we have found no evidence for either an increase in the rate of adenoma formation in APC +/-, p53 -/- animals, or an increased rate of progression to malignancy compared with APC +/- p53 +/+ mice. These findings highlight striking tissue-specific differences in the tumor suppressor effects of p53.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Cummings, Margaret/B-5747-2011	Cummings, Margaret/0000-0002-7657-0240; Clarke, Alan/0000-0002-4281-426X				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAYES PC, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P441; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KLOPPEL G, 1984, PANCREATIC PATHOLOGY, pCH7; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGNECKER DS, 1992, YALE J BIOL MED, V65, P457; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUONGO C, 1994, CANCER RES, V54, P5947; MALCOMSON RDG, IN PRESS BRIT J CANC; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; POWELL SM, 1992, NATURE, V59, P235; PURDIE CA, 1994, ONCOGENE, V9, P603; REDSTON MS, 1994, CANCER RES, V54, P3025; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASHIMA K, 1994, INT J CANCER, V59, P43, DOI 10.1002/ijc.2910590110	36	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478622				2022-12-17	WOS:A1995TD09400029
J	JANKNECHT, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ERNST, WH; NORDHEIM, A			SAP1A IS A NUCLEAR TARGET OF SIGNALING CASCADES INVOLVING ERKS	ONCOGENE			English	Article						C-FOS; ETS PROTEIN SAP1A; PHOSPHORYLATION; TRANSCRIPTION	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; MAP KINASES; RAF; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; COMPLEX; ELK-1; TRANSDUCTION	The Ets protein SAP1a has been shown to interact with the c-fos serum response element upon recruitment by the serum response factor. We demonstrate that SAP1a is a nuclear protein stimulating transcription via the c-fos serum response element, and additionally via an Ets binding site independently of the serum response factor. However, transactivation has only been observed under conditions leading to the activation of extracellular signal-regulated protein kinases (ERKs). The transcriptional activation domain of SAP1a resides within the C-terminal region, the function of which may be impeded by the N-terminus. Several potential ERK consensus sites within the C-terminal region of SAP1a can modulate its transactivation efficacy, implicating that SAP1a is a direct target of ERKs. Since ERKs are activated by a broad range of signals, SAP1a may play an important role in the transformation of extracellular stimuli into a nuclear response.			JANKNECHT, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEUNG S, 1993, ONCOGENE, V8, P989; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	87	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1209	1216						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700646				2022-12-17	WOS:A1995QN35300023
J	KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF				KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF			MUTATIONAL HOT-SPOTS WITHIN THE CARBOXY-TERMINAL REGION OF THE LMP1 ONCOGENE OF EPSTEIN-BARR-VIRUS ARE FREQUENT IN LYMPHOPROLIFERATIVE DISORDERS	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; ONCOGENE; LMP1; MUTATIONAL HOTSPOTS; LYMPHOMA; TRANSLOCATIONS	MEMBRANE-PROTEIN LMP-1; REED-STERNBERG CELLS; LATENT GENE-PRODUCTS; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; B-CELLS; EXPRESSION; INFECTION; LYMPHOMAS	We have recently identified in Epstein-Barr virus (EBV) positive Hodgkin's disease (HD) a variant of the latent membrane protein 1 (LMP1) oncogene characterized by four point mutations and a 30 base pair deletion. These findings led us to test whether such mutants were also present in other lymphoproliferative disorders (LPD). We analysed 98 EBV DNA positive cases (67 LPD, 15 benign conditions, 16 lymphoblastoid cell lines) by PCR for deletions within the LMP1 gene. DNA sequencing of the region coding for the carboxy terminal protein domain was performed on 24 cases. In 13 cases the same combination of 4 point mutations at positions 168 320, 168 308, 168 295 and 168 225 was identified. Of these cases, 12 had an additional point mutation at position 168 357 and eight at position 168 355, and nine had a 30 base pair deletion including nucleotides 168 285 to 168 256. These deletion mutants were identified in HD, angioimmunoblastic lymphadenopathy, B-immunoblastic lymphoma, peripheral T-cell lymphoma, and two lymphoblastoid cell lines. Our findings reveal a high frequency of non-random point mutations at preferential sites within the 3' (carboxy terminal) region of the LMP1 oncogene. The association of these mutational hot spots with LPD suggests that they are involved in EBV related lymphomagenesis and that they define a clinically relevant EBV strain.	CHU VAUDOIS,DEPT INTERNAL MED,CH-1011 LAUSANNE,SWITZERLAND; CHU PURPAN,ANAT PATHOL LAB,TOULOUSE,FRANCE; UNIV TUBINGEN HOSP,MED CLIN,TUBINGEN,GERMANY; ST ANNA CHILDRENS HOSP,CCRI,VIENNA,AUSTRIA; UNIV ZURICH HOSP,INST PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Toulouse; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Saint Anna Children's Hospital; University of Zurich; University Zurich Hospital			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Rothenberger, Sylvia/0000-0001-8633-2994				ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; BROUSSET P, 1993, BLOOD, V82, P872; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; HERBST H, 1991, BLOOD, V78, P2666; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KIEFF E, 1990, FUNDAMENTAL VIROLOGY, P897; KNAPP S, 1994, ONCOGENE, V9, P1501; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, LEUKEMIA, V7, P580; KNECHT H, 1994, ACTA HAEMATOL, V90, P167; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LESTOU VS, 1993, GENE CHROMOSOME CANC, V8, P38, DOI 10.1002/gcc.2870080108; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THORLEYLAWSON DA, 1987, P NATL ACAD SCI USA, V88, P5384; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; VASSALLO J, 1993, APPL IMMUNOHISTO M M, V1, P213; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1992, BLOOD, V79, P1789; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	49	87	89	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845677				2022-12-17	WOS:A1995QF64800013
J	FUNABIKI, T; KREIDER, BL; IHLE, JN				FUNABIKI, T; KREIDER, BL; IHLE, JN			THE CARBOXYL DOMAIN OF ZINC FINGERS OF THE EVI-1 MYELOID TRANSFORMING GENE BINDS A CONSENSUS SEQUENCE OF GAAGATGAG	ONCOGENE			English	Article							DNA-BINDING; RETROVIRAL INSERTIONS; RNA GENE; EXPRESSION; PROTEIN; TRANSCRIPTION; SPECIFICITY; TRANSLOCATIONS; RECOGNITION; ACTIVATION	Inappropriate expression of the Evi-1 zinc finger gene is associated with myeloid leukemia and myelodysplastic syndromes in mice and humans and has been hypothesized to contribute to pathology by blocking myeloid differentiation. Evi-1 contains two domains of zinc fingers, an amino-terminal domain of seven fingers and a carboxyl domain of three fingers. The first domain binds a consensus sequence of GA(C/T)AAGATAAGATAA in binding and amplication reactions or GATA repeat containing regions of genomic DNA. The experiments described here, establish a consensus sequence for the carboxyl domain of zinc fingers consisting of GAAGATGAG. Unlike the first domain, the consensus sequence established for the carboxyl domain is identical to that which would be predicted by the current rules relating to C2H2 zinc fingers and DNA recognition. Substitution of sequences in finger 8 with those in finger 9, demonstrate that the individual fingers bind the predicted region of the consensus sequence. In an attempt to engineer binding of constructs containing the carboxyl domain, a variety of mutations were made in the middle finger that would be predicted to change the consensus sequence in specific ways. Remarkably, most of the mutations were deleterious and destroyed specific DNA binding. Although Evi-1 contains potential transcriptional activation domains, it was not able to activate gene transcription from CAT constructs containing the consensus sequence.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; FUNABIKI T, 1993, UNPUB; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1993, UNPUB; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; OTSUKA S, 1993, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THUKRAL SK, 1991, P NATL ACAD SCI USA, V88, P9188, DOI 10.1073/pnas.88.20.9188; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784	28	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1575	1581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183551				2022-12-17	WOS:A1994NL81500007
J	ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ				ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ			MLK-3 - IDENTIFICATION OF A WIDELY-EXPRESSED PROTEIN-KINASE BEARING AN SH3 DOMAIN AND A LEUCINE ZIPPER-BASIC REGION DOMAIN	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; ENDOCRINE NEOPLASIA TYPE-1; LIGAND-BINDING SITE; CRYSTAL-STRUCTURE; MESSENGER-RNAS; DNA-BINDING; FAMILY; CHROMOSOME-11; SPECIFICITY; FEATURES	We have identified a novel protein kinase, designated MLK-3, from human thymus using RT-PCR and cDNA library screening. The deduced open reading frame, derived from sequencing a 3.5 kb MLK-3 cDNA, encodes a protein of 847 amino acids with several interesting structural features. These include an SH3 domain in the absence of an SH2 domain, a region containing two leucine zippers with an adjacent carboxy-terminal basic region, and a proline rich region. This kinase shows homology with the mixed-lineage family of protein kinases (MLK) and shares the unusual leucine zipper-basic motif found in previously identified MLK kinases. By northern analysis, MLK-3 mRNA was detected in a wide variety of normal and transformed human cell lines and tissue specimens. The gene encoding MLK-3 has been mapped using fluorescence in situ hybridization to human chromosome 11 q13.1-13.3, a region frequently altered in human malignancies.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010					BALE SJ, 1989, GENOMICS, V4, P320, DOI 10.1016/0888-7543(89)90336-4; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Borson N D, 1992, PCR Methods Appl, V2, P144; CLARK SG, 1992, NATURE, V356, P87; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENG HHQ, 1993, IN PRESS METHODS MOL; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; MUSACCHIO A, 1992, FEBS LETT, V359, P851; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHEECKEREN W, 1992, NUCLEIC ACIDS RES, V14, P3721; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	34	87	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1745	1750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183572				2022-12-17	WOS:A1994NL81500029
